{"generated":"2026-10-03T15:50:28-07:00","rows":[{"id":"nct07444788-university-hospital-basel-basel","cat":"research","name":"University Hospital Basel","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","cc":"CH","lat":47.56747,"lon":7.57256,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"4056","condg":["Other"],"status":"RECRUITING","nct":"NCT07444788","study":"Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants","sstatus":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","official":"Severin Vogt, Dr. med. (University Hospital Basel, Division of Clinical Pharmacology and Toxicology)","src":"https://clinicaltrials.gov/study/NCT07444788","contact":{"n":"Livio Erme, MSc Drug Sciences","p":"+41 61 328 48 18","e":"livio.erne@usb.ch"},"phase":"Phase 1","enroll":40,"start":"2026-03-31","eid":"x:site:nct07444788-university-hospital-basel-basel"},{"id":"nct07717866-axial-therapeutic-research-northridge","cat":"research","name":"Axial Therapeutic Research","city":"Northridge","region":"California","country":"United States","cc":"US","lat":34.21653,"lon":-118.52927,"gp":"city","unnamed":0,"drugs":["ibogaine"],"zip":"91325","condg":["Depression","PTSD & trauma","Neurology & cognition"],"nct":"NCT07717866","study":"Trifecta Research Study","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Axial Therapeutic Research","official":"I S Kroop (Axial Therapeutic Research)","src":"https://clinicaltrials.gov/study/NCT07717866","enroll":52,"start":"2022-08-01","eid":"x:site:nct07717866-axial-therapeutic-research-northridge"},{"id":"nct05032833-king-s-college-london-london","cat":"research","name":"King's College London","city":"London","country":"United Kingdom","cc":"GB","lat":51.51893,"lon":-0.11647,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Healthy volunteers"],"nct":"NCT05032833","study":"Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects","sstatus":"COMPLETED","sponsor":"Beckley Psytech Limited","src":"https://clinicaltrials.gov/study/NCT05032833","phase":"Phase 1","enroll":36,"start":"2021-09-22","eid":"x:site:nct05032833-king-s-college-london-london"},{"id":"nct04698603-clinical-trial-site-maastricht","cat":"research","name":"Clinical Trial Site","city":"Maastricht","country":"Netherlands","cc":"NL","lat":50.85581,"lon":5.68197,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Depression"],"nct":"NCT04698603","study":"Clinical Study of GH001 in Depression","sstatus":"COMPLETED","sponsor":"GH Research Ireland Limited","official":"GH Research Clinical Team (GH Research Ireland Limited)","src":"https://clinicaltrials.gov/study/NCT04698603","phase":"Phase 1/Phase 2","enroll":16,"start":"2019-11-12","eid":"x:site:nct04698603-clinical-trial-site-maastricht"},{"id":"nct06816667-hospital-descentralizado-dr-marcial-v-quiroga-san-juan","cat":"research","name":"Hospital Descentralizado Dr. Marcial V. Quiroga.","city":"San Juan","region":"Rivadavia","country":"Argentina","cc":"AR","lat":-31.52761,"lon":-68.53326,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"5400","condg":["Healthy volunteers"],"nct":"NCT06816667","study":"Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety","sstatus":"COMPLETED","sponsor":"Biomind Labs Inc.","official":"Martin A. Bruno, PhD (Biomind Labs Inc.)","src":"https://clinicaltrials.gov/study/NCT06816667","phase":"Phase 1/Phase 2","enroll":40,"start":"2024-10-21","eid":"x:site:nct06816667-hospital-descentralizado-dr-marcial-v-quiroga-san-juan"},{"id":"nct06810765-johns-hopkins-center-for-psychedelic-and-consciousness-research-balt","cat":"research","name":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29579,"lon":-76.61224,"gp":"city","unnamed":0,"drugs":["ibogaine"],"zip":"21224","condg":["PTSD & trauma","Neurology & cognition"],"nct":"NCT06810765","study":"Trifecta Research Study","sstatus":"WITHDRAWN","sponsor":"Johns Hopkins University","official":"Sandeep Nayak, MD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT06810765","phase":"Phase 2","start":"2025-09","eid":"x:site:nct06810765-johns-hopkins-center-for-psychedelic-and-consciousness-research-balt"},{"id":"nct05698095-altasciences-clinical-kansas-inc-overland-park","cat":"research","name":"Altasciences Clinical Kansas, Inc","city":"Overland Park","region":"Kansas","country":"United States","cc":"US","lat":38.98952,"lon":-94.66058,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"66212","condg":["Other"],"nct":"NCT05698095","study":"Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers","sstatus":"COMPLETED","sponsor":"Usona Institute","src":"https://clinicaltrials.gov/study/NCT05698095","phase":"Phase 1","enroll":54,"start":"2022-12-27","eid":"x:site:nct05698095-altasciences-clinical-kansas-inc-overland-park"},{"id":"nct06511947-gh-research-clinical-trial-site-london","cat":"research","name":"GH Research Clinical Trial Site","city":"London","country":"United Kingdom","cc":"GB","lat":51.50632,"lon":-0.13454,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Healthy volunteers"],"status":"RECRUITING","nct":"NCT06511947","study":"Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects","sstatus":"UNKNOWN","sponsor":"GH Research Ireland Limited","src":"https://clinicaltrials.gov/study/NCT06511947","contact":{"n":"GH Research Limited Clinical Trial Enquiries","p":"+353 87 450 3237","e":"clinicaltrials@ghres.com"},"phase":"Phase 1","enroll":52,"start":"2024-08-01","eid":"x:site:nct06511947-gh-research-clinical-trial-site-london"},{"id":"nct06624137-connecticut-mental-health-center-hamden","cat":"research","name":"Connecticut Mental Health Center","city":"Hamden","region":"Connecticut","country":"United States","cc":"US","lat":41.38506,"lon":-72.89089,"gp":"city","unnamed":0,"drugs":["LSD","ayahuasca","psilocybin"],"zip":"06517","condg":["Depression","PTSD & trauma","Addiction & substance use","Chronic pain & headache","OCD","Healthy volunteers"],"nct":"NCT06624137","study":"Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics","sstatus":"TERMINATED","sponsor":"Yale University","official":"Maximillian S Greenwald, BA (Yale University); Albert R Powers, MD, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT06624137","enroll":5,"start":"2024-12-12","eid":"x:site:nct06624137-connecticut-mental-health-center-hamden"},{"id":"nct06624137-west-haven-va-medical-center-west-haven","cat":"research","name":"West Haven VA Medical Center","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.26712,"lon":-72.94051,"gp":"city","unnamed":0,"drugs":["LSD","ayahuasca","psilocybin"],"zip":"06516","condg":["Depression","PTSD & trauma","Addiction & substance use","Chronic pain & headache","OCD","Healthy volunteers"],"nct":"NCT06624137","study":"Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics","sstatus":"TERMINATED","sponsor":"Yale University","official":"Maximillian S Greenwald, BA (Yale University); Albert R Powers, MD, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT06624137","enroll":5,"start":"2024-12-12","eid":"x:site:nct06624137-west-haven-va-medical-center-west-haven"},{"id":"nct05163691-gh-research-clinical-trial-site-groningen","cat":"research","name":"GH Research Clinical Trial Site","city":"Groningen","country":"Netherlands","cc":"NL","lat":53.22345,"lon":6.56625,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Healthy volunteers"],"nct":"NCT05163691","study":"Pharmacokinetics of GH001 in Healthy Volunteers","sstatus":"COMPLETED","sponsor":"GH Research Ireland Limited","official":"GH Research Clinical Team (GH Research Ireland Limited)","src":"https://clinicaltrials.gov/study/NCT05163691","phase":"Phase 1","enroll":46,"start":"2021-06-21","eid":"x:site:nct05163691-gh-research-clinical-trial-site-groningen"},{"id":"nct06812221-hospital-descentralizado-dr-marcial-v-quiroga-san-juan","cat":"research","name":"Hospital Descentralizado Dr. Marcial V. Quiroga.","city":"San Juan","region":"Rivadavia","country":"Argentina","cc":"AR","lat":-31.54088,"lon":-68.52836,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"5400","condg":["Depression","Anxiety","Neurology & cognition"],"nct":"NCT06812221","study":"Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI","sstatus":"COMPLETED","sponsor":"Biomind Labs Inc.","official":"Martin A. Bruno, PhD (Biomind Labs Inc.)","src":"https://clinicaltrials.gov/study/NCT06812221","phase":"Phase 1/Phase 2","enroll":20,"start":"2024-12-15","eid":"x:site:nct06812221-hospital-descentralizado-dr-marcial-v-quiroga-san-juan"},{"id":"nct05804708-amsterdam-umc-amsterdam","cat":"research","name":"Amsterdam UMC","city":"Amsterdam","country":"Netherlands","cc":"NL","lat":52.37822,"lon":4.88108,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Depression"],"nct":"NCT05804708","study":"Phase 2 Clinical Trial of GH001 in Postpartum Depression","sstatus":"TERMINATED","sponsor":"GH Research Ireland Limited","src":"https://clinicaltrials.gov/study/NCT05804708","phase":"Phase 2","enroll":10,"start":"2023-03-02","eid":"x:site:nct05804708-amsterdam-umc-amsterdam"},{"id":"nct05804708-clerkenwell-health-london","cat":"research","name":"Clerkenwell Health","city":"London","country":"United Kingdom","cc":"GB","lat":51.51225,"lon":-0.11638,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Depression"],"nct":"NCT05804708","study":"Phase 2 Clinical Trial of GH001 in Postpartum Depression","sstatus":"TERMINATED","sponsor":"GH Research Ireland Limited","src":"https://clinicaltrials.gov/study/NCT05804708","phase":"Phase 2","enroll":10,"start":"2023-03-02","eid":"x:site:nct05804708-clerkenwell-health-london"},{"id":"nct05804708-st-pancras-clinical-research-london","cat":"research","name":"St. Pancras Clinical Research","city":"London","country":"United Kingdom","cc":"GB","lat":51.52044,"lon":-0.13482,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Depression"],"nct":"NCT05804708","study":"Phase 2 Clinical Trial of GH001 in Postpartum Depression","sstatus":"TERMINATED","sponsor":"GH Research Ireland Limited","src":"https://clinicaltrials.gov/study/NCT05804708","phase":"Phase 2","enroll":10,"start":"2023-03-02","eid":"x:site:nct05804708-st-pancras-clinical-research-london"},{"id":"nct05804708-sheffield-health-and-social-care-nhs-foundation-sheffield","cat":"research","name":"Sheffield Health and Social Care NHS Foundation","city":"Sheffield","country":"United Kingdom","cc":"GB","lat":53.37953,"lon":-1.46472,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Depression"],"nct":"NCT05804708","study":"Phase 2 Clinical Trial of GH001 in Postpartum Depression","sstatus":"TERMINATED","sponsor":"GH Research Ireland Limited","src":"https://clinicaltrials.gov/study/NCT05804708","phase":"Phase 2","enroll":10,"start":"2023-03-02","eid":"x:site:nct05804708-sheffield-health-and-social-care-nhs-foundation-sheffield"},{"id":"nct05800860-investigational-site-pilsen","cat":"research","name":"Investigational site","city":"Pilsen","country":"Czechia","cc":"CZ","lat":49.74535,"lon":13.37293,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Depression"],"nct":"NCT05800860","study":"A Trial of GH001 in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"GH Research Ireland Limited","src":"https://clinicaltrials.gov/study/NCT05800860","phase":"Phase 2","enroll":81,"start":"2023-05-24","eid":"x:site:nct05800860-investigational-site-pilsen"},{"id":"nct05800860-investigational-site-prague","cat":"research","name":"Investigational site","city":"Prague","country":"Czechia","cc":"CZ","lat":50.08413,"lon":14.4177,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Depression"],"nct":"NCT05800860","study":"A Trial of GH001 in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"GH Research Ireland Limited","src":"https://clinicaltrials.gov/study/NCT05800860","phase":"Phase 2","enroll":81,"start":"2023-05-24","eid":"x:site:nct05800860-investigational-site-prague"},{"id":"nct05800860-investigational-site-dresden","cat":"research","name":"Investigational Site","city":"Dresden","country":"Germany","cc":"DE","lat":51.06044,"lon":13.74994,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Depression"],"nct":"NCT05800860","study":"A Trial of GH001 in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"GH Research Ireland Limited","src":"https://clinicaltrials.gov/study/NCT05800860","phase":"Phase 2","enroll":81,"start":"2023-05-24","eid":"x:site:nct05800860-investigational-site-dresden"},{"id":"nct05800860-investigational-site-frankfurt","cat":"research","name":"Investigational Site","city":"Frankfurt","country":"Germany","cc":"DE","lat":50.11058,"lon":8.68751,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Depression"],"nct":"NCT05800860","study":"A Trial of GH001 in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"GH Research Ireland Limited","src":"https://clinicaltrials.gov/study/NCT05800860","phase":"Phase 2","enroll":81,"start":"2023-05-24","eid":"x:site:nct05800860-investigational-site-frankfurt"},{"id":"nct05800860-investigational-site-munster","cat":"research","name":"Investigational Site","city":"Münster","country":"Germany","cc":"DE","lat":51.96514,"lon":7.61456,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Depression"],"nct":"NCT05800860","study":"A Trial of GH001 in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"GH Research Ireland Limited","src":"https://clinicaltrials.gov/study/NCT05800860","phase":"Phase 2","enroll":81,"start":"2023-05-24","eid":"x:site:nct05800860-investigational-site-munster"},{"id":"nct05800860-investigational-site-dublin","cat":"research","name":"Investigational site","city":"Dublin","country":"Ireland","cc":"IE","lat":53.34064,"lon":-6.24781,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Depression"],"nct":"NCT05800860","study":"A Trial of GH001 in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"GH Research Ireland Limited","src":"https://clinicaltrials.gov/study/NCT05800860","phase":"Phase 2","enroll":81,"start":"2023-05-24","eid":"x:site:nct05800860-investigational-site-dublin"},{"id":"nct05800860-investigational-site-galway","cat":"research","name":"Investigational Site","city":"Galway","country":"Ireland","cc":"IE","lat":53.27334,"lon":-9.0461,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Depression"],"nct":"NCT05800860","study":"A Trial of GH001 in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"GH Research Ireland Limited","src":"https://clinicaltrials.gov/study/NCT05800860","phase":"Phase 2","enroll":81,"start":"2023-05-24","eid":"x:site:nct05800860-investigational-site-galway"},{"id":"nct05800860-investigational-site-maastricht","cat":"research","name":"Investigational Site","city":"Maastricht","country":"Netherlands","cc":"NL","lat":50.83981,"lon":5.69345,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Depression"],"nct":"NCT05800860","study":"A Trial of GH001 in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"GH Research Ireland Limited","src":"https://clinicaltrials.gov/study/NCT05800860","phase":"Phase 2","enroll":81,"start":"2023-05-24","eid":"x:site:nct05800860-investigational-site-maastricht"},{"id":"nct05800860-investigational-site-gdansk","cat":"research","name":"Investigational Site","city":"Gdansk","country":"Poland","cc":"PL","lat":54.35495,"lon":18.65171,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Depression"],"nct":"NCT05800860","study":"A Trial of GH001 in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"GH Research Ireland Limited","src":"https://clinicaltrials.gov/study/NCT05800860","phase":"Phase 2","enroll":81,"start":"2023-05-24","eid":"x:site:nct05800860-investigational-site-gdansk"},{"id":"nct05800860-investigational-site-barcelona","cat":"research","name":"Investigational Site","city":"Barcelona","country":"Spain","cc":"ES","lat":41.39627,"lon":2.1708,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Depression"],"nct":"NCT05800860","study":"A Trial of GH001 in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"GH Research Ireland Limited","src":"https://clinicaltrials.gov/study/NCT05800860","phase":"Phase 2","enroll":81,"start":"2023-05-24","eid":"x:site:nct05800860-investigational-site-barcelona"},{"id":"nct05800860-investigational-site-salamanca","cat":"research","name":"Investigational Site","city":"Salamanca","country":"Spain","cc":"ES","lat":40.43824,"lon":-3.66822,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Depression"],"nct":"NCT05800860","study":"A Trial of GH001 in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"GH Research Ireland Limited","src":"https://clinicaltrials.gov/study/NCT05800860","phase":"Phase 2","enroll":81,"start":"2023-05-24","eid":"x:site:nct05800860-investigational-site-salamanca"},{"id":"nct04640831-clinical-trial-site-maastricht","cat":"research","name":"Clinical Trial Site","city":"Maastricht","country":"Netherlands","cc":"NL","lat":50.85657,"lon":5.69571,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Healthy volunteers"],"nct":"NCT04640831","study":"Safety of GH001 in Healthy Volunteers","sstatus":"COMPLETED","sponsor":"GH Research Ireland Limited","official":"GH Research Clinical Team (GH Research Ireland Limited)","src":"https://clinicaltrials.gov/study/NCT04640831","phase":"Phase 1","enroll":22,"start":"2019-03-13","eid":"x:site:nct04640831-clinical-trial-site-maastricht"},{"id":"nct05839509-investigational-site-dresden","cat":"research","name":"Investigational Site","city":"Dresden","country":"Germany","cc":"DE","lat":51.05724,"lon":13.7491,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Bipolar"],"nct":"NCT05839509","study":"Phase 2 Clinical Trial of GH001 in Bipolar II Disorder","sstatus":"TERMINATED","sponsor":"GH Research Ireland Limited","src":"https://clinicaltrials.gov/study/NCT05839509","phase":"Phase 2","enroll":6,"start":"2023-04-06","eid":"x:site:nct05839509-investigational-site-dresden"},{"id":"nct05839509-investigational-site-frankfurt","cat":"research","name":"Investigational Site","city":"Frankfurt","country":"Germany","cc":"DE","lat":50.11896,"lon":8.67546,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Bipolar"],"nct":"NCT05839509","study":"Phase 2 Clinical Trial of GH001 in Bipolar II Disorder","sstatus":"TERMINATED","sponsor":"GH Research Ireland Limited","src":"https://clinicaltrials.gov/study/NCT05839509","phase":"Phase 2","enroll":6,"start":"2023-04-06","eid":"x:site:nct05839509-investigational-site-frankfurt"},{"id":"nct05839509-investigational-site-munster","cat":"research","name":"Investigational Site","city":"Münster","country":"Germany","cc":"DE","lat":51.96467,"lon":7.61606,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Bipolar"],"nct":"NCT05839509","study":"Phase 2 Clinical Trial of GH001 in Bipolar II Disorder","sstatus":"TERMINATED","sponsor":"GH Research Ireland Limited","src":"https://clinicaltrials.gov/study/NCT05839509","phase":"Phase 2","enroll":6,"start":"2023-04-06","eid":"x:site:nct05839509-investigational-site-munster"},{"id":"nct05839509-investigational-site-leiden","cat":"research","name":"Investigational Site","city":"Leiden","country":"Netherlands","cc":"NL","lat":52.16713,"lon":4.49245,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Bipolar"],"nct":"NCT05839509","study":"Phase 2 Clinical Trial of GH001 in Bipolar II Disorder","sstatus":"TERMINATED","sponsor":"GH Research Ireland Limited","src":"https://clinicaltrials.gov/study/NCT05839509","phase":"Phase 2","enroll":6,"start":"2023-04-06","eid":"x:site:nct05839509-investigational-site-leiden"},{"id":"nct05839509-investigational-site-maastricht","cat":"research","name":"Investigational Site","city":"Maastricht","country":"Netherlands","cc":"NL","lat":50.84885,"lon":5.68,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Bipolar"],"nct":"NCT05839509","study":"Phase 2 Clinical Trial of GH001 in Bipolar II Disorder","sstatus":"TERMINATED","sponsor":"GH Research Ireland Limited","src":"https://clinicaltrials.gov/study/NCT05839509","phase":"Phase 2","enroll":6,"start":"2023-04-06","eid":"x:site:nct05839509-investigational-site-maastricht"},{"id":"nct05839509-investigational-site-london","cat":"research","name":"Investigational Site","city":"London","country":"United Kingdom","cc":"GB","lat":51.51771,"lon":-0.11826,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Bipolar"],"nct":"NCT05839509","study":"Phase 2 Clinical Trial of GH001 in Bipolar II Disorder","sstatus":"TERMINATED","sponsor":"GH Research Ireland Limited","src":"https://clinicaltrials.gov/study/NCT05839509","phase":"Phase 2","enroll":6,"start":"2023-04-06","eid":"x:site:nct05839509-investigational-site-london"},{"id":"nct05839509-investigation-site-oxford","cat":"research","name":"Investigation Site","city":"Oxford","country":"United Kingdom","cc":"GB","lat":51.76046,"lon":-1.25281,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Bipolar"],"nct":"NCT05839509","study":"Phase 2 Clinical Trial of GH001 in Bipolar II Disorder","sstatus":"TERMINATED","sponsor":"GH Research Ireland Limited","src":"https://clinicaltrials.gov/study/NCT05839509","phase":"Phase 2","enroll":6,"start":"2023-04-06","eid":"x:site:nct05839509-investigation-site-oxford"},{"id":"nct07540494-gh-research-clinical-trial-site-miami","cat":"research","name":"GH Research Clinical Trial Site","city":"Miami","region":"Florida","country":"United States","cc":"US","lat":25.77187,"lon":-80.18571,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"33319","condg":["Healthy volunteers"],"nct":"NCT07540494","study":"Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects","sstatus":"NOT_YET_RECRUITING","sponsor":"GH Research Ireland Limited","src":"https://clinicaltrials.gov/study/NCT07540494","contact":{"n":"GH Research Clinical Trial Site","p":"+353874503237","e":"clinicaltrials@ghres.com"},"phase":"Phase 1","enroll":12,"start":"2026-04","eid":"x:site:nct07540494-gh-research-clinical-trial-site-miami"},{"id":"nct05753956-gh-research-clinical-trial-site-groningen","cat":"research","name":"GH Research Clinical Trial Site","city":"Groningen","country":"Netherlands","cc":"NL","lat":53.22872,"lon":6.57001,"gp":"city","unnamed":0,"condg":["Healthy volunteers"],"nct":"NCT05753956","study":"Safety and Pharmacokinetics of GH002 in Healthy Volunteers","sstatus":"COMPLETED","sponsor":"GH Research Ireland Limited","src":"https://clinicaltrials.gov/study/NCT05753956","phase":"Phase 1","enroll":64,"start":"2022-12-22","eid":"x:site:nct05753956-gh-research-clinical-trial-site-groningen"},{"id":"nct06741228-lighthouse-psychiatry-gilbert","cat":"research","name":"Lighthouse Psychiatry","city":"Gilbert","region":"Arizona","country":"United States","cc":"US","lat":33.36238,"lon":-111.77957,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"85234","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-lighthouse-psychiatry-gilbert"},{"id":"nct06741228-scottsdale-research-institute-scottsdale","cat":"research","name":"Scottsdale Research Institute","city":"Scottsdale","region":"Arizona","country":"United States","cc":"US","lat":33.51575,"lon":-111.89804,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"85022","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-scottsdale-research-institute-scottsdale"},{"id":"nct06741228-kadima-neuropsychiatry-institute-la-jolla","cat":"research","name":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","cc":"US","lat":32.84628,"lon":-117.26945,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"92037","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-kadima-neuropsychiatry-institute-la-jolla"},{"id":"nct06741228-ucsf-department-of-neurology-san-francisco","cat":"research","name":"UCSF Department of Neurology","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.77949,"lon":-122.43123,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"94158","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-ucsf-department-of-neurology-san-francisco"},{"id":"nct06741228-psychedelic-science-institute-santa-monica","cat":"research","name":"Psychedelic Science Institute","city":"Santa Monica","region":"California","country":"United States","cc":"US","lat":34.01916,"lon":-118.49152,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"90404","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-psychedelic-science-institute-santa-monica"},{"id":"nct06741228-mountain-view-denver","cat":"research","name":"Mountain View","city":"Denver","region":"Colorado","country":"United States","cc":"US","lat":39.74823,"lon":-104.99312,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"80209","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-mountain-view-denver"},{"id":"nct06741228-clinical-neuroscience-solutions-inc-jacksonville","cat":"research","name":"Clinical Neuroscience Solutions Inc.","city":"Jacksonville","region":"Florida","country":"United States","cc":"US","lat":30.33307,"lon":-81.65937,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"32256","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-clinical-neuroscience-solutions-inc-jacksonville"},{"id":"nct06741228-segal-trials-lauderhill","cat":"research","name":"Segal Trials","city":"Lauderhill","region":"Florida","country":"United States","cc":"US","lat":26.1437,"lon":-80.22453,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"33319","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-segal-trials-lauderhill"},{"id":"nct06741228-atlanta-center-for-medical-research-atlanta","cat":"research","name":"Atlanta Center for Medical Research","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.75667,"lon":-84.39264,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"30331","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-atlanta-center-for-medical-research-atlanta"},{"id":"nct06741228-iresearch-atlanta-decatur","cat":"research","name":"iResearch Atlanta","city":"Decatur","region":"Georgia","country":"United States","cc":"US","lat":39.8381,"lon":-88.95438,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"30030","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-iresearch-atlanta-decatur"},{"id":"nct06741228-cenexel-iresearch-llc-savannah","cat":"research","name":"CenExel iResearch, LLC","city":"Savannah","region":"Georgia","country":"United States","cc":"US","lat":32.08688,"lon":-81.09225,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"31405","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-cenexel-iresearch-llc-savannah"},{"id":"nct06741228-uptown-research-institute-chicago","cat":"research","name":"Uptown Research Institute","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.84989,"lon":-87.65386,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"60640","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-uptown-research-institute-chicago"},{"id":"nct06741228-adams-clinical-boston-boston","cat":"research","name":"Adams Clinical Boston","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.35895,"lon":-71.05991,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"02116","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-adams-clinical-boston-boston"},{"id":"nct06741228-adams-clinical-watertown-watertown","cat":"research","name":"Adams Clinical Watertown","city":"Watertown","region":"Massachusetts","country":"United States","cc":"US","lat":42.36928,"lon":-71.17911,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"02472","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-adams-clinical-watertown-watertown"},{"id":"nct06741228-hassman-research-institute-marlton","cat":"research","name":"Hassman Research Institute","city":"Marlton","region":"New Jersey","country":"United States","cc":"US","lat":39.90237,"lon":-74.91359,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"08053","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-hassman-research-institute-marlton"},{"id":"nct06741228-spectrum-neuroscience-and-treatment-institute-new-york","cat":"research","name":"Spectrum Neuroscience and Treatment Institute","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72561,"lon":-73.9951,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"10021","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-spectrum-neuroscience-and-treatment-institute-new-york"},{"id":"nct06741228-adams-clinical-harlem-new-york","cat":"research","name":"Adams Clinical Harlem","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70293,"lon":-74.0143,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"10029","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-adams-clinical-harlem-new-york"},{"id":"nct06741228-new-york-state-psychiatric-institute-nyspi-new-york","cat":"research","name":"New York State Psychiatric Institute (NYSPI)","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71347,"lon":-74.01656,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"10032","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-new-york-state-psychiatric-institute-nyspi-new-york"},{"id":"nct06741228-adams-clinical-bronx-the-bronx","cat":"research","name":"Adams Clinical Bronx","city":"The Bronx","region":"New York","country":"United States","cc":"US","lat":40.84444,"lon":-73.8546,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"10461","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-adams-clinical-bronx-the-bronx"},{"id":"nct06741228-cleveland-clinic-lutheran-hospital-cleveland","cat":"research","name":"Cleveland Clinic Lutheran Hospital","city":"Cleveland","region":"Ohio","country":"United States","cc":"US","lat":41.50962,"lon":-81.68765,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"44113","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-cleveland-clinic-lutheran-hospital-cleveland"},{"id":"nct06741228-summit-headlands-llc-portland","cat":"research","name":"Summit Headlands LLC","city":"Portland","region":"Oregon","country":"United States","cc":"US","lat":45.52425,"lon":-122.67729,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"97210","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-summit-headlands-llc-portland"},{"id":"nct06741228-scranton-medical-institute-moosic","cat":"research","name":"Scranton Medical Institute","city":"Moosic","region":"Pennsylvania","country":"United States","cc":"US","lat":41.35195,"lon":-75.72681,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"18507","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-scranton-medical-institute-moosic"},{"id":"nct06741228-adams-clinical-philadelphia-philadelphia","cat":"research","name":"Adams Clinical Philadelphia","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.9432,"lon":-75.16894,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"19104","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-adams-clinical-philadelphia-philadelphia"},{"id":"nct06741228-coastal-carolina-research-center-north-charleston","cat":"research","name":"Coastal Carolina Research Center","city":"North Charleston","region":"South Carolina","country":"United States","cc":"US","lat":32.8462,"lon":-79.96921,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"29405","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-coastal-carolina-research-center-north-charleston"},{"id":"nct06741228-clinical-neuroscience-solutions-inc-memphis","cat":"research","name":"Clinical Neuroscience Solutions, Inc.","city":"Memphis","region":"Tennessee","country":"United States","cc":"US","lat":35.14233,"lon":-90.04187,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"38119","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-clinical-neuroscience-solutions-inc-memphis"},{"id":"nct06741228-university-of-texas-at-austin-austin","cat":"research","name":"University of Texas at Austin","city":"Austin","region":"Texas","country":"United States","cc":"US","lat":30.26682,"lon":-97.73859,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"78712","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-university-of-texas-at-austin-austin"},{"id":"nct06741228-austin-clinical-trial-partners-austin","cat":"research","name":"Austin Clinical Trial Partners","city":"Austin","region":"Texas","country":"United States","cc":"US","lat":30.27567,"lon":-97.74179,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"78737","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-austin-clinical-trial-partners-austin"},{"id":"nct06741228-biobehavioral-research-of-austin-austin","cat":"research","name":"BioBehavioral Research of Austin","city":"Austin","region":"Texas","country":"United States","cc":"US","lat":30.25929,"lon":-97.74574,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"78759","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-biobehavioral-research-of-austin-austin"},{"id":"nct06741228-futuresearch-trials-of-dallas-llc-dallas","cat":"research","name":"FutureSearch Trials of Dallas, LLC","city":"Dallas","region":"Texas","country":"United States","cc":"US","lat":32.79402,"lon":-96.79825,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"75231","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-futuresearch-trials-of-dallas-llc-dallas"},{"id":"nct06741228-adams-clinical-dallas-desoto","cat":"research","name":"Adams Clinical Dallas","city":"DeSoto","region":"Texas","country":"United States","cc":"US","lat":32.59113,"lon":-96.86208,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"75115","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-adams-clinical-dallas-desoto"},{"id":"nct06741228-cedar-clinical-research-draper","cat":"research","name":"Cedar Clinical Research","city":"Draper","region":"Utah","country":"United States","cc":"US","lat":40.52283,"lon":-111.8665,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"84020","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-cedar-clinical-research-draper"},{"id":"nct06741228-inner-space-research-orem","cat":"research","name":"Inner Space Research","city":"Orem","region":"Utah","country":"United States","cc":"US","lat":40.30081,"lon":-111.70552,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"84058","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-inner-space-research-orem"},{"id":"nct06741228-memory-clinic-inc-bennington","cat":"research","name":"Memory Clinic Inc.","city":"Bennington","region":"Vermont","country":"United States","cc":"US","lat":42.88552,"lon":-73.18609,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"05201","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-memory-clinic-inc-bennington"},{"id":"nct06741228-seattle-neuropsychiatric-treatment-center-seattle","cat":"research","name":"Seattle Neuropsychiatric Treatment Center","city":"Seattle","region":"Washington","country":"United States","cc":"US","lat":47.60165,"lon":-122.33174,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"98104","condg":["Anxiety"],"nct":"NCT06741228","study":"A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06741228","phase":"Phase 3","enroll":214,"start":"2024-12-11","eid":"x:site:nct06741228-seattle-neuropsychiatric-treatment-center-seattle"},{"id":"nct03790358-matthew-bona-chicago","cat":"research","name":"Matthew Bona","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.85638,"lon":-87.65791,"gp":"city","unnamed":0,"drugs":["LSD","MDMA"],"zip":"60637","condg":["Healthy volunteers"],"nct":"NCT03790358","study":"Mood Effects of Serotonin Agonists","sstatus":"COMPLETED","sponsor":"University of Chicago","src":"https://clinicaltrials.gov/study/NCT03790358","phase":"Phase 1","enroll":80,"start":"2018-05-01","eid":"x:site:nct03790358-matthew-bona-chicago"},{"id":"nct03790358-university-of-chicago-chicago","cat":"research","name":"University of Chicago","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.8609,"lon":-87.65471,"gp":"city","unnamed":0,"drugs":["LSD","MDMA"],"zip":"60637","condg":["Healthy volunteers"],"nct":"NCT03790358","study":"Mood Effects of Serotonin Agonists","sstatus":"COMPLETED","sponsor":"University of Chicago","src":"https://clinicaltrials.gov/study/NCT03790358","phase":"Phase 1","enroll":80,"start":"2018-05-01","eid":"x:site:nct03790358-university-of-chicago-chicago"},{"id":"nct04227756-university-hospital-basel-clinical-trial-unit-basel","cat":"research","name":"University Hospital Basel, Clinical Trial Unit","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","cc":"CH","lat":47.5622,"lon":7.56221,"gp":"city","unnamed":0,"drugs":["LSD","mescaline","psilocybin"],"zip":"4031","condg":["Healthy volunteers"],"nct":"NCT04227756","study":"Comparative Acute Effects of LSD, Psilocybin and Mescaline","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E. Liechti, Prof. (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT04227756","phase":"Phase 1","enroll":32,"start":"2020-05-19","eid":"x:site:nct04227756-university-hospital-basel-clinical-trial-unit-basel"},{"id":"nct02308969-university-hospital-basel","cat":"research","name":"University Hospital","city":"Basel","country":"Switzerland","cc":"CH","lat":47.55119,"lon":7.58358,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Healthy volunteers"],"nct":"NCT02308969","study":"Neuronal Correlates of Altered States of Consciousness","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, MD, MAS (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT02308969","phase":"EARLY_Phase 1","enroll":24,"start":"2014-12","eid":"x:site:nct02308969-university-hospital-basel"},{"id":"nct05177419-university-of-fribourg-fribourg","cat":"research","name":"University of Fribourg","city":"Fribourg","region":"Canton of Fribourg","country":"Switzerland","cc":"CH","lat":46.79197,"lon":7.14257,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"1752","condg":["Healthy volunteers"],"nct":"NCT05177419","study":"Effects of LSD on Neuroplasticity in Healthy Subjects","sstatus":"COMPLETED","sponsor":"University of Fribourg","src":"https://clinicaltrials.gov/study/NCT05177419","phase":"Phase 1","enroll":45,"start":"2022-05-02","eid":"x:site:nct05177419-university-of-fribourg-fribourg"},{"id":"nct03019822-university-hospital-basel-basel","cat":"research","name":"University Hospital Basel","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","cc":"CH","lat":47.55015,"lon":7.56965,"gp":"city","unnamed":0,"drugs":["LSD","MDMA"],"zip":"4031","condg":["Healthy volunteers"],"nct":"NCT03019822","study":"Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, MD, MAS (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT03019822","phase":"EARLY_Phase 1","enroll":28,"start":"2017-02-01","eid":"x:site:nct03019822-university-hospital-basel-basel"},{"id":"nct02060526-los-angeles-biomedical-research-torrance","cat":"research","name":"Los Angeles Biomedical Research","city":"Torrance","region":"California","country":"United States","cc":"US","lat":33.84164,"lon":-118.3323,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"90502","condg":["Other"],"nct":"NCT02060526","study":"Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease","sstatus":"COMPLETED","sponsor":"Shire","official":"Study Director (Takeda)","src":"https://clinicaltrials.gov/study/NCT02060526","phase":"Phase 2","enroll":21,"start":"2014-02-26","eid":"x:site:nct02060526-los-angeles-biomedical-research-torrance"},{"id":"nct02060526-university-of-minnesota-department-of-pediatrics-minneapolis","cat":"research","name":"University of Minnesota Department of Pediatrics","city":"Minneapolis","region":"Minnesota","country":"United States","cc":"US","lat":44.98971,"lon":-93.25419,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"55455","condg":["Other"],"nct":"NCT02060526","study":"Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease","sstatus":"COMPLETED","sponsor":"Shire","official":"Study Director (Takeda)","src":"https://clinicaltrials.gov/study/NCT02060526","phase":"Phase 2","enroll":21,"start":"2014-02-26","eid":"x:site:nct02060526-university-of-minnesota-department-of-pediatrics-minneapolis"},{"id":"nct02060526-university-of-north-carolina-chapel-hill","cat":"research","name":"University of North Carolina","city":"Chapel Hill","region":"North Carolina","country":"United States","cc":"US","lat":35.91447,"lon":-79.04516,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"27514","condg":["Other"],"nct":"NCT02060526","study":"Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease","sstatus":"COMPLETED","sponsor":"Shire","official":"Study Director (Takeda)","src":"https://clinicaltrials.gov/study/NCT02060526","phase":"Phase 2","enroll":21,"start":"2014-02-26","eid":"x:site:nct02060526-university-of-north-carolina-chapel-hill"},{"id":"nct02060526-hospital-universitario-austral-a-unidad-de-investigacion-buenos-aire","cat":"research","name":"Hospital Universitario Austral A Unidad de Investigacion","city":"Buenos Aires","country":"Argentina","cc":"AR","lat":-34.62214,"lon":-58.37502,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Other"],"nct":"NCT02060526","study":"Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease","sstatus":"COMPLETED","sponsor":"Shire","official":"Study Director (Takeda)","src":"https://clinicaltrials.gov/study/NCT02060526","phase":"Phase 2","enroll":21,"start":"2014-02-26","eid":"x:site:nct02060526-hospital-universitario-austral-a-unidad-de-investigacion-buenos-aire"},{"id":"nct02060526-chu-bicetre-le-kremlin-bicetre","cat":"research","name":"Chu Bicetre","city":"Le Kremlin-Bicêtre","region":"Paris","country":"France","cc":"FR","lat":48.82417,"lon":2.35466,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"94270","condg":["Other"],"nct":"NCT02060526","study":"Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease","sstatus":"COMPLETED","sponsor":"Shire","official":"Study Director (Takeda)","src":"https://clinicaltrials.gov/study/NCT02060526","phase":"Phase 2","enroll":21,"start":"2014-02-26","eid":"x:site:nct02060526-chu-bicetre-le-kremlin-bicetre"},{"id":"nct02060526-universitatsklinikum-hamburg-eppendorf-hamburg","cat":"research","name":"Universitätsklinikum Hamburg Eppendorf","city":"Hamburg","country":"Germany","cc":"DE","lat":53.54362,"lon":9.99438,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"20246","condg":["Other"],"nct":"NCT02060526","study":"Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease","sstatus":"COMPLETED","sponsor":"Shire","official":"Study Director (Takeda)","src":"https://clinicaltrials.gov/study/NCT02060526","phase":"Phase 2","enroll":21,"start":"2014-02-26","eid":"x:site:nct02060526-universitatsklinikum-hamburg-eppendorf-hamburg"},{"id":"nct02060526-u-o-s-malattie-metaboliche-rare-clinical-pediatrica-monza","cat":"research","name":"U.O.S Malattie Metaboliche Rare Clinical Pediatrica","city":"Monza","country":"Italy","cc":"IT","lat":45.58913,"lon":9.26959,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Other"],"nct":"NCT02060526","study":"Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease","sstatus":"COMPLETED","sponsor":"Shire","official":"Study Director (Takeda)","src":"https://clinicaltrials.gov/study/NCT02060526","phase":"Phase 2","enroll":21,"start":"2014-02-26","eid":"x:site:nct02060526-u-o-s-malattie-metaboliche-rare-clinical-pediatrica-monza"},{"id":"nct02060526-academisch-medisch-centrum-amsterdam","cat":"research","name":"Academisch Medisch Centrum","city":"Amsterdam","country":"Netherlands","cc":"NL","lat":52.37464,"lon":4.8856,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"22660","condg":["Other"],"nct":"NCT02060526","study":"Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease","sstatus":"COMPLETED","sponsor":"Shire","official":"Study Director (Takeda)","src":"https://clinicaltrials.gov/study/NCT02060526","phase":"Phase 2","enroll":21,"start":"2014-02-26","eid":"x:site:nct02060526-academisch-medisch-centrum-amsterdam"},{"id":"nct02060526-hospital-vall-d-hebron-barcelona","cat":"research","name":"Hospital Vall D'Hebron","city":"Barcelona","country":"Spain","cc":"ES","lat":41.38639,"lon":2.14868,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"08035","condg":["Other"],"nct":"NCT02060526","study":"Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease","sstatus":"COMPLETED","sponsor":"Shire","official":"Study Director (Takeda)","src":"https://clinicaltrials.gov/study/NCT02060526","phase":"Phase 2","enroll":21,"start":"2014-02-26","eid":"x:site:nct02060526-hospital-vall-d-hebron-barcelona"},{"id":"nct02060526-great-ormond-street-hospital-london","cat":"research","name":"Great Ormond Street Hospital","city":"London","country":"United Kingdom","cc":"GB","lat":51.51432,"lon":-0.12362,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"WC1N 3JH","condg":["Other"],"nct":"NCT02060526","study":"Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease","sstatus":"COMPLETED","sponsor":"Shire","official":"Study Director (Takeda)","src":"https://clinicaltrials.gov/study/NCT02060526","phase":"Phase 2","enroll":21,"start":"2014-02-26","eid":"x:site:nct02060526-great-ormond-street-hospital-london"},{"id":"nct05175430-clinical-pharmacology-toxicology-university-hospital-basel-basel","cat":"research","name":"Clinical Pharmacology & Toxicology, University Hospital Basel","city":"Basel","country":"Switzerland","cc":"CH","lat":47.56305,"lon":7.58508,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"4031","condg":["Healthy volunteers"],"nct":"NCT05175430","study":"Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, Dr., MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT05175430","phase":"Phase 1","enroll":24,"start":"2022-10-24","eid":"x:site:nct05175430-clinical-pharmacology-toxicology-university-hospital-basel-basel"},{"id":"nct02741622-st-olavs-university-hospital-departement-of-stmarka-trondheim","cat":"research","name":"St.Olavs university Hospital, Departement of Østmarka","city":"Trondheim","country":"Norway","cc":"NO","lat":63.4216,"lon":10.38541,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Depression"],"nct":"NCT02741622","study":"Brain Derived Neurotropic Factor Response to Aerobic Exercise Intensity in Depressive Patients.","sstatus":"COMPLETED","sponsor":"St. Olavs Hospital","official":"Pål Sandvik, MD (St.Olavs University Hospital, Østmarka)","src":"https://clinicaltrials.gov/study/NCT02741622","phase":"N/A","enroll":21,"start":"2016-03","eid":"x:site:nct02741622-st-olavs-university-hospital-departement-of-stmarka-trondheim"},{"id":"nct01697319-children-s-hospital-research-center-oakland-oakland","cat":"research","name":"Children's Hospital & Research Center Oakland","city":"Oakland","region":"California","country":"United States","cc":"US","lat":37.80592,"lon":-122.27198,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01697319","study":"Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, M.D. (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01697319","phase":"Phase 2","enroll":16,"start":"2012-08","eid":"x:site:nct01697319-children-s-hospital-research-center-oakland-oakland"},{"id":"nct01697319-ann-robert-h-lurie-children-s-hospital-of-chicago-chicago","cat":"research","name":"Ann & Robert H. Lurie Children's Hospital of Chicago","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.8481,"lon":-87.658,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01697319","study":"Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, M.D. (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01697319","phase":"Phase 2","enroll":16,"start":"2012-08","eid":"x:site:nct01697319-ann-robert-h-lurie-children-s-hospital-of-chicago-chicago"},{"id":"nct01697319-universitatsklinikum-hamburg-hamburg","cat":"research","name":"Universitätsklinikum Hamburg","city":"Hamburg","country":"Germany","cc":"DE","lat":53.54984,"lon":9.98742,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01697319","study":"Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, M.D. (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01697319","phase":"Phase 2","enroll":16,"start":"2012-08","eid":"x:site:nct01697319-universitatsklinikum-hamburg-hamburg"},{"id":"nct01697319-university-medical-center-mainz-center-of-pediatric-and-adolescent-m","cat":"research","name":"University Medical Center Mainz, Center of Pediatric and Adolescent Medicine Villa Metabolica","city":"Mainz","country":"Germany","cc":"DE","lat":49.98867,"lon":8.28342,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01697319","study":"Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, M.D. (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01697319","phase":"Phase 2","enroll":16,"start":"2012-08","eid":"x:site:nct01697319-university-medical-center-mainz-center-of-pediatric-and-adolescent-m"},{"id":"nct01697319-nihr-wellcome-trust-birmingham-crf-queen-elizabeth-hospital-birmingh","cat":"research","name":"NIHR/Wellcome Trust Birmingham CRF, Queen Elizabeth Hospital","city":"Birmingham","country":"United Kingdom","cc":"GB","lat":52.47864,"lon":-1.89856,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01697319","study":"Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, M.D. (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01697319","phase":"Phase 2","enroll":16,"start":"2012-08","eid":"x:site:nct01697319-nihr-wellcome-trust-birmingham-crf-queen-elizabeth-hospital-birmingh"},{"id":"nct01697319-central-manchester-university-hospitals-nhs-foundation-trust-manches","cat":"research","name":"Central Manchester University Hospitals NHS Foundation Trust","city":"Manchester","country":"United Kingdom","cc":"GB","lat":53.48664,"lon":-2.23635,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01697319","study":"Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, M.D. (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01697319","phase":"Phase 2","enroll":16,"start":"2012-08","eid":"x:site:nct01697319-central-manchester-university-hospitals-nhs-foundation-trust-manches"},{"id":"nct01697319-salford-royal-nhs-foundation-trust-salford","cat":"research","name":"Salford Royal NHS Foundation Trust","city":"Salford","country":"United Kingdom","cc":"GB","lat":53.49896,"lon":-2.2803,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01697319","study":"Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, M.D. (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01697319","phase":"Phase 2","enroll":16,"start":"2012-08","eid":"x:site:nct01697319-salford-royal-nhs-foundation-trust-salford"},{"id":"nct00736307-royan-institute-tehran","cat":"research","name":"Royan Institute","city":"Tehran","region":"Tehran Province","country":"Iran","cc":"IR","lat":35.68625,"lon":51.4129,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"1665659911","condg":["Other"],"nct":"NCT00736307","study":"Autologous Transplantation of Cultivated Limbal Stem Cells on Amniotic Membrane in Limbal Stem Cell Deficiency (LSD) Patients","sstatus":"COMPLETED","sponsor":"Royan Institute","official":"Hamid Gorabi, PhD (Royan institute, Tehran, Iran); Mohammadali Javadi, MD (Labbafinejad Ophthalmic Research Center, Tehran, Iran)","src":"https://clinicaltrials.gov/study/NCT00736307","phase":"Phase 1/Phase 2","enroll":10,"start":"2007-10","eid":"x:site:nct00736307-royan-institute-tehran"},{"id":"nct00736307-labbafinejad-ophthalmic-research-center-tehran","cat":"research","name":"Labbafinejad Ophthalmic Research Center","city":"Tehran","region":"Tehran Province","country":"Iran","cc":"IR","lat":35.69641,"lon":51.42495,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"16666","condg":["Other"],"nct":"NCT00736307","study":"Autologous Transplantation of Cultivated Limbal Stem Cells on Amniotic Membrane in Limbal Stem Cell Deficiency (LSD) Patients","sstatus":"COMPLETED","sponsor":"Royan Institute","official":"Hamid Gorabi, PhD (Royan institute, Tehran, Iran); Mohammadali Javadi, MD (Labbafinejad Ophthalmic Research Center, Tehran, Iran)","src":"https://clinicaltrials.gov/study/NCT00736307","phase":"Phase 1/Phase 2","enroll":10,"start":"2007-10","eid":"x:site:nct00736307-labbafinejad-ophthalmic-research-center-tehran"},{"id":"nct03812055-ldrtc-fairfax","cat":"research","name":"LDRTC","city":"Fairfax","region":"Virginia","country":"United States","cc":"US","lat":38.83563,"lon":-77.3131,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"22030","condg":["Other"],"status":"RECRUITING","nct":"NCT03812055","study":"Cellular Pharmacodynamics of Small Molecules in Lysosomal Storage Disorders","sstatus":"UNKNOWN","sponsor":"Lysosomal and Rare Disorders Research and Treatment Center, Inc.","official":"Margarita M Ivanova, PhD (LDRTC); Ozlem Goker-Alpan, MD (LDRTC)","src":"https://clinicaltrials.gov/study/NCT03812055","contact":{"n":"Margarita Ivanova, PhD","p":"703-261-6220","e":"mivanova@ldrtc.org"},"enroll":50,"start":"2018-07-06","eid":"x:site:nct03812055-ldrtc-fairfax"},{"id":"nct04488874-chu-de-besancon-besancon","cat":"research","name":"CHU de Besançon","city":"Besançon","country":"France","cc":"FR","lat":47.26069,"lon":6.02591,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Other"],"nct":"NCT04488874","study":"Sodium Lactate and Brain Relaxation (LSD)","sstatus":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","src":"https://clinicaltrials.gov/study/NCT04488874","phase":"Phase 3","enroll":50,"start":"2020-09-29","eid":"x:site:nct04488874-chu-de-besancon-besancon"},{"id":"nct05477459-leiden-university-medical-center-lumc-leiden","cat":"research","name":"Leiden University Medical Center (LUMC)","city":"Leiden","country":"Netherlands","cc":"NL","lat":52.15527,"lon":4.48859,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT05477459","study":"LSD to Improve Cluster Headache Impact Trial","sstatus":"RECRUITING","sponsor":"Radboud University Medical Center","official":"Kees Kramers, Prof. (Radboud University Medical Center)","src":"https://clinicaltrials.gov/study/NCT05477459","contact":{"n":"Martien van Liefland","p":"071 526 21 11","e":"LICIT@LUMC.nl"},"phase":"Phase 2","enroll":65,"start":"2025-04-16","eid":"x:site:nct05477459-leiden-university-medical-center-lumc-leiden"},{"id":"nct05477459-canisius-wilhelmina-ziekenhuis-cwz-nijmegen","cat":"research","name":"Canisius-Wilhelmina Ziekenhuis (CWZ)","city":"Nijmegen","country":"Netherlands","cc":"NL","lat":51.83408,"lon":5.84097,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT05477459","study":"LSD to Improve Cluster Headache Impact Trial","sstatus":"RECRUITING","sponsor":"Radboud University Medical Center","official":"Kees Kramers, Prof. (Radboud University Medical Center)","src":"https://clinicaltrials.gov/study/NCT05477459","contact":{"n":"Julia Jansen","p":"024 365 82 10","e":"LICIT@cwz.nl"},"phase":"Phase 2","enroll":65,"start":"2025-04-16","eid":"x:site:nct05477459-canisius-wilhelmina-ziekenhuis-cwz-nijmegen"},{"id":"nct06557239-geneva-university-hospitals-geneva","cat":"research","name":"Geneva University Hospitals","city":"Geneva","country":"Switzerland","cc":"CH","lat":46.20142,"lon":6.14913,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Depression","Anxiety"],"nct":"NCT06557239","study":"Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy","sstatus":"COMPLETED","sponsor":"Tatiana Aboulafia Brakha","src":"https://clinicaltrials.gov/study/NCT06557239","enroll":10,"start":"2024-08-05","eid":"x:site:nct06557239-geneva-university-hospitals-geneva"},{"id":"nct01275066-unnamed-trial-site-oakland","cat":"research","name":"Unnamed trial site","city":"Oakland","region":"California","country":"United States","cc":"US","lat":37.81449,"lon":-122.25889,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-oakland"},{"id":"nct01275066-unnamed-trial-site-wilmington","cat":"research","name":"Unnamed trial site","city":"Wilmington","region":"Delaware","country":"United States","cc":"US","lat":34.2358,"lon":-77.94364,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-wilmington"},{"id":"nct01275066-unnamed-trial-site-washington-d-c","cat":"research","name":"Unnamed trial site","city":"Washington D.C.","region":"District of Columbia","country":"United States","cc":"US","lat":38.88584,"lon":-77.02955,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-washington-d-c"},{"id":"nct01275066-unnamed-trial-site-chicago","cat":"research","name":"Unnamed trial site","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.84274,"lon":-87.64257,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-chicago"},{"id":"nct01275066-unnamed-trial-site-new-york","cat":"research","name":"Unnamed trial site","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71836,"lon":-74.00508,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-new-york"},{"id":"nct01275066-unnamed-trial-site-seattle","cat":"research","name":"Unnamed trial site","city":"Seattle","region":"Washington","country":"United States","cc":"US","lat":47.61379,"lon":-122.34031,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-seattle"},{"id":"nct01275066-unnamed-trial-site-cordoba","cat":"research","name":"Unnamed trial site","city":"Córdoba","country":"Argentina","cc":"AR","lat":-31.4006,"lon":-64.20015,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-cordoba"},{"id":"nct01275066-unnamed-trial-site-campina-grande","cat":"research","name":"Unnamed trial site","city":"Campina Grande","country":"Brazil","cc":"BR","lat":-7.22364,"lon":-35.88106,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-campina-grande"},{"id":"nct01275066-unnamed-trial-site-porto-alegre","cat":"research","name":"Unnamed trial site","city":"Porto Alegre","country":"Brazil","cc":"BR","lat":-30.03645,"lon":-51.24181,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-porto-alegre"},{"id":"nct01275066-unnamed-trial-site-montreal","cat":"research","name":"Unnamed trial site","city":"Montreal","country":"Canada","cc":"CA","lat":45.51369,"lon":-73.5888,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-montreal"},{"id":"nct01275066-unnamed-trial-site-sherbrooke","cat":"research","name":"Unnamed trial site","city":"Sherbrooke","country":"Canada","cc":"CA","lat":45.39297,"lon":-71.88953,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-sherbrooke"},{"id":"nct01275066-unnamed-trial-site-toronto","cat":"research","name":"Unnamed trial site","city":"Toronto","country":"Canada","cc":"CA","lat":43.71259,"lon":-79.40123,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-toronto"},{"id":"nct01275066-unnamed-trial-site-bogota","cat":"research","name":"Unnamed trial site","city":"Bogotá","country":"Colombia","cc":"CO","lat":4.60383,"lon":-74.07794,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-bogota"},{"id":"nct01275066-unnamed-trial-site-copenhagen","cat":"research","name":"Unnamed trial site","city":"Copenhagen","country":"Denmark","cc":"DK","lat":55.67721,"lon":12.57151,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-copenhagen"},{"id":"nct01275066-unnamed-trial-site-lyon","cat":"research","name":"Unnamed trial site","city":"Lyon","country":"France","cc":"FR","lat":45.74845,"lon":4.84389,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-lyon"},{"id":"nct01275066-unnamed-trial-site-paris","cat":"research","name":"Unnamed trial site","city":"Paris","country":"France","cc":"FR","lat":48.84772,"lon":2.35751,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-paris"},{"id":"nct01275066-unnamed-trial-site-mainz","cat":"research","name":"Unnamed trial site","city":"Mainz","country":"Germany","cc":"DE","lat":49.97164,"lon":8.27344,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-mainz"},{"id":"nct01275066-unnamed-trial-site-monza","cat":"research","name":"Unnamed trial site","city":"Monza","country":"Italy","cc":"IT","lat":45.58433,"lon":9.26422,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-monza"},{"id":"nct01275066-unnamed-trial-site-tokyo","cat":"research","name":"Unnamed trial site","city":"Tokyo","country":"Japan","cc":"JP","lat":35.67778,"lon":139.6831,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-tokyo"},{"id":"nct01275066-unnamed-trial-site-amsterdam","cat":"research","name":"Unnamed trial site","city":"Amsterdam","country":"Netherlands","cc":"NL","lat":52.37671,"lon":4.9,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-amsterdam"},{"id":"nct01275066-unnamed-trial-site-coimbra","cat":"research","name":"Unnamed trial site","city":"Coimbra","country":"Portugal","cc":"PT","lat":40.21302,"lon":-8.41408,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-coimbra"},{"id":"nct01275066-unnamed-trial-site-doha","cat":"research","name":"Unnamed trial site","city":"Doha","country":"Qatar","cc":"QA","lat":25.27383,"lon":51.51981,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-doha"},{"id":"nct01275066-unnamed-trial-site-riyadh","cat":"research","name":"Unnamed trial site","city":"Riyadh","country":"Saudi Arabia","cc":"SA","lat":24.68947,"lon":46.73197,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-riyadh"},{"id":"nct01275066-unnamed-trial-site-seoul","cat":"research","name":"Unnamed trial site","city":"Seoul","country":"South Korea","cc":"KR","lat":37.55494,"lon":126.97769,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-seoul"},{"id":"nct01275066-unnamed-trial-site-taipei","cat":"research","name":"Unnamed trial site","city":"Taipei","country":"Taiwan","cc":"TW","lat":25.06242,"lon":121.52371,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-taipei"},{"id":"nct01275066-unnamed-trial-site-birmingham","cat":"research","name":"Unnamed trial site","city":"Birmingham","country":"United Kingdom","cc":"GB","lat":52.48843,"lon":-1.89536,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-birmingham"},{"id":"nct01275066-unnamed-trial-site-london","cat":"research","name":"Unnamed trial site","city":"London","country":"United Kingdom","cc":"GB","lat":51.50434,"lon":-0.13313,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-london"},{"id":"nct01275066-unnamed-trial-site-manchester","cat":"research","name":"Unnamed trial site","city":"Manchester","country":"United Kingdom","cc":"GB","lat":53.48994,"lon":-2.22948,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01275066","study":"A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01275066","phase":"Phase 3","enroll":177,"start":"2011-02","eid":"x:site:nct01275066-unnamed-trial-site-manchester"},{"id":"nct07592689-preferred-research-partners-inc-little-rock","cat":"research","name":"Preferred Research Partners, Inc.","city":"Little Rock","region":"Arkansas","country":"United States","cc":"US","lat":34.73919,"lon":-92.28531,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"72211","condg":["Depression"],"status":"RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Stacy Tierney","p":"501-553-9987","e":"stierney@preferredresearchpartners.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-preferred-research-partners-inc-little-rock"},{"id":"nct07592689-atp-clinical-research-orange-county-orange","cat":"research","name":"ATP Clinical Research Orange County","city":"Orange","region":"California","country":"United States","cc":"US","lat":33.78539,"lon":-117.85222,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"92866","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Raissa Rebollar","p":"949-354-5353","e":"raissar@pnsoc.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-atp-clinical-research-orange-county-orange"},{"id":"nct07592689-kadima-neuropsychiatry-institute-san-diego","cat":"research","name":"Kadima Neuropsychiatry Institute","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.71425,"lon":-117.16025,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"92037","condg":["Depression"],"status":"RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Alexiss Rivas","p":"858-412-4130","e":"alexissr@kadimanp.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-kadima-neuropsychiatry-institute-san-diego"},{"id":"nct07592689-ucsf-department-of-neurology-san-francisco","cat":"research","name":"UCSF Department of Neurology","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.78222,"lon":-122.41815,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"94158","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Jennifer Mitchell","p":"510-985-3522","e":"LSDForDepression@ucsf.edu"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-ucsf-department-of-neurology-san-francisco"},{"id":"nct07592689-psychedelic-science-institute-santa-monica","cat":"research","name":"Psychedelic Science Institute","city":"Santa Monica","region":"California","country":"United States","cc":"US","lat":34.02104,"lon":-118.48842,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"90404","condg":["Depression"],"status":"RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Ashley Ramos","p":"310-378-0303","e":"trialadmin@psychedelicsci.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-psychedelic-science-institute-santa-monica"},{"id":"nct07592689-mountain-view-clinical-research-inc-denver","cat":"research","name":"Mountain View Clinical Research, Inc","city":"Denver","region":"Colorado","country":"United States","cc":"US","lat":39.73844,"lon":-104.97797,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"80209","condg":["Depression"],"status":"RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Jessica Bryant","p":"720-941-8894","e":"jessica@mtnresearch.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-mountain-view-clinical-research-inc-denver"},{"id":"nct07592689-clinical-neuroscience-solutions-llc-jacksonville-jacksonville","cat":"research","name":"Clinical Neuroscience Solutions, LLC (Jacksonville)","city":"Jacksonville","region":"Florida","country":"United States","cc":"US","lat":30.33317,"lon":-81.65184,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"32256","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Susan Angel","p":"904-218-5757","e":"sangel@cnshealthcare.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-clinical-neuroscience-solutions-llc-jacksonville-jacksonville"},{"id":"nct07592689-k2-medical-research-maitland-maitland","cat":"research","name":"K2 Medical Research (Maitland)","city":"Maitland","region":"Florida","country":"United States","cc":"US","lat":28.61587,"lon":-81.36288,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"32751","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Vanessa Carrillo","p":"407-676-5252","e":"vanessa.carrillo@k2med.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-k2-medical-research-maitland-maitland"},{"id":"nct07592689-clinical-neuroscience-solutions-llc-orlando-orlando","cat":"research","name":"Clinical Neuroscience Solutions, LLC (Orlando)","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.52935,"lon":-81.3838,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"32801","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Chanel Adams","p":"407-425-5100","e":"cadams@cnshealthcare.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-clinical-neuroscience-solutions-llc-orlando-orlando"},{"id":"nct07592689-charter-research-orlando","cat":"research","name":"Charter Research","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.53698,"lon":-81.3774,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"32803","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Sarahi Monsalve","p":"407-337-1000","e":"sarahi.monsalve@charterresearch.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-charter-research-orlando"},{"id":"nct07592689-k2-medical-research-tampa-tampa","cat":"research","name":"K2 Medical Research (Tampa)","city":"Tampa","region":"Florida","country":"United States","cc":"US","lat":27.95698,"lon":-82.45594,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"33607","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Karina Perez","p":"813-800-5252","e":"karina.perez@k2med.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-k2-medical-research-tampa-tampa"},{"id":"nct07592689-cenexel-atlanta-center-for-medical-research-atlanta","cat":"research","name":"CenExel - Atlanta Center for Medical Research","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.74105,"lon":-84.3981,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"30331","condg":["Depression"],"status":"RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Denniel Brown","p":"404-881-5800","e":"d.brown@cenexel.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-cenexel-atlanta-center-for-medical-research-atlanta"},{"id":"nct07592689-cenexel-iresearch-atlanta-decatur","cat":"research","name":"CenExel - iResearch Atlanta","city":"Decatur","region":"Georgia","country":"United States","cc":"US","lat":39.84252,"lon":-88.96388,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"30030","condg":["Depression"],"status":"RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Branden Freeman","p":"404-537-1281","e":"b.freeman@cenexel.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-cenexel-iresearch-atlanta-decatur"},{"id":"nct07592689-cenexel-iresearch-savannah-savannah","cat":"research","name":"CenExel - iResearch Savannah","city":"Savannah","region":"Georgia","country":"United States","cc":"US","lat":32.09479,"lon":-81.11089,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"31405","condg":["Depression"],"status":"RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Katie McCants","p":"912-744-0800","e":"k.mccants@cenexel.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-cenexel-iresearch-savannah-savannah"},{"id":"nct07592689-uptown-research-institute-chicago","cat":"research","name":"Uptown Research Institute","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.85676,"lon":-87.63937,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"60640","condg":["Depression"],"status":"RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Chloe Rzeppa","p":"773-989-8313","e":"crzeppa@uptownresearch.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-uptown-research-institute-chicago"},{"id":"nct07592689-adams-clinical-boston-boston","cat":"research","name":"Adams Clinical Boston","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.35264,"lon":-71.06913,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"02116","condg":["Depression"],"status":"RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Anotida Viazhero","p":"617-934-5743","e":"aviazhero@adamsclinical.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-adams-clinical-boston-boston"},{"id":"nct07592689-adams-clinical-watertown-boston","cat":"research","name":"Adams Clinical Watertown","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36469,"lon":-71.06179,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"02472","condg":["Depression"],"status":"RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Harrison Gillman","p":"617-744-8542","e":"hgillman@adamsclinical.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-adams-clinical-watertown-boston"},{"id":"nct07592689-vitalix-clinical-worcester","cat":"research","name":"Vitalix Clinical","city":"Worcester","region":"Massachusetts","country":"United States","cc":"US","lat":42.26057,"lon":-71.79773,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"01608","condg":["Depression"],"status":"RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Rajvi Patel","p":"413-363-5206","e":"rpatel@vitalixclinical.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-vitalix-clinical-worcester"},{"id":"nct07592689-arch-clinical-trials-llc-st-louis","cat":"research","name":"Arch Clinical Trials, LLC","city":"St Louis","region":"Missouri","country":"United States","cc":"US","lat":38.62195,"lon":-90.18937,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"63141","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Erica Ehrhardt","p":"314-282-3521","e":"eehrhardt@archclinicaltrials.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-arch-clinical-trials-llc-st-louis"},{"id":"nct07592689-redbird-research-las-vegas","cat":"research","name":"Redbird Research","city":"Las Vegas","region":"Nevada","country":"United States","cc":"US","lat":36.18208,"lon":-115.14244,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"89119","condg":["Depression"],"status":"RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Pam Pioquinto","p":"702-577-2000","e":"pamela@redbird-research.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-redbird-research-las-vegas"},{"id":"nct07592689-adams-clinical-harlem-new-york","cat":"research","name":"Adams Clinical Harlem","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71309,"lon":-74.01646,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"10029","condg":["Depression"],"status":"RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Ashli Pratt","p":"917-423-6797","e":"apratt@adamsclinical.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-adams-clinical-harlem-new-york"},{"id":"nct07592689-cleveland-clinic-cleveland","cat":"research","name":"Cleveland Clinic","city":"Cleveland","region":"Ohio","country":"United States","cc":"US","lat":41.50548,"lon":-81.68397,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"44113","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Katelyn Schwesinger","p":"440-728-6025","e":"schwesk@ccf.org"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-cleveland-clinic-cleveland"},{"id":"nct07592689-adams-clinical-philadelphia-philadelphia","cat":"research","name":"Adams Clinical Philadelphia","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.96099,"lon":-75.1584,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"19104","condg":["Depression"],"status":"RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Elizabeth Huang","p":"267-207-2511","e":"ehuang@adamsclinical.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-adams-clinical-philadelphia-philadelphia"},{"id":"nct07592689-coastal-carolina-research-north-charleston","cat":"research","name":"Coastal Carolina Research","city":"North Charleston","region":"South Carolina","country":"United States","cc":"US","lat":32.85871,"lon":-79.97043,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"29405","condg":["Depression"],"status":"RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Brandy Dreyer","p":"843-856-3784","e":"brandy.dreyer@coastalcarolinaresearch.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-coastal-carolina-research-north-charleston"},{"id":"nct07592689-austin-clinical-trial-partners-austin","cat":"research","name":"Austin Clinical Trial Partners","city":"Austin","region":"Texas","country":"United States","cc":"US","lat":30.26051,"lon":-97.74198,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"78737","condg":["Depression"],"status":"RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Cara Fonken","p":"512-521-0595","e":"cfonken@austinCTP.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-austin-clinical-trial-partners-austin"},{"id":"nct07592689-cedar-clinical-research-draper","cat":"research","name":"Cedar Clinical Research","city":"Draper","region":"Utah","country":"United States","cc":"US","lat":40.53291,"lon":-111.87356,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"84020","condg":["Depression"],"status":"RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Kye Cutrubus","p":"801-369-4219","e":"kye.cutrubus@numinusnetwork.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-cedar-clinical-research-draper"},{"id":"nct07592689-inner-space-research-orem","cat":"research","name":"Inner Space Research","city":"Orem","region":"Utah","country":"United States","cc":"US","lat":40.30796,"lon":-111.70326,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"84058","condg":["Depression"],"status":"RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Yohan Paitrault","p":"801-871-5516","e":"yohan@innerspaceresearch.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-inner-space-research-orem"},{"id":"nct07592689-memory-clinic-inc-bennington","cat":"research","name":"Memory Clinic Inc.","city":"Bennington","region":"Vermont","country":"United States","cc":"US","lat":42.87639,"lon":-73.19221,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"05201","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Cynthia Murphy, PhD","p":"413-281-0576","e":"research@memorydoc.org"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-memory-clinic-inc-bennington"},{"id":"nct07592689-seattle-neuropsychiatric-treatment-center-seattle","cat":"research","name":"Seattle Neuropsychiatric Treatment Center","city":"Seattle","region":"Washington","country":"United States","cc":"US","lat":47.60193,"lon":-122.34238,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"98104","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Libby Kell","p":"206-467-6300","e":"libby.kell@seattlentc.com"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-seattle-neuropsychiatric-treatment-center-seattle"},{"id":"nct07592689-va-portland-healthcare-system-vancouver","cat":"research","name":"VA Portland Healthcare System","city":"Vancouver","region":"Washington","country":"United States","cc":"US","lat":45.64602,"lon":-122.6557,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"98661","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT07592689","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07592689","contact":{"n":"Bianca Watt","p":"503-781-1205","e":"bianca.watt@va.gov"},"phase":"Phase 3","enroll":165,"start":"2026-05-10","eid":"x:site:nct07592689-va-portland-healthcare-system-vancouver"},{"id":"nct05976698-university-psychiatric-clinics-basel-basel","cat":"research","name":"University Psychiatric Clinics Basel","city":"Basel","country":"Switzerland","cc":"CH","lat":47.55938,"lon":7.57548,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"4002","condg":["Other"],"nct":"NCT05976698","study":"LSD-Perceptual-Choice-Study","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Philipp Sterzer, Prof. Dr. (University Psychiatric Clinics Basel)","src":"https://clinicaltrials.gov/study/NCT05976698","phase":"N/A","enroll":30,"start":"2024-02-26","eid":"x:site:nct05976698-university-psychiatric-clinics-basel-basel"},{"id":"nct00566098-sidney-kimmel-comprehensive-cancer-center-at-johns-hopkins-baltimore","cat":"research","name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.30172,"lon":-76.62155,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"21231-2410","condg":["Cancer-related distress"],"nct":"NCT00566098","study":"Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma","sstatus":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","official":"Ivan Borrello, MD (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins)","src":"https://clinicaltrials.gov/study/NCT00566098","phase":"Phase 1/Phase 2","enroll":26,"start":"2007-11","eid":"x:site:nct00566098-sidney-kimmel-comprehensive-cancer-center-at-johns-hopkins-baltimore"},{"id":"nct04865653-clinical-pharmacology-toxicology-university-hospital-basel-basel","cat":"research","name":"Clinical Pharmacology & Toxicology, University Hospital Basel","city":"Basel","country":"Switzerland","cc":"CH","lat":47.55411,"lon":7.56494,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"4031","condg":["Healthy volunteers"],"nct":"NCT04865653","study":"LSD Base and LSD Tartrate Bioequivalence and Bioavailability in Healthy Subjects","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT04865653","phase":"Phase 1","enroll":20,"start":"2022-03-17","eid":"x:site:nct04865653-clinical-pharmacology-toxicology-university-hospital-basel-basel"},{"id":"nct00920387-private-practices-of-peter-gasser-md-solothurn","cat":"research","name":"Private Practices of Peter Gasser MD","city":"Solothurn","country":"Switzerland","cc":"CH","lat":47.21125,"lon":7.54293,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Anxiety"],"nct":"NCT00920387","study":"Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety","sstatus":"COMPLETED","sponsor":"Multidisciplinary Association for Psychedelic Studies","official":"Peter Gasser, MD (Private practices of Peter Gasser; Swiss Medical Association for Psycholytic Therapy (SAPT))","src":"https://clinicaltrials.gov/study/NCT00920387","phase":"Phase 2","enroll":12,"start":"2008-02","eid":"x:site:nct00920387-private-practices-of-peter-gasser-md-solothurn"},{"id":"nct06899334-university-hospital-basel","cat":"research","name":"University Hospital","city":"Basel","country":"Switzerland","cc":"CH","lat":47.551,"lon":7.57774,"gp":"city","unnamed":0,"drugs":["LSD","psilocybin"],"zip":"4056","condg":["Healthy volunteers"],"status":"RECRUITING","nct":"NCT06899334","study":"Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants","sstatus":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, Prof. Dr. MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT06899334","contact":{"n":"Matthias E Liechti, Prof. Dr. MD","p":"61 328 68 68","e":"matthias.liechti@usb.ch"},"phase":"Phase 1","enroll":24,"start":"2025-04-01","eid":"x:site:nct06899334-university-hospital-basel"},{"id":"nct02120235-o-o-alpan-llc-fairfax","cat":"research","name":"O&O Alpan, LLC","city":"Fairfax","region":"Virginia","country":"United States","cc":"US","lat":38.83883,"lon":-77.30275,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"22030","condg":["Other"],"status":"RECRUITING","nct":"NCT02120235","study":"Investigating Lysosomal Storage Diseases in Minority Groups","sstatus":"UNKNOWN","sponsor":"O & O Alpan LLC","src":"https://clinicaltrials.gov/study/NCT02120235","contact":{"n":"Ozlem Goker-Alpan, M.D.","p":"571-308-1900","e":"ogokeralpan@oandoalpan.com"},"enroll":20000,"start":"2014-02","eid":"x:site:nct02120235-o-o-alpan-llc-fairfax"},{"id":"nct01858103-unnamed-trial-site-birmingham","cat":"research","name":"Unnamed trial site","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.51873,"lon":-86.79416,"gp":"city","unnamed":1,"drugs":["LSD"],"zip":"35294","condg":["Other"],"nct":"NCT01858103","study":"BMN 110 US Expanded Access Program","sstatus":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","src":"https://clinicaltrials.gov/study/NCT01858103","eid":"x:site:nct01858103-unnamed-trial-site-birmingham"},{"id":"nct01858103-unnamed-trial-site-little-rock","cat":"research","name":"Unnamed trial site","city":"Little Rock","region":"Arkansas","country":"United States","cc":"US","lat":34.74173,"lon":-92.28239,"gp":"city","unnamed":1,"drugs":["LSD"],"zip":"72202","condg":["Other"],"nct":"NCT01858103","study":"BMN 110 US Expanded Access Program","sstatus":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","src":"https://clinicaltrials.gov/study/NCT01858103","eid":"x:site:nct01858103-unnamed-trial-site-little-rock"},{"id":"nct01858103-unnamed-trial-site-oakland","cat":"research","name":"Unnamed trial site","city":"Oakland","region":"California","country":"United States","cc":"US","lat":37.79604,"lon":-122.26859,"gp":"city","unnamed":1,"drugs":["LSD"],"zip":"94609","condg":["Other"],"nct":"NCT01858103","study":"BMN 110 US Expanded Access Program","sstatus":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","src":"https://clinicaltrials.gov/study/NCT01858103","eid":"x:site:nct01858103-unnamed-trial-site-oakland"},{"id":"nct01858103-unnamed-trial-site-orange","cat":"research","name":"Unnamed trial site","city":"Orange","region":"California","country":"United States","cc":"US","lat":33.7997,"lon":-117.85466,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01858103","study":"BMN 110 US Expanded Access Program","sstatus":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","src":"https://clinicaltrials.gov/study/NCT01858103","eid":"x:site:nct01858103-unnamed-trial-site-orange"},{"id":"nct01858103-unnamed-trial-site-aurora","cat":"research","name":"Unnamed trial site","city":"Aurora","region":"Colorado","country":"United States","cc":"US","lat":39.72204,"lon":-104.82858,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01858103","study":"BMN 110 US Expanded Access Program","sstatus":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","src":"https://clinicaltrials.gov/study/NCT01858103","eid":"x:site:nct01858103-unnamed-trial-site-aurora"},{"id":"nct01858103-unnamed-trial-site-washington-d-c","cat":"research","name":"Unnamed trial site","city":"Washington D.C.","region":"District of Columbia","country":"United States","cc":"US","lat":38.9041,"lon":-77.03105,"gp":"city","unnamed":1,"drugs":["LSD"],"zip":"20010","condg":["Other"],"nct":"NCT01858103","study":"BMN 110 US Expanded Access Program","sstatus":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","src":"https://clinicaltrials.gov/study/NCT01858103","eid":"x:site:nct01858103-unnamed-trial-site-washington-d-c"},{"id":"nct01858103-unnamed-trial-site-hollywood","cat":"research","name":"Unnamed trial site","city":"Hollywood","region":"Florida","country":"United States","cc":"US","lat":34.10592,"lon":-118.31945,"gp":"city","unnamed":1,"drugs":["LSD"],"zip":"33021","condg":["Other"],"nct":"NCT01858103","study":"BMN 110 US Expanded Access Program","sstatus":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","src":"https://clinicaltrials.gov/study/NCT01858103","eid":"x:site:nct01858103-unnamed-trial-site-hollywood"},{"id":"nct01858103-unnamed-trial-site-miami","cat":"research","name":"Unnamed trial site","city":"Miami","region":"Florida","country":"United States","cc":"US","lat":25.78599,"lon":-80.1906,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01858103","study":"BMN 110 US Expanded Access Program","sstatus":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","src":"https://clinicaltrials.gov/study/NCT01858103","eid":"x:site:nct01858103-unnamed-trial-site-miami"},{"id":"nct01858103-unnamed-trial-site-atlanta","cat":"research","name":"Unnamed trial site","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.74839,"lon":-84.3869,"gp":"city","unnamed":1,"drugs":["LSD"],"zip":"30033","condg":["Other"],"nct":"NCT01858103","study":"BMN 110 US Expanded Access Program","sstatus":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","src":"https://clinicaltrials.gov/study/NCT01858103","eid":"x:site:nct01858103-unnamed-trial-site-atlanta"},{"id":"nct01858103-unnamed-trial-site-chicago","cat":"research","name":"Unnamed trial site","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.84387,"lon":-87.64341,"gp":"city","unnamed":1,"drugs":["LSD"],"zip":"60611","condg":["Other"],"nct":"NCT01858103","study":"BMN 110 US Expanded Access Program","sstatus":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","src":"https://clinicaltrials.gov/study/NCT01858103","eid":"x:site:nct01858103-unnamed-trial-site-chicago"},{"id":"nct01858103-unnamed-trial-site-louisville","cat":"research","name":"Unnamed trial site","city":"Louisville","region":"Kentucky","country":"United States","cc":"US","lat":38.25739,"lon":-85.76699,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01858103","study":"BMN 110 US Expanded Access Program","sstatus":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","src":"https://clinicaltrials.gov/study/NCT01858103","eid":"x:site:nct01858103-unnamed-trial-site-louisville"},{"id":"nct01858103-unnamed-trial-site-new-orleans","cat":"research","name":"Unnamed trial site","city":"New Orleans","region":"Louisiana","country":"United States","cc":"US","lat":29.94933,"lon":-90.08058,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01858103","study":"BMN 110 US Expanded Access Program","sstatus":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","src":"https://clinicaltrials.gov/study/NCT01858103","eid":"x:site:nct01858103-unnamed-trial-site-new-orleans"},{"id":"nct01858103-unnamed-trial-site-minneapolis","cat":"research","name":"Unnamed trial site","city":"Minneapolis","region":"Minnesota","country":"United States","cc":"US","lat":44.97682,"lon":-93.27443,"gp":"city","unnamed":1,"drugs":["LSD"],"zip":"55404","condg":["Other"],"nct":"NCT01858103","study":"BMN 110 US Expanded Access Program","sstatus":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","src":"https://clinicaltrials.gov/study/NCT01858103","eid":"x:site:nct01858103-unnamed-trial-site-minneapolis"},{"id":"nct01858103-unnamed-trial-site-paterson","cat":"research","name":"Unnamed trial site","city":"Paterson","region":"New Jersey","country":"United States","cc":"US","lat":40.90788,"lon":-74.17355,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01858103","study":"BMN 110 US Expanded Access Program","sstatus":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","src":"https://clinicaltrials.gov/study/NCT01858103","eid":"x:site:nct01858103-unnamed-trial-site-paterson"},{"id":"nct01858103-unnamed-trial-site-manhasset","cat":"research","name":"Unnamed trial site","city":"Manhasset","region":"New York","country":"United States","cc":"US","lat":40.79604,"lon":-73.70244,"gp":"city","unnamed":1,"drugs":["LSD"],"zip":"11030","condg":["Other"],"nct":"NCT01858103","study":"BMN 110 US Expanded Access Program","sstatus":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","src":"https://clinicaltrials.gov/study/NCT01858103","eid":"x:site:nct01858103-unnamed-trial-site-manhasset"},{"id":"nct01858103-unnamed-trial-site-new-york","cat":"research","name":"Unnamed trial site","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71168,"lon":-73.99482,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01858103","study":"BMN 110 US Expanded Access Program","sstatus":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","src":"https://clinicaltrials.gov/study/NCT01858103","eid":"x:site:nct01858103-unnamed-trial-site-new-york"},{"id":"nct01858103-unnamed-trial-site-portland","cat":"research","name":"Unnamed trial site","city":"Portland","region":"Oregon","country":"United States","cc":"US","lat":45.53187,"lon":-122.6771,"gp":"city","unnamed":1,"drugs":["LSD"],"zip":"97239","condg":["Other"],"nct":"NCT01858103","study":"BMN 110 US Expanded Access Program","sstatus":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","src":"https://clinicaltrials.gov/study/NCT01858103","eid":"x:site:nct01858103-unnamed-trial-site-portland"},{"id":"nct01858103-unnamed-trial-site-philadelphia","cat":"research","name":"Unnamed trial site","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.94273,"lon":-75.15369,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01858103","study":"BMN 110 US Expanded Access Program","sstatus":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","src":"https://clinicaltrials.gov/study/NCT01858103","eid":"x:site:nct01858103-unnamed-trial-site-philadelphia"},{"id":"nct01858103-unnamed-trial-site-pittsburgh","cat":"research","name":"Unnamed trial site","city":"Pittsburgh","region":"Pennsylvania","country":"United States","cc":"US","lat":40.44377,"lon":-80.00102,"gp":"city","unnamed":1,"drugs":["LSD"],"zip":"15224","condg":["Other"],"nct":"NCT01858103","study":"BMN 110 US Expanded Access Program","sstatus":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","src":"https://clinicaltrials.gov/study/NCT01858103","eid":"x:site:nct01858103-unnamed-trial-site-pittsburgh"},{"id":"nct01858103-unnamed-trial-site-nashville","cat":"research","name":"Unnamed trial site","city":"Nashville","region":"Tennessee","country":"United States","cc":"US","lat":36.15775,"lon":-86.78693,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01858103","study":"BMN 110 US Expanded Access Program","sstatus":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","src":"https://clinicaltrials.gov/study/NCT01858103","eid":"x:site:nct01858103-unnamed-trial-site-nashville"},{"id":"nct01858103-unnamed-trial-site-houston","cat":"research","name":"Unnamed trial site","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.76719,"lon":-95.36511,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01858103","study":"BMN 110 US Expanded Access Program","sstatus":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","src":"https://clinicaltrials.gov/study/NCT01858103","eid":"x:site:nct01858103-unnamed-trial-site-houston"},{"id":"nct01858103-unnamed-trial-site-salt-lake-city","cat":"research","name":"Unnamed trial site","city":"Salt Lake City","region":"Utah","country":"United States","cc":"US","lat":40.76017,"lon":-111.899,"gp":"city","unnamed":1,"drugs":["LSD"],"zip":"84113","condg":["Other"],"nct":"NCT01858103","study":"BMN 110 US Expanded Access Program","sstatus":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","src":"https://clinicaltrials.gov/study/NCT01858103","eid":"x:site:nct01858103-unnamed-trial-site-salt-lake-city"},{"id":"nct01858103-unnamed-trial-site-seattle","cat":"research","name":"Unnamed trial site","city":"Seattle","region":"Washington","country":"United States","cc":"US","lat":47.596,"lon":-122.33381,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01858103","study":"BMN 110 US Expanded Access Program","sstatus":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","src":"https://clinicaltrials.gov/study/NCT01858103","eid":"x:site:nct01858103-unnamed-trial-site-seattle"},{"id":"nct01858103-unnamed-trial-site-tacoma","cat":"research","name":"Unnamed trial site","city":"Tacoma","region":"Washington","country":"United States","cc":"US","lat":47.25142,"lon":-122.44754,"gp":"city","unnamed":1,"drugs":["LSD"],"zip":"98405","condg":["Other"],"nct":"NCT01858103","study":"BMN 110 US Expanded Access Program","sstatus":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","src":"https://clinicaltrials.gov/study/NCT01858103","eid":"x:site:nct01858103-unnamed-trial-site-tacoma"},{"id":"nct01858103-unnamed-trial-site-santurce","cat":"research","name":"Unnamed trial site","city":"Santurce","country":"Puerto Rico","cc":"PR","lat":18.2957,"lon":-65.9234,"gp":"country","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01858103","study":"BMN 110 US Expanded Access Program","sstatus":"APPROVED_FOR_MARKETING","sponsor":"BioMarin Pharmaceutical","src":"https://clinicaltrials.gov/study/NCT01858103","eid":"x:site:nct01858103-unnamed-trial-site-santurce"},{"id":"nct07588334-clinical-medical-college-of-yangzhou-university-yangzhou","cat":"research","name":"Clinical Medical College of Yangzhou University","city":"Yangzhou","region":"Jiangsu","country":"China","cc":"CN","lat":32.3983,"lon":119.42628,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"225001","condg":["Other"],"nct":"NCT07588334","study":"Effect of LSD on Lipid Profiles in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)","sstatus":"NOT_YET_RECRUITING","sponsor":"Northern Jiangsu People's Hospital","official":"Guo-Qing Jiang, MD (Clinical Medical College of Yangzhou University)","src":"https://clinicaltrials.gov/study/NCT07588334","contact":{"n":"Guo-Qing Jiang, MD","p":"+8651487373272","e":"jgqing2003@hotmail.com"},"enroll":30,"start":"2026-05-01","eid":"x:site:nct07588334-clinical-medical-college-of-yangzhou-university-yangzhou"},{"id":"nct03604744-clinical-pharmacology-toxicology-university-hospital-basel-basel","cat":"research","name":"Clinical Pharmacology & Toxicology, University Hospital Basel","city":"Basel","country":"Switzerland","cc":"CH","lat":47.56917,"lon":7.56419,"gp":"city","unnamed":0,"drugs":["LSD","psilocybin"],"zip":"4056","condg":["Healthy volunteers"],"nct":"NCT03604744","study":"Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, MD, MAS (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT03604744","phase":"EARLY_Phase 1","enroll":28,"start":"2019-03-27","eid":"x:site:nct03604744-clinical-pharmacology-toxicology-university-hospital-basel-basel"},{"id":"nct04386538-instituto-portugues-de-reumatologia-lisbon","cat":"research","name":"Instituto Português de Reumatologia","city":"Lisbon","country":"Portugal","cc":"PT","lat":38.71657,"lon":-9.14721,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Other"],"status":"RECRUITING","nct":"NCT04386538","study":"Effect of a Low Starch Diet in Patients With Ankylosing Spondylitis","sstatus":"UNKNOWN","sponsor":"Universidade do Porto","official":"Alexandra MT Cardoso, MD (Universidade do Porto); Maria Leonor Silva, PhD (Centro de Investigação Interdisciplinar Egas Moniz)","src":"https://clinicaltrials.gov/study/NCT04386538","contact":{"n":"Alexandra Cardoso, MD","p":"+351926142356","e":"alexandra.cardoso@gmail.com"},"phase":"N/A","enroll":150,"start":"2022-01-03","eid":"x:site:nct04386538-instituto-portugues-de-reumatologia-lisbon"},{"id":"nct07503002-johns-hopkins-center-for-psychedelic-and-consciousness-research-balt","cat":"research","name":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28892,"lon":-76.61045,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"21224","condg":["Depression"],"nct":"NCT07503002","study":"Shortened LSD Intervention for Major Depressive Disorder","sstatus":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","official":"Sandeep Nayak, MD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT07503002","contact":{"n":"Matthew Nielsen, BA","p":"917-991-0642","e":"mnielse7@jh.edu"},"phase":"Phase 1","enroll":10,"start":"2026-10-01","eid":"x:site:nct07503002-johns-hopkins-center-for-psychedelic-and-consciousness-research-balt"},{"id":"nct07237659-carewell-arthritis-center-apple-valley","cat":"research","name":"Carewell Arthritis Center","city":"Apple Valley","region":"California","country":"United States","cc":"US","lat":34.50822,"lon":-117.18602,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"92307","condg":["Other"],"status":"RECRUITING","nct":"NCT07237659","study":"Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA","sstatus":"RECRUITING","sponsor":"Neutrolis","official":"Andreas Reiff, PhD, MD (Neutrolis)","src":"https://clinicaltrials.gov/study/NCT07237659","contact":{"n":"Diraj Karmani, MD","p":"909-581-8477","e":"reiff@neutrolis.com"},"phase":"Phase 1","enroll":24,"start":"2026-07-15","eid":"x:site:nct07237659-carewell-arthritis-center-apple-valley"},{"id":"nct07237659-attune-health-research-inc-beverly-hills","cat":"research","name":"Attune Health Research Inc","city":"Beverly Hills","region":"California","country":"United States","cc":"US","lat":34.06604,"lon":-118.40737,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"90211","condg":["Other"],"status":"RECRUITING","nct":"NCT07237659","study":"Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA","sstatus":"RECRUITING","sponsor":"Neutrolis","official":"Andreas Reiff, PhD, MD (Neutrolis)","src":"https://clinicaltrials.gov/study/NCT07237659","contact":{"n":"Swamy Venuturupalli, MD","p":"310-652-0010","e":"reiff@neutrolis.com"},"phase":"Phase 1","enroll":24,"start":"2026-07-15","eid":"x:site:nct07237659-attune-health-research-inc-beverly-hills"},{"id":"nct07237659-covina-arthritis-clinic-covina","cat":"research","name":"Covina Arthritis Clinic","city":"Covina","region":"California","country":"United States","cc":"US","lat":34.08987,"lon":-117.88455,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"91722","condg":["Other"],"status":"RECRUITING","nct":"NCT07237659","study":"Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA","sstatus":"RECRUITING","sponsor":"Neutrolis","official":"Andreas Reiff, PhD, MD (Neutrolis)","src":"https://clinicaltrials.gov/study/NCT07237659","contact":{"n":"Samy Metyas, MD","p":"626-966-1909","e":"info@MedvinResearch.com"},"phase":"Phase 1","enroll":24,"start":"2026-07-15","eid":"x:site:nct07237659-covina-arthritis-clinic-covina"},{"id":"nct07237659-novamed-monterey-park","cat":"research","name":"Novamed","city":"Monterey Park","region":"California","country":"United States","cc":"US","lat":34.05898,"lon":-118.12101,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"91752","condg":["Other"],"status":"RECRUITING","nct":"NCT07237659","study":"Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA","sstatus":"RECRUITING","sponsor":"Neutrolis","official":"Andreas Reiff, PhD, MD (Neutrolis)","src":"https://clinicaltrials.gov/study/NCT07237659","contact":{"n":"Soha Dolatabadi, MD","p":"213-266-8200","e":"reiff@neutrolis.com"},"phase":"Phase 1","enroll":24,"start":"2026-07-15","eid":"x:site:nct07237659-novamed-monterey-park"},{"id":"nct07237659-southland-arthritis-clinic-riverside","cat":"research","name":"Southland Arthritis Clinic","city":"Riverside","region":"California","country":"United States","cc":"US","lat":33.95481,"lon":-117.4028,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"92508","condg":["Other"],"status":"RECRUITING","nct":"NCT07237659","study":"Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA","sstatus":"RECRUITING","sponsor":"Neutrolis","official":"Andreas Reiff, PhD, MD (Neutrolis)","src":"https://clinicaltrials.gov/study/NCT07237659","contact":{"n":"Amal Mehta, MD","p":"951-924-6500","e":"reiff@neutrolis.com"},"phase":"Phase 1","enroll":24,"start":"2026-07-15","eid":"x:site:nct07237659-southland-arthritis-clinic-riverside"},{"id":"nct07237659-southland-arthritis-clinic-temecula","cat":"research","name":"Southland Arthritis Clinic","city":"Temecula","region":"California","country":"United States","cc":"US","lat":33.49453,"lon":-117.13749,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"92592","condg":["Other"],"status":"RECRUITING","nct":"NCT07237659","study":"Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA","sstatus":"RECRUITING","sponsor":"Neutrolis","official":"Andreas Reiff, PhD, MD (Neutrolis)","src":"https://clinicaltrials.gov/study/NCT07237659","contact":{"n":"Amal Mehta, MD","p":"714-244-2279","e":"reiff@neutrolis.com"},"phase":"Phase 1","enroll":24,"start":"2026-07-15","eid":"x:site:nct07237659-southland-arthritis-clinic-temecula"},{"id":"nct07237659-foothill-arthritis-clinic-tujunga","cat":"research","name":"Foothill Arthritis Clinic","city":"Tujunga","region":"California","country":"United States","cc":"US","lat":34.24625,"lon":-118.27989,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"91042","condg":["Other"],"status":"RECRUITING","nct":"NCT07237659","study":"Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA","sstatus":"RECRUITING","sponsor":"Neutrolis","official":"Andreas Reiff, PhD, MD (Neutrolis)","src":"https://clinicaltrials.gov/study/NCT07237659","contact":{"n":"Dan La, MD","p":"213-281-5146","e":"reiff@neutrolis.com"},"phase":"Phase 1","enroll":24,"start":"2026-07-15","eid":"x:site:nct07237659-foothill-arthritis-clinic-tujunga"},{"id":"nct03153579-university-hospital-basel-basel","cat":"research","name":"University Hospital Basel","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","cc":"CH","lat":47.56286,"lon":7.56682,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"4056","condg":["Anxiety"],"nct":"NCT03153579","study":"LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Peter Gasser, MD (Private Practice)","src":"https://clinicaltrials.gov/study/NCT03153579","phase":"Phase 2","enroll":46,"start":"2017-06-23","eid":"x:site:nct03153579-university-hospital-basel-basel"},{"id":"nct03153579-private-practice-p-gasser-solothurn","cat":"research","name":"Private Practice P.Gasser","city":"Solothurn","region":"Canton of Solothurn","country":"Switzerland","cc":"CH","lat":47.21718,"lon":7.54236,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"4500","condg":["Anxiety"],"nct":"NCT03153579","study":"LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Peter Gasser, MD (Private Practice)","src":"https://clinicaltrials.gov/study/NCT03153579","phase":"Phase 2","enroll":46,"start":"2017-06-23","eid":"x:site:nct03153579-private-practice-p-gasser-solothurn"},{"id":"nct06941844-preferred-research-partners-inc-little-rock","cat":"research","name":"Preferred Research Partners, Inc","city":"Little Rock","region":"Arkansas","country":"United States","cc":"US","lat":34.7549,"lon":-92.28681,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"72211","condg":["Depression"],"nct":"NCT06941844","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06941844","phase":"Phase 3","enroll":149,"start":"2025-04-14","eid":"x:site:nct06941844-preferred-research-partners-inc-little-rock"},{"id":"nct06941844-kadima-neuropsychiatry-institute-la-jolla","cat":"research","name":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","cc":"US","lat":32.8588,"lon":-117.28356,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"92037","condg":["Depression"],"nct":"NCT06941844","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06941844","phase":"Phase 3","enroll":149,"start":"2025-04-14","eid":"x:site:nct06941844-kadima-neuropsychiatry-institute-la-jolla"},{"id":"nct06941844-psychedelic-science-institute-santa-monica","cat":"research","name":"Psychedelic Science Institute","city":"Santa Monica","region":"California","country":"United States","cc":"US","lat":34.0281,"lon":-118.48804,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"90404","condg":["Depression"],"nct":"NCT06941844","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06941844","phase":"Phase 3","enroll":149,"start":"2025-04-14","eid":"x:site:nct06941844-psychedelic-science-institute-santa-monica"},{"id":"nct06941844-mountain-view-clinical-research-inc-denver","cat":"research","name":"Mountain View Clinical Research, Inc","city":"Denver","region":"Colorado","country":"United States","cc":"US","lat":39.74249,"lon":-104.98757,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"80209","condg":["Depression"],"nct":"NCT06941844","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06941844","phase":"Phase 3","enroll":149,"start":"2025-04-14","eid":"x:site:nct06941844-mountain-view-clinical-research-inc-denver"},{"id":"nct06941844-cns-llc-jacksonville-jacksonville","cat":"research","name":"CNS, LLC (Jacksonville)","city":"Jacksonville","region":"Florida","country":"United States","cc":"US","lat":30.3359,"lon":-81.66671,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"32256","condg":["Depression"],"nct":"NCT06941844","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06941844","phase":"Phase 3","enroll":149,"start":"2025-04-14","eid":"x:site:nct06941844-cns-llc-jacksonville-jacksonville"},{"id":"nct06941844-cns-llc-orlando-orlando","cat":"research","name":"CNS, LLC (Orlando)","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.53886,"lon":-81.38183,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"32801","condg":["Depression"],"nct":"NCT06941844","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06941844","phase":"Phase 3","enroll":149,"start":"2025-04-14","eid":"x:site:nct06941844-cns-llc-orlando-orlando"},{"id":"nct06941844-charter-research-orlando","cat":"research","name":"Charter Research","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.54149,"lon":-81.37148,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"32803","condg":["Depression"],"nct":"NCT06941844","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06941844","phase":"Phase 3","enroll":149,"start":"2025-04-14","eid":"x:site:nct06941844-charter-research-orlando"},{"id":"nct06941844-uptown-research-institute-uri-llc-chicago","cat":"research","name":"Uptown Research Institute (URI), LLC","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.86024,"lon":-87.66177,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"60640","condg":["Depression"],"nct":"NCT06941844","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06941844","phase":"Phase 3","enroll":149,"start":"2025-04-14","eid":"x:site:nct06941844-uptown-research-institute-uri-llc-chicago"},{"id":"nct06941844-sheppard-pratt-baltimore","cat":"research","name":"Sheppard Pratt","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.27847,"lon":-76.60019,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"21204","condg":["Depression"],"nct":"NCT06941844","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06941844","phase":"Phase 3","enroll":149,"start":"2025-04-14","eid":"x:site:nct06941844-sheppard-pratt-baltimore"},{"id":"nct06941844-adams-clinical-boston-boston","cat":"research","name":"Adams Clinical Boston","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36695,"lon":-71.06433,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"02116","condg":["Depression"],"nct":"NCT06941844","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06941844","phase":"Phase 3","enroll":149,"start":"2025-04-14","eid":"x:site:nct06941844-adams-clinical-boston-boston"},{"id":"nct06941844-adams-clinical-watertown","cat":"research","name":"Adams Clinical","city":"Watertown","region":"Massachusetts","country":"United States","cc":"US","lat":42.36429,"lon":-71.19041,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"02472","condg":["Depression"],"nct":"NCT06941844","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06941844","phase":"Phase 3","enroll":149,"start":"2025-04-14","eid":"x:site:nct06941844-adams-clinical-watertown"},{"id":"nct06941844-university-of-missouri-columbia","cat":"research","name":"University of Missouri","city":"Columbia","region":"Missouri","country":"United States","cc":"US","lat":33.99746,"lon":-81.03269,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"65212","condg":["Depression"],"nct":"NCT06941844","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06941844","phase":"Phase 3","enroll":149,"start":"2025-04-14","eid":"x:site:nct06941844-university-of-missouri-columbia"},{"id":"nct06941844-cenexel-hri-berlin","cat":"research","name":"Cenexel HRI","city":"Berlin","region":"New Jersey","country":"United States","cc":"US","lat":44.47455,"lon":-71.18052,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"08053","condg":["Depression"],"nct":"NCT06941844","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06941844","phase":"Phase 3","enroll":149,"start":"2025-04-14","eid":"x:site:nct06941844-cenexel-hri-berlin"},{"id":"nct06941844-adams-clinical-harlem-new-york","cat":"research","name":"Adams Clinical Harlem","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72222,"lon":-74.00959,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"10029","condg":["Depression"],"nct":"NCT06941844","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06941844","phase":"Phase 3","enroll":149,"start":"2025-04-14","eid":"x:site:nct06941844-adams-clinical-harlem-new-york"},{"id":"nct06941844-columbia-new-york-state-psychiatric-institute-new-york","cat":"research","name":"Columbia - New York State Psychiatric Institute","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72533,"lon":-74.00395,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"10032","condg":["Depression"],"nct":"NCT06941844","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06941844","phase":"Phase 3","enroll":149,"start":"2025-04-14","eid":"x:site:nct06941844-columbia-new-york-state-psychiatric-institute-new-york"},{"id":"nct06941844-neuro-behavioral-clinical-research-canton","cat":"research","name":"Neuro-Behavioral Clinical Research","city":"Canton","region":"Ohio","country":"United States","cc":"US","lat":42.299,"lon":-83.47298,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"44720","condg":["Depression"],"nct":"NCT06941844","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06941844","phase":"Phase 3","enroll":149,"start":"2025-04-14","eid":"x:site:nct06941844-neuro-behavioral-clinical-research-canton"},{"id":"nct06941844-university-of-cincinnati-cincinnati","cat":"research","name":"University of Cincinnati","city":"Cincinnati","region":"Ohio","country":"United States","cc":"US","lat":39.11887,"lon":-84.50305,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"45219","condg":["Depression"],"nct":"NCT06941844","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06941844","phase":"Phase 3","enroll":149,"start":"2025-04-14","eid":"x:site:nct06941844-university-of-cincinnati-cincinnati"},{"id":"nct06941844-adams-clinical-philadelphia-philadelphia","cat":"research","name":"Adams Clinical Philadelphia","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.95186,"lon":-75.1696,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"19104","condg":["Depression"],"nct":"NCT06941844","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06941844","phase":"Phase 3","enroll":149,"start":"2025-04-14","eid":"x:site:nct06941844-adams-clinical-philadelphia-philadelphia"},{"id":"nct06941844-cns-llc-memphis-memphis","cat":"research","name":"CNS, LLC (Memphis)","city":"Memphis","region":"Tennessee","country":"United States","cc":"US","lat":35.16059,"lon":-90.05213,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"38119","condg":["Depression"],"nct":"NCT06941844","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06941844","phase":"Phase 3","enroll":149,"start":"2025-04-14","eid":"x:site:nct06941844-cns-llc-memphis-memphis"},{"id":"nct06941844-austin-clinical-trial-partners-austin","cat":"research","name":"Austin Clinical Trial Partners","city":"Austin","region":"Texas","country":"United States","cc":"US","lat":30.26183,"lon":-97.73661,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"78737","condg":["Depression"],"nct":"NCT06941844","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06941844","phase":"Phase 3","enroll":149,"start":"2025-04-14","eid":"x:site:nct06941844-austin-clinical-trial-partners-austin"},{"id":"nct06941844-cedar-clinical-research-murray","cat":"research","name":"Cedar Clinical Research","city":"Murray","region":"Utah","country":"United States","cc":"US","lat":40.66261,"lon":-111.89557,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"84020","condg":["Depression"],"nct":"NCT06941844","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06941844","phase":"Phase 3","enroll":149,"start":"2025-04-14","eid":"x:site:nct06941844-cedar-clinical-research-murray"},{"id":"nct06941844-memory-clinic-inc-bennington","cat":"research","name":"Memory Clinic, Inc","city":"Bennington","region":"Vermont","country":"United States","cc":"US","lat":42.87686,"lon":-73.19748,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"05201","condg":["Depression"],"nct":"NCT06941844","study":"A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06941844","phase":"Phase 3","enroll":149,"start":"2025-04-14","eid":"x:site:nct06941844-memory-clinic-inc-bennington"},{"id":"nct05407064-preferred-research-partners-little-rock","cat":"research","name":"Preferred Research Partners","city":"Little Rock","region":"Arkansas","country":"United States","cc":"US","lat":34.74286,"lon":-92.29303,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"72211","condg":["Anxiety"],"nct":"NCT05407064","study":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","sstatus":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT05407064","phase":"Phase 2","enroll":198,"start":"2022-08-24","eid":"x:site:nct05407064-preferred-research-partners-little-rock"},{"id":"nct05407064-irvine-center-for-clinical-research-irvine","cat":"research","name":"Irvine Center for Clinical Research","city":"Irvine","region":"California","country":"United States","cc":"US","lat":33.67487,"lon":-117.83135,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"92614","condg":["Anxiety"],"nct":"NCT05407064","study":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","sstatus":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT05407064","phase":"Phase 2","enroll":198,"start":"2022-08-24","eid":"x:site:nct05407064-irvine-center-for-clinical-research-irvine"},{"id":"nct05407064-kadima-neuropsychiatry-institute-la-jolla","cat":"research","name":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","cc":"US","lat":32.84139,"lon":-117.27378,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"92037","condg":["Anxiety"],"nct":"NCT05407064","study":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","sstatus":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT05407064","phase":"Phase 2","enroll":198,"start":"2022-08-24","eid":"x:site:nct05407064-kadima-neuropsychiatry-institute-la-jolla"},{"id":"nct05407064-pacific-neuroscience-institute-santa-monica","cat":"research","name":"Pacific Neuroscience Institute","city":"Santa Monica","region":"California","country":"United States","cc":"US","lat":34.02321,"lon":-118.49114,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"90404","condg":["Anxiety"],"nct":"NCT05407064","study":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","sstatus":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT05407064","phase":"Phase 2","enroll":198,"start":"2022-08-24","eid":"x:site:nct05407064-pacific-neuroscience-institute-santa-monica"},{"id":"nct05407064-mountain-view-clinical-research-denver","cat":"research","name":"Mountain View Clinical Research","city":"Denver","region":"Colorado","country":"United States","cc":"US","lat":39.73176,"lon":-104.98663,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"80209","condg":["Anxiety"],"nct":"NCT05407064","study":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","sstatus":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT05407064","phase":"Phase 2","enroll":198,"start":"2022-08-24","eid":"x:site:nct05407064-mountain-view-clinical-research-denver"},{"id":"nct05407064-wholeness-center-fort-collins","cat":"research","name":"Wholeness Center","city":"Fort Collins","region":"Colorado","country":"United States","cc":"US","lat":40.57373,"lon":-105.0824,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"80525","condg":["Anxiety"],"nct":"NCT05407064","study":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","sstatus":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT05407064","phase":"Phase 2","enroll":198,"start":"2022-08-24","eid":"x:site:nct05407064-wholeness-center-fort-collins"},{"id":"nct05407064-segal-trials-lauderhill","cat":"research","name":"Segal Trials","city":"Lauderhill","region":"Florida","country":"United States","cc":"US","lat":26.13165,"lon":-80.22162,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"33319","condg":["Anxiety"],"nct":"NCT05407064","study":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","sstatus":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT05407064","phase":"Phase 2","enroll":198,"start":"2022-08-24","eid":"x:site:nct05407064-segal-trials-lauderhill"},{"id":"nct05407064-cns-healthcare-orlando-orlando","cat":"research","name":"CNS Healthcare - Orlando","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.5445,"lon":-81.38616,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"32801","condg":["Anxiety"],"nct":"NCT05407064","study":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","sstatus":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT05407064","phase":"Phase 2","enroll":198,"start":"2022-08-24","eid":"x:site:nct05407064-cns-healthcare-orlando-orlando"},{"id":"nct05407064-iresearch-atlanta-decatur","cat":"research","name":"iResearch Atlanta","city":"Decatur","region":"Georgia","country":"United States","cc":"US","lat":39.8508,"lon":-88.96002,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"30030","condg":["Anxiety"],"nct":"NCT05407064","study":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","sstatus":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT05407064","phase":"Phase 2","enroll":198,"start":"2022-08-24","eid":"x:site:nct05407064-iresearch-atlanta-decatur"},{"id":"nct05407064-great-lakes-clinical-trials-chicago","cat":"research","name":"Great Lakes Clinical Trials","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.8417,"lon":-87.66101,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"60640","condg":["Anxiety"],"nct":"NCT05407064","study":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","sstatus":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT05407064","phase":"Phase 2","enroll":198,"start":"2022-08-24","eid":"x:site:nct05407064-great-lakes-clinical-trials-chicago"},{"id":"nct05407064-uptown-research-chicago","cat":"research","name":"Uptown Research","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.84914,"lon":-87.6516,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"60640","condg":["Anxiety"],"nct":"NCT05407064","study":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","sstatus":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT05407064","phase":"Phase 2","enroll":198,"start":"2022-08-24","eid":"x:site:nct05407064-uptown-research-chicago"},{"id":"nct05407064-sunstone-therapies-rockville","cat":"research","name":"Sunstone Therapies","city":"Rockville","region":"Maryland","country":"United States","cc":"US","lat":39.07774,"lon":-77.1561,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"20850","condg":["Anxiety"],"nct":"NCT05407064","study":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","sstatus":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT05407064","phase":"Phase 2","enroll":198,"start":"2022-08-24","eid":"x:site:nct05407064-sunstone-therapies-rockville"},{"id":"nct05407064-sisu-springfield","cat":"research","name":"SISU","city":"Springfield","region":"Massachusetts","country":"United States","cc":"US","lat":37.21519,"lon":-93.29179,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"01103","condg":["Anxiety"],"nct":"NCT05407064","study":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","sstatus":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT05407064","phase":"Phase 2","enroll":198,"start":"2022-08-24","eid":"x:site:nct05407064-sisu-springfield"},{"id":"nct05407064-adams-clinical-watertown","cat":"research","name":"Adams Clinical","city":"Watertown","region":"Massachusetts","country":"United States","cc":"US","lat":42.37578,"lon":-71.17187,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"02472","condg":["Anxiety"],"nct":"NCT05407064","study":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","sstatus":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT05407064","phase":"Phase 2","enroll":198,"start":"2022-08-24","eid":"x:site:nct05407064-adams-clinical-watertown"},{"id":"nct05407064-hassman-research-institute-berlin","cat":"research","name":"Hassman Research Institute","city":"Berlin","region":"New Jersey","country":"United States","cc":"US","lat":44.46053,"lon":-71.17694,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"08009","condg":["Anxiety"],"nct":"NCT05407064","study":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","sstatus":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT05407064","phase":"Phase 2","enroll":198,"start":"2022-08-24","eid":"x:site:nct05407064-hassman-research-institute-berlin"},{"id":"nct05407064-gmi-princeton-medical-institute-princeton","cat":"research","name":"GMI - Princeton Medical Institute","city":"Princeton","region":"New Jersey","country":"United States","cc":"US","lat":25.5415,"lon":-80.40805,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"08540","condg":["Anxiety"],"nct":"NCT05407064","study":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","sstatus":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT05407064","phase":"Phase 2","enroll":198,"start":"2022-08-24","eid":"x:site:nct05407064-gmi-princeton-medical-institute-princeton"},{"id":"nct05407064-lutheran-hospital-cleveland-clinic-cleveland","cat":"research","name":"Lutheran Hospital - Cleveland Clinic","city":"Cleveland","region":"Ohio","country":"United States","cc":"US","lat":41.50726,"lon":-81.68972,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"44113","condg":["Anxiety"],"nct":"NCT05407064","study":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","sstatus":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT05407064","phase":"Phase 2","enroll":198,"start":"2022-08-24","eid":"x:site:nct05407064-lutheran-hospital-cleveland-clinic-cleveland"},{"id":"nct05407064-biobehavioral-research-of-austin-austin","cat":"research","name":"BioBehavioral Research of Austin","city":"Austin","region":"Texas","country":"United States","cc":"US","lat":30.26814,"lon":-97.7496,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"78759","condg":["Anxiety"],"nct":"NCT05407064","study":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","sstatus":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT05407064","phase":"Phase 2","enroll":198,"start":"2022-08-24","eid":"x:site:nct05407064-biobehavioral-research-of-austin-austin"},{"id":"nct05407064-university-of-texas-health-houston-houston","cat":"research","name":"University of Texas Health Houston","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.76323,"lon":-95.36285,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"77054","condg":["Anxiety"],"nct":"NCT05407064","study":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","sstatus":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT05407064","phase":"Phase 2","enroll":198,"start":"2022-08-24","eid":"x:site:nct05407064-university-of-texas-health-houston-houston"},{"id":"nct05407064-cedar-clinical-research-draper","cat":"research","name":"Cedar Clinical Research","city":"Draper","region":"Utah","country":"United States","cc":"US","lat":40.53018,"lon":-111.8634,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"84020","condg":["Anxiety"],"nct":"NCT05407064","study":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","sstatus":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT05407064","phase":"Phase 2","enroll":198,"start":"2022-08-24","eid":"x:site:nct05407064-cedar-clinical-research-draper"},{"id":"nct05407064-cedar-clinical-research-murray-murray","cat":"research","name":"Cedar Clinical Research - Murray","city":"Murray","region":"Utah","country":"United States","cc":"US","lat":40.67268,"lon":-111.87674,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"84107","condg":["Anxiety"],"nct":"NCT05407064","study":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","sstatus":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT05407064","phase":"Phase 2","enroll":198,"start":"2022-08-24","eid":"x:site:nct05407064-cedar-clinical-research-murray-murray"},{"id":"nct05407064-woodstock-research-center-woodstock","cat":"research","name":"Woodstock Research Center","city":"Woodstock","region":"Vermont","country":"United States","cc":"US","lat":34.10238,"lon":-84.52686,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"05091","condg":["Anxiety"],"nct":"NCT05407064","study":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","sstatus":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT05407064","phase":"Phase 2","enroll":198,"start":"2022-08-24","eid":"x:site:nct05407064-woodstock-research-center-woodstock"},{"id":"nct00884949-unnamed-trial-site-birmingham","cat":"research","name":"Unnamed trial site","city":"Birmingham","country":"United Kingdom","cc":"GB","lat":52.48975,"lon":-1.88887,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT00884949","study":"A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, MD (BioMarin Pharmceutical Inc.)","src":"https://clinicaltrials.gov/study/NCT00884949","phase":"Phase 1/Phase 2","enroll":20,"start":"2009-04","eid":"x:site:nct00884949-unnamed-trial-site-birmingham"},{"id":"nct00884949-unnamed-trial-site-london","cat":"research","name":"Unnamed trial site","city":"London","country":"United Kingdom","cc":"GB","lat":51.51046,"lon":-0.13002,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT00884949","study":"A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, MD (BioMarin Pharmceutical Inc.)","src":"https://clinicaltrials.gov/study/NCT00884949","phase":"Phase 1/Phase 2","enroll":20,"start":"2009-04","eid":"x:site:nct00884949-unnamed-trial-site-london"},{"id":"nct00884949-unnamed-trial-site-manchester","cat":"research","name":"Unnamed trial site","city":"Manchester","country":"United Kingdom","cc":"GB","lat":53.47657,"lon":-2.23202,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT00884949","study":"A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, MD (BioMarin Pharmceutical Inc.)","src":"https://clinicaltrials.gov/study/NCT00884949","phase":"Phase 1/Phase 2","enroll":20,"start":"2009-04","eid":"x:site:nct00884949-unnamed-trial-site-manchester"},{"id":"nct06809595-preferred-research-partners-inc-little-rock","cat":"research","name":"Preferred Research Partners, Inc.","city":"Little Rock","region":"Arkansas","country":"United States","cc":"US","lat":34.75039,"lon":-92.28117,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"72211","condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-preferred-research-partners-inc-little-rock"},{"id":"nct06809595-psychedelic-science-institute-los-angeles","cat":"research","name":"Psychedelic Science Institute","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.05727,"lon":-118.23535,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"90004","condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-psychedelic-science-institute-los-angeles"},{"id":"nct06809595-west-los-angeles-va-medical-center-los-angeles","cat":"research","name":"West Los Angeles VA Medical Center","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.05981,"lon":-118.24824,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"90073","condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-west-los-angeles-va-medical-center-los-angeles"},{"id":"nct06809595-bradenton-research-center-inc-bradenton","cat":"research","name":"Bradenton Research Center, Inc.","city":"Bradenton","region":"Florida","country":"United States","cc":"US","lat":27.50171,"lon":-82.56367,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"34205","condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-bradenton-research-center-inc-bradenton"},{"id":"nct06809595-clinical-neuroscience-solutions-inc-orlando","cat":"research","name":"Clinical Neuroscience Solutions, Inc","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.52992,"lon":-81.38569,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"32801","condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-clinical-neuroscience-solutions-inc-orlando"},{"id":"nct06809595-atlanta-center-for-medical-research-atlanta","cat":"research","name":"Atlanta Center for Medical Research","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.75968,"lon":-84.38191,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"30331","condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-atlanta-center-for-medical-research-atlanta"},{"id":"nct06809595-sheppard-pratt-health-system-towson","cat":"research","name":"Sheppard Pratt Health System","city":"Towson","region":"Maryland","country":"United States","cc":"US","lat":39.39006,"lon":-76.61043,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"21204","condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-sheppard-pratt-health-system-towson"},{"id":"nct06809595-adams-clinical-boston-boston","cat":"research","name":"Adams Clinical Boston","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.3597,"lon":-71.05022,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"02116","condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-adams-clinical-boston-boston"},{"id":"nct06809595-princeton-medical-institute-princeton","cat":"research","name":"Princeton Medical Institute","city":"Princeton","region":"New Jersey","country":"United States","cc":"US","lat":25.5271,"lon":-80.40428,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"08540","condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-princeton-medical-institute-princeton"},{"id":"nct06809595-university-of-cincinnati-psychiatry-anxiety-disorders-research-progr","cat":"research","name":"University of Cincinnati Psychiatry- Anxiety Disorders Research Program","city":"Cincinnati","region":"Ohio","country":"United States","cc":"US","lat":39.13102,"lon":-84.51491,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"45219","condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-university-of-cincinnati-psychiatry-anxiety-disorders-research-progr"},{"id":"nct06809595-neuro-behavioral-clinical-research-inc-north-canton","cat":"research","name":"Neuro-Behavioral Clinical Research, Inc.","city":"North Canton","region":"Ohio","country":"United States","cc":"US","lat":40.86483,"lon":-81.40107,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"44720","condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-neuro-behavioral-clinical-research-inc-north-canton"},{"id":"nct06809595-austin-clinical-trial-partners-austin","cat":"research","name":"Austin Clinical Trial Partners","city":"Austin","region":"Texas","country":"United States","cc":"US","lat":30.26927,"lon":-97.73868,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"78737","condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-austin-clinical-trial-partners-austin"},{"id":"nct06809595-core-clinical-research-everett","cat":"research","name":"Core Clinical Research","city":"Everett","region":"Washington","country":"United States","cc":"US","lat":47.98006,"lon":-122.21304,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"98201","condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-core-clinical-research-everett"},{"id":"nct06809595-a-shine-s-r-o-pilsen","cat":"research","name":"A-shine s.r.o.","city":"Pilsen","country":"Czechia","cc":"CZ","lat":49.75721,"lon":13.367,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-a-shine-s-r-o-pilsen"},{"id":"nct06809595-institut-neuropsychiatricke-pece-inep-prague","cat":"research","name":"Institut Neuropsychiatricke Pece (INEP)","city":"Prague","country":"Czechia","cc":"CZ","lat":50.07802,"lon":14.42391,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-institut-neuropsychiatricke-pece-inep-prague"},{"id":"nct06809595-psyon-s-r-o-prague","cat":"research","name":"Psyon s.r.o.","city":"Prague","country":"Czechia","cc":"CZ","lat":50.0798,"lon":14.40914,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-psyon-s-r-o-prague"},{"id":"nct06809595-cabinet-dr-desbonnet-residence-saint-michel-douai","cat":"research","name":"Cabinet Dr.Desbonnet : Résidence Saint Michel","city":"Douai","country":"France","cc":"FR","lat":50.36161,"lon":3.06976,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-cabinet-dr-desbonnet-residence-saint-michel-douai"},{"id":"nct06809595-hopital-conception-cic-centre-bat-nephrologie-3eme-etage-marseille","cat":"research","name":"Hôpital Conception, CIC Centre, bat néphrologie 3eme étage","city":"Marseille","country":"France","cc":"FR","lat":43.2874,"lon":5.37462,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-hopital-conception-cic-centre-bat-nephrologie-3eme-etage-marseille"},{"id":"nct06809595-cmme-paris","cat":"research","name":"CMME","city":"Paris","country":"France","cc":"FR","lat":48.84235,"lon":2.33765,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-cmme-paris"},{"id":"nct06809595-ghu-paris-psychiatrie-et-neurosciences-paris","cat":"research","name":"GHU Paris Psychiatrie et Neurosciences","city":"Paris","country":"France","cc":"FR","lat":48.86259,"lon":2.34584,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-ghu-paris-psychiatrie-et-neurosciences-paris"},{"id":"nct06809595-centre-hospitalier-du-rouvray-sotteville-les-rouen","cat":"research","name":"Centre Hospitalier du Rouvray","city":"Sotteville-lès-Rouen","country":"France","cc":"FR","lat":49.41523,"lon":1.09066,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-centre-hospitalier-du-rouvray-sotteville-les-rouen"},{"id":"nct06809595-department-of-psychiatry-and-psychotherapy-campus-charite-mitte-char","cat":"research","name":"Department of Psychiatry and Psychotherapy Campus Charité Mitte Charité Universitätsmedizin Berlin","city":"Berlin","country":"Germany","cc":"DE","lat":52.5215,"lon":13.41029,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-department-of-psychiatry-and-psychotherapy-campus-charite-mitte-char"},{"id":"nct06809595-ovid-clinic-berlin-berlin","cat":"research","name":"OVID Clinic Berlin","city":"Berlin","country":"Germany","cc":"DE","lat":52.52272,"lon":13.40757,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-ovid-clinic-berlin-berlin"},{"id":"nct06809595-central-institute-of-mental-health-mannheim","cat":"research","name":"Central Institute of Mental Health","city":"Mannheim","country":"Germany","cc":"DE","lat":49.49611,"lon":8.46463,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-central-institute-of-mental-health-mannheim"},{"id":"nct06809595-klinik-fur-psychiatrie-und-psychotherapie-abt-allgemeine-psychiatrie","cat":"research","name":"Klinik für Psychiatrie und Psychotherapie, Abt: Allgemeine Psychiatrie und Psychotherapie","city":"Tübingen","country":"Germany","cc":"DE","lat":48.53202,"lon":9.04596,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-klinik-fur-psychiatrie-und-psychotherapie-abt-allgemeine-psychiatrie"},{"id":"nct06809595-centrum-badan-klinicznych-pi-house-sp-z-o-o-gdansk","cat":"research","name":"Centrum Badan Klinicznych PI-House sp. z o.o.","city":"Gdansk","country":"Poland","cc":"PL","lat":54.3526,"lon":18.64361,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-centrum-badan-klinicznych-pi-house-sp-z-o-o-gdansk"},{"id":"nct06809595-department-of-psychiatry-uck-gdansk","cat":"research","name":"Department of Psychiatry, UCK","city":"Gdansk","country":"Poland","cc":"PL","lat":54.34874,"lon":18.65246,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-department-of-psychiatry-uck-gdansk"},{"id":"nct06809595-department-of-affective-and-psychotic-disorders-central-teaching-hos","cat":"research","name":"Department of Affective and Psychotic Disorders, Central Teaching Hospital, Medical University of Lodz","city":"Lodz","country":"Poland","cc":"PL","lat":51.77157,"lon":19.48454,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-department-of-affective-and-psychotic-disorders-central-teaching-hos"},{"id":"nct06809595-neuroclin-glasgow-glasgow","cat":"research","name":"Neuroclin Glasgow","city":"Glasgow","country":"United Kingdom","cc":"GB","lat":55.86011,"lon":-4.26408,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-neuroclin-glasgow-glasgow"},{"id":"nct06809595-cumbria-northumberland-tyne-and-wear-nhs-foundation-trust-st-nichola","cat":"research","name":"Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, St. Nicholas Hospital","city":"Gosforth","country":"United Kingdom","cc":"GB","lat":54.99224,"lon":-1.61107,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-cumbria-northumberland-tyne-and-wear-nhs-foundation-trust-st-nichola"},{"id":"nct06809595-4-medical-clinical-solutions-london","cat":"research","name":"4 Medical Clinical Solutions","city":"London","country":"United Kingdom","cc":"GB","lat":51.51677,"lon":-0.12052,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-4-medical-clinical-solutions-london"},{"id":"nct06809595-clerkenwell-health-baker-street-london","cat":"research","name":"Clerkenwell Health - Baker Street","city":"London","country":"United Kingdom","cc":"GB","lat":51.49822,"lon":-0.13002,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-clerkenwell-health-baker-street-london"},{"id":"nct06809595-clerkenwell-health-london","cat":"research","name":"Clerkenwell Health","city":"London","country":"United Kingdom","cc":"GB","lat":51.51328,"lon":-0.13322,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-clerkenwell-health-london"},{"id":"nct06809595-south-london-and-maudsley-nhs-foundation-trust-of-the-maudsley-hospi","cat":"research","name":"South London and Maudsley NHS Foundation Trust of The Maudsley Hospital","city":"London","country":"United Kingdom","cc":"GB","lat":51.51394,"lon":-0.12099,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-south-london-and-maudsley-nhs-foundation-trust-of-the-maudsley-hospi"},{"id":"nct06809595-4-medical-clinical-solutions-manchester","cat":"research","name":"4 Medical Clinical Solutions","city":"Manchester","country":"United Kingdom","cc":"GB","lat":53.4698,"lon":-2.23409,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-4-medical-clinical-solutions-manchester"},{"id":"nct06809595-st-george-s-community-health-centre-sheffield","cat":"research","name":"St George's Community Health Centre","city":"Sheffield","country":"United Kingdom","cc":"GB","lat":53.3801,"lon":-1.46538,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Anxiety"],"nct":"NCT06809595","study":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT06809595","phase":"Phase 3","enroll":245,"start":"2025-01-29","eid":"x:site:nct06809595-st-george-s-community-health-centre-sheffield"},{"id":"nct01878942-university-hospital-basel-basel","cat":"research","name":"University Hospital Basel","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","cc":"CH","lat":47.55204,"lon":7.56287,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"4031","condg":["Healthy volunteers"],"nct":"NCT01878942","study":"Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, MD, MAS (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT01878942","phase":"EARLY_Phase 1","enroll":16,"start":"2013-06","eid":"x:site:nct01878942-university-hospital-basel-basel"},{"id":"nct02033707-behavioral-pharmacology-research-unit-johns-hopkins-bayview-medical-","cat":"research","name":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28196,"lon":-76.62221,"gp":"city","unnamed":0,"drugs":["LSD","MDMA","ketamine","mescaline","psilocybin","salvinorin A"],"zip":"21224","condg":["Healthy volunteers"],"nct":"NCT02033707","study":"Effects of Hallucinogens and Other Drugs on Mood and Performance","sstatus":"COMPLETED","sponsor":"Johns Hopkins University","official":"Roland R Griffiths, Ph.D. (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT02033707","phase":"Phase 1","enroll":20,"start":"2014-04","eid":"x:site:nct02033707-behavioral-pharmacology-research-unit-johns-hopkins-bayview-medical-"},{"id":"nct01415427-unnamed-trial-site-phoenix","cat":"research","name":"Unnamed trial site","city":"Phoenix","region":"Arizona","country":"United States","cc":"US","lat":33.45012,"lon":-112.07173,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-phoenix"},{"id":"nct01415427-unnamed-trial-site-oakland","cat":"research","name":"Unnamed trial site","city":"Oakland","region":"California","country":"United States","cc":"US","lat":37.80611,"lon":-122.26021,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-oakland"},{"id":"nct01415427-unnamed-trial-site-orange","cat":"research","name":"Unnamed trial site","city":"Orange","region":"California","country":"United States","cc":"US","lat":33.77701,"lon":-117.85899,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-orange"},{"id":"nct01415427-unnamed-trial-site-wilmington","cat":"research","name":"Unnamed trial site","city":"Wilmington","region":"Delaware","country":"United States","cc":"US","lat":34.2246,"lon":-77.93922,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-wilmington"},{"id":"nct01415427-unnamed-trial-site-washington-d-c","cat":"research","name":"Unnamed trial site","city":"Washington D.C.","region":"District of Columbia","country":"United States","cc":"US","lat":38.89525,"lon":-77.04461,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-washington-d-c"},{"id":"nct01415427-unnamed-trial-site-orlando","cat":"research","name":"Unnamed trial site","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.54978,"lon":-81.37891,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-orlando"},{"id":"nct01415427-unnamed-trial-site-honolulu","cat":"research","name":"Unnamed trial site","city":"Honolulu","region":"Hawaii","country":"United States","cc":"US","lat":21.30887,"lon":-157.85828,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-honolulu"},{"id":"nct01415427-unnamed-trial-site-chicago","cat":"research","name":"Unnamed trial site","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.84801,"lon":-87.65659,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-chicago"},{"id":"nct01415427-unnamed-trial-site-new-york","cat":"research","name":"Unnamed trial site","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70227,"lon":-73.99661,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-new-york"},{"id":"nct01415427-unnamed-trial-site-seattle","cat":"research","name":"Unnamed trial site","city":"Seattle","region":"Washington","country":"United States","cc":"US","lat":47.60654,"lon":-122.32826,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-seattle"},{"id":"nct01415427-unnamed-trial-site-cordoba","cat":"research","name":"Unnamed trial site","city":"Córdoba","country":"Argentina","cc":"AR","lat":-31.41302,"lon":-64.18397,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-cordoba"},{"id":"nct01415427-unnamed-trial-site-campina-grande","cat":"research","name":"Unnamed trial site","city":"Campina Grande","country":"Brazil","cc":"BR","lat":-7.24002,"lon":-35.87937,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-campina-grande"},{"id":"nct01415427-unnamed-trial-site-porto-alegre","cat":"research","name":"Unnamed trial site","city":"Porto Alegre","country":"Brazil","cc":"BR","lat":-30.03495,"lon":-51.23184,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-porto-alegre"},{"id":"nct01415427-unnamed-trial-site-rio-de-janeiro","cat":"research","name":"Unnamed trial site","city":"Rio de Janeiro","country":"Brazil","cc":"BR","lat":-22.91249,"lon":-43.17616,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-rio-de-janeiro"},{"id":"nct01415427-unnamed-trial-site-montreal","cat":"research","name":"Unnamed trial site","city":"Montreal","country":"Canada","cc":"CA","lat":45.50136,"lon":-73.58983,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-montreal"},{"id":"nct01415427-unnamed-trial-site-sherbrooke","cat":"research","name":"Unnamed trial site","city":"Sherbrooke","country":"Canada","cc":"CA","lat":45.4005,"lon":-71.89056,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-sherbrooke"},{"id":"nct01415427-unnamed-trial-site-toronto","cat":"research","name":"Unnamed trial site","city":"Toronto","country":"Canada","cc":"CA","lat":43.71824,"lon":-79.40264,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-toronto"},{"id":"nct01415427-unnamed-trial-site-bogota","cat":"research","name":"Unnamed trial site","city":"Bogotá","country":"Colombia","cc":"CO","lat":4.61315,"lon":-74.07587,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-bogota"},{"id":"nct01415427-unnamed-trial-site-copenhagen","cat":"research","name":"Unnamed trial site","city":"Copenhagen","country":"Denmark","cc":"DK","lat":55.6693,"lon":12.562,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-copenhagen"},{"id":"nct01415427-unnamed-trial-site-lyon","cat":"research","name":"Unnamed trial site","city":"Lyon","country":"France","cc":"FR","lat":45.75297,"lon":4.85904,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-lyon"},{"id":"nct01415427-unnamed-trial-site-marseille","cat":"research","name":"Unnamed trial site","city":"Marseille","country":"France","cc":"FR","lat":43.2938,"lon":5.37302,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-marseille"},{"id":"nct01415427-unnamed-trial-site-paris","cat":"research","name":"Unnamed trial site","city":"Paris","country":"France","cc":"FR","lat":48.8495,"lon":2.3592,"gp":"city","unnamed":1,"drugs":["LSD"],"zip":"Cedex 12","condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-paris"},{"id":"nct01415427-unnamed-trial-site-paris-2","cat":"research","name":"Unnamed trial site","city":"Paris","country":"France","cc":"FR","lat":48.85157,"lon":2.3544,"gp":"city","unnamed":1,"drugs":["LSD"],"zip":"Cedex 15","condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-paris-2"},{"id":"nct01415427-unnamed-trial-site-mainz","cat":"research","name":"Unnamed trial site","city":"Mainz","country":"Germany","cc":"DE","lat":49.97267,"lon":8.2822,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-mainz"},{"id":"nct01415427-unnamed-trial-site-monza","cat":"research","name":"Unnamed trial site","city":"Monza","country":"Italy","cc":"IT","lat":45.57313,"lon":9.27947,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-monza"},{"id":"nct01415427-unnamed-trial-site-tokyo","cat":"research","name":"Unnamed trial site","city":"Tokyo","country":"Japan","cc":"JP","lat":35.69322,"lon":139.68018,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-tokyo"},{"id":"nct01415427-unnamed-trial-site-amsterdam","cat":"research","name":"Unnamed trial site","city":"Amsterdam","country":"Netherlands","cc":"NL","lat":52.36909,"lon":4.89633,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-amsterdam"},{"id":"nct01415427-unnamed-trial-site-oslo","cat":"research","name":"Unnamed trial site","city":"Oslo","country":"Norway","cc":"NO","lat":59.91353,"lon":10.75216,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-oslo"},{"id":"nct01415427-unnamed-trial-site-coimbra","cat":"research","name":"Unnamed trial site","city":"Coimbra","country":"Portugal","cc":"PT","lat":40.20493,"lon":-8.41445,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-coimbra"},{"id":"nct01415427-unnamed-trial-site-lisbon","cat":"research","name":"Unnamed trial site","city":"Lisbon","country":"Portugal","cc":"PT","lat":38.73436,"lon":-9.14599,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-lisbon"},{"id":"nct01415427-unnamed-trial-site-doha","cat":"research","name":"Unnamed trial site","city":"Doha","country":"Qatar","cc":"QA","lat":25.29726,"lon":51.53731,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-doha"},{"id":"nct01415427-unnamed-trial-site-riyadh","cat":"research","name":"Unnamed trial site","city":"Riyadh","country":"Saudi Arabia","cc":"SA","lat":24.69173,"lon":46.72237,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-riyadh"},{"id":"nct01415427-unnamed-trial-site-seoul","cat":"research","name":"Unnamed trial site","city":"Seoul","country":"South Korea","cc":"KR","lat":37.56125,"lon":126.96706,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-seoul"},{"id":"nct01415427-unnamed-trial-site-santiago-de-compostela","cat":"research","name":"Unnamed trial site","city":"Santiago de Compostela","country":"Spain","cc":"ES","lat":42.87624,"lon":-8.54489,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-santiago-de-compostela"},{"id":"nct01415427-unnamed-trial-site-taipei","cat":"research","name":"Unnamed trial site","city":"Taipei","country":"Taiwan","cc":"TW","lat":25.05405,"lon":121.53538,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-taipei"},{"id":"nct01415427-unnamed-trial-site-ankara","cat":"research","name":"Unnamed trial site","city":"Ankara","country":"Turkey","cc":"TR","lat":39.93102,"lon":32.85215,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-ankara"},{"id":"nct01415427-unnamed-trial-site-belfast","cat":"research","name":"Unnamed trial site","city":"Belfast","country":"United Kingdom","cc":"GB","lat":54.58764,"lon":-5.91416,"gp":"city","unnamed":1,"drugs":["LSD"],"zip":"BT9 7AB","condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-belfast"},{"id":"nct01415427-unnamed-trial-site-birmingham","cat":"research","name":"Unnamed trial site","city":"Birmingham","country":"United Kingdom","cc":"GB","lat":52.48222,"lon":-1.89602,"gp":"city","unnamed":1,"drugs":["LSD"],"zip":"B15 2TH","condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-birmingham"},{"id":"nct01415427-unnamed-trial-site-birmingham-2","cat":"research","name":"Unnamed trial site","city":"Birmingham","country":"United Kingdom","cc":"GB","lat":52.48401,"lon":-1.89489,"gp":"city","unnamed":1,"drugs":["LSD"],"zip":"B4 6NH","condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-birmingham-2"},{"id":"nct01415427-unnamed-trial-site-london","cat":"research","name":"Unnamed trial site","city":"London","country":"United Kingdom","cc":"GB","lat":51.50933,"lon":-0.13445,"gp":"city","unnamed":1,"drugs":["LSD"],"zip":"NW3 2PF","condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-london"},{"id":"nct01415427-unnamed-trial-site-london-2","cat":"research","name":"Unnamed trial site","city":"London","country":"United Kingdom","cc":"GB","lat":51.50105,"lon":-0.1272,"gp":"city","unnamed":1,"drugs":["LSD"],"zip":"WC1N 3BG","condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-london-2"},{"id":"nct01415427-unnamed-trial-site-london-3","cat":"research","name":"Unnamed trial site","city":"London","country":"United Kingdom","cc":"GB","lat":51.51262,"lon":-0.12438,"gp":"city","unnamed":1,"drugs":["LSD"],"zip":"WC1N 3JH","condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-london-3"},{"id":"nct01415427-unnamed-trial-site-manchester","cat":"research","name":"Unnamed trial site","city":"Manchester","country":"United Kingdom","cc":"GB","lat":53.4889,"lon":-2.22694,"gp":"city","unnamed":1,"drugs":["LSD"],"zip":"M13 9WL","condg":["Other"],"nct":"NCT01415427","study":"Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01415427","phase":"Phase 3","enroll":173,"start":"2011-07","eid":"x:site:nct01415427-unnamed-trial-site-manchester"},{"id":"nct05200936-maastricht-university-maastricht","cat":"research","name":"Maastricht University","city":"Maastricht","country":"Netherlands","cc":"NL","lat":50.84668,"lon":5.68555,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Other"],"nct":"NCT05200936","study":"Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial","sstatus":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","official":"Kim Kuypers (Maastricht University); Matthias Liechti (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT05200936","phase":"Phase 2","enroll":53,"start":"2021-12-17","eid":"x:site:nct05200936-maastricht-university-maastricht"},{"id":"nct05200936-university-hospital-basel-basel","cat":"research","name":"University Hospital Basel","city":"Basel","country":"Switzerland","cc":"CH","lat":47.55825,"lon":7.58329,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Other"],"nct":"NCT05200936","study":"Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial","sstatus":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","official":"Kim Kuypers (Maastricht University); Matthias Liechti (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT05200936","phase":"Phase 2","enroll":53,"start":"2021-12-17","eid":"x:site:nct05200936-university-hospital-basel-basel"},{"id":"nct05570708-university-hospital-basel-basel","cat":"research","name":"University Hospital Basel","city":"Basel","country":"Switzerland","cc":"CH","lat":47.54695,"lon":7.56362,"gp":"city","unnamed":0,"drugs":["LSD","MDMA","psilocybin"],"zip":"4031","condg":["Addiction & substance use"],"nct":"NCT05570708","study":"The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Felix Mueller","official":"Felix Müller, MD (University of Basel)","src":"https://clinicaltrials.gov/study/NCT05570708","phase":"N/A","enroll":48,"start":"2022-10-25","eid":"x:site:nct05570708-university-hospital-basel-basel"},{"id":"nct04080453-hopital-haut-leveque-pessac","cat":"research","name":"Hôpital Haut Lévêque","city":"Pessac","country":"France","cc":"FR","lat":44.8169,"lon":-0.63988,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"33604","condg":["Other"],"nct":"NCT04080453","study":"Pro-inflammatory Role of Blood Platelets in Critically Ill Patients With Septic Shock.","sstatus":"COMPLETED","sponsor":"University Hospital, Bordeaux","official":"Antoine DEWITTE, Dr (University Hospital, Bordeaux)","src":"https://clinicaltrials.gov/study/NCT04080453","enroll":202,"start":"2020-11-09","eid":"x:site:nct04080453-hopital-haut-leveque-pessac"},{"id":"nct03897361-university-of-california-san-diego-la-jolla","cat":"research","name":"University of California San Diego","city":"La Jolla","region":"California","country":"United States","cc":"US","lat":32.84826,"lon":-117.27236,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"92093","condg":["Other"],"nct":"NCT03897361","study":"Stem Cell Gene Therapy for Cystinosis","sstatus":"COMPLETED","sponsor":"University of California, San Diego","official":"Stephanie Cherqui, Ph.D. (University of California, San Diego)","src":"https://clinicaltrials.gov/study/NCT03897361","phase":"Phase 1/Phase 2","enroll":7,"start":"2019-07-08","eid":"x:site:nct03897361-university-of-california-san-diego-la-jolla"},{"id":"nct07189299-clinical-pharmacology-toxicology-university-hospital-basel-basel","cat":"research","name":"Clinical Pharmacology & Toxicology, University Hospital Basel","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","cc":"CH","lat":47.54677,"lon":7.56955,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"4056","condg":["Other"],"nct":"NCT07189299","study":"Microdosing LSD in Women With Premenstrual Disorders","sstatus":"NOT_YET_RECRUITING","sponsor":"Friederike Holze","src":"https://clinicaltrials.gov/study/NCT07189299","contact":{"n":"Friederike Holze, Dr.","p":"+41613287735","e":"friederike.holze@usb.ch"},"phase":"N/A","enroll":150,"start":"2025-10-01","eid":"x:site:nct07189299-clinical-pharmacology-toxicology-university-hospital-basel-basel"},{"id":"nct07461532-clinical-medical-college-yangzhou","cat":"research","name":"Clinical Medical College","city":"Yangzhou","region":"Jiangsu","country":"China","cc":"CN","lat":32.39576,"lon":119.4403,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"225001","condg":["Other"],"status":"RECRUITING","nct":"NCT07461532","study":"Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD","sstatus":"RECRUITING","sponsor":"Northern Jiangsu People's Hospital","official":"Dou-Sheng Bai (Clinical Medical College, Yangzhou University)","src":"https://clinicaltrials.gov/study/NCT07461532","contact":{"n":"Guo-Qing Jiang, MD","p":"+8651487373382","e":"jgqing2003@hotmail.com"},"phase":"N/A","enroll":20,"start":"2026-04-01","eid":"x:site:nct07461532-clinical-medical-college-yangzhou"},{"id":"nct05883540-university-hospital-basel-division-of-clinical-pharmacology-and-toxi","cat":"research","name":"University Hospital Basel, Division of Clinical Pharmacology and Toxicology","city":"Basel","country":"Switzerland","cc":"CH","lat":47.56653,"lon":7.56456,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"4031","condg":["Depression","Anxiety","End-of-life & palliative","Chronic pain & headache"],"status":"RECRUITING","nct":"NCT05883540","study":"Lysergic Acid Diethylamide (LSD) in Palliative Care","sstatus":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","official":"Yasmin Schmid, PD Dr. med. (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT05883540","contact":{"n":"Yasmin Schmid, PD Dr. med.","p":"+41 61 328 68 47","e":"yasmin.schmid@usb.ch"},"phase":"Phase 2","enroll":60,"start":"2024-06-09","eid":"x:site:nct05883540-university-hospital-basel-division-of-clinical-pharmacology-and-toxi"},{"id":"nct05883540-university-hospital-geneva-palliative-medicine-department-collonge-b","cat":"research","name":"University Hospital Geneva, Palliative medicine department","city":"Collonge-Bellerive","country":"Switzerland","cc":"CH","lat":47.0716,"lon":7.5867,"gp":"country","unnamed":0,"drugs":["LSD"],"zip":"1245","condg":["Depression","Anxiety","End-of-life & palliative","Chronic pain & headache"],"status":"RECRUITING","nct":"NCT05883540","study":"Lysergic Acid Diethylamide (LSD) in Palliative Care","sstatus":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","official":"Yasmin Schmid, PD Dr. med. (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT05883540","contact":{"n":"Michael Ljuslin, Dr. med.","p":"+41 79 553 87 92","e":"michael.ljuslin@hug.ch"},"phase":"Phase 2","enroll":60,"start":"2024-06-09","eid":"x:site:nct05883540-university-hospital-geneva-palliative-medicine-department-collonge-b"},{"id":"nct05883540-spital-uster-ag-division-of-internal-medicine-uster","cat":"research","name":"Spital Uster AG, Division of Internal Medicine","city":"Uster","country":"Switzerland","cc":"CH","lat":47.35395,"lon":8.71023,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"8610","condg":["Depression","Anxiety","End-of-life & palliative","Chronic pain & headache"],"status":"RECRUITING","nct":"NCT05883540","study":"Lysergic Acid Diethylamide (LSD) in Palliative Care","sstatus":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","official":"Yasmin Schmid, PD Dr. med. (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT05883540","contact":{"n":"Sivan Schipper, MD","p":"+41 44 911 12 91","e":"sivan.schipper@spitaluster.ch"},"phase":"Phase 2","enroll":60,"start":"2024-06-09","eid":"x:site:nct05883540-spital-uster-ag-division-of-internal-medicine-uster"},{"id":"nct05883540-university-hospital-zurich-clinic-for-radio-oncology-competence-cent","cat":"research","name":"University Hospital Zurich, Clinic for Radio-Oncology, Competence Centre Palliative Care","city":"Zurich","country":"Switzerland","cc":"CH","lat":47.35486,"lon":8.54384,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Depression","Anxiety","End-of-life & palliative","Chronic pain & headache"],"status":"RECRUITING","nct":"NCT05883540","study":"Lysergic Acid Diethylamide (LSD) in Palliative Care","sstatus":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","official":"Yasmin Schmid, PD Dr. med. (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT05883540","contact":{"n":"David Blum, Prof Dr med","p":"+41 44 255 37 42","e":"david.blum@usz.ch"},"phase":"Phase 2","enroll":60,"start":"2024-06-09","eid":"x:site:nct05883540-university-hospital-zurich-clinic-for-radio-oncology-competence-cent"},{"id":"nct01242111-unnamed-trial-site-birmingham","cat":"research","name":"Unnamed trial site","city":"Birmingham","region":"United Kingdom","country":"United Kingdom","cc":"GB","lat":52.47168,"lon":-1.89677,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01242111","study":"A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, MD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01242111","phase":"Phase 1/Phase 2","enroll":20,"start":"2010-11","eid":"x:site:nct01242111-unnamed-trial-site-birmingham"},{"id":"nct01242111-unnamed-trial-site-dumfries","cat":"research","name":"Unnamed trial site","city":"Dumfries","region":"United Kingdom","country":"United Kingdom","cc":"GB","lat":55.07961,"lon":-3.61106,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01242111","study":"A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, MD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01242111","phase":"Phase 1/Phase 2","enroll":20,"start":"2010-11","eid":"x:site:nct01242111-unnamed-trial-site-dumfries"},{"id":"nct01242111-unnamed-trial-site-london","cat":"research","name":"Unnamed trial site","city":"London","region":"United Kingdom","country":"United Kingdom","cc":"GB","lat":51.51131,"lon":-0.11412,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01242111","study":"A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, MD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01242111","phase":"Phase 1/Phase 2","enroll":20,"start":"2010-11","eid":"x:site:nct01242111-unnamed-trial-site-london"},{"id":"nct01242111-unnamed-trial-site-manchester","cat":"research","name":"Unnamed trial site","city":"Manchester","region":"United Kingdom","country":"United Kingdom","cc":"GB","lat":53.48721,"lon":-2.22665,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01242111","study":"A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, MD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01242111","phase":"Phase 1/Phase 2","enroll":20,"start":"2010-11","eid":"x:site:nct01242111-unnamed-trial-site-manchester"},{"id":"nct07490405-northern-jiangsu-people-s-hospital-yangzhou","cat":"research","name":"Northern Jiangsu People's Hospital","city":"Yangzhou","region":"Jiangsu","country":"China","cc":"CN","lat":32.39058,"lon":119.44444,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"225000","condg":["Other"],"nct":"NCT07490405","study":"Long-term Efficacy and Safety of LSD Versus TIPS for Cirrhotic Portal Hypertension Bleeding and Hypersplenism","sstatus":"NOT_YET_RECRUITING","sponsor":"Northern Jiangsu People's Hospital","src":"https://clinicaltrials.gov/study/NCT07490405","contact":{"n":"Guoqing Jiang, MD","p":"18051060606","e":"jgqing2003@hotmail.com"},"enroll":140,"start":"2026-06-01","eid":"x:site:nct07490405-northern-jiangsu-people-s-hospital-yangzhou"},{"id":"nct03321136-university-hospital-basel","cat":"research","name":"University Hospital","city":"Basel","country":"Switzerland","cc":"CH","lat":47.55684,"lon":7.56146,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"4031","condg":["Healthy volunteers"],"nct":"NCT03321136","study":"Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, MD, MAS (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT03321136","phase":"EARLY_Phase 1","enroll":16,"start":"2017-11-28","eid":"x:site:nct03321136-university-hospital-basel"},{"id":"nct04516902-university-hospital-basel-clinical-trial-unit-basel","cat":"research","name":"University Hospital Basel, Clinical Trial Unit","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","cc":"CH","lat":47.56606,"lon":7.58452,"gp":"city","unnamed":0,"drugs":["LSD","MDMA"],"zip":"4056","condg":["Healthy volunteers"],"nct":"NCT04516902","study":"Effects of MDMA Co-administration on the Response to LSD in Healthy Subjects","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, Prof. Dr. MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT04516902","phase":"Phase 1","enroll":24,"start":"2021-01-01","eid":"x:site:nct04516902-university-hospital-basel-clinical-trial-unit-basel"},{"id":"nct02435030-university-hospital-copenhagen-rigshospitalet-copenhagen","cat":"research","name":"University Hospital Copenhagen (Rigshospitalet)","city":"Copenhagen","country":"Denmark","cc":"DK","lat":55.67345,"lon":12.57565,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"2100","condg":["Other"],"nct":"NCT02435030","study":"A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C","sstatus":"COMPLETED","sponsor":"ZevraDenmark","official":"Karl-Eugen Mengel (Villa Metabolica, Mainz, Germany)","src":"https://clinicaltrials.gov/study/NCT02435030","enroll":35,"start":"2015-09","eid":"x:site:nct02435030-university-hospital-copenhagen-rigshospitalet-copenhagen"},{"id":"nct02435030-chu-de-montpellier-montpellier","cat":"research","name":"CHU de Montpellier","city":"Montpellier","country":"France","cc":"FR","lat":43.60373,"lon":3.87,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Other"],"nct":"NCT02435030","study":"A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C","sstatus":"COMPLETED","sponsor":"ZevraDenmark","official":"Karl-Eugen Mengel (Villa Metabolica, Mainz, Germany)","src":"https://clinicaltrials.gov/study/NCT02435030","enroll":35,"start":"2015-09","eid":"x:site:nct02435030-chu-de-montpellier-montpellier"},{"id":"nct02435030-hopital-trousseau-paris","cat":"research","name":"Hôpital Trousseau","city":"Paris","country":"France","cc":"FR","lat":48.86146,"lon":2.3512,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Other"],"nct":"NCT02435030","study":"A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C","sstatus":"COMPLETED","sponsor":"ZevraDenmark","official":"Karl-Eugen Mengel (Villa Metabolica, Mainz, Germany)","src":"https://clinicaltrials.gov/study/NCT02435030","enroll":35,"start":"2015-09","eid":"x:site:nct02435030-hopital-trousseau-paris"},{"id":"nct02435030-villa-metabolica-mainz-mainz","cat":"research","name":"Villa Metabolica Mainz","city":"Mainz","country":"Germany","cc":"DE","lat":49.9819,"lon":8.2917,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"55131","condg":["Other"],"nct":"NCT02435030","study":"A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C","sstatus":"COMPLETED","sponsor":"ZevraDenmark","official":"Karl-Eugen Mengel (Villa Metabolica, Mainz, Germany)","src":"https://clinicaltrials.gov/study/NCT02435030","enroll":35,"start":"2015-09","eid":"x:site:nct02435030-villa-metabolica-mainz-mainz"},{"id":"nct02435030-klinikum-der-universistat-munchen-munich","cat":"research","name":"Klinikum der Universistat, Munchen","city":"Munich","country":"Germany","cc":"DE","lat":48.13098,"lon":11.57714,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Other"],"nct":"NCT02435030","study":"A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C","sstatus":"COMPLETED","sponsor":"ZevraDenmark","official":"Karl-Eugen Mengel (Villa Metabolica, Mainz, Germany)","src":"https://clinicaltrials.gov/study/NCT02435030","enroll":35,"start":"2015-09","eid":"x:site:nct02435030-klinikum-der-universistat-munchen-munich"},{"id":"nct02435030-istituto-carlo-besta-milano-milan","cat":"research","name":"Istituto Carlo Besta (Milano)","city":"Milan","country":"Italy","cc":"IT","lat":45.46931,"lon":9.19831,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"20133","condg":["Other"],"nct":"NCT02435030","study":"A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C","sstatus":"COMPLETED","sponsor":"ZevraDenmark","official":"Karl-Eugen Mengel (Villa Metabolica, Mainz, Germany)","src":"https://clinicaltrials.gov/study/NCT02435030","enroll":35,"start":"2015-09","eid":"x:site:nct02435030-istituto-carlo-besta-milano-milan"},{"id":"nct02435030-azienda-ospedaliera-san-gerardo-monza","cat":"research","name":"Azienda Ospedaliera San Gerardo","city":"Monza","country":"Italy","cc":"IT","lat":45.572,"lon":9.27194,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"20900","condg":["Other"],"nct":"NCT02435030","study":"A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C","sstatus":"COMPLETED","sponsor":"ZevraDenmark","official":"Karl-Eugen Mengel (Villa Metabolica, Mainz, Germany)","src":"https://clinicaltrials.gov/study/NCT02435030","enroll":35,"start":"2015-09","eid":"x:site:nct02435030-azienda-ospedaliera-san-gerardo-monza"},{"id":"nct02435030-universita-federico-ii-naples","cat":"research","name":"Università Federico II","city":"Naples","country":"Italy","cc":"IT","lat":40.86124,"lon":14.26213,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"80138","condg":["Other"],"nct":"NCT02435030","study":"A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C","sstatus":"COMPLETED","sponsor":"ZevraDenmark","official":"Karl-Eugen Mengel (Villa Metabolica, Mainz, Germany)","src":"https://clinicaltrials.gov/study/NCT02435030","enroll":35,"start":"2015-09","eid":"x:site:nct02435030-universita-federico-ii-naples"},{"id":"nct02435030-ospedale-pediatrico-bambino-gesu-rome","cat":"research","name":"Ospedale Pediatrico Bambino Gesù","city":"Rome","country":"Italy","cc":"IT","lat":41.88981,"lon":12.5094,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"00146","condg":["Other"],"nct":"NCT02435030","study":"A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C","sstatus":"COMPLETED","sponsor":"ZevraDenmark","official":"Karl-Eugen Mengel (Villa Metabolica, Mainz, Germany)","src":"https://clinicaltrials.gov/study/NCT02435030","enroll":35,"start":"2015-09","eid":"x:site:nct02435030-ospedale-pediatrico-bambino-gesu-rome"},{"id":"nct02435030-azienda-ospedaliero-universitaria-santa-maria-della-misericordia-udi","cat":"research","name":"Azienda Ospedaliero-Universitaria \"Santa Maria della Misericordia\"","city":"Udine","country":"Italy","cc":"IT","lat":46.0765,"lon":13.23014,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Other"],"nct":"NCT02435030","study":"A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C","sstatus":"COMPLETED","sponsor":"ZevraDenmark","official":"Karl-Eugen Mengel (Villa Metabolica, Mainz, Germany)","src":"https://clinicaltrials.gov/study/NCT02435030","enroll":35,"start":"2015-09","eid":"x:site:nct02435030-azienda-ospedaliero-universitaria-santa-maria-della-misericordia-udi"},{"id":"nct02435030-the-children-s-memorial-istitute-warsaw-warsaw","cat":"research","name":"The Children´s Memorial Istitute Warsaw","city":"Warsaw","country":"Poland","cc":"PL","lat":52.22841,"lon":21.00656,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"04-730","condg":["Other"],"nct":"NCT02435030","study":"A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C","sstatus":"COMPLETED","sponsor":"ZevraDenmark","official":"Karl-Eugen Mengel (Villa Metabolica, Mainz, Germany)","src":"https://clinicaltrials.gov/study/NCT02435030","enroll":35,"start":"2015-09","eid":"x:site:nct02435030-the-children-s-memorial-istitute-warsaw-warsaw"},{"id":"nct02435030-hospital-vall-d-hebron-barcelona","cat":"research","name":"Hospital Vall D'Hebron","city":"Barcelona","country":"Spain","cc":"ES","lat":41.38771,"lon":2.16732,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"08035","condg":["Other"],"nct":"NCT02435030","study":"A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C","sstatus":"COMPLETED","sponsor":"ZevraDenmark","official":"Karl-Eugen Mengel (Villa Metabolica, Mainz, Germany)","src":"https://clinicaltrials.gov/study/NCT02435030","enroll":35,"start":"2015-09","eid":"x:site:nct02435030-hospital-vall-d-hebron-barcelona"},{"id":"nct02435030-hospital-quiron-zaragoza","cat":"research","name":"Hospital Quirón","city":"Zaragoza","country":"Spain","cc":"ES","lat":41.64415,"lon":-0.86628,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"50006","condg":["Other"],"nct":"NCT02435030","study":"A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C","sstatus":"COMPLETED","sponsor":"ZevraDenmark","official":"Karl-Eugen Mengel (Villa Metabolica, Mainz, Germany)","src":"https://clinicaltrials.gov/study/NCT02435030","enroll":35,"start":"2015-09","eid":"x:site:nct02435030-hospital-quiron-zaragoza"},{"id":"nct02435030-inselspital-university-hospital-bern-bern","cat":"research","name":"Inselspital, University Hospital Bern","city":"Bern","country":"Switzerland","cc":"CH","lat":46.9456,"lon":7.45558,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"3010","condg":["Other"],"nct":"NCT02435030","study":"A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C","sstatus":"COMPLETED","sponsor":"ZevraDenmark","official":"Karl-Eugen Mengel (Villa Metabolica, Mainz, Germany)","src":"https://clinicaltrials.gov/study/NCT02435030","enroll":35,"start":"2015-09","eid":"x:site:nct02435030-inselspital-university-hospital-bern-bern"},{"id":"nct02435030-birmingham-children-s-hospital-birmingham","cat":"research","name":"Birmingham Children's Hospital","city":"Birmingham","country":"United Kingdom","cc":"GB","lat":52.47224,"lon":-1.91079,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"B4 6NH","condg":["Other"],"nct":"NCT02435030","study":"A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C","sstatus":"COMPLETED","sponsor":"ZevraDenmark","official":"Karl-Eugen Mengel (Villa Metabolica, Mainz, Germany)","src":"https://clinicaltrials.gov/study/NCT02435030","enroll":35,"start":"2015-09","eid":"x:site:nct02435030-birmingham-children-s-hospital-birmingham"},{"id":"nct02435030-great-ormond-street-hospital-london","cat":"research","name":"Great Ormond Street Hospital","city":"London","country":"United Kingdom","cc":"GB","lat":51.49945,"lon":-0.13172,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"WC1N 3JH","condg":["Other"],"nct":"NCT02435030","study":"A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C","sstatus":"COMPLETED","sponsor":"ZevraDenmark","official":"Karl-Eugen Mengel (Villa Metabolica, Mainz, Germany)","src":"https://clinicaltrials.gov/study/NCT02435030","enroll":35,"start":"2015-09","eid":"x:site:nct02435030-great-ormond-street-hospital-london"},{"id":"nct01515956-unnamed-trial-site-oakland","cat":"research","name":"Unnamed trial site","city":"Oakland","region":"California","country":"United States","cc":"US","lat":37.80621,"lon":-122.28176,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01515956","study":"Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01515956","phase":"Phase 2","enroll":15,"start":"2011-10","eid":"x:site:nct01515956-unnamed-trial-site-oakland"},{"id":"nct01515956-unnamed-trial-site-manhasset","cat":"research","name":"Unnamed trial site","city":"Manhasset","region":"New York","country":"United States","cc":"US","lat":40.78607,"lon":-73.69341,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01515956","study":"Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01515956","phase":"Phase 2","enroll":15,"start":"2011-10","eid":"x:site:nct01515956-unnamed-trial-site-manhasset"},{"id":"nct01515956-unnamed-trial-site-monza","cat":"research","name":"Unnamed trial site","city":"Monza","country":"Italy","cc":"IT","lat":45.5833,"lon":9.26291,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01515956","study":"Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01515956","phase":"Phase 2","enroll":15,"start":"2011-10","eid":"x:site:nct01515956-unnamed-trial-site-monza"},{"id":"nct01515956-unnamed-trial-site-taipei","cat":"research","name":"Unnamed trial site","city":"Taipei","country":"Taiwan","cc":"TW","lat":25.04868,"lon":121.52568,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01515956","study":"Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01515956","phase":"Phase 2","enroll":15,"start":"2011-10","eid":"x:site:nct01515956-unnamed-trial-site-taipei"},{"id":"nct01515956-unnamed-trial-site-central-manchester","cat":"research","name":"Unnamed trial site","city":"Central Manchester","country":"United Kingdom","cc":"GB","lat":51.7889,"lon":0.3194,"gp":"country","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01515956","study":"Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)","sstatus":"COMPLETED","sponsor":"BioMarin Pharmaceutical","official":"Debra Lounsbury (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01515956","phase":"Phase 2","enroll":15,"start":"2011-10","eid":"x:site:nct01515956-unnamed-trial-site-central-manchester"},{"id":"nct03207165-university-of-ottawa-heart-institute-ottawa","cat":"research","name":"University of Ottawa Heart Institute","city":"Ottawa","region":"Ontario","country":"Canada","cc":"CA","lat":45.42317,"lon":-75.69243,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"K1Y 4W7","condg":["Other"],"nct":"NCT03207165","study":"Milrinone Versus Dobutamine in Critically Ill Patients","sstatus":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","official":"Benjamin M Hibbert, MD, PhD (Ottawa Heart Institute Research Corporation)","src":"https://clinicaltrials.gov/study/NCT03207165","phase":"Phase 4","enroll":192,"start":"2017-08-30","eid":"x:site:nct03207165-university-of-ottawa-heart-institute-ottawa"},{"id":"nct03781128-clinical-pharmacology-toxicology-university-hospital-basel-basel","cat":"research","name":"Clinical Pharmacology & Toxicology, University Hospital Basel","city":"Basel","country":"Switzerland","cc":"CH","lat":47.5702,"lon":7.56315,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"4031","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT03781128","study":"Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache","sstatus":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias Liechti (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT03781128","contact":{"n":"Matthias Liechti, Prof.","p":"+41 61 328 68 68","e":"matthias.liechti@usb.ch"},"phase":"Phase 2","enroll":30,"start":"2019-01-02","eid":"x:site:nct03781128-clinical-pharmacology-toxicology-university-hospital-basel-basel"},{"id":"nct07164287-geneva-university-hospital-geneva","cat":"research","name":"Geneva University Hospital","city":"Geneva","country":"Switzerland","cc":"CH","lat":46.21168,"lon":6.15308,"gp":"city","unnamed":0,"drugs":["LSD","psilocybin"],"condg":["Depression","Anxiety","PTSD & trauma","Addiction & substance use"],"nct":"NCT07164287","study":"Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Geneva","src":"https://clinicaltrials.gov/study/NCT07164287","enroll":376,"start":"2020-06-01","eid":"x:site:nct07164287-geneva-university-hospital-geneva"},{"id":"nct05670184-maastricht-university-maastricht","cat":"research","name":"Maastricht University","city":"Maastricht","country":"Netherlands","cc":"NL","lat":50.84838,"lon":5.68847,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Other"],"status":"RECRUITING","nct":"NCT05670184","study":"The Effect of LSD on Neural Synchrony, Prosocial Behavior, and Relationship Quality","sstatus":"UNKNOWN","sponsor":"Maastricht University","official":"Johannes G Ramaekers, PhD (Maastricht University)","src":"https://clinicaltrials.gov/study/NCT05670184","contact":{"n":"Natasha Mason, PhD","p":"+31 43 3881382","e":"natasha.mason@maastrichtuniversity.nl"},"phase":"Phase 1/Phase 2","enroll":60,"start":"2023-01-01","eid":"x:site:nct05670184-maastricht-university-maastricht"},{"id":"nct03934710-matthew-bona-chicago","cat":"research","name":"Matthew Bona","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.85224,"lon":-87.6485,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"60637","condg":["Healthy volunteers"],"nct":"NCT03934710","study":"Mood Effects of Serotonin Agonists Extended","sstatus":"COMPLETED","sponsor":"University of Chicago","official":"Harriet de Wit (University of Chicago)","src":"https://clinicaltrials.gov/study/NCT03934710","phase":"Phase 1","enroll":56,"start":"2019-04-20","eid":"x:site:nct03934710-matthew-bona-chicago"},{"id":"nct04558294-clinical-pharmacology-toxicology-university-hospital-basel-basel","cat":"research","name":"Clinical Pharmacology & Toxicology, University Hospital Basel","city":"Basel","country":"Switzerland","cc":"CH","lat":47.55015,"lon":7.56598,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"4031","condg":["Healthy volunteers"],"nct":"NCT04558294","study":"Effect of Ketanserin After LSD Administration","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, Dr., MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT04558294","phase":"Phase 1","enroll":24,"start":"2020-10-16","eid":"x:site:nct04558294-clinical-pharmacology-toxicology-university-hospital-basel-basel"},{"id":"nct01299727-emma-children-s-hospital-academic-medical-center-amsterdam","cat":"research","name":"Emma Children's Hospital, Academic Medical Center","city":"Amsterdam","country":"Netherlands","cc":"NL","lat":52.36702,"lon":4.89924,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01299727","study":"Extension of Study HGT-SAN-055 Evaluating Administration of rhHNS in Patients With Sanfilippo Syndrome Type A (MPS IIIA)","sstatus":"TERMINATED","sponsor":"Shire","official":"Study Director (Takeda)","src":"https://clinicaltrials.gov/study/NCT01299727","phase":"Phase 1/Phase 2","enroll":12,"start":"2011-03-01","eid":"x:site:nct01299727-emma-children-s-hospital-academic-medical-center-amsterdam"},{"id":"nct01299727-st-mary-s-hospital-manchester","cat":"research","name":"St. Mary's Hospital","city":"Manchester","country":"United Kingdom","cc":"GB","lat":53.48853,"lon":-2.23484,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01299727","study":"Extension of Study HGT-SAN-055 Evaluating Administration of rhHNS in Patients With Sanfilippo Syndrome Type A (MPS IIIA)","sstatus":"TERMINATED","sponsor":"Shire","official":"Study Director (Takeda)","src":"https://clinicaltrials.gov/study/NCT01299727","phase":"Phase 1/Phase 2","enroll":12,"start":"2011-03-01","eid":"x:site:nct01299727-st-mary-s-hospital-manchester"},{"id":"nct03633253-jewish-general-hospital-montreal","cat":"research","name":"Jewish General Hospital","city":"Montreal","region":"Quebec","country":"Canada","cc":"CA","lat":45.50578,"lon":-73.58889,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"H3T 1E2","condg":["Neurology & cognition"],"nct":"NCT03633253","study":"The \"Motoric Cognitive Risk\" Syndrome in the Quebec Population","sstatus":"UNKNOWN","sponsor":"Jewish General Hospital","src":"https://clinicaltrials.gov/study/NCT03633253","enroll":1741,"start":"2016-12-07","eid":"x:site:nct03633253-jewish-general-hospital-montreal"},{"id":"nct05046275-criugm-montreal","cat":"research","name":"CRIUGM","city":"Montreal","region":"Quebec","country":"Canada","cc":"CA","lat":45.51915,"lon":-73.58475,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"H3W 1W5","condg":["Neurology & cognition"],"nct":"NCT05046275","study":"MCR Syndrome in Quebec : Results From NuAge Study","sstatus":"UNKNOWN","sponsor":"Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal","src":"https://clinicaltrials.gov/study/NCT05046275","enroll":1741,"start":"2020-11-03","eid":"x:site:nct05046275-criugm-montreal"},{"id":"nct05474989-university-hospital-of-psychiatry-university-of-basel-basel","cat":"research","name":"University Hospital of Psychiatry, University of Basel","city":"Basel","country":"Switzerland","cc":"CH","lat":47.56013,"lon":7.57209,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT05474989","study":"LSD Treatment for Persons With Alcohol Use Disorder","sstatus":"RECRUITING","sponsor":"Felix Mueller","src":"https://clinicaltrials.gov/study/NCT05474989","contact":{"n":"Felix Müller, PD Dr. med.","p":"+41 (0)61 325 5111","e":"felix.mueller@upk.ch"},"phase":"Phase 2","enroll":128,"start":"2026-01-27","eid":"x:site:nct05474989-university-hospital-of-psychiatry-university-of-basel-basel"},{"id":"nct05474989-university-hospital-of-psychiatry-university-of-bern-bern","cat":"research","name":"University Hospital of Psychiatry, University of Bern","city":"Bern","country":"Switzerland","cc":"CH","lat":46.94842,"lon":7.44956,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT05474989","study":"LSD Treatment for Persons With Alcohol Use Disorder","sstatus":"RECRUITING","sponsor":"Felix Mueller","src":"https://clinicaltrials.gov/study/NCT05474989","contact":{"n":"Leila Soravia, Prof. Dr. phil.","p":"+41 (0)61 325 5111","e":"felix.mueller@upk.ch"},"phase":"Phase 2","enroll":128,"start":"2026-01-27","eid":"x:site:nct05474989-university-hospital-of-psychiatry-university-of-bern-bern"},{"id":"nct02082327-pra-international-groningen","cat":"research","name":"PRA International","city":"Groningen","country":"Netherlands","cc":"NL","lat":53.21517,"lon":6.56107,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"9713 GZ","condg":["Other"],"nct":"NCT02082327","study":"A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers","sstatus":"COMPLETED","sponsor":"Amicus Therapeutics","official":"Medical Monitor Clinical Research (Amicus Therapeutics)","src":"https://clinicaltrials.gov/study/NCT02082327","phase":"Phase 1","enroll":31,"start":"2014-03","eid":"x:site:nct02082327-pra-international-groningen"},{"id":"nct05964647-university-hospital-basel-basel","cat":"research","name":"University Hospital Basel","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","cc":"CH","lat":47.55759,"lon":7.57078,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"4055","condg":["Healthy volunteers"],"nct":"NCT05964647","study":"Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","src":"https://clinicaltrials.gov/study/NCT05964647","phase":"Phase 1","enroll":20,"start":"2024-02-01","eid":"x:site:nct05964647-university-hospital-basel-basel"},{"id":"nct05674669-parexel-early-phase-clinical-unit-london","cat":"research","name":"PAREXEL, Early Phase Clinical Unit","city":"London","country":"United Kingdom","cc":"GB","lat":51.51404,"lon":-0.11459,"gp":"city","unnamed":0,"drugs":["LSD"],"condg":["Healthy volunteers"],"nct":"NCT05674669","study":"A Dose-Ranging Study of 50 µg to 100 µg LSD in Healthy Volunteers","sstatus":"COMPLETED","sponsor":"Eleusis Therapeutics","official":"Director of Research and Development (Eleusis Therapeutics)","src":"https://clinicaltrials.gov/study/NCT05674669","phase":"Phase 1","enroll":32,"start":"2015-10-20","eid":"x:site:nct05674669-parexel-early-phase-clinical-unit-london"},{"id":"nct02451072-center-for-psychiatric-research-department-of-psychiatry-psychothera","cat":"research","name":"Center for Psychiatric Research, Department of Psychiatry, Psychotherapy and Psychosomatic, Psychiatric Hospital, University of Zurich","city":"Zurich","country":"Switzerland","cc":"CH","lat":47.36728,"lon":8.53819,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"8032","condg":["Healthy volunteers"],"nct":"NCT02451072","study":"The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers","sstatus":"COMPLETED","sponsor":"Psychiatric University Hospital, Zurich","official":"Franz X. Vollenweider, Prof. Dr. (Center for Psychiatric Research, Department of Psychiatry, Psychotherapy and Psychosomatic, Psychiatric Hospital, University of Zurich)","src":"https://clinicaltrials.gov/study/NCT02451072","phase":"N/A","enroll":25,"start":"2015-03","eid":"x:site:nct02451072-center-for-psychiatric-research-department-of-psychiatry-psychothera"},{"id":"nct01045460-sidney-kimmel-comprehensive-cancer-center-at-johns-hopkins-baltimore","cat":"research","name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.30069,"lon":-76.61751,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"21231","condg":["Other"],"nct":"NCT01045460","study":"Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the…","sstatus":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","official":"Ivan Borrello, MD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT01045460","phase":"Phase 2","enroll":36,"start":"2010-01-15","eid":"x:site:nct01045460-sidney-kimmel-comprehensive-cancer-center-at-johns-hopkins-baltimore"},{"id":"nct01609062-unnamed-trial-site-oakland","cat":"research","name":"Unnamed trial site","city":"Oakland","region":"California","country":"United States","cc":"US","lat":37.80159,"lon":-122.28252,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01609062","study":"Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Adam Shaywitz, MD PhD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01609062","phase":"Phase 2","enroll":25,"start":"2012-04","eid":"x:site:nct01609062-unnamed-trial-site-oakland"},{"id":"nct01609062-unnamed-trial-site-chicago","cat":"research","name":"Unnamed trial site","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.83831,"lon":-87.6596,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01609062","study":"Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Adam Shaywitz, MD PhD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01609062","phase":"Phase 2","enroll":25,"start":"2012-04","eid":"x:site:nct01609062-unnamed-trial-site-chicago"},{"id":"nct01609062-unnamed-trial-site-new-york","cat":"research","name":"Unnamed trial site","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.7114,"lon":-73.99868,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01609062","study":"Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Adam Shaywitz, MD PhD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01609062","phase":"Phase 2","enroll":25,"start":"2012-04","eid":"x:site:nct01609062-unnamed-trial-site-new-york"},{"id":"nct01609062-unnamed-trial-site-houston","cat":"research","name":"Unnamed trial site","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.76577,"lon":-95.36153,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01609062","study":"Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Adam Shaywitz, MD PhD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01609062","phase":"Phase 2","enroll":25,"start":"2012-04","eid":"x:site:nct01609062-unnamed-trial-site-houston"},{"id":"nct01609062-unnamed-trial-site-calgary","cat":"research","name":"Unnamed trial site","city":"Calgary","region":"Alberta","country":"Canada","cc":"CA","lat":51.06098,"lon":-114.07564,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01609062","study":"Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Adam Shaywitz, MD PhD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01609062","phase":"Phase 2","enroll":25,"start":"2012-04","eid":"x:site:nct01609062-unnamed-trial-site-calgary"},{"id":"nct01609062-unnamed-trial-site-toronto","cat":"research","name":"Unnamed trial site","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70911,"lon":-79.39097,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01609062","study":"Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Adam Shaywitz, MD PhD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01609062","phase":"Phase 2","enroll":25,"start":"2012-04","eid":"x:site:nct01609062-unnamed-trial-site-toronto"},{"id":"nct01609062-unnamed-trial-site-montreal","cat":"research","name":"Unnamed trial site","city":"Montreal","region":"Quebec","country":"Canada","cc":"CA","lat":45.50672,"lon":-73.59125,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01609062","study":"Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Adam Shaywitz, MD PhD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01609062","phase":"Phase 2","enroll":25,"start":"2012-04","eid":"x:site:nct01609062-unnamed-trial-site-montreal"},{"id":"nct01609062-unnamed-trial-site-sherbrook","cat":"research","name":"Unnamed trial site","city":"Sherbrook","region":"Quebec","country":"Canada","cc":"CA","lat":46.3335,"lon":-73.273,"gp":"region","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01609062","study":"Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Adam Shaywitz, MD PhD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01609062","phase":"Phase 2","enroll":25,"start":"2012-04","eid":"x:site:nct01609062-unnamed-trial-site-sherbrook"},{"id":"nct01609062-unnamed-trial-site-hamburg","cat":"research","name":"Unnamed trial site","city":"Hamburg","country":"Germany","cc":"DE","lat":53.55944,"lon":9.98328,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01609062","study":"Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Adam Shaywitz, MD PhD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01609062","phase":"Phase 2","enroll":25,"start":"2012-04","eid":"x:site:nct01609062-unnamed-trial-site-hamburg"},{"id":"nct01609062-unnamed-trial-site-belfast","cat":"research","name":"Unnamed trial site","city":"Belfast","region":"Northern Ireland","country":"United Kingdom","cc":"GB","lat":54.59461,"lon":-5.91765,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01609062","study":"Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Adam Shaywitz, MD PhD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01609062","phase":"Phase 2","enroll":25,"start":"2012-04","eid":"x:site:nct01609062-unnamed-trial-site-belfast"},{"id":"nct01609062-unnamed-trial-site-manchester","cat":"research","name":"Unnamed trial site","city":"Manchester","country":"United Kingdom","cc":"GB","lat":53.47789,"lon":-2.23974,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT01609062","study":"Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Adam Shaywitz, MD PhD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT01609062","phase":"Phase 2","enroll":25,"start":"2012-04","eid":"x:site:nct01609062-unnamed-trial-site-manchester"},{"id":"nct07345858-geneva-university-hospitals-geneva","cat":"research","name":"Geneva University Hospitals","city":"Geneva","country":"Switzerland","cc":"CH","lat":46.20104,"lon":6.15703,"gp":"city","unnamed":0,"drugs":["LSD","psilocybin"],"condg":["Depression"],"nct":"NCT07345858","study":"Salivary Oxytocin as a Biomarker of Psychedelic Treatment","sstatus":"ENROLLING_BY_INVITATION","sponsor":"University of Geneva, Switzerland","src":"https://clinicaltrials.gov/study/NCT07345858","enroll":80,"start":"2026-01-05","eid":"x:site:nct07345858-geneva-university-hospitals-geneva"},{"id":"nct07415395-shanghai-university-of-sport-shanghai","cat":"research","name":"Shanghai University of Sport","city":"Shanghai","region":"Shanghai Municipality","country":"China","cc":"CN","lat":31.23262,"lon":121.45378,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"200438","condg":["Other"],"nct":"NCT07415395","study":"Acute Effects of Aerobic Exercise Intensity on Lower-Limb Muscle Strength and Power in Youth Gymnasts","sstatus":"COMPLETED","sponsor":"Chaoran Han","src":"https://clinicaltrials.gov/study/NCT07415395","phase":"N/A","enroll":18,"start":"2024-03-18","eid":"x:site:nct07415395-shanghai-university-of-sport-shanghai"},{"id":"nct05953038-neurobiology-research-unit-rigshospitalet-copenhagen","cat":"research","name":"Neurobiology Research Unit, Rigshospitalet","city":"Copenhagen","country":"Denmark","cc":"DK","lat":55.68738,"lon":12.55758,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"2100","condg":["Other"],"nct":"NCT05953038","study":"LSD Occupancy of the Serotonin 2A Receptor in the Human Brain","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Copenhagen University Hospital, Rigshospitalet","official":"Gitte M Knudsen, DMsc, MD (Copenhagen University Hospital, Rigshospitalet)","src":"https://clinicaltrials.gov/study/NCT05953038","phase":"EARLY_Phase 1","enroll":40,"start":"2023-11-08","eid":"x:site:nct05953038-neurobiology-research-unit-rigshospitalet-copenhagen"},{"id":"nct03866252-universitare-psychiatrische-kliniken-basel","cat":"research","name":"Universitäre Psychiatrische Kliniken","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","cc":"CH","lat":47.56578,"lon":7.56249,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"4002","condg":["Depression"],"nct":"NCT03866252","study":"LSD Therapy for Persons Suffering From Major Depression","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Dr. med. Felix Müller, MD (Department of Psychiatry)","src":"https://clinicaltrials.gov/study/NCT03866252","phase":"Phase 2","enroll":60,"start":"2019-11-01","eid":"x:site:nct03866252-universitare-psychiatrische-kliniken-basel"},{"id":"nct07309471-university-hospital-basel-basel","cat":"research","name":"University Hospital Basel","city":"Basel","country":"Switzerland","cc":"CH","lat":47.56691,"lon":7.57332,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"4031","condg":["Other"],"status":"RECRUITING","nct":"NCT07309471","study":"Pharmacokinetics of Didehydro-LSD (DDH-LSD) Compared With LSD","sstatus":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias Liechti, Prof.MD (University Hospital of Basel)","src":"https://clinicaltrials.gov/study/NCT07309471","contact":{"n":"Mélusine Humbert-Droz","p":"+41 61 32 84819","e":"melusine.humbert-droz@usb.ch"},"phase":"N/A","enroll":24,"start":"2026-03-06","eid":"x:site:nct07309471-university-hospital-basel-basel"},{"id":"nct01155778-emma-children-s-hospital-academic-medical-center-amsterdam","cat":"research","name":"Emma Children's Hospital, Academic Medical Center","city":"Amsterdam","country":"Netherlands","cc":"NL","lat":52.37069,"lon":4.8952,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"1105 AZ","condg":["Other"],"nct":"NCT01155778","study":"Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients","sstatus":"COMPLETED","sponsor":"Shire","official":"Study Director (Takeda)","src":"https://clinicaltrials.gov/study/NCT01155778","phase":"Phase 1/Phase 2","enroll":12,"start":"2010-06-01","eid":"x:site:nct01155778-emma-children-s-hospital-academic-medical-center-amsterdam"},{"id":"nct01155778-st-mary-s-hospital-manchester","cat":"research","name":"St. Mary's Hospital","city":"Manchester","country":"United Kingdom","cc":"GB","lat":53.49276,"lon":-2.23117,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"M13 9WL","condg":["Other"],"nct":"NCT01155778","study":"Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients","sstatus":"COMPLETED","sponsor":"Shire","official":"Study Director (Takeda)","src":"https://clinicaltrials.gov/study/NCT01155778","phase":"Phase 1/Phase 2","enroll":12,"start":"2010-06-01","eid":"x:site:nct01155778-st-mary-s-hospital-manchester"},{"id":"nct00787995-unnamed-trial-site-oakland","cat":"research","name":"Unnamed trial site","city":"Oakland","region":"California","country":"United States","cc":"US","lat":37.7983,"lon":-122.26285,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT00787995","study":"A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, MD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT00787995","enroll":353,"start":"2008-10","eid":"x:site:nct00787995-unnamed-trial-site-oakland"},{"id":"nct00787995-unnamed-trial-site-chicago","cat":"research","name":"Unnamed trial site","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.85121,"lon":-87.66177,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT00787995","study":"A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, MD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT00787995","enroll":353,"start":"2008-10","eid":"x:site:nct00787995-unnamed-trial-site-chicago"},{"id":"nct00787995-unnamed-trial-site-cordoba","cat":"research","name":"Unnamed trial site","city":"Córdoba","country":"Argentina","cc":"AR","lat":-31.41782,"lon":-64.20044,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT00787995","study":"A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, MD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT00787995","enroll":353,"start":"2008-10","eid":"x:site:nct00787995-unnamed-trial-site-cordoba"},{"id":"nct00787995-unnamed-trial-site-porto-alegre","cat":"research","name":"Unnamed trial site","city":"Porto Alegre","country":"Brazil","cc":"BR","lat":-30.02412,"lon":-51.22195,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT00787995","study":"A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, MD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT00787995","enroll":353,"start":"2008-10","eid":"x:site:nct00787995-unnamed-trial-site-porto-alegre"},{"id":"nct00787995-unnamed-trial-site-sao-paulo","cat":"research","name":"Unnamed trial site","city":"São Paulo","country":"Brazil","cc":"BR","lat":-23.54472,"lon":-46.62816,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT00787995","study":"A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, MD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT00787995","enroll":353,"start":"2008-10","eid":"x:site:nct00787995-unnamed-trial-site-sao-paulo"},{"id":"nct00787995-unnamed-trial-site-montreal","cat":"research","name":"Unnamed trial site","city":"Montreal","region":"Quebec","country":"Canada","cc":"CA","lat":45.51896,"lon":-73.59002,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT00787995","study":"A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, MD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT00787995","enroll":353,"start":"2008-10","eid":"x:site:nct00787995-unnamed-trial-site-montreal"},{"id":"nct00787995-unnamed-trial-site-lyon","cat":"research","name":"Unnamed trial site","city":"Lyon","country":"France","cc":"FR","lat":45.74506,"lon":4.8597,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT00787995","study":"A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, MD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT00787995","enroll":353,"start":"2008-10","eid":"x:site:nct00787995-unnamed-trial-site-lyon"},{"id":"nct00787995-unnamed-trial-site-paris","cat":"research","name":"Unnamed trial site","city":"Paris","country":"France","cc":"FR","lat":48.84885,"lon":2.34565,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT00787995","study":"A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, MD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT00787995","enroll":353,"start":"2008-10","eid":"x:site:nct00787995-unnamed-trial-site-paris"},{"id":"nct00787995-unnamed-trial-site-mainz","cat":"research","name":"Unnamed trial site","city":"Mainz","country":"Germany","cc":"DE","lat":49.9754,"lon":8.28916,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT00787995","study":"A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, MD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT00787995","enroll":353,"start":"2008-10","eid":"x:site:nct00787995-unnamed-trial-site-mainz"},{"id":"nct00787995-unnamed-trial-site-monza","cat":"research","name":"Unnamed trial site","city":"Monza","country":"Italy","cc":"IT","lat":45.57426,"lon":9.26582,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT00787995","study":"A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, MD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT00787995","enroll":353,"start":"2008-10","eid":"x:site:nct00787995-unnamed-trial-site-monza"},{"id":"nct00787995-unnamed-trial-site-amsterdam","cat":"research","name":"Unnamed trial site","city":"Amsterdam","country":"Netherlands","cc":"NL","lat":52.36372,"lon":4.89369,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT00787995","study":"A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, MD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT00787995","enroll":353,"start":"2008-10","eid":"x:site:nct00787995-unnamed-trial-site-amsterdam"},{"id":"nct00787995-unnamed-trial-site-taipei","cat":"research","name":"Unnamed trial site","city":"Taipei","country":"Taiwan","cc":"TW","lat":25.06148,"lon":121.52286,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT00787995","study":"A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, MD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT00787995","enroll":353,"start":"2008-10","eid":"x:site:nct00787995-unnamed-trial-site-taipei"},{"id":"nct00787995-unnamed-trial-site-birmingham","cat":"research","name":"Unnamed trial site","city":"Birmingham","country":"United Kingdom","cc":"GB","lat":52.48307,"lon":-1.89517,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT00787995","study":"A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, MD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT00787995","enroll":353,"start":"2008-10","eid":"x:site:nct00787995-unnamed-trial-site-birmingham"},{"id":"nct00787995-unnamed-trial-site-london","cat":"research","name":"Unnamed trial site","city":"London","country":"United Kingdom","cc":"GB","lat":51.51008,"lon":-0.13614,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT00787995","study":"A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, MD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT00787995","enroll":353,"start":"2008-10","eid":"x:site:nct00787995-unnamed-trial-site-london"},{"id":"nct00787995-unnamed-trial-site-manchester","cat":"research","name":"Unnamed trial site","city":"Manchester","country":"United Kingdom","cc":"GB","lat":53.47413,"lon":-2.23701,"gp":"city","unnamed":1,"drugs":["LSD"],"condg":["Other"],"nct":"NCT00787995","study":"A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)","sstatus":"TERMINATED","sponsor":"BioMarin Pharmaceutical","official":"Celeste Decker, MD (BioMarin Pharmaceutical)","src":"https://clinicaltrials.gov/study/NCT00787995","enroll":353,"start":"2008-10","eid":"x:site:nct00787995-unnamed-trial-site-manchester"},{"id":"nct07017478-university-of-chicago-chicago","cat":"research","name":"University of Chicago","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.85638,"lon":-87.65264,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"60637","condg":["Depression"],"nct":"NCT07017478","study":"Mood Effects of Serotonin Agonists: Depression","sstatus":"COMPLETED","sponsor":"University of Chicago","official":"Hanna Molla (University of Chicago)","src":"https://clinicaltrials.gov/study/NCT07017478","phase":"EARLY_Phase 1","enroll":41,"start":"2025-06-09","eid":"x:site:nct07017478-university-of-chicago-chicago"},{"id":"nct07061886-university-of-chicago-chicago","cat":"research","name":"University of Chicago","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.84311,"lon":-87.64313,"gp":"city","unnamed":0,"drugs":["LSD"],"zip":"60637","condg":["Other"],"nct":"NCT07061886","study":"Drug Effects on Mood and Behavior - Expectancy","sstatus":"COMPLETED","sponsor":"University of Chicago","official":"Hanna Molla (University of Chicago)","src":"https://clinicaltrials.gov/study/NCT07061886","phase":"EARLY_Phase 1","enroll":42,"start":"2025-06-26","eid":"x:site:nct07061886-university-of-chicago-chicago"},{"id":"nct03537014-new-school-research-llt-north-hollywood","cat":"research","name":"New School Research LLT","city":"North Hollywood","region":"California","country":"United States","cc":"US","lat":34.16296,"lon":-118.38768,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"91601","condg":["PTSD & trauma"],"nct":"NCT03537014","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Casey Paleos, MD (Affective Care); Bessel van der Kolk, MD (Trauma Research Foundation)","src":"https://clinicaltrials.gov/study/NCT03537014","phase":"Phase 3","enroll":100,"start":"2018-11-21","eid":"x:site:nct03537014-new-school-research-llt-north-hollywood"},{"id":"nct03537014-san-francisco-insight-and-integration-center-san-francisco","cat":"research","name":"San Francisco Insight and Integration Center","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.77686,"lon":-122.41646,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"94114","condg":["PTSD & trauma"],"nct":"NCT03537014","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Casey Paleos, MD (Affective Care); Bessel van der Kolk, MD (Trauma Research Foundation)","src":"https://clinicaltrials.gov/study/NCT03537014","phase":"Phase 3","enroll":100,"start":"2018-11-21","eid":"x:site:nct03537014-san-francisco-insight-and-integration-center-san-francisco"},{"id":"nct03537014-university-of-california-san-francisco-san-francisco","cat":"research","name":"University of California San Francisco","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.77705,"lon":-122.42069,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"94122","condg":["PTSD & trauma"],"nct":"NCT03537014","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Casey Paleos, MD (Affective Care); Bessel van der Kolk, MD (Trauma Research Foundation)","src":"https://clinicaltrials.gov/study/NCT03537014","phase":"Phase 3","enroll":100,"start":"2018-11-21","eid":"x:site:nct03537014-university-of-california-san-francisco-san-francisco"},{"id":"nct03537014-aguazul-blue-water-inc-boulder","cat":"research","name":"Aguazul-Blue Water Inc.","city":"Boulder","region":"Colorado","country":"United States","cc":"US","lat":40.01428,"lon":-105.2769,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"80302","condg":["PTSD & trauma"],"nct":"NCT03537014","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Casey Paleos, MD (Affective Care); Bessel van der Kolk, MD (Trauma Research Foundation)","src":"https://clinicaltrials.gov/study/NCT03537014","phase":"Phase 3","enroll":100,"start":"2018-11-21","eid":"x:site:nct03537014-aguazul-blue-water-inc-boulder"},{"id":"nct03537014-wholeness-center-fort-collins","cat":"research","name":"Wholeness Center","city":"Fort Collins","region":"Colorado","country":"United States","cc":"US","lat":40.58502,"lon":-105.07581,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"80525","condg":["PTSD & trauma"],"nct":"NCT03537014","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Casey Paleos, MD (Affective Care); Bessel van der Kolk, MD (Trauma Research Foundation)","src":"https://clinicaltrials.gov/study/NCT03537014","phase":"Phase 3","enroll":100,"start":"2018-11-21","eid":"x:site:nct03537014-wholeness-center-fort-collins"},{"id":"nct03537014-ray-worthy-psychiatry-llc-new-orleans","cat":"research","name":"Ray Worthy Psychiatry LLC","city":"New Orleans","region":"Louisiana","country":"United States","cc":"US","lat":29.95498,"lon":-90.07907,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"70123","condg":["PTSD & trauma"],"nct":"NCT03537014","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Casey Paleos, MD (Affective Care); Bessel van der Kolk, MD (Trauma Research Foundation)","src":"https://clinicaltrials.gov/study/NCT03537014","phase":"Phase 3","enroll":100,"start":"2018-11-21","eid":"x:site:nct03537014-ray-worthy-psychiatry-llc-new-orleans"},{"id":"nct03537014-trauma-research-foundation-boston","cat":"research","name":"Trauma Research Foundation","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36431,"lon":-71.07083,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"02446","condg":["PTSD & trauma"],"nct":"NCT03537014","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Casey Paleos, MD (Affective Care); Bessel van der Kolk, MD (Trauma Research Foundation)","src":"https://clinicaltrials.gov/study/NCT03537014","phase":"Phase 3","enroll":100,"start":"2018-11-21","eid":"x:site:nct03537014-trauma-research-foundation-boston"},{"id":"nct03537014-new-york-university-new-york","cat":"research","name":"New York University","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71055,"lon":-74.00206,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"10016","condg":["PTSD & trauma"],"nct":"NCT03537014","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Casey Paleos, MD (Affective Care); Bessel van der Kolk, MD (Trauma Research Foundation)","src":"https://clinicaltrials.gov/study/NCT03537014","phase":"Phase 3","enroll":100,"start":"2018-11-21","eid":"x:site:nct03537014-new-york-university-new-york"},{"id":"nct03537014-new-york-private-practice-new-york","cat":"research","name":"New York Private Practice","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71695,"lon":-74.00122,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"10024","condg":["PTSD & trauma"],"nct":"NCT03537014","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Casey Paleos, MD (Affective Care); Bessel van der Kolk, MD (Trauma Research Foundation)","src":"https://clinicaltrials.gov/study/NCT03537014","phase":"Phase 3","enroll":100,"start":"2018-11-21","eid":"x:site:nct03537014-new-york-private-practice-new-york"},{"id":"nct03537014-zen-therapeutic-solutions-llc-mt-pleasant","cat":"research","name":"Zen Therapeutic Solutions, LLC","city":"Mt. Pleasant","region":"South Carolina","country":"United States","cc":"US","lat":32.80551,"lon":-79.8568,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"29464","condg":["PTSD & trauma"],"nct":"NCT03537014","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Casey Paleos, MD (Affective Care); Bessel van der Kolk, MD (Trauma Research Foundation)","src":"https://clinicaltrials.gov/study/NCT03537014","phase":"Phase 3","enroll":100,"start":"2018-11-21","eid":"x:site:nct03537014-zen-therapeutic-solutions-llc-mt-pleasant"},{"id":"nct03537014-university-of-wisconsin-at-madison-madison","cat":"research","name":"University of Wisconsin at Madison","city":"Madison","region":"Wisconsin","country":"United States","cc":"US","lat":43.08138,"lon":-89.39761,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"53705","condg":["PTSD & trauma"],"nct":"NCT03537014","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Casey Paleos, MD (Affective Care); Bessel van der Kolk, MD (Trauma Research Foundation)","src":"https://clinicaltrials.gov/study/NCT03537014","phase":"Phase 3","enroll":100,"start":"2018-11-21","eid":"x:site:nct03537014-university-of-wisconsin-at-madison-madison"},{"id":"nct03537014-providence-health-center-vancouver","cat":"research","name":"Providence Health Center","city":"Vancouver","region":"British Columbia","country":"Canada","cc":"CA","lat":49.25837,"lon":-123.12626,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"V5R 5H3","condg":["PTSD & trauma"],"nct":"NCT03537014","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Casey Paleos, MD (Affective Care); Bessel van der Kolk, MD (Trauma Research Foundation)","src":"https://clinicaltrials.gov/study/NCT03537014","phase":"Phase 3","enroll":100,"start":"2018-11-21","eid":"x:site:nct03537014-providence-health-center-vancouver"},{"id":"nct03537014-dr-simon-amar-inc-montreal","cat":"research","name":"Dr. Simon Amar, Inc.","city":"Montreal","region":"Quebec","country":"Canada","cc":"CA","lat":45.51529,"lon":-73.59021,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"H2W1Y9","condg":["PTSD & trauma"],"nct":"NCT03537014","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Casey Paleos, MD (Affective Care); Bessel van der Kolk, MD (Trauma Research Foundation)","src":"https://clinicaltrials.gov/study/NCT03537014","phase":"Phase 3","enroll":100,"start":"2018-11-21","eid":"x:site:nct03537014-dr-simon-amar-inc-montreal"},{"id":"nct03537014-assaf-harofeh-research-fund-be-er-ya-aqov","cat":"research","name":"Assaf Harofeh Research Fund","city":"Be’er Ya‘aqov","country":"Israel","cc":"IL","lat":31.93031,"lon":34.83688,"gp":"city","unnamed":0,"drugs":["MDMA"],"condg":["PTSD & trauma"],"nct":"NCT03537014","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Casey Paleos, MD (Affective Care); Bessel van der Kolk, MD (Trauma Research Foundation)","src":"https://clinicaltrials.gov/study/NCT03537014","phase":"Phase 3","enroll":100,"start":"2018-11-21","eid":"x:site:nct03537014-assaf-harofeh-research-fund-be-er-ya-aqov"},{"id":"nct03537014-sheba-fund-for-health-services-and-research-tel-litwinsky","cat":"research","name":"Sheba Fund for Health Services and Research","city":"Tel Litwinsky","country":"Israel","cc":"IL","lat":32.1396,"lon":35.5555,"gp":"country","unnamed":0,"drugs":["MDMA"],"condg":["PTSD & trauma"],"nct":"NCT03537014","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Casey Paleos, MD (Affective Care); Bessel van der Kolk, MD (Trauma Research Foundation)","src":"https://clinicaltrials.gov/study/NCT03537014","phase":"Phase 3","enroll":100,"start":"2018-11-21","eid":"x:site:nct03537014-sheba-fund-for-health-services-and-research-tel-litwinsky"},{"id":"nct05790239-va-greater-los-angeles-healthcare-system-westwood-campus-los-angeles","cat":"research","name":"VA Greater Los Angeles Healthcare System, Westwood campus","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.04277,"lon":-118.24646,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"90073","condg":["PTSD & trauma"],"status":"NOT_YET_RECRUITING","nct":"NCT05790239","study":"MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder","sstatus":"RECRUITING","sponsor":"Stephen Robert Marder","official":"Stephen Marder, MD (VA Greater Los Angeles Healthcare System); Stephanie L Taylor, PhD (VA Greater Los Angeles Healthcare System)","src":"https://clinicaltrials.gov/study/NCT05790239","contact":{"n":"Stephanie L Taylor, PhD","p":"213-505-1140","e":"Stephanie.Taylor8@va.gov"},"phase":"Phase 2","enroll":40,"start":"2025-03-01","eid":"x:site:nct05790239-va-greater-los-angeles-healthcare-system-westwood-campus-los-angeles"},{"id":"nct05790239-west-los-angeles-veteran-affairs-los-angeles","cat":"research","name":"West Los Angeles Veteran Affairs","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.04767,"lon":-118.24156,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"90095","condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT05790239","study":"MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder","sstatus":"RECRUITING","sponsor":"Stephen Robert Marder","official":"Stephen Marder, MD (VA Greater Los Angeles Healthcare System); Stephanie L Taylor, PhD (VA Greater Los Angeles Healthcare System)","src":"https://clinicaltrials.gov/study/NCT05790239","contact":{"n":"Gerard DeVera, BA","p":"310-478-3711","e":"Gerard.Devera@va.gov"},"phase":"Phase 2","enroll":40,"start":"2025-03-01","eid":"x:site:nct05790239-west-los-angeles-veteran-affairs-los-angeles"},{"id":"nct06066853-massachusetts-general-hospital-charlestown","cat":"research","name":"Massachusetts General Hospital","city":"Charlestown","region":"Massachusetts","country":"United States","cc":"US","lat":42.36832,"lon":-71.06647,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"02114","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06066853","study":"MDMA-assisted Therapy for Fibromyalgia","sstatus":"RECRUITING","sponsor":"Spaulding Rehabilitation Hospital","official":"Vitaly Napadow, PhD (Spaulding Rehabilitation Hospital)","src":"https://clinicaltrials.gov/study/NCT06066853","contact":{"n":"Lara Gardiner","p":"617-952-6483","e":"lgardiner1@mgb.org"},"phase":"EARLY_Phase 1","enroll":20,"start":"2026-09-15","eid":"x:site:nct06066853-massachusetts-general-hospital-charlestown"},{"id":"nct05961527-portland-vancouver-va-vancouver","cat":"research","name":"Portland-Vancouver VA","city":"Vancouver","region":"Washington","country":"United States","cc":"US","lat":45.64565,"lon":-122.65485,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"98661","condg":["PTSD & trauma"],"nct":"NCT05961527","study":"Group MDMA-therapy for Veterans With PTSD","sstatus":"COMPLETED","sponsor":"Portland VA Research Foundation, Inc","src":"https://clinicaltrials.gov/study/NCT05961527","phase":"Phase 1/Phase 2","enroll":23,"start":"2023-10-01","eid":"x:site:nct05961527-portland-vancouver-va-vancouver"},{"id":"nct01465685-university-hospital-basel-basel","cat":"research","name":"University Hospital Basel","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","cc":"CH","lat":47.55571,"lon":7.57605,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"4000","condg":["Healthy volunteers"],"nct":"NCT01465685","study":"Emotional Effects of Methylphenidate and MDMA in Healthy Subjects","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT01465685","phase":"Phase 1","enroll":16,"start":"2011-12","eid":"x:site:nct01465685-university-hospital-basel-basel"},{"id":"nct07542145-department-of-psychiatry-eating-and-weight-disorders-program-new-yor","cat":"research","name":"Department of Psychiatry, Eating and Weight Disorders Program","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72571,"lon":-74.00489,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"10028","condg":["Eating disorders"],"status":"RECRUITING","nct":"NCT07542145","study":"MDMA Assisted Therapy for BN","sstatus":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","official":"Tom Hildebrandt, PsyD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT07542145","contact":{"n":"Carson Harran","p":"212-659-8724","e":"carson.harran@mssm.edu"},"phase":"Phase 1","enroll":40,"start":"2026-05-22","eid":"x:site:nct07542145-department-of-psychiatry-eating-and-weight-disorders-program-new-yor"},{"id":"nct03527316-clinical-pharmacology-toxicology-university-hospital-basel-basel","cat":"research","name":"Clinical Pharmacology & Toxicology, University Hospital Basel","city":"Basel","country":"Switzerland","cc":"CH","lat":47.55119,"lon":7.5672,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"4056","condg":["Healthy volunteers"],"nct":"NCT03527316","study":"Effect of Methylenedioxymethamphetamine (MDMA) (Serotonin Release) on Fear Extinction","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, MD, MAS (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT03527316","phase":"EARLY_Phase 1","enroll":30,"start":"2019-10-18","eid":"x:site:nct03527316-clinical-pharmacology-toxicology-university-hospital-basel-basel"},{"id":"nct07584720-dr-vince-clinical-research-overland-park","cat":"research","name":"Dr. Vince Clinical Research","city":"Overland Park","region":"Kansas","country":"United States","cc":"US","lat":38.97719,"lon":-94.66717,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"66212","condg":["Healthy volunteers"],"nct":"NCT07584720","study":"Study of Midomafetamine in Healthy Adults","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT07584720","phase":"Phase 1","enroll":32,"start":"2026-04-23","eid":"x:site:nct07584720-dr-vince-clinical-research-overland-park"},{"id":"nct06044675-remedy-institute-toronto","cat":"research","name":"Remedy Institute","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70798,"lon":-79.40556,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"M6G 1L5","condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT06044675","study":"MDMA-Assisted CBCT for PTSD vs CBCT RCT","sstatus":"RECRUITING","sponsor":"Remedy","official":"Paul Uy, MD (Remedy Institute); Anne Wagner, PhD (Remedy Institute)","src":"https://clinicaltrials.gov/study/NCT06044675","contact":{"n":"Hajara Abdirahman, BS","p":"4372914747","e":"research@remedyinstitute.ca"},"phase":"Phase 2","enroll":60,"start":"2024-11-15","eid":"x:site:nct06044675-remedy-institute-toronto"},{"id":"nct03181763-emory-university-atlanta","cat":"research","name":"Emory University","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.74933,"lon":-84.39142,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"30329","condg":["Other"],"nct":"NCT03181763","study":"Evaluation of MDMA on Startle Response","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Barbara Rothbaum (Emory University)","src":"https://clinicaltrials.gov/study/NCT03181763","phase":"Phase 1","enroll":34,"start":"2017-03-14","eid":"x:site:nct03181763-emory-university-atlanta"},{"id":"nct01136278-clinical-pharmacology-toxicology-university-hospital-basel-basel","cat":"research","name":"Clinical Pharmacology & Toxicology, University Hospital Basel","city":"Basel","region":"Basel","country":"Switzerland","cc":"CH","lat":47.54808,"lon":7.56983,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"4053","condg":["Addiction & substance use"],"nct":"NCT01136278","study":"Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA)","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, MD (Department of Internal Medicine, Division of Pharmacology & Toxicology, University Hospital Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT01136278","phase":"Phase 1","enroll":16,"start":"2010-07","eid":"x:site:nct01136278-clinical-pharmacology-toxicology-university-hospital-basel-basel"},{"id":"nct07765693-mclean-hospital-belmont","cat":"research","name":"McLean Hospital","city":"Belmont","region":"Massachusetts","country":"United States","cc":"US","lat":37.51687,"lon":-122.27585,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"02478","condg":["PTSD & trauma"],"nct":"NCT07765693","study":"MDMA-AT for PTSD in Young Adults With Childhood Trauma","sstatus":"NOT_YET_RECRUITING","sponsor":"Jenna M. Traynor","official":"Jenna M Traynor (Mclean Hospital)","src":"https://clinicaltrials.gov/study/NCT07765693","contact":{"n":"Alexandra Velev, BA","p":"617-855-3430","e":"avelev@mclean.harvard.edu"},"phase":"Phase 2","enroll":15,"start":"2026-10-31","eid":"x:site:nct07765693-mclean-hospital-belmont"},{"id":"nct05895318-stratton-va-medical-center-albany","cat":"research","name":"Stratton VA Medical Center","city":"Albany","region":"New York","country":"United States","cc":"US","lat":42.6515,"lon":-73.75957,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"12208","condg":["PTSD & trauma"],"nct":"NCT05895318","study":"Perceptions of MDMA-Assisted Therapy Among Veterans With PTSD","sstatus":"COMPLETED","sponsor":"Albany Research Institute, Inc.","official":"Caitlin Holley, Ph.D. (Stratton VA Medical Center)","src":"https://clinicaltrials.gov/study/NCT05895318","enroll":30,"start":"2022-08-08","eid":"x:site:nct05895318-stratton-va-medical-center-albany"},{"id":"nct04030169-nudz-national-institute-of-mental-health-klecany","cat":"research","name":"NUDZ - National Institute of Mental Health","city":"Klecany","region":"Central Bohemia","country":"Czechia","cc":"CZ","lat":50.17839,"lon":14.40249,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"250 67","condg":["PTSD & trauma"],"nct":"NCT04030169","study":"Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study","sstatus":"COMPLETED","sponsor":"MAPS Europe B.V.","official":"Prof. Dr. Eric Vermetten, MD (Leiden University Medical Center)","src":"https://clinicaltrials.gov/study/NCT04030169","phase":"Phase 2","enroll":21,"start":"2020-06-24","eid":"x:site:nct04030169-nudz-national-institute-of-mental-health-klecany"},{"id":"nct04030169-charite-universitatsmedizin-berlin-campus-benjamin-franklin-berlin","cat":"research","name":"Charité - Universitätsmedizin, Berlin Campus Benjamin Franklin","city":"Berlin","country":"Germany","cc":"DE","lat":52.51501,"lon":13.40333,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"12203","condg":["PTSD & trauma"],"nct":"NCT04030169","study":"Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study","sstatus":"COMPLETED","sponsor":"MAPS Europe B.V.","official":"Prof. Dr. Eric Vermetten, MD (Leiden University Medical Center)","src":"https://clinicaltrials.gov/study/NCT04030169","phase":"Phase 2","enroll":21,"start":"2020-06-24","eid":"x:site:nct04030169-charite-universitatsmedizin-berlin-campus-benjamin-franklin-berlin"},{"id":"nct04030169-stichting-centrum-45-arq-oegstgeest","cat":"research","name":"Stichting Centrum '45/Arq","city":"Oegstgeest","region":"Noord Holand","country":"Netherlands","cc":"NL","lat":52.184,"lon":4.48088,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"2342 AX","condg":["PTSD & trauma"],"nct":"NCT04030169","study":"Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study","sstatus":"COMPLETED","sponsor":"MAPS Europe B.V.","official":"Prof. Dr. Eric Vermetten, MD (Leiden University Medical Center)","src":"https://clinicaltrials.gov/study/NCT04030169","phase":"Phase 2","enroll":21,"start":"2020-06-24","eid":"x:site:nct04030169-stichting-centrum-45-arq-oegstgeest"},{"id":"nct04030169-sykehuset-stfold-hf-dps-norder-moss","cat":"research","name":"Sykehuset Østfold Hf, DPS Norder","city":"Moss","country":"Norway","cc":"NO","lat":59.42532,"lon":10.66322,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"1535","condg":["PTSD & trauma"],"nct":"NCT04030169","study":"Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study","sstatus":"COMPLETED","sponsor":"MAPS Europe B.V.","official":"Prof. Dr. Eric Vermetten, MD (Leiden University Medical Center)","src":"https://clinicaltrials.gov/study/NCT04030169","phase":"Phase 2","enroll":21,"start":"2020-06-24","eid":"x:site:nct04030169-sykehuset-stfold-hf-dps-norder-moss"},{"id":"nct04030169-university-hospital-of-wales-research-facility-cardiff","cat":"research","name":"University Hospital of Wales - Research Facility","city":"Cardiff","country":"United Kingdom","cc":"GB","lat":51.47694,"lon":-3.16979,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"CF14 4XW","condg":["PTSD & trauma"],"nct":"NCT04030169","study":"Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study","sstatus":"COMPLETED","sponsor":"MAPS Europe B.V.","official":"Prof. Dr. Eric Vermetten, MD (Leiden University Medical Center)","src":"https://clinicaltrials.gov/study/NCT04030169","phase":"Phase 2","enroll":21,"start":"2020-06-24","eid":"x:site:nct04030169-university-hospital-of-wales-research-facility-cardiff"},{"id":"nct04030169-the-institute-of-psychiatry-psychology-and-neuroscience-london","cat":"research","name":"The Institute of Psychiatry, Psychology and Neuroscience","city":"London","country":"United Kingdom","cc":"GB","lat":51.51629,"lon":-0.12052,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"SE5 8AF","condg":["PTSD & trauma"],"nct":"NCT04030169","study":"Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study","sstatus":"COMPLETED","sponsor":"MAPS Europe B.V.","official":"Prof. Dr. Eric Vermetten, MD (Leiden University Medical Center)","src":"https://clinicaltrials.gov/study/NCT04030169","phase":"Phase 2","enroll":21,"start":"2020-06-24","eid":"x:site:nct04030169-the-institute-of-psychiatry-psychology-and-neuroscience-london"},{"id":"nct03606538-alliance-for-multispecialty-research-llc-knoxville","cat":"research","name":"Alliance for Multispecialty Research, LLC.","city":"Knoxville","region":"Tennessee","country":"United States","cc":"US","lat":35.97,"lon":-83.92775,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"37920","condg":["Other"],"nct":"NCT03606538","study":"MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function","sstatus":"NOT_YET_RECRUITING","sponsor":"Resilient Pharmaceuticals","official":"Janel Long-Boyle, PharmD, PhD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT03606538","contact":{"n":"Study coordinator","e":"recruitment@lykospbc.com"},"phase":"Phase 1","enroll":16,"start":"2026-03-29","eid":"x:site:nct03606538-alliance-for-multispecialty-research-llc-knoxville"},{"id":"nct04714359-new-school-research-los-angeles","cat":"research","name":"New School Research","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.04823,"lon":-118.25493,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"90004","condg":["PTSD & trauma"],"nct":"NCT04714359","study":"A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04714359","phase":"Phase 3","enroll":87,"start":"2021-03-08","eid":"x:site:nct04714359-new-school-research-los-angeles"},{"id":"nct04714359-san-francisco-insight-and-integration-center-san-francisco","cat":"research","name":"San Francisco Insight and Integration Center","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.78411,"lon":-122.41015,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"94114","condg":["PTSD & trauma"],"nct":"NCT04714359","study":"A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04714359","phase":"Phase 3","enroll":87,"start":"2021-03-08","eid":"x:site:nct04714359-san-francisco-insight-and-integration-center-san-francisco"},{"id":"nct04714359-ucsf-san-francisco","cat":"research","name":"UCSF","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.78524,"lon":-122.41137,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"94122","condg":["PTSD & trauma"],"nct":"NCT04714359","study":"A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04714359","phase":"Phase 3","enroll":87,"start":"2021-03-08","eid":"x:site:nct04714359-ucsf-san-francisco"},{"id":"nct04714359-aguazul-blue-water-inc-boulder","cat":"research","name":"Aguazul-Blue Water Inc.","city":"Boulder","region":"Colorado","country":"United States","cc":"US","lat":40.02483,"lon":-105.2754,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"80302","condg":["PTSD & trauma"],"nct":"NCT04714359","study":"A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04714359","phase":"Phase 3","enroll":87,"start":"2021-03-08","eid":"x:site:nct04714359-aguazul-blue-water-inc-boulder"},{"id":"nct04714359-wholeness-center-fort-collins","cat":"research","name":"Wholeness Center","city":"Fort Collins","region":"Colorado","country":"United States","cc":"US","lat":40.58804,"lon":-105.08823,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"80525","condg":["PTSD & trauma"],"nct":"NCT04714359","study":"A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04714359","phase":"Phase 3","enroll":87,"start":"2021-03-08","eid":"x:site:nct04714359-wholeness-center-fort-collins"},{"id":"nct04714359-ray-worthy-psychiatry-new-orleans","cat":"research","name":"Ray Worthy Psychiatry","city":"New Orleans","region":"Louisiana","country":"United States","cc":"US","lat":29.96241,"lon":-90.08039,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"70123","condg":["PTSD & trauma"],"nct":"NCT04714359","study":"A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04714359","phase":"Phase 3","enroll":87,"start":"2021-03-08","eid":"x:site:nct04714359-ray-worthy-psychiatry-new-orleans"},{"id":"nct04714359-trauma-research-foundation-boston","cat":"research","name":"Trauma Research Foundation","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36356,"lon":-71.05972,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"02446","condg":["PTSD & trauma"],"nct":"NCT04714359","study":"A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04714359","phase":"Phase 3","enroll":87,"start":"2021-03-08","eid":"x:site:nct04714359-trauma-research-foundation-boston"},{"id":"nct04714359-nyu-new-york","cat":"research","name":"NYU","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70952,"lon":-73.99736,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"10016","condg":["PTSD & trauma"],"nct":"NCT04714359","study":"A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04714359","phase":"Phase 3","enroll":87,"start":"2021-03-08","eid":"x:site:nct04714359-nyu-new-york"},{"id":"nct04714359-new-york-private-practice-new-york","cat":"research","name":"New York Private Practice","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72392,"lon":-74.01091,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"11012","condg":["PTSD & trauma"],"nct":"NCT04714359","study":"A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04714359","phase":"Phase 3","enroll":87,"start":"2021-03-08","eid":"x:site:nct04714359-new-york-private-practice-new-york"},{"id":"nct04714359-zen-therapeutic-solutions-llc-mt-pleasant","cat":"research","name":"Zen Therapeutic Solutions, LLC","city":"Mt. Pleasant","region":"South Carolina","country":"United States","cc":"US","lat":32.78282,"lon":-79.87243,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"29464","condg":["PTSD & trauma"],"nct":"NCT04714359","study":"A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04714359","phase":"Phase 3","enroll":87,"start":"2021-03-08","eid":"x:site:nct04714359-zen-therapeutic-solutions-llc-mt-pleasant"},{"id":"nct04714359-university-of-wisconsin-madison-madison","cat":"research","name":"University of Wisconsin - Madison","city":"Madison","region":"Wisconsin","country":"United States","cc":"US","lat":43.08279,"lon":-89.3993,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"53705-2222","condg":["PTSD & trauma"],"nct":"NCT04714359","study":"A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04714359","phase":"Phase 3","enroll":87,"start":"2021-03-08","eid":"x:site:nct04714359-university-of-wisconsin-madison-madison"},{"id":"nct04714359-numinus-vancouver","cat":"research","name":"Numinus","city":"Vancouver","region":"British Columbia","country":"Canada","cc":"CA","lat":49.24284,"lon":-123.11101,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"V5R 5H3","condg":["PTSD & trauma"],"nct":"NCT04714359","study":"A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04714359","phase":"Phase 3","enroll":87,"start":"2021-03-08","eid":"x:site:nct04714359-numinus-vancouver"},{"id":"nct04714359-numinus-montreal","cat":"research","name":"Numinus","city":"Montreal","region":"Quebec","country":"Canada","cc":"CA","lat":45.51472,"lon":-73.58419,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"H2W 1Y9","condg":["PTSD & trauma"],"nct":"NCT04714359","study":"A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04714359","phase":"Phase 3","enroll":87,"start":"2021-03-08","eid":"x:site:nct04714359-numinus-montreal"},{"id":"nct04714359-beer-yaakov-mental-health-center-beer-yaaqov","cat":"research","name":"Beer Yaakov Mental Health Center","city":"Beer Yaaqov","country":"Israel","cc":"IL","lat":31.3514,"lon":34.8575,"gp":"country","unnamed":0,"drugs":["MDMA"],"condg":["PTSD & trauma"],"nct":"NCT04714359","study":"A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04714359","phase":"Phase 3","enroll":87,"start":"2021-03-08","eid":"x:site:nct04714359-beer-yaakov-mental-health-center-beer-yaaqov"},{"id":"nct04714359-tel-hashomer-tel-aviv","cat":"research","name":"Tel Hashomer","city":"Tel Aviv","country":"Israel","cc":"IL","lat":32.06992,"lon":34.78805,"gp":"city","unnamed":0,"drugs":["MDMA"],"condg":["PTSD & trauma"],"nct":"NCT04714359","study":"A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04714359","phase":"Phase 3","enroll":87,"start":"2021-03-08","eid":"x:site:nct04714359-tel-hashomer-tel-aviv"},{"id":"nct00823407-cpmc-addiction-pharmacology-research-laboratory-aprl-san-francisco","cat":"research","name":"CPMC Addiction & Pharmacology Research Laboratory (APRL)","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.77827,"lon":-122.4173,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"94110","condg":["Healthy volunteers"],"nct":"NCT00823407","study":"Clinical Pharmacology of MDA [3,4-methylenedioxyamphetamine]","sstatus":"COMPLETED","sponsor":"California Pacific Medical Center Research Institute","official":"John E Mendelson, MD (CPMC Research Institute)","src":"https://clinicaltrials.gov/study/NCT00823407","phase":"N/A","enroll":12,"start":"2009-01","eid":"x:site:nct00823407-cpmc-addiction-pharmacology-research-laboratory-aprl-san-francisco"},{"id":"nct06117306-va-san-diego-healthcare-system-san-diego-ca-san-diego","cat":"research","name":"VA San Diego Healthcare System, San Diego, CA","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.71557,"lon":-117.1578,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"92161","condg":["PTSD & trauma"],"nct":"NCT06117306","study":"MDMA-assisted Massed Prolonged Exposure for PTSD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Healing Breakthrough","official":"Leslie Morland, Psy.D. (San Diego Veterans Affairs Health System)","src":"https://clinicaltrials.gov/study/NCT06117306","phase":"Phase 3","enroll":20,"start":"2024-10-25","eid":"x:site:nct06117306-va-san-diego-healthcare-system-san-diego-ca-san-diego"},{"id":"nct07469098-mental-health-medical-center-beer-sheva-beersheba","cat":"research","name":"Mental Health Medical Center Beer Sheva","city":"Beersheba","country":"Israel","cc":"IL","lat":31.24753,"lon":34.78325,"gp":"city","unnamed":0,"drugs":["MDMA"],"condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT07469098","study":"Group vs Individual MDMA-Assisted Therapy for PTSD After the October 7, 2023 Events","sstatus":"RECRUITING","sponsor":"Sheba Medical Center","official":"Revital Amiaz (Sheba Medical Center)","src":"https://clinicaltrials.gov/study/NCT07469098","contact":{"n":"Oded Arbel","p":"972542378757","e":"revital.amiaz@sheba.health.gov.il"},"phase":"Phase 2","enroll":168,"start":"2025-12-24","eid":"x:site:nct07469098-mental-health-medical-center-beer-sheva-beersheba"},{"id":"nct07469098-lev-hasharon-mental-health-medical-center-pardesiyya","cat":"research","name":"Lev-Hasharon Mental Health Medical Center","city":"Pardesiyya","country":"Israel","cc":"IL","lat":32.30941,"lon":34.90526,"gp":"city","unnamed":0,"drugs":["MDMA"],"condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT07469098","study":"Group vs Individual MDMA-Assisted Therapy for PTSD After the October 7, 2023 Events","sstatus":"RECRUITING","sponsor":"Sheba Medical Center","official":"Revital Amiaz (Sheba Medical Center)","src":"https://clinicaltrials.gov/study/NCT07469098","contact":{"n":"Kfir Feffer","p":"972542378757","e":"revital.amiaz@sheba.health.gov.il"},"phase":"Phase 2","enroll":168,"start":"2025-12-24","eid":"x:site:nct07469098-lev-hasharon-mental-health-medical-center-pardesiyya"},{"id":"nct01958593-offices-of-dr-ingrid-pacey-mbbs-frcp-c-vancouver","cat":"research","name":"Offices of Dr. Ingrid Pacey MBBS FRCP[C]","city":"Vancouver","region":"British Columbia","country":"Canada","cc":"CA","lat":49.25742,"lon":-123.11675,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"V6R 1N6","condg":["PTSD & trauma"],"nct":"NCT01958593","study":"Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD","sstatus":"TERMINATED","sponsor":"Resilient Pharmaceuticals","official":"Ingrid Pacey, MBBS FRCP[C] (University of Victoria)","src":"https://clinicaltrials.gov/study/NCT01958593","phase":"Phase 2","enroll":6,"start":"2014-10-14","eid":"x:site:nct01958593-offices-of-dr-ingrid-pacey-mbbs-frcp-c-vancouver"},{"id":"nct05066282-uscf-san-francisco","cat":"research","name":"USCF","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.77639,"lon":-122.40911,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"94158","condg":["PTSD & trauma"],"nct":"NCT05066282","study":"Long-Term Safety and Effectiveness of MDMA-Assisted Therapy for PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Jennifer Mitchell, MD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT05066282","enroll":186,"start":"2021-03-01","eid":"x:site:nct05066282-uscf-san-francisco"},{"id":"nct05066282-dr-simon-amar-inc-montreal","cat":"research","name":"Dr. Simon Amar Inc","city":"Montreal","region":"Quebec","country":"Canada","cc":"CA","lat":45.50804,"lon":-73.58974,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"H2W1Y9","condg":["PTSD & trauma"],"nct":"NCT05066282","study":"Long-Term Safety and Effectiveness of MDMA-Assisted Therapy for PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Jennifer Mitchell, MD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT05066282","enroll":186,"start":"2021-03-01","eid":"x:site:nct05066282-dr-simon-amar-inc-montreal"},{"id":"nct05066282-beer-yaakov-mental-health-center-be-er-ya-aqov","cat":"research","name":"Beer Yaakov Mental Health Center","city":"Be’er Ya‘aqov","country":"Israel","cc":"IL","lat":31.93624,"lon":34.84328,"gp":"city","unnamed":0,"drugs":["MDMA"],"condg":["PTSD & trauma"],"nct":"NCT05066282","study":"Long-Term Safety and Effectiveness of MDMA-Assisted Therapy for PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Jennifer Mitchell, MD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT05066282","enroll":186,"start":"2021-03-01","eid":"x:site:nct05066282-beer-yaakov-mental-health-center-be-er-ya-aqov"},{"id":"nct05066282-tel-hashomer-tel-aviv","cat":"research","name":"Tel Hashomer","city":"Tel Aviv","country":"Israel","cc":"IL","lat":32.08159,"lon":34.78542,"gp":"city","unnamed":0,"drugs":["MDMA"],"condg":["PTSD & trauma"],"nct":"NCT05066282","study":"Long-Term Safety and Effectiveness of MDMA-Assisted Therapy for PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Jennifer Mitchell, MD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT05066282","enroll":186,"start":"2021-03-01","eid":"x:site:nct05066282-tel-hashomer-tel-aviv"},{"id":"nct07494214-clinical-pharmacology-toxicology-university-hospital-basel-basel","cat":"research","name":"Clinical Pharmacology & Toxicology, University Hospital Basel","city":"Basel","country":"Switzerland","cc":"CH","lat":47.55975,"lon":7.57953,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"4056","condg":["Other"],"status":"RECRUITING","nct":"NCT07494214","study":"Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants","sstatus":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","src":"https://clinicaltrials.gov/study/NCT07494214","contact":{"n":"Severin B Vogt, Dr. med.","p":"+41 61 268 68 66","e":"severinbenjamin.vogt@usb.ch"},"phase":"Phase 1","enroll":20,"start":"2026-03-09","eid":"x:site:nct07494214-clinical-pharmacology-toxicology-university-hospital-basel-basel"},{"id":"nct06189027-univeristy-of-southern-california-los-angeles","cat":"research","name":"Univeristy of Southern California","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.04305,"lon":-118.23912,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"90089","condg":["PTSD & trauma"],"nct":"NCT06189027","study":"Epigenetics and MDMA-Assisted Psychotherapy for PTSD","sstatus":"COMPLETED","sponsor":"University of Southern California","official":"Rael Cahn, MD, PhD (University of Southern California)","src":"https://clinicaltrials.gov/study/NCT06189027","phase":"Phase 3","enroll":45,"start":"2018-11-20","eid":"x:site:nct06189027-univeristy-of-southern-california-los-angeles"},{"id":"nct03752918-enact-research-collaborative-new-haven","cat":"research","name":"Enact Research Collaborative","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.29775,"lon":-72.93254,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"06510","condg":["PTSD & trauma"],"nct":"NCT03752918","study":"The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD.","sstatus":"WITHDRAWN","sponsor":"Yale University","official":"Benjamin Kelmendi, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT03752918","phase":"Phase 1","start":"2024-05","eid":"x:site:nct03752918-enact-research-collaborative-new-haven"},{"id":"nct06418178-james-j-peters-va-medical-center-the-bronx","cat":"research","name":"James J. Peters VA Medical Center","city":"The Bronx","region":"New York","country":"United States","cc":"US","lat":40.84585,"lon":-73.87803,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"10468","condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT06418178","study":"Dose Optimization of MDMA-Assisted Therapy for PTSD","sstatus":"RECRUITING","sponsor":"Bronx VA Medical Center","official":"Rachel Yehuda, PhD (James J. Peters VA Medical Center); Amy Lehrner, PhD (James J. Peters VA Medical Center)","src":"https://clinicaltrials.gov/study/NCT06418178","contact":{"n":"Joshua Park","p":"9297363104","e":"joshua.park1@va.gov"},"phase":"Phase 2","enroll":60,"start":"2025-06-03","eid":"x:site:nct06418178-james-j-peters-va-medical-center-the-bronx"},{"id":"nct00353938-offices-of-peter-oehen-md-biberist","cat":"research","name":"Offices of Peter Oehen MD","city":"Biberist","region":"Canton of Solothurn","country":"Switzerland","cc":"CH","lat":47.17477,"lon":7.55357,"gp":"city","unnamed":0,"drugs":["MDMA"],"condg":["PTSD & trauma"],"nct":"NCT00353938","study":"Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Peter Oehen, MD (private practice, Biberist, Switzerland)","src":"https://clinicaltrials.gov/study/NCT00353938","phase":"Phase 2","enroll":14,"start":"2006-09-13","eid":"x:site:nct00353938-offices-of-peter-oehen-md-biberist"},{"id":"nct02954562-university-of-california-berkeley-berkeley","cat":"research","name":"University of California - Berkeley","city":"Berkeley","region":"California","country":"United States","cc":"US","lat":37.88058,"lon":-122.26141,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"94720","condg":["Anxiety"],"nct":"NCT02954562","study":"Correlates of Anxiety Associated With a Life-threatening Illness","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Michael Silver (University of California, Berkeley)","src":"https://clinicaltrials.gov/study/NCT02954562","enroll":12,"start":"2015-11-07","eid":"x:site:nct02954562-university-of-california-berkeley-berkeley"},{"id":"nct06905652-university-hospital-basel-basel","cat":"research","name":"University Hospital Basel","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","cc":"CH","lat":47.55759,"lon":7.56682,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"4031","condg":["Healthy volunteers"],"nct":"NCT06905652","study":"Comparative Acute Effects of R-MDMA and S-MDMA in Healthy Participants","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, Prof. Dr. MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT06905652","phase":"Phase 1","enroll":26,"start":"2025-07-29","eid":"x:site:nct06905652-university-hospital-basel-basel"},{"id":"nct04158778-study-center-university-of-bristol-bristol","cat":"research","name":"Study Center: University of Bristol","city":"Bristol","country":"United Kingdom","cc":"GB","lat":51.46074,"lon":-2.59124,"gp":"city","unnamed":0,"drugs":["MDMA"],"condg":["Addiction & substance use"],"nct":"NCT04158778","study":"Bristol Imperial MDMA in Alcoholism Study","sstatus":"UNKNOWN","sponsor":"Imperial College London","official":"Prof Nutt (Imperial College London)","src":"https://clinicaltrials.gov/study/NCT04158778","phase":"Phase 1","enroll":20,"start":"2018-04-18","eid":"x:site:nct04158778-study-center-university-of-bristol-bristol"},{"id":"nct07555132-university-hospital-basel-endocrinology-diabetes-and-metabolism-base","cat":"research","name":"University Hospital Basel, Endocrinology, Diabetes and Metabolism","city":"Basel","country":"Switzerland","cc":"CH","lat":47.54714,"lon":7.56711,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"4031","condg":["Other"],"nct":"NCT07555132","study":"Circulating Oxytocin Changes in Response to MDMA vs. Placebo in Adult Patients With Autism Spectrum Disorder and Matched Healthy Controls","sstatus":"NOT_YET_RECRUITING","sponsor":"University Hospital, Basel, Switzerland","official":"Mirjam Christ-Crain, Prof. Dr. med. (University Hospital Basel, Endocrinology, Diabetes and Metabolism)","src":"https://clinicaltrials.gov/study/NCT07555132","contact":{"n":"Mirjam Christ-Crain, Prof. Dr. med.","p":"+41 61 265 25 25","e":"mirjam.christ-crain@usb.ch"},"phase":"N/A","enroll":40,"start":"2026-06","eid":"x:site:nct07555132-university-hospital-basel-endocrinology-diabetes-and-metabolism-base"},{"id":"nct01771874-university-hospital-basel-basel","cat":"research","name":"University Hospital Basel","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","cc":"CH","lat":47.56051,"lon":7.58169,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"4000","condg":["Addiction & substance use","Healthy volunteers"],"nct":"NCT01771874","study":"Influence of Bupropion on the Effects of MDMA","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, MD, MAS (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT01771874","phase":"Phase 1","enroll":16,"start":"2013-01","eid":"x:site:nct01771874-university-hospital-basel-basel"},{"id":"nct00402298-be-er-ya-akov-mental-health-center-be-er-ya-aqov","cat":"research","name":"Be'er Ya'akov Mental Health Center","city":"Be’er Ya‘aqov","country":"Israel","cc":"IL","lat":31.94866,"lon":34.82568,"gp":"city","unnamed":0,"drugs":["MDMA"],"condg":["PTSD & trauma"],"nct":"NCT00402298","study":"Randomized Placebo-controlled Study of MDMA-assisted Therapy in People With PTSD - Israel","sstatus":"TERMINATED","sponsor":"Resilient Pharmaceuticals","official":"Moshe Kotler (Director of Psychiatry, Beer Yaakov Mental Health Center)","src":"https://clinicaltrials.gov/study/NCT00402298","phase":"Phase 2","enroll":5,"start":"2007-05-27","eid":"x:site:nct00402298-be-er-ya-akov-mental-health-center-be-er-ya-aqov"},{"id":"nct01270672-clinical-pharmacology-toxicology-university-hospital-basel-basel","cat":"research","name":"Clinical Pharmacology & Toxicology, University Hospital Basel","city":"Basel","country":"Switzerland","cc":"CH","lat":47.56728,"lon":7.57285,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"4053","condg":["Addiction & substance use"],"nct":"NCT01270672","study":"Pharmacological Interaction Between Carvedilol and Methylenedioxymethamphetamine (MDMA)","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, MD (Department of Internal Medicine, Division of Pharmacology & Toxicology, University Hospital Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT01270672","phase":"N/A","enroll":16,"start":"2011-01","eid":"x:site:nct01270672-clinical-pharmacology-toxicology-university-hospital-basel-basel"},{"id":"nct06989957-johns-hopkins-center-for-psychedelic-and-consciousness-research-balt","cat":"research","name":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.30238,"lon":-76.61694,"gp":"city","unnamed":0,"drugs":["MDMA","psilocybin"],"zip":"21224","condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT06989957","study":"Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)","sstatus":"RECRUITING","sponsor":"Johns Hopkins University","official":"Brandon Weiss, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT06989957","contact":{"n":"Chloe Ford, MSc","p":"410-550-0237","e":"cford36@jh.edu"},"phase":"Phase 1","enroll":40,"start":"2025-09-17","eid":"x:site:nct06989957-johns-hopkins-center-for-psychedelic-and-consciousness-research-balt"},{"id":"nct06789705-university-hospital-basel-basel","cat":"research","name":"University Hospital Basel","city":"Basel","country":"Switzerland","cc":"CH","lat":47.55411,"lon":7.5816,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"4031","condg":["Other"],"status":"RECRUITING","nct":"NCT06789705","study":"Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls","sstatus":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","official":"Mirjam Christ-Crain, Prof. (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT06789705","contact":{"n":"Mirjam Christ-Crain, Prof.","p":"+41 61 265 25 25","e":"Mirjam.Christ-Crain@usb.ch"},"phase":"N/A","enroll":24,"start":"2025-01-27","eid":"x:site:nct06789705-university-hospital-basel-basel"},{"id":"nct00838305-cpmc-research-institute-st-luke-s-hospital-san-francisco","cat":"research","name":"CPMC Research Institute, St.Luke's Hospital","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.76698,"lon":-122.42257,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"94110","condg":["Other"],"nct":"NCT00838305","study":"Role of Serotonin in Acute and Subacute MDMA Effects","sstatus":"COMPLETED","sponsor":"California Pacific Medical Center Research Institute","src":"https://clinicaltrials.gov/study/NCT00838305","phase":"N/A","enroll":13,"start":"2009-02","eid":"x:site:nct00838305-cpmc-research-institute-st-luke-s-hospital-san-francisco"},{"id":"nct06353282-ucla-semel-institute-for-neuroscience-and-human-behavior-los-angeles","cat":"research","name":"UCLA Semel Institute for Neuroscience and Human Behavior","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.05011,"lon":-118.23667,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"90095","condg":["PTSD & trauma"],"nct":"NCT06353282","study":"MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents","sstatus":"WITHDRAWN","sponsor":"University of California, Los Angeles","src":"https://clinicaltrials.gov/study/NCT06353282","phase":"Phase 2","start":"2025-07-01","eid":"x:site:nct06353282-ucla-semel-institute-for-neuroscience-and-human-behavior-los-angeles"},{"id":"nct06394284-metiv-israel-psychotrauma-center-herzog-medical-center-jerusalem","cat":"research","name":"METIV Israel Psychotrauma Center, Herzog Medical Center","city":"Jerusalem","country":"Israel","cc":"IL","lat":31.77069,"lon":35.22089,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"3090844","condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT06394284","study":"Examining 3,4-methylenedioxymethamphetamine (MDMA) Effects on Psychological, Relational and Hyperarousal-Related Neural Reactivity Mechanisms in Veterans With PTSD and Moral Injury","sstatus":"RECRUITING","sponsor":"Herzog Hospital","official":"Anna Harwood-Gross, PhD (Metiv Israel Psychotrauma Center); Pinhas Danon, Prof (Herzog Medical Center)","src":"https://clinicaltrials.gov/study/NCT06394284","contact":{"n":"Anna Harwood-Gross, PhD","p":"0549493779","e":"anna@metiv.org"},"phase":"Phase 3","enroll":60,"start":"2024-02-18","eid":"x:site:nct06394284-metiv-israel-psychotrauma-center-herzog-medical-center-jerusalem"},{"id":"nct06772753-johns-hopkins-center-for-psychedelic-and-consciousness-research-balt","cat":"research","name":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29184,"lon":-76.61177,"gp":"city","unnamed":0,"drugs":["MDMA","ketamine","psilocybin"],"zip":"21218","condg":["Healthy volunteers"],"status":"RECRUITING","nct":"NCT06772753","study":"Investigation of Psychedelic Effects in Psychoactive Substances","sstatus":"RECRUITING","sponsor":"Johns Hopkins University","official":"Frederick Barrett, Ph.D. (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT06772753","contact":{"n":"Zach Daily","p":"410-550-2533","e":"zdaily1@jh.edu"},"phase":"Phase 1","enroll":50,"start":"2025-02-05","eid":"x:site:nct06772753-johns-hopkins-center-for-psychedelic-and-consciousness-research-balt"},{"id":"nct04648137-university-hospital-basel-endocrinology-diabetes-and-metabolism-base","cat":"research","name":"University Hospital Basel, Endocrinology, Diabetes and Metabolism","city":"Basel","country":"Switzerland","cc":"CH","lat":47.55966,"lon":7.56466,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"4031","condg":["Other"],"nct":"NCT04648137","study":"Circulating Oxytocin Changes in Response to the Oxytocin System Stimulator MDMA in Patients With Diabetes Insipidus and Healthy Controls","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Mirjam Christ-Crain, Prof. Dr. med. (Endocrinology, Diabetes and Metabolism, University Hospital Basel)","src":"https://clinicaltrials.gov/study/NCT04648137","phase":"N/A","enroll":30,"start":"2021-02-05","eid":"x:site:nct04648137-university-hospital-basel-endocrinology-diabetes-and-metabolism-base"},{"id":"nct05809271-university-hospital-basel","cat":"research","name":"University Hospital","city":"Basel","country":"Switzerland","cc":"CH","lat":47.54865,"lon":7.56409,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"4031","condg":["Healthy volunteers"],"nct":"NCT05809271","study":"Acute Effects of 3,4-methylenedioxymethamphetamine (MDMA) With and Without a Booster Dose","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, Prof. Dr. MD (University Hospital Basel, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT05809271","phase":"Phase 1","enroll":25,"start":"2023-11-17","eid":"x:site:nct05809271-university-hospital-basel"},{"id":"nct05732155-emek-medical-center-afula","cat":"research","name":"Emek medical center","city":"Afula","country":"Israel","cc":"IL","lat":32.60036,"lon":35.29499,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"1910500","condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT05732155","study":"Preliminary Effectiveness of Individual and Group MDMA-assisted Therapy for Israeli Veterans With PTSD and Moral Injury.","sstatus":"RECRUITING","sponsor":"HaEmek Medical Center, Israel","src":"https://clinicaltrials.gov/study/NCT05732155","contact":{"n":"Gilat Ron Avraham","p":"0528495336","e":"gilataavraham@gmail.com"},"phase":"Phase 2","enroll":60,"start":"2023-06-01","eid":"x:site:nct05732155-emek-medical-center-afula"},{"id":"nct05219175-university-of-new-mexico-health-sciences-albuquerque","cat":"research","name":"University of New Mexico Health Sciences","city":"Albuquerque","region":"New Mexico","country":"United States","cc":"US","lat":35.07974,"lon":-106.63999,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"87131","condg":["PTSD & trauma","Addiction & substance use"],"status":"RECRUITING","nct":"NCT05219175","study":"MDMA for Co-occurring PTSD and OUD After Childbirth","sstatus":"RECRUITING","sponsor":"University of New Mexico","official":"Hadya Khawaja, MS, CIP (UNM Health Sciences Human Research Protections Program)","src":"https://clinicaltrials.gov/study/NCT05219175","contact":{"n":"Lawrence Leeman, MD","p":"505-272-9304","e":"lleeman@salud.unm.edu"},"phase":"Phase 2","enroll":15,"start":"2024-04-16","eid":"x:site:nct05219175-university-of-new-mexico-health-sciences-albuquerque"},{"id":"nct06954025-arq-national-psychotrauma-centre-arq-centrum-45-oegstgeest","cat":"research","name":"ARQ National Psychotrauma Centre / ARQ Centrum'45","city":"Oegstgeest","country":"Netherlands","cc":"NL","lat":52.18974,"lon":4.458,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"2342EG","condg":["PTSD & trauma"],"nct":"NCT06954025","study":"High-Intensity Inpatient MDMA-Assisted Psychotherapy for PTSD","sstatus":"ENROLLING_BY_INVITATION","sponsor":"ARQ National Psychotrauma Centre","src":"https://clinicaltrials.gov/study/NCT06954025","phase":"Phase 2","enroll":20,"start":"2025-05-16","eid":"x:site:nct06954025-arq-national-psychotrauma-centre-arq-centrum-45-oegstgeest"},{"id":"nct01400204-utrecht-university-utrecht","cat":"research","name":"Utrecht University","city":"Utrecht","region":"Utrecht","country":"Netherlands","cc":"NL","lat":52.09229,"lon":5.12029,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"3584CG","condg":["Other"],"nct":"NCT01400204","study":"Naturalistic Study Into the Hangover Effects of MDMA","sstatus":"COMPLETED","sponsor":"Utrecht Institute for Pharmaceutical Sciences","official":"Joris C Verster, PhD (Utrecht University)","src":"https://clinicaltrials.gov/study/NCT01400204","enroll":39,"start":"2010-12","eid":"x:site:nct01400204-utrecht-university-utrecht"},{"id":"nct01148342-national-institute-on-drug-abuse-biomedical-research-center-brc-balt","cat":"research","name":"National Institute on Drug Abuse, Biomedical Research Center (BRC)","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29071,"lon":-76.60433,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"21224","condg":["Addiction & substance use"],"nct":"NCT01148342","study":"Neurobiology and Pharmacokinets of Acute MDMA Administration","sstatus":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","official":"Marilyn Huestis, Ph.D. (National Institute on Drug Abuse (NIDA))","src":"https://clinicaltrials.gov/study/NCT01148342","phase":"Phase 1","enroll":187,"start":"2004-02-10","eid":"x:site:nct01148342-national-institute-on-drug-abuse-biomedical-research-center-brc-balt"},{"id":"nct05979844-va-san-diego-healthcare-system-san-diego-ca-san-diego","cat":"research","name":"VA San Diego Healthcare System, San Diego, CA","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.7262,"lon":-117.17013,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"92161","condg":["PTSD & trauma"],"nct":"NCT05979844","study":"MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD","sstatus":"COMPLETED","sponsor":"Dr. Leslie Morland","official":"Leslie Morland (San Diego Veterans Healthcare System)","src":"https://clinicaltrials.gov/study/NCT05979844","phase":"Phase 3","enroll":16,"start":"2023-10-06","eid":"x:site:nct05979844-va-san-diego-healthcare-system-san-diego-ca-san-diego"},{"id":"nct04803448-brigham-young-university-provo","cat":"research","name":"Brigham Young University","city":"Provo","region":"Utah","country":"United States","cc":"US","lat":40.23342,"lon":-111.65688,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"84602","condg":["Other"],"nct":"NCT04803448","study":"Patient Doctor Lies","sstatus":"COMPLETED","sponsor":"University of Utah","official":"Mark Keith, PhD (Brigham Young University)","src":"https://clinicaltrials.gov/study/NCT04803448","phase":"N/A","enroll":619,"start":"2020-02-12","eid":"x:site:nct04803448-brigham-young-university-provo"},{"id":"nct01404754-aguazul-bluewater-inc-boulder","cat":"research","name":"Aguazul Bluewater, Inc.","city":"Boulder","region":"Colorado","country":"United States","cc":"US","lat":40.01635,"lon":-105.27389,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"80304","condg":["Other"],"nct":"NCT01404754","study":"Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Michael M Mithoefer, MD (Resilient Pharmaceuticals)","src":"https://clinicaltrials.gov/study/NCT01404754","phase":"Phase 1","enroll":107,"start":"2011-04-09","eid":"x:site:nct01404754-aguazul-bluewater-inc-boulder"},{"id":"nct01404754-santa-fe-mdma-therapy-training-llc-santa-fe","cat":"research","name":"Santa Fe MDMA Therapy Training, LLC","city":"Santa Fe","region":"New Mexico","country":"United States","cc":"US","lat":35.68787,"lon":-105.93662,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"87508","condg":["Other"],"nct":"NCT01404754","study":"Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Michael M Mithoefer, MD (Resilient Pharmaceuticals)","src":"https://clinicaltrials.gov/study/NCT01404754","phase":"Phase 1","enroll":107,"start":"2011-04-09","eid":"x:site:nct01404754-santa-fe-mdma-therapy-training-llc-santa-fe"},{"id":"nct01404754-zen-therapeutic-solutions-mt-pleasant","cat":"research","name":"Zen Therapeutic Solutions","city":"Mt. Pleasant","region":"South Carolina","country":"United States","cc":"US","lat":32.80447,"lon":-79.86207,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"29464","condg":["Other"],"nct":"NCT01404754","study":"Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Michael M Mithoefer, MD (Resilient Pharmaceuticals)","src":"https://clinicaltrials.gov/study/NCT01404754","phase":"Phase 1","enroll":107,"start":"2011-04-09","eid":"x:site:nct01404754-zen-therapeutic-solutions-mt-pleasant"},{"id":"nct02008396-los-angeles-biomedical-research-institute-torrance","cat":"research","name":"Los Angeles Biomedical Research Institute","city":"Torrance","region":"California","country":"United States","cc":"US","lat":33.83759,"lon":-118.34068,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"90502","condg":["Anxiety"],"nct":"NCT02008396","study":"Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Charles S. Grob, MD (University of California, Los Angeles)","src":"https://clinicaltrials.gov/study/NCT02008396","phase":"Phase 2","enroll":12,"start":"2014-04-11","eid":"x:site:nct02008396-los-angeles-biomedical-research-institute-torrance"},{"id":"nct01053403-cpmc-addiction-pharmacology-research-laboratory-aprl-san-francisco","cat":"research","name":"CPMC Addiction & Pharmacology Research Laboratory (APRL)","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.78674,"lon":-122.4286,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"94110","condg":["Other"],"nct":"NCT01053403","study":"Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition.","sstatus":"COMPLETED","sponsor":"California Pacific Medical Center Research Institute","official":"John Mendelson, MD (CPMC Research Institute)","src":"https://clinicaltrials.gov/study/NCT01053403","phase":"N/A","enroll":12,"start":"2010-04","eid":"x:site:nct01053403-cpmc-addiction-pharmacology-research-laboratory-aprl-san-francisco"},{"id":"nct04438512-sunstone-medical-pc-rockville","cat":"research","name":"Sunstone Medical, PC","city":"Rockville","region":"Maryland","country":"United States","cc":"US","lat":39.08932,"lon":-77.1433,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"20850","condg":["PTSD & trauma"],"nct":"NCT04438512","study":"A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD","sstatus":"NO_LONGER_AVAILABLE","sponsor":"Resilient Pharmaceuticals","official":"Manish Agrawal, MD (Sunstone Medical, PC); Caroline Lewis, MD (Pearl Psychedelic Institute)","src":"https://clinicaltrials.gov/study/NCT04438512","eid":"x:site:nct04438512-sunstone-medical-pc-rockville"},{"id":"nct04438512-pearl-psychedelic-institute-waynesville","cat":"research","name":"Pearl Psychedelic Institute","city":"Waynesville","region":"North Carolina","country":"United States","cc":"US","lat":35.47709,"lon":-82.97844,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"28786","condg":["PTSD & trauma"],"nct":"NCT04438512","study":"A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD","sstatus":"NO_LONGER_AVAILABLE","sponsor":"Resilient Pharmaceuticals","official":"Manish Agrawal, MD (Sunstone Medical, PC); Caroline Lewis, MD (Pearl Psychedelic Institute)","src":"https://clinicaltrials.gov/study/NCT04438512","eid":"x:site:nct04438512-pearl-psychedelic-institute-waynesville"},{"id":"nct05488171-germans-trias-i-pujol-hospital-badalona","cat":"research","name":"Germans Trias i Pujol Hospital","city":"Badalona","region":"Barcelona","country":"Spain","cc":"ES","lat":41.4402,"lon":2.24285,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"08916","condg":["Addiction & substance use","Healthy volunteers"],"nct":"NCT05488171","study":"Abuse Potential and Human Pharmacology of Methylone","sstatus":"UNKNOWN","sponsor":"Germans Trias i Pujol Hospital","official":"Magi Farré, MD, PhD (Germans Trias i Pujol Hospital)","src":"https://clinicaltrials.gov/study/NCT05488171","phase":"Phase 1","enroll":17,"start":"2021-12-01","eid":"x:site:nct05488171-germans-trias-i-pujol-hospital-badalona"},{"id":"nct07288151-emory-brain-health-center-atlanta","cat":"research","name":"Emory Brain Health Center","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.74886,"lon":-84.3981,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"30329","condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT07288151","study":"MDMA-Assisted Massed Exposure Therapy for PTSD","sstatus":"RECRUITING","sponsor":"Emory University","official":"Jessica Maples-Keller, PhD (Emory University)","src":"https://clinicaltrials.gov/study/NCT07288151","contact":{"n":"Jessica Maples-Keller, PhD","p":"404-712-1035","e":"patstudy@emory.edu"},"phase":"Phase 2","enroll":200,"start":"2026-07","eid":"x:site:nct07288151-emory-brain-health-center-atlanta"},{"id":"nct05274230-apollo-neuroscience-inc-pittsburgh","cat":"research","name":"Apollo Neuroscience, Inc.","city":"Pittsburgh","region":"Pennsylvania","country":"United States","cc":"US","lat":40.43916,"lon":-80.00196,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"15219","condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT05274230","study":"Sustaining Remission From PTSD Using Tuned Vibroacoustic Stimulation (TVS) Following MDMA-Assisted Psychotherapy","sstatus":"UNKNOWN","sponsor":"Apollo Neuroscience, Inc.","official":"Belinda Tan, MD PhD (The Board of Medicine)","src":"https://clinicaltrials.gov/study/NCT05274230","contact":{"n":"Nicole Grinsell, MS","p":"855-922-0057","e":"taylor@apolloneuro.com"},"phase":"N/A","enroll":200,"start":"2021-12-08","eid":"x:site:nct05274230-apollo-neuroscience-inc-pittsburgh"},{"id":"nct05584826-sunstone-medical-pc-rockville","cat":"research","name":"Sunstone Medical, PC","city":"Rockville","region":"Maryland","country":"United States","cc":"US","lat":39.0832,"lon":-77.14575,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"20850","condg":["Cancer-related distress"],"status":"RECRUITING","nct":"NCT05584826","study":"MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other","sstatus":"RECRUITING","sponsor":"Sunstone Medical","official":"Manish Agrawal, MD (Sunstone Medical, PC)","src":"https://clinicaltrials.gov/study/NCT05584826","contact":{"n":"Study Contact","p":"301-750-3401","e":"clinical.specialists@sunstonetherapies.com"},"phase":"Phase 2","enroll":20,"start":"2022-10-06","eid":"x:site:nct05584826-sunstone-medical-pc-rockville"},{"id":"nct06884514-university-hospital-basel-basel","cat":"research","name":"University Hospital Basel","city":"Basel","country":"Switzerland","cc":"CH","lat":47.54987,"lon":7.57068,"gp":"city","unnamed":0,"drugs":["MDMA","psilocybin"],"zip":"4031","condg":["Healthy volunteers"],"nct":"NCT06884514","study":"Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, Prof. Dr. MD (University Hospital Basel, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT06884514","phase":"Phase 1","enroll":24,"start":"2025-04-03","eid":"x:site:nct06884514-university-hospital-basel-basel"},{"id":"nct05943665-brown-university-providence","cat":"research","name":"Brown University","city":"Providence","region":"Rhode Island","country":"United States","cc":"US","lat":41.83448,"lon":-71.41787,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"02903","condg":["PTSD & trauma","Addiction & substance use"],"nct":"NCT05943665","study":"MDMA for AUD/PTSD Comorbidity","sstatus":"COMPLETED","sponsor":"Carolina L Haass-Koffler","src":"https://clinicaltrials.gov/study/NCT05943665","phase":"Phase 2","enroll":22,"start":"2024-02-06","eid":"x:site:nct05943665-brown-university-providence"},{"id":"nct05123716-university-of-chicago-chicago","cat":"research","name":"University of Chicago","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.85055,"lon":-87.65339,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"60637","condg":["Other"],"nct":"NCT05123716","study":"Drug Effects on Interpersonal Interaction","sstatus":"COMPLETED","sponsor":"University of Chicago","src":"https://clinicaltrials.gov/study/NCT05123716","phase":"EARLY_Phase 1","enroll":30,"start":"2021-08-01","eid":"x:site:nct05123716-university-of-chicago-chicago"},{"id":"nct07569159-sunstone-therapies-rockville","cat":"research","name":"Sunstone Therapies","city":"Rockville","region":"Maryland","country":"United States","cc":"US","lat":39.08998,"lon":-77.15102,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"20850","condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT07569159","study":"MDMA Therapy in Veterans With PTSD","sstatus":"RECRUITING","sponsor":"Sunstone Medical","official":"Manish Agarwal (Sunstone Medical, PC)","src":"https://clinicaltrials.gov/study/NCT07569159","contact":{"n":"Manish Agarwal","p":"(301) 750-3401","e":"clinical.specialists@sunstonetherapies.com"},"phase":"Phase 2","enroll":52,"start":"2026-06-30","eid":"x:site:nct07569159-sunstone-therapies-rockville"},{"id":"nct06081179-psychiatrische-universitatsklinik-zurich-zurich","cat":"research","name":"Psychiatrische Universitätsklinik Zürich","city":"Zurich","region":"Canton of Zurich","country":"Switzerland","cc":"CH","lat":47.35589,"lon":8.55701,"gp":"city","unnamed":0,"drugs":["MDMA","psilocybin"],"zip":"8032","condg":["Healthy volunteers"],"nct":"NCT06081179","study":"Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans","sstatus":"COMPLETED","sponsor":"University of Zurich","src":"https://clinicaltrials.gov/study/NCT06081179","phase":"Phase 1","enroll":122,"start":"2023-10-24","eid":"x:site:nct06081179-psychiatrische-universitatsklinik-zurich-zurich"},{"id":"nct02342366-hospital-for-psychiatry-university-of-zurich-zurich","cat":"research","name":"Hospital for Psychiatry, University of Zurich","city":"Zurich","country":"Switzerland","cc":"CH","lat":47.35956,"lon":8.55428,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"8032","condg":["Depression","Bipolar"],"nct":"NCT02342366","study":"Characterization of the Prosocial and Prosexual Effects of GHB","sstatus":"COMPLETED","sponsor":"University of Zurich","official":"Erich Seifritz, Professor (University of Zurich)","src":"https://clinicaltrials.gov/study/NCT02342366","phase":"N/A","enroll":19,"start":"2012-02","eid":"x:site:nct02342366-hospital-for-psychiatry-university-of-zurich-zurich"},{"id":"nct05948683-university-of-chicago-chicago","cat":"research","name":"University of Chicago","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.85761,"lon":-87.64464,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"60637","condg":["Other"],"nct":"NCT05948683","study":"Prosocial Effects of MDMA","sstatus":"COMPLETED","sponsor":"University of Chicago","official":"Harriet de Wit (University of Chicago)","src":"https://clinicaltrials.gov/study/NCT05948683","phase":"EARLY_Phase 1","enroll":33,"start":"2023-07-21","eid":"x:site:nct05948683-university-of-chicago-chicago"},{"id":"nct05837845-va-palo-alto-health-care-system-stanford-university-palo-alto","cat":"research","name":"VA Palo Alto Health Care System / Stanford University","city":"Palo Alto","region":"California","country":"United States","cc":"US","lat":37.43901,"lon":-122.14203,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"94304","condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT05837845","study":"MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder","sstatus":"RECRUITING","sponsor":"Patricia Suppes","official":"Trisha Suppes, MD, PhD (VA Palo Alto Healthcare System / Stanford University); Shannon Wiltsey Stirman, PhD (VA Palo Alto Healthcare System / Stanford University)","src":"https://clinicaltrials.gov/study/NCT05837845","contact":{"n":"Anna Donnelly","p":"650-849-0161","e":"anna.donnelly@va.gov"},"phase":"Phase 2","enroll":30,"start":"2025-02-10","eid":"x:site:nct05837845-va-palo-alto-health-care-system-stanford-university-palo-alto"},{"id":"nct03282123-new-school-research-llc-north-hollywood","cat":"research","name":"New School Research LLC","city":"North Hollywood","region":"California","country":"United States","cc":"US","lat":34.16672,"lon":-118.37873,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"91601","condg":["PTSD & trauma"],"nct":"NCT03282123","study":"Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Michael C Mithoefer, MD (MAPS Public Benefit Corp.)","src":"https://clinicaltrials.gov/study/NCT03282123","phase":"Phase 2","enroll":38,"start":"2017-11-16","eid":"x:site:nct03282123-new-school-research-llc-north-hollywood"},{"id":"nct03282123-san-francisco-insight-and-integration-center-san-francisco","cat":"research","name":"San Francisco Insight and Integration Center","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.78072,"lon":-122.4174,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"94114","condg":["PTSD & trauma"],"nct":"NCT03282123","study":"Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Michael C Mithoefer, MD (MAPS Public Benefit Corp.)","src":"https://clinicaltrials.gov/study/NCT03282123","phase":"Phase 2","enroll":38,"start":"2017-11-16","eid":"x:site:nct03282123-san-francisco-insight-and-integration-center-san-francisco"},{"id":"nct03282123-university-of-california-san-francisco-san-francisco","cat":"research","name":"University of California San Francisco","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.78269,"lon":-122.42069,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"94122","condg":["PTSD & trauma"],"nct":"NCT03282123","study":"Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Michael C Mithoefer, MD (MAPS Public Benefit Corp.)","src":"https://clinicaltrials.gov/study/NCT03282123","phase":"Phase 2","enroll":38,"start":"2017-11-16","eid":"x:site:nct03282123-university-of-california-san-francisco-san-francisco"},{"id":"nct03282123-aguazul-blue-water-inc-boulder","cat":"research","name":"Aguazul-Blue Water Inc.","city":"Boulder","region":"Colorado","country":"United States","cc":"US","lat":40.01061,"lon":-105.26871,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"80302","condg":["PTSD & trauma"],"nct":"NCT03282123","study":"Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Michael C Mithoefer, MD (MAPS Public Benefit Corp.)","src":"https://clinicaltrials.gov/study/NCT03282123","phase":"Phase 2","enroll":38,"start":"2017-11-16","eid":"x:site:nct03282123-aguazul-blue-water-inc-boulder"},{"id":"nct03282123-wholeness-center-fort-collins","cat":"research","name":"Wholeness Center","city":"Fort Collins","region":"Colorado","country":"United States","cc":"US","lat":40.58502,"lon":-105.0871,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"80525","condg":["PTSD & trauma"],"nct":"NCT03282123","study":"Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Michael C Mithoefer, MD (MAPS Public Benefit Corp.)","src":"https://clinicaltrials.gov/study/NCT03282123","phase":"Phase 2","enroll":38,"start":"2017-11-16","eid":"x:site:nct03282123-wholeness-center-fort-collins"},{"id":"nct03282123-university-of-connecticut-farmington","cat":"research","name":"University of Connecticut","city":"Farmington","region":"Connecticut","country":"United States","cc":"US","lat":36.71898,"lon":-108.22053,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"06030","condg":["PTSD & trauma"],"nct":"NCT03282123","study":"Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Michael C Mithoefer, MD (MAPS Public Benefit Corp.)","src":"https://clinicaltrials.gov/study/NCT03282123","phase":"Phase 2","enroll":38,"start":"2017-11-16","eid":"x:site:nct03282123-university-of-connecticut-farmington"},{"id":"nct03282123-ray-worthy-psychiatry-llc-new-orleans","cat":"research","name":"Ray Worthy Psychiatry LLC","city":"New Orleans","region":"Louisiana","country":"United States","cc":"US","lat":29.96147,"lon":-90.08029,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"70123","condg":["PTSD & trauma"],"nct":"NCT03282123","study":"Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Michael C Mithoefer, MD (MAPS Public Benefit Corp.)","src":"https://clinicaltrials.gov/study/NCT03282123","phase":"Phase 2","enroll":38,"start":"2017-11-16","eid":"x:site:nct03282123-ray-worthy-psychiatry-llc-new-orleans"},{"id":"nct03282123-trauma-research-foundation-brookline","cat":"research","name":"Trauma Research Foundation","city":"Brookline","region":"Massachusetts","country":"United States","cc":"US","lat":42.32145,"lon":-71.11885,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"02446","condg":["PTSD & trauma"],"nct":"NCT03282123","study":"Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Michael C Mithoefer, MD (MAPS Public Benefit Corp.)","src":"https://clinicaltrials.gov/study/NCT03282123","phase":"Phase 2","enroll":38,"start":"2017-11-16","eid":"x:site:nct03282123-trauma-research-foundation-brookline"},{"id":"nct03282123-new-york-university-new-york","cat":"research","name":"New York University","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72175,"lon":-74.01082,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"10016","condg":["PTSD & trauma"],"nct":"NCT03282123","study":"Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Michael C Mithoefer, MD (MAPS Public Benefit Corp.)","src":"https://clinicaltrials.gov/study/NCT03282123","phase":"Phase 2","enroll":38,"start":"2017-11-16","eid":"x:site:nct03282123-new-york-university-new-york"},{"id":"nct03282123-affective-care-new-york","cat":"research","name":"Affective Care","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71545,"lon":-74.00065,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"10024","condg":["PTSD & trauma"],"nct":"NCT03282123","study":"Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Michael C Mithoefer, MD (MAPS Public Benefit Corp.)","src":"https://clinicaltrials.gov/study/NCT03282123","phase":"Phase 2","enroll":38,"start":"2017-11-16","eid":"x:site:nct03282123-affective-care-new-york"},{"id":"nct03282123-zen-therapeutic-solutions-llc-mt-pleasant","cat":"research","name":"Zen Therapeutic Solutions, LLC","city":"Mt. Pleasant","region":"South Carolina","country":"United States","cc":"US","lat":32.79459,"lon":-79.85078,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"29464","condg":["PTSD & trauma"],"nct":"NCT03282123","study":"Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Michael C Mithoefer, MD (MAPS Public Benefit Corp.)","src":"https://clinicaltrials.gov/study/NCT03282123","phase":"Phase 2","enroll":38,"start":"2017-11-16","eid":"x:site:nct03282123-zen-therapeutic-solutions-llc-mt-pleasant"},{"id":"nct03282123-university-of-wisconsin-at-madison-madison","cat":"research","name":"University of Wisconsin at Madison","city":"Madison","region":"Wisconsin","country":"United States","cc":"US","lat":43.06858,"lon":-89.40438,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"53705","condg":["PTSD & trauma"],"nct":"NCT03282123","study":"Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Michael C Mithoefer, MD (MAPS Public Benefit Corp.)","src":"https://clinicaltrials.gov/study/NCT03282123","phase":"Phase 2","enroll":38,"start":"2017-11-16","eid":"x:site:nct03282123-university-of-wisconsin-at-madison-madison"},{"id":"nct01951508-university-hospital-basel-basel","cat":"research","name":"University Hospital Basel","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","cc":"CH","lat":47.5494,"lon":7.56419,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"4000","condg":["Addiction & substance use","Healthy volunteers"],"nct":"NCT01951508","study":"Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, MD, MAS (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT01951508","phase":"EARLY_Phase 1","enroll":24,"start":"2013-10","eid":"x:site:nct01951508-university-hospital-basel-basel"},{"id":"nct04264026-va-loma-linda-health-care-system-loma-linda","cat":"research","name":"VA Loma Linda Health Care System","city":"Loma Linda","region":"California","country":"United States","cc":"US","lat":34.0372,"lon":-117.26176,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"92357","condg":["PTSD & trauma"],"nct":"NCT04264026","study":"MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD","sstatus":"COMPLETED","sponsor":"VA Loma Linda Health Care System","official":"Shannon Remick, MD (Staff Psychiatrist)","src":"https://clinicaltrials.gov/study/NCT04264026","phase":"Phase 2","enroll":5,"start":"2021-07-29","eid":"x:site:nct04264026-va-loma-linda-health-care-system-loma-linda"},{"id":"nct06565494-university-of-washington-seattle","cat":"research","name":"University of Washington","city":"Seattle","region":"Washington","country":"United States","cc":"US","lat":47.61379,"lon":-122.32675,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"98195","condg":["Other"],"nct":"NCT06565494","study":"MDMA-Assisted Therapy for Pathological Narcissism","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","official":"Anthony Back, MD (University of Washington); Alexa Albert, MD (University of Washington)","src":"https://clinicaltrials.gov/study/NCT06565494","phase":"EARLY_Phase 1","enroll":12,"start":"2024-08-27","eid":"x:site:nct06565494-university-of-washington-seattle"},{"id":"nct06683014-connecticut-mental-health-center-new-haven","cat":"research","name":"Connecticut Mental Health Center","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.30895,"lon":-72.92529,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"06519","condg":["Other"],"status":"RECRUITING","nct":"NCT06683014","study":"MDMA in Borderline Personality Disorder","sstatus":"RECRUITING","sponsor":"Yale University","official":"Sarah K Fineberg, MD, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT06683014","contact":{"n":"Sarah K Fineberg, MD, PhD","p":"(203) 974-7265","e":"fineberg.lab@yale.edu"},"phase":"Phase 2","enroll":10,"start":"2025-09-05","eid":"x:site:nct06683014-connecticut-mental-health-center-new-haven"},{"id":"nct01447472-imim-hospital-del-mar-institut-de-recerca-hospital-del-mar-barcelona","cat":"research","name":"IMIM-Hospital del Mar (Institut de Recerca Hospital del Mar)","city":"Barcelona","region":"Barcelona","country":"Spain","cc":"ES","lat":41.38903,"lon":2.1485,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"08003","condg":["Other"],"nct":"NCT01447472","study":"-Methylenedioxymethamphetamine (MDMA, Ecstasy) Induced Changes in Drug Metabolism: Gender and Genetic Polymorphisms","sstatus":"COMPLETED","sponsor":"Parc de Salut Mar","official":"Magí Farre, PhD (IMIM-Hospital del Mar (Institut de Recerca Hospital del Mar))","src":"https://clinicaltrials.gov/study/NCT01447472","phase":"Phase 1","enroll":27,"start":"2003-05","eid":"x:site:nct01447472-imim-hospital-del-mar-institut-de-recerca-hospital-del-mar-barcelona"},{"id":"nct05746572-emory-brain-health-center-atlanta","cat":"research","name":"Emory Brain Health Center","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.75046,"lon":-84.39443,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"30329","condg":["PTSD & trauma"],"nct":"NCT05746572","study":"MDMA Plus Exposure Therapy for PTSD","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Emory University","official":"Jessica Maples-Keller, PhD (Emory University); Barbara O Rothbaum, PhD (Emory University)","src":"https://clinicaltrials.gov/study/NCT05746572","phase":"Phase 2","enroll":40,"start":"2024-02-13","eid":"x:site:nct05746572-emory-brain-health-center-atlanta"},{"id":"nct05770375-ucla-los-angeles","cat":"research","name":"UCLA","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.05999,"lon":-118.25116,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"90025","condg":["Other"],"status":"RECRUITING","nct":"NCT05770375","study":"Tolerability of MDMA in Schizophrenia","sstatus":"RECRUITING","sponsor":"Anya Bershad, MD, PhD","src":"https://clinicaltrials.gov/study/NCT05770375","contact":{"n":"Gerard De Vera","p":"310-794-5577","e":"gdevera@mednet.ucla.edu"},"phase":"Phase 1/Phase 2","enroll":20,"start":"2024-09-01","eid":"x:site:nct05770375-ucla-los-angeles"},{"id":"nct01849419-university-of-chicago-chicago","cat":"research","name":"University of Chicago","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.84829,"lon":-87.63843,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"60637","condg":["Addiction & substance use"],"nct":"NCT01849419","study":"Effects of MDMA on Social and Emotional Processing","sstatus":"COMPLETED","sponsor":"University of Chicago","official":"Harriet de Wit, PhD (University of Chicago)","src":"https://clinicaltrials.gov/study/NCT01849419","phase":"N/A","enroll":65,"start":"2010-07","eid":"x:site:nct01849419-university-of-chicago-chicago"},{"id":"nct05709353-drug-health-services-royal-prince-alfred-hospital-sydney","cat":"research","name":"Drug Health Services, Royal Prince Alfred Hospital","city":"Sydney","region":"New South Wales","country":"Australia","cc":"AU","lat":-33.86987,"lon":151.20276,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"2050","condg":["PTSD & trauma","Addiction & substance use"],"status":"RECRUITING","nct":"NCT05709353","study":"MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder","sstatus":"UNKNOWN","sponsor":"University of Sydney","official":"Kirsten C Morley, PhD (University of Sydney)","src":"https://clinicaltrials.gov/study/NCT05709353","contact":{"n":"Paul Haber, MBBS","p":"61295153636","e":"paul.haber@sydney.edu.au"},"phase":"Phase 2","enroll":120,"start":"2023-09-19","eid":"x:site:nct05709353-drug-health-services-royal-prince-alfred-hospital-sydney"},{"id":"nct05709353-turning-point-richmond","cat":"research","name":"Turning Point","city":"Richmond","region":"Victoria","country":"Australia","cc":"AU","lat":-37.81155,"lon":145.00435,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"3121","condg":["PTSD & trauma","Addiction & substance use"],"status":"NOT_YET_RECRUITING","nct":"NCT05709353","study":"MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder","sstatus":"UNKNOWN","sponsor":"University of Sydney","official":"Kirsten C Morley, PhD (University of Sydney)","src":"https://clinicaltrials.gov/study/NCT05709353","contact":{"n":"Shalini Arunogiri, MBBS","p":"61295153636","e":"shaliniA@turningpoint.org.au"},"phase":"Phase 2","enroll":120,"start":"2023-09-19","eid":"x:site:nct05709353-turning-point-richmond"},{"id":"nct01689740-beer-yaakov-hospital-be-er-ya-aqov","cat":"research","name":"Beer Yaakov Hospital","city":"Be’er Ya‘aqov","country":"Israel","cc":"IL","lat":31.93473,"lon":34.84648,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"70350","condg":["PTSD & trauma"],"nct":"NCT01689740","study":"Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Moshe Kotler (Beer Yaakov Hospital)","src":"https://clinicaltrials.gov/study/NCT01689740","phase":"Phase 2","enroll":10,"start":"2013-01-17","eid":"x:site:nct01689740-beer-yaakov-hospital-be-er-ya-aqov"},{"id":"nct01793610-offices-of-marcela-d-otalora-boulder","cat":"research","name":"Offices of Marcela d'Otalora","city":"Boulder","region":"Colorado","country":"United States","cc":"US","lat":40.02633,"lon":-105.27436,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"80304","condg":["PTSD & trauma"],"nct":"NCT01793610","study":"Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Marcela d'Otalora, MA, LPC (Private Practice)","src":"https://clinicaltrials.gov/study/NCT01793610","phase":"Phase 2","enroll":29,"start":"2013-05-13","eid":"x:site:nct01793610-offices-of-marcela-d-otalora-boulder"},{"id":"nct05138068-portland-psychotherapy-clinic-research-training-center-portland","cat":"research","name":"Portland Psychotherapy Clinic, Research, & Training Center","city":"Portland","region":"Oregon","country":"United States","cc":"US","lat":45.53498,"lon":-122.68068,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"97227","condg":["Anxiety"],"nct":"NCT05138068","study":"Social Anxiety MDMA-Assisted Therapy Investigation","sstatus":"COMPLETED","sponsor":"Jason B Luoma","official":"Jason B Luoma, Ph.D. (Portland Psychotherapy Clinic, Research, and Training Center)","src":"https://clinicaltrials.gov/study/NCT05138068","phase":"Phase 2","enroll":90,"start":"2022-04-13","eid":"x:site:nct05138068-portland-psychotherapy-clinic-research-training-center-portland"},{"id":"nct04053036-university-of-chicago-chicago","cat":"research","name":"University of Chicago","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.84057,"lon":-87.65386,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"60637","condg":["Healthy volunteers"],"nct":"NCT04053036","study":"Effects of Drugs on Responses to Brain and Emotional Processes","sstatus":"COMPLETED","sponsor":"University of Chicago","official":"Harriet de Wit (Principal Investigator)","src":"https://clinicaltrials.gov/study/NCT04053036","phase":"EARLY_Phase 1","enroll":22,"start":"2019-08-08","eid":"x:site:nct04053036-university-of-chicago-chicago"},{"id":"nct07303907-spectrum-neuroscience-and-treatment-institute-new-york","cat":"research","name":"Spectrum Neuroscience and Treatment Institute","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71535,"lon":-74.00131,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"10021","condg":["Other"],"status":"RECRUITING","nct":"NCT07303907","study":"A Phase 2A Trial of DT402 for Autism Spectrum Disorder","sstatus":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","src":"https://clinicaltrials.gov/study/NCT07303907","contact":{"n":"Casara Ferretti","p":"1-914-315-4236","e":"cferretti@spectrumneuroscience.org"},"phase":"Phase 2","enroll":20,"start":"2025-12-03","eid":"x:site:nct07303907-spectrum-neuroscience-and-treatment-institute-new-york"},{"id":"nct01616407-university-hospital-basel-basel","cat":"research","name":"University Hospital Basel","city":"Basel","country":"Switzerland","cc":"CH","lat":47.55684,"lon":7.56871,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"4031","condg":["Other"],"nct":"NCT01616407","study":"Effects of MDMA and Methylphenidate on Social Cognition","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT01616407","phase":"EARLY_Phase 1","enroll":30,"start":"2012-08","eid":"x:site:nct01616407-university-hospital-basel-basel"},{"id":"nct00886886-university-hospital-basel","cat":"research","name":"University Hospital","city":"Basel","country":"Switzerland","cc":"CH","lat":47.56512,"lon":7.57153,"gp":"city","unnamed":0,"drugs":["MDMA"],"condg":["Addiction & substance use"],"nct":"NCT00886886","study":"Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, MD (Department of Internal Medicine, Division of Pharmacology & Toxicology, University Hospital Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT00886886","phase":"Phase 1","enroll":16,"start":"2009-04","eid":"x:site:nct00886886-university-hospital-basel"},{"id":"nct04847206-university-hospital-basel-clinical-trial-unit-basel","cat":"research","name":"University Hospital Basel, Clinical Trial Unit","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","cc":"CH","lat":47.56597,"lon":7.57068,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"4056","condg":["Healthy volunteers"],"nct":"NCT04847206","study":"Effects of MDMA-like Substances in Healthy Subjects","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, Prof. Dr. MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT04847206","phase":"Phase 1","enroll":23,"start":"2021-12-01","eid":"x:site:nct04847206-university-hospital-basel-clinical-trial-unit-basel"},{"id":"nct00252174-mclean-hospital-belmont","cat":"research","name":"McLean Hospital","city":"Belmont","region":"Massachusetts","country":"United States","cc":"US","lat":37.53136,"lon":-122.28291,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"02478-9106","condg":["Anxiety","Cancer-related distress"],"nct":"NCT00252174","study":"MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer","sstatus":"TERMINATED","sponsor":"Brigham and Women's Hospital","official":"John H Halpern, MD (Mclean Hospital)","src":"https://clinicaltrials.gov/study/NCT00252174","phase":"Phase 2","enroll":2,"start":"2007-02","eid":"x:site:nct00252174-mclean-hospital-belmont"},{"id":"nct04060108-stanford-psychiatry-and-behavioral-sciences-department-palo-alto","cat":"research","name":"Stanford Psychiatry and Behavioral Sciences Department","city":"Palo Alto","region":"California","country":"United States","cc":"US","lat":37.4376,"lon":-122.15464,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"94305","condg":["Healthy volunteers"],"nct":"NCT04060108","study":"Stanford Regulating Circuits of the Brain Study - MDMA","sstatus":"COMPLETED","sponsor":"Stanford University","official":"Leanne M Williams, PhD (Stanford PI)","src":"https://clinicaltrials.gov/study/NCT04060108","enroll":22,"start":"2021-11-02","eid":"x:site:nct04060108-stanford-psychiatry-and-behavioral-sciences-department-palo-alto"},{"id":"nct05783817-stanford-university-medical-center-palo-alto","cat":"research","name":"Stanford University Medical Center","city":"Palo Alto","region":"California","country":"United States","cc":"US","lat":37.43204,"lon":-122.13356,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"94305","condg":["OCD"],"status":"RECRUITING","nct":"NCT05783817","study":"MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)","sstatus":"RECRUITING","sponsor":"Carolyn Rodriguez","official":"Carolyn Rodriguez, MD, PhD (Stanford University)","src":"https://clinicaltrials.gov/study/NCT05783817","contact":{"n":"Alessa Gaeta, BS","p":"650-723-4095","e":"ocdresearch@stanford.edu"},"phase":"Phase 2","enroll":40,"start":"2025-09-10","eid":"x:site:nct05783817-stanford-university-medical-center-palo-alto"},{"id":"nct01458327-offices-of-michael-mithoefer-mt-pleasant","cat":"research","name":"Offices of Michael Mithoefer","city":"Mt. Pleasant","region":"South Carolina","country":"United States","cc":"US","lat":32.79355,"lon":-79.86207,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"29464","condg":["PTSD & trauma"],"nct":"NCT01458327","study":"Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Michael C Mithoefer, MD (Psychiatrist)","src":"https://clinicaltrials.gov/study/NCT01458327","phase":"Phase 2","enroll":3,"start":"2010-12-15","eid":"x:site:nct01458327-offices-of-michael-mithoefer-mt-pleasant"},{"id":"nct02876172-offices-of-michael-mithoefer-md-mt-pleasant","cat":"research","name":"Offices of Michael Mithoefer MD","city":"Mt. Pleasant","region":"South Carolina","country":"United States","cc":"US","lat":32.78715,"lon":-79.86753,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"29464","condg":["PTSD & trauma"],"nct":"NCT02876172","study":"MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Michael C Mithoefer, MD (Private Practice)","src":"https://clinicaltrials.gov/study/NCT02876172","phase":"Phase 1/Phase 2","enroll":12,"start":"2016-07-03","eid":"x:site:nct02876172-offices-of-michael-mithoefer-md-mt-pleasant"},{"id":"nct05523401-university-hospital-basel-basel","cat":"research","name":"University Hospital Basel","city":"Basel","country":"Switzerland","cc":"CH","lat":47.5526,"lon":7.58527,"gp":"city","unnamed":0,"drugs":["MDMA","psilocybin"],"condg":["Healthy volunteers"],"nct":"NCT05523401","study":"Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT05523401","phase":"Phase 1","enroll":24,"start":"2023-08-16","eid":"x:site:nct05523401-university-hospital-basel-basel"},{"id":"nct03485287-british-columbia-centre-on-substance-abuse-vancouver","cat":"research","name":"British Columbia Centre on Substance Abuse","city":"Vancouver","region":"British Columbia","country":"Canada","cc":"CA","lat":49.25093,"lon":-123.12532,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"V64 1H","condg":["PTSD & trauma"],"nct":"NCT03485287","study":"Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD (Canada)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Michael Mithoefer (MAPS Public Benefit Corp.)","src":"https://clinicaltrials.gov/study/NCT03485287","phase":"Phase 2","enroll":4,"start":"2018-03-13","eid":"x:site:nct03485287-british-columbia-centre-on-substance-abuse-vancouver"},{"id":"nct03485287-dr-simon-amar-llc-montreal","cat":"research","name":"Dr. Simon Amar, LLC","city":"Montreal","region":"Quebec","country":"Canada","cc":"CA","lat":45.51406,"lon":-73.59661,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"H2W 1Y9","condg":["PTSD & trauma"],"nct":"NCT03485287","study":"Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD (Canada)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Michael Mithoefer (MAPS Public Benefit Corp.)","src":"https://clinicaltrials.gov/study/NCT03485287","phase":"Phase 2","enroll":4,"start":"2018-03-13","eid":"x:site:nct03485287-dr-simon-amar-llc-montreal"},{"id":"nct02232789-institut-hospital-del-mar-d-investigacions-mediques-imim-parc-de-sal","cat":"research","name":"Institut Hospital del Mar d'Investigacions Mèdiques-IMIM. Parc de Salut Mar.","city":"Barcelona","region":"Barcelona","country":"Spain","cc":"ES","lat":41.38103,"lon":2.1484,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"08003","condg":["Other"],"nct":"NCT02232789","study":"Abuse Liability and Human Pharmacology of Mephedrone","sstatus":"COMPLETED","sponsor":"Parc de Salut Mar","official":"Magi Farre, MD, PhD (Parc de Salut Mar)","src":"https://clinicaltrials.gov/study/NCT02232789","phase":"Phase 1","enroll":12,"start":"2014-09","eid":"x:site:nct02232789-institut-hospital-del-mar-d-investigacions-mediques-imim-parc-de-sal"},{"id":"nct07118839-va-connecticut-healthcare-system-west-haven-campus-west-haven-ct-wes","cat":"research","name":"VA Connecticut Healthcare System West Haven Campus, West Haven, CT","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.27804,"lon":-72.95274,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"06516-2770","condg":["PTSD & trauma","Addiction & substance use"],"status":"RECRUITING","nct":"NCT07118839","study":"MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder","sstatus":"RECRUITING","sponsor":"VA Office of Research and Development","official":"Erica M. Eaton, PhD (Providence VA Medical Center, Providence, RI)","src":"https://clinicaltrials.gov/study/NCT07118839","contact":{"n":"Candice Presseau, PhD","p":"(401) 273-7100","e":"Candice.Presseau@va.gov"},"phase":"Phase 2/Phase 3","enroll":80,"start":"2026-05-18","eid":"x:site:nct07118839-va-connecticut-healthcare-system-west-haven-campus-west-haven-ct-wes"},{"id":"nct07118839-providence-va-medical-center-providence-ri-providence","cat":"research","name":"Providence VA Medical Center, Providence, RI","city":"Providence","region":"Rhode Island","country":"United States","cc":"US","lat":41.81265,"lon":-71.41269,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"02908-4734","condg":["PTSD & trauma","Addiction & substance use"],"status":"RECRUITING","nct":"NCT07118839","study":"MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder","sstatus":"RECRUITING","sponsor":"VA Office of Research and Development","official":"Erica M. Eaton, PhD (Providence VA Medical Center, Providence, RI)","src":"https://clinicaltrials.gov/study/NCT07118839","contact":{"n":"Erica M Eaton, PhD","p":"(401) 273-7100","e":"Erica.Eaton@va.gov"},"phase":"Phase 2/Phase 3","enroll":80,"start":"2026-05-18","eid":"x:site:nct07118839-providence-va-medical-center-providence-ri-providence"},{"id":"nct02102802-offices-of-michael-mithoefer-mt-pleasant","cat":"research","name":"Offices of Michael Mithoefer","city":"Mt. Pleasant","region":"South Carolina","country":"United States","cc":"US","lat":32.79826,"lon":-79.86744,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"29464-4345","condg":["PTSD & trauma"],"nct":"NCT02102802","study":"Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Michael C Mithoefer, MD (Private Practice)","src":"https://clinicaltrials.gov/study/NCT02102802","enroll":10,"start":"2014-01","eid":"x:site:nct02102802-offices-of-michael-mithoefer-mt-pleasant"},{"id":"nct01296802-university-hospital-of-psychiatry-zurich-zurich","cat":"research","name":"University Hospital of Psychiatry Zurich","city":"Zurich","region":"Canton of Zurich","country":"Switzerland","cc":"CH","lat":47.37236,"lon":8.54478,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"8032","condg":["Other"],"nct":"NCT01296802","study":"Investigation of Serotonin Neurotransmission in MDMA Users Using Combinated Dexfenfluramine Challenge and PET Imaging","sstatus":"COMPLETED","sponsor":"University of Zurich","official":"Franz X Vollenweider, Prof. (Psychiatric University Hospital, Zurich); Boris B Quednow, Prof (Psychiatric University Hospital, Zurich)","src":"https://clinicaltrials.gov/study/NCT01296802","phase":"N/A","enroll":50,"start":"2006-04","eid":"x:site:nct01296802-university-hospital-of-psychiatry-zurich-zurich"},{"id":"nct01211405-offices-of-michael-mithoefer-mt-pleasant","cat":"research","name":"Offices of Michael Mithoefer","city":"Mt. Pleasant","region":"South Carolina","country":"United States","cc":"US","lat":32.79562,"lon":-79.85699,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"29464-4345","condg":["PTSD & trauma"],"nct":"NCT01211405","study":"Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Michael Mithoefer, MD (Private Practice)","src":"https://clinicaltrials.gov/study/NCT01211405","phase":"Phase 2","enroll":26,"start":"2010-11-10","eid":"x:site:nct01211405-offices-of-michael-mithoefer-mt-pleasant"},{"id":"nct04784143-james-j-peters-va-medical-center-the-bronx","cat":"research","name":"James J. Peters VA Medical Center","city":"The Bronx","region":"New York","country":"United States","cc":"US","lat":40.85771,"lon":-73.86617,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"10468","condg":["PTSD & trauma"],"nct":"NCT04784143","study":"Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD","sstatus":"TERMINATED","sponsor":"Resilient Pharmaceuticals","official":"Rachel Yehuda (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT04784143","phase":"Phase 2","enroll":26,"start":"2021-11-08","eid":"x:site:nct04784143-james-j-peters-va-medical-center-the-bronx"},{"id":"nct00254306-dept-of-nuclear-medicine-hadassah-hospital-ein-kerem-jerusalem","cat":"research","name":"Dept. of Nuclear Medicine, Hadassah Hospital, Ein Kerem","city":"Jerusalem","country":"Israel","cc":"IL","lat":31.78076,"lon":35.208,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"91120","condg":["Other"],"nct":"NCT00254306","study":"Functional Brain Imaging in Recreational Users of Ecstasy","sstatus":"COMPLETED","sponsor":"Hadassah Medical Organization","official":"Yodphat Krausz, MD (Hadassah Medical Organization); Aviv M Weinstein, Ph.D (Hadassah Medical Organization)","src":"https://clinicaltrials.gov/study/NCT00254306","enroll":18,"start":"2006-01","eid":"x:site:nct00254306-dept-of-nuclear-medicine-hadassah-hospital-ein-kerem-jerusalem"},{"id":"nct05277636-university-hospital-basel-basel","cat":"research","name":"University Hospital Basel","city":"Basel","country":"Switzerland","cc":"CH","lat":47.56568,"lon":7.57943,"gp":"city","unnamed":0,"drugs":["MDMA"],"condg":["Healthy volunteers"],"nct":"NCT05277636","study":"Acute Effects of R- and S-MDMA in Healthy Subjects","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, MD (University Hospital Basel, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT05277636","phase":"Phase 1","enroll":24,"start":"2022-10-01","eid":"x:site:nct05277636-university-hospital-basel-basel"},{"id":"nct07102576-the-parsons-research-center-for-psychedelic-healing-new-york","cat":"research","name":"The Parsons Research Center for Psychedelic Healing","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71309,"lon":-74.01063,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"10025","condg":["Other"],"status":"RECRUITING","nct":"NCT07102576","study":"MDMA-Assisted Therapy for Mental Healthcare Providers","sstatus":"RECRUITING","sponsor":"Rachel Yehuda","official":"Tamar Glatman Zaretsky (Mount Sinai Icahn School of Medicine); Rachel Yehuda (Mount Sinai Icahn School of Medicine)","src":"https://clinicaltrials.gov/study/NCT07102576","contact":{"n":"Tamar Glatman Zaretsky, PsyD","p":"(914) 340-3669","e":"tamar.glatmanzaretsky@mssm.edu"},"phase":"Phase 1","enroll":30,"start":"2026-02-11","eid":"x:site:nct07102576-the-parsons-research-center-for-psychedelic-healing-new-york"},{"id":"nct00235768-bonger-institute-of-criminology-amsterdam","cat":"research","name":"Bonger Institute of Criminology","city":"Amsterdam","region":"North Holland","country":"Netherlands","cc":"NL","lat":52.37455,"lon":4.88164,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"1000 BA","condg":["Addiction & substance use"],"nct":"NCT00235768","study":"The NeXT Study; The Netherlands XTC Toxicity Study","sstatus":"COMPLETED","sponsor":"UMC Utrecht","official":"Wim van den Brink, MD PhD (University of Amsterdam, Academic Medical Center Amsterdam, Dep of Psychiatry); Nick F Ramsey, PhD (University Medical Center Utrecht, Dep of Psychiatry)","src":"https://clinicaltrials.gov/study/NCT00235768","enroll":225,"start":"2002-04","eid":"x:site:nct00235768-bonger-institute-of-criminology-amsterdam"},{"id":"nct00235768-academic-medical-center-amsterdam-amsterdam","cat":"research","name":"Academic Medical Center Amsterdam","city":"Amsterdam","region":"North Holland","country":"Netherlands","cc":"NL","lat":52.36551,"lon":4.8856,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"1100 DD","condg":["Addiction & substance use"],"nct":"NCT00235768","study":"The NeXT Study; The Netherlands XTC Toxicity Study","sstatus":"COMPLETED","sponsor":"UMC Utrecht","official":"Wim van den Brink, MD PhD (University of Amsterdam, Academic Medical Center Amsterdam, Dep of Psychiatry); Nick F Ramsey, PhD (University Medical Center Utrecht, Dep of Psychiatry)","src":"https://clinicaltrials.gov/study/NCT00235768","enroll":225,"start":"2002-04","eid":"x:site:nct00235768-academic-medical-center-amsterdam-amsterdam"},{"id":"nct00235768-university-medical-center-utrecht-utrecht","cat":"research","name":"University Medical Center Utrecht","city":"Utrecht","region":"Utrecht","country":"Netherlands","cc":"NL","lat":52.09172,"lon":5.13196,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"3584 CX","condg":["Addiction & substance use"],"nct":"NCT00235768","study":"The NeXT Study; The Netherlands XTC Toxicity Study","sstatus":"COMPLETED","sponsor":"UMC Utrecht","official":"Wim van den Brink, MD PhD (University of Amsterdam, Academic Medical Center Amsterdam, Dep of Psychiatry); Nick F Ramsey, PhD (University Medical Center Utrecht, Dep of Psychiatry)","src":"https://clinicaltrials.gov/study/NCT00235768","enroll":225,"start":"2002-04","eid":"x:site:nct00235768-university-medical-center-utrecht-utrecht"},{"id":"nct00990067-clinical-pharmacology-toxicology-university-hospital-basel-basel","cat":"research","name":"Clinical Pharmacology & Toxicology, University Hospital Basel","city":"Basel","region":"Basel","country":"Switzerland","cc":"CH","lat":47.54705,"lon":7.58386,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"4031","condg":["Addiction & substance use"],"nct":"NCT00990067","study":"Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, MD (Department of Internal Medicine, Division of Pharmacology & Toxicology, University Hospital Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT00990067","phase":"Phase 1","enroll":16,"start":"2009-11","eid":"x:site:nct00990067-clinical-pharmacology-toxicology-university-hospital-basel-basel"},{"id":"nct00090064-offices-of-michael-mithoefer-md-mt-pleasant","cat":"research","name":"Offices of Michael Mithoefer MD","city":"Mt. Pleasant","region":"South Carolina","country":"United States","cc":"US","lat":32.80315,"lon":-79.85134,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"29464","condg":["PTSD & trauma"],"nct":"NCT00090064","study":"MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Michael Mithoefer, MD (Private Practice)","src":"https://clinicaltrials.gov/study/NCT00090064","phase":"Phase 2","enroll":23,"start":"2004-03-12","eid":"x:site:nct00090064-offices-of-michael-mithoefer-md-mt-pleasant"},{"id":"nct00895804-heffter-research-center-university-hospital-of-psychiatry-zurich","cat":"research","name":"Heffter Research Center, University Hospital of Psychiatry","city":"Zurich","region":"Canton of Zurich","country":"Switzerland","cc":"CH","lat":47.36173,"lon":8.55861,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"8032","condg":["Addiction & substance use"],"nct":"NCT00895804","study":"Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT00895804","phase":"Phase 1","enroll":16,"start":"2001-06","eid":"x:site:nct00895804-heffter-research-center-university-hospital-of-psychiatry-zurich"},{"id":"nct07301632-st-michael-s-hospital-toronto","cat":"research","name":"St. Michael's Hospital","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70648,"lon":-79.4096,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"M5B 1W8","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT07301632","study":"Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial","sstatus":"RECRUITING","sponsor":"Unity Health Toronto","official":"Akash Goel, MD,MPH,FRCPC (Unity Health Toronto)","src":"https://clinicaltrials.gov/study/NCT07301632","contact":{"n":"Akash Goel, MD,MPH,FRCPC","p":"4168645071","e":"Akash.Goel@unityhealth.to"},"phase":"Phase 2","enroll":50,"start":"2026-01-30","eid":"x:site:nct07301632-st-michael-s-hospital-toronto"},{"id":"nct04077437-new-school-research-los-angeles","cat":"research","name":"New School Research","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.04569,"lon":-118.24542,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"90004","condg":["PTSD & trauma"],"nct":"NCT04077437","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04077437","phase":"Phase 3","enroll":121,"start":"2020-09-02","eid":"x:site:nct04077437-new-school-research-los-angeles"},{"id":"nct04077437-san-francisco-insight-and-integration-center-san-francisco","cat":"research","name":"San Francisco Insight and Integration Center","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.77281,"lon":-122.40874,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"94122","condg":["PTSD & trauma"],"nct":"NCT04077437","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04077437","phase":"Phase 3","enroll":121,"start":"2020-09-02","eid":"x:site:nct04077437-san-francisco-insight-and-integration-center-san-francisco"},{"id":"nct04077437-ucsf-san-francisco","cat":"research","name":"UCSF","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.78486,"lon":-122.41853,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"94122","condg":["PTSD & trauma"],"nct":"NCT04077437","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04077437","phase":"Phase 3","enroll":121,"start":"2020-09-02","eid":"x:site:nct04077437-ucsf-san-francisco"},{"id":"nct04077437-aguazul-bluewater-inc-boulder","cat":"research","name":"Aguazul Bluewater, Inc.","city":"Boulder","region":"Colorado","country":"United States","cc":"US","lat":40.0108,"lon":-105.26015,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"80304","condg":["PTSD & trauma"],"nct":"NCT04077437","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04077437","phase":"Phase 3","enroll":121,"start":"2020-09-02","eid":"x:site:nct04077437-aguazul-bluewater-inc-boulder"},{"id":"nct04077437-wholeness-center-fort-collins","cat":"research","name":"Wholeness Center","city":"Fort Collins","region":"Colorado","country":"United States","cc":"US","lat":40.58813,"lon":-105.07929,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"80525","condg":["PTSD & trauma"],"nct":"NCT04077437","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04077437","phase":"Phase 3","enroll":121,"start":"2020-09-02","eid":"x:site:nct04077437-wholeness-center-fort-collins"},{"id":"nct04077437-university-of-connecticut-farmington","cat":"research","name":"University of Connecticut","city":"Farmington","region":"Connecticut","country":"United States","cc":"US","lat":36.72792,"lon":-108.22523,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"06030","condg":["PTSD & trauma"],"nct":"NCT04077437","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04077437","phase":"Phase 3","enroll":121,"start":"2020-09-02","eid":"x:site:nct04077437-university-of-connecticut-farmington"},{"id":"nct04077437-ray-worthy-psychiatry-llc-new-orleans","cat":"research","name":"Ray Worthy Psychiatry LLC","city":"New Orleans","region":"Louisiana","country":"United States","cc":"US","lat":29.94736,"lon":-90.07756,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"70123","condg":["PTSD & trauma"],"nct":"NCT04077437","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04077437","phase":"Phase 3","enroll":121,"start":"2020-09-02","eid":"x:site:nct04077437-ray-worthy-psychiatry-llc-new-orleans"},{"id":"nct04077437-trauma-research-foundation-boston","cat":"research","name":"Trauma Research Foundation","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36375,"lon":-71.07008,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"02446","condg":["PTSD & trauma"],"nct":"NCT04077437","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04077437","phase":"Phase 3","enroll":121,"start":"2020-09-02","eid":"x:site:nct04077437-trauma-research-foundation-boston"},{"id":"nct04077437-new-york-university-new-york","cat":"research","name":"New York University","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.7082,"lon":-74.00818,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"10016","condg":["PTSD & trauma"],"nct":"NCT04077437","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04077437","phase":"Phase 3","enroll":121,"start":"2020-09-02","eid":"x:site:nct04077437-new-york-university-new-york"},{"id":"nct04077437-nautilus-psychiatric-services-new-york","cat":"research","name":"Nautilus Psychiatric Services","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72382,"lon":-73.99397,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"11012","condg":["PTSD & trauma"],"nct":"NCT04077437","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04077437","phase":"Phase 3","enroll":121,"start":"2020-09-02","eid":"x:site:nct04077437-nautilus-psychiatric-services-new-york"},{"id":"nct04077437-zen-therapeutic-solutions-llc-mt-pleasant","cat":"research","name":"Zen Therapeutic Solutions, LLC","city":"Mt. Pleasant","region":"South Carolina","country":"United States","cc":"US","lat":32.78593,"lon":-79.87412,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"29464","condg":["PTSD & trauma"],"nct":"NCT04077437","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04077437","phase":"Phase 3","enroll":121,"start":"2020-09-02","eid":"x:site:nct04077437-zen-therapeutic-solutions-llc-mt-pleasant"},{"id":"nct04077437-university-of-wisconsin-madison-madison","cat":"research","name":"University of Wisconsin - Madison","city":"Madison","region":"Wisconsin","country":"United States","cc":"US","lat":43.06613,"lon":-89.40231,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"53705-2222","condg":["PTSD & trauma"],"nct":"NCT04077437","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04077437","phase":"Phase 3","enroll":121,"start":"2020-09-02","eid":"x:site:nct04077437-university-of-wisconsin-madison-madison"},{"id":"nct04077437-assaf-harofeh-research-fund-beer-yaaqov","cat":"research","name":"Assaf Harofeh Research Fund","city":"Beer Yaaqov","country":"Israel","cc":"IL","lat":31.4494,"lon":35.4418,"gp":"country","unnamed":0,"drugs":["MDMA"],"condg":["PTSD & trauma"],"nct":"NCT04077437","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04077437","phase":"Phase 3","enroll":121,"start":"2020-09-02","eid":"x:site:nct04077437-assaf-harofeh-research-fund-beer-yaaqov"},{"id":"nct04077437-sheba-fund-for-health-services-and-research-tel-litwinsky","cat":"research","name":"Sheba Fund for Health Services and Research","city":"Tel Litwinsky","country":"Israel","cc":"IL","lat":32.0965,"lon":34.9987,"gp":"country","unnamed":0,"drugs":["MDMA"],"condg":["PTSD & trauma"],"nct":"NCT04077437","study":"A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04077437","phase":"Phase 3","enroll":121,"start":"2020-09-02","eid":"x:site:nct04077437-sheba-fund-for-health-services-and-research-tel-litwinsky"},{"id":"nct01386177-university-hospital-basel-basel","cat":"research","name":"University Hospital Basel","city":"Basel","country":"Switzerland","cc":"CH","lat":47.5687,"lon":7.57106,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"4031","condg":["Addiction & substance use"],"nct":"NCT01386177","study":"Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT01386177","phase":"Phase 1","enroll":16,"start":"2011-07","eid":"x:site:nct01386177-university-hospital-basel-basel"},{"id":"nct05147402-alliance-for-multispecialty-research-llc-knoxville","cat":"research","name":"Alliance for Multispecialty Research LLC","city":"Knoxville","region":"Tennessee","country":"United States","cc":"US","lat":35.9556,"lon":-83.92107,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"37920","condg":["Other"],"nct":"NCT05147402","study":"Food Effects on Bioavailability of MDMA in Healthy Volunteers","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"William B Smith, M.D. (Alliance for Multispecialty Research)","src":"https://clinicaltrials.gov/study/NCT05147402","phase":"Phase 1","enroll":14,"start":"2022-07-28","eid":"x:site:nct05147402-alliance-for-multispecialty-research-llc-knoxville"},{"id":"nct05455996-memoru-boulder","cat":"research","name":"Memoru","city":"Boulder","region":"Colorado","country":"United States","cc":"US","lat":40.00534,"lon":-105.26241,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"80302","condg":["PTSD & trauma"],"nct":"NCT05455996","study":"MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers and First Responders","sstatus":"NOT_YET_RECRUITING","sponsor":"Nautilus Sanctuary","official":"Willa Hall, Ph.D. (Nautilus Sanctuary); Casey Paleos, M.D. (InnerMost PBC)","src":"https://clinicaltrials.gov/study/NCT05455996","contact":{"n":"Marcela Ot'alora, MA, LPC","p":"303.818.1419","e":"marcela@memoru.us"},"phase":"Phase 2","enroll":30,"start":"2026-10","eid":"x:site:nct05455996-memoru-boulder"},{"id":"nct05455996-innermost-pbc-new-york","cat":"research","name":"InnerMost, PBC","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72589,"lon":-73.99642,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"10010","condg":["PTSD & trauma"],"nct":"NCT05455996","study":"MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers and First Responders","sstatus":"NOT_YET_RECRUITING","sponsor":"Nautilus Sanctuary","official":"Willa Hall, Ph.D. (Nautilus Sanctuary); Casey Paleos, M.D. (InnerMost PBC)","src":"https://clinicaltrials.gov/study/NCT05455996","contact":{"n":"Liana Eisler Study Coordinator, B.A.","p":"917-336-2608","e":"liana@innermost.one"},"phase":"Phase 2","enroll":30,"start":"2026-10","eid":"x:site:nct05455996-innermost-pbc-new-york"},{"id":"nct05455996-the-pearl-institute-waynesville","cat":"research","name":"The Pearl Institute","city":"Waynesville","region":"North Carolina","country":"United States","cc":"US","lat":35.48264,"lon":-82.98804,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"28786","condg":["PTSD & trauma"],"nct":"NCT05455996","study":"MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers and First Responders","sstatus":"NOT_YET_RECRUITING","sponsor":"Nautilus Sanctuary","official":"Willa Hall, Ph.D. (Nautilus Sanctuary); Casey Paleos, M.D. (InnerMost PBC)","src":"https://clinicaltrials.gov/study/NCT05455996","contact":{"n":"Raymond C Turpin, PsyD","p":"(828) 378-1527","e":"info@pearlpsychedelicinstitute.org"},"phase":"Phase 2","enroll":30,"start":"2026-10","eid":"x:site:nct05455996-the-pearl-institute-waynesville"},{"id":"nct02427568-offices-of-philip-wolfson-md-san-anselmo","cat":"research","name":"Offices of Philip Wolfson MD","city":"San Anselmo","region":"California","country":"United States","cc":"US","lat":37.98025,"lon":-122.56555,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"94960","condg":["Anxiety"],"nct":"NCT02427568","study":"MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness","sstatus":"COMPLETED","sponsor":"Resilient Pharmaceuticals","official":"Philip Wolfson, MD (Private Practice)","src":"https://clinicaltrials.gov/study/NCT02427568","phase":"Phase 2","enroll":18,"start":"2015-05-14","eid":"x:site:nct02427568-offices-of-philip-wolfson-md-san-anselmo"},{"id":"nct03790618-university-of-chicago-chicago","cat":"research","name":"University of Chicago","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.85601,"lon":-87.64897,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"60637","condg":["Healthy volunteers"],"nct":"NCT03790618","study":"Effect of Stimulant Drugs on Social Perception","sstatus":"COMPLETED","sponsor":"University of Chicago","src":"https://clinicaltrials.gov/study/NCT03790618","phase":"Phase 1","enroll":36,"start":"2016-06-01","eid":"x:site:nct03790618-university-of-chicago-chicago"},{"id":"nct05379959-university-of-chicago-chicago","cat":"research","name":"University of Chicago","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.84264,"lon":-87.6468,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"60637","condg":["Addiction & substance use"],"nct":"NCT05379959","study":"Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function","sstatus":"COMPLETED","sponsor":"University of Chicago","src":"https://clinicaltrials.gov/study/NCT05379959","phase":"EARLY_Phase 1","enroll":43,"start":"2022-05-11","eid":"x:site:nct05379959-university-of-chicago-chicago"},{"id":"nct05063097-chu-lariboisiere-aphp-cardiology-paris","cat":"research","name":"CHU Lariboisière, APHP, Cardiology","city":"Paris","region":"Île-de-France Region","country":"France","cc":"FR","lat":48.85289,"lon":2.33925,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"75010","condg":["Addiction & substance use"],"nct":"NCT05063097","study":"Addiction in Intensive Cardiac Care Units","sstatus":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","official":"Jean-Guillaume DILLINGER, MD,PhD (Lariboisière Hospital, APHP, Paris)","src":"https://clinicaltrials.gov/study/NCT05063097","enroll":1500,"start":"2021-04-06","eid":"x:site:nct05063097-chu-lariboisiere-aphp-cardiology-paris"},{"id":"nct05067244-remedy-institute-toronto","cat":"research","name":"Remedy Institute","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.69979,"lon":-79.4081,"gp":"city","unnamed":0,"drugs":["MDMA"],"zip":"M6G 1L5","condg":["PTSD & trauma"],"nct":"NCT05067244","study":"A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD)","sstatus":"COMPLETED","sponsor":"Remedy","official":"Alison Bruni, MD (Remedy Institute); Anne Wagner, PhD (Remedy Institute)","src":"https://clinicaltrials.gov/study/NCT05067244","phase":"Phase 2","enroll":10,"start":"2021-10-04","eid":"x:site:nct05067244-remedy-institute-toronto"},{"id":"nct04620759-johns-hopkins-center-for-psychedelic-and-consciousness-research-balt","cat":"research","name":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28704,"lon":-76.6193,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Depression","Addiction & substance use"],"nct":"NCT04620759","study":"Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","official":"Frederick S Barrett, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT04620759","phase":"Phase 2","enroll":90,"start":"2021-04-14","eid":"x:site:nct04620759-johns-hopkins-center-for-psychedelic-and-consciousness-research-balt"},{"id":"nct06927076-university-hospital-basel-basel","cat":"research","name":"University Hospital Basel","city":"Basel","country":"Switzerland","cc":"CH","lat":47.54921,"lon":7.58188,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"4031","condg":["Depression"],"status":"RECRUITING","nct":"NCT06927076","study":"Antidepressant Response of DMT Masked With Propofol","sstatus":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias Liechti, Prof. Dr. med. (University Hospital, Basel, Switzerland); Felix Müller, PD Dr. med. (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT06927076","contact":{"n":"Felix Mueller, PD Dr. med.","p":"+41 61 325 53 94","e":"felix.mueller@upk.ch"},"phase":"N/A","enroll":112,"start":"2025-08-05","eid":"x:site:nct06927076-university-hospital-basel-basel"},{"id":"nct06258031-cippres-clinic-london","cat":"research","name":"CIPPRes Clinic","city":"London","country":"United Kingdom","cc":"GB","lat":51.51159,"lon":-0.1192,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"W10 6DZ","condg":["OCD"],"nct":"NCT06258031","study":"PsilOCD: A Pharmacological-Challenge Feasibility Study","sstatus":"COMPLETED","sponsor":"Imperial College London","official":"Professor David Nutt (Imperial College London); Dr David Erritzoe (Imperial College London)","src":"https://clinicaltrials.gov/study/NCT06258031","phase":"Phase 1","enroll":19,"start":"2022-10-28","eid":"x:site:nct06258031-cippres-clinic-london"},{"id":"nct05894902-aims-institute-seattle","cat":"research","name":"AIMS Institute","city":"Seattle","region":"Washington","country":"United States","cc":"US","lat":47.61049,"lon":-122.34303,"gp":"city","unnamed":0,"drugs":["ayahuasca"],"zip":"98102","condg":["Depression","PTSD & trauma"],"nct":"NCT05894902","study":"Open-Label Dose-Ranging Study of Oral SM-001 in Healthy Adults","sstatus":"UNKNOWN","sponsor":"Advanced Integrative Medical Science Institute","official":"Leanna J Standish, ND PhD (AIMS Institute)","src":"https://clinicaltrials.gov/study/NCT05894902","contact":{"n":"Michelle Speaks, MBA","p":"206-420-1321","e":"mspeaks@aimsinstitute.net"},"phase":"Phase 1","enroll":12,"start":"2023-10-01","eid":"x:site:nct05894902-aims-institute-seattle"},{"id":"nct04353024-university-hospital-basel-basel","cat":"research","name":"University Hospital Basel","city":"Basel","region":"Basel-Stadt BS","country":"Switzerland","cc":"CH","lat":47.55025,"lon":7.58075,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"4031","condg":["Healthy volunteers"],"nct":"NCT04353024","study":"Effects of Dimethyltryptamine in Healthy Subjects","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, Prof. Dr. MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT04353024","phase":"Phase 1","enroll":31,"start":"2021-06-18","eid":"x:site:nct04353024-university-hospital-basel-basel"},{"id":"nct06070649-connecticut-mental-health-center-new-haven","cat":"research","name":"Connecticut Mental Health Center","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31667,"lon":-72.93705,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"06519","condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT06070649","study":"The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)","sstatus":"RECRUITING","sponsor":"Yale University","official":"Anahita Bassir Nia, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT06070649","contact":{"n":"Anahita Bassir Nia, MD","p":"(203) 974-7525","e":"anahita.bassirnia@yale.edu"},"phase":"Phase 1","enroll":63,"start":"2025-08-04","eid":"x:site:nct06070649-connecticut-mental-health-center-new-haven"},{"id":"nct05829603-university-hospital-of-psychiatry-zurich-zurich","cat":"research","name":"University Hospital of Psychiatry Zurich","city":"Zurich","region":"Canton of Zurich","country":"Switzerland","cc":"CH","lat":47.36559,"lon":8.55315,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"8032","condg":["Healthy volunteers"],"nct":"NCT05829603","study":"Dose-finding Study for the Combination of DMT and Harmine in Healthy Subjects","sstatus":"COMPLETED","sponsor":"Reconnect Labs","official":"Erich Seifritz, Prof (Psychiatric University Hospital, Zurich)","src":"https://clinicaltrials.gov/study/NCT05829603","phase":"Phase 1","enroll":16,"start":"2023-05-05","eid":"x:site:nct05829603-university-hospital-of-psychiatry-zurich-zurich"},{"id":"nct07562191-hospital-de-saude-mental-professor-frota-pinto-fortaleza","cat":"research","name":"Hospital de Saúde Mental Professor Frota Pinto","city":"Fortaleza","region":"Ceará","country":"Brazil","cc":"BR","lat":-3.72856,"lon":-38.55374,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT07562191","study":"Inhaled DMT for Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Universidade Federal do Rio Grande do Norte","src":"https://clinicaltrials.gov/study/NCT07562191","contact":{"n":"Jarbas de Sá Roriz-Filho, MD","p":"+55 85 98206-0526","e":"jarbasroriz@gmail.com"},"phase":"Phase 2","enroll":140,"start":"2026-08-01","eid":"x:site:nct07562191-hospital-de-saude-mental-professor-frota-pinto-fortaleza"},{"id":"nct07562191-complexo-hospitalar-universitario-professor-edgard-santos-federal-un","cat":"research","name":"Complexo Hospitalar Universitário Professor Edgard Santos, Federal University of Bahia (HUPES-UFBA)","city":"Salvador","region":"Estado de Bahia","country":"Brazil","cc":"BR","lat":-12.96739,"lon":-38.48028,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT07562191","study":"Inhaled DMT for Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Universidade Federal do Rio Grande do Norte","src":"https://clinicaltrials.gov/study/NCT07562191","contact":{"n":"Lucas Quarantini, PhD","p":"+5571992767743","e":"quarantini@gmail.com"},"phase":"Phase 2","enroll":140,"start":"2026-08-01","eid":"x:site:nct07562191-complexo-hospitalar-universitario-professor-edgard-santos-federal-un"},{"id":"nct07562191-instituto-de-psiquiatria-da-universidade-federal-do-rio-de-janeiro-i","cat":"research","name":"Instituto de Psiquiatria da Universidade Federal do Rio de Janeiro (IPUB-UFRJ)","city":"Rio de Janeiro","region":"Rio de Janeiro","country":"Brazil","cc":"BR","lat":-22.9027,"lon":-43.1755,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT07562191","study":"Inhaled DMT for Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Universidade Federal do Rio Grande do Norte","src":"https://clinicaltrials.gov/study/NCT07562191","contact":{"n":"Tiago Arruda Sanches, PhD","p":"+55 21 98173-7000","e":"tiago@medicina.ufrj.br"},"phase":"Phase 2","enroll":140,"start":"2026-08-01","eid":"x:site:nct07562191-instituto-de-psiquiatria-da-universidade-federal-do-rio-de-janeiro-i"},{"id":"nct07562191-hospital-universitario-onofre-lopes-huol-ufrn-natal","cat":"research","name":"Hospital Universitário Onofre Lopes - HUOL - UFRN","city":"Natal","region":"Rio Grande do Norte","country":"Brazil","cc":"BR","lat":-5.78328,"lon":-35.21928,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Depression"],"status":"RECRUITING","nct":"NCT07562191","study":"Inhaled DMT for Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Universidade Federal do Rio Grande do Norte","src":"https://clinicaltrials.gov/study/NCT07562191","contact":{"n":"Fernanda Palhano-Fontes, PhD","p":"+5584999435830","e":"fernandapalhano@neuro.ufrn.br"},"phase":"Phase 2","enroll":140,"start":"2026-08-01","eid":"x:site:nct07562191-hospital-universitario-onofre-lopes-huol-ufrn-natal"},{"id":"nct07562191-instituto-de-psiquiatria-hospital-das-clinicas-ipq-hc-usp-sao-paulo","cat":"research","name":"Instituto de Psiquiatria - Hospital das Clínicas - IPq - HC - USP","city":"São Paulo","region":"São Paulo","country":"Brazil","cc":"BR","lat":-23.54642,"lon":-46.63842,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT07562191","study":"Inhaled DMT for Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Universidade Federal do Rio Grande do Norte","src":"https://clinicaltrials.gov/study/NCT07562191","contact":{"n":"Henrique Ribeiro, MD","p":"+55 11 99712-3513","e":"clinicahenriqueribeiro@gmail.com"},"phase":"Phase 2","enroll":140,"start":"2026-08-01","eid":"x:site:nct07562191-instituto-de-psiquiatria-hospital-das-clinicas-ipq-hc-usp-sao-paulo"},{"id":"nct06094907-hospital-universitario-onofre-lopes-natal","cat":"research","name":"Hospital Universitário Onofre Lopes","city":"Natal","region":"Rio Grande do Norte","country":"Brazil","cc":"BR","lat":-5.80154,"lon":-35.20158,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"59012300","condg":["Depression"],"nct":"NCT06094907","study":"Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression","sstatus":"COMPLETED","sponsor":"Universidade Federal do Rio Grande do Norte","official":"Draulio Araujo, Ph.D (Universidade Federal do Rio Grande do Norte); Marcelo Falchi, M.D. (Universidade Federal do Rio Grande do Norte)","src":"https://clinicaltrials.gov/study/NCT06094907","phase":"Phase 2","enroll":14,"start":"2023-10-09","eid":"x:site:nct06094907-hospital-universitario-onofre-lopes-natal"},{"id":"nct00302744-harbor-ucla-medical-center-torrance","cat":"research","name":"Harbor-UCLA Medical Center","city":"Torrance","region":"California","country":"United States","cc":"US","lat":33.82874,"lon":-118.34708,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"90509","condg":["Anxiety"],"nct":"NCT00302744","study":"Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety","sstatus":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","official":"Charles S. Grob, MD (University of California, Los Angeles)","src":"https://clinicaltrials.gov/study/NCT00302744","phase":"Phase 1/Phase 2","enroll":12,"start":"2004-04","eid":"x:site:nct00302744-harbor-ucla-medical-center-torrance"},{"id":"nct04716335-psychiatric-university-hospital-zurich","cat":"research","name":"Psychiatric University Hospital","city":"Zurich","country":"Switzerland","cc":"CH","lat":47.36662,"lon":8.54468,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"8032","condg":["Neurology & cognition"],"nct":"NCT04716335","study":"Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy Subjects","sstatus":"COMPLETED","sponsor":"Psychiatric University Hospital, Zurich","src":"https://clinicaltrials.gov/study/NCT04716335","phase":"EARLY_Phase 1","enroll":34,"start":"2020-12-01","eid":"x:site:nct04716335-psychiatric-university-hospital-zurich"},{"id":"nct07693257-altman-clinical-and-translational-research-institute-la-jolla","cat":"research","name":"Altman Clinical and Translational Research Institute","city":"La Jolla","region":"California","country":"United States","cc":"US","lat":32.84054,"lon":-117.28385,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"92037","condg":["Healthy volunteers"],"nct":"NCT07693257","study":"Neural Effects of Intravenous N,N-dimethyltryptamine (DMT)","sstatus":"NOT_YET_RECRUITING","sponsor":"Jon Dean","official":"Jon Dean, PhD (UCSD)","src":"https://clinicaltrials.gov/study/NCT07693257","contact":{"n":"Jon Dean, PhD","p":"619-786-0375","e":"deanlaboratory@health.ucsd.edu"},"phase":"Phase 1","enroll":20,"start":"2026-09-01","eid":"x:site:nct07693257-altman-clinical-and-translational-research-institute-la-jolla"},{"id":"nct05384678-universtity-hospital-basel-basel","cat":"research","name":"Universtity Hospital Basel","city":"Basel","country":"Switzerland","cc":"CH","lat":47.56267,"lon":7.56438,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"4056","condg":["Healthy volunteers"],"nct":"NCT05384678","study":"Acute Dose-dependent Effects of DMT in Healthy Subjects","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, MD (University Hospital Basel, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT05384678","phase":"Phase 1","enroll":24,"start":"2022-11-15","eid":"x:site:nct05384678-universtity-hospital-basel-basel"},{"id":"nct02950467-university-of-california-san-francisco-san-francisco","cat":"research","name":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.76575,"lon":-122.40789,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94143","condg":["Depression"],"nct":"NCT02950467","study":"Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors","sstatus":"COMPLETED","sponsor":"Joshua Woolley","official":"Joshua Woolley, MD,PhD (University of California, San Francisco); Brian Anderson, MD,MSc (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT02950467","phase":"Phase 1","enroll":30,"start":"2018-01-05","eid":"x:site:nct02950467-university-of-california-san-francisco-san-francisco"},{"id":"nct04673383-mac-clinical-research-liverpool","cat":"research","name":"MAC Clinical Research","city":"Liverpool","country":"United Kingdom","cc":"GB","lat":53.40912,"lon":-2.97996,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"L34 1BH","condg":["Depression"],"nct":"NCT04673383","study":"SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients","sstatus":"COMPLETED","sponsor":"Small Pharma Ltd","official":"David Erritzoe, MD (Imperial College London); Malcolm Boyce, MD (Hammersmith Medicines Research)","src":"https://clinicaltrials.gov/study/NCT04673383","phase":"Phase 1/Phase 2","enroll":66,"start":"2021-02-04","eid":"x:site:nct04673383-mac-clinical-research-liverpool"},{"id":"nct04673383-hammersmith-medicines-research-london","cat":"research","name":"Hammersmith Medicines Research","city":"London","country":"United Kingdom","cc":"GB","lat":51.51262,"lon":-0.12993,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Depression"],"nct":"NCT04673383","study":"SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients","sstatus":"COMPLETED","sponsor":"Small Pharma Ltd","official":"David Erritzoe, MD (Imperial College London); Malcolm Boyce, MD (Hammersmith Medicines Research)","src":"https://clinicaltrials.gov/study/NCT04673383","phase":"Phase 1/Phase 2","enroll":66,"start":"2021-02-04","eid":"x:site:nct04673383-hammersmith-medicines-research-london"},{"id":"nct06455293-university-of-california-san-francisco-san-francisco","cat":"research","name":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.78204,"lon":-122.41231,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94143","condg":["Depression","Neurology & cognition"],"status":"RECRUITING","nct":"NCT06455293","study":"Psilocybin Therapy for Depression in Parkinson's Disease","sstatus":"RECRUITING","sponsor":"Joshua Woolley, MD, PhD","official":"Joshua Woolley, MD,PhD (University of California, San Francisco); Ellen Bradley, MD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT06455293","contact":{"n":"Brigette Sosa","p":"(415) 935-3489","e":"pdp2@ucsf.edu"},"phase":"Phase 2","enroll":60,"start":"2024-08-19","eid":"x:site:nct06455293-university-of-california-san-francisco-san-francisco"},{"id":"nct05548075-imperial-college-london-london","cat":"research","name":"Imperial College London","city":"London","country":"United Kingdom","cc":"GB","lat":51.49879,"lon":-0.13125,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"W12 0NN","condg":["Chronic pain & headache"],"nct":"NCT05548075","study":"Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action","sstatus":"UNKNOWN","sponsor":"Imperial College London","official":"David Nutt (Imperial College London)","src":"https://clinicaltrials.gov/study/NCT05548075","enroll":20,"start":"2022-08-15","eid":"x:site:nct05548075-imperial-college-london-london"},{"id":"nct06252506-department-of-nuclear-medicine-bern-university-hospital-bern","cat":"research","name":"Department of Nuclear Medicine, Bern University Hospital","city":"Bern","country":"Switzerland","cc":"CH","lat":46.95237,"lon":7.45342,"gp":"city","unnamed":0,"drugs":["DMT","ayahuasca"],"zip":"3010","condg":["Other"],"nct":"NCT06252506","study":"Molecular Imaging Study of Harmine/DMT: a Basic Research Approach","sstatus":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","official":"Paul K Cumming, PhD (Insel Group AG)","src":"https://clinicaltrials.gov/study/NCT06252506","phase":"Phase 1","enroll":17,"start":"2024-01-22","eid":"x:site:nct06252506-department-of-nuclear-medicine-bern-university-hospital-bern"},{"id":"nct06252506-psychiatric-university-hospital-zurich-zurich","cat":"research","name":"Psychiatric University Hospital Zurich","city":"Zurich","country":"Switzerland","cc":"CH","lat":47.37528,"lon":8.55824,"gp":"city","unnamed":0,"drugs":["DMT","ayahuasca"],"zip":"8032","condg":["Other"],"nct":"NCT06252506","study":"Molecular Imaging Study of Harmine/DMT: a Basic Research Approach","sstatus":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","official":"Paul K Cumming, PhD (Insel Group AG)","src":"https://clinicaltrials.gov/study/NCT06252506","phase":"Phase 1","enroll":17,"start":"2024-01-22","eid":"x:site:nct06252506-psychiatric-university-hospital-zurich-zurich"},{"id":"nct05573568-hospital-universitario-onofre-lopes-natal","cat":"research","name":"Hospital Universitário Onofre Lopes","city":"Natal","region":"Rio Grande do Norte","country":"Brazil","cc":"BR","lat":-5.78375,"lon":-35.20233,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"59012300","condg":["Healthy volunteers"],"nct":"NCT05573568","study":"Clinical Study of DMT in Healthy Adults","sstatus":"COMPLETED","sponsor":"Biomind Labs Inc.","src":"https://clinicaltrials.gov/study/NCT05573568","phase":"Phase 1","enroll":27,"start":"2022-06-01","eid":"x:site:nct05573568-hospital-universitario-onofre-lopes-natal"},{"id":"nct06051721-research-centers-of-america-hollywood","cat":"research","name":"Research Centers of America","city":"Hollywood","region":"Florida","country":"United States","cc":"US","lat":34.10563,"lon":-118.32415,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"33024","condg":["Anxiety"],"nct":"NCT06051721","study":"A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)","sstatus":"COMPLETED","sponsor":"Cybin IRL Limited","official":"Amir Inamdar, MBBS, DNB, MFPM (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06051721","phase":"Phase 2","enroll":36,"start":"2024-05-10","eid":"x:site:nct06051721-research-centers-of-america-hollywood"},{"id":"nct06051721-innovative-clinical-research-inc-miami-lakes","cat":"research","name":"Innovative Clinical Research, Inc.","city":"Miami Lakes","region":"Florida","country":"United States","cc":"US","lat":25.90076,"lon":-80.30438,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"33016","condg":["Anxiety"],"nct":"NCT06051721","study":"A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)","sstatus":"COMPLETED","sponsor":"Cybin IRL Limited","official":"Amir Inamdar, MBBS, DNB, MFPM (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06051721","phase":"Phase 2","enroll":36,"start":"2024-05-10","eid":"x:site:nct06051721-innovative-clinical-research-inc-miami-lakes"},{"id":"nct06051721-cenexel-acmr-atlanta","cat":"research","name":"CenExel ACMR","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.75667,"lon":-84.39424,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"30331","condg":["Anxiety"],"nct":"NCT06051721","study":"A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)","sstatus":"COMPLETED","sponsor":"Cybin IRL Limited","official":"Amir Inamdar, MBBS, DNB, MFPM (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06051721","phase":"Phase 2","enroll":36,"start":"2024-05-10","eid":"x:site:nct06051721-cenexel-acmr-atlanta"},{"id":"nct06051721-iresearch-atlanta-decatur","cat":"research","name":"iResearch Atlanta","city":"Decatur","region":"Georgia","country":"United States","cc":"US","lat":39.84807,"lon":-88.96285,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"30330","condg":["Anxiety"],"nct":"NCT06051721","study":"A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)","sstatus":"COMPLETED","sponsor":"Cybin IRL Limited","official":"Amir Inamdar, MBBS, DNB, MFPM (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06051721","phase":"Phase 2","enroll":36,"start":"2024-05-10","eid":"x:site:nct06051721-iresearch-atlanta-decatur"},{"id":"nct06051721-uptown-research-institute-chicago","cat":"research","name":"Uptown Research Institute","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.85892,"lon":-87.65894,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"60640","condg":["Anxiety"],"nct":"NCT06051721","study":"A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)","sstatus":"COMPLETED","sponsor":"Cybin IRL Limited","official":"Amir Inamdar, MBBS, DNB, MFPM (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06051721","phase":"Phase 2","enroll":36,"start":"2024-05-10","eid":"x:site:nct06051721-uptown-research-institute-chicago"},{"id":"nct06051721-cedar-clinical-research-murray","cat":"research","name":"Cedar Clinical Research","city":"Murray","region":"Utah","country":"United States","cc":"US","lat":40.66882,"lon":-111.89792,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"84107","condg":["Anxiety"],"nct":"NCT06051721","study":"A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)","sstatus":"COMPLETED","sponsor":"Cybin IRL Limited","official":"Amir Inamdar, MBBS, DNB, MFPM (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06051721","phase":"Phase 2","enroll":36,"start":"2024-05-10","eid":"x:site:nct06051721-cedar-clinical-research-murray"},{"id":"nct04711915-biological-studies-unit-at-the-va-connecticut-healthcare-system-yale","cat":"research","name":"Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.26872,"lon":-72.95849,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"06516","condg":["Depression"],"nct":"NCT04711915","study":"Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","src":"https://clinicaltrials.gov/study/NCT04711915","phase":"Phase 1","enroll":30,"start":"2021-03-17","eid":"x:site:nct04711915-biological-studies-unit-at-the-va-connecticut-healthcare-system-yale"},{"id":"nct01943994-behavioral-pharmacology-research-unit-baltimore","cat":"research","name":"Behavioral Pharmacology Research Unit","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28949,"lon":-76.61685,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Addiction & substance use"],"nct":"NCT01943994","study":"Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study","sstatus":"COMPLETED","sponsor":"Johns Hopkins University","official":"Matthew W Johnson, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT01943994","phase":"N/A","enroll":82,"start":"2008-09","eid":"x:site:nct01943994-behavioral-pharmacology-research-unit-baltimore"},{"id":"nct01943994-neuroimaging-research-branch-nida-irp-baltimore","cat":"research","name":"Neuroimaging Research Branch, NIDA-IRP","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29617,"lon":-76.6097,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Addiction & substance use"],"nct":"NCT01943994","study":"Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study","sstatus":"COMPLETED","sponsor":"Johns Hopkins University","official":"Matthew W Johnson, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT01943994","phase":"N/A","enroll":82,"start":"2008-09","eid":"x:site:nct01943994-neuroimaging-research-branch-nida-irp-baltimore"},{"id":"nct07610369-yale-university-new-haven","cat":"research","name":"Yale University","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31591,"lon":-72.92247,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"06510","condg":["Depression","Neurology & cognition"],"status":"RECRUITING","nct":"NCT07610369","study":"The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease","sstatus":"RECRUITING","sponsor":"Yale University","official":"Sophie Holmes, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT07610369","contact":{"n":"Sophie Holmes, PhD","p":"203-685-4066","e":"sophie.holmes@yale.edu"},"phase":"Phase 2","enroll":40,"start":"2026-07-10","eid":"x:site:nct07610369-yale-university-new-haven"},{"id":"nct04932434-university-of-california-san-francisco-san-francisco","cat":"research","name":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.76924,"lon":-122.41382,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94143","condg":["Depression","Anxiety","Neurology & cognition"],"nct":"NCT04932434","study":"Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease","sstatus":"COMPLETED","sponsor":"Joshua Woolley, MD, PhD","official":"Joshua Woolley, MD/PhD (University of California, San Francisco); Ellen Bradley, MD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT04932434","phase":"Phase 2","enroll":12,"start":"2021-08-15","eid":"x:site:nct04932434-university-of-california-san-francisco-san-francisco"},{"id":"nct05901012-hospital-universitario-onofre-lopes-natal","cat":"research","name":"Hospital Universitário Onofre Lopes","city":"Natal","region":"Rio Grande do Norte","country":"Brazil","cc":"BR","lat":-5.78592,"lon":-35.20563,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"59012300","condg":["Healthy volunteers"],"nct":"NCT05901012","study":"Safety and Tolerability of DMT in Healthy Adults","sstatus":"COMPLETED","sponsor":"Universidade Federal do Rio Grande do Norte","official":"Draulio B. Araujo, Ph.D (Universidade Federal do Rio Grande do Norte)","src":"https://clinicaltrials.gov/study/NCT05901012","phase":"Phase 1","enroll":25,"start":"2023-04-26","eid":"x:site:nct05901012-hospital-universitario-onofre-lopes-natal"},{"id":"nct05553691-mac-clinical-research-manchester","cat":"research","name":"Mac Clinical Research","city":"Manchester","region":"Greater Manchester","country":"United Kingdom","cc":"GB","lat":53.4922,"lon":-2.22618,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"M13 9NQ","condg":["Depression"],"nct":"NCT05553691","study":"SPL026 With or Without SSRIs in Participants With MDD","sstatus":"COMPLETED","sponsor":"Small Pharma Ltd","official":"Fabian Devlin, MD (MAC Clinical Research); Neel Bhatt, MD (MAC Clinical Research)","src":"https://clinicaltrials.gov/study/NCT05553691","phase":"Phase 1","enroll":18,"start":"2022-12-13","eid":"x:site:nct05553691-mac-clinical-research-manchester"},{"id":"nct05553691-mac-clinical-research-liverpool","cat":"research","name":"MAC Clinical Research","city":"Liverpool","region":"Prescot","country":"United Kingdom","cc":"GB","lat":53.41957,"lon":-2.98006,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"L34 1BH","condg":["Depression"],"nct":"NCT05553691","study":"SPL026 With or Without SSRIs in Participants With MDD","sstatus":"COMPLETED","sponsor":"Small Pharma Ltd","official":"Fabian Devlin, MD (MAC Clinical Research); Neel Bhatt, MD (MAC Clinical Research)","src":"https://clinicaltrials.gov/study/NCT05553691","phase":"Phase 1","enroll":18,"start":"2022-12-13","eid":"x:site:nct05553691-mac-clinical-research-liverpool"},{"id":"nct00957359-nyu-college-of-dentistry-bluestone-center-for-clinical-research-new-","cat":"research","name":"NYU College of Dentistry Bluestone Center for Clinical Research","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70594,"lon":-74.00828,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10010","condg":["Cancer-related distress"],"nct":"NCT00957359","study":"Psilocybin Cancer Anxiety Study","sstatus":"COMPLETED","sponsor":"NYU Langone Health","official":"Stephen Ross, MD (NYU Langone Health); Anthony Bossis, PhD (Co-Principal Investigator NYU Langone School of Medicine)","src":"https://clinicaltrials.gov/study/NCT00957359","phase":"EARLY_Phase 1","enroll":29,"start":"2009-02","eid":"x:site:nct00957359-nyu-college-of-dentistry-bluestone-center-for-clinical-research-new-"},{"id":"nct05301608-johns-hopkins-center-for-psychedelic-and-consciousness-research-balt","cat":"research","name":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28742,"lon":-76.61826,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Healthy volunteers"],"status":"RECRUITING","nct":"NCT05301608","study":"Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought","sstatus":"RECRUITING","sponsor":"Johns Hopkins University","official":"Frederick S Barrett, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT05301608","contact":{"n":"Frederick S Barrett","p":"410-550-9777","e":"fbarret2@jh.edu"},"phase":"Phase 1/Phase 2","enroll":30,"start":"2022-03-03","eid":"x:site:nct05301608-johns-hopkins-center-for-psychedelic-and-consciousness-research-balt"},{"id":"nct00465595-behavioral-pharmacology-research-unit-johns-hopkins-bayview-campus-b","cat":"research","name":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Campus","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.286,"lon":-76.60565,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Depression","Anxiety","Cancer-related distress"],"nct":"NCT00465595","study":"Psychopharmacology of Psilocybin in Cancer Patients","sstatus":"COMPLETED","sponsor":"Johns Hopkins University","official":"Roland R Griffiths, Ph.D. (Johns Hopkins School of Medicine, Psychiatry Dept.)","src":"https://clinicaltrials.gov/study/NCT00465595","phase":"Phase 2","enroll":56,"start":"2007-04","eid":"x:site:nct00465595-behavioral-pharmacology-research-unit-johns-hopkins-bayview-campus-b"},{"id":"nct05780216-psychiatric-university-hospital-zurich-zurich","cat":"research","name":"Psychiatric University Hospital Zurich","city":"Zurich","country":"Switzerland","cc":"CH","lat":47.3702,"lon":8.55165,"gp":"city","unnamed":0,"drugs":["ayahuasca"],"zip":"8032","condg":["Healthy volunteers"],"nct":"NCT05780216","study":"Mindfulness and Psychedelics","sstatus":"COMPLETED","sponsor":"Milan Scheidegger","official":"Milan Scheidegger, MD, PhD (Psychiatric University Hospital, Zurich)","src":"https://clinicaltrials.gov/study/NCT05780216","phase":"EARLY_Phase 1","enroll":40,"start":"2023-02-20","eid":"x:site:nct05780216-psychiatric-university-hospital-zurich-zurich"},{"id":"nct05559931-centre-for-human-drug-research-leiden","cat":"research","name":"Centre for Human Drug Research","city":"Leiden","country":"Netherlands","cc":"NL","lat":52.16901,"lon":4.48925,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Neurology & cognition"],"nct":"NCT05559931","study":"Single and Repeat Doses of DMT in Healthy Subjects","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Algernon Pharmaceuticals","official":"Gabriel Jacobs, MD, PhD (Centre for Human Drugs Research)","src":"https://clinicaltrials.gov/study/NCT05559931","phase":"Phase 1","enroll":60,"start":"2023-01-13","eid":"x:site:nct05559931-centre-for-human-drug-research-leiden"},{"id":"nct02145091-behavioral-pharmacology-research-unit-johns-hopkins-bayview-medical-","cat":"research","name":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.2957,"lon":-76.61195,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Healthy volunteers"],"nct":"NCT02145091","study":"Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators","sstatus":"COMPLETED","sponsor":"Johns Hopkins University","src":"https://clinicaltrials.gov/study/NCT02145091","phase":"Phase 1","enroll":40,"start":"2014-05","eid":"x:site:nct02145091-behavioral-pharmacology-research-unit-johns-hopkins-bayview-medical-"},{"id":"nct05351541-university-of-california-san-francisco-san-francisco","cat":"research","name":"University of California San Francisco","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.78674,"lon":-122.41269,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94107","condg":["Chronic pain & headache"],"nct":"NCT05351541","study":"Psilocybin Therapy for Chronic Low Back Pain","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Joshua Woolley, MD, PhD","official":"Joshua Woolley (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT05351541","phase":"Phase 1/Phase 2","enroll":30,"start":"2023-12-01","eid":"x:site:nct05351541-university-of-california-san-francisco-san-francisco"},{"id":"nct05695495-clinical-pharmacology-toxicology-university-hospital-basel-basel","cat":"research","name":"Clinical Pharmacology & Toxicology, University Hospital Basel","city":"Basel","country":"Switzerland","cc":"CH","lat":47.55919,"lon":7.5752,"gp":"city","unnamed":0,"drugs":["DMT"],"zip":"4056","condg":["Healthy volunteers"],"nct":"NCT05695495","study":"Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study)","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","src":"https://clinicaltrials.gov/study/NCT05695495","phase":"Phase 1","enroll":36,"start":"2024-06-12","eid":"x:site:nct05695495-clinical-pharmacology-toxicology-university-hospital-basel-basel"},{"id":"nct07833761-m-health-fairview-dbt-program-minneapolis","cat":"research","name":"M Health Fairview DBT Program","city":"Minneapolis","region":"Minnesota","country":"United States","cc":"US","lat":44.97155,"lon":-93.26125,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"55455","condg":["Depression"],"nct":"NCT07833761","study":"ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disorder","sstatus":"NOT_YET_RECRUITING","sponsor":"University of Minnesota","official":"Ziad Nahas, MD, MSCR (University of Minnesota); Devin H Hanson, PhD, LP (University of Minnesota)","src":"https://clinicaltrials.gov/study/NCT07833761","contact":{"n":"Ziad Nahas, MD, MSCR","p":"952-525-4505","e":"ipl@umn.edu"},"phase":"Phase 1","enroll":18,"start":"2026-12-01","eid":"x:site:nct07833761-m-health-fairview-dbt-program-minneapolis"},{"id":"nct07833761-m-physicians-st-louis-park-clinic-saint-louis-park","cat":"research","name":"M Physicians St. Louis Park Clinic","city":"Saint Louis Park","region":"Minnesota","country":"United States","cc":"US","lat":44.9395,"lon":-93.33883,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"55416","condg":["Depression"],"nct":"NCT07833761","study":"ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disorder","sstatus":"NOT_YET_RECRUITING","sponsor":"University of Minnesota","official":"Ziad Nahas, MD, MSCR (University of Minnesota); Devin H Hanson, PhD, LP (University of Minnesota)","src":"https://clinicaltrials.gov/study/NCT07833761","contact":{"n":"Ziad Nahas, MD, MSCR","p":"952-525-4505","e":"ipl@umn.edu"},"phase":"Phase 1","enroll":18,"start":"2026-12-01","eid":"x:site:nct07833761-m-physicians-st-louis-park-clinic-saint-louis-park"},{"id":"nct05065294-university-of-california-san-francisco-san-francisco","cat":"research","name":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.78279,"lon":-122.42634,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94121","condg":["Bipolar"],"nct":"NCT05065294","study":"Psilocybin Therapy for Depression in Bipolar II Disorder","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","official":"Joshua D Woolley, MD,PhD (University of California, San Francisco); David Guard, PhD (San Francisco State University)","src":"https://clinicaltrials.gov/study/NCT05065294","phase":"Phase 2","enroll":14,"start":"2022-01-28","eid":"x:site:nct05065294-university-of-california-san-francisco-san-francisco"},{"id":"nct05347849-hammersmith-medicines-research-london","cat":"research","name":"Hammersmith Medicines Research","city":"London","country":"United Kingdom","cc":"GB","lat":51.50189,"lon":-0.11487,"gp":"city","unnamed":0,"drugs":["DMT"],"condg":["Healthy volunteers"],"nct":"NCT05347849","study":"Single Ascending Dose Study With BPL-003 in Healthy Subjects","sstatus":"COMPLETED","sponsor":"Beckley Psytech Limited","official":"VP & Head of Clinical Development, PhD (Beckley Psytech Ltd)","src":"https://clinicaltrials.gov/study/NCT05347849","phase":"Phase 1","enroll":62,"start":"2022-02-14","eid":"x:site:nct05347849-hammersmith-medicines-research-london"},{"id":"nct07317232-hospital-das-clinicas-da-fmrp-usp-ribeirao-preto","cat":"research","name":"Hospital das Clínicas da FMRP-USP","city":"Ribeirão Preto","country":"Brazil","cc":"BR","lat":-21.18197,"lon":-47.81842,"gp":"city","unnamed":0,"drugs":["ayahuasca","esketamine"],"condg":["Healthy volunteers"],"status":"RECRUITING","nct":"NCT07317232","study":"Ayahuasca, Esketamine and Premenstrual Symptoms","sstatus":"RECRUITING","sponsor":"University of Sao Paulo","src":"https://clinicaltrials.gov/study/NCT07317232","contact":{"n":"Guimarães Santos","p":"5516997721969","e":"banisteria@gmail.com"},"phase":"N/A","enroll":20,"start":"2025-12-20","eid":"x:site:nct07317232-hospital-das-clinicas-da-fmrp-usp-ribeirao-preto"},{"id":"nct02914769-draulio-b-de-araujo-natal","cat":"research","name":"Draulio B de Araujo","city":"Natal","region":"Rio Grande do Norte","country":"Brazil","cc":"BR","lat":-5.79947,"lon":-35.21683,"gp":"city","unnamed":0,"drugs":["ayahuasca"],"zip":"59012-300","condg":["Depression"],"nct":"NCT02914769","study":"Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Universidade Federal do Rio Grande do Norte","official":"Draulio B de Araujo, Ph.D (Brain Institute - UFRN)","src":"https://clinicaltrials.gov/study/NCT02914769","phase":"Phase 1/Phase 2","enroll":35,"start":"2014-02","eid":"x:site:nct02914769-draulio-b-de-araujo-natal"},{"id":"nct05042765-vireo-health-of-new-york-queens","cat":"research","name":"Vireo Health of New York","city":"Queens","region":"New York","country":"United States","cc":"US","lat":40.6853,"lon":-73.84381,"gp":"city","unnamed":0,"drugs":["ayahuasca"],"zip":"11373","condg":["Other"],"nct":"NCT05042765","study":"Entheogen Resurgence","sstatus":"COMPLETED","sponsor":"Vireo Health","official":"Stephen Dahmer, ND (Resurgent Biosciences, Inc.)","src":"https://clinicaltrials.gov/study/NCT05042765","enroll":102,"start":"2021-09-16","eid":"x:site:nct05042765-vireo-health-of-new-york-queens"},{"id":"nct07212946-hospital-das-clinicas-da-fmrp-usp-ribeirao-preto","cat":"research","name":"Hospital das Clínicas da FMRP-USP","city":"Ribeirão Preto","region":"São Paulo","country":"Brazil","cc":"BR","lat":-21.18781,"lon":-47.81343,"gp":"city","unnamed":0,"drugs":["ayahuasca","esketamine"],"zip":"14049900","condg":["Depression"],"nct":"NCT07212946","study":"Ayahuasca and Esketamine for Major Depression","sstatus":"COMPLETED","sponsor":"University of Sao Paulo","src":"https://clinicaltrials.gov/study/NCT07212946","phase":"Phase 2","enroll":22,"start":"2022-10-30","eid":"x:site:nct07212946-hospital-das-clinicas-da-fmrp-usp-ribeirao-preto"},{"id":"nct06150859-institut-de-recerca-holistica-de-montserat-irehom-barcelona","cat":"research","name":"Institut de Recerca Holistica de Montserat (Irehom)","city":"Barcelona","country":"Spain","cc":"ES","lat":41.38855,"lon":2.14727,"gp":"city","unnamed":0,"drugs":["ayahuasca"],"zip":"08253","condg":["Other"],"nct":"NCT06150859","study":"Ayahuasca Assisted Psychotherapy for Grief","sstatus":"UNKNOWN","sponsor":"Beckley Med Foundation","official":"Magi Farré (Hospital German Trials I Pujol)","src":"https://clinicaltrials.gov/study/NCT06150859","phase":"Phase 2","enroll":84,"start":"2021-10-15","eid":"x:site:nct06150859-institut-de-recerca-holistica-de-montserat-irehom-barcelona"},{"id":"nct07317206-hospital-das-clinicas-da-fmrp-usp-ribeirao-preto","cat":"research","name":"Hospital das Clínicas da FMRP-USP","city":"Ribeirão Preto","region":"São Paulo","country":"Brazil","cc":"BR","lat":-21.17924,"lon":-47.80986,"gp":"city","unnamed":0,"drugs":["ayahuasca","esketamine"],"zip":"14049900","condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT07317206","study":"Ayahuasca, Esketamine and PTSD","sstatus":"RECRUITING","sponsor":"University of Sao Paulo","src":"https://clinicaltrials.gov/study/NCT07317206","contact":{"n":"Rafael Guimarães Santos","p":"5516997721969","e":"banisteria@gmail.com"},"phase":"Phase 2","enroll":10,"start":"2025-12-20","eid":"x:site:nct07317206-hospital-das-clinicas-da-fmrp-usp-ribeirao-preto"},{"id":"nct07317219-hospital-das-clinicas-da-fmrp-usp-ribeirao-preto","cat":"research","name":"Hospital das Clínicas da FMRP-USP","city":"Ribeirão Preto","region":"São Paulo","country":"Brazil","cc":"BR","lat":-21.17246,"lon":-47.81306,"gp":"city","unnamed":0,"drugs":["ayahuasca","esketamine"],"zip":"14049900","condg":["Healthy volunteers"],"status":"RECRUITING","nct":"NCT07317219","study":"Ayahuasca, Esketamine and Body Image Perception","sstatus":"RECRUITING","sponsor":"University of Sao Paulo","src":"https://clinicaltrials.gov/study/NCT07317219","contact":{"n":"Rafael Guimarães Santos","p":"5516997721969","e":"banisteria@gmail.com"},"phase":"N/A","enroll":20,"start":"2025-12-20","eid":"x:site:nct07317219-hospital-das-clinicas-da-fmrp-usp-ribeirao-preto"},{"id":"nct07747324-ribeirao-preto-medical-school-ribeirao-preto","cat":"research","name":"Ribeirão Preto Medical School","city":"Ribeirão Preto","region":"São Paulo","country":"Brazil","cc":"BR","lat":-21.17359,"lon":-47.80487,"gp":"city","unnamed":0,"drugs":["ayahuasca"],"zip":"14048900","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT07747324","study":"Effects of a Sigle Dose of Ayahuasca in Patients With Psychogenic Non-epileptic Seizures: an Open Label Clinical Trial","sstatus":"RECRUITING","sponsor":"University of Sao Paulo","src":"https://clinicaltrials.gov/study/NCT07747324","contact":{"n":"Rafael dos Santos, PhD","p":"+551636022703","e":"banisteria@gmail.com"},"phase":"Phase 1/Phase 2","enroll":15,"start":"2026-07-01","eid":"x:site:nct07747324-ribeirao-preto-medical-school-ribeirao-preto"},{"id":"nct01506921-deprtment-of-radiology-sus-malmo-malmo","cat":"research","name":"Deprtment of radiology, SUS, Malmö","city":"Malmö","region":"Malmö","country":"Sweden","cc":"SE","lat":55.60036,"lon":12.99108,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"205 02","condg":["Healthy volunteers"],"nct":"NCT01506921","study":"Racemic Ketamine Versus S-ketamine With Arterial Spin Labeling (ASL)-MRI in Healthy Volunteers","sstatus":"COMPLETED","sponsor":"Lund University","official":"Jonas Åkeson, profesor (Lund University)","src":"https://clinicaltrials.gov/study/NCT01506921","phase":"N/A","enroll":14,"start":"2011-05","eid":"x:site:nct01506921-deprtment-of-radiology-sus-malmo-malmo"},{"id":"nct06430645-beijing-tiantan-hospital-capital-medical-university-beijing","cat":"research","name":"Beijing Tiantan Hospital, Capital Medical University","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.91461,"lon":116.39709,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100070","condg":["Other"],"status":"RECRUITING","nct":"NCT06430645","study":"Effects of Esketamine on Recovery of Consciousness After Propofol Anesthesia","sstatus":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","official":"Ruquan Han, PhD (Beijing Tiantan Hospital)","src":"https://clinicaltrials.gov/study/NCT06430645","contact":{"n":"Ruquan Han, Ph.D","p":"86-13701285393","e":"ruquan.han@ccmu.edu.cn"},"phase":"N/A","enroll":150,"start":"2024-05-05","eid":"x:site:nct06430645-beijing-tiantan-hospital-capital-medical-university-beijing"},{"id":"nct06012916-carolina-center-for-neurostimulation-chapel-hill","cat":"research","name":"Carolina Center for Neurostimulation","city":"Chapel Hill","region":"North Carolina","country":"United States","cc":"US","lat":35.90525,"lon":-79.06718,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"27516","condg":["Depression"],"nct":"NCT06012916","study":"Brain Network Dynamics of Depression During Esketamine Treatment","sstatus":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","official":"Flavio Frohlich, PhD (University of North Carolina, Chapel Hill)","src":"https://clinicaltrials.gov/study/NCT06012916","enroll":8,"start":"2023-07-03","eid":"x:site:nct06012916-carolina-center-for-neurostimulation-chapel-hill"},{"id":"nct07639099-peking-university-first-hospital-beijing","cat":"research","name":"Peking University First Hospital","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.90491,"lon":116.40584,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100034","condg":["Depression"],"nct":"NCT07639099","study":"Intranasal Esketamine-dexmedetomidine Combination and Postpartum Depression","sstatus":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT07639099","contact":{"n":"Dong-Xin Wang, MD, PhD","p":"010-83572784","e":"wangdongxin@hotmail.com"},"phase":"Phase 4","enroll":164,"start":"2026-06","eid":"x:site:nct07639099-peking-university-first-hospital-beijing"},{"id":"nct02611505-unnamed-trial-site-knoxville","cat":"research","name":"Unnamed trial site","city":"Knoxville","region":"Tennessee","country":"United States","cc":"US","lat":35.97208,"lon":-83.93001,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Other"],"nct":"NCT02611505","study":"A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02611505","phase":"Phase 1","enroll":24,"start":"2015-11-30","eid":"x:site:nct02611505-unnamed-trial-site-knoxville"},{"id":"nct06823024-acacia-clinics-sunnyvale","cat":"research","name":"Acacia Clinics","city":"Sunnyvale","region":"California","country":"United States","cc":"US","lat":37.3653,"lon":-122.04167,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"94087","condg":["Depression","Anxiety","PTSD & trauma","OCD","Bipolar"],"nct":"NCT06823024","study":"Assess the Utility of a Speech-based Machine Learning Algorithm to Predict Treatment Response to Psychiatric Interventions","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Psyrin Inc.","official":"Julianna Olah, B.Sc., M.A., M.Sc., Ph.D. (Psyrin Inc.)","src":"https://clinicaltrials.gov/study/NCT06823024","enroll":200,"start":"2025-02-18","eid":"x:site:nct06823024-acacia-clinics-sunnyvale"},{"id":"nct06823024-fermata-health-new-york","cat":"research","name":"Fermata Health","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70425,"lon":-74.00479,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"11249","condg":["Depression","Anxiety","PTSD & trauma","OCD","Bipolar"],"nct":"NCT06823024","study":"Assess the Utility of a Speech-based Machine Learning Algorithm to Predict Treatment Response to Psychiatric Interventions","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Psyrin Inc.","official":"Julianna Olah, B.Sc., M.A., M.Sc., Ph.D. (Psyrin Inc.)","src":"https://clinicaltrials.gov/study/NCT06823024","enroll":200,"start":"2025-02-18","eid":"x:site:nct06823024-fermata-health-new-york"},{"id":"nct05212571-erasmus-mc-rotterdam","cat":"research","name":"Erasmus MC","city":"Rotterdam","region":"South Holland","country":"Netherlands","cc":"NL","lat":51.92029,"lon":4.46915,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"3000 CA","condg":["Chronic pain & headache"],"nct":"NCT05212571","study":"Long-term Pain Modulation by Intravenous Esketamine in CRPS","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Erasmus Medical Center","official":"Frank JP Huygen, MD, PhD (Erasmus MC, Center for Pain Medicine); Thomas Mangnus, MD (Erasmus MC, Center for Pain Medicine)","src":"https://clinicaltrials.gov/study/NCT05212571","phase":"N/A","enroll":60,"start":"2022-04-19","eid":"x:site:nct05212571-erasmus-mc-rotterdam"},{"id":"nct05973851-medical-university-innsbruck-innsbruck","cat":"research","name":"Medical University Innsbruck","city":"Innsbruck","country":"Austria","cc":"AT","lat":47.27042,"lon":11.40315,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"condg":["Depression"],"status":"RECRUITING","nct":"NCT05973851","study":"The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line…","sstatus":"RECRUITING","sponsor":"Dr. Inge Winter","src":"https://clinicaltrials.gov/study/NCT05973851","contact":{"n":"Alex Hofer, MD, PhD","p":"+31875553227","e":"a.hofer@i-med.ac.at"},"phase":"Phase 3","enroll":418,"start":"2024-08-31","eid":"x:site:nct05973851-medical-university-innsbruck-innsbruck"},{"id":"nct05973851-universitatsklinik-fur-psychiatrie-und-psychotherapie-bielefeld-biel","cat":"research","name":"Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld","city":"Bielefeld","country":"Germany","cc":"DE","lat":52.02745,"lon":8.52905,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"condg":["Depression"],"status":"RECRUITING","nct":"NCT05973851","study":"The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line…","sstatus":"RECRUITING","sponsor":"Dr. Inge Winter","src":"https://clinicaltrials.gov/study/NCT05973851","contact":{"n":"Martin Driessen, MD, PhD","p":"+31875553227","e":"martin.driessen@evkb.de"},"phase":"Phase 3","enroll":418,"start":"2024-08-31","eid":"x:site:nct05973851-universitatsklinik-fur-psychiatrie-und-psychotherapie-bielefeld-biel"},{"id":"nct05973851-lwl-klinik-dortmund-bereich-forschung-wissenschaft-dortmund","cat":"research","name":"LWL-Klinik Dortmund, Bereich Forschung & Wissenschaft","city":"Dortmund","country":"Germany","cc":"DE","lat":51.50501,"lon":7.45475,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"44287","condg":["Depression"],"status":"RECRUITING","nct":"NCT05973851","study":"The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line…","sstatus":"RECRUITING","sponsor":"Dr. Inge Winter","src":"https://clinicaltrials.gov/study/NCT05973851","contact":{"n":"Hans-Jörg Assion, Prof.","p":"+31875553227","e":"hans-joerg.assion@lwl.org"},"phase":"Phase 3","enroll":418,"start":"2024-08-31","eid":"x:site:nct05973851-lwl-klinik-dortmund-bereich-forschung-wissenschaft-dortmund"},{"id":"nct05973851-university-hospital-frankfurt-am-main-goethe-university-frankfurt-am","cat":"research","name":"University Hospital Frankfurt am Main - Goethe University","city":"Frankfurt am Main","country":"Germany","cc":"DE","lat":50.10945,"lon":8.6733,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"condg":["Depression"],"status":"RECRUITING","nct":"NCT05973851","study":"The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line…","sstatus":"RECRUITING","sponsor":"Dr. Inge Winter","src":"https://clinicaltrials.gov/study/NCT05973851","contact":{"n":"Andreas Reif, MD,PhD","p":"+31875553227","e":"andreas.reif@kgu.de"},"phase":"Phase 3","enroll":418,"start":"2024-08-31","eid":"x:site:nct05973851-university-hospital-frankfurt-am-main-goethe-university-frankfurt-am"},{"id":"nct05973851-westfalische-wilhelms-universitat-munster-munster","cat":"research","name":"Westfälische Wilhelms-Universität Münster","city":"Münster","country":"Germany","cc":"DE","lat":51.95798,"lon":7.63432,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"condg":["Depression"],"status":"RECRUITING","nct":"NCT05973851","study":"The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line…","sstatus":"RECRUITING","sponsor":"Dr. Inge Winter","src":"https://clinicaltrials.gov/study/NCT05973851","contact":{"n":"Bernhard Baune","p":"+31875553227","e":"Bernhard.Baune@ukmuenster.de"},"phase":"Phase 3","enroll":418,"start":"2024-08-31","eid":"x:site:nct05973851-westfalische-wilhelms-universitat-munster-munster"},{"id":"nct05973851-eginition-hospital-department-of-psychiatry-athens","cat":"research","name":"Eginition Hospital, department of psychiatry","city":"Athens","country":"Greece","cc":"GR","lat":37.98409,"lon":23.72535,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"11528","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT05973851","study":"The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line…","sstatus":"RECRUITING","sponsor":"Dr. Inge Winter","src":"https://clinicaltrials.gov/study/NCT05973851","contact":{"n":"Nikos Stefanis, Prof.","p":"+31875553227","e":"nistefan@med.uoa.gr"},"phase":"Phase 3","enroll":418,"start":"2024-08-31","eid":"x:site:nct05973851-eginition-hospital-department-of-psychiatry-athens"},{"id":"nct05973851-universita-degli-studi-di-brescia-brescia","cat":"research","name":"Universita degli Studi di Brescia","city":"Brescia","country":"Italy","cc":"IT","lat":45.53412,"lon":10.20705,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT05973851","study":"The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line…","sstatus":"RECRUITING","sponsor":"Dr. Inge Winter","src":"https://clinicaltrials.gov/study/NCT05973851","contact":{"n":"Antonio Vita, MD, PhD","p":"+31875553227","e":"antonio.vita@unibs.it"},"phase":"Phase 3","enroll":418,"start":"2024-08-31","eid":"x:site:nct05973851-universita-degli-studi-di-brescia-brescia"},{"id":"nct05973851-university-of-cagliari-cagliari","cat":"research","name":"University of Cagliari","city":"Cagliari","country":"Italy","cc":"IT","lat":39.23247,"lon":9.11037,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"condg":["Depression"],"status":"RECRUITING","nct":"NCT05973851","study":"The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line…","sstatus":"RECRUITING","sponsor":"Dr. Inge Winter","src":"https://clinicaltrials.gov/study/NCT05973851","contact":{"n":"Mirko Manchia, MD, PhD","p":"+31875553227","e":"mirkomanchia@unica.it"},"phase":"Phase 3","enroll":418,"start":"2024-08-31","eid":"x:site:nct05973851-university-of-cagliari-cagliari"},{"id":"nct05973851-universita-degli-studi-della-campania-luigi-vanvitelli-naples","cat":"research","name":"Università degli studi della Campania Luigi Vanvitelli","city":"Naples","country":"Italy","cc":"IT","lat":40.85409,"lon":14.26307,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"80138","condg":["Depression"],"status":"RECRUITING","nct":"NCT05973851","study":"The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line…","sstatus":"RECRUITING","sponsor":"Dr. Inge Winter","src":"https://clinicaltrials.gov/study/NCT05973851","contact":{"n":"Armida Mucci, MD, PhD","p":"+31875553227","e":"armida.mucci@gmail.com"},"phase":"Phase 3","enroll":418,"start":"2024-08-31","eid":"x:site:nct05973851-universita-degli-studi-della-campania-luigi-vanvitelli-naples"},{"id":"nct05973851-azienda-ospedaliero-universitaria-citta-della-salute-e-della-scienza","cat":"research","name":"Azienda Ospedaliero-Universitaria \"Città della Salute e della Scienza di Torino\"","city":"Turin","country":"Italy","cc":"IT","lat":45.05905,"lon":7.69458,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT05973851","study":"The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line…","sstatus":"RECRUITING","sponsor":"Dr. Inge Winter","src":"https://clinicaltrials.gov/study/NCT05973851","contact":{"n":"Paola Rocca, MD,PhD","p":"+31875553227","e":"paola.rocca@unito.it"},"phase":"Phase 3","enroll":418,"start":"2024-08-31","eid":"x:site:nct05973851-azienda-ospedaliero-universitaria-citta-della-salute-e-della-scienza"},{"id":"nct05973851-fundacio-clinic-per-a-la-recerca-biomedica-barcelona","cat":"research","name":"Fundació Clínic per a la Recerca Biomèdica","city":"Barcelona","country":"Spain","cc":"ES","lat":41.3911,"lon":2.15631,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"condg":["Depression"],"status":"RECRUITING","nct":"NCT05973851","study":"The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line…","sstatus":"RECRUITING","sponsor":"Dr. Inge Winter","src":"https://clinicaltrials.gov/study/NCT05973851","contact":{"n":"Eduard Vieta, MD, PhD","p":"+31875553227","e":"EVIETA@clinic.cat"},"phase":"Phase 3","enroll":418,"start":"2024-08-31","eid":"x:site:nct05973851-fundacio-clinic-per-a-la-recerca-biomedica-barcelona"},{"id":"nct05973851-king-s-college-london-psychiatry-cognitive-neuroscience-london","cat":"research","name":"King's College London, Psychiatry & Cognitive Neuroscience","city":"London","country":"United Kingdom","cc":"GB","lat":51.51978,"lon":-0.12438,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"SE5 8AF","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT05973851","study":"The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line…","sstatus":"RECRUITING","sponsor":"Dr. Inge Winter","src":"https://clinicaltrials.gov/study/NCT05973851","contact":{"n":"Howes Oliver, MD, PhD","p":"+31875553227","e":"oliver.howes@kcl.ac.uk"},"phase":"Phase 3","enroll":418,"start":"2024-08-31","eid":"x:site:nct05973851-king-s-college-london-psychiatry-cognitive-neuroscience-london"},{"id":"nct01640080-unnamed-trial-site-dave","cat":"research","name":"Unnamed trial site","city":"Dave","country":"Belgium","cc":"BE","lat":50.41305,"lon":4.89509,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01640080","study":"A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01640080","phase":"Phase 2","enroll":30,"start":"2012-06-27","eid":"x:site:nct01640080-unnamed-trial-site-dave"},{"id":"nct01640080-unnamed-trial-site-ghent","cat":"research","name":"Unnamed trial site","city":"Ghent","country":"Belgium","cc":"BE","lat":51.06096,"lon":3.71013,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01640080","study":"A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01640080","phase":"Phase 2","enroll":30,"start":"2012-06-27","eid":"x:site:nct01640080-unnamed-trial-site-ghent"},{"id":"nct01640080-unnamed-trial-site-kortenberg","cat":"research","name":"Unnamed trial site","city":"Kortenberg","country":"Belgium","cc":"BE","lat":50.88893,"lon":4.54264,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01640080","study":"A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01640080","phase":"Phase 2","enroll":30,"start":"2012-06-27","eid":"x:site:nct01640080-unnamed-trial-site-kortenberg"},{"id":"nct01640080-unnamed-trial-site-lede","cat":"research","name":"Unnamed trial site","city":"Lede","country":"Belgium","cc":"BE","lat":50.9569,"lon":3.99738,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01640080","study":"A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01640080","phase":"Phase 2","enroll":30,"start":"2012-06-27","eid":"x:site:nct01640080-unnamed-trial-site-lede"},{"id":"nct01640080-unnamed-trial-site-berlin","cat":"research","name":"Unnamed trial site","city":"Berlin","country":"Germany","cc":"DE","lat":52.52696,"lon":13.41077,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01640080","study":"A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01640080","phase":"Phase 2","enroll":30,"start":"2012-06-27","eid":"x:site:nct01640080-unnamed-trial-site-berlin"},{"id":"nct01640080-unnamed-trial-site-freiburg-im-breisgau","cat":"research","name":"Unnamed trial site","city":"Freiburg im Breisgau","country":"Germany","cc":"DE","lat":48.00432,"lon":7.85029,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01640080","study":"A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01640080","phase":"Phase 2","enroll":30,"start":"2012-06-27","eid":"x:site:nct01640080-unnamed-trial-site-freiburg-im-breisgau"},{"id":"nct01640080-unnamed-trial-site-mainz","cat":"research","name":"Unnamed trial site","city":"Mainz","country":"Germany","cc":"DE","lat":49.99357,"lon":8.2837,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01640080","study":"A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01640080","phase":"Phase 2","enroll":30,"start":"2012-06-27","eid":"x:site:nct01640080-unnamed-trial-site-mainz"},{"id":"nct01640080-unnamed-trial-site-munchen","cat":"research","name":"Unnamed trial site","city":"München","country":"Germany","cc":"DE","lat":48.14105,"lon":11.58231,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01640080","study":"A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01640080","phase":"Phase 2","enroll":30,"start":"2012-06-27","eid":"x:site:nct01640080-unnamed-trial-site-munchen"},{"id":"nct01640080-unnamed-trial-site-gdansk","cat":"research","name":"Unnamed trial site","city":"Gdansk","country":"Poland","cc":"PL","lat":54.36371,"lon":18.65086,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01640080","study":"A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01640080","phase":"Phase 2","enroll":30,"start":"2012-06-27","eid":"x:site:nct01640080-unnamed-trial-site-gdansk"},{"id":"nct04843982-department-of-critical-care-medicine-union-hospital-tongji-medical-c","cat":"research","name":"Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","city":"Wuhan","region":"Hubei","country":"China","cc":"CN","lat":30.59025,"lon":114.26248,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"430022","condg":["Other"],"nct":"NCT04843982","study":"Immunoinflammatory Regulation of Esketamine in Septic Patients","sstatus":"TERMINATED","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","official":"Shiying Yuan, PhD, MD (Union Hospital, Tongji Medical College, Huazhong University of Science and Technology)","src":"https://clinicaltrials.gov/study/NCT04843982","phase":"Phase 4","enroll":10,"start":"2021-07-28","eid":"x:site:nct04843982-department-of-critical-care-medicine-union-hospital-tongji-medical-c"},{"id":"nct01394757-department-of-psychiatry-and-psychotherapy-medical-university-of-vie","cat":"research","name":"Department of Psychiatry and Psychotherapy, Medical University of Vienna","city":"Vienna","region":"State of Vienna","country":"Austria","cc":"AT","lat":48.20647,"lon":16.379,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1090","condg":["Healthy volunteers"],"nct":"NCT01394757","study":"Network Dysfunction, Schizophrenia and Pharmacological Magnetic Resonance Imaging (phMRI)","sstatus":"COMPLETED","sponsor":"Medical University of Vienna","official":"Rupert Lanzenberger, A/Prof., MD (Department of Psychiatry and Psychotherapy, Medical University of Vienna)","src":"https://clinicaltrials.gov/study/NCT01394757","phase":"N/A","enroll":52,"start":"2011-08","eid":"x:site:nct01394757-department-of-psychiatry-and-psychotherapy-medical-university-of-vie"},{"id":"nct07199179-chu-montpellier-montpellier","cat":"research","name":"Chu Montpellier","city":"Montpellier","country":"France","cc":"FR","lat":43.60938,"lon":3.87037,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"condg":["Depression"],"nct":"NCT07199179","study":"Link Between Reduction of Suicide Ideation by Esketamine in Add-On and Initial Levels of Psychological Pain and Anhedonia","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Montpellier","src":"https://clinicaltrials.gov/study/NCT07199179","enroll":456,"start":"2024-11-24","eid":"x:site:nct07199179-chu-montpellier-montpellier"},{"id":"nct06370130-liang-yuan-lu-beijing","cat":"research","name":"Liang-Yuan Lu","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.89757,"lon":116.39323,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100049","condg":["Other"],"nct":"NCT06370130","study":"Different Dose of Esketamine Inhibiting Response to Laryngeal Mask Airway Insertion","sstatus":"COMPLETED","sponsor":"Aerospace Center Hospital","src":"https://clinicaltrials.gov/study/NCT06370130","phase":"EARLY_Phase 1","enroll":58,"start":"2022-05-01","eid":"x:site:nct06370130-liang-yuan-lu-beijing"},{"id":"nct02060929-unnamed-trial-site-merksem","cat":"research","name":"Unnamed trial site","city":"Merksem","country":"Belgium","cc":"BE","lat":51.24392,"lon":4.44409,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Healthy volunteers"],"nct":"NCT02060929","study":"A Study to Evaluate the Pharmacokinetics of Intranasal Esketamine Administered With and Without a Nasal Guide on the Intranasal Device","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02060929","phase":"Phase 1","enroll":14,"start":"2013-10","eid":"x:site:nct02060929-unnamed-trial-site-merksem"},{"id":"nct02154334-unnamed-trial-site-hanover","cat":"research","name":"Unnamed trial site","city":"Hanover","country":"Germany","cc":"DE","lat":52.38158,"lon":9.72226,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Other"],"nct":"NCT02154334","study":"Study to Assess the Effects of Allergic Rhinitis and Co-administration of Mometasone or Oxymetazoline on the Pharmacokinetics, Safety, and Tolerability of Intranasal Esketamine","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02154334","phase":"Phase 1","enroll":47,"start":"2014-06","eid":"x:site:nct02154334-unnamed-trial-site-hanover"},{"id":"nct05289440-department-of-anqing-hospital-anesthesiology-anqing","cat":"research","name":"Department of Anqing Hospital Anesthesiology","city":"Anqing","region":"Anhui","country":"China","cc":"CN","lat":30.512,"lon":117.0565,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"246000","condg":["Other"],"nct":"NCT05289440","study":"Esketamine Administration on Recovery Quality After Radical Mastectomy","sstatus":"COMPLETED","sponsor":"Anqing Municipal Hospital","src":"https://clinicaltrials.gov/study/NCT05289440","phase":"N/A","enroll":105,"start":"2022-03-15","eid":"x:site:nct05289440-department-of-anqing-hospital-anesthesiology-anqing"},{"id":"nct06853041-chu-de-nice-nice","cat":"research","name":"CHU de NICE","city":"Nice","region":"Alpes-maritimes","country":"France","cc":"FR","lat":43.69668,"lon":7.27281,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"06000","condg":["Chronic pain & headache"],"nct":"NCT06853041","study":"ESKetamine Low-dose vs Ketamine Low-dose for Severe Acute Pain in Emergency Units, Comparison of PsychodyslEptic Effects","sstatus":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","src":"https://clinicaltrials.gov/study/NCT06853041","phase":"Phase 4","enroll":74,"start":"2025-05-06","eid":"x:site:nct06853041-chu-de-nice-nice"},{"id":"nct06139016-yale-psychiatry-hospital-interventional-psychiatry-services-ips-unit","cat":"research","name":"Yale Psychiatry Hospital Interventional Psychiatry Services (IPS) unit","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.30923,"lon":-72.92915,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"06520","condg":["Depression"],"nct":"NCT06139016","study":"Using Virtual Reality to Control the Audio-visual Inputs During Ketamine/Esketamine Treatment","sstatus":"COMPLETED","sponsor":"Yale University","official":"Sina Nikayin, MD (Assistant Professor, Departement of Psychiatry, Yale University)","src":"https://clinicaltrials.gov/study/NCT06139016","phase":"N/A","enroll":7,"start":"2024-07-11","eid":"x:site:nct06139016-yale-psychiatry-hospital-interventional-psychiatry-services-ips-unit"},{"id":"nct04399070-west-china-hospital-of-sichuan-university-department-of-anesthesiolo","cat":"research","name":"West China Hospital of Sichuan University, Department of Anesthesiology","city":"Chengdu","region":"Sichuan","country":"China","cc":"CN","lat":30.67227,"lon":104.06192,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"610041","condg":["Depression","Bipolar"],"nct":"NCT04399070","study":"The Effect of S-ketamine for Patients Undergoing Electroconvulsive Therapy (ECT)","sstatus":"UNKNOWN","sponsor":"Yan Qiu","official":"Guizhi Du, Doctor (West China Hospital of Sichuan University, Department of Anesthesiology)","src":"https://clinicaltrials.gov/study/NCT04399070","contact":{"n":"Guizhi Du, Doctor","p":"+86-189-8060-2213","e":"du_guizhi@yahoo.com"},"phase":"N/A","enroll":150,"start":"2020-08-01","eid":"x:site:nct04399070-west-china-hospital-of-sichuan-university-department-of-anesthesiolo"},{"id":"nct05823454-beijing-tiantan-hospital-capital-medical-university-beijing","cat":"research","name":"Beijing Tiantan Hospital, Capital Medical University","city":"Beijing","country":"China","cc":"CN","lat":39.89814,"lon":116.40641,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"100070","condg":["Other"],"status":"RECRUITING","nct":"NCT05823454","study":"Consciousness-specific Brain Network Connection of Propofol Sedation and Prolonged Disorders of Consciousness","sstatus":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","src":"https://clinicaltrials.gov/study/NCT05823454","contact":{"n":"Ruquan Han, M.D., Ph.D","p":"8610-59976660","e":"ruquan.han@gmail.com"},"enroll":200,"start":"2022-09-30","eid":"x:site:nct05823454-beijing-tiantan-hospital-capital-medical-university-beijing"},{"id":"nct07836205-affiliated-beijing-chaoyang-hospital-of-capital-medical-university-b","cat":"research","name":"Affiliated Beijing Chaoyang Hospital of Capital Medical University","city":"Beijing","country":"China","cc":"CN","lat":39.89776,"lon":116.39445,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100020","condg":["Other"],"nct":"NCT07836205","study":"Brain Activity and Changes in Consciousness During General Anesthesia","sstatus":"NOT_YET_RECRUITING","sponsor":"Beijing Chao Yang Hospital","src":"https://clinicaltrials.gov/study/NCT07836205","contact":{"n":"Wei","p":"+86 13810678936","e":"changwei.wei@ccmu.edu.cn"},"phase":"Phase 4","enroll":320,"start":"2026-09","eid":"x:site:nct07836205-affiliated-beijing-chaoyang-hospital-of-capital-medical-university-b"},{"id":"nct05670561-the-second-affiliated-hospital-chongqing-medical-university-chongqin","cat":"research","name":"The Second Affiliated Hospital, Chongqing Medical University","city":"Chongqing","region":"Chongqing Municipality","country":"China","cc":"CN","lat":29.55174,"lon":106.55832,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"400010","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT05670561","study":"Effects of Esketamine on Acute Abdominal Pain After TACE in Patients With Hepatocellular Carcinoma","sstatus":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","official":"Huang He, MD (The Second Affiliated Hospital, Chongqing Medical University)","src":"https://clinicaltrials.gov/study/NCT05670561","contact":{"n":"Duan Guangyou, MD","p":"18323376014","e":"duangy@hospital.cqmu.edu.cn"},"phase":"Phase 4","enroll":60,"start":"2023-01-05","eid":"x:site:nct05670561-the-second-affiliated-hospital-chongqing-medical-university-chongqin"},{"id":"nct03808259-clinical-pharmacology-unit-merksem","cat":"research","name":"Clinical Pharmacology Unit","city":"Merksem","country":"Belgium","cc":"BE","lat":51.24759,"lon":4.44597,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"2170","condg":["Healthy volunteers"],"nct":"NCT03808259","study":"A Study to Investigate the Different Modes of (S) Ketamine Administration in Healthy Participants","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03808259","phase":"Phase 1","enroll":96,"start":"2018-12-20","eid":"x:site:nct03808259-clinical-pharmacology-unit-merksem"},{"id":"nct02133001-unnamed-trial-site-birmingham","cat":"research","name":"Unnamed trial site","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.52598,"lon":-86.81054,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02133001","study":"A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02133001","phase":"Phase 2","enroll":68,"start":"2014-05-23","eid":"x:site:nct02133001-unnamed-trial-site-birmingham"},{"id":"nct02133001-unnamed-trial-site-san-diego","cat":"research","name":"Unnamed trial site","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.70522,"lon":-117.16401,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02133001","study":"A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02133001","phase":"Phase 2","enroll":68,"start":"2014-05-23","eid":"x:site:nct02133001-unnamed-trial-site-san-diego"},{"id":"nct02133001-unnamed-trial-site-hartford","cat":"research","name":"Unnamed trial site","city":"Hartford","region":"Connecticut","country":"United States","cc":"US","lat":41.76216,"lon":-72.68617,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02133001","study":"A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02133001","phase":"Phase 2","enroll":68,"start":"2014-05-23","eid":"x:site:nct02133001-unnamed-trial-site-hartford"},{"id":"nct02133001-unnamed-trial-site-new-haven","cat":"research","name":"Unnamed trial site","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31714,"lon":-72.93225,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02133001","study":"A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02133001","phase":"Phase 2","enroll":68,"start":"2014-05-23","eid":"x:site:nct02133001-unnamed-trial-site-new-haven"},{"id":"nct02133001-unnamed-trial-site-atlanta","cat":"research","name":"Unnamed trial site","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.76053,"lon":-84.38812,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02133001","study":"A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02133001","phase":"Phase 2","enroll":68,"start":"2014-05-23","eid":"x:site:nct02133001-unnamed-trial-site-atlanta"},{"id":"nct02133001-unnamed-trial-site-iowa-city","cat":"research","name":"Unnamed trial site","city":"Iowa City","region":"Iowa","country":"United States","cc":"US","lat":41.66014,"lon":-91.52542,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02133001","study":"A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02133001","phase":"Phase 2","enroll":68,"start":"2014-05-23","eid":"x:site:nct02133001-unnamed-trial-site-iowa-city"},{"id":"nct02133001-unnamed-trial-site-baltimore","cat":"research","name":"Unnamed trial site","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28497,"lon":-76.61459,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02133001","study":"A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02133001","phase":"Phase 2","enroll":68,"start":"2014-05-23","eid":"x:site:nct02133001-unnamed-trial-site-baltimore"},{"id":"nct02133001-unnamed-trial-site-towson","cat":"research","name":"Unnamed trial site","city":"Towson","region":"Maryland","country":"United States","cc":"US","lat":39.39392,"lon":-76.5901,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02133001","study":"A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02133001","phase":"Phase 2","enroll":68,"start":"2014-05-23","eid":"x:site:nct02133001-unnamed-trial-site-towson"},{"id":"nct02133001-unnamed-trial-site-ann-arbor","cat":"research","name":"Unnamed trial site","city":"Ann Arbor","region":"Michigan","country":"United States","cc":"US","lat":42.26989,"lon":-83.73302,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02133001","study":"A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02133001","phase":"Phase 2","enroll":68,"start":"2014-05-23","eid":"x:site:nct02133001-unnamed-trial-site-ann-arbor"},{"id":"nct02133001-unnamed-trial-site-rochester","cat":"research","name":"Unnamed trial site","city":"Rochester","region":"Minnesota","country":"United States","cc":"US","lat":43.15502,"lon":-77.60676,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02133001","study":"A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02133001","phase":"Phase 2","enroll":68,"start":"2014-05-23","eid":"x:site:nct02133001-unnamed-trial-site-rochester"},{"id":"nct02133001-unnamed-trial-site-cincinnati","cat":"research","name":"Unnamed trial site","city":"Cincinnati","region":"Ohio","country":"United States","cc":"US","lat":39.1297,"lon":-84.52592,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02133001","study":"A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02133001","phase":"Phase 2","enroll":68,"start":"2014-05-23","eid":"x:site:nct02133001-unnamed-trial-site-cincinnati"},{"id":"nct02133001-unnamed-trial-site-philadelphia","cat":"research","name":"Unnamed trial site","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.9529,"lon":-75.16348,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02133001","study":"A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02133001","phase":"Phase 2","enroll":68,"start":"2014-05-23","eid":"x:site:nct02133001-unnamed-trial-site-philadelphia"},{"id":"nct02133001-unnamed-trial-site-pittsburgh","cat":"research","name":"Unnamed trial site","city":"Pittsburgh","region":"Pennsylvania","country":"United States","cc":"US","lat":40.43446,"lon":-79.99725,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02133001","study":"A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02133001","phase":"Phase 2","enroll":68,"start":"2014-05-23","eid":"x:site:nct02133001-unnamed-trial-site-pittsburgh"},{"id":"nct02133001-unnamed-trial-site-houston","cat":"research","name":"Unnamed trial site","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.7525,"lon":-95.37311,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02133001","study":"A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02133001","phase":"Phase 2","enroll":68,"start":"2014-05-23","eid":"x:site:nct02133001-unnamed-trial-site-houston"},{"id":"nct05565352-department-of-psychiatry-medical-university-of-gdansk-gdansk","cat":"research","name":"Department of Psychiatry, Medical University of Gdańsk","city":"Gdansk","country":"Poland","cc":"PL","lat":54.34563,"lon":18.64832,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"80-952","condg":["Depression","Anxiety","PTSD & trauma","OCD"],"nct":"NCT05565352","study":"Ketamine Safety and Tolerability in Psychiatric Inpatient Care (KetGD)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Medical University of Gdansk","src":"https://clinicaltrials.gov/study/NCT05565352","enroll":140,"start":"2022-09-01","eid":"x:site:nct05565352-department-of-psychiatry-medical-university-of-gdansk-gdansk"},{"id":"nct06773143-nanjing-first-hospital-nanjing","cat":"research","name":"Nanjing First Hospital","city":"Nanjing","region":"Jiangsu","country":"China","cc":"CN","lat":32.05014,"lon":118.77039,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"210006","condg":["Cancer-related distress"],"status":"RECRUITING","nct":"NCT06773143","study":"Effect of Subanesthetic Dose of Esketamine on Sleep Quality","sstatus":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","official":"xiaoliang wang (The First Affiliated Hospital with Nanjing Medical University)","src":"https://clinicaltrials.gov/study/NCT06773143","contact":{"n":"zhang ying, Master degree","p":"86+15380998716","e":"1070434273@qq.com"},"phase":"N/A","enroll":184,"start":"2024-12-30","eid":"x:site:nct06773143-nanjing-first-hospital-nanjing"},{"id":"nct06002100-brainhealth-solutions-costa-mesa","cat":"research","name":"BrainHealth Solutions","city":"Costa Mesa","region":"California","country":"United States","cc":"US","lat":33.64306,"lon":-117.92352,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"92626","condg":["Depression"],"nct":"NCT06002100","study":"Prediction of REsponse to Depression Interventions Using Clinical and TD-fNIRS Measurements","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Kernel","official":"Katherine Perdue, PhD (Kernel)","src":"https://clinicaltrials.gov/study/NCT06002100","enroll":540,"start":"2023-08-14","eid":"x:site:nct06002100-brainhealth-solutions-costa-mesa"},{"id":"nct06002100-kadima-neuropsychiatry-institute-la-jolla","cat":"research","name":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","cc":"US","lat":32.83941,"lon":-117.26841,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"92037","condg":["Depression"],"nct":"NCT06002100","study":"Prediction of REsponse to Depression Interventions Using Clinical and TD-fNIRS Measurements","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Kernel","official":"Katherine Perdue, PhD (Kernel)","src":"https://clinicaltrials.gov/study/NCT06002100","enroll":540,"start":"2023-08-14","eid":"x:site:nct06002100-kadima-neuropsychiatry-institute-la-jolla"},{"id":"nct06002100-kaizen-brain-center-llc-la-jolla","cat":"research","name":"Kaizen Brain Center, LLC","city":"La Jolla","region":"California","country":"United States","cc":"US","lat":32.84271,"lon":-117.27133,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"92037","condg":["Depression"],"nct":"NCT06002100","study":"Prediction of REsponse to Depression Interventions Using Clinical and TD-fNIRS Measurements","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Kernel","official":"Katherine Perdue, PhD (Kernel)","src":"https://clinicaltrials.gov/study/NCT06002100","enroll":540,"start":"2023-08-14","eid":"x:site:nct06002100-kaizen-brain-center-llc-la-jolla"},{"id":"nct06002100-bespoke-treatment-los-angeles","cat":"research","name":"Bespoke Treatment","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.06414,"lon":-118.25069,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"90012","condg":["Depression"],"nct":"NCT06002100","study":"Prediction of REsponse to Depression Interventions Using Clinical and TD-fNIRS Measurements","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Kernel","official":"Katherine Perdue, PhD (Kernel)","src":"https://clinicaltrials.gov/study/NCT06002100","enroll":540,"start":"2023-08-14","eid":"x:site:nct06002100-bespoke-treatment-los-angeles"},{"id":"nct06002100-ucla-tms-los-angeles","cat":"research","name":"UCLA TMS","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.05312,"lon":-118.23366,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"90024","condg":["Depression"],"nct":"NCT06002100","study":"Prediction of REsponse to Depression Interventions Using Clinical and TD-fNIRS Measurements","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Kernel","official":"Katherine Perdue, PhD (Kernel)","src":"https://clinicaltrials.gov/study/NCT06002100","enroll":540,"start":"2023-08-14","eid":"x:site:nct06002100-ucla-tms-los-angeles"},{"id":"nct06002100-bespoke-treatment-los-angeles-2","cat":"research","name":"Bespoke Treatment","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.04268,"lon":-118.24043,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"90025","condg":["Depression"],"nct":"NCT06002100","study":"Prediction of REsponse to Depression Interventions Using Clinical and TD-fNIRS Measurements","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Kernel","official":"Katherine Perdue, PhD (Kernel)","src":"https://clinicaltrials.gov/study/NCT06002100","enroll":540,"start":"2023-08-14","eid":"x:site:nct06002100-bespoke-treatment-los-angeles-2"},{"id":"nct06002100-acacia-clinics-sunnyvale","cat":"research","name":"Acacia Clinics","city":"Sunnyvale","region":"California","country":"United States","cc":"US","lat":37.37368,"lon":-122.03301,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"94087","condg":["Depression"],"nct":"NCT06002100","study":"Prediction of REsponse to Depression Interventions Using Clinical and TD-fNIRS Measurements","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Kernel","official":"Katherine Perdue, PhD (Kernel)","src":"https://clinicaltrials.gov/study/NCT06002100","enroll":540,"start":"2023-08-14","eid":"x:site:nct06002100-acacia-clinics-sunnyvale"},{"id":"nct06002100-metro-psychiatry-inc-columbus","cat":"research","name":"Metro Psychiatry Inc.","city":"Columbus","region":"Ohio","country":"United States","cc":"US","lat":39.95125,"lon":-83.00928,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"43215","condg":["Depression"],"nct":"NCT06002100","study":"Prediction of REsponse to Depression Interventions Using Clinical and TD-fNIRS Measurements","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Kernel","official":"Katherine Perdue, PhD (Kernel)","src":"https://clinicaltrials.gov/study/NCT06002100","enroll":540,"start":"2023-08-14","eid":"x:site:nct06002100-metro-psychiatry-inc-columbus"},{"id":"nct06002100-seattle-neuropsychiatric-treatment-center-bellevue","cat":"research","name":"Seattle Neuropsychiatric Treatment Center","city":"Bellevue","region":"Washington","country":"United States","cc":"US","lat":47.62012,"lon":-122.21146,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"98004","condg":["Depression"],"nct":"NCT06002100","study":"Prediction of REsponse to Depression Interventions Using Clinical and TD-fNIRS Measurements","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Kernel","official":"Katherine Perdue, PhD (Kernel)","src":"https://clinicaltrials.gov/study/NCT06002100","enroll":540,"start":"2023-08-14","eid":"x:site:nct06002100-seattle-neuropsychiatric-treatment-center-bellevue"},{"id":"nct06002100-seattle-neuropsychiatric-treatment-center-seattle","cat":"research","name":"Seattle Neuropsychiatric Treatment Center","city":"Seattle","region":"Washington","country":"United States","cc":"US","lat":47.59929,"lon":-122.33701,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"98104","condg":["Depression"],"nct":"NCT06002100","study":"Prediction of REsponse to Depression Interventions Using Clinical and TD-fNIRS Measurements","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Kernel","official":"Katherine Perdue, PhD (Kernel)","src":"https://clinicaltrials.gov/study/NCT06002100","enroll":540,"start":"2023-08-14","eid":"x:site:nct06002100-seattle-neuropsychiatric-treatment-center-seattle"},{"id":"nct05450432-massachusetts-general-hospital-boston","cat":"research","name":"Massachusetts General Hospital","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36375,"lon":-71.05577,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"02114","condg":["Depression"],"status":"RECRUITING","nct":"NCT05450432","study":"Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression","sstatus":"RECRUITING","sponsor":"Massachusetts General Hospital","src":"https://clinicaltrials.gov/study/NCT05450432","contact":{"n":"Catherine Schuessler, BS","p":"617-643-7690","e":"mghketamindstudy@partners.org"},"phase":"Phase 4","enroll":100,"start":"2022-10-13","eid":"x:site:nct05450432-massachusetts-general-hospital-boston"},{"id":"nct07247968-the-first-affiliated-hospital-of-chongqing-medical-university-chongq","cat":"research","name":"The First Affiliated Hospital of Chongqing Medical University","city":"Chongqing","country":"China","cc":"CN","lat":29.56134,"lon":106.55813,"gp":"city","unnamed":0,"drugs":["esketamine"],"condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT07247968","study":"Subanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study","sstatus":"RECRUITING","sponsor":"Min Su","official":"Su Min (First Affiliated Hospital of Chongqing Medical University)","src":"https://clinicaltrials.gov/study/NCT07247968","contact":{"n":"Su Min, MD","p":"+86-23-89011068","e":"ms89011068@163.com"},"phase":"EARLY_Phase 1","enroll":220,"start":"2025-11-25","eid":"x:site:nct07247968-the-first-affiliated-hospital-of-chongqing-medical-university-chongq"},{"id":"nct07247968-the-first-affiliated-hospital-of-chongqing-medical-university-chongq-2","cat":"research","name":"The First Affiliated Hospital of Chongqing Medical University","city":"Chongqing","country":"China","cc":"CN","lat":29.56746,"lon":106.55522,"gp":"city","unnamed":0,"drugs":["esketamine"],"condg":["Depression"],"status":"RECRUITING","nct":"NCT07247968","study":"Subanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study","sstatus":"RECRUITING","sponsor":"Min Su","official":"Su Min (First Affiliated Hospital of Chongqing Medical University)","src":"https://clinicaltrials.gov/study/NCT07247968","contact":{"n":"Su Min","p":"0086-023-89011876","e":"ms89011068@163.com"},"phase":"EARLY_Phase 1","enroll":220,"start":"2025-11-25","eid":"x:site:nct07247968-the-first-affiliated-hospital-of-chongqing-medical-university-chongq-2"},{"id":"nct02717052-department-of-psychiatry-and-psychotherapy-medical-university-of-vie","cat":"research","name":"Department of Psychiatry and Psychotherapy, Medical University of Vienna","city":"Vienna","country":"Austria","cc":"AT","lat":48.20647,"lon":16.36836,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"1090","condg":["Depression"],"status":"RECRUITING","nct":"NCT02717052","study":"Positron Emission Tomography Assessment of Ketamine Binding of the Serotonin Transporter","sstatus":"UNKNOWN","sponsor":"Medical University of Vienna","official":"Rupert Lanzenberger, Prof. (Department of Psychiatry and Psychotherapy, Medical University of Vienna)","src":"https://clinicaltrials.gov/study/NCT02717052","contact":{"n":"Rupert Lanzenberger, A/Prof.","p":"+43 40400","e":"rupert.lanzenberger@meduniwien.ac.at"},"phase":"Phase 2","enroll":74,"start":"2016-05","eid":"x:site:nct02717052-department-of-psychiatry-and-psychotherapy-medical-university-of-vie"},{"id":"nct02343289-unnamed-trial-site-merksem","cat":"research","name":"Unnamed trial site","city":"Merksem","country":"Belgium","cc":"BE","lat":51.25616,"lon":4.44785,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Healthy volunteers"],"nct":"NCT02343289","study":"A Study to Evaluate the Absolute Bioavailability of Intranasal and Oral Esketamine and the Effects of Clarithromycin on the Pharmacokinetics of Intranasal Esketamine in Healthy Participants","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02343289","phase":"Phase 1","enroll":18,"start":"2015-01","eid":"x:site:nct02343289-unnamed-trial-site-merksem"},{"id":"nct03097133-university-of-california-san-diego-psychiatry-san-diego","cat":"research","name":"University of California San Diego/Psychiatry","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.72564,"lon":-117.15997,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"92103-8229","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-university-of-california-san-diego-psychiatry-san-diego"},{"id":"nct03097133-sharp-mesa-vista-hospital-san-diego","cat":"research","name":"Sharp Mesa Vista Hospital","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.71133,"lon":-117.17352,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"92123","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-sharp-mesa-vista-hospital-san-diego"},{"id":"nct03097133-university-of-conneticut-school-of-medicine-farmington","cat":"research","name":"University of Conneticut School of Medicine","city":"Farmington","region":"Connecticut","country":"United States","cc":"US","lat":36.72274,"lon":-108.20998,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"06030","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-university-of-conneticut-school-of-medicine-farmington"},{"id":"nct03097133-university-of-miami-health-system-miami","cat":"research","name":"University of Miami Health System","city":"Miami","region":"Florida","country":"United States","cc":"US","lat":25.76227,"lon":-80.18947,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"33136","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-university-of-miami-health-system-miami"},{"id":"nct03097133-innovative-clinical-research-inc-north-miami","cat":"research","name":"Innovative Clinical Research Inc","city":"North Miami","region":"Florida","country":"United States","cc":"US","lat":25.89936,"lon":-80.19485,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"33161","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-innovative-clinical-research-inc-north-miami"},{"id":"nct03097133-university-of-south-florida-tampa","cat":"research","name":"University of South Florida","city":"Tampa","region":"Florida","country":"United States","cc":"US","lat":27.95039,"lon":-82.46168,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"33613","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-university-of-south-florida-tampa"},{"id":"nct03097133-atlanta-behavioral-research-llc-atlanta","cat":"research","name":"Atlanta Behavioral Research, LLC","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.74321,"lon":-84.37984,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"30338","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-atlanta-behavioral-research-llc-atlanta"},{"id":"nct03097133-memorial-medical-center-springfield","cat":"research","name":"Memorial Medical Center","city":"Springfield","region":"Illinois","country":"United States","cc":"US","lat":37.22366,"lon":-93.29368,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"62702","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-memorial-medical-center-springfield"},{"id":"nct03097133-neuroscience-research-institute-winfield","cat":"research","name":"Neuroscience Research Institute","city":"Winfield","region":"Illinois","country":"United States","cc":"US","lat":37.24206,"lon":-96.98368,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"60190","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-neuroscience-research-institute-winfield"},{"id":"nct03097133-lake-charles-clinical-trials-lake-charles","cat":"research","name":"Lake Charles Clinical Trials","city":"Lake Charles","region":"Louisiana","country":"United States","cc":"US","lat":30.21963,"lon":-93.20087,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"70629","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-lake-charles-clinical-trials-lake-charles"},{"id":"nct03097133-john-hopkins-hospital-baltimore","cat":"research","name":"John Hopkins Hospital","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28092,"lon":-76.61148,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"21287","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-john-hopkins-hospital-baltimore"},{"id":"nct03097133-altea-research-institute-las-vegas","cat":"research","name":"Altea Research Institute","city":"Las Vegas","region":"Nevada","country":"United States","cc":"US","lat":36.18377,"lon":-115.13134,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"89102","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-altea-research-institute-las-vegas"},{"id":"nct03097133-the-zucker-hillside-hospital-glen-oaks","cat":"research","name":"The Zucker Hillside Hospital","city":"Glen Oaks","region":"New York","country":"United States","cc":"US","lat":40.75096,"lon":-73.71204,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"11004","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-the-zucker-hillside-hospital-glen-oaks"},{"id":"nct03097133-stony-brook-university-medical-center-stony-brook","cat":"research","name":"Stony Brook University Medical Center","city":"Stony Brook","region":"New York","country":"United States","cc":"US","lat":40.91657,"lon":-73.13148,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"11794","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-stony-brook-university-medical-center-stony-brook"},{"id":"nct03097133-university-of-north-carolina-chapel-hill","cat":"research","name":"University of North Carolina","city":"Chapel Hill","region":"North Carolina","country":"United States","cc":"US","lat":35.90299,"lon":-79.06765,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"27599","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-university-of-north-carolina-chapel-hill"},{"id":"nct03097133-university-of-cincinnati-dept-of-psychiatry-behavioral-neuroscience-","cat":"research","name":"University of Cincinnati, Dept of Psychiatry & Behavioral Neuroscience","city":"Cincinnati","region":"Ohio","country":"United States","cc":"US","lat":39.13073,"lon":-84.5134,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"45219","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-university-of-cincinnati-dept-of-psychiatry-behavioral-neuroscience-"},{"id":"nct03097133-east-tennessee-state-university-johnson-city","cat":"research","name":"East Tennessee State University","city":"Johnson City","region":"Tennessee","country":"United States","cc":"US","lat":36.32478,"lon":-82.34335,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"37604","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-east-tennessee-state-university-johnson-city"},{"id":"nct03097133-university-of-wisconsin-medical-center-madison","cat":"research","name":"University of Wisconsin Medical Center","city":"Madison","region":"Wisconsin","country":"United States","cc":"US","lat":43.07827,"lon":-89.40344,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"53705","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-university-of-wisconsin-medical-center-madison"},{"id":"nct03097133-clinica-privada-banfield-s-a-banfield","cat":"research","name":"Clínica Privada Banfield S.A","city":"Banfield","country":"Argentina","cc":"AR","lat":-34.75302,"lon":-58.39003,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"B1828CKR","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-clinica-privada-banfield-s-a-banfield"},{"id":"nct03097133-hospital-fleni-ciudad-de-buenos-aires","cat":"research","name":"Hospital Fleni","city":"Ciudad de Buenos Aires","country":"Argentina","cc":"AR","lat":-34.2935,"lon":-58.0459,"gp":"country","unnamed":0,"drugs":["esketamine"],"zip":"C1428AQK","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-hospital-fleni-ciudad-de-buenos-aires"},{"id":"nct03097133-sanatorio-prof-leon-s-morra-cordoba","cat":"research","name":"Sanatorio Prof. Leon S. Morra","city":"Córdoba","country":"Argentina","cc":"AR","lat":-31.41312,"lon":-64.20025,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"X5009BIN","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-sanatorio-prof-leon-s-morra-cordoba"},{"id":"nct03097133-clinica-privada-de-salud-mental-santa-teresa-de-avila-la-plata","cat":"research","name":"Clinica Privada de Salud Mental Santa Teresa de Ávila","city":"La Plata","country":"Argentina","cc":"AR","lat":-34.91933,"lon":-57.94336,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"B1904ADM","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-clinica-privada-de-salud-mental-santa-teresa-de-avila-la-plata"},{"id":"nct03097133-medical-university-vienna-muv-vienna","cat":"research","name":"Medical University Vienna MUV","city":"Vienna","country":"Austria","cc":"AT","lat":48.21927,"lon":16.36074,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1090","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-medical-university-vienna-muv-vienna"},{"id":"nct03097133-klinikum-wels-grieskirchen-wels","cat":"research","name":"Klinikum Wels Grieskirchen","city":"Wels","country":"Austria","cc":"AT","lat":48.17641,"lon":14.02971,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"4600","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-klinikum-wels-grieskirchen-wels"},{"id":"nct03097133-az-sint-jan-brugge-oostende-av-bruges","cat":"research","name":"AZ Sint Jan Brugge Oostende AV","city":"Bruges","country":"Belgium","cc":"BE","lat":51.20906,"lon":3.2208,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"8000","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-az-sint-jan-brugge-oostende-av-bruges"},{"id":"nct03097133-uz-gent-ghent","cat":"research","name":"UZ Gent","city":"Ghent","country":"Belgium","cc":"BE","lat":51.04722,"lon":3.70815,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"9000","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-uz-gent-ghent"},{"id":"nct03097133-ariadne-lede","cat":"research","name":"ARIADNE","city":"Lede","country":"Belgium","cc":"BE","lat":50.97242,"lon":3.98053,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"9340","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-ariadne-lede"},{"id":"nct03097133-universidade-federal-de-minas-gerais-hospital-das-clinicas-belo-hori","cat":"research","name":"Universidade Federal De Minas Gerais - Hospital das Clínicas","city":"Belo Horizonte","country":"Brazil","cc":"BR","lat":-19.92794,"lon":-43.93642,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"30130-100","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-universidade-federal-de-minas-gerais-hospital-das-clinicas-belo-hori"},{"id":"nct03097133-universidade-federal-do-ceara-fortaleza","cat":"research","name":"Universidade Federal Do Ceara","city":"Fortaleza","country":"Brazil","cc":"BR","lat":-3.70701,"lon":-38.53784,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"60430-370","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-universidade-federal-do-ceara-fortaleza"},{"id":"nct03097133-instituto-bairral-de-psiquiatria-itapira","cat":"research","name":"Instituto Bairral de Psiquiatria","city":"Itapira","country":"Brazil","cc":"BR","lat":-22.43004,"lon":-46.83113,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"13970-905","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-instituto-bairral-de-psiquiatria-itapira"},{"id":"nct03097133-hospital-universitario-professor-edgar-santos-salvador","cat":"research","name":"Hospital Universitario Professor Edgar Santos","city":"Salvador","country":"Brazil","cc":"BR","lat":-12.97314,"lon":-38.48903,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"40110-060","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-hospital-universitario-professor-edgar-santos-salvador"},{"id":"nct03097133-cemec-centro-multidisciplinar-de-estudos-clinicos-santo-andre","cat":"research","name":"CEMEC - Centro Multidisciplinar de Estudos Clínicos","city":"Santo André","country":"Brazil","cc":"BR","lat":-23.67194,"lon":-46.54977,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"09190-510","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-cemec-centro-multidisciplinar-de-estudos-clinicos-santo-andre"},{"id":"nct03097133-hospital-das-clinicas-da-faculdade-de-medicina-da-usp-sao-paulo","cat":"research","name":"Hospital Das Clinicas Da Faculdade De Medicina Da USP","city":"São Paulo","country":"Brazil","cc":"BR","lat":-23.53804,"lon":-46.64237,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"05403-903","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-hospital-das-clinicas-da-faculdade-de-medicina-da-usp-sao-paulo"},{"id":"nct03097133-st-michael-s-hospital-toronto","cat":"research","name":"St. Michael's Hospital","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.71118,"lon":-79.40923,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"M5B 1W8","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-st-michael-s-hospital-toronto"},{"id":"nct03097133-institut-universitaire-en-sante-mentale-de-montreal-montreal","cat":"research","name":"Institut universitaire en sante mentale de Montreal","city":"Montreal","region":"Quebec","country":"Canada","cc":"CA","lat":45.51322,"lon":-73.59388,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"H1N 3M5","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-institut-universitaire-en-sante-mentale-de-montreal-montreal"},{"id":"nct03097133-fakultni-nemocnice-brno-brno","cat":"research","name":"Fakultni nemocnice Brno","city":"Brno","country":"Czechia","cc":"CZ","lat":49.19254,"lon":16.61205,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"62500","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-fakultni-nemocnice-brno-brno"},{"id":"nct03097133-nemocnice-s-pol-havirov-p-o-havirov","cat":"research","name":"Nemocnice s pol. Havirov, p.o.","city":"Havířov","country":"Czechia","cc":"CZ","lat":49.77433,"lon":18.43222,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"73601","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-nemocnice-s-pol-havirov-p-o-havirov"},{"id":"nct03097133-narodni-ustav-dusevniho-zdravi-klecany","cat":"research","name":"Narodni ustav dusevniho zdravi","city":"Klecany","country":"Czechia","cc":"CZ","lat":50.17707,"lon":14.4184,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"25067","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-narodni-ustav-dusevniho-zdravi-klecany"},{"id":"nct03097133-vseobecna-fakultni-nemocnice-prague","cat":"research","name":"Vseobecna Fakultní Nemocnice","city":"Prague","country":"Czechia","cc":"CZ","lat":50.08583,"lon":14.42834,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"12000","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-vseobecna-fakultni-nemocnice-prague"},{"id":"nct03097133-ustredni-vojenske-nemocnice-praha-prague","cat":"research","name":"Ústrední vojenské nemocnice Praha","city":"Prague","country":"Czechia","cc":"CZ","lat":50.08536,"lon":14.42467,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"16902","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-ustredni-vojenske-nemocnice-praha-prague"},{"id":"nct03097133-hopital-de-bohars-bohars","cat":"research","name":"Hôpital de Bohars","city":"Bohars","country":"France","cc":"FR","lat":48.42865,"lon":-4.51899,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"29820","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-hopital-de-bohars-bohars"},{"id":"nct03097133-chru-montpellier-hopital-lapeyronie-montpellier","cat":"research","name":"CHRU Montpellier Hopital Lapeyronie","city":"Montpellier","country":"France","cc":"FR","lat":43.59893,"lon":3.88459,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"34090","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-chru-montpellier-hopital-lapeyronie-montpellier"},{"id":"nct03097133-chu-caremeau-nimes","cat":"research","name":"CHU Caremeau","city":"Nîmes","country":"France","cc":"FR","lat":43.82747,"lon":4.36169,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"30029","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-chu-caremeau-nimes"},{"id":"nct03097133-hopital-sainte-anne-paris","cat":"research","name":"Hopital Sainte Anne","city":"Paris","country":"France","cc":"FR","lat":48.85487,"lon":2.3384,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"75014","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-hopital-sainte-anne-paris"},{"id":"nct03097133-chu-saint-etienne-hopital-nord-saint-priest-en-jarez","cat":"research","name":"CHU Saint Etienne Hopital Nord","city":"Saint-Priest-en-Jarez","country":"France","cc":"FR","lat":45.46943,"lon":4.38229,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"42270","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-chu-saint-etienne-hopital-nord-saint-priest-en-jarez"},{"id":"nct03097133-chu-toulouse-toulouse","cat":"research","name":"CHU Toulouse","city":"Toulouse","country":"France","cc":"FR","lat":43.61438,"lon":1.43252,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"31059","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-chu-toulouse-toulouse"},{"id":"nct03097133-hospital-of-lithuanian-university-of-health-sciences-kaunas-clinics-","cat":"research","name":"Hospital of Lithuanian University of Health Sciences Kaunas Clinics","city":"Kaunas","country":"Lithuania","cc":"LT","lat":54.90227,"lon":23.90415,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"LT-50009","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-hospital-of-lithuanian-university-of-health-sciences-kaunas-clinics-"},{"id":"nct03097133-republic-kaunas-hospital-kaunas-county","cat":"research","name":"Republic Kaunas Hospital","city":"Kaunas County","country":"Lithuania","cc":"LT","lat":55.1539,"lon":25.2229,"gp":"country","unnamed":0,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-republic-kaunas-hospital-kaunas-county"},{"id":"nct03097133-vilnius-mental-health-center-vilnius","cat":"research","name":"Vilnius Mental Health Center","city":"Vilnius","country":"Lithuania","cc":"LT","lat":54.6973,"lon":25.28634,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"10309","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-vilnius-mental-health-center-vilnius"},{"id":"nct03097133-uniwersyteckie-centrum-kliniczne-gdansk","cat":"research","name":"Uniwersyteckie Centrum Kliniczne","city":"Gdansk","country":"Poland","cc":"PL","lat":54.35156,"lon":18.65208,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"80 124","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-uniwersyteckie-centrum-kliniczne-gdansk"},{"id":"nct03097133-szpital-specjalistyczny-im-h-klimontowicza-oddzial-psychiatryczny-go","cat":"research","name":"Szpital Specjalistyczny im H Klimontowicza Oddzial Psychiatryczny","city":"Gorlice","country":"Poland","cc":"PL","lat":49.65784,"lon":21.17197,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"38-300","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-szpital-specjalistyczny-im-h-klimontowicza-oddzial-psychiatryczny-go"},{"id":"nct03097133-spzoz-csk-um-w-lodzi-klinika-zaburzen-afektywnych-i-psychotycznych-l","cat":"research","name":"SPZOZ CSK UM w Lodzi Klinika Zaburzen Afektywnych i Psychotycznych","city":"Lodz","country":"Poland","cc":"PL","lat":51.77562,"lon":19.4628,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"92-216","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-spzoz-csk-um-w-lodzi-klinika-zaburzen-afektywnych-i-psychotycznych-l"},{"id":"nct03097133-klinika-psychiatryczna-wum-mazowieckie-specjalistyczne-centrum-zdrow","cat":"research","name":"Klinika Psychiatryczna WUM Mazowieckie Specjalistyczne Centrum Zdrowia im prof Jana Mazurkiewicza","city":"Pruszków","country":"Poland","cc":"PL","lat":52.17594,"lon":20.8199,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"05 802","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-klinika-psychiatryczna-wum-mazowieckie-specjalistyczne-centrum-zdrow"},{"id":"nct03097133-hosp-univ-vall-d-hebron-barcelona","cat":"research","name":"Hosp Univ Vall D Hebron","city":"Barcelona","country":"Spain","cc":"ES","lat":41.39928,"lon":2.15612,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"08035","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-hosp-univ-vall-d-hebron-barcelona"},{"id":"nct03097133-inst-internac-neurociencias-aplicadas-barcelona","cat":"research","name":"Inst. Internac. Neurociencias Aplicadas","city":"Barcelona","country":"Spain","cc":"ES","lat":41.39957,"lon":2.16111,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"8006","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-inst-internac-neurociencias-aplicadas-barcelona"},{"id":"nct03097133-hosp-univ-de-basurto-bilbao","cat":"research","name":"Hosp. Univ. de Basurto","city":"Bilbao","country":"Spain","cc":"ES","lat":43.26436,"lon":-2.91573,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"48013","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-hosp-univ-de-basurto-bilbao"},{"id":"nct03097133-clinica-univ-de-navarra-pamplona","cat":"research","name":"Clinica Univ. de Navarra","city":"Pamplona","country":"Spain","cc":"ES","lat":42.80628,"lon":-1.65438,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"31008","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-clinica-univ-de-navarra-pamplona"},{"id":"nct03097133-bursa-sevket-yilmaz-research-and-training-hospital-bursa","cat":"research","name":"Bursa Sevket Yilmaz Research and Training Hospital","city":"Bursa","country":"Turkey","cc":"TR","lat":40.18472,"lon":29.05707,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"16240","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-bursa-sevket-yilmaz-research-and-training-hospital-bursa"},{"id":"nct03097133-uludag-university-medical-faculty-bursa","cat":"research","name":"Uludag University Medical Faculty","city":"Bursa","country":"Turkey","cc":"TR","lat":40.19978,"lon":29.06319,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"16285","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-uludag-university-medical-faculty-bursa"},{"id":"nct03097133-sisli-etfal-research-training-hospital-istanbul","cat":"research","name":"Sisli Etfal Research Training Hospital","city":"Istanbul","country":"Turkey","cc":"TR","lat":41.00636,"lon":28.94557,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"34360","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-sisli-etfal-research-training-hospital-istanbul"},{"id":"nct03097133-samsun-psychiatric-hospital-samsun","cat":"research","name":"Samsun Psychiatric Hospital","city":"Samsun","country":"Turkey","cc":"TR","lat":41.28169,"lon":36.33822,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"55070","condg":["Depression"],"nct":"NCT03097133","study":"54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03097133","phase":"Phase 3","enroll":230,"start":"2017-06-15","eid":"x:site:nct03097133-samsun-psychiatric-hospital-samsun"},{"id":"nct07339449-university-hospital-dubrava-zagreb","cat":"research","name":"University hospital Dubrava","city":"Zagreb","region":"Croatia","country":"Croatia","cc":"HR","lat":45.80357,"lon":15.98556,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"10040","condg":["Other"],"status":"RECRUITING","nct":"NCT07339449","study":"Intraoperative Multimodal Monitoring as a Means in Reducing the Duration of Mechanical Ventilation in High-Risk Patients Undergoing Major Abdominal Procedures - A Pilot Study","sstatus":"RECRUITING","sponsor":"University Hospital Dubrava","official":"Jasminka Peršec, M.D., PhD, Ass. Prof (University Hospital Dubrava); Andrej Šribar, Assoc. Prof., MD, PhD (University Hospital Dubrava)","src":"https://clinicaltrials.gov/study/NCT07339449","contact":{"n":"Marko Pražetina, MD","p":"0958150841","e":"mprazetina1991@gmail.com"},"phase":"N/A","enroll":100,"start":"2025-08-01","eid":"x:site:nct07339449-university-hospital-dubrava-zagreb"},{"id":"nct03421275-hyvinkaa-hospital-hyvinkaa","cat":"research","name":"Hyvinkää Hospital","city":"Hyvinkää","country":"Finland","cc":"FI","lat":60.63272,"lon":24.85853,"gp":"city","unnamed":0,"drugs":["esketamine"],"condg":["PTSD & trauma","Chronic pain & headache"],"status":"RECRUITING","nct":"NCT03421275","study":"Intranasal Esketamine and Fentanyl for Pain in Minor Trauma","sstatus":"UNKNOWN","sponsor":"Anna Meuronen, MD","official":"Anna Meuronen, MD,PhD (consultant)","src":"https://clinicaltrials.gov/study/NCT03421275","contact":{"n":"Anna Meuronen, MD, PhD","p":"+35819458711","e":"anna.meuronen@hus.fi"},"phase":"Phase 4","enroll":105,"start":"2017-12-01","eid":"x:site:nct03421275-hyvinkaa-hospital-hyvinkaa"},{"id":"nct04666623-university-hospital-basel-klinik-fur-mund-kiefer-und-gesichtschirurg","cat":"research","name":"University Hospital Basel, Klinik für Mund-, Kiefer- und Gesichtschirurgie","city":"Basel","country":"Switzerland","cc":"CH","lat":47.5638,"lon":7.56729,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"4031","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT04666623","study":"Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain","sstatus":"WITHDRAWN","sponsor":"University Hospital, Basel, Switzerland","official":"Benito Benitez, MD (University Hospital Basel, Klinik für Mund-, Kiefer- und Gesichtschirurgie)","src":"https://clinicaltrials.gov/study/NCT04666623","phase":"Phase 2","start":"2020-11-25","eid":"x:site:nct04666623-university-hospital-basel-klinik-fur-mund-kiefer-und-gesichtschirurg"},{"id":"nct07002684-tea-fabijanic-zagreb","cat":"research","name":"Tea Fabijanić","city":"Zagreb","country":"Croatia","cc":"HR","lat":45.81072,"lon":15.98254,"gp":"city","unnamed":0,"drugs":["esketamine"],"condg":["Depression"],"status":"RECRUITING","nct":"NCT07002684","study":"Metabolic Profiling of Esketamine Treatment in Depressive Disorder","sstatus":"RECRUITING","sponsor":"University of Zagreb","official":"Tea Fabijanić, MD (University of Zagreb)","src":"https://clinicaltrials.gov/study/NCT07002684","contact":{"n":"Tea Fabijanić","p":"+385915698801","e":"tea.fabijan@gmail.com"},"enroll":100,"start":"2023-04-01","eid":"x:site:nct07002684-tea-fabijanic-zagreb"},{"id":"nct05577585-medical-university-of-vienna-department-of-psychiatry-and-psychother","cat":"research","name":"Medical University of Vienna, Department of Psychiatry and Psychotherapy","city":"Vienna","region":"State of Vienna","country":"Austria","cc":"AT","lat":48.21889,"lon":16.37147,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"1090","condg":["OCD"],"status":"RECRUITING","nct":"NCT05577585","study":"Ketamine in OCD: Efficacy and Effects on Stress and Cognition","sstatus":"RECRUITING","sponsor":"Medical University of Vienna","official":"Christoph Kraus, MD PhD (Medical University of Vienna, Department of Psychiatry and Psychotherapy)","src":"https://clinicaltrials.gov/study/NCT05577585","contact":{"n":"Christoph Kraus, MD PhD","p":"+4314040035680","e":"christoph.kraus@muv.ac.at"},"phase":"N/A","enroll":60,"start":"2022-10-01","eid":"x:site:nct05577585-medical-university-of-vienna-department-of-psychiatry-and-psychother"},{"id":"nct02919579-unnamed-trial-site-leiden","cat":"research","name":"Unnamed trial site","city":"Leiden","country":"Netherlands","cc":"NL","lat":52.15565,"lon":4.48991,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02919579","study":"A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02919579","phase":"Phase 1","enroll":27,"start":"2016-10-07","eid":"x:site:nct02919579-unnamed-trial-site-leiden"},{"id":"nct04751812-halland-hospital-halmstad-halmstad","cat":"research","name":"Halland Hospital Halmstad","city":"Halmstad","region":"Halland County","country":"Sweden","cc":"SE","lat":56.67902,"lon":12.86415,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"30582","condg":["Addiction & substance use","Chronic pain & headache"],"nct":"NCT04751812","study":"Venous Cannulation Pain to Guide Choice of Anesthetic Method","sstatus":"COMPLETED","sponsor":"Region Halland","official":"Anna KM Persson, PhD, MD (Region Halland)","src":"https://clinicaltrials.gov/study/NCT04751812","phase":"N/A","enroll":270,"start":"2022-03-01","eid":"x:site:nct04751812-halland-hospital-halmstad-halmstad"},{"id":"nct01780259-unnamed-trial-site-merksem","cat":"research","name":"Unnamed trial site","city":"Merksem","country":"Belgium","cc":"BE","lat":51.25014,"lon":4.4407,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Healthy volunteers"],"nct":"NCT01780259","study":"A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01780259","phase":"Phase 1","enroll":58,"start":"2012-12","eid":"x:site:nct01780259-unnamed-trial-site-merksem"},{"id":"nct07716098-anderson-clinical-research-redlands","cat":"research","name":"Anderson Clinical Research","city":"Redlands","region":"California","country":"United States","cc":"US","lat":34.05901,"lon":-117.17459,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"92374","condg":["Depression"],"status":"RECRUITING","nct":"NCT07716098","study":"A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT07716098","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":348,"start":"2026-07-23","eid":"x:site:nct07716098-anderson-clinical-research-redlands"},{"id":"nct07716098-artemis-institute-for-clinical-research-san-diego","cat":"research","name":"Artemis Institute for Clinical Research","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.707,"lon":-117.17192,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"92123","condg":["Depression"],"status":"RECRUITING","nct":"NCT07716098","study":"A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT07716098","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":348,"start":"2026-07-23","eid":"x:site:nct07716098-artemis-institute-for-clinical-research-san-diego"},{"id":"nct07716098-psych-atlanta-p-c-marietta","cat":"research","name":"Psych Atlanta, P.C.","city":"Marietta","region":"Georgia","country":"United States","cc":"US","lat":33.94634,"lon":-84.56061,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"30060","condg":["Depression"],"status":"RECRUITING","nct":"NCT07716098","study":"A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT07716098","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":348,"start":"2026-07-23","eid":"x:site:nct07716098-psych-atlanta-p-c-marietta"},{"id":"nct07716098-psychiatric-medicine-associates-llc-skokie","cat":"research","name":"Psychiatric Medicine Associates LLC","city":"Skokie","region":"Illinois","country":"United States","cc":"US","lat":42.0272,"lon":-87.74191,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"60076","condg":["Depression"],"status":"RECRUITING","nct":"NCT07716098","study":"A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT07716098","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":348,"start":"2026-07-23","eid":"x:site:nct07716098-psychiatric-medicine-associates-llc-skokie"},{"id":"nct07716098-neurobehavioral-research-inc-cedarhurst","cat":"research","name":"Neurobehavioral Research Inc","city":"Cedarhurst","region":"New York","country":"United States","cc":"US","lat":40.63375,"lon":-73.73235,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"11516","condg":["Depression"],"status":"RECRUITING","nct":"NCT07716098","study":"A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT07716098","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":348,"start":"2026-07-23","eid":"x:site:nct07716098-neurobehavioral-research-inc-cedarhurst"},{"id":"nct07716098-the-medical-research-network-llc-new-york","cat":"research","name":"The Medical Research Network, LLC","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72533,"lon":-74.01722,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"10128","condg":["Depression"],"status":"RECRUITING","nct":"NCT07716098","study":"A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT07716098","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":348,"start":"2026-07-23","eid":"x:site:nct07716098-the-medical-research-network-llc-new-york"},{"id":"nct07716098-northwest-clinical-research-center-bellevue","cat":"research","name":"Northwest Clinical Research Center","city":"Bellevue","region":"Washington","country":"United States","cc":"US","lat":47.61033,"lon":-122.18972,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"98007","condg":["Depression"],"status":"RECRUITING","nct":"NCT07716098","study":"A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT07716098","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":348,"start":"2026-07-23","eid":"x:site:nct07716098-northwest-clinical-research-center-bellevue"},{"id":"nct07716098-kishiro-mental-clinic-kawasaki","cat":"research","name":"Kishiro Mental Clinic","city":"Kawasaki","country":"Japan","cc":"JP","lat":35.532,"lon":139.7071,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"214-0014","condg":["Depression"],"status":"RECRUITING","nct":"NCT07716098","study":"A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT07716098","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":348,"start":"2026-07-23","eid":"x:site:nct07716098-kishiro-mental-clinic-kawasaki"},{"id":"nct07716098-tatsuta-clinic-kobe","cat":"research","name":"Tatsuta Clinic","city":"Kobe","country":"Japan","cc":"JP","lat":34.68203,"lon":135.17222,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"651-0097","condg":["Depression"],"status":"RECRUITING","nct":"NCT07716098","study":"A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT07716098","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":348,"start":"2026-07-23","eid":"x:site:nct07716098-tatsuta-clinic-kobe"},{"id":"nct07716098-national-center-of-neurology-and-psychiatry-kodaira-shi","cat":"research","name":"National Center of Neurology and Psychiatry","city":"Kodaira-shi","country":"Japan","cc":"JP","lat":35.2679,"lon":139.9564,"gp":"country","unnamed":0,"drugs":["esketamine"],"zip":"187-8551","condg":["Depression"],"status":"RECRUITING","nct":"NCT07716098","study":"A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT07716098","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":348,"start":"2026-07-23","eid":"x:site:nct07716098-national-center-of-neurology-and-psychiatry-kodaira-shi"},{"id":"nct07716098-ichikawa-clinic-maebashi","cat":"research","name":"Ichikawa Clinic","city":"Maebashi","country":"Japan","cc":"JP","lat":36.4088,"lon":139.08149,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"371-0031","condg":["Depression"],"status":"RECRUITING","nct":"NCT07716098","study":"A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT07716098","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":348,"start":"2026-07-23","eid":"x:site:nct07716098-ichikawa-clinic-maebashi"},{"id":"nct07716098-the-jikei-university-hospital-minatoku","cat":"research","name":"The Jikei University Hospital","city":"Minatoku","country":"Japan","cc":"JP","lat":35.9346,"lon":140.1799,"gp":"country","unnamed":0,"drugs":["esketamine"],"zip":"105-8471","condg":["Depression"],"status":"RECRUITING","nct":"NCT07716098","study":"A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT07716098","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":348,"start":"2026-07-23","eid":"x:site:nct07716098-the-jikei-university-hospital-minatoku"},{"id":"nct07716098-kyorin-university-hospital-mitaka","cat":"research","name":"Kyorin University Hospital","city":"Mitaka","country":"Japan","cc":"JP","lat":35.68968,"lon":139.56054,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"181-8611","condg":["Depression"],"status":"RECRUITING","nct":"NCT07716098","study":"A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT07716098","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":348,"start":"2026-07-23","eid":"x:site:nct07716098-kyorin-university-hospital-mitaka"},{"id":"nct07716098-arata-clinic-nagasaki","cat":"research","name":"Arata Clinic","city":"Nagasaki","country":"Japan","cc":"JP","lat":32.75099,"lon":129.89062,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"852-8137","condg":["Depression"],"status":"RECRUITING","nct":"NCT07716098","study":"A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT07716098","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":348,"start":"2026-07-23","eid":"x:site:nct07716098-arata-clinic-nagasaki"},{"id":"nct07716098-hokkaido-university-hospital-sapporo","cat":"research","name":"Hokkaido University Hospital","city":"Sapporo","country":"Japan","cc":"JP","lat":43.06295,"lon":141.35428,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"060 8648","condg":["Depression"],"status":"RECRUITING","nct":"NCT07716098","study":"A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT07716098","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":348,"start":"2026-07-23","eid":"x:site:nct07716098-hokkaido-university-hospital-sapporo"},{"id":"nct07716098-sangenjaya-neurology-psychosomatic-clinic-setagaya-ku","cat":"research","name":"Sangenjaya neurology-psychosomatic clinic","city":"Setagaya Ku","country":"Japan","cc":"JP","lat":36.1189,"lon":139.5211,"gp":"country","unnamed":0,"drugs":["esketamine"],"zip":"154 0004","condg":["Depression"],"status":"RECRUITING","nct":"NCT07716098","study":"A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT07716098","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":348,"start":"2026-07-23","eid":"x:site:nct07716098-sangenjaya-neurology-psychosomatic-clinic-setagaya-ku"},{"id":"nct07716098-maynds-tower-mental-clinic-shibuya-ku","cat":"research","name":"Maynds Tower Mental Clinic","city":"Shibuya-ku","country":"Japan","cc":"JP","lat":35.7385,"lon":139.9407,"gp":"country","unnamed":0,"drugs":["esketamine"],"zip":"151-0053","condg":["Depression"],"status":"RECRUITING","nct":"NCT07716098","study":"A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT07716098","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":348,"start":"2026-07-23","eid":"x:site:nct07716098-maynds-tower-mental-clinic-shibuya-ku"},{"id":"nct07716098-tottori-university-hospital-tottori","cat":"research","name":"Tottori University Hospital","city":"Tottori","country":"Japan","cc":"JP","lat":35.49496,"lon":134.23931,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"683-0824","condg":["Depression"],"status":"RECRUITING","nct":"NCT07716098","study":"A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT07716098","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":348,"start":"2026-07-23","eid":"x:site:nct07716098-tottori-university-hospital-tottori"},{"id":"nct07716098-chung-shan-medical-university-hospital-taichung","cat":"research","name":"Chung Shan Medical University Hospital","city":"Taichung","country":"Taiwan","cc":"TW","lat":24.13763,"lon":120.68028,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"402","condg":["Depression"],"status":"RECRUITING","nct":"NCT07716098","study":"A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT07716098","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":348,"start":"2026-07-23","eid":"x:site:nct07716098-chung-shan-medical-university-hospital-taichung"},{"id":"nct07716098-taipei-medical-university-taipei","cat":"research","name":"Taipei Medical University","city":"Taipei","country":"Taiwan","cc":"TW","lat":25.05311,"lon":121.53237,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"110","condg":["Depression"],"status":"RECRUITING","nct":"NCT07716098","study":"A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT07716098","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":348,"start":"2026-07-23","eid":"x:site:nct07716098-taipei-medical-university-taipei"},{"id":"nct07716098-taipei-veterans-general-hospital-taipei","cat":"research","name":"Taipei Veterans General Hospital","city":"Taipei","country":"Taiwan","cc":"TW","lat":25.04624,"lon":121.53491,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"11217","condg":["Depression"],"status":"RECRUITING","nct":"NCT07716098","study":"A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT07716098","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":348,"start":"2026-07-23","eid":"x:site:nct07716098-taipei-veterans-general-hospital-taipei"},{"id":"nct07716098-linkou-chang-gung-memorial-hospital-taoyuan","cat":"research","name":"Linkou Chang Gung Memorial Hospital","city":"Taoyuan","country":"Taiwan","cc":"TW","lat":24.99721,"lon":121.29164,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"333","condg":["Depression"],"status":"RECRUITING","nct":"NCT07716098","study":"A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT07716098","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":348,"start":"2026-07-23","eid":"x:site:nct07716098-linkou-chang-gung-memorial-hospital-taoyuan"},{"id":"nct05752409-anesthesiology-department-of-affiliated-eye-and-ent-hospital-fudan-u","cat":"research","name":"Anesthesiology Department of Affiliated Eye and ENT Hospital, Fudan University","city":"Shanghai","region":"Shanghai Municipality","country":"China","cc":"CN","lat":31.21511,"lon":121.45208,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"200031","condg":["Other"],"status":"RECRUITING","nct":"NCT05752409","study":"Comparison of Esketamine-Propofol and Fentanyl-Propofol","sstatus":"UNKNOWN","sponsor":"Eye & ENT Hospital of Fudan University","official":"Fang Tan (Anesthesiology Department of Affiliated Eye and ENT Hospital, Fudan University)","src":"https://clinicaltrials.gov/study/NCT05752409","contact":{"n":"Fang Tan","p":"+8613611716000","e":"tanfang@eentanesthesia.com"},"phase":"N/A","enroll":120,"start":"2021-10-08","eid":"x:site:nct05752409-anesthesiology-department-of-affiliated-eye-and-ent-hospital-fudan-u"},{"id":"nct06062550-beijing-university-first-hospital-beijing","cat":"research","name":"Beijing University First Hospital","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.91781,"lon":116.39445,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100034","condg":["Chronic pain & headache"],"nct":"NCT06062550","study":"Different Dose Esketamine and Dexmedetomidine Combination for Supplemental Analgesia After Scoliosis Correction Surgery","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD,PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT06062550","phase":"Phase 4","enroll":312,"start":"2023-10-24","eid":"x:site:nct06062550-beijing-university-first-hospital-beijing"},{"id":"nct03927378-peking-university-first-hospital-beijing","cat":"research","name":"Peking University First Hospital","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.91941,"lon":116.39728,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"100034","condg":["Depression"],"nct":"NCT03927378","study":"Low-dose S-Ketamine and Postpartum Depression in Parturients With Prenatal Depression","sstatus":"COMPLETED","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT03927378","phase":"N/A","enroll":364,"start":"2020-06-19","eid":"x:site:nct03927378-peking-university-first-hospital-beijing"},{"id":"nct03927378-beijing-tiantan-hospital-beijing","cat":"research","name":"Beijing Tiantan Hospital","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.91282,"lon":116.39577,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"condg":["Depression"],"nct":"NCT03927378","study":"Low-dose S-Ketamine and Postpartum Depression in Parturients With Prenatal Depression","sstatus":"COMPLETED","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT03927378","phase":"N/A","enroll":364,"start":"2020-06-19","eid":"x:site:nct03927378-beijing-tiantan-hospital-beijing"},{"id":"nct03927378-peking-university-international-hospital-beijing","cat":"research","name":"Peking University International Hospital","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.9051,"lon":116.40179,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"condg":["Depression"],"nct":"NCT03927378","study":"Low-dose S-Ketamine and Postpartum Depression in Parturients With Prenatal Depression","sstatus":"COMPLETED","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT03927378","phase":"N/A","enroll":364,"start":"2020-06-19","eid":"x:site:nct03927378-peking-university-international-hospital-beijing"},{"id":"nct03927378-hunan-provincial-maternal-and-child-health-care-hospital-changsha","cat":"research","name":"Hunan Provincial Maternal and Child Health Care Hospital","city":"Changsha","region":"Hunan","country":"China","cc":"CN","lat":28.19333,"lon":112.97007,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"condg":["Depression"],"nct":"NCT03927378","study":"Low-dose S-Ketamine and Postpartum Depression in Parturients With Prenatal Depression","sstatus":"COMPLETED","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT03927378","phase":"N/A","enroll":364,"start":"2020-06-19","eid":"x:site:nct03927378-hunan-provincial-maternal-and-child-health-care-hospital-changsha"},{"id":"nct03927378-huaian-maternal-and-child-health-care-hospital-huaian","cat":"research","name":"Huaian Maternal and Child Health Care Hospital","city":"Huaian","region":"Jiangsu","country":"China","cc":"CN","lat":32.7217,"lon":119.4205,"gp":"region","unnamed":0,"drugs":["esketamine","ketamine"],"condg":["Depression"],"nct":"NCT03927378","study":"Low-dose S-Ketamine and Postpartum Depression in Parturients With Prenatal Depression","sstatus":"COMPLETED","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT03927378","phase":"N/A","enroll":364,"start":"2020-06-19","eid":"x:site:nct03927378-huaian-maternal-and-child-health-care-hospital-huaian"},{"id":"nct03927378-nanjing-maternal-and-child-health-care-hospital-nanjing","cat":"research","name":"Nanjing Maternal and Child Health Care Hospital","city":"Nanjing","region":"Jiangsu","country":"China","cc":"CN","lat":32.05645,"lon":118.78809,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"condg":["Depression"],"nct":"NCT03927378","study":"Low-dose S-Ketamine and Postpartum Depression in Parturients With Prenatal Depression","sstatus":"COMPLETED","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT03927378","phase":"N/A","enroll":364,"start":"2020-06-19","eid":"x:site:nct03927378-nanjing-maternal-and-child-health-care-hospital-nanjing"},{"id":"nct03927378-women-s-hospital-school-of-medicine-zhejiang-university-hanzhou","cat":"research","name":"Women's Hospital School Of Medicine Zhejiang University","city":"Hanzhou","region":"Zhejiang","country":"China","cc":"CN","lat":29.9427,"lon":120.6692,"gp":"region","unnamed":0,"drugs":["esketamine","ketamine"],"condg":["Depression"],"nct":"NCT03927378","study":"Low-dose S-Ketamine and Postpartum Depression in Parturients With Prenatal Depression","sstatus":"COMPLETED","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT03927378","phase":"N/A","enroll":364,"start":"2020-06-19","eid":"x:site:nct03927378-women-s-hospital-school-of-medicine-zhejiang-university-hanzhou"},{"id":"nct07753772-peking-university-first-hospital-beijing","cat":"research","name":"Peking University First Hospital","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.90472,"lon":116.40142,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100034","condg":["Depression","Anxiety"],"nct":"NCT07753772","study":"Dexmedetomidine-Esketamine Combination on Depression and Anxiety After Laparoscopic Ureteral Reconstruction","sstatus":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT07753772","contact":{"n":"Dong-Xin Wang","p":"8610 83572784","e":"wangdongxin@hotmail.com"},"phase":"Phase 4","enroll":658,"start":"2026-08","eid":"x:site:nct07753772-peking-university-first-hospital-beijing"},{"id":"nct06795659-the-university-of-texas-health-science-center-at-san-antonio-san-ant","cat":"research","name":"The University of Texas Health Science Center at San Antonio","city":"San Antonio","region":"Texas","country":"United States","cc":"US","lat":29.42436,"lon":-98.50271,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"78229","condg":["PTSD & trauma"],"nct":"NCT06795659","study":"Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)","sstatus":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","official":"Casey Straud, PsyD (The University of Texas Health Science Center at San Antonio)","src":"https://clinicaltrials.gov/study/NCT06795659","phase":"Phase 1/Phase 2","enroll":4,"start":"2025-06-09","eid":"x:site:nct06795659-the-university-of-texas-health-science-center-at-san-antonio-san-ant"},{"id":"nct04856124-psychatlanta-marietta","cat":"research","name":"PsychAtlanta","city":"Marietta","region":"Georgia","country":"United States","cc":"US","lat":33.94211,"lon":-84.54141,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"30060","condg":["Depression"],"nct":"NCT04856124","study":"Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine","sstatus":"COMPLETED","sponsor":"Psych Atlanta","src":"https://clinicaltrials.gov/study/NCT04856124","enroll":10,"start":"2018-09-01","eid":"x:site:nct04856124-psychatlanta-marietta"},{"id":"nct06388824-tianjin-medical-university-general-hospital-tianjin","cat":"research","name":"Tianjin Medical University General Hospital","city":"Tianjin","country":"China","cc":"CN","lat":39.13662,"lon":117.1802,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"300052","condg":["Other"],"nct":"NCT06388824","study":"The Effect of Esketamine on Sleep Disturbance","sstatus":"COMPLETED","sponsor":"Tianjin Medical University General Hospital","official":"Guolin Wang, MD, PhD (Tianjin Medical University General Hospital)","src":"https://clinicaltrials.gov/study/NCT06388824","phase":"N/A","enroll":204,"start":"2024-05-03","eid":"x:site:nct06388824-tianjin-medical-university-general-hospital-tianjin"},{"id":"nct07097025-maaynei-hayeshua-medical-center-bnei-brak","cat":"research","name":"Maaynei Hayeshua medical center","city":"Bnei Brak","country":"Israel","cc":"IL","lat":32.07307,"lon":34.82585,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"5154475","condg":["Depression","Bipolar"],"nct":"NCT07097025","study":"2-Year Study of Vagus Nerve Stimulation for Higher-Grade Treatment-Resistant Depression: Clinical Outcomes and Policy Recommendation","sstatus":"COMPLETED","sponsor":"Dr.Yoav Domany","src":"https://clinicaltrials.gov/study/NCT07097025","enroll":19,"start":"2020-01-01","eid":"x:site:nct07097025-maaynei-hayeshua-medical-center-bnei-brak"},{"id":"nct07097025-lev-hasharon-medical-center-netanya","cat":"research","name":"Lev Hasharon Medical Center","city":"Netanya","country":"Israel","cc":"IL","lat":32.33205,"lon":34.86082,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"4281000","condg":["Depression","Bipolar"],"nct":"NCT07097025","study":"2-Year Study of Vagus Nerve Stimulation for Higher-Grade Treatment-Resistant Depression: Clinical Outcomes and Policy Recommendation","sstatus":"COMPLETED","sponsor":"Dr.Yoav Domany","src":"https://clinicaltrials.gov/study/NCT07097025","enroll":19,"start":"2020-01-01","eid":"x:site:nct07097025-lev-hasharon-medical-center-netanya"},{"id":"nct06914193-beijing-tiantan-hospital-beijing","cat":"research","name":"Beijing Tiantan Hospital","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.90576,"lon":116.39699,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100070","condg":["Chronic pain & headache"],"nct":"NCT06914193","study":"Esketamine Combined With PRF of DRG for Postherpetic Neuralgia","sstatus":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","src":"https://clinicaltrials.gov/study/NCT06914193","contact":{"n":"Fang Luo","p":"+86 13611326978","e":"13611326978@163.com"},"phase":"N/A","enroll":186,"start":"2025-04-01","eid":"x:site:nct06914193-beijing-tiantan-hospital-beijing"},{"id":"nct02737605-unnamed-trial-site-berlin","cat":"research","name":"Unnamed trial site","city":"Berlin","country":"Germany","cc":"DE","lat":52.53148,"lon":13.39985,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Healthy volunteers"],"nct":"NCT02737605","study":"A Study to Evaluate the Effects of Esketamine on Cardiac Repolarization in Healthy Participants","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02737605","phase":"Phase 1","enroll":62,"start":"2016-07-01","eid":"x:site:nct02737605-unnamed-trial-site-berlin"},{"id":"nct06161805-nederlandse-endometriose-kliniek-reinier-de-graaf-gasthuis-delft","cat":"research","name":"Nederlandse Endometriose Kliniek, Reinier de Graaf Gasthuis","city":"Delft","country":"Netherlands","cc":"NL","lat":52.0102,"lon":4.35382,"gp":"city","unnamed":0,"drugs":["esketamine"],"condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06161805","study":"Esketamine as Treatment for Chronic Pain Due to Endometriosis: a RCT Study","sstatus":"RECRUITING","sponsor":"Reinier de Graaf Groep","src":"https://clinicaltrials.gov/study/NCT06161805","contact":{"n":"Mathijs Blikkendaal, MD, PhD","p":"070 340 1222","e":"M.Blikkendaal@rdgg.nl"},"phase":"Phase 3","enroll":56,"start":"2024-03-01","eid":"x:site:nct06161805-nederlandse-endometriose-kliniek-reinier-de-graaf-gasthuis-delft"},{"id":"nct07146503-ospedale-policlinico-san-martino-genova","cat":"research","name":"Ospedale Policlinico San Martino","city":"Genova","region":"Ge","country":"Italy","cc":"IT","lat":44.39974,"lon":8.9435,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"16132","condg":["Depression","Anxiety"],"status":"RECRUITING","nct":"NCT07146503","study":"Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression","sstatus":"RECRUITING","sponsor":"Riccardo Guglielmo","official":"Elisa Briasco, MD (Unige); Elisa Cavanna, MD (Unige)","src":"https://clinicaltrials.gov/study/NCT07146503","contact":{"n":"Riccardo Guglielmo","p":"+390105552202","e":"riccardo.guglielmo@unige.it"},"enroll":100,"start":"2022-11-01","eid":"x:site:nct07146503-ospedale-policlinico-san-martino-genova"},{"id":"nct07146503-csm-dds-8-genova","cat":"research","name":"Csm Dds 8","city":"Genova","region":"Ge","country":"Italy","cc":"IT","lat":44.39702,"lon":8.95319,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"16158","condg":["Depression","Anxiety"],"status":"RECRUITING","nct":"NCT07146503","study":"Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression","sstatus":"RECRUITING","sponsor":"Riccardo Guglielmo","official":"Elisa Briasco, MD (Unige); Elisa Cavanna, MD (Unige)","src":"https://clinicaltrials.gov/study/NCT07146503","contact":{"n":"Daniela Malagamba, MD","p":"+390108499160","e":"daniela.malagamba@asl3.liguria.it"},"enroll":100,"start":"2022-11-01","eid":"x:site:nct07146503-csm-dds-8-genova"},{"id":"nct07146503-universita-di-chieti-chieti","cat":"research","name":"Università di Chieti","city":"Chieti","country":"Italy","cc":"IT","lat":42.34211,"lon":14.16499,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"66100","condg":["Depression","Anxiety"],"status":"RECRUITING","nct":"NCT07146503","study":"Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression","sstatus":"RECRUITING","sponsor":"Riccardo Guglielmo","official":"Elisa Briasco, MD (Unige); Elisa Cavanna, MD (Unige)","src":"https://clinicaltrials.gov/study/NCT07146503","contact":{"n":"Giovanni Martinotti, Ph.D","p":"+3908713551","e":"giovanni.martinotti@unich.it"},"enroll":100,"start":"2022-11-01","eid":"x:site:nct07146503-universita-di-chieti-chieti"},{"id":"nct07146503-asst-fatebenefratelli-sacco-milan","cat":"research","name":"ASST Fatebenefratelli Sacco","city":"Milan","country":"Italy","cc":"IT","lat":45.45246,"lon":9.19567,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"20157","condg":["Depression","Anxiety"],"status":"RECRUITING","nct":"NCT07146503","study":"Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression","sstatus":"RECRUITING","sponsor":"Riccardo Guglielmo","official":"Elisa Briasco, MD (Unige); Elisa Cavanna, MD (Unige)","src":"https://clinicaltrials.gov/study/NCT07146503","contact":{"n":"Miriam Olivola, Investigator","p":"+390239042904","e":"miriamolivola@icloud.com"},"enroll":100,"start":"2022-11-01","eid":"x:site:nct07146503-asst-fatebenefratelli-sacco-milan"},{"id":"nct07146503-asst-pavia-pavia","cat":"research","name":"ASST Pavia","city":"Pavia","country":"Italy","cc":"IT","lat":45.18683,"lon":9.16016,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"27100","condg":["Depression","Anxiety"],"status":"RECRUITING","nct":"NCT07146503","study":"Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression","sstatus":"RECRUITING","sponsor":"Riccardo Guglielmo","official":"Elisa Briasco, MD (Unige); Elisa Cavanna, MD (Unige)","src":"https://clinicaltrials.gov/study/NCT07146503","contact":{"n":"Miriam Olivola, Investigator","p":"+390239042904","e":"miriamolivola@icloud.com"},"enroll":100,"start":"2022-11-01","eid":"x:site:nct07146503-asst-pavia-pavia"},{"id":"nct06997549-neuronetics-malvern","cat":"research","name":"Neuronetics","city":"Malvern","region":"Pennsylvania","country":"United States","cc":"US","lat":34.36772,"lon":-92.82269,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"19355","condg":["Depression","Anxiety"],"status":"RECRUITING","nct":"NCT06997549","study":"Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments","sstatus":"RECRUITING","sponsor":"Neuronetics","official":"Eleanor Cole, PhD (Neuronetics)","src":"https://clinicaltrials.gov/study/NCT06997549","contact":{"n":"Eleanor Cole","p":"7635281599","e":"neha.goyal@neurostar.com"},"enroll":12000,"start":"2025-05-15","eid":"x:site:nct06997549-neuronetics-malvern"},{"id":"nct05320120-department-of-psychiatry-and-psychotherapy-vienna","cat":"research","name":"Department of Psychiatry and Psychotherapy","city":"Vienna","country":"Austria","cc":"AT","lat":48.20901,"lon":16.37768,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1090","condg":["Other"],"nct":"NCT05320120","study":"Investigation of Intranasal Ketamine Related Changes in Attentional Brain Networks With Functional and Structural MRI","sstatus":"COMPLETED","sponsor":"Rupert Lanzenberger","src":"https://clinicaltrials.gov/study/NCT05320120","phase":"Phase 1","enroll":33,"start":"2022-06-01","eid":"x:site:nct05320120-department-of-psychiatry-and-psychotherapy-vienna"},{"id":"nct06340958-clinical-site-139-la-jolla","cat":"research","name":"Clinical Site 139","city":"La Jolla","region":"California","country":"United States","cc":"US","lat":32.84863,"lon":-117.27914,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"92037","condg":["Depression"],"nct":"NCT06340958","study":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT06340958","phase":"Phase 2","enroll":99,"start":"2024-03-18","eid":"x:site:nct06340958-clinical-site-139-la-jolla"},{"id":"nct06340958-clinical-site-131-lafayette","cat":"research","name":"Clinical Site 131","city":"Lafayette","region":"California","country":"United States","cc":"US","lat":30.22847,"lon":-92.01076,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"94549","condg":["Depression"],"nct":"NCT06340958","study":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT06340958","phase":"Phase 2","enroll":99,"start":"2024-03-18","eid":"x:site:nct06340958-clinical-site-131-lafayette"},{"id":"nct06340958-clinical-site-130-upland","cat":"research","name":"Clinical Site 130","city":"Upland","region":"California","country":"United States","cc":"US","lat":34.09812,"lon":-117.64241,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"91786","condg":["Depression"],"nct":"NCT06340958","study":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT06340958","phase":"Phase 2","enroll":99,"start":"2024-03-18","eid":"x:site:nct06340958-clinical-site-130-upland"},{"id":"nct06340958-clinical-site-102-hollywood","cat":"research","name":"Clinical Site 102","city":"Hollywood","region":"Florida","country":"United States","cc":"US","lat":34.10243,"lon":-118.33083,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"33024","condg":["Depression"],"nct":"NCT06340958","study":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT06340958","phase":"Phase 2","enroll":99,"start":"2024-03-18","eid":"x:site:nct06340958-clinical-site-102-hollywood"},{"id":"nct06340958-clinical-site-105-lauderhill","cat":"research","name":"Clinical Site 105","city":"Lauderhill","region":"Florida","country":"United States","cc":"US","lat":26.14041,"lon":-80.21409,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"33319","condg":["Depression"],"nct":"NCT06340958","study":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT06340958","phase":"Phase 2","enroll":99,"start":"2024-03-18","eid":"x:site:nct06340958-clinical-site-105-lauderhill"},{"id":"nct06340958-clinical-site-140-miami-springs","cat":"research","name":"Clinical Site 140","city":"Miami Springs","region":"Florida","country":"United States","cc":"US","lat":25.81794,"lon":-80.28578,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"33166","condg":["Depression"],"nct":"NCT06340958","study":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT06340958","phase":"Phase 2","enroll":99,"start":"2024-03-18","eid":"x:site:nct06340958-clinical-site-140-miami-springs"},{"id":"nct06340958-clinical-site-132-pensacola","cat":"research","name":"Clinical Site 132","city":"Pensacola","region":"Florida","country":"United States","cc":"US","lat":30.41467,"lon":-87.22467,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"32502","condg":["Depression"],"nct":"NCT06340958","study":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT06340958","phase":"Phase 2","enroll":99,"start":"2024-03-18","eid":"x:site:nct06340958-clinical-site-132-pensacola"},{"id":"nct06340958-clinical-site-118-atlanta","cat":"research","name":"Clinical Site 118","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.73992,"lon":-84.37664,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"30030","condg":["Depression"],"nct":"NCT06340958","study":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT06340958","phase":"Phase 2","enroll":99,"start":"2024-03-18","eid":"x:site:nct06340958-clinical-site-118-atlanta"},{"id":"nct06340958-clinical-site-138-marietta","cat":"research","name":"Clinical Site 138","city":"Marietta","region":"Georgia","country":"United States","cc":"US","lat":33.94615,"lon":-84.54433,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"30060","condg":["Depression"],"nct":"NCT06340958","study":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT06340958","phase":"Phase 2","enroll":99,"start":"2024-03-18","eid":"x:site:nct06340958-clinical-site-138-marietta"},{"id":"nct06340958-clinical-site-114-savannah","cat":"research","name":"Clinical Site 114","city":"Savannah","region":"Georgia","country":"United States","cc":"US","lat":32.07898,"lon":-81.10797,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"31405","condg":["Depression"],"nct":"NCT06340958","study":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT06340958","phase":"Phase 2","enroll":99,"start":"2024-03-18","eid":"x:site:nct06340958-clinical-site-114-savannah"},{"id":"nct06340958-clinical-site-127-chicago","cat":"research","name":"Clinical Site 127","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.84688,"lon":-87.64925,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"60640","condg":["Depression"],"nct":"NCT06340958","study":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT06340958","phase":"Phase 2","enroll":99,"start":"2024-03-18","eid":"x:site:nct06340958-clinical-site-127-chicago"},{"id":"nct06340958-clinical-site-120-elgin","cat":"research","name":"Clinical Site 120","city":"Elgin","region":"Illinois","country":"United States","cc":"US","lat":42.04643,"lon":-88.27832,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"60123","condg":["Depression"],"nct":"NCT06340958","study":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT06340958","phase":"Phase 2","enroll":99,"start":"2024-03-18","eid":"x:site:nct06340958-clinical-site-120-elgin"},{"id":"nct06340958-clinical-site-108-gaithersburg","cat":"research","name":"Clinical Site 108","city":"Gaithersburg","region":"Maryland","country":"United States","cc":"US","lat":39.15224,"lon":-77.21233,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"20877","condg":["Depression"],"nct":"NCT06340958","study":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT06340958","phase":"Phase 2","enroll":99,"start":"2024-03-18","eid":"x:site:nct06340958-clinical-site-108-gaithersburg"},{"id":"nct06340958-clinical-site-116-flowood","cat":"research","name":"Clinical Site 116","city":"Flowood","region":"Mississippi","country":"United States","cc":"US","lat":32.30324,"lon":-90.14345,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"39232","condg":["Depression"],"nct":"NCT06340958","study":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT06340958","phase":"Phase 2","enroll":99,"start":"2024-03-18","eid":"x:site:nct06340958-clinical-site-116-flowood"},{"id":"nct06340958-clinical-site-126-o-fallon","cat":"research","name":"Clinical Site 126","city":"O'Fallon","region":"Missouri","country":"United States","cc":"US","lat":38.81414,"lon":-90.70489,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"63368","condg":["Depression"],"nct":"NCT06340958","study":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT06340958","phase":"Phase 2","enroll":99,"start":"2024-03-18","eid":"x:site:nct06340958-clinical-site-126-o-fallon"},{"id":"nct06340958-clinical-site-101-toms-river","cat":"research","name":"Clinical Site 101","city":"Toms River","region":"New Jersey","country":"United States","cc":"US","lat":39.96253,"lon":-74.20653,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"08755","condg":["Depression"],"nct":"NCT06340958","study":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT06340958","phase":"Phase 2","enroll":99,"start":"2024-03-18","eid":"x:site:nct06340958-clinical-site-101-toms-river"},{"id":"nct06340958-clinical-site-103-beachwood","cat":"research","name":"Clinical Site 103","city":"Beachwood","region":"Ohio","country":"United States","cc":"US","lat":41.46963,"lon":-81.51584,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"44236","condg":["Depression"],"nct":"NCT06340958","study":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT06340958","phase":"Phase 2","enroll":99,"start":"2024-03-18","eid":"x:site:nct06340958-clinical-site-103-beachwood"},{"id":"nct06340958-clinical-site-119-north-canton","cat":"research","name":"Clinical Site 119","city":"North Canton","region":"Ohio","country":"United States","cc":"US","lat":40.88478,"lon":-81.40568,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"44720","condg":["Depression"],"nct":"NCT06340958","study":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT06340958","phase":"Phase 2","enroll":99,"start":"2024-03-18","eid":"x:site:nct06340958-clinical-site-119-north-canton"},{"id":"nct06340958-clinical-site-135-oklahoma-city","cat":"research","name":"Clinical Site 135","city":"Oklahoma City","region":"Oklahoma","country":"United States","cc":"US","lat":35.46187,"lon":-97.51469,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"73112","condg":["Depression"],"nct":"NCT06340958","study":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT06340958","phase":"Phase 2","enroll":99,"start":"2024-03-18","eid":"x:site:nct06340958-clinical-site-135-oklahoma-city"},{"id":"nct06340958-clinical-site-107-austin","cat":"research","name":"Clinical Site 107","city":"Austin","region":"Texas","country":"United States","cc":"US","lat":30.27397,"lon":-97.75346,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"78737","condg":["Depression"],"nct":"NCT06340958","study":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT06340958","phase":"Phase 2","enroll":99,"start":"2024-03-18","eid":"x:site:nct06340958-clinical-site-107-austin"},{"id":"nct06340958-clinical-site-137-plano","cat":"research","name":"Clinical Site 137","city":"Plano","region":"Texas","country":"United States","cc":"US","lat":33.01471,"lon":-96.70835,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"75093","condg":["Depression"],"nct":"NCT06340958","study":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT06340958","phase":"Phase 2","enroll":99,"start":"2024-03-18","eid":"x:site:nct06340958-clinical-site-137-plano"},{"id":"nct06340958-clinical-site-117-murray","cat":"research","name":"Clinical Site 117","city":"Murray","region":"Utah","country":"United States","cc":"US","lat":40.6787,"lon":-111.88455,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"84107","condg":["Depression"],"nct":"NCT06340958","study":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT06340958","phase":"Phase 2","enroll":99,"start":"2024-03-18","eid":"x:site:nct06340958-clinical-site-117-murray"},{"id":"nct06340958-clinical-site-115-bellevue","cat":"research","name":"Clinical Site 115","city":"Bellevue","region":"Washington","country":"United States","cc":"US","lat":47.61344,"lon":-122.18934,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"98007","condg":["Depression"],"nct":"NCT06340958","study":"A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT06340958","phase":"Phase 2","enroll":99,"start":"2024-03-18","eid":"x:site:nct06340958-clinical-site-115-bellevue"},{"id":"nct04282746-sgs-life-science-services-antwerp","cat":"research","name":"SGS Life Science Services","city":"Antwerp","country":"Belgium","cc":"BE","lat":51.22682,"lon":4.39532,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"2060","condg":["Healthy volunteers"],"nct":"NCT04282746","study":"A Study of Sublingually Administered (S)-Ketamine Oral Solution in Healthy Participants","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04282746","phase":"Phase 1","enroll":17,"start":"2020-02-18","eid":"x:site:nct04282746-sgs-life-science-services-antwerp"},{"id":"nct04850937-affiliated-hospital-of-yangzhou-university-yangzhou","cat":"research","name":"Affiliated hospital of yangzhou university","city":"Yangzhou","region":"Jiangsu","country":"China","cc":"CN","lat":32.40498,"lon":119.43908,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"225100","condg":["Depression"],"nct":"NCT04850937","study":"Effect of Low-dose Esketamine on Postoperative Depression in Patients With Breast Cancer","sstatus":"COMPLETED","sponsor":"Yangzhou University","official":"LIU M YU (Yangzhou University)","src":"https://clinicaltrials.gov/study/NCT04850937","phase":"N/A","enroll":90,"start":"2021-02-10","eid":"x:site:nct04850937-affiliated-hospital-of-yangzhou-university-yangzhou"},{"id":"nct03434041-atlanta-center-for-medical-research-atlanta","cat":"research","name":"Atlanta Center for Medical Research","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.73756,"lon":-84.37598,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"30331","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-atlanta-center-for-medical-research-atlanta"},{"id":"nct03434041-biomedical-research-foundation-of-northwest-louisiana-shreveport","cat":"research","name":"Biomedical Research Foundation of Northwest Louisiana","city":"Shreveport","region":"Louisiana","country":"United States","cc":"US","lat":32.51635,"lon":-93.7427,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"71104-2136","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-biomedical-research-foundation-of-northwest-louisiana-shreveport"},{"id":"nct03434041-cbh-health-gaithersburg","cat":"research","name":"CBH Health","city":"Gaithersburg","region":"Maryland","country":"United States","cc":"US","lat":39.15111,"lon":-77.20556,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"20877","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-cbh-health-gaithersburg"},{"id":"nct03434041-adams-clinical-watertown","cat":"research","name":"Adams Clinical","city":"Watertown","region":"Massachusetts","country":"United States","cc":"US","lat":42.37455,"lon":-71.17281,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"02472","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-adams-clinical-watertown"},{"id":"nct03434041-the-medical-research-network-llc-new-york","cat":"research","name":"The Medical Research Network, LLC","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.7066,"lon":-74.01289,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"10128","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-the-medical-research-network-llc-new-york"},{"id":"nct03434041-ips-research-company-oklahoma-city","cat":"research","name":"IPS Research Company","city":"Oklahoma City","region":"Oklahoma","country":"United States","cc":"US","lat":35.47438,"lon":-97.50594,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"73106","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-ips-research-company-oklahoma-city"},{"id":"nct03434041-beijing-anding-hospital-of-capital-medical-university-beijing","cat":"research","name":"Beijing Anding Hospital of Capital Medical University","city":"Beijing","country":"China","cc":"CN","lat":39.91046,"lon":116.39718,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100088","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-beijing-anding-hospital-of-capital-medical-university-beijing"},{"id":"nct03434041-beijing-huilong-guan-hospital-beijing","cat":"research","name":"Beijing HuiLong Guan Hospital","city":"Beijing","country":"China","cc":"CN","lat":39.91319,"lon":116.39587,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100096","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-beijing-huilong-guan-hospital-beijing"},{"id":"nct03434041-peking-university-sixth-hospital-beijing","cat":"research","name":"Peking University Sixth Hospital","city":"Beijing","country":"China","cc":"CN","lat":39.89654,"lon":116.39191,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100191","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-peking-university-sixth-hospital-beijing"},{"id":"nct03434041-the-second-people-s-hospital-of-hunan-province-brian-hospital-of-hun","cat":"research","name":"The Second People's Hospital of Hunan Province / Brian Hospital of Hunan Province","city":"Changsha","country":"China","cc":"CN","lat":28.21036,"lon":112.97026,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"410007","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-the-second-people-s-hospital-of-hunan-province-brian-hospital-of-hun"},{"id":"nct03434041-the-second-xiangya-hospital-of-central-south-university-changsha","cat":"research","name":"The second Xiangya Hospital of Central South University","city":"Changsha","country":"China","cc":"CN","lat":28.19643,"lon":112.97798,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"410011","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-the-second-xiangya-hospital-of-central-south-university-changsha"},{"id":"nct03434041-west-china-hospital-sichuan-university-chengdu","cat":"research","name":"West China Hospital Sichuan University","city":"Chengdu","country":"China","cc":"CN","lat":30.65655,"lon":104.06879,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"610041","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-west-china-hospital-sichuan-university-chengdu"},{"id":"nct03434041-chongqing-mental-health-center-chongqing","cat":"research","name":"Chongqing Mental Health Center","city":"Chongqing","country":"China","cc":"CN","lat":29.56577,"lon":106.55766,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"401147","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-chongqing-mental-health-center-chongqing"},{"id":"nct03434041-the-3rd-affiliated-hospital-sun-yansen-university-guangzhou","cat":"research","name":"the 3rd Affiliated Hospital,Sun Yansen University","city":"Guangzhou","country":"China","cc":"CN","lat":23.11098,"lon":113.24581,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"510000","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-the-3rd-affiliated-hospital-sun-yansen-university-guangzhou"},{"id":"nct03434041-guangdong-provincial-people-s-hospital-guangzhou","cat":"research","name":"Guangdong Provincial People's Hospital","city":"Guangzhou","country":"China","cc":"CN","lat":23.11531,"lon":113.24092,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"510100","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-guangdong-provincial-people-s-hospital-guangzhou"},{"id":"nct03434041-hangzhou-seventh-people-s-hospital-hangzhou","cat":"research","name":"Hangzhou Seventh People's Hospital","city":"Hangzhou","country":"China","cc":"CN","lat":30.30527,"lon":120.15544,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"310000","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-hangzhou-seventh-people-s-hospital-hangzhou"},{"id":"nct03434041-first-hospital-zhejiang-university-medical-college-hangzhou","cat":"research","name":"First Hospital, Zhejiang University Medical College","city":"Hangzhou","country":"China","cc":"CN","lat":30.2921,"lon":120.15328,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"310003","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-first-hospital-zhejiang-university-medical-college-hangzhou"},{"id":"nct03434041-the-second-affiliated-hospital-of-zhejiang-university-hangzhou","cat":"research","name":"The Second Affiliated Hospital of Zhejiang University","city":"Hangzhou","country":"China","cc":"CN","lat":30.28297,"lon":120.17229,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"310009","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-the-second-affiliated-hospital-of-zhejiang-university-hangzhou"},{"id":"nct03434041-huzhou-third-people-s-hospital-huzhou","cat":"research","name":"Huzhou third people's Hospital","city":"Huzhou","country":"China","cc":"CN","lat":30.86583,"lon":120.09071,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"313000","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-huzhou-third-people-s-hospital-huzhou"},{"id":"nct03434041-first-affiliated-hospital-of-kunming-medical-unversity-kunming","cat":"research","name":"First Affiliated Hospital of Kunming Medical Unversity","city":"Kunming","country":"China","cc":"CN","lat":25.04863,"lon":102.71348,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"650032","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-first-affiliated-hospital-of-kunming-medical-unversity-kunming"},{"id":"nct03434041-nanjing-brain-hospital-affilicated-to-nanjing-medical-university-nan","cat":"research","name":"Nanjing Brain Hospital Affilicated to Nanjing Medical University","city":"Nanjing","country":"China","cc":"CN","lat":32.07056,"lon":118.77576,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"210000","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-nanjing-brain-hospital-affilicated-to-nanjing-medical-university-nan"},{"id":"nct03434041-the-first-hospital-of-hebei-medical-university-shijiazhuang","cat":"research","name":"The First Hospital of Hebei Medical University","city":"Shijiazhuang","country":"China","cc":"CN","lat":38.04633,"lon":114.4891,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"050031","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-the-first-hospital-of-hebei-medical-university-shijiazhuang"},{"id":"nct03434041-tianjin-anding-hospital-tianjin","cat":"research","name":"Tianjin Anding Hospital","city":"Tianjin","country":"China","cc":"CN","lat":39.13907,"lon":117.17361,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"300222","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-tianjin-anding-hospital-tianjin"},{"id":"nct03434041-urumqi-fourth-hospital-urumqi","cat":"research","name":"Urumqi fourth Hospital","city":"Ürümqi","country":"China","cc":"CN","lat":43.79432,"lon":87.6022,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"830000","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-urumqi-fourth-hospital-urumqi"},{"id":"nct03434041-the-first-affiliated-hospital-of-xinjiang-medical-university-urumqi","cat":"research","name":"The first affiliated hospital of Xinjiang medical university","city":"Ürümqi","country":"China","cc":"CN","lat":43.80844,"lon":87.61218,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"830054","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-the-first-affiliated-hospital-of-xinjiang-medical-university-urumqi"},{"id":"nct03434041-renmin-hospital-of-wuhan-university-wuhan","cat":"research","name":"Renmin Hospital of Wuhan University","city":"Wuhan","country":"China","cc":"CN","lat":30.57792,"lon":114.27161,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"430060","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-renmin-hospital-of-wuhan-university-wuhan"},{"id":"nct03434041-the-first-affiliated-hospital-of-xian-jiaotong-university-xi-an","cat":"research","name":"The First Affiliated Hospital of Xian Jiaotong University","city":"Xi'an","country":"China","cc":"CN","lat":34.26054,"lon":108.93148,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"710061","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-the-first-affiliated-hospital-of-xian-jiaotong-university-xi-an"},{"id":"nct03434041-xi-an-mental-health-center-xi-an","cat":"research","name":"Xi'an Mental Health Center","city":"Xi'an","country":"China","cc":"CN","lat":34.25791,"lon":108.93412,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"710061","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-xi-an-mental-health-center-xi-an"},{"id":"nct03434041-xiamen-xianyue-hospital-xiamen","cat":"research","name":"Xiamen Xianyue Hospital","city":"Xiamen","country":"China","cc":"CN","lat":24.47485,"lon":118.08032,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"361012","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-xiamen-xianyue-hospital-xiamen"},{"id":"nct03434041-the-first-affiliated-hospital-of-zhengzhou-university-zhengzhou","cat":"research","name":"The First Affiliated Hospital of Zhengzhou University","city":"Zhengzhou","country":"China","cc":"CN","lat":34.76216,"lon":113.6592,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"450052","condg":["Depression"],"nct":"NCT03434041","study":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03434041","phase":"Phase 3","enroll":252,"start":"2018-05-25","eid":"x:site:nct03434041-the-first-affiliated-hospital-of-zhengzhou-university-zhengzhou"},{"id":"nct07410702-department-of-anaesthesiology-tongji-hospital-of-tongji-medical-coll","cat":"research","name":"Department of Anaesthesiology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology","city":"Wuhan","region":"Hubei","country":"China","cc":"CN","lat":30.59326,"lon":114.27829,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"430030","condg":["Other"],"status":"RECRUITING","nct":"NCT07410702","study":"Correlating EEG Dynamics With Consciousness Alteration Under Anesthesia","sstatus":"RECRUITING","sponsor":"Huazhong University of Science and Technology","official":"Pu Zhou, PhD. (Huazhong University of Science and Technology)","src":"https://clinicaltrials.gov/study/NCT07410702","contact":{"n":"Hua Zheng, Dr.","p":"0086-27-83663173","e":"hzheng@hust.edu.cn"},"enroll":250,"start":"2026-02-10","eid":"x:site:nct07410702-department-of-anaesthesiology-tongji-hospital-of-tongji-medical-coll"},{"id":"nct03407872-bioresearch-group-sp-z-o-o-kajetany","cat":"research","name":"BioResearch Group Sp. z o.o.","city":"Kajetany","country":"Poland","cc":"PL","lat":51.8043,"lon":20.5392,"gp":"country","unnamed":0,"drugs":["esketamine"],"condg":["Healthy volunteers"],"nct":"NCT03407872","study":"Safety and Pharmacokinetic Study of Inhaled Esketamine in Healthy Volunteers","sstatus":"COMPLETED","sponsor":"Celon Pharma SA","src":"https://clinicaltrials.gov/study/NCT03407872","phase":"Phase 1","enroll":63,"start":"2017-12-09","eid":"x:site:nct03407872-bioresearch-group-sp-z-o-o-kajetany"},{"id":"nct03965871-wojewodzki-szpital-im-jana-paw-a-ii-be-chatow","cat":"research","name":"Wojewodzki Szpital im. Jana Pawła II","city":"Bełchatów","country":"Poland","cc":"PL","lat":51.35796,"lon":19.36589,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"97-400","condg":["Depression","Bipolar"],"nct":"NCT03965871","study":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression","sstatus":"COMPLETED","sponsor":"Celon Pharma SA","src":"https://clinicaltrials.gov/study/NCT03965871","phase":"Phase 2","enroll":88,"start":"2019-03-28","eid":"x:site:nct03965871-wojewodzki-szpital-im-jana-paw-a-ii-be-chatow"},{"id":"nct03965871-wojewodzki-szpital-dla-nerwowo-i-psychicznie-chorych-boles-awiec","cat":"research","name":"Wojewodzki Szpital dla Nerwowo i Psychicznie Chorych","city":"Bolesławiec","country":"Poland","cc":"PL","lat":51.26667,"lon":15.56099,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"59-700","condg":["Depression","Bipolar"],"nct":"NCT03965871","study":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression","sstatus":"COMPLETED","sponsor":"Celon Pharma SA","src":"https://clinicaltrials.gov/study/NCT03965871","phase":"Phase 2","enroll":88,"start":"2019-03-28","eid":"x:site:nct03965871-wojewodzki-szpital-dla-nerwowo-i-psychicznie-chorych-boles-awiec"},{"id":"nct03965871-samodzielny-publiczny-psychiatryczny-zaklad-opieki-zdrowotnej-choros","cat":"research","name":"Samodzielny Publiczny Psychiatryczny Zaklad Opieki Zdrowotnej","city":"Choroszcz","country":"Poland","cc":"PL","lat":53.14026,"lon":22.98687,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"16-070","condg":["Depression","Bipolar"],"nct":"NCT03965871","study":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression","sstatus":"COMPLETED","sponsor":"Celon Pharma SA","src":"https://clinicaltrials.gov/study/NCT03965871","phase":"Phase 2","enroll":88,"start":"2019-03-28","eid":"x:site:nct03965871-samodzielny-publiczny-psychiatryczny-zaklad-opieki-zdrowotnej-choros"},{"id":"nct03965871-szpital-miejski-elblag","cat":"research","name":"Szpital Miejski","city":"Elblag","country":"Poland","cc":"PL","lat":54.14688,"lon":19.40766,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"82-300","condg":["Depression","Bipolar"],"nct":"NCT03965871","study":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression","sstatus":"COMPLETED","sponsor":"Celon Pharma SA","src":"https://clinicaltrials.gov/study/NCT03965871","phase":"Phase 2","enroll":88,"start":"2019-03-28","eid":"x:site:nct03965871-szpital-miejski-elblag"},{"id":"nct03965871-uniwersyteckie-centrum-kliniczne-gdansk","cat":"research","name":"Uniwersyteckie Centrum Kliniczne","city":"Gdansk","country":"Poland","cc":"PL","lat":54.35279,"lon":18.64531,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"80-952","condg":["Depression","Bipolar"],"nct":"NCT03965871","study":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression","sstatus":"COMPLETED","sponsor":"Celon Pharma SA","src":"https://clinicaltrials.gov/study/NCT03965871","phase":"Phase 2","enroll":88,"start":"2019-03-28","eid":"x:site:nct03965871-uniwersyteckie-centrum-kliniczne-gdansk"},{"id":"nct03965871-wojewodzki-szpital-dla-nerwowo-i-psychicznie-chorych-gmina-swiecie","cat":"research","name":"Wojewodzki Szpital dla Nerwowo i Psychicznie Chorych","city":"Gmina Świecie","country":"Poland","cc":"PL","lat":53.40449,"lon":18.43551,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"86-100","condg":["Depression","Bipolar"],"nct":"NCT03965871","study":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression","sstatus":"COMPLETED","sponsor":"Celon Pharma SA","src":"https://clinicaltrials.gov/study/NCT03965871","phase":"Phase 2","enroll":88,"start":"2019-03-28","eid":"x:site:nct03965871-wojewodzki-szpital-dla-nerwowo-i-psychicznie-chorych-gmina-swiecie"},{"id":"nct03965871-gornoslaskie-centrum-medyczne-katowice","cat":"research","name":"Gornoslaskie Centrum Medyczne","city":"Katowice","country":"Poland","cc":"PL","lat":50.24939,"lon":19.02149,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"40-635","condg":["Depression","Bipolar"],"nct":"NCT03965871","study":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression","sstatus":"COMPLETED","sponsor":"Celon Pharma SA","src":"https://clinicaltrials.gov/study/NCT03965871","phase":"Phase 2","enroll":88,"start":"2019-03-28","eid":"x:site:nct03965871-gornoslaskie-centrum-medyczne-katowice"},{"id":"nct03965871-specjalistyczny-psychiatryczny-zespol-opieki-zdrowotnej-lodz","cat":"research","name":"Specjalistyczny Psychiatryczny Zespol Opieki Zdrowotnej","city":"Lodz","country":"Poland","cc":"PL","lat":51.78042,"lon":19.47466,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"91-229","condg":["Depression","Bipolar"],"nct":"NCT03965871","study":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression","sstatus":"COMPLETED","sponsor":"Celon Pharma SA","src":"https://clinicaltrials.gov/study/NCT03965871","phase":"Phase 2","enroll":88,"start":"2019-03-28","eid":"x:site:nct03965871-specjalistyczny-psychiatryczny-zespol-opieki-zdrowotnej-lodz"},{"id":"nct03965871-pabianickie-centrum-medyczne-pabianice","cat":"research","name":"Pabianickie Centrum Medyczne","city":"Pabianice","country":"Poland","cc":"PL","lat":51.65585,"lon":19.34602,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"95-200","condg":["Depression","Bipolar"],"nct":"NCT03965871","study":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression","sstatus":"COMPLETED","sponsor":"Celon Pharma SA","src":"https://clinicaltrials.gov/study/NCT03965871","phase":"Phase 2","enroll":88,"start":"2019-03-28","eid":"x:site:nct03965871-pabianickie-centrum-medyczne-pabianice"},{"id":"nct03965871-mazowieckie-specjalistyczne-centrum-zdrowia-pruszkow","cat":"research","name":"Mazowieckie Specjalistyczne Centrum Zdrowia","city":"Pruszków","country":"Poland","cc":"PL","lat":52.17783,"lon":20.80456,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"05-802","condg":["Depression","Bipolar"],"nct":"NCT03965871","study":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression","sstatus":"COMPLETED","sponsor":"Celon Pharma SA","src":"https://clinicaltrials.gov/study/NCT03965871","phase":"Phase 2","enroll":88,"start":"2019-03-28","eid":"x:site:nct03965871-mazowieckie-specjalistyczne-centrum-zdrowia-pruszkow"},{"id":"nct03965871-mazowiecki-szpital-i-centrum-diagnostyczne-allenort-warsaw","cat":"research","name":"Mazowiecki Szpital i Centrum Diagnostyczne Allenort","city":"Warsaw","country":"Poland","cc":"PL","lat":52.22916,"lon":21.01286,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"03-185","condg":["Depression","Bipolar"],"nct":"NCT03965871","study":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression","sstatus":"COMPLETED","sponsor":"Celon Pharma SA","src":"https://clinicaltrials.gov/study/NCT03965871","phase":"Phase 2","enroll":88,"start":"2019-03-28","eid":"x:site:nct03965871-mazowiecki-szpital-i-centrum-diagnostyczne-allenort-warsaw"},{"id":"nct03965871-uniwersytecki-szpital-kliniczny-wroclaw","cat":"research","name":"Uniwersytecki Szpital Kliniczny","city":"Wroclaw","country":"Poland","cc":"PL","lat":51.09575,"lon":17.02578,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"50-556","condg":["Depression","Bipolar"],"nct":"NCT03965871","study":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression","sstatus":"COMPLETED","sponsor":"Celon Pharma SA","src":"https://clinicaltrials.gov/study/NCT03965871","phase":"Phase 2","enroll":88,"start":"2019-03-28","eid":"x:site:nct03965871-uniwersytecki-szpital-kliniczny-wroclaw"},{"id":"nct06914180-beijing-tiantan-hospital-beijing","cat":"research","name":"Beijing Tiantan Hospital","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.91621,"lon":116.38975,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100070","condg":["Chronic pain & headache"],"nct":"NCT06914180","study":"Esketamine Combined With PRF for Trigeminal Postherpetic Neuralgia","sstatus":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","src":"https://clinicaltrials.gov/study/NCT06914180","contact":{"n":"Fang Luo, M.D.","p":"+86 13611326978","e":"13611326978@163.com"},"phase":"N/A","enroll":174,"start":"2025-04-01","eid":"x:site:nct06914180-beijing-tiantan-hospital-beijing"},{"id":"nct06896994-beijing-tiantan-hospital-beijing","cat":"research","name":"Beijing Tiantan Hospital","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.90557,"lon":116.40829,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100070","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06896994","study":"Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia","sstatus":"RECRUITING","sponsor":"Beijing Tiantan Hospital","official":"Fang Luo, M.D. (Beijing Tiantan Hospital)","src":"https://clinicaltrials.gov/study/NCT06896994","contact":{"n":"Fang Luo, M.D.","p":"+86 13611326978","e":"13611326978@163.com"},"phase":"N/A","enroll":150,"start":"2025-04-01","eid":"x:site:nct06896994-beijing-tiantan-hospital-beijing"},{"id":"nct01246765-massachusetts-general-hospital-boston","cat":"research","name":"Massachusetts General Hospital","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.34888,"lon":-71.06857,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"02114","condg":["Other"],"status":"RECRUITING","nct":"NCT01246765","study":"National Pregnancy Registry for Psychiatric Medications","sstatus":"RECRUITING","sponsor":"Massachusetts General Hospital","official":"Lee S Cohen, MD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT01246765","contact":{"n":"Bryn Rediger, BA","p":"(617) 724-8020","e":"admin@womensmentalhealth.org"},"enroll":5000,"start":"2008-11","eid":"x:site:nct01246765-massachusetts-general-hospital-boston"},{"id":"nct06398834-the-second-people-s-hospital-of-hefei-hefei","cat":"research","name":"The Second People's Hospital of Hefei","city":"Hefei","region":"Anhui","country":"China","cc":"CN","lat":31.86921,"lon":117.27034,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"230011","condg":["Chronic pain & headache"],"nct":"NCT06398834","study":"Esketamine and Butorphanol for Post-Lobectomy Pain","sstatus":"COMPLETED","sponsor":"Second People's Hospital of Hefei City","official":"Xianwen Hu, PhD (The Second Hospital of Anhui Medical University); Wensheng He, MD (The Second People's Hospital of Hefei)","src":"https://clinicaltrials.gov/study/NCT06398834","phase":"Phase 4","enroll":223,"start":"2022-03-01","eid":"x:site:nct06398834-the-second-people-s-hospital-of-hefei-hefei"},{"id":"nct02568176-unnamed-trial-site-merksem","cat":"research","name":"Unnamed trial site","city":"Merksem","country":"Belgium","cc":"BE","lat":51.24374,"lon":4.44098,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Healthy volunteers"],"nct":"NCT02568176","study":"Pharmacokinetic Study of Intranasal Esketamine and Its Effects on the Pharmacokinetics of Orally-Administered Midazolam and Bupropion in Healthy Participants","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02568176","phase":"Phase 1","enroll":71,"start":"2015-10","eid":"x:site:nct02568176-unnamed-trial-site-merksem"},{"id":"nct02674295-unnamed-trial-site-madison","cat":"research","name":"Unnamed trial site","city":"Madison","region":"Wisconsin","country":"United States","cc":"US","lat":43.07724,"lon":-89.41191,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Healthy volunteers"],"nct":"NCT02674295","study":"A Mass Balance Study With a Microtracer Dose of 14C-esketamine in Healthy Male Participants","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02674295","phase":"Phase 1","enroll":8,"start":"2016-03","eid":"x:site:nct02674295-unnamed-trial-site-madison"},{"id":"nct07377981-the-first-affiliated-hospital-with-nanjing-medical-university-nanjin","cat":"research","name":"The First Affiliated Hospital with Nanjing Medical University","city":"Nanjing","region":"Jiangsu","country":"China","cc":"CN","lat":32.05918,"lon":118.77491,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"210000","condg":["Other"],"nct":"NCT07377981","study":"Safety and Efficacy of Esketamine - Dexmedetomidine Combination Versus Dexmedetomidine Monotherapy for Hyperactive Delirium in ICU Patients on Non-Invasive Respiratory Support (SEED-NIRS Trial):…","sstatus":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","src":"https://clinicaltrials.gov/study/NCT07377981","contact":{"n":"Xiangrong Zuo","p":"+86 13913979197","e":"zuoxiangrong@njmu.edu.cn"},"phase":"Phase 4","enroll":356,"start":"2026-09-28","eid":"x:site:nct07377981-the-first-affiliated-hospital-with-nanjing-medical-university-nanjin"},{"id":"nct06713616-mood-institute-milford","cat":"research","name":"Mood Institute","city":"Milford","region":"Connecticut","country":"United States","cc":"US","lat":41.22877,"lon":-73.06577,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"06461","condg":["Depression"],"status":"RECRUITING","nct":"NCT06713616","study":"PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study","sstatus":"RECRUITING","sponsor":"Yale University","official":"Samuel Wilkinson, MD (Samuel.Wilkinson@yale.edu)","src":"https://clinicaltrials.gov/study/NCT06713616","contact":{"n":"Lisa Harding, MD","p":"203-701-9737","e":"Trials@DepressionMD.com"},"phase":"Phase 3","enroll":400,"start":"2025-01-27","eid":"x:site:nct06713616-mood-institute-milford"},{"id":"nct06713616-yale-school-of-medicine-new-haven","cat":"research","name":"Yale School of Medicine","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.30773,"lon":-72.91616,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"06512","condg":["Depression"],"status":"RECRUITING","nct":"NCT06713616","study":"PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study","sstatus":"RECRUITING","sponsor":"Yale University","official":"Samuel Wilkinson, MD (Samuel.Wilkinson@yale.edu)","src":"https://clinicaltrials.gov/study/NCT06713616","contact":{"n":"Samuel Wilkinson, MD","p":"203-764-9131","e":"Samuel.Wilkinson@yale.edu"},"phase":"Phase 3","enroll":400,"start":"2025-01-27","eid":"x:site:nct06713616-yale-school-of-medicine-new-haven"},{"id":"nct06713616-emory-university-atlanta","cat":"research","name":"Emory University","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.75356,"lon":-84.38426,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"30322","condg":["Depression"],"status":"RECRUITING","nct":"NCT06713616","study":"PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study","sstatus":"RECRUITING","sponsor":"Yale University","official":"Samuel Wilkinson, MD (Samuel.Wilkinson@yale.edu)","src":"https://clinicaltrials.gov/study/NCT06713616","contact":{"n":"Brandon Kitay, MD","p":"404-712-6939","e":"Cynthia.Voghell@yale.edu"},"phase":"Phase 3","enroll":400,"start":"2025-01-27","eid":"x:site:nct06713616-emory-university-atlanta"},{"id":"nct06713616-university-of-michigan-ann-arbor","cat":"research","name":"University of Michigan","city":"Ann Arbor","region":"Michigan","country":"United States","cc":"US","lat":42.28071,"lon":-83.73773,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"48104","condg":["Depression"],"status":"ACTIVE_NOT_RECRUITING","nct":"NCT06713616","study":"PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study","sstatus":"RECRUITING","sponsor":"Yale University","official":"Samuel Wilkinson, MD (Samuel.Wilkinson@yale.edu)","src":"https://clinicaltrials.gov/study/NCT06713616","contact":{"n":"Cindy Voghell","p":"203-737-4784","e":"Cynthia.Voghell@yale.edu"},"phase":"Phase 3","enroll":400,"start":"2025-01-27","eid":"x:site:nct06713616-university-of-michigan-ann-arbor"},{"id":"nct06713616-lifestance-health-moore","cat":"research","name":"LifeStance Health","city":"Moore","region":"Oklahoma","country":"United States","cc":"US","lat":35.32939,"lon":-97.4859,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"73160","condg":["Depression"],"status":"ACTIVE_NOT_RECRUITING","nct":"NCT06713616","study":"PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study","sstatus":"RECRUITING","sponsor":"Yale University","official":"Samuel Wilkinson, MD (Samuel.Wilkinson@yale.edu)","src":"https://clinicaltrials.gov/study/NCT06713616","contact":{"n":"Cindy Voghell","p":"203-737-4784","e":"Cynthia.Voghell@yale.edu"},"phase":"Phase 3","enroll":400,"start":"2025-01-27","eid":"x:site:nct06713616-lifestance-health-moore"},{"id":"nct06713616-athena-care-nashville","cat":"research","name":"Athena Care","city":"Nashville","region":"Tennessee","country":"United States","cc":"US","lat":36.16791,"lon":-86.77442,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"37228","condg":["Depression"],"status":"RECRUITING","nct":"NCT06713616","study":"PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study","sstatus":"RECRUITING","sponsor":"Yale University","official":"Samuel Wilkinson, MD (Samuel.Wilkinson@yale.edu)","src":"https://clinicaltrials.gov/study/NCT06713616","contact":{"n":"Amanda Sparks-Bushnell, MD","p":"615-861-1000","e":"interventional@athenacare.health"},"phase":"Phase 3","enroll":400,"start":"2025-01-27","eid":"x:site:nct06713616-athena-care-nashville"},{"id":"nct06713616-houston-center-for-advanced-psychiatric-treatment-bellaire","cat":"research","name":"Houston Center for Advanced Psychiatric Treatment","city":"Bellaire","region":"Texas","country":"United States","cc":"US","lat":29.70292,"lon":-95.45436,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"77401","condg":["Depression"],"status":"RECRUITING","nct":"NCT06713616","study":"PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study","sstatus":"RECRUITING","sponsor":"Yale University","official":"Samuel Wilkinson, MD (Samuel.Wilkinson@yale.edu)","src":"https://clinicaltrials.gov/study/NCT06713616","contact":{"n":"Sandhya Prashad, MD","p":"203-737-4784","e":"Cynthia.Voghell@yale.edu"},"phase":"Phase 3","enroll":400,"start":"2025-01-27","eid":"x:site:nct06713616-houston-center-for-advanced-psychiatric-treatment-bellaire"},{"id":"nct06713616-seattle-ntc-seattle","cat":"research","name":"Seattle NTC","city":"Seattle","region":"Washington","country":"United States","cc":"US","lat":47.59948,"lon":-122.32496,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"98104","condg":["Depression"],"status":"RECRUITING","nct":"NCT06713616","study":"PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study","sstatus":"RECRUITING","sponsor":"Yale University","official":"Samuel Wilkinson, MD (Samuel.Wilkinson@yale.edu)","src":"https://clinicaltrials.gov/study/NCT06713616","contact":{"n":"Rebecca Allen, MD","p":"206-467-6300","e":"Rebecca.Allen@seattlentc.com"},"phase":"Phase 3","enroll":400,"start":"2025-01-27","eid":"x:site:nct06713616-seattle-ntc-seattle"},{"id":"nct05887310-fondazione-irccs-san-gerardo-di-monza-monza","cat":"research","name":"Fondazione IRCCS San Gerardo di Monza","city":"Monza","region":"Monza E Brianza","country":"Italy","cc":"IT","lat":45.59149,"lon":9.27401,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"20900","condg":["Depression"],"nct":"NCT05887310","study":"In Vitro Modeling of Drug-resistant Psychiatric Disorders Using Induced Pluripotent Cells","sstatus":"UNKNOWN","sponsor":"University of Milano Bicocca","src":"https://clinicaltrials.gov/study/NCT05887310","enroll":50,"start":"2022-08-05","eid":"x:site:nct05887310-fondazione-irccs-san-gerardo-di-monza-monza"},{"id":"nct02682225-unnamed-trial-site-salt-lake-city","cat":"research","name":"Unnamed trial site","city":"Salt Lake City","region":"Utah","country":"United States","cc":"US","lat":40.76647,"lon":-111.88009,"gp":"city","unnamed":1,"drugs":["esketamine","ketamine"],"condg":["Other"],"nct":"NCT02682225","study":"Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02682225","phase":"Phase 1","enroll":55,"start":"2016-03-25","eid":"x:site:nct02682225-unnamed-trial-site-salt-lake-city"},{"id":"nct06355180-wuhu-fourth-people-s-hospital-wuhu","cat":"research","name":"Wuhu Fourth People's Hospital","city":"Wuhu","region":"Anhui","country":"China","cc":"CN","lat":31.35207,"lon":118.43516,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"241002","condg":["Depression"],"nct":"NCT06355180","study":"Esketamine vs ECT for Acute Suicidality","sstatus":"COMPLETED","sponsor":"Capital Medical University","official":"Gang Wang, MD (Beijing Anding Hospital, Capital Medical University)","src":"https://clinicaltrials.gov/study/NCT06355180","phase":"N/A","enroll":340,"start":"2024-04-16","eid":"x:site:nct06355180-wuhu-fourth-people-s-hospital-wuhu"},{"id":"nct06355180-beijing-anding-hospital-beijing","cat":"research","name":"Beijing Anding Hospital","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.90275,"lon":116.40255,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100088","condg":["Depression"],"nct":"NCT06355180","study":"Esketamine vs ECT for Acute Suicidality","sstatus":"COMPLETED","sponsor":"Capital Medical University","official":"Gang Wang, MD (Beijing Anding Hospital, Capital Medical University)","src":"https://clinicaltrials.gov/study/NCT06355180","phase":"N/A","enroll":340,"start":"2024-04-16","eid":"x:site:nct06355180-beijing-anding-hospital-beijing"},{"id":"nct06355180-beijing-chaoyang-district-third-hospital-beijing","cat":"research","name":"Beijing Chaoyang District Third Hospital","city":"Beijing","country":"China","cc":"CN","lat":39.91225,"lon":116.40819,"gp":"city","unnamed":0,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT06355180","study":"Esketamine vs ECT for Acute Suicidality","sstatus":"COMPLETED","sponsor":"Capital Medical University","official":"Gang Wang, MD (Beijing Anding Hospital, Capital Medical University)","src":"https://clinicaltrials.gov/study/NCT06355180","phase":"N/A","enroll":340,"start":"2024-04-16","eid":"x:site:nct06355180-beijing-chaoyang-district-third-hospital-beijing"},{"id":"nct06355180-beijing-daxing-district-xinkang-hospital-beijing","cat":"research","name":"Beijing Daxing District Xinkang Hospital","city":"Beijing","country":"China","cc":"CN","lat":39.90698,"lon":116.39878,"gp":"city","unnamed":0,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT06355180","study":"Esketamine vs ECT for Acute Suicidality","sstatus":"COMPLETED","sponsor":"Capital Medical University","official":"Gang Wang, MD (Beijing Anding Hospital, Capital Medical University)","src":"https://clinicaltrials.gov/study/NCT06355180","phase":"N/A","enroll":340,"start":"2024-04-16","eid":"x:site:nct06355180-beijing-daxing-district-xinkang-hospital-beijing"},{"id":"nct06355180-the-second-people-s-hospital-of-dali-bai-autonomous-prefecture-dali","cat":"research","name":"The Second People's Hospital of Dali Bai Autonomous Prefecture","city":"Dali","country":"China","cc":"CN","lat":25.5766,"lon":100.20274,"gp":"city","unnamed":0,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT06355180","study":"Esketamine vs ECT for Acute Suicidality","sstatus":"COMPLETED","sponsor":"Capital Medical University","official":"Gang Wang, MD (Beijing Anding Hospital, Capital Medical University)","src":"https://clinicaltrials.gov/study/NCT06355180","phase":"N/A","enroll":340,"start":"2024-04-16","eid":"x:site:nct06355180-the-second-people-s-hospital-of-dali-bai-autonomous-prefecture-dali"},{"id":"nct06355180-inner-mongolia-autonomous-region-mental-health-center-hohhot","cat":"research","name":"Inner Mongolia Autonomous Region Mental Health Center","city":"Hohhot","country":"China","cc":"CN","lat":40.79894,"lon":111.6469,"gp":"city","unnamed":0,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT06355180","study":"Esketamine vs ECT for Acute Suicidality","sstatus":"COMPLETED","sponsor":"Capital Medical University","official":"Gang Wang, MD (Beijing Anding Hospital, Capital Medical University)","src":"https://clinicaltrials.gov/study/NCT06355180","phase":"N/A","enroll":340,"start":"2024-04-16","eid":"x:site:nct06355180-inner-mongolia-autonomous-region-mental-health-center-hohhot"},{"id":"nct05416073-the-second-affiliated-hospital-chongqing-medical-university-chongqin","cat":"research","name":"The Second Affiliated Hospital, Chongqing Medical University","city":"Chongqing","region":"Chongqing Municipality","country":"China","cc":"CN","lat":29.56501,"lon":106.56115,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"400010","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT05416073","study":"Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma","sstatus":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","official":"Huang He, MD (The Second Affiliated Hospital, Chongqing Medical University); Huang yan, MD (The Second Affiliated Hospital, Chongqing Medical University)","src":"https://clinicaltrials.gov/study/NCT05416073","contact":{"n":"Guangyou Duan, MD","p":"(+86)18323376014","e":"duangy@hospital.cqmu.edu.cn"},"phase":"Phase 4","enroll":70,"start":"2022-06-22","eid":"x:site:nct05416073-the-second-affiliated-hospital-chongqing-medical-university-chongqin"},{"id":"nct05586126-jeroen-bosch-ziekenhuis-s-hertogenbosch","cat":"research","name":"Jeroen Bosch Ziekenhuis","city":"'s-Hertogenbosch","region":"North Brabant","country":"Netherlands","cc":"NL","lat":51.6883,"lon":5.30356,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"5200 ME","condg":["Other"],"nct":"NCT05586126","study":"AnaConDa-therapy in COVID-19 Patients","sstatus":"TERMINATED","sponsor":"Jeroen Bosch Ziekenhuis","official":"D. van Nieuwenhuizen, RN (Jeroen Bosch Hospital)","src":"https://clinicaltrials.gov/study/NCT05586126","enroll":42,"start":"2020-10-01","eid":"x:site:nct05586126-jeroen-bosch-ziekenhuis-s-hertogenbosch"},{"id":"nct02606084-unnamed-trial-site-miami","cat":"research","name":"Unnamed trial site","city":"Miami","region":"Florida","country":"United States","cc":"US","lat":25.77836,"lon":-80.19277,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Healthy volunteers"],"nct":"NCT02606084","study":"A Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02606084","phase":"Phase 1","enroll":32,"start":"2015-12-04","eid":"x:site:nct02606084-unnamed-trial-site-miami"},{"id":"nct02606084-unnamed-trial-site-knoxville","cat":"research","name":"Unnamed trial site","city":"Knoxville","region":"Tennessee","country":"United States","cc":"US","lat":35.95608,"lon":-83.93265,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Healthy volunteers"],"nct":"NCT02606084","study":"A Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02606084","phase":"Phase 1","enroll":32,"start":"2015-12-04","eid":"x:site:nct02606084-unnamed-trial-site-knoxville"},{"id":"nct07556172-the-second-affiliated-hospital-of-nanchang-university-nanchang","cat":"research","name":"The Second Affiliated Hospital of Nanchang University","city":"Nanchang","region":"Jiangxi","country":"China","cc":"CN","lat":28.68438,"lon":115.85706,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"330000","condg":["Other"],"nct":"NCT07556172","study":"Clinical Study of Esketamine in Patients With Sepsis Undergoing Invasive Mechanical Ventilation","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","src":"https://clinicaltrials.gov/study/NCT07556172","phase":"Phase 4","enroll":80,"start":"2025-01-01","eid":"x:site:nct07556172-the-second-affiliated-hospital-of-nanchang-university-nanchang"},{"id":"nct05910775-yale-psychiatry-hospital-interventional-psychiatry-services-ips-unit","cat":"research","name":"Yale Psychiatry Hospital Interventional Psychiatry Services (IPS) unit","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.30537,"lon":-72.93696,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"06520","condg":["Depression"],"nct":"NCT05910775","study":"Role Of Non-Specific Effects in The Treatment of Depression With Esketamine","sstatus":"TERMINATED","sponsor":"Yale University","official":"Sina Nikayin, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT05910775","phase":"N/A","enroll":1,"start":"2024-07-13","eid":"x:site:nct05910775-yale-psychiatry-hospital-interventional-psychiatry-services-ips-unit"},{"id":"nct06199700-xiamen-children-s-hospital-children-s-hospital-of-fudan-university-a","cat":"research","name":"Xiamen Children's Hospital (Children's Hospital of Fudan University at Xiamen)","city":"Xiamen","region":"Fujian","country":"China","cc":"CN","lat":24.47805,"lon":118.09255,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"361006","condg":["Other"],"nct":"NCT06199700","study":"Esketamine for the Treatment of Rett Syndrome","sstatus":"COMPLETED","sponsor":"Children's Hospital of Fudan University","official":"Huiping Li (Children's Hospital of Fudan University)","src":"https://clinicaltrials.gov/study/NCT06199700","phase":"EARLY_Phase 1","enroll":3,"start":"2023-11-15","eid":"x:site:nct06199700-xiamen-children-s-hospital-children-s-hospital-of-fudan-university-a"},{"id":"nct07230171-beijing-tiantan-hospital-beijing-beijing-100070-beijing","cat":"research","name":"Beijing Tiantan Hospital, Beijing, Beijing 100070","city":"Beijing","country":"China","cc":"CN","lat":39.90086,"lon":116.39699,"gp":"city","unnamed":0,"drugs":["esketamine"],"condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT07230171","study":"The Efficacy and Safety of Short Term S-ketamine Infusion as an Adjunctive Therapy in Patients With Fibromyalgia","sstatus":"RECRUITING","sponsor":"Beijing Tiantan Hospital","src":"https://clinicaltrials.gov/study/NCT07230171","contact":{"n":"Fang Luo","p":"+8613611326978","e":"13611326978@163.com"},"phase":"N/A","enroll":92,"start":"2025-09-15","eid":"x:site:nct07230171-beijing-tiantan-hospital-beijing-beijing-100070-beijing"},{"id":"nct07369102-pravan-foundation-san-juan","cat":"research","name":"Pravan Foundation","city":"San Juan","country":"Puerto Rico","cc":"PR","lat":18.46506,"lon":-66.11386,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"00909","condg":["Depression"],"status":"RECRUITING","nct":"NCT07369102","study":"Esketamine With or Without Integration Therapy for Treatment-Resistant Depression","sstatus":"RECRUITING","sponsor":"University of Puerto Rico","official":"Karen G Gonzalez-Martinez, MD, MSc (University of Puerto Rico, Medical Sciences Campus, Department of Psychiatry)","src":"https://clinicaltrials.gov/study/NCT07369102","contact":{"n":"David Melchor","p":"787-427-7000","e":"david.melchor@pravanfoundation.org"},"phase":"Phase 4","enroll":20,"start":"2026-02-01","eid":"x:site:nct07369102-pravan-foundation-san-juan"},{"id":"nct07369102-university-of-puerto-rico-department-of-psychiatry-san-juan","cat":"research","name":"University of Puerto Rico, Department of Psychiatry","city":"San Juan","country":"Puerto Rico","cc":"PR","lat":18.45518,"lon":-66.10859,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"00936","condg":["Depression"],"status":"RECRUITING","nct":"NCT07369102","study":"Esketamine With or Without Integration Therapy for Treatment-Resistant Depression","sstatus":"RECRUITING","sponsor":"University of Puerto Rico","official":"Karen G Gonzalez-Martinez, MD, MSc (University of Puerto Rico, Medical Sciences Campus, Department of Psychiatry)","src":"https://clinicaltrials.gov/study/NCT07369102","contact":{"n":"Karen G Martinez-Gonzalez, MD, MSc","p":"787-617-5557","e":"karen.martinez4@upr.edu"},"phase":"Phase 4","enroll":20,"start":"2026-02-01","eid":"x:site:nct07369102-university-of-puerto-rico-department-of-psychiatry-san-juan"},{"id":"nct05323019-city-center-pharmacy-and-medical-clinic-edmonton","cat":"research","name":"City Center Pharmacy and Medical Clinic","city":"Edmonton","region":"Alberta","country":"Canada","cc":"CA","lat":53.5435,"lon":-113.45991,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"T5J 5C2","condg":["Depression"],"nct":"NCT05323019","study":"Repeated Intranasal Esketamine Plus Almond Therapy in Patients With Treatment Resistant Depression","sstatus":"TERMINATED","sponsor":"Zylorion Health","official":"Pierre Chue, MBBCh (Amygdala Associates)","src":"https://clinicaltrials.gov/study/NCT05323019","phase":"Phase 2","enroll":6,"start":"2022-10-13","eid":"x:site:nct05323019-city-center-pharmacy-and-medical-clinic-edmonton"},{"id":"nct06108830-tianjin-medical-university-general-hospital-tianjin","cat":"research","name":"Tianjin Medical University General Hospital","city":"Tianjin","country":"China","cc":"CN","lat":39.15262,"lon":117.18679,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"300052","condg":["Other"],"status":"RECRUITING","nct":"NCT06108830","study":"Esketamine Combined With Remimazolam on Postoperative Sleep Disturbance and Anxiety in Patients","sstatus":"UNKNOWN","sponsor":"Tianjin Medical University General Hospital","official":"Guolin Wang (Tianjin Medical University General Hospital)","src":"https://clinicaltrials.gov/study/NCT06108830","contact":{"n":"Guolin Wang","p":"+8618604755166","e":"wangguolinghad@hotmail.com"},"phase":"N/A","enroll":400,"start":"2023-12-01","eid":"x:site:nct06108830-tianjin-medical-university-general-hospital-tianjin"},{"id":"nct04414943-peking-university-first-hospital-beijing","cat":"research","name":"Peking University First Hospital","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.90322,"lon":116.40358,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"100034","condg":["Depression"],"nct":"NCT04414943","study":"Low-dose S-ketamine in Women With Prenatal Depression","sstatus":"COMPLETED","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT04414943","phase":"N/A","enroll":364,"start":"2020-06-19","eid":"x:site:nct04414943-peking-university-first-hospital-beijing"},{"id":"nct04414943-beijing-tiantan-hospital-beijing","cat":"research","name":"Beijing Tiantan Hospital","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.90604,"lon":116.38815,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"condg":["Depression"],"nct":"NCT04414943","study":"Low-dose S-ketamine in Women With Prenatal Depression","sstatus":"COMPLETED","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT04414943","phase":"N/A","enroll":364,"start":"2020-06-19","eid":"x:site:nct04414943-beijing-tiantan-hospital-beijing"},{"id":"nct04414943-peking-university-international-hospital-beijing","cat":"research","name":"Peking University International Hospital","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.90049,"lon":116.38617,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"condg":["Depression"],"nct":"NCT04414943","study":"Low-dose S-ketamine in Women With Prenatal Depression","sstatus":"COMPLETED","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT04414943","phase":"N/A","enroll":364,"start":"2020-06-19","eid":"x:site:nct04414943-peking-university-international-hospital-beijing"},{"id":"nct04414943-hunan-provincial-maternal-and-child-health-care-hospital-changsha","cat":"research","name":"Hunan Provincial Maternal and Child Health Care Hospital","city":"Changsha","region":"Hunan","country":"China","cc":"CN","lat":28.18712,"lon":112.97769,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"condg":["Depression"],"nct":"NCT04414943","study":"Low-dose S-ketamine in Women With Prenatal Depression","sstatus":"COMPLETED","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT04414943","phase":"N/A","enroll":364,"start":"2020-06-19","eid":"x:site:nct04414943-hunan-provincial-maternal-and-child-health-care-hospital-changsha"},{"id":"nct04414943-huaian-maternal-and-child-health-care-hospital-huaian","cat":"research","name":"Huaian Maternal and Child Health Care Hospital","city":"Huaian","region":"Jiangsu","country":"China","cc":"CN","lat":32.5927,"lon":119.5522,"gp":"region","unnamed":0,"drugs":["esketamine","ketamine"],"condg":["Depression"],"nct":"NCT04414943","study":"Low-dose S-ketamine in Women With Prenatal Depression","sstatus":"COMPLETED","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT04414943","phase":"N/A","enroll":364,"start":"2020-06-19","eid":"x:site:nct04414943-huaian-maternal-and-child-health-care-hospital-huaian"},{"id":"nct04414943-nanjing-maternal-and-child-health-care-hospital-nanjing","cat":"research","name":"Nanjing Maternal and Child Health Care Hospital","city":"Nanjing","region":"Jiangsu","country":"China","cc":"CN","lat":32.05974,"lon":118.78818,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"condg":["Depression"],"nct":"NCT04414943","study":"Low-dose S-ketamine in Women With Prenatal Depression","sstatus":"COMPLETED","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT04414943","phase":"N/A","enroll":364,"start":"2020-06-19","eid":"x:site:nct04414943-nanjing-maternal-and-child-health-care-hospital-nanjing"},{"id":"nct04414943-women-s-hospital-school-of-medicine-zhejiang-university-hangzhou","cat":"research","name":"Women's Hospital School Of Medicine Zhejiang University","city":"Hangzhou","region":"Zhejiang","country":"China","cc":"CN","lat":30.28796,"lon":120.16711,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"condg":["Depression"],"nct":"NCT04414943","study":"Low-dose S-ketamine in Women With Prenatal Depression","sstatus":"COMPLETED","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT04414943","phase":"N/A","enroll":364,"start":"2020-06-19","eid":"x:site:nct04414943-women-s-hospital-school-of-medicine-zhejiang-university-hangzhou"},{"id":"nct06117917-beijing-tiantan-hospital-beijing","cat":"research","name":"Beijing Tiantan Hospital","city":"Beijing","country":"China","cc":"CN","lat":39.90209,"lon":116.39944,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"100070","condg":["Chronic pain & headache"],"nct":"NCT06117917","study":"Esketamine Combined With Pregabalin on CPSP in Spinal Patients.","sstatus":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","official":"Ruquan Han, M.D., Ph D (Beijing Tiantan Hospital)","src":"https://clinicaltrials.gov/study/NCT06117917","contact":{"n":"Ruquan Han, M.D., Ph D.","p":"8610-59976660","e":"ruquan.han@ccmu.edu.cn"},"phase":"Phase 2/Phase 3","enroll":150,"start":"2023-11-10","eid":"x:site:nct06117917-beijing-tiantan-hospital-beijing"},{"id":"nct05530668-service-de-physiologie-explorations-fonctionnelles-chu-de-strasbourg","cat":"research","name":"Service de physiologie - Explorations fonctionnelles - CHU de Strasbourg - France","city":"Strasbourg","country":"France","cc":"FR","lat":48.58058,"lon":7.73814,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"67091","condg":["Depression","Anxiety"],"nct":"NCT05530668","study":"Tolerance and Potential Synergistic Effect of the Combination of Intranasal Esketamine and Non-selective MAOI","sstatus":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","src":"https://clinicaltrials.gov/study/NCT05530668","enroll":13,"start":"2022-04-11","eid":"x:site:nct05530668-service-de-physiologie-explorations-fonctionnelles-chu-de-strasbourg"},{"id":"nct05643066-fujian-provincial-hospital-fuzhou","cat":"research","name":"Fujian provincial hospital","city":"Fuzhou","region":"Fujian","country":"China","cc":"CN","lat":26.06548,"lon":119.31293,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"350001","condg":["Other"],"nct":"NCT05643066","study":"Esketamine-propofol Versus Propofol for Flexible Bronchoscopy","sstatus":"COMPLETED","sponsor":"Fujian Provincial Hospital","official":"Xiaochun Zheng, MD (Fujian Provincial Hospital)","src":"https://clinicaltrials.gov/study/NCT05643066","phase":"Phase 4","enroll":246,"start":"2022-12-07","eid":"x:site:nct05643066-fujian-provincial-hospital-fuzhou"},{"id":"nct06133309-centre-hospitalier-intercommunal-toulon-la-seyne-sur-mer-toulon","cat":"research","name":"Centre Hospitalier Intercommunal Toulon La Seyne sur Mer","city":"Toulon","region":"Var","country":"France","cc":"FR","lat":43.13397,"lon":5.92502,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"83100","condg":["Depression"],"nct":"NCT06133309","study":"Phenomenological Explorations of the Esketamine-Induced Transient Dissociative State","sstatus":"COMPLETED","sponsor":"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","official":"Manuel DIAS ALVES, MD PhD (Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer)","src":"https://clinicaltrials.gov/study/NCT06133309","phase":"N/A","enroll":15,"start":"2024-03-19","eid":"x:site:nct06133309-centre-hospitalier-intercommunal-toulon-la-seyne-sur-mer-toulon"},{"id":"nct07528014-salma-health-la-jolla","cat":"research","name":"Salma Health","city":"La Jolla","region":"California","country":"United States","cc":"US","lat":32.84478,"lon":-117.27076,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"92037","condg":["Depression"],"status":"RECRUITING","nct":"NCT07528014","study":"ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1","sstatus":"RECRUITING","sponsor":"Salma Health, Inc.","src":"https://clinicaltrials.gov/study/NCT07528014","contact":{"n":"Clinical Research Coordinator","p":"858-294-0161","e":"research@salmahealth.com"},"enroll":5000,"start":"2026-03-25","eid":"x:site:nct07528014-salma-health-la-jolla"},{"id":"nct07528014-salma-health-laguna-hills","cat":"research","name":"Salma Health","city":"Laguna Hills","region":"California","country":"United States","cc":"US","lat":33.6168,"lon":-117.71175,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"92653","condg":["Depression"],"status":"RECRUITING","nct":"NCT07528014","study":"ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1","sstatus":"RECRUITING","sponsor":"Salma Health, Inc.","src":"https://clinicaltrials.gov/study/NCT07528014","contact":{"n":"Clinical Research Coordinator","p":"858-294-0161","e":"research@salmahealth.com"},"enroll":5000,"start":"2026-03-25","eid":"x:site:nct07528014-salma-health-laguna-hills"},{"id":"nct05698394-hunan-provincial-maternal-and-child-health-care-hospital-changsha","cat":"research","name":"Hunan Provincial Maternal and Child Health Care Hospital","city":"Changsha","region":"Hunan","country":"China","cc":"CN","lat":28.20716,"lon":112.96546,"gp":"city","unnamed":0,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT05698394","study":"Effect of Low-dose Esketamine on Maternal Depression at 3 Years After Childbirth","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD,PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT05698394","phase":"Phase 4","enroll":364,"start":"2023-09-09","eid":"x:site:nct05698394-hunan-provincial-maternal-and-child-health-care-hospital-changsha"},{"id":"nct05698394-women-s-hospital-of-nanjing-medical-university-nanjing","cat":"research","name":"Women's Hospital of Nanjing Medical University","city":"Nanjing","region":"Jiangsu","country":"China","cc":"CN","lat":32.07235,"lon":118.78903,"gp":"city","unnamed":0,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT05698394","study":"Effect of Low-dose Esketamine on Maternal Depression at 3 Years After Childbirth","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD,PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT05698394","phase":"Phase 4","enroll":364,"start":"2023-09-09","eid":"x:site:nct05698394-women-s-hospital-of-nanjing-medical-university-nanjing"},{"id":"nct05698394-women-s-hospital-zhejiang-university-school-of-medicine-hangzhou","cat":"research","name":"Women's Hospital, Zhejiang University School of Medicine","city":"Hangzhou","region":"Zhejiang","country":"China","cc":"CN","lat":30.30019,"lon":120.16824,"gp":"city","unnamed":0,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT05698394","study":"Effect of Low-dose Esketamine on Maternal Depression at 3 Years After Childbirth","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD,PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT05698394","phase":"Phase 4","enroll":364,"start":"2023-09-09","eid":"x:site:nct05698394-women-s-hospital-zhejiang-university-school-of-medicine-hangzhou"},{"id":"nct05698394-peking-university-first-hospital-beijing","cat":"research","name":"Peking University First Hospital","city":"Beijing","country":"China","cc":"CN","lat":39.89964,"lon":116.39502,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100034","condg":["Depression"],"nct":"NCT05698394","study":"Effect of Low-dose Esketamine on Maternal Depression at 3 Years After Childbirth","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD,PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT05698394","phase":"Phase 4","enroll":364,"start":"2023-09-09","eid":"x:site:nct05698394-peking-university-first-hospital-beijing"},{"id":"nct06432322-department-of-psychiatry-university-of-oxford-warneford-hospital-oxf","cat":"research","name":"Department of Psychiatry, University of Oxford, Warneford Hospital","city":"Oxford","region":"Oxfordshire","country":"United Kingdom","cc":"GB","lat":51.75782,"lon":-1.2642,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"OX3 7JX","condg":["Depression"],"nct":"NCT06432322","study":"(GluEsk) Glutamate and Esketamine","sstatus":"COMPLETED","sponsor":"University of Oxford","official":"Riccardo De Giorgi, MD, DPhil, MRCPsych (University of Oxford, Department of Psychiatry)","src":"https://clinicaltrials.gov/study/NCT06432322","phase":"N/A","enroll":16,"start":"2024-06-14","eid":"x:site:nct06432322-department-of-psychiatry-university-of-oxford-warneford-hospital-oxf"},{"id":"nct02418585-unnamed-trial-site-birmingham","cat":"research","name":"Unnamed trial site","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.52842,"lon":-86.80301,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-birmingham"},{"id":"nct02418585-unnamed-trial-site-orange","cat":"research","name":"Unnamed trial site","city":"Orange","region":"California","country":"United States","cc":"US","lat":33.79631,"lon":-117.86031,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-orange"},{"id":"nct02418585-unnamed-trial-site-san-rafael","cat":"research","name":"Unnamed trial site","city":"San Rafael","region":"California","country":"United States","cc":"US","lat":37.97377,"lon":-122.53537,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-san-rafael"},{"id":"nct02418585-unnamed-trial-site-maitland","cat":"research","name":"Unnamed trial site","city":"Maitland","region":"Florida","country":"United States","cc":"US","lat":28.6203,"lon":-81.37211,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-maitland"},{"id":"nct02418585-unnamed-trial-site-atlanta","cat":"research","name":"Unnamed trial site","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.75535,"lon":-84.37824,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-atlanta"},{"id":"nct02418585-unnamed-trial-site-chicago","cat":"research","name":"Unnamed trial site","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.85544,"lon":-87.63852,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-chicago"},{"id":"nct02418585-unnamed-trial-site-gaithersburg","cat":"research","name":"Unnamed trial site","city":"Gaithersburg","region":"Maryland","country":"United States","cc":"US","lat":39.1513,"lon":-77.19078,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-gaithersburg"},{"id":"nct02418585-unnamed-trial-site-boston","cat":"research","name":"Unnamed trial site","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.34803,"lon":-71.06791,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-boston"},{"id":"nct02418585-unnamed-trial-site-philadelphia","cat":"research","name":"Unnamed trial site","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.95657,"lon":-75.17393,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-philadelphia"},{"id":"nct02418585-unnamed-trial-site-dallas","cat":"research","name":"Unnamed trial site","city":"Dallas","region":"Texas","country":"United States","cc":"US","lat":32.79271,"lon":-96.79825,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-dallas"},{"id":"nct02418585-unnamed-trial-site-klecany","cat":"research","name":"Unnamed trial site","city":"Klecany","country":"Czechia","cc":"CZ","lat":50.18234,"lon":14.4023,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-klecany"},{"id":"nct02418585-unnamed-trial-site-litomerice","cat":"research","name":"Unnamed trial site","city":"Litoměřice","country":"Czechia","cc":"CZ","lat":50.52967,"lon":14.12545,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-litomerice"},{"id":"nct02418585-unnamed-trial-site-pilsen","cat":"research","name":"Unnamed trial site","city":"Pilsen","country":"Czechia","cc":"CZ","lat":49.74131,"lon":13.36738,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-pilsen"},{"id":"nct02418585-unnamed-trial-site-prague","cat":"research","name":"Unnamed trial site","city":"Prague","country":"Czechia","cc":"CZ","lat":50.08451,"lon":14.42175,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-prague"},{"id":"nct02418585-unnamed-trial-site-prerov","cat":"research","name":"Unnamed trial site","city":"Přerov","country":"Czechia","cc":"CZ","lat":49.45732,"lon":17.45942,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-prerov"},{"id":"nct02418585-unnamed-trial-site-berlin","cat":"research","name":"Unnamed trial site","city":"Berlin","country":"Germany","cc":"DE","lat":52.52743,"lon":13.40324,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-berlin"},{"id":"nct02418585-unnamed-trial-site-cham","cat":"research","name":"Unnamed trial site","city":"Cham","country":"Germany","cc":"DE","lat":49.2272,"lon":12.64659,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-cham"},{"id":"nct02418585-unnamed-trial-site-dresden","cat":"research","name":"Unnamed trial site","city":"Dresden","country":"Germany","cc":"DE","lat":51.04463,"lon":13.74561,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-dresden"},{"id":"nct02418585-unnamed-trial-site-gelsenkirchen","cat":"research","name":"Unnamed trial site","city":"Gelsenkirchen","country":"Germany","cc":"DE","lat":51.50692,"lon":7.10176,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-gelsenkirchen"},{"id":"nct02418585-unnamed-trial-site-halle","cat":"research","name":"Unnamed trial site","city":"Halle","country":"Germany","cc":"DE","lat":52.062,"lon":8.34883,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-halle"},{"id":"nct02418585-unnamed-trial-site-leipzig","cat":"research","name":"Unnamed trial site","city":"Leipzig","country":"Germany","cc":"DE","lat":51.34786,"lon":12.37971,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-leipzig"},{"id":"nct02418585-unnamed-trial-site-mainz","cat":"research","name":"Unnamed trial site","city":"Mainz","country":"Germany","cc":"DE","lat":49.98321,"lon":8.26846,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-mainz"},{"id":"nct02418585-unnamed-trial-site-mannheim","cat":"research","name":"Unnamed trial site","city":"Mannheim","country":"Germany","cc":"DE","lat":49.47851,"lon":8.46736,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-mannheim"},{"id":"nct02418585-unnamed-trial-site-mittweida","cat":"research","name":"Unnamed trial site","city":"Mittweida","country":"Germany","cc":"DE","lat":50.97789,"lon":12.96968,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-mittweida"},{"id":"nct02418585-unnamed-trial-site-pfaffenhofen","cat":"research","name":"Unnamed trial site","city":"Pfaffenhofen","country":"Germany","cc":"DE","lat":49.05837,"lon":8.96853,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-pfaffenhofen"},{"id":"nct02418585-unnamed-trial-site-prien-am-chiemsee","cat":"research","name":"Unnamed trial site","city":"Prien am Chiemsee","country":"Germany","cc":"DE","lat":47.86633,"lon":12.34882,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-prien-am-chiemsee"},{"id":"nct02418585-unnamed-trial-site-tubingen","cat":"research","name":"Unnamed trial site","city":"Tübingen","country":"Germany","cc":"DE","lat":48.51292,"lon":9.05613,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-tubingen"},{"id":"nct02418585-unnamed-trial-site-bialystok","cat":"research","name":"Unnamed trial site","city":"Bialystok","country":"Poland","cc":"PL","lat":53.14439,"lon":23.16824,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-bialystok"},{"id":"nct02418585-unnamed-trial-site-bydgoszcz","cat":"research","name":"Unnamed trial site","city":"Bydgoszcz","country":"Poland","cc":"PL","lat":53.13503,"lon":18.00804,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-bydgoszcz"},{"id":"nct02418585-unnamed-trial-site-gdansk","cat":"research","name":"Unnamed trial site","city":"Gdansk","country":"Poland","cc":"PL","lat":54.35947,"lon":18.64296,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-gdansk"},{"id":"nct02418585-unnamed-trial-site-krakow","cat":"research","name":"Unnamed trial site","city":"Krakow","country":"Poland","cc":"PL","lat":50.05159,"lon":19.93305,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-krakow"},{"id":"nct02418585-unnamed-trial-site-mys-owice","cat":"research","name":"Unnamed trial site","city":"Mysłowice","country":"Poland","cc":"PL","lat":50.20129,"lon":19.17303,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-mys-owice"},{"id":"nct02418585-unnamed-trial-site-pruszkow","cat":"research","name":"Unnamed trial site","city":"Pruszków","country":"Poland","cc":"PL","lat":52.16776,"lon":20.82235,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-pruszkow"},{"id":"nct02418585-unnamed-trial-site-torun","cat":"research","name":"Unnamed trial site","city":"Torun","country":"Poland","cc":"PL","lat":53.01747,"lon":18.5979,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-torun"},{"id":"nct02418585-unnamed-trial-site-tuszyn","cat":"research","name":"Unnamed trial site","city":"Tuszyn","country":"Poland","cc":"PL","lat":51.60097,"lon":19.52675,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-tuszyn"},{"id":"nct02418585-unnamed-trial-site-warsaw","cat":"research","name":"Unnamed trial site","city":"Warsaw","country":"Poland","cc":"PL","lat":52.23753,"lon":21.01917,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-warsaw"},{"id":"nct02418585-unnamed-trial-site-alcorcon","cat":"research","name":"Unnamed trial site","city":"Alcorcón","country":"Spain","cc":"ES","lat":40.34088,"lon":-3.81428,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-alcorcon"},{"id":"nct02418585-unnamed-trial-site-barcelona","cat":"research","name":"Unnamed trial site","city":"Barcelona","country":"Spain","cc":"ES","lat":41.39891,"lon":2.15235,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-barcelona"},{"id":"nct02418585-unnamed-trial-site-cordoba","cat":"research","name":"Unnamed trial site","city":"Córdoba","country":"Spain","cc":"ES","lat":37.9028,"lon":-4.76602,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-cordoba"},{"id":"nct02418585-unnamed-trial-site-malaga","cat":"research","name":"Unnamed trial site","city":"Málaga","country":"Spain","cc":"ES","lat":36.72425,"lon":-4.43055,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-malaga"},{"id":"nct02418585-unnamed-trial-site-mostoles","cat":"research","name":"Unnamed trial site","city":"Móstoles","country":"Spain","cc":"ES","lat":40.33321,"lon":-3.87178,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-mostoles"},{"id":"nct02418585-unnamed-trial-site-murcia","cat":"research","name":"Unnamed trial site","city":"Murcia","country":"Spain","cc":"ES","lat":37.98248,"lon":-1.12585,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-murcia"},{"id":"nct02418585-unnamed-trial-site-palma","cat":"research","name":"Unnamed trial site","city":"Palma","country":"Spain","cc":"ES","lat":39.5733,"lon":2.658,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-palma"},{"id":"nct02418585-unnamed-trial-site-pamplona","cat":"research","name":"Unnamed trial site","city":"Pamplona","country":"Spain","cc":"ES","lat":42.81908,"lon":-1.63471,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-pamplona"},{"id":"nct02418585-unnamed-trial-site-sabadell","cat":"research","name":"Unnamed trial site","city":"Sabadell","country":"Spain","cc":"ES","lat":41.53581,"lon":2.10806,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-sabadell"},{"id":"nct02418585-unnamed-trial-site-salamanca","cat":"research","name":"Unnamed trial site","city":"Salamanca","country":"Spain","cc":"ES","lat":40.43127,"lon":-3.68356,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-salamanca"},{"id":"nct02418585-unnamed-trial-site-santa-coloma-de-gramanet","cat":"research","name":"Unnamed trial site","city":"Santa Coloma de Gramanet","country":"Spain","cc":"ES","lat":40.242,"lon":-3.5241,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-santa-coloma-de-gramanet"},{"id":"nct02418585-unnamed-trial-site-vitoria-gasteiz","cat":"research","name":"Unnamed trial site","city":"Vitoria-Gasteiz","country":"Spain","cc":"ES","lat":42.83826,"lon":-2.68242,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02418585","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02418585","phase":"Phase 3","enroll":236,"start":"2015-08-07","eid":"x:site:nct02418585-unnamed-trial-site-vitoria-gasteiz"},{"id":"nct02129088-unnamed-trial-site-merksem","cat":"research","name":"Unnamed trial site","city":"Merksem","country":"Belgium","cc":"BE","lat":51.24863,"lon":4.44945,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Healthy volunteers"],"nct":"NCT02129088","study":"A Pharmacokinetic, Safety and Tolerability Study of Esketamine in Healthy Elderly and Adult Participants","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02129088","phase":"Phase 1","enroll":34,"start":"2014-03","eid":"x:site:nct02129088-unnamed-trial-site-merksem"},{"id":"nct02624401-turku-pet-centre-turku","cat":"research","name":"Turku PET Centre","city":"Turku","country":"Finland","cc":"FI","lat":60.45576,"lon":22.26375,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"FI-20521","condg":["Other"],"nct":"NCT02624401","study":"The Neural Mechanisms of Anesthesia and Human Consciousness (Part 6)","sstatus":"COMPLETED","sponsor":"University of Turku","official":"Harry Scheinin, MD (Turku PET Centre, University of Turku, Turku, Finland)","src":"https://clinicaltrials.gov/study/NCT02624401","phase":"Phase 4","enroll":160,"start":"2016-01","eid":"x:site:nct02624401-turku-pet-centre-turku"},{"id":"nct02417064-unnamed-trial-site-birmingham","cat":"research","name":"Unnamed trial site","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.51167,"lon":-86.80357,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-birmingham"},{"id":"nct02417064-unnamed-trial-site-little-rock","cat":"research","name":"Unnamed trial site","city":"Little Rock","region":"Arkansas","country":"United States","cc":"US","lat":34.74323,"lon":-92.2791,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-little-rock"},{"id":"nct02417064-unnamed-trial-site-garden-grove","cat":"research","name":"Unnamed trial site","city":"Garden Grove","region":"California","country":"United States","cc":"US","lat":33.76323,"lon":-117.95251,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-garden-grove"},{"id":"nct02417064-unnamed-trial-site-orange","cat":"research","name":"Unnamed trial site","city":"Orange","region":"California","country":"United States","cc":"US","lat":33.78134,"lon":-117.85419,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-orange"},{"id":"nct02417064-unnamed-trial-site-san-diego","cat":"research","name":"Unnamed trial site","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.72357,"lon":-117.1643,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-san-diego"},{"id":"nct02417064-unnamed-trial-site-san-marcos","cat":"research","name":"Unnamed trial site","city":"San Marcos","region":"California","country":"United States","cc":"US","lat":33.13184,"lon":-117.1756,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-san-marcos"},{"id":"nct02417064-unnamed-trial-site-san-rafael","cat":"research","name":"Unnamed trial site","city":"San Rafael","region":"California","country":"United States","cc":"US","lat":37.97772,"lon":-122.54093,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-san-rafael"},{"id":"nct02417064-unnamed-trial-site-bradenton","cat":"research","name":"Unnamed trial site","city":"Bradenton","region":"Florida","country":"United States","cc":"US","lat":27.49126,"lon":-82.56329,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-bradenton"},{"id":"nct02417064-unnamed-trial-site-miami","cat":"research","name":"Unnamed trial site","city":"Miami","region":"Florida","country":"United States","cc":"US","lat":25.77808,"lon":-80.1859,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-miami"},{"id":"nct02417064-unnamed-trial-site-orlando","cat":"research","name":"Unnamed trial site","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.52935,"lon":-81.39115,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-orlando"},{"id":"nct02417064-unnamed-trial-site-chicago","cat":"research","name":"Unnamed trial site","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.84481,"lon":-87.64539,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-chicago"},{"id":"nct02417064-unnamed-trial-site-hoffman-estates","cat":"research","name":"Unnamed trial site","city":"Hoffman Estates","region":"Illinois","country":"United States","cc":"US","lat":42.03749,"lon":-88.07091,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-hoffman-estates"},{"id":"nct02417064-unnamed-trial-site-maywood","cat":"research","name":"Unnamed trial site","city":"Maywood","region":"Illinois","country":"United States","cc":"US","lat":33.98212,"lon":-118.18907,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-maywood"},{"id":"nct02417064-unnamed-trial-site-schaumburg","cat":"research","name":"Unnamed trial site","city":"Schaumburg","region":"Illinois","country":"United States","cc":"US","lat":42.03378,"lon":-88.09155,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-schaumburg"},{"id":"nct02417064-unnamed-trial-site-wichita","cat":"research","name":"Unnamed trial site","city":"Wichita","region":"Kansas","country":"United States","cc":"US","lat":37.69031,"lon":-97.32648,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-wichita"},{"id":"nct02417064-unnamed-trial-site-gaithersburg","cat":"research","name":"Unnamed trial site","city":"Gaithersburg","region":"Maryland","country":"United States","cc":"US","lat":39.14829,"lon":-77.20706,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-gaithersburg"},{"id":"nct02417064-unnamed-trial-site-boston","cat":"research","name":"Unnamed trial site","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36977,"lon":-71.05869,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-boston"},{"id":"nct02417064-unnamed-trial-site-quincy","cat":"research","name":"Unnamed trial site","city":"Quincy","region":"Massachusetts","country":"United States","cc":"US","lat":42.2517,"lon":-70.99714,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-quincy"},{"id":"nct02417064-unnamed-trial-site-watertown","cat":"research","name":"Unnamed trial site","city":"Watertown","region":"Massachusetts","country":"United States","cc":"US","lat":42.36128,"lon":-71.17394,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-watertown"},{"id":"nct02417064-unnamed-trial-site-worcester","cat":"research","name":"Unnamed trial site","city":"Worcester","region":"Massachusetts","country":"United States","cc":"US","lat":42.26301,"lon":-71.80102,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-worcester"},{"id":"nct02417064-unnamed-trial-site-minneapolis","cat":"research","name":"Unnamed trial site","city":"Minneapolis","region":"Minnesota","country":"United States","cc":"US","lat":44.98717,"lon":-93.25833,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-minneapolis"},{"id":"nct02417064-unnamed-trial-site-o-fallon","cat":"research","name":"Unnamed trial site","city":"O'Fallon","region":"Missouri","country":"United States","cc":"US","lat":38.82167,"lon":-90.69011,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-o-fallon"},{"id":"nct02417064-unnamed-trial-site-saint-charles","cat":"research","name":"Unnamed trial site","city":"Saint Charles","region":"Missouri","country":"United States","cc":"US","lat":38.78822,"lon":-90.47478,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-saint-charles"},{"id":"nct02417064-unnamed-trial-site-omaha","cat":"research","name":"Unnamed trial site","city":"Omaha","region":"Nebraska","country":"United States","cc":"US","lat":41.26318,"lon":-95.93304,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-omaha"},{"id":"nct02417064-unnamed-trial-site-new-york","cat":"research","name":"Unnamed trial site","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71695,"lon":-73.99463,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-new-york"},{"id":"nct02417064-unnamed-trial-site-durham","cat":"research","name":"Unnamed trial site","city":"Durham","region":"North Carolina","country":"United States","cc":"US","lat":35.99765,"lon":-78.88671,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-durham"},{"id":"nct02417064-unnamed-trial-site-dayton","cat":"research","name":"Unnamed trial site","city":"Dayton","region":"Ohio","country":"United States","cc":"US","lat":39.76173,"lon":-84.18441,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-dayton"},{"id":"nct02417064-unnamed-trial-site-oklahoma-city","cat":"research","name":"Unnamed trial site","city":"Oklahoma City","region":"Oklahoma","country":"United States","cc":"US","lat":35.47363,"lon":-97.5081,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-oklahoma-city"},{"id":"nct02417064-unnamed-trial-site-media","cat":"research","name":"Unnamed trial site","city":"Media","region":"Pennsylvania","country":"United States","cc":"US","lat":39.91767,"lon":-75.39593,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-media"},{"id":"nct02417064-unnamed-trial-site-philadelphia","cat":"research","name":"Unnamed trial site","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.95309,"lon":-75.16866,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-philadelphia"},{"id":"nct02417064-unnamed-trial-site-lincoln","cat":"research","name":"Unnamed trial site","city":"Lincoln","region":"Rhode Island","country":"United States","cc":"US","lat":40.80353,"lon":-96.67322,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-lincoln"},{"id":"nct02417064-unnamed-trial-site-austin","cat":"research","name":"Unnamed trial site","city":"Austin","region":"Texas","country":"United States","cc":"US","lat":30.25571,"lon":-97.75497,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-austin"},{"id":"nct02417064-unnamed-trial-site-dallas","cat":"research","name":"Unnamed trial site","city":"Dallas","region":"Texas","country":"United States","cc":"US","lat":32.78377,"lon":-96.81227,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-dallas"},{"id":"nct02417064-unnamed-trial-site-houston","cat":"research","name":"Unnamed trial site","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.76747,"lon":-95.35136,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-houston"},{"id":"nct02417064-unnamed-trial-site-woodstock","cat":"research","name":"Unnamed trial site","city":"Woodstock","region":"Vermont","country":"United States","cc":"US","lat":34.10681,"lon":-84.51924,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-woodstock"},{"id":"nct02417064-unnamed-trial-site-bothell","cat":"research","name":"Unnamed trial site","city":"Bothell","region":"Washington","country":"United States","cc":"US","lat":47.76717,"lon":-122.21533,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-bothell"},{"id":"nct02417064-unnamed-trial-site-middleton","cat":"research","name":"Unnamed trial site","city":"Middleton","region":"Wisconsin","country":"United States","cc":"US","lat":43.09896,"lon":-89.5049,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-middleton"},{"id":"nct02417064-unnamed-trial-site-aalst","cat":"research","name":"Unnamed trial site","city":"Aalst","country":"Belgium","cc":"BE","lat":50.93938,"lon":4.04326,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-aalst"},{"id":"nct02417064-unnamed-trial-site-bruges","cat":"research","name":"Unnamed trial site","city":"Bruges","country":"Belgium","cc":"BE","lat":51.19871,"lon":3.21704,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-bruges"},{"id":"nct02417064-unnamed-trial-site-brussels","cat":"research","name":"Unnamed trial site","city":"Brussels","country":"Belgium","cc":"BE","lat":50.85125,"lon":4.35645,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-brussels"},{"id":"nct02417064-unnamed-trial-site-ghent","cat":"research","name":"Unnamed trial site","city":"Ghent","country":"Belgium","cc":"BE","lat":51.04384,"lon":3.70825,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-ghent"},{"id":"nct02417064-unnamed-trial-site-hasselt","cat":"research","name":"Unnamed trial site","city":"Hasselt","country":"Belgium","cc":"BE","lat":50.94137,"lon":5.34209,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-hasselt"},{"id":"nct02417064-unnamed-trial-site-heusden-zolder","cat":"research","name":"Unnamed trial site","city":"Heusden-Zolder","country":"Belgium","cc":"BE","lat":50.4642,"lon":4.5429,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-heusden-zolder"},{"id":"nct02417064-unnamed-trial-site-liege","cat":"research","name":"Unnamed trial site","city":"Liège","country":"Belgium","cc":"BE","lat":50.62992,"lon":5.57582,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-liege"},{"id":"nct02417064-unnamed-trial-site-spa","cat":"research","name":"Unnamed trial site","city":"Spa","country":"Belgium","cc":"BE","lat":50.49255,"lon":5.8729,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-spa"},{"id":"nct02417064-unnamed-trial-site-yvoir","cat":"research","name":"Unnamed trial site","city":"Yvoir","country":"Belgium","cc":"BE","lat":50.33096,"lon":4.87358,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-yvoir"},{"id":"nct02417064-unnamed-trial-site-belo-horizonte","cat":"research","name":"Unnamed trial site","city":"Belo Horizonte","country":"Brazil","cc":"BR","lat":-19.92954,"lon":-43.93444,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-belo-horizonte"},{"id":"nct02417064-unnamed-trial-site-curitiba","cat":"research","name":"Unnamed trial site","city":"Curitiba","country":"Brazil","cc":"BR","lat":-25.4202,"lon":-49.26407,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-curitiba"},{"id":"nct02417064-unnamed-trial-site-fortaleza","cat":"research","name":"Unnamed trial site","city":"Fortaleza","country":"Brazil","cc":"BR","lat":-3.71943,"lon":-38.54508,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-fortaleza"},{"id":"nct02417064-unnamed-trial-site-passo-fundo","cat":"research","name":"Unnamed trial site","city":"Passo Fundo","country":"Brazil","cc":"BR","lat":-28.26838,"lon":-52.41001,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-passo-fundo"},{"id":"nct02417064-unnamed-trial-site-porto-alegre","cat":"research","name":"Unnamed trial site","city":"Porto Alegre","country":"Brazil","cc":"BR","lat":-30.02243,"lon":-51.22035,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-porto-alegre"},{"id":"nct02417064-unnamed-trial-site-rio-de-janeiro","cat":"research","name":"Unnamed trial site","city":"Rio de Janeiro","country":"Brazil","cc":"BR","lat":-22.90797,"lon":-43.17955,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-rio-de-janeiro"},{"id":"nct02417064-unnamed-trial-site-santo-andre","cat":"research","name":"Unnamed trial site","city":"Santo André","country":"Brazil","cc":"BR","lat":-23.65933,"lon":-46.54082,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-santo-andre"},{"id":"nct02417064-unnamed-trial-site-calgary","cat":"research","name":"Unnamed trial site","city":"Calgary","region":"Alberta","country":"Canada","cc":"CA","lat":51.04131,"lon":-114.0748,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-calgary"},{"id":"nct02417064-unnamed-trial-site-vancouver","cat":"research","name":"Unnamed trial site","city":"Vancouver","region":"British Columbia","country":"Canada","cc":"CA","lat":49.253,"lon":-123.11421,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-vancouver"},{"id":"nct02417064-unnamed-trial-site-kingston","cat":"research","name":"Unnamed trial site","city":"Kingston","region":"Ontario","country":"Canada","cc":"CA","lat":44.24016,"lon":-76.48545,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-kingston"},{"id":"nct02417064-unnamed-trial-site-ottawa","cat":"research","name":"Unnamed trial site","city":"Ottawa","region":"Ontario","country":"Canada","cc":"CA","lat":45.41225,"lon":-75.71003,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-ottawa"},{"id":"nct02417064-unnamed-trial-site-toronto","cat":"research","name":"Unnamed trial site","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.69556,"lon":-79.39916,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-toronto"},{"id":"nct02417064-unnamed-trial-site-montreal","cat":"research","name":"Unnamed trial site","city":"Montreal","region":"Quebec","country":"Canada","cc":"CA","lat":45.51049,"lon":-73.58099,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-montreal"},{"id":"nct02417064-unnamed-trial-site-parnu","cat":"research","name":"Unnamed trial site","city":"Pärnu","country":"Estonia","cc":"EE","lat":58.39195,"lon":24.49669,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-parnu"},{"id":"nct02417064-unnamed-trial-site-tallinn","cat":"research","name":"Unnamed trial site","city":"Tallinn","country":"Estonia","cc":"EE","lat":59.4292,"lon":24.75791,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-tallinn"},{"id":"nct02417064-unnamed-trial-site-tartu","cat":"research","name":"Unnamed trial site","city":"Tartu","country":"Estonia","cc":"EE","lat":58.38509,"lon":26.72937,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-tartu"},{"id":"nct02417064-unnamed-trial-site-besancon","cat":"research","name":"Unnamed trial site","city":"Besançon","country":"France","cc":"FR","lat":47.2445,"lon":6.02601,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-besancon"},{"id":"nct02417064-unnamed-trial-site-clermont-ferrand","cat":"research","name":"Unnamed trial site","city":"Clermont-Ferrand","country":"France","cc":"FR","lat":45.79075,"lon":3.08875,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-clermont-ferrand"},{"id":"nct02417064-unnamed-trial-site-douai","cat":"research","name":"Unnamed trial site","city":"Douai","country":"France","cc":"FR","lat":50.38175,"lon":3.07607,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-douai"},{"id":"nct02417064-unnamed-trial-site-issy-les-moulineaux","cat":"research","name":"Unnamed trial site","city":"Issy-les-Moulineaux","country":"France","cc":"FR","lat":48.83304,"lon":2.2713,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-issy-les-moulineaux"},{"id":"nct02417064-unnamed-trial-site-la-tronche","cat":"research","name":"Unnamed trial site","city":"La Tronche","country":"France","cc":"FR","lat":45.19561,"lon":5.75754,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-la-tronche"},{"id":"nct02417064-unnamed-trial-site-lille","cat":"research","name":"Unnamed trial site","city":"Lille","country":"France","cc":"FR","lat":50.6444,"lon":3.04397,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-lille"},{"id":"nct02417064-unnamed-trial-site-limoges","cat":"research","name":"Unnamed trial site","city":"Limoges","country":"France","cc":"FR","lat":45.84101,"lon":1.24114,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-limoges"},{"id":"nct02417064-unnamed-trial-site-montpellier","cat":"research","name":"Unnamed trial site","city":"Montpellier","country":"France","cc":"FR","lat":43.62048,"lon":3.86435,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-montpellier"},{"id":"nct02417064-unnamed-trial-site-nantes","cat":"research","name":"Unnamed trial site","city":"Nantes","country":"France","cc":"FR","lat":47.21701,"lon":-1.55294,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-nantes"},{"id":"nct02417064-unnamed-trial-site-neuilly-sur-marne","cat":"research","name":"Unnamed trial site","city":"Neuilly-sur-Marne","country":"France","cc":"FR","lat":48.86262,"lon":2.54955,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-neuilly-sur-marne"},{"id":"nct02417064-unnamed-trial-site-nimes","cat":"research","name":"Unnamed trial site","city":"Nîmes","country":"France","cc":"FR","lat":43.83227,"lon":4.35736,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-nimes"},{"id":"nct02417064-unnamed-trial-site-paris","cat":"research","name":"Unnamed trial site","city":"Paris","country":"France","cc":"FR","lat":48.85402,"lon":2.35271,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-paris"},{"id":"nct02417064-unnamed-trial-site-poitiers","cat":"research","name":"Unnamed trial site","city":"Poitiers","country":"France","cc":"FR","lat":46.58623,"lon":0.3423,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-poitiers"},{"id":"nct02417064-unnamed-trial-site-toulon","cat":"research","name":"Unnamed trial site","city":"Toulon","country":"France","cc":"FR","lat":43.13209,"lon":5.93565,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-toulon"},{"id":"nct02417064-unnamed-trial-site-tours","cat":"research","name":"Unnamed trial site","city":"Tours","country":"France","cc":"FR","lat":47.39536,"lon":0.70911,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-tours"},{"id":"nct02417064-unnamed-trial-site-budapest","cat":"research","name":"Unnamed trial site","city":"Budapest","country":"Hungary","cc":"HU","lat":47.49661,"lon":19.03419,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-budapest"},{"id":"nct02417064-unnamed-trial-site-vac","cat":"research","name":"Unnamed trial site","city":"Vác","country":"Hungary","cc":"HU","lat":47.76767,"lon":19.13598,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-vac"},{"id":"nct02417064-unnamed-trial-site-guadalajara","cat":"research","name":"Unnamed trial site","city":"Guadalajara","country":"Mexico","cc":"MX","lat":20.68627,"lon":-103.35742,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-guadalajara"},{"id":"nct02417064-unnamed-trial-site-leon","cat":"research","name":"Unnamed trial site","city":"León","country":"Mexico","cc":"MX","lat":21.11378,"lon":-101.69331,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-leon"},{"id":"nct02417064-unnamed-trial-site-mazatlan","cat":"research","name":"Unnamed trial site","city":"Mazatlán","country":"Mexico","cc":"MX","lat":23.21641,"lon":-106.40798,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-mazatlan"},{"id":"nct02417064-unnamed-trial-site-mexico-city","cat":"research","name":"Unnamed trial site","city":"Mexico City","country":"Mexico","cc":"MX","lat":19.43849,"lon":-99.1278,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-mexico-city"},{"id":"nct02417064-unnamed-trial-site-monterrey","cat":"research","name":"Unnamed trial site","city":"Monterrey","country":"Mexico","cc":"MX","lat":25.68393,"lon":-100.32902,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-monterrey"},{"id":"nct02417064-unnamed-trial-site-san-luis-potosi-city","cat":"research","name":"Unnamed trial site","city":"San Luis Potosí City","country":"Mexico","cc":"MX","lat":22.15587,"lon":-100.9601,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-san-luis-potosi-city"},{"id":"nct02417064-unnamed-trial-site-bratislava","cat":"research","name":"Unnamed trial site","city":"Bratislava","country":"Slovakia","cc":"SK","lat":48.1403,"lon":17.10443,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-bratislava"},{"id":"nct02417064-unnamed-trial-site-liptovsky-mikulas","cat":"research","name":"Unnamed trial site","city":"Liptovský Mikuláš","country":"Slovakia","cc":"SK","lat":49.07717,"lon":19.63089,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-liptovsky-mikulas"},{"id":"nct02417064-unnamed-trial-site-rimavska-sobota","cat":"research","name":"Unnamed trial site","city":"Rimavská Sobota","country":"Slovakia","cc":"SK","lat":48.39079,"lon":20.03166,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-rimavska-sobota"},{"id":"nct02417064-unnamed-trial-site-roznava","cat":"research","name":"Unnamed trial site","city":"Rožňava","country":"Slovakia","cc":"SK","lat":48.64894,"lon":20.53132,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-roznava"},{"id":"nct02417064-unnamed-trial-site-svidnik","cat":"research","name":"Unnamed trial site","city":"Svidník","country":"Slovakia","cc":"SK","lat":49.31417,"lon":21.58108,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02417064","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02417064","phase":"Phase 3","enroll":346,"start":"2015-08-10","eid":"x:site:nct02417064-unnamed-trial-site-svidnik"},{"id":"nct06543563-beijing-tiantan-hospital-capital-medical-university-beijing","cat":"research","name":"Beijing Tiantan Hospital, Capital Medical University","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.9083,"lon":116.40349,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100070","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06543563","study":"Esketamine in Microelectrode Recording-guided Subthalamic Deep-Brain Stimulation for Parkinson's Disease","sstatus":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","official":"Ruquan Han, MD,PhD (Study Principal Investigator)","src":"https://clinicaltrials.gov/study/NCT06543563","contact":{"n":"Ruquan Han, MD,PhD","p":"8610-59976660","e":"ruquan.han@gmail.com"},"phase":"N/A","enroll":102,"start":"2024-08-09","eid":"x:site:nct06543563-beijing-tiantan-hospital-capital-medical-university-beijing"},{"id":"nct04587778-medical-university-of-vienna-vienna","cat":"research","name":"Medical University of Vienna","city":"Vienna","country":"Austria","cc":"AT","lat":48.20487,"lon":16.37956,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"1090","condg":["Depression"],"status":"RECRUITING","nct":"NCT04587778","study":"Imaging Neural Correlates of Ketamine Using PET/MR","sstatus":"UNKNOWN","sponsor":"Medical University of Vienna","src":"https://clinicaltrials.gov/study/NCT04587778","contact":{"n":"Rupert Lanzenberger, Prof.","p":"004314040035760","e":"rupert.lanzenberger@meduniwien.ac.at"},"phase":"Phase 1","enroll":65,"start":"2020-10-05","eid":"x:site:nct04587778-medical-university-of-vienna-vienna"},{"id":"nct05718024-peking-university-first-hospital-beijing","cat":"research","name":"Peking University First Hospital","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.89635,"lon":116.40763,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100034","condg":["Other"],"nct":"NCT05718024","study":"Night-time Dexmedetomidine-esketamine Infusion and Sleep Quality in ICU Patients","sstatus":"COMPLETED","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT05718024","phase":"Phase 4","enroll":174,"start":"2023-11-01","eid":"x:site:nct05718024-peking-university-first-hospital-beijing"},{"id":"nct06414941-department-of-anqing-hospital-anesthesiology-anqing","cat":"research","name":"Department of Anqing Hospital Anesthesiology","city":"Anqing","region":"Anhui","country":"China","cc":"CN","lat":30.50579,"lon":117.03721,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"246003","condg":["Other"],"status":"RECRUITING","nct":"NCT06414941","study":"The Effect of Dexmedetomidine and Esketamine Combined Infusion Quality of Sleep Undergoing Modified Radical Mastectomy","sstatus":"UNKNOWN","sponsor":"Anqing Municipal Hospital","src":"https://clinicaltrials.gov/study/NCT06414941","contact":{"n":"Xu si qi, Doctor","p":"13865192106","e":"errtg555@163.com"},"phase":"N/A","enroll":105,"start":"2024-05-15","eid":"x:site:nct06414941-department-of-anqing-hospital-anesthesiology-anqing"},{"id":"nct07399756-sheba-medical-center-ramat-gan","cat":"research","name":"Sheba Medical Center","city":"Ramat Gan","region":"Israel","country":"Israel","cc":"IL","lat":32.07366,"lon":34.81926,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"52621","condg":["Depression"],"nct":"NCT07399756","study":"Mitochondrial Function After Ketamine","sstatus":"NOT_YET_RECRUITING","sponsor":"Sheba Medical Center","src":"https://clinicaltrials.gov/study/NCT07399756","contact":{"n":"tzur mayer, dr","p":"972 035303318","e":"tzur.mayer@sheba.health.gov.il"},"enroll":30,"start":"2026-02","eid":"x:site:nct07399756-sheba-medical-center-ramat-gan"},{"id":"nct04436250-grand-hopital-de-charleroi-gilly","cat":"research","name":"Grand Hôpital de Charleroi","city":"Gilly","region":"Hainaut","country":"Belgium","cc":"BE","lat":50.43009,"lon":4.47612,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"6060","condg":["Chronic pain & headache"],"nct":"NCT04436250","study":"ESKETamine for FIBromyalgia Treatment","sstatus":"TERMINATED","sponsor":"Grand Hôpital de Charleroi","official":"Jean-Paul Lechat, MD (Grand Hôpital de Charleroi)","src":"https://clinicaltrials.gov/study/NCT04436250","phase":"N/A","enroll":23,"start":"2020-10-10","eid":"x:site:nct04436250-grand-hopital-de-charleroi-gilly"},{"id":"nct02493868-unnamed-trial-site-birmingham","cat":"research","name":"Unnamed trial site","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.51892,"lon":-86.8048,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-birmingham"},{"id":"nct02493868-unnamed-trial-site-little-rock","cat":"research","name":"Unnamed trial site","city":"Little Rock","region":"Arkansas","country":"United States","cc":"US","lat":34.74003,"lon":-92.28135,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-little-rock"},{"id":"nct02493868-unnamed-trial-site-anaheim","cat":"research","name":"Unnamed trial site","city":"Anaheim","region":"California","country":"United States","cc":"US","lat":33.83807,"lon":-117.90946,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-anaheim"},{"id":"nct02493868-unnamed-trial-site-garden-grove","cat":"research","name":"Unnamed trial site","city":"Garden Grove","region":"California","country":"United States","cc":"US","lat":33.77979,"lon":-117.94639,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-garden-grove"},{"id":"nct02493868-unnamed-trial-site-glendale","cat":"research","name":"Unnamed trial site","city":"Glendale","region":"California","country":"United States","cc":"US","lat":33.52674,"lon":-112.17465,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-glendale"},{"id":"nct02493868-unnamed-trial-site-oakland","cat":"research","name":"Unnamed trial site","city":"Oakland","region":"California","country":"United States","cc":"US","lat":37.80056,"lon":-122.26699,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-oakland"},{"id":"nct02493868-unnamed-trial-site-orange","cat":"research","name":"Unnamed trial site","city":"Orange","region":"California","country":"United States","cc":"US","lat":33.79433,"lon":-117.86266,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-orange"},{"id":"nct02493868-unnamed-trial-site-san-diego","cat":"research","name":"Unnamed trial site","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.70757,"lon":-117.16166,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-san-diego"},{"id":"nct02493868-unnamed-trial-site-san-marcos","cat":"research","name":"Unnamed trial site","city":"San Marcos","region":"California","country":"United States","cc":"US","lat":33.13758,"lon":-117.16769,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-san-marcos"},{"id":"nct02493868-unnamed-trial-site-san-rafael","cat":"research","name":"Unnamed trial site","city":"San Rafael","region":"California","country":"United States","cc":"US","lat":37.97584,"lon":-122.52135,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-san-rafael"},{"id":"nct02493868-unnamed-trial-site-hartford","cat":"research","name":"Unnamed trial site","city":"Hartford","region":"Connecticut","country":"United States","cc":"US","lat":41.77157,"lon":-72.67949,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-hartford"},{"id":"nct02493868-unnamed-trial-site-bradenton","cat":"research","name":"Unnamed trial site","city":"Bradenton","region":"Florida","country":"United States","cc":"US","lat":27.49408,"lon":-82.58447,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-bradenton"},{"id":"nct02493868-unnamed-trial-site-gainesville","cat":"research","name":"Unnamed trial site","city":"Gainesville","region":"Florida","country":"United States","cc":"US","lat":29.64885,"lon":-82.32977,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-gainesville"},{"id":"nct02493868-unnamed-trial-site-miami","cat":"research","name":"Unnamed trial site","city":"Miami","region":"Florida","country":"United States","cc":"US","lat":25.76274,"lon":-80.18571,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-miami"},{"id":"nct02493868-unnamed-trial-site-orlando","cat":"research","name":"Unnamed trial site","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.53415,"lon":-81.38192,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-orlando"},{"id":"nct02493868-unnamed-trial-site-tampa","cat":"research","name":"Unnamed trial site","city":"Tampa","region":"Florida","country":"United States","cc":"US","lat":27.94625,"lon":-82.46864,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-tampa"},{"id":"nct02493868-unnamed-trial-site-atlanta","cat":"research","name":"Unnamed trial site","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.74415,"lon":-84.39782,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-atlanta"},{"id":"nct02493868-unnamed-trial-site-chicago","cat":"research","name":"Unnamed trial site","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.86128,"lon":-87.64078,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-chicago"},{"id":"nct02493868-unnamed-trial-site-hoffman-estates","cat":"research","name":"Unnamed trial site","city":"Hoffman Estates","region":"Illinois","country":"United States","cc":"US","lat":42.03777,"lon":-88.07062,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-hoffman-estates"},{"id":"nct02493868-unnamed-trial-site-joliet","cat":"research","name":"Unnamed trial site","city":"Joliet","region":"Illinois","country":"United States","cc":"US","lat":41.53088,"lon":-88.08665,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-joliet"},{"id":"nct02493868-unnamed-trial-site-maywood","cat":"research","name":"Unnamed trial site","city":"Maywood","region":"Illinois","country":"United States","cc":"US","lat":33.99717,"lon":-118.19208,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-maywood"},{"id":"nct02493868-unnamed-trial-site-schaumburg","cat":"research","name":"Unnamed trial site","city":"Schaumburg","region":"Illinois","country":"United States","cc":"US","lat":42.04112,"lon":-88.08195,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-schaumburg"},{"id":"nct02493868-unnamed-trial-site-skokie","cat":"research","name":"Unnamed trial site","city":"Skokie","region":"Illinois","country":"United States","cc":"US","lat":42.03341,"lon":-87.72167,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-skokie"},{"id":"nct02493868-unnamed-trial-site-prairie-village","cat":"research","name":"Unnamed trial site","city":"Prairie Village","region":"Kansas","country":"United States","cc":"US","lat":38.98362,"lon":-94.64388,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-prairie-village"},{"id":"nct02493868-unnamed-trial-site-wichita","cat":"research","name":"Unnamed trial site","city":"Wichita","region":"Kansas","country":"United States","cc":"US","lat":37.69897,"lon":-97.32573,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-wichita"},{"id":"nct02493868-unnamed-trial-site-lake-charles","cat":"research","name":"Unnamed trial site","city":"Lake Charles","region":"Louisiana","country":"United States","cc":"US","lat":30.21248,"lon":-93.21339,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-lake-charles"},{"id":"nct02493868-unnamed-trial-site-baltimore","cat":"research","name":"Unnamed trial site","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29014,"lon":-76.62184,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-baltimore"},{"id":"nct02493868-unnamed-trial-site-gaithersburg","cat":"research","name":"Unnamed trial site","city":"Gaithersburg","region":"Maryland","country":"United States","cc":"US","lat":39.14019,"lon":-77.2065,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-gaithersburg"},{"id":"nct02493868-unnamed-trial-site-boston","cat":"research","name":"Unnamed trial site","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.34972,"lon":-71.06942,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-boston"},{"id":"nct02493868-unnamed-trial-site-new-bedford","cat":"research","name":"Unnamed trial site","city":"New Bedford","region":"Massachusetts","country":"United States","cc":"US","lat":41.63107,"lon":-70.93026,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-new-bedford"},{"id":"nct02493868-unnamed-trial-site-quincy","cat":"research","name":"Unnamed trial site","city":"Quincy","region":"Massachusetts","country":"United States","cc":"US","lat":42.25999,"lon":-71.00203,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-quincy"},{"id":"nct02493868-unnamed-trial-site-watertown","cat":"research","name":"Unnamed trial site","city":"Watertown","region":"Massachusetts","country":"United States","cc":"US","lat":42.36251,"lon":-71.17572,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-watertown"},{"id":"nct02493868-unnamed-trial-site-worcester","cat":"research","name":"Unnamed trial site","city":"Worcester","region":"Massachusetts","country":"United States","cc":"US","lat":42.27224,"lon":-71.79838,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-worcester"},{"id":"nct02493868-unnamed-trial-site-rochester-hills","cat":"research","name":"Unnamed trial site","city":"Rochester Hills","region":"Michigan","country":"United States","cc":"US","lat":42.6475,"lon":-83.16165,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-rochester-hills"},{"id":"nct02493868-unnamed-trial-site-minneapolis","cat":"research","name":"Unnamed trial site","city":"Minneapolis","region":"Minnesota","country":"United States","cc":"US","lat":44.98124,"lon":-93.2573,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-minneapolis"},{"id":"nct02493868-unnamed-trial-site-o-fallon","cat":"research","name":"Unnamed trial site","city":"O'Fallon","region":"Missouri","country":"United States","cc":"US","lat":38.80623,"lon":-90.69312,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-o-fallon"},{"id":"nct02493868-unnamed-trial-site-saint-charles","cat":"research","name":"Unnamed trial site","city":"Saint Charles","region":"Missouri","country":"United States","cc":"US","lat":38.79227,"lon":-90.49267,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-saint-charles"},{"id":"nct02493868-unnamed-trial-site-omaha","cat":"research","name":"Unnamed trial site","city":"Omaha","region":"Nebraska","country":"United States","cc":"US","lat":41.24511,"lon":-95.94914,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-omaha"},{"id":"nct02493868-unnamed-trial-site-new-york","cat":"research","name":"Unnamed trial site","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70255,"lon":-74.01731,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-new-york"},{"id":"nct02493868-unnamed-trial-site-durham","cat":"research","name":"Unnamed trial site","city":"Durham","region":"North Carolina","country":"United States","cc":"US","lat":35.99408,"lon":-78.90638,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-durham"},{"id":"nct02493868-unnamed-trial-site-hickory","cat":"research","name":"Unnamed trial site","city":"Hickory","region":"North Carolina","country":"United States","cc":"US","lat":35.73079,"lon":-81.34529,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-hickory"},{"id":"nct02493868-unnamed-trial-site-oklahoma-city","cat":"research","name":"Unnamed trial site","city":"Oklahoma City","region":"Oklahoma","country":"United States","cc":"US","lat":35.47297,"lon":-97.51243,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-oklahoma-city"},{"id":"nct02493868-unnamed-trial-site-media","cat":"research","name":"Unnamed trial site","city":"Media","region":"Pennsylvania","country":"United States","cc":"US","lat":39.91654,"lon":-75.37945,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-media"},{"id":"nct02493868-unnamed-trial-site-philadelphia","cat":"research","name":"Unnamed trial site","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.96156,"lon":-75.15454,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-philadelphia"},{"id":"nct02493868-unnamed-trial-site-scranton","cat":"research","name":"Unnamed trial site","city":"Scranton","region":"Pennsylvania","country":"United States","cc":"US","lat":41.4045,"lon":-75.66918,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-scranton"},{"id":"nct02493868-unnamed-trial-site-lincoln","cat":"research","name":"Unnamed trial site","city":"Lincoln","region":"Rhode Island","country":"United States","cc":"US","lat":40.796,"lon":-96.65778,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-lincoln"},{"id":"nct02493868-unnamed-trial-site-providence","cat":"research","name":"Unnamed trial site","city":"Providence","region":"Rhode Island","country":"United States","cc":"US","lat":41.81566,"lon":-71.40601,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-providence"},{"id":"nct02493868-unnamed-trial-site-arlington","cat":"research","name":"Unnamed trial site","city":"Arlington","region":"Texas","country":"United States","cc":"US","lat":32.74054,"lon":-97.11772,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-arlington"},{"id":"nct02493868-unnamed-trial-site-austin","cat":"research","name":"Unnamed trial site","city":"Austin","region":"Texas","country":"United States","cc":"US","lat":30.26786,"lon":-97.75346,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-austin"},{"id":"nct02493868-unnamed-trial-site-dallas","cat":"research","name":"Unnamed trial site","city":"Dallas","region":"Texas","country":"United States","cc":"US","lat":32.79299,"lon":-96.80559,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-dallas"},{"id":"nct02493868-unnamed-trial-site-houston","cat":"research","name":"Unnamed trial site","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.76474,"lon":-95.36868,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-houston"},{"id":"nct02493868-unnamed-trial-site-charlottesville","cat":"research","name":"Unnamed trial site","city":"Charlottesville","region":"Virginia","country":"United States","cc":"US","lat":38.03717,"lon":-78.47052,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-charlottesville"},{"id":"nct02493868-unnamed-trial-site-waukesha","cat":"research","name":"Unnamed trial site","city":"Waukesha","region":"Wisconsin","country":"United States","cc":"US","lat":43.01483,"lon":-88.22117,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-waukesha"},{"id":"nct02493868-unnamed-trial-site-aalst","cat":"research","name":"Unnamed trial site","city":"Aalst","country":"Belgium","cc":"BE","lat":50.93298,"lon":4.04618,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-aalst"},{"id":"nct02493868-unnamed-trial-site-bruges","cat":"research","name":"Unnamed trial site","city":"Bruges","country":"Belgium","cc":"BE","lat":51.21603,"lon":3.23097,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-bruges"},{"id":"nct02493868-unnamed-trial-site-brussels","cat":"research","name":"Unnamed trial site","city":"Brussels","country":"Belgium","cc":"BE","lat":50.85501,"lon":4.35739,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-brussels"},{"id":"nct02493868-unnamed-trial-site-heusden-zolder","cat":"research","name":"Unnamed trial site","city":"Heusden-Zolder","country":"Belgium","cc":"BE","lat":50.6132,"lon":4.4449,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-heusden-zolder"},{"id":"nct02493868-unnamed-trial-site-liege","cat":"research","name":"Unnamed trial site","city":"Liège","country":"Belgium","cc":"BE","lat":50.63415,"lon":5.5778,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-liege"},{"id":"nct02493868-unnamed-trial-site-yvoir","cat":"research","name":"Unnamed trial site","city":"Yvoir","country":"Belgium","cc":"BE","lat":50.33397,"lon":4.87461,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-yvoir"},{"id":"nct02493868-unnamed-trial-site-belo-horizonte","cat":"research","name":"Unnamed trial site","city":"Belo Horizonte","country":"Brazil","cc":"BR","lat":-19.92671,"lon":-43.92936,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-belo-horizonte"},{"id":"nct02493868-unnamed-trial-site-curitiba","cat":"research","name":"Unnamed trial site","city":"Curitiba","country":"Brazil","cc":"BR","lat":-25.4362,"lon":-49.27499,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-curitiba"},{"id":"nct02493868-unnamed-trial-site-fortaleza","cat":"research","name":"Unnamed trial site","city":"Fortaleza","country":"Brazil","cc":"BR","lat":-3.7135,"lon":-38.54292,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-fortaleza"},{"id":"nct02493868-unnamed-trial-site-goiania","cat":"research","name":"Unnamed trial site","city":"Goiânia","country":"Brazil","cc":"BR","lat":-16.68957,"lon":-49.25196,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-goiania"},{"id":"nct02493868-unnamed-trial-site-itapira","cat":"research","name":"Unnamed trial site","city":"Itapira","country":"Brazil","cc":"BR","lat":-22.43719,"lon":-46.82181,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-itapira"},{"id":"nct02493868-unnamed-trial-site-passo-fundo","cat":"research","name":"Unnamed trial site","city":"Passo Fundo","country":"Brazil","cc":"BR","lat":-28.25934,"lon":-52.4118,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-passo-fundo"},{"id":"nct02493868-unnamed-trial-site-porto-alegre","cat":"research","name":"Unnamed trial site","city":"Porto Alegre","country":"Brazil","cc":"BR","lat":-30.03834,"lon":-51.23052,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-porto-alegre"},{"id":"nct02493868-unnamed-trial-site-rio-de-janeiro","cat":"research","name":"Unnamed trial site","city":"Rio de Janeiro","country":"Brazil","cc":"BR","lat":-22.91277,"lon":-43.18049,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-rio-de-janeiro"},{"id":"nct02493868-unnamed-trial-site-santo-andre","cat":"research","name":"Unnamed trial site","city":"Santo André","country":"Brazil","cc":"BR","lat":-23.66413,"lon":-46.53452,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-santo-andre"},{"id":"nct02493868-unnamed-trial-site-sao-jose-do-rio-preto","cat":"research","name":"Unnamed trial site","city":"São José do Rio Preto","country":"Brazil","cc":"BR","lat":-20.816,"lon":-49.38344,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-sao-jose-do-rio-preto"},{"id":"nct02493868-unnamed-trial-site-sao-paulo","cat":"research","name":"Unnamed trial site","city":"São Paulo","country":"Brazil","cc":"BR","lat":-23.54971,"lon":-46.637,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-sao-paulo"},{"id":"nct02493868-unnamed-trial-site-calgary","cat":"research","name":"Unnamed trial site","city":"Calgary","region":"Alberta","country":"Canada","cc":"CA","lat":51.06117,"lon":-114.09475,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-calgary"},{"id":"nct02493868-unnamed-trial-site-vancouver","cat":"research","name":"Unnamed trial site","city":"Vancouver","region":"British Columbia","country":"Canada","cc":"CA","lat":49.24077,"lon":-123.11007,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-vancouver"},{"id":"nct02493868-unnamed-trial-site-kingston","cat":"research","name":"Unnamed trial site","city":"Kingston","region":"Ontario","country":"Canada","cc":"CA","lat":44.23169,"lon":-76.48027,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-kingston"},{"id":"nct02493868-unnamed-trial-site-ottawa","cat":"research","name":"Unnamed trial site","city":"Ottawa","region":"Ontario","country":"Canada","cc":"CA","lat":45.40576,"lon":-75.69619,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-ottawa"},{"id":"nct02493868-unnamed-trial-site-toronto","cat":"research","name":"Unnamed trial site","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70008,"lon":-79.39982,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-toronto"},{"id":"nct02493868-unnamed-trial-site-montreal","cat":"research","name":"Unnamed trial site","city":"Montreal","region":"Quebec","country":"Canada","cc":"CA","lat":45.5038,"lon":-73.584,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-montreal"},{"id":"nct02493868-unnamed-trial-site-brno","cat":"research","name":"Unnamed trial site","city":"Brno","country":"Czechia","cc":"CZ","lat":49.19386,"lon":16.61469,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-brno"},{"id":"nct02493868-unnamed-trial-site-hostivice","cat":"research","name":"Unnamed trial site","city":"Hostivice","country":"Czechia","cc":"CZ","lat":50.08567,"lon":14.24844,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-hostivice"},{"id":"nct02493868-unnamed-trial-site-klecany","cat":"research","name":"Unnamed trial site","city":"Klecany","country":"Czechia","cc":"CZ","lat":50.17575,"lon":14.40701,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-klecany"},{"id":"nct02493868-unnamed-trial-site-kutna-hora","cat":"research","name":"Unnamed trial site","city":"Kutná Hora","country":"Czechia","cc":"CZ","lat":49.95804,"lon":15.27263,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-kutna-hora"},{"id":"nct02493868-unnamed-trial-site-litomerice","cat":"research","name":"Unnamed trial site","city":"Litoměřice","country":"Czechia","cc":"CZ","lat":50.53089,"lon":14.12545,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-litomerice"},{"id":"nct02493868-unnamed-trial-site-pilsen","cat":"research","name":"Unnamed trial site","city":"Pilsen","country":"Czechia","cc":"CZ","lat":49.75514,"lon":13.38507,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-pilsen"},{"id":"nct02493868-unnamed-trial-site-prague","cat":"research","name":"Unnamed trial site","city":"Prague","country":"Czechia","cc":"CZ","lat":50.08969,"lon":14.43201,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-prague"},{"id":"nct02493868-unnamed-trial-site-strakonice","cat":"research","name":"Unnamed trial site","city":"Strakonice","country":"Czechia","cc":"CZ","lat":49.2607,"lon":13.89941,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-strakonice"},{"id":"nct02493868-unnamed-trial-site-parnu","cat":"research","name":"Unnamed trial site","city":"Pärnu","country":"Estonia","cc":"EE","lat":58.38,"lon":24.49857,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-parnu"},{"id":"nct02493868-unnamed-trial-site-tallinn","cat":"research","name":"Unnamed trial site","city":"Tallinn","country":"Estonia","cc":"EE","lat":59.43861,"lon":24.75264,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-tallinn"},{"id":"nct02493868-unnamed-trial-site-tartu","cat":"research","name":"Unnamed trial site","city":"Tartu","country":"Estonia","cc":"EE","lat":58.37954,"lon":26.73013,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-tartu"},{"id":"nct02493868-unnamed-trial-site-clermont-ferrand","cat":"research","name":"Unnamed trial site","city":"Clermont-Ferrand","country":"France","cc":"FR","lat":45.77014,"lon":3.07802,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-clermont-ferrand"},{"id":"nct02493868-unnamed-trial-site-douai","cat":"research","name":"Unnamed trial site","city":"Douai","country":"France","cc":"FR","lat":50.36584,"lon":3.0707,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-douai"},{"id":"nct02493868-unnamed-trial-site-nantes","cat":"research","name":"Unnamed trial site","city":"Nantes","country":"France","cc":"FR","lat":47.22341,"lon":-1.55802,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-nantes"},{"id":"nct02493868-unnamed-trial-site-nimes","cat":"research","name":"Unnamed trial site","city":"Nîmes","country":"France","cc":"FR","lat":43.83914,"lon":4.35981,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-nimes"},{"id":"nct02493868-unnamed-trial-site-paris","cat":"research","name":"Unnamed trial site","city":"Paris","country":"France","cc":"FR","lat":48.85637,"lon":2.34122,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-paris"},{"id":"nct02493868-unnamed-trial-site-poitiers","cat":"research","name":"Unnamed trial site","city":"Poitiers","country":"France","cc":"FR","lat":46.5724,"lon":0.3344,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-poitiers"},{"id":"nct02493868-unnamed-trial-site-toulon","cat":"research","name":"Unnamed trial site","city":"Toulon","country":"France","cc":"FR","lat":43.13491,"lon":5.93387,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-toulon"},{"id":"nct02493868-unnamed-trial-site-berlin","cat":"research","name":"Unnamed trial site","city":"Berlin","country":"Germany","cc":"DE","lat":52.51905,"lon":13.40841,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-berlin"},{"id":"nct02493868-unnamed-trial-site-cham","cat":"research","name":"Unnamed trial site","city":"Cham","country":"Germany","cc":"DE","lat":49.21525,"lon":12.64809,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-cham"},{"id":"nct02493868-unnamed-trial-site-gelsenkirchen","cat":"research","name":"Unnamed trial site","city":"Gelsenkirchen","country":"Germany","cc":"DE","lat":51.49572,"lon":7.09885,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-gelsenkirchen"},{"id":"nct02493868-unnamed-trial-site-halle","cat":"research","name":"Unnamed trial site","city":"Halle","country":"Germany","cc":"DE","lat":52.06831,"lon":8.35335,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-halle"},{"id":"nct02493868-unnamed-trial-site-mainz","cat":"research","name":"Unnamed trial site","city":"Mainz","country":"Germany","cc":"DE","lat":49.98905,"lon":8.28144,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-mainz"},{"id":"nct02493868-unnamed-trial-site-mittweida","cat":"research","name":"Unnamed trial site","city":"Mittweida","country":"Germany","cc":"DE","lat":50.9746,"lon":12.98135,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-mittweida"},{"id":"nct02493868-unnamed-trial-site-pfaffenhofen","cat":"research","name":"Unnamed trial site","city":"Pfaffenhofen","country":"Germany","cc":"DE","lat":49.06919,"lon":8.98641,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-pfaffenhofen"},{"id":"nct02493868-unnamed-trial-site-prien-am-chiemsee","cat":"research","name":"Unnamed trial site","city":"Prien am Chiemsee","country":"Germany","cc":"DE","lat":47.85541,"lon":12.33856,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-prien-am-chiemsee"},{"id":"nct02493868-unnamed-trial-site-balassagyarmat","cat":"research","name":"Unnamed trial site","city":"Balassagyarmat","country":"Hungary","cc":"HU","lat":48.08007,"lon":19.28885,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-balassagyarmat"},{"id":"nct02493868-unnamed-trial-site-budapest","cat":"research","name":"Unnamed trial site","city":"Budapest","country":"Hungary","cc":"HU","lat":47.51026,"lon":19.05019,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-budapest"},{"id":"nct02493868-unnamed-trial-site-debrecen","cat":"research","name":"Unnamed trial site","city":"Debrecen","country":"Hungary","cc":"HU","lat":47.53586,"lon":21.6339,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-debrecen"},{"id":"nct02493868-unnamed-trial-site-gyor","cat":"research","name":"Unnamed trial site","city":"Győr","country":"Hungary","cc":"HU","lat":47.69091,"lon":17.63065,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-gyor"},{"id":"nct02493868-unnamed-trial-site-pecs","cat":"research","name":"Unnamed trial site","city":"Pécs","country":"Hungary","cc":"HU","lat":46.06558,"lon":18.23562,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-pecs"},{"id":"nct02493868-unnamed-trial-site-sopron","cat":"research","name":"Unnamed trial site","city":"Sopron","country":"Hungary","cc":"HU","lat":47.68092,"lon":16.60004,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-sopron"},{"id":"nct02493868-unnamed-trial-site-szeged","cat":"research","name":"Unnamed trial site","city":"Szeged","country":"Hungary","cc":"HU","lat":46.25446,"lon":20.15892,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-szeged"},{"id":"nct02493868-unnamed-trial-site-szekszard","cat":"research","name":"Unnamed trial site","city":"Szekszárd","country":"Hungary","cc":"HU","lat":46.3405,"lon":18.71937,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-szekszard"},{"id":"nct02493868-unnamed-trial-site-vac","cat":"research","name":"Unnamed trial site","city":"Vác","country":"Hungary","cc":"HU","lat":47.76626,"lon":19.12836,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-vac"},{"id":"nct02493868-unnamed-trial-site-guadalajara","cat":"research","name":"Unnamed trial site","city":"Guadalajara","country":"Mexico","cc":"MX","lat":20.68176,"lon":-103.33963,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-guadalajara"},{"id":"nct02493868-unnamed-trial-site-leon","cat":"research","name":"Unnamed trial site","city":"León","country":"Mexico","cc":"MX","lat":21.11519,"lon":-101.69274,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-leon"},{"id":"nct02493868-unnamed-trial-site-mexico-city","cat":"research","name":"Unnamed trial site","city":"Mexico City","country":"Mexico","cc":"MX","lat":19.41958,"lon":-99.11585,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-mexico-city"},{"id":"nct02493868-unnamed-trial-site-monterrey","cat":"research","name":"Unnamed trial site","city":"Monterrey","country":"Mexico","cc":"MX","lat":25.69061,"lon":-100.31952,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-monterrey"},{"id":"nct02493868-unnamed-trial-site-san-luis-potosi-city","cat":"research","name":"Unnamed trial site","city":"San Luis Potosí City","country":"Mexico","cc":"MX","lat":22.15709,"lon":-100.96594,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-san-luis-potosi-city"},{"id":"nct02493868-unnamed-trial-site-be-chatow","cat":"research","name":"Unnamed trial site","city":"Bełchatów","country":"Poland","cc":"PL","lat":51.37123,"lon":19.34951,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-be-chatow"},{"id":"nct02493868-unnamed-trial-site-bialystok","cat":"research","name":"Unnamed trial site","city":"Bialystok","country":"Poland","cc":"PL","lat":53.14269,"lon":23.15468,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-bialystok"},{"id":"nct02493868-unnamed-trial-site-bydgoszcz","cat":"research","name":"Unnamed trial site","city":"Bydgoszcz","country":"Poland","cc":"PL","lat":53.12534,"lon":17.99986,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-bydgoszcz"},{"id":"nct02493868-unnamed-trial-site-gdansk","cat":"research","name":"Unnamed trial site","city":"Gdansk","country":"Poland","cc":"PL","lat":54.34742,"lon":18.64512,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-gdansk"},{"id":"nct02493868-unnamed-trial-site-leszno","cat":"research","name":"Unnamed trial site","city":"Leszno","country":"Poland","cc":"PL","lat":51.83408,"lon":16.57188,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-leszno"},{"id":"nct02493868-unnamed-trial-site-lodz","cat":"research","name":"Unnamed trial site","city":"Lodz","country":"Poland","cc":"PL","lat":51.77863,"lon":19.48557,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-lodz"},{"id":"nct02493868-unnamed-trial-site-lublin","cat":"research","name":"Unnamed trial site","city":"Lublin","country":"Poland","cc":"PL","lat":51.25571,"lon":22.57465,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-lublin"},{"id":"nct02493868-unnamed-trial-site-pruszkow","cat":"research","name":"Unnamed trial site","city":"Pruszków","country":"Poland","cc":"PL","lat":52.16286,"lon":20.82273,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-pruszkow"},{"id":"nct02493868-unnamed-trial-site-torun","cat":"research","name":"Unnamed trial site","city":"Torun","country":"Poland","cc":"PL","lat":53.00674,"lon":18.6028,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-torun"},{"id":"nct02493868-unnamed-trial-site-tuszyn","cat":"research","name":"Unnamed trial site","city":"Tuszyn","country":"Poland","cc":"PL","lat":51.61518,"lon":19.53277,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-tuszyn"},{"id":"nct02493868-unnamed-trial-site-warsaw","cat":"research","name":"Unnamed trial site","city":"Warsaw","country":"Poland","cc":"PL","lat":52.23979,"lon":21.00129,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-warsaw"},{"id":"nct02493868-unnamed-trial-site-bratislava","cat":"research","name":"Unnamed trial site","city":"Bratislava","country":"Slovakia","cc":"SK","lat":48.14171,"lon":17.10867,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-bratislava"},{"id":"nct02493868-unnamed-trial-site-liptovsky-mikulas","cat":"research","name":"Unnamed trial site","city":"Liptovský Mikuláš","country":"Slovakia","cc":"SK","lat":49.09261,"lon":19.62703,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-liptovsky-mikulas"},{"id":"nct02493868-unnamed-trial-site-rimavska-sobota","cat":"research","name":"Unnamed trial site","city":"Rimavská Sobota","country":"Slovakia","cc":"SK","lat":48.38053,"lon":20.03147,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-rimavska-sobota"},{"id":"nct02493868-unnamed-trial-site-roznava","cat":"research","name":"Unnamed trial site","city":"Rožňava","country":"Slovakia","cc":"SK","lat":48.65044,"lon":20.54412,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-roznava"},{"id":"nct02493868-unnamed-trial-site-svidnik","cat":"research","name":"Unnamed trial site","city":"Svidník","country":"Slovakia","cc":"SK","lat":49.3137,"lon":21.57317,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-svidnik"},{"id":"nct02493868-unnamed-trial-site-alcorcon","cat":"research","name":"Unnamed trial site","city":"Alcorcón","country":"Spain","cc":"ES","lat":40.34803,"lon":-3.81503,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-alcorcon"},{"id":"nct02493868-unnamed-trial-site-barcelona","cat":"research","name":"Unnamed trial site","city":"Barcelona","country":"Spain","cc":"ES","lat":41.39147,"lon":2.15132,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-barcelona"},{"id":"nct02493868-unnamed-trial-site-palma","cat":"research","name":"Unnamed trial site","city":"Palma","country":"Spain","cc":"ES","lat":39.57847,"lon":2.64605,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-palma"},{"id":"nct02493868-unnamed-trial-site-pamplona","cat":"research","name":"Unnamed trial site","city":"Pamplona","country":"Spain","cc":"ES","lat":42.80732,"lon":-1.63556,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-pamplona"},{"id":"nct02493868-unnamed-trial-site-ponferrada","cat":"research","name":"Unnamed trial site","city":"Ponferrada","country":"Spain","cc":"ES","lat":42.53869,"lon":-6.59859,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-ponferrada"},{"id":"nct02493868-unnamed-trial-site-sabadell","cat":"research","name":"Unnamed trial site","city":"Sabadell","country":"Spain","cc":"ES","lat":41.54927,"lon":2.11238,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-sabadell"},{"id":"nct02493868-unnamed-trial-site-salamanca","cat":"research","name":"Unnamed trial site","city":"Salamanca","country":"Spain","cc":"ES","lat":40.4308,"lon":-3.67754,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-salamanca"},{"id":"nct02493868-unnamed-trial-site-vitoria-gasteiz","cat":"research","name":"Unnamed trial site","city":"Vitoria-Gasteiz","country":"Spain","cc":"ES","lat":42.85982,"lon":-2.6636,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-vitoria-gasteiz"},{"id":"nct02493868-unnamed-trial-site-lund","cat":"research","name":"Unnamed trial site","city":"Lund","country":"Sweden","cc":"SE","lat":55.70071,"lon":13.18723,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-lund"},{"id":"nct02493868-unnamed-trial-site-skovde","cat":"research","name":"Unnamed trial site","city":"Skövde","country":"Sweden","cc":"SE","lat":58.3964,"lon":13.85461,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-skovde"},{"id":"nct02493868-unnamed-trial-site-solna","cat":"research","name":"Unnamed trial site","city":"Solna","country":"Sweden","cc":"SE","lat":59.36216,"lon":17.98971,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-solna"},{"id":"nct02493868-unnamed-trial-site-stockholm","cat":"research","name":"Unnamed trial site","city":"Stockholm","country":"Sweden","cc":"SE","lat":59.32764,"lon":18.06377,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-stockholm"},{"id":"nct02493868-unnamed-trial-site-adana","cat":"research","name":"Unnamed trial site","city":"Adana","country":"Turkey","cc":"TR","lat":36.98017,"lon":35.33063,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-adana"},{"id":"nct02493868-unnamed-trial-site-ankara","cat":"research","name":"Unnamed trial site","city":"Ankara","country":"Turkey","cc":"TR","lat":39.91427,"lon":32.85385,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-ankara"},{"id":"nct02493868-unnamed-trial-site-bursa","cat":"research","name":"Unnamed trial site","city":"Bursa","country":"Turkey","cc":"TR","lat":40.19771,"lon":29.04917,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-bursa"},{"id":"nct02493868-unnamed-trial-site-denizli","cat":"research","name":"Unnamed trial site","city":"Denizli","country":"Turkey","cc":"TR","lat":37.7713,"lon":29.08623,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-denizli"},{"id":"nct02493868-unnamed-trial-site-istanbul","cat":"research","name":"Unnamed trial site","city":"Istanbul","country":"Turkey","cc":"TR","lat":41.02245,"lon":28.94415,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-istanbul"},{"id":"nct02493868-unnamed-trial-site-izmir","cat":"research","name":"Unnamed trial site","city":"Izmir","country":"Turkey","cc":"TR","lat":38.4076,"lon":27.13758,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-izmir"},{"id":"nct02493868-unnamed-trial-site-kucukcekmece-istanbul","cat":"research","name":"Unnamed trial site","city":"Kucukcekmece/Istanbul","country":"Turkey","cc":"TR","lat":40.212,"lon":32.8053,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-kucukcekmece-istanbul"},{"id":"nct02493868-unnamed-trial-site-manisa","cat":"research","name":"Unnamed trial site","city":"Manisa","country":"Turkey","cc":"TR","lat":38.60858,"lon":27.41607,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-manisa"},{"id":"nct02493868-unnamed-trial-site-oanakkale","cat":"research","name":"Unnamed trial site","city":"Oanakkale","country":"Turkey","cc":"TR","lat":40.2709,"lon":33.2641,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-oanakkale"},{"id":"nct02493868-unnamed-trial-site-sakarya","cat":"research","name":"Unnamed trial site","city":"Sakarya","country":"Turkey","cc":"TR","lat":40.78503,"lon":30.411,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-sakarya"},{"id":"nct02493868-unnamed-trial-site-samsun","cat":"research","name":"Unnamed trial site","city":"Samsun","country":"Turkey","cc":"TR","lat":41.29176,"lon":36.33728,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02493868","study":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02493868","phase":"Phase 3","enroll":719,"start":"2015-10-01","eid":"x:site:nct02493868-unnamed-trial-site-samsun"},{"id":"nct06726382-department-of-clinical-pharmacology-helsinki","cat":"research","name":"Department of Clinical Pharmacology","city":"Helsinki","country":"Finland","cc":"FI","lat":60.16354,"lon":24.93616,"gp":"city","unnamed":0,"drugs":["esketamine"],"condg":["Other"],"nct":"NCT06726382","study":"KF2024#1-trial: Esketamine Interaction Study","sstatus":"COMPLETED","sponsor":"Helsinki University Central Hospital","official":"Janne T Backman, MD, PhD (Helsinki University Central Hospital)","src":"https://clinicaltrials.gov/study/NCT06726382","phase":"Phase 1","enroll":12,"start":"2024-12-09","eid":"x:site:nct06726382-department-of-clinical-pharmacology-helsinki"},{"id":"nct06725277-mood-institute-milford","cat":"research","name":"Mood Institute","city":"Milford","region":"Connecticut","country":"United States","cc":"US","lat":41.2203,"lon":-73.05297,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"06461","condg":["Depression"],"status":"RECRUITING","nct":"NCT06725277","study":"The OBSERVE Protocol","sstatus":"RECRUITING","sponsor":"Yale University","official":"Samuel Wilkinson, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT06725277","contact":{"n":"Lisa Harding, MD","p":"203-701-9737","e":"Trials@DepressionMD.com"},"enroll":450,"start":"2024-01-21","eid":"x:site:nct06725277-mood-institute-milford"},{"id":"nct06725277-yale-school-of-medicine-new-haven","cat":"research","name":"Yale School of Medicine","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31846,"lon":-72.93715,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"06512","condg":["Depression"],"status":"RECRUITING","nct":"NCT06725277","study":"The OBSERVE Protocol","sstatus":"RECRUITING","sponsor":"Yale University","official":"Samuel Wilkinson, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT06725277","contact":{"n":"Cindy Voghell","p":"203-737-4784","e":"cynthia.voghell@yale.edu"},"enroll":450,"start":"2024-01-21","eid":"x:site:nct06725277-yale-school-of-medicine-new-haven"},{"id":"nct06725277-emory-university-atlanta","cat":"research","name":"Emory University","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.75836,"lon":-84.39452,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"30322","condg":["Depression"],"status":"RECRUITING","nct":"NCT06725277","study":"The OBSERVE Protocol","sstatus":"RECRUITING","sponsor":"Yale University","official":"Samuel Wilkinson, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT06725277","contact":{"n":"Brandon Kitay, MD, PhD","p":"404-712-6939","e":"cynthia.voghell@yale.edu"},"enroll":450,"start":"2024-01-21","eid":"x:site:nct06725277-emory-university-atlanta"},{"id":"nct06725277-university-of-michigan-ann-arbor","cat":"research","name":"University of Michigan","city":"Ann Arbor","region":"Michigan","country":"United States","cc":"US","lat":42.26951,"lon":-83.73839,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"48104","condg":["Depression"],"status":"ACTIVE_NOT_RECRUITING","nct":"NCT06725277","study":"The OBSERVE Protocol","sstatus":"RECRUITING","sponsor":"Yale University","official":"Samuel Wilkinson, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT06725277","contact":{"n":"Cindy Voghell","p":"203-737-4784","e":"cynthia.voghell@yale.edu"},"enroll":450,"start":"2024-01-21","eid":"x:site:nct06725277-university-of-michigan-ann-arbor"},{"id":"nct06725277-lifestance-health-moore","cat":"research","name":"LifeStance Health","city":"Moore","region":"Oklahoma","country":"United States","cc":"US","lat":35.34822,"lon":-97.47828,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"73160","condg":["Depression"],"status":"ACTIVE_NOT_RECRUITING","nct":"NCT06725277","study":"The OBSERVE Protocol","sstatus":"RECRUITING","sponsor":"Yale University","official":"Samuel Wilkinson, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT06725277","contact":{"n":"Cindy Voghell","p":"203-737-4784","e":"cynthia.voghell@yale.edu"},"enroll":450,"start":"2024-01-21","eid":"x:site:nct06725277-lifestance-health-moore"},{"id":"nct06725277-athena-care-nashville","cat":"research","name":"Athena Care","city":"Nashville","region":"Tennessee","country":"United States","cc":"US","lat":36.17469,"lon":-86.79032,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"37228","condg":["Depression"],"status":"RECRUITING","nct":"NCT06725277","study":"The OBSERVE Protocol","sstatus":"RECRUITING","sponsor":"Yale University","official":"Samuel Wilkinson, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT06725277","contact":{"n":"Amanda Sparks-Bushnell, MD","p":"615-861-1000","e":"interventional@athenacare.health"},"enroll":450,"start":"2024-01-21","eid":"x:site:nct06725277-athena-care-nashville"},{"id":"nct06725277-houston-center-for-advanced-psychiatric-treatment-bellaire","cat":"research","name":"Houston Center for Advanced Psychiatric Treatment","city":"Bellaire","region":"Texas","country":"United States","cc":"US","lat":29.69906,"lon":-95.46264,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"77401","condg":["Depression"],"status":"RECRUITING","nct":"NCT06725277","study":"The OBSERVE Protocol","sstatus":"RECRUITING","sponsor":"Yale University","official":"Samuel Wilkinson, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT06725277","contact":{"n":"Sandhya Prashad, MD","p":"203-737-4784","e":"cynthia.voghell@yale.edu"},"enroll":450,"start":"2024-01-21","eid":"x:site:nct06725277-houston-center-for-advanced-psychiatric-treatment-bellaire"},{"id":"nct06725277-seattle-ntc-seattle","cat":"research","name":"Seattle NTC","city":"Seattle","region":"Washington","country":"United States","cc":"US","lat":47.5992,"lon":-122.34125,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"98104","condg":["Depression"],"status":"RECRUITING","nct":"NCT06725277","study":"The OBSERVE Protocol","sstatus":"RECRUITING","sponsor":"Yale University","official":"Samuel Wilkinson, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT06725277","contact":{"n":"Rebecca Allen, MD","p":"206-467-6300","e":"Rebecca.Allen@seattlentc.com"},"enroll":450,"start":"2024-01-21","eid":"x:site:nct06725277-seattle-ntc-seattle"},{"id":"nct02857777-unnamed-trial-site-cypress","cat":"research","name":"Unnamed trial site","city":"Cypress","region":"California","country":"United States","cc":"US","lat":29.97207,"lon":-95.70277,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Healthy volunteers"],"nct":"NCT02857777","study":"Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly Japanese, and Healthy Younger Adult Japanese Subjects","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02857777","phase":"Phase 1","enroll":37,"start":"2016-08-09","eid":"x:site:nct02857777-unnamed-trial-site-cypress"},{"id":"nct07153406-clinica-psiquiatrica-padre-menni-pamplona","cat":"research","name":"Clínica Psiquiátrica Padre Menni","city":"Pamplona","region":"Navarre","country":"Spain","cc":"ES","lat":42.82238,"lon":-1.65382,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"31014","condg":["Depression"],"nct":"NCT07153406","study":"Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients","sstatus":"NOT_YET_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","official":"Benedicto Crespo Facorro, MD (Fundación para la Gestión de la Investigación en Salud de Sevilla)","src":"https://clinicaltrials.gov/study/NCT07153406","contact":{"n":"José Joaquín Roldán Larreta, MD","p":"+34948140611","e":"jjroldan.mennipamplona@hospitalarias.es"},"phase":"Phase 3","enroll":220,"start":"2025-09-15","eid":"x:site:nct07153406-clinica-psiquiatrica-padre-menni-pamplona"},{"id":"nct07153406-hospital-vall-d-hebron-barcelona","cat":"research","name":"Hospital Vall d'Hebron","city":"Barcelona","country":"Spain","cc":"ES","lat":41.39477,"lon":2.16713,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"08014","condg":["Depression"],"nct":"NCT07153406","study":"Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients","sstatus":"NOT_YET_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","official":"Benedicto Crespo Facorro, MD (Fundación para la Gestión de la Investigación en Salud de Sevilla)","src":"https://clinicaltrials.gov/study/NCT07153406","contact":{"n":"Clara M Rosso Fernández, MD-PhD","p":"+34955013414","e":"claram.rosso.sspa@juntadeandalucia.es"},"phase":"Phase 3","enroll":220,"start":"2025-09-15","eid":"x:site:nct07153406-hospital-vall-d-hebron-barcelona"},{"id":"nct07153406-hospital-de-la-santa-creu-i-sant-pau-barcelona","cat":"research","name":"Hospital De La Santa Creu i Sant Pau","city":"Barcelona","country":"Spain","cc":"ES","lat":41.38818,"lon":2.16939,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"08041","condg":["Depression"],"nct":"NCT07153406","study":"Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients","sstatus":"NOT_YET_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","official":"Benedicto Crespo Facorro, MD (Fundación para la Gestión de la Investigación en Salud de Sevilla)","src":"https://clinicaltrials.gov/study/NCT07153406","contact":{"n":"Narcís Cardoner Álvarez, MD","p":"+34932183217","e":"ncardoner@santpau.cat"},"phase":"Phase 3","enroll":220,"start":"2025-09-15","eid":"x:site:nct07153406-hospital-de-la-santa-creu-i-sant-pau-barcelona"},{"id":"nct07153406-hospital-mare-de-deu-de-la-merce-barcelona","cat":"research","name":"Hospital Mare de Déu de La Mercè","city":"Barcelona","country":"Spain","cc":"ES","lat":41.38517,"lon":2.15781,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"08042","condg":["Depression"],"nct":"NCT07153406","study":"Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients","sstatus":"NOT_YET_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","official":"Benedicto Crespo Facorro, MD (Fundación para la Gestión de la Investigación en Salud de Sevilla)","src":"https://clinicaltrials.gov/study/NCT07153406","contact":{"n":"Silvana Carolina Roca Bassani, MD","p":"+34934275250","e":"scroca.merced@hospitalarias.es"},"phase":"Phase 3","enroll":220,"start":"2025-09-15","eid":"x:site:nct07153406-hospital-mare-de-deu-de-la-merce-barcelona"},{"id":"nct07153406-hospital-sagrat-cor-martorell-barcelona","cat":"research","name":"Hospital Sagrat Cor. Martorell","city":"Barcelona","country":"Spain","cc":"ES","lat":41.3782,"lon":2.15038,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"08760","condg":["Depression"],"nct":"NCT07153406","study":"Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients","sstatus":"NOT_YET_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","official":"Benedicto Crespo Facorro, MD (Fundación para la Gestión de la Investigación en Salud de Sevilla)","src":"https://clinicaltrials.gov/study/NCT07153406","contact":{"n":"Manuel Sánchez Pérez, MD","p":"+34937752200","e":"hospital.hsagratcor@hospitalarias.es"},"phase":"Phase 3","enroll":220,"start":"2025-09-15","eid":"x:site:nct07153406-hospital-sagrat-cor-martorell-barcelona"},{"id":"nct07153406-hospital-benito-menni-y-fidmag-hermanas-hospitalarias-barcelona","cat":"research","name":"Hospital Benito Menni y Fidmag Hermanas Hospitalarias","city":"Barcelona","country":"Spain","cc":"ES","lat":41.39853,"lon":2.16337,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"08830","condg":["Depression"],"nct":"NCT07153406","study":"Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients","sstatus":"NOT_YET_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","official":"Benedicto Crespo Facorro, MD (Fundación para la Gestión de la Investigación en Salud de Sevilla)","src":"https://clinicaltrials.gov/study/NCT07153406","contact":{"n":"Joan Soler Vidal, MD","p":"+34650113820","e":"jsoler@fidmag.org"},"phase":"Phase 3","enroll":220,"start":"2025-09-15","eid":"x:site:nct07153406-hospital-benito-menni-y-fidmag-hermanas-hospitalarias-barcelona"},{"id":"nct07153406-centro-sociosanitario-hermanas-hospitalarias-de-palencia-palencia","cat":"research","name":"Centro Sociosanitario Hermanas Hospitalarias de Palencia","city":"Palencia","country":"Spain","cc":"ES","lat":42.00997,"lon":-4.51592,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"34004","condg":["Depression"],"nct":"NCT07153406","study":"Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients","sstatus":"NOT_YET_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","official":"Benedicto Crespo Facorro, MD (Fundación para la Gestión de la Investigación en Salud de Sevilla)","src":"https://clinicaltrials.gov/study/NCT07153406","contact":{"n":"Carlos Martín Lorenzo","p":"+34979165324","e":"carlosmartin@fidmag.org"},"phase":"Phase 3","enroll":220,"start":"2025-09-15","eid":"x:site:nct07153406-centro-sociosanitario-hermanas-hospitalarias-de-palencia-palencia"},{"id":"nct07153406-corporacion-sanitaria-parc-tauli-sabadell","cat":"research","name":"Corporacion Sanitaria Parc Tauli","city":"Sabadell","country":"Spain","cc":"ES","lat":41.55058,"lon":2.10335,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"08208","condg":["Depression"],"nct":"NCT07153406","study":"Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients","sstatus":"NOT_YET_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","official":"Benedicto Crespo Facorro, MD (Fundación para la Gestión de la Investigación en Salud de Sevilla)","src":"https://clinicaltrials.gov/study/NCT07153406","contact":{"n":"Virginia Soria Tomás, MD","p":"+34937231010","e":"vsoria@tauli.cat"},"phase":"Phase 3","enroll":220,"start":"2025-09-15","eid":"x:site:nct07153406-corporacion-sanitaria-parc-tauli-sabadell"},{"id":"nct07153406-hospital-universitario-virgen-del-rocio-seville","cat":"research","name":"Hospital Universitario Virgen del Rocio","city":"Seville","country":"Spain","cc":"ES","lat":37.39389,"lon":-5.97124,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"41013","condg":["Depression"],"nct":"NCT07153406","study":"Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients","sstatus":"NOT_YET_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","official":"Benedicto Crespo Facorro, MD (Fundación para la Gestión de la Investigación en Salud de Sevilla)","src":"https://clinicaltrials.gov/study/NCT07153406","contact":{"n":"Benedicto Crespo Facorro, MD","p":"+34955013491","e":"bcrespo@us.es"},"phase":"Phase 3","enroll":220,"start":"2025-09-15","eid":"x:site:nct07153406-hospital-universitario-virgen-del-rocio-seville"},{"id":"nct04924257-medical-university-innsbruck-innsbruck","cat":"research","name":"Medical University Innsbruck","city":"Innsbruck","region":"Tyrol","country":"Austria","cc":"AT","lat":47.26468,"lon":11.39402,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"6020","condg":["Depression"],"nct":"NCT04924257","study":"ECT vs. Esketamine","sstatus":"WITHDRAWN","sponsor":"Medical University Innsbruck","src":"https://clinicaltrials.gov/study/NCT04924257","phase":"Phase 3","start":"2021-07-28","eid":"x:site:nct04924257-medical-university-innsbruck-innsbruck"},{"id":"nct04425473-beijing-tiantan-hospital-capital-medical-university-beijing","cat":"research","name":"Beijing Tiantan Hospital, Capital Medical University","city":"Beijing","country":"China","cc":"CN","lat":39.90962,"lon":116.40819,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100070","condg":["Depression"],"nct":"NCT04425473","study":"Esketamine and Perioperative Depressive Symptoms","sstatus":"COMPLETED","sponsor":"Beijing Tiantan Hospital","official":"Ruquan Han, M.D., Ph D. (Beijing Tiantan Hospital)","src":"https://clinicaltrials.gov/study/NCT04425473","phase":"Phase 2/Phase 3","enroll":435,"start":"2021-02-19","eid":"x:site:nct04425473-beijing-tiantan-hospital-capital-medical-university-beijing"},{"id":"nct02228239-unnamed-trial-site-leiden","cat":"research","name":"Unnamed trial site","city":"Leiden","country":"Netherlands","cc":"NL","lat":52.15979,"lon":4.48812,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Healthy volunteers"],"nct":"NCT02228239","study":"Study to Assess the Effects of Esketamine on Safety of On-road Driving in Healthy Participants","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02228239","phase":"Phase 1","enroll":26,"start":"2014-09","eid":"x:site:nct02228239-unnamed-trial-site-leiden"},{"id":"nct05554627-tuscaloosa-va-medical-center-tuscaloosa-al-tuscaloosa","cat":"research","name":"Tuscaloosa VA Medical Center, Tuscaloosa, AL","city":"Tuscaloosa","region":"Alabama","country":"United States","cc":"US","lat":33.21403,"lon":-87.56828,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"35404","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-tuscaloosa-va-medical-center-tuscaloosa-al-tuscaloosa"},{"id":"nct05554627-phoenix-va-health-care-system-phoenix-az-phoenix","cat":"research","name":"Phoenix VA Health Care System, Phoenix, AZ","city":"Phoenix","region":"Arizona","country":"United States","cc":"US","lat":33.44203,"lon":-112.08265,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"85012","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-phoenix-va-health-care-system-phoenix-az-phoenix"},{"id":"nct05554627-central-arkansas-vhs-john-l-mcclellan-memorial-veterans-hospital-lit","cat":"research","name":"Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR","city":"Little Rock","region":"Arkansas","country":"United States","cc":"US","lat":34.75632,"lon":-92.28239,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"72205-5484","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-central-arkansas-vhs-john-l-mcclellan-memorial-veterans-hospital-lit"},{"id":"nct05554627-va-long-beach-healthcare-system-long-beach-ca-long-beach","cat":"research","name":"VA Long Beach Healthcare System, Long Beach, CA","city":"Long Beach","region":"California","country":"United States","cc":"US","lat":33.77642,"lon":-118.18062,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"90822","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-va-long-beach-healthcare-system-long-beach-ca-long-beach"},{"id":"nct05554627-va-palo-alto-health-care-system-palo-alto-ca-palo-alto","cat":"research","name":"VA Palo Alto Health Care System, Palo Alto, CA","city":"Palo Alto","region":"California","country":"United States","cc":"US","lat":37.44193,"lon":-122.14984,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"94304-1290","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-va-palo-alto-health-care-system-palo-alto-ca-palo-alto"},{"id":"nct05554627-va-san-diego-healthcare-system-san-diego-ca-san-diego","cat":"research","name":"VA San Diego Healthcare System, San Diego, CA","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.71162,"lon":-117.15743,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"92161","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-va-san-diego-healthcare-system-san-diego-ca-san-diego"},{"id":"nct05554627-rocky-mountain-regional-va-medical-center-aurora-co-aurora","cat":"research","name":"Rocky Mountain Regional VA Medical Center, Aurora, CO","city":"Aurora","region":"Colorado","country":"United States","cc":"US","lat":39.73663,"lon":-104.83234,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"80045","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-rocky-mountain-regional-va-medical-center-aurora-co-aurora"},{"id":"nct05554627-va-connecticut-healthcare-system-west-haven-campus-west-haven-ct-wes","cat":"research","name":"VA Connecticut Healthcare System West Haven Campus, West Haven, CT","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.26674,"lon":-72.95717,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"06516-2770","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-va-connecticut-healthcare-system-west-haven-campus-west-haven-ct-wes"},{"id":"nct05554627-cerc-visn1-west-haven-ct-west-haven","cat":"research","name":"CERC (VISN1, West Haven, CT)","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.27644,"lon":-72.95369,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"06516","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-cerc-visn1-west-haven-ct-west-haven"},{"id":"nct05554627-atlanta-va-medical-and-rehab-center-decatur-ga-decatur","cat":"research","name":"Atlanta VA Medical and Rehab Center, Decatur, GA","city":"Decatur","region":"Georgia","country":"United States","cc":"US","lat":39.84911,"lon":-88.95278,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"30033","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-atlanta-va-medical-and-rehab-center-decatur-ga-decatur"},{"id":"nct05554627-edward-hines-jr-va-hospital-hines-il-hines","cat":"research","name":"Edward Hines Jr. VA Hospital, Hines, IL","city":"Hines","region":"Illinois","country":"United States","cc":"US","lat":43.55684,"lon":-119.0842,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"60141-5000","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-edward-hines-jr-va-hospital-hines-il-hines"},{"id":"nct05554627-richard-l-roudebush-va-medical-center-indianapolis-in-indianapolis","cat":"research","name":"Richard L. Roudebush VA Medical Center, Indianapolis, IN","city":"Indianapolis","region":"Indiana","country":"United States","cc":"US","lat":39.76429,"lon":-86.1514,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"46202-2884","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-richard-l-roudebush-va-medical-center-indianapolis-in-indianapolis"},{"id":"nct05554627-va-boston-healthcare-system-jamaica-plain-campus-jamaica-plain-ma-bo","cat":"research","name":"VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.35114,"lon":-71.05897,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"02130","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-va-boston-healthcare-system-jamaica-plain-campus-jamaica-plain-ma-bo"},{"id":"nct05554627-minneapolis-va-health-care-system-minneapolis-mn-minneapolis","cat":"research","name":"Minneapolis VA Health Care System, Minneapolis, MN","city":"Minneapolis","region":"Minnesota","country":"United States","cc":"US","lat":44.98171,"lon":-93.27113,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"55417","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-minneapolis-va-health-care-system-minneapolis-mn-minneapolis"},{"id":"nct05554627-kansas-city-va-medical-center-kansas-city-mo-kansas-city","cat":"research","name":"Kansas City VA Medical Center, Kansas City, MO","city":"Kansas City","region":"Missouri","country":"United States","cc":"US","lat":39.10062,"lon":-94.58473,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"64128","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-kansas-city-va-medical-center-kansas-city-mo-kansas-city"},{"id":"nct05554627-new-mexico-va-health-care-system-albuquerque-nm-albuquerque","cat":"research","name":"New Mexico VA Health Care System, Albuquerque, NM","city":"Albuquerque","region":"New Mexico","country":"United States","cc":"US","lat":35.09122,"lon":-106.6478,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"87108-5153","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-new-mexico-va-health-care-system-albuquerque-nm-albuquerque"},{"id":"nct05554627-asheville-va-medical-center-asheville-nc-asheville","cat":"research","name":"Asheville VA Medical Center, Asheville, NC","city":"Asheville","region":"North Carolina","country":"United States","cc":"US","lat":35.59243,"lon":-82.56348,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"28805","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-asheville-va-medical-center-asheville-nc-asheville"},{"id":"nct05554627-salisbury-w-g-bill-hefner-va-medical-center-salisbury-nc-salisbury","cat":"research","name":"Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC","city":"Salisbury","region":"North Carolina","country":"United States","cc":"US","lat":35.67384,"lon":-80.46552,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"28144","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-salisbury-w-g-bill-hefner-va-medical-center-salisbury-nc-salisbury"},{"id":"nct05554627-cincinnati-va-medical-center-cincinnati-oh-cincinnati","cat":"research","name":"Cincinnati VA Medical Center, Cincinnati, OH","city":"Cincinnati","region":"Ohio","country":"United States","cc":"US","lat":39.11511,"lon":-84.52611,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"45220","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-cincinnati-va-medical-center-cincinnati-oh-cincinnati"},{"id":"nct05554627-louis-stokes-va-medical-center-cleveland-oh-cleveland","cat":"research","name":"Louis Stokes VA Medical Center, Cleveland, OH","city":"Cleveland","region":"Ohio","country":"United States","cc":"US","lat":41.49202,"lon":-81.68642,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"44106","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-louis-stokes-va-medical-center-cleveland-oh-cleveland"},{"id":"nct05554627-jackson-c-montgomery-va-medical-center-muskogee-ok-muskogee","cat":"research","name":"Jackson C. Montgomery VA Medical Center, Muskogee, OK","city":"Muskogee","region":"Oklahoma","country":"United States","cc":"US","lat":35.73663,"lon":-95.37077,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"74401","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-jackson-c-montgomery-va-medical-center-muskogee-ok-muskogee"},{"id":"nct05554627-philadelphia-multiservice-center-philadelphia-pa-philadelphia","cat":"research","name":"Philadelphia MultiService Center, Philadelphia, PA","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.94838,"lon":-75.17176,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"19106","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-philadelphia-multiservice-center-philadelphia-pa-philadelphia"},{"id":"nct05554627-va-pittsburgh-healthcare-system-university-drive-division-pittsburgh","cat":"research","name":"VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA","city":"Pittsburgh","region":"Pennsylvania","country":"United States","cc":"US","lat":40.45074,"lon":-79.99575,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"15240","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-va-pittsburgh-healthcare-system-university-drive-division-pittsburgh"},{"id":"nct05554627-michael-e-debakey-va-medical-center-houston-tx-houston","cat":"research","name":"Michael E. DeBakey VA Medical Center, Houston, TX","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.775,"lon":-95.36473,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"77030","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-michael-e-debakey-va-medical-center-houston-tx-houston"},{"id":"nct05554627-salem-va-medical-center-salem-va-salem","cat":"research","name":"Salem VA Medical Center, Salem, VA","city":"Salem","region":"Virginia","country":"United States","cc":"US","lat":44.94332,"lon":-123.04334,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"24153","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-salem-va-medical-center-salem-va-salem"},{"id":"nct05554627-william-s-middleton-memorial-veterans-hospital-madison-wi-madison","cat":"research","name":"William S. Middleton Memorial Veterans Hospital, Madison, WI","city":"Madison","region":"Wisconsin","country":"United States","cc":"US","lat":43.06877,"lon":-89.40824,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"53705","condg":["Depression"],"nct":"NCT05554627","study":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","sstatus":"WITHDRAWN","sponsor":"VA Office of Research and Development","official":"Somaia Mohamed, PhD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT05554627","phase":"Phase 4","start":"2023-10-27","eid":"x:site:nct05554627-william-s-middleton-memorial-veterans-hospital-madison-wi-madison"},{"id":"nct02846519-unnamed-trial-site-cypress","cat":"research","name":"Unnamed trial site","city":"Cypress","region":"California","country":"United States","cc":"US","lat":29.96963,"lon":-95.68705,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Healthy volunteers"],"nct":"NCT02846519","study":"Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Healthy Han Chinese, Korean, Japanese, and Caucasian Participants and the Effects of Rifampin on the…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02846519","phase":"Phase 1","enroll":66,"start":"2016-02-26","eid":"x:site:nct02846519-unnamed-trial-site-cypress"},{"id":"nct02497287-unnamed-trial-site-new-haven","cat":"research","name":"Unnamed trial site","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.29991,"lon":-72.92736,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-new-haven"},{"id":"nct02497287-unnamed-trial-site-miami","cat":"research","name":"Unnamed trial site","city":"Miami","region":"Florida","country":"United States","cc":"US","lat":25.77761,"lon":-80.19766,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-miami"},{"id":"nct02497287-unnamed-trial-site-marietta","cat":"research","name":"Unnamed trial site","city":"Marietta","region":"Georgia","country":"United States","cc":"US","lat":33.95029,"lon":-84.55468,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-marietta"},{"id":"nct02497287-unnamed-trial-site-iowa-city","cat":"research","name":"Unnamed trial site","city":"Iowa City","region":"Iowa","country":"United States","cc":"US","lat":41.66626,"lon":-91.53276,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-iowa-city"},{"id":"nct02497287-unnamed-trial-site-wichita","cat":"research","name":"Unnamed trial site","city":"Wichita","region":"Kansas","country":"United States","cc":"US","lat":37.68768,"lon":-97.32686,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-wichita"},{"id":"nct02497287-unnamed-trial-site-baltimore","cat":"research","name":"Unnamed trial site","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29476,"lon":-76.60772,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-baltimore"},{"id":"nct02497287-unnamed-trial-site-watertown","cat":"research","name":"Unnamed trial site","city":"Watertown","region":"Massachusetts","country":"United States","cc":"US","lat":42.36495,"lon":-71.18777,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-watertown"},{"id":"nct02497287-unnamed-trial-site-cedarhurst","cat":"research","name":"Unnamed trial site","city":"Cedarhurst","region":"New York","country":"United States","cc":"US","lat":40.62462,"lon":-73.72943,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-cedarhurst"},{"id":"nct02497287-unnamed-trial-site-new-york","cat":"research","name":"Unnamed trial site","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.7178,"lon":-74.00893,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-new-york"},{"id":"nct02497287-unnamed-trial-site-staten-island","cat":"research","name":"Unnamed trial site","city":"Staten Island","region":"New York","country":"United States","cc":"US","lat":40.56784,"lon":-74.14207,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-staten-island"},{"id":"nct02497287-unnamed-trial-site-cincinnati","cat":"research","name":"Unnamed trial site","city":"Cincinnati","region":"Ohio","country":"United States","cc":"US","lat":39.1329,"lon":-84.51312,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-cincinnati"},{"id":"nct02497287-unnamed-trial-site-allentown","cat":"research","name":"Unnamed trial site","city":"Allentown","region":"Pennsylvania","country":"United States","cc":"US","lat":40.6113,"lon":-75.49409,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-allentown"},{"id":"nct02497287-unnamed-trial-site-charleston","cat":"research","name":"Unnamed trial site","city":"Charleston","region":"South Carolina","country":"United States","cc":"US","lat":32.76526,"lon":-79.94193,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-charleston"},{"id":"nct02497287-unnamed-trial-site-dallas","cat":"research","name":"Unnamed trial site","city":"Dallas","region":"Texas","country":"United States","cc":"US","lat":32.79205,"lon":-96.79486,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-dallas"},{"id":"nct02497287-unnamed-trial-site-wichita-falls","cat":"research","name":"Unnamed trial site","city":"Wichita Falls","region":"Texas","country":"United States","cc":"US","lat":33.92251,"lon":-98.4957,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-wichita-falls"},{"id":"nct02497287-unnamed-trial-site-richland","cat":"research","name":"Unnamed trial site","city":"Richland","region":"Washington","country":"United States","cc":"US","lat":46.27482,"lon":-119.27519,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-richland"},{"id":"nct02497287-unnamed-trial-site-banfield","cat":"research","name":"Unnamed trial site","city":"Banfield","country":"Argentina","cc":"AR","lat":-34.73937,"lon":-58.38372,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-banfield"},{"id":"nct02497287-unnamed-trial-site-buenos-aires","cat":"research","name":"Unnamed trial site","city":"Buenos Aires","country":"Argentina","cc":"AR","lat":-34.62186,"lon":-58.37295,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-buenos-aires"},{"id":"nct02497287-unnamed-trial-site-cordoba","cat":"research","name":"Unnamed trial site","city":"Córdoba","country":"Argentina","cc":"AR","lat":-31.41236,"lon":-64.19564,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-cordoba"},{"id":"nct02497287-unnamed-trial-site-la-plata","cat":"research","name":"Unnamed trial site","city":"La Plata","country":"Argentina","cc":"AR","lat":-34.92592,"lon":-57.94694,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-la-plata"},{"id":"nct02497287-unnamed-trial-site-mendoza","cat":"research","name":"Unnamed trial site","city":"Mendoza","country":"Argentina","cc":"AR","lat":-32.87878,"lon":-68.85782,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-mendoza"},{"id":"nct02497287-unnamed-trial-site-rosario","cat":"research","name":"Unnamed trial site","city":"Rosario","country":"Argentina","cc":"AR","lat":-32.94781,"lon":-60.63937,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-rosario"},{"id":"nct02497287-unnamed-trial-site-adelaide","cat":"research","name":"Unnamed trial site","city":"Adelaide","country":"Australia","cc":"AU","lat":-34.9305,"lon":138.59538,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-adelaide"},{"id":"nct02497287-unnamed-trial-site-caulfield","cat":"research","name":"Unnamed trial site","city":"Caulfield","country":"Australia","cc":"AU","lat":-37.8915,"lon":145.03177,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-caulfield"},{"id":"nct02497287-unnamed-trial-site-frankston","cat":"research","name":"Unnamed trial site","city":"Frankston","country":"Australia","cc":"AU","lat":-38.14482,"lon":145.12409,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-frankston"},{"id":"nct02497287-unnamed-trial-site-melbourne","cat":"research","name":"Unnamed trial site","city":"Melbourne","country":"Australia","cc":"AU","lat":-37.81301,"lon":144.96723,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-melbourne"},{"id":"nct02497287-unnamed-trial-site-innsbruck","cat":"research","name":"Unnamed trial site","city":"Innsbruck","country":"Austria","cc":"AT","lat":47.2596,"lon":11.3847,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-innsbruck"},{"id":"nct02497287-unnamed-trial-site-vienna","cat":"research","name":"Unnamed trial site","city":"Vienna","country":"Austria","cc":"AT","lat":48.20129,"lon":16.37655,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-vienna"},{"id":"nct02497287-unnamed-trial-site-bruges","cat":"research","name":"Unnamed trial site","city":"Bruges","country":"Belgium","cc":"BE","lat":51.19861,"lon":3.22664,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-bruges"},{"id":"nct02497287-unnamed-trial-site-hasselt","cat":"research","name":"Unnamed trial site","city":"Hasselt","country":"Belgium","cc":"BE","lat":50.93421,"lon":5.33532,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-hasselt"},{"id":"nct02497287-unnamed-trial-site-belo-horizonte","cat":"research","name":"Unnamed trial site","city":"Belo Horizonte","country":"Brazil","cc":"BR","lat":-19.91608,"lon":-43.93566,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-belo-horizonte"},{"id":"nct02497287-unnamed-trial-site-fortaleza","cat":"research","name":"Unnamed trial site","city":"Fortaleza","country":"Brazil","cc":"BR","lat":-3.7184,"lon":-38.54904,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-fortaleza"},{"id":"nct02497287-unnamed-trial-site-recife","cat":"research","name":"Unnamed trial site","city":"Recife","country":"Brazil","cc":"BR","lat":-8.04236,"lon":-34.88822,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-recife"},{"id":"nct02497287-unnamed-trial-site-rio-de-janeiro","cat":"research","name":"Unnamed trial site","city":"Rio de Janeiro","country":"Brazil","cc":"BR","lat":-22.90289,"lon":-43.17145,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-rio-de-janeiro"},{"id":"nct02497287-unnamed-trial-site-santo-andre","cat":"research","name":"Unnamed trial site","city":"Santo André","country":"Brazil","cc":"BR","lat":-23.67269,"lon":-46.53875,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-santo-andre"},{"id":"nct02497287-unnamed-trial-site-sao-jose-do-rio-preto","cat":"research","name":"Unnamed trial site","city":"São José do Rio Preto","country":"Brazil","cc":"BR","lat":-20.82974,"lon":-49.37657,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-sao-jose-do-rio-preto"},{"id":"nct02497287-unnamed-trial-site-sao-paulo","cat":"research","name":"Unnamed trial site","city":"São Paulo","country":"Brazil","cc":"BR","lat":-23.55809,"lon":-46.62778,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-sao-paulo"},{"id":"nct02497287-unnamed-trial-site-burgas","cat":"research","name":"Unnamed trial site","city":"Burgas","country":"Bulgaria","cc":"BG","lat":42.49997,"lon":27.46354,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-burgas"},{"id":"nct02497287-unnamed-trial-site-kardzhali","cat":"research","name":"Unnamed trial site","city":"Kardzhali","country":"Bulgaria","cc":"BG","lat":41.6494,"lon":25.37063,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-kardzhali"},{"id":"nct02497287-unnamed-trial-site-kazanlak","cat":"research","name":"Unnamed trial site","city":"Kazanlak","country":"Bulgaria","cc":"BG","lat":42.62058,"lon":25.38979,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-kazanlak"},{"id":"nct02497287-unnamed-trial-site-pazardzhik","cat":"research","name":"Unnamed trial site","city":"Pazardzhik","country":"Bulgaria","cc":"BG","lat":42.18847,"lon":24.32824,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-pazardzhik"},{"id":"nct02497287-unnamed-trial-site-pleven","cat":"research","name":"Unnamed trial site","city":"Pleven","country":"Bulgaria","cc":"BG","lat":43.41617,"lon":24.62311,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-pleven"},{"id":"nct02497287-unnamed-trial-site-plovdiv","cat":"research","name":"Unnamed trial site","city":"Plovdiv","country":"Bulgaria","cc":"BG","lat":42.1638,"lon":24.75382,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-plovdiv"},{"id":"nct02497287-unnamed-trial-site-rousse","cat":"research","name":"Unnamed trial site","city":"Rousse","country":"Bulgaria","cc":"BG","lat":43.85856,"lon":25.96248,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-rousse"},{"id":"nct02497287-unnamed-trial-site-sofia","cat":"research","name":"Unnamed trial site","city":"Sofia","country":"Bulgaria","cc":"BG","lat":42.70763,"lon":23.3353,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-sofia"},{"id":"nct02497287-unnamed-trial-site-varna","cat":"research","name":"Unnamed trial site","city":"Varna","country":"Bulgaria","cc":"BG","lat":43.21164,"lon":27.9004,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-varna"},{"id":"nct02497287-unnamed-trial-site-helsinki","cat":"research","name":"Unnamed trial site","city":"Helsinki","country":"Finland","cc":"FI","lat":60.15818,"lon":24.93625,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-helsinki"},{"id":"nct02497287-unnamed-trial-site-kuopio","cat":"research","name":"Unnamed trial site","city":"Kuopio","country":"Finland","cc":"FI","lat":62.88254,"lon":27.68574,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-kuopio"},{"id":"nct02497287-unnamed-trial-site-paris","cat":"research","name":"Unnamed trial site","city":"Paris","country":"France","cc":"FR","lat":48.84819,"lon":2.35741,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-paris"},{"id":"nct02497287-unnamed-trial-site-poitiers","cat":"research","name":"Unnamed trial site","city":"Poitiers","country":"France","cc":"FR","lat":46.57419,"lon":0.33581,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-poitiers"},{"id":"nct02497287-unnamed-trial-site-toulon","cat":"research","name":"Unnamed trial site","city":"Toulon","country":"France","cc":"FR","lat":43.11722,"lon":5.9173,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-toulon"},{"id":"nct02497287-unnamed-trial-site-tours","cat":"research","name":"Unnamed trial site","city":"Tours","country":"France","cc":"FR","lat":47.40232,"lon":0.70826,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-tours"},{"id":"nct02497287-unnamed-trial-site-berlin","cat":"research","name":"Unnamed trial site","city":"Berlin","country":"Germany","cc":"DE","lat":52.52253,"lon":13.42159,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-berlin"},{"id":"nct02497287-unnamed-trial-site-bochum","cat":"research","name":"Unnamed trial site","city":"Bochum","country":"Germany","cc":"DE","lat":51.4929,"lon":7.21135,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-bochum"},{"id":"nct02497287-unnamed-trial-site-oranienburg-sachsenhausen","cat":"research","name":"Unnamed trial site","city":"Oranienburg-Sachsenhausen","country":"Germany","cc":"DE","lat":52.742,"lon":13.5419,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-oranienburg-sachsenhausen"},{"id":"nct02497287-unnamed-trial-site-kaunas","cat":"research","name":"Unnamed trial site","city":"Kaunas","country":"Lithuania","cc":"LT","lat":54.90735,"lon":23.91507,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-kaunas"},{"id":"nct02497287-unnamed-trial-site-silute","cat":"research","name":"Unnamed trial site","city":"Šilutė","country":"Lithuania","cc":"LT","lat":55.35035,"lon":21.49252,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-silute"},{"id":"nct02497287-unnamed-trial-site-vilnius","cat":"research","name":"Unnamed trial site","city":"Vilnius","country":"Lithuania","cc":"LT","lat":54.68723,"lon":25.27298,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-vilnius"},{"id":"nct02497287-unnamed-trial-site-ipoh","cat":"research","name":"Unnamed trial site","city":"Ipoh","country":"Malaysia","cc":"MY","lat":4.59017,"lon":101.09471,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-ipoh"},{"id":"nct02497287-unnamed-trial-site-johor-bahru","cat":"research","name":"Unnamed trial site","city":"Johor Bahru","country":"Malaysia","cc":"MY","lat":1.46715,"lon":103.74947,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-johor-bahru"},{"id":"nct02497287-unnamed-trial-site-kuala-lumpur","cat":"research","name":"Unnamed trial site","city":"Kuala Lumpur","country":"Malaysia","cc":"MY","lat":3.134,"lon":101.68338,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-kuala-lumpur"},{"id":"nct02497287-unnamed-trial-site-acapulco","cat":"research","name":"Unnamed trial site","city":"Acapulco","country":"Mexico","cc":"MX","lat":16.85248,"lon":-99.90293,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-acapulco"},{"id":"nct02497287-unnamed-trial-site-durango","cat":"research","name":"Unnamed trial site","city":"Durango","country":"Mexico","cc":"MX","lat":24.03213,"lon":-104.64622,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-durango"},{"id":"nct02497287-unnamed-trial-site-mexico-city","cat":"research","name":"Unnamed trial site","city":"Mexico City","country":"Mexico","cc":"MX","lat":19.42673,"lon":-99.11773,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-mexico-city"},{"id":"nct02497287-unnamed-trial-site-mexico","cat":"research","name":"Unnamed trial site","city":"México","country":"Mexico","cc":"MX","lat":19.41958,"lon":-99.1375,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-mexico"},{"id":"nct02497287-unnamed-trial-site-monterrey","cat":"research","name":"Unnamed trial site","city":"Monterrey","country":"Mexico","cc":"MX","lat":25.68675,"lon":-100.31123,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-monterrey"},{"id":"nct02497287-unnamed-trial-site-gdansk","cat":"research","name":"Unnamed trial site","city":"Gdansk","country":"Poland","cc":"PL","lat":54.35646,"lon":18.6534,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-gdansk"},{"id":"nct02497287-unnamed-trial-site-cape-town","cat":"research","name":"Unnamed trial site","city":"Cape Town","country":"South Africa","cc":"ZA","lat":-33.91393,"lon":18.42233,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-cape-town"},{"id":"nct02497287-unnamed-trial-site-garsfontein","cat":"research","name":"Unnamed trial site","city":"Garsfontein","country":"South Africa","cc":"ZA","lat":-25.9311,"lon":28.4604,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-garsfontein"},{"id":"nct02497287-unnamed-trial-site-pretoria","cat":"research","name":"Unnamed trial site","city":"Pretoria","country":"South Africa","cc":"ZA","lat":-25.75545,"lon":28.17865,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-pretoria"},{"id":"nct02497287-unnamed-trial-site-gwangju","cat":"research","name":"Unnamed trial site","city":"Gwangju","country":"South Korea","cc":"KR","lat":35.16427,"lon":126.90601,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-gwangju"},{"id":"nct02497287-unnamed-trial-site-gyeonggi-do","cat":"research","name":"Unnamed trial site","city":"Gyeonggi-do","country":"South Korea","cc":"KR","lat":37.249,"lon":127.0767,"gp":"region","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-gyeonggi-do"},{"id":"nct02497287-unnamed-trial-site-seoul","cat":"research","name":"Unnamed trial site","city":"Seoul","country":"South Korea","cc":"KR","lat":37.57254,"lon":126.97628,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-seoul"},{"id":"nct02497287-unnamed-trial-site-badajoz","cat":"research","name":"Unnamed trial site","city":"Badajoz","country":"Spain","cc":"ES","lat":38.88565,"lon":-6.97941,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-badajoz"},{"id":"nct02497287-unnamed-trial-site-bilbao","cat":"research","name":"Unnamed trial site","city":"Bilbao","country":"Spain","cc":"ES","lat":43.26219,"lon":-2.92486,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-bilbao"},{"id":"nct02497287-unnamed-trial-site-madrid","cat":"research","name":"Unnamed trial site","city":"Madrid","country":"Spain","cc":"ES","lat":40.42229,"lon":-3.70938,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-madrid"},{"id":"nct02497287-unnamed-trial-site-ourense","cat":"research","name":"Unnamed trial site","city":"Ourense","country":"Spain","cc":"ES","lat":42.32883,"lon":-7.85386,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-ourense"},{"id":"nct02497287-unnamed-trial-site-oviedo","cat":"research","name":"Unnamed trial site","city":"Oviedo","country":"Spain","cc":"ES","lat":43.36391,"lon":-5.8498,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-oviedo"},{"id":"nct02497287-unnamed-trial-site-sant-boi-de-llobregat","cat":"research","name":"Unnamed trial site","city":"Sant Boi de Llobregat","country":"Spain","cc":"ES","lat":41.34004,"lon":2.042,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-sant-boi-de-llobregat"},{"id":"nct02497287-unnamed-trial-site-torrevieja","cat":"research","name":"Unnamed trial site","city":"Torrevieja","country":"Spain","cc":"ES","lat":37.98319,"lon":-0.67229,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-torrevieja"},{"id":"nct02497287-unnamed-trial-site-valencia","cat":"research","name":"Unnamed trial site","city":"Valencia","country":"Spain","cc":"ES","lat":39.47584,"lon":-0.37641,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-valencia"},{"id":"nct02497287-unnamed-trial-site-zamora","cat":"research","name":"Unnamed trial site","city":"Zamora","country":"Spain","cc":"ES","lat":41.51052,"lon":-5.7544,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-zamora"},{"id":"nct02497287-unnamed-trial-site-gothenburg","cat":"research","name":"Unnamed trial site","city":"Gothenburg","country":"Sweden","cc":"SE","lat":57.70335,"lon":11.9675,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-gothenburg"},{"id":"nct02497287-unnamed-trial-site-halmstad","cat":"research","name":"Unnamed trial site","city":"Halmstad","country":"Sweden","cc":"SE","lat":56.66914,"lon":12.84664,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-halmstad"},{"id":"nct02497287-unnamed-trial-site-lund","cat":"research","name":"Unnamed trial site","city":"Lund","country":"Sweden","cc":"SE","lat":55.70297,"lon":13.19185,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-lund"},{"id":"nct02497287-unnamed-trial-site-skovde","cat":"research","name":"Unnamed trial site","city":"Skövde","country":"Sweden","cc":"SE","lat":58.39132,"lon":13.85358,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-skovde"},{"id":"nct02497287-unnamed-trial-site-solna","cat":"research","name":"Unnamed trial site","city":"Solna","country":"Sweden","cc":"SE","lat":59.36573,"lon":18.00335,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-solna"},{"id":"nct02497287-unnamed-trial-site-stockholm","cat":"research","name":"Unnamed trial site","city":"Stockholm","country":"Sweden","cc":"SE","lat":59.32369,"lon":18.07403,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-stockholm"},{"id":"nct02497287-unnamed-trial-site-umea","cat":"research","name":"Unnamed trial site","city":"Umeå","country":"Sweden","cc":"SE","lat":63.83581,"lon":20.25327,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-umea"},{"id":"nct02497287-unnamed-trial-site-kaohsiung-city","cat":"research","name":"Unnamed trial site","city":"Kaohsiung City","country":"Taiwan","cc":"TW","lat":22.62261,"lon":120.32354,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-kaohsiung-city"},{"id":"nct02497287-unnamed-trial-site-new-taipei-city","cat":"research","name":"Unnamed trial site","city":"New Taipei City","country":"Taiwan","cc":"TW","lat":25.05187,"lon":121.4647,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-new-taipei-city"},{"id":"nct02497287-unnamed-trial-site-taichung","cat":"research","name":"Unnamed trial site","city":"Taichung","country":"Taiwan","cc":"TW","lat":24.14751,"lon":120.69016,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-taichung"},{"id":"nct02497287-unnamed-trial-site-tainan","cat":"research","name":"Unnamed trial site","city":"Tainan","country":"Taiwan","cc":"TW","lat":22.98147,"lon":120.20604,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-tainan"},{"id":"nct02497287-unnamed-trial-site-taipei","cat":"research","name":"Unnamed trial site","city":"Taipei","country":"Taiwan","cc":"TW","lat":25.05217,"lon":121.51514,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-taipei"},{"id":"nct02497287-unnamed-trial-site-taoyuan-county","cat":"research","name":"Unnamed trial site","city":"Taoyuan County","country":"Taiwan","cc":"TW","lat":24.8393,"lon":121.9793,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-taoyuan-county"},{"id":"nct02497287-unnamed-trial-site-ankara","cat":"research","name":"Unnamed trial site","city":"Ankara","country":"Turkey","cc":"TR","lat":39.90928,"lon":32.86486,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-ankara"},{"id":"nct02497287-unnamed-trial-site-bursa","cat":"research","name":"Unnamed trial site","city":"Bursa","country":"Turkey","cc":"TR","lat":40.19055,"lon":29.06093,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-bursa"},{"id":"nct02497287-unnamed-trial-site-gaziantep","cat":"research","name":"Unnamed trial site","city":"Gaziantep","country":"Turkey","cc":"TR","lat":37.05318,"lon":37.37831,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-gaziantep"},{"id":"nct02497287-unnamed-trial-site-istanbul","cat":"research","name":"Unnamed trial site","city":"Istanbul","country":"Turkey","cc":"TR","lat":41.00909,"lon":28.94886,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-istanbul"},{"id":"nct02497287-unnamed-trial-site-kocaeli","cat":"research","name":"Unnamed trial site","city":"Kocaeli","country":"Turkey","cc":"TR","lat":40.74186,"lon":30.00034,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-kocaeli"},{"id":"nct02497287-unnamed-trial-site-manisa","cat":"research","name":"Unnamed trial site","city":"Manisa","country":"Turkey","cc":"TR","lat":38.62186,"lon":27.41475,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-manisa"},{"id":"nct02497287-unnamed-trial-site-bristol","cat":"research","name":"Unnamed trial site","city":"Bristol","country":"United Kingdom","cc":"GB","lat":51.45791,"lon":-2.58484,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-bristol"},{"id":"nct02497287-unnamed-trial-site-chesterfield","cat":"research","name":"Unnamed trial site","city":"Chesterfield","country":"United Kingdom","cc":"GB","lat":53.24534,"lon":-1.41229,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-chesterfield"},{"id":"nct02497287-unnamed-trial-site-derby","cat":"research","name":"Unnamed trial site","city":"Derby","country":"United Kingdom","cc":"GB","lat":52.91312,"lon":-1.48543,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-derby"},{"id":"nct02497287-unnamed-trial-site-london","cat":"research","name":"Unnamed trial site","city":"London","country":"United Kingdom","cc":"GB","lat":51.51357,"lon":-0.11478,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-london"},{"id":"nct02497287-unnamed-trial-site-middlesbrough","cat":"research","name":"Unnamed trial site","city":"Middlesbrough","country":"United Kingdom","cc":"GB","lat":54.57025,"lon":-1.23638,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-middlesbrough"},{"id":"nct02497287-unnamed-trial-site-northampton","cat":"research","name":"Unnamed trial site","city":"Northampton","country":"United Kingdom","cc":"GB","lat":52.2444,"lon":-0.88244,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-northampton"},{"id":"nct02497287-unnamed-trial-site-oxford","cat":"research","name":"Unnamed trial site","city":"Oxford","country":"United Kingdom","cc":"GB","lat":51.74135,"lon":-1.24424,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-oxford"},{"id":"nct02497287-unnamed-trial-site-preston","cat":"research","name":"Unnamed trial site","city":"Preston","country":"United Kingdom","cc":"GB","lat":53.76569,"lon":-2.69713,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02497287","study":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02497287","phase":"Phase 3","enroll":802,"start":"2015-09-30","eid":"x:site:nct02497287-unnamed-trial-site-preston"},{"id":"nct00115102-danish-pain-research-center-aarhus","cat":"research","name":"Danish Pain Research Center","city":"Aarhus","country":"Denmark","cc":"DK","lat":56.16319,"lon":10.2206,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"DK-8000","condg":["Other"],"nct":"NCT00115102","study":"Sensory Examination and Pharmacological Modulation of Oral Hyperexcitability in Patients With Atypical Odontalgia and Matched Healthy Controls","sstatus":"COMPLETED","sponsor":"University of Aarhus","official":"Troels Staehelin Jensen, MD, PhD, Dr.Sci (Aarhus University Hospital)","src":"https://clinicaltrials.gov/study/NCT00115102","phase":"Phase 4","enroll":20,"start":"2004-03","eid":"x:site:nct00115102-danish-pain-research-center-aarhus"},{"id":"nct02233452-university-hospital-in-santa-maria-santa-maria","cat":"research","name":"University Hospital in Santa Maria","city":"Santa Maria","region":"Rio Grande do Sul","country":"Brazil","cc":"BR","lat":-29.67688,"lon":-53.81725,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"97105-900","condg":["Chronic pain & headache"],"nct":"NCT02233452","study":"Methadone and Ketamine for Neuropathic Pain Treatment","sstatus":"COMPLETED","sponsor":"Universidade Federal de Santa Maria","official":"Juliano Ferreira, PhD (Federal University of Santa Catarina)","src":"https://clinicaltrials.gov/study/NCT02233452","phase":"Phase 4","enroll":37,"start":"2012-01","eid":"x:site:nct02233452-university-hospital-in-santa-maria-santa-maria"},{"id":"nct07099235-ontario-ketamine-and-infusion-centre-toronto-site-mississauga","cat":"research","name":"Ontario Ketamine and Infusion Centre - Toronto Site","city":"Mississauga","region":"Ontario","country":"Canada","cc":"CA","lat":43.57697,"lon":-79.66258,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"L4Y 1M3","condg":["Depression"],"nct":"NCT07099235","study":"Chart Review of Patients Undergoing Ketamine Treatments for Depression","sstatus":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","src":"https://clinicaltrials.gov/study/NCT07099235","enroll":250,"start":"2022-04-01","eid":"x:site:nct07099235-ontario-ketamine-and-infusion-centre-toronto-site-mississauga"},{"id":"nct06788444-beijing-tiantan-hospital-beijing","cat":"research","name":"Beijing Tiantan Hospital","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.9163,"lon":116.39417,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100050","condg":["Other"],"status":"RECRUITING","nct":"NCT06788444","study":"Efficacy of Esketamine for Patients With Irritable Bowel Syndrome","sstatus":"RECRUITING","sponsor":"Beijing Tiantan Hospital","src":"https://clinicaltrials.gov/study/NCT06788444","contact":{"n":"Fang Luo, M.D","p":"+86 13611326978","e":"13611326978@163.com"},"phase":"N/A","enroll":552,"start":"2025-02-08","eid":"x:site:nct06788444-beijing-tiantan-hospital-beijing"},{"id":"nct05719909-western-psychiatric-institute-and-clinic-pittsburgh","cat":"research","name":"Western Psychiatric Institute and Clinic","city":"Pittsburgh","region":"Pennsylvania","country":"United States","cc":"US","lat":40.44057,"lon":-79.98822,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"15213","condg":["Depression"],"nct":"NCT05719909","study":"Testing the Effectiveness of Cognitive Training Among Depressed Patients Receiving Esketamine Treatment","sstatus":"SUSPENDED","sponsor":"University of Pittsburgh","src":"https://clinicaltrials.gov/study/NCT05719909","phase":"N/A","enroll":40,"start":"2023-02-14","eid":"x:site:nct05719909-western-psychiatric-institute-and-clinic-pittsburgh"},{"id":"nct07422519-hospital-universitari-vall-d-hebron-barcelona","cat":"research","name":"Hospital Universitari Vall d'Hebron","city":"Barcelona","country":"Spain","cc":"ES","lat":41.39034,"lon":2.16403,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"08035","condg":["Depression"],"status":"RECRUITING","nct":"NCT07422519","study":"Virtual Reality-Based Mindfulness as an Adjunct to Treatment as Usual in Treatment-Resistant Depression","sstatus":"RECRUITING","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","src":"https://clinicaltrials.gov/study/NCT07422519","contact":{"n":"Dr. J. Antoni Ramos-Quiroga","p":"+3493 274 6087","e":"antoni.ramos@vallhebron.cat"},"phase":"N/A","enroll":30,"start":"2025-09-18","eid":"x:site:nct07422519-hospital-universitari-vall-d-hebron-barcelona"},{"id":"nct05155969-beijing-chaoyang-hospital-capital-medical-university-beijing","cat":"research","name":"Beijing Chaoyang Hospital, Capital Medical University","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.90228,"lon":116.3921,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100020","condg":["Depression"],"status":"RECRUITING","nct":"NCT05155969","study":"Intravenous Esketamine on Prevention of Postoperative Depression in Patients Undergoing Cardiac Surgery","sstatus":"UNKNOWN","sponsor":"Anshi Wu","official":"Anshi Wu Wu, Ph.D (Beijing Chao-Yang Hospital, Capital Medical Unive)","src":"https://clinicaltrials.gov/study/NCT05155969","contact":{"n":"Anshi Wu, MD","p":"+8685231330","e":"wuanshi1965@163.com"},"phase":"N/A","enroll":80,"start":"2021-12-01","eid":"x:site:nct05155969-beijing-chaoyang-hospital-capital-medical-university-beijing"},{"id":"nct05155969-beijing-chaoyang-hospital-beijing","cat":"research","name":"Beijing Chaoyang Hospital","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.91734,"lon":116.40763,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100020","condg":["Depression"],"status":"RECRUITING","nct":"NCT05155969","study":"Intravenous Esketamine on Prevention of Postoperative Depression in Patients Undergoing Cardiac Surgery","sstatus":"UNKNOWN","sponsor":"Anshi Wu","official":"Anshi Wu Wu, Ph.D (Beijing Chao-Yang Hospital, Capital Medical Unive)","src":"https://clinicaltrials.gov/study/NCT05155969","contact":{"n":"Anshi Wu, Ph.D","p":"+861085351330","e":"wuanshi1965@163.com"},"phase":"N/A","enroll":80,"start":"2021-12-01","eid":"x:site:nct05155969-beijing-chaoyang-hospital-beijing"},{"id":"nct06051227-ambulance-amsterdam-amsterdam","cat":"research","name":"Ambulance Amsterdam","city":"Amsterdam","country":"Netherlands","cc":"NL","lat":52.38227,"lon":4.89614,"gp":"city","unnamed":0,"drugs":["esketamine"],"condg":["PTSD & trauma","Chronic pain & headache"],"nct":"NCT06051227","study":"Fentanyl OR Esketamine for Traumatic PAIN (FORE-PAIN) Trial","sstatus":"TERMINATED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","official":"Markus W Hollmann, Prof. dr. dr. (Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA))","src":"https://clinicaltrials.gov/study/NCT06051227","phase":"Phase 3","enroll":235,"start":"2024-01-11","eid":"x:site:nct06051227-ambulance-amsterdam-amsterdam"},{"id":"nct06431386-the-royal-ottawa-mental-health-centre-ottawa","cat":"research","name":"The Royal Ottawa Mental Health Centre","city":"Ottawa","region":"Ontario","country":"Canada","cc":"CA","lat":45.41244,"lon":-75.69553,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"K1Z 7K4","condg":["Depression","Bipolar"],"nct":"NCT06431386","study":"Behavioural Activation Therapy and Esketamine for Resistant Depression","sstatus":"TERMINATED","sponsor":"The Royal's Institute of Mental Health Research","official":"Jeanne Talbot, MD PhD FRCP (The Royal's Institute of Mental Health Research)","src":"https://clinicaltrials.gov/study/NCT06431386","phase":"N/A","enroll":6,"start":"2024-06-11","eid":"x:site:nct06431386-the-royal-ottawa-mental-health-centre-ottawa"},{"id":"nct04834427-chinese-pla-general-hospital-beijing","cat":"research","name":"Chinese PLA General Hospital","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.89955,"lon":116.39568,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"condg":["Depression","Anxiety","Chronic pain & headache"],"nct":"NCT04834427","study":"Safety and Efficacy Evaluation of S (+) - Ketamine in Children","sstatus":"UNKNOWN","sponsor":"Chinese PLA General Hospital","official":"Weidong Mi, MD (Chinese PLA General Hospital)","src":"https://clinicaltrials.gov/study/NCT04834427","phase":"Phase 4","enroll":3000,"start":"2022-04-20","eid":"x:site:nct04834427-chinese-pla-general-hospital-beijing"},{"id":"nct07563868-massachusetts-general-hospital-s-depression-and-clinical-research-pr","cat":"research","name":"Massachusetts General Hospital's Depression and Clinical Research program","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.35819,"lon":-71.06725,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"02114","condg":["Depression"],"status":"RECRUITING","nct":"NCT07563868","study":"Coaching as an Adjunct to Ketamine Therapy for Treatment-Resistant Depression","sstatus":"RECRUITING","sponsor":"Massachusetts General Hospital","official":"Maren Nyer, PhD (Massachusetts General Hospital and Harvard Medical School); Franklin King, MD (Massachusetts General Hospital and Harvard Medical School)","src":"https://clinicaltrials.gov/study/NCT07563868","contact":{"n":"Maren Nyer, PhD","p":"6176434897","e":"mnyer@mgh.harvard.edu"},"phase":"N/A","enroll":20,"start":"2026-04-17","eid":"x:site:nct07563868-massachusetts-general-hospital-s-depression-and-clinical-research-pr"},{"id":"nct07563868-massachusetts-general-hospital-boston","cat":"research","name":"Massachusetts General Hospital","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.34643,"lon":-71.05106,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"02114","condg":["Depression"],"status":"RECRUITING","nct":"NCT07563868","study":"Coaching as an Adjunct to Ketamine Therapy for Treatment-Resistant Depression","sstatus":"RECRUITING","sponsor":"Massachusetts General Hospital","official":"Maren Nyer, PhD (Massachusetts General Hospital and Harvard Medical School); Franklin King, MD (Massachusetts General Hospital and Harvard Medical School)","src":"https://clinicaltrials.gov/study/NCT07563868","contact":{"n":"Maren Nyer, PhD","p":"6176434897","e":"mnyer@mgh.harvard.edu"},"phase":"N/A","enroll":20,"start":"2026-04-17","eid":"x:site:nct07563868-massachusetts-general-hospital-boston"},{"id":"nct05283408-department-of-anqing-hospital-anesthesiology-anqing","cat":"research","name":"Department of Anqing Hospital Anesthesiology","city":"Anqing","region":"Anhui","country":"China","cc":"CN","lat":30.50457,"lon":117.05744,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"246000","condg":["Chronic pain & headache"],"nct":"NCT05283408","study":"The Clinical Study of Dexmedetomidine and Esketamine Combined Infusion Undergoing Modified Radical Mastectomy","sstatus":"COMPLETED","sponsor":"Anqing Municipal Hospital","src":"https://clinicaltrials.gov/study/NCT05283408","phase":"N/A","enroll":135,"start":"2022-04-10","eid":"x:site:nct05283408-department-of-anqing-hospital-anesthesiology-anqing"},{"id":"nct02345148-unnamed-trial-site-merksem","cat":"research","name":"Unnamed trial site","city":"Merksem","country":"Belgium","cc":"BE","lat":51.24637,"lon":4.44277,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Healthy volunteers"],"nct":"NCT02345148","study":"Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly and and Healthy Younger Adult Participants","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02345148","phase":"Phase 1","enroll":16,"start":"2014-12","eid":"x:site:nct02345148-unnamed-trial-site-merksem"},{"id":"nct06284668-tianjin-medical-university-general-hospital-tianjin","cat":"research","name":"Tianjin Medical University General Hospital","city":"Tianjin","country":"China","cc":"CN","lat":39.1498,"lon":117.18067,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"300052","condg":["Other"],"nct":"NCT06284668","study":"Esketamine vs Remimazolam for Postoperative Sleep Disturbance and Anxiety","sstatus":"COMPLETED","sponsor":"Tianjin Medical University General Hospital","official":"Guolin Wang (Tianjin Medical University General Hospital)","src":"https://clinicaltrials.gov/study/NCT06284668","phase":"N/A","enroll":315,"start":"2024-03-04","eid":"x:site:nct06284668-tianjin-medical-university-general-hospital-tianjin"},{"id":"nct06890897-beijing-tiantan-hospital-beijing","cat":"research","name":"Beijing Tiantan Hospital","city":"Beijing","country":"China","cc":"CN","lat":39.90726,"lon":116.40283,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100050","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06890897","study":"Esketamine Combined Pulsed Radiofrequency for Acute/Subacute Zoster-associated Trigeminal Neuralgia","sstatus":"RECRUITING","sponsor":"Beijing Tiantan Hospital","official":"Fang Luo, M.D. (Beijing Tiantan Hospital)","src":"https://clinicaltrials.gov/study/NCT06890897","contact":{"n":"Fang Luo, M.D","p":"+86 13611326978","e":"13611326978@163.com"},"phase":"N/A","enroll":174,"start":"2025-04-01","eid":"x:site:nct06890897-beijing-tiantan-hospital-beijing"},{"id":"nct04843462-medical-university-vienna-vienna","cat":"research","name":"Medical University Vienna","city":"Vienna","country":"Austria","cc":"AT","lat":48.21927,"lon":16.36563,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1090","condg":["Depression"],"status":"RECRUITING","nct":"NCT04843462","study":"Add-on Therapy With Edupression.Com® on Therapy Resistant Depressive Patients Treated With Nasal Esketamine Spray","sstatus":"UNKNOWN","sponsor":"Lukas Pezawas","official":"Markus Dold, MD., Priv.Doz. (Medical University of Vienna); Gabriele Fischer, MD, Prof. (Medical University of Vienna)","src":"https://clinicaltrials.gov/study/NCT04843462","contact":{"n":"Lukas M Pezawas, Prof.","p":"004314040035470","e":"lukas.pezawas@meduniwien.ac.at"},"phase":"N/A","enroll":70,"start":"2021-04-29","eid":"x:site:nct04843462-medical-university-vienna-vienna"},{"id":"nct07034950-department-of-anesthesiology-the-first-affiliated-hospital-of-xiamen","cat":"research","name":"Department of Anesthesiology, The First Affiliated Hospital of Xiamen University, 55 Zhenhai Road, Xiamen, China","city":"Xiamen","region":"Fujian","country":"China","cc":"CN","lat":24.48341,"lon":118.08879,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"361000","condg":["Cancer-related distress"],"nct":"NCT07034950","study":"Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","official":"Lijuan Yan (Department of Anesthesiology, The First Affiliated Hospital of Xiamen University)","src":"https://clinicaltrials.gov/study/NCT07034950","phase":"Phase 1/Phase 2","enroll":79,"start":"2025-06-29","eid":"x:site:nct07034950-department-of-anesthesiology-the-first-affiliated-hospital-of-xiamen"},{"id":"nct02094378-unnamed-trial-site-leiden","cat":"research","name":"Unnamed trial site","city":"Leiden","country":"Netherlands","cc":"NL","lat":52.16487,"lon":4.50195,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Healthy volunteers"],"nct":"NCT02094378","study":"A Study to Evaluate the Effect of Intranasal Esketamine on Cognitive Functioning in Healthy Subjects","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02094378","phase":"Phase 1","enroll":24,"start":"2014-06","eid":"x:site:nct02094378-unnamed-trial-site-leiden"},{"id":"nct06784388-the-second-affiliated-hospital-of-zhejiang-university-school-of-medi","cat":"research","name":"The Second Affiliated Hospital of Zhejiang University School of Medicine","city":"Hangzhou","region":"Zhejiang","country":"China","cc":"CN","lat":30.28814,"lon":120.17286,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"310000","condg":["Depression"],"status":"RECRUITING","nct":"NCT06784388","study":"Personalized DBS Targeting for Treating Depression","sstatus":"RECRUITING","sponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","src":"https://clinicaltrials.gov/study/NCT06784388","contact":{"n":"Yuxiao Yang, Ph.D.","p":"+86 15088771810","e":"yuxiao.yang@zju.edu.cn"},"phase":"EARLY_Phase 1","enroll":5,"start":"2025-01-05","eid":"x:site:nct06784388-the-second-affiliated-hospital-of-zhejiang-university-school-of-medi"},{"id":"nct02422186-unnamed-trial-site-san-diego","cat":"research","name":"Unnamed trial site","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.72677,"lon":-117.16505,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-san-diego"},{"id":"nct02422186-unnamed-trial-site-new-haven","cat":"research","name":"Unnamed trial site","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31309,"lon":-72.93677,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-new-haven"},{"id":"nct02422186-unnamed-trial-site-miami","cat":"research","name":"Unnamed trial site","city":"Miami","region":"Florida","country":"United States","cc":"US","lat":25.77488,"lon":-80.1939,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-miami"},{"id":"nct02422186-unnamed-trial-site-marietta","cat":"research","name":"Unnamed trial site","city":"Marietta","region":"Georgia","country":"United States","cc":"US","lat":33.9598,"lon":-84.54207,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-marietta"},{"id":"nct02422186-unnamed-trial-site-iowa-city","cat":"research","name":"Unnamed trial site","city":"Iowa City","region":"Iowa","country":"United States","cc":"US","lat":41.66052,"lon":-91.53078,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-iowa-city"},{"id":"nct02422186-unnamed-trial-site-baltimore","cat":"research","name":"Unnamed trial site","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.27951,"lon":-76.6225,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-baltimore"},{"id":"nct02422186-unnamed-trial-site-watertown","cat":"research","name":"Unnamed trial site","city":"Watertown","region":"Massachusetts","country":"United States","cc":"US","lat":42.37032,"lon":-71.18692,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-watertown"},{"id":"nct02422186-unnamed-trial-site-new-york","cat":"research","name":"Unnamed trial site","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71112,"lon":-74.00282,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-new-york"},{"id":"nct02422186-unnamed-trial-site-staten-island","cat":"research","name":"Unnamed trial site","city":"Staten Island","region":"New York","country":"United States","cc":"US","lat":40.56454,"lon":-74.14113,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-staten-island"},{"id":"nct02422186-unnamed-trial-site-cincinnati","cat":"research","name":"Unnamed trial site","city":"Cincinnati","region":"Ohio","country":"United States","cc":"US","lat":39.136,"lon":-84.52225,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-cincinnati"},{"id":"nct02422186-unnamed-trial-site-allentown","cat":"research","name":"Unnamed trial site","city":"Allentown","region":"Pennsylvania","country":"United States","cc":"US","lat":40.60001,"lon":-75.4939,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-allentown"},{"id":"nct02422186-unnamed-trial-site-dallas","cat":"research","name":"Unnamed trial site","city":"Dallas","region":"Texas","country":"United States","cc":"US","lat":32.79412,"lon":-96.81801,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-dallas"},{"id":"nct02422186-unnamed-trial-site-wichita-falls","cat":"research","name":"Unnamed trial site","city":"Wichita Falls","region":"Texas","country":"United States","cc":"US","lat":33.9019,"lon":-98.49419,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-wichita-falls"},{"id":"nct02422186-unnamed-trial-site-charlottesville","cat":"research","name":"Unnamed trial site","city":"Charlottesville","region":"Virginia","country":"United States","cc":"US","lat":38.0191,"lon":-78.46854,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-charlottesville"},{"id":"nct02422186-unnamed-trial-site-richland","cat":"research","name":"Unnamed trial site","city":"Richland","region":"Washington","country":"United States","cc":"US","lat":46.28771,"lon":-119.29401,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-richland"},{"id":"nct02422186-unnamed-trial-site-aalst","cat":"research","name":"Unnamed trial site","city":"Aalst","country":"Belgium","cc":"BE","lat":50.94089,"lon":4.04308,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-aalst"},{"id":"nct02422186-unnamed-trial-site-bruges","cat":"research","name":"Unnamed trial site","city":"Bruges","country":"Belgium","cc":"BE","lat":51.20614,"lon":3.21299,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-bruges"},{"id":"nct02422186-unnamed-trial-site-brussels","cat":"research","name":"Unnamed trial site","city":"Brussels","country":"Belgium","cc":"BE","lat":50.83939,"lon":4.34647,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-brussels"},{"id":"nct02422186-unnamed-trial-site-hasselt","cat":"research","name":"Unnamed trial site","city":"Hasselt","country":"Belgium","cc":"BE","lat":50.92508,"lon":5.3323,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-hasselt"},{"id":"nct02422186-unnamed-trial-site-heusden-zolder","cat":"research","name":"Unnamed trial site","city":"Heusden-Zolder","country":"Belgium","cc":"BE","lat":50.9936,"lon":4.4919,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-heusden-zolder"},{"id":"nct02422186-unnamed-trial-site-liege","cat":"research","name":"Unnamed trial site","city":"Liège","country":"Belgium","cc":"BE","lat":50.62785,"lon":5.57177,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-liege"},{"id":"nct02422186-unnamed-trial-site-belo-horizonte","cat":"research","name":"Unnamed trial site","city":"Belo Horizonte","country":"Brazil","cc":"BR","lat":-19.92803,"lon":-43.93783,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-belo-horizonte"},{"id":"nct02422186-unnamed-trial-site-fortaleza","cat":"research","name":"Unnamed trial site","city":"Fortaleza","country":"Brazil","cc":"BR","lat":-3.72884,"lon":-38.54,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-fortaleza"},{"id":"nct02422186-unnamed-trial-site-rio-de-janeiro","cat":"research","name":"Unnamed trial site","city":"Rio de Janeiro","country":"Brazil","cc":"BR","lat":-22.90402,"lon":-43.17767,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-rio-de-janeiro"},{"id":"nct02422186-unnamed-trial-site-santo-andre","cat":"research","name":"Unnamed trial site","city":"Santo André","country":"Brazil","cc":"BR","lat":-23.65744,"lon":-46.54977,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-santo-andre"},{"id":"nct02422186-unnamed-trial-site-sao-jose-do-rio-preto","cat":"research","name":"Unnamed trial site","city":"São José do Rio Preto","country":"Brazil","cc":"BR","lat":-20.81977,"lon":-49.38024,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-sao-jose-do-rio-preto"},{"id":"nct02422186-unnamed-trial-site-sao-paulo","cat":"research","name":"Unnamed trial site","city":"São Paulo","country":"Brazil","cc":"BR","lat":-23.54952,"lon":-46.6418,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-sao-paulo"},{"id":"nct02422186-unnamed-trial-site-burgas","cat":"research","name":"Unnamed trial site","city":"Burgas","country":"Bulgaria","cc":"BG","lat":42.49667,"lon":27.47455,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-burgas"},{"id":"nct02422186-unnamed-trial-site-kardzhali","cat":"research","name":"Unnamed trial site","city":"Kardzhali","country":"Bulgaria","cc":"BG","lat":41.65071,"lon":25.35453,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-kardzhali"},{"id":"nct02422186-unnamed-trial-site-sofia","cat":"research","name":"Unnamed trial site","city":"Sofia","country":"Bulgaria","cc":"BG","lat":42.69172,"lon":23.33201,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-sofia"},{"id":"nct02422186-unnamed-trial-site-varna","cat":"research","name":"Unnamed trial site","city":"Varna","country":"Bulgaria","cc":"BG","lat":43.20844,"lon":27.91255,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-varna"},{"id":"nct02422186-unnamed-trial-site-helsinki","cat":"research","name":"Unnamed trial site","city":"Helsinki","country":"Finland","cc":"FI","lat":60.16712,"lon":24.93672,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-helsinki"},{"id":"nct02422186-unnamed-trial-site-kuopio","cat":"research","name":"Unnamed trial site","city":"Kuopio","country":"Finland","cc":"FI","lat":62.88367,"lon":27.68442,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-kuopio"},{"id":"nct02422186-unnamed-trial-site-issy-les-moulineaux","cat":"research","name":"Unnamed trial site","city":"Issy-les-Moulineaux","country":"France","cc":"FR","lat":48.81393,"lon":2.27365,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-issy-les-moulineaux"},{"id":"nct02422186-unnamed-trial-site-la-tronche","cat":"research","name":"Unnamed trial site","city":"La Tronche","country":"France","cc":"FR","lat":45.19354,"lon":5.75613,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-la-tronche"},{"id":"nct02422186-unnamed-trial-site-nice","cat":"research","name":"Unnamed trial site","city":"Nice","country":"France","cc":"FR","lat":43.70901,"lon":7.25728,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-nice"},{"id":"nct02422186-unnamed-trial-site-nimes","cat":"research","name":"Unnamed trial site","city":"Nîmes","country":"France","cc":"FR","lat":43.82634,"lon":4.36113,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-nimes"},{"id":"nct02422186-unnamed-trial-site-paris","cat":"research","name":"Unnamed trial site","city":"Paris","country":"France","cc":"FR","lat":48.85016,"lon":2.35468,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-paris"},{"id":"nct02422186-unnamed-trial-site-poitiers","cat":"research","name":"Unnamed trial site","city":"Poitiers","country":"France","cc":"FR","lat":46.58313,"lon":0.35153,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-poitiers"},{"id":"nct02422186-unnamed-trial-site-toulon","cat":"research","name":"Unnamed trial site","city":"Toulon","country":"France","cc":"FR","lat":43.12306,"lon":5.92248,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-toulon"},{"id":"nct02422186-unnamed-trial-site-toulouse","cat":"research","name":"Unnamed trial site","city":"Toulouse","country":"France","cc":"FR","lat":43.60873,"lon":1.44052,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-toulouse"},{"id":"nct02422186-unnamed-trial-site-tours","cat":"research","name":"Unnamed trial site","city":"Tours","country":"France","cc":"FR","lat":47.39093,"lon":0.71269,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-tours"},{"id":"nct02422186-unnamed-trial-site-kaunas","cat":"research","name":"Unnamed trial site","city":"Kaunas","country":"Lithuania","cc":"LT","lat":54.9066,"lon":23.90142,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-kaunas"},{"id":"nct02422186-unnamed-trial-site-silute","cat":"research","name":"Unnamed trial site","city":"Šilutė","country":"Lithuania","cc":"LT","lat":55.35195,"lon":21.47219,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-silute"},{"id":"nct02422186-unnamed-trial-site-vilnius","cat":"research","name":"Unnamed trial site","city":"Vilnius","country":"Lithuania","cc":"LT","lat":54.69928,"lon":25.27128,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-vilnius"},{"id":"nct02422186-unnamed-trial-site-be-chatow","cat":"research","name":"Unnamed trial site","city":"Bełchatów","country":"Poland","cc":"PL","lat":51.37283,"lon":19.34687,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-be-chatow"},{"id":"nct02422186-unnamed-trial-site-bydgoszcz","cat":"research","name":"Unnamed trial site","city":"Bydgoszcz","country":"Poland","cc":"PL","lat":53.12929,"lon":18.00409,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-bydgoszcz"},{"id":"nct02422186-unnamed-trial-site-gdansk","cat":"research","name":"Unnamed trial site","city":"Gdansk","country":"Poland","cc":"PL","lat":54.34375,"lon":18.64964,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-gdansk"},{"id":"nct02422186-unnamed-trial-site-torun","cat":"research","name":"Unnamed trial site","city":"Torun","country":"Poland","cc":"PL","lat":53.00335,"lon":18.59621,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-torun"},{"id":"nct02422186-unnamed-trial-site-tuszyn","cat":"research","name":"Unnamed trial site","city":"Tuszyn","country":"Poland","cc":"PL","lat":51.59853,"lon":19.53014,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-tuszyn"},{"id":"nct02422186-unnamed-trial-site-cape-town","cat":"research","name":"Unnamed trial site","city":"Cape Town","country":"South Africa","cc":"ZA","lat":-33.91732,"lon":18.42938,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-cape-town"},{"id":"nct02422186-unnamed-trial-site-garsfontein","cat":"research","name":"Unnamed trial site","city":"Garsfontein","country":"South Africa","cc":"ZA","lat":-26.1664,"lon":28.5231,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-garsfontein"},{"id":"nct02422186-unnamed-trial-site-pretoria","cat":"research","name":"Unnamed trial site","city":"Pretoria","country":"South Africa","cc":"ZA","lat":-25.74208,"lon":28.19475,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-pretoria"},{"id":"nct02422186-unnamed-trial-site-badajoz","cat":"research","name":"Unnamed trial site","city":"Badajoz","country":"Spain","cc":"ES","lat":38.88725,"lon":-6.97772,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-badajoz"},{"id":"nct02422186-unnamed-trial-site-bilbao","cat":"research","name":"Unnamed trial site","city":"Bilbao","country":"Spain","cc":"ES","lat":43.26775,"lon":-2.92975,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-bilbao"},{"id":"nct02422186-unnamed-trial-site-madrid","cat":"research","name":"Unnamed trial site","city":"Madrid","country":"Spain","cc":"ES","lat":40.42398,"lon":-3.70327,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-madrid"},{"id":"nct02422186-unnamed-trial-site-ourense","cat":"research","name":"Unnamed trial site","city":"Ourense","country":"Spain","cc":"ES","lat":42.3326,"lon":-7.87174,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-ourense"},{"id":"nct02422186-unnamed-trial-site-sant-boi-de-llobregat","cat":"research","name":"Unnamed trial site","city":"Sant Boi de Llobregat","country":"Spain","cc":"ES","lat":41.34126,"lon":2.03937,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-sant-boi-de-llobregat"},{"id":"nct02422186-unnamed-trial-site-torrevieja","cat":"research","name":"Unnamed trial site","city":"Torrevieja","country":"Spain","cc":"ES","lat":37.97434,"lon":-0.68217,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-torrevieja"},{"id":"nct02422186-unnamed-trial-site-zamora","cat":"research","name":"Unnamed trial site","city":"Zamora","country":"Spain","cc":"ES","lat":41.50534,"lon":-5.75562,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-zamora"},{"id":"nct02422186-unnamed-trial-site-gothenburg","cat":"research","name":"Unnamed trial site","city":"Gothenburg","country":"Sweden","cc":"SE","lat":57.71624,"lon":11.96627,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-gothenburg"},{"id":"nct02422186-unnamed-trial-site-halmstad","cat":"research","name":"Unnamed trial site","city":"Halmstad","country":"Sweden","cc":"SE","lat":56.68608,"lon":12.85417,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-halmstad"},{"id":"nct02422186-unnamed-trial-site-lund","cat":"research","name":"Unnamed trial site","city":"Lund","country":"Sweden","cc":"SE","lat":55.69535,"lon":13.19476,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-lund"},{"id":"nct02422186-unnamed-trial-site-skovde","cat":"research","name":"Unnamed trial site","city":"Skövde","country":"Sweden","cc":"SE","lat":58.4013,"lon":13.84492,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-skovde"},{"id":"nct02422186-unnamed-trial-site-solna","cat":"research","name":"Unnamed trial site","city":"Solna","country":"Sweden","cc":"SE","lat":59.36018,"lon":17.99507,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-solna"},{"id":"nct02422186-unnamed-trial-site-stockholm","cat":"research","name":"Unnamed trial site","city":"Stockholm","country":"Sweden","cc":"SE","lat":59.33413,"lon":18.06151,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-stockholm"},{"id":"nct02422186-unnamed-trial-site-derbyshire","cat":"research","name":"Unnamed trial site","city":"Derbyshire","country":"United Kingdom","cc":"GB","lat":51.4948,"lon":0.3233,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-derbyshire"},{"id":"nct02422186-unnamed-trial-site-oxford","cat":"research","name":"Unnamed trial site","city":"Oxford","country":"United Kingdom","cc":"GB","lat":51.76093,"lon":-1.24603,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-oxford"},{"id":"nct02422186-unnamed-trial-site-preston","cat":"research","name":"Unnamed trial site","city":"Preston","country":"United Kingdom","cc":"GB","lat":53.76494,"lon":-2.71454,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02422186","study":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02422186","phase":"Phase 3","enroll":139,"start":"2015-08-20","eid":"x:site:nct02422186-unnamed-trial-site-preston"},{"id":"nct03185819-institute-of-living-hartford-hospital-hartford","cat":"research","name":"Institute of Living/ Hartford Hospital","city":"Hartford","region":"Connecticut","country":"United States","cc":"US","lat":41.75425,"lon":-72.67808,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"06106","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-institute-of-living-hartford-hospital-hartford"},{"id":"nct03185819-yale-university-new-haven","cat":"research","name":"Yale University","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.30782,"lon":-72.9316,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"06520","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-yale-university-new-haven"},{"id":"nct03185819-atlanta-behavioral-research-llc-atlanta","cat":"research","name":"Atlanta Behavioral Research, LLC","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.74481,"lon":-84.38163,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"30338","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-atlanta-behavioral-research-llc-atlanta"},{"id":"nct03185819-rush-university-medical-center-chicago","cat":"research","name":"Rush University Medical Center","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.84735,"lon":-87.64069,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"60612","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-rush-university-medical-center-chicago"},{"id":"nct03185819-neuroscience-research-institute-winfield","cat":"research","name":"Neuroscience Research Institute","city":"Winfield","region":"Illinois","country":"United States","cc":"US","lat":37.25109,"lon":-96.9851,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"60190","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-neuroscience-research-institute-winfield"},{"id":"nct03185819-beacon-medical-group-clinical-research-south-bend","cat":"research","name":"Beacon Medical Group Clinical Research","city":"South Bend","region":"Indiana","country":"United States","cc":"US","lat":41.68267,"lon":-86.24601,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"46617","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-beacon-medical-group-clinical-research-south-bend"},{"id":"nct03185819-university-of-iowa-carver-college-of-medicine-iowa-city","cat":"research","name":"University of Iowa, Carver College of Medicine","city":"Iowa City","region":"Iowa","country":"United States","cc":"US","lat":41.65817,"lon":-91.53681,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"52242","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-university-of-iowa-carver-college-of-medicine-iowa-city"},{"id":"nct03185819-lake-charles-clinical-trials-lake-charles","cat":"research","name":"Lake Charles Clinical Trials","city":"Lake Charles","region":"Louisiana","country":"United States","cc":"US","lat":30.20645,"lon":-93.19664,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"70629","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-lake-charles-clinical-trials-lake-charles"},{"id":"nct03185819-sheppard-pratt-health-system-baltimore","cat":"research","name":"Sheppard Pratt Health System","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28996,"lon":-76.61864,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"21204","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-sheppard-pratt-health-system-baltimore"},{"id":"nct03185819-cbh-health-gaithersburg","cat":"research","name":"CBH Health","city":"Gaithersburg","region":"Maryland","country":"United States","cc":"US","lat":39.1385,"lon":-77.20217,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"20877","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-cbh-health-gaithersburg"},{"id":"nct03185819-state-university-of-new-york-at-buffalo-buffalo","cat":"research","name":"State University of New York at Buffalo","city":"Buffalo","region":"New York","country":"United States","cc":"US","lat":42.8817,"lon":-78.88764,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"14215","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-state-university-of-new-york-at-buffalo-buffalo"},{"id":"nct03185819-university-north-carolina-at-chapel-hill-chapel-hill","cat":"research","name":"University North Carolina at Chapel Hill","city":"Chapel Hill","region":"North Carolina","country":"United States","cc":"US","lat":35.91184,"lon":-79.04676,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"27599","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-university-north-carolina-at-chapel-hill-chapel-hill"},{"id":"nct03185819-wake-forest-baptist-medical-center-winston-salem","cat":"research","name":"Wake Forest Baptist Medical Center","city":"Winston-Salem","region":"North Carolina","country":"United States","cc":"US","lat":36.10414,"lon":-80.24653,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"27103","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-wake-forest-baptist-medical-center-winston-salem"},{"id":"nct03185819-university-of-cincinnati-hospital-cincinnati","cat":"research","name":"University of Cincinnati Hospital","city":"Cincinnati","region":"Ohio","country":"United States","cc":"US","lat":39.11727,"lon":-84.51039,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"45219","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-university-of-cincinnati-hospital-cincinnati"},{"id":"nct03185819-university-hospital-of-cleveland-cleveland","cat":"research","name":"University Hospital of Cleveland","city":"Cleveland","region":"Ohio","country":"United States","cc":"US","lat":41.49249,"lon":-81.68689,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"44106","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-university-hospital-of-cleveland-cleveland"},{"id":"nct03185819-ohio-state-university-columbus","cat":"research","name":"Ohio State University","city":"Columbus","region":"Ohio","country":"United States","cc":"US","lat":39.97017,"lon":-83.00411,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"43210","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-ohio-state-university-columbus"},{"id":"nct03185819-vanderbilt-university-medical-center-nashville","cat":"research","name":"Vanderbilt University Medical Center","city":"Nashville","region":"Tennessee","country":"United States","cc":"US","lat":36.17271,"lon":-86.78524,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"37212","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-vanderbilt-university-medical-center-nashville"},{"id":"nct03185819-university-of-texas-southwestern-medical-center-dallas","cat":"research","name":"University of Texas Southwestern Medical Center","city":"Dallas","region":"Texas","country":"United States","cc":"US","lat":32.77859,"lon":-96.81067,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"75390-9063","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-university-of-texas-southwestern-medical-center-dallas"},{"id":"nct03185819-hopital-erasme-brussels","cat":"research","name":"Hopital Erasme","city":"Brussels","country":"Belgium","cc":"BE","lat":50.85436,"lon":4.34647,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1070","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-hopital-erasme-brussels"},{"id":"nct03185819-trial-tech-tecnologia-em-pesquisas-com-medicamentos-curitiba","cat":"research","name":"Trial Tech Tecnologia em Pesquisas com Medicamentos","city":"Curitiba","country":"Brazil","cc":"BR","lat":-25.42679,"lon":-49.2636,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"80240-280","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-trial-tech-tecnologia-em-pesquisas-com-medicamentos-curitiba"},{"id":"nct03185819-hospital-universitario-professor-edgar-santos-salvador","cat":"research","name":"Hospital Universitario Professor Edgar Santos","city":"Salvador","country":"Brazil","cc":"BR","lat":-12.98019,"lon":-38.48169,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"40110-060","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-hospital-universitario-professor-edgar-santos-salvador"},{"id":"nct03185819-cemec-centro-multidisciplinar-de-estudos-clinicos-sao-bernardo-do-ca","cat":"research","name":"CEMEC - Centro Multidisciplinar de Estudos Clínicos","city":"São Bernardo do Campo","country":"Brazil","cc":"BR","lat":-23.68311,"lon":-46.55676,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"09715-090","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-cemec-centro-multidisciplinar-de-estudos-clinicos-sao-bernardo-do-ca"},{"id":"nct03185819-hospital-sao-sebastiao-turvo","cat":"research","name":"Hospital São Sebastião","city":"Turvo","country":"Brazil","cc":"BR","lat":-25.03671,"lon":-51.526,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"88930-000","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-hospital-sao-sebastiao-turvo"},{"id":"nct03185819-mental-health-center-rousse-rousse","cat":"research","name":"Mental Health Center - Rousse","city":"Rousse","country":"Bulgaria","cc":"BG","lat":43.84585,"lon":25.94394,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"7003","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-mental-health-center-rousse-rousse"},{"id":"nct03185819-multiprofile-hospital-for-active-treatment-mhat-sveta-marina-ead-var","cat":"research","name":"Multiprofile Hospital for Active Treatment - MHAT Sveta Marina EAD","city":"Varna","country":"Bulgaria","cc":"BG","lat":43.22227,"lon":27.91349,"gp":"city","unnamed":0,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-multiprofile-hospital-for-active-treatment-mhat-sveta-marina-ead-var"},{"id":"nct03185819-hospices-civils-de-lyon-hcl-bron","cat":"research","name":"Hospices Civils de Lyon HCL","city":"Bron","country":"France","cc":"FR","lat":45.7403,"lon":4.92202,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"69677","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-hospices-civils-de-lyon-hcl-bron"},{"id":"nct03185819-chru-lille-hopital-fontan-1-lille","cat":"research","name":"CHRU Lille - Hôpital Fontan 1","city":"Lille","country":"France","cc":"FR","lat":50.62765,"lon":3.05206,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"59000","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-chru-lille-hopital-fontan-1-lille"},{"id":"nct03185819-chu-nantes-nantes","cat":"research","name":"CHU Nantes","city":"Nantes","country":"France","cc":"FR","lat":47.22859,"lon":-1.54974,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"44093","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-chu-nantes-nantes"},{"id":"nct03185819-hopital-universitaire-pitie-salpetriere-paris","cat":"research","name":"Hôpital Universitaire Pitié-Salpêtrière","city":"Paris","country":"France","cc":"FR","lat":48.84461,"lon":2.34546,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"75013","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-hopital-universitaire-pitie-salpetriere-paris"},{"id":"nct03185819-hopital-sainte-anne-paris","cat":"research","name":"Hopital Sainte Anne","city":"Paris","country":"France","cc":"FR","lat":48.84762,"lon":2.34311,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"75014","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-hopital-sainte-anne-paris"},{"id":"nct03185819-hopital-robert-debre-paris","cat":"research","name":"Hôpital Robert Debré","city":"Paris","country":"France","cc":"FR","lat":48.86221,"lon":2.35111,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"75019","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-hopital-robert-debre-paris"},{"id":"nct03185819-vadaskert-gyermek-es-ifjusagpszichiatriai-korhaz-es-szakambulancia-b","cat":"research","name":"Vadaskert Gyermek es Ifjusagpszichiatriai Korhaz es Szakambulancia","city":"Budapest","country":"Hungary","cc":"HU","lat":47.48767,"lon":19.04097,"gp":"city","unnamed":0,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-vadaskert-gyermek-es-ifjusagpszichiatriai-korhaz-es-szakambulancia-b"},{"id":"nct03185819-szegedi-tudomanyegyetem-szeged","cat":"research","name":"Szegedi Tudomanyegyetem","city":"Szeged","country":"Hungary","cc":"HU","lat":46.26462,"lon":20.15996,"gp":"city","unnamed":0,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-szegedi-tudomanyegyetem-szeged"},{"id":"nct03185819-azienda-ospedaliera-g-brotzu-cagliari","cat":"research","name":"Azienda Ospedaliera G. Brotzu","city":"Cagliari","country":"Italy","cc":"IT","lat":39.23332,"lon":9.11865,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"09134","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-azienda-ospedaliera-g-brotzu-cagliari"},{"id":"nct03185819-osp-riuniti-dip-donna-bambino-foggia","cat":"research","name":"OSP RIUNITI-DIP Donna- Bambino","city":"Foggia","country":"Italy","cc":"IT","lat":41.46029,"lon":15.55334,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"71122","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-osp-riuniti-dip-donna-bambino-foggia"},{"id":"nct03185819-ospedale-di-merano-merano","cat":"research","name":"Ospedale di Merano","city":"Merano","country":"Italy","cc":"IT","lat":46.67895,"lon":11.1624,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"39012","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-ospedale-di-merano-merano"},{"id":"nct03185819-azienda-ospedaliera-universitaria-policlinico-g-martino-messina","cat":"research","name":"Azienda Ospedaliera Universitaria Policlinico G. Martino","city":"Messina","country":"Italy","cc":"IT","lat":38.19003,"lon":15.5639,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"98125","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-azienda-ospedaliera-universitaria-policlinico-g-martino-messina"},{"id":"nct03185819-azienda-ospedaliera-universitaria-federico-ii-naples","cat":"research","name":"Azienda Ospedaliera Universitaria Federico II","city":"Naples","country":"Italy","cc":"IT","lat":40.85541,"lon":14.25987,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"80138","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-azienda-ospedaliera-universitaria-federico-ii-naples"},{"id":"nct03185819-irccs-c-mondino-istituto-neurologico-nazionale-fondazione-pavia","cat":"research","name":"IRCCS C. Mondino, Istituto Neurologico Nazionale, Fondazione","city":"Pavia","country":"Italy","cc":"IT","lat":45.18532,"lon":9.16524,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"27100","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-irccs-c-mondino-istituto-neurologico-nazionale-fondazione-pavia"},{"id":"nct03185819-irccs-burlo-garofalo-trieste","cat":"research","name":"Irccs Burlo-Garofalo","city":"Trieste","country":"Italy","cc":"IT","lat":45.64497,"lon":13.78624,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"34137","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-irccs-burlo-garofalo-trieste"},{"id":"nct03185819-klinika-psychiatrii-dzieci-i-mlodziezy-cm-uj-krakow","cat":"research","name":"Klinika Psychiatrii Dzieci i Mlodziezy, CM UJ","city":"Krakow","country":"Poland","cc":"PL","lat":50.06016,"lon":19.92684,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"31-501","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-klinika-psychiatrii-dzieci-i-mlodziezy-cm-uj-krakow"},{"id":"nct03185819-dzieciecy-szpital-kliniczny-im-jozefa-polikarpa-brudzinskiego-warsaw","cat":"research","name":"Dzieciecy Szpital Kliniczny im Jozefa Polikarpa Brudzinskiego","city":"Warsaw","country":"Poland","cc":"PL","lat":52.21796,"lon":21.00082,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"02 091","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-dzieciecy-szpital-kliniczny-im-jozefa-polikarpa-brudzinskiego-warsaw"},{"id":"nct03185819-instytut-psychiatrii-i-neurologii-klinika-psychiatrii-dzieci-i-mlodz","cat":"research","name":"Instytut Psychiatrii i Neurologii Klinika Psychiatrii Dzieci i Mlodziezy","city":"Warsaw","country":"Poland","cc":"PL","lat":52.24008,"lon":21.01512,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"02-957","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-instytut-psychiatrii-i-neurologii-klinika-psychiatrii-dzieci-i-mlodz"},{"id":"nct03185819-hosp-clinic-de-barcelona-barcelona","cat":"research","name":"Hosp Clinic de Barcelona","city":"Barcelona","country":"Spain","cc":"ES","lat":41.38413,"lon":2.15217,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"08036","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-hosp-clinic-de-barcelona-barcelona"},{"id":"nct03185819-hosp-sant-joan-de-deu-esplugues-de-llobregat","cat":"research","name":"Hosp. Sant Joan de Deu","city":"Esplugues de Llobregat","country":"Spain","cc":"ES","lat":41.37266,"lon":2.07863,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"08950","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-hosp-sant-joan-de-deu-esplugues-de-llobregat"},{"id":"nct03185819-hosp-gral-univ-gregorio-maranon-madrid","cat":"research","name":"Hosp. Gral. Univ. Gregorio Maranon","city":"Madrid","country":"Spain","cc":"ES","lat":40.41899,"lon":-3.70609,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"28007","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-hosp-gral-univ-gregorio-maranon-madrid"},{"id":"nct03185819-hosp-infantil-univ-nino-jesus-madrid","cat":"research","name":"Hosp. Infantil Univ. Nino Jesus","city":"Madrid","country":"Spain","cc":"ES","lat":40.41128,"lon":-3.69978,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"28009","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-hosp-infantil-univ-nino-jesus-madrid"},{"id":"nct03185819-hosp-univ-pta-de-hierro-majadahonda-majadahonda","cat":"research","name":"Hosp. Univ. Pta. de Hierro Majadahonda","city":"Majadahonda","country":"Spain","cc":"ES","lat":40.47631,"lon":-3.88363,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"28222","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-hosp-univ-pta-de-hierro-majadahonda-majadahonda"},{"id":"nct03185819-hosp-univ-central-de-asturias-oviedo","cat":"research","name":"Hosp. Univ. Central de Asturias","city":"Oviedo","country":"Spain","cc":"ES","lat":43.34914,"lon":-5.84669,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"33011","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-hosp-univ-central-de-asturias-oviedo"},{"id":"nct03185819-clinica-univ-de-navarra-pamplona","cat":"research","name":"Clinica Univ. de Navarra","city":"Pamplona","country":"Spain","cc":"ES","lat":42.81654,"lon":-1.63518,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"31008","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-clinica-univ-de-navarra-pamplona"},{"id":"nct03185819-corporacio-sanitari-parc-tauli-sabadell","cat":"research","name":"Corporacio Sanitari Parc Tauli","city":"Sabadell","country":"Spain","cc":"ES","lat":41.54682,"lon":2.11427,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"08208","condg":["Depression"],"nct":"NCT03185819","study":"Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03185819","phase":"Phase 2","enroll":147,"start":"2017-10-05","eid":"x:site:nct03185819-corporacio-sanitari-parc-tauli-sabadell"},{"id":"nct05422001-aarhus-university-hospital-aarhus-n","cat":"research","name":"Aarhus University Hospital","city":"Aarhus N","region":"Vælg En Region, Stat Eller Provins.","country":"Denmark","cc":"DK","lat":55.6348,"lon":12.1008,"gp":"country","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"8200","condg":["Addiction & substance use","Chronic pain & headache"],"nct":"NCT05422001","study":"Low-dose KETamine as an Adjunct to MOrphine for Acute Pain in the ED","sstatus":"TERMINATED","sponsor":"University of Aarhus","official":"Stine F Galili, MD (Aarhus University Hospital)","src":"https://clinicaltrials.gov/study/NCT05422001","phase":"Phase 4","enroll":116,"start":"2022-05-31","eid":"x:site:nct05422001-aarhus-university-hospital-aarhus-n"},{"id":"nct04664530-the-second-affiliated-hospital-of-zhejiang-university-anesthesiology","cat":"research","name":"The Second Affiliated Hospital of Zhejiang University anesthesiology department","city":"Hangzhou","region":"Zhejiang","country":"China","cc":"CN","lat":30.30019,"lon":120.16871,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"310000","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT04664530","study":"The Study on the Esketamine in the Treatment of Postherpetic Neuralgia","sstatus":"UNKNOWN","sponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","official":"Min Yan, Doctor (The second affiliated hospital of Zhejiang University hangzhou, Zhejiang, China)","src":"https://clinicaltrials.gov/study/NCT04664530","contact":{"n":"Min Yan, Doctor","p":"18758131223","e":"zryanmin@zju.edu.cn"},"phase":"Phase 4","enroll":48,"start":"2020-11-25","eid":"x:site:nct04664530-the-second-affiliated-hospital-of-zhejiang-university-anesthesiology"},{"id":"nct07610343-peking-university-first-hospital-beijing","cat":"research","name":"Peking University First Hospital","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.90237,"lon":116.39803,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100034","condg":["Neurology & cognition"],"nct":"NCT07610343","study":"Intranasal Dexmedetomidine-esketamine on Sleep and Cognition in Older Adults With Mild-to-moderate Cognitive Impairment","sstatus":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT07610343","contact":{"n":"Dong-Xin Wang, MD, PhD","p":"010-83572784","e":"wangdongxin@hotmail.com"},"phase":"Phase 4","enroll":60,"start":"2026-06","eid":"x:site:nct07610343-peking-university-first-hospital-beijing"},{"id":"nct01998958-unnamed-trial-site-birmingham","cat":"research","name":"Unnamed trial site","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.50932,"lon":-86.79962,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01998958","study":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","phase":"Phase 2","enroll":108,"start":"2014-01-27","eid":"x:site:nct01998958-unnamed-trial-site-birmingham"},{"id":"nct01998958-unnamed-trial-site-garden-grove","cat":"research","name":"Unnamed trial site","city":"Garden Grove","region":"California","country":"United States","cc":"US","lat":33.7765,"lon":-117.95119,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01998958","study":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","phase":"Phase 2","enroll":108,"start":"2014-01-27","eid":"x:site:nct01998958-unnamed-trial-site-garden-grove"},{"id":"nct01998958-unnamed-trial-site-hartford","cat":"research","name":"Unnamed trial site","city":"Hartford","region":"Connecticut","country":"United States","cc":"US","lat":41.75943,"lon":-72.67516,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01998958","study":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","phase":"Phase 2","enroll":108,"start":"2014-01-27","eid":"x:site:nct01998958-unnamed-trial-site-hartford"},{"id":"nct01998958-unnamed-trial-site-jacksonville","cat":"research","name":"Unnamed trial site","city":"Jacksonville","region":"Florida","country":"United States","cc":"US","lat":30.33486,"lon":-81.65137,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01998958","study":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","phase":"Phase 2","enroll":108,"start":"2014-01-27","eid":"x:site:nct01998958-unnamed-trial-site-jacksonville"},{"id":"nct01998958-unnamed-trial-site-tampa","cat":"research","name":"Unnamed trial site","city":"Tampa","region":"Florida","country":"United States","cc":"US","lat":27.94324,"lon":-82.46911,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01998958","study":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","phase":"Phase 2","enroll":108,"start":"2014-01-27","eid":"x:site:nct01998958-unnamed-trial-site-tampa"},{"id":"nct01998958-unnamed-trial-site-atlanta","cat":"research","name":"Unnamed trial site","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.74858,"lon":-84.39669,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01998958","study":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","phase":"Phase 2","enroll":108,"start":"2014-01-27","eid":"x:site:nct01998958-unnamed-trial-site-atlanta"},{"id":"nct01998958-unnamed-trial-site-chicago","cat":"research","name":"Unnamed trial site","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.84245,"lon":-87.6469,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01998958","study":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","phase":"Phase 2","enroll":108,"start":"2014-01-27","eid":"x:site:nct01998958-unnamed-trial-site-chicago"},{"id":"nct01998958-unnamed-trial-site-hoffman-estates","cat":"research","name":"Unnamed trial site","city":"Hoffman Estates","region":"Illinois","country":"United States","cc":"US","lat":42.04982,"lon":-88.08484,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01998958","study":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","phase":"Phase 2","enroll":108,"start":"2014-01-27","eid":"x:site:nct01998958-unnamed-trial-site-hoffman-estates"},{"id":"nct01998958-unnamed-trial-site-rockville","cat":"research","name":"Unnamed trial site","city":"Rockville","region":"Maryland","country":"United States","cc":"US","lat":39.09129,"lon":-77.16156,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01998958","study":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","phase":"Phase 2","enroll":108,"start":"2014-01-27","eid":"x:site:nct01998958-unnamed-trial-site-rockville"},{"id":"nct01998958-unnamed-trial-site-cedarhurst","cat":"research","name":"Unnamed trial site","city":"Cedarhurst","region":"New York","country":"United States","cc":"US","lat":40.62481,"lon":-73.72002,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01998958","study":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","phase":"Phase 2","enroll":108,"start":"2014-01-27","eid":"x:site:nct01998958-unnamed-trial-site-cedarhurst"},{"id":"nct01998958-unnamed-trial-site-new-york","cat":"research","name":"Unnamed trial site","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70801,"lon":-74.00799,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01998958","study":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","phase":"Phase 2","enroll":108,"start":"2014-01-27","eid":"x:site:nct01998958-unnamed-trial-site-new-york"},{"id":"nct01998958-unnamed-trial-site-allentown","cat":"research","name":"Unnamed trial site","city":"Allentown","region":"Pennsylvania","country":"United States","cc":"US","lat":40.61695,"lon":-75.50209,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01998958","study":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","phase":"Phase 2","enroll":108,"start":"2014-01-27","eid":"x:site:nct01998958-unnamed-trial-site-allentown"},{"id":"nct01998958-unnamed-trial-site-philadelphia","cat":"research","name":"Unnamed trial site","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.9481,"lon":-75.16442,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01998958","study":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","phase":"Phase 2","enroll":108,"start":"2014-01-27","eid":"x:site:nct01998958-unnamed-trial-site-philadelphia"},{"id":"nct01998958-unnamed-trial-site-memphis","cat":"research","name":"Unnamed trial site","city":"Memphis","region":"Tennessee","country":"United States","cc":"US","lat":35.15598,"lon":-90.04809,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01998958","study":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","phase":"Phase 2","enroll":108,"start":"2014-01-27","eid":"x:site:nct01998958-unnamed-trial-site-memphis"},{"id":"nct01998958-unnamed-trial-site-lede","cat":"research","name":"Unnamed trial site","city":"Lede","country":"Belgium","cc":"BE","lat":50.97675,"lon":3.98175,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01998958","study":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","phase":"Phase 2","enroll":108,"start":"2014-01-27","eid":"x:site:nct01998958-unnamed-trial-site-lede"},{"id":"nct01998958-unnamed-trial-site-akita","cat":"research","name":"Unnamed trial site","city":"Akita","country":"Japan","cc":"JP","lat":39.72453,"lon":140.12359,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01998958","study":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","phase":"Phase 2","enroll":108,"start":"2014-01-27","eid":"x:site:nct01998958-unnamed-trial-site-akita"},{"id":"nct01998958-unnamed-trial-site-hiroshima","cat":"research","name":"Unnamed trial site","city":"Hiroshima","country":"Japan","cc":"JP","lat":34.39459,"lon":132.45071,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01998958","study":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","phase":"Phase 2","enroll":108,"start":"2014-01-27","eid":"x:site:nct01998958-unnamed-trial-site-hiroshima"},{"id":"nct01998958-unnamed-trial-site-ichikawa","cat":"research","name":"Unnamed trial site","city":"Ichikawa","country":"Japan","cc":"JP","lat":35.72467,"lon":139.91794,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01998958","study":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","phase":"Phase 2","enroll":108,"start":"2014-01-27","eid":"x:site:nct01998958-unnamed-trial-site-ichikawa"},{"id":"nct01998958-unnamed-trial-site-kanzaki","cat":"research","name":"Unnamed trial site","city":"Kanzaki","country":"Japan","cc":"JP","lat":33.32012,"lon":130.34282,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01998958","study":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","phase":"Phase 2","enroll":108,"start":"2014-01-27","eid":"x:site:nct01998958-unnamed-trial-site-kanzaki"},{"id":"nct01998958-unnamed-trial-site-kashihara","cat":"research","name":"Unnamed trial site","city":"Kashihara","country":"Japan","cc":"JP","lat":34.59429,"lon":135.61446,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01998958","study":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","phase":"Phase 2","enroll":108,"start":"2014-01-27","eid":"x:site:nct01998958-unnamed-trial-site-kashihara"},{"id":"nct01998958-unnamed-trial-site-kitakyushu","cat":"research","name":"Unnamed trial site","city":"Kitakyushu","country":"Japan","cc":"JP","lat":33.84197,"lon":130.85293,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01998958","study":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","phase":"Phase 2","enroll":108,"start":"2014-01-27","eid":"x:site:nct01998958-unnamed-trial-site-kitakyushu"},{"id":"nct01998958-unnamed-trial-site-kodaira","cat":"research","name":"Unnamed trial site","city":"Kodaira","country":"Japan","cc":"JP","lat":35.73219,"lon":139.47732,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01998958","study":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","phase":"Phase 2","enroll":108,"start":"2014-01-27","eid":"x:site:nct01998958-unnamed-trial-site-kodaira"},{"id":"nct01998958-unnamed-trial-site-kumamoto","cat":"research","name":"Unnamed trial site","city":"Kumamoto","country":"Japan","cc":"JP","lat":32.80631,"lon":130.70033,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01998958","study":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","phase":"Phase 2","enroll":108,"start":"2014-01-27","eid":"x:site:nct01998958-unnamed-trial-site-kumamoto"},{"id":"nct01998958-unnamed-trial-site-nagano","cat":"research","name":"Unnamed trial site","city":"Nagano","country":"Japan","cc":"JP","lat":36.66172,"lon":138.18855,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01998958","study":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","phase":"Phase 2","enroll":108,"start":"2014-01-27","eid":"x:site:nct01998958-unnamed-trial-site-nagano"},{"id":"nct01998958-unnamed-trial-site-shibukawa","cat":"research","name":"Unnamed trial site","city":"Shibukawa","country":"Japan","cc":"JP","lat":36.48488,"lon":139.0088,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT01998958","study":"A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01998958","phase":"Phase 2","enroll":108,"start":"2014-01-27","eid":"x:site:nct01998958-unnamed-trial-site-shibukawa"},{"id":"nct05506787-anesthesiology-department-jinling-hospital-affiliated-to-nanjing-uni","cat":"research","name":"Anesthesiology Department, Jinling Hospital Affiliated to Nanjing University","city":"Nanjing","region":"Jiangsu","country":"China","cc":"CN","lat":32.06539,"lon":118.78169,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"210018","condg":["Depression"],"nct":"NCT05506787","study":"The Effects of Intraoperative Esketamine on Postoperative Pain and Mood in Patients With Inflammatory Bowel Disease","sstatus":"COMPLETED","sponsor":"Jinling Hospital, China","official":"Ji Qing (Anesthesiology Department, Jinling Hospital Affiliated to Nanjing University)","src":"https://clinicaltrials.gov/study/NCT05506787","phase":"Phase 4","enroll":120,"start":"2020-09-01","eid":"x:site:nct05506787-anesthesiology-department-jinling-hospital-affiliated-to-nanjing-uni"},{"id":"nct06389344-beijing-tiantan-hospital-capital-medical-university-beijing","cat":"research","name":"Beijing Tiantan Hospital, Capital Medical University","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.89889,"lon":116.40481,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100070","condg":["Other"],"status":"RECRUITING","nct":"NCT06389344","study":"Effect of Esketamine on Conscious State in Patients With pDoC","sstatus":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","src":"https://clinicaltrials.gov/study/NCT06389344","contact":{"n":"Ruquan Han, MD,PhD","p":"8610-59976660","e":"ruquan.han@gmail.com"},"phase":"N/A","enroll":116,"start":"2024-05-20","eid":"x:site:nct06389344-beijing-tiantan-hospital-capital-medical-university-beijing"},{"id":"nct04760652-uab-medicine-heersink-school-of-medicine-birmingham","cat":"research","name":"UAB Medicine | Heersink School of Medicine","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.51722,"lon":-86.80781,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"35294","condg":["Depression"],"nct":"NCT04760652","study":"Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention","sstatus":"COMPLETED","sponsor":"Yale University","official":"Samuel T Wilkinson, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT04760652","phase":"N/A","enroll":93,"start":"2021-03-05","eid":"x:site:nct04760652-uab-medicine-heersink-school-of-medicine-birmingham"},{"id":"nct04760652-yale-university-new-haven","cat":"research","name":"Yale University","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.30424,"lon":-72.92604,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"06511","condg":["Depression"],"nct":"NCT04760652","study":"Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention","sstatus":"COMPLETED","sponsor":"Yale University","official":"Samuel T Wilkinson, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT04760652","phase":"N/A","enroll":93,"start":"2021-03-05","eid":"x:site:nct04760652-yale-university-new-haven"},{"id":"nct04760652-emory-university-atlanta","cat":"research","name":"Emory University","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.74924,"lon":-84.38153,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"30329","condg":["Depression"],"nct":"NCT04760652","study":"Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention","sstatus":"COMPLETED","sponsor":"Yale University","official":"Samuel T Wilkinson, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT04760652","phase":"N/A","enroll":93,"start":"2021-03-05","eid":"x:site:nct04760652-emory-university-atlanta"},{"id":"nct07396220-uc-san-diego-health-4s-ranch-san-diego","cat":"research","name":"UC San Diego Health - 4S Ranch","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.72178,"lon":-117.16684,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"92127","condg":["Other"],"nct":"NCT07396220","study":"Psychotherapy Combined With Intranasal Esketamine for the Treatment of Suicidal Ideation","sstatus":"ENROLLING_BY_INVITATION","sponsor":"University of California, San Diego","src":"https://clinicaltrials.gov/study/NCT07396220","phase":"N/A","enroll":56,"start":"2026-01-09","eid":"x:site:nct07396220-uc-san-diego-health-4s-ranch-san-diego"},{"id":"nct06530706-zhejiang-cancer-hospital-hangzhou","cat":"research","name":"Zhejiang cancer hospital","city":"Hangzhou","region":"Zhejiang","country":"China","cc":"CN","lat":30.28485,"lon":120.1561,"gp":"city","unnamed":0,"drugs":["esketamine"],"condg":["Anxiety"],"nct":"NCT06530706","study":"Effect of Esketamine on Anxiety State in Patients Undergoing Abdominal Tumor Surgery","sstatus":"COMPLETED","sponsor":"Zhejiang Cancer Hospital","src":"https://clinicaltrials.gov/study/NCT06530706","phase":"N/A","enroll":185,"start":"2024-08-05","eid":"x:site:nct06530706-zhejiang-cancer-hospital-hangzhou"},{"id":"nct05826327-women-s-hospital-school-of-medicine-zhejiang-university-hangzhou","cat":"research","name":"Women's hospital, school of medicine, Zhejiang university","city":"Hangzhou","region":"Zhejiang","country":"China","cc":"CN","lat":30.28363,"lon":120.1689,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"331000","condg":["Depression"],"status":"RECRUITING","nct":"NCT05826327","study":"Effects of Epidural Labor Analgesia With Esketamine on the Incidence of Postpartum Depression in Parturients","sstatus":"UNKNOWN","sponsor":"Women's Hospital School Of Medicine Zhejiang University","official":"Weiguo Lyv, Dr (Women's Hospital School Of Medicine Zhejiang University)","src":"https://clinicaltrials.gov/study/NCT05826327","contact":{"n":"Xinzhong Chen, Dr","p":"13575738058","e":"chenxinz@zju.edu.cn"},"phase":"Phase 4","enroll":364,"start":"2023-05-01","eid":"x:site:nct05826327-women-s-hospital-school-of-medicine-zhejiang-university-hangzhou"},{"id":"nct04476446-clinica-de-ansiedad-depresion-y-estres-cade-s-de-r-l-de-c-v-guadalaj","cat":"research","name":"Clínica de Ansiedad, Depresión y Estrés CADE, S. de R.L. de C.V.","city":"Guadalajara","country":"Mexico","cc":"MX","lat":20.67536,"lon":-103.34989,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"44520","condg":["Depression"],"nct":"NCT04476446","study":"An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives","sstatus":"COMPLETED","sponsor":"Janssen-Cilag, S.A.","official":"Janssen-Cilag, S.A. Clinical Trial (Janssen-Cilag, S.A.)","src":"https://clinicaltrials.gov/study/NCT04476446","phase":"Phase 3","enroll":41,"start":"2020-09-08","eid":"x:site:nct04476446-clinica-de-ansiedad-depresion-y-estres-cade-s-de-r-l-de-c-v-guadalaj"},{"id":"nct04476446-gabipros-sc-mexico-city","cat":"research","name":"Gabipros SC.","city":"Mexico City","country":"Mexico","cc":"MX","lat":19.41769,"lon":-99.12535,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"07000","condg":["Depression"],"nct":"NCT04476446","study":"An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives","sstatus":"COMPLETED","sponsor":"Janssen-Cilag, S.A.","official":"Janssen-Cilag, S.A. Clinical Trial (Janssen-Cilag, S.A.)","src":"https://clinicaltrials.gov/study/NCT04476446","phase":"Phase 3","enroll":41,"start":"2020-09-08","eid":"x:site:nct04476446-gabipros-sc-mexico-city"},{"id":"nct04476446-avalon-vinculacion-medica-en-salud-mental-mexico-city","cat":"research","name":"Avalon Vinculación Médica En Salud Mental","city":"Mexico City","country":"Mexico","cc":"MX","lat":19.42438,"lon":-99.1214,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"11000","condg":["Depression"],"nct":"NCT04476446","study":"An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives","sstatus":"COMPLETED","sponsor":"Janssen-Cilag, S.A.","official":"Janssen-Cilag, S.A. Clinical Trial (Janssen-Cilag, S.A.)","src":"https://clinicaltrials.gov/study/NCT04476446","phase":"Phase 3","enroll":41,"start":"2020-09-08","eid":"x:site:nct04476446-avalon-vinculacion-medica-en-salud-mental-mexico-city"},{"id":"nct04476446-hospital-espanol-mexico-city","cat":"research","name":"Hospital Espanol","city":"Mexico City","country":"Mexico","cc":"MX","lat":19.41901,"lon":-99.12055,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"11520","condg":["Depression"],"nct":"NCT04476446","study":"An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives","sstatus":"COMPLETED","sponsor":"Janssen-Cilag, S.A.","official":"Janssen-Cilag, S.A. Clinical Trial (Janssen-Cilag, S.A.)","src":"https://clinicaltrials.gov/study/NCT04476446","phase":"Phase 3","enroll":41,"start":"2020-09-08","eid":"x:site:nct04476446-hospital-espanol-mexico-city"},{"id":"nct04476446-ketamine-mexico-s-de-rl-de-c-v-mexico-city","cat":"research","name":"Ketamine Mexico S. de RL. de C.V.","city":"Mexico City","country":"Mexico","cc":"MX","lat":19.4288,"lon":-99.13175,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"4100","condg":["Depression"],"nct":"NCT04476446","study":"An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives","sstatus":"COMPLETED","sponsor":"Janssen-Cilag, S.A.","official":"Janssen-Cilag, S.A. Clinical Trial (Janssen-Cilag, S.A.)","src":"https://clinicaltrials.gov/study/NCT04476446","phase":"Phase 3","enroll":41,"start":"2020-09-08","eid":"x:site:nct04476446-ketamine-mexico-s-de-rl-de-c-v-mexico-city"},{"id":"nct04476446-angel-alberto-ruiz-chow-mexico","cat":"research","name":"Ángel Alberto Ruiz Chow","city":"México","country":"Mexico","cc":"MX","lat":19.43096,"lon":-99.12234,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"01000","condg":["Depression"],"nct":"NCT04476446","study":"An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives","sstatus":"COMPLETED","sponsor":"Janssen-Cilag, S.A.","official":"Janssen-Cilag, S.A. Clinical Trial (Janssen-Cilag, S.A.)","src":"https://clinicaltrials.gov/study/NCT04476446","phase":"Phase 3","enroll":41,"start":"2020-09-08","eid":"x:site:nct04476446-angel-alberto-ruiz-chow-mexico"},{"id":"nct04476446-especialidades-en-neuropsiquiatria-de-mexico-s-c-mexico","cat":"research","name":"Especialidades en Neuropsiquiatría de México S.C.","city":"México","country":"Mexico","cc":"MX","lat":19.41779,"lon":-99.13364,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"11000","condg":["Depression"],"nct":"NCT04476446","study":"An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives","sstatus":"COMPLETED","sponsor":"Janssen-Cilag, S.A.","official":"Janssen-Cilag, S.A. Clinical Trial (Janssen-Cilag, S.A.)","src":"https://clinicaltrials.gov/study/NCT04476446","phase":"Phase 3","enroll":41,"start":"2020-09-08","eid":"x:site:nct04476446-especialidades-en-neuropsiquiatria-de-mexico-s-c-mexico"},{"id":"nct04476446-clinica-de-interdisciplinas-congnitivo-conductuales-mexico","cat":"research","name":"Clínica de Interdisciplinas Congnitivo Conductuales","city":"México","country":"Mexico","cc":"MX","lat":19.42381,"lon":-99.13411,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"11950","condg":["Depression"],"nct":"NCT04476446","study":"An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives","sstatus":"COMPLETED","sponsor":"Janssen-Cilag, S.A.","official":"Janssen-Cilag, S.A. Clinical Trial (Janssen-Cilag, S.A.)","src":"https://clinicaltrials.gov/study/NCT04476446","phase":"Phase 3","enroll":41,"start":"2020-09-08","eid":"x:site:nct04476446-clinica-de-interdisciplinas-congnitivo-conductuales-mexico"},{"id":"nct07053345-cha-ilsan-medical-center-goyang-si-gyeonggi-do","cat":"research","name":"Cha Ilsan Medical Center","city":"Goyang Si Gyeonggi Do","country":"South Korea","cc":"KR","lat":37.8503,"lon":127.298,"gp":"country","unnamed":0,"drugs":["esketamine"],"zip":"10414","condg":["Depression"],"nct":"NCT07053345","study":"A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","official":"Janssen Korea, Ltd., Korea Clinical Trial (Janssen Korea, Ltd., Korea)","src":"https://clinicaltrials.gov/study/NCT07053345","phase":"Phase 4","enroll":47,"start":"2025-06-09","eid":"x:site:nct07053345-cha-ilsan-medical-center-goyang-si-gyeonggi-do"},{"id":"nct07053345-wonkwang-university-hospital-iksan","cat":"research","name":"Wonkwang University Hospital","city":"Iksan","country":"South Korea","cc":"KR","lat":35.93773,"lon":126.96239,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"570 711","condg":["Depression"],"nct":"NCT07053345","study":"A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","official":"Janssen Korea, Ltd., Korea Clinical Trial (Janssen Korea, Ltd., Korea)","src":"https://clinicaltrials.gov/study/NCT07053345","phase":"Phase 4","enroll":47,"start":"2025-06-09","eid":"x:site:nct07053345-wonkwang-university-hospital-iksan"},{"id":"nct07053345-kangbuk-samsung-hospital-seoul","cat":"research","name":"Kangbuk Samsung Hospital","city":"Seoul","country":"South Korea","cc":"KR","lat":37.57518,"lon":126.98852,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"03181","condg":["Depression"],"nct":"NCT07053345","study":"A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","official":"Janssen Korea, Ltd., Korea Clinical Trial (Janssen Korea, Ltd., Korea)","src":"https://clinicaltrials.gov/study/NCT07053345","phase":"Phase 4","enroll":47,"start":"2025-06-09","eid":"x:site:nct07053345-kangbuk-samsung-hospital-seoul"},{"id":"nct07053345-asan-medical-center-seoul","cat":"research","name":"Asan Medical Center","city":"Seoul","country":"South Korea","cc":"KR","lat":37.56925,"lon":126.98899,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"05505","condg":["Depression"],"nct":"NCT07053345","study":"A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","official":"Janssen Korea, Ltd., Korea Clinical Trial (Janssen Korea, Ltd., Korea)","src":"https://clinicaltrials.gov/study/NCT07053345","phase":"Phase 4","enroll":47,"start":"2025-06-09","eid":"x:site:nct07053345-asan-medical-center-seoul"},{"id":"nct07053345-samsung-medical-center-seoul","cat":"research","name":"Samsung Medical Center","city":"Seoul","country":"South Korea","cc":"KR","lat":37.56859,"lon":126.98682,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"06351","condg":["Depression"],"nct":"NCT07053345","study":"A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","official":"Janssen Korea, Ltd., Korea Clinical Trial (Janssen Korea, Ltd., Korea)","src":"https://clinicaltrials.gov/study/NCT07053345","phase":"Phase 4","enroll":47,"start":"2025-06-09","eid":"x:site:nct07053345-samsung-medical-center-seoul"},{"id":"nct07053345-kyung-hee-university-hospital-seoul","cat":"research","name":"Kyung Hee University Hospital","city":"Seoul","country":"South Korea","cc":"KR","lat":37.56454,"lon":126.98136,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"130 050","condg":["Depression"],"nct":"NCT07053345","study":"A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","official":"Janssen Korea, Ltd., Korea Clinical Trial (Janssen Korea, Ltd., Korea)","src":"https://clinicaltrials.gov/study/NCT07053345","phase":"Phase 4","enroll":47,"start":"2025-06-09","eid":"x:site:nct07053345-kyung-hee-university-hospital-seoul"},{"id":"nct06608030-first-medical-center-of-chinese-pla-general-hospital-beijing","cat":"research","name":"First Medical center of Chinese PLA General Hospital","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.90877,"lon":116.40763,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"China","condg":["Depression","Anxiety"],"nct":"NCT06608030","study":"Effect of Esketamine on Perioperative Negative Mood in Patients Undergoing Cardiac Valve Surgery","sstatus":"COMPLETED","sponsor":"Chinese PLA General Hospital","src":"https://clinicaltrials.gov/study/NCT06608030","phase":"N/A","enroll":142,"start":"2024-09-23","eid":"x:site:nct06608030-first-medical-center-of-chinese-pla-general-hospital-beijing"},{"id":"nct06608030-beijing-tiantan-hospital-beijing","cat":"research","name":"Beijing Tiantan Hospital","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.90275,"lon":116.38862,"gp":"city","unnamed":0,"drugs":["esketamine"],"condg":["Depression","Anxiety"],"nct":"NCT06608030","study":"Effect of Esketamine on Perioperative Negative Mood in Patients Undergoing Cardiac Valve Surgery","sstatus":"COMPLETED","sponsor":"Chinese PLA General Hospital","src":"https://clinicaltrials.gov/study/NCT06608030","phase":"N/A","enroll":142,"start":"2024-09-23","eid":"x:site:nct06608030-beijing-tiantan-hospital-beijing"},{"id":"nct05095857-rigshospitalet-copenhagen","cat":"research","name":"Rigshospitalet","city":"Copenhagen","country":"Denmark","cc":"DK","lat":55.68794,"lon":12.56445,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"condg":["PTSD & trauma","Neurology & cognition"],"status":"RECRUITING","nct":"NCT05095857","study":"The Anaesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury","sstatus":"RECRUITING","sponsor":"Copenhagen University Hospital, Rigshospitalet","official":"Trine H Andreasen, MD (Copenhagen University Hospital, Rigshospitalet)","src":"https://clinicaltrials.gov/study/NCT05095857","contact":{"n":"Trine Hjorslev Andreasen, M.D","p":"+4535455982","e":"trine.hjorslev.andreasen@regionh.dk"},"phase":"Phase 4","enroll":400,"start":"2023-09-15","eid":"x:site:nct05095857-rigshospitalet-copenhagen"},{"id":"nct05060068-second-affiliated-hospital-of-anhui-medical-university-hefei","cat":"research","name":"Second Affiliated Hospital of Anhui Medical University","city":"Hefei","country":"China","cc":"CN","lat":31.86996,"lon":117.2805,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"230601","condg":["Cancer-related distress"],"nct":"NCT05060068","study":"Effect of Intravenous S-ketamine on Opioid Consumption","sstatus":"COMPLETED","sponsor":"The Second Hospital of Anhui Medical University","official":"Ye Zhang, M.D., Ph. D. (The Second Hospital of Anhui Medical University)","src":"https://clinicaltrials.gov/study/NCT05060068","phase":"N/A","enroll":345,"start":"2021-10-07","eid":"x:site:nct05060068-second-affiliated-hospital-of-anhui-medical-university-hefei"},{"id":"nct04338321-fundacion-para-el-estudio-y-tratamiento-de-las-enfermedades-mentales","cat":"research","name":"Fundacion para el Estudio y Tratamiento de las Enfermedades Mentales","city":"Buenos Aires","country":"Argentina","cc":"AR","lat":-34.61423,"lon":-58.37314,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"C1133AAH","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-fundacion-para-el-estudio-y-tratamiento-de-las-enfermedades-mentales"},{"id":"nct04338321-fundamos-buenos-aires","cat":"research","name":"FunDaMos","city":"Buenos Aires","country":"Argentina","cc":"AR","lat":-34.60369,"lon":-58.38029,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"C1405BOA","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-fundamos-buenos-aires"},{"id":"nct04338321-cen-consultorios-especializados-en-neurociencias-cordoba","cat":"research","name":"CEN Consultorios Especializados en Neurociencias","city":"Córdoba","country":"Argentina","cc":"AR","lat":-31.39523,"lon":-64.17813,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"5000FJF","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-cen-consultorios-especializados-en-neurociencias-cordoba"},{"id":"nct04338321-fundacion-lennox-cordoba","cat":"research","name":"Fundacion Lennox","city":"Córdoba","country":"Argentina","cc":"AR","lat":-31.41189,"lon":-64.18246,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"5000","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-fundacion-lennox-cordoba"},{"id":"nct04338321-instituto-medico-damic-cordoba","cat":"research","name":"Instituto Medico DAMIC","city":"Córdoba","country":"Argentina","cc":"AR","lat":-31.41839,"lon":-64.17898,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"X5003DCE","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-instituto-medico-damic-cordoba"},{"id":"nct04338321-sanatorio-prof-leon-s-morra-s-a-cordoba","cat":"research","name":"Sanatorio Prof Leon S Morra S A","city":"Córdoba","country":"Argentina","cc":"AR","lat":-31.399,"lon":-64.20006,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"X5009BIN","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-sanatorio-prof-leon-s-morra-s-a-cordoba"},{"id":"nct04338321-instituto-de-neurociencias-san-agustin-la-plata","cat":"research","name":"Instituto de Neurociencias San Agustin","city":"La Plata","country":"Argentina","cc":"AR","lat":-34.91641,"lon":-57.95616,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1900","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-instituto-de-neurociencias-san-agustin-la-plata"},{"id":"nct04338321-c-i-a-p-centro-de-investigacion-y-asistencia-en-psiquiatria-rosario","cat":"research","name":"C I A P Centro de investigacion y Asistencia en Psiquiatria","city":"Rosario","country":"Argentina","cc":"AR","lat":-32.95091,"lon":-60.63984,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"2000","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-c-i-a-p-centro-de-investigacion-y-asistencia-en-psiquiatria-rosario"},{"id":"nct04338321-medical-university-graz-graz","cat":"research","name":"Medical University Graz","city":"Graz","country":"Austria","cc":"AT","lat":47.059,"lon":15.43731,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"8036","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-medical-university-graz-graz"},{"id":"nct04338321-schmitz-and-schmitz-vienna","cat":"research","name":"Schmitz and Schmitz","city":"Vienna","country":"Austria","cc":"AT","lat":48.2172,"lon":16.36394,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1010","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-schmitz-and-schmitz-vienna"},{"id":"nct04338321-medical-university-vienna-muv-vienna","cat":"research","name":"Medical University Vienna MUV","city":"Vienna","country":"Austria","cc":"AT","lat":48.21484,"lon":16.37439,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1090","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-medical-university-vienna-muv-vienna"},{"id":"nct04338321-anima-alken","cat":"research","name":"Anima","city":"Alken","country":"Belgium","cc":"BE","lat":50.8736,"lon":5.31485,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"3570","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-anima-alken"},{"id":"nct04338321-pz-duffel-duffel","cat":"research","name":"Pz Duffel","city":"Duffel","country":"Belgium","cc":"BE","lat":51.0938,"lon":4.51567,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"2570","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-pz-duffel-duffel"},{"id":"nct04338321-clinique-psychiatrique-des-freres-alexiens-henri-chapelle","cat":"research","name":"Clinique Psychiatrique des Frères Alexiens","city":"Henri-Chapelle","country":"Belgium","cc":"BE","lat":50.68399,"lon":5.92327,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"4841","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-clinique-psychiatrique-des-freres-alexiens-henri-chapelle"},{"id":"nct04338321-sint-franciskusziekenhuis-heusden-zolder","cat":"research","name":"Sint-Franciskusziekenhuis","city":"Heusden-Zolder","country":"Belgium","cc":"BE","lat":51.0759,"lon":4.7821,"gp":"country","unnamed":0,"drugs":["esketamine"],"zip":"3550","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-sint-franciskusziekenhuis-heusden-zolder"},{"id":"nct04338321-ariadne-lede","cat":"research","name":"ARIADNE","city":"Lede","country":"Belgium","cc":"BE","lat":50.95793,"lon":3.97695,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"9340","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-ariadne-lede"},{"id":"nct04338321-chu-de-liege-liege","cat":"research","name":"CHU de Liege","city":"Liège","country":"Belgium","cc":"BE","lat":50.64046,"lon":5.5777,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"4000","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-chu-de-liege-liege"},{"id":"nct04338321-cpn-centro-de-pesquisa-em-neurociencias-ltda-belo-horizonte","cat":"research","name":"CPN - Centro de Pesquisa em Neurociências Ltda","city":"Belo Horizonte","country":"Brazil","cc":"BR","lat":-19.92389,"lon":-43.93952,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"30150-270","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-cpn-centro-de-pesquisa-em-neurociencias-ltda-belo-horizonte"},{"id":"nct04338321-trial-tech-tecnologia-em-pesquisas-com-medicamentos-curitiba","cat":"research","name":"Trial Tech Tecnologia em Pesquisas com Medicamentos","city":"Curitiba","country":"Brazil","cc":"BR","lat":-25.43187,"lon":-49.28007,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"80240-280","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-trial-tech-tecnologia-em-pesquisas-com-medicamentos-curitiba"},{"id":"nct04338321-ruschel-medicina-e-pesquisa-clinica-ltda-rio-de-janeiro","cat":"research","name":"Ruschel Medicina e Pesquisa Clínica Ltda","city":"Rio de Janeiro","country":"Brazil","cc":"BR","lat":-22.91268,"lon":-43.18689,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"22270 060","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-ruschel-medicina-e-pesquisa-clinica-ltda-rio-de-janeiro"},{"id":"nct04338321-c-j-s-carvalho-carvalho-ltda-viver-centro-de-desospitalizacao-humana","cat":"research","name":"C J S Carvalho & Carvalho LTDA (Viver - Centro De Desospitalizacao Humana)","city":"São Paulo","country":"Brazil","cc":"BR","lat":-23.53861,"lon":-46.64058,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"04020-060","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-c-j-s-carvalho-carvalho-ltda-viver-centro-de-desospitalizacao-humana"},{"id":"nct04338321-br-trials-sao-paulo","cat":"research","name":"BR Trials","city":"São Paulo","country":"Brazil","cc":"BR","lat":-23.53889,"lon":-46.64651,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"05003-090","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-br-trials-sao-paulo"},{"id":"nct04338321-state-psychiatric-hospital-kardzhali-kardzhali","cat":"research","name":"State Psychiatric Hospital Kardzhali","city":"Kardzhali","country":"Bulgaria","cc":"BG","lat":41.6525,"lon":25.35914,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"6600","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-state-psychiatric-hospital-kardzhali-kardzhali"},{"id":"nct04338321-umhat-dr-georgi-stranski-ead-pleven","cat":"research","name":"UMHAT 'Dr. Georgi Stranski', EAD","city":"Pleven","country":"Bulgaria","cc":"BG","lat":43.41702,"lon":24.62104,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"5800","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-umhat-dr-georgi-stranski-ead-pleven"},{"id":"nct04338321-mental-health-center-plovdiv-plovdiv","cat":"research","name":"Mental Health Center - Plovdiv","city":"Plovdiv","country":"Bulgaria","cc":"BG","lat":42.15185,"lon":24.75232,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"4002","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-mental-health-center-plovdiv-plovdiv"},{"id":"nct04338321-mental-health-center-rousse-rousse","cat":"research","name":"Mental Health Center - Rousse","city":"Rousse","country":"Bulgaria","cc":"BG","lat":43.85432,"lon":25.94592,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"7003","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-mental-health-center-rousse-rousse"},{"id":"nct04338321-multiprofile-hospital-for-active-treatment-in-neurology-and-psychiat","cat":"research","name":"Multiprofile Hospital for Active Treatment in Neurology and Psychiatry Sveti Naum","city":"Sofia","country":"Bulgaria","cc":"BG","lat":42.70255,"lon":23.32702,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1113","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-multiprofile-hospital-for-active-treatment-in-neurology-and-psychiat"},{"id":"nct04338321-mhc-sofia-eood-sofia","cat":"research","name":"MHC - Sofia, EOOD","city":"Sofia","country":"Bulgaria","cc":"BG","lat":42.70226,"lon":23.32382,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1202","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-mhc-sofia-eood-sofia"},{"id":"nct04338321-centre-for-mental-health-prof-n-shipkovenski-eood-sofia","cat":"research","name":"Centre for Mental Health Prof.N.Shipkovenski EOOD","city":"Sofia","country":"Bulgaria","cc":"BG","lat":42.70603,"lon":23.33568,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1377","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-centre-for-mental-health-prof-n-shipkovenski-eood-sofia"},{"id":"nct04338321-university-multiprofile-hospital-for-active-treatment-umhat-alexandr","cat":"research","name":"University Multiprofile Hospital for Active Treatment - UMHAT Alexandrovska EAD","city":"Sofia","country":"Bulgaria","cc":"BG","lat":42.7081,"lon":23.31403,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1431","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-university-multiprofile-hospital-for-active-treatment-umhat-alexandr"},{"id":"nct04338321-psychiatricka-ambulance-saint-anne-s-r-o-brno","cat":"research","name":"Psychiatricka ambulance Saint Anne s.r.o.","city":"Brno","country":"Czechia","cc":"CZ","lat":49.20468,"lon":16.6146,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"60200","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-psychiatricka-ambulance-saint-anne-s-r-o-brno"},{"id":"nct04338321-psychiatricka-ambulance-mudr-marta-holanova-brno","cat":"research","name":"Psychiatricka ambulance, MUDr. Marta Holanova","city":"Brno","country":"Czechia","cc":"CZ","lat":49.18604,"lon":16.60227,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"61500","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-psychiatricka-ambulance-mudr-marta-holanova-brno"},{"id":"nct04338321-neuropsychiatriehk-s-r-o-hradec-kralove-vekose","cat":"research","name":"NeuropsychiatrieHK, s.r.o.","city":"Hradec Kralove-Vekose","country":"Czechia","cc":"CZ","lat":50.3998,"lon":14.8502,"gp":"country","unnamed":0,"drugs":["esketamine"],"zip":"50341","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-neuropsychiatriehk-s-r-o-hradec-kralove-vekose"},{"id":"nct04338321-a-shine-s-r-o-pilsen","cat":"research","name":"A Shine S R O","city":"Pilsen","country":"Czechia","cc":"CZ","lat":49.75683,"lon":13.37161,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"31200","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-a-shine-s-r-o-pilsen"},{"id":"nct04338321-clintrial-s-r-o-prague","cat":"research","name":"Clintrial s r o","city":"Prague","country":"Czechia","cc":"CZ","lat":50.09129,"lon":14.4305,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"10000","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-clintrial-s-r-o-prague"},{"id":"nct04338321-ad71-s-r-o-prague","cat":"research","name":"AD71 s.r.o.","city":"Prague","country":"Czechia","cc":"CZ","lat":50.08743,"lon":14.42354,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"109 00","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-ad71-s-r-o-prague"},{"id":"nct04338321-medical-services-prague-s-r-o-prague","cat":"research","name":"Medical Services Prague S R O","city":"Prague","country":"Czechia","cc":"CZ","lat":50.09364,"lon":14.40942,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"16000","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-medical-services-prague-s-r-o-prague"},{"id":"nct04338321-institut-neuropsychiatricke-pece-prague","cat":"research","name":"Institut Neuropsychiatricke pece","city":"Prague","country":"Czechia","cc":"CZ","lat":50.09392,"lon":14.41629,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"18600","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-institut-neuropsychiatricke-pece-prague"},{"id":"nct04338321-aalborg-university-hospital-aalborg","cat":"research","name":"Aalborg University Hospital","city":"Aalborg","country":"Denmark","cc":"DK","lat":57.04014,"lon":9.90717,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"9000","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-aalborg-university-hospital-aalborg"},{"id":"nct04338321-psykiatrien-i-region-syddanmark-esbjerg-n","cat":"research","name":"Psykiatrien i Region Syddanmark","city":"Esbjerg N","country":"Denmark","cc":"DK","lat":55.5642,"lon":12.3165,"gp":"country","unnamed":0,"drugs":["esketamine"],"zip":"6715","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-psykiatrien-i-region-syddanmark-esbjerg-n"},{"id":"nct04338321-mederon-ltd-at-artes-helsinki","cat":"research","name":"Mederon LTD at ARTES","city":"Helsinki","country":"Finland","cc":"FI","lat":60.16241,"lon":24.94359,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"00270","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-mederon-ltd-at-artes-helsinki"},{"id":"nct04338321-psykiatrinen-palvelukeskus-solvum-oy-helsinki","cat":"research","name":"Psykiatrinen Palvelukeskus Solvum Oy","city":"Helsinki","country":"Finland","cc":"FI","lat":60.17277,"lon":24.93267,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"120","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-psykiatrinen-palvelukeskus-solvum-oy-helsinki"},{"id":"nct04338321-savon-psykiatripalvelu-kuopio","cat":"research","name":"Savon Psykiatripalvelu","city":"Kuopio","country":"Finland","cc":"FI","lat":62.89167,"lon":27.67369,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"70110","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-savon-psykiatripalvelu-kuopio"},{"id":"nct04338321-universitaetsklinikum-der-rwth-aachen-aachen","cat":"research","name":"Universitaetsklinikum der RWTH Aachen","city":"Aachen","country":"Germany","cc":"DE","lat":50.7812,"lon":6.09128,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"52074","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-universitaetsklinikum-der-rwth-aachen-aachen"},{"id":"nct04338321-rheinhessen-fachklinik-alzey-alzey","cat":"research","name":"Rheinhessen Fachklinik Alzey","city":"Alzey","country":"Germany","cc":"DE","lat":49.74003,"lon":8.11913,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"55232","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-rheinhessen-fachklinik-alzey-alzey"},{"id":"nct04338321-emovis-gmbh-berlin","cat":"research","name":"Emovis GmbH","city":"Berlin","country":"Germany","cc":"DE","lat":52.51275,"lon":13.40794,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"10629","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-emovis-gmbh-berlin"},{"id":"nct04338321-charite-campus-benjamin-franklin-berlin","cat":"research","name":"Charite Campus Benjamin Franklin","city":"Berlin","country":"Germany","cc":"DE","lat":52.51821,"lon":13.40182,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"12203","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-charite-campus-benjamin-franklin-berlin"},{"id":"nct04338321-medizinisches-versorgungszentrum-lio-gmbh-berlin","cat":"research","name":"Medizinisches Versorgungszentrum LiO GmbH","city":"Berlin","country":"Germany","cc":"DE","lat":52.53279,"lon":13.40211,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"12209","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-medizinisches-versorgungszentrum-lio-gmbh-berlin"},{"id":"nct04338321-alexander-schulze-germany-berlin","cat":"research","name":"Alexander Schulze - Germany","city":"Berlin","country":"Germany","cc":"DE","lat":52.53025,"lon":13.41999,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"13156","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-alexander-schulze-germany-berlin"},{"id":"nct04338321-praxis-dr-med-kirsten-hahn-berlin","cat":"research","name":"Praxis Dr. med. Kirsten Hahn","city":"Berlin","country":"Germany","cc":"DE","lat":52.51237,"lon":13.399,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"13187","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-praxis-dr-med-kirsten-hahn-berlin"},{"id":"nct04338321-vivantes-klinikum-spandau-berlin","cat":"research","name":"Vivantes Klinikum Spandau","city":"Berlin","country":"Germany","cc":"DE","lat":52.52206,"lon":13.40069,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"13585","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-vivantes-klinikum-spandau-berlin"},{"id":"nct04338321-universitatsklinikum-bonn-bonn","cat":"research","name":"Universitatsklinikum Bonn","city":"Bonn","country":"Germany","cc":"DE","lat":50.73782,"lon":7.10523,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"53105","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-universitatsklinikum-bonn-bonn"},{"id":"nct04338321-klinikum-chemnitz-ggmbh-chemnitz","cat":"research","name":"Klinikum Chemnitz gGmbH","city":"Chemnitz","country":"Germany","cc":"DE","lat":50.84544,"lon":12.9368,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"09131","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-klinikum-chemnitz-ggmbh-chemnitz"},{"id":"nct04338321-carl-thiem-klinikum-cottbus-ggmbh-cottbus","cat":"research","name":"Carl-Thiem-Klinikum Cottbus gGmbH","city":"Cottbus","country":"Germany","cc":"DE","lat":51.75623,"lon":14.31923,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"3048","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-carl-thiem-klinikum-cottbus-ggmbh-cottbus"},{"id":"nct04338321-klinikum-dortmund-ggmbh-dortmund","cat":"research","name":"Klinikum Dortmund gGmbH","city":"Dortmund","country":"Germany","cc":"DE","lat":51.51583,"lon":7.46078,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"44287","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-klinikum-dortmund-ggmbh-dortmund"},{"id":"nct04338321-universitatsklinikum-carl-gustav-carcus-dresden-dresden","cat":"research","name":"Universitatsklinikum Carl Gustav Carcus Dresden","city":"Dresden","country":"Germany","cc":"DE","lat":51.04473,"lon":13.73931,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"01307","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-universitatsklinikum-carl-gustav-carcus-dresden-dresden"},{"id":"nct04338321-universitatsklinikum-frankfurt-frankfurt-am-main","cat":"research","name":"Universitatsklinikum Frankfurt","city":"Frankfurt am Main","country":"Germany","cc":"DE","lat":50.11698,"lon":8.67791,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"60528","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-universitatsklinikum-frankfurt-frankfurt-am-main"},{"id":"nct04338321-universitatsklinikum-freiburg-abteilung-fur-psychiatrie-u-psychother","cat":"research","name":"Universitätsklinikum Freiburg - Abteilung für Psychiatrie u. Psychotherapie mit Poliklinik","city":"Freiburg im Breisgau","country":"Germany","cc":"DE","lat":47.99962,"lon":7.85151,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"79104","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-universitatsklinikum-freiburg-abteilung-fur-psychiatrie-u-psychother"},{"id":"nct04338321-srh-waldklinikum-gera-gmbh-gera","cat":"research","name":"SRH Waldklinikum Gera GmbH","city":"Gera","country":"Germany","cc":"DE","lat":50.8714,"lon":12.08775,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"7548","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-srh-waldklinikum-gera-gmbh-gera"},{"id":"nct04338321-georg-august-universitat-universitatsmedizin-gottingen-gottingen","cat":"research","name":"Georg August Universitat Universitatsmedizin Gottingen","city":"Göttingen","country":"Germany","cc":"DE","lat":51.53467,"lon":9.93402,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"37075","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-georg-august-universitat-universitatsmedizin-gottingen-gottingen"},{"id":"nct04338321-evangelisches-krankenhaus-bethanien-ggmbh-greifswald","cat":"research","name":"Evangelisches Krankenhaus Bethanien gGmbH","city":"Greifswald","country":"Germany","cc":"DE","lat":54.09747,"lon":13.40042,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"17489","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-evangelisches-krankenhaus-bethanien-ggmbh-greifswald"},{"id":"nct04338321-universitaetsklinik-hamburg-eppendorf-hamburg","cat":"research","name":"Universitaetsklinik Hamburg-Eppendorf","city":"Hamburg","country":"Germany","cc":"DE","lat":53.56104,"lon":9.99467,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"20251","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-universitaetsklinik-hamburg-eppendorf-hamburg"},{"id":"nct04338321-klinische-forschung-hamburg-hamburg","cat":"research","name":"Klinische Forschung Hamburg","city":"Hamburg","country":"Germany","cc":"DE","lat":53.55906,"lon":9.99956,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"20253","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-klinische-forschung-hamburg-hamburg"},{"id":"nct04338321-klinische-forschung-hannover-mitte-gmbh-hanover","cat":"research","name":"Klinische Forschung Hannover-Mitte GmbH","city":"Hanover","country":"Germany","cc":"DE","lat":52.36454,"lon":9.72677,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"30159","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-klinische-forschung-hannover-mitte-gmbh-hanover"},{"id":"nct04338321-medizinische-hochschule-hannover-hanover","cat":"research","name":"Medizinische Hochschule Hannover","city":"Hanover","country":"Germany","cc":"DE","lat":52.37753,"lon":9.7328,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"30625","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-medizinische-hochschule-hannover-hanover"},{"id":"nct04338321-universitat-heidelberg-heidelberg","cat":"research","name":"Universität Heidelberg","city":"Heidelberg","country":"Germany","cc":"DE","lat":49.41714,"lon":8.68077,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"69115","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-universitat-heidelberg-heidelberg"},{"id":"nct04338321-oberhavel-kliniken-gmbh-hennigsdorf","cat":"research","name":"Oberhavel Kliniken GmbH","city":"Hennigsdorf","country":"Germany","cc":"DE","lat":52.63471,"lon":13.19595,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"16761","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-oberhavel-kliniken-gmbh-hennigsdorf"},{"id":"nct04338321-universitatsklinikum-des-saarlandes-homburg","cat":"research","name":"Universitätsklinikum des Saarlandes","city":"Homburg","country":"Germany","cc":"DE","lat":49.33828,"lon":7.34916,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"66421","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-universitatsklinikum-des-saarlandes-homburg"},{"id":"nct04338321-universitatsklinikum-jena-jena","cat":"research","name":"Universitatsklinikum Jena","city":"Jena","country":"Germany","cc":"DE","lat":50.92026,"lon":11.58289,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"7743","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-universitatsklinikum-jena-jena"},{"id":"nct04338321-panakeia-arzneimittelforschung-gmbh-leipzig","cat":"research","name":"Panakeia - Arzneimittelforschung GmbH","city":"Leipzig","country":"Germany","cc":"DE","lat":51.3391,"lon":12.36757,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"04275","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-panakeia-arzneimittelforschung-gmbh-leipzig"},{"id":"nct04338321-universitaetsklinikum-magdeburg-a-oe-r-magdeburg","cat":"research","name":"Universitaetsklinikum Magdeburg A.oe.R","city":"Magdeburg","country":"Germany","cc":"DE","lat":52.14169,"lon":11.62045,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"39120","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-universitaetsklinikum-magdeburg-a-oe-r-magdeburg"},{"id":"nct04338321-universitatsmedizin-der-johannes-gutenberg-universitat-mainz-mainz","cat":"research","name":"Universitatsmedizin der Johannes Gutenberg Universitat Mainz","city":"Mainz","country":"Germany","cc":"DE","lat":49.97691,"lon":8.26855,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"55131","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-universitatsmedizin-der-johannes-gutenberg-universitat-mainz-mainz"},{"id":"nct04338321-pharmakologisches-studienzentrum-chemnitz-gmbh-mittweida","cat":"research","name":"Pharmakologisches Studienzentrum Chemnitz GmbH","city":"Mittweida","country":"Germany","cc":"DE","lat":50.99587,"lon":12.98266,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"09648","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-pharmakologisches-studienzentrum-chemnitz-gmbh-mittweida"},{"id":"nct04338321-universitatsklinikum-munster-munster","cat":"research","name":"Universitatsklinikum Munster","city":"Münster","country":"Germany","cc":"DE","lat":51.95083,"lon":7.63395,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"48147","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-universitatsklinikum-munster-munster"},{"id":"nct04338321-ruppiner-kliniken-neuruppin","cat":"research","name":"Ruppiner Kliniken","city":"Neuruppin","country":"Germany","cc":"DE","lat":52.92923,"lon":12.80212,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"16816","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-ruppiner-kliniken-neuruppin"},{"id":"nct04338321-praxis-prof-steinwachs-nuremberg","cat":"research","name":"Praxis Prof. Steinwachs","city":"Nuremberg","country":"Germany","cc":"DE","lat":49.44579,"lon":11.07427,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"90402","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-praxis-prof-steinwachs-nuremberg"},{"id":"nct04338321-johanniter-krankenhaus-oberhausen-oberhausen","cat":"research","name":"Johanniter Krankenhaus Oberhausen","city":"Oberhausen","country":"Germany","cc":"DE","lat":51.47772,"lon":6.87074,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"46145","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-johanniter-krankenhaus-oberhausen-oberhausen"},{"id":"nct04338321-danuvius-klinik-pfaffenhofen-fachklinik-fur-psychiatrie-psychotherap","cat":"research","name":"Danuvius Klinik Pfaffenhofen Fachklinik für Psychiatrie, Psychotherapie und Psychosomatik","city":"Pfaffenhofen","country":"Germany","cc":"DE","lat":49.07089,"lon":8.97973,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"85276","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-danuvius-klinik-pfaffenhofen-fachklinik-fur-psychiatrie-psychotherap"},{"id":"nct04338321-somni-bene-gmbh-schwerin","cat":"research","name":"Somni Bene GmbH","city":"Schwerin","country":"Germany","cc":"DE","lat":53.63073,"lon":11.41132,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"19053","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-somni-bene-gmbh-schwerin"},{"id":"nct04338321-klinische-forschung-schwerin-gmbh-schwerin","cat":"research","name":"Klinische Forschung Schwerin GmbH","city":"Schwerin","country":"Germany","cc":"DE","lat":53.64043,"lon":11.42328,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"19055","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-klinische-forschung-schwerin-gmbh-schwerin"},{"id":"nct04338321-klinikum-der-hansestadt-stralsund-gmbh-ambulanz-klinik-fur-psychiatr","cat":"research","name":"Klinikum der Hansestadt Stralsund GmbH-Ambulanz-Klinik für Psychiatrie und Psychotherapie - Germany","city":"Stralsund","country":"Germany","cc":"DE","lat":54.31876,"lon":13.07046,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"18437","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-klinikum-der-hansestadt-stralsund-gmbh-ambulanz-klinik-fur-psychiatr"},{"id":"nct04338321-aiginition-hospital-of-athens-athens","cat":"research","name":"Aiginition Hospital of Athens","city":"Athens","country":"Greece","cc":"GR","lat":37.97675,"lon":23.7229,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"11528","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-aiginition-hospital-of-athens-athens"},{"id":"nct04338321-dafni-psychiatric-hospital-of-attica-athens","cat":"research","name":"'Dafni' Psychiatric Hospital of Attica","city":"Athens","country":"Greece","cc":"GR","lat":37.97712,"lon":23.72488,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"124 62","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-dafni-psychiatric-hospital-of-attica-athens"},{"id":"nct04338321-venizeleio-general-hospital-crete","cat":"research","name":"Venizeleio General Hospital","city":"Crete","country":"Greece","cc":"GR","lat":35.0143,"lon":24.8068,"gp":"region","unnamed":0,"drugs":["esketamine"],"zip":"71409","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-venizeleio-general-hospital-crete"},{"id":"nct04338321-psychiatric-clinic-agios-charalampos-heraklion","cat":"research","name":"Psychiatric Clinic 'Agios Charalampos'","city":"Heraklion","country":"Greece","cc":"GR","lat":35.33893,"lon":25.15268,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"71305","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-psychiatric-clinic-agios-charalampos-heraklion"},{"id":"nct04338321-university-general-hospital-of-ioannina-ioannina","cat":"research","name":"University General Hospital of Ioannina","city":"Ioannina","country":"Greece","cc":"GR","lat":39.65677,"lon":20.86161,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"45110","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-university-general-hospital-of-ioannina-ioannina"},{"id":"nct04338321-university-general-hospital-of-rio-patras-patrai","cat":"research","name":"University General Hospital of Rio Patras","city":"Pátrai","country":"Greece","cc":"GR","lat":38.2454,"lon":21.72496,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"26504","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-university-general-hospital-of-rio-patras-patrai"},{"id":"nct04338321-424-military-hospital-of-thessaloniki-thessaloniki","cat":"research","name":"424 Military Hospital of Thessaloniki","city":"Thessaloniki","country":"Greece","cc":"GR","lat":40.64773,"lon":22.941,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"54636","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-424-military-hospital-of-thessaloniki-thessaloniki"},{"id":"nct04338321-psychiatric-hospital-of-thessaloniki-thessaloniki","cat":"research","name":"Psychiatric Hospital of Thessaloniki","city":"Thessaloniki","country":"Greece","cc":"GR","lat":40.64481,"lon":22.94335,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"56430","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-psychiatric-hospital-of-thessaloniki-thessaloniki"},{"id":"nct04338321-g-papanikolaou-hospital-of-thessaloniki-thessaloniki","cat":"research","name":"G Papanikolaou Hospital of Thessaloniki","city":"Thessaloniki","country":"Greece","cc":"GR","lat":40.64312,"lon":22.93469,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"57010","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-g-papanikolaou-hospital-of-thessaloniki-thessaloniki"},{"id":"nct04338321-semmelweis-egyetem-budapest","cat":"research","name":"Semmelweis Egyetem","city":"Budapest","country":"Hungary","cc":"HU","lat":47.4951,"lon":19.0453,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1083","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-semmelweis-egyetem-budapest"},{"id":"nct04338321-eszak-kozep-budai-centrum-uj-szent-janos-korhaz-es-szakrendelo-budai","cat":"research","name":"Eszak Kozep budai Centrum Uj Szent Janos Korhaz es Szakrendelo Budai Csaladkozpontu","city":"Budapest","country":"Hungary","cc":"HU","lat":47.508,"lon":19.03833,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1125","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-eszak-kozep-budai-centrum-uj-szent-janos-korhaz-es-szakrendelo-budai"},{"id":"nct04338321-processus-kft-budapest","cat":"research","name":"Processus Kft","city":"Budapest","country":"Hungary","cc":"HU","lat":47.5047,"lon":19.05104,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1137","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-processus-kft-budapest"},{"id":"nct04338321-debreceni-egyetem-kenezy-gyula-egyetemi-oktatokorhaz-debrecen","cat":"research","name":"Debreceni Egyetem, Kenézy Gyula Egyetemi Oktatókórház","city":"Debrecen","country":"Hungary","cc":"HU","lat":47.54103,"lon":21.61611,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"4031","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-debreceni-egyetem-kenezy-gyula-egyetemi-oktatokorhaz-debrecen"},{"id":"nct04338321-bugat-pal-korhaz-gyongyos","cat":"research","name":"Bugat Pal Korhaz","city":"Gyöngyös","country":"Hungary","cc":"HU","lat":47.78478,"lon":19.92541,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"3200","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-bugat-pal-korhaz-gyongyos"},{"id":"nct04338321-petz-aladar-megyei-oktato-korhaz-gyor","cat":"research","name":"Petz Aladar Megyei Oktato Korhaz","city":"Győr","country":"Hungary","cc":"HU","lat":47.67321,"lon":17.62641,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"H-9024","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-petz-aladar-megyei-oktato-korhaz-gyor"},{"id":"nct04338321-bacs-kiskun-megyei-korhaz-a-szegedi-tudomanyegyetem-altalanos-orvost","cat":"research","name":"Bács-Kiskun Megyei Kórház a Szegedi Tudományegyetem Általános Orvostudományi Kar Oktató Kórháza","city":"Kalocsa","country":"Hungary","cc":"HU","lat":46.53983,"lon":18.96591,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"6300","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-bacs-kiskun-megyei-korhaz-a-szegedi-tudomanyegyetem-altalanos-orvost"},{"id":"nct04338321-szabolcs-szatmar-bereg-megyei-korhazak-es-egyetemi-oktatokorhaz-nyir","cat":"research","name":"Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz","city":"Nyíregyháza","country":"Hungary","cc":"HU","lat":47.95468,"lon":21.71516,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"4400","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-szabolcs-szatmar-bereg-megyei-korhazak-es-egyetemi-oktatokorhaz-nyir"},{"id":"nct04338321-pecsi-tudomanyegyetem-klinikai-kozpont-pecs","cat":"research","name":"Pecsi Tudomanyegyetem Klinikai Kozpont","city":"Pécs","country":"Hungary","cc":"HU","lat":46.08469,"lon":18.23459,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"7623","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-pecsi-tudomanyegyetem-klinikai-kozpont-pecs"},{"id":"nct04338321-rambam-medical-center-haifa","cat":"research","name":"Rambam Medical Center","city":"Haifa","country":"Israel","cc":"IL","lat":32.81628,"lon":35.00987,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"3109601","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-rambam-medical-center-haifa"},{"id":"nct04338321-shalvata-mental-health-center-hod-hasharon","cat":"research","name":"Shalvata Mental Health Center","city":"Hod HaSharon","country":"Israel","cc":"IL","lat":32.16739,"lon":34.90153,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"45100","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-shalvata-mental-health-center-hod-hasharon"},{"id":"nct04338321-beer-yaakov-mental-health-center-lod","cat":"research","name":"Beer Yaakov Mental Health Center","city":"Lod","country":"Israel","cc":"IL","lat":31.94195,"lon":34.89675,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"7129434","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-beer-yaakov-mental-health-center-lod"},{"id":"nct04338321-geha-mental-health-center-petah-tikva","cat":"research","name":"Geha Mental Health Center","city":"Petah Tikva","country":"Israel","cc":"IL","lat":32.08448,"lon":34.87858,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"4910002","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-geha-mental-health-center-petah-tikva"},{"id":"nct04338321-sheba-medical-center-ramat-gan","cat":"research","name":"Sheba Medical Center","city":"Ramat Gan","country":"Israel","cc":"IL","lat":32.08232,"lon":34.80044,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"52621","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-sheba-medical-center-ramat-gan"},{"id":"nct04338321-tel-aviv-sourasky-medical-center-telaviv","cat":"research","name":"Tel Aviv Sourasky Medical Center","city":"Telaviv","country":"Israel","cc":"IL","lat":31.6847,"lon":35.5438,"gp":"country","unnamed":0,"drugs":["esketamine"],"zip":"6423914","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-tel-aviv-sourasky-medical-center-telaviv"},{"id":"nct04338321-republican-scientific-and-practical-center-of-mental-health-almaty","cat":"research","name":"Republican Scientific and Practical Center of Mental Health","city":"Almaty","country":"Kazakhstan","cc":"KZ","lat":43.26035,"lon":76.90458,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"50012","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-republican-scientific-and-practical-center-of-mental-health-almaty"},{"id":"nct04338321-medical-center-for-psychological-healt-sme-nur-sultan","cat":"research","name":"Medical Center for Psychological Healt SME","city":"Nur-Sultan","country":"Kazakhstan","cc":"KZ","lat":51.18504,"lon":71.4449,"gp":"city","unnamed":0,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-medical-center-for-psychological-healt-sme-nur-sultan"},{"id":"nct04338321-east-kazakhstan-regional-centre-of-mental-health-ust-kamenogorsk","cat":"research","name":"East-Kazakhstan Regional Centre of Mental Health","city":"Ust-Kamenogorsk","country":"Kazakhstan","cc":"KZ","lat":49.96799,"lon":82.59678,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"70016","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-east-kazakhstan-regional-centre-of-mental-health-ust-kamenogorsk"},{"id":"nct04338321-hospital-raja-permaisuri-bainun-ipoh","cat":"research","name":"Hospital Raja Permaisuri Bainun","city":"Ipoh","country":"Malaysia","cc":"MY","lat":4.59582,"lon":101.07824,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"30990","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-hospital-raja-permaisuri-bainun-ipoh"},{"id":"nct04338321-hospital-kuala-lumpur-kuala-lumpur","cat":"research","name":"Hospital Kuala Lumpur","city":"Kuala Lumpur","country":"Malaysia","cc":"MY","lat":3.13776,"lon":101.68978,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"50586","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-hospital-kuala-lumpur-kuala-lumpur"},{"id":"nct04338321-university-malaya-medical-centre-kuala-lumpur","cat":"research","name":"University Malaya Medical Centre","city":"Kuala Lumpur","country":"Malaysia","cc":"MY","lat":3.13588,"lon":101.67811,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"59100","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-university-malaya-medical-centre-kuala-lumpur"},{"id":"nct04338321-hospital-pengajar-universiti-putra-malaysia-serdang","cat":"research","name":"Hospital Pengajar Universiti Putra Malaysia","city":"Serdang","country":"Malaysia","cc":"MY","lat":5.2017,"lon":100.63516,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"43400","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-hospital-pengajar-universiti-putra-malaysia-serdang"},{"id":"nct04338321-hospital-tuanku-jaafar-seremban","cat":"research","name":"Hospital Tuanku Jaafar","city":"Seremban","country":"Malaysia","cc":"MY","lat":2.72241,"lon":101.93645,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"70300","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-hospital-tuanku-jaafar-seremban"},{"id":"nct04338321-brain-research-center-amsterdam","cat":"research","name":"Brain Research Center","city":"Amsterdam","country":"Netherlands","cc":"NL","lat":52.36918,"lon":4.89153,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1081 GN","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-brain-research-center-amsterdam"},{"id":"nct04338321-amc-amsterdam","cat":"research","name":"AMC","city":"Amsterdam","country":"Netherlands","cc":"NL","lat":52.38368,"lon":4.89087,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1105 AZ","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-amc-amsterdam"},{"id":"nct04338321-lumc-leiden","cat":"research","name":"LUMC","city":"Leiden","country":"Netherlands","cc":"NL","lat":52.14962,"lon":4.50327,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"2300 RC","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-lumc-leiden"},{"id":"nct04338321-haukeland-university-hospital-hordaland","cat":"research","name":"Haukeland University Hospital","city":"Hordaland","country":"Norway","cc":"NO","lat":59.5539,"lon":10.4775,"gp":"country","unnamed":0,"drugs":["esketamine"],"zip":"5021","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-haukeland-university-hospital-hordaland"},{"id":"nct04338321-sykehuset-ostfold-moss","cat":"research","name":"Sykehuset Ostfold","city":"Moss","country":"Norway","cc":"NO","lat":59.43794,"lon":10.66595,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1535","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-sykehuset-ostfold-moss"},{"id":"nct04338321-st-olav-university-hospital-trondheim","cat":"research","name":"St Olav University Hospital","city":"Trondheim","country":"Norway","cc":"NO","lat":63.43487,"lon":10.39021,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"7000","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-st-olav-university-hospital-trondheim"},{"id":"nct04338321-mlynowamed-specjalistyczny-psychiatryczny-gabinet-lekarski-joanna-la","cat":"research","name":"Mlynowamed Specjalistyczny Psychiatryczny Gabinet Lekarski Joanna Lazarczyk","city":"Bialystok","country":"Poland","cc":"PL","lat":53.12538,"lon":23.15487,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"15-404","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-mlynowamed-specjalistyczny-psychiatryczny-gabinet-lekarski-joanna-la"},{"id":"nct04338321-osrodek-badan-klinicznych-clinsante-s-c-bydgoszcz","cat":"research","name":"Osrodek Badan Klinicznych CLINSANTE S C","city":"Bydgoszcz","country":"Poland","cc":"PL","lat":53.12317,"lon":18.00691,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"85 794","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-osrodek-badan-klinicznych-clinsante-s-c-bydgoszcz"},{"id":"nct04338321-uniwersyteckie-centrum-kliniczne-gdansk","cat":"research","name":"Uniwersyteckie Centrum Kliniczne","city":"Gdansk","country":"Poland","cc":"PL","lat":54.34281,"lon":18.66056,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"80 214","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-uniwersyteckie-centrum-kliniczne-gdansk"},{"id":"nct04338321-centrum-badan-klinicznych-pi-house-sp-z-o-o-gdansk","cat":"research","name":"Centrum Badan Klinicznych PI House sp z o o","city":"Gdansk","country":"Poland","cc":"PL","lat":54.34921,"lon":18.65058,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"80 546","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-centrum-badan-klinicznych-pi-house-sp-z-o-o-gdansk"},{"id":"nct04338321-centrum-medyczne-care-clinic-katowice-katowice","cat":"research","name":"Centrum Medyczne Care Clinic Katowice","city":"Katowice","country":"Poland","cc":"PL","lat":50.26191,"lon":19.01359,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"40-568","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-centrum-medyczne-care-clinic-katowice-katowice"},{"id":"nct04338321-niepubliczny-zaklad-opieki-psychiatrycznej-mentis-leszno","cat":"research","name":"Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS","city":"Leszno","country":"Poland","cc":"PL","lat":51.84453,"lon":16.57875,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"64-100","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-niepubliczny-zaklad-opieki-psychiatrycznej-mentis-leszno"},{"id":"nct04338321-specjalistyczny-psychiatryczny-zespol-opieki-zdrowotnej-w-lodzi-szpi","cat":"research","name":"Specjalistyczny Psychiatryczny Zespol Opieki Zdrowotnej w Lodzi Szpital im. J. Babinskiego","city":"Lodz","country":"Poland","cc":"PL","lat":51.76799,"lon":19.4772,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"91-229","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-specjalistyczny-psychiatryczny-zespol-opieki-zdrowotnej-w-lodzi-szpi"},{"id":"nct04338321-spzoz-csk-um-w-lodzi-klinika-zaburzen-afektywnych-i-psychotycznych-l","cat":"research","name":"SPZOZ CSK UM w Lodzi Klinika Zaburzen Afektywnych i Psychotycznych","city":"Lodz","country":"Poland","cc":"PL","lat":51.77242,"lon":19.46769,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"92-216","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-spzoz-csk-um-w-lodzi-klinika-zaburzen-afektywnych-i-psychotycznych-l"},{"id":"nct04338321-centrum-medyczne-luxmed-sp-z-o-o-lublin","cat":"research","name":"Centrum Medyczne Luxmed Sp z o o","city":"Lublin","country":"Poland","cc":"PL","lat":51.24922,"lon":22.56185,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"20 109","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-centrum-medyczne-luxmed-sp-z-o-o-lublin"},{"id":"nct04338321-osrodek-badan-klinicznych-clinsante-s-c-torun","cat":"research","name":"Osrodek Badan Klinicznych CLINSANTE S C","city":"Torun","country":"Poland","cc":"PL","lat":53.00947,"lon":18.58802,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"87 100","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-osrodek-badan-klinicznych-clinsante-s-c-torun"},{"id":"nct04338321-hospital-de-braga-braga","cat":"research","name":"Hospital de Braga","city":"Braga","country":"Portugal","cc":"PT","lat":41.5442,"lon":-8.41139,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"4710-243","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-hospital-de-braga-braga"},{"id":"nct04338321-centro-hospitalar-do-tamega-e-sousa-epe-hospital-padre-americo-vale-","cat":"research","name":"Centro Hospitalar do Tâmega e Sousa, EPE - Hospital Padre Americo, Vale do Sousa","city":"Guilhufe - Penafiel","country":"Portugal","cc":"PT","lat":38.5192,"lon":-8.94,"gp":"country","unnamed":0,"drugs":["esketamine"],"zip":"4564-007","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-centro-hospitalar-do-tamega-e-sousa-epe-hospital-padre-americo-vale-"},{"id":"nct04338321-hosp-cuf-tejo-lisbon","cat":"research","name":"Hosp. Cuf Tejo","city":"Lisbon","country":"Portugal","cc":"PT","lat":38.72693,"lon":-9.14326,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1350-352","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-hosp-cuf-tejo-lisbon"},{"id":"nct04338321-fund-champalimaud-lisbon","cat":"research","name":"Fund. Champalimaud","city":"Lisbon","country":"Portugal","cc":"PT","lat":38.72937,"lon":-9.1538,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1400 038","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-fund-champalimaud-lisbon"},{"id":"nct04338321-centro-hospitalar-de-lisboa-norte-hospital-santa-maria-lisbon","cat":"research","name":"Centro Hospitalar de Lisboa Norte Hospital Santa Maria","city":"Lisbon","country":"Portugal","cc":"PT","lat":38.72448,"lon":-9.15342,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1649-035","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-centro-hospitalar-de-lisboa-norte-hospital-santa-maria-lisbon"},{"id":"nct04338321-uls-loures-odivelas-hosp-loures-loures","cat":"research","name":"Uls Loures Odivelas - Hosp. Loures","city":"Loures","country":"Portugal","cc":"PT","lat":38.81985,"lon":-9.16021,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"2674-514","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-uls-loures-odivelas-hosp-loures-loures"},{"id":"nct04338321-cape-town-clinical-research-centre-cape-town","cat":"research","name":"Cape Town Clinical Research Centre","city":"Cape Town","country":"South Africa","cc":"ZA","lat":-33.92222,"lon":18.41611,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"7530","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-cape-town-clinical-research-centre-cape-town"},{"id":"nct04338321-flexivest-14-research-cape-town","cat":"research","name":"Flexivest 14 Research","city":"Cape Town","country":"South Africa","cc":"ZA","lat":-33.93022,"lon":18.42355,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"7550","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-flexivest-14-research-cape-town"},{"id":"nct04338321-gert-bosch-pretoria-south-africa-garsfontein","cat":"research","name":"Gert Bosch Pretoria South Africa","city":"Garsfontein","country":"South Africa","cc":"ZA","lat":-25.386,"lon":27.8329,"gp":"country","unnamed":0,"drugs":["esketamine"],"zip":"00 45","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-gert-bosch-pretoria-south-africa-garsfontein"},{"id":"nct04338321-chonnam-national-university-hospital-gwangju","cat":"research","name":"Chonnam National University Hospital","city":"Gwangju","country":"South Korea","cc":"KR","lat":35.15354,"lon":126.90704,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"61469","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-chonnam-national-university-hospital-gwangju"},{"id":"nct04338321-wonkwang-university-hospital-iksan","cat":"research","name":"Wonkwang University Hospital","city":"Iksan","country":"South Korea","cc":"KR","lat":35.94723,"lon":126.94583,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"570 711","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-wonkwang-university-hospital-iksan"},{"id":"nct04338321-kyunghee-university-hospital-seoul","cat":"research","name":"KyungHee University Hospital","city":"Seoul","country":"South Korea","cc":"KR","lat":37.562,"lon":126.98965,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"02447","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-kyunghee-university-hospital-seoul"},{"id":"nct04338321-korea-university-anam-hospital-seoul","cat":"research","name":"Korea University Anam Hospital","city":"Seoul","country":"South Korea","cc":"KR","lat":37.55965,"lon":126.97816,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"02841","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-korea-university-anam-hospital-seoul"},{"id":"nct04338321-severance-hospital-yonsei-university-health-system-seoul","cat":"research","name":"Severance Hospital Yonsei University Health System","city":"Seoul","country":"South Korea","cc":"KR","lat":37.55767,"lon":126.98748,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"03722","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-severance-hospital-yonsei-university-health-system-seoul"},{"id":"nct04338321-samsung-medical-center-seoul","cat":"research","name":"Samsung Medical Center","city":"Seoul","country":"South Korea","cc":"KR","lat":37.56426,"lon":126.98861,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"06351","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-samsung-medical-center-seoul"},{"id":"nct04338321-psykiatriska-kliniken-gothenburg","cat":"research","name":"Psykiatriska kliniken","city":"Gothenburg","country":"Sweden","cc":"SE","lat":57.6994,"lon":11.96486,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"41717","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-psykiatriska-kliniken-gothenburg"},{"id":"nct04338321-affecta-pskyiatrimottagning-halmstad","cat":"research","name":"Affecta Pskyiatrimottagning","city":"Halmstad","country":"Sweden","cc":"SE","lat":56.68232,"lon":12.86565,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"SE-30248","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-affecta-pskyiatrimottagning-halmstad"},{"id":"nct04338321-psykiatriska-kliniken-lulea","cat":"research","name":"Psykiatriska kliniken","city":"Luleå","country":"Sweden","cc":"SE","lat":65.59022,"lon":22.15573,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"97180","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-psykiatriska-kliniken-lulea"},{"id":"nct04338321-probare-i-lund-ab-lund","cat":"research","name":"ProbarE i Lund AB","city":"Lund","country":"Sweden","cc":"SE","lat":55.70316,"lon":13.19185,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"22222","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-probare-i-lund-ab-lund"},{"id":"nct04338321-one-lifetime-lakarmottagning-skovde","cat":"research","name":"ONE LIFETIME Lakarmottagning","city":"Skövde","country":"Sweden","cc":"SE","lat":58.39556,"lon":13.85461,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"SE-54150","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-one-lifetime-lakarmottagning-skovde"},{"id":"nct04338321-probare-i-stockholm-ab-stockholm","cat":"research","name":"ProbarE i Stockholm AB","city":"Stockholm","country":"Sweden","cc":"SE","lat":59.33771,"lon":18.06866,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"113 29","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-probare-i-stockholm-ab-stockholm"},{"id":"nct04338321-changhua-christian-hospital-changhua","cat":"research","name":"Changhua Christian Hospital","city":"Changhua","country":"Taiwan","cc":"TW","lat":24.07847,"lon":120.55868,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"500","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-changhua-christian-hospital-changhua"},{"id":"nct04338321-hualien-tzu-chi-hospital-hualien-city","cat":"research","name":"Hualien Tzu Chi Hospital","city":"Hualien City","country":"Taiwan","cc":"TW","lat":23.97774,"lon":121.61324,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"970","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-hualien-tzu-chi-hospital-hualien-city"},{"id":"nct04338321-kai-syuan-psychiatric-hospital-kaohsiung-city","cat":"research","name":"Kai-Syuan Psychiatric Hospital","city":"Kaohsiung City","country":"Taiwan","cc":"TW","lat":22.61273,"lon":120.3194,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"80276","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-kai-syuan-psychiatric-hospital-kaohsiung-city"},{"id":"nct04338321-chang-gung-memorial-hospital-kaohsiung-city","cat":"research","name":"Chang Gung Memorial Hospital","city":"Kaohsiung City","country":"Taiwan","cc":"TW","lat":22.62318,"lon":120.31535,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"83342","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-chang-gung-memorial-hospital-kaohsiung-city"},{"id":"nct04338321-national-cheng-kung-university-hospital-tainan","cat":"research","name":"National Cheng Kung University Hospital","city":"Tainan","country":"Taiwan","cc":"TW","lat":23.00142,"lon":120.20604,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"70403","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-national-cheng-kung-university-hospital-tainan"},{"id":"nct04338321-national-taiwan-university-hospital-taipei","cat":"research","name":"National Taiwan University Hospital","city":"Taipei","country":"Taiwan","cc":"TW","lat":25.04106,"lon":121.52192,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"10002","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-national-taiwan-university-hospital-taipei"},{"id":"nct04338321-mackay-memorial-hospital-taipei","cat":"research","name":"Mackay Memorial Hospital","city":"Taipei","country":"Taiwan","cc":"TW","lat":25.0484,"lon":121.5175,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"10449","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-mackay-memorial-hospital-taipei"},{"id":"nct04338321-taipei-medical-university-taipei","cat":"research","name":"Taipei Medical University","city":"Taipei","country":"Taiwan","cc":"TW","lat":25.04285,"lon":121.52512,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"110","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-taipei-medical-university-taipei"},{"id":"nct04338321-taipei-veterans-general-hospital-taipei","cat":"research","name":"Taipei Veterans General Hospital","city":"Taipei","country":"Taiwan","cc":"TW","lat":25.05885,"lon":121.5286,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"11217","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-taipei-veterans-general-hospital-taipei"},{"id":"nct04338321-chang-gung-memorial-hospital-taoyuan","cat":"research","name":"Chang Gung Memorial Hospital","city":"Taoyuan","country":"Taiwan","cc":"TW","lat":24.98686,"lon":121.28967,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"333","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-chang-gung-memorial-hospital-taoyuan"},{"id":"nct04338321-hacettepe-university-medical-faculty-ankara","cat":"research","name":"Hacettepe University Medical Faculty","city":"Ankara","country":"Turkey","cc":"TR","lat":39.90919,"lon":32.85639,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"6100","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-hacettepe-university-medical-faculty-ankara"},{"id":"nct04338321-bursa-yuksek-ihtisas-training-and-research-hospital-bursa","cat":"research","name":"Bursa Yuksek Ihtisas Training and Research Hospital","city":"Bursa","country":"Turkey","cc":"TR","lat":40.20364,"lon":29.05867,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"16285","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-bursa-yuksek-ihtisas-training-and-research-hospital-bursa"},{"id":"nct04338321-uludag-university-medical-faculty-bursa","cat":"research","name":"Uludag University Medical Faculty","city":"Bursa","country":"Turkey","cc":"TR","lat":40.20401,"lon":29.05378,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"16285","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-uludag-university-medical-faculty-bursa"},{"id":"nct04338321-bakirkoy-mental-health-training-and-research-hospital-istanbul","cat":"research","name":"Bakirkoy Mental Health Training and Research Hospital","city":"Istanbul","country":"Turkey","cc":"TR","lat":41.00711,"lon":28.94302,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"34147","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-bakirkoy-mental-health-training-and-research-hospital-istanbul"},{"id":"nct04338321-erenkoy-mental-health-hospital-istanbul","cat":"research","name":"Erenkoy Mental Health Hospital","city":"Istanbul","country":"Turkey","cc":"TR","lat":41.00786,"lon":28.94359,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"34736","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-erenkoy-mental-health-hospital-istanbul"},{"id":"nct04338321-uskudar-university-neuropsychiatry-hospital-istanbul","cat":"research","name":"Uskudar University Neuropsychiatry Hospital","city":"Istanbul","country":"Turkey","cc":"TR","lat":41.01812,"lon":28.94726,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"34768","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-uskudar-university-neuropsychiatry-hospital-istanbul"},{"id":"nct04338321-ege-universitesi-tip-fakultesi-izmir","cat":"research","name":"Ege Universitesi Tip Fakultesi","city":"Izmir","country":"Turkey","cc":"TR","lat":38.41635,"lon":27.13325,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"34371","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-ege-universitesi-tip-fakultesi-izmir"},{"id":"nct04338321-selcuk-university-medical-faculty-konya","cat":"research","name":"Selcuk University Medical Faculty","city":"Konya","country":"Turkey","cc":"TR","lat":37.87695,"lon":32.47904,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"42130","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-selcuk-university-medical-faculty-konya"},{"id":"nct04338321-liv-hospital-samsun","cat":"research","name":"Liv Hospital","city":"Samsun","country":"Turkey","cc":"TR","lat":41.28018,"lon":36.32626,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"55020","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-liv-hospital-samsun"},{"id":"nct04338321-namik-kemal-university-tekirdag","cat":"research","name":"Namik Kemal University","city":"Tekirdağ","country":"Turkey","cc":"TR","lat":40.98257,"lon":27.50974,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"59030","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-namik-kemal-university-tekirdag"},{"id":"nct04338321-american-center-for-psychiatry-and-neurology-abu-dhabi","cat":"research","name":"American Center for Psychiatry and Neurology","city":"Abu Dhabi","country":"United Arab Emirates","cc":"AE","lat":24.44812,"lon":54.38637,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"51133","condg":["Depression"],"nct":"NCT04338321","study":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in…","sstatus":"COMPLETED","sponsor":"Janssen-Cilag International NV","official":"Janssen-Cilag International NV Clinical Trials (Janssen-Cilag International NV)","src":"https://clinicaltrials.gov/study/NCT04338321","phase":"Phase 3","enroll":676,"start":"2020-08-21","eid":"x:site:nct04338321-american-center-for-psychiatry-and-neurology-abu-dhabi"},{"id":"nct06399185-peking-university-first-hospital-beijing","cat":"research","name":"Peking University First Hospital","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.89691,"lon":116.40471,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100034","condg":["Other"],"status":"RECRUITING","nct":"NCT06399185","study":"Effect of Dexmedetomidine and Esketamine on Catheter-related Bladder Discomfort","sstatus":"RECRUITING","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT06399185","contact":{"n":"Rui Zhang, MD","p":"+86 18810662529","e":"zhangrui_bjmu@163.com"},"phase":"Phase 4","enroll":1740,"start":"2024-06-06","eid":"x:site:nct06399185-peking-university-first-hospital-beijing"},{"id":"nct06399185-peking-university-shenzhen-hospital-shenzhen","cat":"research","name":"Peking University Shenzhen Hospital","city":"Shenzhen","region":"Guangdong","country":"China","cc":"CN","lat":22.54775,"lon":114.06844,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"518036","condg":["Other"],"status":"RECRUITING","nct":"NCT06399185","study":"Effect of Dexmedetomidine and Esketamine on Catheter-related Bladder Discomfort","sstatus":"RECRUITING","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT06399185","contact":{"n":"Tao Luo, MD","p":"+8618810662529","e":"496855048@qq.com"},"phase":"Phase 4","enroll":1740,"start":"2024-06-06","eid":"x:site:nct06399185-peking-university-shenzhen-hospital-shenzhen"},{"id":"nct04682782-2nd-affiliated-hospital-school-of-medicine-zhejiang-universtiy-china","cat":"research","name":"2nd affiliated hospital, School of Medicine, Zhejiang Universtiy, China","city":"Hangzhou","region":"Zhejiang","country":"China","cc":"CN","lat":30.29831,"lon":120.1513,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"310003","condg":["Other"],"status":"RECRUITING","nct":"NCT04682782","study":"Intraoperative Small-dose Esketamine Infusion for Pain Control in Burn Patients","sstatus":"UNKNOWN","sponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","official":"Min YAN, MD (2nd Affiliated Hospital, School of Medicine, Zhejiang University, China)","src":"https://clinicaltrials.gov/study/NCT04682782","contact":{"n":"Qingyu SHI","p":"+8613777564585","e":"shiqinyu_001@zju.edu.cn"},"phase":"Phase 4","enroll":26,"start":"2020-07-14","eid":"x:site:nct04682782-2nd-affiliated-hospital-school-of-medicine-zhejiang-universtiy-china"},{"id":"nct04209296-canadian-rapid-treatment-centre-of-excellence-mississauga","cat":"research","name":"Canadian Rapid Treatment Centre of Excellence","city":"Mississauga","region":"Ontario","country":"Canada","cc":"CA","lat":43.56954,"lon":-79.66004,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"L5C 4E7","condg":["Depression","PTSD & trauma","OCD","Bipolar"],"nct":"NCT04209296","study":"Chart Review of Patients Undergoing Ketamine Infusions","sstatus":"COMPLETED","sponsor":"Brain and Cognition Discovery Foundation","official":"Roger S McIntyre, MD (Brain and Cognition Discovery Foundation)","src":"https://clinicaltrials.gov/study/NCT04209296","enroll":891,"start":"2019-12-03","eid":"x:site:nct04209296-canadian-rapid-treatment-centre-of-excellence-mississauga"},{"id":"nct06914206-beijing-tiantan-hospital-beijing","cat":"research","name":"Beijing Tiantan Hospital","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.90651,"lon":116.38947,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100070","condg":["Other"],"nct":"NCT06914206","study":"Esketamine Combined With PRF of DRG for Acute/Subacute Zoster-associated Pain","sstatus":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","src":"https://clinicaltrials.gov/study/NCT06914206","contact":{"n":"Fang Luo","p":"+86 13611326978","e":"13611326978@163.com"},"phase":"N/A","enroll":184,"start":"2025-04-01","eid":"x:site:nct06914206-beijing-tiantan-hospital-beijing"},{"id":"nct03039192-uab-department-of-psychiatry-and-behavioral-neurobiology-birmingham","cat":"research","name":"UAB Department of Psychiatry and Behavioral Neurobiology","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.50885,"lon":-86.79821,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"35294","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-uab-department-of-psychiatry-and-behavioral-neurobiology-birmingham"},{"id":"nct03039192-metropolitan-neuro-behavioral-institute-chandler","cat":"research","name":"Metropolitan Neuro Behavioral Institute","city":"Chandler","region":"Arizona","country":"United States","cc":"US","lat":33.30997,"lon":-111.8333,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"85226","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-metropolitan-neuro-behavioral-institute-chandler"},{"id":"nct03039192-collaborative-neuroscience-network-garden-grove","cat":"research","name":"Collaborative NeuroScience Network","city":"Garden Grove","region":"California","country":"United States","cc":"US","lat":33.77311,"lon":-117.9319,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"92845","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-collaborative-neuroscience-network-garden-grove"},{"id":"nct03039192-yale-university-new-haven","cat":"research","name":"Yale University","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.30142,"lon":-72.93574,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"06511","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-yale-university-new-haven"},{"id":"nct03039192-rush-university-chicago","cat":"research","name":"Rush University","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.85619,"lon":-87.6484,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"60612","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-rush-university-chicago"},{"id":"nct03039192-alexian-behavioral-health-hospital-hoffman-estates","cat":"research","name":"Alexian Behavioral Health Hospital","city":"Hoffman Estates","region":"Illinois","country":"United States","cc":"US","lat":42.03665,"lon":-88.07382,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"60169","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-alexian-behavioral-health-hospital-hoffman-estates"},{"id":"nct03039192-university-of-louisville-department-of-psychiatry-louisville","cat":"research","name":"University of Louisville Department of Psychiatry","city":"Louisville","region":"Kentucky","country":"United States","cc":"US","lat":38.25956,"lon":-85.76953,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"40202","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-university-of-louisville-department-of-psychiatry-louisville"},{"id":"nct03039192-lsu-health-sciences-center-new-orleans-new-orleans","cat":"research","name":"LSU Health Sciences Center New Orleans","city":"New Orleans","region":"Louisiana","country":"United States","cc":"US","lat":29.95931,"lon":-90.08651,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"70115","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-lsu-health-sciences-center-new-orleans-new-orleans"},{"id":"nct03039192-louisiana-clinical-research-shreveport","cat":"research","name":"Louisiana Clinical Research","city":"Shreveport","region":"Louisiana","country":"United States","cc":"US","lat":32.5331,"lon":-93.7459,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"71101","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-louisiana-clinical-research-shreveport"},{"id":"nct03039192-sheppard-pratt-health-system-baltimore","cat":"research","name":"Sheppard Pratt Health System","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.2956,"lon":-76.60273,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"21204","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-sheppard-pratt-health-system-baltimore"},{"id":"nct03039192-cbh-health-gaithersburg","cat":"research","name":"CBH Health","city":"Gaithersburg","region":"Maryland","country":"United States","cc":"US","lat":39.15102,"lon":-77.20368,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"20877","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-cbh-health-gaithersburg"},{"id":"nct03039192-state-university-of-new-york-buffalo","cat":"research","name":"State University of New York","city":"Buffalo","region":"New York","country":"United States","cc":"US","lat":42.89694,"lon":-78.87795,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"14215","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-state-university-of-new-york-buffalo"},{"id":"nct03039192-columbia-university-medical-center-new-york","cat":"research","name":"Columbia University Medical Center","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72608,"lon":-74.00065,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"10032","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-columbia-university-medical-center-new-york"},{"id":"nct03039192-clinical-trials-of-america-hickory","cat":"research","name":"Clinical Trials of America","city":"Hickory","region":"North Carolina","country":"United States","cc":"US","lat":35.73917,"lon":-81.35066,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"28601","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-clinical-trials-of-america-hickory"},{"id":"nct03039192-the-ohio-state-university-columbus","cat":"research","name":"The Ohio State University","city":"Columbus","region":"Ohio","country":"United States","cc":"US","lat":39.96546,"lon":-82.98933,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"43210","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-the-ohio-state-university-columbus"},{"id":"nct03039192-medical-university-of-south-carolina-charleston","cat":"research","name":"Medical University of South Carolina","city":"Charleston","region":"South Carolina","country":"United States","cc":"US","lat":32.77477,"lon":-79.9344,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"29425","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-medical-university-of-south-carolina-charleston"},{"id":"nct03039192-university-of-texas-southwestern-medical-center-dallas","cat":"research","name":"University of Texas Southwestern Medical Center","city":"Dallas","region":"Texas","country":"United States","cc":"US","lat":32.79139,"lon":-96.79646,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"75235","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-university-of-texas-southwestern-medical-center-dallas"},{"id":"nct03039192-regional-psychiatric-dispansery-bulgaria","cat":"research","name":"Regional Psychiatric Dispansery","city":"Bulgaria","country":"Bulgaria","cc":"BG","lat":42.8289,"lon":23.2085,"gp":"country","unnamed":0,"drugs":["esketamine"],"zip":"7003","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-regional-psychiatric-dispansery-bulgaria"},{"id":"nct03039192-mental-health-center-prof-dr-ivan-temkov-burgas","cat":"research","name":"Mental Health Center Prof. Dr. Ivan Temkov","city":"Burgas","country":"Bulgaria","cc":"BG","lat":42.50383,"lon":27.4595,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"8001","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-mental-health-center-prof-dr-ivan-temkov-burgas"},{"id":"nct03039192-state-psychiatric-hospital-lovech-lovech","cat":"research","name":"State Psychiatric Hospital - Lovech","city":"Lovech","country":"Bulgaria","cc":"BG","lat":43.12093,"lon":24.72069,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"5500","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-state-psychiatric-hospital-lovech-lovech"},{"id":"nct03039192-umhat-sveti-georgi-plovdiv-plovdiv","cat":"research","name":"UMHAT 'Sveti Georgi'-Plovdiv","city":"Plovdiv","country":"Bulgaria","cc":"BG","lat":42.15486,"lon":24.73867,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"4002","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-umhat-sveti-georgi-plovdiv-plovdiv"},{"id":"nct03039192-military-medical-academy-multiprofile-hospital-for-active-treatment-","cat":"research","name":"Military Medical Academy Multiprofile Hospital for Active Treatment Sofia","city":"Sofia","country":"Bulgaria","cc":"BG","lat":42.70753,"lon":23.32486,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1606","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-military-medical-academy-multiprofile-hospital-for-active-treatment-"},{"id":"nct03039192-north-estonian-medical-centre-foundation-tallinn","cat":"research","name":"North Estonian Medical Centre Foundation","city":"Tallinn","country":"Estonia","cc":"EE","lat":59.44378,"lon":24.75132,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"10614","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-north-estonian-medical-centre-foundation-tallinn"},{"id":"nct03039192-tartu-university-hospital-tartu","cat":"research","name":"Tartu University Hospital","city":"Tartu","country":"Estonia","cc":"EE","lat":58.37568,"lon":26.72438,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"50417","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-tartu-university-hospital-tartu"},{"id":"nct03039192-vivantes-humboldt-klinikum-berlin","cat":"research","name":"Vivantes Humboldt Klinikum","city":"Berlin","country":"Germany","cc":"DE","lat":52.5151,"lon":13.41312,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"13509","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-vivantes-humboldt-klinikum-berlin"},{"id":"nct03039192-universitatsklinikum-frankfurt-frankfurt-am-main","cat":"research","name":"Universitatsklinikum Frankfurt","city":"Frankfurt am Main","country":"Germany","cc":"DE","lat":50.10465,"lon":8.67509,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"60528","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-universitatsklinikum-frankfurt-frankfurt-am-main"},{"id":"nct03039192-klinik-fur-psychiatrie-und-psychotherapie-freiburg-im-breisgau","cat":"research","name":"Klinik für Psychiatrie und Psychotherapie","city":"Freiburg im Breisgau","country":"Germany","cc":"DE","lat":47.98795,"lon":7.85029,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"79104","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-klinik-fur-psychiatrie-und-psychotherapie-freiburg-im-breisgau"},{"id":"nct03039192-eszak-kozep-budai-centrum-uj-szent-janos-korhaz-es-szakrendelo-budai","cat":"research","name":"Eszak Kozep budai Centrum Uj Szent Janos Korhaz es Szakrendelo Budai Csaladkozpontu","city":"Budapest","country":"Hungary","cc":"HU","lat":47.49576,"lon":19.03701,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1125","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-eszak-kozep-budai-centrum-uj-szent-janos-korhaz-es-szakrendelo-budai"},{"id":"nct03039192-semmelweis-egyetem-kutvolgyi-klinikai-tomb-budapest","cat":"research","name":"Semmelweis Egyetem Kútvölgyi Klinikai Tömb","city":"Budapest","country":"Hungary","cc":"HU","lat":47.49877,"lon":19.03626,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1125","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-semmelweis-egyetem-kutvolgyi-klinikai-tomb-budapest"},{"id":"nct03039192-nyiro-gyula-korhaz-budapest","cat":"research","name":"Nyiro Gyula Korhaz","city":"Budapest","country":"Hungary","cc":"HU","lat":47.49642,"lon":19.03014,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1135","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-nyiro-gyula-korhaz-budapest"},{"id":"nct03039192-petz-aladar-megyei-oktato-korhaz-gyor","cat":"research","name":"Petz Aladar Megyei Oktato Korhaz","city":"Győr","country":"Hungary","cc":"HU","lat":47.67142,"lon":17.64025,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"H-9024","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-petz-aladar-megyei-oktato-korhaz-gyor"},{"id":"nct03039192-pecsi-tudomanyegyetem-klinikai-kozpont-pecs","cat":"research","name":"Pecsi Tudomanyegyetem Klinikai Kozpont","city":"Pécs","country":"Hungary","cc":"HU","lat":46.07273,"lon":18.22329,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"7623","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-pecsi-tudomanyegyetem-klinikai-kozpont-pecs"},{"id":"nct03039192-university-kebangsaan-malaysia-medical-centre-cheras","cat":"research","name":"University Kebangsaan Malaysia Medical Centre","city":"Cheras","country":"Malaysia","cc":"MY","lat":3.11445,"lon":101.73574,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"56000","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-university-kebangsaan-malaysia-medical-centre-cheras"},{"id":"nct03039192-hospital-kuala-lumpur-kuala-lumpur","cat":"research","name":"Hospital Kuala Lumpur","city":"Kuala Lumpur","country":"Malaysia","cc":"MY","lat":3.13974,"lon":101.68874,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"50586","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-hospital-kuala-lumpur-kuala-lumpur"},{"id":"nct03039192-university-malaya-medical-centre-kuala-lumpur","cat":"research","name":"University Malaya Medical Centre","city":"Kuala Lumpur","country":"Malaysia","cc":"MY","lat":3.15292,"lon":101.69806,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"59100","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-university-malaya-medical-centre-kuala-lumpur"},{"id":"nct03039192-hospital-tuanku-jaafar-seremban","cat":"research","name":"Hospital Tuanku Jaafar","city":"Seremban","country":"Malaysia","cc":"MY","lat":2.7305,"lon":101.93081,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"70300","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-hospital-tuanku-jaafar-seremban"},{"id":"nct03039192-fakultna-nemocnica-s-poliklinikou-v-ziline-zilina","cat":"research","name":"Fakultna nemocnica s poliklinikou v Ziline","city":"Žilina","country":"Slovakia","cc":"SK","lat":49.21557,"lon":18.74482,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"012 07","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-fakultna-nemocnica-s-poliklinikou-v-ziline-zilina"},{"id":"nct03039192-flexivest-14-research-cape-town","cat":"research","name":"Flexivest 14 Research","city":"Cape Town","country":"South Africa","cc":"ZA","lat":-33.93426,"lon":18.41583,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"7550","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-flexivest-14-research-cape-town"},{"id":"nct03039192-juan-schronen-western-cape-south-africa-welgemoed","cat":"research","name":"Juan Schrönen - Western Cape South Africa","city":"Welgemoed","country":"South Africa","cc":"ZA","lat":-26.2096,"lon":28.1584,"gp":"country","unnamed":0,"drugs":["esketamine"],"zip":"7530","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-juan-schronen-western-cape-south-africa-welgemoed"},{"id":"nct03039192-chonnam-national-university-hospital-gwangju","cat":"research","name":"Chonnam National University Hospital","city":"Gwangju","country":"South Korea","cc":"KR","lat":35.14724,"lon":126.92436,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"61469","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-chonnam-national-university-hospital-gwangju"},{"id":"nct03039192-korea-university-ansan-hospital-gyeonggi-do","cat":"research","name":"Korea University Ansan Hospital","city":"Gyeonggi-do","country":"South Korea","cc":"KR","lat":37.3973,"lon":127.1618,"gp":"region","unnamed":0,"drugs":["esketamine"],"zip":"15355","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-korea-university-ansan-hospital-gyeonggi-do"},{"id":"nct03039192-kyung-hee-university-medical-center-seoul","cat":"research","name":"Kyung Hee University Medical Center","city":"Seoul","country":"South Korea","cc":"KR","lat":37.57141,"lon":126.97252,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"02447","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-kyung-hee-university-medical-center-seoul"},{"id":"nct03039192-samsung-medical-center-seoul","cat":"research","name":"Samsung Medical Center","city":"Seoul","country":"South Korea","cc":"KR","lat":37.55776,"lon":126.9856,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"06351","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-samsung-medical-center-seoul"},{"id":"nct03039192-seoul-national-university-hospital-seoul","cat":"research","name":"Seoul National University Hospital","city":"Seoul","country":"South Korea","cc":"KR","lat":37.55569,"lon":126.99012,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"3080","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-seoul-national-university-hospital-seoul"},{"id":"nct03039192-hosp-univ-fundacion-alcorcon-alcorcon","cat":"research","name":"Hosp. Univ. Fundacion Alcorcon","city":"Alcorcón","country":"Spain","cc":"ES","lat":40.34398,"lon":-3.82906,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"28922","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-hosp-univ-fundacion-alcorcon-alcorcon"},{"id":"nct03039192-hosp-univ-vall-d-hebron-barcelona","cat":"research","name":"Hosp Univ Vall D Hebron","city":"Barcelona","country":"Spain","cc":"ES","lat":41.39759,"lon":2.15066,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"08035","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-hosp-univ-vall-d-hebron-barcelona"},{"id":"nct03039192-hosp-clinic-de-barcelona-barcelona","cat":"research","name":"Hosp Clinic de Barcelona","city":"Barcelona","country":"Spain","cc":"ES","lat":41.38611,"lon":2.16054,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"08036","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-hosp-clinic-de-barcelona-barcelona"},{"id":"nct03039192-inst-internac-neurociencias-aplicadas-barcelona","cat":"research","name":"Inst. Internac. Neurociencias Aplicadas","city":"Barcelona","country":"Spain","cc":"ES","lat":41.38931,"lon":2.16271,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"8006","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-inst-internac-neurociencias-aplicadas-barcelona"},{"id":"nct03039192-hosp-univ-de-basurto-bilbao","cat":"research","name":"Hosp. Univ. de Basurto","city":"Bilbao","country":"Spain","cc":"ES","lat":43.27471,"lon":-2.93483,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"48013","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-hosp-univ-de-basurto-bilbao"},{"id":"nct03039192-hosp-univ-ramon-y-cajal-madrid","cat":"research","name":"Hosp. Univ. Ramon Y Cajal","city":"Madrid","country":"Spain","cc":"ES","lat":40.42455,"lon":-3.70072,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"28034","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-hosp-univ-ramon-y-cajal-madrid"},{"id":"nct03039192-clinica-univ-de-navarra-pamplona","cat":"research","name":"Clinica Univ. de Navarra","city":"Pamplona","country":"Spain","cc":"ES","lat":42.81936,"lon":-1.64074,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"31008","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-clinica-univ-de-navarra-pamplona"},{"id":"nct03039192-benito-menni-comp-asist-salut-mental-sant-boi-de-llobregat","cat":"research","name":"Benito Menni Comp. Asist. Salut Mental","city":"Sant Boi de Llobregat","country":"Spain","cc":"ES","lat":41.33571,"lon":2.03127,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"08830","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-benito-menni-comp-asist-salut-mental-sant-boi-de-llobregat"},{"id":"nct03039192-tri-service-genaral-hospital-neihu-district","cat":"research","name":"Tri-Service Genaral Hospital","city":"Neihu District","country":"Taiwan","cc":"TW","lat":25.09049,"lon":121.59962,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"114","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-tri-service-genaral-hospital-neihu-district"},{"id":"nct03039192-taipei-medical-university-shuang-ho-hospital-new-taipei-city","cat":"research","name":"Taipei Medical University Shuang Ho Hospital","city":"New Taipei City","country":"Taiwan","cc":"TW","lat":25.06354,"lon":121.45011,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"23561","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-taipei-medical-university-shuang-ho-hospital-new-taipei-city"},{"id":"nct03039192-chung-shan-medical-university-hospital-taichung","cat":"research","name":"Chung Shan Medical University Hospital","city":"Taichung","country":"Taiwan","cc":"TW","lat":24.13631,"lon":120.6815,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"40201","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-chung-shan-medical-university-hospital-taichung"},{"id":"nct03039192-taipei-veterans-general-hospital-taipei","cat":"research","name":"Taipei Veterans General Hospital","city":"Taipei","country":"Taiwan","cc":"TW","lat":25.05734,"lon":121.52512,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"11217","condg":["Depression"],"nct":"NCT03039192","study":"54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive…","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03039192","phase":"Phase 3","enroll":226,"start":"2017-06-09","eid":"x:site:nct03039192-taipei-veterans-general-hospital-taipei"},{"id":"nct06467513-affiliated-hospital-of-zunyi-medical-university-zunyi","cat":"research","name":"Affiliated Hospital of Zunyi Medical University","city":"Zunyi","region":"Guizhou","country":"China","cc":"CN","lat":27.67542,"lon":106.90821,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"563000","condg":["Other"],"status":"RECRUITING","nct":"NCT06467513","study":"To Investigate the Effect of Esketamine Hydrochloride on Pulmonary Complications","sstatus":"UNKNOWN","sponsor":"Zhang XIao Mei","official":"Wei Chen (Staff member of Department of Anesthesiology, Affiliated Hospital of Zunyi Medical University); Haiying Wang (Director of anesthesiology Department, Affiliated Hospital of Zunyi Medical University)","src":"https://clinicaltrials.gov/study/NCT06467513","contact":{"n":"Xiaomei Zhang","p":"+008618786233321","e":"3233598996@qq.com"},"phase":"Phase 4","enroll":102,"start":"2024-01-01","eid":"x:site:nct06467513-affiliated-hospital-of-zunyi-medical-university-zunyi"},{"id":"nct07227454-university-of-alabama-at-birmingham-birmingham","cat":"research","name":"University of Alabama at Birmingham","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.53031,"lon":-86.81195,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"35294","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-university-of-alabama-at-birmingham-birmingham"},{"id":"nct07227454-children-s-national-medical-center-washington-d-c","cat":"research","name":"Children's National Medical Center","city":"Washington D.C.","region":"District of Columbia","country":"United States","cc":"US","lat":38.89647,"lon":-77.04611,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"20010","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-children-s-national-medical-center-washington-d-c"},{"id":"nct07227454-peachford-hospital-atlanta-behavioral-research-atlanta","cat":"research","name":"Peachford Hospital-Atlanta Behavioral Research","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.74246,"lon":-84.39094,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"30338","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-peachford-hospital-atlanta-behavioral-research-atlanta"},{"id":"nct07227454-endeavor-health-evanston-hospital-evanston","cat":"research","name":"Endeavor Health Evanston Hospital","city":"Evanston","region":"Illinois","country":"United States","cc":"US","lat":42.03272,"lon":-87.6807,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"60201","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-endeavor-health-evanston-hospital-evanston"},{"id":"nct07227454-johns-hopkins-university-baltimore","cat":"research","name":"Johns Hopkins University","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28384,"lon":-76.60461,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"21287","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-johns-hopkins-university-baltimore"},{"id":"nct07227454-boston-childrens-hospital-boston","cat":"research","name":"Boston Childrens Hospital","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36892,"lon":-71.04843,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"02445","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-boston-childrens-hospital-boston"},{"id":"nct07227454-mayo-clinic-rochester","cat":"research","name":"Mayo Clinic","city":"Rochester","region":"Minnesota","country":"United States","cc":"US","lat":43.14297,"lon":-77.61344,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"55905","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-mayo-clinic-rochester"},{"id":"nct07227454-university-of-cincinnati-cincinnati","cat":"research","name":"University of Cincinnati","city":"Cincinnati","region":"Ohio","country":"United States","cc":"US","lat":39.12932,"lon":-84.50267,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"45219","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-university-of-cincinnati-cincinnati"},{"id":"nct07227454-bradley-hospital-east-providence","cat":"research","name":"Bradley Hospital","city":"East Providence","region":"Rhode Island","country":"United States","cc":"US","lat":41.81715,"lon":-71.37132,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"02915","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-bradley-hospital-east-providence"},{"id":"nct07227454-john-s-dunn-behavioral-sciences-center-at-uthealth-houston-houston","cat":"research","name":"John S Dunn Behavioral Sciences Center at UTHealth Houston","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.75787,"lon":-95.37028,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"77021","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-john-s-dunn-behavioral-sciences-center-at-uthealth-houston-houston"},{"id":"nct07227454-sociedade-literaria-e-caritativa-santo-agostinho-hospital-sao-jose-c","cat":"research","name":"Sociedade Literaria e Caritativa Santo Agostinho Hospital Sao Jose","city":"Criciúma","country":"Brazil","cc":"BR","lat":-28.67501,"lon":-49.38153,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"88811 000","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-sociedade-literaria-e-caritativa-santo-agostinho-hospital-sao-jose-c"},{"id":"nct07227454-universidade-federal-do-rio-grande-do-norte-hospital-universitario-o","cat":"research","name":"Universidade Federal do Rio Grande do Norte Hospital Universitario Onofre Lopes","city":"Natal","country":"Brazil","cc":"BR","lat":-5.78884,"lon":-35.20309,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"59012 300","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-universidade-federal-do-rio-grande-do-norte-hospital-universitario-o"},{"id":"nct07227454-instituto-apice-salvador","cat":"research","name":"Instituto Apice","city":"Salvador","country":"Brazil","cc":"BR","lat":-12.98151,"lon":-38.49703,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"40170 108","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-instituto-apice-salvador"},{"id":"nct07227454-centro-integrado-facili-sao-bernardo-do-campo","cat":"research","name":"Centro Integrado Facili","city":"São Bernardo do Campo","country":"Brazil","cc":"BR","lat":-23.69874,"lon":-46.56514,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"09726 150","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-centro-integrado-facili-sao-bernardo-do-campo"},{"id":"nct07227454-instituto-de-pesquisa-pensi-sandra-mutarelli-setubal-sao-paulo","cat":"research","name":"Instituto de Pesquisa Pensi Sandra Mutarelli Setubal","city":"São Paulo","country":"Brazil","cc":"BR","lat":-23.53748,"lon":-46.63936,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"01 227 200","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-instituto-de-pesquisa-pensi-sandra-mutarelli-setubal-sao-paulo"},{"id":"nct07227454-hospital-das-clinicas-da-faculdade-de-medicina-da-usp-sao-paulo","cat":"research","name":"Hospital Das Clinicas Da Faculdade De Medicina Da USP","city":"São Paulo","country":"Brazil","cc":"BR","lat":-23.55009,"lon":-46.63776,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"05403-900","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-hospital-das-clinicas-da-faculdade-de-medicina-da-usp-sao-paulo"},{"id":"nct07227454-debreceni-egyetem-klinikai-kozpont-debrecen","cat":"research","name":"Debreceni Egyetem Klinikai Kozpont","city":"Debrecen","country":"Hungary","cc":"HU","lat":47.53351,"lon":21.62025,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"4031","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-debreceni-egyetem-klinikai-kozpont-debrecen"},{"id":"nct07227454-petz-aladar-megyei-oktato-korhaz-gyor","cat":"research","name":"Petz Aladar Megyei Oktato Korhaz","city":"Győr","country":"Hungary","cc":"HU","lat":47.68752,"lon":17.63366,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"9023","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-petz-aladar-megyei-oktato-korhaz-gyor"},{"id":"nct07227454-szegedi-tudomanyegyetem-szeged","cat":"research","name":"Szegedi Tudomanyegyetem","city":"Szeged","country":"Hungary","cc":"HU","lat":46.25822,"lon":20.15064,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"6720","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-szegedi-tudomanyegyetem-szeged"},{"id":"nct07227454-presidio-ospedaliero-santa-marta-e-santa-venera-acireale","cat":"research","name":"Presidio Ospedaliero Santa Marta e Santa Venera","city":"Acireale","country":"Italy","cc":"IT","lat":37.60768,"lon":15.17269,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"95024","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-presidio-ospedaliero-santa-marta-e-santa-venera-acireale"},{"id":"nct07227454-azienda-ospedaliera-g-brotzu-cagliari","cat":"research","name":"Azienda Ospedaliera G. Brotzu","city":"Cagliari","country":"Italy","cc":"IT","lat":39.23388,"lon":9.12891,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"09134","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-azienda-ospedaliera-g-brotzu-cagliari"},{"id":"nct07227454-aou-meyer-florence","cat":"research","name":"AOU Meyer","city":"Florence","country":"Italy","cc":"IT","lat":43.784,"lon":11.24311,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"50134","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-aou-meyer-florence"},{"id":"nct07227454-azienda-ospedaliera-universitaria-policlinico-riuniti-di-foggia-fogg","cat":"research","name":"Azienda Ospedaliera Universitaria Policlinico Riuniti di Foggia","city":"Foggia","country":"Italy","cc":"IT","lat":41.4617,"lon":15.56379,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"71122","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-azienda-ospedaliera-universitaria-policlinico-riuniti-di-foggia-fogg"},{"id":"nct07227454-g-gaslini-institute-genova","cat":"research","name":"G.Gaslini Institute","city":"Genova","country":"Italy","cc":"IT","lat":44.39711,"lon":8.94143,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"16147","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-g-gaslini-institute-genova"},{"id":"nct07227454-ospedale-di-merano-merano","cat":"research","name":"Ospedale di Merano","city":"Merano","country":"Italy","cc":"IT","lat":46.67066,"lon":11.16607,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"39012","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-ospedale-di-merano-merano"},{"id":"nct07227454-azienda-ospedaliera-universitaria-federico-ii-naples","cat":"research","name":"Azienda Ospedaliera Universitaria Federico II","city":"Naples","country":"Italy","cc":"IT","lat":40.84948,"lon":14.27983,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"80131","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-azienda-ospedaliera-universitaria-federico-ii-naples"},{"id":"nct07227454-azienda-ospedaliero-universitaria-di-sassari-sassari","cat":"research","name":"Azienda Ospedaliero Universitaria di Sassari","city":"Sassari","country":"Italy","cc":"IT","lat":40.72685,"lon":8.56488,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"07100","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-azienda-ospedaliero-universitaria-di-sassari-sassari"},{"id":"nct07227454-spitalul-clinic-de-psihiatrie-prof-dr-alexandru-obregia-bucharest","cat":"research","name":"Spitalul Clinic de Psihiatrie Prof Dr Alexandru Obregia","city":"Bucharest","country":"Romania","cc":"RO","lat":44.4418,"lon":26.09897,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"041914","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-spitalul-clinic-de-psihiatrie-prof-dr-alexandru-obregia-bucharest"},{"id":"nct07227454-spitalul-clinic-de-urgenta-pentru-copii-cluj-napoca-cluj-napoca","cat":"research","name":"Spitalul Clinic de Urgenta pentru Copii Cluj Napoca","city":"Cluj-Napoca","country":"Romania","cc":"RO","lat":46.77161,"lon":23.59233,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"400658","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-spitalul-clinic-de-urgenta-pentru-copii-cluj-napoca-cluj-napoca"},{"id":"nct07227454-spitalul-clinic-de-psihiatrie-doctor-gheorghe-preda-sibiu","cat":"research","name":"Spitalul Clinic De Psihiatrie Doctor Gheorghe Preda","city":"Sibiu","country":"Romania","cc":"RO","lat":45.80758,"lon":24.16068,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"550082","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-spitalul-clinic-de-psihiatrie-doctor-gheorghe-preda-sibiu"},{"id":"nct07227454-spitalul-clinic-de-urgenta-pentru-copii-louis-turcanu-timisoara-timi","cat":"research","name":"Spitalul Clinic de Urgenta pentru Copii 'Louis Turcanu' Timisoara","city":"Timișoara","country":"Romania","cc":"RO","lat":45.75819,"lon":21.23131,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"300329","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-spitalul-clinic-de-urgenta-pentru-copii-louis-turcanu-timisoara-timi"},{"id":"nct07227454-hosp-univ-vall-d-hebron-barcelona","cat":"research","name":"Hosp Univ Vall D Hebron","city":"Barcelona","country":"Spain","cc":"ES","lat":41.39317,"lon":2.14765,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"08035","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-hosp-univ-vall-d-hebron-barcelona"},{"id":"nct07227454-hosp-clinic-de-barcelona-barcelona","cat":"research","name":"Hosp. Clinic de Barcelona","city":"Barcelona","country":"Spain","cc":"ES","lat":41.39665,"lon":2.16497,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"08036","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-hosp-clinic-de-barcelona-barcelona"},{"id":"nct07227454-hosp-sant-joan-de-deu-esplugues-de-llobregat","cat":"research","name":"Hosp. Sant Joan de Deu","city":"Esplugues de Llobregat","country":"Spain","cc":"ES","lat":41.38188,"lon":2.09265,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"08950","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-hosp-sant-joan-de-deu-esplugues-de-llobregat"},{"id":"nct07227454-hosp-gral-univ-gregorio-maranon-madrid","cat":"research","name":"Hosp. Gral. Univ. Gregorio Maranon","city":"Madrid","country":"Spain","cc":"ES","lat":40.40949,"lon":-3.70025,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"28009","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-hosp-gral-univ-gregorio-maranon-madrid"},{"id":"nct07227454-fundacio-althaia-xarxa-assistencial-universitaria-de-manresa-manresa","cat":"research","name":"Fundacio Althaia Xarxa Assistencial Universitaria de Manresa","city":"Manresa","country":"Spain","cc":"ES","lat":41.72848,"lon":1.83288,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"08243","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-fundacio-althaia-xarxa-assistencial-universitaria-de-manresa-manresa"},{"id":"nct07227454-hosp-univ-central-de-asturias-oviedo","cat":"research","name":"Hosp. Univ. Central de Asturias","city":"Oviedo","country":"Spain","cc":"ES","lat":43.35055,"lon":-5.8465,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"33011","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-hosp-univ-central-de-asturias-oviedo"},{"id":"nct07227454-clinica-univ-de-navarra-pamplona","cat":"research","name":"Clinica Univ. de Navarra","city":"Pamplona","country":"Spain","cc":"ES","lat":42.82087,"lon":-1.64168,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"31008","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-clinica-univ-de-navarra-pamplona"},{"id":"nct07227454-hosp-univ-parc-tauli-sabadell","cat":"research","name":"Hosp.Univ.Parc Tauli","city":"Sabadell","country":"Spain","cc":"ES","lat":41.54174,"lon":2.10015,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"08208","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-hosp-univ-parc-tauli-sabadell"},{"id":"nct07227454-mackay-memorial-hospital-tamsui-branch-new-taipei-city","cat":"research","name":"Mackay Memorial Hospital Tamsui Branch","city":"New Taipei City","country":"Taiwan","cc":"TW","lat":25.05055,"lon":121.44917,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"251","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-mackay-memorial-hospital-tamsui-branch-new-taipei-city"},{"id":"nct07227454-national-taiwan-university-hospital-taipei","cat":"research","name":"National Taiwan University Hospital","city":"Taipei","country":"Taiwan","cc":"TW","lat":25.04981,"lon":121.51608,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-national-taiwan-university-hospital-taipei"},{"id":"nct07227454-taipei-medical-university-hospital-taipei","cat":"research","name":"Taipei Medical University Hospital","city":"Taipei","country":"Taiwan","cc":"TW","lat":25.06487,"lon":121.51458,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"110","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-taipei-medical-university-hospital-taipei"},{"id":"nct07227454-taipei-veterans-general-hospital-taipei","cat":"research","name":"Taipei Veterans General Hospital","city":"Taipei","country":"Taiwan","cc":"TW","lat":25.0421,"lon":121.53698,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"112","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-taipei-veterans-general-hospital-taipei"},{"id":"nct07227454-tri-service-general-hospital-taipei","cat":"research","name":"Tri-Service General Hospital","city":"Taipei","country":"Taiwan","cc":"TW","lat":25.06186,"lon":121.51693,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"114","condg":["Depression"],"status":"RECRUITING","nct":"NCT07227454","study":"A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Janssen Research & Development, LLC","src":"https://clinicaltrials.gov/study/NCT07227454","contact":{"n":"Study Contact","p":"844-434-4210","e":"Participate-In-This-Study1@its.jnj.com"},"phase":"Phase 3","enroll":258,"start":"2026-01-08","eid":"x:site:nct07227454-tri-service-general-hospital-taipei"},{"id":"nct04599855-uab-department-of-psychiatry-and-behavioral-neurobiology-birmingham","cat":"research","name":"UAB Department of Psychiatry and Behavioral Neurobiology","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.51591,"lon":-86.79473,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"35294","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-uab-department-of-psychiatry-and-behavioral-neurobiology-birmingham"},{"id":"nct04599855-uab-huntsville-regional-medical-campus-huntsville","cat":"research","name":"UAB Huntsville Regional Medical Campus","city":"Huntsville","region":"Alabama","country":"United States","cc":"US","lat":34.73995,"lon":-86.5953,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"35801","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-uab-huntsville-regional-medical-campus-huntsville"},{"id":"nct04599855-preferred-research-partners-little-rock","cat":"research","name":"Preferred Research Partners","city":"Little Rock","region":"Arkansas","country":"United States","cc":"US","lat":34.75462,"lon":-92.29293,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"72211","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-preferred-research-partners-little-rock"},{"id":"nct04599855-behavioral-research-specialists-llc-glendale","cat":"research","name":"Behavioral Research Specialists LLC","city":"Glendale","region":"California","country":"United States","cc":"US","lat":33.53352,"lon":-112.18481,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"91206","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-behavioral-research-specialists-llc-glendale"},{"id":"nct04599855-calneuro-research-los-angeles","cat":"research","name":"CalNeuro Research","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.05896,"lon":-118.23733,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"90025","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-calneuro-research-los-angeles"},{"id":"nct04599855-pacific-research-partners-oakland","cat":"research","name":"Pacific Research Partners","city":"Oakland","region":"California","country":"United States","cc":"US","lat":37.80733,"lon":-122.25908,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"94607","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-pacific-research-partners-oakland"},{"id":"nct04599855-anderson-clinical-research-redlands","cat":"research","name":"Anderson Clinical Research","city":"Redlands","region":"California","country":"United States","cc":"US","lat":34.05665,"lon":-117.1792,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"92374","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-anderson-clinical-research-redlands"},{"id":"nct04599855-university-of-california-at-san-diego-san-diego","cat":"research","name":"University of California at San Diego","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.72762,"lon":-117.17408,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"92103-8620","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-university-of-california-at-san-diego-san-diego"},{"id":"nct04599855-artemis-institute-for-clinical-research-san-diego","cat":"research","name":"Artemis Institute for Clinical Research","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.70578,"lon":-117.15837,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"92103","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-artemis-institute-for-clinical-research-san-diego"},{"id":"nct04599855-ucsf-nancy-friend-pritzker-psychiatry-building-san-francisco","cat":"research","name":"UCSF Nancy Friend Pritzker Psychiatry Building","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.77846,"lon":-122.4158,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"94143","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-ucsf-nancy-friend-pritzker-psychiatry-building-san-francisco"},{"id":"nct04599855-velocity-clinical-research-santa-ana","cat":"research","name":"Velocity Clinical Research","city":"Santa Ana","region":"California","country":"United States","cc":"US","lat":33.75588,"lon":-117.87654,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"91704","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-velocity-clinical-research-santa-ana"},{"id":"nct04599855-cmb-clinical-trials-santee","cat":"research","name":"CMB Clinical Trials","city":"Santee","region":"California","country":"United States","cc":"US","lat":32.83965,"lon":-116.9671,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"92071","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-cmb-clinical-trials-santee"},{"id":"nct04599855-university-of-connecticut-health-center-farmington","cat":"research","name":"University of Connecticut Health Center","city":"Farmington","region":"Connecticut","country":"United States","cc":"US","lat":36.71719,"lon":-108.22551,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"06032","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-university-of-connecticut-health-center-farmington"},{"id":"nct04599855-velocity-clinical-research-hallandale-beach-hallandale","cat":"research","name":"Velocity Clinical Research, Hallandale Beach","city":"Hallandale","region":"Florida","country":"United States","cc":"US","lat":25.98087,"lon":-80.14814,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"33009","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-velocity-clinical-research-hallandale-beach-hallandale"},{"id":"nct04599855-accel-research-sites-lakeland","cat":"research","name":"Accel Research Sites","city":"Lakeland","region":"Florida","country":"United States","cc":"US","lat":28.03387,"lon":-81.94053,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"33803","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-accel-research-sites-lakeland"},{"id":"nct04599855-apg-research-llc-orlando","cat":"research","name":"APG Research LLC","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.53622,"lon":-81.37251,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"32803","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-apg-research-llc-orlando"},{"id":"nct04599855-usf-department-of-psychiatry-and-behavioral-neurosciences-tampa","cat":"research","name":"USF, Department of Psychiatry and Behavioral Neurosciences","city":"Tampa","region":"Florida","country":"United States","cc":"US","lat":27.95161,"lon":-82.44888,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"33613","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-usf-department-of-psychiatry-and-behavioral-neurosciences-tampa"},{"id":"nct04599855-neuroscience-research-institute-west-palm-beach","cat":"research","name":"Neuroscience Research Institute","city":"West Palm Beach","region":"Florida","country":"United States","cc":"US","lat":26.71652,"lon":-80.05681,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"33407","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-neuroscience-research-institute-west-palm-beach"},{"id":"nct04599855-atlanta-behavioral-research-llc-atlanta","cat":"research","name":"Atlanta Behavioral Research, LLC","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.75761,"lon":-84.38925,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"30338","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-atlanta-behavioral-research-llc-atlanta"},{"id":"nct04599855-psych-atlanta-p-c-marietta","cat":"research","name":"Psych Atlanta, P.C.","city":"Marietta","region":"Georgia","country":"United States","cc":"US","lat":33.94766,"lon":-84.55224,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"30060","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-psych-atlanta-p-c-marietta"},{"id":"nct04599855-rush-university-medical-center-chicago","cat":"research","name":"Rush University Medical Center","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.84772,"lon":-87.65405,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"60612","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-rush-university-medical-center-chicago"},{"id":"nct04599855-chicago-research-center-chicago","cat":"research","name":"Chicago Research Center","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.84735,"lon":-87.64351,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"60634","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-chicago-research-center-chicago"},{"id":"nct04599855-university-of-chicago-chicago","cat":"research","name":"University of Chicago","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.85177,"lon":-87.6581,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"60637","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-university-of-chicago-chicago"},{"id":"nct04599855-joliet-center-for-clinical-research-joliet","cat":"research","name":"Joliet Center for Clinical Research","city":"Joliet","region":"Illinois","country":"United States","cc":"US","lat":41.53521,"lon":-88.07564,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"60435","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-joliet-center-for-clinical-research-joliet"},{"id":"nct04599855-pillar-clinical-research-llc-lincolnwood","cat":"research","name":"Pillar Clinical Research, LLC","city":"Lincolnwood","region":"Illinois","country":"United States","cc":"US","lat":42.00057,"lon":-87.73237,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"60712","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-pillar-clinical-research-llc-lincolnwood"},{"id":"nct04599855-psychiatric-medicine-associates-llc-skokie","cat":"research","name":"Psychiatric Medicine Associates LLC","city":"Skokie","region":"Illinois","country":"United States","cc":"US","lat":42.03943,"lon":-87.74483,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"60076","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-psychiatric-medicine-associates-llc-skokie"},{"id":"nct04599855-ascension-via-christi-research-wichita","cat":"research","name":"Ascension via Christi Research","city":"Wichita","region":"Kansas","country":"United States","cc":"US","lat":37.6921,"lon":-97.33241,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"67214","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-ascension-via-christi-research-wichita"},{"id":"nct04599855-university-of-kansas-school-of-medicine-wichita","cat":"research","name":"University of Kansas School of Medicine","city":"Wichita","region":"Kansas","country":"United States","cc":"US","lat":37.69615,"lon":-97.33185,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"67214","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-university-of-kansas-school-of-medicine-wichita"},{"id":"nct04599855-sheppard-pratt-health-system-baltimore","cat":"research","name":"Sheppard Pratt Health System","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28977,"lon":-76.60603,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"21204","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-sheppard-pratt-health-system-baltimore"},{"id":"nct04599855-cbh-health-gaithersburg","cat":"research","name":"CBH Health","city":"Gaithersburg","region":"Maryland","country":"United States","cc":"US","lat":39.15299,"lon":-77.20208,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"20877","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-cbh-health-gaithersburg"},{"id":"nct04599855-copley-clinical-boston","cat":"research","name":"Copley Clinical","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36817,"lon":-71.04899,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"02116","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-copley-clinical-boston"},{"id":"nct04599855-adams-clinical-watertown","cat":"research","name":"Adams Clinical","city":"Watertown","region":"Massachusetts","country":"United States","cc":"US","lat":42.36307,"lon":-71.18269,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"02472","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-adams-clinical-watertown"},{"id":"nct04599855-university-of-massachusetts-medical-school-worcester","cat":"research","name":"University of Massachusetts Medical School","city":"Worcester","region":"Massachusetts","country":"United States","cc":"US","lat":42.25417,"lon":-71.80789,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"01655","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-university-of-massachusetts-medical-school-worcester"},{"id":"nct04599855-university-of-michigan-ann-arbor","cat":"research","name":"University of Michigan","city":"Ann Arbor","region":"Michigan","country":"United States","cc":"US","lat":42.27008,"lon":-83.73952,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"48109","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-university-of-michigan-ann-arbor"},{"id":"nct04599855-rochester-center-for-behavioral-medicine-rcbm-rochester-hills","cat":"research","name":"Rochester Center for Behavioral Medicine (RCBM)","city":"Rochester Hills","region":"Michigan","country":"United States","cc":"US","lat":42.65042,"lon":-83.15779,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"48307","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-rochester-center-for-behavioral-medicine-rcbm-rochester-hills"},{"id":"nct04599855-midwest-research-group-st-charles-psychiatric-associates-saint-charl","cat":"research","name":"Midwest Research Group - St. Charles Psychiatric Associates","city":"Saint Charles","region":"Missouri","country":"United States","cc":"US","lat":38.79538,"lon":-90.49078,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"63304","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-midwest-research-group-st-charles-psychiatric-associates-saint-charl"},{"id":"nct04599855-clinilabs-new-york","cat":"research","name":"Clinilabs","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72138,"lon":-74.00545,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"10016","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-clinilabs-new-york"},{"id":"nct04599855-the-medical-research-network-llc-new-york","cat":"research","name":"The Medical Research Network, LLC","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71573,"lon":-74.01769,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"10128","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-the-medical-research-network-llc-new-york"},{"id":"nct04599855-stony-brook-university-medical-center-stony-brook","cat":"research","name":"Stony Brook University Medical Center","city":"Stony Brook","region":"New York","country":"United States","cc":"US","lat":40.9273,"lon":-73.13383,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"11794","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-stony-brook-university-medical-center-stony-brook"},{"id":"nct04599855-ohio-state-university-columbus","cat":"research","name":"Ohio State University","city":"Columbus","region":"Ohio","country":"United States","cc":"US","lat":39.96123,"lon":-83.00194,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"43210","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-ohio-state-university-columbus"},{"id":"nct04599855-midwest-clinical-research-center-dayton","cat":"research","name":"Midwest Clinical Research Center","city":"Dayton","region":"Ohio","country":"United States","cc":"US","lat":39.7558,"lon":-84.18705,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"45417","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-midwest-clinical-research-center-dayton"},{"id":"nct04599855-paradigm-research-professionals-llc-oklahoma-city","cat":"research","name":"Paradigm Research Professionals, LLC","city":"Oklahoma City","region":"Oklahoma","country":"United States","cc":"US","lat":35.46629,"lon":-97.51469,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"73118","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-paradigm-research-professionals-llc-oklahoma-city"},{"id":"nct04599855-lehigh-center-for-clinical-research-allentown","cat":"research","name":"Lehigh Center for Clinical Research","city":"Allentown","region":"Pennsylvania","country":"United States","cc":"US","lat":40.61149,"lon":-75.48787,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"18104","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-lehigh-center-for-clinical-research-allentown"},{"id":"nct04599855-university-of-pennsylvania-medical-center-philadelphia","cat":"research","name":"University of Pennsylvania Medical Center","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.94113,"lon":-75.16997,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"19104","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-university-of-pennsylvania-medical-center-philadelphia"},{"id":"nct04599855-the-warren-alpert-medical-school-of-brown-university-butler-hospital","cat":"research","name":"The Warren Alpert Medical School of Brown University - Butler Hospital","city":"Providence","region":"Rhode Island","country":"United States","cc":"US","lat":41.81218,"lon":-71.41749,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"02906","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-the-warren-alpert-medical-school-of-brown-university-butler-hospital"},{"id":"nct04599855-biobehavioral-research-of-austin-pc-austin","cat":"research","name":"BioBehavioral Research of Austin PC","city":"Austin","region":"Texas","country":"United States","cc":"US","lat":30.25967,"lon":-97.75139,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"78759","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-biobehavioral-research-of-austin-pc-austin"},{"id":"nct04599855-relaro-medical-trials-dallas","cat":"research","name":"Relaro Medical Trials","city":"Dallas","region":"Texas","country":"United States","cc":"US","lat":32.77285,"lon":-96.81359,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"75243","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-relaro-medical-trials-dallas"},{"id":"nct04599855-university-of-texas-southwestern-medical-center-dallas","cat":"research","name":"University of Texas Southwestern Medical Center","city":"Dallas","region":"Texas","country":"United States","cc":"US","lat":32.79214,"lon":-96.81142,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"75247","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-university-of-texas-southwestern-medical-center-dallas"},{"id":"nct04599855-brain-health-consultants-and-tms-center-houston","cat":"research","name":"Brain Health Consultants and TMS Center","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.7605,"lon":-95.36351,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"77046","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-brain-health-consultants-and-tms-center-houston"},{"id":"nct04599855-the-university-of-texas-health-science-center-at-houston-houston","cat":"research","name":"The University of Texas Health Science Center at Houston","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.76286,"lon":-95.36379,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"77054","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-the-university-of-texas-health-science-center-at-houston-houston"},{"id":"nct04599855-pillar-clinical-research-llc-richardson","cat":"research","name":"Pillar Clinical Research, LLC","city":"Richardson","region":"Texas","country":"United States","cc":"US","lat":32.95867,"lon":-96.72468,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"75080","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-pillar-clinical-research-llc-richardson"},{"id":"nct04599855-family-psychiatry-of-the-woodlands-the-woodlands","cat":"research","name":"Family Psychiatry of The Woodlands","city":"The Woodlands","region":"Texas","country":"United States","cc":"US","lat":30.15239,"lon":-95.49507,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"77381","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-family-psychiatry-of-the-woodlands-the-woodlands"},{"id":"nct04599855-grayline-research-center-wichita-falls","cat":"research","name":"Grayline Research Center","city":"Wichita Falls","region":"Texas","country":"United States","cc":"US","lat":33.92439,"lon":-98.48675,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"76309","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-grayline-research-center-wichita-falls"},{"id":"nct04599855-university-of-virginia-center-for-psychiatric-clinical-research-char","cat":"research","name":"University of Virginia Center for Psychiatric Clinical Research","city":"Charlottesville","region":"Virginia","country":"United States","cc":"US","lat":38.02107,"lon":-78.47042,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"22903","condg":["Depression"],"nct":"NCT04599855","study":"A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04599855","phase":"Phase 4","enroll":477,"start":"2020-11-04","eid":"x:site:nct04599855-university-of-virginia-center-for-psychiatric-clinical-research-char"},{"id":"nct03965858-wojewodzki-szpital-im-jana-paw-a-ii-be-chatow","cat":"research","name":"Wojewodzki Szpital im. Jana Pawła II","city":"Bełchatów","country":"Poland","cc":"PL","lat":51.36681,"lon":19.3464,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"97-400","condg":["Depression"],"nct":"NCT03965858","study":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Celon Pharma SA","src":"https://clinicaltrials.gov/study/NCT03965858","phase":"Phase 2","enroll":88,"start":"2019-02-25","eid":"x:site:nct03965858-wojewodzki-szpital-im-jana-paw-a-ii-be-chatow"},{"id":"nct03965858-wojewodzki-szpital-dla-nerwowo-i-psychicznie-chorych-boles-awiec","cat":"research","name":"Wojewodzki Szpital dla Nerwowo i Psychicznie Chorych","city":"Bolesławiec","country":"Poland","cc":"PL","lat":51.2615,"lon":15.57492,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"59-700","condg":["Depression"],"nct":"NCT03965858","study":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Celon Pharma SA","src":"https://clinicaltrials.gov/study/NCT03965858","phase":"Phase 2","enroll":88,"start":"2019-02-25","eid":"x:site:nct03965858-wojewodzki-szpital-dla-nerwowo-i-psychicznie-chorych-boles-awiec"},{"id":"nct03965858-samodzielny-publiczny-psychiatryczny-zaklad-opieki-zdrowotnej-choros","cat":"research","name":"Samodzielny Publiczny Psychiatryczny Zaklad Opieki Zdrowotnej","city":"Choroszcz","country":"Poland","cc":"PL","lat":53.14233,"lon":22.98517,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"16-070","condg":["Depression"],"nct":"NCT03965858","study":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Celon Pharma SA","src":"https://clinicaltrials.gov/study/NCT03965858","phase":"Phase 2","enroll":88,"start":"2019-02-25","eid":"x:site:nct03965858-samodzielny-publiczny-psychiatryczny-zaklad-opieki-zdrowotnej-choros"},{"id":"nct03965858-szpital-miejski-elblag","cat":"research","name":"Szpital Miejski","city":"Elblag","country":"Poland","cc":"PL","lat":54.15093,"lon":19.40795,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"82-300","condg":["Depression"],"nct":"NCT03965858","study":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Celon Pharma SA","src":"https://clinicaltrials.gov/study/NCT03965858","phase":"Phase 2","enroll":88,"start":"2019-02-25","eid":"x:site:nct03965858-szpital-miejski-elblag"},{"id":"nct03965858-uniwersyteckie-centrum-kliniczne-gdansk","cat":"research","name":"Uniwersyteckie Centrum Kliniczne","city":"Gdansk","country":"Poland","cc":"PL","lat":54.36116,"lon":18.65557,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"80-952","condg":["Depression"],"nct":"NCT03965858","study":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Celon Pharma SA","src":"https://clinicaltrials.gov/study/NCT03965858","phase":"Phase 2","enroll":88,"start":"2019-02-25","eid":"x:site:nct03965858-uniwersyteckie-centrum-kliniczne-gdansk"},{"id":"nct03965858-wojewodzki-szpital-dla-nerwowo-i-psychicznie-chorych-gmina-swiecie","cat":"research","name":"Wojewodzki Szpital dla Nerwowo i Psychicznie Chorych","city":"Gmina Świecie","country":"Poland","cc":"PL","lat":53.41278,"lon":18.45142,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"86-100","condg":["Depression"],"nct":"NCT03965858","study":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Celon Pharma SA","src":"https://clinicaltrials.gov/study/NCT03965858","phase":"Phase 2","enroll":88,"start":"2019-02-25","eid":"x:site:nct03965858-wojewodzki-szpital-dla-nerwowo-i-psychicznie-chorych-gmina-swiecie"},{"id":"nct03965858-gornoslaskie-centrum-medyczne-katowice","cat":"research","name":"Gornoslaskie Centrum Medyczne","city":"Katowice","country":"Poland","cc":"PL","lat":50.26549,"lon":19.02027,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"40-635","condg":["Depression"],"nct":"NCT03965858","study":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Celon Pharma SA","src":"https://clinicaltrials.gov/study/NCT03965858","phase":"Phase 2","enroll":88,"start":"2019-02-25","eid":"x:site:nct03965858-gornoslaskie-centrum-medyczne-katowice"},{"id":"nct03965858-specjalistyczny-psychiatryczny-zespol-opieki-zdrowotnej-lodz","cat":"research","name":"Specjalistyczny Psychiatryczny Zespol Opieki Zdrowotnej","city":"Lodz","country":"Poland","cc":"PL","lat":51.76987,"lon":19.4628,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"91-229","condg":["Depression"],"nct":"NCT03965858","study":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Celon Pharma SA","src":"https://clinicaltrials.gov/study/NCT03965858","phase":"Phase 2","enroll":88,"start":"2019-02-25","eid":"x:site:nct03965858-specjalistyczny-psychiatryczny-zespol-opieki-zdrowotnej-lodz"},{"id":"nct03965858-pabianickie-centrum-medyczne-pabianice","cat":"research","name":"Pabianickie Centrum Medyczne","city":"Pabianice","country":"Poland","cc":"PL","lat":51.67232,"lon":19.35732,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"95-200","condg":["Depression"],"nct":"NCT03965858","study":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Celon Pharma SA","src":"https://clinicaltrials.gov/study/NCT03965858","phase":"Phase 2","enroll":88,"start":"2019-02-25","eid":"x:site:nct03965858-pabianickie-centrum-medyczne-pabianice"},{"id":"nct03965858-mazowieckie-specalistyczne-centrum-zdrowia-pruszkow","cat":"research","name":"Mazowieckie Specalistyczne Centrum Zdrowia","city":"Pruszków","country":"Poland","cc":"PL","lat":52.1654,"lon":20.81755,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"05-802","condg":["Depression"],"nct":"NCT03965858","study":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Celon Pharma SA","src":"https://clinicaltrials.gov/study/NCT03965858","phase":"Phase 2","enroll":88,"start":"2019-02-25","eid":"x:site:nct03965858-mazowieckie-specalistyczne-centrum-zdrowia-pruszkow"},{"id":"nct03965858-mazowiecki-szpital-i-centrum-diagnostyczne-allenort-warsaw","cat":"research","name":"Mazowiecki Szpital i Centrum Diagnostyczne Allenort","city":"Warsaw","country":"Poland","cc":"PL","lat":52.22135,"lon":21.0075,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"03-185","condg":["Depression"],"nct":"NCT03965858","study":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Celon Pharma SA","src":"https://clinicaltrials.gov/study/NCT03965858","phase":"Phase 2","enroll":88,"start":"2019-02-25","eid":"x:site:nct03965858-mazowiecki-szpital-i-centrum-diagnostyczne-allenort-warsaw"},{"id":"nct03965858-uniwersytecki-szpital-kliniczny-wroclaw","cat":"research","name":"Uniwersytecki Szpital Kliniczny","city":"Wroclaw","country":"Poland","cc":"PL","lat":51.10159,"lon":17.0238,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"50-556","condg":["Depression"],"nct":"NCT03965858","study":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Celon Pharma SA","src":"https://clinicaltrials.gov/study/NCT03965858","phase":"Phase 2","enroll":88,"start":"2019-02-25","eid":"x:site:nct03965858-uniwersytecki-szpital-kliniczny-wroclaw"},{"id":"nct04300621-sgs-life-science-services-antwerp","cat":"research","name":"SGS Life Science Services","city":"Antwerp","country":"Belgium","cc":"BE","lat":51.22767,"lon":4.39184,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"2060","condg":["Healthy volunteers"],"nct":"NCT04300621","study":"A Study of Different Oral Thin Film (S)-Ketamine Formulations for Sublingual Administration in Healthy Participants","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT04300621","phase":"Phase 1","enroll":16,"start":"2020-06-19","eid":"x:site:nct04300621-sgs-life-science-services-antwerp"},{"id":"nct07644663-fudan-university-shanghai-cancer-center-shanghai","cat":"research","name":"Fudan University Shanghai Cancer Center","city":"Shanghai","region":"Shanghai Municipality","country":"China","cc":"CN","lat":31.21398,"lon":121.45914,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"200032","condg":["Other"],"nct":"NCT07644663","study":"The Effects of Different Anesthetics on the Brain's Neural Networks","sstatus":"NOT_YET_RECRUITING","sponsor":"Fudan University","src":"https://clinicaltrials.gov/study/NCT07644663","contact":{"n":"Jun Zhang","p":"+86 13817153025","e":"snapzhang@aliyun.com"},"phase":"Phase 4","enroll":120,"start":"2026-06-09","eid":"x:site:nct07644663-fudan-university-shanghai-cancer-center-shanghai"},{"id":"nct02782104-unnamed-trial-site-birmingham","cat":"research","name":"Unnamed trial site","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.52805,"lon":-86.79181,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-birmingham"},{"id":"nct02782104-unnamed-trial-site-little-rock","cat":"research","name":"Unnamed trial site","city":"Little Rock","region":"Arkansas","country":"United States","cc":"US","lat":34.7518,"lon":-92.28728,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-little-rock"},{"id":"nct02782104-unnamed-trial-site-garden-grove","cat":"research","name":"Unnamed trial site","city":"Garden Grove","region":"California","country":"United States","cc":"US","lat":33.78073,"lon":-117.94827,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-garden-grove"},{"id":"nct02782104-unnamed-trial-site-glendale","cat":"research","name":"Unnamed trial site","city":"Glendale","region":"California","country":"United States","cc":"US","lat":33.54143,"lon":-112.19018,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-glendale"},{"id":"nct02782104-unnamed-trial-site-oakland","cat":"research","name":"Unnamed trial site","city":"Oakland","region":"California","country":"United States","cc":"US","lat":37.80093,"lon":-122.28045,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-oakland"},{"id":"nct02782104-unnamed-trial-site-orange","cat":"research","name":"Unnamed trial site","city":"Orange","region":"California","country":"United States","cc":"US","lat":33.79763,"lon":-117.84111,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-orange"},{"id":"nct02782104-unnamed-trial-site-san-diego","cat":"research","name":"Unnamed trial site","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.71105,"lon":-117.16994,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-san-diego"},{"id":"nct02782104-unnamed-trial-site-san-rafael","cat":"research","name":"Unnamed trial site","city":"San Rafael","region":"California","country":"United States","cc":"US","lat":37.98374,"lon":-122.52483,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-san-rafael"},{"id":"nct02782104-unnamed-trial-site-hartford","cat":"research","name":"Unnamed trial site","city":"Hartford","region":"Connecticut","country":"United States","cc":"US","lat":41.76715,"lon":-72.67422,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-hartford"},{"id":"nct02782104-unnamed-trial-site-new-haven","cat":"research","name":"Unnamed trial site","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31714,"lon":-72.92322,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-new-haven"},{"id":"nct02782104-unnamed-trial-site-gainesville","cat":"research","name":"Unnamed trial site","city":"Gainesville","region":"Florida","country":"United States","cc":"US","lat":29.66231,"lon":-82.32384,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-gainesville"},{"id":"nct02782104-unnamed-trial-site-miami","cat":"research","name":"Unnamed trial site","city":"Miami","region":"Florida","country":"United States","cc":"US","lat":25.78119,"lon":-80.18731,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-miami"},{"id":"nct02782104-unnamed-trial-site-orlando","cat":"research","name":"Unnamed trial site","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.52785,"lon":-81.37025,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-orlando"},{"id":"nct02782104-unnamed-trial-site-atlanta","cat":"research","name":"Unnamed trial site","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.75281,"lon":-84.38887,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-atlanta"},{"id":"nct02782104-unnamed-trial-site-chicago","cat":"research","name":"Unnamed trial site","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.85469,"lon":-87.64021,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-chicago"},{"id":"nct02782104-unnamed-trial-site-hoffman-estates","cat":"research","name":"Unnamed trial site","city":"Hoffman Estates","region":"Illinois","country":"United States","cc":"US","lat":42.04719,"lon":-88.08559,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-hoffman-estates"},{"id":"nct02782104-unnamed-trial-site-joliet","cat":"research","name":"Unnamed trial site","city":"Joliet","region":"Illinois","country":"United States","cc":"US","lat":41.51347,"lon":-88.07469,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-joliet"},{"id":"nct02782104-unnamed-trial-site-maywood","cat":"research","name":"Unnamed trial site","city":"Maywood","region":"Illinois","country":"United States","cc":"US","lat":33.99821,"lon":-118.1949,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-maywood"},{"id":"nct02782104-unnamed-trial-site-skokie","cat":"research","name":"Unnamed trial site","city":"Skokie","region":"Illinois","country":"United States","cc":"US","lat":42.03162,"lon":-87.72986,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-skokie"},{"id":"nct02782104-unnamed-trial-site-iowa-city","cat":"research","name":"Unnamed trial site","city":"Iowa City","region":"Iowa","country":"United States","cc":"US","lat":41.66334,"lon":-91.53784,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-iowa-city"},{"id":"nct02782104-unnamed-trial-site-wichita","cat":"research","name":"Unnamed trial site","city":"Wichita","region":"Kansas","country":"United States","cc":"US","lat":37.6809,"lon":-97.34643,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-wichita"},{"id":"nct02782104-unnamed-trial-site-lake-charles","cat":"research","name":"Unnamed trial site","city":"Lake Charles","region":"Louisiana","country":"United States","cc":"US","lat":30.20213,"lon":-93.21047,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-lake-charles"},{"id":"nct02782104-unnamed-trial-site-shreveport","cat":"research","name":"Unnamed trial site","city":"Shreveport","region":"Louisiana","country":"United States","cc":"US","lat":32.51795,"lon":-93.74853,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-shreveport"},{"id":"nct02782104-unnamed-trial-site-baltimore","cat":"research","name":"Unnamed trial site","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28525,"lon":-76.61497,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-baltimore"},{"id":"nct02782104-unnamed-trial-site-gaithersburg","cat":"research","name":"Unnamed trial site","city":"Gaithersburg","region":"Maryland","country":"United States","cc":"US","lat":39.15525,"lon":-77.19295,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-gaithersburg"},{"id":"nct02782104-unnamed-trial-site-boston","cat":"research","name":"Unnamed trial site","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36337,"lon":-71.05182,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-boston"},{"id":"nct02782104-unnamed-trial-site-new-bedford","cat":"research","name":"Unnamed trial site","city":"New Bedford","region":"Massachusetts","country":"United States","cc":"US","lat":41.64095,"lon":-70.9295,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-new-bedford"},{"id":"nct02782104-unnamed-trial-site-watertown","cat":"research","name":"Unnamed trial site","city":"Watertown","region":"Massachusetts","country":"United States","cc":"US","lat":42.37022,"lon":-71.17667,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-watertown"},{"id":"nct02782104-unnamed-trial-site-worcester","cat":"research","name":"Unnamed trial site","city":"Worcester","region":"Massachusetts","country":"United States","cc":"US","lat":42.25567,"lon":-71.8046,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-worcester"},{"id":"nct02782104-unnamed-trial-site-rochester-hills","cat":"research","name":"Unnamed trial site","city":"Rochester Hills","region":"Michigan","country":"United States","cc":"US","lat":42.65098,"lon":-83.16061,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-rochester-hills"},{"id":"nct02782104-unnamed-trial-site-o-fallon","cat":"research","name":"Unnamed trial site","city":"O'Fallon","region":"Missouri","country":"United States","cc":"US","lat":38.80445,"lon":-90.69227,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-o-fallon"},{"id":"nct02782104-unnamed-trial-site-saint-charles","cat":"research","name":"Unnamed trial site","city":"Saint Charles","region":"Missouri","country":"United States","cc":"US","lat":38.7886,"lon":-90.47836,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-saint-charles"},{"id":"nct02782104-unnamed-trial-site-omaha","cat":"research","name":"Unnamed trial site","city":"Omaha","region":"Nebraska","country":"United States","cc":"US","lat":41.2468,"lon":-95.93699,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-omaha"},{"id":"nct02782104-unnamed-trial-site-cedarhurst","cat":"research","name":"Unnamed trial site","city":"Cedarhurst","region":"New York","country":"United States","cc":"US","lat":40.62283,"lon":-73.71785,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-cedarhurst"},{"id":"nct02782104-unnamed-trial-site-new-york","cat":"research","name":"Unnamed trial site","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70396,"lon":-74.01741,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-new-york"},{"id":"nct02782104-unnamed-trial-site-staten-island","cat":"research","name":"Unnamed trial site","city":"Staten Island","region":"New York","country":"United States","cc":"US","lat":40.56595,"lon":-74.13718,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-staten-island"},{"id":"nct02782104-unnamed-trial-site-hickory","cat":"research","name":"Unnamed trial site","city":"Hickory","region":"North Carolina","country":"United States","cc":"US","lat":35.73983,"lon":-81.35141,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-hickory"},{"id":"nct02782104-unnamed-trial-site-cincinnati","cat":"research","name":"Unnamed trial site","city":"Cincinnati","region":"Ohio","country":"United States","cc":"US","lat":39.1249,"lon":-84.51811,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-cincinnati"},{"id":"nct02782104-unnamed-trial-site-oklahoma-city","cat":"research","name":"Unnamed trial site","city":"Oklahoma City","region":"Oklahoma","country":"United States","cc":"US","lat":35.45829,"lon":-97.51205,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-oklahoma-city"},{"id":"nct02782104-unnamed-trial-site-allentown","cat":"research","name":"Unnamed trial site","city":"Allentown","region":"Pennsylvania","country":"United States","cc":"US","lat":40.60434,"lon":-75.48656,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-allentown"},{"id":"nct02782104-unnamed-trial-site-media","cat":"research","name":"Unnamed trial site","city":"Media","region":"Pennsylvania","country":"United States","cc":"US","lat":39.91542,"lon":-75.38981,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-media"},{"id":"nct02782104-unnamed-trial-site-philadelphia","cat":"research","name":"Unnamed trial site","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.95704,"lon":-75.17553,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-philadelphia"},{"id":"nct02782104-unnamed-trial-site-lincoln","cat":"research","name":"Unnamed trial site","city":"Lincoln","region":"Rhode Island","country":"United States","cc":"US","lat":40.80409,"lon":-96.66014,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-lincoln"},{"id":"nct02782104-unnamed-trial-site-providence","cat":"research","name":"Unnamed trial site","city":"Providence","region":"Rhode Island","country":"United States","cc":"US","lat":41.82545,"lon":-71.40488,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-providence"},{"id":"nct02782104-unnamed-trial-site-charleston","cat":"research","name":"Unnamed trial site","city":"Charleston","region":"South Carolina","country":"United States","cc":"US","lat":32.7662,"lon":-79.93336,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-charleston"},{"id":"nct02782104-unnamed-trial-site-austin","cat":"research","name":"Unnamed trial site","city":"Austin","region":"Texas","country":"United States","cc":"US","lat":30.26729,"lon":-97.75487,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-austin"},{"id":"nct02782104-unnamed-trial-site-dallas","cat":"research","name":"Unnamed trial site","city":"Dallas","region":"Texas","country":"United States","cc":"US","lat":32.77831,"lon":-96.80474,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-dallas"},{"id":"nct02782104-unnamed-trial-site-houston","cat":"research","name":"Unnamed trial site","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.75213,"lon":-95.35729,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-houston"},{"id":"nct02782104-unnamed-trial-site-wichita-falls","cat":"research","name":"Unnamed trial site","city":"Wichita Falls","region":"Texas","country":"United States","cc":"US","lat":33.92307,"lon":-98.48487,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-wichita-falls"},{"id":"nct02782104-unnamed-trial-site-charlottesville","cat":"research","name":"Unnamed trial site","city":"Charlottesville","region":"Virginia","country":"United States","cc":"US","lat":38.0222,"lon":-78.47767,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-charlottesville"},{"id":"nct02782104-unnamed-trial-site-waukesha","cat":"research","name":"Unnamed trial site","city":"Waukesha","region":"Wisconsin","country":"United States","cc":"US","lat":43.01314,"lon":-88.23435,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-waukesha"},{"id":"nct02782104-unnamed-trial-site-banfield","cat":"research","name":"Unnamed trial site","city":"Banfield","country":"Argentina","cc":"AR","lat":-34.74643,"lon":-58.38174,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-banfield"},{"id":"nct02782104-unnamed-trial-site-buenos-aires","cat":"research","name":"Unnamed trial site","city":"Buenos Aires","country":"Argentina","cc":"AR","lat":-34.60539,"lon":-58.3769,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-buenos-aires"},{"id":"nct02782104-unnamed-trial-site-cordoba","cat":"research","name":"Unnamed trial site","city":"Córdoba","country":"Argentina","cc":"AR","lat":-31.39636,"lon":-64.18604,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-cordoba"},{"id":"nct02782104-unnamed-trial-site-la-plata","cat":"research","name":"Unnamed trial site","city":"La Plata","country":"Argentina","cc":"AR","lat":-34.93166,"lon":-57.94251,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-la-plata"},{"id":"nct02782104-unnamed-trial-site-mendoza","cat":"research","name":"Unnamed trial site","city":"Mendoza","country":"Argentina","cc":"AR","lat":-32.89139,"lon":-68.84822,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-mendoza"},{"id":"nct02782104-unnamed-trial-site-rosario","cat":"research","name":"Unnamed trial site","city":"Rosario","country":"Argentina","cc":"AR","lat":-32.93962,"lon":-60.62901,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-rosario"},{"id":"nct02782104-unnamed-trial-site-caulfield","cat":"research","name":"Unnamed trial site","city":"Caulfield","country":"Australia","cc":"AU","lat":-37.87766,"lon":145.02396,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-caulfield"},{"id":"nct02782104-unnamed-trial-site-elizabeth-vale","cat":"research","name":"Unnamed trial site","city":"Elizabeth Vale","country":"Australia","cc":"AU","lat":-34.74692,"lon":138.66052,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-elizabeth-vale"},{"id":"nct02782104-unnamed-trial-site-frankston","cat":"research","name":"Unnamed trial site","city":"Frankston","country":"Australia","cc":"AU","lat":-38.13362,"lon":145.13359,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-frankston"},{"id":"nct02782104-unnamed-trial-site-vienna","cat":"research","name":"Unnamed trial site","city":"Vienna","country":"Austria","cc":"AT","lat":48.21654,"lon":16.36422,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-vienna"},{"id":"nct02782104-unnamed-trial-site-aalst","cat":"research","name":"Unnamed trial site","city":"Aalst","country":"Belgium","cc":"BE","lat":50.94493,"lon":4.03649,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-aalst"},{"id":"nct02782104-unnamed-trial-site-bruges","cat":"research","name":"Unnamed trial site","city":"Bruges","country":"Belgium","cc":"BE","lat":51.20454,"lon":3.2273,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-bruges"},{"id":"nct02782104-unnamed-trial-site-brussels","cat":"research","name":"Unnamed trial site","city":"Brussels","country":"Belgium","cc":"BE","lat":50.84946,"lon":4.3557,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-brussels"},{"id":"nct02782104-unnamed-trial-site-heusden-zolder","cat":"research","name":"Unnamed trial site","city":"Heusden-Zolder","country":"Belgium","cc":"BE","lat":51.0446,"lon":4.7821,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-heusden-zolder"},{"id":"nct02782104-unnamed-trial-site-liege","cat":"research","name":"Unnamed trial site","city":"Liège","country":"Belgium","cc":"BE","lat":50.63331,"lon":5.5585,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-liege"},{"id":"nct02782104-unnamed-trial-site-yvoir","cat":"research","name":"Unnamed trial site","city":"Yvoir","country":"Belgium","cc":"BE","lat":50.32343,"lon":4.87,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-yvoir"},{"id":"nct02782104-unnamed-trial-site-belo-horizonte","cat":"research","name":"Unnamed trial site","city":"Belo Horizonte","country":"Brazil","cc":"BR","lat":-19.92078,"lon":-43.93557,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-belo-horizonte"},{"id":"nct02782104-unnamed-trial-site-curitiba","cat":"research","name":"Unnamed trial site","city":"Curitiba","country":"Brazil","cc":"BR","lat":-25.43084,"lon":-49.27442,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-curitiba"},{"id":"nct02782104-unnamed-trial-site-fortaleza","cat":"research","name":"Unnamed trial site","city":"Fortaleza","country":"Brazil","cc":"BR","lat":-3.71971,"lon":-38.53633,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-fortaleza"},{"id":"nct02782104-unnamed-trial-site-passo-fundo","cat":"research","name":"Unnamed trial site","city":"Passo Fundo","country":"Brazil","cc":"BR","lat":-28.25323,"lon":-52.40276,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-passo-fundo"},{"id":"nct02782104-unnamed-trial-site-porto-alegre","cat":"research","name":"Unnamed trial site","city":"Porto Alegre","country":"Brazil","cc":"BR","lat":-30.02121,"lon":-51.22732,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-porto-alegre"},{"id":"nct02782104-unnamed-trial-site-recife","cat":"research","name":"Unnamed trial site","city":"Recife","country":"Brazil","cc":"BR","lat":-8.0498,"lon":-34.87523,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-recife"},{"id":"nct02782104-unnamed-trial-site-rio-de-janeiro","cat":"research","name":"Unnamed trial site","city":"Rio de Janeiro","country":"Brazil","cc":"BR","lat":-22.90976,"lon":-43.18727,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-rio-de-janeiro"},{"id":"nct02782104-unnamed-trial-site-sao-bernardo-do-campo","cat":"research","name":"Unnamed trial site","city":"São Bernardo do Campo","country":"Brazil","cc":"BR","lat":-23.69083,"lon":-46.57211,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-sao-bernardo-do-campo"},{"id":"nct02782104-unnamed-trial-site-sao-paulo","cat":"research","name":"Unnamed trial site","city":"São Paulo","country":"Brazil","cc":"BR","lat":-23.54068,"lon":-46.63851,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-sao-paulo"},{"id":"nct02782104-unnamed-trial-site-burgas","cat":"research","name":"Unnamed trial site","city":"Burgas","country":"Bulgaria","cc":"BG","lat":42.51832,"lon":27.4771,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-burgas"},{"id":"nct02782104-unnamed-trial-site-kardzhali","cat":"research","name":"Unnamed trial site","city":"Kardzhali","country":"Bulgaria","cc":"BG","lat":41.64864,"lon":25.35962,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-kardzhali"},{"id":"nct02782104-unnamed-trial-site-pazardzhik","cat":"research","name":"Unnamed trial site","city":"Pazardzhik","country":"Bulgaria","cc":"BG","lat":42.19638,"lon":24.34236,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-pazardzhik"},{"id":"nct02782104-unnamed-trial-site-pleven","cat":"research","name":"Unnamed trial site","city":"Pleven","country":"Bulgaria","cc":"BG","lat":43.40873,"lon":24.6152,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-pleven"},{"id":"nct02782104-unnamed-trial-site-plovdiv","cat":"research","name":"Unnamed trial site","city":"Plovdiv","country":"Bulgaria","cc":"BG","lat":42.14582,"lon":24.73895,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-plovdiv"},{"id":"nct02782104-unnamed-trial-site-rousse","cat":"research","name":"Unnamed trial site","city":"Rousse","country":"Bulgaria","cc":"BG","lat":43.85564,"lon":25.96305,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-rousse"},{"id":"nct02782104-unnamed-trial-site-sofia","cat":"research","name":"Unnamed trial site","city":"Sofia","country":"Bulgaria","cc":"BG","lat":42.69182,"lon":23.33342,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-sofia"},{"id":"nct02782104-unnamed-trial-site-varna","cat":"research","name":"Unnamed trial site","city":"Varna","country":"Bulgaria","cc":"BG","lat":43.23065,"lon":27.91264,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-varna"},{"id":"nct02782104-unnamed-trial-site-vancouver","cat":"research","name":"Unnamed trial site","city":"Vancouver","region":"British Columbia","country":"Canada","cc":"CA","lat":49.24745,"lon":-123.11045,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-vancouver"},{"id":"nct02782104-unnamed-trial-site-kingston","cat":"research","name":"Unnamed trial site","city":"Kingston","region":"Ontario","country":"Canada","cc":"CA","lat":44.2364,"lon":-76.48507,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-kingston"},{"id":"nct02782104-unnamed-trial-site-ottawa","cat":"research","name":"Unnamed trial site","city":"Ottawa","region":"Ontario","country":"Canada","cc":"CA","lat":45.40896,"lon":-75.69666,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-ottawa"},{"id":"nct02782104-unnamed-trial-site-toronto","cat":"research","name":"Unnamed trial site","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.71589,"lon":-79.3969,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-toronto"},{"id":"nct02782104-unnamed-trial-site-brno","cat":"research","name":"Unnamed trial site","city":"Brno","country":"Czechia","cc":"CZ","lat":49.18501,"lon":16.6193,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-brno"},{"id":"nct02782104-unnamed-trial-site-pilsen","cat":"research","name":"Unnamed trial site","city":"Pilsen","country":"Czechia","cc":"CZ","lat":49.73603,"lon":13.38441,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-pilsen"},{"id":"nct02782104-unnamed-trial-site-prague","cat":"research","name":"Unnamed trial site","city":"Prague","country":"Czechia","cc":"CZ","lat":50.08056,"lon":14.42241,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-prague"},{"id":"nct02782104-unnamed-trial-site-tallinn","cat":"research","name":"Unnamed trial site","city":"Tallinn","country":"Estonia","cc":"EE","lat":59.4308,"lon":24.74972,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-tallinn"},{"id":"nct02782104-unnamed-trial-site-tartu","cat":"research","name":"Unnamed trial site","city":"Tartu","country":"Estonia","cc":"EE","lat":58.38914,"lon":26.72918,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-tartu"},{"id":"nct02782104-unnamed-trial-site-kuopio","cat":"research","name":"Unnamed trial site","city":"Kuopio","country":"Finland","cc":"FI","lat":62.8881,"lon":27.66559,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-kuopio"},{"id":"nct02782104-unnamed-trial-site-clermont-ferrand","cat":"research","name":"Unnamed trial site","city":"Clermont-Ferrand","country":"France","cc":"FR","lat":45.78096,"lon":3.08282,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-clermont-ferrand"},{"id":"nct02782104-unnamed-trial-site-douai","cat":"research","name":"Unnamed trial site","city":"Douai","country":"France","cc":"FR","lat":50.37883,"lon":3.09103,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-douai"},{"id":"nct02782104-unnamed-trial-site-nantes","cat":"research","name":"Unnamed trial site","city":"Nantes","country":"France","cc":"FR","lat":47.21974,"lon":-1.55915,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-nantes"},{"id":"nct02782104-unnamed-trial-site-nimes","cat":"research","name":"Unnamed trial site","city":"Nîmes","country":"France","cc":"FR","lat":43.83557,"lon":4.35256,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-nimes"},{"id":"nct02782104-unnamed-trial-site-paris","cat":"research","name":"Unnamed trial site","city":"Paris","country":"France","cc":"FR","lat":48.8639,"lon":2.35318,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-paris"},{"id":"nct02782104-unnamed-trial-site-poitiers","cat":"research","name":"Unnamed trial site","city":"Poitiers","country":"France","cc":"FR","lat":46.59019,"lon":0.3343,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-poitiers"},{"id":"nct02782104-unnamed-trial-site-toulon","cat":"research","name":"Unnamed trial site","city":"Toulon","country":"France","cc":"FR","lat":43.13256,"lon":5.93057,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-toulon"},{"id":"nct02782104-unnamed-trial-site-berlin","cat":"research","name":"Unnamed trial site","city":"Berlin","country":"Germany","cc":"DE","lat":52.52376,"lon":13.41924,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-berlin"},{"id":"nct02782104-unnamed-trial-site-bochum","cat":"research","name":"Unnamed trial site","city":"Bochum","country":"Germany","cc":"DE","lat":51.4896,"lon":7.20683,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-bochum"},{"id":"nct02782104-unnamed-trial-site-mainz","cat":"research","name":"Unnamed trial site","city":"Mainz","country":"Germany","cc":"DE","lat":49.99159,"lon":8.27655,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-mainz"},{"id":"nct02782104-unnamed-trial-site-mittweida","cat":"research","name":"Unnamed trial site","city":"Mittweida","country":"Germany","cc":"DE","lat":50.98994,"lon":12.9773,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-mittweida"},{"id":"nct02782104-unnamed-trial-site-oranienburg","cat":"research","name":"Unnamed trial site","city":"Oranienburg","country":"Germany","cc":"DE","lat":52.74296,"lon":13.24032,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-oranienburg"},{"id":"nct02782104-unnamed-trial-site-pfaffenhofen","cat":"research","name":"Unnamed trial site","city":"Pfaffenhofen","country":"Germany","cc":"DE","lat":49.07465,"lon":8.98133,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-pfaffenhofen"},{"id":"nct02782104-unnamed-trial-site-budapest","cat":"research","name":"Unnamed trial site","city":"Budapest","country":"Hungary","cc":"HU","lat":47.4871,"lon":19.05085,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-budapest"},{"id":"nct02782104-unnamed-trial-site-debrecen","cat":"research","name":"Unnamed trial site","city":"Debrecen","country":"Hungary","cc":"HU","lat":47.52202,"lon":21.61404,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-debrecen"},{"id":"nct02782104-unnamed-trial-site-gyor","cat":"research","name":"Unnamed trial site","city":"Győr","country":"Hungary","cc":"HU","lat":47.69401,"lon":17.63479,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-gyor"},{"id":"nct02782104-unnamed-trial-site-pecs","cat":"research","name":"Unnamed trial site","city":"Pécs","country":"Hungary","cc":"HU","lat":46.06596,"lon":18.22,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-pecs"},{"id":"nct02782104-unnamed-trial-site-sopron","cat":"research","name":"Unnamed trial site","city":"Sopron","country":"Hungary","cc":"HU","lat":47.68007,"lon":16.58743,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-sopron"},{"id":"nct02782104-unnamed-trial-site-szekszard","cat":"research","name":"Unnamed trial site","city":"Szekszárd","country":"Hungary","cc":"HU","lat":46.34257,"lon":18.71862,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-szekszard"},{"id":"nct02782104-unnamed-trial-site-vac","cat":"research","name":"Unnamed trial site","city":"Vác","country":"Hungary","cc":"HU","lat":47.77633,"lon":19.13306,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-vac"},{"id":"nct02782104-unnamed-trial-site-kaunas","cat":"research","name":"Unnamed trial site","city":"Kaunas","country":"Lithuania","cc":"LT","lat":54.90744,"lon":23.89728,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-kaunas"},{"id":"nct02782104-unnamed-trial-site-kuala-lumpur","cat":"research","name":"Unnamed trial site","city":"Kuala Lumpur","country":"Malaysia","cc":"MY","lat":3.13635,"lon":101.68714,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-kuala-lumpur"},{"id":"nct02782104-unnamed-trial-site-guadalajara","cat":"research","name":"Unnamed trial site","city":"Guadalajara","country":"Mexico","cc":"MX","lat":20.67865,"lon":-103.34396,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-guadalajara"},{"id":"nct02782104-unnamed-trial-site-leon","cat":"research","name":"Unnamed trial site","city":"León","country":"Mexico","cc":"MX","lat":21.11736,"lon":-101.68813,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-leon"},{"id":"nct02782104-unnamed-trial-site-mexico-city","cat":"research","name":"Unnamed trial site","city":"Mexico City","country":"Mexico","cc":"MX","lat":19.42654,"lon":-99.13928,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-mexico-city"},{"id":"nct02782104-unnamed-trial-site-mexico","cat":"research","name":"Unnamed trial site","city":"México","country":"Mexico","cc":"MX","lat":19.43567,"lon":-99.12432,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-mexico"},{"id":"nct02782104-unnamed-trial-site-monterrey","cat":"research","name":"Unnamed trial site","city":"Monterrey","country":"Mexico","cc":"MX","lat":25.69381,"lon":-100.31283,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-monterrey"},{"id":"nct02782104-unnamed-trial-site-san-luis-potosi-city","cat":"research","name":"Unnamed trial site","city":"San Luis Potosí City","country":"Mexico","cc":"MX","lat":22.16227,"lon":-100.96641,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-san-luis-potosi-city"},{"id":"nct02782104-unnamed-trial-site-be-chatow","cat":"research","name":"Unnamed trial site","city":"Bełchatów","country":"Poland","cc":"PL","lat":51.37518,"lon":19.34885,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-be-chatow"},{"id":"nct02782104-unnamed-trial-site-bialystok","cat":"research","name":"Unnamed trial site","city":"Bialystok","country":"Poland","cc":"PL","lat":53.13441,"lon":23.16485,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-bialystok"},{"id":"nct02782104-unnamed-trial-site-bydgoszcz","cat":"research","name":"Unnamed trial site","city":"Bydgoszcz","country":"Poland","cc":"PL","lat":53.1259,"lon":18.01689,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-bydgoszcz"},{"id":"nct02782104-unnamed-trial-site-gdansk","cat":"research","name":"Unnamed trial site","city":"Gdansk","country":"Poland","cc":"PL","lat":54.34131,"lon":18.65999,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-gdansk"},{"id":"nct02782104-unnamed-trial-site-leszno","cat":"research","name":"Unnamed trial site","city":"Leszno","country":"Poland","cc":"PL","lat":51.83587,"lon":16.58374,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-leszno"},{"id":"nct02782104-unnamed-trial-site-lublin","cat":"research","name":"Unnamed trial site","city":"Lublin","country":"Poland","cc":"PL","lat":51.25129,"lon":22.57183,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-lublin"},{"id":"nct02782104-unnamed-trial-site-warsaw","cat":"research","name":"Unnamed trial site","city":"Warsaw","country":"Poland","cc":"PL","lat":52.23273,"lon":21.00769,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-warsaw"},{"id":"nct02782104-unnamed-trial-site-bratislava","cat":"research","name":"Unnamed trial site","city":"Bratislava","country":"Slovakia","cc":"SK","lat":48.15169,"lon":17.10763,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-bratislava"},{"id":"nct02782104-unnamed-trial-site-liptovsky-mikulas","cat":"research","name":"Unnamed trial site","city":"Liptovský Mikuláš","country":"Slovakia","cc":"SK","lat":49.07435,"lon":19.62147,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-liptovsky-mikulas"},{"id":"nct02782104-unnamed-trial-site-rimavska-sobota","cat":"research","name":"Unnamed trial site","city":"Rimavská Sobota","country":"Slovakia","cc":"SK","lat":48.38289,"lon":20.02865,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-rimavska-sobota"},{"id":"nct02782104-unnamed-trial-site-roznava","cat":"research","name":"Unnamed trial site","city":"Rožňava","country":"Slovakia","cc":"SK","lat":48.672,"lon":20.53622,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-roznava"},{"id":"nct02782104-unnamed-trial-site-svidnik","cat":"research","name":"Unnamed trial site","city":"Svidník","country":"Slovakia","cc":"SK","lat":49.31906,"lon":21.56018,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-svidnik"},{"id":"nct02782104-unnamed-trial-site-cape-town","cat":"research","name":"Unnamed trial site","city":"Cape Town","country":"South Africa","cc":"ZA","lat":-33.92786,"lon":18.41602,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-cape-town"},{"id":"nct02782104-unnamed-trial-site-pretoria","cat":"research","name":"Unnamed trial site","city":"Pretoria","country":"South Africa","cc":"ZA","lat":-25.74585,"lon":28.18703,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-pretoria"},{"id":"nct02782104-unnamed-trial-site-welgemoed","cat":"research","name":"Unnamed trial site","city":"Welgemoed","country":"South Africa","cc":"ZA","lat":-25.59,"lon":28.5976,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-welgemoed"},{"id":"nct02782104-unnamed-trial-site-gwangju","cat":"research","name":"Unnamed trial site","city":"Gwangju","country":"South Korea","cc":"KR","lat":35.16041,"lon":126.92549,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-gwangju"},{"id":"nct02782104-unnamed-trial-site-seoul","cat":"research","name":"Unnamed trial site","city":"Seoul","country":"South Korea","cc":"KR","lat":37.56125,"lon":126.98315,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-seoul"},{"id":"nct02782104-unnamed-trial-site-alcorcon","cat":"research","name":"Unnamed trial site","city":"Alcorcón","country":"Spain","cc":"ES","lat":40.35537,"lon":-3.81776,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-alcorcon"},{"id":"nct02782104-unnamed-trial-site-barcelona","cat":"research","name":"Unnamed trial site","city":"Barcelona","country":"Spain","cc":"ES","lat":41.39063,"lon":2.1628,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-barcelona"},{"id":"nct02782104-unnamed-trial-site-bilbao","cat":"research","name":"Unnamed trial site","city":"Bilbao","country":"Spain","cc":"ES","lat":43.26163,"lon":-2.92994,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-bilbao"},{"id":"nct02782104-unnamed-trial-site-madrid","cat":"research","name":"Unnamed trial site","city":"Madrid","country":"Spain","cc":"ES","lat":40.41956,"lon":-3.70524,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-madrid"},{"id":"nct02782104-unnamed-trial-site-oviedo","cat":"research","name":"Unnamed trial site","city":"Oviedo","country":"Spain","cc":"ES","lat":43.37201,"lon":-5.85412,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-oviedo"},{"id":"nct02782104-unnamed-trial-site-palma","cat":"research","name":"Unnamed trial site","city":"Palma","country":"Spain","cc":"ES","lat":39.56473,"lon":2.65716,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-palma"},{"id":"nct02782104-unnamed-trial-site-pamplona","cat":"research","name":"Unnamed trial site","city":"Pamplona","country":"Spain","cc":"ES","lat":42.81071,"lon":-1.64102,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-pamplona"},{"id":"nct02782104-unnamed-trial-site-sabadell","cat":"research","name":"Unnamed trial site","city":"Sabadell","country":"Spain","cc":"ES","lat":41.55077,"lon":2.10664,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-sabadell"},{"id":"nct02782104-unnamed-trial-site-salamanca","cat":"research","name":"Unnamed trial site","city":"Salamanca","country":"Spain","cc":"ES","lat":40.43824,"lon":-3.67227,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-salamanca"},{"id":"nct02782104-unnamed-trial-site-sant-boi-de-llobregat","cat":"research","name":"Unnamed trial site","city":"Sant Boi de Llobregat","country":"Spain","cc":"ES","lat":41.35435,"lon":2.03974,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-sant-boi-de-llobregat"},{"id":"nct02782104-unnamed-trial-site-torrevieja","cat":"research","name":"Unnamed trial site","city":"Torrevieja","country":"Spain","cc":"ES","lat":37.96964,"lon":-0.68057,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-torrevieja"},{"id":"nct02782104-unnamed-trial-site-vitoria-gasteiz","cat":"research","name":"Unnamed trial site","city":"Vitoria-Gasteiz","country":"Spain","cc":"ES","lat":42.84796,"lon":-2.67593,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-vitoria-gasteiz"},{"id":"nct02782104-unnamed-trial-site-zamora","cat":"research","name":"Unnamed trial site","city":"Zamora","country":"Spain","cc":"ES","lat":41.50647,"lon":-5.73416,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-zamora"},{"id":"nct02782104-unnamed-trial-site-halmstad","cat":"research","name":"Unnamed trial site","city":"Halmstad","country":"Sweden","cc":"SE","lat":56.66801,"lon":12.84551,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-halmstad"},{"id":"nct02782104-unnamed-trial-site-lund","cat":"research","name":"Unnamed trial site","city":"Lund","country":"Sweden","cc":"SE","lat":55.6944,"lon":13.19175,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-lund"},{"id":"nct02782104-unnamed-trial-site-skovde","cat":"research","name":"Unnamed trial site","city":"Skövde","country":"Sweden","cc":"SE","lat":58.37993,"lon":13.83306,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-skovde"},{"id":"nct02782104-unnamed-trial-site-stockholm","cat":"research","name":"Unnamed trial site","city":"Stockholm","country":"Sweden","cc":"SE","lat":59.33809,"lon":18.07873,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-stockholm"},{"id":"nct02782104-unnamed-trial-site-kaohsiung-city","cat":"research","name":"Unnamed trial site","city":"Kaohsiung City","country":"Taiwan","cc":"TW","lat":22.61988,"lon":120.32514,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-kaohsiung-city"},{"id":"nct02782104-unnamed-trial-site-new-taipei-city","cat":"research","name":"Unnamed trial site","city":"New Taipei City","country":"Taiwan","cc":"TW","lat":25.05112,"lon":121.45039,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-new-taipei-city"},{"id":"nct02782104-unnamed-trial-site-taichung","cat":"research","name":"Unnamed trial site","city":"Taichung","country":"Taiwan","cc":"TW","lat":24.13895,"lon":120.6767,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-taichung"},{"id":"nct02782104-unnamed-trial-site-taipei","cat":"research","name":"Unnamed trial site","city":"Taipei","country":"Taiwan","cc":"TW","lat":25.05405,"lon":121.5158,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-taipei"},{"id":"nct02782104-unnamed-trial-site-taoyuan","cat":"research","name":"Unnamed trial site","city":"Taoyuan","country":"Taiwan","cc":"TW","lat":24.98215,"lon":121.28684,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-taoyuan"},{"id":"nct02782104-unnamed-trial-site-adana","cat":"research","name":"Unnamed trial site","city":"Adana","country":"Turkey","cc":"TR","lat":36.9798,"lon":35.33223,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-adana"},{"id":"nct02782104-unnamed-trial-site-ankara","cat":"research","name":"Unnamed trial site","city":"Ankara","country":"Turkey","cc":"TR","lat":39.91549,"lon":32.85902,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-ankara"},{"id":"nct02782104-unnamed-trial-site-bursa","cat":"research","name":"Unnamed trial site","city":"Bursa","country":"Turkey","cc":"TR","lat":40.19328,"lon":29.06507,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-bursa"},{"id":"nct02782104-unnamed-trial-site-istanbul","cat":"research","name":"Unnamed trial site","city":"Istanbul","country":"Turkey","cc":"TR","lat":41.0232,"lon":28.94095,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-istanbul"},{"id":"nct02782104-unnamed-trial-site-kucukcekmece-istanbul","cat":"research","name":"Unnamed trial site","city":"Kucukcekmece/Istanbul","country":"Turkey","cc":"TR","lat":40.0709,"lon":32.5425,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-kucukcekmece-istanbul"},{"id":"nct02782104-unnamed-trial-site-oanakkale","cat":"research","name":"Unnamed trial site","city":"Oanakkale","country":"Turkey","cc":"TR","lat":39.714,"lon":32.4053,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-oanakkale"},{"id":"nct02782104-unnamed-trial-site-samsun","cat":"research","name":"Unnamed trial site","city":"Samsun","country":"Turkey","cc":"TR","lat":41.28903,"lon":36.32871,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-samsun"},{"id":"nct02782104-unnamed-trial-site-chesterfield","cat":"research","name":"Unnamed trial site","city":"Chesterfield","country":"United Kingdom","cc":"GB","lat":53.24807,"lon":-1.42763,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-chesterfield"},{"id":"nct02782104-unnamed-trial-site-derby","cat":"research","name":"Unnamed trial site","city":"Derby","country":"United Kingdom","cc":"GB","lat":52.91717,"lon":-1.48618,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-derby"},{"id":"nct02782104-unnamed-trial-site-london","cat":"research","name":"Unnamed trial site","city":"London","country":"United Kingdom","cc":"GB","lat":51.49662,"lon":-0.13172,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-london"},{"id":"nct02782104-unnamed-trial-site-northampton","cat":"research","name":"Unnamed trial site","city":"Northampton","country":"United Kingdom","cc":"GB","lat":52.25344,"lon":-0.89317,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-northampton"},{"id":"nct02782104-unnamed-trial-site-oxford","cat":"research","name":"Unnamed trial site","city":"Oxford","country":"United Kingdom","cc":"GB","lat":51.76234,"lon":-1.2658,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02782104","study":"A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT02782104","phase":"Phase 3","enroll":1148,"start":"2016-06-09","eid":"x:site:nct02782104-unnamed-trial-site-oxford"},{"id":"nct05603104-sheba-medical-center-ramat-gan","cat":"research","name":"Sheba Medical Center","city":"Ramat Gan","country":"Israel","cc":"IL","lat":32.07102,"lon":34.80787,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"condg":["Depression","Bipolar"],"status":"RECRUITING","nct":"NCT05603104","study":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","sstatus":"RECRUITING","sponsor":"Dr. Inge Winter","src":"https://clinicaltrials.gov/study/NCT05603104","contact":{"n":"Mark Weiser, MD, PhD","p":"+31875553227","e":"mweiser@netvision.net.il"},"phase":"Phase 3","enroll":1254,"start":"2025-04-27","eid":"x:site:nct05603104-sheba-medical-center-ramat-gan"},{"id":"nct07269964-technical-university-of-munich-tum-school-of-medicine-and-health-dep","cat":"research","name":"Technical University of Munich, TUM School of Medicine and Health, Department of Psychiatry and Psychotherapy, Munich,","city":"München","region":"Bavaria","country":"Germany","cc":"DE","lat":48.12938,"lon":11.5874,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"81675","condg":["Depression"],"status":"ENROLLING_BY_INVITATION","nct":"NCT07269964","study":"At-Home tDCS as Maintenance Therapy","sstatus":"RECRUITING","sponsor":"Technical University of Munich","src":"https://clinicaltrials.gov/study/NCT07269964","contact":{"n":"Ulrike Vogelmann, Dr. med.","p":"+4917661535471","e":"ulrike.vogelmann@mri.tum.de"},"phase":"N/A","enroll":30,"start":"2024-10-01","eid":"x:site:nct07269964-technical-university-of-munich-tum-school-of-medicine-and-health-dep"},{"id":"nct07269964-department-of-psychiatry-and-psychotherapy-technical-university-of-m","cat":"research","name":"Department of Psychiatry and Psychotherapy, Technical University of Munich, University Hospital","city":"München","country":"Germany","cc":"DE","lat":48.1371,"lon":11.58194,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"81675","condg":["Depression"],"status":"RECRUITING","nct":"NCT07269964","study":"At-Home tDCS as Maintenance Therapy","sstatus":"RECRUITING","sponsor":"Technical University of Munich","src":"https://clinicaltrials.gov/study/NCT07269964","contact":{"n":"Ulrike Vogelmann, MD","p":"+498941406882","e":"ulrike.vogelmann@mri.tum.de"},"phase":"N/A","enroll":30,"start":"2024-10-01","eid":"x:site:nct07269964-department-of-psychiatry-and-psychotherapy-technical-university-of-m"},{"id":"nct06488586-providence-care-hospital-kingston","cat":"research","name":"Providence Care Hospital","city":"Kingston","region":"Ontario","country":"Canada","cc":"CA","lat":44.22924,"lon":-76.48206,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"K7L4X3","condg":["Depression"],"status":"RECRUITING","nct":"NCT06488586","study":"IV Ketamine vs. IN Esketamine for MDD TRD","sstatus":"RECRUITING","sponsor":"Gustavo Vazquez","official":"Gustavo H Vazquez, MD,PhD,FRCPC (Queen&#39;s University)","src":"https://clinicaltrials.gov/study/NCT06488586","contact":{"n":"Gustavo H Vazquez, MD,PhD,FRCPC","p":"613-544-4900","e":"g.vazquez@queensu.ca"},"enroll":80,"start":"2023-03-20","eid":"x:site:nct06488586-providence-care-hospital-kingston"},{"id":"nct04103892-clinical-site-126-bentonville","cat":"research","name":"Clinical Site 126","city":"Bentonville","region":"Arkansas","country":"United States","cc":"US","lat":36.36226,"lon":-94.21687,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"72712","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-126-bentonville"},{"id":"nct04103892-clinical-site-120-little-rock","cat":"research","name":"Clinical Site 120","city":"Little Rock","region":"Arkansas","country":"United States","cc":"US","lat":34.73796,"lon":-92.28775,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"72209","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-120-little-rock"},{"id":"nct04103892-clinical-site-129-little-rock","cat":"research","name":"Clinical Site 129","city":"Little Rock","region":"Arkansas","country":"United States","cc":"US","lat":34.74483,"lon":-92.27806,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"72209","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-129-little-rock"},{"id":"nct04103892-clinical-site-141-anaheim","cat":"research","name":"Clinical Site 141","city":"Anaheim","region":"California","country":"United States","cc":"US","lat":33.84174,"lon":-117.90316,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"92805","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-141-anaheim"},{"id":"nct04103892-clinical-site-115-bellflower","cat":"research","name":"Clinical Site 115","city":"Bellflower","region":"California","country":"United States","cc":"US","lat":33.88116,"lon":-118.11932,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"90706","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-115-bellflower"},{"id":"nct04103892-clinical-site-132-lafayette","cat":"research","name":"Clinical Site 132","city":"Lafayette","region":"California","country":"United States","cc":"US","lat":30.23449,"lon":-92.02676,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"94549","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-132-lafayette"},{"id":"nct04103892-clinical-site-117-oakland","cat":"research","name":"Clinical Site 117","city":"Oakland","region":"California","country":"United States","cc":"US","lat":37.81223,"lon":-122.28101,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"94607","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-117-oakland"},{"id":"nct04103892-clinical-site-113-oceanside","cat":"research","name":"Clinical Site 113","city":"Oceanside","region":"California","country":"United States","cc":"US","lat":33.19526,"lon":-117.38301,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"92056","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-113-oceanside"},{"id":"nct04103892-clinical-site-123-riverside","cat":"research","name":"Clinical Site 123","city":"Riverside","region":"California","country":"United States","cc":"US","lat":33.94295,"lon":-117.40712,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"92506","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-123-riverside"},{"id":"nct04103892-clinical-site-124-santa-ana","cat":"research","name":"Clinical Site 124","city":"Santa Ana","region":"California","country":"United States","cc":"US","lat":33.74778,"lon":-117.86628,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"92705","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-124-santa-ana"},{"id":"nct04103892-clinical-site-142-santa-rosa","cat":"research","name":"Clinical Site 142","city":"Santa Rosa","region":"California","country":"United States","cc":"US","lat":38.44202,"lon":-122.70958,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"95401","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-142-santa-rosa"},{"id":"nct04103892-clinical-site-112-torrance","cat":"research","name":"Clinical Site 112","city":"Torrance","region":"California","country":"United States","cc":"US","lat":33.82667,"lon":-118.34821,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"90502","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-112-torrance"},{"id":"nct04103892-clinical-site-145-denver","cat":"research","name":"Clinical Site 145","city":"Denver","region":"Colorado","country":"United States","cc":"US","lat":39.73496,"lon":-104.97496,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"80209","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-145-denver"},{"id":"nct04103892-clinical-site-107-hialeah","cat":"research","name":"Clinical Site 107","city":"Hialeah","region":"Florida","country":"United States","cc":"US","lat":25.85012,"lon":-80.28907,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"33016","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-107-hialeah"},{"id":"nct04103892-clinical-site-116-miami","cat":"research","name":"Clinical Site 116","city":"Miami","region":"Florida","country":"United States","cc":"US","lat":25.76538,"lon":-80.19267,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"33145","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-116-miami"},{"id":"nct04103892-clinical-site-108-miami-gardens","cat":"research","name":"Clinical Site 108","city":"Miami Gardens","region":"Florida","country":"United States","cc":"US","lat":25.93051,"lon":-80.25544,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"33014","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-108-miami-gardens"},{"id":"nct04103892-clinical-site-105-orlando","cat":"research","name":"Clinical Site 105","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.5349,"lon":-81.37759,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"32803","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-105-orlando"},{"id":"nct04103892-clinical-site-137-orlando","cat":"research","name":"Clinical Site 137","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.53886,"lon":-81.38343,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"32807","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-137-orlando"},{"id":"nct04103892-clinical-site-140-atlanta","cat":"research","name":"Clinical Site 140","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.74293,"lon":-84.38172,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"30338","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-140-atlanta"},{"id":"nct04103892-clinical-site-104-decatur","cat":"research","name":"Clinical Site 104","city":"Decatur","region":"Georgia","country":"United States","cc":"US","lat":39.83113,"lon":-88.95089,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"30030","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-104-decatur"},{"id":"nct04103892-clinical-site-122-marietta","cat":"research","name":"Clinical Site 122","city":"Marietta","region":"Georgia","country":"United States","cc":"US","lat":33.94568,"lon":-84.54697,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"30060","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-122-marietta"},{"id":"nct04103892-clinical-site-131-baltimore","cat":"research","name":"Clinical Site 131","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.2877,"lon":-76.60744,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"21208","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-131-baltimore"},{"id":"nct04103892-clinical-site-136-rockville","cat":"research","name":"Clinical Site 136","city":"Rockville","region":"Maryland","country":"United States","cc":"US","lat":39.08734,"lon":-77.16325,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"20877","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-136-rockville"},{"id":"nct04103892-clinical-site-103-boston","cat":"research","name":"Clinical Site 103","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.34925,"lon":-71.07168,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"02114","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-103-boston"},{"id":"nct04103892-clinical-site-121-boston","cat":"research","name":"Clinical Site 121","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36252,"lon":-71.06057,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"02131","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-121-boston"},{"id":"nct04103892-clinical-site-151-dearborn-heights","cat":"research","name":"Clinical Site 151","city":"Dearborn Heights","region":"Michigan","country":"United States","cc":"US","lat":42.34098,"lon":-83.27594,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"48034","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-151-dearborn-heights"},{"id":"nct04103892-clinical-site-139-st-louis","cat":"research","name":"Clinical Site 139","city":"St Louis","region":"Missouri","country":"United States","cc":"US","lat":38.62496,"lon":-90.20321,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"63128","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-139-st-louis"},{"id":"nct04103892-clinical-site-125-lincoln","cat":"research","name":"Clinical Site 125","city":"Lincoln","region":"Nebraska","country":"United States","cc":"US","lat":40.80353,"lon":-96.66635,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"68526","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-125-lincoln"},{"id":"nct04103892-clinical-site-110-las-vegas","cat":"research","name":"Clinical Site 110","city":"Las Vegas","region":"Nevada","country":"United States","cc":"US","lat":36.1657,"lon":-115.1319,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"89102","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-110-las-vegas"},{"id":"nct04103892-clinical-site-101-marlton","cat":"research","name":"Clinical Site 101","city":"Marlton","region":"New Jersey","country":"United States","cc":"US","lat":39.886,"lon":-74.91331,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"08053","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-101-marlton"},{"id":"nct04103892-clinical-site-148-toms-river","cat":"research","name":"Clinical Site 148","city":"Toms River","region":"New Jersey","country":"United States","cc":"US","lat":39.9614,"lon":-74.20418,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"08755","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-148-toms-river"},{"id":"nct04103892-clinical-site-128-new-york","cat":"research","name":"Clinical Site 128","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.721,"lon":-74.0111,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"10036","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-128-new-york"},{"id":"nct04103892-clinical-site-102-staten-island","cat":"research","name":"Clinical Site 102","city":"Staten Island","region":"New York","country":"United States","cc":"US","lat":40.55748,"lon":-74.13144,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"10312","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-102-staten-island"},{"id":"nct04103892-clinical-site-111-hickory","cat":"research","name":"Clinical Site 111","city":"Hickory","region":"North Carolina","country":"United States","cc":"US","lat":35.74161,"lon":-81.34614,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"28601","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-111-hickory"},{"id":"nct04103892-clinical-site-143-raleigh","cat":"research","name":"Clinical Site 143","city":"Raleigh","region":"North Carolina","country":"United States","cc":"US","lat":35.77591,"lon":-78.6395,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"27609","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-143-raleigh"},{"id":"nct04103892-clinical-site-138-middleburg-heights","cat":"research","name":"Clinical Site 138","city":"Middleburg Heights","region":"Ohio","country":"United States","cc":"US","lat":41.36977,"lon":-81.81117,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"44130","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-138-middleburg-heights"},{"id":"nct04103892-clinical-site-127-north-canton","cat":"research","name":"Clinical Site 127","city":"North Canton","region":"Ohio","country":"United States","cc":"US","lat":40.88704,"lon":-81.40719,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"44720","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-127-north-canton"},{"id":"nct04103892-clinical-site-106-media","cat":"research","name":"Clinical Site 106","city":"Media","region":"Pennsylvania","country":"United States","cc":"US","lat":39.91146,"lon":-75.39593,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"19063","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-106-media"},{"id":"nct04103892-clinical-site-118-philadelphia","cat":"research","name":"Clinical Site 118","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.95676,"lon":-75.1535,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"19104","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-118-philadelphia"},{"id":"nct04103892-clinical-site-114-fort-worth","cat":"research","name":"Clinical Site 114","city":"Fort Worth","region":"Texas","country":"United States","cc":"US","lat":32.73223,"lon":-97.31676,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"76104","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-114-fort-worth"},{"id":"nct04103892-clinical-site-109-houston","cat":"research","name":"Clinical Site 109","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.75627,"lon":-95.36435,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"77030","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-109-houston"},{"id":"nct04103892-clinical-site-149-missouri-city","cat":"research","name":"Clinical Site 149","city":"Missouri City","region":"Texas","country":"United States","cc":"US","lat":29.60977,"lon":-95.53692,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"88459","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-149-missouri-city"},{"id":"nct04103892-clinical-site-144-plano","cat":"research","name":"Clinical Site 144","city":"Plano","region":"Texas","country":"United States","cc":"US","lat":33.02572,"lon":-96.69743,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"75093","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-144-plano"},{"id":"nct04103892-clinical-site-147-draper","cat":"research","name":"Clinical Site 147","city":"Draper","region":"Utah","country":"United States","cc":"US","lat":40.51756,"lon":-111.86886,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"84020","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-147-draper"},{"id":"nct04103892-clinical-site-135-bellevue","cat":"research","name":"Clinical Site 135","city":"Bellevue","region":"Washington","country":"United States","cc":"US","lat":47.6044,"lon":-122.21221,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"98007","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-135-bellevue"},{"id":"nct04103892-clinical-site-150-san-juan","cat":"research","name":"Clinical Site 150","city":"San Juan","country":"Puerto Rico","cc":"PR","lat":18.47391,"lon":-66.09692,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"00918","condg":["Depression"],"nct":"NCT04103892","study":"A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study","sstatus":"COMPLETED","sponsor":"Clexio Biosciences Ltd.","src":"https://clinicaltrials.gov/study/NCT04103892","phase":"Phase 2","enroll":146,"start":"2019-09-05","eid":"x:site:nct04103892-clinical-site-150-san-juan"},{"id":"nct06303037-the-second-affiliated-hospital-and-yuying-children-s-hospital-of-wen","cat":"research","name":"The second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University","city":"Wenzhou","region":"Zhejiang","country":"China","cc":"CN","lat":28.0037,"lon":120.66498,"gp":"city","unnamed":0,"drugs":["esketamine"],"condg":["Other"],"nct":"NCT06303037","study":"Effect of Esketamine on 95% Induction Dose of Remimazolam","sstatus":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","official":"Huacheng Liu (Second Affiliated Hospital of Wenzhou Medical University); Yuhang Cai (Second Affiliated Hospital of Wenzhou Medical University)","src":"https://clinicaltrials.gov/study/NCT06303037","phase":"Phase 4","enroll":80,"start":"2024-04-01","eid":"x:site:nct06303037-the-second-affiliated-hospital-and-yuying-children-s-hospital-of-wen"},{"id":"nct06103760-royal-north-shore-hospital-st-leonards","cat":"research","name":"Royal North Shore Hospital","city":"St Leonards","region":"New South Wales","country":"Australia","cc":"AU","lat":-33.82829,"lon":151.19888,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"2065","condg":["Depression"],"status":"RECRUITING","nct":"NCT06103760","study":"Positioning of Esketamine Treatment in the Real-world Management of Depression","sstatus":"RECRUITING","sponsor":"Royal North Shore Hospital","official":"Gin Malhi (Royal North Shore Hospital, University of Sydney)","src":"https://clinicaltrials.gov/study/NCT06103760","contact":{"n":"Erica Bell","p":"02 9462 9905","e":"NSLHD-researchpoet@health.nsw.gov.au"},"phase":"Phase 4","enroll":162,"start":"2023-10-31","eid":"x:site:nct06103760-royal-north-shore-hospital-st-leonards"},{"id":"nct04938713-chu-de-charleroi-lodelinsart","cat":"research","name":"CHU de Charleroi","city":"Lodelinsart","region":"Hainaut","country":"Belgium","cc":"BE","lat":50.43858,"lon":4.46048,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"6042","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT04938713","study":"Comparison of Ketamine and Esketamine in Patients Suffering From Fibromyalgia Syndrome.","sstatus":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de Charleroi","official":"Brice Constant, MD (Centre Universitaire de Charleroi)","src":"https://clinicaltrials.gov/study/NCT04938713","contact":{"n":"Brice JD Constant, MD","p":"0032477504934","e":"briceconstant@hotmail.com"},"phase":"N/A","enroll":50,"start":"2021-07-01","eid":"x:site:nct04938713-chu-de-charleroi-lodelinsart"},{"id":"nct05635955-maternal-and-child-health-hospital-of-hubei-province-wuhan","cat":"research","name":"Maternal and Child Health Hospital of Hubei Province","city":"Wuhan","region":"Hubei","country":"China","cc":"CN","lat":30.58084,"lon":114.25627,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"430000","condg":["Other"],"nct":"NCT05635955","study":"Remimazolam Versus Propofol for Painless Abortion","sstatus":"COMPLETED","sponsor":"Maternal and Child Health Hospital of Hubei Province","official":"Na Li, MD (Maternal and Child Health Hospital of Hubei Province)","src":"https://clinicaltrials.gov/study/NCT05635955","phase":"Phase 2","enroll":100,"start":"2022-08-01","eid":"x:site:nct05635955-maternal-and-child-health-hospital-of-hubei-province-wuhan"},{"id":"nct00534586-technische-universitat-munchen-klinikum-rechts-der-isar-department-o","cat":"research","name":"Technische Universität München, Klinikum rechts der Isar, Department of Anesthesiology","city":"Munich","region":"Bavaria","country":"Germany","cc":"DE","lat":48.13061,"lon":11.56453,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"condg":["Healthy volunteers"],"nct":"NCT00534586","study":"Anesthetics and Auditory, Visceral, and Heat Evoked Potentials","sstatus":"COMPLETED","sponsor":"Technical University of Munich","official":"Eberhard Kochs, MD (Technical University of Munich)","src":"https://clinicaltrials.gov/study/NCT00534586","phase":"Phase 4","enroll":60,"start":"2005-12","eid":"x:site:nct00534586-technische-universitat-munchen-klinikum-rechts-der-isar-department-o"},{"id":"nct06087510-beijing-university-first-hospital-beijing","cat":"research","name":"Beijing University First Hospital","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.90256,"lon":116.40274,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100034","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06087510","study":"Different Dose Esketamine and Dexmedetomidine for Supplemental Analgesia and Longterm Outcomes","sstatus":"RECRUITING","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT06087510","contact":{"n":"Dong-Xin Wang, MD, PHD","p":"8610-83572784","e":"wangdongxin@hotmail.com"},"phase":"Phase 4","enroll":312,"start":"2024-01-24","eid":"x:site:nct06087510-beijing-university-first-hospital-beijing"},{"id":"nct00847418-clinical-research-center-university-hospital-basel-basel","cat":"research","name":"Clinical Research Center, University Hospital Basel","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","cc":"CH","lat":47.54714,"lon":7.58292,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"4031","condg":["Chronic pain & headache"],"nct":"NCT00847418","study":"Pharmacokinetics and Pharmacodynamics of Nasally Applied Esketamine","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Manuel Haschke, MD (Clinical Pharmacology and Toxicology, University Hospital Basel)","src":"https://clinicaltrials.gov/study/NCT00847418","phase":"Phase 1","start":"2009-02","eid":"x:site:nct00847418-clinical-research-center-university-hospital-basel-basel"},{"id":"nct05268497-yale-university-new-haven","cat":"research","name":"Yale University","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.30217,"lon":-72.93903,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"06511","condg":["Depression"],"nct":"NCT05268497","study":"A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant…","sstatus":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT05268497","phase":"Phase 1","start":"2022-09-01","eid":"x:site:nct05268497-yale-university-new-haven"},{"id":"nct05268497-rush-university-medical-center-chicago","cat":"research","name":"Rush University Medical Center","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.83907,"lon":-87.6421,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"60612","condg":["Depression"],"nct":"NCT05268497","study":"A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant…","sstatus":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT05268497","phase":"Phase 1","start":"2022-09-01","eid":"x:site:nct05268497-rush-university-medical-center-chicago"},{"id":"nct05268497-university-of-chicago-chicago","cat":"research","name":"University of Chicago","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.86137,"lon":-87.6501,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"60637","condg":["Depression"],"nct":"NCT05268497","study":"A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant…","sstatus":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT05268497","phase":"Phase 1","start":"2022-09-01","eid":"x:site:nct05268497-university-of-chicago-chicago"},{"id":"nct05268497-sheppard-pratt-health-system-baltimore","cat":"research","name":"Sheppard Pratt Health System","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28149,"lon":-76.60273,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"21204","condg":["Depression"],"nct":"NCT05268497","study":"A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant…","sstatus":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT05268497","phase":"Phase 1","start":"2022-09-01","eid":"x:site:nct05268497-sheppard-pratt-health-system-baltimore"},{"id":"nct05268497-university-of-cincinnati-dept-of-psychiatry-behavioral-neuroscience-","cat":"research","name":"University of Cincinnati, Dept of Psychiatry & Behavioral Neuroscience","city":"Cincinnati","region":"Ohio","country":"United States","cc":"US","lat":39.13158,"lon":-84.51453,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"45219","condg":["Depression"],"nct":"NCT05268497","study":"A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant…","sstatus":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT05268497","phase":"Phase 1","start":"2022-09-01","eid":"x:site:nct05268497-university-of-cincinnati-dept-of-psychiatry-behavioral-neuroscience-"},{"id":"nct02918318-unnamed-trial-site-akita","cat":"research","name":"Unnamed trial site","city":"Akita","country":"Japan","cc":"JP","lat":39.71907,"lon":140.10523,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-akita"},{"id":"nct02918318-unnamed-trial-site-fukui-shi","cat":"research","name":"Unnamed trial site","city":"Fukui-shi","country":"Japan","cc":"JP","lat":36.07492,"lon":136.23212,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-fukui-shi"},{"id":"nct02918318-unnamed-trial-site-fukuoka","cat":"research","name":"Unnamed trial site","city":"Fukuoka","country":"Japan","cc":"JP","lat":33.59609,"lon":130.41003,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-fukuoka"},{"id":"nct02918318-unnamed-trial-site-gunma","cat":"research","name":"Unnamed trial site","city":"Gunma","country":"Japan","cc":"JP","lat":36.2229,"lon":139.4764,"gp":"region","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-gunma"},{"id":"nct02918318-unnamed-trial-site-hachinohe-shi","cat":"research","name":"Unnamed trial site","city":"Hachinohe-shi","country":"Japan","cc":"JP","lat":35.6052,"lon":139.576,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-hachinohe-shi"},{"id":"nct02918318-unnamed-trial-site-hachioji-shi","cat":"research","name":"Unnamed trial site","city":"Hachioji-shi","country":"Japan","cc":"JP","lat":35.2483,"lon":139.1996,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-hachioji-shi"},{"id":"nct02918318-unnamed-trial-site-hirakata","cat":"research","name":"Unnamed trial site","city":"Hirakata","country":"Japan","cc":"JP","lat":34.80594,"lon":135.63949,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-hirakata"},{"id":"nct02918318-unnamed-trial-site-hiratsuka-shi","cat":"research","name":"Unnamed trial site","city":"Hiratsuka-shi","country":"Japan","cc":"JP","lat":36.1307,"lon":140.0545,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-hiratsuka-shi"},{"id":"nct02918318-unnamed-trial-site-hokkaido","cat":"research","name":"Unnamed trial site","city":"Hokkaido","country":"Japan","cc":"JP","lat":43.4095,"lon":141.6029,"gp":"region","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-hokkaido"},{"id":"nct02918318-unnamed-trial-site-ibaraki","cat":"research","name":"Unnamed trial site","city":"Ibaraki","country":"Japan","cc":"JP","lat":34.82239,"lon":135.57642,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-ibaraki"},{"id":"nct02918318-unnamed-trial-site-ichikawa","cat":"research","name":"Unnamed trial site","city":"Ichikawa","country":"Japan","cc":"JP","lat":35.74039,"lon":139.90222,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-ichikawa"},{"id":"nct02918318-unnamed-trial-site-kanzaki-gun","cat":"research","name":"Unnamed trial site","city":"Kanzaki-gun","country":"Japan","cc":"JP","lat":35.4483,"lon":139.4623,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-kanzaki-gun"},{"id":"nct02918318-unnamed-trial-site-karatsu","cat":"research","name":"Unnamed trial site","city":"Karatsu","country":"Japan","cc":"JP","lat":33.43841,"lon":129.97174,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-karatsu"},{"id":"nct02918318-unnamed-trial-site-kashihara","cat":"research","name":"Unnamed trial site","city":"Kashihara","country":"Japan","cc":"JP","lat":34.58667,"lon":135.61276,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-kashihara"},{"id":"nct02918318-unnamed-trial-site-kawasaki","cat":"research","name":"Unnamed trial site","city":"Kawasaki","country":"Japan","cc":"JP","lat":35.53134,"lon":139.72263,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-kawasaki"},{"id":"nct02918318-unnamed-trial-site-kita-azumi","cat":"research","name":"Unnamed trial site","city":"Kita-Azumi","country":"Japan","cc":"JP","lat":35.2993,"lon":139.2858,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-kita-azumi"},{"id":"nct02918318-unnamed-trial-site-kita-ku","cat":"research","name":"Unnamed trial site","city":"Kita-ku","country":"Japan","cc":"JP","lat":35.75146,"lon":139.72233,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-kita-ku"},{"id":"nct02918318-unnamed-trial-site-kitakyushu","cat":"research","name":"Unnamed trial site","city":"Kitakyushu","country":"Japan","cc":"JP","lat":33.84066,"lon":130.86215,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-kitakyushu"},{"id":"nct02918318-unnamed-trial-site-kobe","cat":"research","name":"Unnamed trial site","city":"Kobe","country":"Japan","cc":"JP","lat":34.70001,"lon":135.18549,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-kobe"},{"id":"nct02918318-unnamed-trial-site-kochi","cat":"research","name":"Unnamed trial site","city":"Kochi","country":"Japan","cc":"JP","lat":33.53988,"lon":133.52782,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-kochi"},{"id":"nct02918318-unnamed-trial-site-kodaira","cat":"research","name":"Unnamed trial site","city":"Kodaira","country":"Japan","cc":"JP","lat":35.72561,"lon":139.48146,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-kodaira"},{"id":"nct02918318-unnamed-trial-site-komoro-shi","cat":"research","name":"Unnamed trial site","city":"Komoro-shi","country":"Japan","cc":"JP","lat":35.2052,"lon":139.4466,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-komoro-shi"},{"id":"nct02918318-unnamed-trial-site-kumamoto","cat":"research","name":"Unnamed trial site","city":"Kumamoto","country":"Japan","cc":"JP","lat":32.79568,"lon":130.68706,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-kumamoto"},{"id":"nct02918318-unnamed-trial-site-kure","cat":"research","name":"Unnamed trial site","city":"Kure","country":"Japan","cc":"JP","lat":34.23462,"lon":132.56766,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-kure"},{"id":"nct02918318-unnamed-trial-site-kurume-shi","cat":"research","name":"Unnamed trial site","city":"Kurume-shi","country":"Japan","cc":"JP","lat":35.315,"lon":139.3368,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-kurume-shi"},{"id":"nct02918318-unnamed-trial-site-kyoto","cat":"research","name":"Unnamed trial site","city":"Kyoto","country":"Japan","cc":"JP","lat":35.01688,"lon":135.75484,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-kyoto"},{"id":"nct02918318-unnamed-trial-site-maizuru","cat":"research","name":"Unnamed trial site","city":"Maizuru","country":"Japan","cc":"JP","lat":35.4444,"lon":135.33837,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-maizuru"},{"id":"nct02918318-unnamed-trial-site-morioka","cat":"research","name":"Unnamed trial site","city":"Morioka","country":"Japan","cc":"JP","lat":39.70504,"lon":141.14092,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-morioka"},{"id":"nct02918318-unnamed-trial-site-nagakute","cat":"research","name":"Unnamed trial site","city":"Nagakute","country":"Japan","cc":"JP","lat":35.17236,"lon":137.05775,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-nagakute"},{"id":"nct02918318-unnamed-trial-site-nagasaki","cat":"research","name":"Unnamed trial site","city":"Nagasaki","country":"Japan","cc":"JP","lat":32.73894,"lon":129.89185,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-nagasaki"},{"id":"nct02918318-unnamed-trial-site-okayama","cat":"research","name":"Unnamed trial site","city":"Okayama","country":"Japan","cc":"JP","lat":34.65409,"lon":133.93206,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-okayama"},{"id":"nct02918318-unnamed-trial-site-okinawa","cat":"research","name":"Unnamed trial site","city":"Okinawa","country":"Japan","cc":"JP","lat":26.33842,"lon":127.78977,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-okinawa"},{"id":"nct02918318-unnamed-trial-site-osaka","cat":"research","name":"Unnamed trial site","city":"Osaka","country":"Japan","cc":"JP","lat":34.68697,"lon":135.4934,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-osaka"},{"id":"nct02918318-unnamed-trial-site-sapporo","cat":"research","name":"Unnamed trial site","city":"Sapporo","country":"Japan","cc":"JP","lat":43.07622,"lon":141.34336,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-sapporo"},{"id":"nct02918318-unnamed-trial-site-setagaya-ku","cat":"research","name":"Unnamed trial site","city":"Setagaya-ku","country":"Japan","cc":"JP","lat":35.4797,"lon":139.8937,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-setagaya-ku"},{"id":"nct02918318-unnamed-trial-site-shibuya-ku","cat":"research","name":"Unnamed trial site","city":"Shibuya-ku","country":"Japan","cc":"JP","lat":35.464,"lon":139.5486,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-shibuya-ku"},{"id":"nct02918318-unnamed-trial-site-shinjuku","cat":"research","name":"Unnamed trial site","city":"Shinjuku","country":"Japan","cc":"JP","lat":35.69374,"lon":139.70492,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-shinjuku"},{"id":"nct02918318-unnamed-trial-site-shinjuku-ku","cat":"research","name":"Unnamed trial site","city":"Shinjuku-ku","country":"Japan","cc":"JP","lat":35.7424,"lon":139.8584,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-shinjuku-ku"},{"id":"nct02918318-unnamed-trial-site-takatsuki-shi","cat":"research","name":"Unnamed trial site","city":"Takatsuki-shi","country":"Japan","cc":"JP","lat":36.1738,"lon":139.2035,"gp":"country","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-takatsuki-shi"},{"id":"nct02918318-unnamed-trial-site-toyoake","cat":"research","name":"Unnamed trial site","city":"Toyoake","country":"Japan","cc":"JP","lat":35.04812,"lon":136.99672,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-toyoake"},{"id":"nct02918318-unnamed-trial-site-ube","cat":"research","name":"Unnamed trial site","city":"Ube","country":"Japan","cc":"JP","lat":33.93153,"lon":131.24382,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-ube"},{"id":"nct02918318-unnamed-trial-site-yokohama","cat":"research","name":"Unnamed trial site","city":"Yokohama","country":"Japan","cc":"JP","lat":35.42604,"lon":139.64873,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-yokohama"},{"id":"nct02918318-unnamed-trial-site-yonago","cat":"research","name":"Unnamed trial site","city":"Yonago","country":"Japan","cc":"JP","lat":35.43912,"lon":133.32218,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Depression"],"nct":"NCT02918318","study":"A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","official":"Janssen Pharmaceutical K.K., Japan Clinical Trial (Janssen Pharmaceutical K.K.)","src":"https://clinicaltrials.gov/study/NCT02918318","phase":"Phase 2","enroll":202,"start":"2016-12-12","eid":"x:site:nct02918318-unnamed-trial-site-yonago"},{"id":"nct06003218-peking-university-first-hospital-beijing","cat":"research","name":"Peking University First Hospital","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.90068,"lon":116.39125,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100034","condg":["Cancer-related distress"],"nct":"NCT06003218","study":"Dexmedetomidine-esketamine for Percutaneous Radiofrequency Liver Ablation","sstatus":"COMPLETED","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT06003218","phase":"N/A","enroll":88,"start":"2023-10-16","eid":"x:site:nct06003218-peking-university-first-hospital-beijing"},{"id":"nct06531837-beijing-tiantan-hospital-beijing","cat":"research","name":"Beijing Tiantan Hospital","city":"Beijing","country":"China","cc":"CN","lat":39.90388,"lon":116.39982,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100070","condg":["Chronic pain & headache"],"nct":"NCT06531837","study":"Electroencephalographic Characteristics of Chronic Pain in Patients With Spinal Cord Injury","sstatus":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","official":"Ruquan Han, M.D., Ph D (Beijing Tiantan Hospital)","src":"https://clinicaltrials.gov/study/NCT06531837","contact":{"n":"Ruquan Han, M.D., Ph D.","p":"8610-59976660","e":"ruquan.han@ccmu.edu.cn"},"phase":"N/A","enroll":60,"start":"2024-08-25","eid":"x:site:nct06531837-beijing-tiantan-hospital-beijing"},{"id":"nct06278779-royal-prince-alfred-hospital-camperdown","cat":"research","name":"Royal Prince Alfred Hospital","city":"Camperdown","region":"New South Wales","country":"Australia","cc":"AU","lat":-33.87916,"lon":151.18033,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"2050","condg":["Depression"],"status":"RECRUITING","nct":"NCT06278779","study":"Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"The George Institute","official":"Colleen Loo (The University of New South Wales)","src":"https://clinicaltrials.gov/study/NCT06278779","contact":{"n":"Nicollette Thornton","p":"80524300","e":"SLHD-RPA-KetamineClinic@health.nsw.gov.au"},"phase":"Phase 4","enroll":162,"start":"2024-06-03","eid":"x:site:nct06278779-royal-prince-alfred-hospital-camperdown"},{"id":"nct06278779-black-dog-institute-randwick","cat":"research","name":"Black Dog Institute","city":"Randwick","region":"New South Wales","country":"Australia","cc":"AU","lat":-33.91227,"lon":151.24853,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"2031","condg":["Depression"],"status":"RECRUITING","nct":"NCT06278779","study":"Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"The George Institute","official":"Colleen Loo (The University of New South Wales)","src":"https://clinicaltrials.gov/study/NCT06278779","contact":{"n":"Angelo Alonzo","p":"80524300","e":"depressionclinic@blackdog.org.au"},"phase":"Phase 4","enroll":162,"start":"2024-06-03","eid":"x:site:nct06278779-black-dog-institute-randwick"},{"id":"nct06278779-ramsay-clinic-northside-st-leonards","cat":"research","name":"Ramsay Clinic Northside","city":"St Leonards","region":"New South Wales","country":"Australia","cc":"AU","lat":-33.83045,"lon":151.19464,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"2065","condg":["Depression"],"status":"RECRUITING","nct":"NCT06278779","study":"Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"The George Institute","official":"Colleen Loo (The University of New South Wales)","src":"https://clinicaltrials.gov/study/NCT06278779","contact":{"n":"Yalda Pishyar","p":"+61 2 8425 3022","e":"neuroinfo.nsc@ramsayhealth.com.au"},"phase":"Phase 4","enroll":162,"start":"2024-06-03","eid":"x:site:nct06278779-ramsay-clinic-northside-st-leonards"},{"id":"nct06278779-ramsay-clinic-lakeside-warners-bay","cat":"research","name":"Ramsay Clinic Lakeside","city":"Warners Bay","region":"New South Wales","country":"Australia","cc":"AU","lat":-32.96324,"lon":151.64981,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"2282","condg":["Depression"],"status":"RECRUITING","nct":"NCT06278779","study":"Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"The George Institute","official":"Colleen Loo (The University of New South Wales)","src":"https://clinicaltrials.gov/study/NCT06278779","contact":{"n":"Hollie Ritchie","p":"+61 3 4947 5169","e":"ClinicalTrialsUnit.WBP@ramsayhealth.com.au"},"phase":"Phase 4","enroll":162,"start":"2024-06-03","eid":"x:site:nct06278779-ramsay-clinic-lakeside-warners-bay"},{"id":"nct06278779-gold-coast-university-hospital-southport","cat":"research","name":"Gold Coast University Hospital","city":"Southport","region":"Queensland","country":"Australia","cc":"AU","lat":-27.96484,"lon":153.40441,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"4215","condg":["Depression"],"status":"RECRUITING","nct":"NCT06278779","study":"Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"The George Institute","official":"Colleen Loo (The University of New South Wales)","src":"https://clinicaltrials.gov/study/NCT06278779","contact":{"n":"Laura McCosker","p":"+61 417207575","e":"laura.mccosker2@health.qld.gov.au"},"phase":"Phase 4","enroll":162,"start":"2024-06-03","eid":"x:site:nct06278779-gold-coast-university-hospital-southport"},{"id":"nct06278779-ramsay-clinic-albert-road-melbourne","cat":"research","name":"Ramsay Clinic Albert Road","city":"Melbourne","region":"Victoria","country":"Australia","cc":"AU","lat":-37.82299,"lon":144.9628,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"3004","condg":["Depression"],"status":"RECRUITING","nct":"NCT06278779","study":"Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"The George Institute","official":"Colleen Loo (The University of New South Wales)","src":"https://clinicaltrials.gov/study/NCT06278779","contact":{"n":"Melanie Hurley","p":"80524300","e":"research.arc@ramsayhealth.com.au"},"phase":"Phase 4","enroll":162,"start":"2024-06-03","eid":"x:site:nct06278779-ramsay-clinic-albert-road-melbourne"},{"id":"nct06278779-royal-melbourne-hospital-parkville","cat":"research","name":"Royal Melbourne Hospital","city":"Parkville","region":"Victoria","country":"Australia","cc":"AU","lat":-37.79486,"lon":144.95362,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"3052","condg":["Depression"],"status":"RECRUITING","nct":"NCT06278779","study":"Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"The George Institute","official":"Colleen Loo (The University of New South Wales)","src":"https://clinicaltrials.gov/study/NCT06278779","contact":{"n":"Orli Schwartz, Study Coordinator, PHD","p":"61-3-8344-0944","e":"orli@unimelb.edu.au"},"phase":"Phase 4","enroll":162,"start":"2024-06-03","eid":"x:site:nct06278779-royal-melbourne-hospital-parkville"},{"id":"nct07120477-prefeitura-de-indaiatuba-indaiatuba","cat":"research","name":"Prefeitura de Indaiatuba","city":"Indaiatuba","region":"São Paulo","country":"Brazil","cc":"BR","lat":-23.08216,"lon":-47.21628,"gp":"city","unnamed":0,"drugs":["esketamine"],"condg":["Other"],"status":"RECRUITING","nct":"NCT07120477","study":"Esketamine Versus Crisis Response Planning Versus Enhanced Treatment as Usual for Suicide Prevention: A Pragmatic Randomized Trial in a Brazilian Municipality (SAVE)","sstatus":"RECRUITING","sponsor":"University of Sao Paulo","src":"https://clinicaltrials.gov/study/NCT07120477","contact":{"n":"Rodolfo F Damiano, M.D., Ph.D.","p":"+5511933300360","e":"damianorf@usp.br"},"phase":"Phase 4","enroll":478,"start":"2026-06-01","eid":"x:site:nct07120477-prefeitura-de-indaiatuba-indaiatuba"},{"id":"nct03298906-clinical-pharmacology-unit-merksem","cat":"research","name":"Clinical Pharmacology Unit","city":"Merksem","country":"Belgium","cc":"BE","lat":51.23865,"lon":4.45143,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"2170","condg":["Healthy volunteers"],"nct":"NCT03298906","study":"A Study to Assess the Effect of Ticlopidine on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT03298906","phase":"Phase 1","enroll":16,"start":"2017-09-26","eid":"x:site:nct03298906-clinical-pharmacology-unit-merksem"},{"id":"nct06624878-zhejiang-cancer-hospital-hangzhou","cat":"research","name":"Zhejiang cancer hospital","city":"Hangzhou","region":"Zhejiang","country":"China","cc":"CN","lat":30.28956,"lon":120.16598,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"310022","condg":["Depression","Cancer-related distress"],"nct":"NCT06624878","study":"Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer","sstatus":"COMPLETED","sponsor":"Zhejiang Cancer Hospital","src":"https://clinicaltrials.gov/study/NCT06624878","phase":"N/A","enroll":568,"start":"2024-10-08","eid":"x:site:nct06624878-zhejiang-cancer-hospital-hangzhou"},{"id":"nct01980303-unnamed-trial-site-cypress","cat":"research","name":"Unnamed trial site","city":"Cypress","region":"California","country":"United States","cc":"US","lat":29.97763,"lon":-95.69392,"gp":"city","unnamed":1,"drugs":["esketamine"],"condg":["Healthy volunteers"],"nct":"NCT01980303","study":"A Study to Assess the Pharmacokinetics of Intranasally Administered Esketamine in Healthy Japanese and Caucasian Volunteers","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01980303","phase":"Phase 1","enroll":29,"start":"2013-11","eid":"x:site:nct01980303-unnamed-trial-site-cypress"},{"id":"nct06473285-beijing-tiantan-hospital-capital-medical-university-beijing","cat":"research","name":"Beijing Tiantan Hospital, Capital Medical University","city":"Beijing","country":"China","cc":"CN","lat":39.90538,"lon":116.39568,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"100070","condg":["Other"],"status":"RECRUITING","nct":"NCT06473285","study":"Effects of Esketamine on Consciousness-related Brain Network Characteristics in Patients With Prolonged Disorders of Consciousness","sstatus":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","src":"https://clinicaltrials.gov/study/NCT06473285","contact":{"n":"Ruquan Han, M.D., Ph.D","p":"8610-59976660","e":"ruquan.han@gmail.com"},"phase":"N/A","enroll":80,"start":"2024-06-01","eid":"x:site:nct06473285-beijing-tiantan-hospital-capital-medical-university-beijing"},{"id":"nct04303325-the-first-hospital-of-china-medical-university-shenyang","cat":"research","name":"the First Hospital of China Medical University","city":"Shenyang","region":"Liaoning","country":"China","cc":"CN","lat":41.7853,"lon":123.438,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"110001","condg":["Depression"],"status":"RECRUITING","nct":"NCT04303325","study":"Effect of Esketamine on Postoperative Depression、Gut Microbiota、Bispectral Index Data of Depression Patients Undergoing Breast Cancer Operation (ESPOD-BI)","sstatus":"UNKNOWN","sponsor":"China Medical University, China","src":"https://clinicaltrials.gov/study/NCT04303325","contact":{"n":"Wen-fei Tan, M.D.,Ph.D","p":"024-83283100","e":"winfieldtan@hotmail.com"},"phase":"Phase 4","enroll":72,"start":"2021-10-08","eid":"x:site:nct04303325-the-first-hospital-of-china-medical-university-shenyang"},{"id":"nct01022840-medical-university-graz-graz","cat":"research","name":"Medical University Graz","city":"Graz","region":"Styria","country":"Austria","cc":"AT","lat":47.07858,"lon":15.45199,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"8045","condg":["Chronic pain & headache"],"nct":"NCT01022840","study":"The Preemptive Analgetic Potency of Low Dose S-Ketamine","sstatus":"COMPLETED","sponsor":"Medical University of Graz","official":"Mischa Wejbora, MD (Med. U Graz)","src":"https://clinicaltrials.gov/study/NCT01022840","phase":"Phase 3","enroll":60,"start":"2009-02","eid":"x:site:nct01022840-medical-university-graz-graz"},{"id":"nct01022840-medical-university-of-graz-graz","cat":"research","name":"Medical University of Graz","city":"Graz","region":"Styria","country":"Austria","cc":"AT","lat":47.07321,"lon":15.43157,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"8045","condg":["Chronic pain & headache"],"nct":"NCT01022840","study":"The Preemptive Analgetic Potency of Low Dose S-Ketamine","sstatus":"COMPLETED","sponsor":"Medical University of Graz","official":"Mischa Wejbora, MD (Med. U Graz)","src":"https://clinicaltrials.gov/study/NCT01022840","phase":"Phase 3","enroll":60,"start":"2009-02","eid":"x:site:nct01022840-medical-university-of-graz-graz"},{"id":"nct01022840-medical-university-of-graz-graz-2","cat":"research","name":"Medical University of Graz","city":"Graz","country":"Austria","cc":"AT","lat":47.05834,"lon":15.43505,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"8036","condg":["Chronic pain & headache"],"nct":"NCT01022840","study":"The Preemptive Analgetic Potency of Low Dose S-Ketamine","sstatus":"COMPLETED","sponsor":"Medical University of Graz","official":"Mischa Wejbora, MD (Med. U Graz)","src":"https://clinicaltrials.gov/study/NCT01022840","phase":"Phase 3","enroll":60,"start":"2009-02","eid":"x:site:nct01022840-medical-university-of-graz-graz-2"},{"id":"nct04860661-tongji-hospital-wuhan","cat":"research","name":"Tongji Hospital","city":"Wuhan","region":"Hubei","country":"China","cc":"CN","lat":30.57971,"lon":114.26201,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"430000","condg":["Depression"],"nct":"NCT04860661","study":"Esketamine on Postpartum Depression in Cesarean Section Women","sstatus":"COMPLETED","sponsor":"Ailin Luo","official":"Ailin luo, Dr. (Department of Anesthesiology of Tongji Hospital)","src":"https://clinicaltrials.gov/study/NCT04860661","phase":"N/A","enroll":336,"start":"2021-05-01","eid":"x:site:nct04860661-tongji-hospital-wuhan"},{"id":"nct07179913-zhiwen-li-changchun","cat":"research","name":"Zhiwen Li","city":"Changchun","region":"Jilin","country":"China","cc":"CN","lat":43.88795,"lon":125.33092,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"130021","condg":["Depression"],"nct":"NCT07179913","study":"The Improvement of Low-dose Esketamine on Postoperative Depression in Patients Undergoing Bariatric Surgery With Preoperative Depression","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"The First Hospital of Jilin University","official":"Zhiwen Li, Doctor of Medicine (The First Hospital of Jilin University)","src":"https://clinicaltrials.gov/study/NCT07179913","phase":"Phase 4","enroll":40,"start":"2026-05-01","eid":"x:site:nct07179913-zhiwen-li-changchun"},{"id":"nct04829318-fundamos-buenos-aires","cat":"research","name":"FunDaMos","city":"Buenos Aires","country":"Argentina","cc":"AR","lat":-34.61197,"lon":-58.38462,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"C1405BOA","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-fundamos-buenos-aires"},{"id":"nct04829318-cen-consultorios-especializados-en-neurociencias-cordoba","cat":"research","name":"CEN Consultorios Especializados en Neurociencias","city":"Córdoba","country":"Argentina","cc":"AR","lat":-31.40766,"lon":-64.18189,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"5000FJF","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-cen-consultorios-especializados-en-neurociencias-cordoba"},{"id":"nct04829318-fundacion-lennox-cordoba","cat":"research","name":"Fundacion Lennox","city":"Córdoba","country":"Argentina","cc":"AR","lat":-31.40784,"lon":-64.18189,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"5000","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-fundacion-lennox-cordoba"},{"id":"nct04829318-instituto-medico-damic-cordoba","cat":"research","name":"Instituto Medico DAMIC","city":"Córdoba","country":"Argentina","cc":"AR","lat":-31.3957,"lon":-64.17935,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"X5003DCE","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-instituto-medico-damic-cordoba"},{"id":"nct04829318-sanatorio-prof-leon-s-morra-s-a-cordoba","cat":"research","name":"Sanatorio Prof Leon S Morra S A","city":"Córdoba","country":"Argentina","cc":"AR","lat":-31.40813,"lon":-64.19498,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"X5009BIN","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-sanatorio-prof-leon-s-morra-s-a-cordoba"},{"id":"nct04829318-instituto-de-neurociencias-san-agustin-la-plata","cat":"research","name":"Instituto de Neurociencias San Agustin","city":"La Plata","country":"Argentina","cc":"AR","lat":-34.9119,"lon":-57.95466,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1900","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-instituto-de-neurociencias-san-agustin-la-plata"},{"id":"nct04829318-c-i-a-p-centro-de-investigacion-y-asistencia-en-psiquiatria-rosario","cat":"research","name":"C I A P Centro de investigacion y Asistencia en Psiquiatria","city":"Rosario","country":"Argentina","cc":"AR","lat":-32.95063,"lon":-60.63777,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"2000","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-c-i-a-p-centro-de-investigacion-y-asistencia-en-psiquiatria-rosario"},{"id":"nct04829318-anima-alken","cat":"research","name":"Anima","city":"Alken","country":"Belgium","cc":"BE","lat":50.88226,"lon":5.30582,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"3570","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-anima-alken"},{"id":"nct04829318-mental-health-center-rousse-rousse","cat":"research","name":"Mental Health Center - Rousse","city":"Rousse","country":"Bulgaria","cc":"BG","lat":43.85244,"lon":25.95796,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"7003","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-mental-health-center-rousse-rousse"},{"id":"nct04829318-multiprofile-hospital-for-active-treatment-in-neurology-and-psychiat","cat":"research","name":"Multiprofile Hospital for Active Treatment in Neurology and Psychiatry Sveti Naum","city":"Sofia","country":"Bulgaria","cc":"BG","lat":42.70556,"lon":23.33116,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1113","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-multiprofile-hospital-for-active-treatment-in-neurology-and-psychiat"},{"id":"nct04829318-centre-for-mental-health-prof-n-shipkovenski-eood-sofia","cat":"research","name":"Centre for Mental Health Prof.N.Shipkovenski EOOD","city":"Sofia","country":"Bulgaria","cc":"BG","lat":42.69163,"lon":23.33427,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1377","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-centre-for-mental-health-prof-n-shipkovenski-eood-sofia"},{"id":"nct04829318-psychiatricka-ambulance-saint-anne-s-r-o-brno","cat":"research","name":"Psychiatricka ambulance Saint Anne s.r.o.","city":"Brno","country":"Czechia","cc":"CZ","lat":49.19668,"lon":16.60283,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"60200","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-psychiatricka-ambulance-saint-anne-s-r-o-brno"},{"id":"nct04829318-psychiatricka-ambulance-mudr-marta-holanova-brno","cat":"research","name":"Psychiatricka ambulance, MUDr. Marta Holanova","city":"Brno","country":"Czechia","cc":"CZ","lat":49.18369,"lon":16.61676,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"61500","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-psychiatricka-ambulance-mudr-marta-holanova-brno"},{"id":"nct04829318-neuropsychiatriehk-s-r-o-hradec-kralove","cat":"research","name":"NeuropsychiatrieHK, s.r.o.","city":"Hradec Králové","country":"Czechia","cc":"CZ","lat":50.20391,"lon":15.84317,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"50002","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-neuropsychiatriehk-s-r-o-hradec-kralove"},{"id":"nct04829318-a-shine-s-r-o-pilsen","cat":"research","name":"A Shine S R O","city":"Pilsen","country":"Czechia","cc":"CZ","lat":49.75354,"lon":13.37575,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"31200","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-a-shine-s-r-o-pilsen"},{"id":"nct04829318-ad71-s-r-o-prague","cat":"research","name":"AD71 s.r.o.","city":"Prague","country":"Czechia","cc":"CZ","lat":50.08536,"lon":14.41563,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"109 00","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-ad71-s-r-o-prague"},{"id":"nct04829318-medical-services-prague-s-r-o-prague","cat":"research","name":"Medical Services Prague S R O","city":"Prague","country":"Czechia","cc":"CZ","lat":50.08206,"lon":14.41996,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"16000","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-medical-services-prague-s-r-o-prague"},{"id":"nct04829318-institut-neuropsychiatricke-pece-prague","cat":"research","name":"Institut Neuropsychiatricke pece","city":"Prague","country":"Czechia","cc":"CZ","lat":50.09458,"lon":14.41667,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"18600","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-institut-neuropsychiatricke-pece-prague"},{"id":"nct04829318-mederon-ltd-at-artes-helsinki","cat":"research","name":"Mederon LTD at ARTES","city":"Helsinki","country":"Finland","cc":"FI","lat":60.15846,"lon":24.93851,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"00270","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-mederon-ltd-at-artes-helsinki"},{"id":"nct04829318-medizinisches-versorgungszentrum-lio-gmbh-berlin","cat":"research","name":"Medizinisches Versorgungszentrum LiO GmbH","city":"Berlin","country":"Germany","cc":"DE","lat":52.52178,"lon":13.41274,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"12209","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-medizinisches-versorgungszentrum-lio-gmbh-berlin"},{"id":"nct04829318-praxis-dr-med-kirsten-hahn-berlin","cat":"research","name":"Praxis Dr. med. Kirsten Hahn","city":"Berlin","country":"Germany","cc":"DE","lat":52.53477,"lon":13.41171,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"13187","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-praxis-dr-med-kirsten-hahn-berlin"},{"id":"nct04829318-klinikum-dortmund-ggmbh-dortmund","cat":"research","name":"Klinikum Dortmund gGmbH","city":"Dortmund","country":"Germany","cc":"DE","lat":51.50812,"lon":7.47734,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"44287","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-klinikum-dortmund-ggmbh-dortmund"},{"id":"nct04829318-universitatsklinikum-freiburg-abteilung-fur-psychiatrie-u-psychother","cat":"research","name":"Universitätsklinikum Freiburg - Abteilung für Psychiatrie u. Psychotherapie mit Poliklinik","city":"Freiburg im Breisgau","country":"Germany","cc":"DE","lat":47.9903,"lon":7.86111,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"79104","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-universitatsklinikum-freiburg-abteilung-fur-psychiatrie-u-psychother"},{"id":"nct04829318-klinische-forschung-hamburg-hamburg","cat":"research","name":"Klinische Forschung Hamburg","city":"Hamburg","country":"Germany","cc":"DE","lat":53.56264,"lon":9.98742,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"20253","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-klinische-forschung-hamburg-hamburg"},{"id":"nct04829318-oberhavel-kliniken-gmbh-hennigsdorf","cat":"research","name":"Oberhavel Kliniken GmbH","city":"Hennigsdorf","country":"Germany","cc":"DE","lat":52.62869,"lon":13.19445,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"16761","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-oberhavel-kliniken-gmbh-hennigsdorf"},{"id":"nct04829318-pharmakologisches-studienzentrum-chemnitz-gmbh-mittweida","cat":"research","name":"Pharmakologisches Studienzentrum Chemnitz GmbH","city":"Mittweida","country":"Germany","cc":"DE","lat":50.98203,"lon":12.97438,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"09111","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-pharmakologisches-studienzentrum-chemnitz-gmbh-mittweida"},{"id":"nct04829318-danuvius-klinik-pfaffenhofen-fachklinik-fur-psychiatrie-psychotherap","cat":"research","name":"Danuvius Klinik Pfaffenhofen Fachklinik für Psychiatrie, Psychotherapie und Psychosomatik","city":"Pfaffenhofen","country":"Germany","cc":"DE","lat":49.05893,"lon":8.96608,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"85276","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-danuvius-klinik-pfaffenhofen-fachklinik-fur-psychiatrie-psychotherap"},{"id":"nct04829318-somni-bene-gmbh-schwerin","cat":"research","name":"Somni Bene GmbH","city":"Schwerin","country":"Germany","cc":"DE","lat":53.63469,"lon":11.4118,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"19053","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-somni-bene-gmbh-schwerin"},{"id":"nct04829318-klinische-forschung-schwerin-gmbh-schwerin","cat":"research","name":"Klinische Forschung Schwerin GmbH","city":"Schwerin","country":"Germany","cc":"DE","lat":53.62405,"lon":11.41612,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"19055","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-klinische-forschung-schwerin-gmbh-schwerin"},{"id":"nct04829318-psychiatric-clinic-agios-charalampos-heraklion","cat":"research","name":"Psychiatric Clinic 'Agios Charalampos'","city":"Heraklion","country":"Greece","cc":"GR","lat":35.33375,"lon":25.14214,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"71305","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-psychiatric-clinic-agios-charalampos-heraklion"},{"id":"nct04829318-university-general-hospital-of-rio-patras-patrai","cat":"research","name":"University General Hospital of Rio Patras","city":"Pátrai","country":"Greece","cc":"GR","lat":38.2454,"lon":21.73993,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"26504","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-university-general-hospital-of-rio-patras-patrai"},{"id":"nct04829318-g-papanikolaou-hospital-of-thessaloniki-thessaloniki","cat":"research","name":"G Papanikolaou Hospital of Thessaloniki","city":"Thessaloniki","country":"Greece","cc":"GR","lat":40.64717,"lon":22.94524,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"57010","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-g-papanikolaou-hospital-of-thessaloniki-thessaloniki"},{"id":"nct04829318-processus-kft-budapest","cat":"research","name":"Processus Kft","city":"Budapest","country":"Hungary","cc":"HU","lat":47.5095,"lon":19.05141,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"1137","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-processus-kft-budapest"},{"id":"nct04829318-bugat-pal-korhaz-gyongyos","cat":"research","name":"Bugat Pal Korhaz","city":"Gyöngyös","country":"Hungary","cc":"HU","lat":47.77076,"lon":19.92541,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"3200","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-bugat-pal-korhaz-gyongyos"},{"id":"nct04829318-petz-aladar-megyei-oktato-korhaz-gyor","cat":"research","name":"Petz Aladar Megyei Oktato Korhaz","city":"Győr","country":"Hungary","cc":"HU","lat":47.68837,"lon":17.64288,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"H-9024","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-petz-aladar-megyei-oktato-korhaz-gyor"},{"id":"nct04829318-hospital-raja-permaisuri-bainun-ipoh","cat":"research","name":"Hospital Raja Permaisuri Bainun","city":"Ipoh","country":"Malaysia","cc":"MY","lat":4.57652,"lon":101.08812,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"30990","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-hospital-raja-permaisuri-bainun-ipoh"},{"id":"nct04829318-university-malaya-medical-centre-kuala-lumpur","cat":"research","name":"University Malaya Medical Centre","city":"Kuala Lumpur","country":"Malaysia","cc":"MY","lat":3.12958,"lon":101.67942,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"59100","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-university-malaya-medical-centre-kuala-lumpur"},{"id":"nct04829318-hospital-pengajar-universiti-putra-malaysia-serdang","cat":"research","name":"Hospital Pengajar Universiti Putra Malaysia","city":"Serdang","country":"Malaysia","cc":"MY","lat":5.19934,"lon":100.63591,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"43400","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-hospital-pengajar-universiti-putra-malaysia-serdang"},{"id":"nct04829318-hospital-tuanku-jaafar-seremban","cat":"research","name":"Hospital Tuanku Jaafar","city":"Seremban","country":"Malaysia","cc":"MY","lat":2.72476,"lon":101.93137,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"70300","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-hospital-tuanku-jaafar-seremban"},{"id":"nct04829318-mlynowamed-specjalistyczny-psychiatryczny-gabinet-lekarski-joanna-la","cat":"research","name":"Mlynowamed Specjalistyczny Psychiatryczny Gabinet Lekarski Joanna Lazarczyk","city":"Bialystok","country":"Poland","cc":"PL","lat":53.13997,"lon":23.17332,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"15-404","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-mlynowamed-specjalistyczny-psychiatryczny-gabinet-lekarski-joanna-la"},{"id":"nct04829318-osrodek-badan-klinicznych-clinsante-s-c-bydgoszcz","cat":"research","name":"Osrodek Badan Klinicznych CLINSANTE S C","city":"Bydgoszcz","country":"Poland","cc":"PL","lat":53.1131,"lon":18.00249,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"85 794","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-osrodek-badan-klinicznych-clinsante-s-c-bydgoszcz"},{"id":"nct04829318-uniwersyteckie-centrum-kliniczne-gdansk","cat":"research","name":"Uniwersyteckie Centrum Kliniczne","city":"Gdansk","country":"Poland","cc":"PL","lat":54.34912,"lon":18.66018,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"80 214","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-uniwersyteckie-centrum-kliniczne-gdansk"},{"id":"nct04829318-centrum-badan-klinicznych-pi-house-sp-z-o-o-gdansk","cat":"research","name":"Centrum Badan Klinicznych PI House sp z o o","city":"Gdansk","country":"Poland","cc":"PL","lat":54.35458,"lon":18.6535,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"80 546","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-centrum-badan-klinicznych-pi-house-sp-z-o-o-gdansk"},{"id":"nct04829318-centrum-medyczne-care-clinic-katowice-katowice","cat":"research","name":"Centrum Medyczne Care Clinic Katowice","city":"Katowice","country":"Poland","cc":"PL","lat":50.26323,"lon":19.02319,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"40-568","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-centrum-medyczne-care-clinic-katowice-katowice"},{"id":"nct04829318-niepubliczny-zaklad-opieki-psychiatrycznej-mentis-leszno","cat":"research","name":"Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS","city":"Leszno","country":"Poland","cc":"PL","lat":51.8402,"lon":16.56492,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"64-100","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-niepubliczny-zaklad-opieki-psychiatrycznej-mentis-leszno"},{"id":"nct04829318-specjalistyczny-psychiatryczny-zespol-opieki-zdrowotnej-w-lodzi-szpi","cat":"research","name":"Specjalistyczny Psychiatryczny Zespol Opieki Zdrowotnej w Lodzi Szpital im. J. Babinskiego","city":"Lodz","country":"Poland","cc":"PL","lat":51.76065,"lon":19.47023,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"91-229","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-specjalistyczny-psychiatryczny-zespol-opieki-zdrowotnej-w-lodzi-szpi"},{"id":"nct04829318-spzoz-csk-um-w-lodzi-klinika-zaburzen-afektywnych-i-psychotycznych-l","cat":"research","name":"SPZOZ CSK UM w Lodzi Klinika Zaburzen Afektywnych i Psychotycznych","city":"Lodz","country":"Poland","cc":"PL","lat":51.78117,"lon":19.46233,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"92-216","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-spzoz-csk-um-w-lodzi-klinika-zaburzen-afektywnych-i-psychotycznych-l"},{"id":"nct04829318-osrodek-badan-klinicznych-clinsante-s-c-torun","cat":"research","name":"Osrodek Badan Klinicznych CLINSANTE S C","city":"Torun","country":"Poland","cc":"PL","lat":53.01568,"lon":18.59075,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"87 100","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-osrodek-badan-klinicznych-clinsante-s-c-torun"},{"id":"nct04829318-cape-town-clinical-research-centre-cape-town","cat":"research","name":"Cape Town Clinical Research Centre","city":"Cape Town","country":"South Africa","cc":"ZA","lat":-33.91826,"lon":18.41367,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"7530","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-cape-town-clinical-research-centre-cape-town"},{"id":"nct04829318-gert-bosch-pretoria-south-africa-pretoria","cat":"research","name":"Gert Bosch Pretoria South Africa","city":"Pretoria","country":"South Africa","cc":"ZA","lat":-25.74839,"lon":28.1987,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"0 042","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-gert-bosch-pretoria-south-africa-pretoria"},{"id":"nct04829318-severance-hospital-yonsei-university-health-system-seoul","cat":"research","name":"Severance Hospital Yonsei University Health System","city":"Seoul","country":"South Korea","cc":"KR","lat":37.55579,"lon":126.98805,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"03722","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-severance-hospital-yonsei-university-health-system-seoul"},{"id":"nct04829318-samsung-medical-center-seoul","cat":"research","name":"Samsung Medical Center","city":"Seoul","country":"South Korea","cc":"KR","lat":37.56341,"lon":126.97082,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"06351","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-samsung-medical-center-seoul"},{"id":"nct04829318-changhua-christian-hospital-changhua","cat":"research","name":"Changhua Christian Hospital","city":"Changhua","country":"Taiwan","cc":"TW","lat":24.06981,"lon":120.54692,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"500","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-changhua-christian-hospital-changhua"},{"id":"nct04829318-national-taiwan-university-hospital-taipei","cat":"research","name":"National Taiwan University Hospital","city":"Taipei","country":"Taiwan","cc":"TW","lat":25.06007,"lon":121.52728,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"10002","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-national-taiwan-university-hospital-taipei"},{"id":"nct04829318-taipei-veterans-general-hospital-taipei","cat":"research","name":"Taipei Veterans General Hospital","city":"Taipei","country":"Taiwan","cc":"TW","lat":25.05546,"lon":121.52343,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"11217","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-taipei-veterans-general-hospital-taipei"},{"id":"nct04829318-chang-gung-memorial-hospital-taoyuan","cat":"research","name":"Chang Gung Memorial Hospital","city":"Taoyuan","country":"Taiwan","cc":"TW","lat":24.98836,"lon":121.30482,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"333","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-chang-gung-memorial-hospital-taoyuan"},{"id":"nct04829318-hacettepe-university-medical-faculty-ankara","cat":"research","name":"Hacettepe University Medical Faculty","city":"Ankara","country":"Turkey","cc":"TR","lat":39.92406,"lon":32.84745,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"6100","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-hacettepe-university-medical-faculty-ankara"},{"id":"nct04829318-erenkoy-mental-health-hospital-istanbul","cat":"research","name":"Erenkoy Mental Health Hospital","city":"Istanbul","country":"Turkey","cc":"TR","lat":41.00551,"lon":28.9418,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"34736","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-erenkoy-mental-health-hospital-istanbul"},{"id":"nct04829318-liv-hospital-samsun","cat":"research","name":"Liv Hospital","city":"Samsun","country":"Turkey","cc":"TR","lat":41.27228,"lon":36.32542,"gp":"city","unnamed":0,"drugs":["esketamine"],"zip":"55020","condg":["Depression"],"nct":"NCT04829318","study":"A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment","sstatus":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","official":"Janssen-Cilag Ltd. Clinical Trial (Janssen-Cilag Ltd.)","src":"https://clinicaltrials.gov/study/NCT04829318","phase":"Phase 4","enroll":183,"start":"2021-04-26","eid":"x:site:nct04829318-liv-hospital-samsun"},{"id":"nct04480918-university-of-iowa-health-care-iowa-city","cat":"research","name":"University of Iowa Health Care","city":"Iowa City","region":"Iowa","country":"United States","cc":"US","lat":41.66137,"lon":-91.52975,"gp":"city","unnamed":0,"drugs":["esketamine","ketamine"],"zip":"52242","condg":["Depression","OCD","Bipolar"],"status":"RECRUITING","nct":"NCT04480918","study":"University of Iowa Interventional Psychiatry Service Patient Registry","sstatus":"RECRUITING","sponsor":"Mark Niciu","official":"Mark J Niciu, M.D., Ph. D. (University of Iowa Hospitals & Clinics); Nicholas T Trapp, M.D., M.S. (University of Iowa Hospitals & Clinics)","src":"https://clinicaltrials.gov/study/NCT04480918","contact":{"n":"Benjamin Pace, M.S.","p":"319-384-9302","e":"benjamin-pace@uiowa.edu"},"enroll":1000,"start":"2020-11-02","eid":"x:site:nct04480918-university-of-iowa-health-care-iowa-city"},{"id":"nct03380728-ribeirao-preto-medical-school-ribeirao-preto","cat":"research","name":"Ribeirão Preto Medical School","city":"Ribeirão Preto","region":"São Paulo","country":"Brazil","cc":"BR","lat":-21.18479,"lon":-47.80261,"gp":"city","unnamed":0,"drugs":["ibogaine"],"zip":"14048900","condg":["Addiction & substance use"],"nct":"NCT03380728","study":"Ibogaine in the Treatment of Alcoholism: an Open-label Escalating-dose Trial","sstatus":"COMPLETED","sponsor":"University of Sao Paulo","official":"Rafael dos Santos, PhD (Departamento de Neurociências e Ciências do Comportamento, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo); Jaime Hallak, PhD (Departamento de Neurociências e Ciências do Comportamento, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo)","src":"https://clinicaltrials.gov/study/NCT03380728","phase":"Phase 2","enroll":9,"start":"2022-10-30","eid":"x:site:nct03380728-ribeirao-preto-medical-school-ribeirao-preto"},{"id":"nct04003948-hospital-universitari-sant-joan-reus","cat":"research","name":"Hospital Universitari Sant Joan","city":"Reus","region":"Tarragona","country":"Spain","cc":"ES","lat":41.16247,"lon":1.10983,"gp":"city","unnamed":0,"drugs":["ibogaine"],"zip":"43204","condg":["Addiction & substance use"],"nct":"NCT04003948","study":"Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification","sstatus":"COMPLETED","sponsor":"International Center for Ethnobotanical Education, Research, and Service","official":"José Carlos Bouso, PhD (International Center for Ethnobotanical Education, Research, and Service); Tre Borràs, MD (Hospital Universitari Sant Joan de Reus)","src":"https://clinicaltrials.gov/study/NCT04003948","phase":"Phase 2","enroll":20,"start":"2020-10-28","eid":"x:site:nct04003948-hospital-universitari-sant-joan-reus"},{"id":"nct04313712-stanford-university-school-of-medicine-stanford","cat":"research","name":"Stanford University School of Medicine","city":"Stanford","region":"California","country":"United States","cc":"US","lat":37.4267,"lon":-122.17667,"gp":"city","unnamed":0,"drugs":["ibogaine"],"zip":"94305","condg":["PTSD & trauma"],"nct":"NCT04313712","study":"Pre-post Evaluation of the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Repeated Blast Exposure","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Stanford University","official":"Nolan Williams, MD (Stanford University)","src":"https://clinicaltrials.gov/study/NCT04313712","enroll":30,"start":"2021-11-15","eid":"x:site:nct04313712-stanford-university-school-of-medicine-stanford"},{"id":"nct05029401-mac-clinical-research-manchester-early-phase-unit-neuroscience-centr","cat":"research","name":"MAC Clinical Research Manchester (Early Phase Unit), Neuroscience Centre of Excellence","city":"Manchester","region":"Greater Mancherster","country":"United Kingdom","cc":"GB","lat":53.47704,"lon":-2.2467,"gp":"city","unnamed":0,"drugs":["ibogaine"],"zip":"M13 9NQ","condg":["Other"],"nct":"NCT05029401","study":"A Study of Oral Ibogaine in Opioid Withdrawal","sstatus":"COMPLETED","sponsor":"atai Therapeutics, Inc.","src":"https://clinicaltrials.gov/study/NCT05029401","phase":"Phase 1/Phase 2","enroll":116,"start":"2021-04-01","eid":"x:site:nct05029401-mac-clinical-research-manchester-early-phase-unit-neuroscience-centr"},{"id":"nct05029401-hammersmith-medicines-research-hmr-limited-london","cat":"research","name":"Hammersmith Medicines Research (HMR) Limited","city":"London","country":"United Kingdom","cc":"GB","lat":51.51498,"lon":-0.13661,"gp":"city","unnamed":0,"drugs":["ibogaine"],"zip":"NW10 7EW","condg":["Other"],"nct":"NCT05029401","study":"A Study of Oral Ibogaine in Opioid Withdrawal","sstatus":"COMPLETED","sponsor":"atai Therapeutics, Inc.","src":"https://clinicaltrials.gov/study/NCT05029401","phase":"Phase 1/Phase 2","enroll":116,"start":"2021-04-01","eid":"x:site:nct05029401-hammersmith-medicines-research-hmr-limited-london"},{"id":"nct07226570-susan-samueli-integrative-health-institute-university-of-california-","cat":"research","name":"Susan Samueli Integrative Health Institute, University of California, Irvine","city":"Irvine","region":"California","country":"United States","cc":"US","lat":33.66697,"lon":-117.82325,"gp":"city","unnamed":0,"drugs":["ibogaine"],"zip":"92617","condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT07226570","study":"Mapping Ibogaine Neural Dynamics in Opioid Use Disorder","sstatus":"RECRUITING","sponsor":"University of California, Irvine","official":"Richard E Harris, PhD (University of California, Irvine, Susan Samueli Integrative Health Institute)","src":"https://clinicaltrials.gov/study/NCT07226570","contact":{"n":"Charlotte J Lynskey, BA","p":"(949) 824-7000","e":"clynskey@hs.uci.edu"},"enroll":20,"start":"2025-09-08","eid":"x:site:nct07226570-susan-samueli-integrative-health-institute-university-of-california-"},{"id":"nct02664922-ronald-reagan-ucla-medical-center-los-angeles","cat":"research","name":"Ronald Reagan UCLA Medical Center","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.04578,"lon":-118.2426,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"90095","condg":["Other"],"nct":"NCT02664922","study":"Anesthetic Techniques in EP Patients","sstatus":"TERMINATED","sponsor":"University of California, Los Angeles","official":"Aman Mahajan, MD, PhD (University of California, Los Angeles)","src":"https://clinicaltrials.gov/study/NCT02664922","phase":"Phase 4","enroll":35,"start":"2012-05","eid":"x:site:nct02664922-ronald-reagan-ucla-medical-center-los-angeles"},{"id":"nct01942356-university-hospital-san-antonio","cat":"research","name":"University Hospital","city":"San Antonio","region":"Texas","country":"United States","cc":"US","lat":29.41974,"lon":-98.48201,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"78229","condg":["Other"],"nct":"NCT01942356","study":"Evaluation of Closed-loop TIVA Propofol, Sufentanil and Ketamine Guided by BIS Monitor","sstatus":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","official":"Erik Boatman, M.D. (University of Texas)","src":"https://clinicaltrials.gov/study/NCT01942356","phase":"N/A","enroll":4,"start":"2013-09","eid":"x:site:nct01942356-university-hospital-san-antonio"},{"id":"nct00556361-arkansas-children-s-hospital-little-rock","cat":"research","name":"Arkansas Children's Hospital","city":"Little Rock","region":"Arkansas","country":"United States","cc":"US","lat":34.74719,"lon":-92.29886,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"72202","condg":["Other"],"nct":"NCT00556361","study":"Use of Ketamine Prior to Cardiopulmonary Bypass in Children","sstatus":"COMPLETED","sponsor":"Arkansas Children's Hospital Research Institute","official":"Adnan T Bhutta, MD (Arkansas Children's Hospital Research Institute)","src":"https://clinicaltrials.gov/study/NCT00556361","phase":"Phase 2","enroll":24,"start":"2004-07","eid":"x:site:nct00556361-arkansas-children-s-hospital-little-rock"},{"id":"nct02311777-parkland-health-hospital-system-dallas","cat":"research","name":"Parkland Health Hospital System","city":"Dallas","region":"Texas","country":"United States","cc":"US","lat":32.77915,"lon":-96.79815,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"750390","condg":["Chronic pain & headache"],"nct":"NCT02311777","study":"Pre-operative Pregabalin and Ketamine to Prevent Phantom Pain","sstatus":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","official":"Dawood H Nasir, MD (University of Texas Southwestern Medical Center)","src":"https://clinicaltrials.gov/study/NCT02311777","phase":"Phase 3","start":"2015-05-15","eid":"x:site:nct02311777-parkland-health-hospital-system-dallas"},{"id":"nct02311777-utsw-parkland-hospital-dallas","cat":"research","name":"UTSW, Parkland Hospital","city":"Dallas","region":"Texas","country":"United States","cc":"US","lat":32.77831,"lon":-96.81688,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75390","condg":["Chronic pain & headache"],"nct":"NCT02311777","study":"Pre-operative Pregabalin and Ketamine to Prevent Phantom Pain","sstatus":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","official":"Dawood H Nasir, MD (University of Texas Southwestern Medical Center)","src":"https://clinicaltrials.gov/study/NCT02311777","phase":"Phase 3","start":"2015-05-15","eid":"x:site:nct02311777-utsw-parkland-hospital-dallas"},{"id":"nct02556606-michael-e-debakey-va-medical-center-houston-tx-houston","cat":"research","name":"Michael E. DeBakey VA Medical Center, Houston, TX","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.76474,"lon":-95.362,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"77030","condg":["Depression"],"nct":"NCT02556606","study":"Ketamine for Treatment Resistant Late-Life Depression","sstatus":"COMPLETED","sponsor":"VA Office of Research and Development","official":"Sanjay Mathew, MD (Michael E. DeBakey VA Medical Center, Houston, TX)","src":"https://clinicaltrials.gov/study/NCT02556606","phase":"Phase 3","enroll":33,"start":"2015-10-01","eid":"x:site:nct02556606-michael-e-debakey-va-medical-center-houston-tx-houston"},{"id":"nct04852484-aretaieion-university-hospital-athens","cat":"research","name":"Aretaieion University Hospital","city":"Athens","country":"Greece","cc":"GR","lat":37.99416,"lon":23.73608,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"115 28","condg":["Chronic pain & headache"],"nct":"NCT04852484","study":"Morphine Versus Ketamine as Adjuvants in Paravertebral Blocks","sstatus":"UNKNOWN","sponsor":"Aretaieion University Hospital","official":"Kassiani Theodoraki, PhD, DESA (Aretaieion University Hospital)","src":"https://clinicaltrials.gov/study/NCT04852484","phase":"N/A","enroll":90,"start":"2021-04-16","eid":"x:site:nct04852484-aretaieion-university-hospital-athens"},{"id":"nct04852484-kat-general-hospital-of-athens-athens","cat":"research","name":"KAT General Hospital of Athens","city":"Athens","country":"Greece","cc":"GR","lat":37.97534,"lon":23.72685,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Chronic pain & headache"],"nct":"NCT04852484","study":"Morphine Versus Ketamine as Adjuvants in Paravertebral Blocks","sstatus":"UNKNOWN","sponsor":"Aretaieion University Hospital","official":"Kassiani Theodoraki, PhD, DESA (Aretaieion University Hospital)","src":"https://clinicaltrials.gov/study/NCT04852484","phase":"N/A","enroll":90,"start":"2021-04-16","eid":"x:site:nct04852484-kat-general-hospital-of-athens-athens"},{"id":"nct02735343-mike-o-callaghan-federal-medical-center-nellis-air-force-base","cat":"research","name":"Mike O'Callaghan Federal Medical Center","city":"Nellis Air Force Base","region":"Nevada","country":"United States","cc":"US","lat":36.25412,"lon":-115.05556,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"89191","condg":["Chronic pain & headache"],"nct":"NCT02735343","study":"The CHECK Trial: A Comparison of Headache Treatment in the Emergency Department: Compazine Versus Ketamine","sstatus":"TERMINATED","sponsor":"Mike O'Callaghan Military Hospital","official":"Christopher Pitotti, MD (Mike O'Callaghan Federal Medical Center)","src":"https://clinicaltrials.gov/study/NCT02735343","phase":"Phase 3","enroll":5,"start":"2016-08","eid":"x:site:nct02735343-mike-o-callaghan-federal-medical-center-nellis-air-force-base"},{"id":"nct02543983-national-institutes-of-health-clinical-center-bethesda","cat":"research","name":"National Institutes of Health Clinical Center","city":"Bethesda","region":"Maryland","country":"United States","cc":"US","lat":38.98194,"lon":-77.10774,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20892","condg":["Depression","Healthy volunteers"],"status":"RECRUITING","nct":"NCT02543983","study":"Neurobiology of Suicide","sstatus":"RECRUITING","sponsor":"National Institute of Mental Health (NIMH)","official":"Carlos A Zarate, M.D. (National Institute of Mental Health (NIMH))","src":"https://clinicaltrials.gov/study/NCT02543983","contact":{"n":"Carlos Zarate, M.D.","p":"877-646-3644","e":"moodresearch@mail.nih.gov"},"phase":"Phase 2","enroll":325,"start":"2015-12-01","eid":"x:site:nct02543983-national-institutes-of-health-clinical-center-bethesda"},{"id":"nct04746079-mercy-health-st-elizabeth-youngstown-youngstown","cat":"research","name":"Mercy Health St Elizabeth Youngstown","city":"Youngstown","region":"Ohio","country":"United States","cc":"US","lat":41.10265,"lon":-80.64646,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44504","condg":["Other"],"status":"RECRUITING","nct":"NCT04746079","study":"Positive Imagery Therapy and the Incidence of Emergence Reactions With the Use of Ketamine","sstatus":"UNKNOWN","sponsor":"Mercy Health Ohio","official":"Todd Bolotin, MD (Bon Secours Mercy Health)","src":"https://clinicaltrials.gov/study/NCT04746079","contact":{"n":"Todd Bolotin, MD","p":"330-219-3838","e":"tbolotin@gmail.com"},"phase":"N/A","enroll":180,"start":"2021-02-05","eid":"x:site:nct04746079-mercy-health-st-elizabeth-youngstown-youngstown"},{"id":"nct04141696-national-institutes-of-health-clinical-center-bethesda","cat":"research","name":"National Institutes of Health Clinical Center","city":"Bethesda","region":"Maryland","country":"United States","cc":"US","lat":38.98956,"lon":-77.0909,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20892","condg":["Other"],"nct":"NCT04141696","study":"A Proof-of-Concept Trial on the Effect of Ketamine on Fatigue","sstatus":"COMPLETED","sponsor":"National Institute of Nursing Research (NINR)","official":"Leorey N Saligan, C.R.N.P. (National Institute of Nursing Research (NINR))","src":"https://clinicaltrials.gov/study/NCT04141696","phase":"Phase 1/Phase 2","enroll":10,"start":"2021-07-26","eid":"x:site:nct04141696-national-institutes-of-health-clinical-center-bethesda"},{"id":"nct03223220-lankenau-medical-center-wynnewood","cat":"research","name":"Lankenau Medical Center","city":"Wynnewood","region":"Pennsylvania","country":"United States","cc":"US","lat":34.63594,"lon":-97.15529,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"19096","condg":["Neurology & cognition"],"nct":"NCT03223220","study":"Quelling of Excitotoxicity in Acute Stroke With Ketamine","sstatus":"NOT_YET_RECRUITING","sponsor":"Lower Merion Neurology Research Foundation","src":"https://clinicaltrials.gov/study/NCT03223220","contact":{"n":"Sudhir Aggarwal, MD, PhD","p":"484-413-2572","e":"saggarwal@lowermerionneurology.com"},"phase":"Phase 2/Phase 3","enroll":120,"start":"2024-07-01","eid":"x:site:nct03223220-lankenau-medical-center-wynnewood"},{"id":"nct04388774-icahn-school-of-medicine-at-mount-sinai-new-york","cat":"research","name":"Icahn School of Medicine at Mount Sinai","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71498,"lon":-74.00432,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10029","condg":["Other"],"nct":"NCT04388774","study":"Low-Dose Ketamine in Children With ADNP Syndrome","sstatus":"COMPLETED","sponsor":"Alexander Kolevzon","official":"Alexander Kolevzon, MD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT04388774","phase":"Phase 1/Phase 2","enroll":10,"start":"2020-08-19","eid":"x:site:nct04388774-icahn-school-of-medicine-at-mount-sinai-new-york"},{"id":"nct06060210-banha-faculity-of-medicine-banha","cat":"research","name":"Banha faculity of medicine","city":"Banhā","region":"Elqalyoubea","country":"Egypt","cc":"EG","lat":30.45266,"lon":31.18415,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"13511","condg":["Depression","Anxiety"],"nct":"NCT06060210","study":"Impact of Ketamine On Depressive Symptoms In Patients Undergoing Lumbo-peritoneal Shunt Insertion","sstatus":"COMPLETED","sponsor":"Benha University","official":"Fatma Ah Abdelfatah, MD (banha faculity of medicine)","src":"https://clinicaltrials.gov/study/NCT06060210","phase":"Phase 4","enroll":110,"start":"2023-10-29","eid":"x:site:nct06060210-banha-faculity-of-medicine-banha"},{"id":"nct00700076-biological-studies-unit-at-the-va-connecticut-healthcare-system-yale","cat":"research","name":"Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.26731,"lon":-72.95265,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06516","condg":["Healthy volunteers"],"nct":"NCT00700076","study":"Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects","sstatus":"COMPLETED","sponsor":"Yale University","official":"Deepak C D'Souza, M.D. (Yale University)","src":"https://clinicaltrials.gov/study/NCT00700076","phase":"Phase 1","enroll":15,"start":"2008-01-22","eid":"x:site:nct00700076-biological-studies-unit-at-the-va-connecticut-healthcare-system-yale"},{"id":"nct03950817-maimonides-medical-center-brooklyn","cat":"research","name":"Maimonides Medical Center","city":"Brooklyn","region":"New York","country":"United States","cc":"US","lat":40.66088,"lon":-73.95669,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11219","condg":["Chronic pain & headache"],"nct":"NCT03950817","study":"Nebulized Sub-dissociative Dose Ketamine at Three Different Dosing Regimens for Treating Acute Pain in the Pediatric ED","sstatus":"COMPLETED","sponsor":"Antonios Likourezos","official":"John Marshall, MD (Maimonides Medical Center)","src":"https://clinicaltrials.gov/study/NCT03950817","phase":"Phase 4","enroll":80,"start":"2019-05-13","eid":"x:site:nct03950817-maimonides-medical-center-brooklyn"},{"id":"nct01207206-tel-aviv-sourasky-medical-center-pain-medicine-unit-tel-aviv","cat":"research","name":"Tel Aviv Sourasky Medical Center, Pain Medicine Unit","city":"Tel Aviv","country":"Israel","cc":"IL","lat":32.08817,"lon":34.78165,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Cancer-related distress","Chronic pain & headache"],"status":"RECRUITING","nct":"NCT01207206","study":"Oral Ketamine as an Adjuvant to Opioids for Pain Treatment in Cancer Patients","sstatus":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","src":"https://clinicaltrials.gov/study/NCT01207206","contact":{"n":"silviu Brill, M.D","p":"972-3-6974477","e":"silviub@tasmc.health.gov.il"},"phase":"N/A","enroll":50,"start":"2010-10","eid":"x:site:nct01207206-tel-aviv-sourasky-medical-center-pain-medicine-unit-tel-aviv"},{"id":"nct03305055-johns-hopkins-burn-center-baltimore","cat":"research","name":"Johns Hopkins Burn Center","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.294,"lon":-76.62043,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"21224","condg":["PTSD & trauma","Chronic pain & headache"],"nct":"NCT03305055","study":"RCT: Fentanyl Plus Ketamine Versus Fentanyl Alone for Acute Burn Pain","sstatus":"TERMINATED","sponsor":"Johns Hopkins University","official":"James A Fauerbach, PhD (Johns Hopkins University SOM); Kevin Gerold, DOJD (Johns Hopkins University SOM)","src":"https://clinicaltrials.gov/study/NCT03305055","phase":"Phase 4","enroll":4,"start":"2017-12-16","eid":"x:site:nct03305055-johns-hopkins-burn-center-baltimore"},{"id":"nct00520104-javelin-pharmaceuticals-cambridge","cat":"research","name":"Javelin Pharmaceuticals","city":"Cambridge","region":"Massachusetts","country":"United States","cc":"US","lat":42.36649,"lon":-71.10142,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02140","condg":["Other"],"nct":"NCT00520104","study":"Determination of Drug Interactions of Certain Nasal Medications With Intranasal Ketamine","sstatus":"UNKNOWN","sponsor":"Javelin Pharmaceuticals","official":"Javelin Pharmaceuticals (Javelin Pharmaceuticals)","src":"https://clinicaltrials.gov/study/NCT00520104","phase":"Phase 1","enroll":48,"start":"2007-08","eid":"x:site:nct00520104-javelin-pharmaceuticals-cambridge"},{"id":"nct03865550-rothman-institute-philadelphia","cat":"research","name":"Rothman Institute","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.94574,"lon":-75.16762,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"19107","condg":["Other"],"nct":"NCT03865550","study":"Post-op Ketamine Study","sstatus":"UNKNOWN","sponsor":"Rothman Institute Orthopaedics","src":"https://clinicaltrials.gov/study/NCT03865550","phase":"N/A","enroll":75,"start":"2016-03-28","eid":"x:site:nct03865550-rothman-institute-philadelphia"},{"id":"nct06903819-texas-tech-university-health-sciences-center-lubbock-lubbock","cat":"research","name":"Texas Tech University Health Sciences Center Lubbock","city":"Lubbock","region":"Texas","country":"United States","cc":"US","lat":33.58666,"lon":-101.84684,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"79415","condg":["Depression","PTSD & trauma","Addiction & substance use","Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06903819","study":"Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients","sstatus":"RECRUITING","sponsor":"Texas Tech University Health Sciences Center","official":"Max Evan Davis, MD (Texas Tech University Health Sciences Center Department of Orthopaedic Surgery,)","src":"https://clinicaltrials.gov/study/NCT06903819","contact":{"n":"Evan J. Hernandez Project Manager, MBA","p":"806-743-6846","e":"evan.j.hernandez@ttuhsc.edu"},"phase":"Phase 4","enroll":90,"start":"2025-11-06","eid":"x:site:nct06903819-texas-tech-university-health-sciences-center-lubbock-lubbock"},{"id":"nct06903819-university-medical-center-lubbock","cat":"research","name":"University Medical Center","city":"Lubbock","region":"Texas","country":"United States","cc":"US","lat":33.57913,"lon":-101.85672,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"79415","condg":["Depression","PTSD & trauma","Addiction & substance use","Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06903819","study":"Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients","sstatus":"RECRUITING","sponsor":"Texas Tech University Health Sciences Center","official":"Max Evan Davis, MD (Texas Tech University Health Sciences Center Department of Orthopaedic Surgery,)","src":"https://clinicaltrials.gov/study/NCT06903819","contact":{"n":"Ami Knox Program Director of Clinical Research, MBA","p":"806-761-0575","e":"ami.knox@umchealthsystem.com"},"phase":"Phase 4","enroll":90,"start":"2025-11-06","eid":"x:site:nct06903819-university-medical-center-lubbock"},{"id":"nct04099771-the-miriam-hospital-providence","cat":"research","name":"The Miriam Hospital","city":"Providence","region":"Rhode Island","country":"United States","cc":"US","lat":41.81679,"lon":-71.40431,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02905","condg":["Depression"],"status":"RECRUITING","nct":"NCT04099771","study":"Ketamine for Mood Disorders With Suicidal Ideation","sstatus":"UNKNOWN","sponsor":"The Miriam Hospital","official":"Francesca Beaudoin, MD PhD (Rhode Island Hospital)","src":"https://clinicaltrials.gov/study/NCT04099771","contact":{"n":"Principal Investigator","p":"4014444000","e":"Kelly.Wong@Lifespan.org"},"phase":"EARLY_Phase 1","enroll":20,"start":"2019-07-01","eid":"x:site:nct04099771-the-miriam-hospital-providence"},{"id":"nct06597695-massachusetts-general-hospital-chelsea-chelsea","cat":"research","name":"Massachusetts General Hospital, Chelsea","city":"Chelsea","region":"Massachusetts","country":"United States","cc":"US","lat":42.38042,"lon":-71.04351,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02114","condg":["Depression"],"status":"RECRUITING","nct":"NCT06597695","study":"A Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression","sstatus":"RECRUITING","sponsor":"Juliana Zambrano, MD, MPH","official":"Juliana Zambrano, MD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT06597695","contact":{"n":"Juliana zambrano, MD, MPH","p":"6177262000","e":"jzambrano2@mgh.harvard.edu"},"phase":"Phase 1/Phase 2","enroll":10,"start":"2025-07-23","eid":"x:site:nct06597695-massachusetts-general-hospital-chelsea-chelsea"},{"id":"nct03649334-mansoura-university-al-mansurah","cat":"research","name":"Mansoura University","city":"Al Mansurah","region":"DK","country":"Egypt","cc":"EG","lat":31.04103,"lon":31.3845,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"050","condg":["Other"],"nct":"NCT03649334","study":"Ketamine-ketorolac Versus Fentanyl- Ketorolac I.M in Children During Bone Marrow Biopsy","sstatus":"COMPLETED","sponsor":"Mansoura University","official":"Enas A Abd el Motlb, MD (Assisitant Professor)","src":"https://clinicaltrials.gov/study/NCT03649334","phase":"Phase 4","enroll":80,"start":"2018-08-26","eid":"x:site:nct03649334-mansoura-university-al-mansurah"},{"id":"nct06366334-children-s-hospital-of-eastern-ontario-ottawa","cat":"research","name":"Children's Hospital Of Eastern Ontario","city":"Ottawa","region":"Ontario","country":"Canada","cc":"CA","lat":45.41696,"lon":-75.69111,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"K1H 8L1","condg":["Other"],"status":"RECRUITING","nct":"NCT06366334","study":"Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation","sstatus":"UNKNOWN","sponsor":"Children's Hospital of Eastern Ontario","official":"Tyrus Crawford, BA (CHEO)","src":"https://clinicaltrials.gov/study/NCT06366334","contact":{"n":"Maala Bhatt, MD, MSc.","p":"6137377600","e":"mbhatt@cheo.on.ca"},"phase":"N/A","enroll":20,"start":"2024-01-15","eid":"x:site:nct06366334-children-s-hospital-of-eastern-ontario-ottawa"},{"id":"nct07182032-university-hospitals-cleveland-medical-center-cleveland","cat":"research","name":"University Hospitals Cleveland Medical Center","city":"Cleveland","region":"Ohio","country":"United States","cc":"US","lat":41.49729,"lon":-81.69132,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44106","condg":["Chronic pain & headache"],"nct":"NCT07182032","study":"Ketamine in Central Sensitization","sstatus":"WITHDRAWN","sponsor":"University Hospitals Cleveland Medical Center","official":"Adi Cosic, DO (University Hospitals); Morgan Cheeks, MD (University Hosptials)","src":"https://clinicaltrials.gov/study/NCT07182032","phase":"Phase 4","start":"2026-02-01","eid":"x:site:nct07182032-university-hospitals-cleveland-medical-center-cleveland"},{"id":"nct03017248-faculty-of-medicine-of-sousse-sousse","cat":"research","name":"Faculty of medicine of Sousse","city":"Sousse","country":"Tunisia","cc":"TN","lat":35.83645,"lon":10.62979,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"4002","condg":["Chronic pain & headache"],"nct":"NCT03017248","study":"Low-dose Ketamine for Acute Pain in the Emergency Department","sstatus":"UNKNOWN","sponsor":"Faculty of Medicine, Sousse","official":"Hajer KRAIEM, MD (Faculty of medicine of Sousse)","src":"https://clinicaltrials.gov/study/NCT03017248","phase":"Phase 1","enroll":125,"start":"2016-01","eid":"x:site:nct03017248-faculty-of-medicine-of-sousse-sousse"},{"id":"nct04833816-service-anesthesie-reanimation-hopital-nord-marseille","cat":"research","name":"Service Anesthésie Réanimation - Hôpital nord","city":"Marseille","country":"France","cc":"FR","lat":43.29897,"lon":5.38752,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"13015","condg":["PTSD & trauma"],"nct":"NCT04833816","study":"Ketamine Low dOse Evaluation on Morphine Consumption in Traumatic Patient","sstatus":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","official":"Jean Olivier ARNAUD (AP-HM)","src":"https://clinicaltrials.gov/study/NCT04833816","phase":"Phase 3","enroll":140,"start":"2022-08-05","eid":"x:site:nct04833816-service-anesthesie-reanimation-hopital-nord-marseille"},{"id":"nct02000206-pulmonary-institute-rabin-medical-center-beilinson-hospital-petah-ti","cat":"research","name":"Pulmonary Institute, Rabin Medical Center, Beilinson Hospital","city":"Petah Tikva","country":"Israel","cc":"IL","lat":32.07836,"lon":34.89523,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"49100","condg":["Other"],"nct":"NCT02000206","study":"Comparison of Propofol/Alfentanil With Propofol/Ketamine","sstatus":"UNKNOWN","sponsor":"Rabin Medical Center","official":"Mordechai R Kramer, MD (Rabin Medical Center)","src":"https://clinicaltrials.gov/study/NCT02000206","contact":{"n":"Yair Manevich, MD","e":"yair.manevich@gmail.com"},"phase":"N/A","enroll":80,"start":"2014-02","eid":"x:site:nct02000206-pulmonary-institute-rabin-medical-center-beilinson-hospital-petah-ti"},{"id":"nct07139106-new-york-state-psychiatric-institute-new-york","cat":"research","name":"New York State Psychiatric Institute","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71535,"lon":-74.01025,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10032","condg":["Depression"],"nct":"NCT07139106","study":"Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts","sstatus":"NOT_YET_RECRUITING","sponsor":"New York State Psychiatric Institute","src":"https://clinicaltrials.gov/study/NCT07139106","contact":{"n":"Elizabeth A Bartlett, PhD","p":"646-774-7608","e":"BartlettMINDResearch@nyspi.columbia.edu"},"phase":"Phase 4","enroll":12,"start":"2026-10-01","eid":"x:site:nct07139106-new-york-state-psychiatric-institute-new-york"},{"id":"nct04010266-geisinger-medical-center-danville","cat":"research","name":"Geisinger Medical Center","city":"Danville","region":"Pennsylvania","country":"United States","cc":"US","lat":37.82145,"lon":-121.99417,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"17822","condg":["Addiction & substance use","Chronic pain & headache"],"nct":"NCT04010266","study":"RelieVRx for Total Knee Arthroplasty (TKA) for the Reduction of Acute Postoperative Pain and Opioid Use","sstatus":"COMPLETED","sponsor":"AppliedVR Inc.","official":"Dr. Michael Suk (Geisinger Clinic)","src":"https://clinicaltrials.gov/study/NCT04010266","phase":"N/A","enroll":63,"start":"2021-03-01","eid":"x:site:nct04010266-geisinger-medical-center-danville"},{"id":"nct04010266-geisinger-wyoming-valley-medical-center-wilkes-barre","cat":"research","name":"Geisinger Wyoming Valley Medical Center","city":"Wilkes-Barre","region":"Pennsylvania","country":"United States","cc":"US","lat":41.24247,"lon":-75.88992,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"18711","condg":["Addiction & substance use","Chronic pain & headache"],"nct":"NCT04010266","study":"RelieVRx for Total Knee Arthroplasty (TKA) for the Reduction of Acute Postoperative Pain and Opioid Use","sstatus":"COMPLETED","sponsor":"AppliedVR Inc.","official":"Dr. Michael Suk (Geisinger Clinic)","src":"https://clinicaltrials.gov/study/NCT04010266","phase":"N/A","enroll":63,"start":"2021-03-01","eid":"x:site:nct04010266-geisinger-wyoming-valley-medical-center-wilkes-barre"},{"id":"nct04010266-geisinger-south-wilkes-barre-wilkes-barre","cat":"research","name":"Geisinger South Wilkes Barre","city":"Wilkes-Barre","region":"Pennsylvania","country":"United States","cc":"US","lat":41.25546,"lon":-75.87515,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"18765","condg":["Addiction & substance use","Chronic pain & headache"],"nct":"NCT04010266","study":"RelieVRx for Total Knee Arthroplasty (TKA) for the Reduction of Acute Postoperative Pain and Opioid Use","sstatus":"COMPLETED","sponsor":"AppliedVR Inc.","official":"Dr. Michael Suk (Geisinger Clinic)","src":"https://clinicaltrials.gov/study/NCT04010266","phase":"N/A","enroll":63,"start":"2021-03-01","eid":"x:site:nct04010266-geisinger-south-wilkes-barre-wilkes-barre"},{"id":"nct07596095-kartal-dr-lutfi-k-rdar-city-hospital-istanbul","cat":"research","name":"Kartal Dr. Lütfi Kırdar City Hospital","city":"Istanbul","region":"Istanbul","country":"Turkey","cc":"TR","lat":41.01633,"lon":28.95846,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT07596095","study":"Induction Agents in ECT: Effects on Seizure Duration, Quality, and Recovery","sstatus":"COMPLETED","sponsor":"Dr. Lutfi Kirdar Kartal Training and Research Hospital","official":"Gülten Arslan, MD (University of Health Sciences, Kartal Dr. Lütfi Kırdar City Hospital)","src":"https://clinicaltrials.gov/study/NCT07596095","phase":"N/A","enroll":100,"start":"2024-07-17","eid":"x:site:nct07596095-kartal-dr-lutfi-k-rdar-city-hospital-istanbul"},{"id":"nct06745388-corewell-health-william-beaumont-university-hospital-royal-oak","cat":"research","name":"Corewell Health William Beaumont University Hospital","city":"Royal Oak","region":"Michigan","country":"United States","cc":"US","lat":42.49404,"lon":-83.13331,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"48073","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06745388","study":"Magnesium and Cramping","sstatus":"RECRUITING","sponsor":"Corewell Health East","official":"Ray Soto, MD (Corewell Health East)","src":"https://clinicaltrials.gov/study/NCT06745388","contact":{"n":"Ray Soto, MD","p":"248-898-0833","e":"roy.soto@corewellhealth.org"},"phase":"Phase 4","enroll":150,"start":"2025-07-29","eid":"x:site:nct06745388-corewell-health-william-beaumont-university-hospital-royal-oak"},{"id":"nct01833897-new-york-state-psychiatric-institute-new-york","cat":"research","name":"New York State Psychiatric Institute","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72552,"lon":-74.01176,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10032","condg":["Bipolar"],"nct":"NCT01833897","study":"NMDA Antagonists in Bipolar Depression","sstatus":"COMPLETED","sponsor":"New York State Psychiatric Institute","official":"Joshua T Kantrowitz, MD (New York State Psychiatric Institute)","src":"https://clinicaltrials.gov/study/NCT01833897","phase":"Phase 4","enroll":8,"start":"2013-03","eid":"x:site:nct01833897-new-york-state-psychiatric-institute-new-york"},{"id":"nct03979105-hospital-universitario-san-vicente-fundacion-medellin","cat":"research","name":"hospital universitario San Vicente Fundacion","city":"Medellín","region":"Antioquia","country":"Colombia","cc":"CO","lat":6.233,"lon":-75.56525,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Chronic pain & headache"],"nct":"NCT03979105","study":"Cardiovascular Safety After Continuous Ketamine Infusion","sstatus":"COMPLETED","sponsor":"Universidad de Antioquia","official":"Adriana M Cadavid, MD (Anesthesiology Investigator)","src":"https://clinicaltrials.gov/study/NCT03979105","enroll":300,"start":"2017-07-01","eid":"x:site:nct03979105-hospital-universitario-san-vicente-fundacion-medellin"},{"id":"nct03979105-adriana-cadavid-md-medellin","cat":"research","name":"Adriana Cadavid, MD","city":"Medellín","region":"Antiquia","country":"Colombia","cc":"CO","lat":6.25493,"lon":-75.56149,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"050010","condg":["Chronic pain & headache"],"nct":"NCT03979105","study":"Cardiovascular Safety After Continuous Ketamine Infusion","sstatus":"COMPLETED","sponsor":"Universidad de Antioquia","official":"Adriana M Cadavid, MD (Anesthesiology Investigator)","src":"https://clinicaltrials.gov/study/NCT03979105","enroll":300,"start":"2017-07-01","eid":"x:site:nct03979105-adriana-cadavid-md-medellin"},{"id":"nct04701866-jewish-general-hospital-montreal","cat":"research","name":"Jewish General Hospital","city":"Montreal","region":"Quebec","country":"Canada","cc":"CA","lat":45.50268,"lon":-73.5776,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"H3T 1E2","condg":["Depression","Bipolar"],"nct":"NCT04701866","study":"Music as an Intervention to Improve Hemodynamic Tolerability of Ketamine in Depression","sstatus":"COMPLETED","sponsor":"Douglas Mental Health University Institute","official":"Stéphane Richard-Devantoy, MD, PhD (Douglas Mental Health University Insitute)","src":"https://clinicaltrials.gov/study/NCT04701866","phase":"N/A","enroll":32,"start":"2021-01-11","eid":"x:site:nct04701866-jewish-general-hospital-montreal"},{"id":"nct04701866-douglas-mental-health-university-institute-montreal","cat":"research","name":"Douglas Mental Health University Institute","city":"Montreal","region":"Quebec","country":"Canada","cc":"CA","lat":45.5198,"lon":-73.59096,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"H4H 1R3","condg":["Depression","Bipolar"],"nct":"NCT04701866","study":"Music as an Intervention to Improve Hemodynamic Tolerability of Ketamine in Depression","sstatus":"COMPLETED","sponsor":"Douglas Mental Health University Institute","official":"Stéphane Richard-Devantoy, MD, PhD (Douglas Mental Health University Insitute)","src":"https://clinicaltrials.gov/study/NCT04701866","phase":"N/A","enroll":32,"start":"2021-01-11","eid":"x:site:nct04701866-douglas-mental-health-university-institute-montreal"},{"id":"nct03296345-ucsf-benioff-children-s-hospital-and-research-center-oakland-oakland","cat":"research","name":"UCSF Benioff Children's Hospital and Research Center Oakland","city":"Oakland","region":"California","country":"United States","cc":"US","lat":37.80282,"lon":-122.27367,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94609","condg":["Other"],"nct":"NCT03296345","study":"Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis","sstatus":"COMPLETED","sponsor":"UCSF Benioff Children's Hospital Oakland","official":"Jonathan B Cooper-Sood, MD (Children's Hospital and Research Center of Oakland)","src":"https://clinicaltrials.gov/study/NCT03296345","phase":"Phase 2","enroll":62,"start":"2016-06","eid":"x:site:nct03296345-ucsf-benioff-children-s-hospital-and-research-center-oakland-oakland"},{"id":"nct00387556-the-childrens-hospital-denver","cat":"research","name":"The Childrens Hospital","city":"Denver","region":"Colorado","country":"United States","cc":"US","lat":39.73619,"lon":-104.99406,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"80218","condg":["Other"],"nct":"NCT00387556","study":"Ondansetron Reduce Vomiting Associated With Ketamine PSA","sstatus":"COMPLETED","sponsor":"University of Colorado, Denver","official":"Joe E Wathen, MD (University of Colorado Health Science Center)","src":"https://clinicaltrials.gov/study/NCT00387556","phase":"N/A","enroll":268,"start":"2002-12","eid":"x:site:nct00387556-the-childrens-hospital-denver"},{"id":"nct04877977-national-institutes-of-health-clinical-center-bethesda","cat":"research","name":"National Institutes of Health Clinical Center","city":"Bethesda","region":"Maryland","country":"United States","cc":"US","lat":38.98458,"lon":-77.09786,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20892","condg":["Depression"],"status":"RECRUITING","nct":"NCT04877977","study":"Long-term Observation of Participants With Mood Disorders","sstatus":"RECRUITING","sponsor":"National Institute of Mental Health (NIMH)","official":"Elizabeth D Ballard, Ph.D. (National Institute of Mental Health (NIMH))","src":"https://clinicaltrials.gov/study/NCT04877977","contact":{"n":"Elizabeth Ballard, Ph.D.","p":"301-435-9399","e":"elizabeth.ballard@nih.gov"},"enroll":1000,"start":"2021-08-17","eid":"x:site:nct04877977-national-institutes-of-health-clinical-center-bethesda"},{"id":"nct01538745-brooke-army-medical-center-san-antonio","cat":"research","name":"Brooke Army Medical Center","city":"San Antonio","region":"Texas","country":"United States","cc":"US","lat":29.42887,"lon":-98.5045,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"78234","condg":["Chronic pain & headache"],"nct":"NCT01538745","study":"Low Dose Ketamine (LDK) Versus Morphine for Acute Pain Control in the Emergency Department","sstatus":"COMPLETED","sponsor":"Brooke Army Medical Center","official":"Joshua P Miller, MD (United States Air Force)","src":"https://clinicaltrials.gov/study/NCT01538745","phase":"Phase 4","enroll":45,"start":"2012-02","eid":"x:site:nct01538745-brooke-army-medical-center-san-antonio"},{"id":"nct04053400-walter-reed-national-military-medical-center-bethesda","cat":"research","name":"Walter Reed National Military Medical Center","city":"Bethesda","region":"Maryland","country":"United States","cc":"US","lat":38.97121,"lon":-77.1085,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20889","condg":["Chronic pain & headache"],"nct":"NCT04053400","study":"Evaluating Ketamine and Psychological Sequelae","sstatus":"COMPLETED","sponsor":"Defense and Veterans Center for Integrative Pain Management","src":"https://clinicaltrials.gov/study/NCT04053400","enroll":159,"start":"2014-12","eid":"x:site:nct04053400-walter-reed-national-military-medical-center-bethesda"},{"id":"nct07691372-q-pharm-pty-ltd-brisbane","cat":"research","name":"Q-Pharm Pty Ltd.","city":"Brisbane","region":"Queensland","country":"Australia","cc":"AU","lat":-27.46469,"lon":153.02268,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"4006","condg":["Healthy volunteers"],"nct":"NCT07691372","study":"Pharmacokinetics and Safety of Single-Dose Wafermine™ (Ketamine Sublingual Wafer) in Healthy Subjects","sstatus":"NOT_YET_RECRUITING","sponsor":"iX Biopharma Ltd.","official":"Janakan Krishnarajah, MD ()","src":"https://clinicaltrials.gov/study/NCT07691372","contact":{"n":"Michael Wong, MD","p":"+61 (07) 3707 2720","e":"m.wong@nucleusnetwork.com.au"},"phase":"Phase 1","enroll":14,"start":"2026-06-09","eid":"x:site:nct07691372-q-pharm-pty-ltd-brisbane"},{"id":"nct02063620-duzce-univercity-medical-fauculty-duzce","cat":"research","name":"Duzce Univercity Medical Fauculty","city":"Düzce","country":"Turkey","cc":"TR","lat":40.84694,"lon":31.16977,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"81600","condg":["Other"],"nct":"NCT02063620","study":"The Effect of Anesthetic Agents Management on ECG Changes of Patients Who Were Operated Under RIVA","sstatus":"COMPLETED","sponsor":"Duzce University","official":"Gokce Akman Kose (Duzce University School of Medicine)","src":"https://clinicaltrials.gov/study/NCT02063620","phase":"N/A","enroll":60,"start":"2013-10","eid":"x:site:nct02063620-duzce-univercity-medical-fauculty-duzce"},{"id":"nct04600089-university-of-kentucky-medical-center-lexington","cat":"research","name":"University of Kentucky Medical Center","city":"Lexington","region":"Kentucky","country":"United States","cc":"US","lat":37.98714,"lon":-84.47268,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"40536","condg":["Chronic pain & headache"],"nct":"NCT04600089","study":"Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI","sstatus":"COMPLETED","sponsor":"Eric Johnson","official":"Anna Rockich, Pharm D (University of Kentucky); Samuel Tyagi, MD (University of Kentucky)","src":"https://clinicaltrials.gov/study/NCT04600089","phase":"Phase 2","enroll":21,"start":"2020-12-08","eid":"x:site:nct04600089-university-of-kentucky-medical-center-lexington"},{"id":"nct05337618-university-of-cincinnati-cincinnati","cat":"research","name":"University of Cincinnati","city":"Cincinnati","region":"Ohio","country":"United States","cc":"US","lat":39.12857,"lon":-84.50578,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45267","condg":["PTSD & trauma","Neurology & cognition"],"status":"RECRUITING","nct":"NCT05337618","study":"Improving Neurotrauma by Depolarization Inhibition With Combination Therapy (INDICT)","sstatus":"RECRUITING","sponsor":"University of Cincinnati","src":"https://clinicaltrials.gov/study/NCT05337618","contact":{"n":"Jed A Hartings, PhD","p":"513-295-2370","e":"jed.hartings@uc.edu"},"phase":"Phase 2","enroll":72,"start":"2022-12-16","eid":"x:site:nct05337618-university-of-cincinnati-cincinnati"},{"id":"nct04658420-ut-health-east-texas-tyler","cat":"research","name":"UT Health East Texas","city":"Tyler","region":"Texas","country":"United States","cc":"US","lat":32.35893,"lon":-95.29602,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75703","condg":["Depression"],"nct":"NCT04658420","study":"A Single Ketamine Infusion Combined With Music for Suicidal Ideation","sstatus":"UNKNOWN","sponsor":"The University of Texas Health Science Center at Tyler","official":"Richard Idell, MD (University of Texas Health Science Center at Tyler)","src":"https://clinicaltrials.gov/study/NCT04658420","contact":{"n":"Richard Idell, MD","p":"281-608-8348","e":"richard.idell@uthct.edu"},"phase":"Phase 2","enroll":200,"start":"2021-07-01","eid":"x:site:nct04658420-ut-health-east-texas-tyler"},{"id":"nct06665568-university-hospital-zurich-zurich","cat":"research","name":"University Hospital Zurich","city":"Zurich","region":"Canton of Zurich","country":"Switzerland","cc":"CH","lat":47.3686,"lon":8.54704,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"8091","condg":["Depression","Anxiety"],"nct":"NCT06665568","study":"Effects of Intranasal Ketamine on Depression and Anxiety in Palliative Care Cancer Patients","sstatus":"NOT_YET_RECRUITING","sponsor":"University of Zurich","src":"https://clinicaltrials.gov/study/NCT06665568","contact":{"n":"Caroline Hertler, MD, PhD","p":"+41 44 255 13 35.","e":"caroline.hertler@usz.ch"},"phase":"EARLY_Phase 1","enroll":100,"start":"2025-04","eid":"x:site:nct06665568-university-hospital-zurich-zurich"},{"id":"nct02635282-le-bonheur-children-s-hospital-memphis","cat":"research","name":"Le Bonheur Children's Hospital","city":"Memphis","region":"Tennessee","country":"United States","cc":"US","lat":35.14355,"lon":-90.05194,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"38105","condg":["Chronic pain & headache"],"nct":"NCT02635282","study":"IN Ketamine Vs IN Midazolam and Fentanyl for Abscess I&D","sstatus":"COMPLETED","sponsor":"University of Tennessee","src":"https://clinicaltrials.gov/study/NCT02635282","phase":"Phase 4","enroll":19,"start":"2016-08","eid":"x:site:nct02635282-le-bonheur-children-s-hospital-memphis"},{"id":"nct07706478-senz-doorn","cat":"research","name":"SENZ","city":"Doorn","region":"Utrecht","country":"Netherlands","cc":"NL","lat":52.04129,"lon":5.35319,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"3941ZS","condg":["Depression"],"status":"RECRUITING","nct":"NCT07706478","study":"Working Mechanisms and Effectiveness of IV Ketamine-assisted Psychotherapy on Depression in TRD Clients","sstatus":"RECRUITING","sponsor":"Senz","official":"Rutger Engels (Senz)","src":"https://clinicaltrials.gov/study/NCT07706478","contact":{"n":"Rutger Engels, dr","p":"+31 343 235300","e":"r.engels@senzggz.nl"},"enroll":120,"start":"2025-06-01","eid":"x:site:nct07706478-senz-doorn"},{"id":"nct01094990-phramongkutklao-hospital-bangkok","cat":"research","name":"Phramongkutklao hospital","city":"Bangkok","region":"Bangkok","country":"Thailand","cc":"TH","lat":13.75902,"lon":100.50478,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10400","condg":["Other"],"nct":"NCT01094990","study":"Efficacy of Dexamethasone for Prevent Vomiting in Leukemic Children Who Receive Intrathecal Chemotherapy","sstatus":"COMPLETED","sponsor":"CHANCHAI TRAIVAREE","official":"chanchai traivaree, MD (Phramongkutklao College of Medicine and Hospital)","src":"https://clinicaltrials.gov/study/NCT01094990","phase":"Phase 4","enroll":32,"start":"2011-04","eid":"x:site:nct01094990-phramongkutklao-hospital-bangkok"},{"id":"nct01094990-phramongkutklao-hospital-bangkok-2","cat":"research","name":"Phramongkutklao Hospital","city":"Bangkok","region":"Bangkok","country":"Thailand","cc":"TH","lat":13.75393,"lon":100.51118,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT01094990","study":"Efficacy of Dexamethasone for Prevent Vomiting in Leukemic Children Who Receive Intrathecal Chemotherapy","sstatus":"COMPLETED","sponsor":"CHANCHAI TRAIVAREE","official":"chanchai traivaree, MD (Phramongkutklao College of Medicine and Hospital)","src":"https://clinicaltrials.gov/study/NCT01094990","phase":"Phase 4","enroll":32,"start":"2011-04","eid":"x:site:nct01094990-phramongkutklao-hospital-bangkok-2"},{"id":"nct05582213-ain-shams-university-cairo","cat":"research","name":"Ain Shams University","city":"Cairo","country":"Egypt","cc":"EG","lat":30.06832,"lon":31.24228,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT05582213","study":"Effect of Ketamine Versus Sevoflurane On The Right Ventricular Pressure","sstatus":"COMPLETED","sponsor":"Ain Shams University","src":"https://clinicaltrials.gov/study/NCT05582213","phase":"N/A","enroll":40,"start":"2022-10-01","eid":"x:site:nct05582213-ain-shams-university-cairo"},{"id":"nct06731647-centre-hospitalier-universitaire-d-amiens-amiens","cat":"research","name":"Centre Hospitalier Universitaire d'Amiens","city":"Amiens","country":"France","cc":"FR","lat":49.89572,"lon":2.29167,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"80054","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06731647","study":"Non-steroidal Anti-inflammatory Drugs in Pleurodesis","sstatus":"RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","src":"https://clinicaltrials.gov/study/NCT06731647","contact":{"n":"Florent LEVIEL, MD","p":"33 3 22 08 91 09","e":"leviel.florent@chu-amiens.fr"},"phase":"Phase 2","enroll":358,"start":"2025-02-01","eid":"x:site:nct06731647-centre-hospitalier-universitaire-d-amiens-amiens"},{"id":"nct02378740-northwestern-memorial-hospital-chicago","cat":"research","name":"Northwestern Memorial Hospital","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.84885,"lon":-87.65537,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60611","condg":["Chronic pain & headache"],"nct":"NCT02378740","study":"Ketamine in Patients Undergoing Anterior Cervical Discectomy and Fusion","sstatus":"WITHDRAWN","sponsor":"Northwestern University","official":"Natalie Moreland, MD (Northwestern University)","src":"https://clinicaltrials.gov/study/NCT02378740","phase":"Phase 4","start":"2015-04","eid":"x:site:nct02378740-northwestern-memorial-hospital-chicago"},{"id":"nct02289248-connecticut-mental-health-center-new-haven","cat":"research","name":"Connecticut Mental Health Center","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31093,"lon":-72.93188,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06519","condg":["Depression"],"nct":"NCT02289248","study":"Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine","sstatus":"COMPLETED","sponsor":"Yale University","official":"Samuel Wilkinson, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT02289248","phase":"Phase 1","enroll":16,"start":"2015-02","eid":"x:site:nct02289248-connecticut-mental-health-center-new-haven"},{"id":"nct02289248-yale-psychiatric-hospital-new-haven","cat":"research","name":"Yale Psychiatric Hospital","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.29982,"lon":-72.93771,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06519","condg":["Depression"],"nct":"NCT02289248","study":"Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine","sstatus":"COMPLETED","sponsor":"Yale University","official":"Samuel Wilkinson, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT02289248","phase":"Phase 1","enroll":16,"start":"2015-02","eid":"x:site:nct02289248-yale-psychiatric-hospital-new-haven"},{"id":"nct02317341-national-institutes-of-health-clinical-center-9000-rockville-pike-be","cat":"research","name":"National Institutes of Health Clinical Center, 9000 Rockville Pike","city":"Bethesda","region":"Maryland","country":"United States","cc":"US","lat":38.96942,"lon":-77.10972,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20892","condg":["Cancer-related distress"],"nct":"NCT02317341","study":"Effect of Ketamine on Fatigue Following Cancer Therapy","sstatus":"TERMINATED","sponsor":"National Institute of Nursing Research (NINR)","official":"Leorey N Saligan, C.R.N.P. (National Institute of Nursing Research (NINR))","src":"https://clinicaltrials.gov/study/NCT02317341","phase":"EARLY_Phase 1","enroll":2,"start":"2014-12-13","eid":"x:site:nct02317341-national-institutes-of-health-clinical-center-9000-rockville-pike-be"},{"id":"nct01101659-unnamed-trial-site-neuss","cat":"research","name":"Unnamed trial site","city":"Neuss","country":"Germany","cc":"DE","lat":51.19303,"lon":6.67972,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT01101659","study":"Ketamine Challenge Study With JNJ-40411813","sstatus":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","official":"Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial (Johnson & Johnson Pharmaceutical Research & Development, L.L.C.)","src":"https://clinicaltrials.gov/study/NCT01101659","phase":"Phase 1","enroll":40,"start":"2010-02","eid":"x:site:nct01101659-unnamed-trial-site-neuss"},{"id":"nct06767566-magee-womens-hospital-of-upmc-pittsburgh","cat":"research","name":"Magee Womens Hospital of UPMC","city":"Pittsburgh","region":"Pennsylvania","country":"United States","cc":"US","lat":40.43229,"lon":-80.00375,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"15213","condg":["Depression","Chronic pain & headache"],"status":"TERMINATED","nct":"NCT06767566","study":"Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery","sstatus":"RECRUITING","sponsor":"University of Utah","official":"Grace Lim, MD, MSc (University of Utah)","src":"https://clinicaltrials.gov/study/NCT06767566","contact":{"n":"Natalie Bennion, MPH","p":"385-209-1185","e":"natalie.bennion@utah.edu"},"phase":"Phase 1","enroll":50,"start":"2025-03-28","eid":"x:site:nct06767566-magee-womens-hospital-of-upmc-pittsburgh"},{"id":"nct06767566-university-of-utah-salt-lake-city","cat":"research","name":"University of Utah","city":"Salt Lake City","region":"Utah","country":"United States","cc":"US","lat":40.7501,"lon":-111.88696,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"84132","condg":["Depression","Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06767566","study":"Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery","sstatus":"RECRUITING","sponsor":"University of Utah","official":"Grace Lim, MD, MSc (University of Utah)","src":"https://clinicaltrials.gov/study/NCT06767566","contact":{"n":"Natalie R Bennion, MPH","p":"385-209-1185","e":"natalie.bennion@utah.edu"},"phase":"Phase 1","enroll":50,"start":"2025-03-28","eid":"x:site:nct06767566-university-of-utah-salt-lake-city"},{"id":"nct03194594-wonwanguh-iksan","cat":"research","name":"WonwangUH","city":"Iksan","region":"Jeollabuk-do","country":"South Korea","cc":"KR","lat":35.93829,"lon":126.94564,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"570-711","condg":["Depression"],"nct":"NCT03194594","study":"Dexamethasone and Ketamine on Change of Postoperative Mood","sstatus":"COMPLETED","sponsor":"Wonkwang University Hospital","official":"Cheol Lee, M.D.,Ph.D (Wonkwang UH)","src":"https://clinicaltrials.gov/study/NCT03194594","phase":"Phase 4","enroll":93,"start":"2017-05-02","eid":"x:site:nct03194594-wonwanguh-iksan"},{"id":"nct07530146-kasr-al-aini-hospital-cairo","cat":"research","name":"Kasr Al Aini Hospital","city":"Cairo","country":"Egypt","cc":"EG","lat":30.07058,"lon":31.24332,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"RECRUITING","nct":"NCT07530146","study":"Comparative Efficacy and Safety of Propofol-Ketamine Combination Versus Propofol Monotherapy in Geriatric Patients Under Invasive Ventilation","sstatus":"RECRUITING","sponsor":"Helwan University","src":"https://clinicaltrials.gov/study/NCT07530146","contact":{"n":"Ahmed Elsaeed Elshall","p":"+201002998841","e":"dr.ahmedelshall@gmail.com"},"phase":"Phase 3","enroll":70,"start":"2026-05-13","eid":"x:site:nct07530146-kasr-al-aini-hospital-cairo"},{"id":"nct04814888-pusan-national-university-yangsan-hospital-yangsan","cat":"research","name":"Pusan National University Yangsan Hospital","city":"Yangsan","country":"South Korea","cc":"KR","lat":35.33931,"lon":129.02911,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT04814888","study":"3D Airway Model for Pediatric Patients","sstatus":"COMPLETED","sponsor":"Pusan National University Yangsan Hospital","official":"Hee Young Kim (Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University)","src":"https://clinicaltrials.gov/study/NCT04814888","enroll":35,"start":"2019-09-03","eid":"x:site:nct04814888-pusan-national-university-yangsan-hospital-yangsan"},{"id":"nct05522673-national-institutes-of-health-clinical-center-bethesda","cat":"research","name":"National Institutes of Health Clinical Center","city":"Bethesda","region":"Maryland","country":"United States","cc":"US","lat":38.99079,"lon":-77.10473,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20892","condg":["Depression"],"nct":"NCT05522673","study":"[11C]-(R)-Rolipram to Measure cAMP Signaling Before and After Ketamine","sstatus":"TERMINATED","sponsor":"National Institute of Mental Health (NIMH)","official":"Robert B Innis, M.D. (National Institute of Mental Health (NIMH))","src":"https://clinicaltrials.gov/study/NCT05522673","phase":"Phase 1","enroll":1,"start":"2023-02-08","eid":"x:site:nct05522673-national-institutes-of-health-clinical-center-bethesda"},{"id":"nct06011746-tanta-university-tanta","cat":"research","name":"Tanta University","city":"Tanta","region":"El-Gharbia","country":"Egypt","cc":"EG","lat":30.7808,"lon":31.00197,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"31527","condg":["Chronic pain & headache"],"nct":"NCT06011746","study":"Adding Ketamine to Levobupivacaine in Paravertebral Block in Thoracotomy","sstatus":"COMPLETED","sponsor":"Tanta University","src":"https://clinicaltrials.gov/study/NCT06011746","phase":"Phase 4","enroll":60,"start":"2023-08-30","eid":"x:site:nct06011746-tanta-university-tanta"},{"id":"nct06620042-cleveland-clinic-lutheran-hospital-cleveland","cat":"research","name":"Cleveland Clinic Lutheran Hospital","city":"Cleveland","region":"Ohio","country":"United States","cc":"US","lat":41.48835,"lon":-81.69141,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44113","condg":["Depression","Bipolar"],"nct":"NCT06620042","study":"FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression","sstatus":"COMPLETED","sponsor":"Brian Barnett","official":"Brian Barnett, MD (The Cleveland Clinic)","src":"https://clinicaltrials.gov/study/NCT06620042","phase":"Phase 2","enroll":20,"start":"2024-11-12","eid":"x:site:nct06620042-cleveland-clinic-lutheran-hospital-cleveland"},{"id":"nct06620042-cleveland-clinic-lutheran-hospital-ohio-city","cat":"research","name":"Cleveland Clinic Lutheran Hospital","city":"Ohio City","region":"Ohio","country":"United States","cc":"US","lat":41.43784,"lon":-81.73536,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44113","condg":["Depression","Bipolar"],"nct":"NCT06620042","study":"FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression","sstatus":"COMPLETED","sponsor":"Brian Barnett","official":"Brian Barnett, MD (The Cleveland Clinic)","src":"https://clinicaltrials.gov/study/NCT06620042","phase":"Phase 2","enroll":20,"start":"2024-11-12","eid":"x:site:nct06620042-cleveland-clinic-lutheran-hospital-ohio-city"},{"id":"nct00344682-center-for-psychopharmacologic-research-and-treatment-university-of-","cat":"research","name":"Center for Psychopharmacologic Research and Treatment (University of Massachusetts Medical School)","city":"Worcester","region":"Massachusetts","country":"United States","cc":"US","lat":42.26113,"lon":-71.8109,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"01605","condg":["Depression"],"nct":"NCT00344682","study":"Memantine Augmentation of Antidepressants","sstatus":"COMPLETED","sponsor":"University of Massachusetts, Worcester","official":"Kristina M Deligiannidis, M.D. (University of Massachusetts, Worcester)","src":"https://clinicaltrials.gov/study/NCT00344682","phase":"Phase 4","enroll":31,"start":"2006-06","eid":"x:site:nct00344682-center-for-psychopharmacologic-research-and-treatment-university-of-"},{"id":"nct01477242-seoul-national-university-hospital-seoul","cat":"research","name":"Seoul National University Hospital","city":"Seoul","country":"South Korea","cc":"KR","lat":37.56416,"lon":126.98729,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"110744","condg":["Other"],"status":"RECRUITING","nct":"NCT01477242","study":"The Effect of Ondansetron During Intramuscular Ketamine Use in Children: A Trial in Emergency Department","sstatus":"UNKNOWN","sponsor":"Seoul National University Hospital","official":"Do Kyun Kim, M.D. (Seoul National University Hospital)","src":"https://clinicaltrials.gov/study/NCT01477242","contact":{"n":"Do Kyun Kim, M.D.","p":"82-2-2072-0238","e":"birdbeak@naver.com"},"phase":"N/A","enroll":266,"start":"2011-11","eid":"x:site:nct01477242-seoul-national-university-hospital-seoul"},{"id":"nct06410599-universitatsklinikum-tubingen-klinik-fur-psychiatrie-und-psychothera","cat":"research","name":"Universitätsklinikum Tübingen - Klinik für Psychiatrie und Psychotherapie","city":"Tübingen","region":"Baden-Würtemberg","country":"Germany","cc":"DE","lat":48.51772,"lon":9.05104,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"72070","condg":["Depression"],"status":"RECRUITING","nct":"NCT06410599","study":"Pharmacologic Treatment Augmentation in Chronic Depression","sstatus":"RECRUITING","sponsor":"University Hospital Tuebingen","official":"Martin Walter, Prof. Dr. (Universitätsklinikum Jena - Klinik für Psychiatrie und Psychotherapie); Andreas J Fallgatter, Prof. Dr. (Universitätsklinikum Tübingen - Klinik für Psychiatrie und Psychotherapie)","src":"https://clinicaltrials.gov/study/NCT06410599","contact":{"n":"Andreas J Fallgatter, Prof. Dr.","p":"+4970712984858","e":"andreas.fallgatter@med.uni-tuebingen.de"},"phase":"Phase 2","enroll":60,"start":"2024-04-29","eid":"x:site:nct06410599-universitatsklinikum-tubingen-klinik-fur-psychiatrie-und-psychothera"},{"id":"nct06410599-universitatsklinikum-jena-klinik-fur-psychiatrie-und-psychotherapie-","cat":"research","name":"Universitätsklinikum Jena - Klinik für Psychiatrie und Psychotherapie","city":"Jena","region":"Thuringia","country":"Germany","cc":"DE","lat":50.92657,"lon":11.60143,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"07743","condg":["Depression"],"status":"RECRUITING","nct":"NCT06410599","study":"Pharmacologic Treatment Augmentation in Chronic Depression","sstatus":"RECRUITING","sponsor":"University Hospital Tuebingen","official":"Martin Walter, Prof. Dr. (Universitätsklinikum Jena - Klinik für Psychiatrie und Psychotherapie); Andreas J Fallgatter, Prof. Dr. (Universitätsklinikum Tübingen - Klinik für Psychiatrie und Psychotherapie)","src":"https://clinicaltrials.gov/study/NCT06410599","contact":{"n":"Martin Walter, Prof. Dr.","p":"+49 36419390101","e":"martin.walter@med.uni-jena.de"},"phase":"Phase 2","enroll":60,"start":"2024-04-29","eid":"x:site:nct06410599-universitatsklinikum-jena-klinik-fur-psychiatrie-und-psychotherapie-"},{"id":"nct05444036-october-6-university-hospital-giza","cat":"research","name":"October 6 University Hospital","city":"Giza","region":"Cairo Governorate","country":"Egypt","cc":"EG","lat":30.01024,"lon":31.19859,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT05444036","study":"Caudal Ketamine-bupivacaine More Effective Than Bupivacaine-saline","sstatus":"COMPLETED","sponsor":"Egymedicalpedia","official":"Nirvana Elshalakany, Professor (Department of Anesthesia and I.C.U. faculty of Medicine October six university, Egypt)","src":"https://clinicaltrials.gov/study/NCT05444036","phase":"Phase 1","enroll":60,"start":"2018-09-01","eid":"x:site:nct05444036-october-6-university-hospital-giza"},{"id":"nct07294092-university-of-pittsburgh-pittsburgh","cat":"research","name":"University of Pittsburgh","city":"Pittsburgh","region":"Pennsylvania","country":"United States","cc":"US","lat":40.4337,"lon":-80.00243,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"15213","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT07294092","study":"Ketamine and Propofol NeuroImaging","sstatus":"RECRUITING","sponsor":"Keith M Vogt","official":"Keith M Vogt, MD, PhD (University of Pittsburgh)","src":"https://clinicaltrials.gov/study/NCT07294092","contact":{"n":"Keith M Vogt, MD, PhD","p":"4126473147","e":"kev18@pitt.edu"},"phase":"EARLY_Phase 1","enroll":60,"start":"2026-04-10","eid":"x:site:nct07294092-university-of-pittsburgh-pittsburgh"},{"id":"nct07222007-uf-health-jacksonville-shands-hospital-jacksonville","cat":"research","name":"UF Health Jacksonville (Shands Hospital)","city":"Jacksonville","region":"Florida","country":"United States","cc":"US","lat":30.32112,"lon":-81.64638,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"32209","condg":["Other"],"status":"RECRUITING","nct":"NCT07222007","study":"Induction Agent Choice With Early Mortality and Prognostic Outcomes in Critically Ill Patients","sstatus":"RECRUITING","sponsor":"Zeliha Alicikus","official":"TOLGA SARAÇOĞLU, Prof,MD (Florida University Jacksonville)","src":"https://clinicaltrials.gov/study/NCT07222007","contact":{"n":"TOLGA Saraçoğlu, prof,md","p":"904-524-5932","e":"kemaltolgasaracoglu@gmail.com"},"enroll":4,"start":"2026-04-18","eid":"x:site:nct07222007-uf-health-jacksonville-shands-hospital-jacksonville"},{"id":"nct02636218-st-michael-s-hospital-toronto","cat":"research","name":"St Michael's Hospital","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.71787,"lon":-79.39982,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M5B 1W8","condg":["Other"],"nct":"NCT02636218","study":"Ketamine Infusion in Neurologic Deficit","sstatus":"COMPLETED","sponsor":"Unity Health Toronto","official":"Andrew Baker, MD, FRCPC (Unity Health Toronto)","src":"https://clinicaltrials.gov/study/NCT02636218","phase":"Phase 2/Phase 3","enroll":9,"start":"2016-01-26","eid":"x:site:nct02636218-st-michael-s-hospital-toronto"},{"id":"nct02410460-mercy-facial-plastic-surgery-center-springfield","cat":"research","name":"Mercy Facial Plastic Surgery Center","city":"Springfield","region":"Missouri","country":"United States","cc":"US","lat":37.22281,"lon":-93.30968,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"65804","condg":["Other"],"nct":"NCT02410460","study":"Anesthetics in Rhytidoplasty - A Comparison Study","sstatus":"COMPLETED","sponsor":"Mercy Facial Plastic Surgery Center","src":"https://clinicaltrials.gov/study/NCT02410460","phase":"N/A","enroll":30,"start":"2013-09","eid":"x:site:nct02410460-mercy-facial-plastic-surgery-center-springfield"},{"id":"nct05802979-ainshams-university-hospitals-cairo","cat":"research","name":"AinShams University Hospitals","city":"Cairo","country":"Egypt","cc":"EG","lat":30.0655,"lon":31.26045,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Chronic pain & headache"],"nct":"NCT05802979","study":"Ketamine Versus Neostigmine as Adjuvants to Bupivacaine During Ultrasound-guided Serratus Anterior Block","sstatus":"UNKNOWN","sponsor":"Ain Shams University","official":"Mohammed S Abd El Aziz, M.D. (AinShams University)","src":"https://clinicaltrials.gov/study/NCT05802979","phase":"Phase 3","enroll":80,"start":"2023-01-01","eid":"x:site:nct05802979-ainshams-university-hospitals-cairo"},{"id":"nct01244880-pfizer-investigational-site-new-haven","cat":"research","name":"Pfizer Investigational Site","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31554,"lon":-72.91654,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06510","condg":["Healthy volunteers"],"nct":"NCT01244880","study":"Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy Subjects","sstatus":"TERMINATED","sponsor":"Pfizer","official":"Pfizer CT.gov Call Center (Pfizer)","src":"https://clinicaltrials.gov/study/NCT01244880","phase":"Phase 1","enroll":4,"start":"2011-04","eid":"x:site:nct01244880-pfizer-investigational-site-new-haven"},{"id":"nct01244880-pfizer-investigational-site-new-haven-2","cat":"research","name":"Pfizer Investigational Site","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.29831,"lon":-72.93207,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06519","condg":["Healthy volunteers"],"nct":"NCT01244880","study":"Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy Subjects","sstatus":"TERMINATED","sponsor":"Pfizer","official":"Pfizer CT.gov Call Center (Pfizer)","src":"https://clinicaltrials.gov/study/NCT01244880","phase":"Phase 1","enroll":4,"start":"2011-04","eid":"x:site:nct01244880-pfizer-investigational-site-new-haven-2"},{"id":"nct01244880-pfizer-investigational-site-new-haven-3","cat":"research","name":"Pfizer Investigational Site","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.30302,"lon":-72.93894,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06520","condg":["Healthy volunteers"],"nct":"NCT01244880","study":"Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy Subjects","sstatus":"TERMINATED","sponsor":"Pfizer","official":"Pfizer CT.gov Call Center (Pfizer)","src":"https://clinicaltrials.gov/study/NCT01244880","phase":"Phase 1","enroll":4,"start":"2011-04","eid":"x:site:nct01244880-pfizer-investigational-site-new-haven-3"},{"id":"nct04239963-mclean-hospital-belmont","cat":"research","name":"McLean Hospital","city":"Belmont","region":"Massachusetts","country":"United States","cc":"US","lat":37.52722,"lon":-122.26935,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02478","condg":["Depression"],"nct":"NCT04239963","study":"Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression","sstatus":"COMPLETED","sponsor":"Mclean Hospital","official":"Diego Pizzagalli, PhD (Mclean Hospital)","src":"https://clinicaltrials.gov/study/NCT04239963","enroll":60,"start":"2020-08-17","eid":"x:site:nct04239963-mclean-hospital-belmont"},{"id":"nct07648771-stanford-health-care-stanford","cat":"research","name":"Stanford Health Care","city":"Stanford","region":"California","country":"United States","cc":"US","lat":37.43197,"lon":-122.16321,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94305","condg":["Chronic pain & headache"],"nct":"NCT07648771","study":"Outcomes Registry After Ketamine Infusions for Chronic Pain: A Longitudinal Evaluation","sstatus":"NOT_YET_RECRUITING","sponsor":"Stanford University","src":"https://clinicaltrials.gov/study/NCT07648771","contact":{"n":"Protocol Director","p":"650-264-9442","e":"tlii@stanford.edu"},"enroll":800,"start":"2026-10","eid":"x:site:nct07648771-stanford-health-care-stanford"},{"id":"nct03336398-1051-riverside-drive-new-york","cat":"research","name":"1051 Riverside Drive","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71667,"lon":-74.0015,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10032","condg":["Other"],"nct":"NCT03336398","study":"Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus","sstatus":"COMPLETED","sponsor":"New York State Psychiatric Institute","official":"Diana Martinez (NYSPI/Columbia University)","src":"https://clinicaltrials.gov/study/NCT03336398","phase":"Phase 2","enroll":42,"start":"2019-09-01","eid":"x:site:nct03336398-1051-riverside-drive-new-york"},{"id":"nct03844906-sage-investigational-site-long-beach","cat":"research","name":"Sage Investigational Site","city":"Long Beach","region":"California","country":"United States","cc":"US","lat":33.77774,"lon":-118.18325,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"90806","condg":["Healthy volunteers"],"nct":"NCT03844906","study":"A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy Subjects","sstatus":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","src":"https://clinicaltrials.gov/study/NCT03844906","phase":"Phase 1","enroll":40,"start":"2018-12-27","eid":"x:site:nct03844906-sage-investigational-site-long-beach"},{"id":"nct03844906-sage-investigational-site-berlin","cat":"research","name":"Sage Investigational Site","city":"Berlin","region":"New Jersey","country":"United States","cc":"US","lat":44.4578,"lon":-71.19614,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"08009","condg":["Healthy volunteers"],"nct":"NCT03844906","study":"A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy Subjects","sstatus":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","src":"https://clinicaltrials.gov/study/NCT03844906","phase":"Phase 1","enroll":40,"start":"2018-12-27","eid":"x:site:nct03844906-sage-investigational-site-berlin"},{"id":"nct02431663-anna-rosati-florence","cat":"research","name":"Anna Rosati","city":"Florence","country":"Italy","cc":"IT","lat":43.77092,"lon":11.23426,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"50139","condg":["Neurology & cognition"],"nct":"NCT02431663","study":"Ketamine in Refractory Convulsive Status Epilepticus","sstatus":"TERMINATED","sponsor":"Meyer Children's Hospital IRCCS","official":"Anna Rosati, MD, PhD (Children's Hospital A. Meyer of Firenze, Italy)","src":"https://clinicaltrials.gov/study/NCT02431663","phase":"Phase 3","enroll":57,"start":"2015-04","eid":"x:site:nct02431663-anna-rosati-florence"},{"id":"nct07450430-boston-children-s-hospital-brookline","cat":"research","name":"Boston Children's Hospital","city":"Brookline","region":"Massachusetts","country":"United States","cc":"US","lat":42.32277,"lon":-71.12902,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02445","condg":["Other"],"nct":"NCT07450430","study":"Optimal Timing of Ketamine Initiation for SCD Pain","sstatus":"NOT_YET_RECRUITING","sponsor":"Boston Children's Hospital","official":"Natasha Archer (Boston Children's Hospital)","src":"https://clinicaltrials.gov/study/NCT07450430","contact":{"n":"Natasha Archer","p":"617-632-3023","e":"natasha.archer@childrens.harvard.edu"},"phase":"Phase 3","enroll":90,"start":"2026-02","eid":"x:site:nct07450430-boston-children-s-hospital-brookline"},{"id":"nct01546051-pra-international-zuidlaren","cat":"research","name":"PRA International","city":"Zuidlaren","country":"Netherlands","cc":"NL","lat":53.09563,"lon":6.69328,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"9471 GP","condg":["Healthy volunteers"],"nct":"NCT01546051","study":"A Study of BCI-838 and Several BCI-632 Prodrugs in Healthy Volunteers","sstatus":"COMPLETED","sponsor":"BrainCells Inc.","official":"Principal Investigator (PRA Health Sciences)","src":"https://clinicaltrials.gov/study/NCT01546051","phase":"Phase 1","enroll":31,"start":"2011-10","eid":"x:site:nct01546051-pra-international-zuidlaren"},{"id":"nct06741930-haseki-training-and-research-hospital-istanbul","cat":"research","name":"Haseki Training and Research Hospital","city":"Istanbul","region":"Istanbul","country":"Turkey","cc":"TR","lat":41.01398,"lon":28.94961,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"34265","condg":["Neurology & cognition"],"nct":"NCT06741930","study":"Pro-Epileptic Effects of IV Ketamine","sstatus":"COMPLETED","sponsor":"Haseki Training and Research Hospital","src":"https://clinicaltrials.gov/study/NCT06741930","phase":"Phase 4","enroll":300,"start":"2024-12-01","eid":"x:site:nct06741930-haseki-training-and-research-hospital-istanbul"},{"id":"nct03788694-james-j-peters-va-medical-center-the-bronx","cat":"research","name":"James J. Peters VA Medical Center","city":"The Bronx","region":"New York","country":"United States","cc":"US","lat":40.8595,"lon":-73.87737,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10468","condg":["Other"],"nct":"NCT03788694","study":"Intranasal Ketamine for Suicidal Ideation in Veterans","sstatus":"WITHDRAWN","sponsor":"Bronx Veterans Medical Research Foundation, Inc","src":"https://clinicaltrials.gov/study/NCT03788694","phase":"EARLY_Phase 1","start":"2020-01-01","eid":"x:site:nct03788694-james-j-peters-va-medical-center-the-bronx"},{"id":"nct06090422-department-of-addiction-university-hospital-of-north-norway-troms","cat":"research","name":"Department of Addiction, University Hospital of North Norway","city":"Tromsø","country":"Norway","cc":"NO","lat":69.64754,"lon":18.94844,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression","Addiction & substance use"],"status":"RECRUITING","nct":"NCT06090422","study":"Ketamine for Combined Depression and Alcohol Use Disorder","sstatus":"RECRUITING","sponsor":"University Hospital of North Norway","official":"Ole K Grønli, Assoc Prof (University Hospital of North Norway); Andreas W Blomkvist, M.D. (University Hospital of North Norway)","src":"https://clinicaltrials.gov/study/NCT06090422","contact":{"n":"Andreas W Blomkvist, Senior consultant","p":"+4741694637","e":"andreas.wahl.blomkvist@unn.no"},"phase":"Phase 1/Phase 2","enroll":34,"start":"2025-01-20","eid":"x:site:nct06090422-department-of-addiction-university-hospital-of-north-norway-troms"},{"id":"nct05591001-amany-hassan-saleh-giza","cat":"research","name":"Amany Hassan Saleh","city":"Giza","country":"Egypt","cc":"EG","lat":30.01438,"lon":31.20461,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02","condg":["Other"],"nct":"NCT05591001","study":"Effects of Anesthetic Infusion on the Amplitude of Motor Evoked Potential in Pediatrics Undergoing Tethered Spinal Cord Surgeries","sstatus":"COMPLETED","sponsor":"Cairo University","src":"https://clinicaltrials.gov/study/NCT05591001","phase":"Phase 1","enroll":46,"start":"2022-10-30","eid":"x:site:nct05591001-amany-hassan-saleh-giza"},{"id":"nct02418702-naval-medical-center-san-diego-san-diego","cat":"research","name":"Naval Medical Center San Diego","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.71378,"lon":-117.15394,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"92134","condg":["Depression"],"nct":"NCT02418702","study":"A Study to Decrease Suicidal Thinking Using Ketamine","sstatus":"WITHDRAWN","sponsor":"United States Naval Medical Center, San Diego","official":"Marc A Capobianco (United States Naval Medical Center, San Diego)","src":"https://clinicaltrials.gov/study/NCT02418702","phase":"Phase 3","start":"2016-08","eid":"x:site:nct02418702-naval-medical-center-san-diego-san-diego"},{"id":"nct07670507-albany-medical-center-emergency-department-albany","cat":"research","name":"Albany Medical Center Emergency Department","city":"Albany","region":"New York","country":"United States","cc":"US","lat":42.64839,"lon":-73.76522,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"12208","condg":["Chronic pain & headache"],"nct":"NCT07670507","study":"Pilot Randomized Control Trial Comparing Oral Ketamine and Oral Oxycodone for Pain Control in Emergency Department Patients","sstatus":"NOT_YET_RECRUITING","sponsor":"Albany Medical College","src":"https://clinicaltrials.gov/study/NCT07670507","contact":{"n":"Michael Waxman, MD","p":"518-262-3443","e":"waxmanm@amc.edu"},"phase":"Phase 2/Phase 3","enroll":60,"start":"2026-06-24","eid":"x:site:nct07670507-albany-medical-center-emergency-department-albany"},{"id":"nct03714620-loyola-university-medical-center-maywood","cat":"research","name":"Loyola University Medical Center","city":"Maywood","region":"Illinois","country":"United States","cc":"US","lat":33.98889,"lon":-118.18107,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60153","condg":["Chronic pain & headache"],"nct":"NCT03714620","study":"Sub-dissociative Dose Ketamine Dosing Study","sstatus":"COMPLETED","sponsor":"Loyola University","official":"Shannon Lovett, MD (Loyola University Chicago, LUMC)","src":"https://clinicaltrials.gov/study/NCT03714620","phase":"Phase 4","enroll":98,"start":"2018-10-15","eid":"x:site:nct03714620-loyola-university-medical-center-maywood"},{"id":"nct07435077-wake-forest-university-health-sciences-winston-salem","cat":"research","name":"Wake Forest University Health Sciences","city":"Winston-Salem","region":"North Carolina","country":"United States","cc":"US","lat":36.11073,"lon":-80.23561,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"27157","condg":["Addiction & substance use"],"nct":"NCT07435077","study":"Examining Analgesic Synergy and Efficacy in Trauma Care","sstatus":"NOT_YET_RECRUITING","sponsor":"Wake Forest University Health Sciences","official":"Matthew Painter, MD, FACS (Wake Forest University Health Sciences)","src":"https://clinicaltrials.gov/study/NCT07435077","contact":{"n":"D'Ann B Hershel, MS","p":"336-716-1659","e":"Dann.Hershel@wfusm.edu"},"phase":"Phase 4","enroll":282,"start":"2026-10","eid":"x:site:nct07435077-wake-forest-university-health-sciences-winston-salem"},{"id":"nct06989567-children-s-national-hospital-washington-d-c","cat":"research","name":"Children's National Hospital","city":"Washington D.C.","region":"District of Columbia","country":"United States","cc":"US","lat":38.89949,"lon":-77.0431,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20010","condg":["Other"],"nct":"NCT06989567","study":"A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis","sstatus":"NOT_YET_RECRUITING","sponsor":"Asklepion Pharmaceuticals, LLC","official":"Suvankar Majumdar, MD (Center for Cancer and Blood Disorders, Children's National Hospital)","src":"https://clinicaltrials.gov/study/NCT06989567","contact":{"n":"Suvankar Majumdar, MD","p":"+1 202-476-3800","e":"smajumdar@childrensnational.org"},"phase":"Phase 3","enroll":120,"start":"2025-07-25","eid":"x:site:nct06989567-children-s-national-hospital-washington-d-c"},{"id":"nct06989567-university-of-miami-coral-gables","cat":"research","name":"University of Miami","city":"Coral Gables","region":"Florida","country":"United States","cc":"US","lat":25.72558,"lon":-80.26702,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"33146","condg":["Other"],"nct":"NCT06989567","study":"A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis","sstatus":"NOT_YET_RECRUITING","sponsor":"Asklepion Pharmaceuticals, LLC","official":"Suvankar Majumdar, MD (Center for Cancer and Blood Disorders, Children's National Hospital)","src":"https://clinicaltrials.gov/study/NCT06989567","contact":{"n":"Ofelia Alvarez, MD","p":"+1 305-243-0846","e":"oalvarex2@med.miami.edu"},"phase":"Phase 3","enroll":120,"start":"2025-07-25","eid":"x:site:nct06989567-university-of-miami-coral-gables"},{"id":"nct06989567-emory-university-atlanta","cat":"research","name":"Emory University","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.75516,"lon":-84.38464,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"30322","condg":["Other"],"nct":"NCT06989567","study":"A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis","sstatus":"NOT_YET_RECRUITING","sponsor":"Asklepion Pharmaceuticals, LLC","official":"Suvankar Majumdar, MD (Center for Cancer and Blood Disorders, Children's National Hospital)","src":"https://clinicaltrials.gov/study/NCT06989567","contact":{"n":"Claudia Morris, MD","p":"+1 404-727-5500","e":"claudia.r.morris@emory.edu"},"phase":"Phase 3","enroll":120,"start":"2025-07-25","eid":"x:site:nct06989567-emory-university-atlanta"},{"id":"nct06989567-johns-hopkins-hospital-baltimore","cat":"research","name":"Johns Hopkins Hospital","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.2988,"lon":-76.61525,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"21287","condg":["Other"],"nct":"NCT06989567","study":"A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis","sstatus":"NOT_YET_RECRUITING","sponsor":"Asklepion Pharmaceuticals, LLC","official":"Suvankar Majumdar, MD (Center for Cancer and Blood Disorders, Children's National Hospital)","src":"https://clinicaltrials.gov/study/NCT06989567","contact":{"n":"Kemi Badaki-Makun, MD, PhD","p":"+1 410-955-6146","e":"obadaki2@jhmi.edu"},"phase":"Phase 3","enroll":120,"start":"2025-07-25","eid":"x:site:nct06989567-johns-hopkins-hospital-baltimore"},{"id":"nct06989567-children-s-hospital-of-michigan-detroit","cat":"research","name":"Children's Hospital of Michigan","city":"Detroit","region":"Michigan","country":"United States","cc":"US","lat":42.32197,"lon":-83.05681,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"48201","condg":["Other"],"nct":"NCT06989567","study":"A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis","sstatus":"NOT_YET_RECRUITING","sponsor":"Asklepion Pharmaceuticals, LLC","official":"Suvankar Majumdar, MD (Center for Cancer and Blood Disorders, Children's National Hospital)","src":"https://clinicaltrials.gov/study/NCT06989567","contact":{"n":"Alexander Glaros, MD","p":"+1 313-745-5515","e":"glaro1a@cmich.edu"},"phase":"Phase 3","enroll":120,"start":"2025-07-25","eid":"x:site:nct06989567-children-s-hospital-of-michigan-detroit"},{"id":"nct06989567-east-carolina-university-of-north-carolina-greenville","cat":"research","name":"East Carolina (University of North Carolina)","city":"Greenville","region":"North Carolina","country":"United States","cc":"US","lat":35.61017,"lon":-77.36197,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"27858","condg":["Other"],"nct":"NCT06989567","study":"A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis","sstatus":"NOT_YET_RECRUITING","sponsor":"Asklepion Pharmaceuticals, LLC","official":"Suvankar Majumdar, MD (Center for Cancer and Blood Disorders, Children's National Hospital)","src":"https://clinicaltrials.gov/study/NCT06989567","contact":{"n":"Beng Fuh, MD","p":"+1 252-744-2335","e":"fuhb@ecu.edu"},"phase":"Phase 3","enroll":120,"start":"2025-07-25","eid":"x:site:nct06989567-east-carolina-university-of-north-carolina-greenville"},{"id":"nct06986109-sir-ganga-ram-hospital-new-delhi","cat":"research","name":"Sir Ganga Ram Hospital","city":"New Delhi","region":"National Capital Territory of Delhi","country":"India","cc":"IN","lat":28.61916,"lon":77.22162,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"110060","condg":["Other"],"nct":"NCT06986109","study":"Effect of Subanaesthetic Dose of Ketamine on Depth of Anaesthesia Consistency","sstatus":"COMPLETED","sponsor":"Sir Ganga Ram Hospital","official":"Nitin Sethi, DNB (Sir Ganga Ram Hospital, New Delhi, INDIA); Amitabh Dutta, MD, PGDHR (Sir Ganga Ram Hospital, New Delhi, INDIA)","src":"https://clinicaltrials.gov/study/NCT06986109","phase":"N/A","enroll":106,"start":"2025-05-26","eid":"x:site:nct06986109-sir-ganga-ram-hospital-new-delhi"},{"id":"nct05855798-cukurova-university-adana","cat":"research","name":"Cukurova University","city":"Adana","region":"Adana","country":"Turkey","cc":"TR","lat":36.99759,"lon":35.32338,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"01330","condg":["Other"],"nct":"NCT05855798","study":"Ketamine and Magnesium in Erector Spinae Plane Block","sstatus":"COMPLETED","sponsor":"Cukurova University","src":"https://clinicaltrials.gov/study/NCT05855798","phase":"Phase 4","enroll":60,"start":"2023-05-10","eid":"x:site:nct05855798-cukurova-university-adana"},{"id":"nct00579085-drexel-university-college-of-medicine-department-of-neurology-philad","cat":"research","name":"Drexel University College of Medicine Department of Neurology","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.95337,"lon":-75.16913,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"19107","condg":["Chronic pain & headache"],"nct":"NCT00579085","study":"Double Blind Placebo Controlled Study of Outpatient Intravenous Ketamine for the Treatment of CRPS","sstatus":"COMPLETED","sponsor":"Drexel University College of Medicine","src":"https://clinicaltrials.gov/study/NCT00579085","phase":"Phase 2","enroll":40,"start":"2006-09","eid":"x:site:nct00579085-drexel-university-college-of-medicine-department-of-neurology-philad"},{"id":"nct01892189-the-brain-institute-university-of-utah-salt-lake-city","cat":"research","name":"The Brain Institute, University of Utah","city":"Salt Lake City","region":"Utah","country":"United States","cc":"US","lat":40.76384,"lon":-111.89929,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"84108","condg":["Other"],"nct":"NCT01892189","study":"Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults","sstatus":"COMPLETED","sponsor":"Takeda","official":"Medical Director (Takeda Development Center Americas, Inc. (Note: This product was divested to Axsome in 2026))","src":"https://clinicaltrials.gov/study/NCT01892189","phase":"Phase 1","enroll":27,"start":"2013-08","eid":"x:site:nct01892189-the-brain-institute-university-of-utah-salt-lake-city"},{"id":"nct07513935-ainshams-university-cairo","cat":"research","name":"Ainshams University","city":"Cairo","country":"Egypt","cc":"EG","lat":30.06484,"lon":31.23908,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT07513935","study":"Comparison of Combined Dexmedetomidine and Ketamine (Ketodex) Versus Dexmedetomidine Alone in Awake Mapping for Deep Brain Stimulation: A Randomized Controlled Trial","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Ain Shams University","src":"https://clinicaltrials.gov/study/NCT07513935","phase":"Phase 4","enroll":24,"start":"2026-03-03","eid":"x:site:nct07513935-ainshams-university-cairo"},{"id":"nct06631625-faculty-of-medicine-alexandria","cat":"research","name":"Faculty of medicine","city":"Alexandria","country":"Egypt","cc":"EG","lat":31.19635,"lon":29.91681,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Cancer-related distress"],"nct":"NCT06631625","study":"Effect of Addition of Dexmedetomidine or Ketamine to Intravenous Infusion of Lidocaine on Proinflammatory Cytokines in Pelvi-abdominal Cancer Surgeries.","sstatus":"COMPLETED","sponsor":"Alexandria University","src":"https://clinicaltrials.gov/study/NCT06631625","phase":"Phase 1","enroll":45,"start":"2023-09-24","eid":"x:site:nct06631625-faculty-of-medicine-alexandria"},{"id":"nct03090776-brigham-and-women-s-hospital-boston","cat":"research","name":"Brigham and Women's Hospital","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36215,"lon":-71.0569,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02115","condg":["Chronic pain & headache"],"nct":"NCT03090776","study":"Prevention of Post Mastectomy With Intraoperative Ketamine","sstatus":"COMPLETED","sponsor":"Brigham and Women's Hospital","official":"Kristin L Schreiber, MD/PhD (Brigham and Women's Hospital)","src":"https://clinicaltrials.gov/study/NCT03090776","phase":"EARLY_Phase 1","enroll":264,"start":"2017-07-01","eid":"x:site:nct03090776-brigham-and-women-s-hospital-boston"},{"id":"nct06620276-centre-hospitalier-de-l-39-universite-de-montreal-montreal","cat":"research","name":"Centre Hospitalier de l&#39;Université de Montréal","city":"Montreal","region":"Quebec","country":"Canada","cc":"CA","lat":45.51256,"lon":-73.59567,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"H2X3E4","condg":["Depression","Addiction & substance use"],"status":"RECRUITING","nct":"NCT06620276","study":"ACT_for Alcohol Use Disorder and Depression","sstatus":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","official":"Nicolas Garel, MD MSc (Centre Hospitalier d'Université de Montréal)","src":"https://clinicaltrials.gov/study/NCT06620276","contact":{"n":"Nicolas Garel, MD MSc","p":"514-890-8000","e":"nicolas.garel.med@ssss.gouv.qc.ca"},"phase":"N/A","enroll":30,"start":"2025-05-01","eid":"x:site:nct06620276-centre-hospitalier-de-l-39-universite-de-montreal-montreal"},{"id":"nct02583217-cigdem-yildirim-guclu-ankara","cat":"research","name":"Cigdem Yildirim Guclu","city":"Ankara","country":"Turkey","cc":"TR","lat":39.92829,"lon":32.84585,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT02583217","study":"Effect of Ketamine+Propofol vs Remifentanyl+Propofol on Laryngeal Mask Insertion Conditions","sstatus":"COMPLETED","sponsor":"Ankara University","official":"CIGDEM YILDIRIM GUCLU, MD (Ankara University)","src":"https://clinicaltrials.gov/study/NCT02583217","enroll":50,"start":"2015-04","eid":"x:site:nct02583217-cigdem-yildirim-guclu-ankara"},{"id":"nct07369024-harbor-ucla-medical-center-torrance","cat":"research","name":"Harbor UCLA Medical Center","city":"Torrance","region":"California","country":"United States","cc":"US","lat":33.83119,"lon":-118.35131,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"90509","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT07369024","study":"Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults","sstatus":"RECRUITING","sponsor":"Mohsen Saidinejad","src":"https://clinicaltrials.gov/study/NCT07369024","contact":{"n":"Cynthia Luo, MD","p":"310-222-2345","e":"cluo2@dhs.lacounty.gov"},"phase":"Phase 2","enroll":120,"start":"2026-09-10","eid":"x:site:nct07369024-harbor-ucla-medical-center-torrance"},{"id":"nct06245564-center-for-neuroplasticity-and-pain-faculty-of-medicine-aalborg-univ","cat":"research","name":"Center for Neuroplasticity and Pain Faculty of Medicine, Aalborg University","city":"Gistrup","region":"Aalborg","country":"Denmark","cc":"DK","lat":56.98569,"lon":10.00191,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"9260","condg":["Other"],"nct":"NCT06245564","study":"Effect of Ketamine, Amitriptyline and Their Combination on Itch","sstatus":"COMPLETED","sponsor":"Aalborg University","src":"https://clinicaltrials.gov/study/NCT06245564","phase":"N/A","enroll":30,"start":"2024-08-20","eid":"x:site:nct06245564-center-for-neuroplasticity-and-pain-faculty-of-medicine-aalborg-univ"},{"id":"nct03284307-uw-hospital-and-clinics-madison","cat":"research","name":"UW Hospital and Clinics","city":"Madison","region":"Wisconsin","country":"United States","cc":"US","lat":43.0826,"lon":-89.40777,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"53792","condg":["Other"],"nct":"NCT03284307","study":"UNderstanding CONSciousness Connectedness and Intraoperative Unresponsiveness Study","sstatus":"COMPLETED","sponsor":"University of Wisconsin, Madison","official":"Robert A Pearce, MD, PhD (Professor and chair of Anesthesiology at UW- Madison)","src":"https://clinicaltrials.gov/study/NCT03284307","phase":"Phase 4","enroll":35,"start":"2017-08-10","eid":"x:site:nct03284307-uw-hospital-and-clinics-madison"},{"id":"nct01740492-rhode-island-hospital-providence","cat":"research","name":"Rhode Island Hospital","city":"Providence","region":"Rhode Island","country":"United States","cc":"US","lat":41.82968,"lon":-71.41692,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02903","condg":["Chronic pain & headache"],"nct":"NCT01740492","study":"Low Dose Ketamine for Management of Acute Severe Pain in the Emergency Department","sstatus":"COMPLETED","sponsor":"Rhode Island Hospital","official":"Francesca Beaudoin, MD (Rhode Island Hospital)","src":"https://clinicaltrials.gov/study/NCT01740492","phase":"Phase 1","enroll":75,"start":"2012-09","eid":"x:site:nct01740492-rhode-island-hospital-providence"},{"id":"nct02049411-centro-medico-nacional-siglo-xxi-umae-hospital-de-especialidades-mex","cat":"research","name":"Centro Medico Nacional Siglo XXI. UMAE Hospital de Especialidades","city":"Mexico City","region":"Mexico City","country":"Mexico","cc":"MX","lat":19.41929,"lon":-99.11942,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06720","condg":["Neurology & cognition"],"nct":"NCT02049411","study":"Ketamine and Changes of the Short Portable Mental Status Questionnaire","sstatus":"COMPLETED","sponsor":"Instituto Mexicano del Seguro Social","official":"Dulce M. Rascon, M.D (Instituto Mexicano del Seguro Social); Maria E. Ocharan, PhD. (Instituto Politecnico Nacional)","src":"https://clinicaltrials.gov/study/NCT02049411","phase":"Phase 2","enroll":80,"start":"2013-06","eid":"x:site:nct02049411-centro-medico-nacional-siglo-xxi-umae-hospital-de-especialidades-mex"},{"id":"nct04226963-department-of-psychiatry-medical-university-of-gdansk-gdansk","cat":"research","name":"Department of Psychiatry, Medical University of Gdańsk","city":"Gdansk","country":"Poland","cc":"PL","lat":54.34752,"lon":18.65096,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"80-952","condg":["Depression","Bipolar"],"nct":"NCT04226963","study":"A Naturalistic Study of Ketamine for Treatment Resistant Mood Disorders","sstatus":"COMPLETED","sponsor":"Medical University of Gdansk","src":"https://clinicaltrials.gov/study/NCT04226963","enroll":80,"start":"2019-12-04","eid":"x:site:nct04226963-department-of-psychiatry-medical-university-of-gdansk-gdansk"},{"id":"nct02378415-naval-medical-center-san-diego-san-diego","cat":"research","name":"Naval Medical Center San Diego","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.72253,"lon":-117.17079,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"92134","condg":["Depression"],"nct":"NCT02378415","study":"Subanesthetic IV Bolus Ketamine in the Treatment of Acute Depression","sstatus":"TERMINATED","sponsor":"United States Naval Medical Center, San Diego","official":"Robert E Lovern, MD (United States Naval Medical Center, San Diego)","src":"https://clinicaltrials.gov/study/NCT02378415","phase":"Phase 1","enroll":20,"start":"2011-12","eid":"x:site:nct02378415-naval-medical-center-san-diego-san-diego"},{"id":"nct04807335-dantrials-copenhagen","cat":"research","name":"Dantrials","city":"Copenhagen","region":"DK","country":"Denmark","cc":"DK","lat":55.68446,"lon":12.56746,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"2400","condg":["Other"],"nct":"NCT04807335","study":"Study of CT001 in Healthy Volunteers","sstatus":"COMPLETED","sponsor":"Cessatech A/S","official":"Mads Werner, MD (Copenhagen University Hospital, Rigshospitalet)","src":"https://clinicaltrials.gov/study/NCT04807335","phase":"Phase 1","enroll":14,"start":"2021-03-17","eid":"x:site:nct04807335-dantrials-copenhagen"},{"id":"nct06406647-faculty-of-medicine-asyut","cat":"research","name":"Faculty of Medicine","city":"Asyut","country":"Egypt","cc":"EG","lat":27.19061,"lon":31.18796,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06406647","study":"Rectroclavicular Block in Orthopedic Surgey","sstatus":"RECRUITING","sponsor":"New Valley University","official":"ahmed ismail, lecture (New Valley University)","src":"https://clinicaltrials.gov/study/NCT06406647","contact":{"n":"hassan abdel lataf, prof","p":"01097845491","e":"ahmed_ismail87@med.nvu.edu.eg"},"phase":"N/A","enroll":80,"start":"2026-04-01","eid":"x:site:nct06406647-faculty-of-medicine-asyut"},{"id":"nct06480201-wells-medicine-houston","cat":"research","name":"Wells Medicine","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.75815,"lon":-95.35146,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"77024","condg":["Depression","Healthy volunteers"],"status":"RECRUITING","nct":"NCT06480201","study":"Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression","sstatus":"RECRUITING","sponsor":"Texas A&M University","src":"https://clinicaltrials.gov/study/NCT06480201","contact":{"n":"Jesse Wells","p":"(713) 589-5118","e":"mail@wellsmedicine.com"},"phase":"Phase 1","enroll":100,"start":"2024-01-01","eid":"x:site:nct06480201-wells-medicine-houston"},{"id":"nct06480201-texas-a-m-houston-methodist-hospital-location-houston","cat":"research","name":"Texas A&M (Houston Methodist Hospital Location)","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.77312,"lon":-95.36642,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"77030","condg":["Depression","Healthy volunteers"],"status":"RECRUITING","nct":"NCT06480201","study":"Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression","sstatus":"RECRUITING","sponsor":"Texas A&M University","src":"https://clinicaltrials.gov/study/NCT06480201","contact":{"n":"Nicholas Murphy","p":"713-798-7593","e":"nicholas.murphy@bcm.edu"},"phase":"Phase 1","enroll":100,"start":"2024-01-01","eid":"x:site:nct06480201-texas-a-m-houston-methodist-hospital-location-houston"},{"id":"nct02935595-harris-county-psychiatric-center-houston","cat":"research","name":"Harris County Psychiatric Center","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.75599,"lon":-95.35456,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"77021","condg":["Depression"],"nct":"NCT02935595","study":"Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients","sstatus":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","official":"Sudhakar Selvaraj, MBBS, DPhil (University of Texas)","src":"https://clinicaltrials.gov/study/NCT02935595","phase":"Phase 2","enroll":9,"start":"2016-10-14","eid":"x:site:nct02935595-harris-county-psychiatric-center-houston"},{"id":"nct01441505-wesley-hospital-kogarah","cat":"research","name":"Wesley Hospital","city":"Kogarah","region":"New South Wales","country":"Australia","cc":"AU","lat":-33.96099,"lon":151.14482,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"2217","condg":["Depression"],"status":"RECRUITING","nct":"NCT01441505","study":"A Study of Ketamine as an Antidepressant","sstatus":"UNKNOWN","sponsor":"The University of New South Wales","official":"Colleen K Loo, MB BS FRANZCP MD (University of New South Wales)","src":"https://clinicaltrials.gov/study/NCT01441505","contact":{"n":"Angelo Alonzo","p":"61 02 9382 3720","e":"TMSandDCS@unsw.edu.au"},"phase":"Phase 2","enroll":42,"start":"2011-09","eid":"x:site:nct01441505-wesley-hospital-kogarah"},{"id":"nct06125054-psychiatric-university-hospital-zurich-university-of-zurich-zurich","cat":"research","name":"Psychiatric University Hospital Zurich, University of Zurich","city":"Zurich","region":"Canton of Zurich","country":"Switzerland","cc":"CH","lat":47.37218,"lon":8.54384,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"8032","condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT06125054","study":"Ketamine and Neurofeedback-Training: Effects on Neuroplasticity in Cocaine Addiction","sstatus":"RECRUITING","sponsor":"Dr. med. Marcus Herdener","src":"https://clinicaltrials.gov/study/NCT06125054","contact":{"n":"Marcus Herdener, PD Dr. med.","p":"+41583845810","e":"marcus.herdener@bli.uzh.ch"},"phase":"Phase 2","enroll":120,"start":"2024-02-05","eid":"x:site:nct06125054-psychiatric-university-hospital-zurich-university-of-zurich-zurich"},{"id":"nct00252122-the-children-s-hospital-of-philadelphia-philadelphia","cat":"research","name":"The Children's Hospital of Philadelphia","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.94989,"lon":-75.16254,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"19104","condg":["Other"],"nct":"NCT00252122","study":"Pilot Study on the Effects of Intravenous Ketamine on Acute Pain Crisis in Patients With Sickle Cell Disease","sstatus":"TERMINATED","sponsor":"Children's Hospital of Philadelphia","official":"Arjunan Ganesh, MD (Children's Hospital of Philadelphia)","src":"https://clinicaltrials.gov/study/NCT00252122","phase":"Phase 4","enroll":3,"start":"2004-06","eid":"x:site:nct00252122-the-children-s-hospital-of-philadelphia-philadelphia"},{"id":"nct02434939-sickle-cell-clinic-mulago-hospital-complex-kampala","cat":"research","name":"Sickle Cell clinic, Mulago Hospital Complex","city":"Kampala","country":"Uganda","cc":"UG","lat":0.30644,"lon":32.57188,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"256","condg":["Chronic pain & headache"],"nct":"NCT02434939","study":"Low-dose Ketamine vs Morphine for Vaso-occlusive Crisis in Sicklers","sstatus":"COMPLETED","sponsor":"Makerere University","official":"Felix A. Lubega, MBChB (Makerere University, College of Health Sciences, Department of Anesthesia and Critical Care); Tonny S. Luggya, MMed (Makerere University, College of Health Sciences, Department of Anaesthesia and Critical care)","src":"https://clinicaltrials.gov/study/NCT02434939","phase":"Phase 4","enroll":240,"start":"2015-06","eid":"x:site:nct02434939-sickle-cell-clinic-mulago-hospital-complex-kampala"},{"id":"nct06907173-uab-hospital-birmingham","cat":"research","name":"UAB Hospital","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.5224,"lon":-86.80273,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"35233","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Lauren Walter, MD, MSPH","p":"205-996-4791","e":"lwalter@uabmc.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-uab-hospital-birmingham"},{"id":"nct06907173-banner-university-medical-center-tucson-campus-tucson","cat":"research","name":"Banner University Medical Center - Tucson Campus","city":"Tucson","region":"Arizona","country":"United States","cc":"US","lat":32.22969,"lon":-110.93697,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"85724","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Aaron Leetch, MD","p":"520-621-8752","e":"aleetch@arizona.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-banner-university-medical-center-tucson-campus-tucson"},{"id":"nct06907173-uc-san-diego-health-la-jolla-la-jolla","cat":"research","name":"UC San Diego Health La Jolla","city":"La Jolla","region":"California","country":"United States","cc":"US","lat":32.83725,"lon":-117.28375,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"92037","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Vanessa Tamas, MD","p":"858-966-8033","e":"vtamas@rchsd.org"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-uc-san-diego-health-la-jolla-la-jolla"},{"id":"nct06907173-ronald-reagan-ucla-medical-center-los-angeles","cat":"research","name":"Ronald Reagan UCLA Medical Center","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.04851,"lon":-118.24401,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"90024","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Richelle Cooper, MD","p":"424-440-0486","e":"rcooper@mednet.ucla.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-ronald-reagan-ucla-medical-center-los-angeles"},{"id":"nct06907173-children-s-hospital-los-angeles-los-angeles","cat":"research","name":"Children's Hospital Los Angeles","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.04964,"lon":-118.23733,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"90027","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Ara Festekjian, MD","p":"323-804-8142","e":"afestekjian@chla.usc.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-children-s-hospital-los-angeles-los-angeles"},{"id":"nct06907173-stanford-university-medical-center-palo-alto","cat":"research","name":"Stanford University Medical Center","city":"Palo Alto","region":"California","country":"United States","cc":"US","lat":37.43769,"lon":-122.15126,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94304","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Alexandra June Gordon, MD","p":"650-248-7701","e":"ajgordon@stanford.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-stanford-university-medical-center-palo-alto"},{"id":"nct06907173-uc-davis-medical-center-sacramento","cat":"research","name":"UC Davis Medical Center","city":"Sacramento","region":"California","country":"United States","cc":"US","lat":38.58435,"lon":-121.50047,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"95817","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Daniel Nishijima, MD","p":"916-734-5010","e":"dnishijima@ucdavis.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-uc-davis-medical-center-sacramento"},{"id":"nct06907173-uc-san-diego-health-hillcrest-hospital-san-diego","cat":"research","name":"UC San Diego Health Hillcrest Hospital","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.71293,"lon":-117.15319,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"92103","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Vanessa Tamas, MD","p":"858-966-8033","e":"vtamas@rchsd.org"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-uc-san-diego-health-hillcrest-hospital-san-diego"},{"id":"nct06907173-rady-children-s-hospital-san-diego","cat":"research","name":"Rady Children's Hospital","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.71171,"lon":-117.17408,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"92123","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Vanessa Tamas, MD","p":"858-966-8033","e":"vtamas@rchsd.org"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-rady-children-s-hospital-san-diego"},{"id":"nct06907173-san-francisco-general-hospital-san-francisco","cat":"research","name":"San Francisco General Hospital","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.77272,"lon":-122.42511,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94143","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Debbie Madhok, MD","p":"415-601-6399","e":"Debbie.madhok@ucsf.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-san-francisco-general-hospital-san-francisco"},{"id":"nct06907173-ucsf-medical-center-san-francisco","cat":"research","name":"UCSF Medical Center","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.77215,"lon":-122.42511,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94143","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Debbie Madhok, MD","p":"415-601-6399","e":"Debbie.madhok@ucsf.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-ucsf-medical-center-san-francisco"},{"id":"nct06907173-harbor-ucla-medical-center-torrance","cat":"research","name":"Harbor-UCLA Medical Center","city":"Torrance","region":"California","country":"United States","cc":"US","lat":33.84267,"lon":-118.34247,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"90502","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Juliana Tolles, MD","p":"434-243-6768","e":"jtolles@emedharbor.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-harbor-ucla-medical-center-torrance"},{"id":"nct06907173-yale-new-haven-hospital-new-haven","cat":"research","name":"Yale New Haven Hospital","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.29709,"lon":-72.93395,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06519","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Charles Wira, MD","p":"203-785-5781","e":"charles.wira@yale.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-yale-new-haven-hospital-new-haven"},{"id":"nct06907173-christiana-hospital-newark","cat":"research","name":"Christiana Hospital","city":"Newark","region":"Delaware","country":"United States","cc":"US","lat":40.73505,"lon":-74.18032,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"19718","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Jason Nomura, MD","p":"302-733-4113","e":"jnomura@christianacare.org"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-christiana-hospital-newark"},{"id":"nct06907173-nemours-children-s-hospital-wilmington","cat":"research","name":"Nemours Children's Hospital","city":"Wilmington","region":"Delaware","country":"United States","cc":"US","lat":34.24295,"lon":-77.94185,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"19803","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Amy Thompson, MD","p":"302-490-4146","e":"amy.thompson@nemours.org"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-nemours-children-s-hospital-wilmington"},{"id":"nct06907173-children-s-national-medical-center-washington-d-c","cat":"research","name":"Children's National Medical Center","city":"Washington D.C.","region":"District of Columbia","country":"United States","cc":"US","lat":38.89375,"lon":-77.04517,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20010","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"James Chamberlain, MD","p":"202-476-8877","e":"jchamber@childrensnational.org"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-children-s-national-medical-center-washington-d-c"},{"id":"nct06907173-orlando-regional-medical-center-orlando","cat":"research","name":"Orlando Regional Medical Center","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.53763,"lon":-81.36771,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"32806","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Dipali Nemade, MD","p":"321-841-1324","e":"Dipali.Nemade@orlandohealth.com"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-orlando-regional-medical-center-orlando"},{"id":"nct06907173-grady-memorial-hospital-atlanta","cat":"research","name":"Grady Memorial Hospital","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.75714,"lon":-84.38247,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"30303","condg":["Neurology & cognition"],"status":"ACTIVE_NOT_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Megan Wardius","p":"434-243-6768","e":"mew5j@virginia.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-grady-memorial-hospital-atlanta"},{"id":"nct06907173-arthur-m-blank-hospital-atlanta","cat":"research","name":"Arthur M. Blank Hospital","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.73888,"lon":-84.38605,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"30329","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Claudia Morris, MD","p":"404-785-7070","e":"claudia.r.morris@emory.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-arthur-m-blank-hospital-atlanta"},{"id":"nct06907173-northwestern-memorial-hospital-chicago","cat":"research","name":"Northwestern Memorial Hospital","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.84368,"lon":-87.65236,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60611","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Peter Pruitt, MD","p":"312-694-7000","e":"peter.pruitt@nm.org"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-northwestern-memorial-hospital-chicago"},{"id":"nct06907173-rush-university-medical-center-chicago","cat":"research","name":"Rush University Medical Center","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.83963,"lon":-87.66139,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60612","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Michael Gottlieb, MD, MBA","p":"631-922-1705","e":"Michael_A_Gottlieb@rush.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-rush-university-medical-center-chicago"},{"id":"nct06907173-university-of-illinois-hospital-chicago","cat":"research","name":"University of Illinois Hospital","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.8609,"lon":-87.65367,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60612","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Pavitra Kotini-Shah, MD","p":"817-703-1723","e":"pkotini@uic.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-university-of-illinois-hospital-chicago"},{"id":"nct06907173-comer-children-s-hospital-chicago","cat":"research","name":"Comer Children's Hospital","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.85554,"lon":-87.65301,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60637","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"David Beiser, MD","p":"773-834-4135","e":"dbeiser@medicine.bsd.uchicago.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-comer-children-s-hospital-chicago"},{"id":"nct06907173-university-of-chicago-medical-center-chicago","cat":"research","name":"University of Chicago Medical Center","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.84678,"lon":-87.64021,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60637","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"David Beiser, MD","p":"773-834-4135","e":"dbeiser@medicine.bsd.uchicago.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-university-of-chicago-medical-center-chicago"},{"id":"nct06907173-iu-health-methodist-hospital-indianapolis","cat":"research","name":"IU Health Methodist Hospital","city":"Indianapolis","region":"Indiana","country":"United States","cc":"US","lat":39.76344,"lon":-86.14689,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"46202","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Daniel Udrea, MD","p":"317-274-0829","e":"dudrea@iu.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-iu-health-methodist-hospital-indianapolis"},{"id":"nct06907173-riley-hospital-for-children-indianapolis","cat":"research","name":"Riley Hospital for Children","city":"Indianapolis","region":"Indiana","country":"United States","cc":"US","lat":39.76532,"lon":-86.16891,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"46202","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Benjamin Nti, MD","p":"317-416-7997","e":"bnti@iu.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-riley-hospital-for-children-indianapolis"},{"id":"nct06907173-university-of-iowa-medical-center-iowa-city","cat":"research","name":"University of Iowa Medical Center","city":"Iowa City","region":"Iowa","country":"United States","cc":"US","lat":41.65967,"lon":-91.52316,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"52242","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Brett Faine, MD","p":"319-384-5228","e":"brett-faine@uiowa.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-university-of-iowa-medical-center-iowa-city"},{"id":"nct06907173-university-medical-center-new-orleans-new-orleans","cat":"research","name":"University Medical Center New Orleans","city":"New Orleans","region":"Louisiana","country":"United States","cc":"US","lat":29.95291,"lon":-90.08265,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"70112","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Stephen Lim, MD","p":"504-702-2440","e":"slim@lsuhsc.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-university-medical-center-new-orleans-new-orleans"},{"id":"nct06907173-university-of-maryland-medical-center-baltimore","cat":"research","name":"University of Maryland Medical Center","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.2924,"lon":-76.61732,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"21201","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Jennifer Hopp, MD","p":"410-328-7635","e":"jhopp@som.umaryland.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-university-of-maryland-medical-center-baltimore"},{"id":"nct06907173-johns-hopkins-hospital-baltimore","cat":"research","name":"Johns Hopkins Hospital","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29956,"lon":-76.60395,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"21287","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Kathryn Rosenblatt, MD","p":"410-955-6488","e":"krosenb3@jhmi.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-johns-hopkins-hospital-baltimore"},{"id":"nct06907173-massachusetts-general-hospital-boston","cat":"research","name":"Massachusetts General Hospital","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.34963,"lon":-71.04956,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02114","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Michael Filbin, MD","p":"617-724-4758","e":"mfilbin@mgh.harvard.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-massachusetts-general-hospital-boston"},{"id":"nct06907173-university-of-michigan-university-hospital-ann-arbor","cat":"research","name":"University of Michigan University Hospital","city":"Ann Arbor","region":"Michigan","country":"United States","cc":"US","lat":42.28485,"lon":-83.73434,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"48109","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Mariama Runcie, MD","p":"734-232-2145","e":"runciema@med.umich.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-university-of-michigan-university-hospital-ann-arbor"},{"id":"nct06907173-detroit-receiving-hospital-detroit","cat":"research","name":"Detroit Receiving Hospital","city":"Detroit","region":"Michigan","country":"United States","cc":"US","lat":42.3391,"lon":-83.03544,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"48201","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Wazim Mohamed, MD","p":"313-577-8824","e":"wmohamed@med.wayne.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-detroit-receiving-hospital-detroit"},{"id":"nct06907173-sinai-grace-hospital-detroit","cat":"research","name":"Sinai-Grace Hospital","city":"Detroit","region":"Michigan","country":"United States","cc":"US","lat":42.33138,"lon":-83.05719,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"48201","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Arun Sherma, MD","p":"313-745-4238","e":"arun@sherma.org"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-sinai-grace-hospital-detroit"},{"id":"nct06907173-henry-ford-hospital-detroit","cat":"research","name":"Henry Ford Hospital","city":"Detroit","region":"Michigan","country":"United States","cc":"US","lat":42.33628,"lon":-83.03676,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"48202","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Joseph Miller, MD","p":"313-404-9110","e":"jmiller6@hfhs.org"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-henry-ford-hospital-detroit"},{"id":"nct06907173-university-of-minnesota-masonic-children-s-hospital-minneapolis","cat":"research","name":"University of Minnesota Masonic Children's Hospital","city":"Minneapolis","region":"Minnesota","country":"United States","cc":"US","lat":44.97371,"lon":-93.26793,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55414","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"James Miner, MD","p":"612-624-7426","e":"miner015@umn.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-university-of-minnesota-masonic-children-s-hospital-minneapolis"},{"id":"nct06907173-hennepin-county-medical-center-minneapolis","cat":"research","name":"Hennepin County Medical Center","city":"Minneapolis","region":"Minnesota","country":"United States","cc":"US","lat":44.98171,"lon":-93.2749,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55415","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Brian Driver, MD","p":"612-873-7448","e":"brian.driver@hcmed.org"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-hennepin-county-medical-center-minneapolis"},{"id":"nct06907173-university-of-minnesota-medical-center-minneapolis","cat":"research","name":"University of Minnesota Medical Center","city":"Minneapolis","region":"Minnesota","country":"United States","cc":"US","lat":44.97268,"lon":-93.2589,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55455","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"James Miner, MD","p":"612-624-7426","e":"miner015@umn.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-university-of-minnesota-medical-center-minneapolis"},{"id":"nct06907173-cooper-university-hospital-camden","cat":"research","name":"Cooper University Hospital","city":"Camden","region":"New Jersey","country":"United States","cc":"US","lat":39.93644,"lon":-75.11835,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"08103","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Christopher Jones, MD","p":"856-342-2637","e":"jones-christopher@cooperhealth.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-cooper-university-hospital-camden"},{"id":"nct06907173-university-of-new-mexico-hospital-albuquerque","cat":"research","name":"University of New Mexico Hospital","city":"Albuquerque","region":"New Mexico","country":"United States","cc":"US","lat":35.08181,"lon":-106.65053,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"87106","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Masoom Desai, MD","p":"505-272-0356","e":"MDesai@salud.unm.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-university-of-new-mexico-hospital-albuquerque"},{"id":"nct06907173-suny-upstate-medical-university-syracuse","cat":"research","name":"SUNY Upstate Medical University","city":"Syracuse","region":"New York","country":"United States","cc":"US","lat":43.04826,"lon":-76.15057,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"13210","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Lindsay Nausin, DO","p":"315-464-4363","e":"nausinl@upstate.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-suny-upstate-medical-university-syracuse"},{"id":"nct06907173-duke-university-hospital-durham","cat":"research","name":"Duke University Hospital","city":"Durham","region":"North Carolina","country":"United States","cc":"US","lat":35.98419,"lon":-78.89998,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"27710","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Alexander Limkakeng, MD","p":"919-681-0908","e":"alexander.limkakeng@duke.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-duke-university-hospital-durham"},{"id":"nct06907173-university-of-cincinnati-medical-center-cincinnati","cat":"research","name":"University of Cincinnati Medical Center","city":"Cincinnati","region":"Ohio","country":"United States","cc":"US","lat":39.1377,"lon":-84.52488,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45267","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Jason McMullan, MD","p":"513-675-3072","e":"jason.mcmullan@uc.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-university-of-cincinnati-medical-center-cincinnati"},{"id":"nct06907173-nationwide-children-s-hospital-columbus","cat":"research","name":"Nationwide Children's Hospital","city":"Columbus","region":"Ohio","country":"United States","cc":"US","lat":39.95567,"lon":-82.99705,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43205","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Aarti Gaglani Aarti Gaglani, MD","p":"6147226910","e":"kesett@nationwidechildrens.org"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-nationwide-children-s-hospital-columbus"},{"id":"nct06907173-osu-wexner-medical-center-columbus","cat":"research","name":"OSU Wexner Medical Center","city":"Columbus","region":"Ohio","country":"United States","cc":"US","lat":39.96866,"lon":-83.00975,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43210","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Kirstin Acus, MD","p":"614-293-6185","e":"kirstin.acus@osumc.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-osu-wexner-medical-center-columbus"},{"id":"nct06907173-oregon-health-science-university-hospital-portland","cat":"research","name":"Oregon Health & Science University Hospital","city":"Portland","region":"Oregon","country":"United States","cc":"US","lat":45.53329,"lon":-122.66797,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"97239","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Bory Kea, MD","p":"503-494-8083","e":"kea@ohsu.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-oregon-health-science-university-hospital-portland"},{"id":"nct06907173-hospital-of-the-university-of-pennsylvania-philadelphia","cat":"research","name":"Hospital of the University of Pennsylvania","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.95977,"lon":-75.15849,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"19104","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"John Greenwood, MD","p":"267-252-8741","e":"john.greenwood@pennmedicine.upenn.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-hospital-of-the-university-of-pennsylvania-philadelphia"},{"id":"nct06907173-penn-presbyterian-medical-center-philadelphia","cat":"research","name":"Penn Presbyterian Medical Center","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.96231,"lon":-75.15868,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"19104","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"John Greenwood, MD","p":"267-252-8741","e":"john.greenwood@pennmedicine.upenn.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-penn-presbyterian-medical-center-philadelphia"},{"id":"nct06907173-temple-university-hospital-jeanes-campus-philadelphia","cat":"research","name":"Temple University Hospital Jeanes Campus","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.95469,"lon":-75.17148,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"19111","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Derek Isenberg, MD","p":"215-707-0222","e":"derek.isenberg@tuhs.temple.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-temple-university-hospital-jeanes-campus-philadelphia"},{"id":"nct06907173-temple-university-hospital-main-campus-philadelphia","cat":"research","name":"Temple University Hospital Main Campus","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.94217,"lon":-75.15284,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"19140","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Derek Isenberg, MD","p":"215-707-0222","e":"derek.isenberg@tuhs.temple.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-temple-university-hospital-main-campus-philadelphia"},{"id":"nct06907173-jefferson-einstein-philadelphia-hospital-philadelphia","cat":"research","name":"Jefferson Einstein Philadelphia Hospital","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.94396,"lon":-75.15331,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"19141","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Joseph Herres, DO","p":"215-457-5865","e":"Joseph.herres@jefferson.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-jefferson-einstein-philadelphia-hospital-philadelphia"},{"id":"nct06907173-upmc-presbyterian-hospital-pittsburgh","cat":"research","name":"UPMC Presbyterian Hospital","city":"Pittsburgh","region":"Pennsylvania","country":"United States","cc":"US","lat":40.43314,"lon":-79.98464,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"15213","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Adam Frisch, MD","p":"412-647-9047","e":"frischan@upmc.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-upmc-presbyterian-hospital-pittsburgh"},{"id":"nct06907173-upmc-children-s-hospital-of-pittsburgh-pittsburgh","cat":"research","name":"UPMC Children's Hospital of Pittsburgh","city":"Pittsburgh","region":"Pennsylvania","country":"United States","cc":"US","lat":40.4385,"lon":-79.98398,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"15224","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Robert Hickey, MD","p":"412-692-6567","e":"robert.hickey@chp.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-upmc-children-s-hospital-of-pittsburgh-pittsburgh"},{"id":"nct06907173-reading-hospital-west-reading","cat":"research","name":"Reading Hospital","city":"West Reading","region":"Pennsylvania","country":"United States","cc":"US","lat":40.32603,"lon":-75.93901,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"19611","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Adam Sigal, MD","p":"484-628-7016","e":"adam.sigal@towerhealth.org"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-reading-hospital-west-reading"},{"id":"nct06907173-children-s-medical-center-dallas-dallas","cat":"research","name":"Children's Medical Center Dallas","city":"Dallas","region":"Texas","country":"United States","cc":"US","lat":32.78565,"lon":-96.80549,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75235","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Pamela Okada, MD","p":"214-456-7000","e":"pamela.okada@utsouthwestern.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-children-s-medical-center-dallas-dallas"},{"id":"nct06907173-memorial-hermann-texas-medical-center-houston","cat":"research","name":"Memorial Hermann Texas Medical Center","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.75956,"lon":-95.36266,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"77030","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Kayleigh Fischer, MD","p":"713-500-7803","e":"Kayleigh.A.Fischer@uth.tmc.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-memorial-hermann-texas-medical-center-houston"},{"id":"nct06907173-primary-children-s-hospital-salt-lake-city","cat":"research","name":"Primary Children's Hospital","city":"Salt Lake City","region":"Utah","country":"United States","cc":"US","lat":40.76017,"lon":-111.89609,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"84108","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Maija Holsti, MD, MPH","p":"801-656-8833","e":"Maija.Holsti@hsc.utah.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-primary-children-s-hospital-salt-lake-city"},{"id":"nct06907173-university-of-utah-healthcare-salt-lake-city","cat":"research","name":"University of Utah Healthcare","city":"Salt Lake City","region":"Utah","country":"United States","cc":"US","lat":40.77193,"lon":-111.89336,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"84112","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Scott Youngquist, MD","p":"801-349-0241","e":"scott.youngquist@utah.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-university-of-utah-healthcare-salt-lake-city"},{"id":"nct06907173-university-of-virginia-medical-center-charlottesville","cat":"research","name":"University of Virginia Medical Center","city":"Charlottesville","region":"Virginia","country":"United States","cc":"US","lat":38.01844,"lon":-78.4787,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"22908","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Thomas Hartka, MD","p":"434-924-2897","e":"trh6u@uvahealth.org"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-university-of-virginia-medical-center-charlottesville"},{"id":"nct06907173-vcu-medical-center-richmond","cat":"research","name":"VCU Medical Center","city":"Richmond","region":"Virginia","country":"United States","cc":"US","lat":37.55701,"lon":-77.44901,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"23298","condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Lisa Merck, MD, MPH, MHA","p":"862-383-1688","e":"Lisa.Merck@vcuhealth.org"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-vcu-medical-center-richmond"},{"id":"nct06907173-harborview-medical-center-seattle","cat":"research","name":"Harborview Medical Center","city":"Seattle","region":"Washington","country":"United States","cc":"US","lat":47.5976,"lon":-122.33598,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"98104","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Vasisht Srinivasan, MD","p":"585-730-3843","e":"vasishts@uw.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-harborview-medical-center-seattle"},{"id":"nct06907173-children-s-hospital-of-wisconsin-milwaukee","cat":"research","name":"Children's Hospital of Wisconsin","city":"Milwaukee","region":"Wisconsin","country":"United States","cc":"US","lat":43.04921,"lon":-87.91122,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"53226","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Keli Coleman, MD","p":"414-266-2767","e":"kcoleman@mcw.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-children-s-hospital-of-wisconsin-milwaukee"},{"id":"nct06907173-froedtert-hospital-milwaukee","cat":"research","name":"Froedtert Hospital","city":"Milwaukee","region":"Wisconsin","country":"United States","cc":"US","lat":43.04375,"lon":-87.90774,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"53226","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06907173","study":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jaideep Kapur, MD, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06907173","contact":{"n":"Jamie Jasti, MD","p":"414-805-6493","e":"jjasti@mcw.edu"},"phase":"Phase 3","enroll":770,"start":"2026-03-06","eid":"x:site:nct06907173-froedtert-hospital-milwaukee"},{"id":"nct05934669-university-of-oklahoma-health-sciences-center-oklahoma-city","cat":"research","name":"University of Oklahoma Health Sciences Center","city":"Oklahoma City","region":"Oklahoma","country":"United States","cc":"US","lat":35.46629,"lon":-97.51761,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"73104","condg":["Anxiety"],"status":"RECRUITING","nct":"NCT05934669","study":"IN Midazolam vs IN Dexmedetomidine vs IN Ketamine During Minimal Procedures in Pediatric ED","sstatus":"RECRUITING","sponsor":"University of Oklahoma","official":"Ryan Mckee, MD (University of Oklahoma)","src":"https://clinicaltrials.gov/study/NCT05934669","contact":{"n":"Gavely Toor, DO","p":"405-271-2429","e":"Gavely-Toor@ouhsc.edu"},"phase":"Phase 4","enroll":90,"start":"2023-11-14","eid":"x:site:nct05934669-university-of-oklahoma-health-sciences-center-oklahoma-city"},{"id":"nct03362073-pusan-national-university-yangsan-hospital-yangsan","cat":"research","name":"Pusan National University Yangsan Hospital","city":"Yangsan","region":"Gyeongsangnam-do","country":"South Korea","cc":"KR","lat":35.33451,"lon":129.03965,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"50612","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT03362073","study":"Continuous IntraVenous Infusion of Ketamine in Terminally Ill Cancer Patients","sstatus":"TERMINATED","sponsor":"Pusan National University Yangsan Hospital","official":"Kwonoh Park, MD, PhD (Pusan National University Yangsan Hospital)","src":"https://clinicaltrials.gov/study/NCT03362073","phase":"Phase 2","enroll":20,"start":"2018-06-01","eid":"x:site:nct03362073-pusan-national-university-yangsan-hospital-yangsan"},{"id":"nct05056038-istanbul-university-cerrahpasa-istanbul","cat":"research","name":"Istanbul University - Cerrahpasa","city":"Istanbul","country":"Turkey","cc":"TR","lat":41.00683,"lon":28.93992,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"34100","condg":["Chronic pain & headache"],"nct":"NCT05056038","study":"Lateral Versus Posterior Quadratus Lumborum Block in The Pediatric Patients Undergoing Orchiopexy","sstatus":"COMPLETED","sponsor":"Istanbul University - Cerrahpasa","official":"Ayşe Çiğdem Tütüncü, Prof. (Istanbul University - Cerrahpasa)","src":"https://clinicaltrials.gov/study/NCT05056038","phase":"N/A","enroll":103,"start":"2021-07-01","eid":"x:site:nct05056038-istanbul-university-cerrahpasa-istanbul"},{"id":"nct02401139-brain-mind-research-institute-bmri-university-of-sydney-camperdown","cat":"research","name":"Brain & Mind Research Institute (BMRI), University of Sydney","city":"Camperdown","region":"New South Wales","country":"Australia","cc":"AU","lat":-33.88386,"lon":151.18051,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"2050","condg":["Depression"],"nct":"NCT02401139","study":"Ketamine Trial for the Treatment of Depression","sstatus":"COMPLETED","sponsor":"The University of New South Wales","official":"Colleen K Loo, MBBS, MD (University of New South Wales)","src":"https://clinicaltrials.gov/study/NCT02401139","phase":"Phase 1","enroll":10,"start":"2015-03","eid":"x:site:nct02401139-brain-mind-research-institute-bmri-university-of-sydney-camperdown"},{"id":"nct02401139-black-dog-institute-university-of-new-south-wales-sydney","cat":"research","name":"Black Dog Institute, University of New South Wales","city":"Sydney","region":"New South Wales","country":"Australia","cc":"AU","lat":-33.87345,"lon":151.20003,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"2031","condg":["Depression"],"nct":"NCT02401139","study":"Ketamine Trial for the Treatment of Depression","sstatus":"COMPLETED","sponsor":"The University of New South Wales","official":"Colleen K Loo, MBBS, MD (University of New South Wales)","src":"https://clinicaltrials.gov/study/NCT02401139","phase":"Phase 1","enroll":10,"start":"2015-03","eid":"x:site:nct02401139-black-dog-institute-university-of-new-south-wales-sydney"},{"id":"nct06064162-alta-bates-summit-medical-center-berkeley","cat":"research","name":"Alta Bates Summit Medical Center","city":"Berkeley","region":"California","country":"United States","cc":"US","lat":37.86928,"lon":-122.26931,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94705","condg":["Other"],"nct":"NCT06064162","study":"Ketamine for MS Fatigue","sstatus":"COMPLETED","sponsor":"Alta Bates Summit Medical Center","official":"Deepak Soneji, MD (Sutter East Bay Medical Foundation)","src":"https://clinicaltrials.gov/study/NCT06064162","phase":"EARLY_Phase 1","enroll":21,"start":"2023-12-05","eid":"x:site:nct06064162-alta-bates-summit-medical-center-berkeley"},{"id":"nct00516503-mayo-clinic-scottsdale-scottsdale","cat":"research","name":"Mayo Clinic Scottsdale","city":"Scottsdale","region":"Arizona","country":"United States","cc":"US","lat":33.51246,"lon":-111.89569,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"85259-5499","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-mayo-clinic-scottsdale-scottsdale"},{"id":"nct00516503-mayo-clinic-jacksonville-jacksonville","cat":"research","name":"Mayo Clinic - Jacksonville","city":"Jacksonville","region":"Florida","country":"United States","cc":"US","lat":30.33787,"lon":-81.66407,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"32224","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-mayo-clinic-jacksonville-jacksonville"},{"id":"nct00516503-rush-copley-cancer-care-center-aurora","cat":"research","name":"Rush-Copley Cancer Care Center","city":"Aurora","region":"Illinois","country":"United States","cc":"US","lat":39.74011,"lon":-104.83517,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60504","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-rush-copley-cancer-care-center-aurora"},{"id":"nct00516503-st-joseph-medical-center-bloomington","cat":"research","name":"St. Joseph Medical Center","city":"Bloomington","region":"Illinois","country":"United States","cc":"US","lat":44.84668,"lon":-93.29484,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"61701","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-st-joseph-medical-center-bloomington"},{"id":"nct00516503-graham-hospital-canton","cat":"research","name":"Graham Hospital","city":"Canton","region":"Illinois","country":"United States","cc":"US","lat":42.31641,"lon":-83.4823,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"61520","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-graham-hospital-canton"},{"id":"nct00516503-memorial-hospital-carthage","cat":"research","name":"Memorial Hospital","city":"Carthage","region":"Illinois","country":"United States","cc":"US","lat":37.17697,"lon":-94.31582,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"62321","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-memorial-hospital-carthage"},{"id":"nct00516503-eureka-community-hospital-eureka","cat":"research","name":"Eureka Community Hospital","city":"Eureka","region":"Illinois","country":"United States","cc":"US","lat":40.804,"lon":-124.15807,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"61530","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-eureka-community-hospital-eureka"},{"id":"nct00516503-galesburg-clinic-pc-galesburg","cat":"research","name":"Galesburg Clinic, PC","city":"Galesburg","region":"Illinois","country":"United States","cc":"US","lat":40.94815,"lon":-90.38315,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"61401","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-galesburg-clinic-pc-galesburg"},{"id":"nct00516503-galesburg-cottage-hospital-galesburg","cat":"research","name":"Galesburg Cottage Hospital","city":"Galesburg","region":"Illinois","country":"United States","cc":"US","lat":40.94796,"lon":-90.36856,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"61401","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-galesburg-cottage-hospital-galesburg"},{"id":"nct00516503-mason-district-hospital-havana","cat":"research","name":"Mason District Hospital","city":"Havana","region":"Illinois","country":"United States","cc":"US","lat":40.3079,"lon":-90.05667,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"62644","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-mason-district-hospital-havana"},{"id":"nct00516503-hopedale-medical-complex-hopedale","cat":"research","name":"Hopedale Medical Complex","city":"Hopedale","region":"Illinois","country":"United States","cc":"US","lat":42.13634,"lon":-71.54545,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"61747","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-hopedale-medical-complex-hopedale"},{"id":"nct00516503-joliet-oncology-hematology-associates-limited-west-joliet","cat":"research","name":"Joliet Oncology-Hematology Associates, Limited - West","city":"Joliet","region":"Illinois","country":"United States","cc":"US","lat":41.52505,"lon":-88.08138,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60435","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-joliet-oncology-hematology-associates-limited-west-joliet"},{"id":"nct00516503-mcdonough-district-hospital-macomb","cat":"research","name":"McDonough District Hospital","city":"Macomb","region":"Illinois","country":"United States","cc":"US","lat":40.4521,"lon":-90.66714,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"61455","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-mcdonough-district-hospital-macomb"},{"id":"nct00516503-unnamed-trial-site-moline","cat":"research","name":"Unnamed trial site","city":"Moline","region":"Illinois","country":"United States","cc":"US","lat":41.50628,"lon":-90.52177,"gp":"city","unnamed":1,"drugs":["ketamine"],"zip":"61265","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-unnamed-trial-site-moline"},{"id":"nct00516503-community-cancer-center-normal","cat":"research","name":"Community Cancer Center","city":"Normal","region":"Illinois","country":"United States","cc":"US","lat":40.51171,"lon":-88.98399,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"61761","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-community-cancer-center-normal"},{"id":"nct00516503-community-hospital-of-ottawa-ottawa","cat":"research","name":"Community Hospital of Ottawa","city":"Ottawa","region":"Illinois","country":"United States","cc":"US","lat":41.33745,"lon":-88.83444,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"61350","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-community-hospital-of-ottawa-ottawa"},{"id":"nct00516503-oncology-hematology-associates-of-central-illinois-pc-ottawa-ottawa","cat":"research","name":"Oncology Hematology Associates of Central Illinois, PC - Ottawa","city":"Ottawa","region":"Illinois","country":"United States","cc":"US","lat":41.34761,"lon":-88.83067,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"61350","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-oncology-hematology-associates-of-central-illinois-pc-ottawa-ottawa"},{"id":"nct00516503-cancer-treatment-center-at-pekin-hospital-pekin","cat":"research","name":"Cancer Treatment Center at Pekin Hospital","city":"Pekin","region":"Illinois","country":"United States","cc":"US","lat":40.55949,"lon":-89.63666,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"61554","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-cancer-treatment-center-at-pekin-hospital-pekin"},{"id":"nct00516503-proctor-hospital-peoria","cat":"research","name":"Proctor Hospital","city":"Peoria","region":"Illinois","country":"United States","cc":"US","lat":33.57764,"lon":-112.24637,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"61614","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-proctor-hospital-peoria"},{"id":"nct00516503-ccop-illinois-oncology-research-association-peoria","cat":"research","name":"CCOP - Illinois Oncology Research Association","city":"Peoria","region":"Illinois","country":"United States","cc":"US","lat":33.57999,"lon":-112.24571,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"61615","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-ccop-illinois-oncology-research-association-peoria"},{"id":"nct00516503-oncology-hematology-associates-of-central-illinois-pc-peoria-peoria","cat":"research","name":"Oncology Hematology Associates of Central Illinois, PC - Peoria","city":"Peoria","region":"Illinois","country":"United States","cc":"US","lat":33.58404,"lon":-112.24759,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"61615","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-oncology-hematology-associates-of-central-illinois-pc-peoria-peoria"},{"id":"nct00516503-methodist-medical-center-of-illinois-peoria","cat":"research","name":"Methodist Medical Center of Illinois","city":"Peoria","region":"Illinois","country":"United States","cc":"US","lat":33.58027,"lon":-112.2378,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"61636","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-methodist-medical-center-of-illinois-peoria"},{"id":"nct00516503-osf-st-francis-medical-center-peoria","cat":"research","name":"OSF St. Francis Medical Center","city":"Peoria","region":"Illinois","country":"United States","cc":"US","lat":33.57876,"lon":-112.23131,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"61637","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-osf-st-francis-medical-center-peoria"},{"id":"nct00516503-illinois-valley-community-hospital-peru","cat":"research","name":"Illinois Valley Community Hospital","city":"Peru","region":"Illinois","country":"United States","cc":"US","lat":40.74654,"lon":-86.0741,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"61354","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-illinois-valley-community-hospital-peru"},{"id":"nct00516503-perry-memorial-hospital-princeton","cat":"research","name":"Perry Memorial Hospital","city":"Princeton","region":"Illinois","country":"United States","cc":"US","lat":25.53792,"lon":-80.42075,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"61356","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-perry-memorial-hospital-princeton"},{"id":"nct00516503-st-margaret-s-hospital-spring-valley","cat":"research","name":"St. Margaret's Hospital","city":"Spring Valley","region":"Illinois","country":"United States","cc":"US","lat":36.10723,"lon":-115.24721,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"61362","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-st-margaret-s-hospital-spring-valley"},{"id":"nct00516503-carle-cancer-center-at-carle-foundation-hospital-urbana","cat":"research","name":"Carle Cancer Center at Carle Foundation Hospital","city":"Urbana","region":"Illinois","country":"United States","cc":"US","lat":40.10734,"lon":-88.21231,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"61801","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-carle-cancer-center-at-carle-foundation-hospital-urbana"},{"id":"nct00516503-ccop-carle-cancer-center-urbana","cat":"research","name":"CCOP - Carle Cancer Center","city":"Urbana","region":"Illinois","country":"United States","cc":"US","lat":40.10141,"lon":-88.19565,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"61801","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-ccop-carle-cancer-center-urbana"},{"id":"nct00516503-st-francis-hospital-and-health-centers-beech-grove-campus-beech-grov","cat":"research","name":"St. Francis Hospital and Health Centers - Beech Grove Campus","city":"Beech Grove","region":"Indiana","country":"United States","cc":"US","lat":39.72543,"lon":-86.07854,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"46107","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-st-francis-hospital-and-health-centers-beech-grove-campus-beech-grov"},{"id":"nct00516503-elkhart-general-hospital-elkhart","cat":"research","name":"Elkhart General Hospital","city":"Elkhart","region":"Indiana","country":"United States","cc":"US","lat":41.68778,"lon":-85.97559,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"46515","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-elkhart-general-hospital-elkhart"},{"id":"nct00516503-howard-community-hospital-kokomo","cat":"research","name":"Howard Community Hospital","city":"Kokomo","region":"Indiana","country":"United States","cc":"US","lat":40.48968,"lon":-86.14165,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"46904","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-howard-community-hospital-kokomo"},{"id":"nct00516503-center-for-cancer-therapy-at-laporte-hospital-and-health-services-la","cat":"research","name":"Center for Cancer Therapy at LaPorte Hospital and Health Services","city":"La Porte","region":"Indiana","country":"United States","cc":"US","lat":29.65538,"lon":-95.00765,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"46350","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-center-for-cancer-therapy-at-laporte-hospital-and-health-services-la"},{"id":"nct00516503-saint-anthony-memorial-health-centers-michigan-city","cat":"research","name":"Saint Anthony Memorial Health Centers","city":"Michigan City","region":"Indiana","country":"United States","cc":"US","lat":41.71022,"lon":-86.88359,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"46360","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-saint-anthony-memorial-health-centers-michigan-city"},{"id":"nct00516503-reid-hospital-health-care-services-richmond","cat":"research","name":"Reid Hospital & Health Care Services","city":"Richmond","region":"Indiana","country":"United States","cc":"US","lat":37.55823,"lon":-77.46944,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"47374","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-reid-hospital-health-care-services-richmond"},{"id":"nct00516503-ccop-northern-indiana-cr-consortium-south-bend","cat":"research","name":"CCOP - Northern Indiana CR Consortium","city":"South Bend","region":"Indiana","country":"United States","cc":"US","lat":41.67712,"lon":-86.25768,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"46601","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-ccop-northern-indiana-cr-consortium-south-bend"},{"id":"nct00516503-memorial-hospital-of-south-bend-south-bend","cat":"research","name":"Memorial Hospital of South Bend","city":"South Bend","region":"Indiana","country":"United States","cc":"US","lat":41.68484,"lon":-86.25683,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"46601","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-memorial-hospital-of-south-bend-south-bend"},{"id":"nct00516503-saint-joseph-regional-medical-center-south-bend","cat":"research","name":"Saint Joseph Regional Medical Center","city":"South Bend","region":"Indiana","country":"United States","cc":"US","lat":41.6791,"lon":-86.24874,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"46617","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-saint-joseph-regional-medical-center-south-bend"},{"id":"nct00516503-mcfarland-clinic-pc-ames","cat":"research","name":"McFarland Clinic, PC","city":"Ames","region":"Iowa","country":"United States","cc":"US","lat":42.03344,"lon":-93.61246,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"50010","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-mcfarland-clinic-pc-ames"},{"id":"nct00516503-unnamed-trial-site-bettendorf","cat":"research","name":"Unnamed trial site","city":"Bettendorf","region":"Iowa","country":"United States","cc":"US","lat":41.52641,"lon":-90.52421,"gp":"city","unnamed":1,"drugs":["ketamine"],"zip":"52722","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-unnamed-trial-site-bettendorf"},{"id":"nct00516503-cedar-rapids-oncology-associates-cedar-rapids","cat":"research","name":"Cedar Rapids Oncology Associates","city":"Cedar Rapids","region":"Iowa","country":"United States","cc":"US","lat":42.01233,"lon":-91.6428,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"52403","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-cedar-rapids-oncology-associates-cedar-rapids"},{"id":"nct00516503-siouxland-hematology-oncology-associates-llp-sioux-city","cat":"research","name":"Siouxland Hematology-Oncology Associates, LLP","city":"Sioux City","region":"Iowa","country":"United States","cc":"US","lat":42.50484,"lon":-96.39085,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"51101","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-siouxland-hematology-oncology-associates-llp-sioux-city"},{"id":"nct00516503-mercy-medical-center-sioux-city-sioux-city","cat":"research","name":"Mercy Medical Center - Sioux City","city":"Sioux City","region":"Iowa","country":"United States","cc":"US","lat":42.49288,"lon":-96.38953,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"51104","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-mercy-medical-center-sioux-city-sioux-city"},{"id":"nct00516503-st-luke-s-regional-medical-center-sioux-city","cat":"research","name":"St. Luke's Regional Medical Center","city":"Sioux City","region":"Iowa","country":"United States","cc":"US","lat":42.49213,"lon":-96.3933,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"51104","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-st-luke-s-regional-medical-center-sioux-city"},{"id":"nct00516503-hickman-cancer-center-at-bixby-medical-center-adrian","cat":"research","name":"Hickman Cancer Center at Bixby Medical Center","city":"Adrian","region":"Michigan","country":"United States","cc":"US","lat":41.8975,"lon":-84.03044,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"49221","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-hickman-cancer-center-at-bixby-medical-center-adrian"},{"id":"nct00516503-haematology-oncology-associates-of-ohio-and-michigan-pc-lambertville","cat":"research","name":"Haematology-Oncology Associates of Ohio and Michigan, PC","city":"Lambertville","region":"Michigan","country":"United States","cc":"US","lat":41.76837,"lon":-83.61797,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"48144","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-haematology-oncology-associates-of-ohio-and-michigan-pc-lambertville"},{"id":"nct00516503-community-cancer-center-of-monroe-monroe","cat":"research","name":"Community Cancer Center of Monroe","city":"Monroe","region":"Michigan","country":"United States","cc":"US","lat":32.52037,"lon":-92.11577,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"48162","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-community-cancer-center-of-monroe-monroe"},{"id":"nct00516503-mercy-memorial-hospital-monroe-monroe","cat":"research","name":"Mercy Memorial Hospital - Monroe","city":"Monroe","region":"Michigan","country":"United States","cc":"US","lat":32.51726,"lon":-92.12866,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"48162","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-mercy-memorial-hospital-monroe-monroe"},{"id":"nct00516503-lakeland-regional-cancer-care-center-st-joseph-saint-joseph","cat":"research","name":"Lakeland Regional Cancer Care Center - St. Joseph","city":"Saint Joseph","region":"Michigan","country":"United States","cc":"US","lat":39.76706,"lon":-94.85355,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"49085","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-lakeland-regional-cancer-care-center-st-joseph-saint-joseph"},{"id":"nct00516503-meritcare-bemidji-bemidji","cat":"research","name":"MeritCare Bemidji","city":"Bemidji","region":"Minnesota","country":"United States","cc":"US","lat":47.47031,"lon":-94.87553,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"56601","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-meritcare-bemidji-bemidji"},{"id":"nct00516503-fairview-ridges-hospital-burnsville","cat":"research","name":"Fairview Ridges Hospital","city":"Burnsville","region":"Minnesota","country":"United States","cc":"US","lat":44.77334,"lon":-93.28473,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55337","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-fairview-ridges-hospital-burnsville"},{"id":"nct00516503-mercy-and-unity-cancer-center-at-mercy-hospital-coon-rapids","cat":"research","name":"Mercy and Unity Cancer Center at Mercy Hospital","city":"Coon Rapids","region":"Minnesota","country":"United States","cc":"US","lat":45.11635,"lon":-93.28947,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55433","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-mercy-and-unity-cancer-center-at-mercy-hospital-coon-rapids"},{"id":"nct00516503-duluth-clinic-cancer-center-duluth-duluth","cat":"research","name":"Duluth Clinic Cancer Center - Duluth","city":"Duluth","region":"Minnesota","country":"United States","cc":"US","lat":46.78802,"lon":-92.11491,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55805-1983","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-duluth-clinic-cancer-center-duluth-duluth"},{"id":"nct00516503-ccop-duluth-duluth","cat":"research","name":"CCOP - Duluth","city":"Duluth","region":"Minnesota","country":"United States","cc":"US","lat":46.78049,"lon":-92.0958,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55805","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-ccop-duluth-duluth"},{"id":"nct00516503-miller-dwan-medical-center-duluth","cat":"research","name":"Miller - Dwan Medical Center","city":"Duluth","region":"Minnesota","country":"United States","cc":"US","lat":46.78388,"lon":-92.11547,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55805","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-miller-dwan-medical-center-duluth"},{"id":"nct00516503-fairview-southdale-hospital-edina","cat":"research","name":"Fairview Southdale Hospital","city":"Edina","region":"Minnesota","country":"United States","cc":"US","lat":44.88974,"lon":-93.36073,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55435","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-fairview-southdale-hospital-edina"},{"id":"nct00516503-mercy-and-unity-cancer-center-at-unity-hospital-fridley","cat":"research","name":"Mercy and Unity Cancer Center at Unity Hospital","city":"Fridley","region":"Minnesota","country":"United States","cc":"US","lat":45.07512,"lon":-93.25467,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55432","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-mercy-and-unity-cancer-center-at-unity-hospital-fridley"},{"id":"nct00516503-immanuel-st-joseph-s-mankato","cat":"research","name":"Immanuel St. Joseph's","city":"Mankato","region":"Minnesota","country":"United States","cc":"US","lat":44.16071,"lon":-94.00129,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"56002","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-immanuel-st-joseph-s-mankato"},{"id":"nct00516503-minnesota-oncology-hematology-pa-maplewood-maplewood","cat":"research","name":"Minnesota Oncology Hematology, PA - Maplewood","city":"Maplewood","region":"Minnesota","country":"United States","cc":"US","lat":44.96286,"lon":-92.99282,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55109","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-minnesota-oncology-hematology-pa-maplewood-maplewood"},{"id":"nct00516503-virginia-piper-cancer-institute-at-abbott-northwestern-hospital-minn","cat":"research","name":"Virginia Piper Cancer Institute at Abbott - Northwestern Hospital","city":"Minneapolis","region":"Minnesota","country":"United States","cc":"US","lat":44.97559,"lon":-93.26078,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55407","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-virginia-piper-cancer-institute-at-abbott-northwestern-hospital-minn"},{"id":"nct00516503-hubert-h-humphrey-cancer-center-at-north-memorial-outpatient-center-","cat":"research","name":"Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center","city":"Robbinsdale","region":"Minnesota","country":"United States","cc":"US","lat":45.03741,"lon":-93.34924,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55422-2900","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-hubert-h-humphrey-cancer-center-at-north-memorial-outpatient-center-"},{"id":"nct00516503-mayo-clinic-cancer-center-rochester","cat":"research","name":"Mayo Clinic Cancer Center","city":"Rochester","region":"Minnesota","country":"United States","cc":"US","lat":43.16546,"lon":-77.62615,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55905","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-mayo-clinic-cancer-center-rochester"},{"id":"nct00516503-ccop-metro-minnesota-saint-louis-park","cat":"research","name":"CCOP - Metro-Minnesota","city":"Saint Louis Park","region":"Minnesota","country":"United States","cc":"US","lat":44.94204,"lon":-93.35267,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55416","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-ccop-metro-minnesota-saint-louis-park"},{"id":"nct00516503-park-nicollet-cancer-center-saint-louis-park","cat":"research","name":"Park Nicollet Cancer Center","city":"Saint Louis Park","region":"Minnesota","country":"United States","cc":"US","lat":44.94759,"lon":-93.3361,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55416","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-park-nicollet-cancer-center-saint-louis-park"},{"id":"nct00516503-united-hospital-saint-paul","cat":"research","name":"United Hospital","city":"Saint Paul","region":"Minnesota","country":"United States","cc":"US","lat":44.95537,"lon":-93.09633,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55102","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-united-hospital-saint-paul"},{"id":"nct00516503-ridgeview-medical-center-waconia","cat":"research","name":"Ridgeview Medical Center","city":"Waconia","region":"Minnesota","country":"United States","cc":"US","lat":44.85489,"lon":-93.7815,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55387","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-ridgeview-medical-center-waconia"},{"id":"nct00516503-willmar-cancer-center-at-rice-memorial-hospital-willmar","cat":"research","name":"Willmar Cancer Center at Rice Memorial Hospital","city":"Willmar","region":"Minnesota","country":"United States","cc":"US","lat":45.11038,"lon":-95.05158,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"56201","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-willmar-cancer-center-at-rice-memorial-hospital-willmar"},{"id":"nct00516503-minnesota-oncology-hematology-pa-woodbury-woodbury","cat":"research","name":"Minnesota Oncology Hematology, PA - Woodbury","city":"Woodbury","region":"Minnesota","country":"United States","cc":"US","lat":44.93068,"lon":-92.9518,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55125","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-minnesota-oncology-hematology-pa-woodbury-woodbury"},{"id":"nct00516503-ccop-montana-cancer-consortium-billings","cat":"research","name":"CCOP - Montana Cancer Consortium","city":"Billings","region":"Montana","country":"United States","cc":"US","lat":45.77647,"lon":-108.49914,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"59101","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-ccop-montana-cancer-consortium-billings"},{"id":"nct00516503-hematology-oncology-centers-of-the-northern-rockies-billings-billing","cat":"research","name":"Hematology-Oncology Centers of the Northern Rockies - Billings","city":"Billings","region":"Montana","country":"United States","cc":"US","lat":45.79105,"lon":-108.4901,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"59101","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-hematology-oncology-centers-of-the-northern-rockies-billings-billing"},{"id":"nct00516503-northern-rockies-radiation-oncology-center-billings","cat":"research","name":"Northern Rockies Radiation Oncology Center","city":"Billings","region":"Montana","country":"United States","cc":"US","lat":45.79294,"lon":-108.50234,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"59101","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-northern-rockies-radiation-oncology-center-billings"},{"id":"nct00516503-st-vincent-healthcare-cancer-care-services-billings","cat":"research","name":"St. Vincent Healthcare Cancer Care Services","city":"Billings","region":"Montana","country":"United States","cc":"US","lat":45.77901,"lon":-108.50365,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"59101","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-st-vincent-healthcare-cancer-care-services-billings"},{"id":"nct00516503-billings-clinic-downtown-billings","cat":"research","name":"Billings Clinic - Downtown","city":"Billings","region":"Montana","country":"United States","cc":"US","lat":45.77571,"lon":-108.50657,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"59107-7000","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-billings-clinic-downtown-billings"},{"id":"nct00516503-st-james-healthcare-cancer-care-butte","cat":"research","name":"St. James Healthcare Cancer Care","city":"Butte","region":"Montana","country":"United States","cc":"US","lat":46.00584,"lon":-112.52942,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"59701","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-st-james-healthcare-cancer-care-butte"},{"id":"nct00516503-big-sky-oncology-great-falls","cat":"research","name":"Big Sky Oncology","city":"Great Falls","region":"Montana","country":"United States","cc":"US","lat":47.51083,"lon":-111.28947,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"59405-5309","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-big-sky-oncology-great-falls"},{"id":"nct00516503-great-falls-clinic-main-facility-great-falls","cat":"research","name":"Great Falls Clinic - Main Facility","city":"Great Falls","region":"Montana","country":"United States","cc":"US","lat":47.49803,"lon":-111.29888,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"59405","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-great-falls-clinic-main-facility-great-falls"},{"id":"nct00516503-sletten-cancer-institute-at-benefis-healthcare-great-falls","cat":"research","name":"Sletten Cancer Institute at Benefis Healthcare","city":"Great Falls","region":"Montana","country":"United States","cc":"US","lat":47.50029,"lon":-111.29342,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"59405","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-sletten-cancer-institute-at-benefis-healthcare-great-falls"},{"id":"nct00516503-unnamed-trial-site-great-falls","cat":"research","name":"Unnamed trial site","city":"Great Falls","region":"Montana","country":"United States","cc":"US","lat":47.50057,"lon":-111.29662,"gp":"city","unnamed":1,"drugs":["ketamine"],"zip":"59405","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-unnamed-trial-site-great-falls"},{"id":"nct00516503-glacier-oncology-pllc-kalispell","cat":"research","name":"Glacier Oncology, PLLC","city":"Kalispell","region":"Montana","country":"United States","cc":"US","lat":48.19819,"lon":-114.30298,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"59901","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-glacier-oncology-pllc-kalispell"},{"id":"nct00516503-kalispell-medical-oncology-at-krmc-kalispell","cat":"research","name":"Kalispell Medical Oncology at KRMC","city":"Kalispell","region":"Montana","country":"United States","cc":"US","lat":48.20346,"lon":-114.32152,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"59901","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-kalispell-medical-oncology-at-krmc-kalispell"},{"id":"nct00516503-kalispell-regional-medical-center-kalispell","cat":"research","name":"Kalispell Regional Medical Center","city":"Kalispell","region":"Montana","country":"United States","cc":"US","lat":48.18803,"lon":-114.31747,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"59901","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-kalispell-regional-medical-center-kalispell"},{"id":"nct00516503-community-medical-center-missoula","cat":"research","name":"Community Medical Center","city":"Missoula","region":"Montana","country":"United States","cc":"US","lat":46.8609,"lon":-113.99838,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"59801","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-community-medical-center-missoula"},{"id":"nct00516503-guardian-oncology-and-center-for-wellness-missoula","cat":"research","name":"Guardian Oncology and Center for Wellness","city":"Missoula","region":"Montana","country":"United States","cc":"US","lat":46.87728,"lon":-114.00374,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"59804","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-guardian-oncology-and-center-for-wellness-missoula"},{"id":"nct00516503-montana-cancer-specialists-at-montana-cancer-center-missoula","cat":"research","name":"Montana Cancer Specialists at Montana Cancer Center","city":"Missoula","region":"Montana","country":"United States","cc":"US","lat":46.87173,"lon":-113.99329,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"59807-7877","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-montana-cancer-specialists-at-montana-cancer-center-missoula"},{"id":"nct00516503-montana-cancer-center-at-st-patrick-hospital-and-health-sciences-cen","cat":"research","name":"Montana Cancer Center at St. Patrick Hospital and Health Sciences Center","city":"Missoula","region":"Montana","country":"United States","cc":"US","lat":46.86034,"lon":-113.98642,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"59807","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-montana-cancer-center-at-st-patrick-hospital-and-health-sciences-cen"},{"id":"nct00516503-cancer-resource-center-lincoln-lincoln","cat":"research","name":"Cancer Resource Center - Lincoln","city":"Lincoln","region":"Nebraska","country":"United States","cc":"US","lat":40.79929,"lon":-96.6672,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"68510","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-cancer-resource-center-lincoln-lincoln"},{"id":"nct00516503-ccop-missouri-valley-cancer-consortium-omaha","cat":"research","name":"CCOP - Missouri Valley Cancer Consortium","city":"Omaha","region":"Nebraska","country":"United States","cc":"US","lat":41.25762,"lon":-95.93361,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"68106","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-ccop-missouri-valley-cancer-consortium-omaha"},{"id":"nct00516503-immanuel-medical-center-omaha","cat":"research","name":"Immanuel Medical Center","city":"Omaha","region":"Nebraska","country":"United States","cc":"US","lat":41.25273,"lon":-95.94085,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"68122","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-immanuel-medical-center-omaha"},{"id":"nct00516503-alegant-health-cancer-center-at-bergan-mercy-medical-center-omaha","cat":"research","name":"Alegant Health Cancer Center at Bergan Mercy Medical Center","city":"Omaha","region":"Nebraska","country":"United States","cc":"US","lat":41.25047,"lon":-95.92984,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"68124","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-alegant-health-cancer-center-at-bergan-mercy-medical-center-omaha"},{"id":"nct00516503-creighton-university-medical-center-omaha","cat":"research","name":"Creighton University Medical Center","city":"Omaha","region":"Nebraska","country":"United States","cc":"US","lat":41.24699,"lon":-95.93652,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"68131-2197","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-creighton-university-medical-center-omaha"},{"id":"nct00516503-rutherford-hospital-rutherfordton","cat":"research","name":"Rutherford Hospital","city":"Rutherfordton","region":"North Carolina","country":"United States","cc":"US","lat":35.37094,"lon":-81.95597,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"28139","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-rutherford-hospital-rutherfordton"},{"id":"nct00516503-bismarck-cancer-center-bismarck","cat":"research","name":"Bismarck Cancer Center","city":"Bismarck","region":"North Dakota","country":"United States","cc":"US","lat":46.79642,"lon":-100.77362,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"58501","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-bismarck-cancer-center-bismarck"},{"id":"nct00516503-medcenter-one-hospital-cancer-care-center-bismarck","cat":"research","name":"Medcenter One Hospital Cancer Care Center","city":"Bismarck","region":"North Dakota","country":"United States","cc":"US","lat":46.79727,"lon":-100.79452,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"58501","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-medcenter-one-hospital-cancer-care-center-bismarck"},{"id":"nct00516503-mid-dakota-clinic-pc-bismarck","cat":"research","name":"Mid Dakota Clinic, PC","city":"Bismarck","region":"North Dakota","country":"United States","cc":"US","lat":46.80565,"lon":-100.79038,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"58501","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-mid-dakota-clinic-pc-bismarck"},{"id":"nct00516503-st-alexius-medical-center-cancer-center-bismarck","cat":"research","name":"St. Alexius Medical Center Cancer Center","city":"Bismarck","region":"North Dakota","country":"United States","cc":"US","lat":46.81346,"lon":-100.77692,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"58502","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-st-alexius-medical-center-cancer-center-bismarck"},{"id":"nct00516503-ccop-meritcare-hospital-fargo","cat":"research","name":"CCOP - MeritCare Hospital","city":"Fargo","region":"North Dakota","country":"United States","cc":"US","lat":46.86547,"lon":-96.77865,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"58122","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-ccop-meritcare-hospital-fargo"},{"id":"nct00516503-meritcare-broadway-fargo","cat":"research","name":"MeritCare Broadway","city":"Fargo","region":"North Dakota","country":"United States","cc":"US","lat":46.88298,"lon":-96.80076,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"58122","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-meritcare-broadway-fargo"},{"id":"nct00516503-altru-cancer-center-at-altru-hospital-grand-forks","cat":"research","name":"Altru Cancer Center at Altru Hospital","city":"Grand Forks","region":"North Dakota","country":"United States","cc":"US","lat":47.92945,"lon":-97.03826,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"58201","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-altru-cancer-center-at-altru-hospital-grand-forks"},{"id":"nct00516503-mary-rutan-hospital-bellefontaine","cat":"research","name":"Mary Rutan Hospital","city":"Bellefontaine","region":"Ohio","country":"United States","cc":"US","lat":40.37118,"lon":-83.75839,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43311","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-mary-rutan-hospital-bellefontaine"},{"id":"nct00516503-wood-county-oncology-center-bowling-green","cat":"research","name":"Wood County Oncology Center","city":"Bowling Green","region":"Ohio","country":"United States","cc":"US","lat":36.9946,"lon":-86.43725,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43402","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-wood-county-oncology-center-bowling-green"},{"id":"nct00516503-adena-regional-medical-center-chillicothe","cat":"research","name":"Adena Regional Medical Center","city":"Chillicothe","region":"Ohio","country":"United States","cc":"US","lat":39.33891,"lon":-82.9768,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45601","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-adena-regional-medical-center-chillicothe"},{"id":"nct00516503-north-coast-cancer-care-clyde-clyde","cat":"research","name":"North Coast Cancer Care - Clyde","city":"Clyde","region":"Ohio","country":"United States","cc":"US","lat":41.30351,"lon":-82.97684,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43410","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-north-coast-cancer-care-clyde-clyde"},{"id":"nct00516503-riverside-methodist-hospital-cancer-care-columbus","cat":"research","name":"Riverside Methodist Hospital Cancer Care","city":"Columbus","region":"Ohio","country":"United States","cc":"US","lat":39.95934,"lon":-83.00091,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43214-3998","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-riverside-methodist-hospital-cancer-care-columbus"},{"id":"nct00516503-ccop-columbus-columbus","cat":"research","name":"CCOP - Columbus","city":"Columbus","region":"Ohio","country":"United States","cc":"US","lat":39.96433,"lon":-82.99291,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43215","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-ccop-columbus-columbus"},{"id":"nct00516503-grant-medical-center-cancer-care-columbus","cat":"research","name":"Grant Medical Center Cancer Care","city":"Columbus","region":"Ohio","country":"United States","cc":"US","lat":39.97205,"lon":-83.00505,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43215","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-grant-medical-center-cancer-care-columbus"},{"id":"nct00516503-mount-carmel-health-west-hospital-columbus","cat":"research","name":"Mount Carmel Health - West Hospital","city":"Columbus","region":"Ohio","country":"United States","cc":"US","lat":39.97017,"lon":-83.0091,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43222","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-mount-carmel-health-west-hospital-columbus"},{"id":"nct00516503-doctors-hospital-at-ohio-health-columbus","cat":"research","name":"Doctors Hospital at Ohio Health","city":"Columbus","region":"Ohio","country":"United States","cc":"US","lat":39.97252,"lon":-82.98783,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43228","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-doctors-hospital-at-ohio-health-columbus"},{"id":"nct00516503-grandview-hospital-dayton","cat":"research","name":"Grandview Hospital","city":"Dayton","region":"Ohio","country":"United States","cc":"US","lat":39.75617,"lon":-84.20352,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45405","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-grandview-hospital-dayton"},{"id":"nct00516503-good-samaritan-hospital-dayton","cat":"research","name":"Good Samaritan Hospital","city":"Dayton","region":"Ohio","country":"United States","cc":"US","lat":39.76446,"lon":-84.19345,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45406","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-good-samaritan-hospital-dayton"},{"id":"nct00516503-samaritan-north-cancer-care-center-dayton","cat":"research","name":"Samaritan North Cancer Care Center","city":"Dayton","region":"Ohio","country":"United States","cc":"US","lat":39.74723,"lon":-84.18817,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45415","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-samaritan-north-cancer-care-center-dayton"},{"id":"nct00516503-ccop-dayton-dayton","cat":"research","name":"CCOP - Dayton","city":"Dayton","region":"Ohio","country":"United States","cc":"US","lat":39.7558,"lon":-84.18243,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45429","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-ccop-dayton-dayton"},{"id":"nct00516503-grady-memorial-hospital-delaware","cat":"research","name":"Grady Memorial Hospital","city":"Delaware","region":"Ohio","country":"United States","cc":"US","lat":40.30173,"lon":-83.05597,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43015","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-grady-memorial-hospital-delaware"},{"id":"nct00516503-hematology-oncology-center-elyria","cat":"research","name":"Hematology Oncology Center","city":"Elyria","region":"Ohio","country":"United States","cc":"US","lat":41.37746,"lon":-82.1045,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44035","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-hematology-oncology-center-elyria"},{"id":"nct00516503-blanchard-valley-medical-associates-findlay","cat":"research","name":"Blanchard Valley Medical Associates","city":"Findlay","region":"Ohio","country":"United States","cc":"US","lat":41.05349,"lon":-83.65431,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45840","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-blanchard-valley-medical-associates-findlay"},{"id":"nct00516503-middletown-regional-hospital-franklin","cat":"research","name":"Middletown Regional Hospital","city":"Franklin","region":"Ohio","country":"United States","cc":"US","lat":35.92878,"lon":-86.86997,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45005-1066","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-middletown-regional-hospital-franklin"},{"id":"nct00516503-charles-f-kettering-memorial-hospital-kettering","cat":"research","name":"Charles F. Kettering Memorial Hospital","city":"Kettering","region":"Ohio","country":"United States","cc":"US","lat":39.67835,"lon":-84.1573,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45429","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-charles-f-kettering-memorial-hospital-kettering"},{"id":"nct00516503-fairfield-medical-center-lancaster","cat":"research","name":"Fairfield Medical Center","city":"Lancaster","region":"Ohio","country":"United States","cc":"US","lat":34.70609,"lon":-118.12578,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43130","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-fairfield-medical-center-lancaster"},{"id":"nct00516503-lima-memorial-hospital-lima","cat":"research","name":"Lima Memorial Hospital","city":"Lima","region":"Ohio","country":"United States","cc":"US","lat":40.7345,"lon":-84.1113,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45804","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-lima-memorial-hospital-lima"},{"id":"nct00516503-strecker-cancer-center-at-marietta-memorial-hospital-marietta","cat":"research","name":"Strecker Cancer Center at Marietta Memorial Hospital","city":"Marietta","region":"Ohio","country":"United States","cc":"US","lat":33.94653,"lon":-84.56024,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45750","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-strecker-cancer-center-at-marietta-memorial-hospital-marietta"},{"id":"nct00516503-northwest-ohio-oncology-center-maumee","cat":"research","name":"Northwest Ohio Oncology Center","city":"Maumee","region":"Ohio","country":"United States","cc":"US","lat":41.5689,"lon":-83.66027,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43537","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-northwest-ohio-oncology-center-maumee"},{"id":"nct00516503-st-luke-s-hospital-maumee","cat":"research","name":"St. Luke's Hospital","city":"Maumee","region":"Ohio","country":"United States","cc":"US","lat":41.57191,"lon":-83.64643,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43537","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-st-luke-s-hospital-maumee"},{"id":"nct00516503-licking-memorial-cancer-care-program-at-licking-memorial-hospital-ne","cat":"research","name":"Licking Memorial Cancer Care Program at Licking Memorial Hospital","city":"Newark","region":"Ohio","country":"United States","cc":"US","lat":40.72639,"lon":-74.17863,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43055","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-licking-memorial-cancer-care-program-at-licking-memorial-hospital-ne"},{"id":"nct00516503-st-charles-mercy-hospital-oregon","cat":"research","name":"St. Charles Mercy Hospital","city":"Oregon","region":"Ohio","country":"United States","cc":"US","lat":41.63486,"lon":-83.49888,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43616","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-st-charles-mercy-hospital-oregon"},{"id":"nct00516503-toledo-clinic-oregon-oregon","cat":"research","name":"Toledo Clinic - Oregon","city":"Oregon","region":"Ohio","country":"United States","cc":"US","lat":41.63542,"lon":-83.47827,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43616","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-toledo-clinic-oregon-oregon"},{"id":"nct00516503-north-coast-cancer-care-incorporated-sandusky","cat":"research","name":"North Coast Cancer Care, Incorporated","city":"Sandusky","region":"Ohio","country":"United States","cc":"US","lat":41.44005,"lon":-82.71874,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44870","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-north-coast-cancer-care-incorporated-sandusky"},{"id":"nct00516503-mercy-medical-center-springfield","cat":"research","name":"Mercy Medical Center","city":"Springfield","region":"Ohio","country":"United States","cc":"US","lat":37.22404,"lon":-93.30422,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45504","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-mercy-medical-center-springfield"},{"id":"nct00516503-community-hospital-of-springfield-and-clark-county-springfield","cat":"research","name":"Community Hospital of Springfield and Clark County","city":"Springfield","region":"Ohio","country":"United States","cc":"US","lat":37.21058,"lon":-93.30638,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45505","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-community-hospital-of-springfield-and-clark-county-springfield"},{"id":"nct00516503-flower-hospital-cancer-center-sylvania","cat":"research","name":"Flower Hospital Cancer Center","city":"Sylvania","region":"Ohio","country":"United States","cc":"US","lat":41.72219,"lon":-83.72217,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43560","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-flower-hospital-cancer-center-sylvania"},{"id":"nct00516503-mercy-hospital-of-tiffin-tiffin","cat":"research","name":"Mercy Hospital of Tiffin","city":"Tiffin","region":"Ohio","country":"United States","cc":"US","lat":41.11756,"lon":-83.17821,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44883","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-mercy-hospital-of-tiffin-tiffin"},{"id":"nct00516503-toledo-hospital-toledo","cat":"research","name":"Toledo Hospital","city":"Toledo","region":"Ohio","country":"United States","cc":"US","lat":41.66286,"lon":-83.55027,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43606","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-toledo-hospital-toledo"},{"id":"nct00516503-st-vincent-mercy-medical-center-toledo","cat":"research","name":"St. Vincent Mercy Medical Center","city":"Toledo","region":"Ohio","country":"United States","cc":"US","lat":41.66719,"lon":-83.54829,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43608","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-st-vincent-mercy-medical-center-toledo"},{"id":"nct00516503-medical-university-of-ohio-cancer-center-toledo","cat":"research","name":"Medical University of Ohio Cancer Center","city":"Toledo","region":"Ohio","country":"United States","cc":"US","lat":41.66079,"lon":-83.54415,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43614","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-medical-university-of-ohio-cancer-center-toledo"},{"id":"nct00516503-ccop-toledo-community-hospital-toledo","cat":"research","name":"CCOP - Toledo Community Hospital","city":"Toledo","region":"Ohio","country":"United States","cc":"US","lat":41.6701,"lon":-83.55554,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43617","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-ccop-toledo-community-hospital-toledo"},{"id":"nct00516503-st-anne-mercy-hospital-toledo","cat":"research","name":"St. Anne Mercy Hospital","city":"Toledo","region":"Ohio","country":"United States","cc":"US","lat":41.67349,"lon":-83.56599,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43623","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-st-anne-mercy-hospital-toledo"},{"id":"nct00516503-toledo-clinic-incorporated-main-clinic-toledo","cat":"research","name":"Toledo Clinic, Incorporated - Main Clinic","city":"Toledo","region":"Ohio","country":"United States","cc":"US","lat":41.65618,"lon":-83.54905,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43623","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-toledo-clinic-incorporated-main-clinic-toledo"},{"id":"nct00516503-uvmc-cancer-care-center-at-upper-valley-medical-center-troy","cat":"research","name":"UVMC Cancer Care Center at Upper Valley Medical Center","city":"Troy","region":"Ohio","country":"United States","cc":"US","lat":42.59886,"lon":-83.14753,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45373-1300","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-uvmc-cancer-care-center-at-upper-valley-medical-center-troy"},{"id":"nct00516503-fulton-county-health-center-wauseon","cat":"research","name":"Fulton County Health Center","city":"Wauseon","region":"Ohio","country":"United States","cc":"US","lat":41.53835,"lon":-84.14401,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43567","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-fulton-county-health-center-wauseon"},{"id":"nct00516503-mount-carmel-st-ann-s-cancer-center-westerville","cat":"research","name":"Mount Carmel St. Ann's Cancer Center","city":"Westerville","region":"Ohio","country":"United States","cc":"US","lat":40.13008,"lon":-82.92375,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43081","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-mount-carmel-st-ann-s-cancer-center-westerville"},{"id":"nct00516503-clinton-memorial-hospital-wilmington","cat":"research","name":"Clinton Memorial Hospital","city":"Wilmington","region":"Ohio","country":"United States","cc":"US","lat":34.24201,"lon":-77.94166,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45177","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-clinton-memorial-hospital-wilmington"},{"id":"nct00516503-ruth-g-mcmillan-cancer-center-at-greene-memorial-hospital-xenia","cat":"research","name":"Ruth G. McMillan Cancer Center at Greene Memorial Hospital","city":"Xenia","region":"Ohio","country":"United States","cc":"US","lat":39.67758,"lon":-83.9216,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45385","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-ruth-g-mcmillan-cancer-center-at-greene-memorial-hospital-xenia"},{"id":"nct00516503-genesis-good-samaritan-hospital-zanesville","cat":"research","name":"Genesis - Good Samaritan Hospital","city":"Zanesville","region":"Ohio","country":"United States","cc":"US","lat":39.93531,"lon":-82.01568,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43701","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-genesis-good-samaritan-hospital-zanesville"},{"id":"nct00516503-legacy-mount-hood-medical-center-gresham","cat":"research","name":"Legacy Mount Hood Medical Center","city":"Gresham","region":"Oregon","country":"United States","cc":"US","lat":45.49343,"lon":-122.43416,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"97030","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-legacy-mount-hood-medical-center-gresham"},{"id":"nct00516503-providence-milwaukie-hospital-milwaukie","cat":"research","name":"Providence Milwaukie Hospital","city":"Milwaukie","region":"Oregon","country":"United States","cc":"US","lat":45.44552,"lon":-122.64232,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"97222","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-providence-milwaukie-hospital-milwaukie"},{"id":"nct00516503-legacy-good-samaritan-hospital-comprehensive-cancer-center-portland","cat":"research","name":"Legacy Good Samaritan Hospital & Comprehensive Cancer Center","city":"Portland","region":"Oregon","country":"United States","cc":"US","lat":45.51616,"lon":-122.68576,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"97210","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-legacy-good-samaritan-hospital-comprehensive-cancer-center-portland"},{"id":"nct00516503-providence-cancer-center-at-providence-portland-medical-center-portl","cat":"research","name":"Providence Cancer Center at Providence Portland Medical Center","city":"Portland","region":"Oregon","country":"United States","cc":"US","lat":45.52557,"lon":-122.66525,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"97213-2967","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-providence-cancer-center-at-providence-portland-medical-center-portl"},{"id":"nct00516503-adventist-medical-center-portland","cat":"research","name":"Adventist Medical Center","city":"Portland","region":"Oregon","country":"United States","cc":"US","lat":45.53216,"lon":-122.66619,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"97216","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-adventist-medical-center-portland"},{"id":"nct00516503-ccop-columbia-river-oncology-program-portland","cat":"research","name":"CCOP - Columbia River Oncology Program","city":"Portland","region":"Oregon","country":"United States","cc":"US","lat":45.51409,"lon":-122.66779,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"97225","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-ccop-columbia-river-oncology-program-portland"},{"id":"nct00516503-providence-st-vincent-medical-center-portland","cat":"research","name":"Providence St. Vincent Medical Center","city":"Portland","region":"Oregon","country":"United States","cc":"US","lat":45.52783,"lon":-122.67362,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"97225","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-providence-st-vincent-medical-center-portland"},{"id":"nct00516503-legacy-emanuel-hospital-and-health-center-and-children-s-hospital-po","cat":"research","name":"Legacy Emanuel Hospital and Health Center and Children's Hospital","city":"Portland","region":"Oregon","country":"United States","cc":"US","lat":45.51729,"lon":-122.68209,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"97227","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-legacy-emanuel-hospital-and-health-center-and-children-s-hospital-po"},{"id":"nct00516503-legacy-meridian-park-hospital-tualatin","cat":"research","name":"Legacy Meridian Park Hospital","city":"Tualatin","region":"Oregon","country":"United States","cc":"US","lat":45.39065,"lon":-122.75924,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"97062","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-legacy-meridian-park-hospital-tualatin"},{"id":"nct00516503-geisinger-cancer-institute-at-geisinger-health-danville","cat":"research","name":"Geisinger Cancer Institute at Geisinger Health","city":"Danville","region":"Pennsylvania","country":"United States","cc":"US","lat":37.82738,"lon":-121.99267,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"17822-0001","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-geisinger-cancer-institute-at-geisinger-health-danville"},{"id":"nct00516503-geisinger-hazleton-cancer-center-hazleton","cat":"research","name":"Geisinger Hazleton Cancer Center","city":"Hazleton","region":"Pennsylvania","country":"United States","cc":"US","lat":40.95066,"lon":-75.97329,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"18201","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-geisinger-hazleton-cancer-center-hazleton"},{"id":"nct00516503-guthrie-cancer-center-at-guthrie-clinic-sayre-sayre","cat":"research","name":"Guthrie Cancer Center at Guthrie Clinic Sayre","city":"Sayre","region":"Pennsylvania","country":"United States","cc":"US","lat":41.96912,"lon":-76.51997,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"18840","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-guthrie-cancer-center-at-guthrie-clinic-sayre-sayre"},{"id":"nct00516503-geisinger-medical-group-scenery-park-state-college","cat":"research","name":"Geisinger Medical Group - Scenery Park","city":"State College","region":"Pennsylvania","country":"United States","cc":"US","lat":40.80068,"lon":-77.85092,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"16801","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-geisinger-medical-group-scenery-park-state-college"},{"id":"nct00516503-frank-m-and-dorothea-henry-cancer-center-at-geisinger-wyoming-valley","cat":"research","name":"Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center","city":"Wilkes-Barre","region":"Pennsylvania","country":"United States","cc":"US","lat":41.23523,"lon":-75.87863,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"18711","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-frank-m-and-dorothea-henry-cancer-center-at-geisinger-wyoming-valley"},{"id":"nct00516503-mercy-hospital-at-wilkes-barre-wilkes-barre","cat":"research","name":"Mercy Hospital at Wilkes-Barre","city":"Wilkes-Barre","region":"Pennsylvania","country":"United States","cc":"US","lat":41.24332,"lon":-75.88239,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"18765","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-mercy-hospital-at-wilkes-barre-wilkes-barre"},{"id":"nct00516503-anmed-cancer-center-anderson","cat":"research","name":"AnMed Cancer Center","city":"Anderson","region":"South Carolina","country":"United States","cc":"US","lat":40.10537,"lon":-85.68058,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"29621","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-anmed-cancer-center-anderson"},{"id":"nct00516503-ccop-upstate-carolina-spartanburg","cat":"research","name":"CCOP - Upstate Carolina","city":"Spartanburg","region":"South Carolina","country":"United States","cc":"US","lat":34.93785,"lon":-81.93116,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"29303","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-ccop-upstate-carolina-spartanburg"},{"id":"nct00516503-gibbs-regional-cancer-center-at-spartanburg-regional-medical-center-","cat":"research","name":"Gibbs Regional Cancer Center at Spartanburg Regional Medical Center","city":"Spartanburg","region":"South Carolina","country":"United States","cc":"US","lat":34.96091,"lon":-81.94349,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"29303","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-gibbs-regional-cancer-center-at-spartanburg-regional-medical-center-"},{"id":"nct00516503-rapid-city-regional-hospital-rapid-city","cat":"research","name":"Rapid City Regional Hospital","city":"Rapid City","region":"South Dakota","country":"United States","cc":"US","lat":44.07955,"lon":-103.2319,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"57701","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-rapid-city-regional-hospital-rapid-city"},{"id":"nct00516503-avera-cancer-institute-sioux-falls","cat":"research","name":"Avera Cancer Institute","city":"Sioux Falls","region":"South Dakota","country":"United States","cc":"US","lat":43.54374,"lon":-96.72518,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"57105","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-avera-cancer-institute-sioux-falls"},{"id":"nct00516503-medical-x-ray-center-pc-sioux-falls","cat":"research","name":"Medical X-Ray Center, PC","city":"Sioux Falls","region":"South Dakota","country":"United States","cc":"US","lat":43.54195,"lon":-96.7378,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"57105","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-medical-x-ray-center-pc-sioux-falls"},{"id":"nct00516503-sanford-cancer-center-at-sanford-usd-medical-center-sioux-falls","cat":"research","name":"Sanford Cancer Center at Sanford USD Medical Center","city":"Sioux Falls","region":"South Dakota","country":"United States","cc":"US","lat":43.53254,"lon":-96.733,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"57117-5039","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-sanford-cancer-center-at-sanford-usd-medical-center-sioux-falls"},{"id":"nct00516503-fredericksburg-oncology-incorporated-fredericksburg","cat":"research","name":"Fredericksburg Oncology, Incorporated","city":"Fredericksburg","region":"Virginia","country":"United States","cc":"US","lat":38.31349,"lon":-77.4491,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"22401","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-fredericksburg-oncology-incorporated-fredericksburg"},{"id":"nct00516503-southwest-washington-medical-center-cancer-center-vancouver","cat":"research","name":"Southwest Washington Medical Center Cancer Center","city":"Vancouver","region":"Washington","country":"United States","cc":"US","lat":45.63934,"lon":-122.66483,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"98668","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-southwest-washington-medical-center-cancer-center-vancouver"},{"id":"nct00516503-franciscan-skemp-healthcare-la-crosse-campus-la-crosse","cat":"research","name":"Franciscan Skemp Healthcare - La Crosse Campus","city":"La Crosse","region":"Wisconsin","country":"United States","cc":"US","lat":43.79501,"lon":-91.23069,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"54601","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00516503","study":"Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","official":"Debra Barton, RN, PhD, AOCN, FAAN (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT00516503","phase":"Phase 3","enroll":208,"start":"2008-02","eid":"x:site:nct00516503-franciscan-skemp-healthcare-la-crosse-campus-la-crosse"},{"id":"nct03233035-nouira-samir-monastir","cat":"research","name":"Nouira Samir","city":"Monastir","region":"Emergency Department Monastir, Tunisia 5000","country":"Tunisia","cc":"TN","lat":35.7754,"lon":10.83723,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"5000","condg":["PTSD & trauma"],"nct":"NCT03233035","study":"Low Dose Ketamine Intra Nasal Traumatology","sstatus":"COMPLETED","sponsor":"University of Monastir","official":"Nouira Semir, Professor (university Hospital of Monastir)","src":"https://clinicaltrials.gov/study/NCT03233035","phase":"Phase 2","enroll":1102,"start":"2018-01-01","eid":"x:site:nct03233035-nouira-samir-monastir"},{"id":"nct03233035-emergency-department-of-university-hospital-fattouma-bourguiba-of-mo","cat":"research","name":"Emergency department of university hospital Fattouma Bourguiba of Monastir","city":"Monastir","country":"Tunisia","cc":"TN","lat":35.77917,"lon":10.83026,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"5000","condg":["PTSD & trauma"],"nct":"NCT03233035","study":"Low Dose Ketamine Intra Nasal Traumatology","sstatus":"COMPLETED","sponsor":"University of Monastir","official":"Nouira Semir, Professor (university Hospital of Monastir)","src":"https://clinicaltrials.gov/study/NCT03233035","phase":"Phase 2","enroll":1102,"start":"2018-01-01","eid":"x:site:nct03233035-emergency-department-of-university-hospital-fattouma-bourguiba-of-mo"},{"id":"nct05502211-kasr-al-ainy-cairo","cat":"research","name":"Kasr Al Ainy","city":"Cairo","country":"Egypt","cc":"EG","lat":30.05722,"lon":31.24068,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"12566","condg":["Other"],"status":"RECRUITING","nct":"NCT05502211","study":"A Comparison Between Ketamine-lidocaine Versus Ketamine-fentanyl for Induction on the Hemodynamic Effects in Patients With Coronary Artery Disease","sstatus":"UNKNOWN","sponsor":"Kasr El Aini Hospital","official":"Ayman Abougabal, MD (lecturer of anesthesia Kasr Al Ainy hospital)","src":"https://clinicaltrials.gov/study/NCT05502211","contact":{"n":"Ramy Alkonaesy, MD","p":"01224883990","e":"ayman.abougabal@kasralainy.edu.eg"},"phase":"N/A","enroll":100,"start":"2022-11-01","eid":"x:site:nct05502211-kasr-al-ainy-cairo"},{"id":"nct05502211-kasr-al-ainy-cairo-2","cat":"research","name":"Kasr al ainy","city":"Cairo","country":"Egypt","cc":"EG","lat":30.06371,"lon":31.25489,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"RECRUITING","nct":"NCT05502211","study":"A Comparison Between Ketamine-lidocaine Versus Ketamine-fentanyl for Induction on the Hemodynamic Effects in Patients With Coronary Artery Disease","sstatus":"UNKNOWN","sponsor":"Kasr El Aini Hospital","official":"Ayman Abougabal, MD (lecturer of anesthesia Kasr Al Ainy hospital)","src":"https://clinicaltrials.gov/study/NCT05502211","contact":{"n":"Ramy Alkonaesy","p":"01020671408","e":"ayman.abougabal@kasralainy.edu.eg"},"phase":"N/A","enroll":100,"start":"2022-11-01","eid":"x:site:nct05502211-kasr-al-ainy-cairo-2"},{"id":"nct03711734-hospital-for-special-surgery-new-york","cat":"research","name":"Hospital for Special Surgery","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71196,"lon":-74.01693,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10021","condg":["Other"],"nct":"NCT03711734","study":"Acupuncture ACL (Anterior Cruciate Ligament)","sstatus":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","official":"Stephanie Cheng, MD (Hospital for Special Surgey)","src":"https://clinicaltrials.gov/study/NCT03711734","phase":"N/A","enroll":40,"start":"2018-11-01","eid":"x:site:nct03711734-hospital-for-special-surgery-new-york"},{"id":"nct07596810-alexandria-university-alexandria","cat":"research","name":"Alexandria University","city":"Alexandria","country":"Egypt","cc":"EG","lat":31.20303,"lon":29.92246,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Chronic pain & headache"],"nct":"NCT07596810","study":"Ketamine Added to Quadratus Lumborum Block for Pain Relief After Infant Pyeloplasty","sstatus":"COMPLETED","sponsor":"Alexandria University","src":"https://clinicaltrials.gov/study/NCT07596810","phase":"Phase 4","enroll":40,"start":"2025-06-01","eid":"x:site:nct07596810-alexandria-university-alexandria"},{"id":"nct06138691-washington-university-school-of-medicine-st-louis","cat":"research","name":"Washington University School of Medicine","city":"St Louis","region":"Missouri","country":"United States","cc":"US","lat":38.6244,"lon":-90.19144,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"63110-1010","condg":["Depression"],"nct":"NCT06138691","study":"KET-RO Plus RO DBT for Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Washington University School of Medicine","official":"Kirsten Gilbert, PhD (Washington University School of Medicine)","src":"https://clinicaltrials.gov/study/NCT06138691","phase":"Phase 1","enroll":16,"start":"2023-10-04","eid":"x:site:nct06138691-washington-university-school-of-medicine-st-louis"},{"id":"nct05249309-hospital-moinhos-de-vento-porto-alegre","cat":"research","name":"Hospital Moinhos de Vento","city":"Porto Alegre","region":"Rio Grande do Sul","country":"Brazil","cc":"BR","lat":-30.03627,"lon":-51.24021,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"90035-000","condg":["Depression","Bipolar"],"nct":"NCT05249309","study":"Naturalistic Study of Ketamine in the Treatment of Depression","sstatus":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","official":"Ana P Anzolin, Master (Laboratory of Molecular Psychiatry, Hospital de Clínicas de Porto Alegre); Keila Maria M Ceresér, PhD (Laboratory of Molecular Psychiatry, Hospital de Clínicas de Porto Alegre)","src":"https://clinicaltrials.gov/study/NCT05249309","enroll":90,"start":"2021-05-01","eid":"x:site:nct05249309-hospital-moinhos-de-vento-porto-alegre"},{"id":"nct05249309-hospital-de-clinicas-de-porto-alegre-porto-alegre","cat":"research","name":"Hospital de Clinicas de Porto Alegre","city":"Porto Alegre","region":"Rio Grande do Sul","country":"Brazil","cc":"BR","lat":-30.02215,"lon":-51.24097,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"90035-903","condg":["Depression","Bipolar"],"nct":"NCT05249309","study":"Naturalistic Study of Ketamine in the Treatment of Depression","sstatus":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","official":"Ana P Anzolin, Master (Laboratory of Molecular Psychiatry, Hospital de Clínicas de Porto Alegre); Keila Maria M Ceresér, PhD (Laboratory of Molecular Psychiatry, Hospital de Clínicas de Porto Alegre)","src":"https://clinicaltrials.gov/study/NCT05249309","enroll":90,"start":"2021-05-01","eid":"x:site:nct05249309-hospital-de-clinicas-de-porto-alegre-porto-alegre"},{"id":"nct06036511-university-of-new-mexico-albuquerque","cat":"research","name":"University of New Mexico","city":"Albuquerque","region":"New Mexico","country":"United States","cc":"US","lat":35.09075,"lon":-106.64149,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"87106","condg":["PTSD & trauma"],"nct":"NCT06036511","study":"Connectivity Changes Associated With Ketamine Assisted Psychotherapy for PTSD","sstatus":"WITHDRAWN","sponsor":"University of New Mexico","official":"Snehal Bhatt, MD (UNM)","src":"https://clinicaltrials.gov/study/NCT06036511","phase":"Phase 1/Phase 2","start":"2023-12-31","eid":"x:site:nct06036511-university-of-new-mexico-albuquerque"},{"id":"nct04711005-duke-early-phase-clinical-research-durham","cat":"research","name":"Duke Early Phase Clinical Research","city":"Durham","region":"North Carolina","country":"United States","cc":"US","lat":35.99549,"lon":-78.88766,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"27710","condg":["Depression"],"nct":"NCT04711005","study":"Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine","sstatus":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","official":"Shruti Raja, MD, MHS (Duke University)","src":"https://clinicaltrials.gov/study/NCT04711005","phase":"Phase 1","enroll":74,"start":"2021-01-11","eid":"x:site:nct04711005-duke-early-phase-clinical-research-durham"},{"id":"nct04613453-yale-new-haven-hospital-new-haven","cat":"research","name":"Yale New Haven Hospital","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31836,"lon":-72.93611,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06510","condg":["Depression"],"nct":"NCT04613453","study":"Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine","sstatus":"TERMINATED","sponsor":"Yale University","official":"Michael Bloch, MD MS (Yale University)","src":"https://clinicaltrials.gov/study/NCT04613453","phase":"Phase 2","enroll":12,"start":"2022-01-21","eid":"x:site:nct04613453-yale-new-haven-hospital-new-haven"},{"id":"nct06588907-ankara-etlik-city-hospital-ankara","cat":"research","name":"Ankara Etlik City Hospital","city":"Ankara","region":"Yenimahalle","country":"Turkey","cc":"TR","lat":39.92011,"lon":32.85018,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"38000","condg":["Other"],"nct":"NCT06588907","study":"Pain Palliation in Forearm Fractures in the Emergency Department","sstatus":"COMPLETED","sponsor":"Ankara Etlik City Hospital","official":"Ahmet Burak Erdem (Ankara Etlik City Hospital)","src":"https://clinicaltrials.gov/study/NCT06588907","phase":"N/A","enroll":85,"start":"2024-06-01","eid":"x:site:nct06588907-ankara-etlik-city-hospital-ankara"},{"id":"nct04916548-western-psychiatric-institute-and-clinic-pittsburgh","cat":"research","name":"Western Psychiatric Institute and Clinic","city":"Pittsburgh","region":"Pennsylvania","country":"United States","cc":"US","lat":40.44471,"lon":-79.98521,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"15213","condg":["Depression"],"nct":"NCT04916548","study":"Repeated Neurocognitive Measurements in Depressed Patients","sstatus":"COMPLETED","sponsor":"Rebecca Price","src":"https://clinicaltrials.gov/study/NCT04916548","phase":"Phase 1/Phase 2","enroll":15,"start":"2021-09-16","eid":"x:site:nct04916548-western-psychiatric-institute-and-clinic-pittsburgh"},{"id":"nct03431285-imam-abdulrahman-bin-faisal-university-dammam","cat":"research","name":"Imam Abdulrahman Bin Faisal University","city":"Dammam","region":"Eastern Province","country":"Saudi Arabia","cc":"SA","lat":26.42251,"lon":50.09832,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"31952","condg":["Other"],"nct":"NCT03431285","study":"Ketamine for Acute Painful Crisis in Sickle Cell Disease Patients","sstatus":"COMPLETED","sponsor":"Imam Abdulrahman Bin Faisal University","official":"Mohammed SS Alshahrani, MD (King Fahad Hospital of the University -Imam Abdulrahman Bin Faisal University - (Dammam University))","src":"https://clinicaltrials.gov/study/NCT03431285","phase":"N/A","enroll":278,"start":"2018-01-01","eid":"x:site:nct03431285-imam-abdulrahman-bin-faisal-university-dammam"},{"id":"nct03164590-south-egypt-cancer-instiitute-asyut","cat":"research","name":"South Egypt Cancer instIitute","city":"Asyut","country":"Egypt","cc":"EG","lat":27.18317,"lon":31.17479,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"171516","condg":["Other"],"nct":"NCT03164590","study":"Effects of Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Cytokines","sstatus":"COMPLETED","sponsor":"Assiut University","official":"fatma el sherif, MD (South Egypt Cancer Institute)","src":"https://clinicaltrials.gov/study/NCT03164590","phase":"Phase 4","enroll":60,"start":"2017-06-01","eid":"x:site:nct03164590-south-egypt-cancer-instiitute-asyut"},{"id":"nct05217706-rady-children-s-hospital-san-diego-san-diego","cat":"research","name":"Rady Children's Hospital San Diego","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.72432,"lon":-117.17004,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"92123","condg":["Depression"],"status":"RECRUITING","nct":"NCT05217706","study":"Low-Dose Intravenous Ketamine for Adolescents With Depression and Suicidal Ideation in the Emergency Department","sstatus":"UNKNOWN","sponsor":"Rady Children's Hospital, San Diego","src":"https://clinicaltrials.gov/study/NCT05217706","contact":{"n":"Tatyana Vayngortin","p":"8589668036","e":"tvayngortin@rchsd.org"},"phase":"EARLY_Phase 1","enroll":30,"start":"2022-03-01","eid":"x:site:nct05217706-rady-children-s-hospital-san-diego-san-diego"},{"id":"nct03814733-collaborative-neuroscience-network-san-clemente","cat":"research","name":"Collaborative Neuroscience Network","city":"San Clemente","region":"California","country":"United States","cc":"US","lat":33.43041,"lon":-117.61326,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"92673","condg":["Other"],"nct":"NCT03814733","study":"Assessment of Effect of Rapastinel on Driving Performance","sstatus":"COMPLETED","sponsor":"Naurex, Inc, an affiliate of Allergan plc","official":"Sheng Fang Su (Allergan)","src":"https://clinicaltrials.gov/study/NCT03814733","phase":"Phase 1","enroll":107,"start":"2018-11-05","eid":"x:site:nct03814733-collaborative-neuroscience-network-san-clemente"},{"id":"nct03814733-algorithme-pharma-aurora","cat":"research","name":"Algorithme Pharma","city":"Aurora","region":"Ontario","country":"Canada","cc":"CA","lat":43.99103,"lon":-79.47728,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"L4G 0A5","condg":["Other"],"nct":"NCT03814733","study":"Assessment of Effect of Rapastinel on Driving Performance","sstatus":"COMPLETED","sponsor":"Naurex, Inc, an affiliate of Allergan plc","official":"Sheng Fang Su (Allergan)","src":"https://clinicaltrials.gov/study/NCT03814733","phase":"Phase 1","enroll":107,"start":"2018-11-05","eid":"x:site:nct03814733-algorithme-pharma-aurora"},{"id":"nct05190952-ain-shams-university-hospitals-cairo","cat":"research","name":"Ain Shams university hospitals","city":"Cairo","region":"Al Abbassia","country":"Egypt","cc":"EG","lat":30.05063,"lon":31.24398,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11591","condg":["Other"],"nct":"NCT05190952","study":"Dexamethasone & Ketamine as Adjuvants to Bupivacaine for Incisional Infiltration in Pediatric Abdominal Operations","sstatus":"COMPLETED","sponsor":"Ain Shams University","src":"https://clinicaltrials.gov/study/NCT05190952","phase":"N/A","enroll":150,"start":"2020-12-05","eid":"x:site:nct05190952-ain-shams-university-hospitals-cairo"},{"id":"nct06232291-medical-university-of-gdansk-gdansk","cat":"research","name":"Medical University of Gdańsk","city":"Gdansk","country":"Poland","cc":"PL","lat":54.35712,"lon":18.64004,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"80-214","condg":["Depression"],"nct":"NCT06232291","study":"Observation of Safety and Tolerability Within 1 Year of the Use of R-ketamine / Placebo in Drug-resistant Depression","sstatus":"COMPLETED","sponsor":"Medical University of Gdansk","src":"https://clinicaltrials.gov/study/NCT06232291","enroll":3,"start":"2023-04-21","eid":"x:site:nct06232291-medical-university-of-gdansk-gdansk"},{"id":"nct01535976-prentice-womens-hospital-chicago","cat":"research","name":"Prentice Womens Hospital","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.85412,"lon":-87.65923,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60611","condg":["Other"],"nct":"NCT01535976","study":"Ketamine Infusion and Hypoventilation","sstatus":"COMPLETED","sponsor":"Northwestern University","official":"Gildasio De Oliveira, MD (Northwestern University)","src":"https://clinicaltrials.gov/study/NCT01535976","phase":"N/A","enroll":54,"start":"2011-08","eid":"x:site:nct01535976-prentice-womens-hospital-chicago"},{"id":"nct06428838-royal-columbian-hospital-new-westminster","cat":"research","name":"Royal Columbian Hospital","city":"New Westminster","region":"British Columbia","country":"Canada","cc":"CA","lat":49.20466,"lon":-122.90231,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"V3L 3W7","condg":["Chronic pain & headache"],"nct":"NCT06428838","study":"Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Dr George Medvedev","src":"https://clinicaltrials.gov/study/NCT06428838","phase":"Phase 3","enroll":102,"start":"2025-05-05","eid":"x:site:nct06428838-royal-columbian-hospital-new-westminster"},{"id":"nct06428838-surrey-memorial-hospital-surrey","cat":"research","name":"Surrey Memorial Hospital","city":"Surrey","region":"British Columbia","country":"Canada","cc":"CA","lat":49.10348,"lon":-122.83323,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"V3V 1Z2","condg":["Chronic pain & headache"],"nct":"NCT06428838","study":"Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Dr George Medvedev","src":"https://clinicaltrials.gov/study/NCT06428838","phase":"Phase 3","enroll":102,"start":"2025-05-05","eid":"x:site:nct06428838-surrey-memorial-hospital-surrey"},{"id":"nct06185426-rteu-faculty-of-dentistry-rize","cat":"research","name":"RTEU Faculty of Dentistry","city":"Rize","country":"Turkey","cc":"TR","lat":41.02332,"lon":40.51079,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT06185426","study":"Histopathological, Biochemical And Electrophysiological Evaluation Of Single Or Combined Use Of Diode Laser/Steroid Treatment On Facial Nerve Injury","sstatus":"UNKNOWN","sponsor":"Recep Tayyip Erdogan University","official":"zeynep gümrükçü, Associate Professor (RTEU)","src":"https://clinicaltrials.gov/study/NCT06185426","phase":"EARLY_Phase 1","enroll":35,"start":"2021-01-01","eid":"x:site:nct06185426-rteu-faculty-of-dentistry-rize"},{"id":"nct06919198-university-of-wisconsin-madison-madison","cat":"research","name":"University of Wisconsin - Madison","city":"Madison","region":"Wisconsin","country":"United States","cc":"US","lat":43.0683,"lon":-89.4057,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"53705","condg":["Other"],"nct":"NCT06919198","study":"The Dreamy Jet Study","sstatus":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","official":"Megan Peters, MD (University of Wisconsin, Madison)","src":"https://clinicaltrials.gov/study/NCT06919198","phase":"Phase 1","start":"2025-09","eid":"x:site:nct06919198-university-of-wisconsin-madison-madison"},{"id":"nct04889664-depression-and-anxiety-center-icahn-school-of-medicine-at-mount-sina","cat":"research","name":"Depression and Anxiety Center, Icahn School of Medicine at Mount Sinai","city":"Manhattan","region":"New York","country":"United States","cc":"US","lat":40.79308,"lon":-73.97656,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10029","condg":["PTSD & trauma"],"nct":"NCT04889664","study":"Adding Trauma-focused Psychotherapy to Ketamine Treatment for Chronic PTSD","sstatus":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","official":"Adriana Feder, MD (Depression and Anxiety Center, Icahn School of Medicine at Mount Sinai); Oneysha Brown, BA (Depression and Anxiety Center, Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT04889664","phase":"Phase 2","enroll":16,"start":"2021-06-04","eid":"x:site:nct04889664-depression-and-anxiety-center-icahn-school-of-medicine-at-mount-sina"},{"id":"nct03165149-south-egypt-cancer-instuite-asyut","cat":"research","name":"South Egypt Cancer Instuite","city":"Asyut","country":"Egypt","cc":"EG","lat":27.18185,"lon":31.1937,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"171516","condg":["Cancer-related distress"],"nct":"NCT03165149","study":"Effect of a Topical Ketamine on Acute and Chronic Pain, Dose Finding","sstatus":"COMPLETED","sponsor":"Assiut University","src":"https://clinicaltrials.gov/study/NCT03165149","phase":"Phase 2/Phase 3","enroll":90,"start":"2017-06-01","eid":"x:site:nct03165149-south-egypt-cancer-instuite-asyut"},{"id":"nct02183272-university-of-cincinnati-cincinnati","cat":"research","name":"University of Cincinnati","city":"Cincinnati","region":"Ohio","country":"United States","cc":"US","lat":39.13779,"lon":-84.52055,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45219","condg":["Depression"],"status":"RECRUITING","nct":"NCT02183272","study":"Emergency Ketamine Treatment of Suicidal Ideation","sstatus":"UNKNOWN","sponsor":"University of Cincinnati","official":"Cheryl McCullumsmith, MD PhD (University of Cincinnati)","src":"https://clinicaltrials.gov/study/NCT02183272","contact":{"n":"Faryal Mallick, MD","p":"513-558-4997","e":"mallicfl@ucmail.uc.edu"},"phase":"Phase 2/Phase 3","enroll":60,"start":"2016-08","eid":"x:site:nct02183272-university-of-cincinnati-cincinnati"},{"id":"nct04414800-al-zahra-university-hospital-isfahan","cat":"research","name":"Al-Zahra University Hospital","city":"Isfahan","country":"Iran","cc":"IR","lat":32.64535,"lon":51.66761,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"8138938728","condg":["PTSD & trauma","Chronic pain & headache"],"nct":"NCT04414800","study":"Intranasal Ketamine Versus Intranasal Fentanyl","sstatus":"COMPLETED","sponsor":"Isfahan University of Medical Sciences","src":"https://clinicaltrials.gov/study/NCT04414800","phase":"Phase 3","enroll":125,"start":"2017-04-01","eid":"x:site:nct04414800-al-zahra-university-hospital-isfahan"},{"id":"nct03674671-providence-care-hospital-kingston","cat":"research","name":"Providence Care Hospital","city":"Kingston","region":"Ontario","country":"Canada","cc":"CA","lat":44.22021,"lon":-76.47547,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"K7M 9A7","condg":["Depression","Bipolar"],"nct":"NCT03674671","study":"Ketamine Versus Electroconvulsive Therapy in Depression","sstatus":"SUSPENDED","sponsor":"University of Ottawa","official":"Pierre Blier, MD, PhD (The Royal's Institute of Mental Health Research)","src":"https://clinicaltrials.gov/study/NCT03674671","phase":"Phase 3","enroll":240,"start":"2018-10-29","eid":"x:site:nct03674671-providence-care-hospital-kingston"},{"id":"nct03674671-royal-ottawa-mental-health-centre-ottawa","cat":"research","name":"Royal Ottawa Mental Health Centre","city":"Ottawa","region":"Ontario","country":"Canada","cc":"CA","lat":45.40086,"lon":-75.70711,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"K1Z 7K4","condg":["Depression","Bipolar"],"nct":"NCT03674671","study":"Ketamine Versus Electroconvulsive Therapy in Depression","sstatus":"SUSPENDED","sponsor":"University of Ottawa","official":"Pierre Blier, MD, PhD (The Royal's Institute of Mental Health Research)","src":"https://clinicaltrials.gov/study/NCT03674671","phase":"Phase 3","enroll":240,"start":"2018-10-29","eid":"x:site:nct03674671-royal-ottawa-mental-health-centre-ottawa"},{"id":"nct03674671-university-health-network-toronto","cat":"research","name":"University Health Network","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70036,"lon":-79.40113,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M5G 1J6","condg":["Depression","Bipolar"],"nct":"NCT03674671","study":"Ketamine Versus Electroconvulsive Therapy in Depression","sstatus":"SUSPENDED","sponsor":"University of Ottawa","official":"Pierre Blier, MD, PhD (The Royal's Institute of Mental Health Research)","src":"https://clinicaltrials.gov/study/NCT03674671","phase":"Phase 3","enroll":240,"start":"2018-10-29","eid":"x:site:nct03674671-university-health-network-toronto"},{"id":"nct03674671-ontario-shores-centre-for-mental-health-sciences-whitby","cat":"research","name":"Ontario Shores Centre for Mental Health Sciences","city":"Whitby","region":"Ontario","country":"Canada","cc":"CA","lat":43.8733,"lon":-78.92943,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"L1N 5S9","condg":["Depression","Bipolar"],"nct":"NCT03674671","study":"Ketamine Versus Electroconvulsive Therapy in Depression","sstatus":"SUSPENDED","sponsor":"University of Ottawa","official":"Pierre Blier, MD, PhD (The Royal's Institute of Mental Health Research)","src":"https://clinicaltrials.gov/study/NCT03674671","phase":"Phase 3","enroll":240,"start":"2018-10-29","eid":"x:site:nct03674671-ontario-shores-centre-for-mental-health-sciences-whitby"},{"id":"nct07230392-mohamed-taher-maamouri-university-hospital-nabeul","cat":"research","name":"Mohamed Taher Maamouri University Hospital","city":"Nabeul","region":"Nabeul Governorate","country":"Tunisia","cc":"TN","lat":36.45997,"lon":10.74775,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"8000","condg":["Chronic pain & headache"],"nct":"NCT07230392","study":"Superficial Cervical Plexus Block Versus Ketamine in the Prevention of Chronic Pain After Thyroidectomy","sstatus":"COMPLETED","sponsor":"University Tunis El Manar","official":"ibtissem BEN TALEB (University of Tunis El Manar, Anesthesia and critical care department, Taher Maamouri University Hospital,)","src":"https://clinicaltrials.gov/study/NCT07230392","phase":"Phase 4","enroll":69,"start":"2024-10-14","eid":"x:site:nct07230392-mohamed-taher-maamouri-university-hospital-nabeul"},{"id":"nct00474110-bc-children-s-hospital-vancouver","cat":"research","name":"BC Children's Hospital","city":"Vancouver","region":"British Columbia","country":"Canada","cc":"CA","lat":49.24905,"lon":-123.10875,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"V6H 3V4","condg":["Other"],"nct":"NCT00474110","study":"Ketamine and Hydromorphone for Patient Controlled Pain Relief in Children's Mucositis","sstatus":"WITHDRAWN","sponsor":"University of British Columbia","official":"Carolyne Montgomery, MD (University of British Columbia); Mark Ansermino, MD (University of British Columbia)","src":"https://clinicaltrials.gov/study/NCT00474110","phase":"Phase 3","start":"2009-08","eid":"x:site:nct00474110-bc-children-s-hospital-vancouver"},{"id":"nct02935959-assiut-university-asyut","cat":"research","name":"Assiut University","city":"Asyut","country":"Egypt","cc":"EG","lat":27.18223,"lon":31.18674,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"171516","condg":["Cancer-related distress"],"nct":"NCT02935959","study":"Premedication With Nebulized Ketamine,Dexmedetomidine Versus Midazolam in Oncologic Preschool Children","sstatus":"COMPLETED","sponsor":"Assiut University","official":"fatma a elsherif, lecturer (South Egypt Cancer Institute)","src":"https://clinicaltrials.gov/study/NCT02935959","phase":"Phase 1/Phase 2","enroll":90,"start":"2016-10","eid":"x:site:nct02935959-assiut-university-asyut"},{"id":"nct02935725-university-of-manchester-london","cat":"research","name":"University Of Manchester","city":"London","country":"United Kingdom","cc":"GB","lat":51.51658,"lon":-0.13407,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT02935725","study":"A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males","sstatus":"COMPLETED","sponsor":"Autifony Therapeutics Limited","official":"Bill Deakin, Prof (University of Manchester)","src":"https://clinicaltrials.gov/study/NCT02935725","phase":"Phase 1","enroll":22,"start":"2016-10","eid":"x:site:nct02935725-university-of-manchester-london"},{"id":"nct05402189-faculty-of-medicine-ain-shams-university-cairo","cat":"research","name":"Faculty of Medicine Ain Shams University","city":"Cairo","country":"Egypt","cc":"EG","lat":30.07002,"lon":31.24012,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT05402189","study":"Ketodex Versus Opioid Based Anaesthesia in Cleft Palate Repair Ketodex Versus Opioid Based Anaesthesia in Cleft Palate Repair Ketodex Versus Opioid Based Anaesthesia in Cleft Palate Repair Ketodex…","sstatus":"UNKNOWN","sponsor":"Ain Shams University","src":"https://clinicaltrials.gov/study/NCT05402189","contact":{"n":"Marwa M Mamdouh, Lecturer","p":"01000205686","e":"marwaemam600@gmail.com"},"phase":"Phase 1","enroll":50,"start":"2022-02-01","eid":"x:site:nct05402189-faculty-of-medicine-ain-shams-university-cairo"},{"id":"nct07463911-pamukkale-university-denizli","cat":"research","name":"Pamukkale University","city":"Denizli","country":"Turkey","cc":"TR","lat":37.77855,"lon":29.08811,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20570","condg":["Depression","Bipolar"],"nct":"NCT07463911","study":"Treatment Response In ECT Patients","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Nurdan Sağbaş","official":"ceyhan M şengül balcı (Pamukkale University)","src":"https://clinicaltrials.gov/study/NCT07463911","enroll":65,"start":"2025-05-20","eid":"x:site:nct07463911-pamukkale-university-denizli"},{"id":"nct05828199-faculty-of-medicine-al-azhar-university-cairo","cat":"research","name":"Faculty of Medicine, Al-Azhar University","city":"Cairo","country":"Egypt","cc":"EG","lat":30.05665,"lon":31.24661,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"RECRUITING","nct":"NCT05828199","study":"The Effect of Intraoperative Infusion of Dexmedetomidine Versus Low Dose Ketamine","sstatus":"UNKNOWN","sponsor":"Al-Azhar University","official":"Essam Ali, Professor (Al-Azhar University, Faculty of medicine for boys)","src":"https://clinicaltrials.gov/study/NCT05828199","contact":{"n":"Essam Ali, Professor","p":"01223215181","e":"essamalhalawany@gmail.com"},"phase":"Phase 1","enroll":80,"start":"2022-12-01","eid":"x:site:nct05828199-faculty-of-medicine-al-azhar-university-cairo"},{"id":"nct05137587-marmara-university-school-of-medicine-istanbul","cat":"research","name":"Marmara University School of Medicine","city":"Istanbul","region":"Pendik","country":"Turkey","cc":"TR","lat":41.01577,"lon":28.94839,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"34899","condg":["Other"],"nct":"NCT05137587","study":"Importance of Integrated Pulmonary Index in Pediatric Bronchoscopy","sstatus":"COMPLETED","sponsor":"Marmara University","official":"Ruslan Abdullayev (Marmara University Department of Anesthesiology and Reanimation)","src":"https://clinicaltrials.gov/study/NCT05137587","phase":"N/A","enroll":60,"start":"2022-09-01","eid":"x:site:nct05137587-marmara-university-school-of-medicine-istanbul"},{"id":"nct00701909-university-of-california-san-francisco-san-francisco","cat":"research","name":"University of California San Francisco","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.76293,"lon":-122.43076,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94143-0610","condg":["Chronic pain & headache"],"nct":"NCT00701909","study":"Pain Medicine for Wound Care Procedures","sstatus":"COMPLETED","sponsor":"University of California, San Francisco","official":"Kathleen A Puntillo, RN, DNSc (Regents of the University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT00701909","phase":"Phase 3","enroll":12,"start":"2008-06","eid":"x:site:nct00701909-university-of-california-san-francisco-san-francisco"},{"id":"nct00701909-trauma-hospital-puerto-rico-medical-center-san-juan","cat":"research","name":"Trauma Hospital Puerto Rico Medical Center","city":"San Juan","country":"Puerto Rico","cc":"PR","lat":18.47108,"lon":-66.09861,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Chronic pain & headache"],"nct":"NCT00701909","study":"Pain Medicine for Wound Care Procedures","sstatus":"COMPLETED","sponsor":"University of California, San Francisco","official":"Kathleen A Puntillo, RN, DNSc (Regents of the University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT00701909","phase":"Phase 3","enroll":12,"start":"2008-06","eid":"x:site:nct00701909-trauma-hospital-puerto-rico-medical-center-san-juan"},{"id":"nct06219928-ataturk-university-erzurum","cat":"research","name":"Ataturk University","city":"Erzurum","country":"Turkey","cc":"TR","lat":39.90254,"lon":41.28113,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT06219928","study":"Comparison of the Effects of Dexmedetomidine and Ketamine Infusion on the Inflammatory Response in Liver Resection","sstatus":"COMPLETED","sponsor":"Ataturk University","src":"https://clinicaltrials.gov/study/NCT06219928","phase":"N/A","enroll":45,"start":"2022-06-30","eid":"x:site:nct06219928-ataturk-university-erzurum"},{"id":"nct03246971-lotus-clinical-research-pasadena","cat":"research","name":"Lotus Clinical Research","city":"Pasadena","region":"California","country":"United States","cc":"US","lat":29.68584,"lon":-95.20783,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"91105","condg":["Chronic pain & headache"],"nct":"NCT03246971","study":"Study of Wafermine™ for Post-bunionectomy or Abdominoplasty Pain","sstatus":"COMPLETED","sponsor":"iX Biopharma Ltd.","src":"https://clinicaltrials.gov/study/NCT03246971","phase":"Phase 2","enroll":125,"start":"2017-08-24","eid":"x:site:nct03246971-lotus-clinical-research-pasadena"},{"id":"nct05378555-boston-children-s-hospital-boston","cat":"research","name":"Boston Children's Hospital","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36205,"lon":-71.05417,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02115","condg":["Other"],"nct":"NCT05378555","study":"Oral Ketamine for Treatment of Vaso-Occlusive Pain","sstatus":"COMPLETED","sponsor":"Boston Children's Hospital","src":"https://clinicaltrials.gov/study/NCT05378555","phase":"Phase 1","enroll":10,"start":"2023-05-26","eid":"x:site:nct05378555-boston-children-s-hospital-boston"},{"id":"nct01135758-service-de-psychiatrie-adulte-programme-depression-geneva","cat":"research","name":"Service de Psychiatrie Adulte, Programme dépression","city":"Geneva","country":"Switzerland","cc":"CH","lat":46.21403,"lon":6.15656,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"1207","condg":["Depression"],"nct":"NCT01135758","study":"Study of Depression-Ketamine-Brain Function","sstatus":"TERMINATED","sponsor":"Markus KOSEL","official":"Markus Kosel, MD-PhD (Departement of Adult Psychiatry, University Hospital of Geneva)","src":"https://clinicaltrials.gov/study/NCT01135758","phase":"Phase 2","enroll":10,"start":"2010-06","eid":"x:site:nct01135758-service-de-psychiatrie-adulte-programme-depression-geneva"},{"id":"nct02305394-china-chongqing-the-first-affiliated-hospital-of-chongqing-medical-u","cat":"research","name":"China,Chongqing The First Affiliated Hospital of Chongqing Medical University","city":"Chongqing","region":"Chongqing Municipality","country":"China","cc":"CN","lat":29.55212,"lon":106.55155,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"400016","condg":["Depression"],"nct":"NCT02305394","study":"Effect of Subanesthetic Dose of Ketamine Combined With Propofol on Cognitive Function in Depressive Patients Undergoing Electroconvulsive Therapy","sstatus":"UNKNOWN","sponsor":"First Affiliated Hospital of Chongqing Medical University","official":"Su Min (First Affiliated Hospital of Chongqing Medical University)","src":"https://clinicaltrials.gov/study/NCT02305394","contact":{"n":"Su Min, MD","p":"+86-23-89011068","e":"ms89011068@163.com"},"phase":"Phase 4","enroll":132,"start":"2015-01","eid":"x:site:nct02305394-china-chongqing-the-first-affiliated-hospital-of-chongqing-medical-u"},{"id":"nct03434366-guangzhou-women-and-children-medical-center-guangzhou","cat":"research","name":"Guangzhou Women and Children Medical Center","city":"Guangzhou","region":"Guangdong","country":"China","cc":"CN","lat":23.11455,"lon":113.25193,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"510000","condg":["Other"],"nct":"NCT03434366","study":"Intranasal Ketamine With Dexmedetomidine for the Treatment of Children With Autism Spectrum Disorder","sstatus":"SUSPENDED","sponsor":"Guangzhou Women and Children's Medical Center","official":"Qing Zhao, Doctor (Guangzhou Women and Children's Medical Center)","src":"https://clinicaltrials.gov/study/NCT03434366","phase":"Phase 2","enroll":50,"start":"2018-01-20","eid":"x:site:nct03434366-guangzhou-women-and-children-medical-center-guangzhou"},{"id":"nct06085937-university-of-kansas-strawberry-hill-campus-kansas-city","cat":"research","name":"University of Kansas Strawberry Hill Campus","city":"Kansas City","region":"Kansas","country":"United States","cc":"US","lat":39.09046,"lon":-94.56798,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"66101","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT06085937","study":"Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department","sstatus":"RECRUITING","sponsor":"Lindsay Maguire, MD","src":"https://clinicaltrials.gov/study/NCT06085937","contact":{"n":"Tyler Kjorvestad, MD","p":"913-588-3580","e":"tkjorvestad@kumc.edu"},"phase":"Phase 1","enroll":50,"start":"2024-05-01","eid":"x:site:nct06085937-university-of-kansas-strawberry-hill-campus-kansas-city"},{"id":"nct06085937-university-of-kansas-medical-center-emergency-department-kansas-city","cat":"research","name":"University of Kansas Medical Center Emergency Department","city":"Kansas City","region":"Kansas","country":"United States","cc":"US","lat":39.10081,"lon":-94.57203,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"66160","condg":["Depression"],"status":"RECRUITING","nct":"NCT06085937","study":"Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department","sstatus":"RECRUITING","sponsor":"Lindsay Maguire, MD","src":"https://clinicaltrials.gov/study/NCT06085937","contact":{"n":"Lindsay Maguire, MD","p":"8048144509","e":"lmaguire@kumc.edu"},"phase":"Phase 1","enroll":50,"start":"2024-05-01","eid":"x:site:nct06085937-university-of-kansas-medical-center-emergency-department-kansas-city"},{"id":"nct03498391-university-of-pennsylvania-perelman-school-of-medicine-philadelphia","cat":"research","name":"University of Pennsylvania, Perelman School of Medicine","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.95092,"lon":-75.16771,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"19104","condg":["Other"],"nct":"NCT03498391","study":"A Study of Human Multi-Sensory Integration","sstatus":"SUSPENDED","sponsor":"University of Pennsylvania","official":"Max Kelz, MD, PhD (University of Pennsylvania)","src":"https://clinicaltrials.gov/study/NCT03498391","phase":"Phase 2","enroll":40,"start":"2018-07-30","eid":"x:site:nct03498391-university-of-pennsylvania-perelman-school-of-medicine-philadelphia"},{"id":"nct07177235-thomas-jefferson-university-hospital-philadelphia","cat":"research","name":"Thomas Jefferson University Hospital","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.95873,"lon":-75.16781,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"19107","condg":["Neurology & cognition"],"nct":"NCT07177235","study":"Ketamine for the Treatment of Refractory Status Epilepticus","sstatus":"NOT_YET_RECRUITING","sponsor":"Thomas Jefferson University","official":"Syed O Shah, MD (Thomas Jefferson University)","src":"https://clinicaltrials.gov/study/NCT07177235","contact":{"n":"Elizabeth Fletman, DO","p":"215-955-7000","e":"elizabeth.fletman@jefferson.edu"},"phase":"Phase 4","enroll":50,"start":"2025-11","eid":"x:site:nct07177235-thomas-jefferson-university-hospital-philadelphia"},{"id":"nct05597878-atrium-health-wake-forest-baptist-comprehensive-cancer-center-winsto","cat":"research","name":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center","city":"Winston-Salem","region":"North Carolina","country":"United States","cc":"US","lat":36.10697,"lon":-80.24756,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"27157","condg":["Addiction & substance use","Cancer-related distress","Chronic pain & headache"],"nct":"NCT05597878","study":"Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy","sstatus":"TERMINATED","sponsor":"Wake Forest University Health Sciences","official":"Ashok Hemal, MD (Atrium Health Wake Forest Baptist Comprehensive Cancer Center)","src":"https://clinicaltrials.gov/study/NCT05597878","phase":"Phase 2/Phase 3","enroll":58,"start":"2023-04-18","eid":"x:site:nct05597878-atrium-health-wake-forest-baptist-comprehensive-cancer-center-winsto"},{"id":"nct06354673-zagazig-university-zagazig","cat":"research","name":"Zagazig university","city":"Zagazig","country":"Egypt","cc":"EG","lat":30.5849,"lon":31.49546,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT06354673","study":"Stellate Ganglion Block Combined With Dexmedetomidine or Subanesthetic Ketamine Infusion for Treatment of Neurostorm.","sstatus":"COMPLETED","sponsor":"Zagazig University","official":"Eslam S. Almaghawry Mohamed, MD (Zagazig University)","src":"https://clinicaltrials.gov/study/NCT06354673","phase":"N/A","enroll":205,"start":"2024-04-04","eid":"x:site:nct06354673-zagazig-university-zagazig"},{"id":"nct03040024-emory-university-hospital-midtown-atlanta","cat":"research","name":"Emory University Hospital Midtown","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.75027,"lon":-84.39584,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"30308","condg":["Cancer-related distress"],"nct":"NCT03040024","study":"Delirium Prevention With Ketamine in Ear, Nose, and Throat (ENT) Patients","sstatus":"TERMINATED","sponsor":"Emory University","official":"Vanessa Moll, PhD (Emory University)","src":"https://clinicaltrials.gov/study/NCT03040024","phase":"Phase 4","enroll":71,"start":"2017-03-17","eid":"x:site:nct03040024-emory-university-hospital-midtown-atlanta"},{"id":"nct02294162-galillee-medical-center-nahariya","cat":"research","name":"Galillee medical center","city":"Nahariya","country":"Israel","cc":"IL","lat":32.9973,"lon":35.10976,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"2210001","condg":["Other"],"nct":"NCT02294162","study":"Pain Relief for Submucosal Resection of Nasal Septum in Adults Does Ketamine Have a Pre-Emptive Effect?","sstatus":"WITHDRAWN","sponsor":"Western Galilee Hospital-Nahariya","src":"https://clinicaltrials.gov/study/NCT02294162","phase":"N/A","start":"2015-04-01","eid":"x:site:nct02294162-galillee-medical-center-nahariya"},{"id":"nct02836288-cedars-sinai-medical-center-los-angeles","cat":"research","name":"Cedars-Sinai Medical Center","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.06319,"lon":-118.23752,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"90048","condg":["Depression","Cancer-related distress"],"nct":"NCT02836288","study":"Study of Oral Ketamine Versus Placebo for Treating Depression in Patients Undergoing Treatment for Cancer","sstatus":"COMPLETED","sponsor":"Scott A. Irwin, MD, PhD","official":"Scott Irwin, MD, PhD (Cedars-Sinal Medical Center)","src":"https://clinicaltrials.gov/study/NCT02836288","phase":"EARLY_Phase 1","enroll":4,"start":"2016-12-20","eid":"x:site:nct02836288-cedars-sinai-medical-center-los-angeles"},{"id":"nct03149991-collaborative-neuroscience-network-llc-garden-grove","cat":"research","name":"Collaborative Neuroscience Network, LLC.","city":"Garden Grove","region":"California","country":"United States","cc":"US","lat":33.78083,"lon":-117.93877,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"92845","condg":["Depression"],"nct":"NCT03149991","study":"A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)","sstatus":"COMPLETED","sponsor":"Massachusetts General Hospital","official":"Maurizio Fava, MD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT03149991","phase":"Phase 4","enroll":51,"start":"2017-09-14","eid":"x:site:nct03149991-collaborative-neuroscience-network-llc-garden-grove"},{"id":"nct03149991-pacific-research-partners-llc-oakland","cat":"research","name":"Pacific Research Partners, LLC","city":"Oakland","region":"California","country":"United States","cc":"US","lat":37.81411,"lon":-122.26049,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94607","condg":["Depression"],"nct":"NCT03149991","study":"A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)","sstatus":"COMPLETED","sponsor":"Massachusetts General Hospital","official":"Maurizio Fava, MD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT03149991","phase":"Phase 4","enroll":51,"start":"2017-09-14","eid":"x:site:nct03149991-pacific-research-partners-llc-oakland"},{"id":"nct03149991-rush-university-medical-center-chicago","cat":"research","name":"Rush University Medical Center","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.84349,"lon":-87.64313,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60612","condg":["Depression"],"nct":"NCT03149991","study":"A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)","sstatus":"COMPLETED","sponsor":"Massachusetts General Hospital","official":"Maurizio Fava, MD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT03149991","phase":"Phase 4","enroll":51,"start":"2017-09-14","eid":"x:site:nct03149991-rush-university-medical-center-chicago"},{"id":"nct03149991-massachusetts-general-hospital-depression-clinical-and-research-prog","cat":"research","name":"Massachusetts General Hospital, Depression Clinical and Research Program","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.35518,"lon":-71.06603,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02114","condg":["Depression"],"nct":"NCT03149991","study":"A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)","sstatus":"COMPLETED","sponsor":"Massachusetts General Hospital","official":"Maurizio Fava, MD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT03149991","phase":"Phase 4","enroll":51,"start":"2017-09-14","eid":"x:site:nct03149991-massachusetts-general-hospital-depression-clinical-and-research-prog"},{"id":"nct03149991-nathan-kline-institute-for-psychiatric-research-orangeburg","cat":"research","name":"Nathan Kline Institute for Psychiatric Research","city":"Orangeburg","region":"New York","country":"United States","cc":"US","lat":33.49733,"lon":-80.84939,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10562","condg":["Depression"],"nct":"NCT03149991","study":"A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)","sstatus":"COMPLETED","sponsor":"Massachusetts General Hospital","official":"Maurizio Fava, MD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT03149991","phase":"Phase 4","enroll":51,"start":"2017-09-14","eid":"x:site:nct03149991-nathan-kline-institute-for-psychiatric-research-orangeburg"},{"id":"nct03149991-montefiore-medical-center-the-bronx","cat":"research","name":"Montefiore Medical Center","city":"The Bronx","region":"New York","country":"United States","cc":"US","lat":40.85093,"lon":-73.86693,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10467","condg":["Depression"],"nct":"NCT03149991","study":"A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)","sstatus":"COMPLETED","sponsor":"Massachusetts General Hospital","official":"Maurizio Fava, MD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT03149991","phase":"Phase 4","enroll":51,"start":"2017-09-14","eid":"x:site:nct03149991-montefiore-medical-center-the-bronx"},{"id":"nct07781462-alexandria-main-university-hospital-amuh-alexandria","cat":"research","name":"Alexandria Main University Hospital (AMUH)","city":"Alexandria","country":"Egypt","cc":"EG","lat":31.19701,"lon":29.90627,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"21500","condg":["Other"],"nct":"NCT07781462","study":"Intravenous Infusion of Low Dose Ketamine Versus Dexmedetomedine for Delirium Treatment in Acute Heart Failure","sstatus":"NOT_YET_RECRUITING","sponsor":"Alexandria University","src":"https://clinicaltrials.gov/study/NCT07781462","contact":{"n":"Nada H Abd El-Rahim, PharmD","p":"01008328380","e":"gs-nada.hesham@alexu.edu.eg"},"phase":"Phase 4","enroll":150,"start":"2026-09","eid":"x:site:nct07781462-alexandria-main-university-hospital-amuh-alexandria"},{"id":"nct05945147-stanford-university-stanford","cat":"research","name":"Stanford University","city":"Stanford","region":"California","country":"United States","cc":"US","lat":37.41286,"lon":-122.15596,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94305","condg":["Chronic pain & headache"],"nct":"NCT05945147","study":"Ketamine and Midazolam Infusions for CRPS: Feasibility Study","sstatus":"WITHDRAWN","sponsor":"Stanford University","official":"Theresa R Lii, MD, MS (Stanford University)","src":"https://clinicaltrials.gov/study/NCT05945147","phase":"Phase 2","start":"2099-01-01","eid":"x:site:nct05945147-stanford-university-stanford"},{"id":"nct01691092-connecticut-mental-health-center-new-haven","cat":"research","name":"Connecticut Mental Health Center","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31695,"lon":-72.92595,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06519","condg":["Depression","PTSD & trauma"],"nct":"NCT01691092","study":"PET Imaging of mGLuR5 With Drug Challenge","sstatus":"COMPLETED","sponsor":"Yale University","official":"Irina Esterlis, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT01691092","phase":"N/A","enroll":79,"start":"2012-06","eid":"x:site:nct01691092-connecticut-mental-health-center-new-haven"},{"id":"nct01691092-yale-university-magnetic-resonance-research-center-mrrc-new-haven","cat":"research","name":"Yale University Magnetic Resonance Research Center (MRRC)","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31488,"lon":-72.92934,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06519","condg":["Depression","PTSD & trauma"],"nct":"NCT01691092","study":"PET Imaging of mGLuR5 With Drug Challenge","sstatus":"COMPLETED","sponsor":"Yale University","official":"Irina Esterlis, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT01691092","phase":"N/A","enroll":79,"start":"2012-06","eid":"x:site:nct01691092-yale-university-magnetic-resonance-research-center-mrrc-new-haven"},{"id":"nct01691092-yale-university-pet-center-new-haven","cat":"research","name":"Yale University PET Center","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31403,"lon":-72.91955,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06519","condg":["Depression","PTSD & trauma"],"nct":"NCT01691092","study":"PET Imaging of mGLuR5 With Drug Challenge","sstatus":"COMPLETED","sponsor":"Yale University","official":"Irina Esterlis, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT01691092","phase":"N/A","enroll":79,"start":"2012-06","eid":"x:site:nct01691092-yale-university-pet-center-new-haven"},{"id":"nct04459234-institut-bergonie-bordeaux","cat":"research","name":"Institut Bergonié","city":"Bordeaux","country":"France","cc":"FR","lat":44.8522,"lon":-0.57467,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"33076","condg":["Addiction & substance use","Cancer-related distress","Chronic pain & headache"],"nct":"NCT04459234","study":"Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC","sstatus":"COMPLETED","sponsor":"Centre Leon Berard","official":"Gisèle CHVETZOFF, MD (Centre Leon Berard)","src":"https://clinicaltrials.gov/study/NCT04459234","enroll":81,"start":"2021-02-02","eid":"x:site:nct04459234-institut-bergonie-bordeaux"},{"id":"nct04459234-centre-francois-baclesse-caen","cat":"research","name":"Centre François Baclesse","city":"Caen","country":"France","cc":"FR","lat":49.17921,"lon":-0.3587,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Addiction & substance use","Cancer-related distress","Chronic pain & headache"],"nct":"NCT04459234","study":"Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC","sstatus":"COMPLETED","sponsor":"Centre Leon Berard","official":"Gisèle CHVETZOFF, MD (Centre Leon Berard)","src":"https://clinicaltrials.gov/study/NCT04459234","enroll":81,"start":"2021-02-02","eid":"x:site:nct04459234-centre-francois-baclesse-caen"},{"id":"nct04459234-centre-jean-perrin-clermont-ferrand","cat":"research","name":"Centre Jean Perrin","city":"Clermont-Ferrand","country":"France","cc":"FR","lat":45.78887,"lon":3.08357,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"63011","condg":["Addiction & substance use","Cancer-related distress","Chronic pain & headache"],"nct":"NCT04459234","study":"Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC","sstatus":"COMPLETED","sponsor":"Centre Leon Berard","official":"Gisèle CHVETZOFF, MD (Centre Leon Berard)","src":"https://clinicaltrials.gov/study/NCT04459234","enroll":81,"start":"2021-02-02","eid":"x:site:nct04459234-centre-jean-perrin-clermont-ferrand"},{"id":"nct04459234-centre-leon-berard-lyon","cat":"research","name":"Centre Leon Berard","city":"Lyon","country":"France","cc":"FR","lat":45.75607,"lon":4.85801,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"69008","condg":["Addiction & substance use","Cancer-related distress","Chronic pain & headache"],"nct":"NCT04459234","study":"Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC","sstatus":"COMPLETED","sponsor":"Centre Leon Berard","official":"Gisèle CHVETZOFF, MD (Centre Leon Berard)","src":"https://clinicaltrials.gov/study/NCT04459234","enroll":81,"start":"2021-02-02","eid":"x:site:nct04459234-centre-leon-berard-lyon"},{"id":"nct04459234-institut-paoli-calmettes-marseille","cat":"research","name":"Institut Paoli Calmettes","city":"Marseille","country":"France","cc":"FR","lat":43.29154,"lon":5.36945,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"13273","condg":["Addiction & substance use","Cancer-related distress","Chronic pain & headache"],"nct":"NCT04459234","study":"Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC","sstatus":"COMPLETED","sponsor":"Centre Leon Berard","official":"Gisèle CHVETZOFF, MD (Centre Leon Berard)","src":"https://clinicaltrials.gov/study/NCT04459234","enroll":81,"start":"2021-02-02","eid":"x:site:nct04459234-institut-paoli-calmettes-marseille"},{"id":"nct04459234-institut-de-cancerologie-de-montpellier-montpellier","cat":"research","name":"Institut de Cancérologie de Montpellier","city":"Montpellier","country":"France","cc":"FR","lat":43.60561,"lon":3.87856,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"34298","condg":["Addiction & substance use","Cancer-related distress","Chronic pain & headache"],"nct":"NCT04459234","study":"Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC","sstatus":"COMPLETED","sponsor":"Centre Leon Berard","official":"Gisèle CHVETZOFF, MD (Centre Leon Berard)","src":"https://clinicaltrials.gov/study/NCT04459234","enroll":81,"start":"2021-02-02","eid":"x:site:nct04459234-institut-de-cancerologie-de-montpellier-montpellier"},{"id":"nct04459234-institut-curie-paris","cat":"research","name":"Institut Curie","city":"Paris","country":"France","cc":"FR","lat":48.86099,"lon":2.34988,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75005","condg":["Addiction & substance use","Cancer-related distress","Chronic pain & headache"],"nct":"NCT04459234","study":"Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC","sstatus":"COMPLETED","sponsor":"Centre Leon Berard","official":"Gisèle CHVETZOFF, MD (Centre Leon Berard)","src":"https://clinicaltrials.gov/study/NCT04459234","enroll":81,"start":"2021-02-02","eid":"x:site:nct04459234-institut-curie-paris"},{"id":"nct04459234-institut-godinot-reims","cat":"research","name":"Institut Godinot","city":"Reims","country":"France","cc":"FR","lat":49.25768,"lon":4.03535,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"51056","condg":["Addiction & substance use","Cancer-related distress","Chronic pain & headache"],"nct":"NCT04459234","study":"Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC","sstatus":"COMPLETED","sponsor":"Centre Leon Berard","official":"Gisèle CHVETZOFF, MD (Centre Leon Berard)","src":"https://clinicaltrials.gov/study/NCT04459234","enroll":81,"start":"2021-02-02","eid":"x:site:nct04459234-institut-godinot-reims"},{"id":"nct04459234-centre-eugene-marquis-rennes","cat":"research","name":"Centre Eugène Marquis","city":"Rennes","country":"France","cc":"FR","lat":48.10351,"lon":-1.68518,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"35042","condg":["Addiction & substance use","Cancer-related distress","Chronic pain & headache"],"nct":"NCT04459234","study":"Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC","sstatus":"COMPLETED","sponsor":"Centre Leon Berard","official":"Gisèle CHVETZOFF, MD (Centre Leon Berard)","src":"https://clinicaltrials.gov/study/NCT04459234","enroll":81,"start":"2021-02-02","eid":"x:site:nct04459234-centre-eugene-marquis-rennes"},{"id":"nct04459234-institut-universitaire-du-cancer-iuct-toulouse","cat":"research","name":"Institut Universitaire du Cancer (IUCT)","city":"Toulouse","country":"France","cc":"FR","lat":43.6141,"lon":1.44042,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"31059","condg":["Addiction & substance use","Cancer-related distress","Chronic pain & headache"],"nct":"NCT04459234","study":"Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC","sstatus":"COMPLETED","sponsor":"Centre Leon Berard","official":"Gisèle CHVETZOFF, MD (Centre Leon Berard)","src":"https://clinicaltrials.gov/study/NCT04459234","enroll":81,"start":"2021-02-02","eid":"x:site:nct04459234-institut-universitaire-du-cancer-iuct-toulouse"},{"id":"nct04459234-institut-de-cancerologie-de-lorraine-alexis-vautrin-vand-uvre-les-na","cat":"research","name":"Institut de Cancérologie de Lorraine Alexis Vautrin","city":"Vandœuvre-lès-Nancy","country":"France","cc":"FR","lat":48.6675,"lon":6.17994,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"54519","condg":["Addiction & substance use","Cancer-related distress","Chronic pain & headache"],"nct":"NCT04459234","study":"Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC","sstatus":"COMPLETED","sponsor":"Centre Leon Berard","official":"Gisèle CHVETZOFF, MD (Centre Leon Berard)","src":"https://clinicaltrials.gov/study/NCT04459234","enroll":81,"start":"2021-02-02","eid":"x:site:nct04459234-institut-de-cancerologie-de-lorraine-alexis-vautrin-vand-uvre-les-na"},{"id":"nct04459234-institut-gustave-roussy-villejuif","cat":"research","name":"Institut Gustave Roussy","city":"Villejuif","country":"France","cc":"FR","lat":48.79235,"lon":2.3531,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94805","condg":["Addiction & substance use","Cancer-related distress","Chronic pain & headache"],"nct":"NCT04459234","study":"Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC","sstatus":"COMPLETED","sponsor":"Centre Leon Berard","official":"Gisèle CHVETZOFF, MD (Centre Leon Berard)","src":"https://clinicaltrials.gov/study/NCT04459234","enroll":81,"start":"2021-02-02","eid":"x:site:nct04459234-institut-gustave-roussy-villejuif"},{"id":"nct04285684-ketamine-research-foundation-san-anselmo","cat":"research","name":"Ketamine Research Foundation","city":"San Anselmo","region":"California","country":"United States","cc":"US","lat":37.97103,"lon":-122.55896,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94960","condg":["Other"],"nct":"NCT04285684","study":"The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women","sstatus":"COMPLETED","sponsor":"The Ketamine Research Foundation","official":"Philip E Wolfson, MD (Ketamine Research Foundation)","src":"https://clinicaltrials.gov/study/NCT04285684","phase":"EARLY_Phase 1","enroll":4,"start":"2019-12-20","eid":"x:site:nct04285684-ketamine-research-foundation-san-anselmo"},{"id":"nct00833755-massachusetts-general-hospital-boston","cat":"research","name":"Massachusetts General Hospital","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36855,"lon":-71.06904,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02114","condg":["Chronic pain & headache"],"nct":"NCT00833755","study":"Effect of Ketamine on Opioid-Induced Hyperalgesia","sstatus":"COMPLETED","sponsor":"Massachusetts General Hospital","official":"Jianren Mao, M.D., Ph.D. (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT00833755","phase":"N/A","enroll":79,"start":"2008-09","eid":"x:site:nct00833755-massachusetts-general-hospital-boston"},{"id":"nct06165848-ankara-bilkent-sehir-hastanesi-ankara","cat":"research","name":"Ankara Bilkent Şehir Hastanesi","city":"Ankara","country":"Turkey","cc":"TR","lat":39.91003,"lon":32.84566,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06800","condg":["Other"],"nct":"NCT06165848","study":"Effects Of Different Anesthesia Applications On Mood, Depression, And Anxiety Levels In Burn Patients","sstatus":"COMPLETED","sponsor":"T.C. Sağlık Bakanlığı Ankara Bilkent Şehir Hastanesi","official":"Ayça Tuba Özcan (Ankara Bilkent Şehir Hastanesi)","src":"https://clinicaltrials.gov/study/NCT06165848","enroll":67,"start":"2020-07-09","eid":"x:site:nct06165848-ankara-bilkent-sehir-hastanesi-ankara"},{"id":"nct04162028-maimonides-medical-center-brooklyn","cat":"research","name":"Maimonides Medical Center","city":"Brooklyn","region":"New York","country":"United States","cc":"US","lat":40.65015,"lon":-73.94182,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11219","condg":["Chronic pain & headache"],"nct":"NCT04162028","study":"Pre-hospital Nebulized Ketamine for Pain","sstatus":"WITHDRAWN","sponsor":"Antonios Likourezos","src":"https://clinicaltrials.gov/study/NCT04162028","phase":"Phase 4","start":"2019-01-15","eid":"x:site:nct04162028-maimonides-medical-center-brooklyn"},{"id":"nct03102736-icahn-school-of-medicine-at-mount-sinai-new-york","cat":"research","name":"Icahn School of Medicine at Mount Sinai","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71018,"lon":-74.00282,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10029","condg":["Depression"],"nct":"NCT03102736","study":"Ketamine and Nitroprusside for Depression","sstatus":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","official":"James Murrough, MD, PhD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT03102736","phase":"Phase 2","enroll":40,"start":"2017-02-14","eid":"x:site:nct03102736-icahn-school-of-medicine-at-mount-sinai-new-york"},{"id":"nct01868802-abc-neurological-center-mexico-city","cat":"research","name":"ABC Neurological Center","city":"Mexico City","region":"Mexico City","country":"Mexico","cc":"MX","lat":19.43445,"lon":-99.12375,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"05300","condg":["Depression"],"status":"RECRUITING","nct":"NCT01868802","study":"Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population","sstatus":"UNKNOWN","sponsor":"Paul J. Lamothe","official":"Paul J Lamothe, M.D. (American British Cowdray Medical Center); David N Lopez-Garza, M.D. (American British Cowdray Medical Center)","src":"https://clinicaltrials.gov/study/NCT01868802","contact":{"n":"Eduardo San Esteban, M.D.","p":"+52 (55) 52308000","e":"esanesteban@hotmail.com"},"phase":"Phase 2","enroll":60,"start":"2013-09","eid":"x:site:nct01868802-abc-neurological-center-mexico-city"},{"id":"nct07698665-cairo-university-cairo","cat":"research","name":"Cairo university","city":"Cairo","region":"Governorate","country":"Egypt","cc":"EG","lat":30.06456,"lon":31.25423,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"002","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT07698665","study":"Ketamine Versus Dexmedetomidine as an Adjuvant in Scalp Block in Supratentorial Brain Tumor Excision Surgeries","sstatus":"RECRUITING","sponsor":"Cairo University","src":"https://clinicaltrials.gov/study/NCT07698665","contact":{"n":"Nagy Malak","p":"01552480258","e":"nagymalak12345@gmail.com"},"phase":"N/A","enroll":90,"start":"2026-01-01","eid":"x:site:nct07698665-cairo-university-cairo"},{"id":"nct07698665-cairo-university-hospitals-kasralainy-cairo","cat":"research","name":"Cairo university Hospitals. kasralainy","city":"Cairo","country":"Egypt","cc":"EG","lat":30.06258,"lon":31.24689,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT07698665","study":"Ketamine Versus Dexmedetomidine as an Adjuvant in Scalp Block in Supratentorial Brain Tumor Excision Surgeries","sstatus":"RECRUITING","sponsor":"Cairo University","src":"https://clinicaltrials.gov/study/NCT07698665","contact":{"n":"Nagy M Nashed, MD","p":"01552480258","e":"nagymalak12345@gmail.com"},"phase":"N/A","enroll":90,"start":"2026-01-01","eid":"x:site:nct07698665-cairo-university-hospitals-kasralainy-cairo"},{"id":"nct06427707-ain-shams-university-cairo","cat":"research","name":"Ain Shams University","city":"Cairo","region":"Cairo Governorate","country":"Egypt","cc":"EG","lat":30.06315,"lon":31.26082,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"69711","condg":["Other"],"status":"RECRUITING","nct":"NCT06427707","study":"The Effect of Adding Either Propofol or Ketamine to Magnesium and Lidocaine Infusions in Nasal Surgeries.","sstatus":"RECRUITING","sponsor":"Ain Shams University","src":"https://clinicaltrials.gov/study/NCT06427707","contact":{"n":"Rania M Hussien, MD","p":"026213948","e":"drrania_maamon@med.asu.edu.eg"},"phase":"Phase 2/Phase 3","enroll":90,"start":"2024-06-15","eid":"x:site:nct06427707-ain-shams-university-cairo"},{"id":"nct03257800-university-hospital-of-fattouma-bourguiba-monastir","cat":"research","name":"University Hospital of Fattouma Bourguiba","city":"Monastir","country":"Tunisia","cc":"TN","lat":35.77484,"lon":10.83403,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"5000","condg":["Other"],"nct":"NCT03257800","study":"Laryngeal Mask Insertion Conditions And Hemodynamic Effects","sstatus":"COMPLETED","sponsor":"Leila mansali stambouli","official":"leila Mansali Stambouli, MD PhD (university Hospital of Fattouma Bourguiba, Monastir, TUNISIA)","src":"https://clinicaltrials.gov/study/NCT03257800","phase":"N/A","enroll":120,"start":"2013-06-01","eid":"x:site:nct03257800-university-hospital-of-fattouma-bourguiba-monastir"},{"id":"nct02772211-psychiatry-clinic-sheba-medical-center-ramat-gan","cat":"research","name":"Psychiatry Clinic - Sheba Medical Center","city":"Ramat Gan","country":"Israel","cc":"IL","lat":32.07705,"lon":34.80194,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT02772211","study":"D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression","sstatus":"UNKNOWN","sponsor":"Sheba Medical Center","src":"https://clinicaltrials.gov/study/NCT02772211","contact":{"n":"Revital Amiaz, MD","p":"+972-542378757","e":"revital.amiaz@sheba.health.gov.il"},"phase":"Phase 4","enroll":60,"start":"2016-06","eid":"x:site:nct02772211-psychiatry-clinic-sheba-medical-center-ramat-gan"},{"id":"nct03933865-zuckerberg-san-francisco-general-hospital-san-francisco","cat":"research","name":"Zuckerberg San Francisco General Hospital","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.77601,"lon":-122.41297,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94110","condg":["Addiction & substance use","Chronic pain & headache"],"nct":"NCT03933865","study":"Acute Pain Management in Patients on Opioid Replacement Therapy","sstatus":"TERMINATED","sponsor":"University of California, San Francisco","official":"D. Andrew Tompkins, MD MHS (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT03933865","phase":"Phase 1","enroll":1,"start":"2018-10-31","eid":"x:site:nct03933865-zuckerberg-san-francisco-general-hospital-san-francisco"},{"id":"nct02655692-va-connecticut-healthcare-system-west-haven-campus-west-haven-ct-wes","cat":"research","name":"VA Connecticut Healthcare System West Haven Campus, West Haven, CT","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.2626,"lon":-72.95274,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06516","condg":["PTSD & trauma"],"nct":"NCT02655692","study":"CAP-Ketamine for Antidepressant Resistant PTSD","sstatus":"COMPLETED","sponsor":"VA Office of Research and Development","official":"John H. Krystal, MD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT02655692","phase":"Phase 2","enroll":163,"start":"2016-04-18","eid":"x:site:nct02655692-va-connecticut-healthcare-system-west-haven-campus-west-haven-ct-wes"},{"id":"nct02655692-minneapolis-va-health-care-system-minneapolis-mn-minneapolis","cat":"research","name":"Minneapolis VA Health Care System, Minneapolis, MN","city":"Minneapolis","region":"Minnesota","country":"United States","cc":"US","lat":44.97597,"lon":-93.27264,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55417","condg":["PTSD & trauma"],"nct":"NCT02655692","study":"CAP-Ketamine for Antidepressant Resistant PTSD","sstatus":"COMPLETED","sponsor":"VA Office of Research and Development","official":"John H. Krystal, MD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT02655692","phase":"Phase 2","enroll":163,"start":"2016-04-18","eid":"x:site:nct02655692-minneapolis-va-health-care-system-minneapolis-mn-minneapolis"},{"id":"nct02655692-brooke-army-medical-center-san-antonio","cat":"research","name":"Brooke Army Medical Center","city":"San Antonio","region":"Texas","country":"United States","cc":"US","lat":29.42285,"lon":-98.50168,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"78234","condg":["PTSD & trauma"],"nct":"NCT02655692","study":"CAP-Ketamine for Antidepressant Resistant PTSD","sstatus":"COMPLETED","sponsor":"VA Office of Research and Development","official":"John H. Krystal, MD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT02655692","phase":"Phase 2","enroll":163,"start":"2016-04-18","eid":"x:site:nct02655692-brooke-army-medical-center-san-antonio"},{"id":"nct04602221-collaborative-neuroscience-research-llc-long-beach","cat":"research","name":"Collaborative Neuroscience Research, LLC","city":"Long Beach","region":"California","country":"United States","cc":"US","lat":33.76098,"lon":-118.19361,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"90806","condg":["Healthy volunteers"],"nct":"NCT04602221","study":"A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine","sstatus":"COMPLETED","sponsor":"Boehringer Ingelheim","src":"https://clinicaltrials.gov/study/NCT04602221","phase":"Phase 1","enroll":40,"start":"2020-12-01","eid":"x:site:nct04602221-collaborative-neuroscience-research-llc-long-beach"},{"id":"nct04602221-hassman-research-institute-marlton","cat":"research","name":"Hassman Research Institute","city":"Marlton","region":"New Jersey","country":"United States","cc":"US","lat":39.88251,"lon":-74.92781,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"08053","condg":["Healthy volunteers"],"nct":"NCT04602221","study":"A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine","sstatus":"COMPLETED","sponsor":"Boehringer Ingelheim","src":"https://clinicaltrials.gov/study/NCT04602221","phase":"Phase 1","enroll":40,"start":"2020-12-01","eid":"x:site:nct04602221-hassman-research-institute-marlton"},{"id":"nct04939987-wake-forest-health-sciences-winston-salem","cat":"research","name":"Wake Forest Health Sciences","city":"Winston-Salem","region":"North Carolina","country":"United States","cc":"US","lat":36.09398,"lon":-80.25095,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"27157","condg":["Other"],"nct":"NCT04939987","study":"Opioid-Free Pain Control Regiment Following Robotic Radical Prostatectomy","sstatus":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","official":"Ram Pathak, MD (Wake Forest Health Sciences)","src":"https://clinicaltrials.gov/study/NCT04939987","phase":"Phase 2/Phase 3","start":"2022-08","eid":"x:site:nct04939987-wake-forest-health-sciences-winston-salem"},{"id":"nct06048263-barnes-jewish-hospital-st-louis","cat":"research","name":"Barnes-Jewish Hospital","city":"St Louis","region":"Missouri","country":"United States","cc":"US","lat":38.62111,"lon":-90.20274,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"63110","condg":["Depression"],"nct":"NCT06048263","study":"The Perinatal Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms. A Case Series","sstatus":"WITHDRAWN","sponsor":"Washington University School of Medicine","official":"David Monks, MBCHB (Washington University School of Medicine)","src":"https://clinicaltrials.gov/study/NCT06048263","phase":"Phase 2/Phase 3","start":"2025-10-15","eid":"x:site:nct06048263-barnes-jewish-hospital-st-louis"},{"id":"nct01573741-the-pla-102nd-hospital-and-mental-health-center-of-military-changzho","cat":"research","name":"The PLA 102nd Hospital and mental health center of military","city":"Changzhou","region":"Jiangsu","country":"China","cc":"CN","lat":31.77364,"lon":119.95095,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"213003","condg":["Depression"],"status":"RECRUITING","nct":"NCT01573741","study":"Study of Ketamine as an Antidepressant in Major Depressive Disorder","sstatus":"UNKNOWN","sponsor":"Shi Jinyun","official":"Jianjun Yang, Dr (Department of Anesthesiology, Jinling Hospital, School of Medicine, Nanjing University)","src":"https://clinicaltrials.gov/study/NCT01573741","contact":{"n":"Qin zhi Gao, MD","p":"0519-83064728","e":"gzq_102@hotmail.com"},"phase":"Phase 1/Phase 2","enroll":35,"start":"2012-02","eid":"x:site:nct01573741-the-pla-102nd-hospital-and-mental-health-center-of-military-changzho"},{"id":"nct07074262-beni-suef-university-hospital-bani-suwayf","cat":"research","name":"Beni- Suef University Hospital","city":"Banī Suwayf","region":"Beni Suweif Governorate","country":"Egypt","cc":"EG","lat":29.077,"lon":31.09714,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"62511","condg":["Neurology & cognition"],"nct":"NCT07074262","study":"Comparison Between the Effect of Dexmedetomidine _midazolam and ketamine_midazolam Combination","sstatus":"COMPLETED","sponsor":"Beni-Suef University","official":"Mahmoud Attia Nassef, Professor (Anaesthesiology,Surgical intensive care and pain management,Faculty of Medicine,Beni-Suef University)","src":"https://clinicaltrials.gov/study/NCT07074262","phase":"N/A","enroll":114,"start":"2024-10-10","eid":"x:site:nct07074262-beni-suef-university-hospital-bani-suwayf"},{"id":"nct00661063-santa-casa-de-sao-paulo-sao-paulo","cat":"research","name":"Santa Casa de São Paulo","city":"São Paulo","region":"São Paulo","country":"Brazil","cc":"BR","lat":-23.55884,"lon":-46.62618,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"01277-900","condg":["Chronic pain & headache"],"nct":"NCT00661063","study":"Diabetic Neuropathy Topical Treatment","sstatus":"UNKNOWN","sponsor":"Irmandade da Santa Casa de Misericordia de Sao Paulo","official":"Judymara L Gozzani, Investigator (Santa Casa de São Paulo)","src":"https://clinicaltrials.gov/study/NCT00661063","contact":{"n":"Judymara L Gozzani, investigator","p":"55-11-3884-0865","e":"gozzani@osite.com.br"},"phase":"Phase 3","enroll":200,"start":"2008-04","eid":"x:site:nct00661063-santa-casa-de-sao-paulo-sao-paulo"},{"id":"nct01816958-the-neuroscience-center-deerfield","cat":"research","name":"The Neuroscience Center","city":"Deerfield","region":"Illinois","country":"United States","cc":"US","lat":42.16987,"lon":-87.84992,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60015","condg":["Depression","Addiction & substance use","Chronic pain & headache"],"nct":"NCT01816958","study":"Neuromodulation to Facilitate the Effect of Ketamine","sstatus":"COMPLETED","sponsor":"The Neuroscience Center, LLC","official":"Steven R Devore Best, M.D. (The Neuroscience Center)","src":"https://clinicaltrials.gov/study/NCT01816958","enroll":35,"start":"2011-01","eid":"x:site:nct01816958-the-neuroscience-center-deerfield"},{"id":"nct03096444-university-of-miami-miami","cat":"research","name":"University of Miami","city":"Miami","region":"Florida","country":"United States","cc":"US","lat":25.78072,"lon":-80.19841,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"33136","condg":["Other"],"nct":"NCT03096444","study":"Antipruritic Effect of Topical Ketamine, Amitriptyline, and Lidocaine","sstatus":"TERMINATED","sponsor":"Gil Yosipovitch","official":"Gil Yosipovitch, MD (University of Miami)","src":"https://clinicaltrials.gov/study/NCT03096444","phase":"Phase 2","enroll":13,"start":"2017-05-23","eid":"x:site:nct03096444-university-of-miami-miami"},{"id":"nct05306899-women-s-college-hospital-toronto","cat":"research","name":"Women's College Hospital","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70911,"lon":-79.38711,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M5S 1B2","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT05306899","study":"Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches","sstatus":"RECRUITING","sponsor":"University Health Network, Toronto","official":"Anuj Bhatia, MD, PhD (University Health Network, Toronto)","src":"https://clinicaltrials.gov/study/NCT05306899","contact":{"n":"Didem Bozak","p":"+1 (416) 603 5800","e":"kethead@uhn.ca"},"phase":"Phase 3","enroll":56,"start":"2022-06-01","eid":"x:site:nct05306899-women-s-college-hospital-toronto"},{"id":"nct05306899-toronto-western-hospital-toronto","cat":"research","name":"Toronto Western Hospital","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70017,"lon":-79.40142,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M5T 2S8","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT05306899","study":"Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches","sstatus":"RECRUITING","sponsor":"University Health Network, Toronto","official":"Anuj Bhatia, MD, PhD (University Health Network, Toronto)","src":"https://clinicaltrials.gov/study/NCT05306899","contact":{"n":"Emad Al Azazi","p":"+1-416-603-5800","e":"kethead@uhn.ca"},"phase":"Phase 3","enroll":56,"start":"2022-06-01","eid":"x:site:nct05306899-toronto-western-hospital-toronto"},{"id":"nct01944293-columbia-university-new-york-state-psychiatric-institute-new-york","cat":"research","name":"Columbia University/New York State Psychiatric Institute","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72194,"lon":-73.9999,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10032","condg":["Depression","Bipolar"],"nct":"NCT01944293","study":"Ketamine for Suicidality in Bipolar Depression","sstatus":"COMPLETED","sponsor":"New York State Psychiatric Institute","official":"Michael F Grunebaum, M.D. (Columbia Unviversity/New York State Psychiatric Institute)","src":"https://clinicaltrials.gov/study/NCT01944293","phase":"Phase 1/Phase 2","enroll":16,"start":"2013-09","eid":"x:site:nct01944293-columbia-university-new-york-state-psychiatric-institute-new-york"},{"id":"nct02299440-chu-de-clermont-ferrand-hopital-gabriel-montpied-clermont-ferrand","cat":"research","name":"CHU de Clermont Ferrand - Hôpital Gabriel-Montpied","city":"Clermont-Ferrand","country":"France","cc":"FR","lat":45.77042,"lon":3.09411,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"63003","condg":["Other"],"nct":"NCT02299440","study":"Effects of Ketamine in the Acute Phase of Suicidal Ideation","sstatus":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","official":"Mocrane Abbar, MD (Centre Hospitalier Universitaire de Nīmes)","src":"https://clinicaltrials.gov/study/NCT02299440","phase":"Phase 3","enroll":156,"start":"2015-04","eid":"x:site:nct02299440-chu-de-clermont-ferrand-hopital-gabriel-montpied-clermont-ferrand"},{"id":"nct02299440-chru-de-lille-hopital-michel-fontan-lille","cat":"research","name":"CHRU de Lille - Hôpital Michel Fontan","city":"Lille","country":"France","cc":"FR","lat":50.64158,"lon":3.05441,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"59037","condg":["Other"],"nct":"NCT02299440","study":"Effects of Ketamine in the Acute Phase of Suicidal Ideation","sstatus":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","official":"Mocrane Abbar, MD (Centre Hospitalier Universitaire de Nīmes)","src":"https://clinicaltrials.gov/study/NCT02299440","phase":"Phase 3","enroll":156,"start":"2015-04","eid":"x:site:nct02299440-chru-de-lille-hopital-michel-fontan-lille"},{"id":"nct02299440-chru-de-montpellier-hopital-lapeyronie-montpellier","cat":"research","name":"CHRU de Montpellier - Hôpital Lapeyronie","city":"Montpellier","country":"France","cc":"FR","lat":43.61804,"lon":3.8715,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"34295","condg":["Other"],"nct":"NCT02299440","study":"Effects of Ketamine in the Acute Phase of Suicidal Ideation","sstatus":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","official":"Mocrane Abbar, MD (Centre Hospitalier Universitaire de Nīmes)","src":"https://clinicaltrials.gov/study/NCT02299440","phase":"Phase 3","enroll":156,"start":"2015-04","eid":"x:site:nct02299440-chru-de-montpellier-hopital-lapeyronie-montpellier"},{"id":"nct02299440-clinique-les-sophoras-nimes","cat":"research","name":"Clinique Les Sophoras","city":"Nîmes","country":"France","cc":"FR","lat":43.82813,"lon":4.35623,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"30000","condg":["Other"],"nct":"NCT02299440","study":"Effects of Ketamine in the Acute Phase of Suicidal Ideation","sstatus":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","official":"Mocrane Abbar, MD (Centre Hospitalier Universitaire de Nīmes)","src":"https://clinicaltrials.gov/study/NCT02299440","phase":"Phase 3","enroll":156,"start":"2015-04","eid":"x:site:nct02299440-clinique-les-sophoras-nimes"},{"id":"nct02299440-chru-de-nimes-hopital-universitaire-caremeau-nimes","cat":"research","name":"CHRU de Nîmes - Hôpital Universitaire Carémeau","city":"Nîmes","country":"France","cc":"FR","lat":43.83604,"lon":4.34663,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"30029","condg":["Other"],"nct":"NCT02299440","study":"Effects of Ketamine in the Acute Phase of Suicidal Ideation","sstatus":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","official":"Mocrane Abbar, MD (Centre Hospitalier Universitaire de Nīmes)","src":"https://clinicaltrials.gov/study/NCT02299440","phase":"Phase 3","enroll":156,"start":"2015-04","eid":"x:site:nct02299440-chru-de-nimes-hopital-universitaire-caremeau-nimes"},{"id":"nct02299440-aphp-hopital-lariboisiere-paris","cat":"research","name":"APHP - Hôpital Lariboisière","city":"Paris","country":"France","cc":"FR","lat":48.84677,"lon":2.35534,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75010","condg":["Other"],"nct":"NCT02299440","study":"Effects of Ketamine in the Acute Phase of Suicidal Ideation","sstatus":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","official":"Mocrane Abbar, MD (Centre Hospitalier Universitaire de Nīmes)","src":"https://clinicaltrials.gov/study/NCT02299440","phase":"Phase 3","enroll":156,"start":"2015-04","eid":"x:site:nct02299440-aphp-hopital-lariboisiere-paris"},{"id":"nct02299440-centre-hospitalier-sainte-anne-paris","cat":"research","name":"Centre Hospitalier Sainte-Anne","city":"Paris","country":"France","cc":"FR","lat":48.86513,"lon":2.35459,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75674","condg":["Other"],"nct":"NCT02299440","study":"Effects of Ketamine in the Acute Phase of Suicidal Ideation","sstatus":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","official":"Mocrane Abbar, MD (Centre Hospitalier Universitaire de Nīmes)","src":"https://clinicaltrials.gov/study/NCT02299440","phase":"Phase 3","enroll":156,"start":"2015-04","eid":"x:site:nct02299440-centre-hospitalier-sainte-anne-paris"},{"id":"nct02299440-cmme-centre-hospitalier-sainte-anne-paris","cat":"research","name":"CMME Centre Hospitalier Sainte Anne","city":"Paris","country":"France","cc":"FR","lat":48.85741,"lon":2.34969,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75674","condg":["Other"],"nct":"NCT02299440","study":"Effects of Ketamine in the Acute Phase of Suicidal Ideation","sstatus":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","official":"Mocrane Abbar, MD (Centre Hospitalier Universitaire de Nīmes)","src":"https://clinicaltrials.gov/study/NCT02299440","phase":"Phase 3","enroll":156,"start":"2015-04","eid":"x:site:nct02299440-cmme-centre-hospitalier-sainte-anne-paris"},{"id":"nct02299440-chru-de-tours-clinique-psychiatrique-universitaire-saint-cyr-sur-loi","cat":"research","name":"CHRU de Tours - Clinique Psychiatrique Universitaire","city":"Saint-Cyr-sur-Loire","country":"France","cc":"FR","lat":47.3992,"lon":0.66455,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"37540","condg":["Other"],"nct":"NCT02299440","study":"Effects of Ketamine in the Acute Phase of Suicidal Ideation","sstatus":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","official":"Mocrane Abbar, MD (Centre Hospitalier Universitaire de Nīmes)","src":"https://clinicaltrials.gov/study/NCT02299440","phase":"Phase 3","enroll":156,"start":"2015-04","eid":"x:site:nct02299440-chru-de-tours-clinique-psychiatrique-universitaire-saint-cyr-sur-loi"},{"id":"nct04013958-tel-aviv-sourasky-medical-center-department-of-emergency-medicine-te","cat":"research","name":"Tel Aviv Sourasky Medical Center, department of Emergency Medicine","city":"Tel Aviv","country":"Israel","cc":"IL","lat":32.08384,"lon":34.77563,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"6423906","condg":["Chronic pain & headache"],"nct":"NCT04013958","study":"Comparison of Treatment by IM Ketamine to IV Ketamine in Patients With Renal Colic","sstatus":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","src":"https://clinicaltrials.gov/study/NCT04013958","contact":{"n":"Daniel Trotzky, MD","p":"+97236973829","e":"danieltro@tlvmc.gov.il"},"phase":"Phase 3","enroll":100,"start":"2019-08-01","eid":"x:site:nct04013958-tel-aviv-sourasky-medical-center-department-of-emergency-medicine-te"},{"id":"nct02648412-departement-d-anesthesie-hopital-armand-trousseau-paris","cat":"research","name":"Departement d'anesthesie Hopital Armand Trousseau","city":"Paris","country":"France","cc":"FR","lat":48.84649,"lon":2.34311,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75012","condg":["Chronic pain & headache"],"nct":"NCT02648412","study":"Pupillary Dilation After Incremental Tetanic Stimulations Under Ketamine Sedation","sstatus":"COMPLETED","sponsor":"Pr Isabelle CONSTANT","official":"Isabelle Constant, PHD (University Hospital Armand Trousseau)","src":"https://clinicaltrials.gov/study/NCT02648412","phase":"N/A","enroll":24,"start":"2012-04","eid":"x:site:nct02648412-departement-d-anesthesie-hopital-armand-trousseau-paris"},{"id":"nct01046630-research-site-manchester","cat":"research","name":"Research Site","city":"Manchester","country":"United Kingdom","cc":"GB","lat":53.47535,"lon":-2.23785,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01046630","study":"Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects","sstatus":"COMPLETED","sponsor":"AstraZeneca","official":"Bill Deakin, Prof (University of Manchester, Neurosciance and Psychiatry Unit, UK); Guy Goodwin, Prof (University of Oxford, Departmentof Psychiatry, UK)","src":"https://clinicaltrials.gov/study/NCT01046630","phase":"Phase 1","enroll":128,"start":"2009-12","eid":"x:site:nct01046630-research-site-manchester"},{"id":"nct01046630-research-site-oxford","cat":"research","name":"Research Site","city":"Oxford","country":"United Kingdom","cc":"GB","lat":51.75641,"lon":-1.24829,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01046630","study":"Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects","sstatus":"COMPLETED","sponsor":"AstraZeneca","official":"Bill Deakin, Prof (University of Manchester, Neurosciance and Psychiatry Unit, UK); Guy Goodwin, Prof (University of Oxford, Departmentof Psychiatry, UK)","src":"https://clinicaltrials.gov/study/NCT01046630","phase":"Phase 1","enroll":128,"start":"2009-12","eid":"x:site:nct01046630-research-site-oxford"},{"id":"nct01881763-zucker-hillside-hospital-glen-oaks","cat":"research","name":"Zucker Hillside Hospital","city":"Glen Oaks","region":"New York","country":"United States","cc":"US","lat":40.74616,"lon":-73.71241,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11004","condg":["Depression","Bipolar"],"nct":"NCT01881763","study":"Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression","sstatus":"COMPLETED","sponsor":"Northwell Health","official":"Georgios Petrides, M.D. (The Zucker Hillside Hospital)","src":"https://clinicaltrials.gov/study/NCT01881763","phase":"Phase 4","enroll":31,"start":"2010-06","eid":"x:site:nct01881763-zucker-hillside-hospital-glen-oaks"},{"id":"nct01260649-massachusetts-general-hospital-boston","cat":"research","name":"Massachusetts General Hospital","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36648,"lon":-71.06735,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02114","condg":["Depression"],"nct":"NCT01260649","study":"N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression","sstatus":"TERMINATED","sponsor":"Massachusetts General Hospital","src":"https://clinicaltrials.gov/study/NCT01260649","phase":"Phase 4","enroll":17,"start":"2010-11-01","eid":"x:site:nct01260649-massachusetts-general-hospital-boston"},{"id":"nct02414932-st-patrick-s-university-hospital-dublin","cat":"research","name":"St Patrick's University Hospital","city":"Dublin","country":"Ireland","cc":"IE","lat":53.3429,"lon":-6.24273,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"8","condg":["Depression"],"nct":"NCT02414932","study":"Ketamine for Depression Relapse Prevention Following ECT","sstatus":"COMPLETED","sponsor":"St Patrick's Hospital, Ireland","official":"Declan M McLoughlin (St Patrick's Hospital/Trinity College)","src":"https://clinicaltrials.gov/study/NCT02414932","phase":"EARLY_Phase 1","enroll":6,"start":"2015-04","eid":"x:site:nct02414932-st-patrick-s-university-hospital-dublin"},{"id":"nct01385904-pain-clinic-st-joseph-s-health-care-london-hospitals-london","cat":"research","name":"Pain Clinic, St. Joseph's Health Care London Hospitals","city":"London","region":"Ontario","country":"Canada","cc":"CA","lat":42.97384,"lon":-81.236,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"N6A 4V2","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT01385904","study":"Blood Levels of Ketamine in Patients Using Topical Application of 10% Ketamine Gel for Neuropathic Pain","sstatus":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","official":"Patricia Morley- Forster, MD, FRCPC (Western University, Canada)","src":"https://clinicaltrials.gov/study/NCT01385904","contact":{"n":"Patricia Morley - Forster, MD, FRCPC","p":"(519) 646-6000","e":"pat.morley-forster@sjhc.london.on.ca"},"enroll":15,"start":"2011-06","eid":"x:site:nct01385904-pain-clinic-st-joseph-s-health-care-london-hospitals-london"},{"id":"nct04947085-maimonides-medical-center-brooklyn","cat":"research","name":"Maimonides Medical Center","city":"Brooklyn","region":"New York","country":"United States","cc":"US","lat":40.64808,"lon":-73.94351,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11219","condg":["Chronic pain & headache"],"nct":"NCT04947085","study":"Comparison of Nebulized Ketamine to Intravenous Sub-Dissociative Dose Ketamine for Pain","sstatus":"COMPLETED","sponsor":"Antonios Likourezos","official":"Sergey Motov, MD (Maimonides Medical Center)","src":"https://clinicaltrials.gov/study/NCT04947085","phase":"Phase 4","enroll":150,"start":"2021-10-04","eid":"x:site:nct04947085-maimonides-medical-center-brooklyn"},{"id":"nct02669043-massachusetts-general-hospital-boston","cat":"research","name":"Massachusetts General Hospital","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36714,"lon":-71.05229,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02114","condg":["Depression"],"nct":"NCT02669043","study":"Physiological and Cognitive Biomarkers for Ketamine's Antidepressant Effects","sstatus":"TERMINATED","sponsor":"Massachusetts General Hospital","official":"Dawn Ionescu, M.D. (MGH)","src":"https://clinicaltrials.gov/study/NCT02669043","phase":"N/A","enroll":8,"start":"2016-07","eid":"x:site:nct02669043-massachusetts-general-hospital-boston"},{"id":"nct05985811-salem-anaesthesia-pain-clinic-surrey","cat":"research","name":"Salem Anaesthesia Pain Clinic","city":"Surrey","region":"British Columbia","country":"Canada","cc":"CA","lat":49.1112,"lon":-122.82721,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"V3S 7J1","condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT05985811","study":"Ketamine Enhances Analgesia and Mood in Chronic Pain Patients","sstatus":"RECRUITING","sponsor":"Salem Anaesthesia Pain Clinic","official":"Olumuyiwa Bamgbade, MD,FRCPC (Salem Anaesthesia Pain Clinic)","src":"https://clinicaltrials.gov/study/NCT05985811","contact":{"n":"Olumuyiwa Bamgbade, MD, FRCPC","p":"+17786286600","e":"salem.painclinic@gmail.com"},"enroll":500,"start":"2018-02-02","eid":"x:site:nct05985811-salem-anaesthesia-pain-clinic-surrey"},{"id":"nct06506565-regional-one-health-memphis","cat":"research","name":"Regional One Health","city":"Memphis","region":"Tennessee","country":"United States","cc":"US","lat":35.14195,"lon":-90.05637,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"38103","condg":["Addiction & substance use","Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06506565","study":"Low-Dose Ketamine Infusion During Burn Wound Care","sstatus":"RECRUITING","sponsor":"University of Tennessee","src":"https://clinicaltrials.gov/study/NCT06506565","contact":{"n":"Yvonne Shaw, RN","p":"901-448-2714","e":"yshaw@uthsc.edu"},"phase":"Phase 4","enroll":140,"start":"2024-07-08","eid":"x:site:nct06506565-regional-one-health-memphis"},{"id":"nct02962999-cukurova-university-adana","cat":"research","name":"Cukurova University","city":"Adana","country":"Turkey","cc":"TR","lat":36.99608,"lon":35.32244,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"01330","condg":["Cancer-related distress"],"nct":"NCT02962999","study":"Effect Of Ketamine Infusion In Patients With COPD Applied One Lung Ventilation","sstatus":"COMPLETED","sponsor":"Cukurova University","official":"Feride Karacaer, Specialist (Cukurova University)","src":"https://clinicaltrials.gov/study/NCT02962999","phase":"Phase 4","enroll":30,"start":"2017-01","eid":"x:site:nct02962999-cukurova-university-adana"},{"id":"nct02962999-cukurova-university-faculty-of-medicine-research-hospital-adana","cat":"research","name":"Cukurova University Faculty of Medicine Research Hospital","city":"Adana","country":"Turkey","cc":"TR","lat":36.97547,"lon":35.32319,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Cancer-related distress"],"nct":"NCT02962999","study":"Effect Of Ketamine Infusion In Patients With COPD Applied One Lung Ventilation","sstatus":"COMPLETED","sponsor":"Cukurova University","official":"Feride Karacaer, Specialist (Cukurova University)","src":"https://clinicaltrials.gov/study/NCT02962999","phase":"Phase 4","enroll":30,"start":"2017-01","eid":"x:site:nct02962999-cukurova-university-faculty-of-medicine-research-hospital-adana"},{"id":"nct07590687-department-of-intensive-care-medicine-aphp-nord-hopital-bichat-claud","cat":"research","name":"Department of Intensive Care Medicine, APHP.Nord, hôpital Bichat Claude Bernard,","city":"Paris","country":"France","cc":"FR","lat":48.86099,"lon":2.33708,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75018","condg":["Other"],"nct":"NCT07590687","study":"KetAmine and Recovery After Mechanical VentilAtion ( KARMA )","sstatus":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","official":"Romain Prof SONNEVILLE, MD-PHD (APHP)","src":"https://clinicaltrials.gov/study/NCT07590687","contact":{"n":"Romain Prof SONNEVILLE, MD-PHD","p":"1 40 25 61 39","e":"romain.sonneville@aphp.fr"},"phase":"Phase 3","enroll":640,"start":"2026-10-19","eid":"x:site:nct07590687-department-of-intensive-care-medicine-aphp-nord-hopital-bichat-claud"},{"id":"nct03735563-oulu-university-hospital-oulu","cat":"research","name":"Oulu University Hospital","city":"Oulu","country":"Finland","cc":"FI","lat":65.0062,"lon":25.47489,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"RECRUITING","nct":"NCT03735563","study":"Premedication for Less Invasive Surfactant Administration","sstatus":"RECRUITING","sponsor":"University of Oulu","official":"Riitta Marttila, MD, docent (Oulu University and Oulu University Hospital)","src":"https://clinicaltrials.gov/study/NCT03735563","contact":{"n":"Eveliina Ronkainen, MD, PhD","p":"+358 8 3152011","e":"eveliina.ronkainen@oulu.fi"},"phase":"Phase 4","enroll":40,"start":"2019-02-11","eid":"x:site:nct03735563-oulu-university-hospital-oulu"},{"id":"nct03290963-mayo-clinic-in-rochester-rochester","cat":"research","name":"Mayo Clinic in Rochester","city":"Rochester","region":"Minnesota","country":"United States","cc":"US","lat":43.16433,"lon":-77.61504,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55905","condg":["Depression"],"nct":"NCT03290963","study":"Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine","sstatus":"WITHDRAWN","sponsor":"William V. Bobo, M.D.","official":"William V Bobo (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT03290963","phase":"Phase 2","start":"2017-11-30","eid":"x:site:nct03290963-mayo-clinic-in-rochester-rochester"},{"id":"nct03375671-st-paul-s-hospital-emergency-department-vancouver","cat":"research","name":"St. Paul's Hospital Emergency Department","city":"Vancouver","region":"British Columbia","country":"Canada","cc":"CA","lat":49.24519,"lon":-123.11318,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"V6Z 1Y6","condg":["Other"],"nct":"NCT03375671","study":"Rapid Agitation Control With Ketamine in the Emergency Department","sstatus":"COMPLETED","sponsor":"David Barbic","official":"David Barbic, MD MSc FRCPC, (University of British Columbia)","src":"https://clinicaltrials.gov/study/NCT03375671","phase":"Phase 2","enroll":81,"start":"2018-05-29","eid":"x:site:nct03375671-st-paul-s-hospital-emergency-department-vancouver"},{"id":"nct02501941-university-of-new-mexico-albuquerque","cat":"research","name":"University of New Mexico","city":"Albuquerque","region":"New Mexico","country":"United States","cc":"US","lat":35.08341,"lon":-106.66276,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"87131","condg":["Depression","PTSD & trauma","Neurology & cognition"],"nct":"NCT02501941","study":"Spreading Depolarization and Ketamine Suppression","sstatus":"COMPLETED","sponsor":"University of New Mexico","official":"Andrew P Carlson, MD (University of New Mexico)","src":"https://clinicaltrials.gov/study/NCT02501941","phase":"Phase 1","enroll":10,"start":"2015-07","eid":"x:site:nct02501941-university-of-new-mexico-albuquerque"},{"id":"nct05821972-assiut-university-asyut","cat":"research","name":"Assiut University","city":"Asyut","country":"Egypt","cc":"EG","lat":27.1908,"lon":31.19399,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"71515","condg":["Other"],"status":"RECRUITING","nct":"NCT05821972","study":"Nebulized Dexmedetomidine Combined With Ketamine Versus Nebulized Dexmedetomidine for Cleft Palate","sstatus":"RECRUITING","sponsor":"Assiut University","src":"https://clinicaltrials.gov/study/NCT05821972","contact":{"n":"Fatma N. Mohamed, M.D.","p":"+201003633992","e":"fatmanabil2012@aun.edu.eg"},"phase":"Phase 4","enroll":60,"start":"2024-04-10","eid":"x:site:nct05821972-assiut-university-asyut"},{"id":"nct02422290-new-york-state-psychiatric-institute-columbia-university-new-york","cat":"research","name":"New York State Psychiatric Institute/Columbia University","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72015,"lon":-74.00941,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10032","condg":["OCD"],"nct":"NCT02422290","study":"Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)","sstatus":"COMPLETED","sponsor":"New York State Psychiatric Institute","official":"Pablo Goldberg, M.D. (Columbia University/NYSPI)","src":"https://clinicaltrials.gov/study/NCT02422290","phase":"Phase 1/Phase 2","enroll":5,"start":"2015-03","eid":"x:site:nct02422290-new-york-state-psychiatric-institute-columbia-university-new-york"},{"id":"nct05086250-cedars-sinai-medical-center-los-angeles","cat":"research","name":"Cedars-Sinai Medical Center","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.05576,"lon":-118.2409,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"90048","condg":["Anxiety","Cancer-related distress"],"nct":"NCT05086250","study":"Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer","sstatus":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","official":"Scott Irwin, MD, PhD (Cedars-Sinai Medical Center)","src":"https://clinicaltrials.gov/study/NCT05086250","phase":"EARLY_Phase 1","enroll":12,"start":"2022-10-20","eid":"x:site:nct05086250-cedars-sinai-medical-center-los-angeles"},{"id":"nct06508710-psychiatry-unit-le-kremlin-bicetre","cat":"research","name":"Psychiatry unit","city":"Le Kremlin-Bicêtre","region":"France","country":"France","cc":"FR","lat":48.80666,"lon":2.37245,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94270","condg":["Depression"],"status":"RECRUITING","nct":"NCT06508710","study":"Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients","sstatus":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","official":"Romain COLLE (Service Hospitalo-Universitaire de Psychiatrie - Hôpital Bicêtre)","src":"https://clinicaltrials.gov/study/NCT06508710","contact":{"n":"Romain COLLE, MD - PHD","p":"+33145212524","e":"romain.colle@aphp.fr"},"phase":"Phase 3","enroll":60,"start":"2024-10-20","eid":"x:site:nct06508710-psychiatry-unit-le-kremlin-bicetre"},{"id":"nct06508710-eps-barthelemy-durand-etampes","cat":"research","name":"EPS Barthélémy Durand","city":"Étampes","country":"France","cc":"FR","lat":48.42825,"lon":2.15701,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"91152","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT06508710","study":"Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients","sstatus":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","official":"Romain COLLE (Service Hospitalo-Universitaire de Psychiatrie - Hôpital Bicêtre)","src":"https://clinicaltrials.gov/study/NCT06508710","contact":{"n":"christian trichard","p":"01.69.46.86.66","e":"Christian.Trichard@eps-etampes.fr"},"phase":"Phase 3","enroll":60,"start":"2024-10-20","eid":"x:site:nct06508710-eps-barthelemy-durand-etampes"},{"id":"nct06508710-bicetre-hospital-crc-le-kremlin-bicetre","cat":"research","name":"Bicetre Hospital - CRC","city":"Le Kremlin-Bicêtre","country":"France","cc":"FR","lat":48.80911,"lon":2.35504,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94250","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT06508710","study":"Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients","sstatus":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","official":"Romain COLLE (Service Hospitalo-Universitaire de Psychiatrie - Hôpital Bicêtre)","src":"https://clinicaltrials.gov/study/NCT06508710","contact":{"n":"laurent becquemont","p":"01.45.21.74.51","e":"laurent.becquemont@aphp.fr"},"phase":"Phase 3","enroll":60,"start":"2024-10-20","eid":"x:site:nct06508710-bicetre-hospital-crc-le-kremlin-bicetre"},{"id":"nct06508710-cea-shfj-orsay","cat":"research","name":"CEA/SHFJ","city":"Orsay","country":"France","cc":"FR","lat":48.68965,"lon":2.1844,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94401","condg":["Depression"],"status":"ACTIVE_NOT_RECRUITING","nct":"NCT06508710","study":"Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients","sstatus":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","official":"Romain COLLE (Service Hospitalo-Universitaire de Psychiatrie - Hôpital Bicêtre)","src":"https://clinicaltrials.gov/study/NCT06508710","contact":{"n":"Romain COLLE","p":"+33145212524","e":"romain.colle@aphp.fr"},"phase":"Phase 3","enroll":60,"start":"2024-10-20","eid":"x:site:nct06508710-cea-shfj-orsay"},{"id":"nct03256162-st-patrick-s-university-hospital-dublin","cat":"research","name":"St Patrick's University Hospital","city":"Dublin","country":"Ireland","cc":"IE","lat":53.32125,"lon":-6.25863,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"D8","condg":["Depression","Bipolar"],"nct":"NCT03256162","study":"Ketamine as an Adjunctive Therapy for Major Depression","sstatus":"COMPLETED","sponsor":"St Patrick's Hospital, Ireland","official":"Declan M McLoughlin, PhD (St Patrick's Mental Health Services and Trinity College Dublin)","src":"https://clinicaltrials.gov/study/NCT03256162","phase":"Phase 1","enroll":25,"start":"2017-09-07","eid":"x:site:nct03256162-st-patrick-s-university-hospital-dublin"},{"id":"nct02452060-nyu-langone-medical-center-new-york","cat":"research","name":"NYU Langone Medical Center","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70603,"lon":-74.01458,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10016","condg":["Depression","Chronic pain & headache"],"nct":"NCT02452060","study":"Study on the Use of Low Dose Ketamine After Gastric Bypass and Gastrectomy","sstatus":"COMPLETED","sponsor":"NYU Langone Health","official":"Jing Wang, MD, PHD (NYU School of Medicine)","src":"https://clinicaltrials.gov/study/NCT02452060","phase":"Phase 2/Phase 3","enroll":90,"start":"2014-10","eid":"x:site:nct02452060-nyu-langone-medical-center-new-york"},{"id":"nct03541408-rush-university-medical-center-chicago","cat":"research","name":"Rush University Medical Center","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.8497,"lon":-87.65838,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60612","condg":["Other"],"nct":"NCT03541408","study":"Preventative Delirium Protocol in Elderly Patients","sstatus":"COMPLETED","sponsor":"Rush University Medical Center","official":"Asokumar Buvanendran, MD (Rush University Medical Center)","src":"https://clinicaltrials.gov/study/NCT03541408","phase":"N/A","enroll":263,"start":"2016-05-01","eid":"x:site:nct03541408-rush-university-medical-center-chicago"},{"id":"nct03560102-kantonsspital-winterthur-winterthur","cat":"research","name":"Kantonsspital Winterthur","city":"Winterthur","country":"Switzerland","cc":"CH","lat":47.50625,"lon":8.73105,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"CH-8401","condg":["Cancer-related distress"],"nct":"NCT03560102","study":"Efficacy of Magnetic Resonance-guided High Intensity Focused Ultrasound for the Ablation of Breast Cancer","sstatus":"TERMINATED","sponsor":"Kantonsspital Winterthur KSW","official":"Christoph A Binkert, MD (Kantonsspital Winterthur KSW)","src":"https://clinicaltrials.gov/study/NCT03560102","phase":"N/A","enroll":1,"start":"2020-01-13","eid":"x:site:nct03560102-kantonsspital-winterthur-winterthur"},{"id":"nct07563296-university-of-utah-health-salt-lake-city","cat":"research","name":"University of Utah Health","city":"Salt Lake City","region":"Utah","country":"United States","cc":"US","lat":40.75697,"lon":-111.88507,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"84102","condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT07563296","study":"KALM-B: Ketamine-assisted Psychotherapy (KAP) to Lessen Morbidity After Burn Injury","sstatus":"RECRUITING","sponsor":"Irma Fleming","official":"Irma Fleming, MD (The University of Utah); Benjamin Lewis, MD (The University of Utah)","src":"https://clinicaltrials.gov/study/NCT07563296","contact":{"n":"Claire Ausbeck, BA","p":"801-213-1223","e":"claire.ausbeck@hsc.utah.edu"},"phase":"Phase 2","enroll":12,"start":"2026-08-24","eid":"x:site:nct07563296-university-of-utah-health-salt-lake-city"},{"id":"nct04330183-rhode-island-hospital-providence","cat":"research","name":"Rhode Island Hospital","city":"Providence","region":"Rhode Island","country":"United States","cc":"US","lat":41.81943,"lon":-71.41937,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02905","condg":["Other"],"nct":"NCT04330183","study":"Low Dose Ketamine and Acute Pain Crisis","sstatus":"COMPLETED","sponsor":"Rhode Island Hospital","official":"Taneisha Wison, MD, ScM (Brown Emergency Medicine)","src":"https://clinicaltrials.gov/study/NCT04330183","phase":"Phase 4","enroll":20,"start":"2020-07-01","eid":"x:site:nct04330183-rhode-island-hospital-providence"},{"id":"nct04330183-the-miriam-hospital-providence","cat":"research","name":"The Miriam Hospital","city":"Providence","region":"Rhode Island","country":"United States","cc":"US","lat":41.82037,"lon":-71.41288,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02906","condg":["Other"],"nct":"NCT04330183","study":"Low Dose Ketamine and Acute Pain Crisis","sstatus":"COMPLETED","sponsor":"Rhode Island Hospital","official":"Taneisha Wison, MD, ScM (Brown Emergency Medicine)","src":"https://clinicaltrials.gov/study/NCT04330183","phase":"Phase 4","enroll":20,"start":"2020-07-01","eid":"x:site:nct04330183-the-miriam-hospital-providence"},{"id":"nct04767035-worldwide-clinical-trials-san-antonio","cat":"research","name":"Worldwide Clinical Trials","city":"San Antonio","region":"Texas","country":"United States","cc":"US","lat":29.4221,"lon":-98.48521,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"78217","condg":["Other"],"nct":"NCT04767035","study":"Relative Bioavailability Study of MELT-100, IV Midazolam, and IV Ketamine","sstatus":"COMPLETED","sponsor":"Melt Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04767035","phase":"Phase 1","enroll":25,"start":"2020-12-01","eid":"x:site:nct04767035-worldwide-clinical-trials-san-antonio"},{"id":"nct03962725-massachusetts-general-hospital-boston","cat":"research","name":"Massachusetts General Hospital","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36309,"lon":-71.06048,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02114","condg":["Other"],"nct":"NCT03962725","study":"Avoiding Neuromuscular Blockers to Reduce Complications","sstatus":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","official":"Maximilian S Schaefer, MD (Beth Israel Deaconess Medical Center)","src":"https://clinicaltrials.gov/study/NCT03962725","phase":"Phase 4","enroll":3,"start":"2019-08-07","eid":"x:site:nct03962725-massachusetts-general-hospital-boston"},{"id":"nct03962725-beth-israel-deaconess-medical-center-boston","cat":"research","name":"Beth Israel Deaconess Medical Center","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.34954,"lon":-71.04862,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02215","condg":["Other"],"nct":"NCT03962725","study":"Avoiding Neuromuscular Blockers to Reduce Complications","sstatus":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","official":"Maximilian S Schaefer, MD (Beth Israel Deaconess Medical Center)","src":"https://clinicaltrials.gov/study/NCT03962725","phase":"Phase 4","enroll":3,"start":"2019-08-07","eid":"x:site:nct03962725-beth-israel-deaconess-medical-center-boston"},{"id":"nct02593643-sunnybook-health-sciences-centre-toronto","cat":"research","name":"Sunnybook Health Sciences Centre","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70403,"lon":-79.40575,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M4N 3M5","condg":["Depression","Bipolar"],"nct":"NCT02593643","study":"Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.","sstatus":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","src":"https://clinicaltrials.gov/study/NCT02593643","phase":"EARLY_Phase 1","enroll":9,"start":"2016-01","eid":"x:site:nct02593643-sunnybook-health-sciences-centre-toronto"},{"id":"nct03554915-hennepin-county-medical-center-minneapolis","cat":"research","name":"Hennepin County Medical Center","city":"Minneapolis","region":"Minnesota","country":"United States","cc":"US","lat":44.98613,"lon":-93.26172,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55415","condg":["Other"],"nct":"NCT03554915","study":"Ketamine Versus Midazolam for Prehospital Agitation","sstatus":"COMPLETED","sponsor":"Hennepin Healthcare Research Institute","src":"https://clinicaltrials.gov/study/NCT03554915","enroll":314,"start":"2017-08-01","eid":"x:site:nct03554915-hennepin-county-medical-center-minneapolis"},{"id":"nct05156060-vanderbilt-ingram-cancer-center-nashville","cat":"research","name":"Vanderbilt-Ingram Cancer Center","city":"Nashville","region":"Tennessee","country":"United States","cc":"US","lat":36.16773,"lon":-86.77931,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"37232","condg":["Cancer-related distress"],"status":"RECRUITING","nct":"NCT05156060","study":"Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer","sstatus":"RECRUITING","sponsor":"Natalie Lockney","official":"Natalie Lockney, MD (Vanderbilt-Ingram Cancer Center)","src":"https://clinicaltrials.gov/study/NCT05156060","contact":{"n":"Vanderbilt-Ingram Service for Timely Access","p":"800-811-8480","e":"cip@vumc.org"},"phase":"Phase 1/Phase 2","enroll":64,"start":"2022-01-24","eid":"x:site:nct05156060-vanderbilt-ingram-cancer-center-nashville"},{"id":"nct06310850-ankara-ataturk-sanatorium-training-and-research-hospital-ankara","cat":"research","name":"Ankara Atatürk Sanatorium Training and Research Hospital","city":"Ankara","region":"Keçiören","country":"Turkey","cc":"TR","lat":39.9138,"lon":32.85592,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06290","condg":["Chronic pain & headache"],"nct":"NCT06310850","study":"The Effect of Preprocedural Subanesthetic Ketamine on Pain and Anxiety","sstatus":"COMPLETED","sponsor":"Ankara Ataturk Sanatorium Training and Research Hospital","official":"Onur KÜÇÜK, specialist (Ankara Ataturk Sanatorium Training and Research Hospital)","src":"https://clinicaltrials.gov/study/NCT06310850","phase":"Phase 3","enroll":60,"start":"2013-06-01","eid":"x:site:nct06310850-ankara-ataturk-sanatorium-training-and-research-hospital-ankara"},{"id":"nct01790490-nyspi-new-york","cat":"research","name":"NYSPI","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70839,"lon":-74.0159,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10032","condg":["Addiction & substance use"],"nct":"NCT01790490","study":"Glutamatergic Modulation of Cocaine-related Deficits","sstatus":"COMPLETED","sponsor":"New York State Psychiatric Institute","official":"Elias Dakwar, MD (NYSPI/Columbia College of Physicians and Surgeons); Carl Hart, PhD (NYSPI/Columbia College of Physicians and Surgeons)","src":"https://clinicaltrials.gov/study/NCT01790490","phase":"Phase 2","enroll":8,"start":"2011-02","eid":"x:site:nct01790490-nyspi-new-york"},{"id":"nct05339074-toronto-general-hospital-toronto","cat":"research","name":"Toronto General Hospital","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.71382,"lon":-79.40368,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M5G 2C4","condg":["Depression","Bipolar"],"nct":"NCT05339074","study":"Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression","sstatus":"COMPLETED","sponsor":"Joshua Rosenblat","official":"Joshua Rosenblat, MD, MSc (Toronto Western Hospital, Psychiatry)","src":"https://clinicaltrials.gov/study/NCT05339074","phase":"Phase 2","enroll":41,"start":"2022-08-11","eid":"x:site:nct05339074-toronto-general-hospital-toronto"},{"id":"nct05339074-toronto-western-hospital-toronto","cat":"research","name":"Toronto Western Hospital","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70742,"lon":-79.40904,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M5T 2S8","condg":["Depression","Bipolar"],"nct":"NCT05339074","study":"Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression","sstatus":"COMPLETED","sponsor":"Joshua Rosenblat","official":"Joshua Rosenblat, MD, MSc (Toronto Western Hospital, Psychiatry)","src":"https://clinicaltrials.gov/study/NCT05339074","phase":"Phase 2","enroll":41,"start":"2022-08-11","eid":"x:site:nct05339074-toronto-western-hospital-toronto"},{"id":"nct05339074-ontario-shores-centre-for-mental-health-sciences-whitby","cat":"research","name":"Ontario Shores Centre for Mental Health Sciences","city":"Whitby","region":"Ontario","country":"Canada","cc":"CA","lat":43.87321,"lon":-78.93386,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"L1N 5S9","condg":["Depression","Bipolar"],"nct":"NCT05339074","study":"Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression","sstatus":"COMPLETED","sponsor":"Joshua Rosenblat","official":"Joshua Rosenblat, MD, MSc (Toronto Western Hospital, Psychiatry)","src":"https://clinicaltrials.gov/study/NCT05339074","phase":"Phase 2","enroll":41,"start":"2022-08-11","eid":"x:site:nct05339074-ontario-shores-centre-for-mental-health-sciences-whitby"},{"id":"nct04281017-university-of-florida-gainesville","cat":"research","name":"University of Florida","city":"Gainesville","region":"Florida","country":"United States","cc":"US","lat":29.65234,"lon":-82.3277,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"32610","condg":["Cancer-related distress"],"nct":"NCT04281017","study":"Effect of Position and Anesthetic Choice in Intraocular Pressure in Robotic GYN (Gynecologic) Oncology Patients","sstatus":"COMPLETED","sponsor":"University of Florida","official":"Sonia Mehta, MD (University of Florida)","src":"https://clinicaltrials.gov/study/NCT04281017","phase":"Phase 4","enroll":22,"start":"2020-11-10","eid":"x:site:nct04281017-university-of-florida-gainesville"},{"id":"nct06660017-ou-health-stephenson-cancer-center-oklahoma-city","cat":"research","name":"OU Health Stephenson Cancer Center","city":"Oklahoma City","region":"Oklahoma","country":"United States","cc":"US","lat":35.47382,"lon":-97.51987,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"73117","condg":["Cancer-related distress"],"nct":"NCT06660017","study":"Head and Neck Cancer Patients With Oral Mucositis Treated With Ketamine Oral Rinse","sstatus":"NOT_YET_RECRUITING","sponsor":"University of Oklahoma","official":"Rusha Patel, MD (OU Health Stephenson Cancer Center)","src":"https://clinicaltrials.gov/study/NCT06660017","contact":{"n":"Lead Nurse","p":"405-271-8777","e":"SCC-IIT-Office@ouhsc.edu"},"phase":"Phase 2","enroll":62,"start":"2026-09","eid":"x:site:nct06660017-ou-health-stephenson-cancer-center-oklahoma-city"},{"id":"nct02911597-stanford-university-stanford","cat":"research","name":"Stanford University","city":"Stanford","region":"California","country":"United States","cc":"US","lat":37.41785,"lon":-122.15963,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94305","condg":["Depression"],"nct":"NCT02911597","study":"Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)","sstatus":"COMPLETED","sponsor":"Stanford University","official":"Alan Schatzberg, MD (Stanford University)","src":"https://clinicaltrials.gov/study/NCT02911597","phase":"Phase 1","enroll":16,"start":"2016-09","eid":"x:site:nct02911597-stanford-university-stanford"},{"id":"nct03115489-uab-department-of-anesthesiology-and-perioperative-medicine-birmingh","cat":"research","name":"UAB Department of Anesthesiology and Perioperative Medicine","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.52061,"lon":-86.80037,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"35249","condg":["Neurology & cognition"],"nct":"NCT03115489","study":"Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus","sstatus":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","official":"Vinodkumar Singh, MD (University of Alabama at Birmingham)","src":"https://clinicaltrials.gov/study/NCT03115489","phase":"Phase 2/Phase 3","start":"2017-05-04","eid":"x:site:nct03115489-uab-department-of-anesthesiology-and-perioperative-medicine-birmingh"},{"id":"nct03729973-zagazig-university-hospitsals-zagazig","cat":"research","name":"Zagazig University Hospitsals","city":"Zagazig","country":"Egypt","cc":"EG","lat":30.5961,"lon":31.50525,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"055","condg":["Other"],"nct":"NCT03729973","study":"Comparing Efficacy Preoperative Nebulized: Ketamine , Mgspo4 ,and Lidocaine In Attenuating Endotracheal Sore Throat","sstatus":"COMPLETED","sponsor":"Zagazig University","official":"Alshaimaa Kamel, MD (Zagazig University)","src":"https://clinicaltrials.gov/study/NCT03729973","phase":"Phase 3","enroll":100,"start":"2018-11-15","eid":"x:site:nct03729973-zagazig-university-hospitsals-zagazig"},{"id":"nct05779657-sohag-university-hospital-sohag","cat":"research","name":"Sohag University Hospital","city":"Sohag","country":"Egypt","cc":"EG","lat":26.55813,"lon":31.68711,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"82524","condg":["Neurology & cognition"],"nct":"NCT05779657","study":"Combined Ketamine and Midazolam for Generalized Convulsive Status Epilepticus","sstatus":"COMPLETED","sponsor":"Sohag University","official":"Abdelrahim A Sadek, MD, PhD (Faculty of Medicine, Sohag University)","src":"https://clinicaltrials.gov/study/NCT05779657","phase":"Phase 2/Phase 3","enroll":144,"start":"2023-03-21","eid":"x:site:nct05779657-sohag-university-hospital-sohag"},{"id":"nct01435213-university-of-turku-clinical-research-services-turku-crst-turku","cat":"research","name":"University of Turku, Clinical Research Services Turku CRST","city":"Turku","country":"Finland","cc":"FI","lat":60.45219,"lon":22.27438,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20520","condg":["Healthy volunteers"],"nct":"NCT01435213","study":"Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline","sstatus":"COMPLETED","sponsor":"University of Turku","official":"Juha Rinne, MD, PhD (University of Turku)","src":"https://clinicaltrials.gov/study/NCT01435213","phase":"Phase 1","enroll":10,"start":"2011-09","eid":"x:site:nct01435213-university-of-turku-clinical-research-services-turku-crst-turku"},{"id":"nct01435213-university-of-turku-turku-pet-centre-turku","cat":"research","name":"University of Turku, Turku PET Centre","city":"Turku","country":"Finland","cc":"FI","lat":60.44136,"lon":22.26224,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20520","condg":["Healthy volunteers"],"nct":"NCT01435213","study":"Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline","sstatus":"COMPLETED","sponsor":"University of Turku","official":"Juha Rinne, MD, PhD (University of Turku)","src":"https://clinicaltrials.gov/study/NCT01435213","phase":"Phase 1","enroll":10,"start":"2011-09","eid":"x:site:nct01435213-university-of-turku-turku-pet-centre-turku"},{"id":"nct04698772-christus-corpus-christi","cat":"research","name":"CHRISTUS","city":"Corpus Christi","region":"Texas","country":"United States","cc":"US","lat":27.79225,"lon":-97.39379,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"78404","condg":["Chronic pain & headache"],"nct":"NCT04698772","study":"Patient Satisfaction With Subdissociative Dose Ketamine Versus Morphine for Emergency Department Pain Control","sstatus":"COMPLETED","sponsor":"CHRISTUS Health","official":"Rebekka Lee, DO (CHRISTUS Health)","src":"https://clinicaltrials.gov/study/NCT04698772","enroll":32,"start":"2019-12-19","eid":"x:site:nct04698772-christus-corpus-christi"},{"id":"nct05604794-la-centre-los-angeles","cat":"research","name":"LA Centre","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.06028,"lon":-118.24787,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"90404","condg":["Depression","Anxiety","PTSD & trauma"],"nct":"NCT05604794","study":"A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health","sstatus":"COMPLETED","sponsor":"Field Trip Health","official":"Ryan Yermus, MD (Field Trip Health); Chris Lo, PhD (University of Toronto)","src":"https://clinicaltrials.gov/study/NCT05604794","phase":"Phase 4","enroll":1806,"start":"2020-03-13","eid":"x:site:nct05604794-la-centre-los-angeles"},{"id":"nct05604794-san-diego-centre-san-diego","cat":"research","name":"San Diego Centre","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.71858,"lon":-117.16138,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"92037","condg":["Depression","Anxiety","PTSD & trauma"],"nct":"NCT05604794","study":"A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health","sstatus":"COMPLETED","sponsor":"Field Trip Health","official":"Ryan Yermus, MD (Field Trip Health); Chris Lo, PhD (University of Toronto)","src":"https://clinicaltrials.gov/study/NCT05604794","phase":"Phase 4","enroll":1806,"start":"2020-03-13","eid":"x:site:nct05604794-san-diego-centre-san-diego"},{"id":"nct05604794-washington-dc-centre-washington-d-c","cat":"research","name":"Washington DC Centre","city":"Washington D.C.","region":"District of Columbia","country":"United States","cc":"US","lat":38.90231,"lon":-77.02569,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20005","condg":["Depression","Anxiety","PTSD & trauma"],"nct":"NCT05604794","study":"A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health","sstatus":"COMPLETED","sponsor":"Field Trip Health","official":"Ryan Yermus, MD (Field Trip Health); Chris Lo, PhD (University of Toronto)","src":"https://clinicaltrials.gov/study/NCT05604794","phase":"Phase 4","enroll":1806,"start":"2020-03-13","eid":"x:site:nct05604794-washington-dc-centre-washington-d-c"},{"id":"nct05604794-atlanta-centre-atlanta","cat":"research","name":"Atlanta Centre","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.76025,"lon":-84.38087,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"30316","condg":["Depression","Anxiety","PTSD & trauma"],"nct":"NCT05604794","study":"A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health","sstatus":"COMPLETED","sponsor":"Field Trip Health","official":"Ryan Yermus, MD (Field Trip Health); Chris Lo, PhD (University of Toronto)","src":"https://clinicaltrials.gov/study/NCT05604794","phase":"Phase 4","enroll":1806,"start":"2020-03-13","eid":"x:site:nct05604794-atlanta-centre-atlanta"},{"id":"nct05604794-chicago-centre-chicago","cat":"research","name":"Chicago Centre","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.8545,"lon":-87.6613,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60654","condg":["Depression","Anxiety","PTSD & trauma"],"nct":"NCT05604794","study":"A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health","sstatus":"COMPLETED","sponsor":"Field Trip Health","official":"Ryan Yermus, MD (Field Trip Health); Chris Lo, PhD (University of Toronto)","src":"https://clinicaltrials.gov/study/NCT05604794","phase":"Phase 4","enroll":1806,"start":"2020-03-13","eid":"x:site:nct05604794-chicago-centre-chicago"},{"id":"nct05604794-nyc-centre-new-york","cat":"research","name":"NYC Centre","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72561,"lon":-74.01581,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10010","condg":["Depression","Anxiety","PTSD & trauma"],"nct":"NCT05604794","study":"A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health","sstatus":"COMPLETED","sponsor":"Field Trip Health","official":"Ryan Yermus, MD (Field Trip Health); Chris Lo, PhD (University of Toronto)","src":"https://clinicaltrials.gov/study/NCT05604794","phase":"Phase 4","enroll":1806,"start":"2020-03-13","eid":"x:site:nct05604794-nyc-centre-new-york"},{"id":"nct05604794-houston-centre-houston","cat":"research","name":"Houston Centre","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.75599,"lon":-95.35447,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"77027","condg":["Depression","Anxiety","PTSD & trauma"],"nct":"NCT05604794","study":"A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health","sstatus":"COMPLETED","sponsor":"Field Trip Health","official":"Ryan Yermus, MD (Field Trip Health); Chris Lo, PhD (University of Toronto)","src":"https://clinicaltrials.gov/study/NCT05604794","phase":"Phase 4","enroll":1806,"start":"2020-03-13","eid":"x:site:nct05604794-houston-centre-houston"},{"id":"nct05604794-seattle-centre-seattle","cat":"research","name":"Seattle Centre","city":"Seattle","region":"Washington","country":"United States","cc":"US","lat":47.60165,"lon":-122.32073,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"98109","condg":["Depression","Anxiety","PTSD & trauma"],"nct":"NCT05604794","study":"A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health","sstatus":"COMPLETED","sponsor":"Field Trip Health","official":"Ryan Yermus, MD (Field Trip Health); Chris Lo, PhD (University of Toronto)","src":"https://clinicaltrials.gov/study/NCT05604794","phase":"Phase 4","enroll":1806,"start":"2020-03-13","eid":"x:site:nct05604794-seattle-centre-seattle"},{"id":"nct05604794-vancouver-centre-vancouver","cat":"research","name":"Vancouver Centre","city":"Vancouver","region":"British Columbia","country":"Canada","cc":"CA","lat":49.25385,"lon":-123.12607,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"V6J 5B3","condg":["Depression","Anxiety","PTSD & trauma"],"nct":"NCT05604794","study":"A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health","sstatus":"COMPLETED","sponsor":"Field Trip Health","official":"Ryan Yermus, MD (Field Trip Health); Chris Lo, PhD (University of Toronto)","src":"https://clinicaltrials.gov/study/NCT05604794","phase":"Phase 4","enroll":1806,"start":"2020-03-13","eid":"x:site:nct05604794-vancouver-centre-vancouver"},{"id":"nct05604794-fredericton-centre-fredericton","cat":"research","name":"Fredericton Centre","city":"Fredericton","region":"New Brunswick","country":"Canada","cc":"CA","lat":45.94734,"lon":-66.67692,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"E3B 7E6","condg":["Depression","Anxiety","PTSD & trauma"],"nct":"NCT05604794","study":"A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health","sstatus":"COMPLETED","sponsor":"Field Trip Health","official":"Ryan Yermus, MD (Field Trip Health); Chris Lo, PhD (University of Toronto)","src":"https://clinicaltrials.gov/study/NCT05604794","phase":"Phase 4","enroll":1806,"start":"2020-03-13","eid":"x:site:nct05604794-fredericton-centre-fredericton"},{"id":"nct05604794-field-trip-health-toronto-centre-toronto","cat":"research","name":"Field Trip Health, Toronto Centre","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70667,"lon":-79.40057,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M5V 2C3","condg":["Depression","Anxiety","PTSD & trauma"],"nct":"NCT05604794","study":"A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health","sstatus":"COMPLETED","sponsor":"Field Trip Health","official":"Ryan Yermus, MD (Field Trip Health); Chris Lo, PhD (University of Toronto)","src":"https://clinicaltrials.gov/study/NCT05604794","phase":"Phase 4","enroll":1806,"start":"2020-03-13","eid":"x:site:nct05604794-field-trip-health-toronto-centre-toronto"},{"id":"nct07462559-department-of-clinical-pharmacology-helsinki","cat":"research","name":"Department of Clinical Pharmacology","city":"Helsinki","country":"Finland","cc":"FI","lat":60.16627,"lon":24.93776,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT07462559","study":"KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study","sstatus":"NOT_YET_RECRUITING","sponsor":"Helsinki University Central Hospital","official":"Janne T Backman, MD, PhD (Helsinki University Central Hospital)","src":"https://clinicaltrials.gov/study/NCT07462559","contact":{"n":"Janne T Backman, MD, PhD","p":"+35894711","e":"janne.backman@hus.fi"},"phase":"Phase 1","enroll":12,"start":"2026-03-04","eid":"x:site:nct07462559-department-of-clinical-pharmacology-helsinki"},{"id":"nct07526454-tanta-university-tanta","cat":"research","name":"Tanta University","city":"Tanta","region":"El-Gharbia","country":"Egypt","cc":"EG","lat":30.79878,"lon":30.99331,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"31527","condg":["Depression"],"nct":"NCT07526454","study":"Electroconvulsive Therapy Versus Intravenous Ketamine in Treatment-Resistant Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Tanta University","src":"https://clinicaltrials.gov/study/NCT07526454","phase":"N/A","enroll":70,"start":"2025-07-01","eid":"x:site:nct07526454-tanta-university-tanta"},{"id":"nct02729805-the-university-of-hong-kong-hong-kong","cat":"research","name":"The University of Hong Kong","city":"Hong Kong","country":"Hong Kong","cc":"HK","lat":22.26905,"lon":114.17991,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"0000","condg":["Chronic pain & headache"],"nct":"NCT02729805","study":"Intraoperative Ketamine on Chronic Pain After Mastectomy","sstatus":"SUSPENDED","sponsor":"The University of Hong Kong","official":"Stanley SC Wong, MBBS (The University of Hong Kong)","src":"https://clinicaltrials.gov/study/NCT02729805","phase":"Phase 4","enroll":135,"start":"2015-08-18","eid":"x:site:nct02729805-the-university-of-hong-kong-hong-kong"},{"id":"nct04179266-danish-headache-center-glostrup-municipality","cat":"research","name":"Danish Headache Center","city":"Glostrup Municipality","country":"Denmark","cc":"DK","lat":55.65752,"lon":12.39648,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"DK-2600","condg":["Chronic pain & headache"],"nct":"NCT04179266","study":"Effect of Ketamine Intranasal Spray in Treatment of Chronic Cluster Headache","sstatus":"COMPLETED","sponsor":"CCH Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT04179266","phase":"Phase 1/Phase 2","enroll":23,"start":"2019-11-20","eid":"x:site:nct04179266-danish-headache-center-glostrup-municipality"},{"id":"nct06344858-pontificia-universidad-catolica-de-chile-santiago","cat":"research","name":"Pontificia Universidad Catolica de Chile","city":"Santiago","region":"Santiago Metropolitan","country":"Chile","cc":"CL","lat":-33.44927,"lon":-70.64446,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"450881","condg":["Other"],"nct":"NCT06344858","study":"Characterization of the Temporal Profile of the Anti-nociceptive Effect of Ketamine Bolus Measured With ANI","sstatus":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","official":"Luis I Cortinez, MD (Pontificia Universidad Catolica de Chile)","src":"https://clinicaltrials.gov/study/NCT06344858","enroll":20,"start":"2024-04-30","eid":"x:site:nct06344858-pontificia-universidad-catolica-de-chile-santiago"},{"id":"nct06419439-va-ann-arbor-healthcare-system-ann-arbor-mi-ann-arbor","cat":"research","name":"VA Ann Arbor Healthcare System, Ann Arbor, MI","city":"Ann Arbor","region":"Michigan","country":"United States","cc":"US","lat":42.28561,"lon":-83.74601,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"48105-2303","condg":["Depression","Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06419439","study":"Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression","sstatus":"RECRUITING","sponsor":"VA Office of Research and Development","official":"Victoria D Powell, MD (VA Ann Arbor Healthcare System, Ann Arbor, MI)","src":"https://clinicaltrials.gov/study/NCT06419439","contact":{"n":"Victoria D Powell, MD","p":"734-845-3072","e":"Victoria.Powell2@va.gov"},"phase":"Phase 2","enroll":44,"start":"2025-12-03","eid":"x:site:nct06419439-va-ann-arbor-healthcare-system-ann-arbor-mi-ann-arbor"},{"id":"nct06038409-river-telehealth-helena","cat":"research","name":"RIVER Telehealth","city":"Helena","region":"Montana","country":"United States","cc":"US","lat":46.58909,"lon":-112.03192,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"59601","condg":["Depression","Anxiety","Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06038409","study":"Ketamine Treatment Plans for Chronic Conditions","sstatus":"RECRUITING","sponsor":"RIVER Foundation","official":"Edward Lesofski, MS (RIVER Foundation)","src":"https://clinicaltrials.gov/study/NCT06038409","contact":{"n":"Ed Lesofski, MS","p":"406-465-9504","e":"ed@riverofchange.org"},"enroll":500,"start":"2023-01-01","eid":"x:site:nct06038409-river-telehealth-helena"},{"id":"nct04824157-the-chaim-sheba-medical-center-tel-litwinsky","cat":"research","name":"The Chaim Sheba Medical Center","city":"Tel Litwinsky","country":"Israel","cc":"IL","lat":31.4769,"lon":35.2732,"gp":"country","unnamed":0,"drugs":["ketamine"],"zip":"52621","condg":["Depression"],"nct":"NCT04824157","study":"Ketamine IV Classic Protocol : Five Years Follow up","sstatus":"COMPLETED","sponsor":"Sheba Medical Center","src":"https://clinicaltrials.gov/study/NCT04824157","enroll":11,"start":"2019-08-08","eid":"x:site:nct04824157-the-chaim-sheba-medical-center-tel-litwinsky"},{"id":"nct07284667-university-of-alabama-at-birmingham-birmingham","cat":"research","name":"University of Alabama at Birmingham","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.51384,"lon":-86.81185,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"35294","condg":["Depression"],"status":"WITHDRAWN","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-university-of-alabama-at-birmingham-birmingham"},{"id":"nct07284667-inland-psychiatric-medical-group-chino","cat":"research","name":"Inland Psychiatric Medical Group","city":"Chino","region":"California","country":"United States","cc":"US","lat":34.0039,"lon":-117.68805,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"91710","condg":["Depression"],"status":"RECRUITING","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-inland-psychiatric-medical-group-chino"},{"id":"nct07284667-behavioral-research-specialists-llc-glendale","cat":"research","name":"Behavioral Research Specialists, LLC","city":"Glendale","region":"California","country":"United States","cc":"US","lat":33.53531,"lon":-112.17973,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"91107","condg":["Depression"],"status":"RECRUITING","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-behavioral-research-specialists-llc-glendale"},{"id":"nct07284667-kadima-neuropsychiatry-institute-la-jolla","cat":"research","name":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","cc":"US","lat":32.84628,"lon":-117.26775,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"92037","condg":["Depression"],"status":"RECRUITING","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-kadima-neuropsychiatry-institute-la-jolla"},{"id":"nct07284667-pns-clinical-research-llc-dba-atp-clinical-research-orange","cat":"research","name":"PNS Clinical Research LLC dba ATP Clinical Research","city":"Orange","region":"California","country":"United States","cc":"US","lat":33.79283,"lon":-117.85579,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"92866","condg":["Depression"],"status":"RECRUITING","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-pns-clinical-research-llc-dba-atp-clinical-research-orange"},{"id":"nct07284667-mountain-view-clinical-research-denver","cat":"research","name":"Mountain View Clinical Research","city":"Denver","region":"Colorado","country":"United States","cc":"US","lat":39.73496,"lon":-104.97703,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"80209","condg":["Depression"],"status":"RECRUITING","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-mountain-view-clinical-research-denver"},{"id":"nct07284667-new-access-research-and-medical-services-inc-fort-myers","cat":"research","name":"New Access Research and Medical Services, Inc.","city":"Fort Myers","region":"Florida","country":"United States","cc":"US","lat":26.61156,"lon":-81.84186,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"33901","condg":["Depression"],"status":"RECRUITING","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-new-access-research-and-medical-services-inc-fort-myers"},{"id":"nct07284667-the-medici-medical-research-hollywood","cat":"research","name":"The Medici Medical Research","city":"Hollywood","region":"Florida","country":"United States","cc":"US","lat":34.08738,"lon":-118.31907,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"33021","condg":["Depression"],"status":"RECRUITING","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-the-medici-medical-research-hollywood"},{"id":"nct07284667-sandhill-research-llc-dba-accel-research-sites-largo","cat":"research","name":"Sandhill Research, LLC/DBA Accel Research Sites","city":"Largo","region":"Florida","country":"United States","cc":"US","lat":27.91388,"lon":-82.79261,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"33777","condg":["Depression"],"status":"WITHDRAWN","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-sandhill-research-llc-dba-accel-research-sites-largo"},{"id":"nct07284667-clinical-neuroscience-solutions-inc-orlando","cat":"research","name":"Clinical Neuroscience Solutions, Inc.","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.53707,"lon":-81.37637,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"32801","condg":["Depression"],"status":"RECRUITING","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-clinical-neuroscience-solutions-inc-orlando"},{"id":"nct07284667-iptb-clinical-research-tampa","cat":"research","name":"IPTB Clinical Research","city":"Tampa","region":"Florida","country":"United States","cc":"US","lat":27.9454,"lon":-82.45989,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"33629","condg":["Depression"],"status":"RECRUITING","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-iptb-clinical-research-tampa"},{"id":"nct07284667-neuroscience-research-institute-inc-west-palm-beach","cat":"research","name":"Neuroscience Research Institute, Inc.","city":"West Palm Beach","region":"Florida","country":"United States","cc":"US","lat":26.70767,"lon":-80.05784,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"33407","condg":["Depression"],"status":"RECRUITING","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-neuroscience-research-institute-inc-west-palm-beach"},{"id":"nct07284667-adams-clinical-inc-watertown","cat":"research","name":"Adams Clinical, Inc.","city":"Watertown","region":"Massachusetts","country":"United States","cc":"US","lat":42.37267,"lon":-71.17572,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02472","condg":["Depression"],"status":"RECRUITING","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-adams-clinical-inc-watertown"},{"id":"nct07284667-vitalix-clinical-inc-worcester","cat":"research","name":"Vitalix Clinical, Inc.","city":"Worcester","region":"Massachusetts","country":"United States","cc":"US","lat":42.25831,"lon":-71.80525,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"01608","condg":["Depression"],"status":"RECRUITING","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-vitalix-clinical-inc-worcester"},{"id":"nct07284667-precise-research-centers-flowood","cat":"research","name":"Precise Research Centers","city":"Flowood","region":"Mississippi","country":"United States","cc":"US","lat":32.31321,"lon":-90.1315,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"39232","condg":["Depression"],"status":"RECRUITING","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-precise-research-centers-flowood"},{"id":"nct07284667-st-charles-psychiatric-associates-inc-dba-midwest-research-group-sai","cat":"research","name":"St. Charles Psychiatric Associates, Inc. dba Midwest Research Group","city":"Saint Charles","region":"Missouri","country":"United States","cc":"US","lat":38.78841,"lon":-90.47996,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"63304","condg":["Depression"],"status":"RECRUITING","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-st-charles-psychiatric-associates-inc-dba-midwest-research-group-sai"},{"id":"nct07284667-alivation-research-llc-lincoln","cat":"research","name":"Alivation Research, LLC","city":"Lincoln","region":"Nebraska","country":"United States","cc":"US","lat":40.81162,"lon":-96.67557,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"68526","condg":["Depression"],"status":"RECRUITING","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-alivation-research-llc-lincoln"},{"id":"nct07284667-redbird-research-llc-las-vegas","cat":"research","name":"Redbird Research LLC","city":"Las Vegas","region":"Nevada","country":"United States","cc":"US","lat":36.17539,"lon":-115.14395,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"89134","condg":["Depression"],"status":"RECRUITING","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-redbird-research-llc-las-vegas"},{"id":"nct07284667-cenexel-hassman-research-institute-llc-marlton","cat":"research","name":"CenExel Hassman Research Institute, LLC","city":"Marlton","region":"New Jersey","country":"United States","cc":"US","lat":39.89136,"lon":-74.92752,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"08053","condg":["Depression"],"status":"WITHDRAWN","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-cenexel-hassman-research-institute-llc-marlton"},{"id":"nct07284667-integrative-clinical-trials-llc-brooklyn","cat":"research","name":"Integrative Clinical Trials LLC","city":"Brooklyn","region":"New York","country":"United States","cc":"US","lat":40.64544,"lon":-73.94944,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11229","condg":["Depression"],"status":"RECRUITING","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-integrative-clinical-trials-llc-brooklyn"},{"id":"nct07284667-magnolia-clinical-research-llc-cary","cat":"research","name":"Magnolia Clinical Research, LLC","city":"Cary","region":"North Carolina","country":"United States","cc":"US","lat":35.79752,"lon":-78.77044,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"27511","condg":["Depression"],"status":"RECRUITING","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-magnolia-clinical-research-llc-cary"},{"id":"nct07284667-neuro-behavioral-clinical-research-north-canton","cat":"research","name":"Neuro-Behavioral Clinical Research","city":"North Canton","region":"Ohio","country":"United States","cc":"US","lat":40.87669,"lon":-81.41255,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44720","condg":["Depression"],"status":"RECRUITING","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-neuro-behavioral-clinical-research-north-canton"},{"id":"nct07284667-baylor-college-of-medicine-houston","cat":"research","name":"Baylor College of Medicine","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.7541,"lon":-95.37282,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"77030","condg":["Depression"],"status":"RECRUITING","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-baylor-college-of-medicine-houston"},{"id":"nct07284667-dynamed-clinical-research-lp-d-b-a-dm-clinical-research-houston","cat":"research","name":"Dynamed Clinical Research LP d/b/a DM Clinical Research","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.7685,"lon":-95.36294,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"77081","condg":["Depression"],"status":"WITHDRAWN","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-dynamed-clinical-research-lp-d-b-a-dm-clinical-research-houston"},{"id":"nct07284667-olympus-clinical-research-llc-katy","cat":"research","name":"Olympus Clinical Research, LLC","city":"Katy","region":"Texas","country":"United States","cc":"US","lat":29.79704,"lon":-95.83207,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"77450","condg":["Depression"],"status":"RECRUITING","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-olympus-clinical-research-llc-katy"},{"id":"nct07284667-family-psychiatry-of-the-woodlands-the-woodlands","cat":"research","name":"Family Psychiatry of The Woodlands","city":"The Woodlands","region":"Texas","country":"United States","cc":"US","lat":30.1491,"lon":-95.49451,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"77381","condg":["Depression"],"status":"RECRUITING","nct":"NCT07284667","study":"ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response","sstatus":"RECRUITING","sponsor":"ACADIA Pharmaceuticals Inc.","src":"https://clinicaltrials.gov/study/NCT07284667","contact":{"n":"Sandy Filosi","p":"+1(609) 250-6920","e":"sfilosi@ACADIA-Pharm.com"},"phase":"Phase 2","enroll":153,"start":"2025-11-14","eid":"x:site:nct07284667-family-psychiatry-of-the-woodlands-the-woodlands"},{"id":"nct04504175-ucla-late-life-mood-stress-and-wellness-research-program-los-angeles","cat":"research","name":"UCLA Late-Life Mood, Stress, and Wellness Research Program","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.04719,"lon":-118.24081,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"90095","condg":["Depression"],"nct":"NCT04504175","study":"Ketamine for Older Adults Pilot","sstatus":"COMPLETED","sponsor":"Washington University School of Medicine","official":"Eric Lenze, MD (Washington University School of Medicine)","src":"https://clinicaltrials.gov/study/NCT04504175","phase":"Phase 4","enroll":25,"start":"2020-10-22","eid":"x:site:nct04504175-ucla-late-life-mood-stress-and-wellness-research-program-los-angeles"},{"id":"nct04504175-washington-university-school-of-medicine-healthy-mind-lab-st-louis","cat":"research","name":"Washington University School of Medicine Healthy Mind Lab","city":"St Louis","region":"Missouri","country":"United States","cc":"US","lat":38.62534,"lon":-90.19784,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"63110","condg":["Depression"],"nct":"NCT04504175","study":"Ketamine for Older Adults Pilot","sstatus":"COMPLETED","sponsor":"Washington University School of Medicine","official":"Eric Lenze, MD (Washington University School of Medicine)","src":"https://clinicaltrials.gov/study/NCT04504175","phase":"Phase 4","enroll":25,"start":"2020-10-22","eid":"x:site:nct04504175-washington-university-school-of-medicine-healthy-mind-lab-st-louis"},{"id":"nct04504175-columbia-university-adult-and-late-life-depression-clinic-new-york","cat":"research","name":"Columbia University Adult and Late Life Depression Clinic","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71403,"lon":-74.00423,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10032","condg":["Depression"],"nct":"NCT04504175","study":"Ketamine for Older Adults Pilot","sstatus":"COMPLETED","sponsor":"Washington University School of Medicine","official":"Eric Lenze, MD (Washington University School of Medicine)","src":"https://clinicaltrials.gov/study/NCT04504175","phase":"Phase 4","enroll":25,"start":"2020-10-22","eid":"x:site:nct04504175-columbia-university-adult-and-late-life-depression-clinic-new-york"},{"id":"nct04504175-upmc-late-life-depression-evaluation-prevention-and-treatment-progra","cat":"research","name":"UPMC Late-Life Depression, Evaluation, Prevention, and Treatment Program","city":"Pittsburgh","region":"Pennsylvania","country":"United States","cc":"US","lat":40.4337,"lon":-80.00497,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"15213","condg":["Depression"],"nct":"NCT04504175","study":"Ketamine for Older Adults Pilot","sstatus":"COMPLETED","sponsor":"Washington University School of Medicine","official":"Eric Lenze, MD (Washington University School of Medicine)","src":"https://clinicaltrials.gov/study/NCT04504175","phase":"Phase 4","enroll":25,"start":"2020-10-22","eid":"x:site:nct04504175-upmc-late-life-depression-evaluation-prevention-and-treatment-progra"},{"id":"nct04504175-university-health-network-toronto","cat":"research","name":"University Health Network","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.69744,"lon":-79.38862,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M6J-1H4","condg":["Depression"],"nct":"NCT04504175","study":"Ketamine for Older Adults Pilot","sstatus":"COMPLETED","sponsor":"Washington University School of Medicine","official":"Eric Lenze, MD (Washington University School of Medicine)","src":"https://clinicaltrials.gov/study/NCT04504175","phase":"Phase 4","enroll":25,"start":"2020-10-22","eid":"x:site:nct04504175-university-health-network-toronto"},{"id":"nct03528512-beaumont-hospital-royal-oak-royal-oak","cat":"research","name":"Beaumont Hospital - Royal Oak","city":"Royal Oak","region":"Michigan","country":"United States","cc":"US","lat":42.47767,"lon":-83.14884,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"48073","condg":["Other"],"nct":"NCT03528512","study":"IN Ketamine vs IN Midazolam and Fentanyl for Laceration Repair","sstatus":"TERMINATED","sponsor":"Corewell Health East","official":"Kelly Levasseur, DO (Corewell Health East)","src":"https://clinicaltrials.gov/study/NCT03528512","phase":"Phase 4","enroll":5,"start":"2018-09-04","eid":"x:site:nct03528512-beaumont-hospital-royal-oak-royal-oak"},{"id":"nct03861988-stanford-university-stanford","cat":"research","name":"Stanford University","city":"Stanford","region":"California","country":"United States","cc":"US","lat":37.41446,"lon":-122.1617,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94305","condg":["Depression"],"nct":"NCT03861988","study":"Intraoperative Ketamine Versus Saline in Depressed Patients Undergoing Anesthesia for Non-cardiac Surgery","sstatus":"COMPLETED","sponsor":"Stanford University","official":"Boris D Heifets, MD, PhD (Stanford University)","src":"https://clinicaltrials.gov/study/NCT03861988","phase":"Phase 4","enroll":45,"start":"2019-08-22","eid":"x:site:nct03861988-stanford-university-stanford"},{"id":"nct01501786-ibaraki-children-s-hospital-mito","cat":"research","name":"Ibaraki Children's Hospital","city":"Mito","region":"Ibaraki","country":"Japan","cc":"JP","lat":36.34327,"lon":140.44336,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"311-4145","condg":["Other"],"nct":"NCT01501786","study":"Does Ketamine Attenuate Depression of Respiratory and Cardiac Functions","sstatus":"COMPLETED","sponsor":"Ibaraki Children's Hospital","official":"Kazuhiko Okuyama, MD (Ibaraki Children's Hospital); Yuki Takeda, MD (Ibaraki Children's Hospital)","src":"https://clinicaltrials.gov/study/NCT01501786","phase":"N/A","enroll":150,"start":"2012-01","eid":"x:site:nct01501786-ibaraki-children-s-hospital-mito"},{"id":"nct02848963-cukurova-university-adana","cat":"research","name":"Cukurova University","city":"Adana","region":"Sarıçam","country":"Turkey","cc":"TR","lat":36.98008,"lon":35.31886,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"01380","condg":["Chronic pain & headache"],"nct":"NCT02848963","study":"Comparison of Ketamine-propofol Combinations","sstatus":"COMPLETED","sponsor":"Cukurova University","official":"Dilek Özcengiz, Professor (Cukurova University)","src":"https://clinicaltrials.gov/study/NCT02848963","phase":"Phase 4","enroll":75,"start":"2016-07","eid":"x:site:nct02848963-cukurova-university-adana"},{"id":"nct05962424-stanford-university-palo-alto","cat":"research","name":"Stanford University","city":"Palo Alto","region":"California","country":"United States","cc":"US","lat":37.45021,"lon":-122.149,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94306","condg":["Other"],"status":"RECRUITING","nct":"NCT05962424","study":"HNC: Human Neural Circuits Electrophysiology During Cognition","sstatus":"RECRUITING","sponsor":"Stanford University","official":"Karl Deisseroth, MD, PhD (Stanford University)","src":"https://clinicaltrials.gov/study/NCT05962424","contact":{"n":"Kishandra Patron, BS","p":"650-580-9000","e":"arjayc@stanford.edu"},"phase":"Phase 1","enroll":120,"start":"2023-10-05","eid":"x:site:nct05962424-stanford-university-palo-alto"},{"id":"nct05477004-stanford-university-stanford","cat":"research","name":"Stanford University","city":"Stanford","region":"California","country":"United States","cc":"US","lat":37.43507,"lon":-122.15719,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94305","condg":["Chronic pain & headache"],"nct":"NCT05477004","study":"Observational Study of Ketamine Infusions for the Treatment of Chronic Pain","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Theresa Lii","official":"Theresa Lii, MD (Stanford University)","src":"https://clinicaltrials.gov/study/NCT05477004","enroll":100,"start":"2022-06-01","eid":"x:site:nct05477004-stanford-university-stanford"},{"id":"nct05577247-gh-pitie-salpetriere-paris","cat":"research","name":"GH Pitié Salpêtrière","city":"Paris","country":"France","cc":"FR","lat":48.86353,"lon":2.35092,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"status":"RECRUITING","nct":"NCT05577247","study":"Belief Updating in Treatment Resistant Depression","sstatus":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","src":"https://clinicaltrials.gov/study/NCT05577247","contact":{"n":"Philippe Fossati, PU-PH","p":"+33142162891","e":"philippe.fossati@aphp.fr"},"enroll":60,"start":"2024-05-13","eid":"x:site:nct05577247-gh-pitie-salpetriere-paris"},{"id":"nct03272698-royal-university-hospital-saskatoon","cat":"research","name":"Royal University Hospital","city":"Saskatoon","region":"Saskatchewan","country":"Canada","cc":"CA","lat":52.13384,"lon":-106.6621,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"S7N 0W8","condg":["Depression"],"status":"RECRUITING","nct":"NCT03272698","study":"ECT with Ketamine Anesthesia Vs High Intensity Ketamine with ECT Rescue for Treatment-Resistant Depression","sstatus":"RECRUITING","sponsor":"University of Saskatchewan","official":"Jonathan Gamble, MD (University of Saskatchewan)","src":"https://clinicaltrials.gov/study/NCT03272698","contact":{"n":"Stephen Lee, MD","p":"3065010928","e":"stl960@mail.usask.ca"},"phase":"Phase 4","enroll":62,"start":"2017-09-01","eid":"x:site:nct03272698-royal-university-hospital-saskatoon"},{"id":"nct06191770-gauhar-afshan-karachi","cat":"research","name":"Gauhar Afshan","city":"Karachi","region":"Sindh","country":"Pakistan","cc":"PK","lat":24.85642,"lon":67.00273,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"65200","condg":["Chronic pain & headache"],"nct":"NCT06191770","study":"Comparison of Morphine With Nalbuphine in a Multimodal Approach for Pain Relief in Patients Undergoing Gynecological Procedures: Randomized Controlled Double Blind Clinical Trial","sstatus":"COMPLETED","sponsor":"Aga Khan University Hospital, Pakistan","src":"https://clinicaltrials.gov/study/NCT06191770","phase":"N/A","enroll":66,"start":"2019-10-01","eid":"x:site:nct06191770-gauhar-afshan-karachi"},{"id":"nct02048423-nationwide-children-s-hospital-columbus","cat":"research","name":"Nationwide Children's Hospital","city":"Columbus","region":"Ohio","country":"United States","cc":"US","lat":39.96565,"lon":-83.00138,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43205","condg":["Depression"],"status":"RECRUITING","nct":"NCT02048423","study":"An Open Prospective Trial of IV Ketamine in Suicidal Adolescents","sstatus":"UNKNOWN","sponsor":"Nationwide Children's Hospital","official":"Robert A Kowatch, MD, PhD (OSU Medical Center/Nationwide Childrens Hospital)","src":"https://clinicaltrials.gov/study/NCT02048423","contact":{"n":"Melinda Helton, RN","p":"614-722-2607","e":"robert.kowatch@nationwidechildrens.org"},"phase":"Phase 2/Phase 3","enroll":10,"start":"2013-06","eid":"x:site:nct02048423-nationwide-children-s-hospital-columbus"},{"id":"nct06131970-centre-hospitalier-princesse-grace-monaco","cat":"research","name":"Centre Hospitalier Princesse Grace","city":"Monaco","country":"Monaco","cc":"MC","lat":43.73356,"lon":7.42507,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"98000","condg":["Chronic pain & headache"],"nct":"NCT06131970","study":"The Effectiveness of Continuous Ketamine Infusion (KONTINUE)","sstatus":"COMPLETED","sponsor":"Centre Hospitalier Princesse Grace","src":"https://clinicaltrials.gov/study/NCT06131970","enroll":80,"start":"2022-02-22","eid":"x:site:nct06131970-centre-hospitalier-princesse-grace-monaco"},{"id":"nct04781673-corewell-health-west-grand-rapids","cat":"research","name":"Corewell Health West","city":"Grand Rapids","region":"Michigan","country":"United States","cc":"US","lat":42.97272,"lon":-85.66362,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"49503","condg":["PTSD & trauma"],"nct":"NCT04781673","study":"Ketamine vs Lidocaine in Traumatic Rib Fractures","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Brittany Hoyte","src":"https://clinicaltrials.gov/study/NCT04781673","phase":"Phase 4","enroll":74,"start":"2021-04-01","eid":"x:site:nct04781673-corewell-health-west-grand-rapids"},{"id":"nct00662883-unnamed-trial-site-baltimore","cat":"research","name":"Unnamed trial site","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28949,"lon":-76.60753,"gp":"city","unnamed":1,"drugs":["ketamine"],"zip":"21225","condg":["Healthy volunteers"],"nct":"NCT00662883","study":"Assessing the Effects of a Nasal Corticosteroid on PMI-150 (Intranasal Ketamine)","sstatus":"COMPLETED","sponsor":"Javelin Pharmaceuticals","official":"Javelin Pharmaceuticals, Inc (Javelin Pharmaceuticals)","src":"https://clinicaltrials.gov/study/NCT00662883","phase":"Phase 1","enroll":18,"start":"2007-11","eid":"x:site:nct00662883-unnamed-trial-site-baltimore"},{"id":"nct03860831-sanaa-farag-mahmoud-cairo","cat":"research","name":"Sanaa Farag Mahmoud","city":"Cairo","region":"New Cairo","country":"Egypt","cc":"EG","lat":30.07312,"lon":31.2452,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11835","condg":["Other"],"status":"RECRUITING","nct":"NCT03860831","study":"Intranasal Ketamine and Midazolam Mixture for Procedural Sedation in Children With Mental Disabilities:","sstatus":"UNKNOWN","sponsor":"Ain Shams University","src":"https://clinicaltrials.gov/study/NCT03860831","contact":{"n":"sanaa wasfy, lecturer","p":"01061262757","e":"sanaawasfy@gmail.com"},"phase":"Phase 1","enroll":40,"start":"2019-03-06","eid":"x:site:nct03860831-sanaa-farag-mahmoud-cairo"},{"id":"nct03860831-ainshams-hospitals-cairo","cat":"research","name":"Ainshams hospitals","city":"Cairo","country":"Egypt","cc":"EG","lat":30.06221,"lon":31.2612,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11591","condg":["Other"],"status":"NOT_YET_RECRUITING","nct":"NCT03860831","study":"Intranasal Ketamine and Midazolam Mixture for Procedural Sedation in Children With Mental Disabilities:","sstatus":"UNKNOWN","sponsor":"Ain Shams University","src":"https://clinicaltrials.gov/study/NCT03860831","contact":{"n":"sanaa fFM wasfy, MD","p":"00201061262757","e":"sanaawasfy@gmail.com"},"phase":"Phase 1","enroll":40,"start":"2019-03-06","eid":"x:site:nct03860831-ainshams-hospitals-cairo"},{"id":"nct01209845-yale-new-haven-hospital-emergency-department-new-haven","cat":"research","name":"Yale New Haven Hospital Emergency Department","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.30895,"lon":-72.93141,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06519","condg":["Depression"],"nct":"NCT01209845","study":"Ketamine for Low Mood States in the ER","sstatus":"COMPLETED","sponsor":"Yale University","official":"Gregory L Larkin, MD (Yale University School of Medicine, Department of Emergency Medicine)","src":"https://clinicaltrials.gov/study/NCT01209845","phase":"Phase 1","enroll":14,"start":"2010-04","eid":"x:site:nct01209845-yale-new-haven-hospital-emergency-department-new-haven"},{"id":"nct05957302-ahmed-mohamed-hasanin-cairo","cat":"research","name":"Ahmed Mohamed Hasanin","city":"Cairo","country":"Egypt","cc":"EG","lat":30.06108,"lon":31.23842,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11432","condg":["Other"],"nct":"NCT05957302","study":"Hemodynamic Effects of Bolus of Ketamine Versus Fentanyl in Patients With Septic Shock","sstatus":"COMPLETED","sponsor":"Cairo University","official":"ahmed hasanin, MD (Cairo University Kasr Alainy Faculty of Medicine)","src":"https://clinicaltrials.gov/study/NCT05957302","phase":"N/A","enroll":86,"start":"2023-08-01","eid":"x:site:nct05957302-ahmed-mohamed-hasanin-cairo"},{"id":"nct06735079-mediolanum-cardio-research-milan","cat":"research","name":"Mediolanum Cardio Research","city":"Milan","region":"Italy","country":"Italy","cc":"IT","lat":45.46093,"lon":9.19106,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20123","condg":["Depression"],"nct":"NCT06735079","study":"A Study to Evaluate the Efficacy and Safety of REL-1017 As Adjunctive Treatment of Major Depressive Disorder (MDD)","sstatus":"WITHDRAWN","sponsor":"MGGM LLC","src":"https://clinicaltrials.gov/study/NCT06735079","phase":"Phase 3","start":"2024-12-27","eid":"x:site:nct06735079-mediolanum-cardio-research-milan"},{"id":"nct06735079-clinical-trial-unit-ente-ospedaliero-cantonale-ctu-eoc-area-formazio","cat":"research","name":"Clinical Trial Unit - Ente Ospedaliero Cantonale (CTU-EOC) Area Formazione medica e Ricerca (AFRi)","city":"Lugano","region":"Switzerland","country":"Switzerland","cc":"CH","lat":45.99987,"lon":8.95529,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"6900","condg":["Depression"],"nct":"NCT06735079","study":"A Study to Evaluate the Efficacy and Safety of REL-1017 As Adjunctive Treatment of Major Depressive Disorder (MDD)","sstatus":"WITHDRAWN","sponsor":"MGGM LLC","src":"https://clinicaltrials.gov/study/NCT06735079","phase":"Phase 3","start":"2024-12-27","eid":"x:site:nct06735079-clinical-trial-unit-ente-ospedaliero-cantonale-ctu-eoc-area-formazio"},{"id":"nct01304147-icahn-school-of-medicine-at-mount-sinai-new-york","cat":"research","name":"Icahn School of Medicine at Mount Sinai","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71102,"lon":-73.99435,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10029","condg":["Depression"],"nct":"NCT01304147","study":"Intranasal Ketamine in Treatment-Resistant Depression","sstatus":"COMPLETED","sponsor":"James Murrough","official":"James W Murrough, MD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT01304147","phase":"N/A","enroll":20,"start":"2011-10","eid":"x:site:nct01304147-icahn-school-of-medicine-at-mount-sinai-new-york"},{"id":"nct05026203-keerati-pattanaseri-bangkok","cat":"research","name":"Keerati Pattanaseri","city":"Bangkok","country":"Thailand","cc":"TH","lat":13.74772,"lon":100.49885,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10700","condg":["Depression"],"nct":"NCT05026203","study":"Effectiveness of Ketamine Treatment for Three Consecutive Days in Depression","sstatus":"COMPLETED","sponsor":"Mahidol University","src":"https://clinicaltrials.gov/study/NCT05026203","phase":"Phase 4","enroll":24,"start":"2021-09-01","eid":"x:site:nct05026203-keerati-pattanaseri-bangkok"},{"id":"nct01951911-haukeland-university-hospital-bergen","cat":"research","name":"Haukeland University Hospital","city":"Bergen","region":"Hordaland","country":"Norway","cc":"NO","lat":60.384,"lon":5.321,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"5021","condg":["Chronic pain & headache"],"nct":"NCT01951911","study":"Effectiveness of Ketamine in Malignant Neuropathic Pain Relief","sstatus":"WITHDRAWN","sponsor":"Haukeland University Hospital","official":"Rae F Bell, M.D. PhD. (Pain Clinic, Haukeland University Hospital, 5021 Bergen, Norway)","src":"https://clinicaltrials.gov/study/NCT01951911","phase":"Phase 3","start":"2013-09","eid":"x:site:nct01951911-haukeland-university-hospital-bergen"},{"id":"nct01807260-department-of-urology-erciyes-university-medical-faculty-kayseri","cat":"research","name":"Department of Urology, Erciyes University Medical Faculty,","city":"Kayseri","region":"Talas","country":"Turkey","cc":"TR","lat":38.72803,"lon":35.47592,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"38280","condg":["Other"],"nct":"NCT01807260","study":"Stepwise Shock Wave Lithotripsy in Pediatric Urolithiasis","sstatus":"COMPLETED","sponsor":"TC Erciyes University","official":"Deniz Demirci, Prof. (Department of Urology, Erciyes University Medical faculty,)","src":"https://clinicaltrials.gov/study/NCT01807260","phase":"N/A","enroll":81,"start":"2008-03","eid":"x:site:nct01807260-department-of-urology-erciyes-university-medical-faculty-kayseri"},{"id":"nct01600885-connecticut-mental-health-center-new-haven","cat":"research","name":"Connecticut Mental Health Center","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.30311,"lon":-72.91945,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06511","condg":["Other"],"nct":"NCT01600885","study":"The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects","sstatus":"COMPLETED","sponsor":"Yale University","official":"John H Krystal, M.D. (Yale University); Naomi R Driesen, Ph.D. (Yale University)","src":"https://clinicaltrials.gov/study/NCT01600885","phase":"N/A","enroll":16,"start":"2008-08","eid":"x:site:nct01600885-connecticut-mental-health-center-new-haven"},{"id":"nct01600885-yale-magnetic-resonance-research-center-new-haven","cat":"research","name":"Yale Magnetic Resonance Research Center","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31883,"lon":-72.91823,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06520","condg":["Other"],"nct":"NCT01600885","study":"The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects","sstatus":"COMPLETED","sponsor":"Yale University","official":"John H Krystal, M.D. (Yale University); Naomi R Driesen, Ph.D. (Yale University)","src":"https://clinicaltrials.gov/study/NCT01600885","phase":"N/A","enroll":16,"start":"2008-08","eid":"x:site:nct01600885-yale-magnetic-resonance-research-center-new-haven"},{"id":"nct01600885-veterans-affairs-hospital-west-haven","cat":"research","name":"Veterans Affairs Hospital","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.26844,"lon":-72.94776,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06516","condg":["Other"],"nct":"NCT01600885","study":"The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects","sstatus":"COMPLETED","sponsor":"Yale University","official":"John H Krystal, M.D. (Yale University); Naomi R Driesen, Ph.D. (Yale University)","src":"https://clinicaltrials.gov/study/NCT01600885","phase":"N/A","enroll":16,"start":"2008-08","eid":"x:site:nct01600885-veterans-affairs-hospital-west-haven"},{"id":"nct02701933-university-of-bonn-bonn","cat":"research","name":"University of Bonn","city":"Bonn","region":"North Rhine-Westphalia","country":"Germany","cc":"DE","lat":50.72285,"lon":7.09394,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"53111","condg":["Other"],"nct":"NCT02701933","study":"Effects of Ketamine on Eye Movements, Perception and Brain Function","sstatus":"COMPLETED","sponsor":"University of Bonn","official":"Ulrich Ettinger, PhD (Department of Psychology, University of Bonn)","src":"https://clinicaltrials.gov/study/NCT02701933","phase":"N/A","enroll":24,"start":"2014-04","eid":"x:site:nct02701933-university-of-bonn-bonn"},{"id":"nct02909049-jose-luis-ponce-diaz-reixa-a-coruna","cat":"research","name":"Jose Luis Ponce Diaz-Reixa","city":"A Coruña","country":"Spain","cc":"ES","lat":43.36387,"lon":-8.39802,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"15006","condg":["Cancer-related distress"],"nct":"NCT02909049","study":"Clinical Trial to Examine Individual Pain Tolerance in the Use of Two Anesthetic Techniques to Perform Saturation Prostate Biopsy","sstatus":"COMPLETED","sponsor":"Complexo Hospitalario Universitario de A Coruña","official":"Jose L Ponce, MD (Complejo Hospitalario Universitario, A Coruña)","src":"https://clinicaltrials.gov/study/NCT02909049","phase":"Phase 4","enroll":100,"start":"2016-04","eid":"x:site:nct02909049-jose-luis-ponce-diaz-reixa-a-coruna"},{"id":"nct02661061-st-patrick-s-university-hospital-dublin","cat":"research","name":"St Patrick's University Hospital","city":"Dublin","country":"Ireland","cc":"IE","lat":53.34431,"lon":-6.24988,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"8","condg":["Depression"],"nct":"NCT02661061","study":"Ketamine for Relapse Prevention in Recurrent Depressive Disorder","sstatus":"TERMINATED","sponsor":"St Patrick's Hospital, Ireland","official":"Declan McLoughlin (University of Dublin, Trinity College)","src":"https://clinicaltrials.gov/study/NCT02661061","phase":"Phase 1","enroll":9,"start":"2015-12","eid":"x:site:nct02661061-st-patrick-s-university-hospital-dublin"},{"id":"nct05829486-gaziosmanpasa-treh-istanbul","cat":"research","name":"Gaziosmanpaşa TREH","city":"Istanbul","region":"Gaziosmanpaşa","country":"Turkey","cc":"TR","lat":41.02415,"lon":28.94227,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"34255","condg":["Other"],"status":"RECRUITING","nct":"NCT05829486","study":"Integrated Pulmonary Index in Gastroscopic Procedures","sstatus":"UNKNOWN","sponsor":"Gaziosmanpasa Research and Education Hospital","official":"zuhal çavuş, MD (gaziosmanpasa TREH); döndü genç moralar, MD (gaziosmanpasa TREH)","src":"https://clinicaltrials.gov/study/NCT05829486","contact":{"n":"sibel bektaş, prof.MD","p":"02129453030","e":"sibel-bektas@yahoo.com"},"enroll":60,"start":"2023-02-06","eid":"x:site:nct05829486-gaziosmanpasa-treh-istanbul"},{"id":"nct02306759-the-brooklyn-hospital-center-brooklyn","cat":"research","name":"The Brooklyn Hospital Center","city":"Brooklyn","region":"New York","country":"United States","cc":"US","lat":40.65984,"lon":-73.95424,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11201","condg":["Chronic pain & headache"],"nct":"NCT02306759","study":"Ketamine For Acute Treatment of Pain in Emergency Department","sstatus":"COMPLETED","sponsor":"The Brooklyn Hospital Center","official":"Billy Sin, Pharm.D. (The Brooklyn Hospital Center)","src":"https://clinicaltrials.gov/study/NCT02306759","phase":"Phase 4","enroll":60,"start":"2015-01","eid":"x:site:nct02306759-the-brooklyn-hospital-center-brooklyn"},{"id":"nct05414422-preferred-research-partners-little-rock","cat":"research","name":"Preferred Research Partners","city":"Little Rock","region":"Arkansas","country":"United States","cc":"US","lat":34.74775,"lon":-92.29152,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"72211","condg":["Depression"],"nct":"NCT05414422","study":"A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD","sstatus":"COMPLETED","sponsor":"Perception Neuroscience","official":"Chief Medical Officer (Perception Neuroscience)","src":"https://clinicaltrials.gov/study/NCT05414422","phase":"Phase 2","enroll":102,"start":"2022-02-01","eid":"x:site:nct05414422-preferred-research-partners-little-rock"},{"id":"nct05414422-cns-network-garden-grove","cat":"research","name":"CNS Network","city":"Garden Grove","region":"California","country":"United States","cc":"US","lat":33.77744,"lon":-117.95006,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"92845","condg":["Depression"],"nct":"NCT05414422","study":"A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD","sstatus":"COMPLETED","sponsor":"Perception Neuroscience","official":"Chief Medical Officer (Perception Neuroscience)","src":"https://clinicaltrials.gov/study/NCT05414422","phase":"Phase 2","enroll":102,"start":"2022-02-01","eid":"x:site:nct05414422-cns-network-garden-grove"},{"id":"nct05414422-kadima-neuropsychiatry-institute-la-jolla","cat":"research","name":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","cc":"US","lat":32.85861,"lon":-117.28036,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"92037","condg":["Depression"],"nct":"NCT05414422","study":"A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD","sstatus":"COMPLETED","sponsor":"Perception Neuroscience","official":"Chief Medical Officer (Perception Neuroscience)","src":"https://clinicaltrials.gov/study/NCT05414422","phase":"Phase 2","enroll":102,"start":"2022-02-01","eid":"x:site:nct05414422-kadima-neuropsychiatry-institute-la-jolla"},{"id":"nct05414422-synergy-san-diego-lemon-grove","cat":"research","name":"Synergy San Diego","city":"Lemon Grove","region":"California","country":"United States","cc":"US","lat":32.75436,"lon":-117.02196,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"91945","condg":["Depression"],"nct":"NCT05414422","study":"A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD","sstatus":"COMPLETED","sponsor":"Perception Neuroscience","official":"Chief Medical Officer (Perception Neuroscience)","src":"https://clinicaltrials.gov/study/NCT05414422","phase":"Phase 2","enroll":102,"start":"2022-02-01","eid":"x:site:nct05414422-synergy-san-diego-lemon-grove"},{"id":"nct05414422-nrc-research-institute-orange","cat":"research","name":"NRC Research Institute","city":"Orange","region":"California","country":"United States","cc":"US","lat":33.78699,"lon":-117.86238,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"92868","condg":["Depression"],"nct":"NCT05414422","study":"A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD","sstatus":"COMPLETED","sponsor":"Perception Neuroscience","official":"Chief Medical Officer (Perception Neuroscience)","src":"https://clinicaltrials.gov/study/NCT05414422","phase":"Phase 2","enroll":102,"start":"2022-02-01","eid":"x:site:nct05414422-nrc-research-institute-orange"},{"id":"nct05414422-premier-clinical-research-institute-inc-miami","cat":"research","name":"Premier Clinical Research Institute Inc.","city":"Miami","region":"Florida","country":"United States","cc":"US","lat":25.76331,"lon":-80.20265,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"33122","condg":["Depression"],"nct":"NCT05414422","study":"A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD","sstatus":"COMPLETED","sponsor":"Perception Neuroscience","official":"Chief Medical Officer (Perception Neuroscience)","src":"https://clinicaltrials.gov/study/NCT05414422","phase":"Phase 2","enroll":102,"start":"2022-02-01","eid":"x:site:nct05414422-premier-clinical-research-institute-inc-miami"},{"id":"nct05414422-psych-atlanta-marietta","cat":"research","name":"Psych Atlanta","city":"Marietta","region":"Georgia","country":"United States","cc":"US","lat":33.94945,"lon":-84.55092,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"30060","condg":["Depression"],"nct":"NCT05414422","study":"A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD","sstatus":"COMPLETED","sponsor":"Perception Neuroscience","official":"Chief Medical Officer (Perception Neuroscience)","src":"https://clinicaltrials.gov/study/NCT05414422","phase":"Phase 2","enroll":102,"start":"2022-02-01","eid":"x:site:nct05414422-psych-atlanta-marietta"},{"id":"nct05414422-hassman-research-institute-berlin","cat":"research","name":"Hassman Research Institute","city":"Berlin","region":"New Jersey","country":"United States","cc":"US","lat":44.45883,"lon":-71.17383,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"08009","condg":["Depression"],"nct":"NCT05414422","study":"A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD","sstatus":"COMPLETED","sponsor":"Perception Neuroscience","official":"Chief Medical Officer (Perception Neuroscience)","src":"https://clinicaltrials.gov/study/NCT05414422","phase":"Phase 2","enroll":102,"start":"2022-02-01","eid":"x:site:nct05414422-hassman-research-institute-berlin"},{"id":"nct05414422-princeton-medical-institute-princeton","cat":"research","name":"Princeton Medical Institute","city":"Princeton","region":"New Jersey","country":"United States","cc":"US","lat":25.54573,"lon":-80.42028,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"08540","condg":["Depression"],"nct":"NCT05414422","study":"A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD","sstatus":"COMPLETED","sponsor":"Perception Neuroscience","official":"Chief Medical Officer (Perception Neuroscience)","src":"https://clinicaltrials.gov/study/NCT05414422","phase":"Phase 2","enroll":102,"start":"2022-02-01","eid":"x:site:nct05414422-princeton-medical-institute-princeton"},{"id":"nct05414422-midwest-clinical-research-center-dayton","cat":"research","name":"Midwest Clinical Research Center","city":"Dayton","region":"Ohio","country":"United States","cc":"US","lat":39.74855,"lon":-84.18337,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45417","condg":["Depression"],"nct":"NCT05414422","study":"A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD","sstatus":"COMPLETED","sponsor":"Perception Neuroscience","official":"Chief Medical Officer (Perception Neuroscience)","src":"https://clinicaltrials.gov/study/NCT05414422","phase":"Phase 2","enroll":102,"start":"2022-02-01","eid":"x:site:nct05414422-midwest-clinical-research-center-dayton"},{"id":"nct05414422-neuro-behavioral-clinical-research-north-canton","cat":"research","name":"Neuro-Behavioral Clinical Research","city":"North Canton","region":"Ohio","country":"United States","cc":"US","lat":40.86662,"lon":-81.39279,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44720","condg":["Depression"],"nct":"NCT05414422","study":"A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD","sstatus":"COMPLETED","sponsor":"Perception Neuroscience","official":"Chief Medical Officer (Perception Neuroscience)","src":"https://clinicaltrials.gov/study/NCT05414422","phase":"Phase 2","enroll":102,"start":"2022-02-01","eid":"x:site:nct05414422-neuro-behavioral-clinical-research-north-canton"},{"id":"nct05414422-insite-clinical-research-llc-inpatient-facility-name-serenity-desoto","cat":"research","name":"Insite Clinical Research LLC; Inpatient facility name: Serenity","city":"DeSoto","region":"Texas","country":"United States","cc":"US","lat":32.60064,"lon":-96.85079,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75115","condg":["Depression"],"nct":"NCT05414422","study":"A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD","sstatus":"COMPLETED","sponsor":"Perception Neuroscience","official":"Chief Medical Officer (Perception Neuroscience)","src":"https://clinicaltrials.gov/study/NCT05414422","phase":"Phase 2","enroll":102,"start":"2022-02-01","eid":"x:site:nct05414422-insite-clinical-research-llc-inpatient-facility-name-serenity-desoto"},{"id":"nct05414422-pillar-clinical-research-llc-richardson","cat":"research","name":"Pillar Clinical Research, LLC","city":"Richardson","region":"Texas","country":"United States","cc":"US","lat":32.95547,"lon":-96.72986,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75080","condg":["Depression"],"nct":"NCT05414422","study":"A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD","sstatus":"COMPLETED","sponsor":"Perception Neuroscience","official":"Chief Medical Officer (Perception Neuroscience)","src":"https://clinicaltrials.gov/study/NCT05414422","phase":"Phase 2","enroll":102,"start":"2022-02-01","eid":"x:site:nct05414422-pillar-clinical-research-llc-richardson"},{"id":"nct05414422-klinikum-der-johann-wolfgang-goethe-universitaet-frankfurt","cat":"research","name":"Klinikum der Johann Wolfgang Goethe-Universitaet","city":"Frankfurt","country":"Germany","cc":"DE","lat":50.11519,"lon":8.67575,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60528","condg":["Depression"],"nct":"NCT05414422","study":"A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD","sstatus":"COMPLETED","sponsor":"Perception Neuroscience","official":"Chief Medical Officer (Perception Neuroscience)","src":"https://clinicaltrials.gov/study/NCT05414422","phase":"Phase 2","enroll":102,"start":"2022-02-01","eid":"x:site:nct05414422-klinikum-der-johann-wolfgang-goethe-universitaet-frankfurt"},{"id":"nct05414422-pharmakologisches-studienzentrum-chemnitz-gmbh-mittweida","cat":"research","name":"Pharmakologisches Studienzentrum Chemnitz GmbH","city":"Mittweida","country":"Germany","cc":"DE","lat":50.99511,"lon":12.97372,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"09648","condg":["Depression"],"nct":"NCT05414422","study":"A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD","sstatus":"COMPLETED","sponsor":"Perception Neuroscience","official":"Chief Medical Officer (Perception Neuroscience)","src":"https://clinicaltrials.gov/study/NCT05414422","phase":"Phase 2","enroll":102,"start":"2022-02-01","eid":"x:site:nct05414422-pharmakologisches-studienzentrum-chemnitz-gmbh-mittweida"},{"id":"nct05414422-somni-bene-gmbh-schwerin","cat":"research","name":"Somni bene GmbH","city":"Schwerin","country":"Germany","cc":"DE","lat":53.62725,"lon":11.41942,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"19053","condg":["Depression"],"nct":"NCT05414422","study":"A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD","sstatus":"COMPLETED","sponsor":"Perception Neuroscience","official":"Chief Medical Officer (Perception Neuroscience)","src":"https://clinicaltrials.gov/study/NCT05414422","phase":"Phase 2","enroll":102,"start":"2022-02-01","eid":"x:site:nct05414422-somni-bene-gmbh-schwerin"},{"id":"nct05414422-universitaetsklinikum-wuerzburg-wurzburg","cat":"research","name":"Universitaetsklinikum Wuerzburg","city":"Würzburg","country":"Germany","cc":"DE","lat":49.80469,"lon":9.9553,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"97080","condg":["Depression"],"nct":"NCT05414422","study":"A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD","sstatus":"COMPLETED","sponsor":"Perception Neuroscience","official":"Chief Medical Officer (Perception Neuroscience)","src":"https://clinicaltrials.gov/study/NCT05414422","phase":"Phase 2","enroll":102,"start":"2022-02-01","eid":"x:site:nct05414422-universitaetsklinikum-wuerzburg-wurzburg"},{"id":"nct05414422-indywidualna-specjalistyczna-praktyka-lekarska-gdansk","cat":"research","name":"Indywidualna Specjalistyczna Praktyka Lekarska","city":"Gdansk","country":"Poland","cc":"PL","lat":54.34319,"lon":18.65594,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"80-438","condg":["Depression"],"nct":"NCT05414422","study":"A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD","sstatus":"COMPLETED","sponsor":"Perception Neuroscience","official":"Chief Medical Officer (Perception Neuroscience)","src":"https://clinicaltrials.gov/study/NCT05414422","phase":"Phase 2","enroll":102,"start":"2022-02-01","eid":"x:site:nct05414422-indywidualna-specjalistyczna-praktyka-lekarska-gdansk"},{"id":"nct05414422-centrum-badan-klinicznych-pi-house-sp-z-o-o-gdansk","cat":"research","name":"Centrum Badan Klinicznych PI-House sp. z o.o.","city":"Gdansk","country":"Poland","cc":"PL","lat":54.36305,"lon":18.6486,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"80-546","condg":["Depression"],"nct":"NCT05414422","study":"A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD","sstatus":"COMPLETED","sponsor":"Perception Neuroscience","official":"Chief Medical Officer (Perception Neuroscience)","src":"https://clinicaltrials.gov/study/NCT05414422","phase":"Phase 2","enroll":102,"start":"2022-02-01","eid":"x:site:nct05414422-centrum-badan-klinicznych-pi-house-sp-z-o-o-gdansk"},{"id":"nct05414422-wojewodzki-szpital-dla-nerwowo-i-psychicznie-chorych-gmina-swiecie","cat":"research","name":"Wojewodzki Szpital Dla Nerwowo i Psychicznie Chorych","city":"Gmina Świecie","country":"Poland","cc":"PL","lat":53.42097,"lon":18.44907,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"86-100","condg":["Depression"],"nct":"NCT05414422","study":"A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD","sstatus":"COMPLETED","sponsor":"Perception Neuroscience","official":"Chief Medical Officer (Perception Neuroscience)","src":"https://clinicaltrials.gov/study/NCT05414422","phase":"Phase 2","enroll":102,"start":"2022-02-01","eid":"x:site:nct05414422-wojewodzki-szpital-dla-nerwowo-i-psychicznie-chorych-gmina-swiecie"},{"id":"nct05414422-prywatny-gabinet-lekarski-jaroslaw-strzelec-tuszyn","cat":"research","name":"Prywatny Gabinet Lekarski Jaroslaw Strzelec","city":"Tuszyn","country":"Poland","cc":"PL","lat":51.60756,"lon":19.53277,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"95-080","condg":["Depression"],"nct":"NCT05414422","study":"A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD","sstatus":"COMPLETED","sponsor":"Perception Neuroscience","official":"Chief Medical Officer (Perception Neuroscience)","src":"https://clinicaltrials.gov/study/NCT05414422","phase":"Phase 2","enroll":102,"start":"2022-02-01","eid":"x:site:nct05414422-prywatny-gabinet-lekarski-jaroslaw-strzelec-tuszyn"},{"id":"nct03896256-thomas-jefferson-university-hospital-philadelphia","cat":"research","name":"Thomas Jefferson University Hospital","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.95233,"lon":-75.1728,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"19107","condg":["Chronic pain & headache"],"nct":"NCT03896256","study":"Ketamine for Refractory Chronic Migraine: a Pilot Study","sstatus":"COMPLETED","sponsor":"Thomas Jefferson University","src":"https://clinicaltrials.gov/study/NCT03896256","phase":"EARLY_Phase 1","enroll":6,"start":"2019-03-22","eid":"x:site:nct03896256-thomas-jefferson-university-hospital-philadelphia"},{"id":"nct07408193-university-general-hospital-of-athens-attikon-national-and-kapodistr","cat":"research","name":"University General Hospital of Athens \"Attikon\" - National and Kapodistrian University of Athens Medical School","city":"Athens","region":"Attica","country":"Greece","cc":"GR","lat":37.97496,"lon":23.73015,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"12461","condg":["Addiction & substance use","Cancer-related distress","Chronic pain & headache"],"status":"RECRUITING","nct":"NCT07408193","study":"The Role of Coadministration of Lidocaine and Ketamine in Opioid-Refractory Chronic Cancer-Related Pain.","sstatus":"RECRUITING","sponsor":"National and Kapodistrian University of Athens","official":"Konstantinos Kalimeris, Assoc Prof of Anesthesiology (National and Kapodistrian University of Athens); Maria Riga, Assis Prof of Anesthesiology (National and Kapodistrian University of Athens)","src":"https://clinicaltrials.gov/study/NCT07408193","contact":{"n":"Konstantinos Kalimeris MD, PhD, Associate Professor of Anesthesiology","p":"+302105831997","e":"kkalimeris@med.uoa.gr"},"phase":"EARLY_Phase 1","enroll":24,"start":"2026-03-01","eid":"x:site:nct07408193-university-general-hospital-of-athens-attikon-national-and-kapodistr"},{"id":"nct03573349-mayo-clinic-in-rochester-rochester","cat":"research","name":"Mayo Clinic in Rochester","city":"Rochester","region":"Minnesota","country":"United States","cc":"US","lat":43.16085,"lon":-77.62172,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55905","condg":["Depression","Bipolar"],"nct":"NCT03573349","study":"Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","official":"Balwinder Singh, MD, MS (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT03573349","phase":"EARLY_Phase 1","enroll":18,"start":"2019-01-03","eid":"x:site:nct03573349-mayo-clinic-in-rochester-rochester"},{"id":"nct02062658-new-york-state-psychiatric-insitute-new-york","cat":"research","name":"New York State Psychiatric Insitute","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71921,"lon":-73.99821,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10032","condg":["OCD"],"nct":"NCT02062658","study":"Extending Ketamine's Effects in OCD With Exposure and Response Prevention (EX/RP)","sstatus":"COMPLETED","sponsor":"New York State Psychiatric Institute","official":"H Blair Simpson, MD, PhD (Columbia-NYSPI-RFMH)","src":"https://clinicaltrials.gov/study/NCT02062658","phase":"Phase 2","enroll":10,"start":"2013-12","eid":"x:site:nct02062658-new-york-state-psychiatric-insitute-new-york"},{"id":"nct00956085-new-york-state-psychiatric-institute-new-york","cat":"research","name":"New York State Psychiatric Institute","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71855,"lon":-73.99792,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10032","condg":["OCD"],"nct":"NCT00956085","study":"Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive Disorder","sstatus":"COMPLETED","sponsor":"New York State Psychiatric Institute","official":"Carolyn I Rodriguez, M.D., Ph.D. (Stanford University); Helen B Simpson, MD, PhD (NYSPI-Columbia)","src":"https://clinicaltrials.gov/study/NCT00956085","phase":"Phase 2","enroll":12,"start":"2009-08","eid":"x:site:nct00956085-new-york-state-psychiatric-institute-new-york"},{"id":"nct04578938-university-of-pittsburgh-pittsburgh","cat":"research","name":"University of Pittsburgh","city":"Pittsburgh","region":"Pennsylvania","country":"United States","cc":"US","lat":40.43907,"lon":-79.99123,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"15213","condg":["Other"],"nct":"NCT04578938","study":"Ketamine + Cognitive Training for Suicidality in the Medical Setting","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Rebecca Price","official":"Rebecca B Price, PhD (University of Pittsburgh)","src":"https://clinicaltrials.gov/study/NCT04578938","phase":"Phase 4","enroll":200,"start":"2021-03-15","eid":"x:site:nct04578938-university-of-pittsburgh-pittsburgh"},{"id":"nct02532153-massachusetts-general-hospital-boston","cat":"research","name":"Massachusetts General Hospital","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.35904,"lon":-71.06801,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02114","condg":["Other"],"nct":"NCT02532153","study":"The Impact of Ketamine on the Reward Circuitry of Suicidal Patients","sstatus":"WITHDRAWN","sponsor":"Massachusetts General Hospital","official":"Dawn Ionescu, M.D. (MGH)","src":"https://clinicaltrials.gov/study/NCT02532153","phase":"Phase 3","start":"2017-02","eid":"x:site:nct02532153-massachusetts-general-hospital-boston"},{"id":"nct04427605-azienda-ospedale-universita-padova-padova","cat":"research","name":"Azienda Ospedale Università Padova","city":"Padova","region":"PD","country":"Italy","cc":"IT","lat":45.41103,"lon":11.89447,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"35127","condg":["Other"],"nct":"NCT04427605","study":"Efficacy and Safety of Continuous Infusion of Ketamine in Pediatric Intensive Care Unit (KISS Study)","sstatus":"COMPLETED","sponsor":"Azienda Ospedaliera di Padova","official":"angela amigoni, MD (Azienda Ospedaliera di Padova); andrea pettenazzo, MD (Azienda Ospedaliera di Padova)","src":"https://clinicaltrials.gov/study/NCT04427605","enroll":57,"start":"2019-04-01","eid":"x:site:nct04427605-azienda-ospedale-universita-padova-padova"},{"id":"nct05233566-washington-university-school-of-medicine-st-louis","cat":"research","name":"Washington University School of Medicine","city":"St Louis","region":"Missouri","country":"United States","cc":"US","lat":38.62092,"lon":-90.19756,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"63110","condg":["Depression"],"nct":"NCT05233566","study":"Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial","sstatus":"COMPLETED","sponsor":"Washington University School of Medicine","src":"https://clinicaltrials.gov/study/NCT05233566","phase":"Phase 3","enroll":32,"start":"2022-04-25","eid":"x:site:nct05233566-washington-university-school-of-medicine-st-louis"},{"id":"nct07193901-the-sixth-hospital-of-peking-university-beijin","cat":"research","name":"The Sixth Hospital of Peking University","city":"Beijin","country":"China","cc":"CN","lat":40.1644,"lon":116.4659,"gp":"country","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT07193901","study":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior","sstatus":"COMPLETED","sponsor":"Sichuan Purity Pharmaceutical Technology Co., Ltd.","src":"https://clinicaltrials.gov/study/NCT07193901","phase":"Phase 2","enroll":98,"start":"2025-05-27","eid":"x:site:nct07193901-the-sixth-hospital-of-peking-university-beijin"},{"id":"nct07193901-beijing-anding-hospital-capital-medical-university-beijing","cat":"research","name":"BEIjing AnDing hospital capital medical university","city":"Beijing","country":"China","cc":"CN","lat":39.91686,"lon":116.40311,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT07193901","study":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior","sstatus":"COMPLETED","sponsor":"Sichuan Purity Pharmaceutical Technology Co., Ltd.","src":"https://clinicaltrials.gov/study/NCT07193901","phase":"Phase 2","enroll":98,"start":"2025-05-27","eid":"x:site:nct07193901-beijing-anding-hospital-capital-medical-university-beijing"},{"id":"nct07193901-beijing-huilongguan-hospital-beijing","cat":"research","name":"Beijing Huilongguan Hospital","city":"Beijing","country":"China","cc":"CN","lat":39.89682,"lon":116.40415,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT07193901","study":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior","sstatus":"COMPLETED","sponsor":"Sichuan Purity Pharmaceutical Technology Co., Ltd.","src":"https://clinicaltrials.gov/study/NCT07193901","phase":"Phase 2","enroll":98,"start":"2025-05-27","eid":"x:site:nct07193901-beijing-huilongguan-hospital-beijing"},{"id":"nct07193901-brain-hospital-of-hunan-province-changsha","cat":"research","name":"Brain Hospital of Hunan Province","city":"Changsha","country":"China","cc":"CN","lat":28.20387,"lon":112.96583,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT07193901","study":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior","sstatus":"COMPLETED","sponsor":"Sichuan Purity Pharmaceutical Technology Co., Ltd.","src":"https://clinicaltrials.gov/study/NCT07193901","phase":"Phase 2","enroll":98,"start":"2025-05-27","eid":"x:site:nct07193901-brain-hospital-of-hunan-province-changsha"},{"id":"nct07193901-the-second-xiangya-hospital-of-central-south-university-changsha","cat":"research","name":"The Second Xiangya Hospital of Central South University","city":"Changsha","country":"China","cc":"CN","lat":28.197,"lon":112.96066,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT07193901","study":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior","sstatus":"COMPLETED","sponsor":"Sichuan Purity Pharmaceutical Technology Co., Ltd.","src":"https://clinicaltrials.gov/study/NCT07193901","phase":"Phase 2","enroll":98,"start":"2025-05-27","eid":"x:site:nct07193901-the-second-xiangya-hospital-of-central-south-university-changsha"},{"id":"nct07193901-the-fourth-people-s-hospital-of-chengdu-chengdu","cat":"research","name":"The Fourth People's Hospital of Chengdu","city":"Chengdu","country":"China","cc":"CN","lat":30.66088,"lon":104.0782,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT07193901","study":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior","sstatus":"COMPLETED","sponsor":"Sichuan Purity Pharmaceutical Technology Co., Ltd.","src":"https://clinicaltrials.gov/study/NCT07193901","phase":"Phase 2","enroll":98,"start":"2025-05-27","eid":"x:site:nct07193901-the-fourth-people-s-hospital-of-chengdu-chengdu"},{"id":"nct07193901-hangzhou-seventh-people-s-hospital-hangzhou","cat":"research","name":"Hangzhou Seventh People's Hospital","city":"Hangzhou","country":"China","cc":"CN","lat":30.29652,"lon":120.15281,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT07193901","study":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior","sstatus":"COMPLETED","sponsor":"Sichuan Purity Pharmaceutical Technology Co., Ltd.","src":"https://clinicaltrials.gov/study/NCT07193901","phase":"Phase 2","enroll":98,"start":"2025-05-27","eid":"x:site:nct07193901-hangzhou-seventh-people-s-hospital-hangzhou"},{"id":"nct07193901-hefei-fourth-people-s-hospital-anhui-mental-health-prevention-and-tr","cat":"research","name":"Hefei Fourth People's Hospital(Anhui Mental Health Prevention and Treatment Center)","city":"Hefei","country":"China","cc":"CN","lat":31.85349,"lon":117.27514,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT07193901","study":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior","sstatus":"COMPLETED","sponsor":"Sichuan Purity Pharmaceutical Technology Co., Ltd.","src":"https://clinicaltrials.gov/study/NCT07193901","phase":"Phase 2","enroll":98,"start":"2025-05-27","eid":"x:site:nct07193901-hefei-fourth-people-s-hospital-anhui-mental-health-prevention-and-tr"},{"id":"nct07193901-the-fourth-affiliated-hospital-of-anhui-medical-university-hefei","cat":"research","name":"The fourth affiliated hospital of Anhui medical university","city":"Hefei","country":"China","cc":"CN","lat":31.85848,"lon":117.29076,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT07193901","study":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior","sstatus":"COMPLETED","sponsor":"Sichuan Purity Pharmaceutical Technology Co., Ltd.","src":"https://clinicaltrials.gov/study/NCT07193901","phase":"Phase 2","enroll":98,"start":"2025-05-27","eid":"x:site:nct07193901-the-fourth-affiliated-hospital-of-anhui-medical-university-hefei"},{"id":"nct07193901-the-affiliated-hospital-of-southwest-medical-university-luzhou","cat":"research","name":"The Affiliated Hospital of Southwest Medical University","city":"Luzhou","country":"China","cc":"CN","lat":28.88037,"lon":105.43577,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT07193901","study":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior","sstatus":"COMPLETED","sponsor":"Sichuan Purity Pharmaceutical Technology Co., Ltd.","src":"https://clinicaltrials.gov/study/NCT07193901","phase":"Phase 2","enroll":98,"start":"2025-05-27","eid":"x:site:nct07193901-the-affiliated-hospital-of-southwest-medical-university-luzhou"},{"id":"nct07193901-the-first-affiliated-hospital-of-nanchang-university-nanchang","cat":"research","name":"The First Affiliated Hospital of Nanchang University","city":"Nanchang","country":"China","cc":"CN","lat":28.6906,"lon":115.84407,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT07193901","study":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior","sstatus":"COMPLETED","sponsor":"Sichuan Purity Pharmaceutical Technology Co., Ltd.","src":"https://clinicaltrials.gov/study/NCT07193901","phase":"Phase 2","enroll":98,"start":"2025-05-27","eid":"x:site:nct07193901-the-first-affiliated-hospital-of-nanchang-university-nanchang"},{"id":"nct07193901-the-affiliated-kangning-hospital-of-ningbo-university-ningbo","cat":"research","name":"The affiliated Kangning Hospital of Ningbo University","city":"Ningbo","country":"China","cc":"CN","lat":29.8725,"lon":121.53745,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT07193901","study":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior","sstatus":"COMPLETED","sponsor":"Sichuan Purity Pharmaceutical Technology Co., Ltd.","src":"https://clinicaltrials.gov/study/NCT07193901","phase":"Phase 2","enroll":98,"start":"2025-05-27","eid":"x:site:nct07193901-the-affiliated-kangning-hospital-of-ningbo-university-ningbo"},{"id":"nct07193901-suzhou-guangji-hospital-suzhou","cat":"research","name":"Suzhou Guangji Hospital","city":"Suzhou","country":"China","cc":"CN","lat":31.29584,"lon":120.60653,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT07193901","study":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior","sstatus":"COMPLETED","sponsor":"Sichuan Purity Pharmaceutical Technology Co., Ltd.","src":"https://clinicaltrials.gov/study/NCT07193901","phase":"Phase 2","enroll":98,"start":"2025-05-27","eid":"x:site:nct07193901-suzhou-guangji-hospital-suzhou"},{"id":"nct07193901-wuxi-mental-health-center-wuxi","cat":"research","name":"Wuxi Mental Health Center","city":"Wuxi","country":"China","cc":"CN","lat":31.57381,"lon":120.28749,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT07193901","study":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior","sstatus":"COMPLETED","sponsor":"Sichuan Purity Pharmaceutical Technology Co., Ltd.","src":"https://clinicaltrials.gov/study/NCT07193901","phase":"Phase 2","enroll":98,"start":"2025-05-27","eid":"x:site:nct07193901-wuxi-mental-health-center-wuxi"},{"id":"nct07193901-zhumadian-second-people-s-hospital-zhumadian-psychiatric-hospital-zh","cat":"research","name":"Zhumadian Second People's Hospital(Zhumadian Psychiatric Hospital )","city":"Zhumadian","country":"China","cc":"CN","lat":32.97571,"lon":114.02111,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT07193901","study":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior","sstatus":"COMPLETED","sponsor":"Sichuan Purity Pharmaceutical Technology Co., Ltd.","src":"https://clinicaltrials.gov/study/NCT07193901","phase":"Phase 2","enroll":98,"start":"2025-05-27","eid":"x:site:nct07193901-zhumadian-second-people-s-hospital-zhumadian-psychiatric-hospital-zh"},{"id":"nct03109418-uab-department-of-anesthesiology-and-perioperative-medicine-birmingh","cat":"research","name":"UAB Department of Anesthesiology and Perioperative Medicine","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.52711,"lon":-86.79962,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"35249","condg":["Other"],"nct":"NCT03109418","study":"Intraoperative Low-dose Ketamine Infusion for Patients With Obstructive Sleep Apnea","sstatus":"TERMINATED","sponsor":"University of Alabama at Birmingham","official":"Peter A Nagi, MD (University of Alabama at Birmingham)","src":"https://clinicaltrials.gov/study/NCT03109418","phase":"Phase 2/Phase 3","enroll":9,"start":"2016-06-02","eid":"x:site:nct03109418-uab-department-of-anesthesiology-and-perioperative-medicine-birmingh"},{"id":"nct02368782-istanbul-university-cerrahpasa-medical-faculty-istanbul","cat":"research","name":"Istanbul University Cerrahpasa Medical Faculty","city":"Istanbul","country":"Turkey","cc":"TR","lat":41.0104,"lon":28.96119,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"34303","condg":["Healthy volunteers"],"nct":"NCT02368782","study":"Effects of Ketamine and Propofol in Otoacoustic Emissions (OAE) in Children","sstatus":"COMPLETED","sponsor":"Istanbul University","src":"https://clinicaltrials.gov/study/NCT02368782","enroll":30,"start":"2013-12","eid":"x:site:nct02368782-istanbul-university-cerrahpasa-medical-faculty-istanbul"},{"id":"nct02778880-cincinnati-children-s-hospital-medical-center-cincinnati","cat":"research","name":"Cincinnati Children's Hospital Medical Center","city":"Cincinnati","region":"Ohio","country":"United States","cc":"US","lat":39.12885,"lon":-84.50352,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45229","condg":["PTSD & trauma","Chronic pain & headache"],"nct":"NCT02778880","study":"Pain Reduction With Intranasal Medications for Extremity Injuries","sstatus":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","official":"Theresa M Frey, MD (Children's Hospital Medical Center, Cincinnati); Matthew R Mittiga, MD (Children's Hospital Medical Center, Cincinnati)","src":"https://clinicaltrials.gov/study/NCT02778880","phase":"Phase 3","enroll":90,"start":"2016-03-31","eid":"x:site:nct02778880-cincinnati-children-s-hospital-medical-center-cincinnati"},{"id":"nct05177146-centre-for-addiction-and-mental-health-toronto","cat":"research","name":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70092,"lon":-79.39342,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M5T 1R8","condg":["Bipolar"],"nct":"NCT05177146","study":"Neural Correlates of Ketamine's Anti-suicidal Effects in Bipolar Depression","sstatus":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","official":"Yuliya Knyahnytska, MD, PhD (Centre for Addiction and Mental Health)","src":"https://clinicaltrials.gov/study/NCT05177146","phase":"N/A","enroll":16,"start":"2022-05-04","eid":"x:site:nct05177146-centre-for-addiction-and-mental-health-toronto"},{"id":"nct05297422-national-and-kapodistrian-university-of-athens-athens","cat":"research","name":"National and Kapodistrian University of Athens","city":"Athens","region":"Attica","country":"Greece","cc":"GR","lat":37.98475,"lon":23.72732,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"115 27","condg":["Other"],"status":"RECRUITING","nct":"NCT05297422","study":"Axillary Approach to Brachial Plexus Blockade Using Ketamine, Regional Versus Intravenous Administration","sstatus":"UNKNOWN","sponsor":"National and Kapodistrian University of Athens","official":"Theodoros Xanthos, Professor (National and Kapodistrian University of Athens)","src":"https://clinicaltrials.gov/study/NCT05297422","contact":{"n":"Ioanna Tessi","p":"+302112136842","e":"ioannatessi@yahoo.com"},"phase":"N/A","enroll":81,"start":"2022-01-20","eid":"x:site:nct05297422-national-and-kapodistrian-university-of-athens-athens"},{"id":"nct00205712-washington-university-school-of-medicine-psychiatry-dept-st-louis","cat":"research","name":"Washington University School of Medicine, Psychiatry Dept.","city":"St Louis","region":"Missouri","country":"United States","cc":"US","lat":38.63842,"lon":-90.19408,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"63110","condg":["Addiction & substance use"],"nct":"NCT00205712","study":"Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids","sstatus":"COMPLETED","sponsor":"Washington University School of Medicine","official":"John W. Newcomer, M.D. (Washington University School of Medicine and Florida Atlantic University)","src":"https://clinicaltrials.gov/study/NCT00205712","phase":"Phase 4","enroll":40,"start":"2003-02","eid":"x:site:nct00205712-washington-university-school-of-medicine-psychiatry-dept-st-louis"},{"id":"nct04771767-queen-s-university-kingston","cat":"research","name":"Queen's University","city":"Kingston","region":"Ontario","country":"Canada","cc":"CA","lat":44.24025,"lon":-76.4735,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"K7L 3N6","condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT04771767","study":"Combined Ketamine and eCBT Intervention for PTSD","sstatus":"UNKNOWN","sponsor":"Queen's University","official":"Taras Reshetukha, MD (Queen's University)","src":"https://clinicaltrials.gov/study/NCT04771767","contact":{"n":"Aaron Philipp-Muller, B.Sc.","p":"4169393164","e":"19aepm1@queensu.ca"},"phase":"Phase 2","enroll":16,"start":"2021-08-01","eid":"x:site:nct04771767-queen-s-university-kingston"},{"id":"nct04751175-hospital-dr-josep-trueta-girona","cat":"research","name":"Hospital Dr Josep Trueta","city":"Girona","country":"Spain","cc":"ES","lat":41.99003,"lon":2.83062,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"17007","condg":["Chronic pain & headache"],"nct":"NCT04751175","study":"Management of Pain in Lumbar Arthrodesis","sstatus":"COMPLETED","sponsor":"Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta","official":"Emili Leon, MD (Hospital Dr Josep Trueta and Hospital Santa Caterina)","src":"https://clinicaltrials.gov/study/NCT04751175","phase":"Phase 4","enroll":128,"start":"2013-07-04","eid":"x:site:nct04751175-hospital-dr-josep-trueta-girona"},{"id":"nct02220400-shanghai-tongji-hospital-shanghai","cat":"research","name":"Shanghai Tongji Hospital","city":"Shanghai","region":"Shanghai Municipality","country":"China","cc":"CN","lat":31.22631,"lon":121.44728,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"200065","condg":["Other"],"nct":"NCT02220400","study":"Ketamine Prevent POCD","sstatus":"UNKNOWN","sponsor":"RenJi Hospital","src":"https://clinicaltrials.gov/study/NCT02220400","contact":{"n":"Xiaoqing Zhang, M.S.","e":"xq_820175@163.com"},"phase":"N/A","enroll":484,"start":"2014-09","eid":"x:site:nct02220400-shanghai-tongji-hospital-shanghai"},{"id":"nct02220400-renji-hospital-school-of-medicine-shanghai-jiaotong-university-shang","cat":"research","name":"Renji Hospital, School of Medicine, Shanghai Jiaotong University","city":"Shanghai","region":"Shanghai Municipality","country":"China","cc":"CN","lat":31.2138,"lon":121.46611,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"200127","condg":["Other"],"nct":"NCT02220400","study":"Ketamine Prevent POCD","sstatus":"UNKNOWN","sponsor":"RenJi Hospital","src":"https://clinicaltrials.gov/study/NCT02220400","contact":{"n":"Diansan Su, Dr.","p":"0086-21-68383702","e":"diansansu@yahoo.com"},"phase":"N/A","enroll":484,"start":"2014-09","eid":"x:site:nct02220400-renji-hospital-school-of-medicine-shanghai-jiaotong-university-shang"},{"id":"nct02220400-shanghai-pudong-new-area-people-s-hospital-shanghai","cat":"research","name":"Shanghai Pudong New Area People's Hospital","city":"Shanghai","region":"Shanghai Municipality","country":"China","cc":"CN","lat":31.22321,"lon":121.4678,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT02220400","study":"Ketamine Prevent POCD","sstatus":"UNKNOWN","sponsor":"RenJi Hospital","src":"https://clinicaltrials.gov/study/NCT02220400","contact":{"n":"Lizhi Li, M.S.","e":"Fmlilizhi@sina.com.cn"},"phase":"N/A","enroll":484,"start":"2014-09","eid":"x:site:nct02220400-shanghai-pudong-new-area-people-s-hospital-shanghai"},{"id":"nct05648526-faculty-of-medicine-universitas-sumatera-utara-medan","cat":"research","name":"Faculty of Medicine Universitas Sumatera Utara","city":"Medan","region":"North Sumatra","country":"Indonesia","cc":"ID","lat":3.58545,"lon":98.65853,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20155","condg":["Other"],"nct":"NCT05648526","study":"Neuroprotective Effects of ACTH4-10PRO8-GLY9-PRO10","sstatus":"COMPLETED","sponsor":"Universitas Sumatera Utara","src":"https://clinicaltrials.gov/study/NCT05648526","phase":"N/A","enroll":42,"start":"2021-08-01","eid":"x:site:nct05648526-faculty-of-medicine-universitas-sumatera-utara-medan"},{"id":"nct07072117-faculty-of-medicine-zagazig-university-zagazig","cat":"research","name":"Faculty of Medicine - Zagazig University","city":"Zagazig","country":"Egypt","cc":"EG","lat":30.59667,"lon":31.50092,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT07072117","study":"Intranasal Dexmedetomidine, Ketamine or Midazolam for Anxiety and Respiratory Complications in Children","sstatus":"COMPLETED","sponsor":"Zagazig University","official":"Amira Saeed Kenawy, MD (Faculty of Medicine - Zagazig University)","src":"https://clinicaltrials.gov/study/NCT07072117","phase":"N/A","enroll":148,"start":"2023-02-20","eid":"x:site:nct07072117-faculty-of-medicine-zagazig-university-zagazig"},{"id":"nct02397889-depression-and-anxiety-center-dac-new-york","cat":"research","name":"Depression and Anxiety Center (DAC)","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72081,"lon":-74.01025,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10029","condg":["PTSD & trauma"],"nct":"NCT02397889","study":"Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD)","sstatus":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","official":"Adriana Feder, MD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT02397889","phase":"Phase 2/Phase 3","enroll":30,"start":"2015-05-18","eid":"x:site:nct02397889-depression-and-anxiety-center-dac-new-york"},{"id":"nct02992496-department-of-psychiatry-and-psychotherapy-medical-university-of-vie","cat":"research","name":"Department of Psychiatry and Psychotherapy, Medical University of Vienna","city":"Vienna","country":"Austria","cc":"AT","lat":48.21663,"lon":16.37269,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"1090","condg":["Depression"],"status":"RECRUITING","nct":"NCT02992496","study":"Investigation of Antidepressant Efficacy of Oral Ketamine Treatment","sstatus":"UNKNOWN","sponsor":"Medical University of Vienna","src":"https://clinicaltrials.gov/study/NCT02992496","contact":{"n":"Rupert Lanzenberger, A/Prof.","p":"+43 40400","e":"rupert.lanzenberger@meduniwien.ac.at"},"phase":"Phase 2","enroll":60,"start":"2017-04-24","eid":"x:site:nct02992496-department-of-psychiatry-and-psychotherapy-medical-university-of-vie"},{"id":"nct04234776-nucleo-de-pesquisas-em-saude-mental-blumenau","cat":"research","name":"Núcleo de Pesquisas em Saúde Mental","city":"Blumenau","region":"Santa Catarina","country":"Brazil","cc":"BR","lat":-26.9288,"lon":-49.06606,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"89.020-070","condg":["Depression"],"nct":"NCT04234776","study":"Intramuscular Ketamine Versus Aripiprazole and Escitalopram in the Treatment of Resistant Depression","sstatus":"UNKNOWN","sponsor":"University of Sao Paulo","official":"Ricardo A Moreno, MD, PhD (Department and Institute of Psychiatry, University of Sao Paulo)","src":"https://clinicaltrials.gov/study/NCT04234776","phase":"Phase 4","enroll":88,"start":"2018-04-03","eid":"x:site:nct04234776-nucleo-de-pesquisas-em-saude-mental-blumenau"},{"id":"nct06184958-maha-sadek-el-derh-cairo","cat":"research","name":"maha sadek El Derh","city":"Cairo","country":"Egypt","cc":"EG","lat":30.06738,"lon":31.24426,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11721","condg":["Other"],"status":"RECRUITING","nct":"NCT06184958","study":"Potential Role of Intravenous Lidocaine Versus Intravenous Ketamine for Pain Management in Fibromyalgia Patients","sstatus":"UNKNOWN","sponsor":"Ain Shams University","src":"https://clinicaltrials.gov/study/NCT06184958","contact":{"n":"maha S El Derh, MD","p":"01144866675","e":"mahasadek81@yahoo.com"},"phase":"Phase 4","enroll":75,"start":"2023-09-02","eid":"x:site:nct06184958-maha-sadek-el-derh-cairo"},{"id":"nct06821087-ut-health-austin-austin","cat":"research","name":"UT Health Austin","city":"Austin","region":"Texas","country":"United States","cc":"US","lat":30.27727,"lon":-97.73878,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"78712","condg":["Other"],"nct":"NCT06821087","study":"Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19","sstatus":"COMPLETED","sponsor":"University of Texas at Austin","official":"W. Michael Brode, MD (University of Texas at Austin)","src":"https://clinicaltrials.gov/study/NCT06821087","phase":"Phase 2","enroll":20,"start":"2025-06-05","eid":"x:site:nct06821087-ut-health-austin-austin"},{"id":"nct01947114-bezmialem-vakif-university-faculty-of-medicine-istanbul","cat":"research","name":"Bezmialem Vakif University Faculty of Medicine","city":"Istanbul","country":"Turkey","cc":"TR","lat":41.01379,"lon":28.94142,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"34093","condg":["Other"],"nct":"NCT01947114","study":"Remifentanil Use in Pediatric Rigid Bronchoscopy","sstatus":"COMPLETED","sponsor":"Bezmialem Vakif University","src":"https://clinicaltrials.gov/study/NCT01947114","phase":"Phase 4","enroll":40,"start":"2005-11","eid":"x:site:nct01947114-bezmialem-vakif-university-faculty-of-medicine-istanbul"},{"id":"nct07743333-alexandria-university-faculty-of-medicine-alexandria","cat":"research","name":"Alexandria University Faculty of Medicine","city":"Alexandria","region":"Alexandria Governorate","country":"Egypt","cc":"EG","lat":31.19691,"lon":29.91841,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"21526","condg":["Cancer-related distress"],"nct":"NCT07743333","study":"Nebulized Lidocaine And Ketamine Before Fiberoptic Bronchoscopy","sstatus":"COMPLETED","sponsor":"Alexandria University","src":"https://clinicaltrials.gov/study/NCT07743333","phase":"Phase 4","enroll":134,"start":"2024-09-01","eid":"x:site:nct07743333-alexandria-university-faculty-of-medicine-alexandria"},{"id":"nct05751304-sohag-university-hospital-sohag","cat":"research","name":"Sohag University Hospital","city":"Sohag","country":"Egypt","cc":"EG","lat":26.54617,"lon":31.69022,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT05751304","study":"A Comparative Study Between Intrathecal Dexmedetomidine VS Ketamine With Intrathecal Bupivacaine in Orthopedic Lower Limb Surgeries.","sstatus":"UNKNOWN","sponsor":"Sohag University","src":"https://clinicaltrials.gov/study/NCT05751304","contact":{"n":"Magdy M Amin, Professor","p":"01159596946","e":"zeyadahmed@med.sohag.edu.eg"},"phase":"N/A","enroll":100,"start":"2023-03-01","eid":"x:site:nct05751304-sohag-university-hospital-sohag"},{"id":"nct03001843-university-of-florida-gainesville","cat":"research","name":"University of Florida","city":"Gainesville","region":"Florida","country":"United States","cc":"US","lat":29.64575,"lon":-82.32412,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"32611","condg":["Chronic pain & headache"],"nct":"NCT03001843","study":"Ketamine vs Hydromorphone","sstatus":"COMPLETED","sponsor":"University of Florida","official":"David M Smyth, MSN (Shands Hospital at the University of Florida)","src":"https://clinicaltrials.gov/study/NCT03001843","phase":"Phase 4","enroll":54,"start":"2017-02-22","eid":"x:site:nct03001843-university-of-florida-gainesville"},{"id":"nct05907213-magee-womens-hospital-of-upmc-pittsburgh","cat":"research","name":"Magee Womens Hospital of UPMC","city":"Pittsburgh","region":"Pennsylvania","country":"United States","cc":"US","lat":40.43643,"lon":-79.99528,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"15213","condg":["Depression","Chronic pain & headache"],"nct":"NCT05907213","study":"Ketamine Tolerated Dose for Postpartum Depression and Pain After Cesarean Delivery (PREPARE 1)","sstatus":"COMPLETED","sponsor":"Grace Lim, MD, MS","official":"Grace Lim, MD, MSc (University of Pittsburgh)","src":"https://clinicaltrials.gov/study/NCT05907213","phase":"Phase 1","enroll":12,"start":"2023-09-25","eid":"x:site:nct05907213-magee-womens-hospital-of-upmc-pittsburgh"},{"id":"nct04860713-maimonides-medical-center-brooklyn","cat":"research","name":"Maimonides Medical Center","city":"Brooklyn","region":"New York","country":"United States","cc":"US","lat":40.65561,"lon":-73.95273,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11219","condg":["Chronic pain & headache"],"nct":"NCT04860713","study":"An Efficacy and Safety of Proprietary Formulations of Oral Ketamine + Aspirin in Treatment of Acute Headache","sstatus":"COMPLETED","sponsor":"Antonios Likourezos","official":"Leily Naraghi, MD (Maimonides Medical Center)","src":"https://clinicaltrials.gov/study/NCT04860713","phase":"Phase 4","enroll":5,"start":"2021-04-22","eid":"x:site:nct04860713-maimonides-medical-center-brooklyn"},{"id":"nct05163366-mbarara-regional-referral-hospital-mbarara","cat":"research","name":"Mbarara Regional Referral Hospital","city":"Mbarara","country":"Uganda","cc":"UG","lat":-0.61347,"lon":30.64018,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"00256","condg":["Chronic pain & headache"],"nct":"NCT05163366","study":"Oral Morphine Versus Ketamine in Pain Management","sstatus":"COMPLETED","sponsor":"Mbarara University of Science and Technology","official":"ALICE G. ATAI, MbChB (Mbarara University of Science and Technology)","src":"https://clinicaltrials.gov/study/NCT05163366","phase":"Phase 3","enroll":44,"start":"2021-03-01","eid":"x:site:nct05163366-mbarara-regional-referral-hospital-mbarara"},{"id":"nct05163366-mbarara-regional-referral-hospital-mbarara-2","cat":"research","name":"Mbarara Regional Referral Hospital","city":"Mbarara","country":"Uganda","cc":"UG","lat":-0.60698,"lon":30.65769,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"256","condg":["Chronic pain & headache"],"nct":"NCT05163366","study":"Oral Morphine Versus Ketamine in Pain Management","sstatus":"COMPLETED","sponsor":"Mbarara University of Science and Technology","official":"ALICE G. ATAI, MbChB (Mbarara University of Science and Technology)","src":"https://clinicaltrials.gov/study/NCT05163366","phase":"Phase 3","enroll":44,"start":"2021-03-01","eid":"x:site:nct05163366-mbarara-regional-referral-hospital-mbarara-2"},{"id":"nct03410446-princess-margaret-cancer-centre-toronto","cat":"research","name":"Princess Margaret Cancer Centre","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70299,"lon":-79.38937,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M5G 2M9","condg":["Depression","End-of-life & palliative","Cancer-related distress"],"nct":"NCT03410446","study":"Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care","sstatus":"COMPLETED","sponsor":"University Health Network, Toronto","official":"Madeline Li, M.D. (Princess Margaret Cancer Centre)","src":"https://clinicaltrials.gov/study/NCT03410446","phase":"Phase 2","enroll":22,"start":"2018-07-16","eid":"x:site:nct03410446-princess-margaret-cancer-centre-toronto"},{"id":"nct00300794-vilnius-university-emergency-hospital-vilnius","cat":"research","name":"Vilnius University Emergency Hospital","city":"Vilnius","country":"Lithuania","cc":"LT","lat":54.68874,"lon":25.28728,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT00300794","study":"Effects of Ketamine On Precipitated Opioid Withdrawal Under General Anaesthesia","sstatus":"COMPLETED","sponsor":"Vilnius University","official":"Juozas Ivaskevicius, Prof. (Vilnius University Clinic of Anaesthesiology and Intensive Care); Tomas Jovaisa, MD (Vilnius University Clinic of Anaesthesiology and Intensive Care)","src":"https://clinicaltrials.gov/study/NCT00300794","phase":"Phase 4","enroll":60,"start":"2003-02","eid":"x:site:nct00300794-vilnius-university-emergency-hospital-vilnius"},{"id":"nct05403086-marin-cancer-care-greenbrae","cat":"research","name":"Marin Cancer Care","city":"Greenbrae","region":"California","country":"United States","cc":"US","lat":35.264,"lon":-119.2474,"gp":"region","unnamed":0,"drugs":["ketamine","psilocybin"],"zip":"94904","condg":["Other"],"status":"RECRUITING","nct":"NCT05403086","study":"Pragmatic Trial of Psilocybin Therapy in Palliative Care","sstatus":"RECRUITING","sponsor":"Charles S. Grob, M.D.","official":"Charles S. Grob, M.D. (Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center)","src":"https://clinicaltrials.gov/study/NCT05403086","contact":{"n":"Barbara M. Galligan, M.D.","p":"415-925-5000","e":"pt2pc@marincancercare.com"},"phase":"Phase 2","enroll":100,"start":"2025-01-19","eid":"x:site:nct05403086-marin-cancer-care-greenbrae"},{"id":"nct05403086-university-of-california-los-angeles-los-angeles","cat":"research","name":"University of California, Los Angeles","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.04343,"lon":-118.25097,"gp":"city","unnamed":0,"drugs":["ketamine","psilocybin"],"zip":"90095","condg":["Other"],"status":"RECRUITING","nct":"NCT05403086","study":"Pragmatic Trial of Psilocybin Therapy in Palliative Care","sstatus":"RECRUITING","sponsor":"Charles S. Grob, M.D.","official":"Charles S. Grob, M.D. (Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center)","src":"https://clinicaltrials.gov/study/NCT05403086","contact":{"n":"Ziva M. Cooper, Ph.D.","p":"310-983-3417","e":"ZCooper@mednet.ucla.edu"},"phase":"Phase 2","enroll":100,"start":"2025-01-19","eid":"x:site:nct05403086-university-of-california-los-angeles-los-angeles"},{"id":"nct05403086-university-of-san-francisco-san-francisco","cat":"research","name":"University of San Francisco","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.77065,"lon":-122.41486,"gp":"city","unnamed":0,"drugs":["ketamine","psilocybin"],"zip":"94518","condg":["Other"],"status":"RECRUITING","nct":"NCT05403086","study":"Pragmatic Trial of Psilocybin Therapy in Palliative Care","sstatus":"RECRUITING","sponsor":"Charles S. Grob, M.D.","official":"Charles S. Grob, M.D. (Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center)","src":"https://clinicaltrials.gov/study/NCT05403086","contact":{"n":"Brian T. Anderson, M.D.","p":"510-985-3522","e":"pt2pc@ucsf.edu"},"phase":"Phase 2","enroll":100,"start":"2025-01-19","eid":"x:site:nct05403086-university-of-san-francisco-san-francisco"},{"id":"nct05403086-lundquist-institute-for-biomedical-innovation-at-harbor-ucla-medical","cat":"research","name":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","city":"Torrance","region":"California","country":"United States","cc":"US","lat":33.84427,"lon":-118.3515,"gp":"city","unnamed":0,"drugs":["ketamine","psilocybin"],"zip":"90502","condg":["Other"],"status":"RECRUITING","nct":"NCT05403086","study":"Pragmatic Trial of Psilocybin Therapy in Palliative Care","sstatus":"RECRUITING","sponsor":"Charles S. Grob, M.D.","official":"Charles S. Grob, M.D. (Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center)","src":"https://clinicaltrials.gov/study/NCT05403086","contact":{"n":"Charles S Grob, M.D.","p":"626-522-8615","e":"pt2pc@lundquist.org"},"phase":"Phase 2","enroll":100,"start":"2025-01-19","eid":"x:site:nct05403086-lundquist-institute-for-biomedical-innovation-at-harbor-ucla-medical"},{"id":"nct05403086-sunstone-therapies-rockville","cat":"research","name":"Sunstone Therapies","city":"Rockville","region":"Maryland","country":"United States","cc":"US","lat":39.07558,"lon":-77.14095,"gp":"city","unnamed":0,"drugs":["ketamine","psilocybin"],"zip":"20850","condg":["Other"],"status":"RECRUITING","nct":"NCT05403086","study":"Pragmatic Trial of Psilocybin Therapy in Palliative Care","sstatus":"RECRUITING","sponsor":"Charles S. Grob, M.D.","official":"Charles S. Grob, M.D. (Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center)","src":"https://clinicaltrials.gov/study/NCT05403086","contact":{"n":"Manish Agrawal, M.D.","p":"301-337-7570","e":"manish.agrawal@sunstonetherapies.com"},"phase":"Phase 2","enroll":100,"start":"2025-01-19","eid":"x:site:nct05403086-sunstone-therapies-rockville"},{"id":"nct07728851-sultan-qaboos-university-hospital-muscat","cat":"research","name":"Sultan Qaboos University Hospital","city":"Muscat","country":"Oman","cc":"OM","lat":23.58446,"lon":58.4051,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT07728851","study":"Nebulized Ketamine for Severe Asthma Attacks in Children","sstatus":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","official":"Zahraa Ali Al Lawati (College of Medicine and Health Sciences , Sultan Qaboos University)","src":"https://clinicaltrials.gov/study/NCT07728851","contact":{"n":"Zahraa Ali Al Lawati","p":"+96892347374","e":"zlawati@squ.edu.om"},"phase":"Phase 2","enroll":60,"start":"2027-01-01","eid":"x:site:nct07728851-sultan-qaboos-university-hospital-muscat"},{"id":"nct03852797-mount-sinai-hospital-toronto","cat":"research","name":"Mount Sinai Hospital","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70554,"lon":-79.40838,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M5G1X5","condg":["Other"],"nct":"NCT03852797","study":"Spontaneous and Oxytocin-induced Contractility After Exposure to Intravenous Anesthetic Agents: an In-vitro Study in Human Myometrium","sstatus":"COMPLETED","sponsor":"Samuel Lunenfeld Research Institute, Mount Sinai Hospital","official":"Mrinalini Balki, MD (MOUNT SINAI HOSPITAL)","src":"https://clinicaltrials.gov/study/NCT03852797","phase":"N/A","enroll":33,"start":"2019-03-28","eid":"x:site:nct03852797-mount-sinai-hospital-toronto"},{"id":"nct03771586-sage-investigational-site-long-beach","cat":"research","name":"Sage Investigational Site","city":"Long Beach","region":"California","country":"United States","cc":"US","lat":33.76569,"lon":-118.17864,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"90806","condg":["Healthy volunteers"],"nct":"NCT03771586","study":"A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects","sstatus":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","src":"https://clinicaltrials.gov/study/NCT03771586","phase":"Phase 1","enroll":22,"start":"2018-09-24","eid":"x:site:nct03771586-sage-investigational-site-long-beach"},{"id":"nct03771586-sage-investigational-site-berlin","cat":"research","name":"Sage Investigational Site","city":"Berlin","region":"New Jersey","country":"United States","cc":"US","lat":44.47107,"lon":-71.17308,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"08009","condg":["Healthy volunteers"],"nct":"NCT03771586","study":"A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects","sstatus":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","src":"https://clinicaltrials.gov/study/NCT03771586","phase":"Phase 1","enroll":22,"start":"2018-09-24","eid":"x:site:nct03771586-sage-investigational-site-berlin"},{"id":"nct00690170-veterans-administration-hospital-west-haven","cat":"research","name":"Veterans Administration Hospital","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.26383,"lon":-72.9358,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06516","condg":["Healthy volunteers"],"nct":"NCT00690170","study":"Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects","sstatus":"COMPLETED","sponsor":"Yale University","official":"Deepak C D'Souza, M.D. (Yale University)","src":"https://clinicaltrials.gov/study/NCT00690170","phase":"Phase 1","enroll":30,"start":"2002-12","eid":"x:site:nct00690170-veterans-administration-hospital-west-haven"},{"id":"nct04560660-minneapolis-va-health-care-system-minneapolis-mn-minneapolis","cat":"research","name":"Minneapolis VA Health Care System, Minneapolis, MN","city":"Minneapolis","region":"Minnesota","country":"United States","cc":"US","lat":44.98341,"lon":-93.26699,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55417-2309","condg":["PTSD & trauma"],"nct":"NCT04560660","study":"Ketamine-enhanced Prolonged Exposure Therapy in PTSD","sstatus":"COMPLETED","sponsor":"VA Office of Research and Development","official":"Paulo R Shiroma, MD (Minneapolis VA Health Care System, Minneapolis, MN)","src":"https://clinicaltrials.gov/study/NCT04560660","phase":"Phase 2","enroll":73,"start":"2021-03-09","eid":"x:site:nct04560660-minneapolis-va-health-care-system-minneapolis-mn-minneapolis"},{"id":"nct03770780-sage-investigational-site-long-beach","cat":"research","name":"Sage Investigational Site","city":"Long Beach","region":"California","country":"United States","cc":"US","lat":33.77821,"lon":-118.17902,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"90806","condg":["Healthy volunteers"],"nct":"NCT03770780","study":"A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy…","sstatus":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","src":"https://clinicaltrials.gov/study/NCT03770780","phase":"Phase 1","enroll":19,"start":"2018-11-12","eid":"x:site:nct03770780-sage-investigational-site-long-beach"},{"id":"nct03770780-sage-investigational-site-berlin","cat":"research","name":"Sage Investigational Site","city":"Berlin","region":"New Jersey","country":"United States","cc":"US","lat":44.47512,"lon":-71.17449,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"08009","condg":["Healthy volunteers"],"nct":"NCT03770780","study":"A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy…","sstatus":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","src":"https://clinicaltrials.gov/study/NCT03770780","phase":"Phase 1","enroll":19,"start":"2018-11-12","eid":"x:site:nct03770780-sage-investigational-site-berlin"},{"id":"nct00749203-icahn-school-of-medicine-at-mount-sinai-new-york","cat":"research","name":"Icahn School of Medicine at Mount Sinai","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72382,"lon":-74.00413,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10029","condg":["Depression","Anxiety","PTSD & trauma"],"nct":"NCT00749203","study":"Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)","sstatus":"COMPLETED","sponsor":"Dennis Charney","official":"Dennis Charney, MD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT00749203","phase":"Phase 2","enroll":41,"start":"2009-01","eid":"x:site:nct00749203-icahn-school-of-medicine-at-mount-sinai-new-york"},{"id":"nct00822419-tel-aviv-sourasky-medical-center-tel-aviv","cat":"research","name":"Tel Aviv Sourasky Medical center","city":"Tel Aviv","country":"Israel","cc":"IL","lat":32.08526,"lon":34.7873,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"64239","condg":["Other"],"nct":"NCT00822419","study":"Percutaneous Ketamine Versus Lidocaine for Mid-Sternotomy","sstatus":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","src":"https://clinicaltrials.gov/study/NCT00822419","contact":{"n":"Avi A Weinbroum, MD","p":"972-3-697-3237","e":"draviw@tasmc.health.gov.il"},"phase":"Phase 4","enroll":75,"start":"2009-02","eid":"x:site:nct00822419-tel-aviv-sourasky-medical-center-tel-aviv"},{"id":"nct00548964-icahn-school-of-medicine-at-mount-sinai-new-york","cat":"research","name":"Icahn School of Medicine at Mount Sinai","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71507,"lon":-74.00056,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10029","condg":["Depression"],"nct":"NCT00548964","study":"Continuation Ketamine in Major Depression","sstatus":"COMPLETED","sponsor":"James Murrough","official":"James W Murrough, MD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT00548964","phase":"Phase 1","enroll":36,"start":"2007-10","eid":"x:site:nct00548964-icahn-school-of-medicine-at-mount-sinai-new-york"},{"id":"nct05874245-menoufia-university-hospitails-shibin-al-kawm","cat":"research","name":"Menoufia university hospitails","city":"Shibīn al Kawm","region":"Menoufia","country":"Egypt","cc":"EG","lat":30.54378,"lon":31.01078,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"32111","condg":["Other"],"status":"RECRUITING","nct":"NCT05874245","study":"Effect of Oral Dexmedetomidine, Ketamine, Or Midazolam as Preioperative Medications.","sstatus":"UNKNOWN","sponsor":"Menoufia University","src":"https://clinicaltrials.gov/study/NCT05874245","contact":{"n":"Ahmed Abosayar","p":"+201064070141","e":"Aabosayar@gmail.com"},"phase":"Phase 4","enroll":222,"start":"2023-03-01","eid":"x:site:nct05874245-menoufia-university-hospitails-shibin-al-kawm"},{"id":"nct03753737-csapa-service-hepato-gastroenterologie-lyon","cat":"research","name":"CSAPA - Service Hépato-gastroentérologie","city":"Lyon","country":"France","cc":"FR","lat":45.73819,"lon":4.84483,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"69004","condg":["Addiction & substance use"],"nct":"NCT03753737","study":"Personality Disorders and Substance Use Disorders in a Sexual Context in the Man Having Sex With Other Men Population","sstatus":"COMPLETED","sponsor":"Hospices Civils de Lyon","src":"https://clinicaltrials.gov/study/NCT03753737","enroll":94,"start":"2018-11-22","eid":"x:site:nct03753737-csapa-service-hepato-gastroenterologie-lyon"},{"id":"nct02587130-ghicl-lomme","cat":"research","name":"GHICL","city":"Lomme","country":"France","cc":"FR","lat":50.63751,"lon":2.98626,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"59462","condg":["Chronic pain & headache"],"nct":"NCT02587130","study":"Ketamine and Refractory Painful Care in a Palliative Unit","sstatus":"TERMINATED","sponsor":"Lille Catholic University","official":"Marie Danel Delerue, MD (Groupment des Hôpitaux de l'Institut Catholique de Lille)","src":"https://clinicaltrials.gov/study/NCT02587130","phase":"Phase 4","enroll":8,"start":"2016-05","eid":"x:site:nct02587130-ghicl-lomme"},{"id":"nct00720330-cleveland-clinic-hillcrest-hospital-mayfield-heights","cat":"research","name":"Cleveland Clinic/Hillcrest Hospital","city":"Mayfield Heights","region":"Ohio","country":"United States","cc":"US","lat":41.51023,"lon":-81.46915,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44124","condg":["Chronic pain & headache"],"nct":"NCT00720330","study":"Lidocaine and Ketamine Versus Standard Care on Acute and Chronic Pain","sstatus":"TERMINATED","sponsor":"The Cleveland Clinic","official":"Kenneth Cummings, MD (The Cleveland Clinic); Daniel I Sessler, MD (The Cleveland Clinic)","src":"https://clinicaltrials.gov/study/NCT00720330","phase":"N/A","enroll":12,"start":"2008-07","eid":"x:site:nct00720330-cleveland-clinic-hillcrest-hospital-mayfield-heights"},{"id":"nct01524237-for-additional-information-regarding-investigative-sites-for-this-tr","cat":"research","name":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"London","region":"Greater London","country":"United Kingdom","cc":"GB","lat":51.49832,"lon":-0.1367,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"SE5 8AF","condg":["Healthy volunteers"],"nct":"NCT01524237","study":"A Study of LY2979165 and LY2140023 in Healthy Volunteers","sstatus":"COMPLETED","sponsor":"Eli Lilly and Company","official":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) (Eli Lilly and Company)","src":"https://clinicaltrials.gov/study/NCT01524237","phase":"Phase 1","enroll":52,"start":"2012-04","eid":"x:site:nct01524237-for-additional-information-regarding-investigative-sites-for-this-tr"},{"id":"nct01524237-for-additional-information-regarding-investigative-sites-for-this-tr-2","cat":"research","name":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"London","region":"UK","country":"United Kingdom","cc":"GB","lat":51.50989,"lon":-0.13303,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"SE 1 1YR","condg":["Healthy volunteers"],"nct":"NCT01524237","study":"A Study of LY2979165 and LY2140023 in Healthy Volunteers","sstatus":"COMPLETED","sponsor":"Eli Lilly and Company","official":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) (Eli Lilly and Company)","src":"https://clinicaltrials.gov/study/NCT01524237","phase":"Phase 1","enroll":52,"start":"2012-04","eid":"x:site:nct01524237-for-additional-information-regarding-investigative-sites-for-this-tr-2"},{"id":"nct04070521-massachusetts-general-hospital-boston","cat":"research","name":"Massachusetts General Hospital","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36723,"lon":-71.06095,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02114","condg":["Addiction & substance use"],"nct":"NCT04070521","study":"EEG Monitoring in the Emergency Department","sstatus":"UNKNOWN","sponsor":"Massachusetts General Hospital","official":"Patrick L Purdon, Ph.D. (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT04070521","enroll":10,"start":"2019-09-06","eid":"x:site:nct04070521-massachusetts-general-hospital-boston"},{"id":"nct04912115-investigative-site-7-tucson","cat":"research","name":"Investigative Site #7","city":"Tucson","region":"Arizona","country":"United States","cc":"US","lat":32.22593,"lon":-110.91909,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"85719","condg":["Other"],"nct":"NCT04912115","study":"Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia","sstatus":"SUSPENDED","sponsor":"PharmaTher Inc.","official":"Study Director (PharmaTher Inc.)","src":"https://clinicaltrials.gov/study/NCT04912115","phase":"Phase 2","enroll":30,"start":"2021-10-05","eid":"x:site:nct04912115-investigative-site-7-tucson"},{"id":"nct04912115-investigative-site-2-chula-vista","cat":"research","name":"Investigative Site #2","city":"Chula Vista","region":"California","country":"United States","cc":"US","lat":32.64518,"lon":-117.07587,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"91910","condg":["Other"],"nct":"NCT04912115","study":"Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia","sstatus":"SUSPENDED","sponsor":"PharmaTher Inc.","official":"Study Director (PharmaTher Inc.)","src":"https://clinicaltrials.gov/study/NCT04912115","phase":"Phase 2","enroll":30,"start":"2021-10-05","eid":"x:site:nct04912115-investigative-site-2-chula-vista"},{"id":"nct04912115-investigative-site-1-fountain-valley","cat":"research","name":"Investigative Site #1","city":"Fountain Valley","region":"California","country":"United States","cc":"US","lat":33.69718,"lon":-117.95645,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"92708","condg":["Other"],"nct":"NCT04912115","study":"Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia","sstatus":"SUSPENDED","sponsor":"PharmaTher Inc.","official":"Study Director (PharmaTher Inc.)","src":"https://clinicaltrials.gov/study/NCT04912115","phase":"Phase 2","enroll":30,"start":"2021-10-05","eid":"x:site:nct04912115-investigative-site-1-fountain-valley"},{"id":"nct04912115-investigative-site-3-miami","cat":"research","name":"Investigative Site #3","city":"Miami","region":"Florida","country":"United States","cc":"US","lat":25.7634,"lon":-80.197,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"33032","condg":["Other"],"nct":"NCT04912115","study":"Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia","sstatus":"SUSPENDED","sponsor":"PharmaTher Inc.","official":"Study Director (PharmaTher Inc.)","src":"https://clinicaltrials.gov/study/NCT04912115","phase":"Phase 2","enroll":30,"start":"2021-10-05","eid":"x:site:nct04912115-investigative-site-3-miami"},{"id":"nct04912115-investigative-site-6-miami","cat":"research","name":"Investigative Site #6","city":"Miami","region":"Florida","country":"United States","cc":"US","lat":25.76519,"lon":-80.19982,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"33175","condg":["Other"],"nct":"NCT04912115","study":"Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia","sstatus":"SUSPENDED","sponsor":"PharmaTher Inc.","official":"Study Director (PharmaTher Inc.)","src":"https://clinicaltrials.gov/study/NCT04912115","phase":"Phase 2","enroll":30,"start":"2021-10-05","eid":"x:site:nct04912115-investigative-site-6-miami"},{"id":"nct04912115-investigative-site-5-rolling-meadows","cat":"research","name":"Investigative Site #5","city":"Rolling Meadows","region":"Illinois","country":"United States","cc":"US","lat":42.08038,"lon":-88.01017,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60008","condg":["Other"],"nct":"NCT04912115","study":"Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia","sstatus":"SUSPENDED","sponsor":"PharmaTher Inc.","official":"Study Director (PharmaTher Inc.)","src":"https://clinicaltrials.gov/study/NCT04912115","phase":"Phase 2","enroll":30,"start":"2021-10-05","eid":"x:site:nct04912115-investigative-site-5-rolling-meadows"},{"id":"nct04912115-investigative-site-4-plymouth","cat":"research","name":"Investigative Site #4","city":"Plymouth","region":"Michigan","country":"United States","cc":"US","lat":45.01499,"lon":-93.45057,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"48170","condg":["Other"],"nct":"NCT04912115","study":"Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia","sstatus":"SUSPENDED","sponsor":"PharmaTher Inc.","official":"Study Director (PharmaTher Inc.)","src":"https://clinicaltrials.gov/study/NCT04912115","phase":"Phase 2","enroll":30,"start":"2021-10-05","eid":"x:site:nct04912115-investigative-site-4-plymouth"},{"id":"nct06549426-hopital-universitaire-de-bruxelles-brussels","cat":"research","name":"Hôpital Universitaire de Bruxelles","city":"Brussels","country":"Belgium","cc":"BE","lat":50.84014,"lon":4.35382,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06549426","study":"Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)","sstatus":"RECRUITING","sponsor":"University of Twente","official":"Jeannette Hofmeijer, MD (University of Twente)","src":"https://clinicaltrials.gov/study/NCT06549426","contact":{"n":"F. Taccone","p":"+31 53 489 4835","e":"j.hofmeijer@utwente.nl"},"phase":"N/A","enroll":150,"start":"2025-04-10","eid":"x:site:nct06549426-hopital-universitaire-de-bruxelles-brussels"},{"id":"nct06549426-universitair-ziekenhuis-brussel-brussels","cat":"research","name":"Universitair Ziekenhuis Brussel","city":"Brussels","country":"Belgium","cc":"BE","lat":50.83901,"lon":4.36012,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06549426","study":"Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)","sstatus":"RECRUITING","sponsor":"University of Twente","official":"Jeannette Hofmeijer, MD (University of Twente)","src":"https://clinicaltrials.gov/study/NCT06549426","contact":{"n":"R. van Lancker","p":"+31 53 489 4835","e":"j.hofmeijer@utwente.nl"},"phase":"N/A","enroll":150,"start":"2025-04-10","eid":"x:site:nct06549426-universitair-ziekenhuis-brussel-brussels"},{"id":"nct06549426-centre-hospitalier-universitaire-marie-curie-charleroi","cat":"research","name":"Centre Hospitalier Universitaire Marie Curie","city":"Charleroi","country":"Belgium","cc":"BE","lat":50.40708,"lon":4.4546,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06549426","study":"Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)","sstatus":"RECRUITING","sponsor":"University of Twente","official":"Jeannette Hofmeijer, MD (University of Twente)","src":"https://clinicaltrials.gov/study/NCT06549426","contact":{"n":"M. Piagnerelli","p":"+31 53 489 4835","e":"j.hofmeijer@utwente.nl"},"phase":"N/A","enroll":150,"start":"2025-04-10","eid":"x:site:nct06549426-centre-hospitalier-universitaire-marie-curie-charleroi"},{"id":"nct06549426-centre-hospitalier-chretien-montlegia-liege","cat":"research","name":"Centre Hospitalier Chrétien - MontLégia","city":"Liège","country":"Belgium","cc":"BE","lat":50.6446,"lon":5.55907,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06549426","study":"Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)","sstatus":"RECRUITING","sponsor":"University of Twente","official":"Jeannette Hofmeijer, MD (University of Twente)","src":"https://clinicaltrials.gov/study/NCT06549426","contact":{"n":"B. Marx","p":"+31 53 489 4835","e":"j.hofmeijer@utwente.nl"},"phase":"N/A","enroll":150,"start":"2025-04-10","eid":"x:site:nct06549426-centre-hospitalier-chretien-montlegia-liege"},{"id":"nct06549426-centre-hospitalier-universitaire-sart-tilmant-liege","cat":"research","name":"Centre Hospitalier Universitaire Sart-Tilmant","city":"Liège","country":"Belgium","cc":"BE","lat":50.64328,"lon":5.57469,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06549426","study":"Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)","sstatus":"RECRUITING","sponsor":"University of Twente","official":"Jeannette Hofmeijer, MD (University of Twente)","src":"https://clinicaltrials.gov/study/NCT06549426","contact":{"n":"O. Bodart","p":"+31 53 489 4835","e":"j.hofmeijer@utwente.nl"},"phase":"N/A","enroll":150,"start":"2025-04-10","eid":"x:site:nct06549426-centre-hospitalier-universitaire-sart-tilmant-liege"},{"id":"nct06549426-centre-hospitalier-universitaire-tivoli-louviere","cat":"research","name":"Centre Hospitalier Universitaire Tivoli","city":"Louvière","country":"Belgium","cc":"BE","lat":50.9191,"lon":4.6135,"gp":"country","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06549426","study":"Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)","sstatus":"RECRUITING","sponsor":"University of Twente","official":"Jeannette Hofmeijer, MD (University of Twente)","src":"https://clinicaltrials.gov/study/NCT06549426","contact":{"n":"Y. Bouckaert","p":"+31 53 489 4835","e":"j.hofmeijer@utwente.nl"},"phase":"N/A","enroll":150,"start":"2025-04-10","eid":"x:site:nct06549426-centre-hospitalier-universitaire-tivoli-louviere"},{"id":"nct06549426-centre-hospitalier-universitaire-saint-pierre-ottignies","cat":"research","name":"Centre Hospitalier Universitaire Saint-Pierre","city":"Ottignies","country":"Belgium","cc":"BE","lat":50.65664,"lon":4.56938,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06549426","study":"Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)","sstatus":"RECRUITING","sponsor":"University of Twente","official":"Jeannette Hofmeijer, MD (University of Twente)","src":"https://clinicaltrials.gov/study/NCT06549426","contact":{"n":"M. Vinetti","p":"+31 53 489 4835","e":"j.hofmeijer@utwente.nl"},"phase":"N/A","enroll":150,"start":"2025-04-10","eid":"x:site:nct06549426-centre-hospitalier-universitaire-saint-pierre-ottignies"},{"id":"nct06549426-amsterdam-university-medical-center-amsterdam","cat":"research","name":"Amsterdam University Medical Center","city":"Amsterdam","country":"Netherlands","cc":"NL","lat":52.38603,"lon":4.88842,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06549426","study":"Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)","sstatus":"RECRUITING","sponsor":"University of Twente","official":"Jeannette Hofmeijer, MD (University of Twente)","src":"https://clinicaltrials.gov/study/NCT06549426","contact":{"n":"J. Horn","p":"+31 53 489 4835","e":"j.hofmeijer@utwente.nl"},"phase":"N/A","enroll":150,"start":"2025-04-10","eid":"x:site:nct06549426-amsterdam-university-medical-center-amsterdam"},{"id":"nct06549426-rijnstate-hospital-arnhem","cat":"research","name":"Rijnstate Hospital","city":"Arnhem","country":"Netherlands","cc":"NL","lat":51.97205,"lon":5.91737,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06549426","study":"Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)","sstatus":"RECRUITING","sponsor":"University of Twente","official":"Jeannette Hofmeijer, MD (University of Twente)","src":"https://clinicaltrials.gov/study/NCT06549426","contact":{"n":"J. Hofmeijer","p":"+31 53 489 4835","e":"j.hofmeijer@utwente.nl"},"phase":"N/A","enroll":150,"start":"2025-04-10","eid":"x:site:nct06549426-rijnstate-hospital-arnhem"},{"id":"nct06549426-amphia-ziekenhuis-breda","cat":"research","name":"Amphia Ziekenhuis","city":"Breda","country":"Netherlands","cc":"NL","lat":51.57531,"lon":4.7729,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06549426","study":"Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)","sstatus":"RECRUITING","sponsor":"University of Twente","official":"Jeannette Hofmeijer, MD (University of Twente)","src":"https://clinicaltrials.gov/study/NCT06549426","contact":{"n":"T. Rettig","p":"+31 53 489 4835","e":"j.hofmeijer@utwente.nl"},"phase":"N/A","enroll":150,"start":"2025-04-10","eid":"x:site:nct06549426-amphia-ziekenhuis-breda"},{"id":"nct06549426-catharina-hospital-eindhoven","cat":"research","name":"Catharina Hospital","city":"Eindhoven","country":"Netherlands","cc":"NL","lat":51.43429,"lon":5.47594,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06549426","study":"Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)","sstatus":"RECRUITING","sponsor":"University of Twente","official":"Jeannette Hofmeijer, MD (University of Twente)","src":"https://clinicaltrials.gov/study/NCT06549426","contact":{"n":"M. Van Eijck","p":"+31 53 489 4835","e":"j.hofmeijer@utwente.nl"},"phase":"N/A","enroll":150,"start":"2025-04-10","eid":"x:site:nct06549426-catharina-hospital-eindhoven"},{"id":"nct06549426-medical-spectrum-twente-enschede","cat":"research","name":"Medical Spectrum Twente","city":"Enschede","country":"Netherlands","cc":"NL","lat":52.20812,"lon":6.88599,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06549426","study":"Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)","sstatus":"RECRUITING","sponsor":"University of Twente","official":"Jeannette Hofmeijer, MD (University of Twente)","src":"https://clinicaltrials.gov/study/NCT06549426","contact":{"n":"M. C. Tjepkema-Cloostermans","p":"+31 53 489 4835","e":"j.hofmeijer@utwente.nl"},"phase":"N/A","enroll":150,"start":"2025-04-10","eid":"x:site:nct06549426-medical-spectrum-twente-enschede"},{"id":"nct06549426-university-medical-center-groningen-groningen","cat":"research","name":"University Medical Center Groningen","city":"Groningen","country":"Netherlands","cc":"NL","lat":53.22703,"lon":6.57745,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06549426","study":"Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)","sstatus":"RECRUITING","sponsor":"University of Twente","official":"Jeannette Hofmeijer, MD (University of Twente)","src":"https://clinicaltrials.gov/study/NCT06549426","contact":{"n":"G. Drost","p":"+31 53 489 4835","e":"j.hofmeijer@utwente.nl"},"phase":"N/A","enroll":150,"start":"2025-04-10","eid":"x:site:nct06549426-university-medical-center-groningen-groningen"},{"id":"nct06549426-leiden-university-medical-center-leiden","cat":"research","name":"Leiden University Medical Center","city":"Leiden","country":"Netherlands","cc":"NL","lat":52.1628,"lon":4.48511,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06549426","study":"Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)","sstatus":"RECRUITING","sponsor":"University of Twente","official":"Jeannette Hofmeijer, MD (University of Twente)","src":"https://clinicaltrials.gov/study/NCT06549426","contact":{"n":"S. Tromp","p":"+31 53 489 4835","e":"j.hofmeijer@utwente.nl"},"phase":"N/A","enroll":150,"start":"2025-04-10","eid":"x:site:nct06549426-leiden-university-medical-center-leiden"},{"id":"nct06549426-st-antonius-hospital-nieuwegein","cat":"research","name":"St. Antonius Hospital","city":"Nieuwegein","country":"Netherlands","cc":"NL","lat":52.03035,"lon":5.0712,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06549426","study":"Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)","sstatus":"RECRUITING","sponsor":"University of Twente","official":"Jeannette Hofmeijer, MD (University of Twente)","src":"https://clinicaltrials.gov/study/NCT06549426","contact":{"n":"E. Scholten","p":"+31 53 489 4835","e":"j.hofmeijer@utwente.nl"},"phase":"N/A","enroll":150,"start":"2025-04-10","eid":"x:site:nct06549426-st-antonius-hospital-nieuwegein"},{"id":"nct06549426-canisius-wilhelmina-hospital-nijmegen","cat":"research","name":"Canisius Wilhelmina Hospital","city":"Nijmegen","country":"Netherlands","cc":"NL","lat":51.83737,"lon":5.84389,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"status":"ACTIVE_NOT_RECRUITING","nct":"NCT06549426","study":"Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)","sstatus":"RECRUITING","sponsor":"University of Twente","official":"Jeannette Hofmeijer, MD (University of Twente)","src":"https://clinicaltrials.gov/study/NCT06549426","contact":{"n":"Jeannette Hofmeijer, MD","p":"+31 53 489 4835","e":"j.hofmeijer@utwente.nl"},"phase":"N/A","enroll":150,"start":"2025-04-10","eid":"x:site:nct06549426-canisius-wilhelmina-hospital-nijmegen"},{"id":"nct06549426-radboud-university-medical-center-nijmegen","cat":"research","name":"Radboud University Medical Center","city":"Nijmegen","country":"Netherlands","cc":"NL","lat":51.84405,"lon":5.85217,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06549426","study":"Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)","sstatus":"RECRUITING","sponsor":"University of Twente","official":"Jeannette Hofmeijer, MD (University of Twente)","src":"https://clinicaltrials.gov/study/NCT06549426","contact":{"n":"C.W. E. Hoedemaekers","p":"+31 53 489 4835","e":"j.hofmeijer@utwente.nl"},"phase":"N/A","enroll":150,"start":"2025-04-10","eid":"x:site:nct06549426-radboud-university-medical-center-nijmegen"},{"id":"nct06549426-erasmus-university-medical-center-rotterdam","cat":"research","name":"Erasmus University Medical Center","city":"Rotterdam","country":"Netherlands","cc":"NL","lat":51.91954,"lon":4.47931,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06549426","study":"Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)","sstatus":"RECRUITING","sponsor":"University of Twente","official":"Jeannette Hofmeijer, MD (University of Twente)","src":"https://clinicaltrials.gov/study/NCT06549426","contact":{"n":"M. Van der Jagt","p":"+31 53 489 4835","e":"j.hofmeijer@utwente.nl"},"phase":"N/A","enroll":150,"start":"2025-04-10","eid":"x:site:nct06549426-erasmus-university-medical-center-rotterdam"},{"id":"nct06549426-maasstad-hospital-rotterdam","cat":"research","name":"Maasstad Hospital","city":"Rotterdam","country":"Netherlands","cc":"NL","lat":51.93121,"lon":4.48524,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06549426","study":"Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)","sstatus":"RECRUITING","sponsor":"University of Twente","official":"Jeannette Hofmeijer, MD (University of Twente)","src":"https://clinicaltrials.gov/study/NCT06549426","contact":{"n":"W. Moudrous","p":"+31 53 489 4835","e":"j.hofmeijer@utwente.nl"},"phase":"N/A","enroll":150,"start":"2025-04-10","eid":"x:site:nct06549426-maasstad-hospital-rotterdam"},{"id":"nct06549426-haga-ziekenhuis-the-hague","cat":"research","name":"Haga Ziekenhuis","city":"The Hague","country":"Netherlands","cc":"NL","lat":52.06749,"lon":4.3044,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"status":"NOT_YET_RECRUITING","nct":"NCT06549426","study":"Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)","sstatus":"RECRUITING","sponsor":"University of Twente","official":"Jeannette Hofmeijer, MD (University of Twente)","src":"https://clinicaltrials.gov/study/NCT06549426","contact":{"n":"S. Arends","p":"+31 53 489 4835","e":"j.hofmeijer@utwente.nl"},"phase":"N/A","enroll":150,"start":"2025-04-10","eid":"x:site:nct06549426-haga-ziekenhuis-the-hague"},{"id":"nct06549426-viecuri-medical-center-venlo","cat":"research","name":"VieCuri Medical Center","city":"Venlo","country":"Netherlands","cc":"NL","lat":51.37946,"lon":6.16688,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06549426","study":"Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation-2 (TELSTAR-2)","sstatus":"RECRUITING","sponsor":"University of Twente","official":"Jeannette Hofmeijer, MD (University of Twente)","src":"https://clinicaltrials.gov/study/NCT06549426","contact":{"n":"A. Bos","p":"+31 53 489 4835","e":"j.hofmeijer@utwente.nl"},"phase":"N/A","enroll":150,"start":"2025-04-10","eid":"x:site:nct06549426-viecuri-medical-center-venlo"},{"id":"nct01945047-institute-of-mental-health-research-royal-ottawa-hospital-ottawa","cat":"research","name":"Institute of Mental Health Research, Royal Ottawa Hospital","city":"Ottawa","region":"Ontario","country":"Canada","cc":"CA","lat":45.41555,"lon":-75.70918,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"K1Z 7K4","condg":["Depression"],"nct":"NCT01945047","study":"Action of Ketamine in Treatment-Resistant Depression","sstatus":"COMPLETED","sponsor":"University of Ottawa","official":"Pierre Blier, M.D, Ph.D (University of Ottawa)","src":"https://clinicaltrials.gov/study/NCT01945047","phase":"Phase 2/Phase 3","enroll":46,"start":"2013-05","eid":"x:site:nct01945047-institute-of-mental-health-research-royal-ottawa-hospital-ottawa"},{"id":"nct02373449-toronto-western-hospital-toronto","cat":"research","name":"Toronto Western Hospital","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70347,"lon":-79.40528,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M5T2S8","condg":["Chronic pain & headache"],"nct":"NCT02373449","study":"Ketamine and fMRI for Neuropathic Pain","sstatus":"COMPLETED","sponsor":"University Health Network, Toronto","official":"Anuj Bhatia (UHN)","src":"https://clinicaltrials.gov/study/NCT02373449","phase":"N/A","enroll":39,"start":"2015-02","eid":"x:site:nct02373449-toronto-western-hospital-toronto"},{"id":"nct02356965-jean-brown-research-salt-lake-city","cat":"research","name":"Jean Brown Research","city":"Salt Lake City","region":"Utah","country":"United States","cc":"US","lat":40.76214,"lon":-111.88291,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"84124","condg":["Chronic pain & headache"],"nct":"NCT02356965","study":"Study Testing Ketamine Sublingual Wafer After Wisdom Tooth Extraction","sstatus":"COMPLETED","sponsor":"iX Biopharma Ltd.","official":"Derek D Muse, MD (Jean Brown Research)","src":"https://clinicaltrials.gov/study/NCT02356965","phase":"Phase 2","enroll":80,"start":"2014-12","eid":"x:site:nct02356965-jean-brown-research-salt-lake-city"},{"id":"nct02033434-whistler-blackcomb-whistler","cat":"research","name":"Whistler Blackcomb","city":"Whistler","region":"British Columbia","country":"Canada","cc":"CA","lat":50.12471,"lon":-122.94347,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"V0N 1B4","condg":["PTSD & trauma","Chronic pain & headache"],"nct":"NCT02033434","study":"Pre-hospital Care With Intra-Nasal Ketamine for Transport (PRECINKT): A Pilot Study","sstatus":"COMPLETED","sponsor":"University of Calgary","official":"Gary Andolfatto, MD (University of British Columbia)","src":"https://clinicaltrials.gov/study/NCT02033434","phase":"Phase 1","enroll":30,"start":"2014-03-01","eid":"x:site:nct02033434-whistler-blackcomb-whistler"},{"id":"nct02388321-maimonides-medical-center-brooklyn","cat":"research","name":"Maimonides Medical Center","city":"Brooklyn","region":"New York","country":"United States","cc":"US","lat":40.64883,"lon":-73.94407,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11219","condg":["Chronic pain & headache"],"nct":"NCT02388321","study":"Pediatric Ketamine Study for Pain Management","sstatus":"TERMINATED","sponsor":"Antonios Likourezos","official":"Sabina Zavolkovskaya, MD (Maimonides Medical Center); Sergey Motov, MD (Maimonides Medical Center)","src":"https://clinicaltrials.gov/study/NCT02388321","phase":"Phase 4","enroll":22,"start":"2015-05-01","eid":"x:site:nct02388321-maimonides-medical-center-brooklyn"},{"id":"nct00985933-research-site-new-haven","cat":"research","name":"Research Site","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.29831,"lon":-72.92077,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Healthy volunteers"],"nct":"NCT00985933","study":"The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers","sstatus":"COMPLETED","sponsor":"AstraZeneca","official":"John Krystal (Chair, Department of PsychiatryYale University School of MedicineChief of Psychiatry, Yale-New Haven Hospital)","src":"https://clinicaltrials.gov/study/NCT00985933","phase":"EARLY_Phase 1","enroll":20,"start":"2010-02","eid":"x:site:nct00985933-research-site-new-haven"},{"id":"nct05315271-sohag-university-sohag","cat":"research","name":"Sohag University","city":"Sohag","country":"Egypt","cc":"EG","lat":26.54928,"lon":31.69069,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT05315271","study":"Supraclavicular Brachial Plexus Block During Upper Limb Surgeries","sstatus":"COMPLETED","sponsor":"Sohag University","src":"https://clinicaltrials.gov/study/NCT05315271","phase":"EARLY_Phase 1","enroll":60,"start":"2022-06-01","eid":"x:site:nct05315271-sohag-university-sohag"},{"id":"nct02610712-national-institute-of-neurology-and-neurosurgery-mexico-city","cat":"research","name":"National Institute of Neurology and Neurosurgery","city":"Mexico City","region":"Mexico City","country":"Mexico","cc":"MX","lat":19.43285,"lon":-99.12808,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"14269","condg":["Depression"],"status":"RECRUITING","nct":"NCT02610712","study":"Clinical Trial of the Use of Ketamine in Treatment Resistant Depression","sstatus":"UNKNOWN","sponsor":"National Institute of Neurology and Neurosurgery, Mexico","official":"Rodrigo Pérez-Esparza, MD (National Institute of Neurology and Neurosurgery, Mexico); Jesús Ramírez-Bermúdez, MD, MSc (National Institute of Neurology and Neurosurgery, Mexico)","src":"https://clinicaltrials.gov/study/NCT02610712","contact":{"n":"Rodrigo Pérez-Esparza, MD","p":"56063822","e":"dr.rodrigope@gmail.com"},"phase":"Phase 4","enroll":20,"start":"2014-05","eid":"x:site:nct02610712-national-institute-of-neurology-and-neurosurgery-mexico-city"},{"id":"nct07396272-adult-psychiatry-lund","cat":"research","name":"Adult Psychiatry","city":"Lund","region":"Skåne County","country":"Sweden","cc":"SE","lat":55.70457,"lon":13.1814,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"22240","condg":["Depression"],"nct":"NCT07396272","study":"A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Daniel Lindqvist","official":"Daniel Lindqvist, PhD, MD (Region Skane)","src":"https://clinicaltrials.gov/study/NCT07396272","phase":"Phase 2","enroll":12,"start":"2026-03-13","eid":"x:site:nct07396272-adult-psychiatry-lund"},{"id":"nct03909607-maimonides-medical-center-brooklyn","cat":"research","name":"Maimonides Medical Center","city":"Brooklyn","region":"New York","country":"United States","cc":"US","lat":40.65834,"lon":-73.95951,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11219","condg":["Chronic pain & headache"],"nct":"NCT03909607","study":"Nebulized Sub-dissociative Dose Ketamine for Treating Pain","sstatus":"COMPLETED","sponsor":"Antonios Likourezos","official":"Sergey Motov, MD (Maimonides Medical Center)","src":"https://clinicaltrials.gov/study/NCT03909607","phase":"Phase 4","enroll":120,"start":"2019-04-16","eid":"x:site:nct03909607-maimonides-medical-center-brooklyn"},{"id":"nct05256264-taipei-veterans-general-hospital-taipei","cat":"research","name":"Taipei Veterans General Hospital","city":"Taipei","region":"Beitou","country":"Taiwan","cc":"TW","lat":25.04652,"lon":121.52757,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"112","condg":["Other"],"status":"RECRUITING","nct":"NCT05256264","study":"Machine-learning Algorithm to Differentiate Intraoperative Ketamine Dosing Based on Electroencephalographic Density Spectrum Array Analysis","sstatus":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","official":"Chien-Kun Ting, MD, PhD (Taipei Veterans General Hospital, Taiwan)","src":"https://clinicaltrials.gov/study/NCT05256264","contact":{"n":"Hui Zen Hee","p":"+886928507736","e":"huizen.hee@gmail.com"},"enroll":90,"start":"2022-03-01","eid":"x:site:nct05256264-taipei-veterans-general-hospital-taipei"},{"id":"nct07369089-university-of-california-san-diego-la-jolla","cat":"research","name":"University of California, San Diego","city":"La Jolla","region":"California","country":"United States","cc":"US","lat":32.84638,"lon":-117.28441,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"92093","condg":["Addiction & substance use"],"nct":"NCT07369089","study":"Targeting Treatment-Resistant OUD With Ketamine-Assisted Mindfulness Oriented Recovery Enhancement","sstatus":"NOT_YET_RECRUITING","sponsor":"University of California, San Diego","src":"https://clinicaltrials.gov/study/NCT07369089","contact":{"n":"Hannah Pfeffer, LMSW","p":"619-500-4668","e":"hapfeffer@health.ucsd.edu"},"phase":"Phase 2","enroll":88,"start":"2026-02","eid":"x:site:nct07369089-university-of-california-san-diego-la-jolla"},{"id":"nct07369089-university-of-utah-salt-lake-city","cat":"research","name":"University Of Utah","city":"Salt Lake City","region":"Utah","country":"United States","cc":"US","lat":40.76582,"lon":-111.88451,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"84112","condg":["Addiction & substance use"],"nct":"NCT07369089","study":"Targeting Treatment-Resistant OUD With Ketamine-Assisted Mindfulness Oriented Recovery Enhancement","sstatus":"NOT_YET_RECRUITING","sponsor":"University of California, San Diego","src":"https://clinicaltrials.gov/study/NCT07369089","contact":{"n":"Hannah Pfeffer, LMSW","p":"619-500-4668","e":"hapfeffer@health.ucsd.edu"},"phase":"Phase 2","enroll":88,"start":"2026-02","eid":"x:site:nct07369089-university-of-utah-salt-lake-city"},{"id":"nct01957410-unnamed-trial-site-durham","cat":"research","name":"Unnamed trial site","city":"Durham","region":"North Carolina","country":"United States","cc":"US","lat":35.98222,"lon":-78.90441,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01957410","study":"A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder","sstatus":"TERMINATED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01957410","phase":"Phase 2","enroll":13,"start":"2014-02","eid":"x:site:nct01957410-unnamed-trial-site-durham"},{"id":"nct03500289-johns-hopkins-university-baltimore","cat":"research","name":"Johns Hopkins University","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.30238,"lon":-76.61092,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"21287","condg":["Other"],"nct":"NCT03500289","study":"Ketamine for Treatment of MS Fatigue","sstatus":"COMPLETED","sponsor":"Johns Hopkins University","official":"Bardia Nourbakhsh, MD, MAS (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT03500289","phase":"Phase 1/Phase 2","enroll":18,"start":"2018-08-10","eid":"x:site:nct03500289-johns-hopkins-university-baltimore"},{"id":"nct06531590-etlik-city-hospital-ankara","cat":"research","name":"Etlik City Hospital","city":"Ankara","region":"Yenimahalle","country":"Turkey","cc":"TR","lat":39.93121,"lon":32.85385,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06110","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06531590","study":"Anterior Shoulder Dislocation at Emergency Department","sstatus":"UNKNOWN","sponsor":"Saglik Bilimleri Universitesi","official":"gulsen akcay, ass. prof. (ass. prof. of organization)","src":"https://clinicaltrials.gov/study/NCT06531590","contact":{"n":"gulsen akcay, ass. prof.","p":"+905052874949","e":"gulakcay@yahoo.com.tr"},"enroll":140,"start":"2024-03-01","eid":"x:site:nct06531590-etlik-city-hospital-ankara"},{"id":"nct05786066-va-connecticut-healthcare-system-west-haven","cat":"research","name":"VA Connecticut Healthcare System","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.27361,"lon":-72.94493,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06516","condg":["Depression","PTSD & trauma","Bipolar"],"status":"RECRUITING","nct":"NCT05786066","study":"The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects","sstatus":"RECRUITING","sponsor":"Yale University","official":"Naomi Driesen, PhD (Yale University / VACHS West Haven)","src":"https://clinicaltrials.gov/study/NCT05786066","contact":{"n":"Naomi Driesen, PhD","p":"203-508-7765","e":"naomi.driesen@yale.edu"},"phase":"Phase 2","enroll":30,"start":"2023-04-03","eid":"x:site:nct05786066-va-connecticut-healthcare-system-west-haven"},{"id":"nct03780556-ain-shams-university-hospitals-cairo","cat":"research","name":"ِAin Shams University hospitals","city":"Cairo","country":"Egypt","cc":"EG","lat":30.06719,"lon":31.23842,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT03780556","study":"Lornoxicam With Low Dose Ketamine Versus Pethidine to Control Pain of Acute Renal Colic","sstatus":"COMPLETED","sponsor":"Ain Shams University","src":"https://clinicaltrials.gov/study/NCT03780556","phase":"N/A","enroll":120,"start":"2016-01-02","eid":"x:site:nct03780556-ain-shams-university-hospitals-cairo"},{"id":"nct07057193-faculty-of-medicine-zagazig-university-zagazig","cat":"research","name":"Faculty of Medicine Zagazig University","city":"Zagazig","country":"Egypt","cc":"EG","lat":30.57568,"lon":31.50233,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44511","condg":["Other"],"nct":"NCT07057193","study":"Effect of Different Drugs on Emergency Delirium in Preschool Age Patient","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Zagazig University","src":"https://clinicaltrials.gov/study/NCT07057193","phase":"N/A","enroll":92,"start":"2026-01-15","eid":"x:site:nct07057193-faculty-of-medicine-zagazig-university-zagazig"},{"id":"nct03081416-brooke-army-medical-center-san-antonio","cat":"research","name":"Brooke Army Medical Center","city":"San Antonio","region":"Texas","country":"United States","cc":"US","lat":29.42548,"lon":-98.50252,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"78236","condg":["Chronic pain & headache"],"nct":"NCT03081416","study":"\"THINK Trial: Treatment of Headache With IntraNasal Ketamine: A Randomized Controlled Trial Evaluating the Efficacy of Intranasal Ketamine Versus Standard Therapy in the Management of Primary…","sstatus":"COMPLETED","sponsor":"Brooke Army Medical Center","src":"https://clinicaltrials.gov/study/NCT03081416","phase":"Phase 3","enroll":80,"start":"2016-05","eid":"x:site:nct03081416-brooke-army-medical-center-san-antonio"},{"id":"nct02817477-tel-aviv-medical-center-tel-aviv","cat":"research","name":"Tel Aviv Medical Center","city":"Tel Aviv","country":"Israel","cc":"IL","lat":32.08036,"lon":34.77224,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Chronic pain & headache"],"nct":"NCT02817477","study":"Intranasal Ketamine for Acute Traumatic Pain","sstatus":"COMPLETED","sponsor":"Tel Aviv Medical Center","official":"Pinchas Halpern, MD (Tel Aviv Medical Center)","src":"https://clinicaltrials.gov/study/NCT02817477","phase":"Phase 4","enroll":90,"start":"2012-09","eid":"x:site:nct02817477-tel-aviv-medical-center-tel-aviv"},{"id":"nct06062628-parkland-memorial-hospital-dallas","cat":"research","name":"Parkland Memorial Hospital","city":"Dallas","region":"Texas","country":"United States","cc":"US","lat":32.78395,"lon":-96.81095,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75235","condg":["PTSD & trauma","Neurology & cognition"],"status":"RECRUITING","nct":"NCT06062628","study":"Ketamine in Severe Traumatic Brain Injury","sstatus":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","official":"Anna Bashmakov, D.O. (University of Texas Southwestern Medical Center)","src":"https://clinicaltrials.gov/study/NCT06062628","contact":{"n":"Anna Bashmakov, D.O.","p":"214/648-4827","e":"Anna.Bashmakov@UTSouthwestern.edu"},"phase":"EARLY_Phase 1","enroll":10,"start":"2026-06-01","eid":"x:site:nct06062628-parkland-memorial-hospital-dallas"},{"id":"nct06062628-parkland-memorial-hospital-dallas-2","cat":"research","name":"Parkland Memorial Hospital","city":"Dallas","region":"Texas","country":"United States","cc":"US","lat":32.78264,"lon":-96.81773,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75235","condg":["PTSD & trauma","Neurology & cognition"],"status":"RECRUITING","nct":"NCT06062628","study":"Ketamine in Severe Traumatic Brain Injury","sstatus":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","official":"Anna Bashmakov, D.O. (University of Texas Southwestern Medical Center)","src":"https://clinicaltrials.gov/study/NCT06062628","contact":{"n":"Anna Bashmakov, D.O.","p":"214-648-4827","e":"Anna.Bashmakov@UTSouthwestern.edu"},"phase":"EARLY_Phase 1","enroll":10,"start":"2026-06-01","eid":"x:site:nct06062628-parkland-memorial-hospital-dallas-2"},{"id":"nct04242914-psychiatric-service-tel-aviv-sourasky-medical-center-tel-aviv","cat":"research","name":"Psychiatric Service, Tel-Aviv Sourasky Medical Center","city":"Tel Aviv","country":"Israel","cc":"IL","lat":32.07255,"lon":34.77262,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"RECRUITING","nct":"NCT04242914","study":"The Effect of Intravenous Ketamine on Non Suicidal Self Injuries.","sstatus":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","official":"Miki Bloch, Prof. (Tel Aviv University)","src":"https://clinicaltrials.gov/study/NCT04242914","contact":{"n":"Miki Bloch, Ph.D.","p":"972-3-6974568","e":"liordv@tlvmc.gov.il"},"phase":"Phase 1/Phase 2","enroll":30,"start":"2019-02-25","eid":"x:site:nct04242914-psychiatric-service-tel-aviv-sourasky-medical-center-tel-aviv"},{"id":"nct01377831-pain-and-anaesthesia-research-clinic-parc-royal-adelaide-hospital-ad","cat":"research","name":"Pain and Anaesthesia Research Clinic (PARC), Royal Adelaide Hospital","city":"Adelaide","region":"South Australia","country":"Australia","cc":"AU","lat":-34.91779,"lon":138.59049,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"5000","condg":["Chronic pain & headache"],"nct":"NCT01377831","study":"Study of Ketamine Administered Intravenously and by Sublingual Wafer","sstatus":"COMPLETED","sponsor":"iX Biopharma Ltd.","official":"Pual Rolan (Pain and Anaesthesia Research Clinic - PARC)","src":"https://clinicaltrials.gov/study/NCT01377831","enroll":8,"start":"2011-06","eid":"x:site:nct01377831-pain-and-anaesthesia-research-clinic-parc-royal-adelaide-hospital-ad"},{"id":"nct03051945-huntsman-cancer-institute-salt-lake-city","cat":"research","name":"Huntsman Cancer Institute","city":"Salt Lake City","region":"Utah","country":"United States","cc":"US","lat":40.75311,"lon":-111.88432,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"84112","condg":["Depression"],"nct":"NCT03051945","study":"Endogenous Opioid Modulation by Ketamine","sstatus":"WITHDRAWN","sponsor":"University of Utah","src":"https://clinicaltrials.gov/study/NCT03051945","phase":"Phase 3","start":"2019-08","eid":"x:site:nct03051945-huntsman-cancer-institute-salt-lake-city"},{"id":"nct01047241-copenhagen-university-hospital-rigshospitalet-copenhagen","cat":"research","name":"Copenhagen University Hospital Rigshospitalet","city":"Copenhagen","country":"Denmark","cc":"DK","lat":55.67843,"lon":12.57744,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"2100","condg":["Chronic pain & headache"],"nct":"NCT01047241","study":"Nasal Administration of Sufentanil+Ketamine for Procedure-related Pain in Children","sstatus":"COMPLETED","sponsor":"Danish University of Pharmaceutical Sciences","official":"Steen W Henneberg, MD DMSc (Copenhagen University Hospital, Rigshospitalet); Kjeld Schmiegelow, MD DMSc (Copenhagen University Hospital Righospitalet)","src":"https://clinicaltrials.gov/study/NCT01047241","phase":"Phase 2","enroll":50,"start":"2010-04","eid":"x:site:nct01047241-copenhagen-university-hospital-rigshospitalet-copenhagen"},{"id":"nct03947099-klarisana-san-antonio","cat":"research","name":"Klarisana","city":"San Antonio","region":"Texas","country":"United States","cc":"US","lat":29.42483,"lon":-98.50187,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"78240","condg":["Anxiety","PTSD & trauma"],"nct":"NCT03947099","study":"Ketamine Infusion Therapy for the Treatment of PTSD in Paramedics","sstatus":"COMPLETED","sponsor":"Klarisana Physician Services PLLC","official":"Carl J Bonnett, MD (Klarisana Physician Services PLLC)","src":"https://clinicaltrials.gov/study/NCT03947099","enroll":7,"start":"2019-05-02","eid":"x:site:nct03947099-klarisana-san-antonio"},{"id":"nct03539887-the-university-of-texas-health-science-center-at-houston-houston","cat":"research","name":"The University of Texas Health Science Center at Houston","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.76474,"lon":-95.35654,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"77006","condg":["Depression","Addiction & substance use"],"nct":"NCT03539887","study":"Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse","sstatus":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","official":"Rodrigo Machado-Vieira, MD, PhD, MSc (The University of Texas Health Science Center, Houston)","src":"https://clinicaltrials.gov/study/NCT03539887","phase":"Phase 3","enroll":33,"start":"2018-05-01","eid":"x:site:nct03539887-the-university-of-texas-health-science-center-at-houston-houston"},{"id":"nct02556060-taipei-city-hospital-and-psychiatric-center-taipei","cat":"research","name":"Taipei City Hospital and Psychiatric Center","city":"Taipei","country":"Taiwan","cc":"TW","lat":25.06374,"lon":121.5367,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"110","condg":["Addiction & substance use"],"nct":"NCT02556060","study":"Lamotrigine for Ketamine Dependence Trial","sstatus":"COMPLETED","sponsor":"Taipei City Hospital","official":"Shih-Ku Lin, MD (Taipei City Hospital)","src":"https://clinicaltrials.gov/study/NCT02556060","phase":"Phase 2/Phase 3","enroll":30,"start":"2015-09","eid":"x:site:nct02556060-taipei-city-hospital-and-psychiatric-center-taipei"},{"id":"nct05444751-hospital-for-special-surgery-new-york","cat":"research","name":"Hospital for Special Surgery","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72363,"lon":-74.00461,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10021","condg":["Other"],"nct":"NCT05444751","study":"GA + ESP vs. SA + ESP in Lumbar Decompression Surgeries","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Hospital for Special Surgery, New York","src":"https://clinicaltrials.gov/study/NCT05444751","phase":"Phase 3","enroll":142,"start":"2022-03-22","eid":"x:site:nct05444751-hospital-for-special-surgery-new-york"},{"id":"nct04283058-loma-linda-university-medical-center-loma-linda","cat":"research","name":"Loma Linda University Medical Center","city":"Loma Linda","region":"California","country":"United States","cc":"US","lat":34.04331,"lon":-117.266,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"92354","condg":["Depression"],"nct":"NCT04283058","study":"Low Dose Ketamine Infusion for the Treatment of Resistant Depression","sstatus":"WITHDRAWN","sponsor":"Loma Linda University","official":"Patricia Radovich, PhD (Loma Linda University Medical Center)","src":"https://clinicaltrials.gov/study/NCT04283058","start":"2020-06-29","eid":"x:site:nct04283058-loma-linda-university-medical-center-loma-linda"},{"id":"nct03969316-istanbul-university-cerrahpasa-istanbul","cat":"research","name":"Istanbul University - Cerrahpasa","city":"Istanbul","country":"Turkey","cc":"TR","lat":41.02245,"lon":28.94095,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"34100","condg":["Chronic pain & headache"],"nct":"NCT03969316","study":"Transversus Abdominis Plane Block Versus Quadratus Lumborum Block in The Pediatric Population Undergoing Orchiopexy","sstatus":"COMPLETED","sponsor":"Istanbul University - Cerrahpasa","official":"Ozgecan P Zanbak, MD (Istanbul University - Cerrahpasa); Ayse C Tutuncu, MD,Prof (Istanbul University - Cerrahpasa)","src":"https://clinicaltrials.gov/study/NCT03969316","phase":"N/A","enroll":102,"start":"2019-05-10","eid":"x:site:nct03969316-istanbul-university-cerrahpasa-istanbul"},{"id":"nct03664622-cairo-university-cairo","cat":"research","name":"Cairo University","city":"Cairo","region":"Giza Governorate","country":"Egypt","cc":"EG","lat":30.06183,"lon":31.25471,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"1234","condg":["Chronic pain & headache"],"nct":"NCT03664622","study":"Ketamine Versus Morphine Change Pain Profile","sstatus":"COMPLETED","sponsor":"Cairo University","official":"hassan Ali (Cairo University)","src":"https://clinicaltrials.gov/study/NCT03664622","phase":"N/A","enroll":160,"start":"2018-09-15","eid":"x:site:nct03664622-cairo-university-cairo"},{"id":"nct02461927-va-connecticut-healthcare-system-west-haven-campus-west-haven-ct-wes","cat":"research","name":"VA Connecticut Healthcare System West Haven Campus, West Haven, CT","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.27804,"lon":-72.93797,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06516-2770","condg":["Depression","Addiction & substance use"],"nct":"NCT02461927","study":"Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder","sstatus":"COMPLETED","sponsor":"VA Office of Research and Development","official":"Gihyun Yoon, MD (VA Connecticut Healthcare System West Haven Campus, West Haven, CT)","src":"https://clinicaltrials.gov/study/NCT02461927","phase":"Phase 1/Phase 2","enroll":65,"start":"2015-01-01","eid":"x:site:nct02461927-va-connecticut-healthcare-system-west-haven-campus-west-haven-ct-wes"},{"id":"nct06981494-faculty-of-medicine-sohag","cat":"research","name":"Faculty of medicine","city":"Sohag","country":"Egypt","cc":"EG","lat":26.56349,"lon":31.68598,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"RECRUITING","nct":"NCT06981494","study":"Dexmedetomidine Versus Dexmedetomidine and Ketamine (Ketodex) in Ear and Nose Surgeries","sstatus":"RECRUITING","sponsor":"Sohag University","src":"https://clinicaltrials.gov/study/NCT06981494","contact":{"n":"Magdy M Amin","p":"0934602963","e":"Portal@med.sohag.edu.eg"},"phase":"N/A","enroll":84,"start":"2025-02-05","eid":"x:site:nct06981494-faculty-of-medicine-sohag"},{"id":"nct03060070-south-egypt-cancer-institute-asyut","cat":"research","name":"South Egypt Cancer Institute","city":"Asyut","region":"Assiut University","country":"Egypt","cc":"EG","lat":27.17621,"lon":31.18476,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"171516","condg":["Cancer-related distress"],"nct":"NCT03060070","study":"Ketamine Versus Dexmedetomidine With Local Anesthetic in TAP Block","sstatus":"COMPLETED","sponsor":"Assiut University","src":"https://clinicaltrials.gov/study/NCT03060070","phase":"Phase 2/Phase 3","enroll":90,"start":"2017-03-10","eid":"x:site:nct03060070-south-egypt-cancer-institute-asyut"},{"id":"nct02072083-erciyes-university-hospital-kayseri","cat":"research","name":"Erciyes university hospital","city":"Kayseri","country":"Turkey","cc":"TR","lat":38.73933,"lon":35.49521,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"38039","condg":["Other"],"nct":"NCT02072083","study":"Intranasal Dexmedetomidine vs Midazolam-ketamine Combination for Premedication of Pediatric Patients","sstatus":"COMPLETED","sponsor":"TC Erciyes University","official":"Müge Yüce Yıldırım, resident (erciyes univercity)","src":"https://clinicaltrials.gov/study/NCT02072083","phase":"Phase 4","enroll":60,"start":"2014-02","eid":"x:site:nct02072083-erciyes-university-hospital-kayseri"},{"id":"nct03499886-al-zahra-university-hospital-isfahan","cat":"research","name":"Al-Zahra University Hospital","city":"Isfahan","country":"Iran","cc":"IR","lat":32.6494,"lon":51.67203,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"8138938728","condg":["Other"],"status":"COMPLETED","nct":"NCT03499886","study":"Low-Dose Intravenous Ketamine Bolus Versus Conventional Technique","sstatus":"UNKNOWN","sponsor":"Isfahan University of Medical Sciences","official":"Mehdi Nasr Isfahani, M.D. (Isfahan University of Medical Sciences)","src":"https://clinicaltrials.gov/study/NCT03499886","contact":{"n":"Mehdi Nasr Isfahani, M.D.","p":"+989132034381","e":"mni.papillon@gmail.com"},"phase":"Phase 2/Phase 3","enroll":198,"start":"2017-01-17","eid":"x:site:nct03499886-al-zahra-university-hospital-isfahan"},{"id":"nct03499886-mehdi-nasr-isfahani-isfahan","cat":"research","name":"Mehdi Nasr Isfahani","city":"Isfahan","country":"Iran","cc":"IR","lat":32.64215,"lon":51.68615,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"8194856781","condg":["Other"],"status":"RECRUITING","nct":"NCT03499886","study":"Low-Dose Intravenous Ketamine Bolus Versus Conventional Technique","sstatus":"UNKNOWN","sponsor":"Isfahan University of Medical Sciences","official":"Mehdi Nasr Isfahani, M.D. (Isfahan University of Medical Sciences)","src":"https://clinicaltrials.gov/study/NCT03499886","contact":{"n":"Mehdi Nasr Isfahani","p":"+989132034381","e":"m_nasr54@yahoo.com"},"phase":"Phase 2/Phase 3","enroll":198,"start":"2017-01-17","eid":"x:site:nct03499886-mehdi-nasr-isfahani-isfahan"},{"id":"nct03345173-new-york-state-psychiatric-institute-new-york","cat":"research","name":"New York State Psychiatric Institute","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71959,"lon":-74.01637,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10032","condg":["Addiction & substance use"],"nct":"NCT03345173","study":"Facilitating Rapid Naltrexone Initiation","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"New York State Psychiatric Institute","official":"Elias Dakwar, MD (NYSPI)","src":"https://clinicaltrials.gov/study/NCT03345173","phase":"Phase 3","enroll":100,"start":"2017-11-25","eid":"x:site:nct03345173-new-york-state-psychiatric-institute-new-york"},{"id":"nct03586154-mansourau-al-mansurah","cat":"research","name":"MansouraU","city":"Al Mansurah","region":"Mansoura","country":"Egypt","cc":"EG","lat":31.03397,"lon":31.3701,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"35516","condg":["Cancer-related distress"],"nct":"NCT03586154","study":"Combined Intra-articular Shoulder Injection and Stellate Ganglion Block in Chronic Post-mastectomy Shoulder Pain","sstatus":"COMPLETED","sponsor":"Mansoura University","official":"Mohamed Tahan, MD (Professor of Anesthesia, Medical Faculty, Mansoura University)","src":"https://clinicaltrials.gov/study/NCT03586154","phase":"Phase 4","enroll":70,"start":"2017-08-01","eid":"x:site:nct03586154-mansourau-al-mansurah"},{"id":"nct02122562-university-of-iowa-health-care-iowa-city","cat":"research","name":"University of Iowa Health Care","city":"Iowa City","region":"Iowa","country":"United States","cc":"US","lat":41.65581,"lon":-91.53276,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"52242","condg":["Depression","Addiction & substance use"],"status":"RECRUITING","nct":"NCT02122562","study":"Ketamine Alcohol (in Treatment-Resistant Depression)","sstatus":"RECRUITING","sponsor":"Mark Niciu","official":"Mark J Niciu, M.D. Ph.D. (University of Iowa Health Care (UIHC))","src":"https://clinicaltrials.gov/study/NCT02122562","contact":{"n":"Osura R Amarajeewa, M.B.B.S.","p":"319-353-8536","e":"emerson-buse@uiowa.edu"},"phase":"Phase 2","enroll":60,"start":"2014-04-23","eid":"x:site:nct02122562-university-of-iowa-health-care-iowa-city"},{"id":"nct02467517-chu-de-clermont-ferrand-clermont-ferrand","cat":"research","name":"CHU de Clermont-Ferrand","city":"Clermont-Ferrand","country":"France","cc":"FR","lat":45.7836,"lon":3.07764,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"63003","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT02467517","study":"Ketamine and Neuropathic Pain","sstatus":"UNKNOWN","sponsor":"University Hospital, Clermont-Ferrand","official":"Gisèle PICKERING (University Hospital, Clermont-Ferrand)","src":"https://clinicaltrials.gov/study/NCT02467517","contact":{"n":"Patrick LACARIN","p":"04 73 75 11 95","e":"placarin@chu-clermontferrand.fr"},"phase":"Phase 2","enroll":22,"start":"2015-11","eid":"x:site:nct02467517-chu-de-clermont-ferrand-clermont-ferrand"},{"id":"nct04944017-yale-new-haven-hospital-new-haven","cat":"research","name":"Yale New Haven Hospital","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31479,"lon":-72.91861,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06510","condg":["Depression","Neurology & cognition"],"nct":"NCT04944017","study":"Ketamine for the Treatment of Depression in Parkinson's Disease","sstatus":"COMPLETED","sponsor":"Yale University","official":"Sophie E. Holmes, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT04944017","phase":"Phase 2","enroll":51,"start":"2021-11-23","eid":"x:site:nct04944017-yale-new-haven-hospital-new-haven"},{"id":"nct00957333-taipei-medical-university-wan-fang-hospital-taipei","cat":"research","name":"Taipei Medical University-Wan Fang Hospital","city":"Taipei","country":"Taiwan","cc":"TW","lat":25.04445,"lon":121.53067,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT00957333","study":"Effects of Ketamine on Human Bladders and Its Possible Mechanisms","sstatus":"COMPLETED","sponsor":"Taipei Medical University WanFang Hospital","official":"Ruei-Ming Chen, PhD (Taipei Medical University-Wan Fang Hospital)","src":"https://clinicaltrials.gov/study/NCT00957333","enroll":44,"start":"2009-03","eid":"x:site:nct00957333-taipei-medical-university-wan-fang-hospital-taipei"},{"id":"nct03319238-chu-clermont-ferrand-clermont-ferrand","cat":"research","name":"CHU Clermont-Ferrand","city":"Clermont-Ferrand","country":"France","cc":"FR","lat":45.78924,"lon":3.08376,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"63003","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT03319238","study":"OBSERVATIONAL STUDY OF THE MANAGEMENT OF PATIENTS WITH CHRONIC PAIN","sstatus":"UNKNOWN","sponsor":"University Hospital, Clermont-Ferrand","official":"Gisèle PICKERING (University Hospital, Clermont-Ferrand)","src":"https://clinicaltrials.gov/study/NCT03319238","contact":{"n":"Patrick LACARIN","p":"04 73 75 11 95","e":"placarin@chu-clermontferrand.fr"},"enroll":1000,"start":"2016-07-07","eid":"x:site:nct03319238-chu-clermont-ferrand-clermont-ferrand"},{"id":"nct04939649-st-patrick-s-univeristy-hospital-dublin","cat":"research","name":"St Patrick's Univeristy Hospital","city":"Dublin","country":"Ireland","cc":"IE","lat":53.33198,"lon":-6.23745,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"D8","condg":["Depression","Bipolar"],"nct":"NCT04939649","study":"Ketamine As an Adjunctive Therapy for Major Depression (2)","sstatus":"COMPLETED","sponsor":"University of Dublin, Trinity College","official":"Declan M McLoughlin, PhD (University of Dublin, Trinity College and St Patrick's Mental Health Services)","src":"https://clinicaltrials.gov/study/NCT04939649","phase":"Phase 3","enroll":63,"start":"2021-09-13","eid":"x:site:nct04939649-st-patrick-s-univeristy-hospital-dublin"},{"id":"nct02083926-connecticut-mental-health-center-new-haven","cat":"research","name":"Connecticut Mental Health Center","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.30471,"lon":-72.93451,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06519","condg":["Anxiety"],"nct":"NCT02083926","study":"Ketamine Infusion for Social Anxiety Disorder","sstatus":"COMPLETED","sponsor":"Yale University","official":"Michael H. Bloch, MD, MS (Yale University)","src":"https://clinicaltrials.gov/study/NCT02083926","phase":"EARLY_Phase 1","enroll":18,"start":"2015-01-02","eid":"x:site:nct02083926-connecticut-mental-health-center-new-haven"},{"id":"nct05229055-university-of-monastir-monastir","cat":"research","name":"university of Monastir","city":"Monastir","country":"Tunisia","cc":"TN","lat":35.78801,"lon":10.83657,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"5000","condg":["Chronic pain & headache"],"nct":"NCT05229055","study":"Intranasal Ketamine Versus Subcutaneous Ketamine for Treatment of Post-traumatic Acute Pain in the Emergency Department ( INVESCK )","sstatus":"COMPLETED","sponsor":"University of Monastir","official":"Nouira Semir, Professor (University of Monastir)","src":"https://clinicaltrials.gov/study/NCT05229055","phase":"Phase 2/Phase 3","enroll":1000,"start":"2023-04-15","eid":"x:site:nct05229055-university-of-monastir-monastir"},{"id":"nct07307768-columbia-university-irving-medical-center-new-york","cat":"research","name":"Columbia University Irving Medical Center","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71611,"lon":-74.00931,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10032","condg":["Depression"],"nct":"NCT07307768","study":"Ketamine Biomarker Validation","sstatus":"NOT_YET_RECRUITING","sponsor":"Soterix Medical","src":"https://clinicaltrials.gov/study/NCT07307768","contact":{"n":"Yishai Valter, MS","p":"8889908327","e":"trials@soterixmedical.com"},"phase":"Phase 1","enroll":20,"start":"2025-12-20","eid":"x:site:nct07307768-columbia-university-irving-medical-center-new-york"},{"id":"nct07839338-nimhans-bangalore","cat":"research","name":"NIMHANS","city":"Bangalore","region":"Karnataka","country":"India","cc":"IN","lat":12.96145,"lon":77.58197,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT07839338","study":"A Study Comparing Oral Ketamine With Oral Midazolam for the Treatment of Major Depressive Episodes","sstatus":"NOT_YET_RECRUITING","sponsor":"Jawaharlal Institute of Postgraduate Medical Education & Research","src":"https://clinicaltrials.gov/study/NCT07839338","contact":{"n":"Suhas Satish","p":"+91 8884493142","e":"suhas.academic@gmail.com"},"phase":"Phase 3","enroll":220,"start":"2026-10","eid":"x:site:nct07839338-nimhans-bangalore"},{"id":"nct07839338-kasturba-medical-college-udupi","cat":"research","name":"Kasturba Medical College","city":"Udupi","region":"Karnataka","country":"India","cc":"IN","lat":13.34149,"lon":74.75441,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT07839338","study":"A Study Comparing Oral Ketamine With Oral Midazolam for the Treatment of Major Depressive Episodes","sstatus":"NOT_YET_RECRUITING","sponsor":"Jawaharlal Institute of Postgraduate Medical Education & Research","src":"https://clinicaltrials.gov/study/NCT07839338","contact":{"n":"Samir K Praharaj","p":"+91 8971026304","e":"samirpsyche@yahoo.co.in"},"phase":"Phase 3","enroll":220,"start":"2026-10","eid":"x:site:nct07839338-kasturba-medical-college-udupi"},{"id":"nct07839338-mgm-medical-college-mumbai-mumbai","cat":"research","name":"MGM Medical College, Mumbai","city":"Mumbai","region":"Maharashtra","country":"India","cc":"IN","lat":19.06751,"lon":72.89066,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT07839338","study":"A Study Comparing Oral Ketamine With Oral Midazolam for the Treatment of Major Depressive Episodes","sstatus":"NOT_YET_RECRUITING","sponsor":"Jawaharlal Institute of Postgraduate Medical Education & Research","src":"https://clinicaltrials.gov/study/NCT07839338","contact":{"n":"Sagar Karia","p":"+91 9594530457","e":"karia777@yahoo.com"},"phase":"Phase 3","enroll":220,"start":"2026-10","eid":"x:site:nct07839338-mgm-medical-college-mumbai-mumbai"},{"id":"nct07839338-aiims-bhubaneswar-bhubaneswar","cat":"research","name":"AIIMS, Bhubaneswar","city":"Bhubaneswar","region":"Odisha","country":"India","cc":"IN","lat":20.28036,"lon":85.83117,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT07839338","study":"A Study Comparing Oral Ketamine With Oral Midazolam for the Treatment of Major Depressive Episodes","sstatus":"NOT_YET_RECRUITING","sponsor":"Jawaharlal Institute of Postgraduate Medical Education & Research","src":"https://clinicaltrials.gov/study/NCT07839338","contact":{"n":"Susanta K Padhy","p":"+91 9463895852","e":"psych_susanta@aiimsbhubaneswar.edu.in"},"phase":"Phase 3","enroll":220,"start":"2026-10","eid":"x:site:nct07839338-aiims-bhubaneswar-bhubaneswar"},{"id":"nct07839338-jawaharlal-institute-of-postgraduate-medical-education-and-research-","cat":"research","name":"Jawaharlal Institute of Postgraduate Medical Education and Research","city":"Puducherry","region":"Puducherry","country":"India","cc":"IN","lat":11.93245,"lon":79.82683,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT07839338","study":"A Study Comparing Oral Ketamine With Oral Midazolam for the Treatment of Major Depressive Episodes","sstatus":"NOT_YET_RECRUITING","sponsor":"Jawaharlal Institute of Postgraduate Medical Education & Research","src":"https://clinicaltrials.gov/study/NCT07839338","contact":{"n":"Vikas Menon, MD","p":"+91 8098158528","e":"drvmenon@gmail.com"},"phase":"Phase 3","enroll":220,"start":"2026-10","eid":"x:site:nct07839338-jawaharlal-institute-of-postgraduate-medical-education-and-research-"},{"id":"nct05045378-taipei-veterans-general-hospital-taiwan-taipei","cat":"research","name":"Taipei Veterans General Hospital, Taiwan","city":"Taipei","country":"Taiwan","cc":"TW","lat":25.06148,"lon":121.52728,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"112","condg":["Depression"],"nct":"NCT05045378","study":"Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Taipei Veterans General Hospital, Taiwan","official":"Mu-Hong Chen, M.D., Ph.D. (Taipei Veterans General Hospital, Taiwan)","src":"https://clinicaltrials.gov/study/NCT05045378","phase":"Phase 4","enroll":12,"start":"2022-03-15","eid":"x:site:nct05045378-taipei-veterans-general-hospital-taiwan-taipei"},{"id":"nct05991232-the-ohio-state-university-department-of-psychiatry-behavioral-health","cat":"research","name":"The Ohio State University, Department of Psychiatry & Behavioral Health","city":"Columbus","region":"Ohio","country":"United States","cc":"US","lat":39.96217,"lon":-82.98858,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43210","condg":["Depression"],"nct":"NCT05991232","study":"Repeated Neurocognitive Measurements in Depressed Patients","sstatus":"WITHDRAWN","sponsor":"Jay Fournier","src":"https://clinicaltrials.gov/study/NCT05991232","phase":"Phase 1/Phase 2","start":"2025-05-01","eid":"x:site:nct05991232-the-ohio-state-university-department-of-psychiatry-behavioral-health"},{"id":"nct05464264-st-michael-s-hospital-toronto","cat":"research","name":"St. Michael's Hospital","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.69537,"lon":-79.40368,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M5B1M8","condg":["Depression"],"status":"RECRUITING","nct":"NCT05464264","study":"Auditory MMN EEG in TRD in Response to Ketamine","sstatus":"UNKNOWN","sponsor":"Unity Health Toronto","src":"https://clinicaltrials.gov/study/NCT05464264","contact":{"n":"Venkat Bhat, MD MSc","p":"4163604000","e":"Venkat.Bhat@unityhealth.to"},"enroll":30,"start":"2022-10-03","eid":"x:site:nct05464264-st-michael-s-hospital-toronto"},{"id":"nct01567852-university-of-new-mexico-albuquerque","cat":"research","name":"University of New Mexico","city":"Albuquerque","region":"New Mexico","country":"United States","cc":"US","lat":35.08369,"lon":-106.66305,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"87131","condg":["Other"],"nct":"NCT01567852","study":"Use of Ketamine vs Methohexital for Electroconvulsive Therapy (ECT) on Patient Recovery and Re-orientation Time","sstatus":"COMPLETED","sponsor":"University of New Mexico","official":"Tony Yen, MD (University of New Mexico)","src":"https://clinicaltrials.gov/study/NCT01567852","phase":"N/A","enroll":20,"start":"2011-08","eid":"x:site:nct01567852-university-of-new-mexico-albuquerque"},{"id":"nct02429011-icahn-school-of-medicine-at-mount-sinai-new-york","cat":"research","name":"Icahn School of Medicine at Mount Sinai","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71488,"lon":-74.00988,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10029","condg":["Depression"],"nct":"NCT02429011","study":"MRI Studies of Emotion in Depression","sstatus":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","official":"James Murrough, MD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT02429011","enroll":135,"start":"2011-07-15","eid":"x:site:nct02429011-icahn-school-of-medicine-at-mount-sinai-new-york"},{"id":"nct00646087-st-mary-s-duluth-clinic-health-system-duluth","cat":"research","name":"St. Mary's Duluth Clinic Health System","city":"Duluth","region":"Minnesota","country":"United States","cc":"US","lat":46.78878,"lon":-92.10813,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55805","condg":["Depression"],"nct":"NCT00646087","study":"Ketamine Frequency Treatment for Major Depressive Disorder","sstatus":"WITHDRAWN","sponsor":"Essentia Health","official":"Micheal Messer, MD (Essentia Health)","src":"https://clinicaltrials.gov/study/NCT00646087","phase":"Phase 4","start":"2008-03","eid":"x:site:nct00646087-st-mary-s-duluth-clinic-health-system-duluth"},{"id":"nct03221569-the-brooklyn-hospital-center-brooklyn","cat":"research","name":"The Brooklyn Hospital Center","city":"Brooklyn","region":"New York","country":"United States","cc":"US","lat":40.65504,"lon":-73.95857,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11201","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT03221569","study":"Ketamine v. Ketorolac for Management of Generalized Tension Type Headache","sstatus":"UNKNOWN","sponsor":"The Brooklyn Hospital Center","src":"https://clinicaltrials.gov/study/NCT03221569","contact":{"n":"Billy W Sin, Pharm.D.","p":"718-250-6250","e":"bsin@tbh.org"},"phase":"Phase 4","enroll":60,"start":"2016-02-01","eid":"x:site:nct03221569-the-brooklyn-hospital-center-brooklyn"},{"id":"nct02997722-university-of-mississippi-medical-center-jackson","cat":"research","name":"University of Mississippi Medical Center","city":"Jackson","region":"Mississippi","country":"United States","cc":"US","lat":32.29467,"lon":-90.19662,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"39216","condg":["Other"],"nct":"NCT02997722","study":"The Effect of Ketamine on the Length of Hospital Stay of Patients Hospitalized With Suicidal Ideation.","sstatus":"TERMINATED","sponsor":"Allen Richert","official":"Allen C Richert, MD (University of Mississippi Medical Center)","src":"https://clinicaltrials.gov/study/NCT02997722","phase":"Phase 4","enroll":4,"start":"2017-03-02","eid":"x:site:nct02997722-university-of-mississippi-medical-center-jackson"},{"id":"nct06164756-yale-new-haven-hospital-new-haven","cat":"research","name":"Yale New Haven Hospital","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31563,"lon":-72.9316,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06510","condg":["Depression","Neurology & cognition"],"nct":"NCT06164756","study":"Long Term Follow Up KET-PD","sstatus":"COMPLETED","sponsor":"Yale University","official":"Sophie E. Holmes, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT06164756","enroll":49,"start":"2023-10-18","eid":"x:site:nct06164756-yale-new-haven-hospital-new-haven"},{"id":"nct06762288-istanbul-university-cerrahpasa-istanbul","cat":"research","name":"Istanbul University-Cerrahpaşa","city":"Istanbul","country":"Turkey","cc":"TR","lat":41.02226,"lon":28.96034,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT06762288","study":"Transversus Abdominis Plan (TAP) Block for Transcatheter Aortic Valve Implantation (TAVI)","sstatus":"COMPLETED","sponsor":"Istanbul University - Cerrahpasa","official":"Kerem Erkalp, professor (Istanbul University - Cerrahpasa)","src":"https://clinicaltrials.gov/study/NCT06762288","phase":"N/A","enroll":50,"start":"2024-12-28","eid":"x:site:nct06762288-istanbul-university-cerrahpasa-istanbul"},{"id":"nct07126795-hennepin-county-medical-center-minneapolis","cat":"research","name":"Hennepin County Medical Center","city":"Minneapolis","region":"Minnesota","country":"United States","cc":"US","lat":44.97343,"lon":-93.26756,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55415","condg":["Other"],"nct":"NCT07126795","study":"Magnesium Sulfate in Pediatric Burn Dressing Changes","sstatus":"NOT_YET_RECRUITING","sponsor":"Hennepin Healthcare Research Institute","src":"https://clinicaltrials.gov/study/NCT07126795","contact":{"n":"Joseph Resch, M.D.","p":"612-481-5885","e":"joseph.resch@hcmed.org"},"phase":"Phase 1","enroll":10,"start":"2026-01-01","eid":"x:site:nct07126795-hennepin-county-medical-center-minneapolis"},{"id":"nct01892995-brooke-army-medical-center-fort-sam-houston","cat":"research","name":"Brooke Army Medical Center","city":"Fort Sam Houston","region":"Texas","country":"United States","cc":"US","lat":29.43283,"lon":-98.48897,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"78234","condg":["Other"],"nct":"NCT01892995","study":"Ketamine for Acute Suicidal Ideation in the Emergency Department: Randomized Controlled Trial","sstatus":"UNKNOWN","sponsor":"Brooke Army Medical Center","src":"https://clinicaltrials.gov/study/NCT01892995","contact":{"n":"Steven G Schauer, DO","p":"2109160808","e":"sgschauer@gmail.com"},"phase":"N/A","enroll":53,"start":"2015-06","eid":"x:site:nct01892995-brooke-army-medical-center-fort-sam-houston"},{"id":"nct03977675-new-york-state-psychiatric-institute-new-york","cat":"research","name":"New York State Psychiatric Institute","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.7082,"lon":-73.99613,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10032","condg":["Depression"],"nct":"NCT03977675","study":"The Role of HNKs in the Antidepressant Effect of Ketamine","sstatus":"TERMINATED","sponsor":"Columbia University","official":"Michael Grunebaum, MD (New York Psychiatric Institute)","src":"https://clinicaltrials.gov/study/NCT03977675","phase":"Phase 1","enroll":8,"start":"2019-05-15","eid":"x:site:nct03977675-new-york-state-psychiatric-institute-new-york"},{"id":"nct04011592-the-university-of-texas-health-science-center-at-houston-houston","cat":"research","name":"The University of Texas Health Science Center at Houston","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.76389,"lon":-95.35419,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"77054","condg":["Depression"],"nct":"NCT04011592","study":"Efficacy And Tolerability Of Sub-Anesthetic Ketamine In Postpartum Depression","sstatus":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","official":"Sudhakar Selvaraj, 713-486-2837 (UTHealth Science Center at Houston)","src":"https://clinicaltrials.gov/study/NCT04011592","phase":"Phase 2","enroll":1,"start":"2019-03-04","eid":"x:site:nct04011592-the-university-of-texas-health-science-center-at-houston-houston"},{"id":"nct01316744-royal-brompton-hospital-london","cat":"research","name":"Royal Brompton Hospital","city":"London","region":"England","country":"United Kingdom","cc":"GB","lat":51.51366,"lon":-0.13153,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"SW3 6NP","condg":["Cancer-related distress"],"status":"RECRUITING","nct":"NCT01316744","study":"Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain","sstatus":"UNKNOWN","sponsor":"University of Glasgow","official":"Marie T. Fallon (Edinburgh Cancer Centre at Western General Hospital); Barry J.A. Laird, MD (Edinburgh Cancer Centre at Western General Hospital)","src":"https://clinicaltrials.gov/study/NCT01316744","contact":{"n":"Contact Person","p":"44-207-886-6011","e":"c.urch@ucl.ac.uk"},"phase":"Phase 3","enroll":214,"start":"2009-04","eid":"x:site:nct01316744-royal-brompton-hospital-london"},{"id":"nct01316744-edinburgh-cancer-centre-at-western-general-hospital-edinburgh","cat":"research","name":"Edinburgh Cancer Centre at Western General Hospital","city":"Edinburgh","region":"Scotland","country":"United Kingdom","cc":"GB","lat":55.94608,"lon":-3.19352,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"EH4 2XR","condg":["Cancer-related distress"],"status":"RECRUITING","nct":"NCT01316744","study":"Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain","sstatus":"UNKNOWN","sponsor":"University of Glasgow","official":"Marie T. Fallon (Edinburgh Cancer Centre at Western General Hospital); Barry J.A. Laird, MD (Edinburgh Cancer Centre at Western General Hospital)","src":"https://clinicaltrials.gov/study/NCT01316744","contact":{"n":"Contact Person","p":"44-131-777-3520","e":"marie.fallon@ed.ac.uk"},"phase":"Phase 3","enroll":214,"start":"2009-04","eid":"x:site:nct01316744-edinburgh-cancer-centre-at-western-general-hospital-edinburgh"},{"id":"nct01316744-beatson-west-of-scotland-cancer-centre-glasgow","cat":"research","name":"Beatson West of Scotland Cancer Centre","city":"Glasgow","region":"Scotland","country":"United Kingdom","cc":"GB","lat":55.87414,"lon":-4.26577,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"G12 0YN","condg":["Cancer-related distress"],"status":"RECRUITING","nct":"NCT01316744","study":"Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain","sstatus":"UNKNOWN","sponsor":"University of Glasgow","official":"Marie T. Fallon (Edinburgh Cancer Centre at Western General Hospital); Barry J.A. Laird, MD (Edinburgh Cancer Centre at Western General Hospital)","src":"https://clinicaltrials.gov/study/NCT01316744","contact":{"n":"Contact Person","p":"44-141-301-7033","e":"john.welsh@ggc.scot.nhs.uk"},"phase":"Phase 3","enroll":214,"start":"2009-04","eid":"x:site:nct01316744-beatson-west-of-scotland-cancer-centre-glasgow"},{"id":"nct02016664-st-joseph-s-health-care-western-university-london","cat":"research","name":"St.Joseph's Health Care, Western University","city":"London","region":"Ontario","country":"Canada","cc":"CA","lat":42.98701,"lon":-81.23073,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"N6A4V2","condg":["Chronic pain & headache"],"nct":"NCT02016664","study":"Plasma Concentration of Ketamine and Norketamine .","sstatus":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","official":"Patricia Morley-Foster, MD, FRCPC (Department of Anesthesia and Perioperative Medicine, Western University, Canada.)","src":"https://clinicaltrials.gov/study/NCT02016664","phase":"N/A","enroll":12,"start":"2014-04","eid":"x:site:nct02016664-st-joseph-s-health-care-western-university-london"},{"id":"nct03742557-instituto-nacional-de-neurologia-y-neurocirugia-national-institute-o","cat":"research","name":"Instituto Nacional de Neurología y Neurocirugía (National Institute of Neurology and Neurosurgery)","city":"Mexico City","region":"Tlalpan","country":"Mexico","cc":"MX","lat":19.44,"lon":-99.13721,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"14269","condg":["Depression"],"status":"RECRUITING","nct":"NCT03742557","study":"Evaluation of Schemes of Administration of Intravenous Ketamine in Depression","sstatus":"UNKNOWN","sponsor":"National Institute of Neurology and Neurosurgery, Mexico","official":"Rodrigo Pérez-Esparza, M.D., M.Sc. (National Institute of Neurology and Neurosurgery, Mexico)","src":"https://clinicaltrials.gov/study/NCT03742557","contact":{"n":"Rodrigo Pérez-Esparza, M.D. M.Sc","p":"+5256063822","e":"dr.rodrigope@gmail.com"},"phase":"Phase 3","enroll":30,"start":"2018-10-01","eid":"x:site:nct03742557-instituto-nacional-de-neurologia-y-neurocirugia-national-institute-o"},{"id":"nct06231563-san-francisco-va-medical-center-san-francisco-ca-san-francisco","cat":"research","name":"San Francisco VA Medical Center, San Francisco, CA","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.78241,"lon":-122.41824,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94121-1563","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06231563","study":"Ketamine for Veterans With Parkinson's Disease","sstatus":"RECRUITING","sponsor":"VA Office of Research and Development","official":"Ellen R Bradley, MD (San Francisco VA Medical Center, San Francisco, CA)","src":"https://clinicaltrials.gov/study/NCT06231563","contact":{"n":"Anusha Badathala, MD","p":"415-688-1923","e":"anusha.badathala@ncire.org"},"phase":"Phase 2","enroll":80,"start":"2026-03-01","eid":"x:site:nct06231563-san-francisco-va-medical-center-san-francisco-ca-san-francisco"},{"id":"nct07046611-department-of-pediatrics-at-sohag-university-hospital-sohag","cat":"research","name":"Department of Pediatrics at Sohag University Hospital","city":"Sohag","country":"Egypt","cc":"EG","lat":26.54947,"lon":31.68466,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"82524","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT07046611","study":"Ketamine and Levetiracetam as Second-line Antiseizure Medication for Status Epilepticus in Children","sstatus":"RECRUITING","sponsor":"Sohag University","src":"https://clinicaltrials.gov/study/NCT07046611","contact":{"n":"Abdelrahim A Sadek, MD, PhD","p":"1114232126","e":"abdoneurology@yahoo.com"},"phase":"Phase 2/Phase 3","enroll":124,"start":"2025-07-02","eid":"x:site:nct07046611-department-of-pediatrics-at-sohag-university-hospital-sohag"},{"id":"nct03105765-dr-horst-schmidt-klinik-wiesbaden","cat":"research","name":"Dr. Horst Schmidt Klinik","city":"Wiesbaden","region":"Hesse","country":"Germany","cc":"DE","lat":50.09236,"lon":8.23856,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"65199","condg":["Chronic pain & headache"],"nct":"NCT03105765","study":"Acute and Chronic Pain, Especially Neuropathic Pain, After Thoracotomy and Continuous Application of Ketamine.","sstatus":"COMPLETED","sponsor":"Dr. Horst Schmidt Klinik GmbH","src":"https://clinicaltrials.gov/study/NCT03105765","phase":"N/A","enroll":200,"start":"2011-01","eid":"x:site:nct03105765-dr-horst-schmidt-klinik-wiesbaden"},{"id":"nct02697071-carilion-roanoke-memorial-emergency-department-roanoke","cat":"research","name":"Carilion Roanoke Memorial Emergency Department","city":"Roanoke","region":"Virginia","country":"United States","cc":"US","lat":37.27986,"lon":-79.94223,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"24014","condg":["Chronic pain & headache"],"nct":"NCT02697071","study":"Ketamine for Acute Migraine in the Emergency Department","sstatus":"COMPLETED","sponsor":"Carilion Clinic","official":"Corey Corey, MD (Carilion Clinic)","src":"https://clinicaltrials.gov/study/NCT02697071","phase":"N/A","enroll":34,"start":"2016-02","eid":"x:site:nct02697071-carilion-roanoke-memorial-emergency-department-roanoke"},{"id":"nct04527757-university-hospital-brno-brno","cat":"research","name":"University Hospital Brno","city":"Brno","country":"Czechia","cc":"CZ","lat":49.20138,"lon":16.61488,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"62500","condg":["Other"],"nct":"NCT04527757","study":"Duration of Anaesthesia Induction in Paediatric Patients: Prospective Observational Trial","sstatus":"COMPLETED","sponsor":"Brno University Hospital","official":"Petr Štourač, prof. MD., Ph.D. (Faculty of medicince Masaryk University and University Hospital Brno)","src":"https://clinicaltrials.gov/study/NCT04527757","enroll":1000,"start":"2020-10-01","eid":"x:site:nct04527757-university-hospital-brno-brno"},{"id":"nct06916403-wilderman-medical-clinic-thornhill","cat":"research","name":"Wilderman Medical Clinic","city":"Thornhill","region":"Ontario","country":"Canada","cc":"CA","lat":43.81044,"lon":-79.41512,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"L4J 1W3","condg":["Chronic pain & headache"],"nct":"NCT06916403","study":"Safety and Efficacy of Ketamine Intravenous Infusions in the Treatment of Fibromyalgia","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Wilderman Medical Clinic","official":"Igor Wilderman, MD (Wilderman Medical Clinic)","src":"https://clinicaltrials.gov/study/NCT06916403","enroll":50,"start":"2020-11-30","eid":"x:site:nct06916403-wilderman-medical-clinic-thornhill"},{"id":"nct01089361-beth-israel-deaconess-medical-center-boston","cat":"research","name":"Beth Israel Deaconess Medical Center","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.35245,"lon":-71.04965,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02215","condg":["Other"],"nct":"NCT01089361","study":"Immunomodulatory Properties of Ketamine in Sepsis","sstatus":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","official":"Daniel Talmor, MD, MPH (Beth Israel Deaconess Medical Center)","src":"https://clinicaltrials.gov/study/NCT01089361","phase":"Phase 1/Phase 2","enroll":19,"start":"2009-12","eid":"x:site:nct01089361-beth-israel-deaconess-medical-center-boston"},{"id":"nct07838831-tanta-university-tanta","cat":"research","name":"Tanta University","city":"Tanta","country":"Egypt","cc":"EG","lat":30.78918,"lon":30.99943,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT07838831","study":"Ketamine Versus Dexmedetomidine as Adjuvants to Bupivacaine in Ultrasound Guided Bilateral Superficial Cervical Plexus Block in Thyroidectomy","sstatus":"COMPLETED","sponsor":"Tanta University","src":"https://clinicaltrials.gov/study/NCT07838831","phase":"N/A","enroll":60,"start":"2025-08-31","eid":"x:site:nct07838831-tanta-university-tanta"},{"id":"nct02422303-university-hospital-san-antonio","cat":"research","name":"University Hospital","city":"San Antonio","region":"Texas","country":"United States","cc":"US","lat":29.41504,"lon":-98.49707,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"78229","condg":["Depression"],"nct":"NCT02422303","study":"Effects of Low Dose Ketamine Given at Induction of Anesthesia on Postoperative Mood in Patients With Depressive Symptoms","sstatus":"TERMINATED","sponsor":"The University of Texas Health Science Center at San Antonio","official":"Bonny C Gillis, M.D. (Department of Anesthesiology UTHSCSA)","src":"https://clinicaltrials.gov/study/NCT02422303","phase":"N/A","enroll":12,"start":"2015-12","eid":"x:site:nct02422303-university-hospital-san-antonio"},{"id":"nct02649231-nihr-exeter-clinical-research-facility-exeter","cat":"research","name":"NIHR Exeter Clinical Research Facility","city":"Exeter","country":"United Kingdom","cc":"GB","lat":50.72233,"lon":-3.53179,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"EX4 5DW","condg":["Addiction & substance use"],"nct":"NCT02649231","study":"Ketamine for Reduction of Alcoholic Relapse","sstatus":"COMPLETED","sponsor":"University College, London","official":"Celia Morgan, Ph.D. (UCL)","src":"https://clinicaltrials.gov/study/NCT02649231","phase":"Phase 2","enroll":96,"start":"2016-10","eid":"x:site:nct02649231-nihr-exeter-clinical-research-facility-exeter"},{"id":"nct02649231-nihr-uclh-clinical-research-facility-london","cat":"research","name":"NIHR UCLH Clinical Research Facility","city":"London","country":"United Kingdom","cc":"GB","lat":51.50265,"lon":-0.13445,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"NW1 2BU","condg":["Addiction & substance use"],"nct":"NCT02649231","study":"Ketamine for Reduction of Alcoholic Relapse","sstatus":"COMPLETED","sponsor":"University College, London","official":"Celia Morgan, Ph.D. (UCL)","src":"https://clinicaltrials.gov/study/NCT02649231","phase":"Phase 2","enroll":96,"start":"2016-10","eid":"x:site:nct02649231-nihr-uclh-clinical-research-facility-london"},{"id":"nct06968546-hopital-lenval-nice","cat":"research","name":"Hôpital lenval","city":"Nice","region":"France","country":"France","cc":"FR","lat":43.70901,"lon":7.26001,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06000","condg":["PTSD & trauma","Chronic pain & headache"],"nct":"NCT06968546","study":"Sufentanil Versus Ketamine Intranasally in the Management of Severe Acute Trauma-related Pain in Children.","sstatus":"NOT_YET_RECRUITING","sponsor":"Fondation Lenval","official":"MARCO OLLA, MD (Fondation Lenval Hôpitaux pediatrique Nice chu Lenval)","src":"https://clinicaltrials.gov/study/NCT06968546","contact":{"n":"Marco OLLA, MD","p":"+33 4-92-03-04-29","e":"marco.olla@hpu.lenval.com"},"phase":"Phase 2","enroll":116,"start":"2026-02-05","eid":"x:site:nct06968546-hopital-lenval-nice"},{"id":"nct04129086-the-university-of-texas-health-science-center-at-houston-houston","cat":"research","name":"The University of Texas Health Science Center at Houston","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.7637,"lon":-95.37019,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"77030","condg":["PTSD & trauma","Addiction & substance use","Chronic pain & headache"],"nct":"NCT04129086","study":"Ketamine for Acute Pain Management After Trauma","sstatus":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","official":"John P Harvin, MD (The University of Texas Health Science Center, Houston)","src":"https://clinicaltrials.gov/study/NCT04129086","phase":"Phase 4","enroll":305,"start":"2020-07-01","eid":"x:site:nct04129086-the-university-of-texas-health-science-center-at-houston-houston"},{"id":"nct06736769-university-of-california-san-francisco-san-francisco","cat":"research","name":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.78175,"lon":-122.42897,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94158","condg":["Eating disorders"],"nct":"NCT06736769","study":"Ketamine Effects on Learning In Eating Disorders","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Amanda Downey, MD","official":"Amanda E. Downey, MD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT06736769","phase":"Phase 2","enroll":20,"start":"2025-06-05","eid":"x:site:nct06736769-university-of-california-san-francisco-san-francisco"},{"id":"nct01369680-university-of-rochester-rochester","cat":"research","name":"University of Rochester","city":"Rochester","region":"New York","country":"United States","cc":"US","lat":43.15878,"lon":-77.61881,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"14642","condg":["Chronic pain & headache"],"nct":"NCT01369680","study":"Oral Ketamine for Control of Chronic Pain in Children","sstatus":"COMPLETED","sponsor":"University of Rochester","official":"David Korones, MD (University of Rochester)","src":"https://clinicaltrials.gov/study/NCT01369680","phase":"Phase 1","enroll":12,"start":"2011-05","eid":"x:site:nct01369680-university-of-rochester-rochester"},{"id":"nct02823977-university-of-colorado-hospital-aurora","cat":"research","name":"University of Colorado Hospital","city":"Aurora","region":"Colorado","country":"United States","cc":"US","lat":39.72863,"lon":-104.82576,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"80010","condg":["Addiction & substance use"],"nct":"NCT02823977","study":"Ketamine vs. Placebo as Adjunctive Therapies for Severe Alcohol Withdrawal","sstatus":"WITHDRAWN","sponsor":"University of Colorado, Denver","official":"Robert MacLaren, PharmD, MPH (University of Colorado, Denver)","src":"https://clinicaltrials.gov/study/NCT02823977","phase":"Phase 4","start":"2018-02","eid":"x:site:nct02823977-university-of-colorado-hospital-aurora"},{"id":"nct06498700-faculty-of-medicine-zagazig-university-zagazig","cat":"research","name":"Faculty of Medicine,Zagazig University","city":"Zagazig","region":"Sharqia Province","country":"Egypt","cc":"EG","lat":30.58735,"lon":31.49141,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44519","condg":["Other"],"nct":"NCT06498700","study":"Intraoperative Subanesthetic Ketamine Versus Dexmedetomidine Infusion for Prevention of Post-traumatic Stress Disorder After Traumatic Brain Surgeries","sstatus":"UNKNOWN","sponsor":"Zagazig University","official":"marwa M Medhat (Zagazig University)","src":"https://clinicaltrials.gov/study/NCT06498700","phase":"N/A","enroll":52,"start":"2024-07-15","eid":"x:site:nct06498700-faculty-of-medicine-zagazig-university-zagazig"},{"id":"nct03756129-novartis-investigative-site-birmingham","cat":"research","name":"Novartis Investigative Site","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.52645,"lon":-86.79585,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"35294","condg":["Depression"],"nct":"NCT03756129","study":"Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Novartis Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT03756129","phase":"Phase 2","enroll":70,"start":"2019-02-08","eid":"x:site:nct03756129-novartis-investigative-site-birmingham"},{"id":"nct03756129-novartis-investigative-site-garden-grove","cat":"research","name":"Novartis Investigative Site","city":"Garden Grove","region":"California","country":"United States","cc":"US","lat":33.7796,"lon":-117.94921,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"92845","condg":["Depression"],"nct":"NCT03756129","study":"Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Novartis Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT03756129","phase":"Phase 2","enroll":70,"start":"2019-02-08","eid":"x:site:nct03756129-novartis-investigative-site-garden-grove"},{"id":"nct03756129-novartis-investigative-site-oakland","cat":"research","name":"Novartis Investigative Site","city":"Oakland","region":"California","country":"United States","cc":"US","lat":37.80432,"lon":-122.26096,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94607","condg":["Depression"],"nct":"NCT03756129","study":"Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Novartis Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT03756129","phase":"Phase 2","enroll":70,"start":"2019-02-08","eid":"x:site:nct03756129-novartis-investigative-site-oakland"},{"id":"nct03756129-novartis-investigative-site-bradenton","cat":"research","name":"Novartis Investigative Site","city":"Bradenton","region":"Florida","country":"United States","cc":"US","lat":27.49145,"lon":-82.5759,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"34201","condg":["Depression"],"nct":"NCT03756129","study":"Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Novartis Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT03756129","phase":"Phase 2","enroll":70,"start":"2019-02-08","eid":"x:site:nct03756129-novartis-investigative-site-bradenton"},{"id":"nct03756129-novartis-investigative-site-atlanta","cat":"research","name":"Novartis Investigative Site","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.75225,"lon":-84.37871,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"30331","condg":["Depression"],"nct":"NCT03756129","study":"Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Novartis Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT03756129","phase":"Phase 2","enroll":70,"start":"2019-02-08","eid":"x:site:nct03756129-novartis-investigative-site-atlanta"},{"id":"nct03756129-novartis-investigative-site-skokie","cat":"research","name":"Novartis Investigative Site","city":"Skokie","region":"Illinois","country":"United States","cc":"US","lat":42.03171,"lon":-87.73155,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60076","condg":["Depression"],"nct":"NCT03756129","study":"Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Novartis Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT03756129","phase":"Phase 2","enroll":70,"start":"2019-02-08","eid":"x:site:nct03756129-novartis-investigative-site-skokie"},{"id":"nct03756129-novartis-investigative-site-rockville","cat":"research","name":"Novartis Investigative Site","city":"Rockville","region":"Maryland","country":"United States","cc":"US","lat":39.09402,"lon":-77.15714,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20850","condg":["Depression"],"nct":"NCT03756129","study":"Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Novartis Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT03756129","phase":"Phase 2","enroll":70,"start":"2019-02-08","eid":"x:site:nct03756129-novartis-investigative-site-rockville"},{"id":"nct03756129-novartis-investigative-site-berlin","cat":"research","name":"Novartis Investigative Site","city":"Berlin","region":"New Jersey","country":"United States","cc":"US","lat":44.45667,"lon":-71.17769,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"08009","condg":["Depression"],"nct":"NCT03756129","study":"Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Novartis Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT03756129","phase":"Phase 2","enroll":70,"start":"2019-02-08","eid":"x:site:nct03756129-novartis-investigative-site-berlin"},{"id":"nct03756129-novartis-investigative-site-palma-de-mallorca","cat":"research","name":"Novartis Investigative Site","city":"Palma de Mallorca","region":"Balearic Islands","country":"Spain","cc":"ES","lat":39.57151,"lon":2.63871,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"07120","condg":["Depression"],"nct":"NCT03756129","study":"Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Novartis Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT03756129","phase":"Phase 2","enroll":70,"start":"2019-02-08","eid":"x:site:nct03756129-novartis-investigative-site-palma-de-mallorca"},{"id":"nct03756129-novartis-investigative-site-vitoria-gasteiz","cat":"research","name":"Novartis Investigative Site","city":"Vitoria-Gasteiz","region":"Basque Country","country":"Spain","cc":"ES","lat":42.84447,"lon":-2.68063,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"01004","condg":["Depression"],"nct":"NCT03756129","study":"Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Novartis Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT03756129","phase":"Phase 2","enroll":70,"start":"2019-02-08","eid":"x:site:nct03756129-novartis-investigative-site-vitoria-gasteiz"},{"id":"nct03756129-novartis-investigative-site-barcelona","cat":"research","name":"Novartis Investigative Site","city":"Barcelona","region":"Catalonia","country":"Spain","cc":"ES","lat":41.39731,"lon":2.1501,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"08036","condg":["Depression"],"nct":"NCT03756129","study":"Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Novartis Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT03756129","phase":"Phase 2","enroll":70,"start":"2019-02-08","eid":"x:site:nct03756129-novartis-investigative-site-barcelona"},{"id":"nct03756129-novartis-investigative-site-barcelona-2","cat":"research","name":"Novartis Investigative Site","city":"Barcelona","country":"Spain","cc":"ES","lat":41.38667,"lon":2.15028,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"08006","condg":["Depression"],"nct":"NCT03756129","study":"Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Novartis Pharmaceuticals","src":"https://clinicaltrials.gov/study/NCT03756129","phase":"Phase 2","enroll":70,"start":"2019-02-08","eid":"x:site:nct03756129-novartis-investigative-site-barcelona-2"},{"id":"nct00921765-ullevaal-university-hospital-oslo","cat":"research","name":"Ullevaal University Hospital","city":"Oslo","country":"Norway","cc":"NO","lat":59.90224,"lon":10.74256,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"NO-0407","condg":["Chronic pain & headache"],"nct":"NCT00921765","study":"Reversal of Ketamine Pharmacodynamic Effects With Naloxone","sstatus":"TERMINATED","sponsor":"Ullevaal University Hospital","official":"Olav Hustveit, MD, PhD (University of Oslo); Elena Landari, DDS (University of Oslo)","src":"https://clinicaltrials.gov/study/NCT00921765","phase":"Phase 4","enroll":3,"start":"2009-12","eid":"x:site:nct00921765-ullevaal-university-hospital-oslo"},{"id":"nct03799900-vince-and-associates-clinical-research-inc-overland-park","cat":"research","name":"Vince and Associates Clinical Research Inc","city":"Overland Park","region":"Kansas","country":"United States","cc":"US","lat":38.9723,"lon":-94.665,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"66212","condg":["Other"],"nct":"NCT03799900","study":"Assessment of Abuse Potential of Rapastinel in Humans","sstatus":"COMPLETED","sponsor":"Naurex, Inc, an affiliate of Allergan plc","official":"Sheng Fang Su (Allergan)","src":"https://clinicaltrials.gov/study/NCT03799900","phase":"Phase 1","enroll":72,"start":"2018-11-01","eid":"x:site:nct03799900-vince-and-associates-clinical-research-inc-overland-park"},{"id":"nct04260607-naval-medical-center-camp-lejeune-marine-corps-base-camp-lejeune","cat":"research","name":"Naval Medical Center Camp Lejeune","city":"Marine Corps Base Camp Lejeune","region":"North Carolina","country":"United States","cc":"US","lat":35.1999,"lon":-79.2829,"gp":"region","unnamed":0,"drugs":["ketamine"],"zip":"28547","condg":["Depression"],"nct":"NCT04260607","study":"Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department","sstatus":"TERMINATED","sponsor":"Naval Medical Center Camp Lejeune","official":"Nathan H Butler, DO (Naval Medical Center Camp Lejeune)","src":"https://clinicaltrials.gov/study/NCT04260607","phase":"Phase 3","enroll":1,"start":"2020-01-14","eid":"x:site:nct04260607-naval-medical-center-camp-lejeune-marine-corps-base-camp-lejeune"},{"id":"nct05421065-university-of-iowa-iowa-city","cat":"research","name":"University of Iowa","city":"Iowa City","region":"Iowa","country":"United States","cc":"US","lat":41.66664,"lon":-91.53097,"gp":"city","unnamed":0,"drugs":["ketamine","psilocybin"],"zip":"52242","condg":["Addiction & substance use"],"nct":"NCT05421065","study":"Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Peggy C Nopoulos","official":"Peggy C Nopoulos, MD (University of Iowa)","src":"https://clinicaltrials.gov/study/NCT05421065","phase":"Phase 2","enroll":20,"start":"2024-02-02","eid":"x:site:nct05421065-university-of-iowa-iowa-city"},{"id":"nct02783430-chu-amiens-picardie-amiens","cat":"research","name":"Chu Amiens Picardie","city":"Amiens","country":"France","cc":"FR","lat":49.89704,"lon":2.29393,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT02783430","study":"Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease","sstatus":"COMPLETED","sponsor":"University Hospital, Lille","official":"Antoine LEMAIRE, MD (Hospital of Valenciennes)","src":"https://clinicaltrials.gov/study/NCT02783430","phase":"Phase 2/Phase 3","enroll":42,"start":"2016-09-08","eid":"x:site:nct02783430-chu-amiens-picardie-amiens"},{"id":"nct02783430-ch-calais-calais","cat":"research","name":"Ch Calais","city":"Calais","country":"France","cc":"FR","lat":50.95886,"lon":1.84906,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT02783430","study":"Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease","sstatus":"COMPLETED","sponsor":"University Hospital, Lille","official":"Antoine LEMAIRE, MD (Hospital of Valenciennes)","src":"https://clinicaltrials.gov/study/NCT02783430","phase":"Phase 2/Phase 3","enroll":42,"start":"2016-09-08","eid":"x:site:nct02783430-ch-calais-calais"},{"id":"nct02783430-maison-medicale-jean-xxiii-lille-lille","cat":"research","name":"Maison Medicale Jean Xxiii - Lille","city":"Lille","country":"France","cc":"FR","lat":50.63716,"lon":3.06317,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"59037","condg":["Depression"],"nct":"NCT02783430","study":"Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease","sstatus":"COMPLETED","sponsor":"University Hospital, Lille","official":"Antoine LEMAIRE, MD (Hospital of Valenciennes)","src":"https://clinicaltrials.gov/study/NCT02783430","phase":"Phase 2/Phase 3","enroll":42,"start":"2016-09-08","eid":"x:site:nct02783430-maison-medicale-jean-xxiii-lille-lille"},{"id":"nct02783430-university-hospital-lille","cat":"research","name":"University Hospital,","city":"Lille","country":"France","cc":"FR","lat":50.62502,"lon":3.05921,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT02783430","study":"Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease","sstatus":"COMPLETED","sponsor":"University Hospital, Lille","official":"Antoine LEMAIRE, MD (Hospital of Valenciennes)","src":"https://clinicaltrials.gov/study/NCT02783430","phase":"Phase 2/Phase 3","enroll":42,"start":"2016-09-08","eid":"x:site:nct02783430-university-hospital-lille"},{"id":"nct02783430-groupt-hopitaux-instit-catho-de-lille-lomme-lomme","cat":"research","name":"Groupt Hopitaux Instit Catho de Lille - Lomme","city":"Lomme","country":"France","cc":"FR","lat":50.64862,"lon":2.98851,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT02783430","study":"Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease","sstatus":"COMPLETED","sponsor":"University Hospital, Lille","official":"Antoine LEMAIRE, MD (Hospital of Valenciennes)","src":"https://clinicaltrials.gov/study/NCT02783430","phase":"Phase 2/Phase 3","enroll":42,"start":"2016-09-08","eid":"x:site:nct02783430-groupt-hopitaux-instit-catho-de-lille-lomme-lomme"},{"id":"nct02783430-c-h-de-roubaix-roubaix","cat":"research","name":"C.H de Roubaix","city":"Roubaix","country":"France","cc":"FR","lat":50.69492,"lon":3.16397,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT02783430","study":"Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease","sstatus":"COMPLETED","sponsor":"University Hospital, Lille","official":"Antoine LEMAIRE, MD (Hospital of Valenciennes)","src":"https://clinicaltrials.gov/study/NCT02783430","phase":"Phase 2/Phase 3","enroll":42,"start":"2016-09-08","eid":"x:site:nct02783430-c-h-de-roubaix-roubaix"},{"id":"nct02783430-ch-ghpso-senlis-senlis","cat":"research","name":"Ch Ghpso Senlis","city":"Senlis","country":"France","cc":"FR","lat":49.20042,"lon":2.59353,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT02783430","study":"Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease","sstatus":"COMPLETED","sponsor":"University Hospital, Lille","official":"Antoine LEMAIRE, MD (Hospital of Valenciennes)","src":"https://clinicaltrials.gov/study/NCT02783430","phase":"Phase 2/Phase 3","enroll":42,"start":"2016-09-08","eid":"x:site:nct02783430-ch-ghpso-senlis-senlis"},{"id":"nct02783430-ch-tourcoing-tourcoing","cat":"research","name":"Ch Tourcoing","city":"Tourcoing","country":"France","cc":"FR","lat":50.72264,"lon":3.16169,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT02783430","study":"Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease","sstatus":"COMPLETED","sponsor":"University Hospital, Lille","official":"Antoine LEMAIRE, MD (Hospital of Valenciennes)","src":"https://clinicaltrials.gov/study/NCT02783430","phase":"Phase 2/Phase 3","enroll":42,"start":"2016-09-08","eid":"x:site:nct02783430-ch-tourcoing-tourcoing"},{"id":"nct02783430-centre-hospitalier-de-valenciennes-valenciennes","cat":"research","name":"Centre Hospitalier de Valenciennes","city":"Valenciennes","country":"France","cc":"FR","lat":50.36318,"lon":3.51438,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT02783430","study":"Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease","sstatus":"COMPLETED","sponsor":"University Hospital, Lille","official":"Antoine LEMAIRE, MD (Hospital of Valenciennes)","src":"https://clinicaltrials.gov/study/NCT02783430","phase":"Phase 2/Phase 3","enroll":42,"start":"2016-09-08","eid":"x:site:nct02783430-centre-hospitalier-de-valenciennes-valenciennes"},{"id":"nct05383313-national-institute-of-mental-health-klecany","cat":"research","name":"National Institute of Mental Health","city":"Klecany","country":"Czechia","cc":"CZ","lat":50.1734,"lon":14.41915,"gp":"city","unnamed":0,"drugs":["ketamine","psilocybin"],"zip":"250 67","condg":["Depression"],"status":"RECRUITING","nct":"NCT05383313","study":"Psilocybin Versus Ketamine in Treatment-Resistant Depression","sstatus":"UNKNOWN","sponsor":"National Institute of Mental Health, Czech Republic","src":"https://clinicaltrials.gov/study/NCT05383313","contact":{"n":"Vivian Winkler, MD","p":"773137373","e":"vivian.winkler@nudz.cz"},"phase":"Phase 2","enroll":60,"start":"2021-05-01","eid":"x:site:nct05383313-national-institute-of-mental-health-klecany"},{"id":"nct02494830-department-of-clinical-pharmacology-ernst-moritz-arndt-university-gr","cat":"research","name":"Department of Clinical Pharmacology, Ernst-Moritz-Arndt-University Greifswald","city":"Greifswald","region":"Mecklenburg-Vorpommern","country":"Germany","cc":"DE","lat":54.07903,"lon":13.41011,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"17487","condg":["Healthy volunteers"],"nct":"NCT02494830","study":"Single Dose Administration of Ketamine 10, 20, 40 and 80 mg and 5 mg Solution for Infusion in 15 Healthy Subjects","sstatus":"COMPLETED","sponsor":"University Medicine Greifswald","official":"Werner Siegmund, Prof (Department of Clinical Pharmacology)","src":"https://clinicaltrials.gov/study/NCT02494830","phase":"Phase 1","enroll":15,"start":"2014-08","eid":"x:site:nct02494830-department-of-clinical-pharmacology-ernst-moritz-arndt-university-gr"},{"id":"nct04281628-faculty-of-medicine-cairo-university-cairo","cat":"research","name":"Faculty of Medicine, Cairo University.","city":"Cairo","country":"Egypt","cc":"EG","lat":30.05562,"lon":31.25649,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11451","condg":["Other"],"nct":"NCT04281628","study":"Comparison Between Low-dose Ketamine Infusion and Intravenous Morphine","sstatus":"COMPLETED","sponsor":"Cairo University","official":"amr wahadan, MD (lecture)","src":"https://clinicaltrials.gov/study/NCT04281628","phase":"Phase 4","enroll":80,"start":"2019-02-21","eid":"x:site:nct04281628-faculty-of-medicine-cairo-university-cairo"},{"id":"nct05786365-cagr-turkucu-aksaray","cat":"research","name":"Çağrı Türkücü","city":"Aksaray","country":"Turkey","cc":"TR","lat":38.37081,"lon":34.01544,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT05786365","study":"Comparison of Emergence/Dysphoric Reaction Frequency of Using 2 Different Doses Ketamine","sstatus":"COMPLETED","sponsor":"Aksaray University Training and Research Hospital","official":"Kamil Kokulu, M.D. (Aksaray UTRH)","src":"https://clinicaltrials.gov/study/NCT05786365","enroll":108,"start":"2023-01-01","eid":"x:site:nct05786365-cagr-turkucu-aksaray"},{"id":"nct03273231-department-of-anesthesiology-and-pain-medicine-yonsei-university-col","cat":"research","name":"Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine","city":"Seoul","country":"South Korea","cc":"KR","lat":37.56746,"lon":126.98362,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"03722","condg":["Cancer-related distress"],"status":"RECRUITING","nct":"NCT03273231","study":"The Effect of Ketamine on Immune Function and Prognosis in Patients Undergoing Colorectal Cancer Resection","sstatus":"UNKNOWN","sponsor":"Yonsei University","src":"https://clinicaltrials.gov/study/NCT03273231","contact":{"n":"Jin Sun Cho, MD","p":"82-2-2228-5448","e":"chjs0214@yuhs.ac"},"phase":"N/A","enroll":100,"start":"2017-09-01","eid":"x:site:nct03273231-department-of-anesthesiology-and-pain-medicine-yonsei-university-col"},{"id":"nct00595530-university-of-connecticut-health-center-farmington","cat":"research","name":"University of Connecticut Health Center","city":"Farmington","region":"Connecticut","country":"United States","cc":"US","lat":36.71945,"lon":-108.22598,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06030","condg":["Other"],"nct":"NCT00595530","study":"Low-Dose Ketamine Infusion for Children With Sickle Cell Disease-Related Pain","sstatus":"TERMINATED","sponsor":"Connecticut Children's Medical Center","official":"William T Zempsky, MD (Connecticut Children's Medical Center)","src":"https://clinicaltrials.gov/study/NCT00595530","phase":"Phase 2","enroll":3,"start":"2008-03-04","eid":"x:site:nct00595530-university-of-connecticut-health-center-farmington"},{"id":"nct00595530-connecticut-children-s-medical-center-hartford","cat":"research","name":"Connecticut Children's Medical Center","city":"Hartford","region":"Connecticut","country":"United States","cc":"US","lat":41.75839,"lon":-72.68787,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06106","condg":["Other"],"nct":"NCT00595530","study":"Low-Dose Ketamine Infusion for Children With Sickle Cell Disease-Related Pain","sstatus":"TERMINATED","sponsor":"Connecticut Children's Medical Center","official":"William T Zempsky, MD (Connecticut Children's Medical Center)","src":"https://clinicaltrials.gov/study/NCT00595530","phase":"Phase 2","enroll":3,"start":"2008-03-04","eid":"x:site:nct00595530-connecticut-children-s-medical-center-hartford"},{"id":"nct02734602-pet-center-new-haven","cat":"research","name":"PET Center","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.29963,"lon":-72.93451,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06519","condg":["Depression","PTSD & trauma"],"nct":"NCT02734602","study":"Imaging SV2A in Mood Disorders","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","official":"Irina Esterlis, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT02734602","phase":"N/A","enroll":130,"start":"2016-04","eid":"x:site:nct02734602-pet-center-new-haven"},{"id":"nct04365985-william-beaumont-hospital-royal-oak","cat":"research","name":"William Beaumont Hospital","city":"Royal Oak","region":"Michigan","country":"United States","cc":"US","lat":42.49932,"lon":-83.14281,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"48073","condg":["Other"],"nct":"NCT04365985","study":"Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19","sstatus":"TERMINATED","sponsor":"Corewell Health East","official":"Matthew Sims, MD PhD (Beaumont Health)","src":"https://clinicaltrials.gov/study/NCT04365985","phase":"Phase 2","enroll":70,"start":"2020-04-29","eid":"x:site:nct04365985-william-beaumont-hospital-royal-oak"},{"id":"nct00611897-vha-connecticut-west-haven","cat":"research","name":"VHA Connecticut","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.27917,"lon":-72.95745,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06516","condg":["Neurology & cognition"],"nct":"NCT00611897","study":"N-acetylcysteine and NMDA Antagonist Interactions","sstatus":"COMPLETED","sponsor":"Yale University","official":"Handan Gunduz-Bruce, M.D. (Yale University)","src":"https://clinicaltrials.gov/study/NCT00611897","phase":"Phase 1/Phase 2","enroll":16,"start":"2006-01","eid":"x:site:nct00611897-vha-connecticut-west-haven"},{"id":"nct01371110-clinical-research-centers-at-icahn-school-of-medicine-at-mount-sinai","cat":"research","name":"Clinical Research Centers at Icahn School of Medicine at Mount Sinai","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70462,"lon":-74.00639,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10029","condg":["OCD"],"nct":"NCT01371110","study":"Intravenous Ketamine in the Treatment of Obsessive-Compulsive Disorder","sstatus":"TERMINATED","sponsor":"Wayne Goodman MD","official":"Wayne K Goodman, MD (Baylor College of Medicine (previously Icahn School of Medicine at Mount Sinai)); Kyle Lapidus, MD ((previously Icahn School of Medicine at Mount Sinai))","src":"https://clinicaltrials.gov/study/NCT01371110","phase":"Phase 1/Phase 2","enroll":3,"start":"2012-06","eid":"x:site:nct01371110-clinical-research-centers-at-icahn-school-of-medicine-at-mount-sinai"},{"id":"nct03666390-taipei-veterans-general-hospital-taipei","cat":"research","name":"Taipei Veterans General Hospital","city":"Taipei","country":"Taiwan","cc":"TW","lat":25.0453,"lon":121.51966,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"111","condg":["Depression"],"status":"RECRUITING","nct":"NCT03666390","study":"Using a Low Dose of Ketamine vs. Active Placebo in Treating Severe Depression and Suicide","sstatus":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","official":"Mu-Hong Chen, M.D. (Taipei Veterans General Hospital, Taiwan)","src":"https://clinicaltrials.gov/study/NCT03666390","contact":{"n":"Mu-Hong Chen, M.D.","p":"886 -2- 28712121","e":"kremer7119@gmail.com"},"phase":"N/A","enroll":48,"start":"2018-09-10","eid":"x:site:nct03666390-taipei-veterans-general-hospital-taipei"},{"id":"nct05915013-yale-university-new-haven","cat":"research","name":"Yale University","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.30867,"lon":-72.92416,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06511","condg":["Depression","PTSD & trauma"],"status":"RECRUITING","nct":"NCT05915013","study":"Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response","sstatus":"RECRUITING","sponsor":"Yale University","official":"John Krystal, MD (Yale University Medical School); Naomi R Driesen, Ph.D. (Yale University Medical School)","src":"https://clinicaltrials.gov/study/NCT05915013","contact":{"n":"Naomi Drieson, PhD","p":"203-508-7765","e":"naomi.driesen@yale.edu"},"phase":"Phase 1","enroll":50,"start":"2023-09-07","eid":"x:site:nct05915013-yale-university-new-haven"},{"id":"nct04199468-va-connecticut-healthcare-system-west-haven","cat":"research","name":"VA Connecticut Healthcare System","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.27804,"lon":-72.94738,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06516","condg":["Addiction & substance use"],"nct":"NCT04199468","study":"THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis","sstatus":"COMPLETED","sponsor":"Yale University","official":"Rajiv Radhakrishnan, M.D. (Yale University)","src":"https://clinicaltrials.gov/study/NCT04199468","phase":"Phase 1","enroll":22,"start":"2019-09-24","eid":"x:site:nct04199468-va-connecticut-healthcare-system-west-haven"},{"id":"nct03043430-san-antonio-military-medical-center-fort-sam-houston","cat":"research","name":"San Antonio Military Medical Center","city":"Fort Sam Houston","region":"Texas","country":"United States","cc":"US","lat":29.43499,"lon":-98.4821,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"78234","condg":["Anxiety"],"nct":"NCT03043430","study":"Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients","sstatus":"TERMINATED","sponsor":"Brooke Army Medical Center","official":"Nadia M Pearson, MD (Faculty Physician)","src":"https://clinicaltrials.gov/study/NCT03043430","phase":"Phase 4","enroll":10,"start":"2016-05","eid":"x:site:nct03043430-san-antonio-military-medical-center-fort-sam-houston"},{"id":"nct06824532-stratton-va-medical-center-albany","cat":"research","name":"Stratton VA Medical Center","city":"Albany","region":"New York","country":"United States","cc":"US","lat":42.6563,"lon":-73.76352,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"12208","condg":["Depression"],"status":"RECRUITING","nct":"NCT06824532","study":"Veteran's Perceptions of Ketamine-Assisted Psychotherapy for Depression and End-of-Life","sstatus":"RECRUITING","sponsor":"Albany Research Institute, Inc.","official":"Caitlin Holley, Ph.D. (Albany Research Institute, Inc.)","src":"https://clinicaltrials.gov/study/NCT06824532","contact":{"n":"Caitlin Holley, Ph.D.","p":"518-626-5365","e":"caitlin.holley@va.gov"},"enroll":30,"start":"2024-11-08","eid":"x:site:nct06824532-stratton-va-medical-center-albany"},{"id":"nct02235012-centre-hospitalier-sainte-anne-paris","cat":"research","name":"Centre Hospitalier Sainte Anne","city":"Paris","country":"France","cc":"FR","lat":48.85412,"lon":2.35148,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75014","condg":["Healthy volunteers"],"nct":"NCT02235012","study":"Cognitive Biases Under Ketamine","sstatus":"COMPLETED","sponsor":"Centre Hospitalier St Anne","official":"Raphaël GAILLARD (Centre Hospitalier St Anne)","src":"https://clinicaltrials.gov/study/NCT02235012","phase":"N/A","enroll":84,"start":"2014-09-08","eid":"x:site:nct02235012-centre-hospitalier-sainte-anne-paris"},{"id":"nct06419985-pain-center-keck-medical-center-of-university-of-southern-california","cat":"research","name":"Pain Center, Keck Medical Center of University of Southern California","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.04192,"lon":-118.25088,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"90033","condg":["Chronic pain & headache"],"nct":"NCT06419985","study":"Ketamine HCl Prolonged Release Oral Tablets for CRPS","sstatus":"SUSPENDED","sponsor":"University of Southern California","official":"Steven Richeimer, MD (Keck Medical Center of USC)","src":"https://clinicaltrials.gov/study/NCT06419985","phase":"Phase 2","enroll":65,"start":"2027-01","eid":"x:site:nct06419985-pain-center-keck-medical-center-of-university-of-southern-california"},{"id":"nct00680433-wesley-hospital-sydney","cat":"research","name":"Wesley Hospital","city":"Sydney","region":"New South Wales","country":"Australia","cc":"AU","lat":-33.87251,"lon":151.21584,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"2217","condg":["Depression"],"nct":"NCT00680433","study":"Ketamine as an Anaesthetic Agent in Electroconvulsive Therapy (ECT)","sstatus":"COMPLETED","sponsor":"Northside Clinic, Australia","official":"Colleen K Loo, MB BS FRANZCP, MD (University of New South Wales)","src":"https://clinicaltrials.gov/study/NCT00680433","phase":"Phase 4","enroll":83,"start":"2008-04","eid":"x:site:nct00680433-wesley-hospital-sydney"},{"id":"nct01602185-chu-clermont-ferrand-clermont-ferrand","cat":"research","name":"CHU Clermont-Ferrand","city":"Clermont-Ferrand","country":"France","cc":"FR","lat":45.79113,"lon":3.08837,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"63003","condg":["Chronic pain & headache"],"nct":"NCT01602185","study":"Study of NMDA Antagonists and Neuropathic Pain","sstatus":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","official":"Gisèle PICKERING (University Hospital, Clermont-Ferrand)","src":"https://clinicaltrials.gov/study/NCT01602185","phase":"Phase 2","enroll":7,"start":"2012-05","eid":"x:site:nct01602185-chu-clermont-ferrand-clermont-ferrand"},{"id":"nct03156504-johns-hopkins-hospital-baltimore","cat":"research","name":"Johns Hopkins Hospital","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28892,"lon":-76.61167,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"21287","condg":["Depression","Bipolar"],"nct":"NCT03156504","study":"The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.","sstatus":"COMPLETED","sponsor":"Mayo Clinic","official":"Mark A Frye, MD (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT03156504","phase":"Phase 4","enroll":75,"start":"2017-06-01","eid":"x:site:nct03156504-johns-hopkins-hospital-baltimore"},{"id":"nct03156504-university-of-michigan-ann-arbor","cat":"research","name":"University of Michigan","city":"Ann Arbor","region":"Michigan","country":"United States","cc":"US","lat":42.28297,"lon":-83.75288,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"48109","condg":["Depression","Bipolar"],"nct":"NCT03156504","study":"The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.","sstatus":"COMPLETED","sponsor":"Mayo Clinic","official":"Mark A Frye, MD (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT03156504","phase":"Phase 4","enroll":75,"start":"2017-06-01","eid":"x:site:nct03156504-university-of-michigan-ann-arbor"},{"id":"nct03156504-mayo-clinic-rochester","cat":"research","name":"Mayo Clinic","city":"Rochester","region":"Minnesota","country":"United States","cc":"US","lat":43.14965,"lon":-77.61438,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55905","condg":["Depression","Bipolar"],"nct":"NCT03156504","study":"The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.","sstatus":"COMPLETED","sponsor":"Mayo Clinic","official":"Mark A Frye, MD (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT03156504","phase":"Phase 4","enroll":75,"start":"2017-06-01","eid":"x:site:nct03156504-mayo-clinic-rochester"},{"id":"nct03156504-university-of-cincinnati-medical-center-cincinnati","cat":"research","name":"University of Cincinnati Medical Center","city":"Cincinnati","region":"Ohio","country":"United States","cc":"US","lat":39.11652,"lon":-84.52545,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45219","condg":["Depression","Bipolar"],"nct":"NCT03156504","study":"The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.","sstatus":"COMPLETED","sponsor":"Mayo Clinic","official":"Mark A Frye, MD (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT03156504","phase":"Phase 4","enroll":75,"start":"2017-06-01","eid":"x:site:nct03156504-university-of-cincinnati-medical-center-cincinnati"},{"id":"nct03086148-beijing-tiantan-hospital-beijing","cat":"research","name":"Beijing TianTan Hospital","city":"Beijing","country":"China","cc":"CN","lat":39.90294,"lon":116.40001,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"100070","condg":["Depression"],"nct":"NCT03086148","study":"Ketamine and Postoperative Depressive Symptom-PASSION","sstatus":"COMPLETED","sponsor":"Beijing Tiantan Hospital","official":"Ruquan Han, M.D., Ph.D (Department of Anesthesiology, Beijing Tiantan Hospital)","src":"https://clinicaltrials.gov/study/NCT03086148","phase":"Phase 2/Phase 3","enroll":84,"start":"2017-07-05","eid":"x:site:nct03086148-beijing-tiantan-hospital-beijing"},{"id":"nct03721900-clinical-research-site-gaithersburg","cat":"research","name":"Clinical Research Site","city":"Gaithersburg","region":"Maryland","country":"United States","cc":"US","lat":39.14678,"lon":-77.1985,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20877","condg":["Depression"],"nct":"NCT03721900","study":"Ketamine for Major Depressive Disorder","sstatus":"UNKNOWN","sponsor":"Shenox Pharmaceuticals, LLC","official":"Mason Freeman, MD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT03721900","phase":"Phase 1","enroll":14,"start":"2018-12-28","eid":"x:site:nct03721900-clinical-research-site-gaithersburg"},{"id":"nct03721900-clinical-research-site-boston","cat":"research","name":"Clinical Research Site","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.35725,"lon":-71.05869,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02114","condg":["Depression"],"nct":"NCT03721900","study":"Ketamine for Major Depressive Disorder","sstatus":"UNKNOWN","sponsor":"Shenox Pharmaceuticals, LLC","official":"Mason Freeman, MD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT03721900","phase":"Phase 1","enroll":14,"start":"2018-12-28","eid":"x:site:nct03721900-clinical-research-site-boston"},{"id":"nct03721900-clinical-research-site-dayton","cat":"research","name":"Clinical Research Site","city":"Dayton","region":"Ohio","country":"United States","cc":"US","lat":39.77076,"lon":-84.19561,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45417","condg":["Depression"],"nct":"NCT03721900","study":"Ketamine for Major Depressive Disorder","sstatus":"UNKNOWN","sponsor":"Shenox Pharmaceuticals, LLC","official":"Mason Freeman, MD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT03721900","phase":"Phase 1","enroll":14,"start":"2018-12-28","eid":"x:site:nct03721900-clinical-research-site-dayton"},{"id":"nct01179009-washington-university-school-of-medicine-st-louis","cat":"research","name":"Washington University School of Medicine","city":"St Louis","region":"Missouri","country":"United States","cc":"US","lat":38.61527,"lon":-90.19173,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"63110","condg":["Depression"],"nct":"NCT01179009","study":"Treatment Resistant Depression (Pilot)","sstatus":"COMPLETED","sponsor":"Washington University School of Medicine","official":"Eric Lenze, MD (Washington University School of Medicine); John W Newcomer, MD (Washington University School of Medicine)","src":"https://clinicaltrials.gov/study/NCT01179009","phase":"N/A","enroll":20,"start":"2012-04","eid":"x:site:nct01179009-washington-university-school-of-medicine-st-louis"},{"id":"nct04640636-comprehensive-psychiatric-emergency-department-of-columbia-universit","cat":"research","name":"Comprehensive Psychiatric Emergency Department of Columbia University Medical Center","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.7098,"lon":-74.0175,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10032","condg":["Depression","Bipolar"],"nct":"NCT04640636","study":"IM Ketamine vs Midazolam for Suicidal ER Patients","sstatus":"SUSPENDED","sponsor":"New York State Psychiatric Institute","official":"Michael Grunebaum, MD (New York State Psychiatric Institute/Columbia University Irving Medical Center)","src":"https://clinicaltrials.gov/study/NCT04640636","phase":"Phase 4","enroll":90,"start":"2021-02-09","eid":"x:site:nct04640636-comprehensive-psychiatric-emergency-department-of-columbia-universit"},{"id":"nct05950711-harding-hospital-columbus","cat":"research","name":"Harding Hospital","city":"Columbus","region":"Ohio","country":"United States","cc":"US","lat":39.95087,"lon":-82.99046,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43210","condg":["Depression"],"nct":"NCT05950711","study":"Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot Study","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","src":"https://clinicaltrials.gov/study/NCT05950711","phase":"Phase 4","enroll":21,"start":"2022-03-30","eid":"x:site:nct05950711-harding-hospital-columbus"},{"id":"nct04997967-assiut-university-asyut","cat":"research","name":"Assiut University","city":"Asyut","country":"Egypt","cc":"EG","lat":27.18948,"lon":31.18203,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"71515","condg":["Other"],"status":"RECRUITING","nct":"NCT04997967","study":"Ketofol Versus Propofol in Urgent ERCP for Acute Cholangitis","sstatus":"UNKNOWN","sponsor":"Assiut University","official":"Haidi Ramadan, PhD (faculty of medicine)","src":"https://clinicaltrials.gov/study/NCT04997967","contact":{"n":"Haidi Ramadan, rofessor","p":"+0201028186710","e":"haidikaram@aun.edu.eg"},"phase":"Phase 4","enroll":100,"start":"2020-07-01","eid":"x:site:nct04997967-assiut-university-asyut"},{"id":"nct03470675-northwestern-university-chicago","cat":"research","name":"Northwestern University","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.84678,"lon":-87.64304,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60611","condg":["Depression","Chronic pain & headache"],"nct":"NCT03470675","study":"Postpartum Perineal Pain After Obstetric Anal Sphincter Injuries","sstatus":"COMPLETED","sponsor":"Northwestern University","official":"Feyce Peralta, MD (Northwestern University)","src":"https://clinicaltrials.gov/study/NCT03470675","phase":"Phase 4","enroll":67,"start":"2018-06-27","eid":"x:site:nct03470675-northwestern-university-chicago"},{"id":"nct06951802-inselspital-bern-bern","cat":"research","name":"Inselspital Bern","city":"Bern","country":"Switzerland","cc":"CH","lat":46.94701,"lon":7.44222,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"3010","condg":["Other"],"status":"RECRUITING","nct":"NCT06951802","study":"Endometriosis and Pain Treatment by Intraoperative Administration of Low-dose Ketamine","sstatus":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","official":"Christian Vetter, MD (Dep. of Anaesthesiology and Pain Medicine, Inselsptial Bern)","src":"https://clinicaltrials.gov/study/NCT06951802","contact":{"n":"Christian cv Vetter, MD","p":"+41 632 52 83","e":"christian.vetter@freenet.de"},"phase":"Phase 4","enroll":118,"start":"2024-12-03","eid":"x:site:nct06951802-inselspital-bern-bern"},{"id":"nct06752759-maimonides-medical-center-brooklyn","cat":"research","name":"Maimonides Medical Center","city":"Brooklyn","region":"New York","country":"United States","cc":"US","lat":40.65146,"lon":-73.95678,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11219","condg":["Depression","Anxiety"],"status":"RECRUITING","nct":"NCT06752759","study":"Nebulized Ketamine for the Treatment of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Theresa Jacob, PhD, MPH","official":"Theresa Jacob, PhD, MPH (Maimonides Medical Center)","src":"https://clinicaltrials.gov/study/NCT06752759","contact":{"n":"Mayank Kumar, PhD","p":"718-283-8170","e":"Maykumar@maimo.org"},"phase":"Phase 3","enroll":40,"start":"2024-10-16","eid":"x:site:nct06752759-maimonides-medical-center-brooklyn"},{"id":"nct07247370-drug-health-services-royal-prince-alfred-hospital-sydney","cat":"research","name":"Drug Health Services, Royal Prince Alfred Hospital","city":"Sydney","region":"New South Wales","country":"Australia","cc":"AU","lat":-33.87797,"lon":151.20097,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"2050","condg":["Depression","Addiction & substance use"],"nct":"NCT07247370","study":"Ketamine-Enhanced Therapy for Individuals With Alcohol Use Disorder and Depression: A Pilot Study (KET-DUAL)","sstatus":"NOT_YET_RECRUITING","sponsor":"South West Sydney Local Health District","src":"https://clinicaltrials.gov/study/NCT07247370","contact":{"n":"Kirsten Morley, PhD","p":"+61295153636","e":"Kirsten.morley@sydney.edu.au"},"phase":"Phase 1/Phase 2","enroll":20,"start":"2025-12-10","eid":"x:site:nct07247370-drug-health-services-royal-prince-alfred-hospital-sydney"},{"id":"nct04955470-bc-children-s-hospital-vancouver","cat":"research","name":"BC Children's Hospital","city":"Vancouver","region":"British Columbia","country":"Canada","cc":"CA","lat":49.24848,"lon":-123.11289,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"V6H 3N1","condg":["Other"],"nct":"NCT04955470","study":"Ketamine Infusion for Rapid Reduction of Suicidality in Pediatrics","sstatus":"TERMINATED","sponsor":"University of British Columbia","official":"Quynh Doan, PhD MHSc MD (University of British Columbia)","src":"https://clinicaltrials.gov/study/NCT04955470","phase":"Phase 1/Phase 2","enroll":15,"start":"2022-06-01","eid":"x:site:nct04955470-bc-children-s-hospital-vancouver"},{"id":"nct00476151-multiple-centers-new-delhi","cat":"research","name":"Multiple Centers","city":"New Delhi","country":"India","cc":"IN","lat":28.6137,"lon":77.22435,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Chronic pain & headache"],"nct":"NCT00476151","study":"A Study of the Efficacy and Safety of Amitriptyline/Ketamine Topical Cream in Patients With Diabetic Peripheral Neuropathy","sstatus":"COMPLETED","sponsor":"EpiCept Corporation","official":"Robert H Dworkin, Ph.D. (University of Rochester)","src":"https://clinicaltrials.gov/study/NCT00476151","phase":"Phase 2","enroll":226,"start":"2007-07","eid":"x:site:nct00476151-multiple-centers-new-delhi"},{"id":"nct02967640-department-of-orthopedic-surgery-kristiansund-hospital-kristiansund","cat":"research","name":"Department of Orthopedic Surgery, Kristiansund Hospital","city":"Kristiansund","country":"Norway","cc":"NO","lat":63.11341,"lon":7.7263,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Chronic pain & headache"],"nct":"NCT02967640","study":"Does Subacromial Injection With Glutamate Receptor Antagonist, Ketamine, Attenuate Pain in Rotator Cuff Tendinopathy?","sstatus":"COMPLETED","sponsor":"Helse Møre og Romsdal HF","official":"Oystein B Lian, md phd (Helse Nord-Trøndelag HF)","src":"https://clinicaltrials.gov/study/NCT02967640","phase":"Phase 2/Phase 3","enroll":14,"start":"2018-05-30","eid":"x:site:nct02967640-department-of-orthopedic-surgery-kristiansund-hospital-kristiansund"},{"id":"nct01809340-unnamed-trial-site-duffel","cat":"research","name":"Unnamed trial site","city":"Duffel","country":"Belgium","cc":"BE","lat":51.08683,"lon":4.52065,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01809340","study":"The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression","sstatus":"TERMINATED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01809340","phase":"Phase 2","enroll":29,"start":"2013-06","eid":"x:site:nct01809340-unnamed-trial-site-duffel"},{"id":"nct01809340-unnamed-trial-site-lede","cat":"research","name":"Unnamed trial site","city":"Lede","country":"Belgium","cc":"BE","lat":50.95445,"lon":3.97874,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01809340","study":"The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression","sstatus":"TERMINATED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01809340","phase":"Phase 2","enroll":29,"start":"2013-06","eid":"x:site:nct01809340-unnamed-trial-site-lede"},{"id":"nct01809340-unnamed-trial-site-leuven","cat":"research","name":"Unnamed trial site","city":"Leuven","country":"Belgium","cc":"BE","lat":50.88218,"lon":4.69806,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01809340","study":"The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression","sstatus":"TERMINATED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01809340","phase":"Phase 2","enroll":29,"start":"2013-06","eid":"x:site:nct01809340-unnamed-trial-site-leuven"},{"id":"nct01809340-unnamed-trial-site-besancon","cat":"research","name":"Unnamed trial site","city":"Besançon","country":"France","cc":"FR","lat":47.25174,"lon":6.02761,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01809340","study":"The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression","sstatus":"TERMINATED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01809340","phase":"Phase 2","enroll":29,"start":"2013-06","eid":"x:site:nct01809340-unnamed-trial-site-besancon"},{"id":"nct01809340-unnamed-trial-site-clermont-ferrand","cat":"research","name":"Unnamed trial site","city":"Clermont-Ferrand","country":"France","cc":"FR","lat":45.76854,"lon":3.08056,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01809340","study":"The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression","sstatus":"TERMINATED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01809340","phase":"Phase 2","enroll":29,"start":"2013-06","eid":"x:site:nct01809340-unnamed-trial-site-clermont-ferrand"},{"id":"nct01809340-unnamed-trial-site-nimes","cat":"research","name":"Unnamed trial site","city":"Nîmes","country":"France","cc":"FR","lat":43.82465,"lon":4.3519,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01809340","study":"The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression","sstatus":"TERMINATED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01809340","phase":"Phase 2","enroll":29,"start":"2013-06","eid":"x:site:nct01809340-unnamed-trial-site-nimes"},{"id":"nct01809340-unnamed-trial-site-leiden","cat":"research","name":"Unnamed trial site","city":"Leiden","country":"Netherlands","cc":"NL","lat":52.15273,"lon":4.50186,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01809340","study":"The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression","sstatus":"TERMINATED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01809340","phase":"Phase 2","enroll":29,"start":"2013-06","eid":"x:site:nct01809340-unnamed-trial-site-leiden"},{"id":"nct01809340-unnamed-trial-site-alicante","cat":"research","name":"Unnamed trial site","city":"Alicante","country":"Spain","cc":"ES","lat":38.35096,"lon":-0.47062,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01809340","study":"The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression","sstatus":"TERMINATED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01809340","phase":"Phase 2","enroll":29,"start":"2013-06","eid":"x:site:nct01809340-unnamed-trial-site-alicante"},{"id":"nct01809340-unnamed-trial-site-barcelona","cat":"research","name":"Unnamed trial site","city":"Barcelona","country":"Spain","cc":"ES","lat":41.383,"lon":2.15386,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01809340","study":"The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression","sstatus":"TERMINATED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01809340","phase":"Phase 2","enroll":29,"start":"2013-06","eid":"x:site:nct01809340-unnamed-trial-site-barcelona"},{"id":"nct01809340-unnamed-trial-site-coslada","cat":"research","name":"Unnamed trial site","city":"Coslada","country":"Spain","cc":"ES","lat":40.42693,"lon":-3.57235,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01809340","study":"The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression","sstatus":"TERMINATED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01809340","phase":"Phase 2","enroll":29,"start":"2013-06","eid":"x:site:nct01809340-unnamed-trial-site-coslada"},{"id":"nct01809340-unnamed-trial-site-madrid","cat":"research","name":"Unnamed trial site","city":"Madrid","country":"Spain","cc":"ES","lat":40.40657,"lon":-3.69178,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01809340","study":"The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression","sstatus":"TERMINATED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01809340","phase":"Phase 2","enroll":29,"start":"2013-06","eid":"x:site:nct01809340-unnamed-trial-site-madrid"},{"id":"nct01809340-unnamed-trial-site-zamora","cat":"research","name":"Unnamed trial site","city":"Zamora","country":"Spain","cc":"ES","lat":41.50704,"lon":-5.73529,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01809340","study":"The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression","sstatus":"TERMINATED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01809340","phase":"Phase 2","enroll":29,"start":"2013-06","eid":"x:site:nct01809340-unnamed-trial-site-zamora"},{"id":"nct06879496-mohamed-zakarea-wfa-tanta","cat":"research","name":"Mohamed Zakarea Wfa","city":"Tanta","region":"Tanta","country":"Egypt","cc":"EG","lat":30.79943,"lon":31.00168,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"6620010","condg":["Other"],"nct":"NCT06879496","study":"Comparison of Oral Dexmedetomidine, Ketamine Versus Midazolam for Premedication in Children Undergoing Injuinal Surgeries","sstatus":"COMPLETED","sponsor":"Tanta University","src":"https://clinicaltrials.gov/study/NCT06879496","phase":"N/A","enroll":60,"start":"2025-03-10","eid":"x:site:nct06879496-mohamed-zakarea-wfa-tanta"},{"id":"nct04538573-st-justine-s-hospital-montreal","cat":"research","name":"St. Justine's Hospital","city":"Montreal","region":"Quebec","country":"Canada","cc":"CA","lat":45.5118,"lon":-73.57637,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"H1T 3C5","condg":["Other"],"status":"RECRUITING","nct":"NCT04538573","study":"Virtual Reality MObility for Burn Patients","sstatus":"UNKNOWN","sponsor":"St. Justine's Hospital","official":"Sylvie Le May, PhD (St. Justine's Hospital)","src":"https://clinicaltrials.gov/study/NCT04538573","contact":{"n":"Sylvie Le May, PhD","p":"514-345-4931","e":"sylvie.lemay@umontreal.ca"},"phase":"N/A","enroll":20,"start":"2022-05-27","eid":"x:site:nct04538573-st-justine-s-hospital-montreal"},{"id":"nct04892251-center-on-mindfulness-and-integrative-health-intervention-developmen","cat":"research","name":"Center on Mindfulness and Integrative Health Intervention Development","city":"Salt Lake City","region":"Utah","country":"United States","cc":"US","lat":40.76883,"lon":-111.90249,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"84112","condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT04892251","study":"Ketamine Assisted Psychotherapy for Opioid Use Disorder","sstatus":"RECRUITING","sponsor":"University of Utah","official":"Eric L Garland (University of Utah)","src":"https://clinicaltrials.gov/study/NCT04892251","contact":{"n":"Research Coordinator","p":"801-581-3826","e":"KetaMORE@utah.edu"},"phase":"Phase 1/Phase 2","enroll":60,"start":"2021-05-20","eid":"x:site:nct04892251-center-on-mindfulness-and-integrative-health-intervention-developmen"},{"id":"nct01669642-st-louis-children-s-hospital-washington-university-st-louis","cat":"research","name":"St Louis Children's hospital, Washington university","city":"St Louis","region":"Missouri","country":"United States","cc":"US","lat":38.63315,"lon":-90.20358,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"63123","condg":["Other"],"nct":"NCT01669642","study":"Study to Find the Dose of Rapidly Administered Ketamine for Brief Painful Procedures in Children","sstatus":"COMPLETED","sponsor":"Washington University School of Medicine","official":"sri s chinta, MD (Washington University School of Medicine)","src":"https://clinicaltrials.gov/study/NCT01669642","phase":"N/A","enroll":111,"start":"2012-04","eid":"x:site:nct01669642-st-louis-children-s-hospital-washington-university-st-louis"},{"id":"nct00611572-vha-connecticut-west-haven","cat":"research","name":"VHA Connecticut","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.28124,"lon":-72.95096,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06516","condg":["Neurology & cognition"],"nct":"NCT00611572","study":"GABA-glutamate Interactions and Psychosis","sstatus":"COMPLETED","sponsor":"Yale University","official":"Mohini Ranganathan, M.D. (Yale School of Medicine, Associate Professor)","src":"https://clinicaltrials.gov/study/NCT00611572","phase":"Phase 1","enroll":23,"start":"2007-01","eid":"x:site:nct00611572-vha-connecticut-west-haven"},{"id":"nct07614581-open-medicine-studio-ganges","cat":"research","name":"Open Medicine Studio","city":"Ganges","region":"British Columbia","country":"Canada","cc":"CA","lat":48.86194,"lon":-123.49557,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"V8K 1R1","condg":["PTSD & trauma"],"nct":"NCT07614581","study":"Intra-Sessional Autonomic Arc Detection in Ketamine-Assisted Therapy for PTSD: A Signal Characterisation Pilot Study","sstatus":"NOT_YET_RECRUITING","sponsor":"Adriaan Dirk van der Wart","src":"https://clinicaltrials.gov/study/NCT07614581","contact":{"n":"Adriaan D van der Wart, MBChB","p":"7789513194","e":"doctor@medicinestudio.com"},"enroll":5,"start":"2026-07-15","eid":"x:site:nct07614581-open-medicine-studio-ganges"},{"id":"nct00834730-seoul-national-university-bundang-hospital-gyeonggi-do","cat":"research","name":"Seoul National University Bundang Hospital","city":"Gyeonggi-do","country":"South Korea","cc":"KR","lat":37.2847,"lon":126.8461,"gp":"region","unnamed":0,"drugs":["ketamine"],"zip":"463-707","condg":["Other"],"nct":"NCT00834730","study":"Comparison of N2O Inhalation and Ketamine in Pediatric PSA","sstatus":"COMPLETED","sponsor":"Seoul National University Hospital","official":"Jin Hee Lee, Professor (Seoul National University Bundang Hospital)","src":"https://clinicaltrials.gov/study/NCT00834730","phase":"Phase 4","enroll":32,"start":"2009-01","eid":"x:site:nct00834730-seoul-national-university-bundang-hospital-gyeonggi-do"},{"id":"nct04108234-beijing-anding-hospital-affiliated-to-capital-medical-university-bei","cat":"research","name":"Beijing AnDing hospital affiliated to Capital Medical University","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.91235,"lon":116.39728,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"100000","condg":["Depression"],"nct":"NCT04108234","study":"A Study of HR071603(Ketamine Nasal Spray) in Healthy Subjects","sstatus":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","src":"https://clinicaltrials.gov/study/NCT04108234","phase":"Phase 1","enroll":50,"start":"2019-10-24","eid":"x:site:nct04108234-beijing-anding-hospital-affiliated-to-capital-medical-university-bei"},{"id":"nct00899600-dartmouth-hitchcock-medical-center-lebanon","cat":"research","name":"Dartmouth-Hitchcock Medical Center","city":"Lebanon","region":"New Hampshire","country":"United States","cc":"US","lat":36.20383,"lon":-86.29943,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"03756","condg":["Chronic pain & headache"],"nct":"NCT00899600","study":"Intra-operative Ketamine Infusions in Opioid-dependent Patients With Chronic Lower Back Pain","sstatus":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","official":"Jeffrey A Clark, MD (DHMC)","src":"https://clinicaltrials.gov/study/NCT00899600","phase":"N/A","enroll":102,"start":"2007-02","eid":"x:site:nct00899600-dartmouth-hitchcock-medical-center-lebanon"},{"id":"nct05046184-ut-southwestern-medical-center-dallas","cat":"research","name":"UT Southwestern Medical Center","city":"Dallas","region":"Texas","country":"United States","cc":"US","lat":32.77482,"lon":-96.79561,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75235","condg":["Depression","Healthy volunteers"],"nct":"NCT05046184","study":"Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets","sstatus":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","src":"https://clinicaltrials.gov/study/NCT05046184","phase":"Phase 2","enroll":165,"start":"2022-05-05","eid":"x:site:nct05046184-ut-southwestern-medical-center-dallas"},{"id":"nct01325493-children-s-national-medical-center-washington-d-c","cat":"research","name":"Children's National Medical Center","city":"Washington D.C.","region":"District of Columbia","country":"United States","cc":"US","lat":38.88753,"lon":-77.04639,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20010","condg":["Other"],"nct":"NCT01325493","study":"Low Dose Ketamine Study on Opioid Tolerance and Hyperalgesia","sstatus":"COMPLETED","sponsor":"Julia Finkel","official":"Pestieau Sophie, MD (Children's National Research Institute); Finkel C Julie, MD (Children's National Research Institute)","src":"https://clinicaltrials.gov/study/NCT01325493","phase":"Phase 4","enroll":54,"start":"2010-01","eid":"x:site:nct01325493-children-s-national-medical-center-washington-d-c"},{"id":"nct02544607-massachusetts-general-hospital-boston","cat":"research","name":"Massachusetts General Hospital","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.34756,"lon":-71.06358,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02114","condg":["Depression"],"nct":"NCT02544607","study":"Ketamine for Depression: An MRI Study","sstatus":"COMPLETED","sponsor":"Massachusetts General Hospital","official":"Cristina Cusin, M.D. (MGH)","src":"https://clinicaltrials.gov/study/NCT02544607","phase":"Phase 4","enroll":25,"start":"2016-03","eid":"x:site:nct02544607-massachusetts-general-hospital-boston"},{"id":"nct06788249-university-of-pennsylvania-philadelphia","cat":"research","name":"University of Pennsylvania","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.95638,"lon":-75.16188,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"19104","condg":["Depression"],"status":"RECRUITING","nct":"NCT06788249","study":"Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine","sstatus":"RECRUITING","sponsor":"University of Pennsylvania","official":"Jennifer R Goldschmied, PhD (University of Pennsylvania)","src":"https://clinicaltrials.gov/study/NCT06788249","contact":{"n":"Isabel Koh","p":"215-573-6173","e":"Isabel.Koh@PennMedicine.upenn.edu"},"phase":"EARLY_Phase 1","enroll":10,"start":"2026-04-01","eid":"x:site:nct06788249-university-of-pennsylvania-philadelphia"},{"id":"nct03959852-st-elizabeth-boardman-hospital-boardman","cat":"research","name":"St. Elizabeth Boardman Hospital","city":"Boardman","region":"Ohio","country":"United States","cc":"US","lat":41.01374,"lon":-80.66139,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44512","condg":["Chronic pain & headache"],"nct":"NCT03959852","study":"Sub-Dissociative Ketamine and Fentanyl to Treat Moderate to Severe Pain","sstatus":"TERMINATED","sponsor":"Mercy Health Ohio","official":"David Gemmel (Director of Research)","src":"https://clinicaltrials.gov/study/NCT03959852","phase":"Phase 4","enroll":6,"start":"2019-11-18","eid":"x:site:nct03959852-st-elizabeth-boardman-hospital-boardman"},{"id":"nct04016740-beth-israel-deaconess-medical-center-boston","cat":"research","name":"Beth Israel Deaconess Medical Center","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.35678,"lon":-71.06226,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02215","condg":["Other"],"nct":"NCT04016740","study":"The PATHFINDER Study: A Feasibility Trial","sstatus":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","official":"Balachundhar Subramaniam, MD, MPH (Beth Israel Deaconess Medical Center)","src":"https://clinicaltrials.gov/study/NCT04016740","phase":"EARLY_Phase 1","enroll":22,"start":"2019-08-20","eid":"x:site:nct04016740-beth-israel-deaconess-medical-center-boston"},{"id":"nct02012335-federal-university-of-rio-grande-do-sul-hospital-de-clinicas-de-port","cat":"research","name":"Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA)","city":"Porto Alegre","region":"Rio Grande do Sul","country":"Brazil","cc":"BR","lat":-30.02704,"lon":-51.22798,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"90035-003","condg":["Depression"],"nct":"NCT02012335","study":"Ketamine Use in Electroconvulsive Therapy","sstatus":"WITHDRAWN","sponsor":"Hospital de Clinicas de Porto Alegre","src":"https://clinicaltrials.gov/study/NCT02012335","phase":"N/A","start":"2014-01","eid":"x:site:nct02012335-federal-university-of-rio-grande-do-sul-hospital-de-clinicas-de-port"},{"id":"nct01920555-stanford-university-palo-alto","cat":"research","name":"Stanford University","city":"Palo Alto","region":"California","country":"United States","cc":"US","lat":37.44484,"lon":-122.1346,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94304","condg":["Depression"],"nct":"NCT01920555","study":"Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)","sstatus":"COMPLETED","sponsor":"Massachusetts General Hospital","official":"Maurizio Fava, MD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT01920555","phase":"Phase 2","enroll":99,"start":"2014-12","eid":"x:site:nct01920555-stanford-university-palo-alto"},{"id":"nct01920555-yale-university-new-haven","cat":"research","name":"Yale University","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31234,"lon":-72.93018,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06520","condg":["Depression"],"nct":"NCT01920555","study":"Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)","sstatus":"COMPLETED","sponsor":"Massachusetts General Hospital","official":"Maurizio Fava, MD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT01920555","phase":"Phase 2","enroll":99,"start":"2014-12","eid":"x:site:nct01920555-yale-university-new-haven"},{"id":"nct01920555-massachusetts-general-hospital-boston","cat":"research","name":"Massachusetts General Hospital","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36328,"lon":-71.07139,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02114","condg":["Depression"],"nct":"NCT01920555","study":"Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)","sstatus":"COMPLETED","sponsor":"Massachusetts General Hospital","official":"Maurizio Fava, MD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT01920555","phase":"Phase 2","enroll":99,"start":"2014-12","eid":"x:site:nct01920555-massachusetts-general-hospital-boston"},{"id":"nct01920555-mount-sinai-school-of-medicine-new-york","cat":"research","name":"Mount Sinai School of Medicine","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70914,"lon":-73.99773,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10029","condg":["Depression"],"nct":"NCT01920555","study":"Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)","sstatus":"COMPLETED","sponsor":"Massachusetts General Hospital","official":"Maurizio Fava, MD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT01920555","phase":"Phase 2","enroll":99,"start":"2014-12","eid":"x:site:nct01920555-mount-sinai-school-of-medicine-new-york"},{"id":"nct01920555-university-of-texas-southwestern-dallas","cat":"research","name":"University of Texas Southwestern","city":"Dallas","region":"Texas","country":"United States","cc":"US","lat":32.78537,"lon":-96.81688,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75390","condg":["Depression"],"nct":"NCT01920555","study":"Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)","sstatus":"COMPLETED","sponsor":"Massachusetts General Hospital","official":"Maurizio Fava, MD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT01920555","phase":"Phase 2","enroll":99,"start":"2014-12","eid":"x:site:nct01920555-university-of-texas-southwestern-dallas"},{"id":"nct01920555-baylor-college-of-medicine-houston","cat":"research","name":"Baylor College of Medicine","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.77208,"lon":-95.3652,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"77030","condg":["Depression"],"nct":"NCT01920555","study":"Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)","sstatus":"COMPLETED","sponsor":"Massachusetts General Hospital","official":"Maurizio Fava, MD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT01920555","phase":"Phase 2","enroll":99,"start":"2014-12","eid":"x:site:nct01920555-baylor-college-of-medicine-houston"},{"id":"nct04322968-ann-arbor-va-medical-center-ann-arbor","cat":"research","name":"Ann Arbor VA Medical Center","city":"Ann Arbor","region":"Michigan","country":"United States","cc":"US","lat":42.27356,"lon":-83.73133,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"48105","condg":["PTSD & trauma","Chronic pain & headache"],"nct":"NCT04322968","study":"Ketamine Infusion for Comorbid PTSD and Chronic Pain","sstatus":"COMPLETED","sponsor":"VA Ann Arbor Healthcare System","src":"https://clinicaltrials.gov/study/NCT04322968","phase":"Phase 3","enroll":41,"start":"2018-01-09","eid":"x:site:nct04322968-ann-arbor-va-medical-center-ann-arbor"},{"id":"nct02487485-yale-new-haven-hospital-new-haven","cat":"research","name":"Yale New Haven Hospital","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31864,"lon":-72.93301,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06511","condg":["Depression"],"nct":"NCT02487485","study":"Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects","sstatus":"COMPLETED","sponsor":"Yale University","official":"Chadi Abdallah, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT02487485","phase":"Phase 2","enroll":23,"start":"2016-03","eid":"x:site:nct02487485-yale-new-haven-hospital-new-haven"},{"id":"nct02487485-west-haven-veterans-affairs-west-haven","cat":"research","name":"West Haven Veterans Affairs","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.26853,"lon":-72.94277,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06516","condg":["Depression"],"nct":"NCT02487485","study":"Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects","sstatus":"COMPLETED","sponsor":"Yale University","official":"Chadi Abdallah, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT02487485","phase":"Phase 2","enroll":23,"start":"2016-03","eid":"x:site:nct02487485-west-haven-veterans-affairs-west-haven"},{"id":"nct05320991-department-of-psychiatry-and-psychotherapy-university-hospital-bonn-","cat":"research","name":"Department of Psychiatry and Psychotherapy, University Hospital Bonn","city":"Bonn","country":"Germany","cc":"DE","lat":50.72784,"lon":7.09027,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"53127","condg":["Other"],"nct":"NCT05320991","study":"Effects of Ketamine on Mentalizing and Metacognition in Healthy Volunteers","sstatus":"COMPLETED","sponsor":"University Hospital, Bonn","src":"https://clinicaltrials.gov/study/NCT05320991","phase":"Phase 4","enroll":70,"start":"2019-06-15","eid":"x:site:nct05320991-department-of-psychiatry-and-psychotherapy-university-hospital-bonn-"},{"id":"nct01349231-connecticut-mental-health-center-ynhh-new-haven","cat":"research","name":"Connecticut Mental Health Center/ YNHH","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31695,"lon":-72.91663,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06520","condg":["OCD"],"nct":"NCT01349231","study":"Ketamine Infusion for Obsessive-Compulsive Disorder","sstatus":"COMPLETED","sponsor":"Yale University","official":"Michael H Bloch, MD, MS (Yale University)","src":"https://clinicaltrials.gov/study/NCT01349231","phase":"Phase 2","enroll":10,"start":"2009-02","eid":"x:site:nct01349231-connecticut-mental-health-center-ynhh-new-haven"},{"id":"nct04592809-ut-southwestern-medical-center-dallas","cat":"research","name":"UT Southwestern Medical Center","city":"Dallas","region":"Texas","country":"United States","cc":"US","lat":32.77351,"lon":-96.80531,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75235","condg":["Depression"],"nct":"NCT04592809","study":"Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents","sstatus":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","official":"Madhukar Trivedi, MD (University of Texas Southwestern Medical Center)","src":"https://clinicaltrials.gov/study/NCT04592809","phase":"Phase 3","enroll":50,"start":"2022-10-03","eid":"x:site:nct04592809-ut-southwestern-medical-center-dallas"},{"id":"nct05775393-ahmed-fakher-cairo","cat":"research","name":"Ahmed Fakher","city":"Cairo","region":"Matareya","country":"Egypt","cc":"EG","lat":30.05167,"lon":31.26129,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11756","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT05775393","study":"Effects of Adding Dexamethasone Plus Ketamine to Bupivacine in Serrtatus Plane Block","sstatus":"UNKNOWN","sponsor":"National Cancer Institute, Egypt","src":"https://clinicaltrials.gov/study/NCT05775393","contact":{"n":"Ahmed Fakher","p":"+201097419966","e":"ahmezfakhr66@gmail.com"},"phase":"N/A","enroll":60,"start":"2022-02-20","eid":"x:site:nct05775393-ahmed-fakher-cairo"},{"id":"nct03511833-tel-aviv-sourasky-medical-center-department-of-emergency-medicine-te","cat":"research","name":"Tel Aviv Sourasky Medical Center, department of Emergency Medicine","city":"Tel Aviv","country":"Israel","cc":"IL","lat":32.08789,"lon":34.77497,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"6423906","condg":["PTSD & trauma","Chronic pain & headache"],"nct":"NCT03511833","study":"Comparison of Treatment by IN Ketamine to IV Morphine in Acute Pain","sstatus":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","src":"https://clinicaltrials.gov/study/NCT03511833","contact":{"n":"Pinchas Halpern, MD","p":"972-3-6973829","e":"dr_halperin@tasmc.health.gov.il"},"phase":"Phase 3","enroll":120,"start":"2019-12","eid":"x:site:nct03511833-tel-aviv-sourasky-medical-center-department-of-emergency-medicine-te"},{"id":"nct02708849-yale-center-for-clinical-investigation-yale-university-new-haven","cat":"research","name":"Yale Center for Clinical Investigation, Yale University","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.3018,"lon":-72.9379,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06519","condg":["Other"],"nct":"NCT02708849","study":"The Sustained Effects of Ketamine","sstatus":"TERMINATED","sponsor":"Yale University","official":"Chadi Abdallah, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT02708849","phase":"Phase 1","enroll":3,"start":"2015-06","eid":"x:site:nct02708849-yale-center-for-clinical-investigation-yale-university-new-haven"},{"id":"nct05719506-tanta-university-hospitals-tanta","cat":"research","name":"Tanta University Hospitals","city":"Tanta","country":"Egypt","cc":"EG","lat":30.79172,"lon":30.99745,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"31511","condg":["Other"],"nct":"NCT05719506","study":"A Comparative Evaluation of Nebulized Dexmedetomidine and Nebulized Ketamine as a Premedication in Pediatric Surgeries","sstatus":"COMPLETED","sponsor":"Tanta University","src":"https://clinicaltrials.gov/study/NCT05719506","phase":"Phase 4","enroll":60,"start":"2021-07-21","eid":"x:site:nct05719506-tanta-university-hospitals-tanta"},{"id":"nct05719506-tanta-university-tanta","cat":"research","name":"Tanta University","city":"Tanta","country":"Egypt","cc":"EG","lat":30.79849,"lon":31.01119,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"31511","condg":["Other"],"nct":"NCT05719506","study":"A Comparative Evaluation of Nebulized Dexmedetomidine and Nebulized Ketamine as a Premedication in Pediatric Surgeries","sstatus":"COMPLETED","sponsor":"Tanta University","src":"https://clinicaltrials.gov/study/NCT05719506","phase":"Phase 4","enroll":60,"start":"2021-07-21","eid":"x:site:nct05719506-tanta-university-tanta"},{"id":"nct02525978-emory-university-hospital-atlanta","cat":"research","name":"Emory University Hospital","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.75978,"lon":-84.37956,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"30322","condg":["Depression"],"nct":"NCT02525978","study":"Heart Rate Variability in Depression","sstatus":"COMPLETED","sponsor":"Emory University","official":"Andrea Crowell, MD (Emory University)","src":"https://clinicaltrials.gov/study/NCT02525978","phase":"N/A","enroll":8,"start":"2015-07","eid":"x:site:nct02525978-emory-university-hospital-atlanta"},{"id":"nct02525978-12-executive-park-drive-atlanta","cat":"research","name":"12 Executive Park Drive","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.74999,"lon":-84.38633,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"30329","condg":["Depression"],"nct":"NCT02525978","study":"Heart Rate Variability in Depression","sstatus":"COMPLETED","sponsor":"Emory University","official":"Andrea Crowell, MD (Emory University)","src":"https://clinicaltrials.gov/study/NCT02525978","phase":"N/A","enroll":8,"start":"2015-07","eid":"x:site:nct02525978-12-executive-park-drive-atlanta"},{"id":"nct02525978-emory-university-at-wesley-woods-hospital-atlanta","cat":"research","name":"Emory University at Wesley Woods Hospital","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.73916,"lon":-84.38313,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"30329","condg":["Depression"],"nct":"NCT02525978","study":"Heart Rate Variability in Depression","sstatus":"COMPLETED","sponsor":"Emory University","official":"Andrea Crowell, MD (Emory University)","src":"https://clinicaltrials.gov/study/NCT02525978","phase":"N/A","enroll":8,"start":"2015-07","eid":"x:site:nct02525978-emory-university-at-wesley-woods-hospital-atlanta"},{"id":"nct07768618-emory-university-atlanta","cat":"research","name":"Emory University","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.74999,"lon":-84.398,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"30322","condg":["Depression","Neurology & cognition"],"nct":"NCT07768618","study":"Electrophysiologic Mechanisms of Ketamine Antidepressant Response","sstatus":"NOT_YET_RECRUITING","sponsor":"Emory University","official":"Carl Hacker, MD, PhD (Emory University)","src":"https://clinicaltrials.gov/study/NCT07768618","contact":{"n":"Carl Hacker, MD, PhD","p":"404-778-5770","e":"carl.hacker@emory.edu"},"phase":"Phase 2","enroll":37,"start":"2026-12","eid":"x:site:nct07768618-emory-university-atlanta"},{"id":"nct00947791-mount-sinai-school-of-medicine-new-york","cat":"research","name":"Mount Sinai School of Medicine","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71008,"lon":-73.99566,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10029","condg":["Bipolar"],"nct":"NCT00947791","study":"Treatment Study of Bipolar Depression","sstatus":"TERMINATED","sponsor":"Icahn School of Medicine at Mount Sinai","official":"James W Murrough, MD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT00947791","phase":"Phase 4","enroll":1,"start":"2009-07","eid":"x:site:nct00947791-mount-sinai-school-of-medicine-new-york"},{"id":"nct02336308-university-of-colorado-aurora","cat":"research","name":"University of Colorado","city":"Aurora","region":"Colorado","country":"United States","cc":"US","lat":39.73861,"lon":-104.84016,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"80045","condg":["Anxiety","Chronic pain & headache"],"nct":"NCT02336308","study":"A Randomized, Double-Blind Study of Placebo vs. Ketamine For Use During Dressing Changes in Critically Ill Burn Patients","sstatus":"WITHDRAWN","sponsor":"University of Colorado, Denver","official":"Robert MacLaren, PharmD, MPH (University of Colorado, Denver)","src":"https://clinicaltrials.gov/study/NCT02336308","phase":"Phase 4","start":"2015-01","eid":"x:site:nct02336308-university-of-colorado-aurora"},{"id":"nct06331182-tanta-university-tanta","cat":"research","name":"Tanta University","city":"Tanta","region":"ElGharbia","country":"Egypt","cc":"EG","lat":30.78118,"lon":30.99453,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"31527","condg":["Chronic pain & headache"],"nct":"NCT06331182","study":"Dexmedetomidine and Ketamine as an Adjuvant in External Oblique Intercostal Plane Block for Post Thoracotomy Pain","sstatus":"COMPLETED","sponsor":"Tanta University","official":"Mohammed S Elsharkawy, MD (Tanta University)","src":"https://clinicaltrials.gov/study/NCT06331182","phase":"N/A","enroll":40,"start":"2024-03-26","eid":"x:site:nct06331182-tanta-university-tanta"},{"id":"nct00858624-university-of-manchester-education-and-research-centre-wythenshawe-h","cat":"research","name":"University of Manchester, Education and Research Centre, Wythenshawe Hospital","city":"Manchester","region":"Manchester","country":"United Kingdom","cc":"GB","lat":53.47535,"lon":-2.22647,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M23 9LT","condg":["Other"],"nct":"NCT00858624","study":"Neurophysiology and Pharmacology of Cough Reflex Hypersensitivity","sstatus":"COMPLETED","sponsor":"Jacky Smith","src":"https://clinicaltrials.gov/study/NCT00858624","phase":"N/A","enroll":24,"start":"2008-02","eid":"x:site:nct00858624-university-of-manchester-education-and-research-centre-wythenshawe-h"},{"id":"nct01169025-university-of-utah-medical-center-salt-lake-city","cat":"research","name":"University of Utah Medical Center","city":"Salt Lake City","region":"Utah","country":"United States","cc":"US","lat":40.74916,"lon":-111.88517,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"84132","condg":["PTSD & trauma","Chronic pain & headache"],"nct":"NCT01169025","study":"Fentanyl vs. Low-Dose Ketamine for the Relief of Moderate to Severe Pain in Aeromedical Patients","sstatus":"WITHDRAWN","sponsor":"University of Utah","official":"Scott T Youngquist, MD, MS (University of Utah)","src":"https://clinicaltrials.gov/study/NCT01169025","phase":"N/A","start":"2012-09","eid":"x:site:nct01169025-university-of-utah-medical-center-salt-lake-city"},{"id":"nct05209217-mclean-hospital-belmont","cat":"research","name":"McLean Hospital","city":"Belmont","region":"Massachusetts","country":"United States","cc":"US","lat":37.52082,"lon":-122.28046,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02478","condg":["Bipolar"],"status":"RECRUITING","nct":"NCT05209217","study":"Open Study of the Neurobiological Effects of Intranasal Ketamine in Children and Adults With Bipolar Disorder","sstatus":"UNKNOWN","sponsor":"Mclean Hospital","official":"Martin H Teicher, MD, PhD (Mclean Hospital)","src":"https://clinicaltrials.gov/study/NCT05209217","contact":{"n":"Elizabeth Bolger, MA","p":"617-855-2964","e":"lbolger@mclean.harvard.edu"},"enroll":20,"start":"2019-06-04","eid":"x:site:nct05209217-mclean-hospital-belmont"},{"id":"nct04216888-nathan-kline-institute-orangeburg","cat":"research","name":"Nathan Kline Institute","city":"Orangeburg","region":"New York","country":"United States","cc":"US","lat":33.48848,"lon":-80.84384,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10962","condg":["Depression"],"nct":"NCT04216888","study":"Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine","sstatus":"COMPLETED","sponsor":"Dan Iosifescu","official":"Dan Iosifescu, MD, MSc (Nathan Kline Institute)","src":"https://clinicaltrials.gov/study/NCT04216888","phase":"Phase 2/Phase 3","enroll":9,"start":"2019-06-26","eid":"x:site:nct04216888-nathan-kline-institute-orangeburg"},{"id":"nct04274361-froedtert-hospital-milwaukee","cat":"research","name":"Froedtert Hospital","city":"Milwaukee","region":"Wisconsin","country":"United States","cc":"US","lat":43.04394,"lon":-87.89475,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"53226","condg":["PTSD & trauma","Chronic pain & headache"],"nct":"NCT04274361","study":"Ketamine for Pain Control After Severe Traumatic Injury","sstatus":"COMPLETED","sponsor":"Medical College of Wisconsin","official":"Thomas Carver, MD (Medical College of WI)","src":"https://clinicaltrials.gov/study/NCT04274361","phase":"N/A","enroll":93,"start":"2021-01-20","eid":"x:site:nct04274361-froedtert-hospital-milwaukee"},{"id":"nct04173962-icahn-school-of-medicine-at-mount-sinai-new-york","cat":"research","name":"Icahn School of Medicine at Mount Sinai","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70566,"lon":-74.00028,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10029","condg":["Healthy volunteers"],"nct":"NCT04173962","study":"Effect of Ketamine on Laboratory-induced Stress in Healthy Subjects","sstatus":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","official":"James Murrough, MD, PhD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT04173962","phase":"Phase 2","enroll":24,"start":"2019-08-08","eid":"x:site:nct04173962-icahn-school-of-medicine-at-mount-sinai-new-york"},{"id":"nct05105061-icahn-school-of-medicine-at-mount-sinai-new-york","cat":"research","name":"Icahn School of Medicine at Mount Sinai","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71921,"lon":-74.00922,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10029","condg":["Other"],"nct":"NCT05105061","study":"Intramuscular Ketamine for Suicidal Ideation","sstatus":"WITHDRAWN","sponsor":"Icahn School of Medicine at Mount Sinai","official":"Matthew Klein (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT05105061","phase":"Phase 2","start":"2022-02","eid":"x:site:nct05105061-icahn-school-of-medicine-at-mount-sinai-new-york"},{"id":"nct06832683-bedirhan-gunel-kocaeli","cat":"research","name":"Bedirhan Günel","city":"Kocaeli","region":"İ̇zmi̇t","country":"Turkey","cc":"TR","lat":40.738,"lon":30.00401,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"41100","condg":["Other"],"nct":"NCT06832683","study":"Efficacy of Propofol-Ketamine and Sevoflurane in Children Undergoing Magnetic Resonance Imaging","sstatus":"COMPLETED","sponsor":"Kocaeli City Hospital","official":"Bedirhan Günel, MD (Kocaeli City Hospital)","src":"https://clinicaltrials.gov/study/NCT06832683","phase":"N/A","enroll":230,"start":"2025-06-19","eid":"x:site:nct06832683-bedirhan-gunel-kocaeli"},{"id":"nct02577250-minneapolis-va-health-care-system-minneapolis-mn-minneapolis","cat":"research","name":"Minneapolis Va Health Care System, Minneapolis MN","city":"Minneapolis","region":"Minnesota","country":"United States","cc":"US","lat":44.98962,"lon":-93.27066,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55417","condg":["Depression","PTSD & trauma"],"nct":"NCT02577250","study":"Ketamine Infusions for PTSD and Treatment-Resistant Depression","sstatus":"COMPLETED","sponsor":"Minneapolis Veterans Affairs Medical Center","official":"Paulo Shiroma, MD (Minneapolis Veterans Affairs Medical Center); Cristina S Albott, MD,MA (Minneapolis Veterans Affairs Medical Center)","src":"https://clinicaltrials.gov/study/NCT02577250","phase":"Phase 1","enroll":20,"start":"2015-05","eid":"x:site:nct02577250-minneapolis-va-health-care-system-minneapolis-mn-minneapolis"},{"id":"nct05696691-university-hospital-san-antonio","cat":"research","name":"University Hospital","city":"San Antonio","region":"Texas","country":"United States","cc":"US","lat":29.4172,"lon":-98.48163,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"78229","condg":["Other"],"status":"RECRUITING","nct":"NCT05696691","study":"Ketamine & Crisis Response Plan for Suicidal Ideation in the ED","sstatus":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","official":"Robert De Lorenzo, MD, MSM (The University of Texas Health Science Center at San Antonio); Romeo Fairley, MD, MPH (The University of Texas Health Science Center at San Antonio)","src":"https://clinicaltrials.gov/study/NCT05696691","contact":{"n":"Robert DeLorenzo, MD","p":"210-567-4292","e":"delorenzo@uthscsa.edu"},"phase":"Phase 2/Phase 3","enroll":24,"start":"2023-01-06","eid":"x:site:nct05696691-university-hospital-san-antonio"},{"id":"nct02857361-linear-clinical-research-nedlands","cat":"research","name":"Linear Clinical Research","city":"Nedlands","region":"Western Australia","country":"Australia","cc":"AU","lat":-31.98518,"lon":115.81676,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"6009","condg":["Chronic pain & headache"],"nct":"NCT02857361","study":"Crossover Study to Evaluate the PK Effects of Two Different Wafer Administration Protocols.","sstatus":"COMPLETED","sponsor":"iX Biopharma Ltd.","official":"Sam Salman, MD (iX Biopharma)","src":"https://clinicaltrials.gov/study/NCT02857361","phase":"Phase 2","enroll":10,"start":"2016-07","eid":"x:site:nct02857361-linear-clinical-research-nedlands"},{"id":"nct06140927-university-of-california-san-francisco-san-francisco","cat":"research","name":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.77837,"lon":-122.43133,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94143","condg":["Other"],"status":"RECRUITING","nct":"NCT06140927","study":"Effect of Ketamine on Intraoperative Motor Evoked Potentials","sstatus":"RECRUITING","sponsor":"University of California, San Francisco","official":"Marc Buren, MD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT06140927","contact":{"n":"Marc Buren, MD","p":"415-514-3781","e":"marc.buren@ucsf.edu"},"phase":"Phase 3","enroll":20,"start":"2023-12-01","eid":"x:site:nct06140927-university-of-california-san-francisco-san-francisco"},{"id":"nct06943859-university-of-maryland-addiction-programs-and-affiliated-clinics-bal","cat":"research","name":"University of Maryland Addiction Programs and Affiliated Clinics","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29203,"lon":-76.6193,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"21201","condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT06943859","study":"Ketamine for Opioid Use Disorder","sstatus":"RECRUITING","sponsor":"University of Maryland, Baltimore","official":"Peter Manza, PhD (University of Maryland, Baltimore)","src":"https://clinicaltrials.gov/study/NCT06943859","contact":{"n":"Annabelle Belcher, PhD","p":"443-462-3400","e":"abelcher@som.umaryland.edu"},"phase":"Phase 2","enroll":50,"start":"2026-02-04","eid":"x:site:nct06943859-university-of-maryland-addiction-programs-and-affiliated-clinics-bal"},{"id":"nct02644629-shalvata-mhc-hod-hasharon","cat":"research","name":"Shalvata MHC","city":"Hod HaSharon","country":"Israel","cc":"IL","lat":32.16202,"lon":34.88572,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"POB 94","condg":["Depression"],"nct":"NCT02644629","study":"Intra-nasal vs. Intra-venous Ketamine Administration","sstatus":"COMPLETED","sponsor":"Shalvata Mental Health Center","official":"Aviv Segev, MD (Shalvata MHC)","src":"https://clinicaltrials.gov/study/NCT02644629","phase":"Phase 4","enroll":45,"start":"2016-04","eid":"x:site:nct02644629-shalvata-mhc-hod-hasharon"},{"id":"nct05468840-cheo-ottawa","cat":"research","name":"CHEO","city":"Ottawa","region":"Ontario","country":"Canada","cc":"CA","lat":45.41329,"lon":-75.69083,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"K1H 8L1","condg":["Other"],"nct":"NCT05468840","study":"Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation","sstatus":"UNKNOWN","sponsor":"University of Ottawa","src":"https://clinicaltrials.gov/study/NCT05468840","contact":{"n":"Maala Bhatt, MD","p":"1-613-737-7600","e":"mbhatt@cheo.on.ca"},"phase":"Phase 3","enroll":20,"start":"2023-06","eid":"x:site:nct05468840-cheo-ottawa"},{"id":"nct03065335-national-institutes-of-health-clinical-center-bethesda","cat":"research","name":"National Institutes of Health Clinical Center","city":"Bethesda","region":"Maryland","country":"United States","cc":"US","lat":38.97686,"lon":-77.10802,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20892","condg":["Depression","Healthy volunteers"],"status":"RECRUITING","nct":"NCT03065335","study":"Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"National Institute of Mental Health (NIMH)","official":"Carlos A Zarate, M.D. (National Institute of Mental Health (NIMH))","src":"https://clinicaltrials.gov/study/NCT03065335","contact":{"n":"NIH Clinical Center Office of Patient Recruitment (OPR)","p":"800-411-1222","e":"ccopr@nih.gov"},"phase":"Phase 1","enroll":150,"start":"2017-05-25","eid":"x:site:nct03065335-national-institutes-of-health-clinical-center-bethesda"},{"id":"nct04471818-instituto-nacional-de-cancerologia-incan-mexico-city","cat":"research","name":"Instituto Nacional de Cancerología (INCan)","city":"Mexico City","country":"Mexico","cc":"MX","lat":19.42965,"lon":-99.12338,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression","Cancer-related distress"],"nct":"NCT04471818","study":"Ketamine or Placebo in Patients With Major Depression and Advanced Cancer","sstatus":"COMPLETED","sponsor":"Instituto Nacional de Cancerologia de Mexico","src":"https://clinicaltrials.gov/study/NCT04471818","phase":"Phase 1/Phase 2","enroll":19,"start":"2019-09-19","eid":"x:site:nct04471818-instituto-nacional-de-cancerologia-incan-mexico-city"},{"id":"nct03395314-connecticut-mental-health-center-new-haven","cat":"research","name":"Connecticut Mental Health Center","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.29747,"lon":-72.92642,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06519","condg":["Other"],"nct":"NCT03395314","study":"Ketamine in Borderline Personality Disorder","sstatus":"TERMINATED","sponsor":"Yale University","official":"Sarah Fineberg, MD/PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT03395314","phase":"Phase 2","enroll":22,"start":"2018-02-15","eid":"x:site:nct03395314-connecticut-mental-health-center-new-haven"},{"id":"nct03395314-yale-new-haven-hospital-new-haven","cat":"research","name":"Yale New Haven Hospital","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.29756,"lon":-72.92632,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06519","condg":["Other"],"nct":"NCT03395314","study":"Ketamine in Borderline Personality Disorder","sstatus":"TERMINATED","sponsor":"Yale University","official":"Sarah Fineberg, MD/PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT03395314","phase":"Phase 2","enroll":22,"start":"2018-02-15","eid":"x:site:nct03395314-yale-new-haven-hospital-new-haven"},{"id":"nct04021433-hadassah-hebrew-university-medical-center-jerusalem","cat":"research","name":"Hadassah Hebrew University Medical Center","city":"Jerusalem","country":"Israel","cc":"IL","lat":31.76956,"lon":35.20979,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"status":"RECRUITING","nct":"NCT04021433","study":"Ketamine for Treatment Resistant MDD","sstatus":"UNKNOWN","sponsor":"Hadassah Medical Organization","src":"https://clinicaltrials.gov/study/NCT04021433","contact":{"n":"Isserles Moshe, MD, MSc","p":"00972 2 6777184","e":"moshay@hadassah.org.il"},"phase":"N/A","enroll":20,"start":"2018-09-01","eid":"x:site:nct04021433-hadassah-hebrew-university-medical-center-jerusalem"},{"id":"nct04544228-faculty-of-medicine-cairo-university-cairo","cat":"research","name":"Faculty of medicine-Cairo University","city":"Cairo","country":"Egypt","cc":"EG","lat":30.06249,"lon":31.25593,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"1772","condg":["Chronic pain & headache"],"nct":"NCT04544228","study":"Ketamine or Neostigmine for Serratus Anterior Plane Block in Modified Radical Mastectomy","sstatus":"COMPLETED","sponsor":"Cairo University","official":"Bassant abdelhamid, M.D. (Cairo University)","src":"https://clinicaltrials.gov/study/NCT04544228","phase":"N/A","enroll":90,"start":"2020-09-05","eid":"x:site:nct04544228-faculty-of-medicine-cairo-university-cairo"},{"id":"nct02920528-emergency-department-harbor-ucla-medical-center-torrance","cat":"research","name":"Emergency Department, Harbor-UCLA Medical Center","city":"Torrance","region":"California","country":"United States","cc":"US","lat":33.84343,"lon":-118.34632,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"90501","condg":["Chronic pain & headache"],"nct":"NCT02920528","study":"Subdissociative Dose Ketamine for Treatment of Acute Pain in Subjects With Chronic Pain","sstatus":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","official":"David Tanen, MD (Los Angeles Biomedical Institute)","src":"https://clinicaltrials.gov/study/NCT02920528","phase":"Phase 3","enroll":106,"start":"2017-05-01","eid":"x:site:nct02920528-emergency-department-harbor-ucla-medical-center-torrance"},{"id":"nct04057989-walter-reed-national-military-medical-center-bethesda","cat":"research","name":"Walter Reed National Military Medical Center","city":"Bethesda","region":"Maryland","country":"United States","cc":"US","lat":38.97093,"lon":-77.09739,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20889","condg":["PTSD & trauma","Chronic pain & headache"],"nct":"NCT04057989","study":"Retrospective Evaluation of Ketamine Effectiveness for the Treatment of Acute Battlefield Related Pain","sstatus":"COMPLETED","sponsor":"Defense and Veterans Center for Integrative Pain Management","official":"Michael Kent, MD (Walter Reed National Military Medical Center)","src":"https://clinicaltrials.gov/study/NCT04057989","enroll":80,"start":"2014-08","eid":"x:site:nct04057989-walter-reed-national-military-medical-center-bethesda"},{"id":"nct03237286-western-psychiatric-institute-and-clinic-pittsburgh","cat":"research","name":"Western Psychiatric Institute and Clinic","city":"Pittsburgh","region":"Pennsylvania","country":"United States","cc":"US","lat":40.43775,"lon":-80.00158,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"15213","condg":["Depression"],"nct":"NCT03237286","study":"Intravenous Ketamine Plus Neurocognitive Training for Depression","sstatus":"COMPLETED","sponsor":"Rebecca Price","src":"https://clinicaltrials.gov/study/NCT03237286","phase":"Phase 1/Phase 2","enroll":154,"start":"2017-12-01","eid":"x:site:nct03237286-western-psychiatric-institute-and-clinic-pittsburgh"},{"id":"nct06070766-river-foundation-bigfork","cat":"research","name":"RIVER Foundation","city":"Bigfork","region":"Montana","country":"United States","cc":"US","lat":48.06249,"lon":-114.06475,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"59911","condg":["Depression","Anxiety","PTSD & trauma","Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06070766","study":"RIVER At Home Ketamine Protocols","sstatus":"RECRUITING","sponsor":"RIVER Foundation","official":"Dharma Rose, D.O. M.S. (RIVER Foundation); Frank Yurseak, Ph.D. (RIVER Foundation)","src":"https://clinicaltrials.gov/study/NCT06070766","contact":{"n":"Ed Lesofski, MS","p":"406-431-4890","e":"ed@riverofchange.org"},"enroll":50000,"start":"2023-10-01","eid":"x:site:nct06070766-river-foundation-bigfork"},{"id":"nct06070766-river-telehealth-helena","cat":"research","name":"RIVER Telehealth","city":"Helena","region":"Montana","country":"United States","cc":"US","lat":46.60273,"lon":-112.0275,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"59601","condg":["Depression","Anxiety","PTSD & trauma","Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06070766","study":"RIVER At Home Ketamine Protocols","sstatus":"RECRUITING","sponsor":"RIVER Foundation","official":"Dharma Rose, D.O. M.S. (RIVER Foundation); Frank Yurseak, Ph.D. (RIVER Foundation)","src":"https://clinicaltrials.gov/study/NCT06070766","contact":{"n":"Ed Lesofski, MS","p":"406-465-9504","e":"ed@riverofchange.org"},"enroll":50000,"start":"2023-10-01","eid":"x:site:nct06070766-river-telehealth-helena"},{"id":"nct05799729-treviso-regional-hospital-treviso","cat":"research","name":"Treviso Regional Hospital","city":"Treviso","region":"TV","country":"Italy","cc":"IT","lat":45.66113,"lon":12.23732,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"31100","condg":["Other"],"nct":"NCT05799729","study":"Effect of Ketamine Infusion on BIS Values","sstatus":"COMPLETED","sponsor":"University of Padova","src":"https://clinicaltrials.gov/study/NCT05799729","enroll":40,"start":"2023-04-01","eid":"x:site:nct05799729-treviso-regional-hospital-treviso"},{"id":"nct05074823-assiut-university-hospital-asyut","cat":"research","name":"Assiut University hospital","city":"Asyut","country":"Egypt","cc":"EG","lat":27.17564,"lon":31.18166,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11111","condg":["Other"],"nct":"NCT05074823","study":"Comparing Three Different Doses of Intrathecal Ketamine","sstatus":"COMPLETED","sponsor":"Assiut University","src":"https://clinicaltrials.gov/study/NCT05074823","phase":"Phase 4","enroll":105,"start":"2022-02-26","eid":"x:site:nct05074823-assiut-university-hospital-asyut"},{"id":"nct06873906-faculty-of-medicine-ain-shams-university-cairo","cat":"research","name":"Faculty of Medicine, Ain Shams University","city":"Cairo","country":"Egypt","cc":"EG","lat":30.05129,"lon":31.24285,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11591","condg":["Other"],"nct":"NCT06873906","study":"Deep Parasternal Intercostal Plane Block Versus Erector Spinae Plane Block in Pediatric Cardiac Patients Undergoing Primary Repair of Septal Defects Via Median Sternotomy","sstatus":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","src":"https://clinicaltrials.gov/study/NCT06873906","contact":{"n":"Sarah A. H. Bakr, Ms degree of Anesthesia","p":"[202] 01062638487","e":"sarahhanee@med.asu.edu.eg"},"phase":"Phase 3","enroll":45,"start":"2025-03-20","eid":"x:site:nct06873906-faculty-of-medicine-ain-shams-university-cairo"},{"id":"nct00437814-pediatric-icu-rambam-medical-center-haifa","cat":"research","name":"Pediatric ICU, Rambam Medical Center","city":"Haifa","country":"Israel","cc":"IL","lat":32.81157,"lon":34.99575,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"31096","condg":["PTSD & trauma","Neurology & cognition"],"status":"RECRUITING","nct":"NCT00437814","study":"Effect of Ketamine (Ketalar) on Intracranial Pressure","sstatus":"UNKNOWN","sponsor":"Rambam Health Care Campus","official":"Gad Bar-Joseph, MD (Director, Pediatric ICU, Rambam Medical Center)","src":"https://clinicaltrials.gov/study/NCT00437814","contact":{"n":"Gad Bar-Joseph, MD","p":"972-4-8542855","e":"g_barjoseph@rambam.health.gov.il"},"phase":"N/A","enroll":30,"start":"2005-09","eid":"x:site:nct00437814-pediatric-icu-rambam-medical-center-haifa"},{"id":"nct06733129-chr-angers-angers","cat":"research","name":"Chr Angers","city":"Angers","country":"France","cc":"FR","lat":47.45984,"lon":-0.55084,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"RECRUITING","nct":"NCT06733129","study":"Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room","sstatus":"RECRUITING","sponsor":"Nantes University Hospital","src":"https://clinicaltrials.gov/study/NCT06733129","contact":{"n":"Sigismond LASOCKI","p":"02 41 35 36 35","e":"silasocki@chu-angers.fr"},"phase":"Phase 3","enroll":1218,"start":"2025-04-14","eid":"x:site:nct06733129-chr-angers-angers"},{"id":"nct06733129-chru-de-brest-hopital-cavale-blanche-brest","cat":"research","name":"CHRU de Brest Hôpital Cavale Blanche","city":"Brest","country":"France","cc":"FR","lat":48.39495,"lon":-4.48463,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"RECRUITING","nct":"NCT06733129","study":"Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room","sstatus":"RECRUITING","sponsor":"Nantes University Hospital","src":"https://clinicaltrials.gov/study/NCT06733129","contact":{"n":"Anais CAILLARD","p":"02 98 34 76 23","e":"anais.caillard@chu-brest.fr"},"phase":"Phase 3","enroll":1218,"start":"2025-04-14","eid":"x:site:nct06733129-chru-de-brest-hopital-cavale-blanche-brest"},{"id":"nct06733129-ch-louis-pasteur-chartres","cat":"research","name":"Ch Louis Pasteur","city":"Chartres","country":"France","cc":"FR","lat":48.45254,"lon":1.48666,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"NOT_YET_RECRUITING","nct":"NCT06733129","study":"Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room","sstatus":"RECRUITING","sponsor":"Nantes University Hospital","src":"https://clinicaltrials.gov/study/NCT06733129","contact":{"n":"Nidhal CHEBBI","p":"02 53 48 22 24","e":"nicolas.grillot@chu-nantes.fr"},"phase":"Phase 3","enroll":1218,"start":"2025-04-14","eid":"x:site:nct06733129-ch-louis-pasteur-chartres"},{"id":"nct06733129-chu-dijon-dijon","cat":"research","name":"CHU Dijon","city":"Dijon","country":"France","cc":"FR","lat":47.3245,"lon":5.01631,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"RECRUITING","nct":"NCT06733129","study":"Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room","sstatus":"RECRUITING","sponsor":"Nantes University Hospital","src":"https://clinicaltrials.gov/study/NCT06733129","contact":{"n":"Pierre-Grégoire GUINOT","p":"03 80 28 15 54","e":"guinotpierregregoire@gmail.com"},"phase":"Phase 3","enroll":1218,"start":"2025-04-14","eid":"x:site:nct06733129-chu-dijon-dijon"},{"id":"nct06733129-chu-grenoble-alpes-grenoble","cat":"research","name":"CHU Grenoble Alpes","city":"Grenoble","country":"France","cc":"FR","lat":45.1874,"lon":5.70975,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"NOT_YET_RECRUITING","nct":"NCT06733129","study":"Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room","sstatus":"RECRUITING","sponsor":"Nantes University Hospital","src":"https://clinicaltrials.gov/study/NCT06733129","contact":{"n":"Pierre BOUZAT","p":"04 76 76 72 53","e":"PBouzat@chu-grenoble.fr"},"phase":"Phase 3","enroll":1218,"start":"2025-04-14","eid":"x:site:nct06733129-chu-grenoble-alpes-grenoble"},{"id":"nct06733129-chd-vendee-la-roche-sur-yon","cat":"research","name":"CHD Vendée","city":"La Roche-sur-Yon","country":"France","cc":"FR","lat":46.67534,"lon":-1.42799,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"RECRUITING","nct":"NCT06733129","study":"Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room","sstatus":"RECRUITING","sponsor":"Nantes University Hospital","src":"https://clinicaltrials.gov/study/NCT06733129","contact":{"n":"Mathieu OUDOT","p":"02 51 44 62 37","e":"Mathieu.oudot@chd-vendee.fr"},"phase":"Phase 3","enroll":1218,"start":"2025-04-14","eid":"x:site:nct06733129-chd-vendee-la-roche-sur-yon"},{"id":"nct06733129-aphp-bicetre-le-kremlin-bicetre","cat":"research","name":"APHP Bicêtre","city":"Le Kremlin-Bicêtre","country":"France","cc":"FR","lat":48.82455,"lon":2.35334,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"NOT_YET_RECRUITING","nct":"NCT06733129","study":"Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room","sstatus":"RECRUITING","sponsor":"Nantes University Hospital","src":"https://clinicaltrials.gov/study/NCT06733129","contact":{"n":"Samy FIGUEIREDO","p":"01 45 21 34 41","e":"samy.figueiredo@aphp.fr"},"phase":"Phase 3","enroll":1218,"start":"2025-04-14","eid":"x:site:nct06733129-aphp-bicetre-le-kremlin-bicetre"},{"id":"nct06733129-ch-le-mans-le-mans","cat":"research","name":"CH Le Mans","city":"Le Mans","country":"France","cc":"FR","lat":47.99754,"lon":0.20849,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"RECRUITING","nct":"NCT06733129","study":"Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room","sstatus":"RECRUITING","sponsor":"Nantes University Hospital","src":"https://clinicaltrials.gov/study/NCT06733129","contact":{"n":"Laurent BLANCHET","p":"02 43 43 28 40","e":"lblanchet@ch-lemans.fr"},"phase":"Phase 3","enroll":1218,"start":"2025-04-14","eid":"x:site:nct06733129-ch-le-mans-le-mans"},{"id":"nct06733129-chu-lille-hopital-salengro-lille","cat":"research","name":"CHU Lille Hopital Salengro","city":"Lille","country":"France","cc":"FR","lat":50.63687,"lon":3.05912,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"RECRUITING","nct":"NCT06733129","study":"Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room","sstatus":"RECRUITING","sponsor":"Nantes University Hospital","src":"https://clinicaltrials.gov/study/NCT06733129","contact":{"n":"Nathalie BRUNEAU","p":"03 20 44 59 62","e":"nathaliemarie.bruneau@chru-lille.fr"},"phase":"Phase 3","enroll":1218,"start":"2025-04-14","eid":"x:site:nct06733129-chu-lille-hopital-salengro-lille"},{"id":"nct06733129-chu-lille-hopital-claude-huriez-lille","cat":"research","name":"CHU Lille Hôpital Claude Huriez","city":"Lille","country":"France","cc":"FR","lat":50.64346,"lon":3.05008,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"RECRUITING","nct":"NCT06733129","study":"Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room","sstatus":"RECRUITING","sponsor":"Nantes University Hospital","src":"https://clinicaltrials.gov/study/NCT06733129","contact":{"n":"Cédric CIRENEI","p":"03 20 44 59 62","e":"cedric.cirenei@chu-lille.fr"},"phase":"Phase 3","enroll":1218,"start":"2025-04-14","eid":"x:site:nct06733129-chu-lille-hopital-claude-huriez-lille"},{"id":"nct06733129-chu-lyon-hopital-sud-lyon","cat":"research","name":"CHU Lyon Hôpital Sud","city":"Lyon","country":"France","cc":"FR","lat":45.74835,"lon":4.85387,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"NOT_YET_RECRUITING","nct":"NCT06733129","study":"Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room","sstatus":"RECRUITING","sponsor":"Nantes University Hospital","src":"https://clinicaltrials.gov/study/NCT06733129","contact":{"n":"Jean-Stephane DAVID","p":"04 72 11 73 11","e":"jean-stephane.david@univ-lyon1.fr"},"phase":"Phase 3","enroll":1218,"start":"2025-04-14","eid":"x:site:nct06733129-chu-lyon-hopital-sud-lyon"},{"id":"nct06733129-hcl-lyon-croix-rousse-lyon","cat":"research","name":"HCL Lyon Croix-Rousse","city":"Lyon","country":"France","cc":"FR","lat":45.75353,"lon":4.84907,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"NOT_YET_RECRUITING","nct":"NCT06733129","study":"Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room","sstatus":"RECRUITING","sponsor":"Nantes University Hospital","src":"https://clinicaltrials.gov/study/NCT06733129","contact":{"n":"Alice BLET","p":"04 72 07 12 39","e":"alice.blet@chu-lyon.fr"},"phase":"Phase 3","enroll":1218,"start":"2025-04-14","eid":"x:site:nct06733129-hcl-lyon-croix-rousse-lyon"},{"id":"nct06733129-chu-nantes-laennec-nantes","cat":"research","name":"Chu Nantes (Laennec)","city":"Nantes","country":"France","cc":"FR","lat":47.2268,"lon":-1.544,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44093","condg":["Other"],"status":"RECRUITING","nct":"NCT06733129","study":"Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room","sstatus":"RECRUITING","sponsor":"Nantes University Hospital","src":"https://clinicaltrials.gov/study/NCT06733129","contact":{"n":"Xavier AMBROSI","p":"02 53 48 27 85","e":"xavier.ambrosi@chu-nantes.fr"},"phase":"Phase 3","enroll":1218,"start":"2025-04-14","eid":"x:site:nct06733129-chu-nantes-laennec-nantes"},{"id":"nct06733129-chu-nantes-nantes","cat":"research","name":"Chu Nantes","city":"Nantes","country":"France","cc":"FR","lat":47.222,"lon":-1.56216,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44093","condg":["Other"],"status":"RECRUITING","nct":"NCT06733129","study":"Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room","sstatus":"RECRUITING","sponsor":"Nantes University Hospital","src":"https://clinicaltrials.gov/study/NCT06733129","contact":{"n":"Nicolas GRILLOT, MD","p":"02 53 48 22 24","e":"nicolas.grillot@chu-nantes.fr"},"phase":"Phase 3","enroll":1218,"start":"2025-04-14","eid":"x:site:nct06733129-chu-nantes-nantes"},{"id":"nct06733129-aphp-st-antoine-paris","cat":"research","name":"APHP St-Antoine","city":"Paris","country":"France","cc":"FR","lat":48.86466,"lon":2.35026,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"NOT_YET_RECRUITING","nct":"NCT06733129","study":"Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room","sstatus":"RECRUITING","sponsor":"Nantes University Hospital","src":"https://clinicaltrials.gov/study/NCT06733129","contact":{"n":"Franck VERDON","p":"01 71 97 70 70","e":"franck.verdonk@aphp.fr"},"phase":"Phase 3","enroll":1218,"start":"2025-04-14","eid":"x:site:nct06733129-aphp-st-antoine-paris"},{"id":"nct06733129-aphp-tenon-paris","cat":"research","name":"APHP Tenon","city":"Paris","country":"France","cc":"FR","lat":48.85581,"lon":2.34904,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"NOT_YET_RECRUITING","nct":"NCT06733129","study":"Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room","sstatus":"RECRUITING","sponsor":"Nantes University Hospital","src":"https://clinicaltrials.gov/study/NCT06733129","contact":{"n":"Franck VERDONK","p":"01 71 97 70 70","e":"franck.verdonk@aphp.fr"},"phase":"Phase 3","enroll":1218,"start":"2025-04-14","eid":"x:site:nct06733129-aphp-tenon-paris"},{"id":"nct06733129-chu-poitiers-poitiers","cat":"research","name":"CHU Poitiers","city":"Poitiers","country":"France","cc":"FR","lat":46.57852,"lon":0.3536,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"RECRUITING","nct":"NCT06733129","study":"Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room","sstatus":"RECRUITING","sponsor":"Nantes University Hospital","src":"https://clinicaltrials.gov/study/NCT06733129","contact":{"n":"Quentin SAINT GENIS","p":"05 49 44 38 95","e":"quentin.saint-genis@chu-poitiers.fr"},"phase":"Phase 3","enroll":1218,"start":"2025-04-14","eid":"x:site:nct06733129-chu-poitiers-poitiers"},{"id":"nct06733129-hopital-foch-suresnes","cat":"research","name":"Hopital Foch","city":"Suresnes","country":"France","cc":"FR","lat":48.86809,"lon":2.23084,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"RECRUITING","nct":"NCT06733129","study":"Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room","sstatus":"RECRUITING","sponsor":"Nantes University Hospital","src":"https://clinicaltrials.gov/study/NCT06733129","contact":{"n":"Morgan LE GUEN","p":"02 53 48 22 24","e":"nicolas.grillot@chu-nantes.fr"},"phase":"Phase 3","enroll":1218,"start":"2025-04-14","eid":"x:site:nct06733129-hopital-foch-suresnes"},{"id":"nct06733129-chu-toulouse-hopital-purpan-toulouse","cat":"research","name":"CHU Toulouse Hôpital Purpan","city":"Toulouse","country":"France","cc":"FR","lat":43.59414,"lon":1.43534,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"NOT_YET_RECRUITING","nct":"NCT06733129","study":"Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room","sstatus":"RECRUITING","sponsor":"Nantes University Hospital","src":"https://clinicaltrials.gov/study/NCT06733129","contact":{"n":"Maxime POMMIER","p":"05 61 77 23 88","e":"pommier.max@chu-toulouse.fr"},"phase":"Phase 3","enroll":1218,"start":"2025-04-14","eid":"x:site:nct06733129-chu-toulouse-hopital-purpan-toulouse"},{"id":"nct06733129-chu-toulouse-hopital-rangueil-toulouse","cat":"research","name":"CHU Toulouse Hôpital Rangueil","city":"Toulouse","country":"France","cc":"FR","lat":43.60788,"lon":1.44306,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"NOT_YET_RECRUITING","nct":"NCT06733129","study":"Best Hypnotic Drug Choice for Rapid Sequence Induction in the Operating Room","sstatus":"RECRUITING","sponsor":"Nantes University Hospital","src":"https://clinicaltrials.gov/study/NCT06733129","contact":{"n":"Francois LABASTE","p":"05 61 32 28 22","e":"labaste.f@chu-toulouse.fr"},"phase":"Phase 3","enroll":1218,"start":"2025-04-14","eid":"x:site:nct06733129-chu-toulouse-hopital-rangueil-toulouse"},{"id":"nct05331131-center-for-advanced-medicine-lake-success","cat":"research","name":"Center for Advanced Medicine","city":"Lake Success","region":"New York","country":"United States","cc":"US","lat":40.76864,"lon":-73.72172,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11042","condg":["Cancer-related distress"],"nct":"NCT05331131","study":"Efficacy of Ketamine Mouthwash in the Management of Oral and Pharyngeal Toxicity Associated With Head and Neck Chemoradiotherapy: A Phase 2, Simon 2-stage Trial","sstatus":"WITHDRAWN","sponsor":"Northwell Health","official":"Bhupesh Parashar, MD, DrPH (Northwell Health)","src":"https://clinicaltrials.gov/study/NCT05331131","phase":"Phase 2","start":"2022-09-19","eid":"x:site:nct05331131-center-for-advanced-medicine-lake-success"},{"id":"nct05175781-ahu-aswan","cat":"research","name":"AHU","city":"Aswān","country":"Egypt","cc":"EG","lat":24.09378,"lon":32.90238,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"81511","condg":["PTSD & trauma"],"nct":"NCT05175781","study":"Sedation for Non-invasive Ventilation in Blunt Chest Trauma","sstatus":"COMPLETED","sponsor":"Aswan University Hospital","src":"https://clinicaltrials.gov/study/NCT05175781","phase":"N/A","enroll":45,"start":"2022-01-18","eid":"x:site:nct05175781-ahu-aswan"},{"id":"nct01627782-unnamed-trial-site-birmingham","cat":"research","name":"Unnamed trial site","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.51713,"lon":-86.80809,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01627782","study":"A Study of Ketamine in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01627782","phase":"Phase 2","enroll":68,"start":"2012-08-06","eid":"x:site:nct01627782-unnamed-trial-site-birmingham"},{"id":"nct01627782-unnamed-trial-site-little-rock","cat":"research","name":"Unnamed trial site","city":"Little Rock","region":"Arkansas","country":"United States","cc":"US","lat":34.73476,"lon":-92.27778,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01627782","study":"A Study of Ketamine in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01627782","phase":"Phase 2","enroll":68,"start":"2012-08-06","eid":"x:site:nct01627782-unnamed-trial-site-little-rock"},{"id":"nct01627782-unnamed-trial-site-centennial","cat":"research","name":"Unnamed trial site","city":"Centennial","region":"Colorado","country":"United States","cc":"US","lat":39.57055,"lon":-104.88017,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01627782","study":"A Study of Ketamine in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01627782","phase":"Phase 2","enroll":68,"start":"2012-08-06","eid":"x:site:nct01627782-unnamed-trial-site-centennial"},{"id":"nct01627782-unnamed-trial-site-hartford","cat":"research","name":"Unnamed trial site","city":"Hartford","region":"Connecticut","country":"United States","cc":"US","lat":41.76282,"lon":-72.69643,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01627782","study":"A Study of Ketamine in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01627782","phase":"Phase 2","enroll":68,"start":"2012-08-06","eid":"x:site:nct01627782-unnamed-trial-site-hartford"},{"id":"nct01627782-unnamed-trial-site-new-haven","cat":"research","name":"Unnamed trial site","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.29756,"lon":-72.92162,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01627782","study":"A Study of Ketamine in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01627782","phase":"Phase 2","enroll":68,"start":"2012-08-06","eid":"x:site:nct01627782-unnamed-trial-site-new-haven"},{"id":"nct01627782-unnamed-trial-site-atlanta","cat":"research","name":"Unnamed trial site","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.73879,"lon":-84.38549,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01627782","study":"A Study of Ketamine in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01627782","phase":"Phase 2","enroll":68,"start":"2012-08-06","eid":"x:site:nct01627782-unnamed-trial-site-atlanta"},{"id":"nct01627782-unnamed-trial-site-rockville","cat":"research","name":"Unnamed trial site","city":"Rockville","region":"Maryland","country":"United States","cc":"US","lat":39.07802,"lon":-77.15507,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01627782","study":"A Study of Ketamine in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01627782","phase":"Phase 2","enroll":68,"start":"2012-08-06","eid":"x:site:nct01627782-unnamed-trial-site-rockville"},{"id":"nct01627782-unnamed-trial-site-marlton","cat":"research","name":"Unnamed trial site","city":"Marlton","region":"New Jersey","country":"United States","cc":"US","lat":39.88129,"lon":-74.93374,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01627782","study":"A Study of Ketamine in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01627782","phase":"Phase 2","enroll":68,"start":"2012-08-06","eid":"x:site:nct01627782-unnamed-trial-site-marlton"},{"id":"nct01627782-unnamed-trial-site-new-york","cat":"research","name":"Unnamed trial site","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72222,"lon":-74.00018,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01627782","study":"A Study of Ketamine in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01627782","phase":"Phase 2","enroll":68,"start":"2012-08-06","eid":"x:site:nct01627782-unnamed-trial-site-new-york"},{"id":"nct01627782-unnamed-trial-site-allentown","cat":"research","name":"Unnamed trial site","city":"Allentown","region":"Pennsylvania","country":"United States","cc":"US","lat":40.60763,"lon":-75.49249,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01627782","study":"A Study of Ketamine in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01627782","phase":"Phase 2","enroll":68,"start":"2012-08-06","eid":"x:site:nct01627782-unnamed-trial-site-allentown"},{"id":"nct01627782-unnamed-trial-site-charleston","cat":"research","name":"Unnamed trial site","city":"Charleston","region":"South Carolina","country":"United States","cc":"US","lat":32.7758,"lon":-79.93835,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01627782","study":"A Study of Ketamine in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01627782","phase":"Phase 2","enroll":68,"start":"2012-08-06","eid":"x:site:nct01627782-unnamed-trial-site-charleston"},{"id":"nct01627782-unnamed-trial-site-dallas","cat":"research","name":"Unnamed trial site","city":"Dallas","region":"Texas","country":"United States","cc":"US","lat":32.78781,"lon":-96.81735,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01627782","study":"A Study of Ketamine in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01627782","phase":"Phase 2","enroll":68,"start":"2012-08-06","eid":"x:site:nct01627782-unnamed-trial-site-dallas"},{"id":"nct01627782-unnamed-trial-site-salt-lake-city","cat":"research","name":"Unnamed trial site","city":"Salt Lake City","region":"Utah","country":"United States","cc":"US","lat":40.75556,"lon":-111.89957,"gp":"city","unnamed":1,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT01627782","study":"A Study of Ketamine in Patients With Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Janssen Research & Development, LLC","official":"Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC)","src":"https://clinicaltrials.gov/study/NCT01627782","phase":"Phase 2","enroll":68,"start":"2012-08-06","eid":"x:site:nct01627782-unnamed-trial-site-salt-lake-city"},{"id":"nct03027362-yale-university-new-haven","cat":"research","name":"Yale University","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.30123,"lon":-72.91945,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06511","condg":["Depression"],"nct":"NCT03027362","study":"Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Yale University","official":"Samuel Wilkinson, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT03027362","phase":"N/A","enroll":28,"start":"2017-01","eid":"x:site:nct03027362-yale-university-new-haven"},{"id":"nct05508594-dantrials-copenhagen","cat":"research","name":"DanTrials","city":"Copenhagen","region":"NV","country":"Denmark","cc":"DK","lat":55.68408,"lon":12.56746,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"2400","condg":["Chronic pain & headache"],"nct":"NCT05508594","study":"Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001","sstatus":"COMPLETED","sponsor":"Cessatech A/S","src":"https://clinicaltrials.gov/study/NCT05508594","phase":"Phase 2/Phase 3","enroll":220,"start":"2022-09-05","eid":"x:site:nct05508594-dantrials-copenhagen"},{"id":"nct06236113-north-memorial-health-hospital-robbinsdale","cat":"research","name":"North Memorial Health Hospital","city":"Robbinsdale","region":"Minnesota","country":"United States","cc":"US","lat":45.03478,"lon":-93.35047,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55422","condg":["Other"],"nct":"NCT06236113","study":"Low Dose Ketamine for Blunt Thoracic Trauma","sstatus":"COMPLETED","sponsor":"North Memorial Health Care","official":"Michaela A West, MD, PhD (North Memorial Health); Joseph Farhat, MD (North Memorial Health)","src":"https://clinicaltrials.gov/study/NCT06236113","phase":"Phase 4","enroll":50,"start":"2021-10-01","eid":"x:site:nct06236113-north-memorial-health-hospital-robbinsdale"},{"id":"nct01535937-new-york-state-psychiatric-institute-new-york","cat":"research","name":"New York State Psychiatric Institute","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71676,"lon":-74.00253,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10032","condg":["Addiction & substance use"],"nct":"NCT01535937","study":"The Effect of Brief Potent Glutamatergic Modulation on Cocaine Dependence","sstatus":"TERMINATED","sponsor":"New York State Psychiatric Institute","official":"Herbert Kleber, M.D. (NYSPI); Elias Dakwar, MD (New York State Psychiatric Institute)","src":"https://clinicaltrials.gov/study/NCT01535937","phase":"Phase 1/Phase 2","enroll":55,"start":"2012-02","eid":"x:site:nct01535937-new-york-state-psychiatric-institute-new-york"},{"id":"nct06891300-royal-ottawa-mental-health-centre-ottawa","cat":"research","name":"Royal Ottawa Mental Health Centre","city":"Ottawa","region":"Ontario","country":"Canada","cc":"CA","lat":45.40689,"lon":-75.70287,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"K1Z7K4","condg":["Depression"],"status":"RECRUITING","nct":"NCT06891300","study":"Understanding and Treating Suicidal Ideation With Ketamine","sstatus":"RECRUITING","sponsor":"The Royal's Institute of Mental Health Research","official":"Jennifer Phillips, PhD (University of Ottawa Institute for Mental Health Research at The Royal)","src":"https://clinicaltrials.gov/study/NCT06891300","contact":{"n":"Research Coordinator","p":"613-722-6521","e":"suzannah.wojcik@theroyal.ca"},"phase":"Phase 2/Phase 3","enroll":36,"start":"2025-04-08","eid":"x:site:nct06891300-royal-ottawa-mental-health-centre-ottawa"},{"id":"nct03613792-beth-israel-deaconess-medical-center-bidmc-boston","cat":"research","name":"Beth Israel Deaconess Medical Center (BIDMC)","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.35932,"lon":-71.06575,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02215","condg":["Other"],"nct":"NCT03613792","study":"Remifentanil Plus Ketamine for Dynamic Flexible Bronchoscopy","sstatus":"WITHDRAWN","sponsor":"Beth Israel Deaconess Medical Center","official":"Satya Krishna Ramachandran, MD (Beth Israel Deaconess Medical Center)","src":"https://clinicaltrials.gov/study/NCT03613792","phase":"Phase 4","start":"2023-09","eid":"x:site:nct03613792-beth-israel-deaconess-medical-center-bidmc-boston"},{"id":"nct05320107-medical-university-of-vienna-vienna","cat":"research","name":"Medical University of Vienna","city":"Vienna","country":"Austria","cc":"AT","lat":48.20665,"lon":16.3822,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"1090","condg":["Depression"],"status":"RECRUITING","nct":"NCT05320107","study":"The Effect of Ketamine on Aesthetics and Role for Antidepressant Effects","sstatus":"UNKNOWN","sponsor":"Medical University of Vienna","src":"https://clinicaltrials.gov/study/NCT05320107","contact":{"n":"Rupert Lanzenberger, MD","p":"0043 1 40400","e":"rupert.lanzenberger@meduniwien.ac.at"},"phase":"Phase 1","enroll":60,"start":"2022-06-01","eid":"x:site:nct05320107-medical-university-of-vienna-vienna"},{"id":"nct04177706-medical-university-of-south-carolina-charleston","cat":"research","name":"Medical University of South Carolina","city":"Charleston","region":"South Carolina","country":"United States","cc":"US","lat":32.78258,"lon":-79.94117,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"29425","condg":["Depression","Addiction & substance use"],"nct":"NCT04177706","study":"Ketamine for the Treatment of Opioid Use Disorder and Depression","sstatus":"COMPLETED","sponsor":"Medical University of South Carolina","official":"Jennifer Jones, MD (Medical University of South Carolina)","src":"https://clinicaltrials.gov/study/NCT04177706","phase":"Phase 2","enroll":21,"start":"2020-12-17","eid":"x:site:nct04177706-medical-university-of-south-carolina-charleston"},{"id":"nct04291521-keck-school-of-medicine-of-the-university-of-southern-california-los","cat":"research","name":"Keck School of Medicine of the University of Southern California","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.04663,"lon":-118.25549,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"90033","condg":["PTSD & trauma"],"nct":"NCT04291521","study":"Prospective Study of Induction Medications Used in the Trauma RSI","sstatus":"WITHDRAWN","sponsor":"University of Southern California","official":"Catherine M Kuza, MD (Keck School of Medicine of the University of Southern California)","src":"https://clinicaltrials.gov/study/NCT04291521","start":"2027-01-01","eid":"x:site:nct04291521-keck-school-of-medicine-of-the-university-of-southern-california-los"},{"id":"nct05951387-benha-university-banha","cat":"research","name":"Benha university","city":"Banhā","region":"Qalyubia Governorate","country":"Egypt","cc":"EG","lat":30.46518,"lon":31.18199,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"13511","condg":["Other"],"nct":"NCT05951387","study":"Dexmedetomidine Versus Dexmedetomidine with Ketamine in Mechanically Ventilated ARDS Patients","sstatus":"COMPLETED","sponsor":"Benha University","official":"Marwa Elnaggar, MD (Benha University, Faculty of medicine)","src":"https://clinicaltrials.gov/study/NCT05951387","phase":"Phase 4","enroll":60,"start":"2023-06-01","eid":"x:site:nct05951387-benha-university-banha"},{"id":"nct04860804-maimonides-medical-center-brooklyn","cat":"research","name":"Maimonides Medical Center","city":"Brooklyn","region":"New York","country":"United States","cc":"US","lat":40.65674,"lon":-73.94125,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11219","condg":["Chronic pain & headache"],"nct":"NCT04860804","study":"A Comparison of Proprietary Formulations of Oral Ketamine + Aspirin and Oral Ketamine Alone for Musculoskeletal Pain","sstatus":"COMPLETED","sponsor":"Antonios Likourezos","official":"Leily Naraghi Bagher Pour, MD (Maimonides Medical Center)","src":"https://clinicaltrials.gov/study/NCT04860804","phase":"Phase 4","enroll":60,"start":"2021-04-22","eid":"x:site:nct04860804-maimonides-medical-center-brooklyn"},{"id":"nct00088699-national-institutes-of-health-clinical-center-9000-rockville-pike-be","cat":"research","name":"National Institutes of Health Clinical Center, 9000 Rockville Pike","city":"Bethesda","region":"Maryland","country":"United States","cc":"US","lat":38.97375,"lon":-77.10482,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20892","condg":["Depression"],"nct":"NCT00088699","study":"Rapid Antidepressant Effects of Ketamine in Major Depression","sstatus":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","official":"Carlos A Zarate, M.D. (National Institute of Mental Health (NIMH))","src":"https://clinicaltrials.gov/study/NCT00088699","phase":"Phase 1/Phase 2","enroll":67,"start":"2004-07-26","eid":"x:site:nct00088699-national-institutes-of-health-clinical-center-9000-rockville-pike-be"},{"id":"nct00475904-multiple-centers-new-delhi","cat":"research","name":"Multiple Centers","city":"New Delhi","country":"India","cc":"IN","lat":28.6105,"lon":77.20713,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"110016","condg":["Chronic pain & headache"],"nct":"NCT00475904","study":"A Comparison of EpiCept™ NP-1 Topical Cream vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)","sstatus":"COMPLETED","sponsor":"EpiCept Corporation","official":"Robert H Dworkin, Ph.D. (University of Rochester)","src":"https://clinicaltrials.gov/study/NCT00475904","phase":"Phase 2","enroll":360,"start":"2007-07","eid":"x:site:nct00475904-multiple-centers-new-delhi"},{"id":"nct06213324-icahn-school-of-medicine-at-mount-sinai-new-york","cat":"research","name":"Icahn School of Medicine at Mount Sinai","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.721,"lon":-74.00385,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10029","condg":["Depression"],"status":"RECRUITING","nct":"NCT06213324","study":"Neural Circuit Effects of Ketamine in Depression","sstatus":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","official":"James Murrough, MD/PhD (Icahn School of Medicine at Mount Sinai); Laurel Morris (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT06213324","contact":{"n":"Sibilla Masieri","e":"Sibilla.Masieri@mssm.edu,"},"phase":"Phase 4","enroll":120,"start":"2024-01-31","eid":"x:site:nct06213324-icahn-school-of-medicine-at-mount-sinai-new-york"},{"id":"nct01551329-va-ct-healthcare-systems-west-haven","cat":"research","name":"VA CT Healthcare Systems","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.26364,"lon":-72.95585,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06516","condg":["Depression","Addiction & substance use"],"nct":"NCT01551329","study":"Ketamine for Depression and Alcohol Dependence","sstatus":"COMPLETED","sponsor":"Yale University","official":"Ismene Petrakis, M.D. (Yale University)","src":"https://clinicaltrials.gov/study/NCT01551329","phase":"Phase 1","enroll":5,"start":"2012-03","eid":"x:site:nct01551329-va-ct-healthcare-systems-west-haven"},{"id":"nct04714541-lori-calabrese-md-innovative-psychiatry-south-windsor","cat":"research","name":"Lori Calabrese MD Innovative Psychiatry","city":"South Windsor","region":"Connecticut","country":"United States","cc":"US","lat":41.81952,"lon":-72.61372,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06074","condg":["Eating disorders"],"nct":"NCT04714541","study":"Modified Ketogenic Diet and Ketamine for Anorexia Nervosa","sstatus":"COMPLETED","sponsor":"Homeostasis Therapeutics, LLC","official":"Lori Calabrese, MD (Innovative Psychiatry So Windsor); Lori Calabrese, MD (Innovative Psychiatry, So Windsor)","src":"https://clinicaltrials.gov/study/NCT04714541","phase":"Phase 1","enroll":5,"start":"2021-04-12","eid":"x:site:nct04714541-lori-calabrese-md-innovative-psychiatry-south-windsor"},{"id":"nct01626755-massachusetts-general-hospital-dept-of-anesthesiology-perioperative-","cat":"research","name":"Massachusetts General Hospital, Dept. of Anesthesiology, Perioperative and Pain Medicine","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36064,"lon":-71.06452,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02115","condg":["Chronic pain & headache"],"nct":"NCT01626755","study":"Prevention of Phantom Limb Pain After Transtibial Amputation","sstatus":"TERMINATED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","official":"Markus Hollmann, MD PhD (Dept. of Anaesthesiology, Academic Medical Center / University of Amsterdam, The Netherlands); Philipp Lirk, MD PhD (Dept. of Anaesthesiology, Academic Medical Center / University of Amsterdam, The Netherlands)","src":"https://clinicaltrials.gov/study/NCT01626755","phase":"N/A","enroll":12,"start":"2013-08","eid":"x:site:nct01626755-massachusetts-general-hospital-dept-of-anesthesiology-perioperative-"},{"id":"nct01626755-general-hospital-klagenfurt-klagenfurt","cat":"research","name":"General Hospital Klagenfurt","city":"Klagenfurt","region":"Carinthia","country":"Austria","cc":"AT","lat":46.62336,"lon":14.31577,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Chronic pain & headache"],"nct":"NCT01626755","study":"Prevention of Phantom Limb Pain After Transtibial Amputation","sstatus":"TERMINATED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","official":"Markus Hollmann, MD PhD (Dept. of Anaesthesiology, Academic Medical Center / University of Amsterdam, The Netherlands); Philipp Lirk, MD PhD (Dept. of Anaesthesiology, Academic Medical Center / University of Amsterdam, The Netherlands)","src":"https://clinicaltrials.gov/study/NCT01626755","phase":"N/A","enroll":12,"start":"2013-08","eid":"x:site:nct01626755-general-hospital-klagenfurt-klagenfurt"},{"id":"nct01626755-innsbruck-medical-university-hospital-innsbruck","cat":"research","name":"Innsbruck Medical University Hospital","city":"Innsbruck","region":"Tyrol","country":"Austria","cc":"AT","lat":47.27014,"lon":11.39393,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"6020","condg":["Chronic pain & headache"],"nct":"NCT01626755","study":"Prevention of Phantom Limb Pain After Transtibial Amputation","sstatus":"TERMINATED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","official":"Markus Hollmann, MD PhD (Dept. of Anaesthesiology, Academic Medical Center / University of Amsterdam, The Netherlands); Philipp Lirk, MD PhD (Dept. of Anaesthesiology, Academic Medical Center / University of Amsterdam, The Netherlands)","src":"https://clinicaltrials.gov/study/NCT01626755","phase":"N/A","enroll":12,"start":"2013-08","eid":"x:site:nct01626755-innsbruck-medical-university-hospital-innsbruck"},{"id":"nct01626755-ziekenhuis-oost-limburg-genk","cat":"research","name":"Ziekenhuis Oost Limburg","city":"Genk","region":"Limburg","country":"Belgium","cc":"BE","lat":50.95771,"lon":5.5052,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Chronic pain & headache"],"nct":"NCT01626755","study":"Prevention of Phantom Limb Pain After Transtibial Amputation","sstatus":"TERMINATED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","official":"Markus Hollmann, MD PhD (Dept. of Anaesthesiology, Academic Medical Center / University of Amsterdam, The Netherlands); Philipp Lirk, MD PhD (Dept. of Anaesthesiology, Academic Medical Center / University of Amsterdam, The Netherlands)","src":"https://clinicaltrials.gov/study/NCT01626755","phase":"N/A","enroll":12,"start":"2013-08","eid":"x:site:nct01626755-ziekenhuis-oost-limburg-genk"},{"id":"nct01626755-academic-medical-center-university-of-amsterdam-amsterdam","cat":"research","name":"Academic Medical Center, University of Amsterdam","city":"Amsterdam","region":"North Holland","country":"Netherlands","cc":"NL","lat":52.37163,"lon":4.88767,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"1105AZ","condg":["Chronic pain & headache"],"nct":"NCT01626755","study":"Prevention of Phantom Limb Pain After Transtibial Amputation","sstatus":"TERMINATED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","official":"Markus Hollmann, MD PhD (Dept. of Anaesthesiology, Academic Medical Center / University of Amsterdam, The Netherlands); Philipp Lirk, MD PhD (Dept. of Anaesthesiology, Academic Medical Center / University of Amsterdam, The Netherlands)","src":"https://clinicaltrials.gov/study/NCT01626755","phase":"N/A","enroll":12,"start":"2013-08","eid":"x:site:nct01626755-academic-medical-center-university-of-amsterdam-amsterdam"},{"id":"nct01626755-westfriesgasthuis-hoorn","cat":"research","name":"Westfriesgasthuis","city":"Hoorn","region":"North Holland","country":"Netherlands","cc":"NL","lat":52.64264,"lon":5.06814,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Chronic pain & headache"],"nct":"NCT01626755","study":"Prevention of Phantom Limb Pain After Transtibial Amputation","sstatus":"TERMINATED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","official":"Markus Hollmann, MD PhD (Dept. of Anaesthesiology, Academic Medical Center / University of Amsterdam, The Netherlands); Philipp Lirk, MD PhD (Dept. of Anaesthesiology, Academic Medical Center / University of Amsterdam, The Netherlands)","src":"https://clinicaltrials.gov/study/NCT01626755","phase":"N/A","enroll":12,"start":"2013-08","eid":"x:site:nct01626755-westfriesgasthuis-hoorn"},{"id":"nct01626755-erasmus-medical-center-rotterdam","cat":"research","name":"Erasmus Medical Center","city":"Rotterdam","region":"North Holland","country":"Netherlands","cc":"NL","lat":51.91822,"lon":4.48948,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Chronic pain & headache"],"nct":"NCT01626755","study":"Prevention of Phantom Limb Pain After Transtibial Amputation","sstatus":"TERMINATED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","official":"Markus Hollmann, MD PhD (Dept. of Anaesthesiology, Academic Medical Center / University of Amsterdam, The Netherlands); Philipp Lirk, MD PhD (Dept. of Anaesthesiology, Academic Medical Center / University of Amsterdam, The Netherlands)","src":"https://clinicaltrials.gov/study/NCT01626755","phase":"N/A","enroll":12,"start":"2013-08","eid":"x:site:nct01626755-erasmus-medical-center-rotterdam"},{"id":"nct01626755-canisius-wilhelmus-ziekenhuis-nijmegen","cat":"research","name":"Canisius Wilhelmus Ziekenhuis","city":"Nijmegen","country":"Netherlands","cc":"NL","lat":51.83502,"lon":5.85226,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Chronic pain & headache"],"nct":"NCT01626755","study":"Prevention of Phantom Limb Pain After Transtibial Amputation","sstatus":"TERMINATED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","official":"Markus Hollmann, MD PhD (Dept. of Anaesthesiology, Academic Medical Center / University of Amsterdam, The Netherlands); Philipp Lirk, MD PhD (Dept. of Anaesthesiology, Academic Medical Center / University of Amsterdam, The Netherlands)","src":"https://clinicaltrials.gov/study/NCT01626755","phase":"N/A","enroll":12,"start":"2013-08","eid":"x:site:nct01626755-canisius-wilhelmus-ziekenhuis-nijmegen"},{"id":"nct01626755-valencia-university-hospital-valencia","cat":"research","name":"Valencia University Hospital","city":"Valencia","country":"Spain","cc":"ES","lat":39.47057,"lon":-0.3798,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Chronic pain & headache"],"nct":"NCT01626755","study":"Prevention of Phantom Limb Pain After Transtibial Amputation","sstatus":"TERMINATED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","official":"Markus Hollmann, MD PhD (Dept. of Anaesthesiology, Academic Medical Center / University of Amsterdam, The Netherlands); Philipp Lirk, MD PhD (Dept. of Anaesthesiology, Academic Medical Center / University of Amsterdam, The Netherlands)","src":"https://clinicaltrials.gov/study/NCT01626755","phase":"N/A","enroll":12,"start":"2013-08","eid":"x:site:nct01626755-valencia-university-hospital-valencia"},{"id":"nct02099006-university-of-rochester-rochester","cat":"research","name":"University of Rochester","city":"Rochester","region":"New York","country":"United States","cc":"US","lat":43.14974,"lon":-77.62361,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"14642","condg":["Other"],"nct":"NCT02099006","study":"Novel Topical Therapies for the Treatment of Genital Pain","sstatus":"COMPLETED","sponsor":"University of Rochester","official":"Adrienne D Bonham, MD (University of Rochester)","src":"https://clinicaltrials.gov/study/NCT02099006","phase":"Phase 2/Phase 3","enroll":9,"start":"2013-11","eid":"x:site:nct02099006-university-of-rochester-rochester"},{"id":"nct02232347-sainte-anne-military-teaching-hospital-toulon","cat":"research","name":"Sainte Anne Military Teaching Hospital","city":"Toulon","country":"France","cc":"FR","lat":43.12757,"lon":5.93264,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"83130","condg":["PTSD & trauma"],"nct":"NCT02232347","study":"Ketamine and Glutamate After Brain Injury : a Microdialysis Study","sstatus":"UNKNOWN","sponsor":"Pierre-Julien CUNGI","official":"Ambroise MONTCRIOL, MD (Direction Centrale du Service de Santé des Armées)","src":"https://clinicaltrials.gov/study/NCT02232347","contact":{"n":"Pierre Julien CUNGI, MD","p":"0483162358","e":"ambroise.montcriol@free.fr"},"phase":"Phase 2","enroll":20,"start":"2014-10","eid":"x:site:nct02232347-sainte-anne-military-teaching-hospital-toulon"},{"id":"nct06609538-wonwanguh-iksan","cat":"research","name":"WonwangUH","city":"Iksan","region":"Please Select","country":"South Korea","cc":"KR","lat":35.95561,"lon":126.9446,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"54538","condg":["Other"],"nct":"NCT06609538","study":"The Impact of Preoperative Suggestion on Dreaming","sstatus":"COMPLETED","sponsor":"Wonkwang University Hospital","official":"Cheol Lee, M.D.,Ph.D (Wonkwang University Hospital)","src":"https://clinicaltrials.gov/study/NCT06609538","phase":"N/A","enroll":250,"start":"2024-09-19","eid":"x:site:nct06609538-wonwanguh-iksan"},{"id":"nct07211399-upmc-shadyside-hospital-pittsburgh","cat":"research","name":"UPMC Shadyside Hospital","city":"Pittsburgh","region":"Pennsylvania","country":"United States","cc":"US","lat":40.43173,"lon":-79.99123,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"15232","condg":["Addiction & substance use"],"nct":"NCT07211399","study":"Transition From Acute to Chronic Opioid Use and Chronic Pain","sstatus":"WITHDRAWN","sponsor":"Jacques E. Chelly","official":"Jacques Chelly, MD, PhD, MBA (University of Pittsburgh, UPMC)","src":"https://clinicaltrials.gov/study/NCT07211399","phase":"EARLY_Phase 1","start":"2026-07-01","eid":"x:site:nct07211399-upmc-shadyside-hospital-pittsburgh"},{"id":"nct06034821-uc-san-francisco-san-francisco","cat":"research","name":"UC San Francisco","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.76575,"lon":-122.40789,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94143","condg":["Depression"],"nct":"NCT06034821","study":"Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Brigham and Women's Hospital","official":"Amit Anand, MD (Brigham and Woman's Hospital, Harvard Medical School)","src":"https://clinicaltrials.gov/study/NCT06034821","phase":"Phase 4","enroll":1500,"start":"2023-10-01","eid":"x:site:nct06034821-uc-san-francisco-san-francisco"},{"id":"nct06034821-johns-hopkins-university-baltimore","cat":"research","name":"Johns Hopkins University","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28233,"lon":-76.60066,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"21287","condg":["Depression"],"nct":"NCT06034821","study":"Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Brigham and Women's Hospital","official":"Amit Anand, MD (Brigham and Woman's Hospital, Harvard Medical School)","src":"https://clinicaltrials.gov/study/NCT06034821","phase":"Phase 4","enroll":1500,"start":"2023-10-01","eid":"x:site:nct06034821-johns-hopkins-university-baltimore"},{"id":"nct06034821-mclean-hospital-belmont","cat":"research","name":"McLean Hospital","city":"Belmont","region":"Massachusetts","country":"United States","cc":"US","lat":37.51339,"lon":-122.27989,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02478","condg":["Depression"],"nct":"NCT06034821","study":"Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Brigham and Women's Hospital","official":"Amit Anand, MD (Brigham and Woman's Hospital, Harvard Medical School)","src":"https://clinicaltrials.gov/study/NCT06034821","phase":"Phase 4","enroll":1500,"start":"2023-10-01","eid":"x:site:nct06034821-mclean-hospital-belmont"},{"id":"nct06034821-massachusetts-general-hospital-boston","cat":"research","name":"Massachusetts General Hospital","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.35095,"lon":-71.05502,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02114","condg":["Depression"],"nct":"NCT06034821","study":"Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Brigham and Women's Hospital","official":"Amit Anand, MD (Brigham and Woman's Hospital, Harvard Medical School)","src":"https://clinicaltrials.gov/study/NCT06034821","phase":"Phase 4","enroll":1500,"start":"2023-10-01","eid":"x:site:nct06034821-massachusetts-general-hospital-boston"},{"id":"nct06034821-mount-sinai-school-of-medicine-new-york","cat":"research","name":"Mount Sinai School of Medicine","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70829,"lon":-74.01213,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10029","condg":["Depression"],"nct":"NCT06034821","study":"Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Brigham and Women's Hospital","official":"Amit Anand, MD (Brigham and Woman's Hospital, Harvard Medical School)","src":"https://clinicaltrials.gov/study/NCT06034821","phase":"Phase 4","enroll":1500,"start":"2023-10-01","eid":"x:site:nct06034821-mount-sinai-school-of-medicine-new-york"},{"id":"nct06034821-cleveland-clinic-cleveland","cat":"research","name":"Cleveland Clinic","city":"Cleveland","region":"Ohio","country":"United States","cc":"US","lat":41.49164,"lon":-81.6964,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44195","condg":["Depression"],"nct":"NCT06034821","study":"Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Brigham and Women's Hospital","official":"Amit Anand, MD (Brigham and Woman's Hospital, Harvard Medical School)","src":"https://clinicaltrials.gov/study/NCT06034821","phase":"Phase 4","enroll":1500,"start":"2023-10-01","eid":"x:site:nct06034821-cleveland-clinic-cleveland"},{"id":"nct06034821-university-of-pittsburgh-pittsburgh","cat":"research","name":"University of Pittsburgh","city":"Pittsburgh","region":"Pennsylvania","country":"United States","cc":"US","lat":40.43634,"lon":-79.98398,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"15213","condg":["Depression"],"nct":"NCT06034821","study":"Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Brigham and Women's Hospital","official":"Amit Anand, MD (Brigham and Woman's Hospital, Harvard Medical School)","src":"https://clinicaltrials.gov/study/NCT06034821","phase":"Phase 4","enroll":1500,"start":"2023-10-01","eid":"x:site:nct06034821-university-of-pittsburgh-pittsburgh"},{"id":"nct06034821-uthealth-houston-houston","cat":"research","name":"UTHealth Houston","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.76606,"lon":-95.35231,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"77030","condg":["Depression"],"nct":"NCT06034821","study":"Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Brigham and Women's Hospital","official":"Amit Anand, MD (Brigham and Woman's Hospital, Harvard Medical School)","src":"https://clinicaltrials.gov/study/NCT06034821","phase":"Phase 4","enroll":1500,"start":"2023-10-01","eid":"x:site:nct06034821-uthealth-houston-houston"},{"id":"nct06034821-university-of-utah-salt-lake-city","cat":"research","name":"University of Utah","city":"Salt Lake City","region":"Utah","country":"United States","cc":"US","lat":40.75725,"lon":-111.88056,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"84132","condg":["Depression"],"nct":"NCT06034821","study":"Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Brigham and Women's Hospital","official":"Amit Anand, MD (Brigham and Woman's Hospital, Harvard Medical School)","src":"https://clinicaltrials.gov/study/NCT06034821","phase":"Phase 4","enroll":1500,"start":"2023-10-01","eid":"x:site:nct06034821-university-of-utah-salt-lake-city"},{"id":"nct06034821-center-for-addiction-and-mental-health-university-of-toronto-toronto","cat":"research","name":"Center for Addiction and Mental Health (University of Toronto)","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70055,"lon":-79.38805,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M6J 1H4","condg":["Depression"],"nct":"NCT06034821","study":"Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Brigham and Women's Hospital","official":"Amit Anand, MD (Brigham and Woman's Hospital, Harvard Medical School)","src":"https://clinicaltrials.gov/study/NCT06034821","phase":"Phase 4","enroll":1500,"start":"2023-10-01","eid":"x:site:nct06034821-center-for-addiction-and-mental-health-university-of-toronto-toronto"},{"id":"nct04005209-duke-hospital-durham","cat":"research","name":"Duke Hospital","city":"Durham","region":"North Carolina","country":"United States","cc":"US","lat":35.99455,"lon":-78.89396,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"27710","condg":["Chronic pain & headache"],"nct":"NCT04005209","study":"Ketamine Infusion for Sickle Cell Pain Crisis","sstatus":"WITHDRAWN","sponsor":"Duke University","src":"https://clinicaltrials.gov/study/NCT04005209","phase":"Phase 4","start":"2022-01","eid":"x:site:nct04005209-duke-hospital-durham"},{"id":"nct05343507-centre-hospitalier-neurologique-william-lennox-ottignies-louvain-la-","cat":"research","name":"Centre Hospitalier Neurologique William Lennox","city":"Ottignies-Louvain-la-Neuve","region":"Wallonia","country":"Belgium","cc":"BE","lat":50.5706,"lon":5.0795,"gp":"region","unnamed":0,"drugs":["ketamine"],"zip":"1340","condg":["Other"],"status":"RECRUITING","nct":"NCT05343507","study":"Ketamine to Treat Patients With Post-comatose Disorders of Consciousness","sstatus":"UNKNOWN","sponsor":"University of Liege","official":"Olivia Gosseries, PhD (Coma Science Group (ULiege) & Centre du Cerveau2 (CHU Liege))","src":"https://clinicaltrials.gov/study/NCT05343507","contact":{"n":"Paolo Cardone, M.Sc.","p":"0456309880","e":"p.cardone@uliege.be"},"phase":"Phase 2/Phase 3","enroll":30,"start":"2022-05-01","eid":"x:site:nct05343507-centre-hospitalier-neurologique-william-lennox-ottignies-louvain-la-"},{"id":"nct02726867-midatlantic-epilepsy-and-sleep-center-bethesda","cat":"research","name":"MidAtlantic Epilepsy and Sleep Center","city":"Bethesda","region":"Maryland","country":"United States","cc":"US","lat":38.97601,"lon":-77.09899,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20817","condg":["Neurology & cognition"],"nct":"NCT02726867","study":"Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus","sstatus":"WITHDRAWN","sponsor":"Mid-Atlantic Epilepsy and Sleep Center, LLC","official":"Pavel Klein, M.D. (Mid-Atlantic Epilepsy and Sleep Center)","src":"https://clinicaltrials.gov/study/NCT02726867","phase":"Phase 3","start":"2014-02","eid":"x:site:nct02726867-midatlantic-epilepsy-and-sleep-center-bethesda"},{"id":"nct03396601-research-centers-of-america-hollywood","cat":"research","name":"Research Centers of America","city":"Hollywood","region":"Florida","country":"United States","cc":"US","lat":34.10498,"lon":-118.32274,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"33024","condg":["Depression","Bipolar"],"nct":"NCT03396601","study":"NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression","sstatus":"UNKNOWN","sponsor":"NeuroRx, Inc.","official":"Martin Brecher, MD (VP, Clinical Development, NeuroRx, Inc.)","src":"https://clinicaltrials.gov/study/NCT03396601","phase":"Phase 3","enroll":150,"start":"2019-06-25","eid":"x:site:nct03396601-research-centers-of-america-hollywood"},{"id":"nct03396601-jp-smith-hospital-fort-worth","cat":"research","name":"JP Smith Hospital","city":"Fort Worth","region":"Texas","country":"United States","cc":"US","lat":32.7167,"lon":-97.32654,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"76104","condg":["Depression","Bipolar"],"nct":"NCT03396601","study":"NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression","sstatus":"UNKNOWN","sponsor":"NeuroRx, Inc.","official":"Martin Brecher, MD (VP, Clinical Development, NeuroRx, Inc.)","src":"https://clinicaltrials.gov/study/NCT03396601","phase":"Phase 3","enroll":150,"start":"2019-06-25","eid":"x:site:nct03396601-jp-smith-hospital-fort-worth"},{"id":"nct01582945-depression-clinical-and-research-program-mgh-boston","cat":"research","name":"Depression Clinical and Research Program - MGH","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.37005,"lon":-71.05709,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02114","condg":["Depression"],"nct":"NCT01582945","study":"Ketamine Infusion for Treatment-resistant Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Massachusetts General Hospital","official":"Cristina Cusin, MD (MGH Department of Psychiatry)","src":"https://clinicaltrials.gov/study/NCT01582945","phase":"N/A","enroll":14,"start":"2012-04","eid":"x:site:nct01582945-depression-clinical-and-research-program-mgh-boston"},{"id":"nct01680172-mayo-clinic-in-arizona-scottsdale","cat":"research","name":"Mayo Clinic in Arizona","city":"Scottsdale","region":"Arizona","country":"United States","cc":"US","lat":33.5037,"lon":-111.90454,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"85259","condg":["Depression","Anxiety","Cancer-related distress"],"nct":"NCT01680172","study":"Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer","sstatus":"TERMINATED","sponsor":"Mayo Clinic","official":"Robert P. Bright, MD (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT01680172","phase":"Phase 2","enroll":5,"start":"2012-08","eid":"x:site:nct01680172-mayo-clinic-in-arizona-scottsdale"},{"id":"nct01680172-yuma-regional-medical-center-yuma","cat":"research","name":"Yuma Regional Medical Center","city":"Yuma","region":"Arizona","country":"United States","cc":"US","lat":32.72565,"lon":-114.63471,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"85364","condg":["Depression","Anxiety","Cancer-related distress"],"nct":"NCT01680172","study":"Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer","sstatus":"TERMINATED","sponsor":"Mayo Clinic","official":"Robert P. Bright, MD (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT01680172","phase":"Phase 2","enroll":5,"start":"2012-08","eid":"x:site:nct01680172-yuma-regional-medical-center-yuma"},{"id":"nct04700592-mechaal-benali-nabeul","cat":"research","name":"Mechaal Benali","city":"Nabeul","country":"Tunisia","cc":"TN","lat":36.4546,"lon":10.74314,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"8000","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT04700592","study":"A Comparison of Gabapentin and Ketamine in Acute and Chronic Pain After Inguinal Hernia Repair","sstatus":"COMPLETED","sponsor":"University Tunis El Manar","official":"mechaal benali, PROFESSOR (university manar Tunis tunisia)","src":"https://clinicaltrials.gov/study/NCT04700592","phase":"N/A","enroll":60,"start":"2020-10-02","eid":"x:site:nct04700592-mechaal-benali-nabeul"},{"id":"nct06816433-homestead-associates-in-research-inc-miami","cat":"research","name":"Homestead Associates in Research, Inc.","city":"Miami","region":"Florida","country":"United States","cc":"US","lat":25.76227,"lon":-80.20077,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"33032","condg":["PTSD & trauma"],"nct":"NCT06816433","study":"Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002","sstatus":"SUSPENDED","sponsor":"Global Coalition for Adaptive Research","src":"https://clinicaltrials.gov/study/NCT06816433","phase":"Phase 2","enroll":200,"start":"2028-05","eid":"x:site:nct06816433-homestead-associates-in-research-inc-miami"},{"id":"nct06816433-advanced-discovery-research-atlanta","cat":"research","name":"Advanced Discovery Research","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.75187,"lon":-84.37918,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"30318","condg":["PTSD & trauma"],"nct":"NCT06816433","study":"Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002","sstatus":"SUSPENDED","sponsor":"Global Coalition for Adaptive Research","src":"https://clinicaltrials.gov/study/NCT06816433","phase":"Phase 2","enroll":200,"start":"2028-05","eid":"x:site:nct06816433-advanced-discovery-research-atlanta"},{"id":"nct06816433-tripler-army-medical-center-tamc-tripler-amc","cat":"research","name":"Tripler Army Medical Center (TAMC)","city":"Tripler AMC","region":"Hawaii","country":"United States","cc":"US","lat":21.132,"lon":-157.6964,"gp":"region","unnamed":0,"drugs":["ketamine"],"zip":"96859","condg":["PTSD & trauma"],"nct":"NCT06816433","study":"Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002","sstatus":"SUSPENDED","sponsor":"Global Coalition for Adaptive Research","src":"https://clinicaltrials.gov/study/NCT06816433","phase":"Phase 2","enroll":200,"start":"2028-05","eid":"x:site:nct06816433-tripler-army-medical-center-tamc-tripler-amc"},{"id":"nct06816433-cincinnati-veteran-s-affairs-medical-center-fort-thomas","cat":"research","name":"Cincinnati Veteran's Affairs Medical Center","city":"Fort Thomas","region":"Kentucky","country":"United States","cc":"US","lat":39.0704,"lon":-84.44109,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"41075","condg":["PTSD & trauma"],"nct":"NCT06816433","study":"Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002","sstatus":"SUSPENDED","sponsor":"Global Coalition for Adaptive Research","src":"https://clinicaltrials.gov/study/NCT06816433","phase":"Phase 2","enroll":200,"start":"2028-05","eid":"x:site:nct06816433-cincinnati-veteran-s-affairs-medical-center-fort-thomas"},{"id":"nct06816433-walter-reed-national-military-medical-center-wrnmc-bethesda","cat":"research","name":"Walter Reed National Military Medical Center (WRNMC)","city":"Bethesda","region":"Maryland","country":"United States","cc":"US","lat":38.98938,"lon":-77.10257,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20889-5632","condg":["PTSD & trauma"],"nct":"NCT06816433","study":"Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002","sstatus":"SUSPENDED","sponsor":"Global Coalition for Adaptive Research","src":"https://clinicaltrials.gov/study/NCT06816433","phase":"Phase 2","enroll":200,"start":"2028-05","eid":"x:site:nct06816433-walter-reed-national-military-medical-center-wrnmc-bethesda"},{"id":"nct06816433-upstate-clinical-research-associates-llc-williamsville","cat":"research","name":"Upstate Clinical Research Associates, LLC","city":"Williamsville","region":"New York","country":"United States","cc":"US","lat":42.9672,"lon":-78.74614,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"14221","condg":["PTSD & trauma"],"nct":"NCT06816433","study":"Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002","sstatus":"SUSPENDED","sponsor":"Global Coalition for Adaptive Research","src":"https://clinicaltrials.gov/study/NCT06816433","phase":"Phase 2","enroll":200,"start":"2028-05","eid":"x:site:nct06816433-upstate-clinical-research-associates-llc-williamsville"},{"id":"nct06816433-wilford-hall-ambulatory-surgical-center-whasc-san-antonio","cat":"research","name":"Wilford Hall Ambulatory Surgical Center (WHASC)","city":"San Antonio","region":"Texas","country":"United States","cc":"US","lat":29.41476,"lon":-98.49932,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"78236","condg":["PTSD & trauma"],"nct":"NCT06816433","study":"Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002","sstatus":"SUSPENDED","sponsor":"Global Coalition for Adaptive Research","src":"https://clinicaltrials.gov/study/NCT06816433","phase":"Phase 2","enroll":200,"start":"2028-05","eid":"x:site:nct06816433-wilford-hall-ambulatory-surgical-center-whasc-san-antonio"},{"id":"nct06816433-alexander-t-augusta-military-medical-center-atammc-fort-belvoir","cat":"research","name":"Alexander T. Augusta Military Medical Center (ATAMMC):","city":"Fort Belvoir","region":"Virginia","country":"United States","cc":"US","lat":38.70846,"lon":-77.14151,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"22060-5285","condg":["PTSD & trauma"],"nct":"NCT06816433","study":"Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002","sstatus":"SUSPENDED","sponsor":"Global Coalition for Adaptive Research","src":"https://clinicaltrials.gov/study/NCT06816433","phase":"Phase 2","enroll":200,"start":"2028-05","eid":"x:site:nct06816433-alexander-t-augusta-military-medical-center-atammc-fort-belvoir"},{"id":"nct06816433-madigan-army-medical-center-joint-base-lewis-mcchord","cat":"research","name":"Madigan Army Medical Center","city":"Joint Base Lewis McChord","region":"Washington","country":"United States","cc":"US","lat":47.10989,"lon":-122.572,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"98433","condg":["PTSD & trauma"],"nct":"NCT06816433","study":"Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002","sstatus":"SUSPENDED","sponsor":"Global Coalition for Adaptive Research","src":"https://clinicaltrials.gov/study/NCT06816433","phase":"Phase 2","enroll":200,"start":"2028-05","eid":"x:site:nct06816433-madigan-army-medical-center-joint-base-lewis-mcchord"},{"id":"nct00588952-va-connecticut-healthcare-system-west-haven","cat":"research","name":"VA Connecticut Healthcare System","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.28256,"lon":-72.95133,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06516","condg":["Addiction & substance use"],"nct":"NCT00588952","study":"Ketamine/Placebo Family History Positive Study","sstatus":"COMPLETED","sponsor":"Yale University","official":"Ismene L. Petrakis, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT00588952","phase":"N/A","enroll":99,"start":"2001-03","eid":"x:site:nct00588952-va-connecticut-healthcare-system-west-haven"},{"id":"nct05970380-izmir-bozyaka-training-and-research-hospital-izmir","cat":"research","name":"Izmir Bozyaka Training and Research Hospital","city":"Izmir","country":"Turkey","cc":"TR","lat":38.41089,"lon":27.15,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT05970380","study":"Effect of Erector Spinae Plane Block in Patients Scheduled for Kyphoplasty","sstatus":"COMPLETED","sponsor":"Bozyaka Training and Research Hospital","official":"Halide H Şahinkaya, MD (Izmir Bozyaka Training and Research Hospital); Alper Tabanlı, MD (Izmir Bozyaka Training and Research Hospital)","src":"https://clinicaltrials.gov/study/NCT05970380","enroll":61,"start":"2023-07-25","eid":"x:site:nct05970380-izmir-bozyaka-training-and-research-hospital-izmir"},{"id":"nct05737693-yale-university-school-of-medicine-new-haven","cat":"research","name":"Yale University School of Medicine","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.30857,"lon":-72.93527,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06510","condg":["PTSD & trauma"],"nct":"NCT05737693","study":"Enhancing Week-long Psychological Treatment for PTSD With Ketamine","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","official":"Ilan Harpaz-Rotem, PhD ABPP (Yale University)","src":"https://clinicaltrials.gov/study/NCT05737693","phase":"Phase 2","enroll":350,"start":"2023-08-21","eid":"x:site:nct05737693-yale-university-school-of-medicine-new-haven"},{"id":"nct05737693-tel-aviv-university-tel-aviv","cat":"research","name":"Tel Aviv University","city":"Tel Aviv","country":"Israel","cc":"IL","lat":32.06992,"lon":34.77742,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["PTSD & trauma"],"nct":"NCT05737693","study":"Enhancing Week-long Psychological Treatment for PTSD With Ketamine","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","official":"Ilan Harpaz-Rotem, PhD ABPP (Yale University)","src":"https://clinicaltrials.gov/study/NCT05737693","phase":"Phase 2","enroll":350,"start":"2023-08-21","eid":"x:site:nct05737693-tel-aviv-university-tel-aviv"},{"id":"nct00441792-advocate-christ-medical-center-oak-lawn","cat":"research","name":"Advocate Christ Medical Center","city":"Oak Lawn","region":"Illinois","country":"United States","cc":"US","lat":41.716,"lon":-87.77011,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60453","condg":["PTSD & trauma"],"nct":"NCT00441792","study":"The Effect of Etomidate on Patient Outcomes After Single Bolus Doses","sstatus":"COMPLETED","sponsor":"Advocate Hospital System","official":"Erik B Kulstad, MD, MS (advocate christ medical center)","src":"https://clinicaltrials.gov/study/NCT00441792","phase":"N/A","enroll":122,"start":"2007-10","eid":"x:site:nct00441792-advocate-christ-medical-center-oak-lawn"},{"id":"nct05796232-irccs-burlo-garofolo-trieste","cat":"research","name":"IRCCS Burlo Garofolo","city":"Trieste","country":"Italy","cc":"IT","lat":45.64035,"lon":13.76986,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"34137","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT05796232","study":"Pharmacogenetics of Ketamine in Children","sstatus":"UNKNOWN","sponsor":"IRCCS Burlo Garofolo","official":"Egidio Barbi, MD (IRCCS materno infantile Burlo Garofolo)","src":"https://clinicaltrials.gov/study/NCT05796232","contact":{"n":"Egidio Barbi, MD","p":"+390403785251","e":"egidio.barbi@burlo.trieste.it"},"enroll":250,"start":"2020-06-26","eid":"x:site:nct05796232-irccs-burlo-garofolo-trieste"},{"id":"nct05864053-rush-university-medical-center-chicago","cat":"research","name":"Rush University Medical Center","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.83841,"lon":-87.6613,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60612","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT05864053","study":"(2R,6R)-Hydroxynorketamine for the Treatment of Neuropathic Pain","sstatus":"RECRUITING","sponsor":"Rush University Medical Center","official":"Asokumar Buvanendran, MD (Rush University Medical Center)","src":"https://clinicaltrials.gov/study/NCT05864053","contact":{"n":"Robert J McCarthy, Pharm D","p":"3125630448","e":"robert_j_mccarthy@rush.edu"},"phase":"Phase 1/Phase 2","enroll":25,"start":"2024-09-19","eid":"x:site:nct05864053-rush-university-medical-center-chicago"},{"id":"nct04116528-stanford-university-school-of-medicine-stanford","cat":"research","name":"Stanford University School of Medicine","city":"Stanford","region":"California","country":"United States","cc":"US","lat":37.41832,"lon":-122.1649,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94305","condg":["Depression"],"nct":"NCT04116528","study":"Opiate Suicide Study in Patients With Major Depression","sstatus":"COMPLETED","sponsor":"Stanford University","official":"Alan F. Schatzberg (Stanford University)","src":"https://clinicaltrials.gov/study/NCT04116528","phase":"Phase 3","enroll":50,"start":"2020-08-01","eid":"x:site:nct04116528-stanford-university-school-of-medicine-stanford"},{"id":"nct06405607-university-of-iowa-health-care-iowa-city","cat":"research","name":"University of Iowa Health Care","city":"Iowa City","region":"Iowa","country":"United States","cc":"US","lat":41.65431,"lon":-91.53257,"gp":"city","unnamed":0,"drugs":["ketamine","psilocybin"],"zip":"52240","condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT06405607","study":"Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial","sstatus":"RECRUITING","sponsor":"University of Iowa","official":"Peggy C Nopoulos, MD (University of Iowa)","src":"https://clinicaltrials.gov/study/NCT06405607","contact":{"n":"Lindsay E Golden","p":"319-384-5243","e":"lindsay-golden@uiowa.edu"},"phase":"Phase 2","enroll":80,"start":"2025-06-12","eid":"x:site:nct06405607-university-of-iowa-health-care-iowa-city"},{"id":"nct05803551-mayo-clinic-florida-jacksonville","cat":"research","name":"Mayo Clinic Florida","city":"Jacksonville","region":"Florida","country":"United States","cc":"US","lat":30.33213,"lon":-81.65457,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"32224","condg":["Depression"],"nct":"NCT05803551","study":"A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients","sstatus":"TERMINATED","sponsor":"Mayo Clinic","official":"Devang Sanghavi, MBBS, MD (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT05803551","phase":"Phase 2","enroll":1,"start":"2025-07-07","eid":"x:site:nct05803551-mayo-clinic-florida-jacksonville"},{"id":"nct04032301-minneapolis-veterans-affairs-health-care-system-minneapolis","cat":"research","name":"Minneapolis Veterans Affairs Health Care System","city":"Minneapolis","region":"Minnesota","country":"United States","cc":"US","lat":44.97352,"lon":-93.26436,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55417","condg":["Depression","PTSD & trauma"],"nct":"NCT04032301","study":"Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans","sstatus":"COMPLETED","sponsor":"University of Minnesota","official":"Cristina S Albott, MD, MA (Minneapolis Veterans Affairs Medical Center)","src":"https://clinicaltrials.gov/study/NCT04032301","phase":"Phase 1","enroll":67,"start":"2019-09-30","eid":"x:site:nct04032301-minneapolis-veterans-affairs-health-care-system-minneapolis"},{"id":"nct04669665-seelos-investigational-site-orange","cat":"research","name":"Seelos Investigational Site","city":"Orange","region":"California","country":"United States","cc":"US","lat":33.79047,"lon":-117.86012,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"92868","condg":["Depression"],"nct":"NCT04669665","study":"A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide","sstatus":"COMPLETED","sponsor":"Seelos Therapeutics, Inc.","src":"https://clinicaltrials.gov/study/NCT04669665","phase":"Phase 2","enroll":164,"start":"2020-12-17","eid":"x:site:nct04669665-seelos-investigational-site-orange"},{"id":"nct04669665-seelos-investigational-site-panorama-city","cat":"research","name":"Seelos Investigational Site","city":"Panorama City","region":"California","country":"United States","cc":"US","lat":35.22,"lon":-119.5384,"gp":"region","unnamed":0,"drugs":["ketamine"],"zip":"91402","condg":["Depression"],"nct":"NCT04669665","study":"A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide","sstatus":"COMPLETED","sponsor":"Seelos Therapeutics, Inc.","src":"https://clinicaltrials.gov/study/NCT04669665","phase":"Phase 2","enroll":164,"start":"2020-12-17","eid":"x:site:nct04669665-seelos-investigational-site-panorama-city"},{"id":"nct04669665-seelos-investigational-site-san-diego","cat":"research","name":"Seelos Investigational Site","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.72583,"lon":-117.15931,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"92103","condg":["Depression"],"nct":"NCT04669665","study":"A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide","sstatus":"COMPLETED","sponsor":"Seelos Therapeutics, Inc.","src":"https://clinicaltrials.gov/study/NCT04669665","phase":"Phase 2","enroll":164,"start":"2020-12-17","eid":"x:site:nct04669665-seelos-investigational-site-san-diego"},{"id":"nct04669665-seelos-investigational-site-hollywood","cat":"research","name":"Seelos Investigational Site","city":"Hollywood","region":"Florida","country":"United States","cc":"US","lat":34.09378,"lon":-118.32425,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"33021","condg":["Depression"],"nct":"NCT04669665","study":"A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide","sstatus":"COMPLETED","sponsor":"Seelos Therapeutics, Inc.","src":"https://clinicaltrials.gov/study/NCT04669665","phase":"Phase 2","enroll":164,"start":"2020-12-17","eid":"x:site:nct04669665-seelos-investigational-site-hollywood"},{"id":"nct04669665-seelos-investigational-site-miami","cat":"research","name":"Seelos Investigational Site","city":"Miami","region":"Florida","country":"United States","cc":"US","lat":25.78429,"lon":-80.20133,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"33144","condg":["Depression"],"nct":"NCT04669665","study":"A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide","sstatus":"COMPLETED","sponsor":"Seelos Therapeutics, Inc.","src":"https://clinicaltrials.gov/study/NCT04669665","phase":"Phase 2","enroll":164,"start":"2020-12-17","eid":"x:site:nct04669665-seelos-investigational-site-miami"},{"id":"nct04669665-seelos-investigational-site-miami-lakes","cat":"research","name":"Seelos Investigational Site","city":"Miami Lakes","region":"Florida","country":"United States","cc":"US","lat":25.9049,"lon":-80.3056,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"33016","condg":["Depression"],"nct":"NCT04669665","study":"A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide","sstatus":"COMPLETED","sponsor":"Seelos Therapeutics, Inc.","src":"https://clinicaltrials.gov/study/NCT04669665","phase":"Phase 2","enroll":164,"start":"2020-12-17","eid":"x:site:nct04669665-seelos-investigational-site-miami-lakes"},{"id":"nct04669665-seelos-investigational-site-miramar","cat":"research","name":"Seelos Investigational Site","city":"Miramar","region":"Florida","country":"United States","cc":"US","lat":25.99291,"lon":-80.22874,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"33025","condg":["Depression"],"nct":"NCT04669665","study":"A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide","sstatus":"COMPLETED","sponsor":"Seelos Therapeutics, Inc.","src":"https://clinicaltrials.gov/study/NCT04669665","phase":"Phase 2","enroll":164,"start":"2020-12-17","eid":"x:site:nct04669665-seelos-investigational-site-miramar"},{"id":"nct04669665-seelos-investigational-site-oakland-park","cat":"research","name":"Seelos Investigational Site","city":"Oakland Park","region":"Florida","country":"United States","cc":"US","lat":26.17358,"lon":-80.14371,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"33324","condg":["Depression"],"nct":"NCT04669665","study":"A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide","sstatus":"COMPLETED","sponsor":"Seelos Therapeutics, Inc.","src":"https://clinicaltrials.gov/study/NCT04669665","phase":"Phase 2","enroll":164,"start":"2020-12-17","eid":"x:site:nct04669665-seelos-investigational-site-oakland-park"},{"id":"nct04669665-seelos-investigational-site-atlanta","cat":"research","name":"Seelos Investigational Site","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.74453,"lon":-84.37626,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"30331","condg":["Depression"],"nct":"NCT04669665","study":"A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide","sstatus":"COMPLETED","sponsor":"Seelos Therapeutics, Inc.","src":"https://clinicaltrials.gov/study/NCT04669665","phase":"Phase 2","enroll":164,"start":"2020-12-17","eid":"x:site:nct04669665-seelos-investigational-site-atlanta"},{"id":"nct04669665-seelos-investigational-site-decatur","cat":"research","name":"Seelos Investigational Site","city":"Decatur","region":"Georgia","country":"United States","cc":"US","lat":39.83462,"lon":-88.94882,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"30030","condg":["Depression"],"nct":"NCT04669665","study":"A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide","sstatus":"COMPLETED","sponsor":"Seelos Therapeutics, Inc.","src":"https://clinicaltrials.gov/study/NCT04669665","phase":"Phase 2","enroll":164,"start":"2020-12-17","eid":"x:site:nct04669665-seelos-investigational-site-decatur"},{"id":"nct04669665-seelos-investigational-site-springfield","cat":"research","name":"Seelos Investigational Site","city":"Springfield","region":"Illinois","country":"United States","cc":"US","lat":37.20625,"lon":-93.30271,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"62781","condg":["Depression"],"nct":"NCT04669665","study":"A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide","sstatus":"COMPLETED","sponsor":"Seelos Therapeutics, Inc.","src":"https://clinicaltrials.gov/study/NCT04669665","phase":"Phase 2","enroll":164,"start":"2020-12-17","eid":"x:site:nct04669665-seelos-investigational-site-springfield"},{"id":"nct04669665-seelos-investigational-site-gaithersburg","cat":"research","name":"Seelos Investigational Site","city":"Gaithersburg","region":"Maryland","country":"United States","cc":"US","lat":39.13483,"lon":-77.18937,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20877","condg":["Depression"],"nct":"NCT04669665","study":"A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide","sstatus":"COMPLETED","sponsor":"Seelos Therapeutics, Inc.","src":"https://clinicaltrials.gov/study/NCT04669665","phase":"Phase 2","enroll":164,"start":"2020-12-17","eid":"x:site:nct04669665-seelos-investigational-site-gaithersburg"},{"id":"nct04669665-seelos-investigational-site-flowood","cat":"research","name":"Seelos Investigational Site","city":"Flowood","region":"Mississippi","country":"United States","cc":"US","lat":32.30173,"lon":-90.12717,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"39232","condg":["Depression"],"nct":"NCT04669665","study":"A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide","sstatus":"COMPLETED","sponsor":"Seelos Therapeutics, Inc.","src":"https://clinicaltrials.gov/study/NCT04669665","phase":"Phase 2","enroll":164,"start":"2020-12-17","eid":"x:site:nct04669665-seelos-investigational-site-flowood"},{"id":"nct04669665-seelos-investigational-site-buffalo","cat":"research","name":"Seelos Investigational Site","city":"Buffalo","region":"New York","country":"United States","cc":"US","lat":42.88603,"lon":-78.87691,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"14215","condg":["Depression"],"nct":"NCT04669665","study":"A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide","sstatus":"COMPLETED","sponsor":"Seelos Therapeutics, Inc.","src":"https://clinicaltrials.gov/study/NCT04669665","phase":"Phase 2","enroll":164,"start":"2020-12-17","eid":"x:site:nct04669665-seelos-investigational-site-buffalo"},{"id":"nct04669665-seelos-investigational-site-cincinnati","cat":"research","name":"Seelos Investigational Site","city":"Cincinnati","region":"Ohio","country":"United States","cc":"US","lat":39.12019,"lon":-84.51237,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45219","condg":["Depression"],"nct":"NCT04669665","study":"A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide","sstatus":"COMPLETED","sponsor":"Seelos Therapeutics, Inc.","src":"https://clinicaltrials.gov/study/NCT04669665","phase":"Phase 2","enroll":164,"start":"2020-12-17","eid":"x:site:nct04669665-seelos-investigational-site-cincinnati"},{"id":"nct04669665-seelos-investigational-site-north-canton","cat":"research","name":"Seelos Investigational Site","city":"North Canton","region":"Ohio","country":"United States","cc":"US","lat":40.88394,"lon":-81.39109,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44720","condg":["Depression"],"nct":"NCT04669665","study":"A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide","sstatus":"COMPLETED","sponsor":"Seelos Therapeutics, Inc.","src":"https://clinicaltrials.gov/study/NCT04669665","phase":"Phase 2","enroll":164,"start":"2020-12-17","eid":"x:site:nct04669665-seelos-investigational-site-north-canton"},{"id":"nct04669665-seelos-investigational-site-desoto","cat":"research","name":"Seelos Investigational Site","city":"DeSoto","region":"Texas","country":"United States","cc":"US","lat":32.59819,"lon":-96.86481,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75115","condg":["Depression"],"nct":"NCT04669665","study":"A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide","sstatus":"COMPLETED","sponsor":"Seelos Therapeutics, Inc.","src":"https://clinicaltrials.gov/study/NCT04669665","phase":"Phase 2","enroll":164,"start":"2020-12-17","eid":"x:site:nct04669665-seelos-investigational-site-desoto"},{"id":"nct04669665-seelos-investigational-site-houston","cat":"research","name":"Seelos Investigational Site","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.76737,"lon":-95.35889,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"77054","condg":["Depression"],"nct":"NCT04669665","study":"A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide","sstatus":"COMPLETED","sponsor":"Seelos Therapeutics, Inc.","src":"https://clinicaltrials.gov/study/NCT04669665","phase":"Phase 2","enroll":164,"start":"2020-12-17","eid":"x:site:nct04669665-seelos-investigational-site-houston"},{"id":"nct04669665-seelos-investigational-site-richardson","cat":"research","name":"Seelos Investigational Site","city":"Richardson","region":"Texas","country":"United States","cc":"US","lat":32.94832,"lon":-96.73541,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75080","condg":["Depression"],"nct":"NCT04669665","study":"A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide","sstatus":"COMPLETED","sponsor":"Seelos Therapeutics, Inc.","src":"https://clinicaltrials.gov/study/NCT04669665","phase":"Phase 2","enroll":164,"start":"2020-12-17","eid":"x:site:nct04669665-seelos-investigational-site-richardson"},{"id":"nct04669665-seelos-investigational-site-salt-lake-city","cat":"research","name":"Seelos Investigational Site","city":"Salt Lake City","region":"Utah","country":"United States","cc":"US","lat":40.76704,"lon":-111.87999,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"84108","condg":["Depression"],"nct":"NCT04669665","study":"A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide","sstatus":"COMPLETED","sponsor":"Seelos Therapeutics, Inc.","src":"https://clinicaltrials.gov/study/NCT04669665","phase":"Phase 2","enroll":164,"start":"2020-12-17","eid":"x:site:nct04669665-seelos-investigational-site-salt-lake-city"},{"id":"nct04669665-seelos-investigational-site-morgantown","cat":"research","name":"Seelos Investigational Site","city":"Morgantown","region":"West Virginia","country":"United States","cc":"US","lat":39.63532,"lon":-79.95322,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"26505","condg":["Depression"],"nct":"NCT04669665","study":"A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide","sstatus":"COMPLETED","sponsor":"Seelos Therapeutics, Inc.","src":"https://clinicaltrials.gov/study/NCT04669665","phase":"Phase 2","enroll":164,"start":"2020-12-17","eid":"x:site:nct04669665-seelos-investigational-site-morgantown"},{"id":"nct06378528-university-of-wisconsin-madison","cat":"research","name":"University of Wisconsin","city":"Madison","region":"Wisconsin","country":"United States","cc":"US","lat":43.07206,"lon":-89.39224,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"53705","condg":["PTSD & trauma"],"nct":"NCT06378528","study":"Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP)","sstatus":"SUSPENDED","sponsor":"University of Wisconsin, Madison","official":"Christopher Nicholas, PhD (University of Wisconsin, Madison)","src":"https://clinicaltrials.gov/study/NCT06378528","phase":"EARLY_Phase 1","enroll":5,"start":"2026-09","eid":"x:site:nct06378528-university-of-wisconsin-madison"},{"id":"nct03792672-chdr-leiden","cat":"research","name":"CHDR","city":"Leiden","country":"Netherlands","cc":"NL","lat":52.15781,"lon":4.49828,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Healthy volunteers"],"nct":"NCT03792672","study":"A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)","sstatus":"COMPLETED","sponsor":"Neurocrine Biosciences","official":"Medical Director (Millennium Pharmaceuticals, Inc.)","src":"https://clinicaltrials.gov/study/NCT03792672","phase":"Phase 1","enroll":24,"start":"2019-02-11","eid":"x:site:nct03792672-chdr-leiden"},{"id":"nct05327699-emory-university-atlanta","cat":"research","name":"Emory University","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.75244,"lon":-84.38934,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"30322","condg":["Depression"],"status":"RECRUITING","nct":"NCT05327699","study":"Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine","sstatus":"RECRUITING","sponsor":"Emory University","official":"Michael Treadway, PhD (Emory University)","src":"https://clinicaltrials.gov/study/NCT05327699","contact":{"n":"Michael Treadway, PhD","p":"(404) 727-7541","e":"ketaminestudy@emory.edu"},"phase":"EARLY_Phase 1","enroll":140,"start":"2022-11-08","eid":"x:site:nct05327699-emory-university-atlanta"},{"id":"nct01130909-research-site-rouffach","cat":"research","name":"Research Site","city":"Rouffach","country":"France","cc":"FR","lat":47.95019,"lon":7.29936,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Healthy volunteers"],"nct":"NCT01130909","study":"A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765","sstatus":"TERMINATED","sponsor":"AstraZeneca","official":"Albena Patroneva, MD (AstraZeneca); Francine Santoro (Forenap)","src":"https://clinicaltrials.gov/study/NCT01130909","phase":"Phase 1","enroll":36,"start":"2010-05","eid":"x:site:nct01130909-research-site-rouffach"},{"id":"nct00553839-lucile-packard-children-s-hospital-palo-alto","cat":"research","name":"Lucile Packard Children's Hospital","city":"Palo Alto","region":"California","country":"United States","cc":"US","lat":37.43619,"lon":-122.14655,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94304","condg":["Other"],"nct":"NCT00553839","study":"Pharmacokinetics of Ketamine in Infants and Children","sstatus":"COMPLETED","sponsor":"Stanford University","official":"Chandra Ramamoorthy, MBBS, FRCA (Stanford University)","src":"https://clinicaltrials.gov/study/NCT00553839","phase":"N/A","enroll":21,"start":"2007-07","eid":"x:site:nct00553839-lucile-packard-children-s-hospital-palo-alto"},{"id":"nct00553839-the-children-s-hospital-denver","cat":"research","name":"The Children's Hospital","city":"Denver","region":"Colorado","country":"United States","cc":"US","lat":39.73816,"lon":-104.98023,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"80218","condg":["Other"],"nct":"NCT00553839","study":"Pharmacokinetics of Ketamine in Infants and Children","sstatus":"COMPLETED","sponsor":"Stanford University","official":"Chandra Ramamoorthy, MBBS, FRCA (Stanford University)","src":"https://clinicaltrials.gov/study/NCT00553839","phase":"N/A","enroll":21,"start":"2007-07","eid":"x:site:nct00553839-the-children-s-hospital-denver"},{"id":"nct07099534-toulouse-purpan-university-hospital-head-of-psychiatry-clinic-in-the","cat":"research","name":"Toulouse Purpan University Hospital, Head of Psychiatry Clinic in the UF3 department","city":"Toulouse","country":"France","cc":"FR","lat":43.59847,"lon":1.43421,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"31059","condg":["Other"],"nct":"NCT07099534","study":"Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder","sstatus":"NOT_YET_RECRUITING","sponsor":"University Hospital, Toulouse","src":"https://clinicaltrials.gov/study/NCT07099534","contact":{"n":"Gaël Galliot","p":"+33 (0)5 34 55 76 51","e":"galliot.g@chu-toulouse.fr"},"phase":"Phase 2","enroll":38,"start":"2026-09-01","eid":"x:site:nct07099534-toulouse-purpan-university-hospital-head-of-psychiatry-clinic-in-the"},{"id":"nct02521415-carolinas-medical-center-main-levine-children-s-hospital-emergency-d","cat":"research","name":"Carolinas Medical Center Main - Levine Children's Hospital Emergency Department","city":"Charlotte","region":"North Carolina","country":"United States","cc":"US","lat":35.22168,"lon":-80.83113,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"28203","condg":["Other"],"nct":"NCT02521415","study":"IN Sub-Dissociative Ketamine vs IN Fentanyl","sstatus":"COMPLETED","sponsor":"Wake Forest University Health Sciences","official":"Stacy Reynolds, MD (Carolinas Medical Center)","src":"https://clinicaltrials.gov/study/NCT02521415","phase":"Phase 2","enroll":87,"start":"2015-12","eid":"x:site:nct02521415-carolinas-medical-center-main-levine-children-s-hospital-emergency-d"},{"id":"nct06317636-stanford-university-stanford","cat":"research","name":"Stanford University","city":"Stanford","region":"California","country":"United States","cc":"US","lat":37.43065,"lon":-122.1698,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94305","condg":["Depression","Chronic pain & headache"],"nct":"NCT06317636","study":"Propofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Stanford University","official":"Theresa Lii, MD, MS (Stanford University)","src":"https://clinicaltrials.gov/study/NCT06317636","phase":"Phase 4","enroll":40,"start":"2025-01-28","eid":"x:site:nct06317636-stanford-university-stanford"},{"id":"nct02766192-cooper-university-hospital-camden","cat":"research","name":"Cooper University Hospital","city":"Camden","region":"New Jersey","country":"United States","cc":"US","lat":39.92882,"lon":-75.11618,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT02766192","study":"TIMBER Psychotherapy and Ketamine Single Infusion in Chronic PTSD","sstatus":"UNKNOWN","sponsor":"The Cooper Health System","official":"Basant Pradhan, MD (Cooper Health System)","src":"https://clinicaltrials.gov/study/NCT02766192","contact":{"n":"Basant Pradhan, MD","p":"856-757-7814","e":"jean-smith@cooperhealth.edu"},"phase":"N/A","enroll":50,"start":"2013-08","eid":"x:site:nct02766192-cooper-university-hospital-camden"},{"id":"nct06538285-san-francisco-department-of-public-health-san-francicso","cat":"research","name":"San Francisco Department of Public Health","city":"San Francicso","region":"California","country":"United States","cc":"US","lat":35.4177,"lon":-119.4286,"gp":"region","unnamed":0,"drugs":["ketamine"],"zip":"94102","condg":["Addiction & substance use"],"nct":"NCT06538285","study":"Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV","sstatus":"COMPLETED","sponsor":"Nicky Mehtani, MD, MPH","official":"Nicky Mehtani, MD MPH (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT06538285","phase":"Phase 2","enroll":17,"start":"2025-03-04","eid":"x:site:nct06538285-san-francisco-department-of-public-health-san-francicso"},{"id":"nct05756621-asst-spedali-civili-brescia-brescia","cat":"research","name":"ASST Spedali Civili Brescia","city":"Brescia","region":"BS","country":"Italy","cc":"IT","lat":45.53346,"lon":10.20498,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"nct":"NCT05756621","study":"Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest","sstatus":"COMPLETED","sponsor":"University of Milano Bicocca","official":"Simone Beretta, MD, PhD (University of Milano Bicocca); Matteo Pozzi, MD (Fondazione IRCCS Gerardo dei Tintori Monza)","src":"https://clinicaltrials.gov/study/NCT05756621","enroll":84,"start":"2022-01-15","eid":"x:site:nct05756621-asst-spedali-civili-brescia-brescia"},{"id":"nct05756621-ospedale-centrale-di-bolzano-bolzano","cat":"research","name":"Ospedale Centrale di Bolzano","city":"Bolzano","region":"BZ","country":"Italy","cc":"IT","lat":46.47905,"lon":11.34504,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"nct":"NCT05756621","study":"Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest","sstatus":"COMPLETED","sponsor":"University of Milano Bicocca","official":"Simone Beretta, MD, PhD (University of Milano Bicocca); Matteo Pozzi, MD (Fondazione IRCCS Gerardo dei Tintori Monza)","src":"https://clinicaltrials.gov/study/NCT05756621","enroll":84,"start":"2022-01-15","eid":"x:site:nct05756621-ospedale-centrale-di-bolzano-bolzano"},{"id":"nct05756621-ospedale-g-brotzu-cagliari","cat":"research","name":"Ospedale G. Brotzu","city":"Cagliari","region":"CA","country":"Italy","cc":"IT","lat":39.22014,"lon":9.11978,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"nct":"NCT05756621","study":"Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest","sstatus":"COMPLETED","sponsor":"University of Milano Bicocca","official":"Simone Beretta, MD, PhD (University of Milano Bicocca); Matteo Pozzi, MD (Fondazione IRCCS Gerardo dei Tintori Monza)","src":"https://clinicaltrials.gov/study/NCT05756621","enroll":84,"start":"2022-01-15","eid":"x:site:nct05756621-ospedale-g-brotzu-cagliari"},{"id":"nct05756621-ospedale-m-bufalini-cesena","cat":"research","name":"Ospedale M. Bufalini","city":"Cesena","region":"FC","country":"Italy","cc":"IT","lat":44.13962,"lon":12.24715,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"nct":"NCT05756621","study":"Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest","sstatus":"COMPLETED","sponsor":"University of Milano Bicocca","official":"Simone Beretta, MD, PhD (University of Milano Bicocca); Matteo Pozzi, MD (Fondazione IRCCS Gerardo dei Tintori Monza)","src":"https://clinicaltrials.gov/study/NCT05756621","enroll":84,"start":"2022-01-15","eid":"x:site:nct05756621-ospedale-m-bufalini-cesena"},{"id":"nct05756621-aou-careggi-florence","cat":"research","name":"AOU Careggi","city":"Florence","region":"FI","country":"Italy","cc":"IT","lat":43.78786,"lon":11.24932,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"nct":"NCT05756621","study":"Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest","sstatus":"COMPLETED","sponsor":"University of Milano Bicocca","official":"Simone Beretta, MD, PhD (University of Milano Bicocca); Matteo Pozzi, MD (Fondazione IRCCS Gerardo dei Tintori Monza)","src":"https://clinicaltrials.gov/study/NCT05756621","enroll":84,"start":"2022-01-15","eid":"x:site:nct05756621-aou-careggi-florence"},{"id":"nct05756621-fondazione-irccs-san-gerardo-dei-tintori-monza-monza","cat":"research","name":"Fondazione IRCCS San Gerardo dei Tintori Monza","city":"Monza","region":"MB","country":"Italy","cc":"IT","lat":45.57643,"lon":9.26328,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20900","condg":["Neurology & cognition"],"nct":"NCT05756621","study":"Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest","sstatus":"COMPLETED","sponsor":"University of Milano Bicocca","official":"Simone Beretta, MD, PhD (University of Milano Bicocca); Matteo Pozzi, MD (Fondazione IRCCS Gerardo dei Tintori Monza)","src":"https://clinicaltrials.gov/study/NCT05756621","enroll":84,"start":"2022-01-15","eid":"x:site:nct05756621-fondazione-irccs-san-gerardo-dei-tintori-monza-monza"},{"id":"nct05756621-azienda-ospedaliero-universitaria-di-modena-modena","cat":"research","name":"Azienda Ospedaliero-Universitaria di Modena","city":"Modena","region":"MO","country":"Italy","cc":"IT","lat":44.65729,"lon":10.92148,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"nct":"NCT05756621","study":"Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest","sstatus":"COMPLETED","sponsor":"University of Milano Bicocca","official":"Simone Beretta, MD, PhD (University of Milano Bicocca); Matteo Pozzi, MD (Fondazione IRCCS Gerardo dei Tintori Monza)","src":"https://clinicaltrials.gov/study/NCT05756621","enroll":84,"start":"2022-01-15","eid":"x:site:nct05756621-azienda-ospedaliero-universitaria-di-modena-modena"},{"id":"nct05756621-azienda-ospedaliero-universitaria-di-parma-parma","cat":"research","name":"Azienda Ospedaliero-Universitaria di Parma","city":"Parma","region":"PR","country":"Italy","cc":"IT","lat":44.80476,"lon":10.33696,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"nct":"NCT05756621","study":"Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest","sstatus":"COMPLETED","sponsor":"University of Milano Bicocca","official":"Simone Beretta, MD, PhD (University of Milano Bicocca); Matteo Pozzi, MD (Fondazione IRCCS Gerardo dei Tintori Monza)","src":"https://clinicaltrials.gov/study/NCT05756621","enroll":84,"start":"2022-01-15","eid":"x:site:nct05756621-azienda-ospedaliero-universitaria-di-parma-parma"},{"id":"nct05756621-ospedale-santa-chiara-trento-trento","cat":"research","name":"Ospedale Santa Chiara Trento","city":"Trento","region":"TN","country":"Italy","cc":"IT","lat":46.0666,"lon":11.1264,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"nct":"NCT05756621","study":"Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest","sstatus":"COMPLETED","sponsor":"University of Milano Bicocca","official":"Simone Beretta, MD, PhD (University of Milano Bicocca); Matteo Pozzi, MD (Fondazione IRCCS Gerardo dei Tintori Monza)","src":"https://clinicaltrials.gov/study/NCT05756621","enroll":84,"start":"2022-01-15","eid":"x:site:nct05756621-ospedale-santa-chiara-trento-trento"},{"id":"nct05756621-azienda-ospedaliero-universitaria-integrata-di-verona-verona","cat":"research","name":"Azienda Ospedaliero-Universitaria Integrata di Verona","city":"Verona","region":"VR","country":"Italy","cc":"IT","lat":45.43727,"lon":10.99225,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"nct":"NCT05756621","study":"Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest","sstatus":"COMPLETED","sponsor":"University of Milano Bicocca","official":"Simone Beretta, MD, PhD (University of Milano Bicocca); Matteo Pozzi, MD (Fondazione IRCCS Gerardo dei Tintori Monza)","src":"https://clinicaltrials.gov/study/NCT05756621","enroll":84,"start":"2022-01-15","eid":"x:site:nct05756621-azienda-ospedaliero-universitaria-integrata-di-verona-verona"},{"id":"nct07504601-national-institutes-of-health-clinical-center-bethesda","cat":"research","name":"National Institutes of Health Clinical Center","city":"Bethesda","region":"Maryland","country":"United States","cc":"US","lat":38.97714,"lon":-77.09306,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20892","condg":["Healthy volunteers"],"nct":"NCT07504601","study":"Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers","sstatus":"NOT_YET_RECRUITING","sponsor":"National Center for Complementary and Integrative Health (NCCIH)","official":"Lauren Y Atlas, Ph.D. (National Center for Complementary and Integrative Health (NCCIH))","src":"https://clinicaltrials.gov/study/NCT07504601","contact":{"n":"NIH Clinical Center Office of Patient Recruitment (OPR)","p":"800-411-1222","e":"ccopr@nih.gov"},"phase":"Phase 2","enroll":92,"start":"2026-10-07","eid":"x:site:nct07504601-national-institutes-of-health-clinical-center-bethesda"},{"id":"nct06707532-4th-military-clinical-hospital-with-polyclinic-wroclaw","cat":"research","name":"4th Military Clinical Hospital with Polyclinic","city":"Wroclaw","region":"Lower Silesian Voivodeship","country":"Poland","cc":"PL","lat":51.11486,"lon":17.02879,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"50-981","condg":["Other"],"status":"RECRUITING","nct":"NCT06707532","study":"The Potential Protective Effect of Using Muscle Relaxants During Electroporation Ablation (PFA)","sstatus":"RECRUITING","sponsor":"4th Military Clinical Hospital with Polyclinic, Poland","official":"Marek Szamborski, MD (Senior Assistant)","src":"https://clinicaltrials.gov/study/NCT06707532","contact":{"n":"Marek Szamborski, MD","p":"698-448-639","e":"mszamborski@4wsk.pl"},"phase":"N/A","enroll":32,"start":"2024-08-01","eid":"x:site:nct06707532-4th-military-clinical-hospital-with-polyclinic-wroclaw"},{"id":"nct05997134-tanta-university-tanta","cat":"research","name":"Tanta University","city":"Tanta","region":"El-garbia","country":"Egypt","cc":"EG","lat":30.78061,"lon":31.01185,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"31527","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT05997134","study":"Three Regimens of Ketamine Infusion in Complex Regional Pain Syndrome","sstatus":"UNKNOWN","sponsor":"Tanta University","src":"https://clinicaltrials.gov/study/NCT05997134","contact":{"n":"Aml M Abo elsafa, MBBCh","p":"+20 101 260 2853","e":"amlabouelsafa67@gmail.com"},"phase":"Phase 4","enroll":75,"start":"2023-08-30","eid":"x:site:nct05997134-tanta-university-tanta"},{"id":"nct03525912-hospital-universitario-san-vicente-fundacion-medellin","cat":"research","name":"hospital universitario San Vicente Fundacion","city":"Medellín","region":"Antioquia","country":"Colombia","cc":"CO","lat":6.24533,"lon":-75.57579,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Chronic pain & headache"],"nct":"NCT03525912","study":"Neuropsychiatric and Cardiovascular Side Effects in Ketamine Analgesic Infusions","sstatus":"COMPLETED","sponsor":"Universidad de Antioquia","official":"Adriana M Cadavid, MD (Anesthesiology professor)","src":"https://clinicaltrials.gov/study/NCT03525912","phase":"N/A","enroll":101,"start":"2017-07-01","eid":"x:site:nct03525912-hospital-universitario-san-vicente-fundacion-medellin"},{"id":"nct04091971-new-york-state-psychiatric-institute-columbia-university-new-york","cat":"research","name":"New York State Psychiatric Institute/Columbia University","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72392,"lon":-73.99604,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10032","condg":["Depression"],"nct":"NCT04091971","study":"Ketamine Treatment Effects on Synaptic Plasticity in Depression","sstatus":"COMPLETED","sponsor":"New York State Psychiatric Institute","official":"Jeffrey Miller, MD (New York State Psychiatric Institute)","src":"https://clinicaltrials.gov/study/NCT04091971","phase":"Phase 4","enroll":9,"start":"2020-10-09","eid":"x:site:nct04091971-new-york-state-psychiatric-institute-columbia-university-new-york"},{"id":"nct01794975-clinical-research-services-turku-crst-turku-pet-centre-turku","cat":"research","name":"Clinical Research Services Turku (CRST) / Turku PET Centre","city":"Turku","country":"Finland","cc":"FI","lat":60.44955,"lon":22.25697,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT01794975","study":"Changes in Striatal [11C]ORM-13070 Binding Elicited by Changing Levels of Endogenous Noradrenaline","sstatus":"COMPLETED","sponsor":"University of Turku","official":"Juha Rinne, PhD (Turku PET Centre)","src":"https://clinicaltrials.gov/study/NCT01794975","phase":"Phase 1","enroll":8,"start":"2012-08","eid":"x:site:nct01794975-clinical-research-services-turku-crst-turku-pet-centre-turku"},{"id":"nct00224588-georges-pompidou-european-hospital-paris","cat":"research","name":"Georges Pompidou European Hospital","city":"Paris","region":"Île-de-France Region","country":"France","cc":"FR","lat":48.85261,"lon":2.34536,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75015","condg":["Chronic pain & headache"],"nct":"NCT00224588","study":"KETOR: Effects of Peri Operative Administration of Ketamine on Long Term Post Thoracotomy Pain","sstatus":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","official":"Thierry GUENOUN, MD (Assistance Publique - Hôpitaux de Paris)","src":"https://clinicaltrials.gov/study/NCT00224588","phase":"Phase 3","enroll":80,"start":"2003-01","eid":"x:site:nct00224588-georges-pompidou-european-hospital-paris"},{"id":"nct03502551-university-of-california-davis-medical-center-sacramento","cat":"research","name":"University of California Davis Medical Center","city":"Sacramento","region":"California","country":"United States","cc":"US","lat":38.58152,"lon":-121.48701,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"95817","condg":["Other"],"nct":"NCT03502551","study":"ED Treatment of Suicidal Patients With Ketamine Infusion","sstatus":"WITHDRAWN","sponsor":"University of California, Davis","official":"Aimee Moulin, MD (University of California, Davis)","src":"https://clinicaltrials.gov/study/NCT03502551","phase":"Phase 2","start":"2019-04-01","eid":"x:site:nct03502551-university-of-california-davis-medical-center-sacramento"},{"id":"nct02541396-jean-brown-research-salt-lake-city","cat":"research","name":"Jean Brown Research","city":"Salt Lake City","region":"Utah","country":"United States","cc":"US","lat":40.7581,"lon":-111.88432,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"84124","condg":["Chronic pain & headache"],"nct":"NCT02541396","study":"A Study Of The Effectiveness Of Wafermine Alone And In Combination With Opioids In Subjects Undergoing Bunionectomy","sstatus":"COMPLETED","sponsor":"iX Biopharma Ltd.","src":"https://clinicaltrials.gov/study/NCT02541396","phase":"Phase 2","enroll":72,"start":"2015-10","eid":"x:site:nct02541396-jean-brown-research-salt-lake-city"},{"id":"nct04876066-wvu-medicine-morgantown","cat":"research","name":"WVU Medicine","city":"Morgantown","region":"West Virginia","country":"United States","cc":"US","lat":39.63052,"lon":-79.96254,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"26506","condg":["Depression","Neurology & cognition"],"status":"RECRUITING","nct":"NCT04876066","study":"Use of Transmucosal Ketamine in Post Stroke Depression","sstatus":"UNKNOWN","sponsor":"West Virginia University","src":"https://clinicaltrials.gov/study/NCT04876066","contact":{"n":"Amelia Adcock","p":"(304) 293-3527","e":"akadcock@hsc.wvu.edu"},"phase":"Phase 1","enroll":21,"start":"2020-11-30","eid":"x:site:nct04876066-wvu-medicine-morgantown"},{"id":"nct07705022-university-of-michigan-ann-arbor","cat":"research","name":"University of Michigan","city":"Ann Arbor","region":"Michigan","country":"United States","cc":"US","lat":42.27384,"lon":-83.74093,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"48109","condg":["Healthy volunteers"],"nct":"NCT07705022","study":"Assessing Covert Consciousness During Dexmedetomidine and Ketamine Sedation: An fMRI Study","sstatus":"ENROLLING_BY_INVITATION","sponsor":"University of Michigan","official":"Zirui Huang, PhD (University of Michigan)","src":"https://clinicaltrials.gov/study/NCT07705022","phase":"Phase 2","enroll":60,"start":"2026-08-07","eid":"x:site:nct07705022-university-of-michigan-ann-arbor"},{"id":"nct05752110-istanbul-training-and-research-hospital-istanbul","cat":"research","name":"Istanbul Training and Research Hospital","city":"Istanbul","region":"Fatih","country":"Turkey","cc":"TR","lat":41.01125,"lon":28.95865,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT05752110","study":"Effects of Subanesthetic Dose of Ketamine Given on Postoperative Mood in Patients Undergoing Fractional Curettage","sstatus":"COMPLETED","sponsor":"Istanbul Training and Research Hospital","official":"Mehmet TOPTAS, Ass.Prof.Dr (Istanbul Training and Research Hospital)","src":"https://clinicaltrials.gov/study/NCT05752110","phase":"Phase 4","enroll":140,"start":"2022-04-01","eid":"x:site:nct05752110-istanbul-training-and-research-hospital-istanbul"},{"id":"nct05752110-istanbultrh-istanbul","cat":"research","name":"IstanbulTRH","city":"Istanbul","country":"Turkey","cc":"TR","lat":41.02283,"lon":28.94792,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT05752110","study":"Effects of Subanesthetic Dose of Ketamine Given on Postoperative Mood in Patients Undergoing Fractional Curettage","sstatus":"COMPLETED","sponsor":"Istanbul Training and Research Hospital","official":"Mehmet TOPTAS, Ass.Prof.Dr (Istanbul Training and Research Hospital)","src":"https://clinicaltrials.gov/study/NCT05752110","phase":"Phase 4","enroll":140,"start":"2022-04-01","eid":"x:site:nct05752110-istanbultrh-istanbul"},{"id":"nct04429685-university-of-texas-southwestern-medical-center-dallas","cat":"research","name":"University of Texas Southwestern Medical Center","city":"Dallas","region":"Texas","country":"United States","cc":"US","lat":32.78499,"lon":-96.80192,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75390","condg":["Healthy volunteers"],"nct":"NCT04429685","study":"The Effects of Low Dose Ketamine on Cardiovascular Function","sstatus":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","src":"https://clinicaltrials.gov/study/NCT04429685","phase":"Phase 1","enroll":6,"start":"2020-11-01","eid":"x:site:nct04429685-university-of-texas-southwestern-medical-center-dallas"},{"id":"nct03647579-south-egypt-cancer-institute-assiut-university-asyut","cat":"research","name":"South Egypt Cancer Institute, Assiut University","city":"Asyut","country":"Egypt","cc":"EG","lat":27.17931,"lon":31.17855,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"171516","condg":["Other"],"nct":"NCT03647579","study":"Dexmedetomidine Versus Midazolam Added to Ketamine in Pediatric Patients Undergoing Bone Marrow Aspiration and Biopsy","sstatus":"COMPLETED","sponsor":"Assiut University","src":"https://clinicaltrials.gov/study/NCT03647579","phase":"N/A","enroll":100,"start":"2018-08-30","eid":"x:site:nct03647579-south-egypt-cancer-institute-assiut-university-asyut"},{"id":"nct05218161-cpeic-multan","cat":"research","name":"CPEIC","city":"Multan","country":"Pakistan","cc":"PK","lat":30.19477,"lon":71.48299,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT05218161","study":"Hemodynamic Effect of Dexmedetomidine Alone With Dexmedetomidine Plus Ketamine Combination in CABG","sstatus":"UNKNOWN","sponsor":"Chaudhry Pervaiz Elahi Institute of Cardiology","official":"Dr Shumaila Rai, FCPS (Chaudhry Pervaiz Elahi Institute of Cardiology)","src":"https://clinicaltrials.gov/study/NCT05218161","phase":"N/A","enroll":40,"start":"2021-01-01","eid":"x:site:nct05218161-cpeic-multan"},{"id":"nct07103720-mayo-clinic-arizona-scottsdale","cat":"research","name":"Mayo Clinic Arizona","city":"Scottsdale","region":"Arizona","country":"United States","cc":"US","lat":33.50963,"lon":-111.89588,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"85268","condg":["Other"],"nct":"NCT07103720","study":"The Nonirritating Concentrations of Midazolam, Ketamine, and Ondansetron","sstatus":"COMPLETED","sponsor":"Mayo Clinic","official":"Alexei Gonzalez Estrada, MD (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT07103720","phase":"Phase 4","enroll":21,"start":"2025-11-05","eid":"x:site:nct07103720-mayo-clinic-arizona-scottsdale"},{"id":"nct02105415-mayo-clinic-rochester","cat":"research","name":"Mayo Clinic","city":"Rochester","region":"Minnesota","country":"United States","cc":"US","lat":43.1473,"lon":-77.62643,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55905","condg":["Other"],"nct":"NCT02105415","study":"Ketamine / Propofol Admixture \"Ketofol\" at Induction in the Critically Ill Against Etomidate: KEEP PACE Trial","sstatus":"COMPLETED","sponsor":"Mayo Clinic","official":"Nathan J Smischney, MD (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT02105415","phase":"Phase 2/Phase 3","enroll":160,"start":"2014-04","eid":"x:site:nct02105415-mayo-clinic-rochester"},{"id":"nct01887990-university-of-alabama-birmingham-birmingham","cat":"research","name":"University of Alabama Birmingham","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.52795,"lon":-86.80376,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"35205","condg":["Depression"],"nct":"NCT01887990","study":"Treatment of Suicidal Ideation With Intravenous Ketamine Infusion","sstatus":"COMPLETED","sponsor":"University of Alabama at Birmingham","official":"Cheryl B McCullumsmith, MD PhD (University of Alabama at Birmingham)","src":"https://clinicaltrials.gov/study/NCT01887990","phase":"N/A","enroll":18,"start":"2012-05","eid":"x:site:nct01887990-university-of-alabama-birmingham-birmingham"},{"id":"nct02106325-bellevue-hospital-center-new-york","cat":"research","name":"Bellevue Hospital Center","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71215,"lon":-74.00649,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10016","condg":["Depression"],"nct":"NCT02106325","study":"Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients","sstatus":"COMPLETED","sponsor":"NYU Langone Health","official":"Stephen Ross, MD (NYU Langone Health); K. Casey Paleos, MD (New York Unversity School of Medicine)","src":"https://clinicaltrials.gov/study/NCT02106325","phase":"Phase 2","enroll":21,"start":"2013-12","eid":"x:site:nct02106325-bellevue-hospital-center-new-york"},{"id":"nct02106325-nyu-langone-medical-center-tisch-hospital-new-york","cat":"research","name":"NYU Langone Medical Center/Tisch Hospital","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71046,"lon":-74.00169,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10016","condg":["Depression"],"nct":"NCT02106325","study":"Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients","sstatus":"COMPLETED","sponsor":"NYU Langone Health","official":"Stephen Ross, MD (NYU Langone Health); K. Casey Paleos, MD (New York Unversity School of Medicine)","src":"https://clinicaltrials.gov/study/NCT02106325","phase":"Phase 2","enroll":21,"start":"2013-12","eid":"x:site:nct02106325-nyu-langone-medical-center-tisch-hospital-new-york"},{"id":"nct06077487-university-of-california-san-francisco-san-francisco","cat":"research","name":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.78655,"lon":-122.41787,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94143","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT06077487","study":"Ketamine-assisted Therapy for Advanced GI Cancer","sstatus":"TERMINATED","sponsor":"Brian Anderson, MD","official":"Brian T Anderson, MD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT06077487","phase":"Phase 4","enroll":1,"start":"2024-05-17","eid":"x:site:nct06077487-university-of-california-san-francisco-san-francisco"},{"id":"nct03088384-klarisana-san-antonio","cat":"research","name":"Klarisana","city":"San Antonio","region":"Texas","country":"United States","cc":"US","lat":29.41476,"lon":-98.50092,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"78240","condg":["PTSD & trauma"],"nct":"NCT03088384","study":"Ketamine Infusion Therapy for PTSD in Combat Veterans","sstatus":"COMPLETED","sponsor":"Klarisana Physician Services PLLC","src":"https://clinicaltrials.gov/study/NCT03088384","enroll":30,"start":"2016-11-28","eid":"x:site:nct03088384-klarisana-san-antonio"},{"id":"nct03367533-yale-university-new-haven","cat":"research","name":"Yale University","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.29615,"lon":-72.93668,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06511","condg":["Depression","PTSD & trauma","Bipolar"],"nct":"NCT03367533","study":"Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial","sstatus":"COMPLETED","sponsor":"Yale University","official":"John Krystal, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT03367533","phase":"Phase 1","enroll":13,"start":"2018-11-29","eid":"x:site:nct03367533-yale-university-new-haven"},{"id":"nct04123652-allevio-pain-management-clinic-toronto","cat":"research","name":"Allevio Pain Management Clinic","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70996,"lon":-79.39012,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M3B 3S6","condg":["Chronic pain & headache"],"nct":"NCT04123652","study":"Ambulatory Infusions of Lidocaine and Ketamine for Management of Chronic Pain","sstatus":"COMPLETED","sponsor":"Allevio Pain Management Clinic","official":"Ramin Safakish, MD.FRCPC (Allevio Pain Management Clinic)","src":"https://clinicaltrials.gov/study/NCT04123652","phase":"Phase 4","enroll":162,"start":"2017-11-05","eid":"x:site:nct04123652-allevio-pain-management-clinic-toronto"},{"id":"nct07009158-providence-care-hospital-kingston-health-sciences-centre-hotel-dieu-","cat":"research","name":"Providence Care Hospital / Kingston Health Sciences Centre Hotel Dieu Hospital site","city":"Kingston","region":"Ontario","country":"Canada","cc":"CA","lat":44.22802,"lon":-76.47971,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"K7L 4X3","condg":["PTSD & trauma","Chronic pain & headache"],"status":"RECRUITING","nct":"NCT07009158","study":"Ketamine Assisted Psychotherapy for Treating Comorbid Chronic Pain and PTSD","sstatus":"RECRUITING","sponsor":"Dr. Yuliya Knyahnytska","src":"https://clinicaltrials.gov/study/NCT07009158","contact":{"n":"Etienne Bisson, PhD","p":"855-544-3400","e":"chronicpain.research@kingstonhsc.ca"},"phase":"Phase 1/Phase 2","enroll":30,"start":"2026-03-31","eid":"x:site:nct07009158-providence-care-hospital-kingston-health-sciences-centre-hotel-dieu-"},{"id":"nct05103319-department-of-anesthesiology-university-of-basel-usb-basel","cat":"research","name":"Department of Anesthesiology, University of Basel (USB)","city":"Basel","country":"Switzerland","cc":"CH","lat":47.55938,"lon":7.56136,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"4031","condg":["Chronic pain & headache"],"nct":"NCT05103319","study":"Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Tobias Schneider, Dr. med. (Department of Anesthesiology University of Basel (USB))","src":"https://clinicaltrials.gov/study/NCT05103319","enroll":319,"start":"2021-09-07","eid":"x:site:nct05103319-department-of-anesthesiology-university-of-basel-usb-basel"},{"id":"nct02418195-university-of-alabama-at-birmingham-birmingham","cat":"research","name":"University of Alabama at Birmingham","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.51581,"lon":-86.79868,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"35294","condg":["Depression"],"nct":"NCT02418195","study":"miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome","sstatus":"COMPLETED","sponsor":"University of Alabama at Birmingham","official":"Yogesh Dwivedi, Ph.D. (University of Alabama at Birmingham); Richard C Shelton, M.D. (University of Alabama at Birmingham)","src":"https://clinicaltrials.gov/study/NCT02418195","phase":"Phase 2","enroll":247,"start":"2015-04-20","eid":"x:site:nct02418195-university-of-alabama-at-birmingham-birmingham"},{"id":"nct02522377-cleveland-clinic-foundation-center-for-behavioral-health-cleveland","cat":"research","name":"Cleveland Clinic Foundation Center for Behavioral Health","city":"Cleveland","region":"Ohio","country":"United States","cc":"US","lat":41.4907,"lon":-81.68614,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44195","condg":["Depression"],"nct":"NCT02522377","study":"Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"The Cleveland Clinic","official":"Murat Altinay, MD (The Cleveland Clinic)","src":"https://clinicaltrials.gov/study/NCT02522377","phase":"N/A","enroll":15,"start":"2015-08","eid":"x:site:nct02522377-cleveland-clinic-foundation-center-for-behavioral-health-cleveland"},{"id":"nct04238039-revital-amiaz-ramat-gan","cat":"research","name":"Revital Amiaz","city":"Ramat Gan","region":"RI","country":"Israel","cc":"IL","lat":32.0714,"lon":34.81973,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"52621","condg":["Other"],"status":"RECRUITING","nct":"NCT04238039","study":"Ketamine Long Therm Follow Up Study","sstatus":"UNKNOWN","sponsor":"The Chaim Sheba Medical Center","src":"https://clinicaltrials.gov/study/NCT04238039","contact":{"n":"Revital Amiaz, MD","p":"0542378757","e":"amiazr@gmail.com"},"enroll":16,"start":"2019-12-14","eid":"x:site:nct04238039-revital-amiaz-ramat-gan"},{"id":"nct02882711-the-university-of-texas-health-science-center-at-houston-houston","cat":"research","name":"The University of Texas Health Science Center at Houston","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.76615,"lon":-95.37094,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"77030","condg":["Depression","Bipolar"],"nct":"NCT02882711","study":"The UTHealth Ketamine Project","sstatus":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","official":"Salih Selek, MD (The University of Texas Health Science Center, Houston)","src":"https://clinicaltrials.gov/study/NCT02882711","phase":"Phase 2","enroll":10,"start":"2016-11-07","eid":"x:site:nct02882711-the-university-of-texas-health-science-center-at-houston-houston"},{"id":"nct03113968-yale-school-of-medicine-new-haven","cat":"research","name":"Yale School of Medicine","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31742,"lon":-72.93611,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06510","condg":["Depression"],"nct":"NCT03113968","study":"ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)","sstatus":"COMPLETED","sponsor":"Bo Hu","official":"Amit Anand, MD (The Cleveland Clinic)","src":"https://clinicaltrials.gov/study/NCT03113968","phase":"Phase 2/Phase 3","enroll":403,"start":"2017-04-07","eid":"x:site:nct03113968-yale-school-of-medicine-new-haven"},{"id":"nct03113968-johns-hopkins-university-school-of-medicine-baltimore","cat":"research","name":"Johns Hopkins University School of Medicine","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28243,"lon":-76.61045,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"21205","condg":["Depression"],"nct":"NCT03113968","study":"ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)","sstatus":"COMPLETED","sponsor":"Bo Hu","official":"Amit Anand, MD (The Cleveland Clinic)","src":"https://clinicaltrials.gov/study/NCT03113968","phase":"Phase 2/Phase 3","enroll":403,"start":"2017-04-07","eid":"x:site:nct03113968-johns-hopkins-university-school-of-medicine-baltimore"},{"id":"nct03113968-mount-sinai-new-york","cat":"research","name":"Mount Sinai","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70773,"lon":-74.01101,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10029","condg":["Depression"],"nct":"NCT03113968","study":"ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)","sstatus":"COMPLETED","sponsor":"Bo Hu","official":"Amit Anand, MD (The Cleveland Clinic)","src":"https://clinicaltrials.gov/study/NCT03113968","phase":"Phase 2/Phase 3","enroll":403,"start":"2017-04-07","eid":"x:site:nct03113968-mount-sinai-new-york"},{"id":"nct03113968-cleveland-clinic-cleveland","cat":"research","name":"Cleveland Clinic","city":"Cleveland","region":"Ohio","country":"United States","cc":"US","lat":41.50745,"lon":-81.68567,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44195","condg":["Depression"],"nct":"NCT03113968","study":"ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)","sstatus":"COMPLETED","sponsor":"Bo Hu","official":"Amit Anand, MD (The Cleveland Clinic)","src":"https://clinicaltrials.gov/study/NCT03113968","phase":"Phase 2/Phase 3","enroll":403,"start":"2017-04-07","eid":"x:site:nct03113968-cleveland-clinic-cleveland"},{"id":"nct03113968-baylor-college-of-medicine-houston","cat":"research","name":"Baylor College of Medicine","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.775,"lon":-95.36887,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"77030","condg":["Depression"],"nct":"NCT03113968","study":"ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)","sstatus":"COMPLETED","sponsor":"Bo Hu","official":"Amit Anand, MD (The Cleveland Clinic)","src":"https://clinicaltrials.gov/study/NCT03113968","phase":"Phase 2/Phase 3","enroll":403,"start":"2017-04-07","eid":"x:site:nct03113968-baylor-college-of-medicine-houston"},{"id":"nct06668571-mayo-clinic-in-rochester-rochester","cat":"research","name":"Mayo Clinic in Rochester","city":"Rochester","region":"Minnesota","country":"United States","cc":"US","lat":43.15379,"lon":-77.61711,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55905","condg":["Depression"],"status":"RECRUITING","nct":"NCT06668571","study":"Intravenous Ketamine for Treatment-Resistant Depression","sstatus":"RECRUITING","sponsor":"Mayo Clinic","official":"Balwinder Singh, M.D., M.S. (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT06668571","contact":{"n":"Balwinder Singh","p":"507-422-1835","e":"reinicke.nicole@mayo.edu"},"phase":"Phase 2","enroll":30,"start":"2025-02-10","eid":"x:site:nct06668571-mayo-clinic-in-rochester-rochester"},{"id":"nct05487885-loeffler-building-pittsburgh","cat":"research","name":"Loeffler Building","city":"Pittsburgh","region":"Pennsylvania","country":"United States","cc":"US","lat":40.4417,"lon":-79.98709,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"15213","condg":["Depression"],"nct":"NCT05487885","study":"Anhedonia, Development, and Emotions: Phenotyping and Therapeutics","sstatus":"COMPLETED","sponsor":"Erika Forbes","official":"Erika E Forbes, PhD (University of Pittsburgh)","src":"https://clinicaltrials.gov/study/NCT05487885","phase":"Phase 4","enroll":123,"start":"2022-07-22","eid":"x:site:nct05487885-loeffler-building-pittsburgh"},{"id":"nct06297915-hacettepe-university-ankara","cat":"research","name":"Hacettepe University","city":"Ankara","region":"Cankaya","country":"Turkey","cc":"TR","lat":39.90909,"lon":32.84246,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06360","condg":["Chronic pain & headache"],"nct":"NCT06297915","study":"Infusion Treatments of Chronic Peripheral Neuropathic Pain","sstatus":"COMPLETED","sponsor":"Hacettepe University","official":"Gokhan Sucu, MD (HACETTEPE UNIVERSİTY)","src":"https://clinicaltrials.gov/study/NCT06297915","enroll":102,"start":"2022-05-17","eid":"x:site:nct06297915-hacettepe-university-ankara"},{"id":"nct05855876-stella-center-westmont","cat":"research","name":"Stella Center","city":"Westmont","region":"Illinois","country":"United States","cc":"US","lat":33.93429,"lon":-118.2983,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60656","condg":["PTSD & trauma","Neurology & cognition"],"status":"RECRUITING","nct":"NCT05855876","study":"Reversal of Battle-Related Aging (ROBRA) in a Special Operations Forces Cohort","sstatus":"UNKNOWN","sponsor":"Stella Center","official":"Eugene Lipov, MD (Stella Center)","src":"https://clinicaltrials.gov/study/NCT05855876","contact":{"n":"Eugene Lipov, MD","p":"773-992-1349","e":"hope4ptsi@gmail.com"},"enroll":20,"start":"2023-07-05","eid":"x:site:nct05855876-stella-center-westmont"},{"id":"nct01339065-mulago-hospital-national-refferal-surgical-wards-kampala","cat":"research","name":"Mulago Hospital National Refferal, surgical wards","city":"Kampala","country":"Uganda","cc":"UG","lat":0.30983,"lon":32.58243,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"+256","condg":["Other"],"status":"RECRUITING","nct":"NCT01339065","study":"The Effect of Ketamine on Production of Inflammatory Markers in Post Operative Patients in Mulago Hospital","sstatus":"UNKNOWN","sponsor":"Makerere University","src":"https://clinicaltrials.gov/study/NCT01339065","contact":{"n":"John M Kasumba, MBChB, MMed Anaesthesia- MUK","p":"+25675625678","e":"drkasmaya@gmail.com"},"phase":"Phase 4","enroll":30,"start":"2011-04","eid":"x:site:nct01339065-mulago-hospital-national-refferal-surgical-wards-kampala"},{"id":"nct04814381-ch-annecy-genevois-annecy","cat":"research","name":"CH Annecy Genevois","city":"Annecy","country":"France","cc":"FR","lat":45.90694,"lon":6.13294,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"74370","condg":["Chronic pain & headache"],"nct":"NCT04814381","study":"Ketamine + Magnesium for Chronic Cluster Headache (KETALGIA)","sstatus":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","official":"Xavier MOISSET (University Hospital, Clermont-Ferrand)","src":"https://clinicaltrials.gov/study/NCT04814381","phase":"Phase 4","enroll":93,"start":"2021-09-15","eid":"x:site:nct04814381-ch-annecy-genevois-annecy"},{"id":"nct04814381-polyclinique-jean-villar-bruges","cat":"research","name":"Polyclinique Jean Villar","city":"Bruges","country":"France","cc":"FR","lat":44.88612,"lon":-0.60756,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"33520","condg":["Chronic pain & headache"],"nct":"NCT04814381","study":"Ketamine + Magnesium for Chronic Cluster Headache (KETALGIA)","sstatus":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","official":"Xavier MOISSET (University Hospital, Clermont-Ferrand)","src":"https://clinicaltrials.gov/study/NCT04814381","phase":"Phase 4","enroll":93,"start":"2021-09-15","eid":"x:site:nct04814381-polyclinique-jean-villar-bruges"},{"id":"nct04814381-chu-de-clermont-ferrand-clermont-ferrand","cat":"research","name":"CHU de Clermont-Ferrand","city":"Clermont-Ferrand","country":"France","cc":"FR","lat":45.78294,"lon":3.0896,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"63000","condg":["Chronic pain & headache"],"nct":"NCT04814381","study":"Ketamine + Magnesium for Chronic Cluster Headache (KETALGIA)","sstatus":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","official":"Xavier MOISSET (University Hospital, Clermont-Ferrand)","src":"https://clinicaltrials.gov/study/NCT04814381","phase":"Phase 4","enroll":93,"start":"2021-09-15","eid":"x:site:nct04814381-chu-de-clermont-ferrand-clermont-ferrand"},{"id":"nct04814381-chru-de-lille-lille","cat":"research","name":"CHRU De Lille","city":"Lille","country":"France","cc":"FR","lat":50.6413,"lon":3.04378,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"59000","condg":["Chronic pain & headache"],"nct":"NCT04814381","study":"Ketamine + Magnesium for Chronic Cluster Headache (KETALGIA)","sstatus":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","official":"Xavier MOISSET (University Hospital, Clermont-Ferrand)","src":"https://clinicaltrials.gov/study/NCT04814381","phase":"Phase 4","enroll":93,"start":"2021-09-15","eid":"x:site:nct04814381-chru-de-lille-lille"},{"id":"nct04814381-hospices-civils-de-lyon-hopital-pierre-wertheimer-lyon","cat":"research","name":"Hospices civils de Lyon, Hôpital Pierre Wertheimer","city":"Lyon","country":"France","cc":"FR","lat":45.73904,"lon":4.85716,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"69500","condg":["Chronic pain & headache"],"nct":"NCT04814381","study":"Ketamine + Magnesium for Chronic Cluster Headache (KETALGIA)","sstatus":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","official":"Xavier MOISSET (University Hospital, Clermont-Ferrand)","src":"https://clinicaltrials.gov/study/NCT04814381","phase":"Phase 4","enroll":93,"start":"2021-09-15","eid":"x:site:nct04814381-hospices-civils-de-lyon-hopital-pierre-wertheimer-lyon"},{"id":"nct04814381-ap-hm-marseille-marseille","cat":"research","name":"AP-HM Marseille","city":"Marseille","country":"France","cc":"FR","lat":43.30321,"lon":5.38065,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"13005","condg":["Chronic pain & headache"],"nct":"NCT04814381","study":"Ketamine + Magnesium for Chronic Cluster Headache (KETALGIA)","sstatus":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","official":"Xavier MOISSET (University Hospital, Clermont-Ferrand)","src":"https://clinicaltrials.gov/study/NCT04814381","phase":"Phase 4","enroll":93,"start":"2021-09-15","eid":"x:site:nct04814381-ap-hm-marseille-marseille"},{"id":"nct04814381-clinique-beau-soleil-montpellier","cat":"research","name":"Clinique Beau Soleil","city":"Montpellier","country":"France","cc":"FR","lat":43.61079,"lon":3.87066,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"34070","condg":["Chronic pain & headache"],"nct":"NCT04814381","study":"Ketamine + Magnesium for Chronic Cluster Headache (KETALGIA)","sstatus":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","official":"Xavier MOISSET (University Hospital, Clermont-Ferrand)","src":"https://clinicaltrials.gov/study/NCT04814381","phase":"Phase 4","enroll":93,"start":"2021-09-15","eid":"x:site:nct04814381-clinique-beau-soleil-montpellier"},{"id":"nct04814381-chu-de-montpellier-montpellier","cat":"research","name":"CHU de Montpellier","city":"Montpellier","country":"France","cc":"FR","lat":43.60797,"lon":3.88073,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"34295","condg":["Chronic pain & headache"],"nct":"NCT04814381","study":"Ketamine + Magnesium for Chronic Cluster Headache (KETALGIA)","sstatus":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","official":"Xavier MOISSET (University Hospital, Clermont-Ferrand)","src":"https://clinicaltrials.gov/study/NCT04814381","phase":"Phase 4","enroll":93,"start":"2021-09-15","eid":"x:site:nct04814381-chu-de-montpellier-montpellier"},{"id":"nct04814381-chu-nantes-hopital-nord-laennec-nantes","cat":"research","name":"CHU Nantes, Hopital Nord Laennec","city":"Nantes","country":"France","cc":"FR","lat":47.22549,"lon":-1.55341,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44000","condg":["Chronic pain & headache"],"nct":"NCT04814381","study":"Ketamine + Magnesium for Chronic Cluster Headache (KETALGIA)","sstatus":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","official":"Xavier MOISSET (University Hospital, Clermont-Ferrand)","src":"https://clinicaltrials.gov/study/NCT04814381","phase":"Phase 4","enroll":93,"start":"2021-09-15","eid":"x:site:nct04814381-chu-nantes-hopital-nord-laennec-nantes"},{"id":"nct04814381-hopital-lariboisiere-paris","cat":"research","name":"Hôpital Lariboisière","city":"Paris","country":"France","cc":"FR","lat":48.85336,"lon":2.34979,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75010","condg":["Chronic pain & headache"],"nct":"NCT04814381","study":"Ketamine + Magnesium for Chronic Cluster Headache (KETALGIA)","sstatus":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","official":"Xavier MOISSET (University Hospital, Clermont-Ferrand)","src":"https://clinicaltrials.gov/study/NCT04814381","phase":"Phase 4","enroll":93,"start":"2021-09-15","eid":"x:site:nct04814381-hopital-lariboisiere-paris"},{"id":"nct04814381-chu-rouen-rouen","cat":"research","name":"CHU Rouen","city":"Rouen","country":"France","cc":"FR","lat":49.44525,"lon":1.08732,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"76100","condg":["Chronic pain & headache"],"nct":"NCT04814381","study":"Ketamine + Magnesium for Chronic Cluster Headache (KETALGIA)","sstatus":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","official":"Xavier MOISSET (University Hospital, Clermont-Ferrand)","src":"https://clinicaltrials.gov/study/NCT04814381","phase":"Phase 4","enroll":93,"start":"2021-09-15","eid":"x:site:nct04814381-chu-rouen-rouen"},{"id":"nct04814381-hopital-de-hautepierre-strasbourg","cat":"research","name":"Hopital de Hautepierre","city":"Strasbourg","country":"France","cc":"FR","lat":48.57983,"lon":7.74727,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"67098","condg":["Chronic pain & headache"],"nct":"NCT04814381","study":"Ketamine + Magnesium for Chronic Cluster Headache (KETALGIA)","sstatus":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","official":"Xavier MOISSET (University Hospital, Clermont-Ferrand)","src":"https://clinicaltrials.gov/study/NCT04814381","phase":"Phase 4","enroll":93,"start":"2021-09-15","eid":"x:site:nct04814381-hopital-de-hautepierre-strasbourg"},{"id":"nct04814381-hopital-pierre-paul-riquet-toulouse","cat":"research","name":"Hopital Pierre Paul Riquet","city":"Toulouse","country":"France","cc":"FR","lat":43.59753,"lon":1.45096,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"31059","condg":["Chronic pain & headache"],"nct":"NCT04814381","study":"Ketamine + Magnesium for Chronic Cluster Headache (KETALGIA)","sstatus":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","official":"Xavier MOISSET (University Hospital, Clermont-Ferrand)","src":"https://clinicaltrials.gov/study/NCT04814381","phase":"Phase 4","enroll":93,"start":"2021-09-15","eid":"x:site:nct04814381-hopital-pierre-paul-riquet-toulouse"},{"id":"nct04814381-chu-grenoble-alpes-voiron","cat":"research","name":"CHU Grenoble-Alpes","city":"Voiron","country":"France","cc":"FR","lat":45.36024,"lon":5.59261,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"38500","condg":["Chronic pain & headache"],"nct":"NCT04814381","study":"Ketamine + Magnesium for Chronic Cluster Headache (KETALGIA)","sstatus":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","official":"Xavier MOISSET (University Hospital, Clermont-Ferrand)","src":"https://clinicaltrials.gov/study/NCT04814381","phase":"Phase 4","enroll":93,"start":"2021-09-15","eid":"x:site:nct04814381-chu-grenoble-alpes-voiron"},{"id":"nct00798083-bc-cancer-agency-vancouver-island-bcca-victoria","cat":"research","name":"BC Cancer Agency Vancouver Island BCCA","city":"Victoria","region":"British Columbia","country":"Canada","cc":"CA","lat":48.42776,"lon":-123.35254,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"V8R 6V5","condg":["Chronic pain & headache"],"nct":"NCT00798083","study":"Neuropathic Pain Caused by Radiation Therapy","sstatus":"COMPLETED","sponsor":"British Columbia Cancer Agency","official":"Isabella Uzaraga, MD (BC Cancer Agency - Vancouver Island Centre)","src":"https://clinicaltrials.gov/study/NCT00798083","phase":"Phase 3","enroll":22,"start":"2008-04","eid":"x:site:nct00798083-bc-cancer-agency-vancouver-island-bcca-victoria"},{"id":"nct04101474-assiut-university-asyut","cat":"research","name":"Assiut university","city":"Asyut","country":"Egypt","cc":"EG","lat":27.17376,"lon":31.17281,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT04101474","study":"Role Of Ketamine in Treatment-Resistant Major Depressive Disorder And Its Effect on Suicidality","sstatus":"COMPLETED","sponsor":"Assiut University","src":"https://clinicaltrials.gov/study/NCT04101474","phase":"N/A","enroll":36,"start":"2020-09-01","eid":"x:site:nct04101474-assiut-university-asyut"},{"id":"nct01736020-university-of-california-irvine-irvine","cat":"research","name":"University of California, Irvine","city":"Irvine","region":"California","country":"United States","cc":"US","lat":33.67788,"lon":-117.83285,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"92697","condg":["Healthy volunteers"],"nct":"NCT01736020","study":"Developing Anesthesia as Post Traumatic Stress Disorder (PTSD) Therapy","sstatus":"UNKNOWN","sponsor":"Southern California Institute for Research and Education","official":"Michael T Alkire, MD (University of California, Irvine and Long Beach VA Medical Center)","src":"https://clinicaltrials.gov/study/NCT01736020","phase":"Phase 1","enroll":293,"start":"2009-09","eid":"x:site:nct01736020-university-of-california-irvine-irvine"},{"id":"nct01969227-massachusetts-general-hospital-boston","cat":"research","name":"Massachusetts General Hospital","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.34916,"lon":-71.06123,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02114","condg":["Depression"],"nct":"NCT01969227","study":"The Effects of Ketamine on Respiratory Stimulation and Transpulmonary Pressures","sstatus":"COMPLETED","sponsor":"Massachusetts General Hospital","official":"Lorenzo Berra, MD (Massachusetts General Hospital); Matthias Eikermann, MD, PhD (Beth Israel Deaconess Medical Center)","src":"https://clinicaltrials.gov/study/NCT01969227","phase":"N/A","enroll":15,"start":"2014-01","eid":"x:site:nct01969227-massachusetts-general-hospital-boston"},{"id":"nct01969227-beth-israel-deaconess-medical-center-boston","cat":"research","name":"Beth Israel Deaconess Medical Center","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36149,"lon":-71.05709,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02215","condg":["Depression"],"nct":"NCT01969227","study":"The Effects of Ketamine on Respiratory Stimulation and Transpulmonary Pressures","sstatus":"COMPLETED","sponsor":"Massachusetts General Hospital","official":"Lorenzo Berra, MD (Massachusetts General Hospital); Matthias Eikermann, MD, PhD (Beth Israel Deaconess Medical Center)","src":"https://clinicaltrials.gov/study/NCT01969227","phase":"N/A","enroll":15,"start":"2014-01","eid":"x:site:nct01969227-beth-israel-deaconess-medical-center-boston"},{"id":"nct04082858-st-patrick-s-university-hospital-dublin","cat":"research","name":"St Patrick's University Hospital","city":"Dublin","region":"Co. Dublin","country":"Ireland","cc":"IE","lat":53.32934,"lon":-6.256,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"D08 K7YW","condg":["Depression"],"nct":"NCT04082858","study":"Ketamine Interleaved With Electroconvulsive Therapy for Depression","sstatus":"TERMINATED","sponsor":"St Patrick's Hospital, Ireland","official":"Declan McLoughlin, PhD (St Patrick's Hospital)","src":"https://clinicaltrials.gov/study/NCT04082858","phase":"Phase 1","enroll":3,"start":"2020-01-06","eid":"x:site:nct04082858-st-patrick-s-university-hospital-dublin"},{"id":"nct06525584-artem-ivkin-kemerovo","cat":"research","name":"Artem Ivkin","city":"Kemerovo","region":"Please Select","country":"Russia","cc":"RU","lat":55.36391,"lon":86.09386,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"650066","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT06525584","study":"Ketamine Infusion as a Method of Cerebral Protection in Children","sstatus":"RECRUITING","sponsor":"Kemerovo State Medical University","src":"https://clinicaltrials.gov/study/NCT06525584","contact":{"n":"Artem Ivkin","p":"+79030701880","e":"ivkiaa@kemcardio.ru"},"phase":"N/A","enroll":196,"start":"2023-11-05","eid":"x:site:nct06525584-artem-ivkin-kemerovo"},{"id":"nct02624596-stanford-university-stanford","cat":"research","name":"Stanford University","city":"Stanford","region":"California","country":"United States","cc":"US","lat":37.41427,"lon":-122.1746,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94305","condg":["OCD"],"nct":"NCT02624596","study":"Understanding How Ketamine Brings About Rapid Improvement in OCD","sstatus":"COMPLETED","sponsor":"Stanford University","official":"Carolyn I Rodriguez, MD, PhD (Stanford University)","src":"https://clinicaltrials.gov/study/NCT02624596","phase":"Phase 2","enroll":120,"start":"2016-08-16","eid":"x:site:nct02624596-stanford-university-stanford"},{"id":"nct06464146-ambroise-pare-hospital-boulogne-billancourt","cat":"research","name":"Ambroise Paré Hospital","city":"Boulogne-Billancourt","country":"France","cc":"FR","lat":48.82957,"lon":2.23483,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"92100","condg":["Other"],"status":"RECRUITING","nct":"NCT06464146","study":"Pain Reduction for Limb Injuries in Pediatric Emergency Departments: Intranasal Fentanyl or Intranasal Ketamine vs Oral Morphine","sstatus":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","official":"Hélène CHAPPUY, MD, PhD (Assistance Publique - Hôpitaux de Paris)","src":"https://clinicaltrials.gov/study/NCT06464146","contact":{"n":"Marlène MICHELON JOUNEAUX, MD, PhD","p":"01 49 09 57 00","e":"marlene.michelonjouneaux@aphp.fr"},"phase":"Phase 3","enroll":300,"start":"2025-02-26","eid":"x:site:nct06464146-ambroise-pare-hospital-boulogne-billancourt"},{"id":"nct06464146-roger-salengro-hospital-lille","cat":"research","name":"Roger Salengro Hospital","city":"Lille","country":"France","cc":"FR","lat":50.64356,"lon":3.05253,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"59000","condg":["Other"],"status":"RECRUITING","nct":"NCT06464146","study":"Pain Reduction for Limb Injuries in Pediatric Emergency Departments: Intranasal Fentanyl or Intranasal Ketamine vs Oral Morphine","sstatus":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","official":"Hélène CHAPPUY, MD, PhD (Assistance Publique - Hôpitaux de Paris)","src":"https://clinicaltrials.gov/study/NCT06464146","contact":{"n":"Melany LIBER, MD, PhD","p":"03 20 44 46 64","e":"melany.liber@chu-lille.fr"},"phase":"Phase 3","enroll":300,"start":"2025-02-26","eid":"x:site:nct06464146-roger-salengro-hospital-lille"},{"id":"nct06464146-timone-hospital-marseille","cat":"research","name":"Timone Hospital","city":"Marseille","country":"France","cc":"FR","lat":43.29295,"lon":5.38959,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"13005","condg":["Other"],"status":"RECRUITING","nct":"NCT06464146","study":"Pain Reduction for Limb Injuries in Pediatric Emergency Departments: Intranasal Fentanyl or Intranasal Ketamine vs Oral Morphine","sstatus":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","official":"Hélène CHAPPUY, MD, PhD (Assistance Publique - Hôpitaux de Paris)","src":"https://clinicaltrials.gov/study/NCT06464146","contact":{"n":"Aurélie MORAND, MD, PHD","p":"04 91 38 96 99","e":"aurelie.morand@ap-hm.fr"},"phase":"Phase 3","enroll":300,"start":"2025-02-26","eid":"x:site:nct06464146-timone-hospital-marseille"},{"id":"nct06464146-mere-enfant-hospital-nantes","cat":"research","name":"Mère-Enfant Hospital","city":"Nantes","country":"France","cc":"FR","lat":47.20892,"lon":-1.54757,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44000","condg":["Other"],"status":"RECRUITING","nct":"NCT06464146","study":"Pain Reduction for Limb Injuries in Pediatric Emergency Departments: Intranasal Fentanyl or Intranasal Ketamine vs Oral Morphine","sstatus":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","official":"Hélène CHAPPUY, MD, PhD (Assistance Publique - Hôpitaux de Paris)","src":"https://clinicaltrials.gov/study/NCT06464146","contact":{"n":"Adeline BOUCHERON","p":"02 44 76 84 79","e":"adeline.boucheron@chu-lille.fr"},"phase":"Phase 3","enroll":300,"start":"2025-02-26","eid":"x:site:nct06464146-mere-enfant-hospital-nantes"},{"id":"nct06464146-hopital-necker-enfants-malades-paris","cat":"research","name":"Hopital Necker Enfants malades","city":"Paris","country":"France","cc":"FR","lat":48.85779,"lon":2.34376,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75015","condg":["Other"],"status":"RECRUITING","nct":"NCT06464146","study":"Pain Reduction for Limb Injuries in Pediatric Emergency Departments: Intranasal Fentanyl or Intranasal Ketamine vs Oral Morphine","sstatus":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","official":"Hélène CHAPPUY, MD, PhD (Assistance Publique - Hôpitaux de Paris)","src":"https://clinicaltrials.gov/study/NCT06464146","contact":{"n":"Hélène CHAPPUY, MD, PhD","p":"+33 1 44 49 41 26","e":"helene.chappuy@aphp.fr"},"phase":"Phase 3","enroll":300,"start":"2025-02-26","eid":"x:site:nct06464146-hopital-necker-enfants-malades-paris"},{"id":"nct01755169-medical-university-of-south-carolina-charleston","cat":"research","name":"Medical University of South Carolina","city":"Charleston","region":"South Carolina","country":"United States","cc":"US","lat":32.76978,"lon":-79.93383,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"29425","condg":["Chronic pain & headache"],"nct":"NCT01755169","study":"Ketamine in Chronic Kid's (KiCK) Pain","sstatus":"TERMINATED","sponsor":"Medical University of South Carolina","official":"Amy-Lee Bredlau, MD (Medical University of South Carolina)","src":"https://clinicaltrials.gov/study/NCT01755169","phase":"Phase 2","enroll":7,"start":"2013-01","eid":"x:site:nct01755169-medical-university-of-south-carolina-charleston"},{"id":"nct06473896-shamir-asaf-harofe-medical-center-be-er-ya-aqov","cat":"research","name":"Shamir (Asaf Harofe) Medical Center","city":"Be’er Ya‘aqov","country":"Israel","cc":"IL","lat":31.93869,"lon":34.83076,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"70300","condg":["Other"],"status":"RECRUITING","nct":"NCT06473896","study":"Effect of Ketalar or Dexmedetomidine on Increased Sensitivity to Pain Following Treatment With Remifentanil","sstatus":"UNKNOWN","sponsor":"Assaf-Harofeh Medical Center","official":"Sara Bar Yehuda, PhD (Shamir (Asaf Harofe) medical center)","src":"https://clinicaltrials.gov/study/NCT06473896","contact":{"n":"Sara Bar Yehuda, PhD","p":"972528981004","e":"sarabar1@shamur.gov.il"},"phase":"N/A","enroll":90,"start":"2024-04-18","eid":"x:site:nct06473896-shamir-asaf-harofe-medical-center-be-er-ya-aqov"},{"id":"nct02145169-albert-einstein-healthcare-network-philadelphia","cat":"research","name":"Albert Einstein Healthcare Network","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.95582,"lon":-75.17233,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"19141","condg":["Other"],"nct":"NCT02145169","study":"Inhaled Nitrous Oxide for the Prevention of Emergence Reaction During Ketamine Administration in Adults, a Pilot Study","sstatus":"COMPLETED","sponsor":"Albert Einstein Healthcare Network","official":"Paul Dominici, MD (Albert Einstein Healthcare Network)","src":"https://clinicaltrials.gov/study/NCT02145169","phase":"N/A","enroll":20,"start":"2013-10","eid":"x:site:nct02145169-albert-einstein-healthcare-network-philadelphia"},{"id":"nct01667926-depression-clinical-and-reseach-program-mgh-boston","cat":"research","name":"Depression Clinical and Reseach Program - MGH","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.35471,"lon":-71.06575,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02114","condg":["Depression"],"nct":"NCT01667926","study":"Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Massachusetts General Hospital","official":"Cristina Cusin, M.D. (MGH Department of Psychiatry)","src":"https://clinicaltrials.gov/study/NCT01667926","phase":"N/A","enroll":37,"start":"2013-01","eid":"x:site:nct01667926-depression-clinical-and-reseach-program-mgh-boston"},{"id":"nct02591017-pain-relief-unit-and-anaesthesiology-university-hospital-basel-basel","cat":"research","name":"Pain Relief Unit and Anaesthesiology, University Hospital Basel","city":"Basel","country":"Switzerland","cc":"CH","lat":47.54931,"lon":7.58301,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"4031","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT02591017","study":"Comparison of Oral Morphine Versus Nasal Ketamine Spray With Chitosan in Cancer Pain Outpatients","sstatus":"TERMINATED","sponsor":"University Hospital, Basel, Switzerland","official":"Wilhelm Ruppen, PD Dr. med. (Pain Relief Unit and Anaesthesiology, University Hospital Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT02591017","phase":"Phase 3","enroll":11,"start":"2015-02","eid":"x:site:nct02591017-pain-relief-unit-and-anaesthesiology-university-hospital-basel-basel"},{"id":"nct07066306-bezmialem-vak-f-universty-istanbul","cat":"research","name":"Bezmialem Vakıf Universty","city":"Istanbul","region":"Fatih","country":"Turkey","cc":"TR","lat":41.00758,"lon":28.9498,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"34093","condg":["Other"],"nct":"NCT07066306","study":"Effects of Local Ketamine in Orthognathic Procedures","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Bezmialem Vakif University","src":"https://clinicaltrials.gov/study/NCT07066306","phase":"N/A","enroll":40,"start":"2025-06-21","eid":"x:site:nct07066306-bezmialem-vak-f-universty-istanbul"},{"id":"nct05051449-university-of-maryland-baltimore-baltimore","cat":"research","name":"University of Maryland Baltimore","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.27989,"lon":-76.61967,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"21223","condg":["Depression","Addiction & substance use"],"nct":"NCT05051449","study":"Ketamine for OUD and Comorbid Depression (OUDCD)","sstatus":"TERMINATED","sponsor":"University of Maryland, Baltimore","official":"Annabelle Belcher, PhD (University of Maryland, Baltimore)","src":"https://clinicaltrials.gov/study/NCT05051449","phase":"Phase 1","enroll":5,"start":"2022-04-04","eid":"x:site:nct05051449-university-of-maryland-baltimore-baltimore"},{"id":"nct06868589-lahey-clinicc-burlington","cat":"research","name":"Lahey Clinicc","city":"Burlington","region":"Massachusetts","country":"United States","cc":"US","lat":36.10317,"lon":-79.4386,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"01805","condg":["Other"],"nct":"NCT06868589","study":"Reducing Pain With Methadone and Ketamine in Liver Transplant","sstatus":"COMPLETED","sponsor":"Lahey Clinic","official":"Ryan Nazemian, MD, PhD (Lahey Clinic, Department of Anesthesiology, Perioperative and Pain Medicine)","src":"https://clinicaltrials.gov/study/NCT06868589","phase":"Phase 4","enroll":50,"start":"2025-06-30","eid":"x:site:nct06868589-lahey-clinicc-burlington"},{"id":"nct06868589-lahey-clinic-burlington","cat":"research","name":"Lahey Clinic","city":"Burlington","region":"Massachusetts","country":"United States","cc":"US","lat":36.08943,"lon":-79.44152,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"01805","condg":["Other"],"nct":"NCT06868589","study":"Reducing Pain With Methadone and Ketamine in Liver Transplant","sstatus":"COMPLETED","sponsor":"Lahey Clinic","official":"Ryan Nazemian, MD, PhD (Lahey Clinic, Department of Anesthesiology, Perioperative and Pain Medicine)","src":"https://clinicaltrials.gov/study/NCT06868589","phase":"Phase 4","enroll":50,"start":"2025-06-30","eid":"x:site:nct06868589-lahey-clinic-burlington"},{"id":"nct02134951-university-of-california-davis-sacramento","cat":"research","name":"University of California Davis","city":"Sacramento","region":"California","country":"United States","cc":"US","lat":38.57079,"lon":-121.50311,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"95817","condg":["Healthy volunteers"],"nct":"NCT02134951","study":"Biomarker Assessment of Glutamatergic Target Engagement","sstatus":"COMPLETED","sponsor":"New York State Psychiatric Institute","official":"Jeffrey A Lieberman, MD (New York State Psychiatric Institute)","src":"https://clinicaltrials.gov/study/NCT02134951","phase":"Phase 4","enroll":65,"start":"2014-05","eid":"x:site:nct02134951-university-of-california-davis-sacramento"},{"id":"nct02134951-yale-university-new-haven","cat":"research","name":"Yale University","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.30989,"lon":-72.93094,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06511","condg":["Healthy volunteers"],"nct":"NCT02134951","study":"Biomarker Assessment of Glutamatergic Target Engagement","sstatus":"COMPLETED","sponsor":"New York State Psychiatric Institute","official":"Jeffrey A Lieberman, MD (New York State Psychiatric Institute)","src":"https://clinicaltrials.gov/study/NCT02134951","phase":"Phase 4","enroll":65,"start":"2014-05","eid":"x:site:nct02134951-yale-university-new-haven"},{"id":"nct02134951-new-york-state-psychiatric-institute-new-york","cat":"research","name":"New York State Psychiatric Institute","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71347,"lon":-73.99726,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10032","condg":["Healthy volunteers"],"nct":"NCT02134951","study":"Biomarker Assessment of Glutamatergic Target Engagement","sstatus":"COMPLETED","sponsor":"New York State Psychiatric Institute","official":"Jeffrey A Lieberman, MD (New York State Psychiatric Institute)","src":"https://clinicaltrials.gov/study/NCT02134951","phase":"Phase 4","enroll":65,"start":"2014-05","eid":"x:site:nct02134951-new-york-state-psychiatric-institute-new-york"},{"id":"nct06237569-inonu-universitesi-malatya","cat":"research","name":"Inonu universitesi","city":"Malatya","country":"Turkey","cc":"TR","lat":38.34533,"lon":38.31408,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44050","condg":["Depression","Chronic pain & headache"],"nct":"NCT06237569","study":"Dose Low Dose Ketamine in Casesarian","sstatus":"UNKNOWN","sponsor":"Inonu University","official":"DUYGU DEMIROZ (Inonu University)","src":"https://clinicaltrials.gov/study/NCT06237569","contact":{"n":"DUYGU DEMIROZ, dr","p":"+905319504421","e":"drduygudemiroz@hotmail.com"},"enroll":150,"start":"2024-06-01","eid":"x:site:nct06237569-inonu-universitesi-malatya"},{"id":"nct04695405-canadian-rapid-treatment-centre-of-excellence-mississauga","cat":"research","name":"Canadian Rapid Treatment Centre of Excellence","city":"Mississauga","region":"Ontario","country":"Canada","cc":"CA","lat":43.56897,"lon":-79.66051,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"L5C 4E7","condg":["Depression"],"nct":"NCT04695405","study":"Pharmacogenetics Associated With IV Ketamine","sstatus":"COMPLETED","sponsor":"Brain and Cognition Discovery Foundation","official":"Joshua D Rosenblat, MD, MSc (Canadian Rapid Treatment Center of Excellence)","src":"https://clinicaltrials.gov/study/NCT04695405","enroll":85,"start":"2021-01-21","eid":"x:site:nct04695405-canadian-rapid-treatment-centre-of-excellence-mississauga"},{"id":"nct03889756-yale-child-study-center-new-haven","cat":"research","name":"Yale Child Study Center","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31751,"lon":-72.93752,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06520","condg":["Depression"],"nct":"NCT03889756","study":"Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy","sstatus":"TERMINATED","sponsor":"Yale University","official":"Michael H. Bloch, MD (Yale University); Jennifer Dwyer, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT03889756","phase":"Phase 2/Phase 3","enroll":3,"start":"2019-07-17","eid":"x:site:nct03889756-yale-child-study-center-new-haven"},{"id":"nct01700829-columbia-university-new-york-state-psychiatric-institute-new-york","cat":"research","name":"Columbia University/New York State Psychiatric Institute","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71723,"lon":-74.00009,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10032","condg":["Depression"],"nct":"NCT01700829","study":"Ketamine in the Treatment of Suicidal Depression","sstatus":"COMPLETED","sponsor":"New York State Psychiatric Institute","official":"Michael F. Grunebaum, M.D. (Columbia University/New York State Psychiatric Institute)","src":"https://clinicaltrials.gov/study/NCT01700829","phase":"Phase 4","enroll":82,"start":"2012-06","eid":"x:site:nct01700829-columbia-university-new-york-state-psychiatric-institute-new-york"},{"id":"nct05097261-imelda-bonheiden-bonheiden","cat":"research","name":"Imelda Bonheiden","city":"Bonheiden","country":"Belgium","cc":"BE","lat":51.02294,"lon":4.5373,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["PTSD & trauma","Neurology & cognition"],"status":"RECRUITING","nct":"NCT05097261","study":"Ketamine in Acute Brain Injury Patients.","sstatus":"UNKNOWN","sponsor":"Geert Meyfroidt, MD, PhD","official":"Geert Meyfroidt, MD PhD (Associate Professor of Medicine)","src":"https://clinicaltrials.gov/study/NCT05097261","contact":{"n":"Emmanuel Van Der Hauwaert, MD","p":"003216343125","e":"liese.mebis@uzleuven.be"},"phase":"Phase 4","enroll":100,"start":"2021-09-06","eid":"x:site:nct05097261-imelda-bonheiden-bonheiden"},{"id":"nct05097261-az-sint-jan-bruges","cat":"research","name":"AZ Sint-Jan","city":"Bruges","country":"Belgium","cc":"BE","lat":51.20633,"lon":3.23257,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["PTSD & trauma","Neurology & cognition"],"status":"RECRUITING","nct":"NCT05097261","study":"Ketamine in Acute Brain Injury Patients.","sstatus":"UNKNOWN","sponsor":"Geert Meyfroidt, MD, PhD","official":"Geert Meyfroidt, MD PhD (Associate Professor of Medicine)","src":"https://clinicaltrials.gov/study/NCT05097261","contact":{"n":"Marc Bourgeois, MD","p":"003216343125","e":"liese.mebis@uzleuven.be"},"phase":"Phase 4","enroll":100,"start":"2021-09-06","eid":"x:site:nct05097261-az-sint-jan-bruges"},{"id":"nct05097261-jessa-ziekenhuis-hasselt","cat":"research","name":"Jessa Ziekenhuis","city":"Hasselt","country":"Belgium","cc":"BE","lat":50.93948,"lon":5.34576,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"3500","condg":["PTSD & trauma","Neurology & cognition"],"status":"RECRUITING","nct":"NCT05097261","study":"Ketamine in Acute Brain Injury Patients.","sstatus":"UNKNOWN","sponsor":"Geert Meyfroidt, MD, PhD","official":"Geert Meyfroidt, MD PhD (Associate Professor of Medicine)","src":"https://clinicaltrials.gov/study/NCT05097261","contact":{"n":"Jasperina Dubois, MD","p":"003216343125","e":"jasperina.dubois@jessazh.be"},"phase":"Phase 4","enroll":100,"start":"2021-09-06","eid":"x:site:nct05097261-jessa-ziekenhuis-hasselt"},{"id":"nct05097261-uzleuven-leuven","cat":"research","name":"UZLeuven","city":"Leuven","country":"Belgium","cc":"BE","lat":50.88933,"lon":4.70267,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"3001","condg":["PTSD & trauma","Neurology & cognition"],"status":"RECRUITING","nct":"NCT05097261","study":"Ketamine in Acute Brain Injury Patients.","sstatus":"UNKNOWN","sponsor":"Geert Meyfroidt, MD, PhD","official":"Geert Meyfroidt, MD PhD (Associate Professor of Medicine)","src":"https://clinicaltrials.gov/study/NCT05097261","contact":{"n":"Liese Mebis, PhD, MSc","p":"+3216343125","e":"liese.mebis@uzleuven.be"},"phase":"Phase 4","enroll":100,"start":"2021-09-06","eid":"x:site:nct05097261-uzleuven-leuven"},{"id":"nct05097261-chr-de-la-citadelle-liege-liege","cat":"research","name":"CHR de la Citadelle Liège","city":"Liège","country":"Belgium","cc":"BE","lat":50.62662,"lon":5.56914,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["PTSD & trauma","Neurology & cognition"],"status":"RECRUITING","nct":"NCT05097261","study":"Ketamine in Acute Brain Injury Patients.","sstatus":"UNKNOWN","sponsor":"Geert Meyfroidt, MD, PhD","official":"Geert Meyfroidt, MD PhD (Associate Professor of Medicine)","src":"https://clinicaltrials.gov/study/NCT05097261","contact":{"n":"Hugues Maréchal, MD","p":"003216343125","e":"liese.mebis@uzleuven.be"},"phase":"Phase 4","enroll":100,"start":"2021-09-06","eid":"x:site:nct05097261-chr-de-la-citadelle-liege-liege"},{"id":"nct05097261-chu-de-liege-liege","cat":"research","name":"CHU de Liège","city":"Liège","country":"Belgium","cc":"BE","lat":50.64093,"lon":5.55709,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["PTSD & trauma","Neurology & cognition"],"status":"RECRUITING","nct":"NCT05097261","study":"Ketamine in Acute Brain Injury Patients.","sstatus":"UNKNOWN","sponsor":"Geert Meyfroidt, MD, PhD","official":"Geert Meyfroidt, MD PhD (Associate Professor of Medicine)","src":"https://clinicaltrials.gov/study/NCT05097261","contact":{"n":"Didier Ledoux, MD","p":"003216343125","e":"liese.mebis@uzleuven.be"},"phase":"Phase 4","enroll":100,"start":"2021-09-06","eid":"x:site:nct05097261-chu-de-liege-liege"},{"id":"nct05097261-az-delta-roeselare","cat":"research","name":"AZ Delta","city":"Roeselare","country":"Belgium","cc":"BE","lat":50.94564,"lon":3.11907,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["PTSD & trauma","Neurology & cognition"],"status":"RECRUITING","nct":"NCT05097261","study":"Ketamine in Acute Brain Injury Patients.","sstatus":"UNKNOWN","sponsor":"Geert Meyfroidt, MD, PhD","official":"Geert Meyfroidt, MD PhD (Associate Professor of Medicine)","src":"https://clinicaltrials.gov/study/NCT05097261","contact":{"n":"Peiter Lormans, MD","p":"003216343125","e":"liese.mebis@uzleuven.be"},"phase":"Phase 4","enroll":100,"start":"2021-09-06","eid":"x:site:nct05097261-az-delta-roeselare"},{"id":"nct05097261-az-turnhout-turnhout","cat":"research","name":"AZ Turnhout","city":"Turnhout","country":"Belgium","cc":"BE","lat":51.31732,"lon":4.94109,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["PTSD & trauma","Neurology & cognition"],"status":"RECRUITING","nct":"NCT05097261","study":"Ketamine in Acute Brain Injury Patients.","sstatus":"UNKNOWN","sponsor":"Geert Meyfroidt, MD, PhD","official":"Geert Meyfroidt, MD PhD (Associate Professor of Medicine)","src":"https://clinicaltrials.gov/study/NCT05097261","contact":{"n":"Eva Boonen, MD, PhD","p":"003216343125","e":"liese.mebis@uzleuven.be"},"phase":"Phase 4","enroll":100,"start":"2021-09-06","eid":"x:site:nct05097261-az-turnhout-turnhout"},{"id":"nct04861051-stanford-university-school-of-medicine-palo-alto","cat":"research","name":"Stanford University School of Medicine","city":"Palo Alto","region":"California","country":"United States","cc":"US","lat":37.436,"lon":-122.15013,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94305","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT04861051","study":"Understanding Ketamine's Dissociative Effects (KD Study)","sstatus":"RECRUITING","sponsor":"Stanford University","official":"Karl Deisseroth, MD, PhD (Stanford University)","src":"https://clinicaltrials.gov/study/NCT04861051","contact":{"n":"Karl Deisseroth, MD, PhD","p":"650-580-9000","e":"arjayc@stanford.edu"},"phase":"Phase 1","enroll":20,"start":"2021-07-26","eid":"x:site:nct04861051-stanford-university-school-of-medicine-palo-alto"},{"id":"nct02165488-the-university-of-hong-kong-hong-kong","cat":"research","name":"The University of Hong Kong","city":"Hong Kong","country":"Hong Kong","cc":"HK","lat":22.27592,"lon":114.18669,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT02165488","study":"Frequent Ketamine Use and Gastrointestinal, Liver and Biliary Sequelae","sstatus":"COMPLETED","sponsor":"The University of Hong Kong","src":"https://clinicaltrials.gov/study/NCT02165488","enroll":100,"start":"2014-06","eid":"x:site:nct02165488-the-university-of-hong-kong-hong-kong"},{"id":"nct06806475-university-hospital-montpellier-montpellier","cat":"research","name":"University Hospital, Montpellier","city":"Montpellier","country":"France","cc":"FR","lat":43.60495,"lon":3.8731,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"34000","condg":["Depression"],"nct":"NCT06806475","study":"Sustained Ketamine Effectiveness for Suicidal Ideation","sstatus":"COMPLETED","sponsor":"University Hospital, Montpellier","official":"Emilie OLIE, MD PhD (University Hospital, Montpellier)","src":"https://clinicaltrials.gov/study/NCT06806475","enroll":128,"start":"2023-12-01","eid":"x:site:nct06806475-university-hospital-montpellier-montpellier"},{"id":"nct03473431-centro-medico-nacional-siglo-xxi-umae-hospital-de-especialidades-mex","cat":"research","name":"Centro Medico Nacional Siglo XXI. UMAE Hospital de Especialidades","city":"Mexico City","region":"Mexico City","country":"Mexico","cc":"MX","lat":19.43238,"lon":-99.13712,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06720","condg":["Depression"],"nct":"NCT03473431","study":"Effect of Ketamine in Depressive Symptoms of Elderly Patients With Visual Impairment.","sstatus":"COMPLETED","sponsor":"Instituto Mexicano del Seguro Social","official":"DULCE RASCON MARTINEZ, M.D (imss)","src":"https://clinicaltrials.gov/study/NCT03473431","phase":"N/A","enroll":90,"start":"2018-04-15","eid":"x:site:nct03473431-centro-medico-nacional-siglo-xxi-umae-hospital-de-especialidades-mex"},{"id":"nct05386069-prisma-health-upstate-greenville","cat":"research","name":"Prisma Health - Upstate","city":"Greenville","region":"South Carolina","country":"United States","cc":"US","lat":35.61421,"lon":-77.37656,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"29615","condg":["Addiction & substance use"],"nct":"NCT05386069","study":"Does a Non-Opioid Multimodal Pain (NOMO) Protocol Decrease Narcotic Use","sstatus":"COMPLETED","sponsor":"Prisma Health-Upstate","official":"Hema Brazell, MD (Prisma Health)","src":"https://clinicaltrials.gov/study/NCT05386069","phase":"Phase 3","enroll":10,"start":"2019-11-15","eid":"x:site:nct05386069-prisma-health-upstate-greenville"},{"id":"nct04266288-mercyone-des-moines-medical-center-des-moines","cat":"research","name":"MercyOne Des Moines Medical Center","city":"Des Moines","region":"Iowa","country":"United States","cc":"US","lat":41.59786,"lon":-93.61113,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"50314","condg":["Depression"],"nct":"NCT04266288","study":"Effectiveness of Ketamine for Depression and Suicidal Ideation in the Emergency Department","sstatus":"COMPLETED","sponsor":"MercyOne Des Moines Medical Center","official":"Kathryn Bress, PharmD (MercyOne Des Moines Medical Center); Adnan Iqbal, MD (MercyOne Des Moines Medical Center)","src":"https://clinicaltrials.gov/study/NCT04266288","phase":"Phase 4","enroll":29,"start":"2019-10-18","eid":"x:site:nct04266288-mercyone-des-moines-medical-center-des-moines"},{"id":"nct03485339-queen-mary-hospital-hong-kong","cat":"research","name":"Queen Mary Hospital","city":"Hong Kong","country":"Hong Kong","cc":"HK","lat":22.2843,"lon":114.18377,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"000000","condg":["Addiction & substance use"],"nct":"NCT03485339","study":"Substance Misuse To Psychosis for Ketamine (SToP-K)","sstatus":"COMPLETED","sponsor":"The University of Hong Kong","official":"albert KK Chung, MBBS(HK) (The University of Hong Kong)","src":"https://clinicaltrials.gov/study/NCT03485339","enroll":162,"start":"2018-06-12","eid":"x:site:nct03485339-queen-mary-hospital-hong-kong"},{"id":"nct03485339-western-psychiatric-centre-hong-kong","cat":"research","name":"Western Psychiatric Centre","city":"Hong Kong","country":"Hong Kong","cc":"HK","lat":22.26698,"lon":114.17285,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"00000","condg":["Addiction & substance use"],"nct":"NCT03485339","study":"Substance Misuse To Psychosis for Ketamine (SToP-K)","sstatus":"COMPLETED","sponsor":"The University of Hong Kong","official":"albert KK Chung, MBBS(HK) (The University of Hong Kong)","src":"https://clinicaltrials.gov/study/NCT03485339","enroll":162,"start":"2018-06-12","eid":"x:site:nct03485339-western-psychiatric-centre-hong-kong"},{"id":"nct05639322-st-michael-s-hospital-toronto","cat":"research","name":"St. Michael's Hospital","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70403,"lon":-79.38871,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M5B 1W8","condg":["Chronic pain & headache"],"nct":"NCT05639322","study":"Psychotherapy for Ketamine's Enhanced Durability in Chronic Neuropathic Pain: A Randomized Controlled Pilot Trial","sstatus":"COMPLETED","sponsor":"Unity Health Toronto","src":"https://clinicaltrials.gov/study/NCT05639322","phase":"Phase 4","enroll":30,"start":"2023-10-12","eid":"x:site:nct05639322-st-michael-s-hospital-toronto"},{"id":"nct06490731-asyut-university-asyut","cat":"research","name":"asyut University","city":"Asyut","country":"Egypt","cc":"EG","lat":27.17847,"lon":31.1729,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"RECRUITING","nct":"NCT06490731","study":"Effects of Dexmedetomidine Versus Ketamine on Inflammatory Response and Hemodynamic in Patients","sstatus":"RECRUITING","sponsor":"New Valley University","official":"Ahmed Ismail Abdel Sabour, MD (NewValley University)","src":"https://clinicaltrials.gov/study/NCT06490731","contact":{"n":"Alaa attia, professur","p":"01099923117","e":"ahmed_ismail87@med.nvu.edu.eg"},"phase":"Phase 1/Phase 2","enroll":2,"start":"2026-04-01","eid":"x:site:nct06490731-asyut-university-asyut"},{"id":"nct02657031-university-medical-center-of-southern-nevada-las-vegas","cat":"research","name":"University Medical Center of Southern Nevada","city":"Las Vegas","region":"Nevada","country":"United States","cc":"US","lat":36.17116,"lon":-115.14508,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"89102","condg":["Chronic pain & headache"],"nct":"NCT02657031","study":"The CHECK Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine","sstatus":"COMPLETED","sponsor":"University Medical Center of Southern Nevada","official":"Joseph A Zitek, MD (Unviersity of Nevada School of Medicine)","src":"https://clinicaltrials.gov/study/NCT02657031","phase":"Phase 4","enroll":54,"start":"2016-03-17","eid":"x:site:nct02657031-university-medical-center-of-southern-nevada-las-vegas"},{"id":"nct01558063-new-york-state-psychiatric-institute-new-york","cat":"research","name":"New York State Psychiatric Institute","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71874,"lon":-74.01609,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10032","condg":["Depression"],"nct":"NCT01558063","study":"Ketamine in the Treatment of Depression","sstatus":"COMPLETED","sponsor":"Columbia University","official":"Michael F. Grunebaum, M.D. (Columbia University)","src":"https://clinicaltrials.gov/study/NCT01558063","phase":"Phase 2","enroll":38,"start":"2012-02","eid":"x:site:nct01558063-new-york-state-psychiatric-institute-new-york"},{"id":"nct07138781-tanta-university-tanta","cat":"research","name":"Tanta University","city":"Tanta","region":"El-Gharbia","country":"Egypt","cc":"EG","lat":30.80009,"lon":31.00103,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"31527","condg":["Chronic pain & headache"],"nct":"NCT07138781","study":"Ketamine as an Adjuvant in External Oblique Intercostal Plane Block for Post Thoracotomy Pain","sstatus":"COMPLETED","sponsor":"Tanta University","src":"https://clinicaltrials.gov/study/NCT07138781","phase":"N/A","enroll":50,"start":"2025-08-23","eid":"x:site:nct07138781-tanta-university-tanta"},{"id":"nct03832309-christus-health-corpus-christi","cat":"research","name":"CHRISTUS Health","city":"Corpus Christi","region":"Texas","country":"United States","cc":"US","lat":27.79178,"lon":-97.40687,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"78404","condg":["Other"],"nct":"NCT03832309","study":"Techniques to Reduce the Severity and Frequency of Emergent Reactions","sstatus":"TERMINATED","sponsor":"CHRISTUS Health","official":"Paul Crapo, DO (CHRISTUS Health)","src":"https://clinicaltrials.gov/study/NCT03832309","phase":"N/A","enroll":38,"start":"2017-11-21","eid":"x:site:nct03832309-christus-health-corpus-christi"},{"id":"nct04850911-university-of-oxford-oxford","cat":"research","name":"University of Oxford","city":"Oxford","country":"United Kingdom","cc":"GB","lat":51.74276,"lon":-1.25328,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"OX3 7JZ","condg":["Depression"],"status":"RECRUITING","nct":"NCT04850911","study":"Reward Emotion Learning and Ketamine Study","sstatus":"UNKNOWN","sponsor":"University of Oxford","official":"Catherine Harmer, PhD (University of Oxford)","src":"https://clinicaltrials.gov/study/NCT04850911","contact":{"n":"Erdem Pulcu, PhD","p":"01865613154","e":"erdem.pulcu@psych.ox.ac.uk"},"phase":"N/A","enroll":70,"start":"2021-08-25","eid":"x:site:nct04850911-university-of-oxford-oxford"},{"id":"nct03632915-university-of-maryland-medical-center-baltimore","cat":"research","name":"University of Maryland Medical Center","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29344,"lon":-76.60283,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"21201","condg":["Other"],"nct":"NCT03632915","study":"Pharmacokinetics of Antiepileptics in Patients on CRRT","sstatus":"COMPLETED","sponsor":"University of Maryland, Baltimore","official":"Neeraj Badjatia, MD (University of Maryland, College Park)","src":"https://clinicaltrials.gov/study/NCT03632915","enroll":18,"start":"2017-11-20","eid":"x:site:nct03632915-university-of-maryland-medical-center-baltimore"},{"id":"nct03633058-university-of-alabama-birmingham-school-of-medicine-birmingham","cat":"research","name":"University of Alabama Birmingham School of Medicine","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.5209,"lon":-86.8031,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"35294","condg":["Other"],"nct":"NCT03633058","study":"A Study to Evaluate Ketamine for the Treatment of Rett Syndrome","sstatus":"COMPLETED","sponsor":"Rett Syndrome Research Trust","official":"Jeffrey Neul, MD, PhD (Vanderbilt University Medical Center); Jana von Hehn, PhD (Rett Syndrome Research Trust)","src":"https://clinicaltrials.gov/study/NCT03633058","phase":"Phase 2","enroll":23,"start":"2019-03-12","eid":"x:site:nct03633058-university-of-alabama-birmingham-school-of-medicine-birmingham"},{"id":"nct03633058-children-s-hospital-colorado-aurora","cat":"research","name":"Children's Hospital Colorado","city":"Aurora","region":"Colorado","country":"United States","cc":"US","lat":39.71988,"lon":-104.84392,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"80045","condg":["Other"],"nct":"NCT03633058","study":"A Study to Evaluate Ketamine for the Treatment of Rett Syndrome","sstatus":"COMPLETED","sponsor":"Rett Syndrome Research Trust","official":"Jeffrey Neul, MD, PhD (Vanderbilt University Medical Center); Jana von Hehn, PhD (Rett Syndrome Research Trust)","src":"https://clinicaltrials.gov/study/NCT03633058","phase":"Phase 2","enroll":23,"start":"2019-03-12","eid":"x:site:nct03633058-children-s-hospital-colorado-aurora"},{"id":"nct03633058-rush-university-medical-center-chicago","cat":"research","name":"Rush University Medical Center","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.83954,"lon":-87.65838,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60612","condg":["Other"],"nct":"NCT03633058","study":"A Study to Evaluate Ketamine for the Treatment of Rett Syndrome","sstatus":"COMPLETED","sponsor":"Rett Syndrome Research Trust","official":"Jeffrey Neul, MD, PhD (Vanderbilt University Medical Center); Jana von Hehn, PhD (Rett Syndrome Research Trust)","src":"https://clinicaltrials.gov/study/NCT03633058","phase":"Phase 2","enroll":23,"start":"2019-03-12","eid":"x:site:nct03633058-rush-university-medical-center-chicago"},{"id":"nct03633058-boston-children-s-hospital-boston","cat":"research","name":"Boston Children's Hospital","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.35227,"lon":-71.06302,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02115","condg":["Other"],"nct":"NCT03633058","study":"A Study to Evaluate Ketamine for the Treatment of Rett Syndrome","sstatus":"COMPLETED","sponsor":"Rett Syndrome Research Trust","official":"Jeffrey Neul, MD, PhD (Vanderbilt University Medical Center); Jana von Hehn, PhD (Rett Syndrome Research Trust)","src":"https://clinicaltrials.gov/study/NCT03633058","phase":"Phase 2","enroll":23,"start":"2019-03-12","eid":"x:site:nct03633058-boston-children-s-hospital-boston"},{"id":"nct03633058-children-s-hospital-of-philadelphia-philadelphia","cat":"research","name":"Children's Hospital of Philadelphia","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.95252,"lon":-75.15482,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"19104","condg":["Other"],"nct":"NCT03633058","study":"A Study to Evaluate Ketamine for the Treatment of Rett Syndrome","sstatus":"COMPLETED","sponsor":"Rett Syndrome Research Trust","official":"Jeffrey Neul, MD, PhD (Vanderbilt University Medical Center); Jana von Hehn, PhD (Rett Syndrome Research Trust)","src":"https://clinicaltrials.gov/study/NCT03633058","phase":"Phase 2","enroll":23,"start":"2019-03-12","eid":"x:site:nct03633058-children-s-hospital-of-philadelphia-philadelphia"},{"id":"nct03633058-vanderbilt-university-medical-center-nashville","cat":"research","name":"Vanderbilt University Medical Center","city":"Nashville","region":"Tennessee","country":"United States","cc":"US","lat":36.16773,"lon":-86.7938,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"37203","condg":["Other"],"nct":"NCT03633058","study":"A Study to Evaluate Ketamine for the Treatment of Rett Syndrome","sstatus":"COMPLETED","sponsor":"Rett Syndrome Research Trust","official":"Jeffrey Neul, MD, PhD (Vanderbilt University Medical Center); Jana von Hehn, PhD (Rett Syndrome Research Trust)","src":"https://clinicaltrials.gov/study/NCT03633058","phase":"Phase 2","enroll":23,"start":"2019-03-12","eid":"x:site:nct03633058-vanderbilt-university-medical-center-nashville"},{"id":"nct03633058-texas-children-s-hospital-houston","cat":"research","name":"Texas Children's Hospital","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.77274,"lon":-95.36322,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"77030","condg":["Other"],"nct":"NCT03633058","study":"A Study to Evaluate Ketamine for the Treatment of Rett Syndrome","sstatus":"COMPLETED","sponsor":"Rett Syndrome Research Trust","official":"Jeffrey Neul, MD, PhD (Vanderbilt University Medical Center); Jana von Hehn, PhD (Rett Syndrome Research Trust)","src":"https://clinicaltrials.gov/study/NCT03633058","phase":"Phase 2","enroll":23,"start":"2019-03-12","eid":"x:site:nct03633058-texas-children-s-hospital-houston"},{"id":"nct02573714-mbingo-baptist-hospital-bamenda","cat":"research","name":"Mbingo Baptist Hospital","city":"Bamenda","region":"Northwest Province","country":"Cameroon","cc":"CM","lat":5.9717,"lon":10.15759,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"RECRUITING","nct":"NCT02573714","study":"Sub-dissociative Intranasal Ketamine for Pediatric Sickle Cell Pain Crises","sstatus":"UNKNOWN","sponsor":"Cameroon Baptist Convention Health","official":"Ernest Nshom, MD (Cameroon Baptist Convention Health); Michael Runyon, MD (Carolinas Medical Center)","src":"https://clinicaltrials.gov/study/NCT02573714","contact":{"n":"James R Young, MD","p":"704-578-5078","e":"james.young@carolinashealthcare.org"},"phase":"N/A","enroll":160,"start":"2015-12","eid":"x:site:nct02573714-mbingo-baptist-hospital-bamenda"},{"id":"nct02573714-muhimbili-national-hospital-dar-es-salaam","cat":"research","name":"Muhimbili National Hospital","city":"Dar es Salaam","country":"Tanzania","cc":"TZ","lat":-6.82071,"lon":39.26052,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"status":"NOT_YET_RECRUITING","nct":"NCT02573714","study":"Sub-dissociative Intranasal Ketamine for Pediatric Sickle Cell Pain Crises","sstatus":"UNKNOWN","sponsor":"Cameroon Baptist Convention Health","official":"Ernest Nshom, MD (Cameroon Baptist Convention Health); Michael Runyon, MD (Carolinas Medical Center)","src":"https://clinicaltrials.gov/study/NCT02573714","contact":{"n":"Hendry R Sawe, MD","p":"704-578-5078","e":"Hendry_sawe@yahoo.com"},"phase":"N/A","enroll":160,"start":"2015-12","eid":"x:site:nct02573714-muhimbili-national-hospital-dar-es-salaam"},{"id":"nct02417298-the-brooklyn-hospital-center-brooklyn","cat":"research","name":"The Brooklyn Hospital Center","city":"Brooklyn","region":"New York","country":"United States","cc":"US","lat":40.65862,"lon":-73.93758,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11201","condg":["Chronic pain & headache"],"nct":"NCT02417298","study":"Ketamine Infusion for Acute Sickle Cell Crisis in the Emergency Department","sstatus":"TERMINATED","sponsor":"Billy Sin","official":"Michael Hochberg, MD (The Brooklyn Hospital Center)","src":"https://clinicaltrials.gov/study/NCT02417298","phase":"N/A","enroll":12,"start":"2015-11","eid":"x:site:nct02417298-the-brooklyn-hospital-center-brooklyn"},{"id":"nct02219867-sheba-mc-ramat-gan","cat":"research","name":"Sheba MC","city":"Ramat Gan","country":"Israel","cc":"IL","lat":32.09371,"lon":34.81926,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"5265601","condg":["Depression"],"nct":"NCT02219867","study":"Ketamine Infusions for Major Depression Disorder","sstatus":"UNKNOWN","sponsor":"Sheba Medical Center","src":"https://clinicaltrials.gov/study/NCT02219867","contact":{"n":"Revital Amiaz, Dr","p":"972-35303436","e":"revital.amiaz@sheba.health.gov.il"},"phase":"N/A","enroll":10,"start":"2014-08","eid":"x:site:nct02219867-sheba-mc-ramat-gan"},{"id":"nct02675530-vha-ct-west-haven","cat":"research","name":"VHA CT","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.26731,"lon":-72.94371,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06516","condg":["Other"],"nct":"NCT02675530","study":"Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism","sstatus":"COMPLETED","sponsor":"Yale University","official":"Handan Gunduz-Bruce, M.D. (Yale Medical School)","src":"https://clinicaltrials.gov/study/NCT02675530","phase":"Phase 1","enroll":33,"start":"2007-12","eid":"x:site:nct02675530-vha-ct-west-haven"},{"id":"nct02303847-pioneer-family-practice-lacey","cat":"research","name":"Pioneer Family Practice","city":"Lacey","region":"Washington","country":"United States","cc":"US","lat":47.0328,"lon":-122.82248,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"98503","condg":["Chronic pain & headache"],"nct":"NCT02303847","study":"Ultra-low Dose Oral Ketamine for Chronic Pain in the Primary Care Setting","sstatus":"UNKNOWN","sponsor":"University of Washington","official":"Lucinda Grande, MD (University of Washington Department of Family Medicine)","src":"https://clinicaltrials.gov/study/NCT02303847","phase":"Phase 3","enroll":32,"start":"2014-11","eid":"x:site:nct02303847-pioneer-family-practice-lacey"},{"id":"nct02234011-mclean-hospital-belmont","cat":"research","name":"McLean Hospital","city":"Belmont","region":"Massachusetts","country":"United States","cc":"US","lat":37.526,"lon":-122.28074,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02478","condg":["OCD"],"nct":"NCT02234011","study":"A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder","sstatus":"TERMINATED","sponsor":"Mclean Hospital","official":"Brian P Brennan, M.D. (Mclean Hospital)","src":"https://clinicaltrials.gov/study/NCT02234011","phase":"Phase 2","enroll":1,"start":"2014-09","eid":"x:site:nct02234011-mclean-hospital-belmont"},{"id":"nct04712071-marijn-lijffijt-houston","cat":"research","name":"Marijn Lijffijt","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.75429,"lon":-95.35936,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"77030","condg":["Other"],"nct":"NCT04712071","study":"Ketamine in Veterans With Gulf War Illness","sstatus":"TERMINATED","sponsor":"Baylor College of Medicine","official":"Marijn Lijffijt, PhD (Baylor College of Medicine)","src":"https://clinicaltrials.gov/study/NCT04712071","phase":"EARLY_Phase 1","enroll":1,"start":"2021-02-01","eid":"x:site:nct04712071-marijn-lijffijt-houston"},{"id":"nct06526078-kaiser-foundation-research-institute-a-division-of-kaiser-foundation","cat":"research","name":"Kaiser Foundation Research Institute, a division of Kaiser Foundation Hospitals","city":"Oakland","region":"California","country":"United States","cc":"US","lat":37.80818,"lon":-122.26285,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94612","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT06526078","study":"Cognitive Training as an Adjunct to Ketamine in Real-world Clinics","sstatus":"RECRUITING","sponsor":"University of Pittsburgh","official":"Rebecca B Price, PhD (University of Pittsburgh)","src":"https://clinicaltrials.gov/study/NCT06526078","contact":{"n":"Steven Hamilton, MD","p":"412-383-2150","e":"Steven.P.Hamilton@kp.org"},"phase":"N/A","enroll":600,"start":"2024-11-12","eid":"x:site:nct06526078-kaiser-foundation-research-institute-a-division-of-kaiser-foundation"},{"id":"nct06526078-university-of-illinois-at-chicago-chicago","cat":"research","name":"University of Illinois at Chicago","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.83982,"lon":-87.64257,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60612","condg":["Depression"],"status":"RECRUITING","nct":"NCT06526078","study":"Cognitive Training as an Adjunct to Ketamine in Real-world Clinics","sstatus":"RECRUITING","sponsor":"University of Pittsburgh","official":"Rebecca B Price, PhD (University of Pittsburgh)","src":"https://clinicaltrials.gov/study/NCT06526078","contact":{"n":"Alex Leow, MD","p":"412-383-2150","e":"alexfeuillet@gmail.com"},"phase":"N/A","enroll":600,"start":"2024-11-12","eid":"x:site:nct06526078-university-of-illinois-at-chicago-chicago"},{"id":"nct06526078-baylor-college-of-medicine-houston","cat":"research","name":"Baylor College of Medicine","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.75608,"lon":-95.37433,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"77030","condg":["Depression"],"status":"RECRUITING","nct":"NCT06526078","study":"Cognitive Training as an Adjunct to Ketamine in Real-world Clinics","sstatus":"RECRUITING","sponsor":"University of Pittsburgh","official":"Rebecca B Price, PhD (University of Pittsburgh)","src":"https://clinicaltrials.gov/study/NCT06526078","contact":{"n":"Sanjay Mathew, MD","p":"412-383-2150","e":"sjmathew@bcm.edu"},"phase":"N/A","enroll":600,"start":"2024-11-12","eid":"x:site:nct06526078-baylor-college-of-medicine-houston"},{"id":"nct02727998-yale-university-school-of-medicine-new-haven","cat":"research","name":"Yale University School of Medicine","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31582,"lon":-72.9219,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06510","condg":["PTSD & trauma"],"nct":"NCT02727998","study":"Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure Therapy","sstatus":"TERMINATED","sponsor":"Yale University","official":"Ilan Harpaz-Rotem, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT02727998","phase":"Phase 2","enroll":28,"start":"2015-12","eid":"x:site:nct02727998-yale-university-school-of-medicine-new-haven"},{"id":"nct03088306-johns-hopkins-university-school-of-medicine-baltimore","cat":"research","name":"Johns Hopkins University School of Medicine","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28365,"lon":-76.61995,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"21287","condg":["Other"],"nct":"NCT03088306","study":"Improving Pain and Reducing Opioid Use (IPaRO) in Lumbar Spine Surgery Patients","sstatus":"COMPLETED","sponsor":"Johns Hopkins University","official":"Richard L Skolasky, ScD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT03088306","phase":"EARLY_Phase 1","enroll":49,"start":"2017-07-01","eid":"x:site:nct03088306-johns-hopkins-university-school-of-medicine-baltimore"},{"id":"nct04589208-new-york-state-psychiatric-new-york","cat":"research","name":"New York State Psychiatric","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70246,"lon":-74.0159,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10023","condg":["Healthy volunteers"],"nct":"NCT04589208","study":"Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"New York State Psychiatric Institute","src":"https://clinicaltrials.gov/study/NCT04589208","phase":"Phase 1/Phase 2","enroll":35,"start":"2021-01-01","eid":"x:site:nct04589208-new-york-state-psychiatric-new-york"},{"id":"nct02094898-mayo-clinic-rochester","cat":"research","name":"Mayo Clinic","city":"Rochester","region":"Minnesota","country":"United States","cc":"US","lat":43.14673,"lon":-77.61052,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55905","condg":["Depression"],"nct":"NCT02094898","study":"Ketamine for Depression and Suicide Risk","sstatus":"COMPLETED","sponsor":"Mayo Clinic","official":"William V Bobo, MD (Consultant - Psychiatry)","src":"https://clinicaltrials.gov/study/NCT02094898","phase":"Phase 2","enroll":12,"start":"2014-09","eid":"x:site:nct02094898-mayo-clinic-rochester"},{"id":"nct05294835-wild-health-lexington","cat":"research","name":"Wild Health","city":"Lexington","region":"Kentucky","country":"United States","cc":"US","lat":37.98102,"lon":-84.4869,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"40503","condg":["Depression","PTSD & trauma"],"status":"RECRUITING","nct":"NCT05294835","study":"Ketamine and Epigenetic Aging","sstatus":"UNKNOWN","sponsor":"TruDiagnostic","src":"https://clinicaltrials.gov/study/NCT05294835","contact":{"n":"Jessica Klunder","p":"615-278-6394","e":"jessica.klunder@wildhealth.com"},"phase":"Phase 2","enroll":20,"start":"2022-04-01","eid":"x:site:nct05294835-wild-health-lexington"},{"id":"nct06630065-groupe-hospitalo-universitaire-paris-psychiatrie-et-neurosciences-pa","cat":"research","name":"- Groupe hospitalo-universitaire Paris Psychiatrie et Neurosciences","city":"Paris","region":"Paris","country":"France","cc":"FR","lat":48.85948,"lon":2.35355,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75014","condg":["Depression"],"status":"RECRUITING","nct":"NCT06630065","study":"Study of the Neural Circuits Underlying the Negative Emotional Bias of Depressive Disorders and Their Response to Ketamine","sstatus":"RECRUITING","sponsor":"Centre Hospitalier St Anne","official":"Chantal Henry, Pr (GHU Paris Psychiatry & Neurosciences)","src":"https://clinicaltrials.gov/study/NCT06630065","contact":{"n":"Chantal Henry, Pr","p":"0145658452","e":"ch.henry@ghu-paris.fr"},"phase":"N/A","enroll":96,"start":"2023-03-13","eid":"x:site:nct06630065-groupe-hospitalo-universitaire-paris-psychiatrie-et-neurosciences-pa"},{"id":"nct05004896-toronto-general-hospital-toronto","cat":"research","name":"Toronto General Hospital","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70742,"lon":-79.40989,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M5G 2C4","condg":["Depression","Bipolar"],"nct":"NCT05004896","study":"Ketamine for Treatment-Resistant Bipolar Disorder","sstatus":"COMPLETED","sponsor":"Joshua Rosenblat","official":"Joshua Rosenblat, MD, MSc (Toronto Western Hospital, Psychiatry)","src":"https://clinicaltrials.gov/study/NCT05004896","phase":"Phase 2","enroll":71,"start":"2022-07-04","eid":"x:site:nct05004896-toronto-general-hospital-toronto"},{"id":"nct05004896-toronto-western-hospital-toronto","cat":"research","name":"Toronto Western Hospital","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.69443,"lon":-79.40349,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M5T 2S8","condg":["Depression","Bipolar"],"nct":"NCT05004896","study":"Ketamine for Treatment-Resistant Bipolar Disorder","sstatus":"COMPLETED","sponsor":"Joshua Rosenblat","official":"Joshua Rosenblat, MD, MSc (Toronto Western Hospital, Psychiatry)","src":"https://clinicaltrials.gov/study/NCT05004896","phase":"Phase 2","enroll":71,"start":"2022-07-04","eid":"x:site:nct05004896-toronto-western-hospital-toronto"},{"id":"nct05004896-ontario-shores-centre-for-mental-health-sciences-whitby","cat":"research","name":"Ontario Shores Centre for Mental Health Sciences","city":"Whitby","region":"Ontario","country":"Canada","cc":"CA","lat":43.88347,"lon":-78.92303,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"L1N 5S9","condg":["Depression","Bipolar"],"nct":"NCT05004896","study":"Ketamine for Treatment-Resistant Bipolar Disorder","sstatus":"COMPLETED","sponsor":"Joshua Rosenblat","official":"Joshua Rosenblat, MD, MSc (Toronto Western Hospital, Psychiatry)","src":"https://clinicaltrials.gov/study/NCT05004896","phase":"Phase 2","enroll":71,"start":"2022-07-04","eid":"x:site:nct05004896-ontario-shores-centre-for-mental-health-sciences-whitby"},{"id":"nct01504659-individual-homes-of-subjects-not-predetermined","cat":"research","name":"Individual homes of subjects","city":"Not Predetermined","region":"Connecticut","country":"United States","cc":"US","lat":41.5322,"lon":-72.6707,"gp":"region","unnamed":0,"drugs":["ketamine"],"condg":["Bipolar"],"nct":"NCT01504659","study":"Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder","sstatus":"TERMINATED","sponsor":"Juvenile Bipolar Research Foundation","official":"Demitri Papolos, MD (Juvenile Bipolar Research Foundation)","src":"https://clinicaltrials.gov/study/NCT01504659","phase":"Phase 2/Phase 3","enroll":5,"start":"2012-07","eid":"x:site:nct01504659-individual-homes-of-subjects-not-predetermined"},{"id":"nct01504659-juvenile-bipolar-research-foundation-maplewood","cat":"research","name":"Juvenile Bipolar Research Foundation","city":"Maplewood","region":"New Jersey","country":"United States","cc":"US","lat":44.95937,"lon":-92.98482,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"07040","condg":["Bipolar"],"nct":"NCT01504659","study":"Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder","sstatus":"TERMINATED","sponsor":"Juvenile Bipolar Research Foundation","official":"Demitri Papolos, MD (Juvenile Bipolar Research Foundation)","src":"https://clinicaltrials.gov/study/NCT01504659","phase":"Phase 2/Phase 3","enroll":5,"start":"2012-07","eid":"x:site:nct01504659-juvenile-bipolar-research-foundation-maplewood"},{"id":"nct01504659-individual-homes-of-subjects-not-predetermined-2","cat":"research","name":"Individual homes of subjects","city":"Not Predetermined","region":"New Jersey","country":"United States","cc":"US","lat":40.6471,"lon":-74.4435,"gp":"region","unnamed":0,"drugs":["ketamine"],"condg":["Bipolar"],"nct":"NCT01504659","study":"Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder","sstatus":"TERMINATED","sponsor":"Juvenile Bipolar Research Foundation","official":"Demitri Papolos, MD (Juvenile Bipolar Research Foundation)","src":"https://clinicaltrials.gov/study/NCT01504659","phase":"Phase 2/Phase 3","enroll":5,"start":"2012-07","eid":"x:site:nct01504659-individual-homes-of-subjects-not-predetermined-2"},{"id":"nct01504659-individual-homes-of-subjects-not-predetermined-3","cat":"research","name":"Individual homes of subjects","city":"Not Predetermined","region":"New York","country":"United States","cc":"US","lat":41.1038,"lon":-73.9184,"gp":"region","unnamed":0,"drugs":["ketamine"],"condg":["Bipolar"],"nct":"NCT01504659","study":"Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder","sstatus":"TERMINATED","sponsor":"Juvenile Bipolar Research Foundation","official":"Demitri Papolos, MD (Juvenile Bipolar Research Foundation)","src":"https://clinicaltrials.gov/study/NCT01504659","phase":"Phase 2/Phase 3","enroll":5,"start":"2012-07","eid":"x:site:nct01504659-individual-homes-of-subjects-not-predetermined-3"},{"id":"nct03141658-new-york-state-psychiatric-institute-new-york","cat":"research","name":"New York State Psychiatric Institute","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70858,"lon":-74.00479,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10032","condg":["Healthy volunteers"],"nct":"NCT03141658","study":"Effects of TS-134 on Ketamine-induced BOLD Signals in Healthy Subjects","sstatus":"COMPLETED","sponsor":"Taisho Pharmaceutical R&D Inc.","official":"Jeffrey A Lieberman, MD (New York State Psychiatric Institute)","src":"https://clinicaltrials.gov/study/NCT03141658","phase":"Phase 1","enroll":63,"start":"2017-06-28","eid":"x:site:nct03141658-new-york-state-psychiatric-institute-new-york"},{"id":"nct02037035-yale-depression-research-program-new-haven","cat":"research","name":"Yale Depression Research Program","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.30697,"lon":-72.9251,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06511","condg":["Depression"],"nct":"NCT02037035","study":"Examining The Effect Of Ketamine On Glutamate/Glutamine Cycling","sstatus":"COMPLETED","sponsor":"Yale University","official":"Lynnette Averill, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT02037035","phase":"EARLY_Phase 1","enroll":36,"start":"2013-07","eid":"x:site:nct02037035-yale-depression-research-program-new-haven"},{"id":"nct02037503-tel-aviv-sourasky-medical-center-tel-aviv","cat":"research","name":"Tel Aviv Sourasky Medical Center","city":"Tel Aviv","region":"N/A = Not Applicable","country":"Israel","cc":"IL","lat":32.0845,"lon":34.77478,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"64288","condg":["Depression","Healthy volunteers"],"status":"RECRUITING","nct":"NCT02037503","study":"The Effect of Ketamine on Mechanises Underlying Suicidal Ideation and Drug-resistant Major Depression","sstatus":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","src":"https://clinicaltrials.gov/study/NCT02037503","contact":{"n":"Haggai","p":"97236973953","e":"haggaisharon@gmail.com"},"phase":"Phase 3","enroll":100,"start":"2014-01","eid":"x:site:nct02037503-tel-aviv-sourasky-medical-center-tel-aviv"},{"id":"nct00961194-service-de-neurochirurgie-toulouse","cat":"research","name":"Service de Neurochirurgie","city":"Toulouse","country":"France","cc":"FR","lat":43.61108,"lon":1.45266,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"31059","condg":["Chronic pain & headache"],"nct":"NCT00961194","study":"Oral Ketamine Administration in Patients With Peripheral Neuropathic Pain","sstatus":"COMPLETED","sponsor":"University Hospital, Toulouse","official":"Nathalie Cantagrel, MD (University Hospital, Toulouse)","src":"https://clinicaltrials.gov/study/NCT00961194","phase":"Phase 2","enroll":22,"start":"2009-03","eid":"x:site:nct00961194-service-de-neurochirurgie-toulouse"},{"id":"nct04508894-minya-university-minya","cat":"research","name":"Minya University","city":"Minya","country":"Egypt","cc":"EG","lat":28.10158,"lon":30.75874,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"61519","condg":["Other"],"nct":"NCT04508894","study":"Ketamine Versus Dexmedetomidine in Supraclavicular Brachial Plexus Block","sstatus":"COMPLETED","sponsor":"Minia University","official":"Haidy S Mansour, MD (assistant professor of Anesthesia and Surgical Intensive Care)","src":"https://clinicaltrials.gov/study/NCT04508894","phase":"N/A","enroll":75,"start":"2019-04-21","eid":"x:site:nct04508894-minya-university-minya"},{"id":"nct07824973-brain-stimulation-clinic-skaraborg-s-hospital-skovde","cat":"research","name":"Brain Stimulation Clinic, Skaraborg's Hospital","city":"Skövde","region":"Västra Götaland County","country":"Sweden","cc":"SE","lat":58.38247,"lon":13.83908,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"54160","condg":["Depression"],"nct":"NCT07824973","study":"Ketamine Treatment for Treatment-Resistant Depression - the Role of Framing","sstatus":"NOT_YET_RECRUITING","sponsor":"Valdemar Landgren","src":"https://clinicaltrials.gov/study/NCT07824973","contact":{"n":"Alexandra Leinonen, MD","p":"+46706371348","e":"alexandra.leinonen@gu.se"},"phase":"N/A","enroll":120,"start":"2026-09","eid":"x:site:nct07824973-brain-stimulation-clinic-skaraborg-s-hospital-skovde"},{"id":"nct03896230-hackensack-university-medical-center-hackensack","cat":"research","name":"Hackensack University Medical Center","city":"Hackensack","region":"New Jersey","country":"United States","cc":"US","lat":40.89755,"lon":-74.04738,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"07601","condg":["Chronic pain & headache"],"nct":"NCT03896230","study":"Ketamine for Pain in the Emergency Department","sstatus":"TERMINATED","sponsor":"Hackensack Meridian Health","src":"https://clinicaltrials.gov/study/NCT03896230","phase":"Phase 4","enroll":11,"start":"2019-05-03","eid":"x:site:nct03896230-hackensack-university-medical-center-hackensack"},{"id":"nct06732089-st-michael-s-hospital-unity-health-toronto-toronto","cat":"research","name":"St. Michael's Hospital, Unity Health Toronto","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70685,"lon":-79.39775,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M5B 1W8","condg":["Depression"],"status":"RECRUITING","nct":"NCT06732089","study":"Digital Interventions for Adults with Treatment-Resistant Depression: a Pilot Study","sstatus":"RECRUITING","sponsor":"Unity Health Toronto","official":"Dr. Srihar Krishnan, Ph.D., Peng., F.C.A.E. (Toronto Metropolitan University); Dr. Wendy Lou, Ph.D. (Dalla Lana School of Public Health, University of Toronto)","src":"https://clinicaltrials.gov/study/NCT06732089","contact":{"n":"Dr. Venkat Bhat, M.D., F.R.C.P.C.","p":"416-360-4000","e":"venkat.bhat@unityhealth.to"},"enroll":200,"start":"2024-12-16","eid":"x:site:nct06732089-st-michael-s-hospital-unity-health-toronto-toronto"},{"id":"nct07680140-weill-cornell-medicine-new-york","cat":"research","name":"Weill Cornell Medicine","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71912,"lon":-74.01693,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10065","condg":["Depression"],"status":"RECRUITING","nct":"NCT07680140","study":"Biomarker-Guided Antidepressant Selection","sstatus":"RECRUITING","sponsor":"Weill Medical College of Cornell University","official":"Conor Liston, MD, PhD (Weill Medical College of Cornell University)","src":"https://clinicaltrials.gov/study/NCT07680140","contact":{"n":"Research Coordinator, Interventional Psychiatry Program","p":"646-962-2900","e":"tmsinfo@med.cornell.edu"},"phase":"Phase 4","enroll":27,"start":"2026-08-10","eid":"x:site:nct07680140-weill-cornell-medicine-new-york"},{"id":"nct01955070-nationwide-childrens-columbus","cat":"research","name":"Nationwide Childrens","city":"Columbus","region":"Ohio","country":"United States","cc":"US","lat":39.95163,"lon":-82.98735,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"43205","condg":["Other"],"nct":"NCT01955070","study":"Use of a Multimedia Presentation for Informed Consent","sstatus":"COMPLETED","sponsor":"Nationwide Children's Hospital","official":"Sandra P Spencer, MD (Nationwide Childrens, Department of Emergency Medicine)","src":"https://clinicaltrials.gov/study/NCT01955070","phase":"N/A","enroll":184,"start":"2011-05","eid":"x:site:nct01955070-nationwide-childrens-columbus"},{"id":"nct01507181-icahn-school-of-medicine-at-mount-sinai-new-york","cat":"research","name":"Icahn School of Medicine at Mount Sinai","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72279,"lon":-73.99971,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10027","condg":["Other"],"nct":"NCT01507181","study":"Ketamine For Suicidal Ideation","sstatus":"COMPLETED","sponsor":"James Murrough","official":"James Murrough, MD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT01507181","phase":"Phase 4","enroll":24,"start":"2012-01","eid":"x:site:nct01507181-icahn-school-of-medicine-at-mount-sinai-new-york"},{"id":"nct05095792-heading-health-austin","cat":"research","name":"Heading Health","city":"Austin","region":"Texas","country":"United States","cc":"US","lat":30.26908,"lon":-97.74537,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"78746","condg":["Depression"],"nct":"NCT05095792","study":"Effect of Ketamine on Neurological Activity as Measured by Electroencephalogram (EEG)","sstatus":"TERMINATED","sponsor":"Entheon Biomedical Corp.","official":"Steven Levine, MD (Heading Health)","src":"https://clinicaltrials.gov/study/NCT05095792","enroll":1,"start":"2021-11-09","eid":"x:site:nct05095792-heading-health-austin"},{"id":"nct06001372-huntsman-cancer-institute-salt-lake-city","cat":"research","name":"Huntsman Cancer Institute","city":"Salt Lake City","region":"Utah","country":"United States","cc":"US","lat":40.75424,"lon":-111.88347,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"84108","condg":["Depression","Anxiety","Cancer-related distress"],"nct":"NCT06001372","study":"Ketamine-assisted Psychotherapy (KAP) for Patients With Existential Distress Associated With Non-operable GI Cancers","sstatus":"TERMINATED","sponsor":"University of Utah","official":"Benjamin Lewis, MD (Huntsman Cancer Institute)","src":"https://clinicaltrials.gov/study/NCT06001372","phase":"EARLY_Phase 1","enroll":2,"start":"2023-10-13","eid":"x:site:nct06001372-huntsman-cancer-institute-salt-lake-city"},{"id":"nct00978757-hospital-italiano-de-buenos-aires-buenos-aires","cat":"research","name":"Hospital Italiano de Buenos Aires","city":"Buenos Aires","country":"Argentina","cc":"AR","lat":-34.61188,"lon":-58.37841,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"1181","condg":["Other"],"nct":"NCT00978757","study":"The Effect of Ketamine on Interleukin-6 Synthesis in Hepatic Resections Requiring Temporary Porto-arterial Occlusion","sstatus":"COMPLETED","sponsor":"Hospital Italiano de Buenos Aires","official":"Francisco C Bonofiglio, MD PhD (Hospital Italiano of Buenos Aires, Argentina)","src":"https://clinicaltrials.gov/study/NCT00978757","phase":"Phase 4","enroll":42,"start":"2001-06","eid":"x:site:nct00978757-hospital-italiano-de-buenos-aires-buenos-aires"},{"id":"nct03842800-magnetic-resonance-research-center-new-haven","cat":"research","name":"Magnetic Resonance Research Center","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31121,"lon":-72.938,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06520-8043","condg":["Neurology & cognition"],"nct":"NCT03842800","study":"Characterizing Clinical and Pharmacological Neuroimaging Biomarkers","sstatus":"COMPLETED","sponsor":"Yale University","official":"Alan Anticevic, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT03842800","phase":"EARLY_Phase 1","enroll":143,"start":"2013-04-01","eid":"x:site:nct03842800-magnetic-resonance-research-center-new-haven"},{"id":"nct06414356-brooke-army-medical-center-san-antonio","cat":"research","name":"Brooke Army Medical Center","city":"San Antonio","region":"Texas","country":"United States","cc":"US","lat":29.42059,"lon":-98.50309,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"78234","condg":["PTSD & trauma","Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06414356","study":"The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD","sstatus":"RECRUITING","sponsor":"Margaux M. Salas, PhD","src":"https://clinicaltrials.gov/study/NCT06414356","contact":{"n":"Kevin Peterson, MD","p":"210-916-2888","e":"kevin.c.peterson3.mil@health.mil"},"phase":"Phase 4","enroll":30,"start":"2024-10-02","eid":"x:site:nct06414356-brooke-army-medical-center-san-antonio"},{"id":"nct01557712-centre-hospitalier-universitaire-grenoble","cat":"research","name":"Centre hospitalier universitaire","city":"Grenoble","country":"France","cc":"FR","lat":45.17102,"lon":5.70411,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"38000","condg":["Depression"],"nct":"NCT01557712","study":"Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks","sstatus":"COMPLETED","sponsor":"University Hospital, Grenoble","src":"https://clinicaltrials.gov/study/NCT01557712","phase":"Phase 3","enroll":25,"start":"2012-03","eid":"x:site:nct01557712-centre-hospitalier-universitaire-grenoble"},{"id":"nct06021756-scott-j-sherman-tucson","cat":"research","name":"Scott J Sherman","city":"Tucson","region":"Arizona","country":"United States","cc":"US","lat":32.21661,"lon":-110.91495,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"85724","condg":["Neurology & cognition"],"nct":"NCT06021756","study":"Phase I Open-label Study of Low-dose Ketamine Infusion Treatment in Levodopa-Induced Dyskinesia in Parkinson's Disease","sstatus":"UNKNOWN","sponsor":"University of Arizona","official":"Scott J Sherman (University of Arizona Health Sciences Center - Dep. of Neurology)","src":"https://clinicaltrials.gov/study/NCT06021756","phase":"Phase 1","enroll":9,"start":"2019-07-28","eid":"x:site:nct06021756-scott-j-sherman-tucson"},{"id":"nct03475277-stanford-psychiatry-palo-alto","cat":"research","name":"Stanford Psychiatry","city":"Palo Alto","region":"California","country":"United States","cc":"US","lat":37.43468,"lon":-122.15267,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94304","condg":["Healthy volunteers"],"nct":"NCT03475277","study":"Stanford Regulating Circuits of the Brain Study- Ketamine","sstatus":"COMPLETED","sponsor":"Stanford University","official":"Leanne M Williams, PhD (Study PI)","src":"https://clinicaltrials.gov/study/NCT03475277","enroll":13,"start":"2019-08-19","eid":"x:site:nct03475277-stanford-psychiatry-palo-alto"},{"id":"nct05870501-the-institute-of-psychiatry-psychology-neuroscience-king-s-college-l","cat":"research","name":"The Institute of Psychiatry, Psychology & Neuroscience, King's College London","city":"London","country":"United Kingdom","cc":"GB","lat":51.50114,"lon":-0.12212,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"SE5 8AF","condg":["Depression","Bipolar"],"nct":"NCT05870501","study":"Synaptic Imaging and Network Activity in Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"King's College London","official":"Mitul Mehta, PhD (King's College London)","src":"https://clinicaltrials.gov/study/NCT05870501","phase":"N/A","enroll":56,"start":"2021-10-20","eid":"x:site:nct05870501-the-institute-of-psychiatry-psychology-neuroscience-king-s-college-l"},{"id":"nct07273851-department-of-anesthesia-fauji-foundation-hospital-rawalpindi-pakist","cat":"research","name":"Department of Anesthesia, Fauji Foundation Hospital, Rawalpindi, Pakistan","city":"Rawalpindi","country":"Pakistan","cc":"PK","lat":33.60688,"lon":73.04494,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"nct":"NCT07273851","study":"Comparison of Propofol and Ketofol as Induction Agents for Electroconvulsive Therapy","sstatus":"COMPLETED","sponsor":"Fauji Foundation Hospital","src":"https://clinicaltrials.gov/study/NCT07273851","phase":"N/A","enroll":80,"start":"2025-07-01","eid":"x:site:nct07273851-department-of-anesthesia-fauji-foundation-hospital-rawalpindi-pakist"},{"id":"nct04763343-the-cleveland-clinic-cleveland","cat":"research","name":"The Cleveland Clinic","city":"Cleveland","region":"Ohio","country":"United States","cc":"US","lat":41.49785,"lon":-81.7043,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44195","condg":["Other"],"status":"RECRUITING","nct":"NCT04763343","study":"Ketamine Treatment of Youth Suicide Attempters","sstatus":"RECRUITING","sponsor":"Tatiana Falcone, MD","official":"Tatiana Falcone, M.D. (The Cleveland Clinic)","src":"https://clinicaltrials.gov/study/NCT04763343","contact":{"n":"Tatiana Falcone, M.D.","p":"216-444-7459","e":"falcont1@ccf.org"},"phase":"Phase 3","enroll":60,"start":"2022-06-27","eid":"x:site:nct04763343-the-cleveland-clinic-cleveland"},{"id":"nct03053830-va-healthcare-system-west-haven","cat":"research","name":"VA Healthcare System","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.2595,"lon":-72.95481,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06516","condg":["Depression"],"nct":"NCT03053830","study":"Open Label Ketamine Treatment for Major Depressive Disorder in Veterans","sstatus":"COMPLETED","sponsor":"VA Connecticut Healthcare System","src":"https://clinicaltrials.gov/study/NCT03053830","phase":"Phase 2","enroll":11,"start":"2017-01-31","eid":"x:site:nct03053830-va-healthcare-system-west-haven"},{"id":"nct00492388-beth-israel-deaconess-medical-center-boston","cat":"research","name":"Beth Israel Deaconess Medical Center","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.35584,"lon":-71.06245,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02115","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT00492388","study":"Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients","sstatus":"TERMINATED","sponsor":"Hospira, now a wholly owned subsidiary of Pfizer","official":"Zahid Bajwa, MD (Beth Israel Deaconess Medical Center)","src":"https://clinicaltrials.gov/study/NCT00492388","phase":"Phase 3","enroll":2,"start":"2007-06","eid":"x:site:nct00492388-beth-israel-deaconess-medical-center-boston"},{"id":"nct02866071-university-of-cincinnati-medical-center-cincinnati","cat":"research","name":"University of Cincinnati Medical Center","city":"Cincinnati","region":"Ohio","country":"United States","cc":"US","lat":39.12123,"lon":-84.51698,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45219","condg":["PTSD & trauma","Chronic pain & headache"],"nct":"NCT02866071","study":"Intranasal Ketamine as an Adjunct to Fentanyl for the Prehospital Treatment of Acute Traumatic Pain","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Jason McMullan","src":"https://clinicaltrials.gov/study/NCT02866071","phase":"Phase 3","enroll":224,"start":"2017-10-03","eid":"x:site:nct02866071-university-of-cincinnati-medical-center-cincinnati"},{"id":"nct01900847-university-of-arizona-health-network-university-campus-1501-north-ca","cat":"research","name":"University of Arizona Health Network University Campus 1501 North Campbell Ave","city":"Tucson","region":"Arizona","country":"United States","cc":"US","lat":32.22913,"lon":-110.93104,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"85724","condg":["Chronic pain & headache"],"nct":"NCT01900847","study":"Ketamine and Morphine Versus Morphine Alone for the Treatment of Acute Pain in the Emergency Department","sstatus":"TERMINATED","sponsor":"University of Arizona","src":"https://clinicaltrials.gov/study/NCT01900847","phase":"N/A","enroll":17,"start":"2013-06-01","eid":"x:site:nct01900847-university-of-arizona-health-network-university-campus-1501-north-ca"},{"id":"nct05019885-mount-sinai-hospital-new-york","cat":"research","name":"Mount Sinai Hospital","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70622,"lon":-73.99698,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10035","condg":["Neurology & cognition"],"nct":"NCT05019885","study":"The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy","sstatus":"COMPLETED","sponsor":"Madeline Fields","official":"Madeline Fields, MD (Icahn School of Medicine); Lara Marcuse, MD (Icahn School of Medicine)","src":"https://clinicaltrials.gov/study/NCT05019885","phase":"Phase 2","enroll":12,"start":"2022-08-26","eid":"x:site:nct05019885-mount-sinai-hospital-new-york"},{"id":"nct01951963-regions-hospital-saint-paul","cat":"research","name":"Regions Hospital","city":"Saint Paul","region":"Minnesota","country":"United States","cc":"US","lat":44.95622,"lon":-93.10245,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55101","condg":["Chronic pain & headache"],"nct":"NCT01951963","study":"Sub-dissociative Ketamine for the Management of Acute Pediatric Pain","sstatus":"COMPLETED","sponsor":"HealthPartners Institute","official":"Aaron M Burnett, MD (Regions Hospital)","src":"https://clinicaltrials.gov/study/NCT01951963","phase":"Phase 4","enroll":77,"start":"2012-12","eid":"x:site:nct01951963-regions-hospital-saint-paul"},{"id":"nct06496750-alameda-health-system-san-leandro","cat":"research","name":"Alameda Health System","city":"San Leandro","region":"California","country":"United States","cc":"US","lat":37.7166,"lon":-122.15029,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94578","condg":["Addiction & substance use"],"nct":"NCT06496750","study":"Ketamine for Methamphetamine Use Disorder","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","official":"Madhukar Trivedi, MD (Professor (Tenured))","src":"https://clinicaltrials.gov/study/NCT06496750","phase":"Phase 2","enroll":120,"start":"2024-09-11","eid":"x:site:nct06496750-alameda-health-system-san-leandro"},{"id":"nct06496750-interdisciplinary-substance-use-and-brain-injury-facility-albuquerqu","cat":"research","name":"Interdisciplinary Substance Use and Brain Injury Facility","city":"Albuquerque","region":"New Mexico","country":"United States","cc":"US","lat":35.07343,"lon":-106.64818,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"87106","condg":["Addiction & substance use"],"nct":"NCT06496750","study":"Ketamine for Methamphetamine Use Disorder","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","official":"Madhukar Trivedi, MD (Professor (Tenured))","src":"https://clinicaltrials.gov/study/NCT06496750","phase":"Phase 2","enroll":120,"start":"2024-09-11","eid":"x:site:nct06496750-interdisciplinary-substance-use-and-brain-injury-facility-albuquerqu"},{"id":"nct06496750-addiction-institute-of-mount-sinai-new-york","cat":"research","name":"Addiction Institute of Mount Sinai","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.721,"lon":-74.01345,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10029","condg":["Addiction & substance use"],"nct":"NCT06496750","study":"Ketamine for Methamphetamine Use Disorder","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","official":"Madhukar Trivedi, MD (Professor (Tenured))","src":"https://clinicaltrials.gov/study/NCT06496750","phase":"Phase 2","enroll":120,"start":"2024-09-11","eid":"x:site:nct06496750-addiction-institute-of-mount-sinai-new-york"},{"id":"nct06496750-prisma-health-greenville","cat":"research","name":"Prisma Health","city":"Greenville","region":"South Carolina","country":"United States","cc":"US","lat":35.60367,"lon":-77.36188,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"29617","condg":["Addiction & substance use"],"nct":"NCT06496750","study":"Ketamine for Methamphetamine Use Disorder","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","official":"Madhukar Trivedi, MD (Professor (Tenured))","src":"https://clinicaltrials.gov/study/NCT06496750","phase":"Phase 2","enroll":120,"start":"2024-09-11","eid":"x:site:nct06496750-prisma-health-greenville"},{"id":"nct06496750-ut-southwestern-medical-center-dallas","cat":"research","name":"UT Southwestern Medical Center","city":"Dallas","region":"Texas","country":"United States","cc":"US","lat":32.78725,"lon":-96.81312,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75247","condg":["Addiction & substance use"],"nct":"NCT06496750","study":"Ketamine for Methamphetamine Use Disorder","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","official":"Madhukar Trivedi, MD (Professor (Tenured))","src":"https://clinicaltrials.gov/study/NCT06496750","phase":"Phase 2","enroll":120,"start":"2024-09-11","eid":"x:site:nct06496750-ut-southwestern-medical-center-dallas"},{"id":"nct04650074-department-of-orthopedic-surgery-and-trauma-emergencies-of-the-lower","cat":"research","name":"Department of orthopedic surgery and trauma emergencies of the lower limb, Edouard Herriot Hospital, Hospices Civils de Lyon","city":"Lyon","country":"France","cc":"FR","lat":45.75221,"lon":4.83645,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"69437","condg":["Chronic pain & headache"],"nct":"NCT04650074","study":"Effectiveness of Ketamine Administered by Mesotherapy in Complex Regional Pain Syndrome Type 1 (CRPS1)","sstatus":"COMPLETED","sponsor":"Hospices Civils de Lyon","src":"https://clinicaltrials.gov/study/NCT04650074","phase":"Phase 2/Phase 3","enroll":31,"start":"2021-11-05","eid":"x:site:nct04650074-department-of-orthopedic-surgery-and-trauma-emergencies-of-the-lower"},{"id":"nct03679390-national-taiwan-university-hospital-taipei","cat":"research","name":"National Taiwan University Hospital","city":"Taipei","country":"Taiwan","cc":"TW","lat":25.06214,"lon":121.51552,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT03679390","study":"The Electroencephalogram and Clinical Effect of Ketamine","sstatus":"TERMINATED","sponsor":"National Taiwan University Hospital","src":"https://clinicaltrials.gov/study/NCT03679390","phase":"N/A","enroll":17,"start":"2017-03-01","eid":"x:site:nct03679390-national-taiwan-university-hospital-taipei"},{"id":"nct00520169-javelin-pharmaceuticals-cambridge","cat":"research","name":"Javelin Pharmaceuticals","city":"Cambridge","region":"Massachusetts","country":"United States","cc":"US","lat":42.37204,"lon":-71.10349,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02140","condg":["Healthy volunteers"],"nct":"NCT00520169","study":"Absolute Bioavailability and Nasopharyngeal Absorption of Intranasal Ketamine","sstatus":"COMPLETED","sponsor":"Javelin Pharmaceuticals","official":"Javelin Pharmaceuticals (Javelin Pharmaceuticals)","src":"https://clinicaltrials.gov/study/NCT00520169","phase":"Phase 1","enroll":32,"start":"2007-07","eid":"x:site:nct00520169-javelin-pharmaceuticals-cambridge"},{"id":"nct03415191-alfonso-fiorelli-naples","cat":"research","name":"Alfonso Fiorelli","city":"Naples","country":"Italy","cc":"IT","lat":40.84148,"lon":14.26543,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"84100","condg":["Chronic pain & headache"],"nct":"NCT03415191","study":"The Pre-Emptive Administration Of Ketamine for Controlling Post-thoracotomy Pain","sstatus":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","official":"Alfonso Fiorelli, MD, PhD (University of Campania Luigi Vanvitelli)","src":"https://clinicaltrials.gov/study/NCT03415191","phase":"N/A","enroll":75,"start":"2012-01-05","eid":"x:site:nct03415191-alfonso-fiorelli-naples"},{"id":"nct02363270-maimonides-medical-center-brooklyn","cat":"research","name":"Maimonides Medical Center","city":"Brooklyn","region":"New York","country":"United States","cc":"US","lat":40.64601,"lon":-73.95584,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11219","condg":["Chronic pain & headache"],"nct":"NCT02363270","study":"Ketamine: Comparison of IV Push vs. IV Drip","sstatus":"COMPLETED","sponsor":"Antonios Likourezos","official":"Sergey Motov, MD (Maimonides Medical Center); John Marshall, MD (Maimonides Medical Center)","src":"https://clinicaltrials.gov/study/NCT02363270","phase":"N/A","enroll":48,"start":"2015-04-01","eid":"x:site:nct02363270-maimonides-medical-center-brooklyn"},{"id":"nct07801703-the-royal-ottawa","cat":"research","name":"The Royal","city":"Ottawa","region":"Ontario","country":"Canada","cc":"CA","lat":45.42082,"lon":-75.69205,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"K1Z 7K4","condg":["Depression"],"nct":"NCT07801703","study":"Behavioural Activation Therapy and Ketamine for Treatment-Resistant Depression","sstatus":"NOT_YET_RECRUITING","sponsor":"The Royal's Institute of Mental Health Research","official":"Jeanne Talbot, MD, PhD (The University of Ottawa Institute of Mental Health Research (IMHR) at The Royal); Jennifer Phillips, PhD (The University of Ottawa Institute of Mental Health Research (IMHR) at The Royal)","src":"https://clinicaltrials.gov/study/NCT07801703","contact":{"n":"Research Coordinator","p":"613-722-6521","e":"suwojcik@theroyal.ca"},"phase":"Phase 2/Phase 3","enroll":60,"start":"2026-09","eid":"x:site:nct07801703-the-royal-ottawa"},{"id":"nct03973268-national-institutes-of-health-clinical-center-bethesda","cat":"research","name":"National Institutes of Health Clinical Center","city":"Bethesda","region":"Maryland","country":"United States","cc":"US","lat":38.97658,"lon":-77.10285,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20892","condg":["Depression"],"status":"RECRUITING","nct":"NCT03973268","study":"Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression","sstatus":"RECRUITING","sponsor":"National Institute of Mental Health (NIMH)","official":"Carlos A Zarate, M.D. (National Institute of Mental Health (NIMH))","src":"https://clinicaltrials.gov/study/NCT03973268","contact":{"n":"NIH Clinical Center Office of Patient Recruitment (OPR)","p":"800-411-1222","e":"ccopr@nih.gov"},"phase":"Phase 1","enroll":70,"start":"2020-01-21","eid":"x:site:nct03973268-national-institutes-of-health-clinical-center-bethesda"},{"id":"nct04205890-neurological-associates-of-west-los-angeles-santa-monica","cat":"research","name":"Neurological Associates of West Los Angeles","city":"Santa Monica","region":"California","country":"United States","cc":"US","lat":34.01643,"lon":-118.47976,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"90403","condg":["Depression"],"nct":"NCT04205890","study":"Intravenous Ketamine Effects on Functional Neuroanatomy","sstatus":"WITHDRAWN","sponsor":"Neurological Associates of West Los Angeles","official":"Sheldon Jordan, MD (The Neurological Associates of West Los Angeles); Taylor Kuhn, PhD (The Neurological Associates of West Los Angeles)","src":"https://clinicaltrials.gov/study/NCT04205890","phase":"Phase 1","start":"2020-05-02","eid":"x:site:nct04205890-neurological-associates-of-west-los-angeles-santa-monica"},{"id":"nct01070108-tel-aviv-medical-center-tel-aviv","cat":"research","name":"Tel Aviv Medical Center","city":"Tel Aviv","country":"Israel","cc":"IL","lat":32.0701,"lon":34.7921,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Chronic pain & headache"],"nct":"NCT01070108","study":"Escalating Ketamine Doses and Pre-emption","sstatus":"COMPLETED","sponsor":"Tel-Aviv Sourasky Medical Center","src":"https://clinicaltrials.gov/study/NCT01070108","phase":"N/A","enroll":120,"start":"2007-01","eid":"x:site:nct01070108-tel-aviv-medical-center-tel-aviv"},{"id":"nct02078817-university-of-minnesota-minneapolis","cat":"research","name":"University of Minnesota","city":"Minneapolis","region":"Minnesota","country":"United States","cc":"US","lat":44.97776,"lon":-93.27433,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55454","condg":["Depression"],"nct":"NCT02078817","study":"Ketamine in Adolescents With Treatment-Resistant Depression","sstatus":"COMPLETED","sponsor":"University of Minnesota","src":"https://clinicaltrials.gov/study/NCT02078817","phase":"Phase 2","enroll":14,"start":"2014-09","eid":"x:site:nct02078817-university-of-minnesota-minneapolis"},{"id":"nct03960658-minneapolis-va-medical-center-minneapolis","cat":"research","name":"Minneapolis VA Medical Center","city":"Minneapolis","region":"Minnesota","country":"United States","cc":"US","lat":44.98849,"lon":-93.25344,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55417","condg":["PTSD & trauma"],"nct":"NCT03960658","study":"Ketamine and Prolonged Exposure in PTSD","sstatus":"COMPLETED","sponsor":"Minneapolis Veterans Affairs Medical Center","official":"Paulo R Shiroma, MD (Minneapolis Veterans Affairs Medical Center)","src":"https://clinicaltrials.gov/study/NCT03960658","phase":"Phase 1/Phase 2","enroll":12,"start":"2019-04-03","eid":"x:site:nct03960658-minneapolis-va-medical-center-minneapolis"},{"id":"nct05049343-sage-investigational-site-newark","cat":"research","name":"Sage Investigational Site","city":"Newark","region":"New Jersey","country":"United States","cc":"US","lat":40.7311,"lon":-74.18126,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"07103","condg":["Healthy volunteers"],"nct":"NCT05049343","study":"Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants","sstatus":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","src":"https://clinicaltrials.gov/study/NCT05049343","phase":"Phase 1","enroll":22,"start":"2021-09-21","eid":"x:site:nct05049343-sage-investigational-site-newark"},{"id":"nct05071352-cairo-university-hospitals-kasr-alainy-cairo","cat":"research","name":"Cairo University Hospitals (Kasr Alainy)","city":"Cairo","country":"Egypt","cc":"EG","lat":30.06164,"lon":31.25489,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT05071352","study":"Adjuvant Continuous Infusion of Nefopam Versus Standard of Care in Mechanically Ventilated Critically Ill Patients: Randomized Double-blind Controlled Study","sstatus":"COMPLETED","sponsor":"Cairo University","official":"Mohammed Gamal Abdelraouf Amer, Pharm D (Cairo University)","src":"https://clinicaltrials.gov/study/NCT05071352","phase":"Phase 3","enroll":60,"start":"2021-10-01","eid":"x:site:nct05071352-cairo-university-hospitals-kasr-alainy-cairo"},{"id":"nct00146926-gregoire-chatain-lyon","cat":"research","name":"Grégoire CHATAIN","city":"Lyon","country":"France","cc":"FR","lat":45.7381,"lon":4.84304,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"69495","condg":["Other"],"nct":"NCT00146926","study":"Comparison of Three Different Strategies to Prevent Propofol Induced Pain During Infusion","sstatus":"UNKNOWN","sponsor":"Hospices Civils de Lyon","official":"Vincent PIRIOU, MD (Hospices Civils de Lyon)","src":"https://clinicaltrials.gov/study/NCT00146926","phase":"Phase 3","enroll":200,"start":"2005-09","eid":"x:site:nct00146926-gregoire-chatain-lyon"},{"id":"nct02258204-chu-caen-caen","cat":"research","name":"CHU Caen","city":"Caen","country":"France","cc":"FR","lat":49.19427,"lon":-0.35201,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT02258204","study":"Ketamine for Thrombolysis in Acute Ischemic Stroke","sstatus":"UNKNOWN","sponsor":"University Hospital, Caen","src":"https://clinicaltrials.gov/study/NCT02258204","contact":{"n":"Emmanuel Touzé, MD PhD","p":"+33231064624","e":"touze-e@chu-caen.fr"},"phase":"Phase 1/Phase 2","enroll":50,"start":"2015-03","eid":"x:site:nct02258204-chu-caen-caen"},{"id":"nct02652507-cincinnati-children-s-hospital-medical-center-cincinnati","cat":"research","name":"Cincinnati Children's Hospital Medical Center","city":"Cincinnati","region":"Ohio","country":"United States","cc":"US","lat":39.12264,"lon":-84.50531,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45229","condg":["Other"],"nct":"NCT02652507","study":"Dexmedetomidine and Ketamine in MRI","sstatus":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","official":"Mohamed Mahmoud, MD (Children's Hospital Medical Center, Cincinnati)","src":"https://clinicaltrials.gov/study/NCT02652507","phase":"Phase 1","enroll":22,"start":"2016-06","eid":"x:site:nct02652507-cincinnati-children-s-hospital-medical-center-cincinnati"},{"id":"nct05786833-nada-maged-shaheen-tanta","cat":"research","name":"Nada Maged Shaheen","city":"Tanta","region":"El-Gharbia","country":"Egypt","cc":"EG","lat":30.78268,"lon":30.99378,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"31527","condg":["Other"],"status":"RECRUITING","nct":"NCT05786833","study":"Dexmedetomidine vs Ketofol on Delirium in Children Undergoing Congenital Inguinal Hernia Repair","sstatus":"UNKNOWN","sponsor":"Tanta University","src":"https://clinicaltrials.gov/study/NCT05786833","contact":{"n":"Nada M Shaheen, Master","p":"+201006151953","e":"nada169730_pg@med.tanta.edu.eg"},"phase":"N/A","enroll":60,"start":"2023-03-20","eid":"x:site:nct05786833-nada-maged-shaheen-tanta"},{"id":"nct02950233-cleveland-clinic-cleveland","cat":"research","name":"Cleveland Clinic","city":"Cleveland","region":"Ohio","country":"United States","cc":"US","lat":41.49494,"lon":-81.69546,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44106","condg":["Chronic pain & headache"],"nct":"NCT02950233","study":"Preventing pAIn With NMDA Antagonists - Steroids in Thoracoscopic lObectomy Procedures (PAIN-STOP) Pilot Trial","sstatus":"TERMINATED","sponsor":"Population Health Research Institute","official":"PJ Devereaux, MD, PhD (McMaster University)","src":"https://clinicaltrials.gov/study/NCT02950233","phase":"Phase 3","enroll":27,"start":"2017-05-04","eid":"x:site:nct02950233-cleveland-clinic-cleveland"},{"id":"nct02950233-st-joseph-s-healthcare-hamilton","cat":"research","name":"St. Joseph's Healthcare","city":"Hamilton","region":"Ontario","country":"Canada","cc":"CA","lat":43.25646,"lon":-79.83791,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"L8N4A6","condg":["Chronic pain & headache"],"nct":"NCT02950233","study":"Preventing pAIn With NMDA Antagonists - Steroids in Thoracoscopic lObectomy Procedures (PAIN-STOP) Pilot Trial","sstatus":"TERMINATED","sponsor":"Population Health Research Institute","official":"PJ Devereaux, MD, PhD (McMaster University)","src":"https://clinicaltrials.gov/study/NCT02950233","phase":"Phase 3","enroll":27,"start":"2017-05-04","eid":"x:site:nct02950233-st-joseph-s-healthcare-hamilton"},{"id":"nct06575075-stanford-university-school-of-medicine-palo-alto","cat":"research","name":"Stanford University School of Medicine","city":"Palo Alto","region":"California","country":"United States","cc":"US","lat":37.43195,"lon":-122.14514,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94305","condg":["OCD"],"status":"RECRUITING","nct":"NCT06575075","study":"Pilot Study of RR-HNK in OCD","sstatus":"RECRUITING","sponsor":"Carolyn Rodriguez","official":"Carolyn Rodriguez, MD, PhD (Stanford University)","src":"https://clinicaltrials.gov/study/NCT06575075","contact":{"n":"Daniel Bello, BS","p":"650-723-4095","e":"ocdresearch@stanford.edu"},"phase":"Phase 1/Phase 2","enroll":45,"start":"2026-01-23","eid":"x:site:nct06575075-stanford-university-school-of-medicine-palo-alto"},{"id":"nct06969937-psychiatric-university-zurich-university-of-zurich-zurich","cat":"research","name":"Psychiatric University Zurich, University of Zurich","city":"Zurich","country":"Switzerland","cc":"CH","lat":47.36314,"lon":8.54845,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"8032","condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT06969937","study":"Ketamine and Neurofeedback as Combined Therapeutic Interventions to Target Glutamatergic Neurotransmission in Alcohol Use Disorder","sstatus":"RECRUITING","sponsor":"Dr. med. Marcus Herdener","src":"https://clinicaltrials.gov/study/NCT06969937","contact":{"n":"Marcus Herdener, PD Dr. med.","p":"+41583845810","e":"marcus.herdener@bli.uzh.ch"},"phase":"Phase 2","enroll":75,"start":"2025-06-01","eid":"x:site:nct06969937-psychiatric-university-zurich-university-of-zurich-zurich"},{"id":"nct03631875-mahdia-university-hospital-mahdia","cat":"research","name":"Mahdia University Hospital","city":"Mahdia","country":"Tunisia","cc":"TN","lat":35.49488,"lon":11.06048,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"5100","condg":["Other"],"nct":"NCT03631875","study":"Co-induction Ketamine-propofol: Effects on Laryngeal Mask Airway Insertion Conditions in Children","sstatus":"COMPLETED","sponsor":"University Hospital, Mahdia","official":"ali majdoub, professor (Ministery of Health)","src":"https://clinicaltrials.gov/study/NCT03631875","phase":"Phase 4","enroll":120,"start":"2019-05-01","eid":"x:site:nct03631875-mahdia-university-hospital-mahdia"},{"id":"nct02442739-cedars-sinai-medical-center-los-angeles","cat":"research","name":"Cedars-Sinai Medical Center","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.06385,"lon":-118.23206,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"90048","condg":["Depression","Cancer-related distress"],"nct":"NCT02442739","study":"Ketamine for Preventing Depression in Patients Undergoing Treatment for Pancreatic or Head and Neck Cancers","sstatus":"WITHDRAWN","sponsor":"Cedars-Sinai Medical Center","official":"Scott Irwin, MD, PhD (Cedars-Sinal Medical Center)","src":"https://clinicaltrials.gov/study/NCT02442739","phase":"EARLY_Phase 1","start":"2016-08-15","eid":"x:site:nct02442739-cedars-sinai-medical-center-los-angeles"},{"id":"nct03095222-university-of-kansas-medical-center-kansas-city","cat":"research","name":"University of Kansas Medical Center","city":"Kansas City","region":"Kansas","country":"United States","cc":"US","lat":39.10928,"lon":-94.57118,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"66160","condg":["Chronic pain & headache"],"nct":"NCT03095222","study":"Exploring the Safety and Efficacy of Low-dose Ketamine Infusions for Pain Control in Acute Burn Injury","sstatus":"WITHDRAWN","sponsor":"University of Kansas Medical Center","official":"Andrea Nicol, MD (University of Kansas Medical Center)","src":"https://clinicaltrials.gov/study/NCT03095222","phase":"Phase 4","start":"2017-04-01","eid":"x:site:nct03095222-university-of-kansas-medical-center-kansas-city"},{"id":"nct06429657-brooke-army-medical-center-fort-sam-houston","cat":"research","name":"Brooke Army Medical Center","city":"Fort Sam Houston","region":"Texas","country":"United States","cc":"US","lat":29.41523,"lon":-98.5045,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"78234","condg":["PTSD & trauma","Neurology & cognition"],"nct":"NCT06429657","study":"Ketamine for Sedation in Severe Traumatic Brain Injury","sstatus":"SUSPENDED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","official":"Bradley Dengler, MD (Uniformed Services University of the Health Sciences)","src":"https://clinicaltrials.gov/study/NCT06429657","phase":"Phase 4","enroll":50,"start":"2024-09-23","eid":"x:site:nct06429657-brooke-army-medical-center-fort-sam-houston"},{"id":"nct06111339-brigham-and-women-s-hospital-boston","cat":"research","name":"Brigham and Women's Hospital","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36215,"lon":-71.05492,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02115","condg":["Addiction & substance use"],"nct":"NCT06111339","study":"Ketamine for OUD and Suicidal Ideation in the ED","sstatus":"TERMINATED","sponsor":"Brigham and Women's Hospital","src":"https://clinicaltrials.gov/study/NCT06111339","phase":"Phase 2","enroll":4,"start":"2024-06-14","eid":"x:site:nct06111339-brigham-and-women-s-hospital-boston"},{"id":"nct05906121-department-of-anaesthesiology-university-hospital-of-basel-usb-basel","cat":"research","name":"Department of Anaesthesiology, University Hospital of Basel (USB)","city":"Basel","country":"Switzerland","cc":"CH","lat":47.5638,"lon":7.57369,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"4031","condg":["Chronic pain & headache"],"nct":"NCT05906121","study":"Lidocaine and Ketamine Levels in Plasma After Simultaneous Lidocaine/Ketamine Infusions","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Wilhelm Ruppen, Prof. (Department of Anaesthesiology, University Hospital of Basel (USB))","src":"https://clinicaltrials.gov/study/NCT05906121","enroll":15,"start":"2023-05-16","eid":"x:site:nct05906121-department-of-anaesthesiology-university-hospital-of-basel-usb-basel"},{"id":"nct02651792-al-rajhy-liver-hospital-asyut","cat":"research","name":"Al Rajhy liver hospital","city":"Asyut","country":"Egypt","cc":"EG","lat":27.18054,"lon":31.17582,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"71515","condg":["Other"],"nct":"NCT02651792","study":"Ketamine- Propofol Versus Pethidine- Propofol in ERCP","sstatus":"COMPLETED","sponsor":"Assiut University","official":"Mostafa S Abbas, MD (Assiut University)","src":"https://clinicaltrials.gov/study/NCT02651792","phase":"Phase 2","enroll":50,"start":"2015-01","eid":"x:site:nct02651792-al-rajhy-liver-hospital-asyut"},{"id":"nct01880593-icahn-school-of-medicine-at-mount-sinai-new-york","cat":"research","name":"Icahn School of Medicine at Mount Sinai","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72081,"lon":-73.99491,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10029","condg":["Depression"],"nct":"NCT01880593","study":"Ketamine Plus Lithium in Treatment-Resistant Depression","sstatus":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","official":"James W Murrough, MD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT01880593","phase":"Phase 2","enroll":34,"start":"2013-07","eid":"x:site:nct01880593-icahn-school-of-medicine-at-mount-sinai-new-york"},{"id":"nct03146806-winship-cancer-institute-atlanta","cat":"research","name":"Winship Cancer Institute","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.76053,"lon":-84.3917,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"30322","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT03146806","study":"Intranasal (NAS) Ketamine for Cancer Pain","sstatus":"COMPLETED","sponsor":"Emory University","official":"Vinita Singh, MD (Emory University)","src":"https://clinicaltrials.gov/study/NCT03146806","phase":"Phase 1/Phase 2","enroll":10,"start":"2017-07-25","eid":"x:site:nct03146806-winship-cancer-institute-atlanta"},{"id":"nct01749098-pfizer-investigational-site-new-haven","cat":"research","name":"Pfizer Investigational Site","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.30669,"lon":-72.93856,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06511","condg":["Other"],"nct":"NCT01749098","study":"A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers","sstatus":"COMPLETED","sponsor":"Biogen","official":"Medical Director (Biogen)","src":"https://clinicaltrials.gov/study/NCT01749098","phase":"Phase 1","enroll":29,"start":"2012-12","eid":"x:site:nct01749098-pfizer-investigational-site-new-haven"},{"id":"nct01749098-pfizer-investigational-site-west-haven","cat":"research","name":"Pfizer Investigational Site","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.28152,"lon":-72.94493,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06516","condg":["Other"],"nct":"NCT01749098","study":"A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers","sstatus":"COMPLETED","sponsor":"Biogen","official":"Medical Director (Biogen)","src":"https://clinicaltrials.gov/study/NCT01749098","phase":"Phase 1","enroll":29,"start":"2012-12","eid":"x:site:nct01749098-pfizer-investigational-site-west-haven"},{"id":"nct02673372-maimonides-medical-center-brooklyn","cat":"research","name":"Maimonides Medical Center","city":"Brooklyn","region":"New York","country":"United States","cc":"US","lat":40.65099,"lon":-73.95857,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11219","condg":["Chronic pain & headache"],"nct":"NCT02673372","study":"Geriatric Ketamine for Pain Management Study","sstatus":"COMPLETED","sponsor":"Antonios Likourezos","official":"Sergey Motov, MD (Maimonides Medical Center)","src":"https://clinicaltrials.gov/study/NCT02673372","phase":"Phase 4","enroll":60,"start":"2016-04","eid":"x:site:nct02673372-maimonides-medical-center-brooklyn"},{"id":"nct01997801-seoul-national-university-hospital-seoul","cat":"research","name":"Seoul National University Hospital","city":"Seoul","country":"South Korea","cc":"KR","lat":37.57047,"lon":126.97628,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"110-744","condg":["Chronic pain & headache"],"nct":"NCT01997801","study":"Ketamine in Robot-assisted Thyroidectomy","sstatus":"UNKNOWN","sponsor":"Seoul National University Hospital","official":"Hee-Pyoung Park, PhD (Seoul National University of Hospital)","src":"https://clinicaltrials.gov/study/NCT01997801","contact":{"n":"Hee-Pyoung Park, PhD","p":"+82-10-2971-7647","e":"hppark@snu.ac.kr"},"phase":"N/A","enroll":64,"start":"2013-12","eid":"x:site:nct01997801-seoul-national-university-hospital-seoul"},{"id":"nct05661669-brigham-and-women-s-faulkner-hospital-boston","cat":"research","name":"Brigham and Women's Faulkner Hospital","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36055,"lon":-71.0585,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02130","condg":["Addiction & substance use"],"nct":"NCT05661669","study":"Ketamine for the Treatment for Alcohol Use Disorder in the ED","sstatus":"WITHDRAWN","sponsor":"Brigham and Women's Hospital","src":"https://clinicaltrials.gov/study/NCT05661669","phase":"Phase 2","start":"2023-09-01","eid":"x:site:nct05661669-brigham-and-women-s-faulkner-hospital-boston"},{"id":"nct03513822-raymond-poincare-hospital-garches","cat":"research","name":"Raymond Poincaré Hospital","city":"Garches","region":"Hauts De Seine","country":"France","cc":"FR","lat":48.84297,"lon":2.17079,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"92380","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT03513822","study":"Ketamine's Efficiency in the Treatment of Chronic Pain: Kynurenin Pathway","sstatus":"UNKNOWN","sponsor":"Redar","official":"Didier Bouhassira, Md, PhD (INSERM U987)","src":"https://clinicaltrials.gov/study/NCT03513822","contact":{"n":"Cyril QUEMENEUR, Resident","p":"0033681193981","e":"c.quemeneur@gmx.com"},"phase":"Phase 3","enroll":48,"start":"2018-02-16","eid":"x:site:nct03513822-raymond-poincare-hospital-garches"},{"id":"nct04485702-wwct-san-antonio","cat":"research","name":"WWCT","city":"San Antonio","region":"Texas","country":"United States","cc":"US","lat":29.41278,"lon":-98.50271,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"78217","condg":["Healthy volunteers"],"nct":"NCT04485702","study":"Phase 1 Bioavailability Study of MELT-100 (Midazolam and Ketamine Sublingual) and IV Midazolam or Ketamine","sstatus":"COMPLETED","sponsor":"Melt Pharmaceuticals","official":"Cynthia Zamora, MD (Worldwide Clinical Trials)","src":"https://clinicaltrials.gov/study/NCT04485702","phase":"Phase 1","enroll":17,"start":"2020-07-20","eid":"x:site:nct04485702-wwct-san-antonio"},{"id":"nct01100255-new-york-state-psychiatric-institute-new-york","cat":"research","name":"New York State Psychiatric Institute","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71112,"lon":-73.99802,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10032","condg":["OCD"],"nct":"NCT01100255","study":"Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD)","sstatus":"COMPLETED","sponsor":"New York State Psychiatric Institute","official":"Carolyn I. Rodriguez, M.D., Ph.D. (Columbia-NYSPI-RFMH)","src":"https://clinicaltrials.gov/study/NCT01100255","phase":"Phase 2","enroll":15,"start":"2010-04","eid":"x:site:nct01100255-new-york-state-psychiatric-institute-new-york"},{"id":"nct06402955-yale-university-new-haven","cat":"research","name":"Yale University","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31526,"lon":-72.91644,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06520","condg":["Depression","Neurology & cognition"],"status":"RECRUITING","nct":"NCT06402955","study":"Imaging Depression in Parkinson's Disease","sstatus":"RECRUITING","sponsor":"Yale University","src":"https://clinicaltrials.gov/study/NCT06402955","contact":{"n":"Sophie Holmes, PhD","p":"203-685-4066","e":"sophie.holmes@yale.edu"},"phase":"Phase 2","enroll":120,"start":"2024-09-01","eid":"x:site:nct06402955-yale-university-new-haven"},{"id":"nct02659085-department-of-psychiatry-lund","cat":"research","name":"Department of Psychiatry","city":"Lund","country":"Sweden","cc":"SE","lat":55.69516,"lon":13.19279,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"221 85","condg":["Depression"],"nct":"NCT02659085","study":"Ketamine as an Alternative Treatment to ECT in Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Pouya Movahed Rad","official":"Pouya Movahed Rad, MD, PhD (Dept of Clinical Sciences Lund, Faculty of Medicine Lund University, Sweden)","src":"https://clinicaltrials.gov/study/NCT02659085","phase":"Phase 2/Phase 3","enroll":198,"start":"2015-02","eid":"x:site:nct02659085-department-of-psychiatry-lund"},{"id":"nct04022226-university-of-new-mexico-mental-health-center-albuquerque","cat":"research","name":"University of New Mexico Mental Health Center","city":"Albuquerque","region":"New Mexico","country":"United States","cc":"US","lat":35.08463,"lon":-106.65872,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"87106","condg":["Depression"],"nct":"NCT04022226","study":"EEG Characteristics in ECT","sstatus":"COMPLETED","sponsor":"University of New Mexico","src":"https://clinicaltrials.gov/study/NCT04022226","phase":"EARLY_Phase 1","enroll":11,"start":"2019-10-01","eid":"x:site:nct04022226-university-of-new-mexico-mental-health-center-albuquerque"},{"id":"nct05137938-centre-for-addiction-and-mental-health-toronto","cat":"research","name":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70798,"lon":-79.39577,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M5T 1R8","condg":["Depression"],"nct":"NCT05137938","study":"Intranasal Ketamine in Ultra-REsistant Depression (SURE-ECT Non Responders)","sstatus":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","official":"Yuliya Knyahnytska, MD, PhD (Centre for Addiction and Mental Health)","src":"https://clinicaltrials.gov/study/NCT05137938","phase":"N/A","enroll":25,"start":"2021-10-25","eid":"x:site:nct05137938-centre-for-addiction-and-mental-health-toronto"},{"id":"nct00768430-mount-sinai-school-of-medicine-new-york","cat":"research","name":"Mount Sinai School of Medicine","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70519,"lon":-74.00301,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10029","condg":["Depression"],"nct":"NCT00768430","study":"Optimization of IV Ketamine for Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Baylor College of Medicine","official":"Sanjay J. Mathew, MD (Baylor College of Medicine); Dan V Iosifescu, MD,M.Sc. (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT00768430","phase":"Phase 2","enroll":73,"start":"2008-11","eid":"x:site:nct00768430-mount-sinai-school-of-medicine-new-york"},{"id":"nct00768430-michael-e-dabakey-va-medical-center-baylor-college-of-medicine-houst","cat":"research","name":"Michael E. Dabakey VA Medical Center & Baylor College of Medicine","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.76963,"lon":-95.36398,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"77030","condg":["Depression"],"nct":"NCT00768430","study":"Optimization of IV Ketamine for Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"Baylor College of Medicine","official":"Sanjay J. Mathew, MD (Baylor College of Medicine); Dan V Iosifescu, MD,M.Sc. (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT00768430","phase":"Phase 2","enroll":73,"start":"2008-11","eid":"x:site:nct00768430-michael-e-dabakey-va-medical-center-baylor-college-of-medicine-houst"},{"id":"nct05288764-ulss-2-marca-trevigiana-treviso","cat":"research","name":"ULSS 2 Marca Trevigiana","city":"Treviso","region":"Tv","country":"Italy","cc":"IT","lat":45.65548,"lon":12.252,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"31100","condg":["Other"],"nct":"NCT05288764","study":"Effect of Ketamine on BIS Values","sstatus":"COMPLETED","sponsor":"University of Padova","src":"https://clinicaltrials.gov/study/NCT05288764","enroll":14,"start":"2022-03-31","eid":"x:site:nct05288764-ulss-2-marca-trevigiana-treviso"},{"id":"nct00232492-department-of-oral-and-maxillofacial-surgery-ullevaal-university-hos","cat":"research","name":"Department of Oral and Maxillofacial Surgery, Ullevaal University Hospital","city":"Oslo","country":"Norway","cc":"NO","lat":59.91861,"lon":10.74745,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"NO-0407","condg":["Other"],"nct":"NCT00232492","study":"Ketamine on Acute Pain in Females and Males","sstatus":"COMPLETED","sponsor":"Ullevaal University Hospital","official":"Lasse A Skoglund, DDS, PhD (Section of Dental Pharmacology and Pharmacotherapy, Faculty of Dentistry, POB 1119 Blindern, University of Oslo, N-0317 Oslo, Norway); Olav Hustveit, MD (Section of Dental Pharmacology and Pharmacotherapy, Faculty of Dentistry, POB 1119 Blindern, University of Oslo, N-0317 Oslo, Norway)","src":"https://clinicaltrials.gov/study/NCT00232492","phase":"Phase 4","enroll":128,"start":"2005-01","eid":"x:site:nct00232492-department-of-oral-and-maxillofacial-surgery-ullevaal-university-hos"},{"id":"nct02611921-cincinnati-childrens-hospital-medical-center-cincinnati","cat":"research","name":"Cincinnati Childrens Hospital Medical Center","city":"Cincinnati","region":"Ohio","country":"United States","cc":"US","lat":39.12499,"lon":-84.51594,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"45229","condg":["Other"],"nct":"NCT02611921","study":"Study of Intranasal Ketamine for Social Impairment in Autism Spectrum Disorder","sstatus":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","official":"Logan K Wink, MD (Children's Hospital Medical Center, Cincinnati)","src":"https://clinicaltrials.gov/study/NCT02611921","phase":"Phase 1","enroll":21,"start":"2015-12-22","eid":"x:site:nct02611921-cincinnati-childrens-hospital-medical-center-cincinnati"},{"id":"nct02579928-hospital-research-unit-at-the-yale-new-haven-hospital-new-haven","cat":"research","name":"Hospital Research Unit at the Yale New Haven Hospital","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31563,"lon":-72.9331,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06510","condg":["Depression","Anxiety"],"nct":"NCT02579928","study":"Ketamine Infusion for Adolescent Depression and Anxiety","sstatus":"COMPLETED","sponsor":"Yale University","official":"Michael H. Bloch, MD MS (Yale University)","src":"https://clinicaltrials.gov/study/NCT02579928","phase":"Phase 4","enroll":17,"start":"2015-10","eid":"x:site:nct02579928-hospital-research-unit-at-the-yale-new-haven-hospital-new-haven"},{"id":"nct02579928-yale-child-study-center-new-haven","cat":"research","name":"Yale Child Study Center","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.29643,"lon":-72.93037,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"06520","condg":["Depression","Anxiety"],"nct":"NCT02579928","study":"Ketamine Infusion for Adolescent Depression and Anxiety","sstatus":"COMPLETED","sponsor":"Yale University","official":"Michael H. Bloch, MD MS (Yale University)","src":"https://clinicaltrials.gov/study/NCT02579928","phase":"Phase 4","enroll":17,"start":"2015-10","eid":"x:site:nct02579928-yale-child-study-center-new-haven"},{"id":"nct05809609-department-of-psychiatry-university-of-oxford-oxford","cat":"research","name":"Department of Psychiatry, University of Oxford","city":"Oxford","country":"United Kingdom","cc":"GB","lat":51.74304,"lon":-1.2641,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"status":"RECRUITING","nct":"NCT05809609","study":"Glutamate Emotion Memory Study","sstatus":"UNKNOWN","sponsor":"University of Oxford","official":"Catherine Harmer, DPhil (University of Oxford)","src":"https://clinicaltrials.gov/study/NCT05809609","contact":{"n":"Catherine J Harmer, DPhil","p":"+44 (0)1865 618326","e":"catherine.harmer@psych.ox.ac.uk"},"phase":"N/A","enroll":60,"start":"2022-07-01","eid":"x:site:nct05809609-department-of-psychiatry-university-of-oxford-oxford"},{"id":"nct05615948-maimonides-medical-center-brooklyn","cat":"research","name":"Maimonides Medical Center","city":"Brooklyn","region":"New York","country":"United States","cc":"US","lat":40.64026,"lon":-73.95104,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11219","condg":["Depression"],"nct":"NCT05615948","study":"Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression","sstatus":"COMPLETED","sponsor":"Theresa Jacob, PhD, MPH","official":"Theresa Jacob, PhD, MPH (Maimonides Medical Center)","src":"https://clinicaltrials.gov/study/NCT05615948","phase":"Phase 4","enroll":15,"start":"2022-12-06","eid":"x:site:nct05615948-maimonides-medical-center-brooklyn"},{"id":"nct03458143-erasme-university-hospital-brussels","cat":"research","name":"Erasme University Hospital","city":"Brussels","country":"Belgium","cc":"BE","lat":50.86151,"lon":4.3428,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"1070","condg":["Depression"],"status":"RECRUITING","nct":"NCT03458143","study":"Respiratory Depression During an Analgosedation Combining Remifentanil and Ketamine in TCI for Oocyte Retrieval","sstatus":"UNKNOWN","sponsor":"Erasme University Hospital","official":"Peres-Bota Iulia, student (Erasme University Hospital); Barvais Luc, MDPhD (Erasme University Hospital)","src":"https://clinicaltrials.gov/study/NCT03458143","contact":{"n":"Luc Barvais, phd","p":"+3225553919","e":"Luc.Barvais@erasme.ulb.ac.be"},"enroll":20,"start":"2018-02-12","eid":"x:site:nct03458143-erasme-university-hospital-brussels"},{"id":"nct01870219-turgut-ozal-medical-center-malatya","cat":"research","name":"Turgut Ozal Medical Center","city":"Malatya","country":"Turkey","cc":"TR","lat":38.35051,"lon":38.31098,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44315","condg":["Depression"],"nct":"NCT01870219","study":"Effects of Sevoflurane and Ketamine on QT in Electroconvulsive Therapy","sstatus":"COMPLETED","sponsor":"Inonu University","official":"Feray Erdil, MD (Associated Prof Dr)","src":"https://clinicaltrials.gov/study/NCT01870219","phase":"Phase 4","enroll":24,"start":"2012-02","eid":"x:site:nct01870219-turgut-ozal-medical-center-malatya"},{"id":"nct01146145-hopital-louis-mourier-colombes","cat":"research","name":"Hopital Louis Mourier","city":"Colombes","country":"France","cc":"FR","lat":48.92969,"lon":2.24675,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"92700","condg":["Chronic pain & headache"],"nct":"NCT01146145","study":"Efficacity, Safety and Cost of Intravenous Morphine Titration Alone or Combined to Ketamine","sstatus":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","official":"Hawa Keita (Assistance Publique - Hôpitaux de Paris)","src":"https://clinicaltrials.gov/study/NCT01146145","phase":"N/A","enroll":160,"start":"2003-05","eid":"x:site:nct01146145-hopital-louis-mourier-colombes"},{"id":"nct05768477-az-st-lucas-ghent","cat":"research","name":"AZ St Lucas","city":"Ghent","country":"Belgium","cc":"BE","lat":51.05776,"lon":3.71013,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"9000","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT05768477","study":"Different Treatments in Chronic Pain Patients.","sstatus":"RECRUITING","sponsor":"University Ghent","official":"Jessica Van Oosterwijck (Department of Rehabilitation Sciences, Faculty of Health Sciences, Ghent University, Belgium)","src":"https://clinicaltrials.gov/study/NCT05768477","contact":{"n":"Elise Cnockaert","p":"+32 9 332 69 19","e":"Elise.Cnockaert@azstlucas.be"},"enroll":1000,"start":"2023-04-06","eid":"x:site:nct05768477-az-st-lucas-ghent"},{"id":"nct06608277-anesthesiology-pain-medicine-center-chicago","cat":"research","name":"Anesthesiology Pain Medicine Center","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.85714,"lon":-87.64163,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60611","condg":["PTSD & trauma","Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06608277","study":"Ketamine, SGB and Combination Treatment for TBI-associated Headache or PTSD","sstatus":"RECRUITING","sponsor":"Northwestern University","official":"Steven Cohen, MD (Northwestern University)","src":"https://clinicaltrials.gov/study/NCT06608277","contact":{"n":"Jordan Wood","p":"312-695-0915","e":"jordan.wood1@northwestern.edu"},"phase":"Phase 2","enroll":175,"start":"2025-07-02","eid":"x:site:nct06608277-anesthesiology-pain-medicine-center-chicago"},{"id":"nct06608277-walter-reed-national-military-medical-center-bethesda","cat":"research","name":"Walter Reed National Military Medical Center","city":"Bethesda","region":"Maryland","country":"United States","cc":"US","lat":38.98185,"lon":-77.10981,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20889","condg":["PTSD & trauma","Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06608277","study":"Ketamine, SGB and Combination Treatment for TBI-associated Headache or PTSD","sstatus":"RECRUITING","sponsor":"Northwestern University","official":"Steven Cohen, MD (Northwestern University)","src":"https://clinicaltrials.gov/study/NCT06608277","contact":{"n":"Elsa Ermer, PhD","p":"301-550-0507","e":"crsr_research@usuhs.edu"},"phase":"Phase 2","enroll":175,"start":"2025-07-02","eid":"x:site:nct06608277-walter-reed-national-military-medical-center-bethesda"},{"id":"nct06608277-womack-army-medical-center-fort-bragg","cat":"research","name":"Womack Army Medical Center","city":"Fort Bragg","region":"North Carolina","country":"United States","cc":"US","lat":35.15025,"lon":-79.00429,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"28310","condg":["PTSD & trauma","Chronic pain & headache"],"status":"NOT_YET_RECRUITING","nct":"NCT06608277","study":"Ketamine, SGB and Combination Treatment for TBI-associated Headache or PTSD","sstatus":"RECRUITING","sponsor":"Northwestern University","official":"Steven Cohen, MD (Northwestern University)","src":"https://clinicaltrials.gov/study/NCT06608277","contact":{"n":"Min H Chang, MD","p":"910-643-2310","e":"min.h.chang.mil@health.mil"},"phase":"Phase 2","enroll":175,"start":"2025-07-02","eid":"x:site:nct06608277-womack-army-medical-center-fort-bragg"},{"id":"nct04150757-jacobi-medical-center-the-bronx","cat":"research","name":"Jacobi Medical Center","city":"The Bronx","region":"New York","country":"United States","cc":"US","lat":40.86016,"lon":-73.87229,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10461","condg":["Chronic pain & headache"],"nct":"NCT04150757","study":"Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the PED","sstatus":"TERMINATED","sponsor":"Abigail Nixon","src":"https://clinicaltrials.gov/study/NCT04150757","phase":"Phase 3","enroll":5,"start":"2019-12-19","eid":"x:site:nct04150757-jacobi-medical-center-the-bronx"},{"id":"nct04150757-jacobi-the-bronx","cat":"research","name":"JACOBI","city":"The Bronx","region":"New York","country":"United States","cc":"US","lat":40.85169,"lon":-73.8625,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10461","condg":["Chronic pain & headache"],"nct":"NCT04150757","study":"Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the PED","sstatus":"TERMINATED","sponsor":"Abigail Nixon","src":"https://clinicaltrials.gov/study/NCT04150757","phase":"Phase 3","enroll":5,"start":"2019-12-19","eid":"x:site:nct04150757-jacobi-the-bronx"},{"id":"nct01309581-icahn-school-of-medicine-at-mount-sinai-new-york","cat":"research","name":"Icahn School of Medicine at Mount Sinai","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72523,"lon":-74.01185,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10029","condg":["Depression","Bipolar"],"nct":"NCT01309581","study":"Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in Depression","sstatus":"TERMINATED","sponsor":"James Murrough","official":"James W Murrough, MD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT01309581","phase":"N/A","enroll":3,"start":"2010-04","eid":"x:site:nct01309581-icahn-school-of-medicine-at-mount-sinai-new-york"},{"id":"nct04576637-rabin-medical-center-beilinson-campus-petah-tikva","cat":"research","name":"Rabin Medical Center/Beilinson Campus","city":"Petah Tikva","country":"Israel","cc":"IL","lat":32.0874,"lon":34.89392,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"49100","condg":["Other"],"status":"RECRUITING","nct":"NCT04576637","study":"Neurophysiological Monitoring and Videolaryngoscopy","sstatus":"UNKNOWN","sponsor":"Rabin Medical Center","official":"Leonid O Eidelman (Rabin Medical Center)","src":"https://clinicaltrials.gov/study/NCT04576637","contact":{"n":"Binyamin Yafa Zerbi, M.D.","p":"97239376850","e":"leidelman@clalit.org.il"},"phase":"N/A","enroll":20,"start":"2020-10-21","eid":"x:site:nct04576637-rabin-medical-center-beilinson-campus-petah-tikva"},{"id":"nct01548703-pra-international-zuidlaren","cat":"research","name":"PRA International","city":"Zuidlaren","country":"Netherlands","cc":"NL","lat":53.09968,"lon":6.68707,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"9471 GP","condg":["Healthy volunteers"],"nct":"NCT01548703","study":"A Multiple Ascending Dose Study of BCI-838 in Healthy Volunteers","sstatus":"COMPLETED","sponsor":"BrainCells Inc.","official":"Salah Hadi, MD (PRA Health Sciences)","src":"https://clinicaltrials.gov/study/NCT01548703","phase":"Phase 1","enroll":30,"start":"2012-02","eid":"x:site:nct01548703-pra-international-zuidlaren"},{"id":"nct07095842-department-of-pediatrics-at-sohag-university-hospital-sohag","cat":"research","name":"Department of Pediatrics at Sohag University Hospital","city":"Sohag","country":"Egypt","cc":"EG","lat":26.55455,"lon":31.69078,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"82524","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT07095842","study":"Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)","sstatus":"RECRUITING","sponsor":"Sohag University","src":"https://clinicaltrials.gov/study/NCT07095842","contact":{"n":"Abdelrahim A Sadek, MD, PhD","p":"1114232126","e":"abdoneurology@yahoo.com"},"phase":"Phase 2/Phase 3","enroll":668,"start":"2025-08-03","eid":"x:site:nct07095842-department-of-pediatrics-at-sohag-university-hospital-sohag"},{"id":"nct03336541-department-of-anesthesiology-and-critical-care-medicine-peking-unive","cat":"research","name":"Department of Anesthesiology and Critical Care Medicine, Peking University First Hospital","city":"Beijing","region":"Beijing Municipality","country":"China","cc":"CN","lat":39.91894,"lon":116.39492,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"100034","condg":["Depression"],"nct":"NCT03336541","study":"Low-dose Ketamine and Postpartum Depression in Parturients With Prenatal Depression","sstatus":"COMPLETED","sponsor":"Peking University First Hospital","official":"Dong-Xin Wang, MD, PhD (Peking University First Hospital)","src":"https://clinicaltrials.gov/study/NCT03336541","phase":"Phase 4","enroll":64,"start":"2017-11-23","eid":"x:site:nct03336541-department-of-anesthesiology-and-critical-care-medicine-peking-unive"},{"id":"nct07810023-endeavor-health-evanston-hospital-evanston","cat":"research","name":"Endeavor Health Evanston Hospital","city":"Evanston","region":"Illinois","country":"United States","cc":"US","lat":42.02952,"lon":-87.69688,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60201","condg":["Depression"],"nct":"NCT07810023","study":"Intramuscular Ketamine for Suicidal Patients in the Evanston Hospital Emergency Department for Suicidal Distress","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Endeavor Health","src":"https://clinicaltrials.gov/study/NCT07810023","phase":"N/A","enroll":8,"start":"2026-09-10","eid":"x:site:nct07810023-endeavor-health-evanston-hospital-evanston"},{"id":"nct02360280-minneapolis-va-health-care-system-minneapolis-mn-minneapolis","cat":"research","name":"Minneapolis VA Health Care System, Minneapolis, MN","city":"Minneapolis","region":"Minnesota","country":"United States","cc":"US","lat":44.98425,"lon":-93.2684,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55417-2309","condg":["Depression"],"nct":"NCT02360280","study":"Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"VA Office of Research and Development","official":"Paulo R Shiroma, MD (Minneapolis VA Health Care System, Minneapolis, MN)","src":"https://clinicaltrials.gov/study/NCT02360280","phase":"Phase 2","enroll":62,"start":"2015-04-01","eid":"x:site:nct02360280-minneapolis-va-health-care-system-minneapolis-mn-minneapolis"},{"id":"nct06559826-icahn-school-of-medicine-at-mount-sinai-new-york","cat":"research","name":"Icahn School of Medicine at Mount Sinai","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71695,"lon":-74.01176,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10029","condg":["Depression"],"status":"RECRUITING","nct":"NCT06559826","study":"Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression","sstatus":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","official":"James Murrough, MD, PhD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT06559826","contact":{"n":"James Murrough, MD, PhD","p":"212-241-6539","e":"james.murrough@mssm.edu"},"phase":"Phase 2","enroll":70,"start":"2025-01-10","eid":"x:site:nct06559826-icahn-school-of-medicine-at-mount-sinai-new-york"},{"id":"nct06069843-icahn-school-of-medicine-at-mount-sinai-depression-and-anxiety-cente","cat":"research","name":"Icahn School of Medicine at Mount Sinai (Depression and Anxiety Center)","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72288,"lon":-73.99642,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10029","condg":["Depression","Neurology & cognition"],"nct":"NCT06069843","study":"Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","official":"Rachel Fremont, MD, PhD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT06069843","phase":"Phase 2","enroll":15,"start":"2024-11-01","eid":"x:site:nct06069843-icahn-school-of-medicine-at-mount-sinai-depression-and-anxiety-cente"},{"id":"nct02752724-va-puget-sound-health-care-system-seattle","cat":"research","name":"VA Puget Sound Health Care System","city":"Seattle","region":"Washington","country":"United States","cc":"US","lat":47.60795,"lon":-122.33071,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"98108","condg":["Depression"],"nct":"NCT02752724","study":"Ketamine Anesthesia for Improvement of Depression in ECT","sstatus":"COMPLETED","sponsor":"VA Puget Sound Health Care System","official":"Anna Borisovskaya, MD (Puget Sound VA Medical Center, Dept of Psychiatry); Irene Rozet, MD (Puget Sound VA Medical Center, Dept of Anesthesiology)","src":"https://clinicaltrials.gov/study/NCT02752724","phase":"N/A","enroll":52,"start":"2016-03","eid":"x:site:nct02752724-va-puget-sound-health-care-system-seattle"},{"id":"nct01938079-newyork-presbyterian-hospital-new-york","cat":"research","name":"NewYork-Presbyterian Hospital","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72523,"lon":-73.9967,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10032","condg":["Other"],"nct":"NCT01938079","study":"Pharmacokinetic Alterations During ECMO","sstatus":"COMPLETED","sponsor":"Columbia University","official":"Daniel Brodie, MD (Columbia University)","src":"https://clinicaltrials.gov/study/NCT01938079","phase":"N/A","enroll":20,"start":"2013-09","eid":"x:site:nct01938079-newyork-presbyterian-hospital-new-york"},{"id":"nct00419003-mount-sinai-school-of-medicine-new-york","cat":"research","name":"Mount Sinai School of Medicine","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71074,"lon":-74.00677,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10029","condg":["Depression"],"nct":"NCT00419003","study":"Research Study for Major Depressive Disorder: Investigation of Glutamate Medications","sstatus":"COMPLETED","sponsor":"Baylor College of Medicine","official":"Sanjay Mathew, MD (Baylor College of Medicine)","src":"https://clinicaltrials.gov/study/NCT00419003","phase":"Phase 4","enroll":26,"start":"2006-12","eid":"x:site:nct00419003-mount-sinai-school-of-medicine-new-york"},{"id":"nct03000413-hospital-nossa-senhora-da-conceicao-porto-alegre","cat":"research","name":"Hospital Nossa Senhora da Conceição","city":"Porto Alegre","country":"Brazil","cc":"BR","lat":-30.02544,"lon":-51.2357,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT03000413","study":"Ketamine Efficacy for Acute Severe Bronchospasm in ICU: MACANUDO Trial","sstatus":"COMPLETED","sponsor":"Hospital Nossa Senhora da Conceicao","src":"https://clinicaltrials.gov/study/NCT03000413","phase":"Phase 2/Phase 3","enroll":45,"start":"2015-06-04","eid":"x:site:nct03000413-hospital-nossa-senhora-da-conceicao-porto-alegre"},{"id":"nct01613820-depression-clinical-and-reseach-program-mgh-boston","cat":"research","name":"Depression Clinical and Reseach Program - MGH","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.35349,"lon":-71.06998,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02114","condg":["Depression"],"nct":"NCT01613820","study":"Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder","sstatus":"WITHDRAWN","sponsor":"Massachusetts General Hospital","official":"Cristina Cusin, M.D. (MGH Department of Psychiatry)","src":"https://clinicaltrials.gov/study/NCT01613820","phase":"N/A","start":"2015-09","eid":"x:site:nct01613820-depression-clinical-and-reseach-program-mgh-boston"},{"id":"nct03469089-university-of-eastern-finland-clinical-research-centre-brain-researc","cat":"research","name":"University of Eastern Finland, Clinical Research Centre, Brain Research Unit","city":"Kuopio","country":"Finland","cc":"FI","lat":62.88546,"lon":27.67811,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"70210","condg":["Neurology & cognition"],"nct":"NCT03469089","study":"Touchscreen-based Cognitive Tests in Healthy Volunteers","sstatus":"UNKNOWN","sponsor":"University of Eastern Finland","official":"Markus M Forsberg, PhD (University of Eastern Finland)","src":"https://clinicaltrials.gov/study/NCT03469089","phase":"Phase 1","enroll":16,"start":"2018-03-12","eid":"x:site:nct03469089-university-of-eastern-finland-clinical-research-centre-brain-researc"},{"id":"nct02562820-cleveland-clinic-cleveland","cat":"research","name":"Cleveland Clinic","city":"Cleveland","region":"Ohio","country":"United States","cc":"US","lat":41.50905,"lon":-81.70459,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44195","condg":["Other"],"nct":"NCT02562820","study":"An Exploratory Trial of Ketamine for the Treatment of Rett Syndrome","sstatus":"TERMINATED","sponsor":"The Cleveland Clinic","official":"Daniel Sessler, MD (The Cleveland Clinic)","src":"https://clinicaltrials.gov/study/NCT02562820","phase":"Phase 1","enroll":4,"start":"2015-11","eid":"x:site:nct02562820-cleveland-clinic-cleveland"},{"id":"nct06179485-university-of-alabama-hospital-birmingham","cat":"research","name":"University of Alabama Hospital","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.52899,"lon":-86.80574,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"35233","condg":["PTSD & trauma"],"nct":"NCT06179485","study":"Effect of Ketamine and Etomidate During RSI on Long Term Outcomes","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","src":"https://clinicaltrials.gov/study/NCT06179485","enroll":1756,"start":"2022-04-06","eid":"x:site:nct06179485-university-of-alabama-hospital-birmingham"},{"id":"nct06179485-university-of-colorado-denver-aurora","cat":"research","name":"University of Colorado Denver","city":"Aurora","region":"Colorado","country":"United States","cc":"US","lat":39.73964,"lon":-104.82161,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"80045","condg":["PTSD & trauma"],"nct":"NCT06179485","study":"Effect of Ketamine and Etomidate During RSI on Long Term Outcomes","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","src":"https://clinicaltrials.gov/study/NCT06179485","enroll":1756,"start":"2022-04-06","eid":"x:site:nct06179485-university-of-colorado-denver-aurora"},{"id":"nct06179485-denver-health-medical-center-denver","cat":"research","name":"Denver Health Medical Center","city":"Denver","region":"Colorado","country":"United States","cc":"US","lat":39.73101,"lon":-104.97458,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"80204","condg":["PTSD & trauma"],"nct":"NCT06179485","study":"Effect of Ketamine and Etomidate During RSI on Long Term Outcomes","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","src":"https://clinicaltrials.gov/study/NCT06179485","enroll":1756,"start":"2022-04-06","eid":"x:site:nct06179485-denver-health-medical-center-denver"},{"id":"nct06179485-hennepin-county-medical-center-minneapolis","cat":"research","name":"Hennepin County Medical Center","city":"Minneapolis","region":"Minnesota","country":"United States","cc":"US","lat":44.97418,"lon":-93.26088,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55415","condg":["PTSD & trauma"],"nct":"NCT06179485","study":"Effect of Ketamine and Etomidate During RSI on Long Term Outcomes","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","src":"https://clinicaltrials.gov/study/NCT06179485","enroll":1756,"start":"2022-04-06","eid":"x:site:nct06179485-hennepin-county-medical-center-minneapolis"},{"id":"nct06179485-wake-forest-baptist-medical-center-winston-salem","cat":"research","name":"Wake Forest Baptist Medical Center","city":"Winston-Salem","region":"North Carolina","country":"United States","cc":"US","lat":36.0985,"lon":-80.2502,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"27157","condg":["PTSD & trauma"],"nct":"NCT06179485","study":"Effect of Ketamine and Etomidate During RSI on Long Term Outcomes","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","src":"https://clinicaltrials.gov/study/NCT06179485","enroll":1756,"start":"2022-04-06","eid":"x:site:nct06179485-wake-forest-baptist-medical-center-winston-salem"},{"id":"nct06179485-vanderbilt-university-medical-center-nashville","cat":"research","name":"Vanderbilt University Medical Center","city":"Nashville","region":"Tennessee","country":"United States","cc":"US","lat":36.17554,"lon":-86.77442,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"37203","condg":["PTSD & trauma"],"nct":"NCT06179485","study":"Effect of Ketamine and Etomidate During RSI on Long Term Outcomes","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","src":"https://clinicaltrials.gov/study/NCT06179485","enroll":1756,"start":"2022-04-06","eid":"x:site:nct06179485-vanderbilt-university-medical-center-nashville"},{"id":"nct05625555-mood-disorders-program-halifax","cat":"research","name":"Mood Disorders Program","city":"Halifax","region":"Nova Scotia","country":"Canada","cc":"CA","lat":44.64424,"lon":-63.56827,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"B3H2E2","condg":["Depression","Bipolar"],"nct":"NCT05625555","study":"Predictors of Intravenous Ketamine Response in TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Abraham Nunes","official":"Abraham Nunes, MD PhD MBA FRCPC (Nova Scotia Health Authority)","src":"https://clinicaltrials.gov/study/NCT05625555","phase":"Phase 3","enroll":40,"start":"2024-01-19","eid":"x:site:nct05625555-mood-disorders-program-halifax"},{"id":"nct01827020-turgut-ozal-medical-center-malatya","cat":"research","name":"Turgut Ozal Medical Center","city":"Malatya","country":"Turkey","cc":"TR","lat":38.36049,"lon":38.32321,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"44315","condg":["Other"],"nct":"NCT01827020","study":"Effect of Ketamine Addition to Lidocaine in Rhinoplasty","sstatus":"COMPLETED","sponsor":"Inonu University","official":"Mukadder Sanli, MD (Turgut Ozal Medical Center)","src":"https://clinicaltrials.gov/study/NCT01827020","phase":"Phase 4","enroll":90,"start":"2013-01","eid":"x:site:nct01827020-turgut-ozal-medical-center-malatya"},{"id":"nct06994559-montreal-general-hospital-montreal","cat":"research","name":"Montreal General Hospital","city":"Montreal","region":"Quebec","country":"Canada","cc":"CA","lat":45.50917,"lon":-73.59087,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"H3G 1A4","condg":["Cancer-related distress","Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06994559","study":"Music as an Adjunct to Ketamine Therapy for Chronic Pain","sstatus":"RECRUITING","sponsor":"McGill University","official":"Mark A Ware, MD (McGill University Health Centre/Research Institute of the McGill University Health Centre); Mathieu Roy, PhD (McGill University)","src":"https://clinicaltrials.gov/study/NCT06994559","contact":{"n":"Mark A Ware, MD","p":"+1-5149348222","e":"mark.ware@mcgill.ca"},"phase":"N/A","enroll":25,"start":"2025-06-01","eid":"x:site:nct06994559-montreal-general-hospital-montreal"},{"id":"nct05690503-new-york-state-psychiatric-institute-new-york","cat":"research","name":"New York State Psychiatric Institute","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71949,"lon":-74.01157,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10032","condg":["Depression","Neurology & cognition"],"nct":"NCT05690503","study":"Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"New York State Psychiatric Institute","official":"Saleena Subaiya, MD (New York State Psychiatric Institute); Elias Dakwar, MD (New York State Psychiatric Institute)","src":"https://clinicaltrials.gov/study/NCT05690503","phase":"Phase 2","enroll":12,"start":"2023-03-20","eid":"x:site:nct05690503-new-york-state-psychiatric-institute-new-york"},{"id":"nct04928703-hassman-research-institute-marlton","cat":"research","name":"Hassman Research Institute","city":"Marlton","region":"New Jersey","country":"United States","cc":"US","lat":39.89023,"lon":-74.93317,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"08053","condg":["Healthy volunteers"],"nct":"NCT04928703","study":"Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers","sstatus":"COMPLETED","sponsor":"ERP Biomarker Qualification Consortium","official":"Marco Cecchi, PhD (The ERP Biomarker Qualification Consortium)","src":"https://clinicaltrials.gov/study/NCT04928703","phase":"EARLY_Phase 1","enroll":33,"start":"2022-05-26","eid":"x:site:nct04928703-hassman-research-institute-marlton"},{"id":"nct06185127-naval-hospital-athens","cat":"research","name":"Naval Hospital","city":"Athens","region":"Attica","country":"Greece","cc":"GR","lat":37.97825,"lon":23.72262,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"15561","condg":["Other"],"nct":"NCT06185127","study":"Dexmedetomidine-ketamine Combination Versus Fentanyl-midazolam During Bronchoscopy","sstatus":"COMPLETED","sponsor":"University of Patras","official":"Sotirios Fouzas, MD, PhD (University of Patras)","src":"https://clinicaltrials.gov/study/NCT06185127","phase":"Phase 3","enroll":50,"start":"2019-09-01","eid":"x:site:nct06185127-naval-hospital-athens"},{"id":"nct02974010-research-site-birmingham-birmingham","cat":"research","name":"Research Site, Birmingham","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.51337,"lon":-86.81449,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"35294","condg":["Depression","Bipolar"],"nct":"NCT02974010","study":"Sequential Therapy for the Treatment of Severe Bipolar Depression.","sstatus":"COMPLETED","sponsor":"NeuroRx, Inc.","official":"Andrew Nierenberg, MD (Massachusetts General Hospital); Daniel C Javitt, MD (NeuroRx, Inc.)","src":"https://clinicaltrials.gov/study/NCT02974010","phase":"Phase 2","enroll":22,"start":"2018-01-15","eid":"x:site:nct02974010-research-site-birmingham-birmingham"},{"id":"nct02974010-research-site-fort-lauderdale-fort-lauderdale","cat":"research","name":"Research Site, Fort Lauderdale","city":"Fort Lauderdale","region":"Florida","country":"United States","cc":"US","lat":26.11539,"lon":-80.1471,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"33024","condg":["Depression","Bipolar"],"nct":"NCT02974010","study":"Sequential Therapy for the Treatment of Severe Bipolar Depression.","sstatus":"COMPLETED","sponsor":"NeuroRx, Inc.","official":"Andrew Nierenberg, MD (Massachusetts General Hospital); Daniel C Javitt, MD (NeuroRx, Inc.)","src":"https://clinicaltrials.gov/study/NCT02974010","phase":"Phase 2","enroll":22,"start":"2018-01-15","eid":"x:site:nct02974010-research-site-fort-lauderdale-fort-lauderdale"},{"id":"nct02974010-research-site-charlotte-charlotte","cat":"research","name":"Research Site, Charlotte","city":"Charlotte","region":"North Carolina","country":"United States","cc":"US","lat":35.23231,"lon":-80.83781,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"28211","condg":["Depression","Bipolar"],"nct":"NCT02974010","study":"Sequential Therapy for the Treatment of Severe Bipolar Depression.","sstatus":"COMPLETED","sponsor":"NeuroRx, Inc.","official":"Andrew Nierenberg, MD (Massachusetts General Hospital); Daniel C Javitt, MD (NeuroRx, Inc.)","src":"https://clinicaltrials.gov/study/NCT02974010","phase":"Phase 2","enroll":22,"start":"2018-01-15","eid":"x:site:nct02974010-research-site-charlotte-charlotte"},{"id":"nct02974010-research-site-houston-houston","cat":"research","name":"Research Site, Houston","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.77387,"lon":-95.35729,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"77030","condg":["Depression","Bipolar"],"nct":"NCT02974010","study":"Sequential Therapy for the Treatment of Severe Bipolar Depression.","sstatus":"COMPLETED","sponsor":"NeuroRx, Inc.","official":"Andrew Nierenberg, MD (Massachusetts General Hospital); Daniel C Javitt, MD (NeuroRx, Inc.)","src":"https://clinicaltrials.gov/study/NCT02974010","phase":"Phase 2","enroll":22,"start":"2018-01-15","eid":"x:site:nct02974010-research-site-houston-houston"},{"id":"nct06781697-sunnybrook-health-sciences-centre-toronto","cat":"research","name":"Sunnybrook Health Sciences Centre","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70544,"lon":-79.40556,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M4N 3M5","condg":["Depression"],"status":"RECRUITING","nct":"NCT06781697","study":"InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression","sstatus":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","src":"https://clinicaltrials.gov/study/NCT06781697","contact":{"n":"Fahad Alam, MD","p":"(416) 480-4864","e":"fahad.alam@sunnybrook.ca"},"phase":"Phase 3","enroll":31,"start":"2026-05-03","eid":"x:site:nct06781697-sunnybrook-health-sciences-centre-toronto"},{"id":"nct06070090-cardea-ketamine-space-new-york","cat":"research","name":"Cardea Ketamine Space","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70556,"lon":-74.00413,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10013","condg":["Other"],"nct":"NCT06070090","study":"Tapping in Together: A Pilot Study on Group Acupuncture for Ketamine Experience Integration","sstatus":"COMPLETED","sponsor":"Academy of Oriental Medicine Austin","official":"William Morris, PhD, DAOM (Academy of Oriental Medicine Austin)","src":"https://clinicaltrials.gov/study/NCT06070090","phase":"N/A","enroll":15,"start":"2023-10-09","eid":"x:site:nct06070090-cardea-ketamine-space-new-york"},{"id":"nct02924090-health-sciences-centre-winnipeg","cat":"research","name":"Health Sciences Centre","city":"Winnipeg","region":"Manitoba","country":"Canada","cc":"CA","lat":49.89518,"lon":-97.13862,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"R3A 1R9","condg":["Depression"],"status":"RECRUITING","nct":"NCT02924090","study":"Hyperventilation Combined With Etomidate or Ketamine Anesthesia in ECT Treatment of Major Depression","sstatus":"UNKNOWN","sponsor":"University of Manitoba","official":"Ian McIntyre, MD, MSc (University of Manitoba); Michael Harrington, MD (University of Manitoba)","src":"https://clinicaltrials.gov/study/NCT02924090","contact":{"n":"Ian McIntyre, MD, MSc","p":"204 787-2560","e":"ian.mcintyre@umanitoba.ca"},"phase":"Phase 4","enroll":48,"start":"2016-09","eid":"x:site:nct02924090-health-sciences-centre-winnipeg"},{"id":"nct04621110-itaci-instituto-de-tratamento-do-cancer-infantil-icr-hcfmusp-sao-pau","cat":"research","name":"ITACI - Instituto de Tratamento do Câncer Infantil/ ICR HCFMUSP","city":"São Paulo","country":"Brazil","cc":"BR","lat":-23.53569,"lon":-46.64143,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"05410-030","condg":["Cancer-related distress","Chronic pain & headache"],"nct":"NCT04621110","study":"Intranasal Versus Intravenous Drug in Painful Procedure for Outpatient Oncologic Participants","sstatus":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","src":"https://clinicaltrials.gov/study/NCT04621110","contact":{"n":"Clarissa A Archanjo, M.D.","p":"+5511964593842","e":"clarissa.archanjo@yahoo.com.br"},"phase":"Phase 3","enroll":60,"start":"2021-06-01","eid":"x:site:nct04621110-itaci-instituto-de-tratamento-do-cancer-infantil-icr-hcfmusp-sao-pau"},{"id":"nct05193318-medical-university-of-south-carolina-centerspace-charleston","cat":"research","name":"Medical University of South Carolina Centerspace","city":"Charleston","region":"South Carolina","country":"United States","cc":"US","lat":32.76968,"lon":-79.94249,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"29403","condg":["Depression","Addiction & substance use"],"nct":"NCT05193318","study":"KAP for Depression in Abstinent Opioid Users","sstatus":"TERMINATED","sponsor":"Medical University of South Carolina","official":"Eric T Dobson, MD (Medical University of South Carolina)","src":"https://clinicaltrials.gov/study/NCT05193318","phase":"Phase 2","enroll":5,"start":"2022-01-13","eid":"x:site:nct05193318-medical-university-of-south-carolina-centerspace-charleston"},{"id":"nct02206776-new-york-state-psychiatric-institute-new-york","cat":"research","name":"New York State Psychiatric Institute","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71187,"lon":-74.00037,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10032","condg":["OCD"],"nct":"NCT02206776","study":"Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCD","sstatus":"TERMINATED","sponsor":"New York State Psychiatric Institute","official":"Carolyn I Rodriguez, M.D., Ph.D. (Stanford University)","src":"https://clinicaltrials.gov/study/NCT02206776","phase":"Phase 2","enroll":2,"start":"2014-09","eid":"x:site:nct02206776-new-york-state-psychiatric-institute-new-york"},{"id":"nct04977674-king-s-college-london-london","cat":"research","name":"King's College London","city":"London","country":"United Kingdom","cc":"GB","lat":51.49832,"lon":-0.12758,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"SE58AF","condg":["Depression"],"nct":"NCT04977674","study":"Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine","sstatus":"COMPLETED","sponsor":"King's College London","src":"https://clinicaltrials.gov/study/NCT04977674","phase":"EARLY_Phase 1","enroll":27,"start":"2021-09-27","eid":"x:site:nct04977674-king-s-college-london-london"},{"id":"nct05168735-western-psychiatric-institute-and-clinic-pittsburgh","cat":"research","name":"Western Psychiatric Institute and Clinic","city":"Pittsburgh","region":"Pennsylvania","country":"United States","cc":"US","lat":40.44038,"lon":-79.98888,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"15213","condg":["Depression"],"nct":"NCT05168735","study":"Ketamine + Mindfulness for Depression","sstatus":"COMPLETED","sponsor":"Rebecca Price","official":"Rebecca Price, PhD (University of Pittsburgh)","src":"https://clinicaltrials.gov/study/NCT05168735","phase":"Phase 1/Phase 2","enroll":43,"start":"2022-02-01","eid":"x:site:nct05168735-western-psychiatric-institute-and-clinic-pittsburgh"},{"id":"nct05379179-banner-university-medical-center-phoenix-campus-phoenix","cat":"research","name":"Banner - University Medical Center, Phoenix campus","city":"Phoenix","region":"Arizona","country":"United States","cc":"US","lat":33.44758,"lon":-112.0643,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"85006","condg":["Other"],"nct":"NCT05379179","study":"Ketamine Pilot Study","sstatus":"TERMINATED","sponsor":"Meghan Spyres","official":"Meghan Spyres, MD (University of Arizona)","src":"https://clinicaltrials.gov/study/NCT05379179","phase":"Phase 4","enroll":3,"start":"2022-06-20","eid":"x:site:nct05379179-banner-university-medical-center-phoenix-campus-phoenix"},{"id":"nct05940324-department-of-psychiatry-behavioral-sciences-stanford","cat":"research","name":"Department of Psychiatry & Behavioral Sciences","city":"Stanford","region":"California","country":"United States","cc":"US","lat":37.4235,"lon":-122.16839,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94305","condg":["OCD"],"status":"RECRUITING","nct":"NCT05940324","study":"Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)","sstatus":"RECRUITING","sponsor":"Stanford University","src":"https://clinicaltrials.gov/study/NCT05940324","contact":{"n":"OCD Research","p":"650-723-4095","e":"ocdresearch@stanford.edu"},"phase":"Phase 2","enroll":150,"start":"2024-02-24","eid":"x:site:nct05940324-department-of-psychiatry-behavioral-sciences-stanford"},{"id":"nct05401227-nyspi-new-york","cat":"research","name":"NYSPI","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71554,"lon":-74.00743,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"10032","condg":["Healthy volunteers"],"status":"RECRUITING","nct":"NCT05401227","study":"Glutamatergic Mechanisms: Aim2","sstatus":"RECRUITING","sponsor":"New York State Psychiatric Institute","official":"Joshua Kantrowitz, MD (NYSPI)","src":"https://clinicaltrials.gov/study/NCT05401227","contact":{"n":"Joshua Kantrowitz, MD","p":"6467748477","e":"joshua.kantrowitz@nyspi.columbia.edu"},"phase":"Phase 1","enroll":120,"start":"2022-10-15","eid":"x:site:nct05401227-nyspi-new-york"},{"id":"nct00471445-mbccop-hawaii-honolulu","cat":"research","name":"MBCCOP - Hawaii","city":"Honolulu","region":"Hawaii","country":"United States","cc":"US","lat":21.30087,"lon":-157.85461,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"96813","condg":["Chronic pain & headache"],"nct":"NCT00471445","study":"Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients","sstatus":"COMPLETED","sponsor":"Gary Morrow","official":"Supriya Mohile, MD (James P. Wilmot Cancer Center)","src":"https://clinicaltrials.gov/study/NCT00471445","phase":"Phase 3","enroll":462,"start":"2007-10","eid":"x:site:nct00471445-mbccop-hawaii-honolulu"},{"id":"nct00471445-mbccop-university-of-illinois-at-chicago-chicago","cat":"research","name":"MBCCOP - University of Illinois at Chicago","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.85798,"lon":-87.64539,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60612-7323","condg":["Chronic pain & headache"],"nct":"NCT00471445","study":"Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients","sstatus":"COMPLETED","sponsor":"Gary Morrow","official":"Supriya Mohile, MD (James P. Wilmot Cancer Center)","src":"https://clinicaltrials.gov/study/NCT00471445","phase":"Phase 3","enroll":462,"start":"2007-10","eid":"x:site:nct00471445-mbccop-university-of-illinois-at-chicago-chicago"},{"id":"nct00471445-ccop-central-illinois-decatur","cat":"research","name":"CCOP - Central Illinois","city":"Decatur","region":"Illinois","country":"United States","cc":"US","lat":39.85175,"lon":-88.95306,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"62526","condg":["Chronic pain & headache"],"nct":"NCT00471445","study":"Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients","sstatus":"COMPLETED","sponsor":"Gary Morrow","official":"Supriya Mohile, MD (James P. Wilmot Cancer Center)","src":"https://clinicaltrials.gov/study/NCT00471445","phase":"Phase 3","enroll":462,"start":"2007-10","eid":"x:site:nct00471445-ccop-central-illinois-decatur"},{"id":"nct00471445-ccop-evanston-evanston","cat":"research","name":"CCOP - Evanston","city":"Evanston","region":"Illinois","country":"United States","cc":"US","lat":42.0362,"lon":-87.68126,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60201","condg":["Chronic pain & headache"],"nct":"NCT00471445","study":"Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients","sstatus":"COMPLETED","sponsor":"Gary Morrow","official":"Supriya Mohile, MD (James P. Wilmot Cancer Center)","src":"https://clinicaltrials.gov/study/NCT00471445","phase":"Phase 3","enroll":462,"start":"2007-10","eid":"x:site:nct00471445-ccop-evanston-evanston"},{"id":"nct00471445-ccop-wichita-wichita","cat":"research","name":"CCOP - Wichita","city":"Wichita","region":"Kansas","country":"United States","cc":"US","lat":37.69248,"lon":-97.33919,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"67214-3882","condg":["Chronic pain & headache"],"nct":"NCT00471445","study":"Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients","sstatus":"COMPLETED","sponsor":"Gary Morrow","official":"Supriya Mohile, MD (James P. Wilmot Cancer Center)","src":"https://clinicaltrials.gov/study/NCT00471445","phase":"Phase 3","enroll":462,"start":"2007-10","eid":"x:site:nct00471445-ccop-wichita-wichita"},{"id":"nct00471445-ccop-grand-rapids-grand-rapids","cat":"research","name":"CCOP - Grand Rapids","city":"Grand Rapids","region":"Michigan","country":"United States","cc":"US","lat":42.96952,"lon":-85.66588,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"49503","condg":["Chronic pain & headache"],"nct":"NCT00471445","study":"Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients","sstatus":"COMPLETED","sponsor":"Gary Morrow","official":"Supriya Mohile, MD (James P. Wilmot Cancer Center)","src":"https://clinicaltrials.gov/study/NCT00471445","phase":"Phase 3","enroll":462,"start":"2007-10","eid":"x:site:nct00471445-ccop-grand-rapids-grand-rapids"},{"id":"nct00471445-ccop-metro-minnesota-saint-louis-park","cat":"research","name":"CCOP - Metro-Minnesota","city":"Saint Louis Park","region":"Minnesota","country":"United States","cc":"US","lat":44.94054,"lon":-93.35342,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55416","condg":["Chronic pain & headache"],"nct":"NCT00471445","study":"Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients","sstatus":"COMPLETED","sponsor":"Gary Morrow","official":"Supriya Mohile, MD (James P. Wilmot Cancer Center)","src":"https://clinicaltrials.gov/study/NCT00471445","phase":"Phase 3","enroll":462,"start":"2007-10","eid":"x:site:nct00471445-ccop-metro-minnesota-saint-louis-park"},{"id":"nct00471445-ccop-nevada-cancer-research-foundation-las-vegas","cat":"research","name":"CCOP - Nevada Cancer Research Foundation","city":"Las Vegas","region":"Nevada","country":"United States","cc":"US","lat":36.17671,"lon":-115.13962,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"89106","condg":["Chronic pain & headache"],"nct":"NCT00471445","study":"Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients","sstatus":"COMPLETED","sponsor":"Gary Morrow","official":"Supriya Mohile, MD (James P. Wilmot Cancer Center)","src":"https://clinicaltrials.gov/study/NCT00471445","phase":"Phase 3","enroll":462,"start":"2007-10","eid":"x:site:nct00471445-ccop-nevada-cancer-research-foundation-las-vegas"},{"id":"nct00471445-ccop-hematology-oncology-associates-of-central-new-york-east-syracus","cat":"research","name":"CCOP - Hematology-Oncology Associates of Central New York","city":"East Syracuse","region":"New York","country":"United States","cc":"US","lat":43.06501,"lon":-76.075,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"13057","condg":["Chronic pain & headache"],"nct":"NCT00471445","study":"Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients","sstatus":"COMPLETED","sponsor":"Gary Morrow","official":"Supriya Mohile, MD (James P. Wilmot Cancer Center)","src":"https://clinicaltrials.gov/study/NCT00471445","phase":"Phase 3","enroll":462,"start":"2007-10","eid":"x:site:nct00471445-ccop-hematology-oncology-associates-of-central-new-york-east-syracus"},{"id":"nct00471445-ccop-north-shore-university-hospital-manhasset","cat":"research","name":"CCOP - North Shore University Hospital","city":"Manhasset","region":"New York","country":"United States","cc":"US","lat":40.78644,"lon":-73.68936,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11030","condg":["Chronic pain & headache"],"nct":"NCT00471445","study":"Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients","sstatus":"COMPLETED","sponsor":"Gary Morrow","official":"Supriya Mohile, MD (James P. Wilmot Cancer Center)","src":"https://clinicaltrials.gov/study/NCT00471445","phase":"Phase 3","enroll":462,"start":"2007-10","eid":"x:site:nct00471445-ccop-north-shore-university-hospital-manhasset"},{"id":"nct00471445-ccop-southeast-cancer-control-consortium-winston-salem","cat":"research","name":"CCOP - Southeast Cancer Control Consortium","city":"Winston-Salem","region":"North Carolina","country":"United States","cc":"US","lat":36.10132,"lon":-80.25556,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"27104-4241","condg":["Chronic pain & headache"],"nct":"NCT00471445","study":"Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients","sstatus":"COMPLETED","sponsor":"Gary Morrow","official":"Supriya Mohile, MD (James P. Wilmot Cancer Center)","src":"https://clinicaltrials.gov/study/NCT00471445","phase":"Phase 3","enroll":462,"start":"2007-10","eid":"x:site:nct00471445-ccop-southeast-cancer-control-consortium-winston-salem"},{"id":"nct00471445-ccop-columbia-river-oncology-program-portland","cat":"research","name":"CCOP - Columbia River Oncology Program","city":"Portland","region":"Oregon","country":"United States","cc":"US","lat":45.53451,"lon":-122.67485,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"97225","condg":["Chronic pain & headache"],"nct":"NCT00471445","study":"Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients","sstatus":"COMPLETED","sponsor":"Gary Morrow","official":"Supriya Mohile, MD (James P. Wilmot Cancer Center)","src":"https://clinicaltrials.gov/study/NCT00471445","phase":"Phase 3","enroll":462,"start":"2007-10","eid":"x:site:nct00471445-ccop-columbia-river-oncology-program-portland"},{"id":"nct00471445-ccop-greenville-greenville","cat":"research","name":"CCOP - Greenville","city":"Greenville","region":"South Carolina","country":"United States","cc":"US","lat":35.60264,"lon":-77.35689,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"29615","condg":["Chronic pain & headache"],"nct":"NCT00471445","study":"Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients","sstatus":"COMPLETED","sponsor":"Gary Morrow","official":"Supriya Mohile, MD (James P. Wilmot Cancer Center)","src":"https://clinicaltrials.gov/study/NCT00471445","phase":"Phase 3","enroll":462,"start":"2007-10","eid":"x:site:nct00471445-ccop-greenville-greenville"},{"id":"nct00471445-ccop-upstate-carolina-spartanburg","cat":"research","name":"CCOP - Upstate Carolina","city":"Spartanburg","region":"South Carolina","country":"United States","cc":"US","lat":34.95865,"lon":-81.92984,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"29303","condg":["Chronic pain & headache"],"nct":"NCT00471445","study":"Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients","sstatus":"COMPLETED","sponsor":"Gary Morrow","official":"Supriya Mohile, MD (James P. Wilmot Cancer Center)","src":"https://clinicaltrials.gov/study/NCT00471445","phase":"Phase 3","enroll":462,"start":"2007-10","eid":"x:site:nct00471445-ccop-upstate-carolina-spartanburg"},{"id":"nct00471445-ccop-virginia-mason-research-center-seattle","cat":"research","name":"CCOP - Virginia Mason Research Center","city":"Seattle","region":"Washington","country":"United States","cc":"US","lat":47.61275,"lon":-122.33165,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"98101","condg":["Chronic pain & headache"],"nct":"NCT00471445","study":"Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients","sstatus":"COMPLETED","sponsor":"Gary Morrow","official":"Supriya Mohile, MD (James P. Wilmot Cancer Center)","src":"https://clinicaltrials.gov/study/NCT00471445","phase":"Phase 3","enroll":462,"start":"2007-10","eid":"x:site:nct00471445-ccop-virginia-mason-research-center-seattle"},{"id":"nct00471445-ccop-northwest-tacoma","cat":"research","name":"CCOP - Northwest","city":"Tacoma","region":"Washington","country":"United States","cc":"US","lat":47.24879,"lon":-122.45036,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"98405-0986","condg":["Chronic pain & headache"],"nct":"NCT00471445","study":"Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients","sstatus":"COMPLETED","sponsor":"Gary Morrow","official":"Supriya Mohile, MD (James P. Wilmot Cancer Center)","src":"https://clinicaltrials.gov/study/NCT00471445","phase":"Phase 3","enroll":462,"start":"2007-10","eid":"x:site:nct00471445-ccop-northwest-tacoma"},{"id":"nct00471445-ccop-marshfield-clinic-research-foundation-marshfield","cat":"research","name":"CCOP - Marshfield Clinic Research Foundation","city":"Marshfield","region":"Wisconsin","country":"United States","cc":"US","lat":44.66692,"lon":-90.17806,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"54449","condg":["Chronic pain & headache"],"nct":"NCT00471445","study":"Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients","sstatus":"COMPLETED","sponsor":"Gary Morrow","official":"Supriya Mohile, MD (James P. Wilmot Cancer Center)","src":"https://clinicaltrials.gov/study/NCT00471445","phase":"Phase 3","enroll":462,"start":"2007-10","eid":"x:site:nct00471445-ccop-marshfield-clinic-research-foundation-marshfield"},{"id":"nct01140620-institute-of-psychiatry-king-s-college-london-london","cat":"research","name":"Institute of Psychiatry, King's College London","city":"London","region":"Greater London","country":"United Kingdom","cc":"GB","lat":51.50764,"lon":-0.1287,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"SE5 8AF","condg":["Healthy volunteers"],"nct":"NCT01140620","study":"Effects of Ketamine and Risperidone on Cognition","sstatus":"COMPLETED","sponsor":"University of Manchester","official":"Professor Bill Deakin (University of Manchester)","src":"https://clinicaltrials.gov/study/NCT01140620","phase":"Phase 4","enroll":87,"start":"2010-06","eid":"x:site:nct01140620-institute-of-psychiatry-king-s-college-london-london"},{"id":"nct01140620-university-of-manchester-dept-of-neuropyschiatry-manchester","cat":"research","name":"University of Manchester (Dept of Neuropyschiatry)","city":"Manchester","region":"Manchester","country":"United Kingdom","cc":"GB","lat":53.48326,"lon":-2.24416,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M13 9PT","condg":["Healthy volunteers"],"nct":"NCT01140620","study":"Effects of Ketamine and Risperidone on Cognition","sstatus":"COMPLETED","sponsor":"University of Manchester","official":"Professor Bill Deakin (University of Manchester)","src":"https://clinicaltrials.gov/study/NCT01140620","phase":"Phase 4","enroll":87,"start":"2010-06","eid":"x:site:nct01140620-university-of-manchester-dept-of-neuropyschiatry-manchester"},{"id":"nct01140620-school-of-psychology-university-of-cardiff-cardiff","cat":"research","name":"School of Psychology, University of Cardiff","city":"Cardiff","country":"United Kingdom","cc":"GB","lat":51.476,"lon":-3.18438,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"CF10 3AT","condg":["Healthy volunteers"],"nct":"NCT01140620","study":"Effects of Ketamine and Risperidone on Cognition","sstatus":"COMPLETED","sponsor":"University of Manchester","official":"Professor Bill Deakin (University of Manchester)","src":"https://clinicaltrials.gov/study/NCT01140620","phase":"Phase 4","enroll":87,"start":"2010-06","eid":"x:site:nct01140620-school-of-psychology-university-of-cardiff-cardiff"},{"id":"nct05149586-zagazig-university-zagazig","cat":"research","name":"Zagazig university","city":"Zagazig","country":"Egypt","cc":"EG","lat":30.5978,"lon":31.50176,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Other"],"nct":"NCT05149586","study":"Impact of Low Dose Ketamine Infusion in Septic Patient on Non-invasive Estimators of ICP","sstatus":"COMPLETED","sponsor":"Zagazig University","src":"https://clinicaltrials.gov/study/NCT05149586","enroll":100,"start":"2021-12-10","eid":"x:site:nct05149586-zagazig-university-zagazig"},{"id":"nct07194694-ain-shams-university-hospitals-cairo","cat":"research","name":"Ain Shams University Hospitals","city":"Cairo","country":"Egypt","cc":"EG","lat":30.07256,"lon":31.24379,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Chronic pain & headache"],"nct":"NCT07194694","study":"Dexmedetomidine vs Ketamine as Adjuvants to Bupivacaine in Transversus Abdominus Plane Block in Inguinal Hernioplasty","sstatus":"COMPLETED","sponsor":"Ain Shams University","src":"https://clinicaltrials.gov/study/NCT07194694","phase":"Phase 3","enroll":60,"start":"2025-10-22","eid":"x:site:nct07194694-ain-shams-university-hospitals-cairo"},{"id":"nct00486902-northwestern-university-chicago","cat":"research","name":"Northwestern University","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.85074,"lon":-87.64219,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"60611","condg":["Other"],"nct":"NCT00486902","study":"Does a Single Intravenous Dose of Ketamine Reduce the Need for Supplemental Opioids in Post-Cesarean Section Patients?","sstatus":"COMPLETED","sponsor":"Northwestern University","official":"Cynthia A Wong, M.D. (Northwestern University)","src":"https://clinicaltrials.gov/study/NCT00486902","phase":"N/A","enroll":188,"start":"2006-07","eid":"x:site:nct00486902-northwestern-university-chicago"},{"id":"nct01988922-washington-university-school-of-medicine-st-louis","cat":"research","name":"Washington University School of Medicine","city":"St Louis","region":"Missouri","country":"United States","cc":"US","lat":38.61743,"lon":-90.18815,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"63110","condg":["Healthy volunteers"],"nct":"NCT01988922","study":"CYP2B6 Polymorphisms in Ketamine","sstatus":"COMPLETED","sponsor":"Washington University School of Medicine","official":"Lesley Rao, MD (Washington University School of Medicine)","src":"https://clinicaltrials.gov/study/NCT01988922","phase":"N/A","enroll":30,"start":"2013-11","eid":"x:site:nct01988922-washington-university-school-of-medicine-st-louis"},{"id":"nct00329394-clermont-ferrand-university-hospital-clermont-ferrand","cat":"research","name":"Clermont-Ferrand University Hospital","city":"Clermont-Ferrand","country":"France","cc":"FR","lat":45.79169,"lon":3.088,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"63000","condg":["Addiction & substance use"],"nct":"NCT00329394","study":"Systemic Ketamine for the Improvement of Post-Operative Analgesia at the Alcohol-Dependent Patient","sstatus":"SUSPENDED","sponsor":"University Hospital, Clermont-Ferrand","official":"Nicolas Rascol, Dr (University Hospital, Clermont-Ferrand)","src":"https://clinicaltrials.gov/study/NCT00329394","phase":"Phase 3","enroll":56,"start":"2006-04","eid":"x:site:nct00329394-clermont-ferrand-university-hospital-clermont-ferrand"},{"id":"nct07569198-toronto-western-hospital-toronto","cat":"research","name":"Toronto Western Hospital","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.71212,"lon":-79.39784,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M5T 2S8","condg":["Depression","Bipolar"],"status":"RECRUITING","nct":"NCT07569198","study":"Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)","sstatus":"RECRUITING","sponsor":"Joshua Rosenblat","official":"Joshua D. Rosenblat, MD, MSc (Toronto Western Hospital, Psychiatry)","src":"https://clinicaltrials.gov/study/NCT07569198","contact":{"n":"Diana Orsini","p":"416-603-5106","e":"ket.dbt@uhn.ca"},"phase":"Phase 2","enroll":120,"start":"2026-07-16","eid":"x:site:nct07569198-toronto-western-hospital-toronto"},{"id":"nct02987985-royal-university-hospital-saskatoon","cat":"research","name":"Royal University Hospital","city":"Saskatoon","region":"Saskatchewan","country":"Canada","cc":"CA","lat":52.13657,"lon":-106.65711,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"S7N 0W8","condg":["Depression","Addiction & substance use"],"nct":"NCT02987985","study":"Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy","sstatus":"COMPLETED","sponsor":"University of Saskatchewan","official":"Jon Gamble, MD (University of Saskatchewan)","src":"https://clinicaltrials.gov/study/NCT02987985","phase":"Phase 3","enroll":50,"start":"2017-10-15","eid":"x:site:nct02987985-royal-university-hospital-saskatoon"},{"id":"nct05796791-medical-university-of-south-carolina-charleston","cat":"research","name":"Medical University of South Carolina","city":"Charleston","region":"South Carolina","country":"United States","cc":"US","lat":32.77401,"lon":-79.9295,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"29412","condg":["Addiction & substance use"],"nct":"NCT05796791","study":"Ketamine and Motivational Enhancement Therapy for the Treatment of Tobacco Use Disorder","sstatus":"COMPLETED","sponsor":"Medical University of South Carolina","src":"https://clinicaltrials.gov/study/NCT05796791","phase":"EARLY_Phase 1","enroll":7,"start":"2023-05-02","eid":"x:site:nct05796791-medical-university-of-south-carolina-charleston"},{"id":"nct04154150-university-of-pittsburgh-pittsburgh","cat":"research","name":"University of Pittsburgh","city":"Pittsburgh","region":"Pennsylvania","country":"United States","cc":"US","lat":40.43831,"lon":-80.00403,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"15213","condg":["Other"],"nct":"NCT04154150","study":"Ketamine + Cognitive Training for Suicidality in the Medical Setting: Pilot","sstatus":"TERMINATED","sponsor":"Rebecca Price","src":"https://clinicaltrials.gov/study/NCT04154150","phase":"Phase 4","enroll":16,"start":"2019-12-19","eid":"x:site:nct04154150-university-of-pittsburgh-pittsburgh"},{"id":"nct01065350-dartmouth-hitchcock-medical-center-lebanon","cat":"research","name":"Dartmouth Hitchcock Medical Center","city":"Lebanon","region":"New Hampshire","country":"United States","cc":"US","lat":36.21183,"lon":-86.28926,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"03756","condg":["Other"],"nct":"NCT01065350","study":"A Comparison of Ketofol (Ketamine and Propofol Admixture) Versus Propofol as Induction Agents on Hemodynamic Parameters","sstatus":"COMPLETED","sponsor":"Mayo Clinic","official":"Nathan J Smischney, MD (Mayo Clinic); Matthew Koff, MD (Dartmouth-Hitchcock Medical Center)","src":"https://clinicaltrials.gov/study/NCT01065350","phase":"N/A","enroll":85,"start":"2010-12","eid":"x:site:nct01065350-dartmouth-hitchcock-medical-center-lebanon"},{"id":"nct05837000-karelsheikh-university-hospital-kafr-ash-shaykh","cat":"research","name":"Karelsheikh University Hospital","city":"Kafr ash Shaykh","region":"Karelsheikh","country":"Egypt","cc":"EG","lat":31.11809,"lon":30.95012,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"33516","condg":["Other"],"status":"RECRUITING","nct":"NCT05837000","study":"Dexmedetomidine, Ketamine and Magnesium Sulphate in Caudal Block for Hypospadias Repair","sstatus":"UNKNOWN","sponsor":"Kafrelsheikh University","official":"Kafrelsheikh University (Research ethics committee - Kafrelsheikh University)","src":"https://clinicaltrials.gov/study/NCT05837000","contact":{"n":"Gamal H Shams, MD","p":"00201095927971","e":"gamal.shams@yahoo.com"},"phase":"Phase 4","enroll":75,"start":"2023-05-15","eid":"x:site:nct05837000-karelsheikh-university-hospital-kafr-ash-shaykh"},{"id":"nct03053947-sickkids-toronto","cat":"research","name":"Sickkids","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.71212,"lon":-79.39078,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"M5G 1X8","condg":["Other"],"nct":"NCT03053947","study":"Pain Free Laceration Repairs Using Intra-nasal Ketamine","sstatus":"COMPLETED","sponsor":"Evelyne D.Trottier","official":"Evelyne D Trottier, MD, FRCPC (St. Justine's Hospital)","src":"https://clinicaltrials.gov/study/NCT03053947","phase":"Phase 2","enroll":42,"start":"2017-02-16","eid":"x:site:nct03053947-sickkids-toronto"},{"id":"nct03053947-st-justine-s-hospital-montreal","cat":"research","name":"St. Justine's Hospital","city":"Montreal","region":"Quebec","country":"Canada","cc":"CA","lat":45.50973,"lon":-73.58061,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"H3T 1C5","condg":["Other"],"nct":"NCT03053947","study":"Pain Free Laceration Repairs Using Intra-nasal Ketamine","sstatus":"COMPLETED","sponsor":"Evelyne D.Trottier","official":"Evelyne D Trottier, MD, FRCPC (St. Justine's Hospital)","src":"https://clinicaltrials.gov/study/NCT03053947","phase":"Phase 2","enroll":42,"start":"2017-02-16","eid":"x:site:nct03053947-st-justine-s-hospital-montreal"},{"id":"nct02165449-geffen-school-of-medicine-ucla-los-angeles","cat":"research","name":"Geffen School of Medicine, UCLA","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.05651,"lon":-118.24486,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"90095","condg":["Depression"],"nct":"NCT02165449","study":"Biomarkers of Fast Acting Therapies in Major Depression","sstatus":"COMPLETED","sponsor":"University of California, Los Angeles","official":"Katherine Narr, Ph.D. (Geffen School of Medicine, University of California, Los Angeles (UCLA))","src":"https://clinicaltrials.gov/study/NCT02165449","phase":"Phase 1","enroll":60,"start":"2014-06","eid":"x:site:nct02165449-geffen-school-of-medicine-ucla-los-angeles"},{"id":"nct01879826-university-of-california-san-francisco-hospital-san-francisco","cat":"research","name":"University of California San Francisco Hospital","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.77921,"lon":-122.4174,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94143","condg":["Anxiety","Chronic pain & headache"],"nct":"NCT01879826","study":"Pediatric Laser Acupuncture and Renal Biopsy","sstatus":"COMPLETED","sponsor":"University of California, San Francisco","official":"Cynthia Kim, MD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT01879826","phase":"N/A","enroll":81,"start":"2013-07","eid":"x:site:nct01879826-university-of-california-san-francisco-hospital-san-francisco"},{"id":"nct01879826-university-of-california-san-francisco-san-francisco","cat":"research","name":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.76349,"lon":-122.41062,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94143","condg":["Anxiety","Chronic pain & headache"],"nct":"NCT01879826","study":"Pediatric Laser Acupuncture and Renal Biopsy","sstatus":"COMPLETED","sponsor":"University of California, San Francisco","official":"Cynthia Kim, MD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT01879826","phase":"N/A","enroll":81,"start":"2013-07","eid":"x:site:nct01879826-university-of-california-san-francisco-san-francisco"},{"id":"nct00484484-hopital-saint-antoine-paris","cat":"research","name":"Hopital Saint Antoine","city":"Paris","country":"France","cc":"FR","lat":48.85637,"lon":2.35148,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75012","condg":["Chronic pain & headache"],"nct":"NCT00484484","study":"Ketamine Associated With Opioids in Refractory Cancer Pain Treatment","sstatus":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","official":"Sylvie ROSTAING-RIGATTIERI, MD (Assistance Publique - Hôpitaux de Paris)","src":"https://clinicaltrials.gov/study/NCT00484484","phase":"Phase 3","enroll":100,"start":"2007-05","eid":"x:site:nct00484484-hopital-saint-antoine-paris"},{"id":"nct01566448-west-virginia-university-hospitals-mary-babb-randolph-cancer-center-","cat":"research","name":"West Virginia University Hospitals Mary Babb Randolph Cancer Center","city":"Morgantown","region":"West Virginia","country":"United States","cc":"US","lat":39.62271,"lon":-79.94465,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"26506","condg":["Other"],"nct":"NCT01566448","study":"Treatment of Severe Mucositis Pain With Oral Ketamine Mouthwash","sstatus":"COMPLETED","sponsor":"Aaron Cumpston, PharmD, BCOP","official":"Aaron Cumpston, PharmD (West Virginia University)","src":"https://clinicaltrials.gov/study/NCT01566448","phase":"Phase 2","enroll":30,"start":"2012-02","eid":"x:site:nct01566448-west-virginia-university-hospitals-mary-babb-randolph-cancer-center-"},{"id":"nct04048226-tanta-university-hospitals-tanta","cat":"research","name":"Tanta University hospitals","city":"Tanta","country":"Egypt","cc":"EG","lat":30.7952,"lon":31.00234,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"31511","condg":["Other"],"nct":"NCT04048226","study":"Dexmedetomidine-Ketamine Infusion in Breast Surgeries","sstatus":"COMPLETED","sponsor":"Tanta University","official":"Sameh Ismaiel, M.D (Lecturer of Anesthesia and Intensive Care, Tanta University)","src":"https://clinicaltrials.gov/study/NCT04048226","phase":"Phase 4","enroll":103,"start":"2019-09-01","eid":"x:site:nct04048226-tanta-university-hospitals-tanta"},{"id":"nct02860117-hospital-das-clinicas-da-fmusp-sao-paulo","cat":"research","name":"Hospital das Clínicas da FMUSP","city":"São Paulo","region":"São Paulo","country":"Brazil","cc":"BR","lat":-23.54341,"lon":-46.6434,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"05403-000","condg":["Chronic pain & headache"],"nct":"NCT02860117","study":"Ketamine Continuous Infusion on Opioid Consumption and Pain Management in Severe Burned Patients","sstatus":"WITHDRAWN","sponsor":"University of Sao Paulo General Hospital","official":"Claudia Palmeira, MD, PhD (University of Sao Paulo General Hospital)","src":"https://clinicaltrials.gov/study/NCT02860117","phase":"Phase 3","start":"2018-01","eid":"x:site:nct02860117-hospital-das-clinicas-da-fmusp-sao-paulo"},{"id":"nct06698848-massachusetts-general-hosipital-boston","cat":"research","name":"Massachusetts General Hosipital","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36958,"lon":-71.06424,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"02114","condg":["Depression"],"nct":"NCT06698848","study":"Integrating Ketamine Effects on Neuronal Molecular Signatures and the Brain Functional and Structural Connectome","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","src":"https://clinicaltrials.gov/study/NCT06698848","phase":"Phase 1","enroll":120,"start":"2025-01-01","eid":"x:site:nct06698848-massachusetts-general-hosipital-boston"},{"id":"nct01301079-federal-university-of-sao-paulo-sao-paulo","cat":"research","name":"Federal University of São Paulo","city":"São Paulo","region":"São Paulo","country":"Brazil","cc":"BR","lat":-23.55555,"lon":-46.64115,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Chronic pain & headache"],"nct":"NCT01301079","study":"Evaluation of the Effect of Ketamine on Remifentanil-induced Hyperalgesia","sstatus":"COMPLETED","sponsor":"Federal University of São Paulo","official":"Plínio da Cunha Leal, PhD (Federal University of São Paulo)","src":"https://clinicaltrials.gov/study/NCT01301079","phase":"Phase 3","enroll":60,"start":"2010-09","eid":"x:site:nct01301079-federal-university-of-sao-paulo-sao-paulo"},{"id":"nct07088380-irccs-ospedale-san-raffaele-turro-milan","cat":"research","name":"IRCCS Ospedale San Raffaele Turro","city":"Milan","country":"Italy","cc":"IT","lat":45.47486,"lon":9.20142,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20127","condg":["Depression"],"status":"RECRUITING","nct":"NCT07088380","study":"Ketamine Augmentation of ECT in Treatment-Resistant Depression","sstatus":"RECRUITING","sponsor":"Università Vita-Salute San Raffaele","official":"Alberto AZ Zangrillo, MD (Università Vita-Salute San Raffaele); Cristina CC Colombo, MD (IRCCS Ospedale San Raffaele Turro)","src":"https://clinicaltrials.gov/study/NCT07088380","contact":{"n":"Alberto AZ Zangrillo, MD","p":"0226436154","e":"zangrillo.alberto@hsr.it"},"phase":"Phase 3","enroll":30,"start":"2025-07-10","eid":"x:site:nct07088380-irccs-ospedale-san-raffaele-turro-milan"},{"id":"nct07276542-shamynds-sacramento","cat":"research","name":"Shamynds","city":"Sacramento","region":"California","country":"United States","cc":"US","lat":38.57503,"lon":-121.49548,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"95818","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT07276542","study":"Clinical Trial Exploring the Outpatient Treatment of Phantom Limb Pain With Ketamine Administration in a Six Month Study With a Minimum Remission Period of 7 Days Between Treatment Session. 25-30…","sstatus":"RECRUITING","sponsor":"The Ketamine Research Foundation","src":"https://clinicaltrials.gov/study/NCT07276542","contact":{"n":"Alya Ahmad, MD","p":"916 538 6498","e":"Aahmad@shamynds.com"},"phase":"Phase 2/Phase 3","enroll":30,"start":"2026-01-15","eid":"x:site:nct07276542-shamynds-sacramento"},{"id":"nct07276542-ketamine-research-foundation-san-anselmo","cat":"research","name":"Ketamine Research Foundation","city":"San Anselmo","region":"California","country":"United States","cc":"US","lat":37.96745,"lon":-122.55698,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"94960","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT07276542","study":"Clinical Trial Exploring the Outpatient Treatment of Phantom Limb Pain With Ketamine Administration in a Six Month Study With a Minimum Remission Period of 7 Days Between Treatment Session. 25-30…","sstatus":"RECRUITING","sponsor":"The Ketamine Research Foundation","src":"https://clinicaltrials.gov/study/NCT07276542","contact":{"n":"Philip E Wolfson, MD","p":"415-785-3797","e":"ketamine.research@gmail.com"},"phase":"Phase 2/Phase 3","enroll":30,"start":"2026-01-15","eid":"x:site:nct07276542-ketamine-research-foundation-san-anselmo"},{"id":"nct07276542-mystic-health-santa-monica","cat":"research","name":"Mystic Health","city":"Santa Monica","region":"California","country":"United States","cc":"US","lat":34.01671,"lon":-118.49576,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"90403","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT07276542","study":"Clinical Trial Exploring the Outpatient Treatment of Phantom Limb Pain With Ketamine Administration in a Six Month Study With a Minimum Remission Period of 7 Days Between Treatment Session. 25-30…","sstatus":"RECRUITING","sponsor":"The Ketamine Research Foundation","src":"https://clinicaltrials.gov/study/NCT07276542","contact":{"n":"Houman Farzin, MD","p":"310.526.7619","e":"info@mystic.health"},"phase":"Phase 2/Phase 3","enroll":30,"start":"2026-01-15","eid":"x:site:nct07276542-mystic-health-santa-monica"},{"id":"nct07276542-lisa-feierman-md-albuquerque","cat":"research","name":"Lisa Feierman MD","city":"Albuquerque","region":"New Mexico","country":"United States","cc":"US","lat":35.08934,"lon":-106.6493,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"87109","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT07276542","study":"Clinical Trial Exploring the Outpatient Treatment of Phantom Limb Pain With Ketamine Administration in a Six Month Study With a Minimum Remission Period of 7 Days Between Treatment Session. 25-30…","sstatus":"RECRUITING","sponsor":"The Ketamine Research Foundation","src":"https://clinicaltrials.gov/study/NCT07276542","contact":{"n":"Lisa Feierman, MD","p":"(505) 450-7626","e":"lisafeierman@gmail.com"},"phase":"Phase 2/Phase 3","enroll":30,"start":"2026-01-15","eid":"x:site:nct07276542-lisa-feierman-md-albuquerque"},{"id":"nct04562779-denver-health-medical-center-denver","cat":"research","name":"Denver Health Medical Center","city":"Denver","region":"Colorado","country":"United States","cc":"US","lat":39.73637,"lon":-104.97618,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"80204","condg":["Addiction & substance use"],"nct":"NCT04562779","study":"Inpatient Single Dose Interventions for Alcohol Use Disorder","sstatus":"COMPLETED","sponsor":"Denver Health and Hospital Authority","src":"https://clinicaltrials.gov/study/NCT04562779","phase":"EARLY_Phase 1","enroll":44,"start":"2021-01-19","eid":"x:site:nct04562779-denver-health-medical-center-denver"},{"id":"nct04769297-limbic-medical-toluca-lake","cat":"research","name":"Limbic Medical","city":"Toluca Lake","region":"California","country":"United States","cc":"US","lat":34.04428,"lon":-118.25239,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"91602","condg":["Other"],"nct":"NCT04769297","study":"Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic","sstatus":"UNKNOWN","sponsor":"Limbic Medical","official":"Andre Atoian, MD (Limbic Medical)","src":"https://clinicaltrials.gov/study/NCT04769297","phase":"Phase 4","enroll":30,"start":"2020-04-15","eid":"x:site:nct04769297-limbic-medical-toluca-lake"},{"id":"nct07682662-university-of-mississippi-medical-center-pediatric-emergency-departm","cat":"research","name":"University of Mississippi Medical Center, Pediatric Emergency Department","city":"Jackson","region":"Mississippi","country":"United States","cc":"US","lat":32.31029,"lon":-90.19342,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"39216","condg":["Chronic pain & headache"],"nct":"NCT07682662","study":"Low Dose Bolus Ketamine For Use In Sickle Cell Pain Crisis","sstatus":"NOT_YET_RECRUITING","sponsor":"University of Mississippi Medical Center","official":"John N Freeman, MD (University of Mississippi Medical Center)","src":"https://clinicaltrials.gov/study/NCT07682662","contact":{"n":"Cynthia Karlson, Ph.D.","p":"601-984-2723","e":"ckarlson@umc.edu"},"phase":"Phase 4","enroll":400,"start":"2026-08-01","eid":"x:site:nct07682662-university-of-mississippi-medical-center-pediatric-emergency-departm"},{"id":"nct06180759-clinical-pharmacology-toxicology-university-hospital-basel-basel","cat":"research","name":"Clinical Pharmacology & Toxicology, University Hospital Basel","city":"Basel","region":"Basel","country":"Switzerland","cc":"CH","lat":47.56898,"lon":7.57482,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"4056","condg":["Healthy volunteers"],"nct":"NCT06180759","study":"Acute Analgesic Effects of DMT on Experimentally Induced Pain in Healthy Participants","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","src":"https://clinicaltrials.gov/study/NCT06180759","phase":"Phase 1","enroll":17,"start":"2025-01-23","eid":"x:site:nct06180759-clinical-pharmacology-toxicology-university-hospital-basel-basel"},{"id":"nct00618397-children-s-medical-center-dallas-university-of-texas-southwestern-da","cat":"research","name":"Children's Medical Center Dallas, University of Texas Southwestern","city":"Dallas","region":"Texas","country":"United States","cc":"US","lat":32.77699,"lon":-96.80926,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"75235","condg":["Addiction & substance use"],"nct":"NCT00618397","study":"Pharmacokinetics of Low Dose Ketamine Infusion","sstatus":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","official":"Cindy Darnell, MD (University of Texas)","src":"https://clinicaltrials.gov/study/NCT00618397","phase":"Phase 1","enroll":5,"start":"2006-06","eid":"x:site:nct00618397-children-s-medical-center-dallas-university-of-texas-southwestern-da"},{"id":"nct04120870-ajou-university-school-of-medicine-suwon","cat":"research","name":"Ajou university school of medicine","city":"Suwon","region":"Gyeonggi-do","country":"South Korea","cc":"KR","lat":37.2793,"lon":127.01684,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"16499","condg":["PTSD & trauma"],"nct":"NCT04120870","study":"Comparison of Ketamine and Etomidate During Rapid Sequence Intubation in Trauma Patients","sstatus":"TERMINATED","sponsor":"Ajou University School of Medicine","official":"In Kyong Yi, MD (Ajou University School of Medicine)","src":"https://clinicaltrials.gov/study/NCT04120870","phase":"N/A","enroll":10,"start":"2019-10-01","eid":"x:site:nct04120870-ajou-university-school-of-medicine-suwon"},{"id":"nct07165262-children-s-cancer-hospital-egypt-57357-cairo","cat":"research","name":"Children's Cancer Hospital Egypt 57357","city":"Cairo","country":"Egypt","cc":"EG","lat":30.05807,"lon":31.25668,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11511","condg":["Neurology & cognition"],"nct":"NCT07165262","study":"Effect of Different Anesthetic Drugs on Electrocorticography (ECOG).","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Hospital Egypt 57357","official":"Suzan A. Abdelrahman, consultant (Children's Cancer Hospital Egypt 57357)","src":"https://clinicaltrials.gov/study/NCT07165262","phase":"Phase 3","enroll":88,"start":"2025-08-18","eid":"x:site:nct07165262-children-s-cancer-hospital-egypt-57357-cairo"},{"id":"nct07165262-children-cancer-hospital-57357-cairo","cat":"research","name":"Children Cancer Hospital 57357","city":"Cairo","country":"Egypt","cc":"EG","lat":30.06776,"lon":31.24059,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11617","condg":["Neurology & cognition"],"nct":"NCT07165262","study":"Effect of Different Anesthetic Drugs on Electrocorticography (ECOG).","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Hospital Egypt 57357","official":"Suzan A. Abdelrahman, consultant (Children's Cancer Hospital Egypt 57357)","src":"https://clinicaltrials.gov/study/NCT07165262","phase":"Phase 3","enroll":88,"start":"2025-08-18","eid":"x:site:nct07165262-children-cancer-hospital-57357-cairo"},{"id":"nct07639359-mayo-clinic-jacksonville","cat":"research","name":"Mayo Clinic","city":"Jacksonville","region":"Florida","country":"United States","cc":"US","lat":30.3311,"lon":-81.6589,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"32224","condg":["Depression"],"status":"RECRUITING","nct":"NCT07639359","study":"Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients","sstatus":"RECRUITING","sponsor":"Hospital Italiano de Buenos Aires","official":"Ivan A Huespe, M.D., M.P.H. (Hospital Italiano de Buenos Aires); Devang K Sanghavi, M.B.B.S., M.D. (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT07639359","contact":{"n":"Devang K Sanghavi, MD","p":"+13146408772","e":"Sanghavi.Devang@mayo.edu"},"phase":"Phase 2","enroll":50,"start":"2026-05-14","eid":"x:site:nct07639359-mayo-clinic-jacksonville"},{"id":"nct07639359-hospital-italiano-de-buenos-aires-sede-central-buenos-aires","cat":"research","name":"Hospital Italiano de Buenos Aires - Sede Central","city":"Buenos Aires","region":"Buenos Aires","country":"Argentina","cc":"AR","lat":-34.62167,"lon":-58.36843,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"status":"RECRUITING","nct":"NCT07639359","study":"Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients","sstatus":"RECRUITING","sponsor":"Hospital Italiano de Buenos Aires","official":"Ivan A Huespe, M.D., M.P.H. (Hospital Italiano de Buenos Aires); Devang K Sanghavi, M.B.B.S., M.D. (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT07639359","contact":{"n":"Ivan A Huespe, MD","p":"+5493425382554","e":"ivan.huespe@hospitalitaliano.org.ar"},"phase":"Phase 2","enroll":50,"start":"2026-05-14","eid":"x:site:nct07639359-hospital-italiano-de-buenos-aires-sede-central-buenos-aires"},{"id":"nct04933149-mayo-clinic-in-rochester-rochester","cat":"research","name":"Mayo Clinic in Rochester","city":"Rochester","region":"Minnesota","country":"United States","cc":"US","lat":43.14909,"lon":-77.61081,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55905","condg":["Other"],"nct":"NCT04933149","study":"Ketamine Infusion for Neuropathic Pain in Brachial Plexus Injuries","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Mayo Clinic","official":"Alexander Shin, MD (Mayo Clinic)","src":"https://clinicaltrials.gov/study/NCT04933149","phase":"Phase 4","enroll":100,"start":"2021-12-15","eid":"x:site:nct04933149-mayo-clinic-in-rochester-rochester"},{"id":"nct06364540-maimonides-medical-center-brooklyn","cat":"research","name":"Maimonides Medical Center","city":"Brooklyn","region":"New York","country":"United States","cc":"US","lat":40.65683,"lon":-73.95396,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11219","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06364540","study":"Nebulized Ketamine to Nebulized Fentanyl for Treating Acute Painful Conditions in the ED","sstatus":"RECRUITING","sponsor":"Antonios Likourezos","official":"Sergey Motov, MD (Maimonides Medical Center)","src":"https://clinicaltrials.gov/study/NCT06364540","contact":{"n":"Sergey Motov, MD","p":"718-283-6896","e":"smotov@maimo.org"},"phase":"Phase 4","enroll":150,"start":"2024-05-01","eid":"x:site:nct06364540-maimonides-medical-center-brooklyn"},{"id":"nct01306760-royal-cornhill-hospital-nhs-grampian-aberdeen","cat":"research","name":"Royal Cornhill Hospital, NHS Grampian","city":"Aberdeen","country":"United Kingdom","cc":"GB","lat":57.13235,"lon":-2.10694,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"AB25 2ZH","condg":["Depression"],"nct":"NCT01306760","study":"The Use of Ketamine as an Anaesthetic During Electroconvulsive Therapy","sstatus":"COMPLETED","sponsor":"University of Aberdeen","official":"Ian C Reid, PhD (University of Aberdeen)","src":"https://clinicaltrials.gov/study/NCT01306760","phase":"Phase 4","enroll":40,"start":"2011-03","eid":"x:site:nct01306760-royal-cornhill-hospital-nhs-grampian-aberdeen"},{"id":"nct01835262-maimonides-medical-center-brooklyn","cat":"research","name":"Maimonides Medical Center","city":"Brooklyn","region":"New York","country":"United States","cc":"US","lat":40.65909,"lon":-73.94605,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"11219","condg":["Chronic pain & headache"],"nct":"NCT01835262","study":"Low Dose Ketamine Versus Morphine for Moderate to Severe Pain in the Emergency Department","sstatus":"COMPLETED","sponsor":"Antonios Likourezos","official":"Sergey Motov, MD (Maimonides Medical Center)","src":"https://clinicaltrials.gov/study/NCT01835262","phase":"Phase 4","enroll":90,"start":"2013-04","eid":"x:site:nct01835262-maimonides-medical-center-brooklyn"},{"id":"nct06228391-minneapolis-va-medical-center-minneapolis","cat":"research","name":"Minneapolis VA Medical Center","city":"Minneapolis","region":"Minnesota","country":"United States","cc":"US","lat":44.98086,"lon":-93.25655,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"55417","condg":["Depression","PTSD & trauma","Neurology & cognition"],"nct":"NCT06228391","study":"Ketamine Treatment for PTSD and MDD in TBI","sstatus":"NOT_YET_RECRUITING","sponsor":"Minneapolis Veterans Affairs Medical Center","src":"https://clinicaltrials.gov/study/NCT06228391","contact":{"n":"Paulo Shiroma, MD","p":"612-467-2264","e":"paulo.shiroma@va.gov"},"phase":"Phase 2","enroll":40,"start":"2024-03","eid":"x:site:nct06228391-minneapolis-va-medical-center-minneapolis"},{"id":"nct06511908-national-institutes-of-health-clinical-center-bethesda","cat":"research","name":"National Institutes of Health Clinical Center","city":"Bethesda","region":"Maryland","country":"United States","cc":"US","lat":38.97065,"lon":-77.0893,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"20892","condg":["Depression"],"status":"RECRUITING","nct":"NCT06511908","study":"Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression","sstatus":"RECRUITING","sponsor":"National Institute of Mental Health (NIMH)","official":"Carlos A Zarate, M.D. (National Institute of Mental Health (NIMH))","src":"https://clinicaltrials.gov/study/NCT06511908","contact":{"n":"NIH Clinical Center Office of Patient Recruitment (OPR)","p":"800-411-1222","e":"ccopr@nih.gov"},"phase":"Phase 2","enroll":50,"start":"2024-11-06","eid":"x:site:nct06511908-national-institutes-of-health-clinical-center-bethesda"},{"id":"nct06537375-hopital-universitaire-de-bruxelles-hopital-erasme-brussels","cat":"research","name":"Hôpital Universitaire de Bruxelles - Hôpital erasme","city":"Brussels","country":"Belgium","cc":"BE","lat":50.84871,"lon":4.35683,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"1070","condg":["Chronic pain & headache"],"nct":"NCT06537375","study":"Use of Ketamine in Severe Pain Syndromes","sstatus":"COMPLETED","sponsor":"Erasme University Hospital","src":"https://clinicaltrials.gov/study/NCT06537375","enroll":89,"start":"2024-08-01","eid":"x:site:nct06537375-hopital-universitaire-de-bruxelles-hopital-erasme-brussels"},{"id":"nct06480500-toronto-general-hospital-toronto","cat":"research","name":"Toronto General Hospital","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.7013,"lon":-79.39304,"gp":"city","unnamed":0,"drugs":["ketamine"],"condg":["Depression"],"status":"RECRUITING","nct":"NCT06480500","study":"i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial","sstatus":"RECRUITING","sponsor":"University Health Network, Toronto","official":"Rodrigo Mansur (University Health Network, Toronto)","src":"https://clinicaltrials.gov/study/NCT06480500","contact":{"n":"Simryn Selby","p":"416-603-5800","e":"simryn.selby@uhn.ca"},"phase":"Phase 2","enroll":110,"start":"2024-01-02","eid":"x:site:nct06480500-toronto-general-hospital-toronto"},{"id":"nct07247006-university-of-rochester-medical-center-rochester","cat":"research","name":"University of Rochester Medical Center","city":"Rochester","region":"New York","country":"United States","cc":"US","lat":43.15774,"lon":-77.62652,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"14642","condg":["Depression","Chronic pain & headache"],"nct":"NCT07247006","study":"Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression","sstatus":"NOT_YET_RECRUITING","sponsor":"University of Rochester","src":"https://clinicaltrials.gov/study/NCT07247006","contact":{"n":"Paul Geha, MD","p":"(585)-275-8675","e":"paul_geha@urmc.rochester.edu"},"phase":"Phase 2","enroll":25,"start":"2026-12","eid":"x:site:nct07247006-university-of-rochester-medical-center-rochester"},{"id":"nct04156035-medical-school-berlin-berlin","cat":"research","name":"Medical School Berlin","city":"Berlin","country":"Germany","cc":"DE","lat":52.53242,"lon":13.40973,"gp":"city","unnamed":0,"drugs":["ketamine"],"zip":"12247","condg":["Other"],"nct":"NCT04156035","study":"Ketamine-Induced Brain Changes and Their Modulation by Lamotrigine","sstatus":"COMPLETED","sponsor":"Charite University, Berlin, Germany","official":"Simone Grimm, PhD (Medical School Berlin)","src":"https://clinicaltrials.gov/study/NCT04156035","phase":"N/A","enroll":75,"start":"2020-03-10","eid":"x:site:nct04156035-medical-school-berlin-berlin"},{"id":"nct04849013-university-hospital-basel-clinical-trial-unit-basel","cat":"research","name":"University Hospital Basel, Clinical Trial Unit","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","cc":"CH","lat":47.56926,"lon":7.56485,"gp":"city","unnamed":0,"drugs":["mescaline"],"zip":"4056","condg":["Healthy volunteers"],"nct":"NCT04849013","study":"Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, Prof. Dr. MD (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT04849013","phase":"Phase 1","enroll":16,"start":"2021-08-11","eid":"x:site:nct04849013-university-hospital-basel-clinical-trial-unit-basel"},{"id":"nct06746441-lady-reading-hospital-pakistan-peshawar","cat":"research","name":"Lady Reading Hospital, Pakistan","city":"Peshawar","region":"Khyber Pakhtunkhwa","country":"Pakistan","cc":"PK","lat":34.012,"lon":71.56715,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"25000","condg":["Depression"],"nct":"NCT06746441","study":"Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and…","sstatus":"COMPLETED","sponsor":"Khyber Medical University Peshawar","official":"Dr Mahvash Khan (Hayat Abad Medical Complex, Peshawar)","src":"https://clinicaltrials.gov/study/NCT06746441","phase":"Phase 2","enroll":60,"start":"2024-12-01","eid":"x:site:nct06746441-lady-reading-hospital-pakistan-peshawar"},{"id":"nct07737054-tel-aviv-sourasky-medical-center-tel-aviv","cat":"research","name":"Tel Aviv Sourasky Medical Center","city":"Tel Aviv","country":"Israel","cc":"IL","lat":32.08714,"lon":34.78645,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"6423906","condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT07737054","study":"Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for PTSD","sstatus":"RECRUITING","sponsor":"Tel-Aviv Sourasky Medical Center","official":"Talma Hendler, Prof. (Tel Aviv University and Tel Aviv Sourasky Medical Center)","src":"https://clinicaltrials.gov/study/NCT07737054","contact":{"n":"Ayelet Or-Borichev, PhD","p":"+972507941243","e":"ayeletorb@gmail.com"},"phase":"EARLY_Phase 1","enroll":13,"start":"2025-07-22","eid":"x:site:nct07737054-tel-aviv-sourasky-medical-center-tel-aviv"},{"id":"nct06820723-the-ohio-state-university-department-of-psychiatry-columbus","cat":"research","name":"The Ohio State University Department of Psychiatry","city":"Columbus","region":"Ohio","country":"United States","cc":"US","lat":39.97318,"lon":-83.00891,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"43210","condg":["Depression","Anxiety"],"status":"RECRUITING","nct":"NCT06820723","study":"A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety","sstatus":"RECRUITING","sponsor":"Ohio State University","official":"Luan Phan, MD (Ohio State University)","src":"https://clinicaltrials.gov/study/NCT06820723","contact":{"n":"Anne-Marie Duchemin","p":"6142935517","e":"anne-marie.duchemin@osumc.edu"},"phase":"Phase 2","enroll":40,"start":"2026-08-01","eid":"x:site:nct06820723-the-ohio-state-university-department-of-psychiatry-columbus"},{"id":"nct06564818-scottsdale-research-institute-phoenix","cat":"research","name":"Scottsdale Research Institute","city":"Phoenix","region":"Arizona","country":"United States","cc":"US","lat":33.44918,"lon":-112.07588,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"85022","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-scottsdale-research-institute-phoenix"},{"id":"nct06564818-mountain-clinical-trials-phoenix","cat":"research","name":"Mountain Clinical Trials","city":"Phoenix","region":"Arizona","country":"United States","cc":"US","lat":33.43836,"lon":-112.07324,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"85050","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-mountain-clinical-trials-phoenix"},{"id":"nct06564818-noble-clinical-research-tucson","cat":"research","name":"Noble Clinical Research","city":"Tucson","region":"Arizona","country":"United States","cc":"US","lat":32.21661,"lon":-110.91947,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"85704","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-noble-clinical-research-tucson"},{"id":"nct06564818-del-sol-research-management-tucson","cat":"research","name":"Del Sol Research Management","city":"Tucson","region":"Arizona","country":"United States","cc":"US","lat":32.22743,"lon":-110.9366,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"85715","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-del-sol-research-management-tucson"},{"id":"nct06564818-cenexel-cit-clinical-innovations-inc-bellflower","cat":"research","name":"CenExel CIT (Clinical Innovations, Inc)","city":"Bellflower","region":"California","country":"United States","cc":"US","lat":33.88672,"lon":-118.12892,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"90706","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-cenexel-cit-clinical-innovations-inc-bellflower"},{"id":"nct06564818-kadima-neuropsychiatry-institute-la-jolla","cat":"research","name":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","cc":"US","lat":32.84863,"lon":-117.27387,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92037","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-kadima-neuropsychiatry-institute-la-jolla"},{"id":"nct06564818-bespoke-treatment-lipov-medical-group-los-angeles","cat":"research","name":"Bespoke Treatment/Lipov Medical Group","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.06263,"lon":-118.23403,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"90025","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-bespoke-treatment-lipov-medical-group-los-angeles"},{"id":"nct06564818-catalina-research-institute-montclair","cat":"research","name":"Catalina Research Institute","city":"Montclair","region":"California","country":"United States","cc":"US","lat":40.81506,"lon":-74.21002,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"91763","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-catalina-research-institute-montclair"},{"id":"nct06564818-excell-research-inc-oceanside","cat":"research","name":"Excell Research, Inc","city":"Oceanside","region":"California","country":"United States","cc":"US","lat":33.18453,"lon":-117.37717,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92056","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-excell-research-inc-oceanside"},{"id":"nct06564818-open-mind-therapeutics-san-francisco","cat":"research","name":"Open Mind Therapeutics","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.77347,"lon":-122.41674,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94114","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-open-mind-therapeutics-san-francisco"},{"id":"nct06564818-inland-psychiatric-medical-group-inc-san-juan-capistrano","cat":"research","name":"Inland Psychiatric Medical Group Inc","city":"San Juan Capistrano","region":"California","country":"United States","cc":"US","lat":33.49129,"lon":-117.67276,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92675","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-inland-psychiatric-medical-group-inc-san-juan-capistrano"},{"id":"nct06564818-mountain-view-clinical-research-denver","cat":"research","name":"Mountain View Clinical Research","city":"Denver","region":"Colorado","country":"United States","cc":"US","lat":39.73346,"lon":-104.98606,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"80209","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-mountain-view-clinical-research-denver"},{"id":"nct06564818-starlight-clinical-research-evergreen","cat":"research","name":"Starlight Clinical Research","city":"Evergreen","region":"Colorado","country":"United States","cc":"US","lat":39.628,"lon":-105.31763,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"80439","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-starlight-clinical-research-evergreen"},{"id":"nct06564818-research-centers-of-america-hollywood","cat":"research","name":"Research Centers of America","city":"Hollywood","region":"Florida","country":"United States","cc":"US","lat":34.10008,"lon":-118.33479,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"33024","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-research-centers-of-america-hollywood"},{"id":"nct06564818-k2-medical-research-maitland-maitland","cat":"research","name":"K2 Medical Research-Maitland","city":"Maitland","region":"Florida","country":"United States","cc":"US","lat":28.63526,"lon":-81.35677,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"32751","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-k2-medical-research-maitland-maitland"},{"id":"nct06564818-floridian-neuroscience-institute-miami","cat":"research","name":"Floridian Neuroscience Institute","city":"Miami","region":"Florida","country":"United States","cc":"US","lat":25.76952,"lon":-80.19926,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"33135","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-floridian-neuroscience-institute-miami"},{"id":"nct06564818-segal-trials-west-broward-north-miami","cat":"research","name":"Segal Trials West Broward","city":"North Miami","region":"Florida","country":"United States","cc":"US","lat":25.89635,"lon":-80.19852,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"33161","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-segal-trials-west-broward-north-miami"},{"id":"nct06564818-clinical-neuroscience-solutions-inc-orlando","cat":"research","name":"Clinical Neuroscience Solutions, Inc","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.53359,"lon":-81.38089,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"32801","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-clinical-neuroscience-solutions-inc-orlando"},{"id":"nct06564818-charter-research-orlando","cat":"research","name":"Charter Research","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.53519,"lon":-81.37722,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"32803","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-charter-research-orlando"},{"id":"nct06564818-combined-research-orlando-phase-i-iv-orlando","cat":"research","name":"Combined Research Orlando Phase I-IV","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.54272,"lon":-81.38531,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"32807","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-combined-research-orlando-phase-i-iv-orlando"},{"id":"nct06564818-k2-medical-research-tampa-tampa","cat":"research","name":"K2 Medical Research - Tampa","city":"Tampa","region":"Florida","country":"United States","cc":"US","lat":27.95528,"lon":-82.45283,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"33634","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-k2-medical-research-tampa-tampa"},{"id":"nct06564818-atlanta-center-for-medical-research-cenexel-atlanta","cat":"research","name":"Atlanta Center for Medical Research, CenExel","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.75535,"lon":-84.3805,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30331","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-atlanta-center-for-medical-research-cenexel-atlanta"},{"id":"nct06564818-cenexel-iresearch-atlanta-decatur","cat":"research","name":"CenExel iResearch Atlanta","city":"Decatur","region":"Georgia","country":"United States","cc":"US","lat":39.84676,"lon":-88.96125,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30330","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-cenexel-iresearch-atlanta-decatur"},{"id":"nct06564818-cenexel-iresearch-savannah-savannah","cat":"research","name":"CenExel iResearch Savannah","city":"Savannah","region":"Georgia","country":"United States","cc":"US","lat":32.08858,"lon":-81.10835,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"31405","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-cenexel-iresearch-savannah-savannah"},{"id":"nct06564818-great-lakes-clinical-trials-dba-flourish-research-chicago","cat":"research","name":"Great Lakes Clinical Trials, DBA Flourish Research","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.83935,"lon":-87.63814,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"60640","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-great-lakes-clinical-trials-dba-flourish-research-chicago"},{"id":"nct06564818-uptown-research-institute-chicago","cat":"research","name":"Uptown Research Institute","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.84114,"lon":-87.65132,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"60640","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-uptown-research-institute-chicago"},{"id":"nct06564818-psychiatric-medicine-associates-llc-skokie","cat":"research","name":"Psychiatric Medicine Associates, LLC","city":"Skokie","region":"Illinois","country":"United States","cc":"US","lat":42.02268,"lon":-87.73767,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"60076","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-psychiatric-medicine-associates-llc-skokie"},{"id":"nct06564818-delricht-research-new-orleans","cat":"research","name":"DelRicht Research","city":"New Orleans","region":"Louisiana","country":"United States","cc":"US","lat":29.96665,"lon":-90.07352,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"70115","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-delricht-research-new-orleans"},{"id":"nct06564818-sunstone-medical-pc-rockville","cat":"research","name":"Sunstone Medical, PC","city":"Rockville","region":"Maryland","country":"United States","cc":"US","lat":39.08998,"lon":-77.15855,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"20850","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-sunstone-medical-pc-rockville"},{"id":"nct06564818-adams-clinical-boston-boston","cat":"research","name":"Adams Clinical Boston","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36017,"lon":-71.06556,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"02116","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-adams-clinical-boston-boston"},{"id":"nct06564818-adams-clinical-boston","cat":"research","name":"Adams Clinical","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.35311,"lon":-71.05135,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"02472","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-adams-clinical-boston"},{"id":"nct06564818-elixia-health-springfield","cat":"research","name":"Elixia Health","city":"Springfield","region":"Massachusetts","country":"United States","cc":"US","lat":37.20691,"lon":-93.3029,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"01103","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-elixia-health-springfield"},{"id":"nct06564818-redbird-research-llc-las-vegas","cat":"research","name":"Redbird Research, LLC","city":"Las Vegas","region":"Nevada","country":"United States","cc":"US","lat":36.16975,"lon":-115.12522,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"89119","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-redbird-research-llc-las-vegas"},{"id":"nct06564818-oasis-clinical-trials-las-vegas","cat":"research","name":"Oasis Clinical Trials","city":"Las Vegas","region":"Nevada","country":"United States","cc":"US","lat":36.16928,"lon":-115.14753,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"89121","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-oasis-clinical-trials-las-vegas"},{"id":"nct06564818-global-medical-institutes-princeton-medical-institute-princeton","cat":"research","name":"Global Medical Institutes, Princeton Medical Institute","city":"Princeton","region":"New Jersey","country":"United States","cc":"US","lat":25.54263,"lon":-80.41906,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"08540","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-global-medical-institutes-princeton-medical-institute-princeton"},{"id":"nct06564818-adams-clinical-harlem-new-york","cat":"research","name":"Adams Clinical Harlem","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71253,"lon":-74.00545,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"100029","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-adams-clinical-harlem-new-york"},{"id":"nct06564818-adams-clinical-bronx-the-bronx","cat":"research","name":"Adams Clinical Bronx","city":"The Bronx","region":"New York","country":"United States","cc":"US","lat":40.85178,"lon":-73.87229,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10461","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-adams-clinical-bronx-the-bronx"},{"id":"nct06564818-monroe-biomedical-research-monroe","cat":"research","name":"Monroe Biomedical Research","city":"Monroe","region":"North Carolina","country":"United States","cc":"US","lat":32.52046,"lon":-92.13036,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"28112","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-monroe-biomedical-research-monroe"},{"id":"nct06564818-neurobehavioral-clinical-research-north-canton","cat":"research","name":"Neurobehavioral Clinical Research","city":"North Canton","region":"Ohio","country":"United States","cc":"US","lat":40.87998,"lon":-81.40032,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"44720","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-neurobehavioral-clinical-research-north-canton"},{"id":"nct06564818-adams-clinical-philadelphia-philadelphia","cat":"research","name":"Adams Clinical Philadelphia","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.95045,"lon":-75.16433,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"19104","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-adams-clinical-philadelphia-philadelphia"},{"id":"nct06564818-clinical-neuroscience-solutions-cns-healthcare-memphis","cat":"research","name":"Clinical Neuroscience Solutions, CNS Healthcare","city":"Memphis","region":"Tennessee","country":"United States","cc":"US","lat":35.14732,"lon":-90.0511,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"38119","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-clinical-neuroscience-solutions-cns-healthcare-memphis"},{"id":"nct06564818-insite-clinical-research-llc-desoto","cat":"research","name":"InSite Clinical Research, LLC","city":"DeSoto","region":"Texas","country":"United States","cc":"US","lat":32.58868,"lon":-96.86622,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"75115","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-insite-clinical-research-llc-desoto"},{"id":"nct06564818-zillan-clinical-research-houston","cat":"research","name":"Zillan Clinical Research","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.76455,"lon":-95.35193,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"77433","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-zillan-clinical-research-houston"},{"id":"nct06564818-cedar-clinical-research-murray","cat":"research","name":"Cedar Clinical Research","city":"Murray","region":"Utah","country":"United States","cc":"US","lat":40.67371,"lon":-111.8983,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"84107","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-cedar-clinical-research-murray"},{"id":"nct06564818-inner-space-research-llc-orem","cat":"research","name":"Inner Space Research, LLC","city":"Orem","region":"Utah","country":"United States","cc":"US","lat":40.29384,"lon":-111.68481,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"84058","condg":["Depression"],"nct":"NCT06564818","study":"\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06564818","phase":"Phase 3","enroll":220,"start":"2024-12-17","eid":"x:site:nct06564818-inner-space-research-llc-orem"},{"id":"nct06341426-toronto-western-hospital-toronto","cat":"research","name":"Toronto Western Hospital","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.69481,"lon":-79.40857,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"M5T 2S8","condg":["Depression"],"nct":"NCT06341426","study":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","official":"Joshua Rosenblat, MD, MSc (University Health Network, Toronto)","src":"https://clinicaltrials.gov/study/NCT06341426","phase":"Phase 2","enroll":92,"start":"2024-02-05","eid":"x:site:nct06341426-toronto-western-hospital-toronto"},{"id":"nct06341426-centre-for-addiction-and-mental-health-camh-toronto","cat":"research","name":"Centre for Addiction and Mental Health (CAMH)","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.69499,"lon":-79.4081,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"M6J 1H4","condg":["Depression"],"nct":"NCT06341426","study":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","official":"Joshua Rosenblat, MD, MSc (University Health Network, Toronto)","src":"https://clinicaltrials.gov/study/NCT06341426","phase":"Phase 2","enroll":92,"start":"2024-02-05","eid":"x:site:nct06341426-centre-for-addiction-and-mental-health-camh-toronto"},{"id":"nct05434156-mac-clinical-research-liverpool","cat":"research","name":"MAC Clinical Research","city":"Liverpool","country":"United Kingdom","cc":"GB","lat":53.42258,"lon":-2.98636,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"L34 1BH","condg":["Depression","Healthy volunteers"],"nct":"NCT05434156","study":"ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Eleusis Therapeutics","official":"Neel Bhatt (MAC Clinical Research)","src":"https://clinicaltrials.gov/study/NCT05434156","phase":"Phase 1/Phase 2","enroll":84,"start":"2022-10-27","eid":"x:site:nct05434156-mac-clinical-research-liverpool"},{"id":"nct05434156-mac-clinical-research-manchester","cat":"research","name":"MAC Clinical Research","city":"Manchester","country":"United Kingdom","cc":"GB","lat":53.48523,"lon":-2.24764,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"M13 9NQ","condg":["Depression","Healthy volunteers"],"nct":"NCT05434156","study":"ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Eleusis Therapeutics","official":"Neel Bhatt (MAC Clinical Research)","src":"https://clinicaltrials.gov/study/NCT05434156","phase":"Phase 1/Phase 2","enroll":84,"start":"2022-10-27","eid":"x:site:nct05434156-mac-clinical-research-manchester"},{"id":"nct05317689-university-of-california-san-francisco-san-francisco","cat":"research","name":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.76575,"lon":-122.40798,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94143","condg":["Healthy volunteers"],"nct":"NCT05317689","study":"Comparing the Effects of Psilocin and Psilocybin in Healthy Adults","sstatus":"UNKNOWN","sponsor":"University of California, San Francisco","official":"Joshua Woolley, MD/PhD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT05317689","phase":"Phase 1","enroll":20,"start":"2022-05-26","eid":"x:site:nct05317689-university-of-california-san-francisco-san-francisco"},{"id":"nct05385783-cenexel-acmr-atlanta","cat":"research","name":"CenExel ACMR","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.75404,"lon":-84.39019,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30331","condg":["Depression"],"nct":"NCT05385783","study":"A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Cybin IRL Limited","official":"Amir Inamdar, MBBS,DNB,MFPM (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT05385783","phase":"Phase 1/Phase 2","enroll":57,"start":"2022-08-02","eid":"x:site:nct05385783-cenexel-acmr-atlanta"},{"id":"nct05385783-iresearch-atlanta-decatur","cat":"research","name":"iResearch Atlanta","city":"Decatur","region":"Georgia","country":"United States","cc":"US","lat":39.85099,"lon":-88.95842,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30030","condg":["Depression"],"nct":"NCT05385783","study":"A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Cybin IRL Limited","official":"Amir Inamdar, MBBS,DNB,MFPM (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT05385783","phase":"Phase 1/Phase 2","enroll":57,"start":"2022-08-02","eid":"x:site:nct05385783-iresearch-atlanta-decatur"},{"id":"nct05385783-clinilabs-drug-development-corporation-eatontown","cat":"research","name":"Clinilabs Drug Development Corporation","city":"Eatontown","region":"New Jersey","country":"United States","cc":"US","lat":40.30634,"lon":-74.04866,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"07724","condg":["Depression"],"nct":"NCT05385783","study":"A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Cybin IRL Limited","official":"Amir Inamdar, MBBS,DNB,MFPM (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT05385783","phase":"Phase 1/Phase 2","enroll":57,"start":"2022-08-02","eid":"x:site:nct05385783-clinilabs-drug-development-corporation-eatontown"},{"id":"nct07072728-mind-medicine-australia-clinic-abbotsford","cat":"research","name":"Mind Medicine Australia Clinic","city":"Abbotsford","region":"Victoria","country":"Australia","cc":"AU","lat":-37.79374,"lon":144.99958,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"3067","condg":["Cancer-related distress"],"status":"RECRUITING","nct":"NCT07072728","study":"Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder","sstatus":"RECRUITING","sponsor":"Psyence Australia Pty Ltd","official":"Clive Ward-Able (Psyence Biomedical)","src":"https://clinicaltrials.gov/study/NCT07072728","contact":{"n":"Simon Perdriau","p":"+61 469 837 72","e":"simonperdriau@clarionclinics.com"},"phase":"Phase 2","enroll":87,"start":"2025-10-01","eid":"x:site:nct07072728-mind-medicine-australia-clinic-abbotsford"},{"id":"nct07072728-paratus-clinical-research-melbourne-northcote","cat":"research","name":"Paratus Clinical Research Melbourne","city":"Northcote","region":"Victoria","country":"Australia","cc":"AU","lat":-37.75467,"lon":145.01115,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"3070","condg":["Cancer-related distress"],"status":"RECRUITING","nct":"NCT07072728","study":"Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder","sstatus":"RECRUITING","sponsor":"Psyence Australia Pty Ltd","official":"Clive Ward-Able (Psyence Biomedical)","src":"https://clinicaltrials.gov/study/NCT07072728","contact":{"n":"Bernadette Fitzgibbon","p":"+61 1300 742 326","e":"bernadette.fitzgibbon@paratusclinical.com"},"phase":"Phase 2","enroll":87,"start":"2025-10-01","eid":"x:site:nct07072728-paratus-clinical-research-melbourne-northcote"},{"id":"nct07072728-empax-centre-leederville","cat":"research","name":"Empax Centre","city":"Leederville","region":"Western Australia","country":"Australia","cc":"AU","lat":-31.92513,"lon":115.83272,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"6007","condg":["Cancer-related distress"],"status":"RECRUITING","nct":"NCT07072728","study":"Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder","sstatus":"RECRUITING","sponsor":"Psyence Australia Pty Ltd","official":"Clive Ward-Able (Psyence Biomedical)","src":"https://clinicaltrials.gov/study/NCT07072728","contact":{"n":"Claudia Sullivan","p":"+61 403 768 280","e":"csullivan@emyria.com"},"phase":"Phase 2","enroll":87,"start":"2025-10-01","eid":"x:site:nct07072728-empax-centre-leederville"},{"id":"nct04501653-washington-university-st-louis","cat":"research","name":"Washington University","city":"St Louis","region":"Missouri","country":"United States","cc":"US","lat":38.63052,"lon":-90.18749,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"63110","condg":["Other"],"nct":"NCT04501653","study":"Precision Functional Brain Mapping in Psilocybin","sstatus":"COMPLETED","sponsor":"Washington University School of Medicine","src":"https://clinicaltrials.gov/study/NCT04501653","phase":"EARLY_Phase 1","enroll":11,"start":"2021-06-01","eid":"x:site:nct04501653-washington-university-st-louis"},{"id":"nct06605105-scottsdale-research-institute-phoenix","cat":"research","name":"Scottsdale Research Institute","city":"Phoenix","region":"Arizona","country":"United States","cc":"US","lat":33.44306,"lon":-112.07625,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"85022","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-scottsdale-research-institute-phoenix"},{"id":"nct06605105-behavioral-research-specialists-llc-glendale","cat":"research","name":"Behavioral Research Specialists, LLC","city":"Glendale","region":"California","country":"United States","cc":"US","lat":33.5435,"lon":-112.18161,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"91206","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-behavioral-research-specialists-llc-glendale"},{"id":"nct06605105-kadima-neuropsychiatry-institute-la-jolla","cat":"research","name":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","cc":"US","lat":32.85918,"lon":-117.27613,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92037","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-kadima-neuropsychiatry-institute-la-jolla"},{"id":"nct06605105-trip-clinic-and-psychedelic-science-institute-los-angeles","cat":"research","name":"TRIP Clinic and Psychedelic Science Institute","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.05482,"lon":-118.24006,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"90004","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-trip-clinic-and-psychedelic-science-institute-los-angeles"},{"id":"nct06605105-calneuro-research-group-los-angeles","cat":"research","name":"CalNeuro Research Group","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.04597,"lon":-118.24222,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"90025","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-calneuro-research-group-los-angeles"},{"id":"nct06605105-lipov-medical-group-los-angeles","cat":"research","name":"Lipov Medical Group","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.04202,"lon":-118.24363,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"90025","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-lipov-medical-group-los-angeles"},{"id":"nct06605105-excell-research-inc-oceanside","cat":"research","name":"Excell Research, Inc","city":"Oceanside","region":"California","country":"United States","cc":"US","lat":33.19996,"lon":-117.37115,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92056","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-excell-research-inc-oceanside"},{"id":"nct06605105-open-mind-collective-ucsf-medical-center-mount-zion-san-francisco","cat":"research","name":"Open Mind Collective / UCSF Medical Center - Mount Zion","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.76368,"lon":-122.40902,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94114","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-open-mind-collective-ucsf-medical-center-mount-zion-san-francisco"},{"id":"nct06605105-inland-psychiatric-medical-group-inc-ipmg-research-san-juan-capistra","cat":"research","name":"Inland Psychiatric Medical Group Inc (IPMG Research)","city":"San Juan Capistrano","region":"California","country":"United States","cc":"US","lat":33.51134,"lon":-117.65846,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92675","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-inland-psychiatric-medical-group-inc-ipmg-research-san-juan-capistra"},{"id":"nct06605105-mountain-view-clinical-research-denver","cat":"research","name":"Mountain View Clinical Research","city":"Denver","region":"Colorado","country":"United States","cc":"US","lat":39.73995,"lon":-104.98522,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"80209","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-mountain-view-clinical-research-denver"},{"id":"nct06605105-starlight-clinical-research-evergreen","cat":"research","name":"Starlight Clinical Research","city":"Evergreen","region":"Colorado","country":"United States","cc":"US","lat":39.63958,"lon":-105.31952,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"80439","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-starlight-clinical-research-evergreen"},{"id":"nct06605105-research-centers-of-america-hollywood","cat":"research","name":"Research Centers of America","city":"Hollywood","region":"Florida","country":"United States","cc":"US","lat":34.08982,"lon":-118.32396,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"33024","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-research-centers-of-america-hollywood"},{"id":"nct06605105-clinical-neuroscience-solutions-jacksonville","cat":"research","name":"Clinical Neuroscience Solutions","city":"Jacksonville","region":"Florida","country":"United States","cc":"US","lat":30.34305,"lon":-81.66614,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"32256","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-clinical-neuroscience-solutions-jacksonville"},{"id":"nct06605105-k2-medical-research-lady-lake","cat":"research","name":"K2 Medical Research","city":"Lady Lake","region":"Florida","country":"United States","cc":"US","lat":28.91509,"lon":-81.91133,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"32159","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-k2-medical-research-lady-lake"},{"id":"nct06605105-segal-trials-center-for-psychedelic-research-lauderhill","cat":"research","name":"Segal Trials Center for Psychedelic Research","city":"Lauderhill","region":"Florida","country":"United States","cc":"US","lat":26.12892,"lon":-80.21446,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"33319","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-segal-trials-center-for-psychedelic-research-lauderhill"},{"id":"nct06605105-accel-research-sites-maitland-maitland","cat":"research","name":"Accel Research Sites - Maitland","city":"Maitland","region":"Florida","country":"United States","cc":"US","lat":28.62406,"lon":-81.36618,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"32751","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-accel-research-sites-maitland-maitland"},{"id":"nct06605105-k2-medical-research-maitland","cat":"research","name":"K2 Medical Research","city":"Maitland","region":"Florida","country":"United States","cc":"US","lat":28.62237,"lon":-81.36448,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"32751","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-k2-medical-research-maitland"},{"id":"nct06605105-clinical-neuroscience-solutions-inc-orlando","cat":"research","name":"Clinical Neuroscience Solutions, Inc","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.5429,"lon":-81.38418,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"32801","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-clinical-neuroscience-solutions-inc-orlando"},{"id":"nct06605105-charter-research-orlando","cat":"research","name":"Charter Research","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.54008,"lon":-81.38286,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"32803","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-charter-research-orlando"},{"id":"nct06605105-combined-research-orlando-phase-i-iv-orlando","cat":"research","name":"Combined Research Orlando Phase I-IV","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.52963,"lon":-81.38531,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"32807","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-combined-research-orlando-phase-i-iv-orlando"},{"id":"nct06605105-cenexel-iresearcvh-atlanta-llc-atlanta","cat":"research","name":"Cenexel iResearcvh Atlanta, LLC","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.73964,"lon":-84.39396,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30030","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-cenexel-iresearcvh-atlanta-llc-atlanta"},{"id":"nct06605105-atlanta-center-for-medical-research-atlanta","cat":"research","name":"Atlanta Center For Medical Research","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.75611,"lon":-84.38869,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30331","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-atlanta-center-for-medical-research-atlanta"},{"id":"nct06605105-cenexel-iresearch-savannah","cat":"research","name":"CenExel iResearch","city":"Savannah","region":"Georgia","country":"United States","cc":"US","lat":32.07446,"lon":-81.10995,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"31405","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-cenexel-iresearch-savannah"},{"id":"nct06605105-uptown-research-institute-chicago","cat":"research","name":"Uptown Research Institute","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.84095,"lon":-87.63956,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"60640","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-uptown-research-institute-chicago"},{"id":"nct06605105-psychiatric-medicine-associates-llc-skokie","cat":"research","name":"Psychiatric Medicine Associates, LLC","city":"Skokie","region":"Illinois","country":"United States","cc":"US","lat":42.03303,"lon":-87.73927,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"60076","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-psychiatric-medicine-associates-llc-skokie"},{"id":"nct06605105-psychiatric-medicine-associates-skokie","cat":"research","name":"Psychiatric Medicine Associates","city":"Skokie","region":"Illinois","country":"United States","cc":"US","lat":42.03388,"lon":-87.72525,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"60076","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-psychiatric-medicine-associates-skokie"},{"id":"nct06605105-sunstone-medical-pc-rockville","cat":"research","name":"Sunstone Medical, PC","city":"Rockville","region":"Maryland","country":"United States","cc":"US","lat":39.08518,"lon":-77.15751,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"20850","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-sunstone-medical-pc-rockville"},{"id":"nct06605105-adams-clinical-boston-boston","cat":"research","name":"Adams Clinical Boston","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.34869,"lon":-71.06782,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"02116","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-adams-clinical-boston-boston"},{"id":"nct06605105-elixia-health-springfield","cat":"research","name":"Elixia Health","city":"Springfield","region":"Massachusetts","country":"United States","cc":"US","lat":37.22357,"lon":-93.30309,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"01103","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-elixia-health-springfield"},{"id":"nct06605105-adams-clinical-watertown","cat":"research","name":"Adams Clinical","city":"Watertown","region":"Massachusetts","country":"United States","cc":"US","lat":42.36044,"lon":-71.18674,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"02472","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-adams-clinical-watertown"},{"id":"nct06605105-institute-for-integrative-therapies-eden-prairie","cat":"research","name":"Institute for Integrative Therapies","city":"Eden Prairie","region":"Minnesota","country":"United States","cc":"US","lat":44.86227,"lon":-93.4827,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"55347","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-institute-for-integrative-therapies-eden-prairie"},{"id":"nct06605105-redbird-research-las-vegas","cat":"research","name":"Redbird Research","city":"Las Vegas","region":"Nevada","country":"United States","cc":"US","lat":36.1721,"lon":-115.1304,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"89119","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-redbird-research-las-vegas"},{"id":"nct06605105-global-medical-institutes-princeton-medical-institute-princeton","cat":"research","name":"Global Medical Institutes, Princeton Medical Institute","city":"Princeton","region":"New Jersey","country":"United States","cc":"US","lat":25.54903,"lon":-80.41172,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"08540","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-global-medical-institutes-princeton-medical-institute-princeton"},{"id":"nct06605105-bio-behavioral-health-toms-river","cat":"research","name":"Bio Behavioral Health","city":"Toms River","region":"New Jersey","country":"United States","cc":"US","lat":39.95858,"lon":-74.20013,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"08755","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-bio-behavioral-health-toms-river"},{"id":"nct06605105-adams-clinical-harlem-new-york","cat":"research","name":"Adams Clinical Harlem","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70509,"lon":-74.01411,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10029","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-adams-clinical-harlem-new-york"},{"id":"nct06605105-adams-clinical-bronx-the-bronx","cat":"research","name":"Adams Clinical Bronx","city":"The Bronx","region":"New York","country":"United States","cc":"US","lat":40.85686,"lon":-73.87361,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10461","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-adams-clinical-bronx-the-bronx"},{"id":"nct06605105-neurobehavioral-clinical-research-canton","cat":"research","name":"Neurobehavioral Clinical Research","city":"Canton","region":"Ohio","country":"United States","cc":"US","lat":42.3087,"lon":-83.48908,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"44720","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-neurobehavioral-clinical-research-canton"},{"id":"nct06605105-adams-clinical-philadelphia-philadelphia","cat":"research","name":"Adams Clinical Philadelphia","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.9625,"lon":-75.16451,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"19104","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-adams-clinical-philadelphia-philadelphia"},{"id":"nct06605105-clinical-neuroscience-solutions-cns-healthcare-memphis","cat":"research","name":"Clinical Neuroscience Solutions, CNS Healthcare","city":"Memphis","region":"Tennessee","country":"United States","cc":"US","lat":35.15504,"lon":-90.0446,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"38119","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-clinical-neuroscience-solutions-cns-healthcare-memphis"},{"id":"nct06605105-adams-clinical-dallas-desoto","cat":"research","name":"Adams Clinical Dallas","city":"DeSoto","region":"Texas","country":"United States","cc":"US","lat":32.59932,"lon":-96.85511,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"75115","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-adams-clinical-dallas-desoto"},{"id":"nct06605105-zillan-clinical-research-houston","cat":"research","name":"Zillan Clinical Research","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.76935,"lon":-95.35278,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"77082","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-zillan-clinical-research-houston"},{"id":"nct06605105-cedar-clinical-research-draper","cat":"research","name":"Cedar Clinical Research","city":"Draper","region":"Utah","country":"United States","cc":"US","lat":40.52236,"lon":-111.85577,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"84020","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-cedar-clinical-research-draper"},{"id":"nct06605105-thompson-brain-mind-healthcare-maroochydore","cat":"research","name":"Thompson Brain & Mind Healthcare","city":"Maroochydore","region":"Queensland","country":"Australia","cc":"AU","lat":-26.66022,"lon":153.10372,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"4558","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-thompson-brain-mind-healthcare-maroochydore"},{"id":"nct06605105-ramsay-clinic-melbourne","cat":"research","name":"Ramsay Clinic","city":"Melbourne","region":"Victoria","country":"Australia","cc":"AU","lat":-37.81546,"lon":144.96723,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"3004","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-ramsay-clinic-melbourne"},{"id":"nct06605105-monash-university-notting-hill-notting-hill","cat":"research","name":"Monash University - Notting Hill","city":"Notting Hill","region":"Victoria","country":"Australia","cc":"AU","lat":-37.91493,"lon":145.14501,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"3168","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-monash-university-notting-hill-notting-hill"},{"id":"nct06605105-eginition-hospital-first-department-of-psychiatry-of-the-national-an","cat":"research","name":"Eginition Hospital, First Department of Psychiatry of the National and Kapodistrian University of Athens (NKUA)","city":"Athens","country":"Greece","cc":"GR","lat":37.97468,"lon":23.71753,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-eginition-hospital-first-department-of-psychiatry-of-the-national-an"},{"id":"nct06605105-aristotle-university-of-tessaloniki-thessaloniki","cat":"research","name":"Aristotle University of Tessaloniki","city":"Thessaloniki","country":"Greece","cc":"GR","lat":40.64801,"lon":22.93921,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-aristotle-university-of-tessaloniki-thessaloniki"},{"id":"nct06605105-promente-centrum-neurologii-i-psychogeriatrii-w-bydgoszczy-bydgoszcz","cat":"research","name":"Promente - Centrum Neurologii i Psychogeriatrii w Bydgoszczy","city":"Bydgoszcz","country":"Poland","cc":"PL","lat":53.11931,"lon":18.00268,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"85-133","condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-promente-centrum-neurologii-i-psychogeriatrii-w-bydgoszczy-bydgoszcz"},{"id":"nct06605105-ascend-clinical-research-reading","cat":"research","name":"Ascend Clinical Research","city":"Reading","country":"United Kingdom","cc":"GB","lat":51.44839,"lon":-0.97617,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT06605105","study":"Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Cybin IRL Limited","official":"Clinical Development (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06605105","phase":"Phase 3","enroll":468,"start":"2025-07-18","eid":"x:site:nct06605105-ascend-clinical-research-reading"},{"id":"nct04718792-psychiatric-center-copenhagen-copenhagen","cat":"research","name":"Psychiatric Center Copenhagen","city":"Copenhagen","region":"Frederiksberg","country":"Denmark","cc":"DK","lat":55.67203,"lon":12.56454,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"2000","condg":["Addiction & substance use"],"nct":"NCT04718792","study":"Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study","sstatus":"UNKNOWN","sponsor":"Anders Fink-Jensen, MD, DMSci","official":"Anders Fink-Jensen, Professor (Professor)","src":"https://clinicaltrials.gov/study/NCT04718792","phase":"Phase 2","enroll":10,"start":"2023-02-09","eid":"x:site:nct04718792-psychiatric-center-copenhagen-copenhagen"},{"id":"nct06035900-pharmaceutical-research-unit-amman","cat":"research","name":"Pharmaceutical Research Unit","city":"Amman","country":"Jordan","cc":"JO","lat":31.96044,"lon":35.94414,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"11910","condg":["Other"],"nct":"NCT06035900","study":"Evaluation of Safety, Rate and Extent of Absorption of Psilocin Mucate","sstatus":"COMPLETED","sponsor":"Lobe Sciences Ltd.","official":"Ahmad Abdulkhaleq, MD (Arab Pharmaceutical Industry Pharmaceutical Research)","src":"https://clinicaltrials.gov/study/NCT06035900","phase":"Phase 1","enroll":10,"start":"2023-06-21","eid":"x:site:nct06035900-pharmaceutical-research-unit-amman"},{"id":"nct06471959-centre-for-neurology-studies-surrey","cat":"research","name":"Centre for Neurology Studies","city":"Surrey","region":"British Columbia","country":"Canada","cc":"CA","lat":49.09633,"lon":-122.82015,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"V3V 0C6","condg":["Other"],"status":"RECRUITING","nct":"NCT06471959","study":"Psychedelic-assisted Group Program for First Responders","sstatus":"UNKNOWN","sponsor":"Empower Research Inc","official":"Reginald Peters, MD (University of British Columbia (Clinical Assistant Professor))","src":"https://clinicaltrials.gov/study/NCT06471959","contact":{"n":"Sonia Brodie, CCRP","p":"604-308-5900","e":"soniabrodie@healthtechconnex.com"},"phase":"Phase 1/Phase 2","enroll":32,"start":"2025-01-01","eid":"x:site:nct06471959-centre-for-neurology-studies-surrey"},{"id":"nct07710027-biopharma-services-inc-toronto","cat":"research","name":"BioPharma Services Inc.","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70864,"lon":-79.3905,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"M9L 3A2","condg":["Healthy volunteers"],"nct":"NCT07710027","study":"Identification of a Safe and Non-Psychedelic Dose of Psilocybin","sstatus":"COMPLETED","sponsor":"Diamond Therapeutics Inc.","src":"https://clinicaltrials.gov/study/NCT07710027","phase":"Phase 1","enroll":56,"start":"2021-10-19","eid":"x:site:nct07710027-biopharma-services-inc-toronto"},{"id":"nct07275970-scottsdale-research-institute-scottsdale","cat":"research","name":"Scottsdale Research Institute","city":"Scottsdale","region":"Arizona","country":"United States","cc":"US","lat":33.51359,"lon":-111.89239,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"85022","condg":["PTSD & trauma"],"nct":"NCT07275970","study":"Safety and Preliminary Efficacy of Organic Whole Psilocybin-Containing Mushrooms to Treat Patients Suffering From PTSD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Scottsdale Research Institute","src":"https://clinicaltrials.gov/study/NCT07275970","phase":"Phase 1","enroll":24,"start":"2026-03-20","eid":"x:site:nct07275970-scottsdale-research-institute-scottsdale"},{"id":"nct07490353-medical-university-of-vienna-department-of-psychiatry-and-psychother","cat":"research","name":"Medical University of Vienna, Department of Psychiatry and Psychotherapy, Division of General Psychiatry","city":"Vienna","region":"State of Vienna","country":"Austria","cc":"AT","lat":48.2027,"lon":16.37759,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"1160","condg":["Depression"],"status":"RECRUITING","nct":"NCT07490353","study":"Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects","sstatus":"RECRUITING","sponsor":"Medical University of Vienna","official":"Marie Spies, Priv.-Doz. DDr. (Medical University of Vienna, Department of Psychiatry and Psychotherapy, Division of General Psychiatry)","src":"https://clinicaltrials.gov/study/NCT07490353","contact":{"n":"Marie Spies, Priv.-Doz. DDr.","p":"+43 1 40400","e":"marie.spies@meduniwien.ac.at"},"phase":"Phase 1","enroll":85,"start":"2025-11-01","eid":"x:site:nct07490353-medical-university-of-vienna-department-of-psychiatry-and-psychother"},{"id":"nct06793397-uab-psychiatry-and-behavioral-neurology-birmingham","cat":"research","name":"UAB Psychiatry and Behavioral Neurology","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.5257,"lon":-86.79745,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"35209","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Seher Premani","p":"205-996-1198","e":"spremani@uab.edu"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-uab-psychiatry-and-behavioral-neurology-birmingham"},{"id":"nct06793397-lighthouse-psychiatry-gilbert","cat":"research","name":"Lighthouse Psychiatry","city":"Gilbert","region":"Arizona","country":"United States","cc":"US","lat":33.35871,"lon":-111.77967,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"85234","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Chung Trinh","p":"435-268-5800","e":"ctrinh@neosciclinicalresearch.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-lighthouse-psychiatry-gilbert"},{"id":"nct06793397-pillar-clinical-research-little-rock-little-rock","cat":"research","name":"Pillar Clinical Research - Little Rock","city":"Little Rock","region":"Arkansas","country":"United States","cc":"US","lat":34.7581,"lon":-92.28004,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"72204","condg":["Depression"],"status":"WITHDRAWN","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"877-361-4003","e":"clinicaltrialsinfo@cybin.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-pillar-clinical-research-little-rock-little-rock"},{"id":"nct06793397-behavioral-research-specialists-llc-glendale","cat":"research","name":"Behavioral Research Specialists, LLC","city":"Glendale","region":"California","country":"United States","cc":"US","lat":33.54049,"lon":-112.17681,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"91206","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Laisha Uribe","p":"888-255-5798","e":"laisha@brstrials.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-behavioral-research-specialists-llc-glendale"},{"id":"nct06793397-sun-valley-research-center-imperial","cat":"research","name":"Sun Valley Research Center","city":"Imperial","region":"California","country":"United States","cc":"US","lat":32.8412,"lon":-115.57758,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92251","condg":["Depression"],"status":"WITHDRAWN","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"877-361-4003","e":"clinicaltrialsinfo@cybin.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-sun-valley-research-center-imperial"},{"id":"nct06793397-calneuro-research-group-los-angeles","cat":"research","name":"CalNeuro Research Group","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.04362,"lon":-118.23629,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"90025","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"310-208-7144","e":"info@calneuroresearch.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-calneuro-research-group-los-angeles"},{"id":"nct06793397-lipov-medical-group-los-angeles","cat":"research","name":"Lipov Medical Group","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.04108,"lon":-118.2553,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"90025","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Brittany Juhlmann","p":"262-352-8835","e":"brittany.juhlmann@stellacenter.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-lipov-medical-group-los-angeles"},{"id":"nct06793397-atp-clinical-research-orange","cat":"research","name":"ATP Clinical Research","city":"Orange","region":"California","country":"United States","cc":"US","lat":33.78925,"lon":-117.86257,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92866","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Sarah Perkins","p":"949-354-5353","e":"sarahp@pnsoc.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-atp-clinical-research-orange"},{"id":"nct06793397-nrc-research-institute-orange","cat":"research","name":"NRC Research Institute","city":"Orange","region":"California","country":"United States","cc":"US","lat":33.79348,"lon":-117.84732,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92868","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Christian Ortiz","p":"714-289-1100","e":"cortiz@nrcresearch.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-nrc-research-institute-orange"},{"id":"nct06793397-inland-psychiatric-medical-group-inc-ipmg-research-san-juan-capistra","cat":"research","name":"Inland Psychiatric Medical Group Inc (IPMG Research)","city":"San Juan Capistrano","region":"California","country":"United States","cc":"US","lat":33.50418,"lon":-117.67135,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92675","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"909-955-5865","e":"research@inlandpsych.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-inland-psychiatric-medical-group-inc-ipmg-research-san-juan-capistra"},{"id":"nct06793397-psychedelic-science-institute-santa-monica","cat":"research","name":"Psychedelic Science Institute","city":"Santa Monica","region":"California","country":"United States","cc":"US","lat":34.03036,"lon":-118.49077,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"90404","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"213-973-7512","e":"trialadmin@psychedelicsci.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-psychedelic-science-institute-santa-monica"},{"id":"nct06793397-stanford-university-stanford","cat":"research","name":"Stanford University","city":"Stanford","region":"California","country":"United States","cc":"US","lat":37.4251,"lon":-122.16584,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94305","condg":["Depression"],"status":"WITHDRAWN","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"877-361-4003","e":"clinicaltrialsinfo@cybin.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-stanford-university-stanford"},{"id":"nct06793397-yale-school-of-medicine-yale-program-for-psychedelic-science-new-hav","cat":"research","name":"Yale School of Medicine - Yale Program for Psychedelic Science","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31497,"lon":-72.93781,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"06511","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Daidre Chamberlain","p":"203-693-1591","e":"enact@yale.edu"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-yale-school-of-medicine-yale-program-for-psychedelic-science-new-hav"},{"id":"nct06793397-cns-healthcare-jacksonville","cat":"research","name":"CNS Healthcare","city":"Jacksonville","region":"Florida","country":"United States","cc":"US","lat":30.32159,"lon":-81.65692,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"32256","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"904-281-5757","e":"clinicaltrialsinfo@cybin.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-cns-healthcare-jacksonville"},{"id":"nct06793397-accel-research-sites-maitland-maitland","cat":"research","name":"Accel Research Sites - Maitland","city":"Maitland","region":"Florida","country":"United States","cc":"US","lat":28.62689,"lon":-81.35997,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"32751","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"407-644-1165","e":"clinicaltrialsinfo@cybin.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-accel-research-sites-maitland-maitland"},{"id":"nct06793397-aqualane-clinical-research-naples","cat":"research","name":"Aqualane Clinical Research","city":"Naples","region":"Florida","country":"United States","cc":"US","lat":26.1437,"lon":-81.80457,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"34105","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Rachel Novella","p":"239-529-6780","e":"Rachel@Aqualaneresearch.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-aqualane-clinical-research-naples"},{"id":"nct06793397-k2-medical-research-tampa-tampa","cat":"research","name":"K2 Medical Research Tampa","city":"Tampa","region":"Florida","country":"United States","cc":"US","lat":27.9567,"lon":-82.45819,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"33634","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Jessica Myers","p":"352-500-5252","e":"Jessica.Myers@k2med.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-k2-medical-research-tampa-tampa"},{"id":"nct06793397-emory-university-dept-of-psychiatry-and-behavioral-studies-atlanta","cat":"research","name":"Emory University Dept of Psychiatry and Behavioral Studies","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.74867,"lon":-84.39876,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30329","condg":["Depression"],"status":"WITHDRAWN","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"877-361-4003","e":"clinicaltrialsinfo@cybin.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-emory-university-dept-of-psychiatry-and-behavioral-studies-atlanta"},{"id":"nct06793397-psych-atlanta-marietta","cat":"research","name":"Psych Atlanta","city":"Marietta","region":"Georgia","country":"United States","cc":"US","lat":33.95406,"lon":-84.54659,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30060","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"770-422-2846","e":"research@hightophealth.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-psych-atlanta-marietta"},{"id":"nct06793397-rush-university-chicago","cat":"research","name":"Rush University","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.85092,"lon":-87.6452,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"60612","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Stephanie Gutierrez","p":"312-942-8995","e":"stephanie_z_gutierrez@rush.edu"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-rush-university-chicago"},{"id":"nct06793397-tandem-clinical-research-marrero","cat":"research","name":"Tandem Clinical Research","city":"Marrero","region":"Louisiana","country":"United States","cc":"US","lat":29.89641,"lon":-90.10219,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"70006","condg":["Depression"],"status":"WITHDRAWN","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"877-361-4003","e":"clinicaltrialsinfo@cybin.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-tandem-clinical-research-marrero"},{"id":"nct06793397-atlas-psychiatry-new-orleans","cat":"research","name":"Atlas Psychiatry","city":"New Orleans","region":"Louisiana","country":"United States","cc":"US","lat":29.9467,"lon":-90.06307,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"70115","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Milton Boresoff","p":"504-899-1682","e":"m.boresoff@atlaspsychiatry.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-atlas-psychiatry-new-orleans"},{"id":"nct06793397-johns-hopkins-medicine-baltimore","cat":"research","name":"Johns Hopkins Medicine","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.302,"lon":-76.6017,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Depression"],"status":"WITHDRAWN","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"877-361-4003","e":"clinicaltrialsinfo@cybin.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-johns-hopkins-medicine-baltimore"},{"id":"nct06793397-sunstone-medical-pc-rockville","cat":"research","name":"Sunstone Medical, PC","city":"Rockville","region":"Maryland","country":"United States","cc":"US","lat":39.09101,"lon":-77.15422,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"20850","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Manish Agrawal, MD","p":"301-750-3401","e":"Manish.agrawal@sunstonetherapies.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-sunstone-medical-pc-rockville"},{"id":"nct06793397-adams-clinical-boston-boston","cat":"research","name":"Adams Clinical Boston","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.34709,"lon":-71.05775,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"02116","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Darin Dougherty, MD","p":"617-934-5733","e":"ddougherty@adamsclinical.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-adams-clinical-boston-boston"},{"id":"nct06793397-institute-for-integrative-therapies-eden-prairie","cat":"research","name":"Institute for Integrative Therapies","city":"Eden Prairie","region":"Minnesota","country":"United States","cc":"US","lat":44.84467,"lon":-93.47752,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"55347","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Sena Ostwalt","p":"651-280-8774","e":"sena.ostwalt@iit-mn.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-institute-for-integrative-therapies-eden-prairie"},{"id":"nct06793397-the-remedy-mental-health-golden-valley","cat":"research","name":"The Remedy Mental Health","city":"Golden Valley","region":"Minnesota","country":"United States","cc":"US","lat":44.99967,"lon":-93.35707,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"55427","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Emmanuel Arhin","p":"651-382-9518","e":"emmanuel.arhin@theremedymn.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-the-remedy-mental-health-golden-valley"},{"id":"nct06793397-redbird-research-llc-las-vegas","cat":"research","name":"Redbird Research, LLC","city":"Las Vegas","region":"Nevada","country":"United States","cc":"US","lat":36.17812,"lon":-115.12776,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"89119","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"702-577-2000","e":"info@redbird-research.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-redbird-research-llc-las-vegas"},{"id":"nct06793397-bio-behavioral-health-toms-river","cat":"research","name":"Bio Behavioral Health","city":"Toms River","region":"New Jersey","country":"United States","cc":"US","lat":39.94945,"lon":-74.19947,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"08755","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Jessica Sutton","p":"732-244-2299","e":"jessica@bbhnj.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-bio-behavioral-health-toms-river"},{"id":"nct06793397-adams-clinical-harlem-new-york","cat":"research","name":"Adams Clinical Harlem","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72561,"lon":-73.99566,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10029","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Kayla Collins","p":"917-423-6797","e":"kcollins@adamsclinical.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-adams-clinical-harlem-new-york"},{"id":"nct06793397-new-york-state-psychiatric-institute-new-york","cat":"research","name":"New York State Psychiatric Institute","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.7098,"lon":-73.99632,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10032","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Alexandra Mackay","p":"212-342-1424","e":"alexandra.mackay@nyspi.columbia.edu"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-new-york-state-psychiatric-institute-new-york"},{"id":"nct06793397-davis-clinical-adams-clinical-bronx-the-bronx","cat":"research","name":"Davis Clinical (Adams Clinical Bronx)","city":"The Bronx","region":"New York","country":"United States","cc":"US","lat":40.83992,"lon":-73.87295,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10461","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Daniela Grimard","p":"646-970-7804","e":"dgrimard@adamsclinical.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-davis-clinical-adams-clinical-bronx-the-bronx"},{"id":"nct06793397-adams-clinical-watertown-watertown","cat":"research","name":"Adams Clinical Watertown","city":"Watertown","region":"New York","country":"United States","cc":"US","lat":42.36919,"lon":-71.17732,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"02472","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Stephanie Ellickson","p":"574-514-4554","e":"sellickson@adamsclinical.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-adams-clinical-watertown-watertown"},{"id":"nct06793397-sp-research-pllc-oklahoma-city","cat":"research","name":"SP Research PLLC","city":"Oklahoma City","region":"Oklahoma","country":"United States","cc":"US","lat":35.47109,"lon":-97.50622,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"73112","condg":["Depression"],"status":"WITHDRAWN","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"877-361-4003","e":"clinicaltrialsinfo@cybin.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-sp-research-pllc-oklahoma-city"},{"id":"nct06793397-adams-clinical-philadelphia-philadelphia","cat":"research","name":"Adams Clinical Philadelphia","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.96062,"lon":-75.1647,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"19104","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"267-207-2511","e":"info@adamsclinical.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-adams-clinical-philadelphia-philadelphia"},{"id":"nct06793397-flourish-research-philadelphia-philadelphia","cat":"research","name":"Flourish Research Philadelphia","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.94377,"lon":-75.16009,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"19462","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"215-614-5606","e":"clinicaltrialsinfo@cybin.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-flourish-research-philadelphia-philadelphia"},{"id":"nct06793397-austin-clinical-trial-partners-austin","cat":"research","name":"Austin Clinical Trial Partners","city":"Austin","region":"Texas","country":"United States","cc":"US","lat":30.25779,"lon":-97.75478,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"78737","condg":["Depression"],"status":"WITHDRAWN","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"877-361-4003","e":"clinicaltrialsinfo@cybin.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-austin-clinical-trial-partners-austin"},{"id":"nct06793397-adams-clinical-dallas-desoto","cat":"research","name":"Adams Clinical Dallas","city":"DeSoto","region":"Texas","country":"United States","cc":"US","lat":32.60073,"lon":-96.85182,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"75115","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Camille Condron","p":"972-283-6286","e":"ccondron@adamsclinical.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-adams-clinical-dallas-desoto"},{"id":"nct06793397-north-texas-clinical-trials-fort-worth","cat":"research","name":"North Texas Clinical Trials","city":"Fort Worth","region":"Texas","country":"United States","cc":"US","lat":32.71934,"lon":-97.31092,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"76104","condg":["Depression"],"status":"WITHDRAWN","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"877-361-4003","e":"clinicaltrialsinfo@cybin.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-north-texas-clinical-trials-fort-worth"},{"id":"nct06793397-brain-health-consultants-and-tms-center-houston","cat":"research","name":"Brain Health Consultants and TMS Center","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.76464,"lon":-95.35532,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"77046","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"713-489-5000","e":"info@brainhealthconsultants.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-brain-health-consultants-and-tms-center-houston"},{"id":"nct06793397-flourish-research-san-antonio-san-antonio","cat":"research","name":"Flourish Research San Antonio","city":"San Antonio","region":"Texas","country":"United States","cc":"US","lat":29.42925,"lon":-98.48398,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"78229","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Xavier Martinez","p":"210-949-0122","e":"xmartinez@flourishresearch.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-flourish-research-san-antonio-san-antonio"},{"id":"nct06793397-core-clinical-research-everett","cat":"research","name":"Core Clinical Research","city":"Everett","region":"Washington","country":"United States","cc":"US","lat":47.97743,"lon":-122.20533,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"98201","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Maria Golescu","p":"425-443-9551","e":"maria.golescu@ccrtrial.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-core-clinical-research-everett"},{"id":"nct06793397-seattle-neuropsychiatric-treatment-center-seattle","cat":"research","name":"Seattle Neuropsychiatric Treatment Center","city":"Seattle","region":"Washington","country":"United States","cc":"US","lat":47.61529,"lon":-122.3404,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"98104","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"206-467-6300","e":"research@seattlentc.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-seattle-neuropsychiatric-treatment-center-seattle"},{"id":"nct06793397-royal-prince-alfred-hospital-camperdown","cat":"research","name":"Royal Prince Alfred Hospital","city":"Camperdown","region":"New South Wales","country":"Australia","cc":"AU","lat":-33.88283,"lon":151.17844,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"2050","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Nicholas Glozier","p":"877-361-4003","e":"clinicaltrialsinfo@cybin.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-royal-prince-alfred-hospital-camperdown"},{"id":"nct06793397-thompson-brain-mind-healthcare-tbmh-maroochydore","cat":"research","name":"Thompson Brain & Mind Healthcare (TBMH)","city":"Maroochydore","region":"Queensland","country":"Australia","cc":"AU","lat":-26.66333,"lon":153.08998,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"4558","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Megan Dutton","p":"+61 4160 40977","e":"mdutton@tbmh.org.au"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-thompson-brain-mind-healthcare-tbmh-maroochydore"},{"id":"nct06793397-ramsay-clinic-melbourne","cat":"research","name":"Ramsay Clinic","city":"Melbourne","region":"Victoria","country":"Australia","cc":"AU","lat":-37.82421,"lon":144.96478,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"3004","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Melanie Hurley","p":"03 9279 3569","e":"research.arc@ramsayhealth.com.au"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-ramsay-clinic-melbourne"},{"id":"nct06793397-neurocentrix-research-melbourne","cat":"research","name":"Neurocentrix Research","city":"Melbourne","region":"Victoria","country":"Australia","cc":"AU","lat":-37.80416,"lon":144.95904,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"3053","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Mai-Anh Bui","p":"+61 3 9546 0009","e":"mai@neurocentrix.com.au"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-neurocentrix-research-melbourne"},{"id":"nct06793397-monash-university-notting-hill-notting-hill","cat":"research","name":"Monash University - Notting Hill","city":"Notting Hill","region":"Victoria","country":"Australia","cc":"AU","lat":-37.90062,"lon":145.13672,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"3168","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Olivia Lavalette","p":"0426359494","e":"olivia.lavalette@monash.edu"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-monash-university-notting-hill-notting-hill"},{"id":"nct06793397-institute-of-neuropsychiatric-care-inep-prague","cat":"research","name":"Institute of neuropsychiatric Care (INEP)","city":"Prague","country":"Czechia","cc":"CZ","lat":50.09938,"lon":14.41403,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"+420 222 201 020","e":"info@inep.cz"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-institute-of-neuropsychiatric-care-inep-prague"},{"id":"nct06793397-psyon-s-r-o-prague","cat":"research","name":"Psyon s.r.o.","city":"Prague","country":"Czechia","cc":"CZ","lat":50.0846,"lon":14.41318,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"+420 774 401 161","e":"info@psyon.cz"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-psyon-s-r-o-prague"},{"id":"nct06793397-a-shine-s-r-o-predmesti","cat":"research","name":"A-SHINE s.r.o.","city":"Předměstí","country":"Czechia","cc":"CZ","lat":50.0978,"lon":14.7443,"gp":"country","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Blanka Vopelková","p":"+490 777 732 244","e":"blanka.vopelkova@seznam.cz"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-a-shine-s-r-o-predmesti"},{"id":"nct06793397-universitatsklinikum-des-saarlandes-und-medizinische-fakultat-der-un","cat":"research","name":"Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes","city":"Homburg","region":"Saarland","country":"Germany","cc":"DE","lat":49.31766,"lon":7.34634,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"66421","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Christine Geiger","p":"+49 6841 1624227","e":"christine.geiger@uks.eu"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-universitatsklinikum-des-saarlandes-und-medizinische-fakultat-der-un"},{"id":"nct06793397-charite-universitaetsmedizin-berlin-berlin","cat":"research","name":"Charité Universitaetsmedizin Berlin","city":"Berlin","country":"Germany","cc":"DE","lat":52.53035,"lon":13.40069,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10117","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"+49 30 450 617734","e":"psychedelika-studien@charite.de"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-charite-universitaetsmedizin-berlin-berlin"},{"id":"nct06793397-university-hospital-frankfurt-frankfurt-am-main","cat":"research","name":"University Hospital Frankfurt","city":"Frankfurt am Main","country":"Germany","cc":"DE","lat":50.12046,"lon":8.68535,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"60528","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"SIgrid Schichtel","p":"+496963015222","e":"schichtel@med.uni-frankfurt.de"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-university-hospital-frankfurt-frankfurt-am-main"},{"id":"nct06793397-central-institute-of-mental-health-mannheim","cat":"research","name":"Central Institute of Mental Health","city":"Mannheim","country":"Germany","cc":"DE","lat":49.49734,"lon":8.47198,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"68159","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Karin Bopp","p":"+49 621 1703 3163","e":"Karin.bopp@zi-mannheim.de"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-central-institute-of-mental-health-mannheim"},{"id":"nct06793397-eginitio-hospital-athens","cat":"research","name":"Eginitio Hospital","city":"Athens","country":"Greece","cc":"GR","lat":37.9919,"lon":23.71819,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"11528","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Adam Adamopoulos","p":"+30 6976032181","e":"adam_adamopoulos@yahoo.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-eginitio-hospital-athens"},{"id":"nct06793397-attikon-university-hospital-athens","cat":"research","name":"Attikon University Hospital","city":"Athens","country":"Greece","cc":"GR","lat":37.9775,"lon":23.71631,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"12462","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Thomas Karantinos","p":"+30697466610","e":"tkarantinos@gmail.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-attikon-university-hospital-athens"},{"id":"nct06793397-papageorgiou-general-hospital-thessaloniki","cat":"research","name":"Papageorgiou General Hospital","city":"Thessaloniki","country":"Greece","cc":"GR","lat":40.63625,"lon":22.94655,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"56404","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Ogla Vampertzi","p":"+306973852659","e":"olgatrieste@hotmail.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-papageorgiou-general-hospital-thessaloniki"},{"id":"nct06793397-sheaf-house-tallaght-adult-mental-health-service-dublin","cat":"research","name":"Sheaf House - Tallaght Adult Mental Health Service","city":"Dublin","country":"Ireland","cc":"IE","lat":53.33668,"lon":-6.25825,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"D24 WK80","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Ann Connolly","p":"+353 8616 79619","e":"aconnolly@crp.healthcare"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-sheaf-house-tallaght-adult-mental-health-service-dublin"},{"id":"nct06793397-la-nua-day-hospital-mental-health-centre-galway","cat":"research","name":"La Nua Day Hospital Mental Health Centre","city":"Galway","country":"Ireland","cc":"IE","lat":53.2741,"lon":-9.05542,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"H91 VE03","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Prathyusha Nedunuru","p":"+353 874283750","e":"pnedunuru@crp.healthcare"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-la-nua-day-hospital-mental-health-centre-galway"},{"id":"nct06793397-uniwersytecki-szpital-kliniczny-w-bia-ymstoku-bialystok","cat":"research","name":"Uniwersytecki Szpital Kliniczny W Białymstoku","city":"Bialystok","country":"Poland","cc":"PL","lat":53.13046,"lon":23.17087,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"15-272","condg":["Depression"],"status":"WITHDRAWN","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"877-361-4003","e":"clinicaltrialsinfo@cybin.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-uniwersytecki-szpital-kliniczny-w-bia-ymstoku-bialystok"},{"id":"nct06793397-promente-centrum-neurologii-i-psychogeriatrii-w-bydgoszczy-bydgoszcz","cat":"research","name":"Promente - Centrum Neurologii i Psychogeriatrii w Bydgoszczy","city":"Bydgoszcz","country":"Poland","cc":"PL","lat":53.11564,"lon":18.01491,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"85-133","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Franciszek Lauchut","p":"+48 790 219 501","e":"f.lachut@pro-mente.pl"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-promente-centrum-neurologii-i-psychogeriatrii-w-bydgoszczy-bydgoszcz"},{"id":"nct06793397-uck-gdansk","cat":"research","name":"UCK","city":"Gdansk","country":"Poland","cc":"PL","lat":54.34196,"lon":18.65726,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"80-214","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Natalia Sudol","p":"+48 669 439 740","e":"nat.sudol13@gmail.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-uck-gdansk"},{"id":"nct06793397-centrum-badan-klinicznych-pi-house-sp-z-o-o-gdansk","cat":"research","name":"Centrum Badan Klinicznych PI-House Sp. z o.o","city":"Gdansk","country":"Poland","cc":"PL","lat":54.34771,"lon":18.65651,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"80-546","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Monika Drzewiecka","p":"+48 508-348-938","e":"m.drzewiecka@pihouse.pl"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-centrum-badan-klinicznych-pi-house-sp-z-o-o-gdansk"},{"id":"nct06793397-mtz-clinical-research-powered-by-pratia-warsaw","cat":"research","name":"MTZ Clinical Research Powered by Pratia","city":"Warsaw","country":"Poland","cc":"PL","lat":52.23669,"lon":21.01126,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"02-172","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Monika Gawlowicz","p":"877-361-4003","e":"clinicaltrialsinfo@cybin.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-mtz-clinical-research-powered-by-pratia-warsaw"},{"id":"nct06793397-department-of-pharmacology-and-physiology-of-cns-warsaw","cat":"research","name":"Department of Pharmacology and Physiology of CNS","city":"Warsaw","country":"Poland","cc":"PL","lat":52.23217,"lon":21.00844,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"02-957","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Justyna Holka-Pokorska","p":"877-361-4003","e":"clinicaltrialsinfo@cybin.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-department-of-pharmacology-and-physiology-of-cns-warsaw"},{"id":"nct06793397-cambridge-university-hospital-nhs-cambridge","cat":"research","name":"Cambridge University Hospital NHS","city":"Cambridge","country":"United Kingdom","cc":"GB","lat":52.18875,"lon":0.10533,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"CB1 2EU","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Tracy Assari","p":"+44 1223 219751","e":"t.assari@nhs.net"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-cambridge-university-hospital-nhs-cambridge"},{"id":"nct06793397-clerkenwell-health-doncaster-doncaster","cat":"research","name":"Clerkenwell Health - Doncaster","city":"Doncaster","country":"United Kingdom","cc":"GB","lat":53.51405,"lon":-1.13902,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"DN4 8QN","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Celia Creaghan","p":"+44 7849 640886","e":"ccreaghan@clerkenwellhealth.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-clerkenwell-health-doncaster-doncaster"},{"id":"nct06793397-nhs-research-scotland-edinburgh","cat":"research","name":"NHS Research Scotland","city":"Edinburgh","country":"United Kingdom","cc":"GB","lat":55.94919,"lon":-3.18476,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"EH16 4TJ","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Carrie Wardhaugh","p":"+44 1315375867","e":"carrie.wardhaugh@ed.ac.uk"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-nhs-research-scotland-edinburgh"},{"id":"nct06793397-queen-elizabeth-university-hospital-glasgow","cat":"research","name":"Queen Elizabeth University Hospital","city":"Glasgow","country":"United Kingdom","cc":"GB","lat":55.85908,"lon":-4.26831,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"G51 4TF","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Rebecca Baird","p":"877-361-4003","e":"ggc.mentalhealthresearch@nhs.scot"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-queen-elizabeth-university-hospital-glasgow"},{"id":"nct06793397-st-pancras-clinical-research-london","cat":"research","name":"St Pancras Clinical Research","city":"London","country":"United Kingdom","cc":"GB","lat":51.50237,"lon":-0.13652,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"EC2Y 8EA","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Katherine Nuttall","p":"+44 20 38651142","e":"katherinenuttall@stpancrasclinical.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-st-pancras-clinical-research-london"},{"id":"nct06793397-king-s-college-london-london","cat":"research","name":"King's College London","city":"London","country":"United Kingdom","cc":"GB","lat":51.50189,"lon":-0.13708,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"SE5 9RS","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Catheine Bird","p":"877-361-4003","e":"catherine.bird@kcl.ac.uk"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-king-s-college-london-london"},{"id":"nct06793397-clerkenwell-health-welbeck-street-london","cat":"research","name":"Clerkenwell Health - Welbeck Street","city":"London","country":"United Kingdom","cc":"GB","lat":51.51931,"lon":-0.12842,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"W1G 8DR","condg":["Depression"],"status":"WITHDRAWN","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"877-361-4003","e":"clinicaltrialsinfo@cybin.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-clerkenwell-health-welbeck-street-london"},{"id":"nct06793397-re-cognition-health-london","cat":"research","name":"Re:Cognition Health","city":"London","country":"United Kingdom","cc":"GB","lat":51.50999,"lon":-0.13379,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"W1G9 RU","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Clinical Development","p":"+44-0800-802-1030","e":"clinicaltrialsinfo@cybin.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-re-cognition-health-london"},{"id":"nct06793397-clerkenwell-health-baker-street-london","cat":"research","name":"Clerkenwell Health - Baker Street","city":"London","country":"United Kingdom","cc":"GB","lat":51.50745,"lon":-0.13322,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"W1U 6RP","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Victor Jardim","p":"+44 2038974867","e":"vjardim@clerkenwellhealth.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-clerkenwell-health-baker-street-london"},{"id":"nct06793397-edwardson-building-campus-for-ageing-and-vitality-newcastle-upon-tyn","cat":"research","name":"Edwardson Building - Campus for Ageing and Vitality","city":"Newcastle upon Tyne","country":"United Kingdom","cc":"GB","lat":54.97502,"lon":-1.61815,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"NE4 5PL","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Victoria Wilson","p":"+44 191 246 8647","e":"victoria.wilson3@cntw.nhs.uk"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-edwardson-building-campus-for-ageing-and-vitality-newcastle-upon-tyn"},{"id":"nct06793397-ascend-clinical-research-reading","cat":"research","name":"Ascend Clinical Research","city":"Reading","country":"United Kingdom","cc":"GB","lat":51.46006,"lon":-0.96779,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"RG7 8PA","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Alexandra Diaz","p":"+44 118 3045905","e":"adiaz@ascendclinical-research.com"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-ascend-clinical-research-reading"},{"id":"nct06793397-sheffield-health-and-social-care-nhs-foundation-trust-sheffield","cat":"research","name":"Sheffield Health and Social Care NHS Foundation Trust","city":"Sheffield","country":"United Kingdom","cc":"GB","lat":53.39168,"lon":-1.46134,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"S4 7QQ","condg":["Depression"],"status":"RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Mishell Cunningham","p":"+44 114 271 6731","e":"mishell.cunningham@sheffieldpartnership.nhs.uk"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-sheffield-health-and-social-care-nhs-foundation-trust-sheffield"},{"id":"nct06793397-hollins-park-hospital-winwick-warrington","cat":"research","name":"Hollins Park Hospital, Winwick","city":"Warrington","country":"United Kingdom","cc":"GB","lat":53.4004,"lon":-2.59036,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"WA2 8WA","condg":["Depression"],"status":"NOT_YET_RECRUITING","nct":"NCT06793397","study":"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Cybin IRL Limited","official":"Felix Mazer (Cybin IRL Limited)","src":"https://clinicaltrials.gov/study/NCT06793397","contact":{"n":"Rachel Crick","p":"+44730 861 3597","e":"Rachel.Crick@merseycare.nhs.uk"},"phase":"Phase 3","enroll":330,"start":"2025-12-10","eid":"x:site:nct06793397-hollins-park-hospital-winwick-warrington"},{"id":"nct05305105-behavioral-pharmacology-research-unit-baltimore","cat":"research","name":"Behavioral Pharmacology Research Unit","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29871,"lon":-76.60264,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Other"],"nct":"NCT05305105","study":"Effects of Psilocybin in Post-Treatment Lyme Disease","sstatus":"COMPLETED","sponsor":"Johns Hopkins University","official":"Albert Garcia-Romeu, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT05305105","phase":"Phase 1","enroll":20,"start":"2022-07-01","eid":"x:site:nct05305105-behavioral-pharmacology-research-unit-baltimore"},{"id":"nct02981173-va-connecticut-healthcare-system-west-haven","cat":"research","name":"VA Connecticut Healthcare System","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.27041,"lon":-72.94004,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"06516","condg":["Chronic pain & headache"],"nct":"NCT02981173","study":"Psilocybin for the Treatment of Cluster Headache","sstatus":"COMPLETED","sponsor":"Yale University","src":"https://clinicaltrials.gov/study/NCT02981173","phase":"Phase 1","enroll":25,"start":"2016-12-05","eid":"x:site:nct02981173-va-connecticut-healthcare-system-west-haven"},{"id":"nct03181529-behavioral-pharmacology-research-unit-johns-hopkins-bayview-medical-","cat":"research","name":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29579,"lon":-76.61035,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Depression"],"nct":"NCT03181529","study":"Effects of Psilocybin in Major Depressive Disorder","sstatus":"COMPLETED","sponsor":"Johns Hopkins University","official":"Roland R Griffiths, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT03181529","phase":"Phase 2","enroll":27,"start":"2017-08-10","eid":"x:site:nct03181529-behavioral-pharmacology-research-unit-johns-hopkins-bayview-medical-"},{"id":"nct06512194-vail-health-behavioral-health-edwards","cat":"research","name":"Vail Health Behavioral Health","city":"Edwards","region":"Colorado","country":"United States","cc":"US","lat":39.6361,"lon":-106.58973,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"81632","condg":["Depression"],"status":"RECRUITING","nct":"NCT06512194","study":"Investigation to Understand and Optimize Psilocybin","sstatus":"RECRUITING","sponsor":"Charles Raison","official":"Charles Raison, MD (Vail Health Behavioral Health)","src":"https://clinicaltrials.gov/study/NCT06512194","contact":{"n":"Program Manager","p":"(970) 855-7374","e":"bhic@vailhealth.org"},"phase":"Phase 2","enroll":141,"start":"2025-05-13","eid":"x:site:nct06512194-vail-health-behavioral-health-edwards"},{"id":"nct06988319-oregon-health-science-university-portland","cat":"research","name":"Oregon Health & Science University","city":"Portland","region":"Oregon","country":"United States","cc":"US","lat":45.52359,"lon":-122.67861,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"97239","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06988319","study":"Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study","sstatus":"RECRUITING","sponsor":"Oregon Health and Science University","src":"https://clinicaltrials.gov/study/NCT06988319","contact":{"n":"Lynne Shinto, ND, MPH","p":"(503) 494-5035","e":"shintol@ohsu.edu"},"phase":"Phase 1","enroll":15,"start":"2026-11-01","eid":"x:site:nct06988319-oregon-health-science-university-portland"},{"id":"nct06786325-university-of-pennsylvania-philadelphia","cat":"research","name":"University of Pennsylvania","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.95949,"lon":-75.16084,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"19104","condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT06786325","study":"Wellcome Leap Psilocybin for OUD","sstatus":"RECRUITING","sponsor":"Anna Rose Childress, Ph.D.","src":"https://clinicaltrials.gov/study/NCT06786325","contact":{"n":"Megan Ivey, MS","p":"215-746-7712","e":"megan.ivey@pennmedicine.upenn.edu"},"phase":"Phase 2","enroll":36,"start":"2025-10-07","eid":"x:site:nct06786325-university-of-pennsylvania-philadelphia"},{"id":"nct06001749-dana-farber-cancer-institute-boston","cat":"research","name":"Dana-Farber Cancer Institute","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.35989,"lon":-71.07073,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"02215","condg":["Addiction & substance use","Cancer-related distress","Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06001749","study":"Psilocybin in Cancer Pain Study","sstatus":"RECRUITING","sponsor":"Yvan Beaussant, MD, MSci","official":"Yvan Beaussant, MD (Dana-Farber Cancer Institute)","src":"https://clinicaltrials.gov/study/NCT06001749","contact":{"n":"Isabel Kristan","p":"857-215-1476","e":"patresearch@dfci.harvard.edu"},"phase":"Phase 2","enroll":15,"start":"2024-09-23","eid":"x:site:nct06001749-dana-farber-cancer-institute-boston"},{"id":"nct05554094-ohio-state-university-department-of-psychiatry-and-behavioral-health","cat":"research","name":"Ohio State University Department of Psychiatry and Behavioral Health at the Davis Medical Research Center","city":"Columbus","region":"Ohio","country":"United States","cc":"US","lat":39.9633,"lon":-83.00853,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"43210","condg":["PTSD & trauma"],"nct":"NCT05554094","study":"Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","official":"Alan K Davis, PhD (Ohio State University)","src":"https://clinicaltrials.gov/study/NCT05554094","phase":"Phase 2","enroll":15,"start":"2023-01-01","eid":"x:site:nct05554094-ohio-state-university-department-of-psychiatry-and-behavioral-health"},{"id":"nct07732166-centro-de-pesquisas-matteo-ricci-rio-de-janeiro","cat":"research","name":"Centro de Pesquisas Matteo Ricci","city":"Rio de Janeiro","region":"Rio de Janeiro","country":"Brazil","cc":"BR","lat":-22.90346,"lon":-43.18981,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"22451-263","condg":["Healthy volunteers"],"status":"RECRUITING","nct":"NCT07732166","study":"Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin.","sstatus":"RECRUITING","sponsor":"Pontifícia Universidade Católica do Rio de Janeiro","src":"https://clinicaltrials.gov/study/NCT07732166","contact":{"n":"Mograbi","p":"+ 55 21 35272505","e":"mograbilab@gmail.com"},"phase":"EARLY_Phase 1","enroll":100,"start":"2026-04-01","eid":"x:site:nct07732166-centro-de-pesquisas-matteo-ricci-rio-de-janeiro"},{"id":"nct06943573-djavad-mowafaghian-centre-for-brain-health-vancouver","cat":"research","name":"Djavad Mowafaghian Centre for Brain Health","city":"Vancouver","region":"British Columbia","country":"Canada","cc":"CA","lat":49.24641,"lon":-123.11468,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"V6T 1Z3","condg":["Depression","Bipolar"],"status":"RECRUITING","nct":"NCT06943573","study":"Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder","sstatus":"RECRUITING","sponsor":"Lakshmi N Yatham","official":"Dr. Lakshmi N Yatham (UBC Department of Psychiatry)","src":"https://clinicaltrials.gov/study/NCT06943573","contact":{"n":"Vy Ngo","p":"604-822-3769","e":"vy.ngo@ubc.ca"},"phase":"Phase 2","enroll":90,"start":"2026-06-15","eid":"x:site:nct06943573-djavad-mowafaghian-centre-for-brain-health-vancouver"},{"id":"nct06943573-department-of-psychiatry-university-of-ottawa-the-ottawa-hospital-ot","cat":"research","name":"Department of Psychiatry, University of Ottawa, The Ottawa Hospital","city":"Ottawa","region":"Ontario","country":"Canada","cc":"CA","lat":45.41159,"lon":-75.70758,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"K1H 8L6","condg":["Depression","Bipolar"],"status":"NOT_YET_RECRUITING","nct":"NCT06943573","study":"Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder","sstatus":"RECRUITING","sponsor":"Lakshmi N Yatham","official":"Dr. Lakshmi N Yatham (UBC Department of Psychiatry)","src":"https://clinicaltrials.gov/study/NCT06943573","contact":{"n":"Nicole Edgar","p":"613-737-8899","e":"nedgar@ohri.ca"},"phase":"Phase 2","enroll":90,"start":"2026-06-15","eid":"x:site:nct06943573-department-of-psychiatry-university-of-ottawa-the-ottawa-hospital-ot"},{"id":"nct06943573-department-of-psychiatry-university-of-toronto-university-health-net","cat":"research","name":"Department of Psychiatry, University of Toronto, University Health Network,","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70459,"lon":-79.4097,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"M5T 2S8","condg":["Depression","Bipolar"],"status":"NOT_YET_RECRUITING","nct":"NCT06943573","study":"Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder","sstatus":"RECRUITING","sponsor":"Lakshmi N Yatham","official":"Dr. Lakshmi N Yatham (UBC Department of Psychiatry)","src":"https://clinicaltrials.gov/study/NCT06943573","contact":{"n":"Zoe Doyle","p":"437-727-2252","e":"zoe.doyle@uhn.ca"},"phase":"Phase 2","enroll":90,"start":"2026-06-15","eid":"x:site:nct06943573-department-of-psychiatry-university-of-toronto-university-health-net"},{"id":"nct06919640-university-of-california-san-francisco-san-francisco","cat":"research","name":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.78373,"lon":-122.41297,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94143","condg":["Chronic pain & headache"],"nct":"NCT06919640","study":"Psilocybin With Intracranial Neural Sensing","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Joshua Woolley, MD, PhD","official":"Joshua Woolley, MD/PhD (University of California, San Francisco); Prasad Shirvalkar, MD/PhD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT06919640","phase":"Phase 1","enroll":20,"start":"2025-06-01","eid":"x:site:nct06919640-university-of-california-san-francisco-san-francisco"},{"id":"nct05399498-university-of-chicago-chicago","cat":"research","name":"University of Chicago","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.85892,"lon":-87.64633,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"60637","condg":["Depression"],"nct":"NCT05399498","study":"Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder","sstatus":"COMPLETED","sponsor":"University of Chicago","official":"Jon E Grant, MD, JD, MPH (University of Chicago)","src":"https://clinicaltrials.gov/study/NCT05399498","phase":"Phase 2","enroll":9,"start":"2023-11-01","eid":"x:site:nct05399498-university-of-chicago-chicago"},{"id":"nct05029466-canadian-rapid-treatment-centre-of-excellence-crtce-mississauga","cat":"research","name":"Canadian Rapid Treatment Centre of Excellence (CRTCE)","city":"Mississauga","region":"Ontario","country":"Canada","cc":"CA","lat":43.57951,"lon":-79.65072,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"L5G 3H4","condg":["Depression"],"nct":"NCT05029466","study":"Psilocybin for Treatment-Resistant Depression","sstatus":"COMPLETED","sponsor":"Brain and Cognition Discovery Foundation","official":"Joshua D Rosenblat, MD, MSc (Canadian Rapid Treatment Centre of Excellence)","src":"https://clinicaltrials.gov/study/NCT05029466","phase":"Phase 2","enroll":30,"start":"2021-11-19","eid":"x:site:nct05029466-canadian-rapid-treatment-centre-of-excellence-crtce-mississauga"},{"id":"nct06647056-chu-de-nimes-hopital-universitaire-caremeau-nimes","cat":"research","name":"CHU de Nîmes, Hôpital Universitaire Carémeau","city":"Nîmes","country":"France","cc":"FR","lat":43.84037,"lon":4.36762,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30029","condg":["Neurology & cognition"],"nct":"NCT06647056","study":"Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic Seizures","sstatus":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","official":"Ismaël CONEJERO (CHU Nimes)","src":"https://clinicaltrials.gov/study/NCT06647056","phase":"N/A","enroll":4,"start":"2024-12-19","eid":"x:site:nct06647056-chu-de-nimes-hopital-universitaire-caremeau-nimes"},{"id":"nct06160284-yale-university-new-haven","cat":"research","name":"Yale University","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.3178,"lon":-72.93028,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"06520","condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT06160284","study":"Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)","sstatus":"RECRUITING","sponsor":"Yale University","official":"Gustavo Angarita, MD, MHS (Yale University)","src":"https://clinicaltrials.gov/study/NCT06160284","contact":{"n":"Gustavo Angarita, MD, MHS","p":"(203) 974-7536","e":"gustavo.angarita@yale.edu"},"phase":"Phase 1","enroll":12,"start":"2025-05-28","eid":"x:site:nct06160284-yale-university-new-haven"},{"id":"nct07226232-birmingham-va-medical-center-birmingham-al-birmingham","cat":"research","name":"Birmingham VA Medical Center, Birmingham, AL","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.52955,"lon":-86.80753,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"35233-1927","condg":["Depression"],"status":"RECRUITING","nct":"NCT07226232","study":"Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression","sstatus":"RECRUITING","sponsor":"VA Office of Research and Development","official":"Lori Lynne Davis, MD AB (Birmingham VA Medical Center, Birmingham, AL)","src":"https://clinicaltrials.gov/study/NCT07226232","contact":{"n":"Lori L Davis, MD AB","p":"(205) 554-3819","e":"lori.davis@va.gov"},"phase":"Phase 3","enroll":240,"start":"2026-08-03","eid":"x:site:nct07226232-birmingham-va-medical-center-birmingham-al-birmingham"},{"id":"nct07226232-tuscaloosa-va-medical-center-tuscaloosa-al-tuscaloosa","cat":"research","name":"Tuscaloosa VA Medical Center, Tuscaloosa, AL","city":"Tuscaloosa","region":"Alabama","country":"United States","cc":"US","lat":33.20424,"lon":-87.5743,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"35404-5015","condg":["Depression"],"status":"RECRUITING","nct":"NCT07226232","study":"Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression","sstatus":"RECRUITING","sponsor":"VA Office of Research and Development","official":"Lori Lynne Davis, MD AB (Birmingham VA Medical Center, Birmingham, AL)","src":"https://clinicaltrials.gov/study/NCT07226232","contact":{"n":"Patricia Pilkinton, MD","p":"205-554-2000","e":"patricia.pilkinton@va.gov"},"phase":"Phase 3","enroll":240,"start":"2026-08-03","eid":"x:site:nct07226232-tuscaloosa-va-medical-center-tuscaloosa-al-tuscaloosa"},{"id":"nct07226232-va-portland-health-care-system-portland-or-portland","cat":"research","name":"VA Portland Health Care System, Portland, OR","city":"Portland","region":"Oregon","country":"United States","cc":"US","lat":45.51154,"lon":-122.68605,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"97207-2964","condg":["Depression"],"status":"RECRUITING","nct":"NCT07226232","study":"Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression","sstatus":"RECRUITING","sponsor":"VA Office of Research and Development","official":"Lori Lynne Davis, MD AB (Birmingham VA Medical Center, Birmingham, AL)","src":"https://clinicaltrials.gov/study/NCT07226232","contact":{"n":"Christopher Stauffer, MD","p":"503-781-1205","e":"christopher.stauffer@va.gov"},"phase":"Phase 3","enroll":240,"start":"2026-08-03","eid":"x:site:nct07226232-va-portland-health-care-system-portland-or-portland"},{"id":"nct07226232-corporal-michael-j-crescenz-va-medical-center-philadelphia-pa-philad","cat":"research","name":"Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.95892,"lon":-75.15746,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"19104-4551","condg":["Depression"],"status":"RECRUITING","nct":"NCT07226232","study":"Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression","sstatus":"RECRUITING","sponsor":"VA Office of Research and Development","official":"Lori Lynne Davis, MD AB (Birmingham VA Medical Center, Birmingham, AL)","src":"https://clinicaltrials.gov/study/NCT07226232","contact":{"n":"Michael Thase, MD","p":"215-823-5800","e":"michael.thase@va.gov"},"phase":"Phase 3","enroll":240,"start":"2026-08-03","eid":"x:site:nct07226232-corporal-michael-j-crescenz-va-medical-center-philadelphia-pa-philad"},{"id":"nct07226232-va-puget-sound-health-care-system-seattle-division-seattle-wa-seattl","cat":"research","name":"VA Puget Sound Health Care System Seattle Division, Seattle, WA","city":"Seattle","region":"Washington","country":"United States","cc":"US","lat":47.61539,"lon":-122.33099,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"98108-1532","condg":["Depression"],"status":"RECRUITING","nct":"NCT07226232","study":"Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression","sstatus":"RECRUITING","sponsor":"VA Office of Research and Development","official":"Lori Lynne Davis, MD AB (Birmingham VA Medical Center, Birmingham, AL)","src":"https://clinicaltrials.gov/study/NCT07226232","contact":{"n":"Rebecca Hendrickson, MD","p":"206-277-1337","e":"rebecca.hendrickson@va.gov"},"phase":"Phase 3","enroll":240,"start":"2026-08-03","eid":"x:site:nct07226232-va-puget-sound-health-care-system-seattle-division-seattle-wa-seattl"},{"id":"nct06303739-unc-chapel-hill-medical-center-chapel-hill","cat":"research","name":"UNC Chapel Hill Medical Center","city":"Chapel Hill","region":"North Carolina","country":"United States","cc":"US","lat":35.92285,"lon":-79.05739,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"27514","condg":["Depression"],"nct":"NCT06303739","study":"Psilocybin-Assisted Therapy in Treatment-Resistant Depression","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"University of North Carolina, Chapel Hill","official":"Robert K McClure, MD (Director of Interventional Psychiatry)","src":"https://clinicaltrials.gov/study/NCT06303739","phase":"Phase 3","enroll":20,"start":"2024-04-19","eid":"x:site:nct06303739-unc-chapel-hill-medical-center-chapel-hill"},{"id":"nct07104916-the-ohio-state-university-medical-center-columbus","cat":"research","name":"The Ohio State University Medical Center","city":"Columbus","region":"Ohio","country":"United States","cc":"US","lat":39.97214,"lon":-82.98952,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"43210","condg":["Depression","PTSD & trauma"],"status":"RECRUITING","nct":"NCT07104916","study":"Mindfulness-based Psilocybin Therapy for PTSD","sstatus":"RECRUITING","sponsor":"Anthony P King","src":"https://clinicaltrials.gov/study/NCT07104916","contact":{"n":"Anthony King, PhD","p":"7347094744","e":"anthony.king@osumc.edu"},"phase":"Phase 2","enroll":30,"start":"2026-07-01","eid":"x:site:nct07104916-the-ohio-state-university-medical-center-columbus"},{"id":"nct07405606-centre-for-addiction-and-mental-health-toronto","cat":"research","name":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70271,"lon":-79.40763,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression","Addiction & substance use"],"nct":"NCT07405606","study":"Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder","sstatus":"NOT_YET_RECRUITING","sponsor":"Centre for Addiction and Mental Health","src":"https://clinicaltrials.gov/study/NCT07405606","contact":{"n":"Bernard Le Foll","p":"+14165358501","e":"bernard.lefoll@camh.ca"},"phase":"Phase 2","enroll":30,"start":"2026-03","eid":"x:site:nct07405606-centre-for-addiction-and-mental-health-toronto"},{"id":"nct02061293-university-of-new-mexico-health-sciences-center-albuquerque","cat":"research","name":"University of New Mexico Health Sciences Center","city":"Albuquerque","region":"New Mexico","country":"United States","cc":"US","lat":35.08811,"lon":-106.65486,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"87131","condg":["Addiction & substance use"],"nct":"NCT02061293","study":"A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence","sstatus":"COMPLETED","sponsor":"NYU Langone Health","official":"Michael P Bogenschutz, MD (NYU Langone Health)","src":"https://clinicaltrials.gov/study/NCT02061293","phase":"Phase 2","enroll":95,"start":"2014-06","eid":"x:site:nct02061293-university-of-new-mexico-health-sciences-center-albuquerque"},{"id":"nct02061293-clinical-and-translational-science-institute-nyu-langone-medical-cen","cat":"research","name":"Clinical and Translational Science Institute, NYU Langone Medical Center","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71582,"lon":-74.01675,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10016","condg":["Addiction & substance use"],"nct":"NCT02061293","study":"A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence","sstatus":"COMPLETED","sponsor":"NYU Langone Health","official":"Michael P Bogenschutz, MD (NYU Langone Health)","src":"https://clinicaltrials.gov/study/NCT02061293","phase":"Phase 2","enroll":95,"start":"2014-06","eid":"x:site:nct02061293-clinical-and-translational-science-institute-nyu-langone-medical-cen"},{"id":"nct07306364-connecticut-mental-health-center-new-haven","cat":"research","name":"Connecticut Mental Health Center","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.313,"lon":-72.93894,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"06519","condg":["Chronic pain & headache"],"nct":"NCT07306364","study":"Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain","sstatus":"NOT_YET_RECRUITING","sponsor":"Yale University","official":"Joao De Aquino, M.D. (Yale University)","src":"https://clinicaltrials.gov/study/NCT07306364","contact":{"n":"Joao P. De Aquino, M.D.","p":"203-932-5711","e":"joao.deaquinolima@yale.edu"},"phase":"Phase 2","enroll":45,"start":"2026-10","eid":"x:site:nct07306364-connecticut-mental-health-center-new-haven"},{"id":"nct07048743-toronto-general-hospital-toronto","cat":"research","name":"Toronto General Hospital","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.69518,"lon":-79.39398,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"M5G 2C4","condg":["Other"],"status":"RECRUITING","nct":"NCT07048743","study":"Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Caregivers of Patients With Advanced Cancer","sstatus":"RECRUITING","sponsor":"University Health Network, Toronto","official":"Sarah Hales, MD, PhD (Princess Margaret Cancer Centre)","src":"https://clinicaltrials.gov/study/NCT07048743","contact":{"n":"Sarah Hales, MD, PhD","p":"416-340-4800","e":"uhnpprg@uhn.ca"},"phase":"Phase 2","enroll":15,"start":"2025-07-16","eid":"x:site:nct07048743-toronto-general-hospital-toronto"},{"id":"nct07281352-ucla-semel-institute-los-angeles","cat":"research","name":"UCLA Semel Institute","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.05369,"lon":-118.24712,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"90095","condg":["Depression"],"status":"RECRUITING","nct":"NCT07281352","study":"RCT of Psilocybin-assisted CBT for Depression","sstatus":"RECRUITING","sponsor":"University of California, Los Angeles","src":"https://clinicaltrials.gov/study/NCT07281352","contact":{"n":"Shelby Grody","p":"3108254354","e":"UCLAPAT@mednet.ucla.edu"},"phase":"Phase 1/Phase 2","enroll":50,"start":"2026-01-05","eid":"x:site:nct07281352-ucla-semel-institute-los-angeles"},{"id":"nct07347405-the-clinical-and-translational-sciences-research-center-tucson","cat":"research","name":"The Clinical and Translational Sciences Research Center","city":"Tucson","region":"Arizona","country":"United States","cc":"US","lat":32.22263,"lon":-110.9286,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"85724","condg":["OCD"],"status":"RECRUITING","nct":"NCT07347405","study":"Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.","sstatus":"RECRUITING","sponsor":"Francisco A Moreno","official":"Francisco Moreno, MD (University of Arizona)","src":"https://clinicaltrials.gov/study/NCT07347405","contact":{"n":"Study Coordinator","p":"(520) 626-4804","e":"OCD@psychiatry.arizona.edu"},"phase":"Phase 1","enroll":30,"start":"2026-05-18","eid":"x:site:nct07347405-the-clinical-and-translational-sciences-research-center-tucson"},{"id":"nct06796361-clinical-trial-unit-basel","cat":"research","name":"Clinical Trial Unit","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","cc":"CH","lat":47.57001,"lon":7.56485,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"4056","condg":["Healthy volunteers"],"status":"RECRUITING","nct":"NCT06796361","study":"Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness","sstatus":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","src":"https://clinicaltrials.gov/study/NCT06796361","contact":{"n":"Friederike Holze, Doctor","p":"+41613287735","e":"friederike.holze@usb.ch"},"phase":"Phase 1","enroll":16,"start":"2025-04-21","eid":"x:site:nct06796361-clinical-trial-unit-basel"},{"id":"nct06827054-roswell-park-cancer-institute-buffalo","cat":"research","name":"Roswell Park Cancer Institute","city":"Buffalo","region":"New York","country":"United States","cc":"US","lat":42.8913,"lon":-78.8787,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"14263","condg":["Cancer-related distress"],"nct":"NCT06827054","study":"Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids","sstatus":"NOT_YET_RECRUITING","sponsor":"Roswell Park Cancer Institute","official":"William Alexander (Roswell Park Cancer Institute)","src":"https://clinicaltrials.gov/study/NCT06827054","contact":{"n":"William Alexander","p":"716-845-1479","e":"William.Alexander@roswellpark.org"},"phase":"Phase 2","enroll":20,"start":"2026-09-15","eid":"x:site:nct06827054-roswell-park-cancer-institute-buffalo"},{"id":"nct06299319-centre-for-addiction-and-mental-health-toronto","cat":"research","name":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.71664,"lon":-79.3872,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"M6J 1H1","condg":["OCD"],"nct":"NCT06299319","study":"Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD","sstatus":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","official":"Gwyneth Zai, MD, MSc, PhD (Centre for Addiction and Mental Health)","src":"https://clinicaltrials.gov/study/NCT06299319","phase":"Phase 1","enroll":10,"start":"2024-09-01","eid":"x:site:nct06299319-centre-for-addiction-and-mental-health-toronto"},{"id":"nct07721467-national-institute-of-aging-clinical-research-unit-baltimore","cat":"research","name":"National Institute of Aging, Clinical Research Unit","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29862,"lon":-76.60518,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Neurology & cognition"],"nct":"NCT07721467","study":"Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin","sstatus":"NOT_YET_RECRUITING","sponsor":"National Institute on Aging (NIA)","official":"Dimitrios I Kapogiannis, M.D. (National Institute on Aging (NIA))","src":"https://clinicaltrials.gov/study/NCT07721467","contact":{"n":"Dimitrios Kapogiannis, M.D.","p":"667-391-0063","e":"kapogiannisd@mail.nih.gov"},"phase":"Phase 2","enroll":200,"start":"2026-10-07","eid":"x:site:nct07721467-national-institute-of-aging-clinical-research-unit-baltimore"},{"id":"nct03289949-neurobiology-research-unit-rigshospitalet-copenhagen","cat":"research","name":"Neurobiology Research Unit, Rigshospitalet","city":"Copenhagen","country":"Denmark","cc":"DK","lat":55.68145,"lon":12.55381,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"2100","condg":["Other"],"status":"RECRUITING","nct":"NCT03289949","study":"The Neurobiological Effect of 5-HT2AR Modulation","sstatus":"RECRUITING","sponsor":"Gitte Moos Knudsen","official":"Gitte M Knudsen, Professor (Neurobiology Research Unit, Rigshospitalet)","src":"https://clinicaltrials.gov/study/NCT03289949","contact":{"n":"Gitte M Knudsen, Professor","p":"+45 35456720","e":"gmk@nru.dk"},"phase":"Phase 1","enroll":200,"start":"2017-03-03","eid":"x:site:nct03289949-neurobiology-research-unit-rigshospitalet-copenhagen"},{"id":"nct04433858-va-palo-alto-healthcare-system-stanford-medicine-palo-alto","cat":"research","name":"VA Palo Alto Healthcare System/Stanford Medicine","city":"Palo Alto","region":"California","country":"United States","cc":"US","lat":37.44889,"lon":-122.14918,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94304","condg":["Depression"],"nct":"NCT04433858","study":"An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)","sstatus":"UNKNOWN","sponsor":"Sheppard Pratt Health System","official":"Scott Aaronson, MD (Sheppard Pratt Health System)","src":"https://clinicaltrials.gov/study/NCT04433858","phase":"Phase 2","enroll":27,"start":"2021-03-01","eid":"x:site:nct04433858-va-palo-alto-healthcare-system-stanford-medicine-palo-alto"},{"id":"nct04433858-sheppard-pratt-health-system-baltimore","cat":"research","name":"Sheppard Pratt Health System","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29212,"lon":-76.61798,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21204","condg":["Depression"],"nct":"NCT04433858","study":"An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)","sstatus":"UNKNOWN","sponsor":"Sheppard Pratt Health System","official":"Scott Aaronson, MD (Sheppard Pratt Health System)","src":"https://clinicaltrials.gov/study/NCT04433858","phase":"Phase 2","enroll":27,"start":"2021-03-01","eid":"x:site:nct04433858-sheppard-pratt-health-system-baltimore"},{"id":"nct06814522-uc-san-diego-san-diego","cat":"research","name":"UC San Diego","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.71773,"lon":-117.16016,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92037","condg":["Other"],"status":"RECRUITING","nct":"NCT06814522","study":"Psilocybin-Assisted Therapy for Physician Well-Being and Burnout","sstatus":"RECRUITING","sponsor":"University of California, San Diego","src":"https://clinicaltrials.gov/study/NCT06814522","contact":{"n":"Vy Nguyen","p":"619-363-2465","e":"vyn014@health.ucsd.edu"},"phase":"Phase 1/Phase 2","enroll":30,"start":"2025-01-13","eid":"x:site:nct06814522-uc-san-diego-san-diego"},{"id":"nct02163707-university-of-wisconsin-school-of-pharmacy-madison","cat":"research","name":"University of Wisconsin, School of Pharmacy","city":"Madison","region":"Wisconsin","country":"United States","cc":"US","lat":43.06171,"lon":-89.40043,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"53705","condg":["Healthy volunteers"],"nct":"NCT02163707","study":"UW Psilocybin Pharmacokinetics Study","sstatus":"COMPLETED","sponsor":"University of Wisconsin, Madison","official":"Paul Hutson, PharmD (University of Wisconsin, School of Pharmacy)","src":"https://clinicaltrials.gov/study/NCT02163707","phase":"Phase 1","enroll":12,"start":"2014-06","eid":"x:site:nct02163707-university-of-wisconsin-school-of-pharmacy-madison"},{"id":"nct06233344-univeristy-of-southern-california-brain-and-creativity-institute-los","cat":"research","name":"Univeristy of Southern California Brain and Creativity Institute","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.06188,"lon":-118.24222,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"90089","condg":["Other"],"status":"RECRUITING","nct":"NCT06233344","study":"Mindfulness-Assisted Psychedelic Therapy","sstatus":"RECRUITING","sponsor":"University of Southern California","official":"Baruch R Cahn, MD, PhD (University of Southern California)","src":"https://clinicaltrials.gov/study/NCT06233344","contact":{"n":"Anna Zandueta-Duarte, BS","p":"323-442-0938","e":"a.zandueta@usc.edu"},"phase":"Phase 2","enroll":40,"start":"2025-07-30","eid":"x:site:nct06233344-univeristy-of-southern-california-brain-and-creativity-institute-los"},{"id":"nct07756736-ucsf-at-zuckerberg-san-francisco-general-hospital-san-francisco","cat":"research","name":"UCSF at Zuckerberg San Francisco General Hospital","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.78542,"lon":-122.41664,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94110","condg":["Addiction & substance use"],"nct":"NCT07756736","study":"Psilocybin Therapy for Methamphetamine Use Disorder and HIV","sstatus":"NOT_YET_RECRUITING","sponsor":"Nicky Mehtani, MD, MPH","official":"Nicky J. Mehtani, MD, MPH (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT07756736","contact":{"n":"Eliza Banbury, BA","p":"510-985-3522","e":"prism.trial@ucsf.edu"},"phase":"Phase 2","enroll":30,"start":"2026-11","eid":"x:site:nct07756736-ucsf-at-zuckerberg-san-francisco-general-hospital-san-francisco"},{"id":"nct07570654-fl-miami","cat":"research","name":"FL","city":"Miami","region":"Florida","country":"United States","cc":"US","lat":25.77573,"lon":-80.19248,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"33125","condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT07570654","study":"Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder","sstatus":"RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT07570654","contact":{"n":"Redefine Study Call Center","p":"202-459-9258","e":"TheRedefineStudy@compasspathways.com"},"phase":"Phase 2/Phase 3","enroll":300,"start":"2026-09","eid":"x:site:nct07570654-fl-miami"},{"id":"nct07570654-fl-orlando","cat":"research","name":"FL","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.53952,"lon":-81.3774,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"32801","condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT07570654","study":"Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder","sstatus":"RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT07570654","contact":{"n":"Redefine Study Call Center","p":"202-459-9258","e":"TheRedefineStudy@compasspathways.com"},"phase":"Phase 2/Phase 3","enroll":300,"start":"2026-09","eid":"x:site:nct07570654-fl-orlando"},{"id":"nct07570654-ne-lincoln","cat":"research","name":"NE","city":"Lincoln","region":"Nebraska","country":"United States","cc":"US","lat":40.804,"lon":-96.6783,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"68526","condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT07570654","study":"Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder","sstatus":"RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT07570654","contact":{"n":"Redefine Study Call Center","p":"202-459-9258","e":"TheRedefineStudy@compasspathways.com"},"phase":"Phase 2/Phase 3","enroll":300,"start":"2026-09","eid":"x:site:nct07570654-ne-lincoln"},{"id":"nct07570654-ny-new-york","cat":"research","name":"NY","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72241,"lon":-73.99538,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10025","condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT07570654","study":"Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder","sstatus":"RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT07570654","contact":{"n":"Redefine Study Call Center","p":"202-459-9258","e":"TheRedefineStudy@compasspathways.com"},"phase":"Phase 2/Phase 3","enroll":300,"start":"2026-09","eid":"x:site:nct07570654-ny-new-york"},{"id":"nct03912974-university-hospital-basel-clinical-trial-unit-basel","cat":"research","name":"University Hospital Basel, Clinical Trial Unit","city":"Basel","region":"Canton of Basel-City","country":"Switzerland","cc":"CH","lat":47.56173,"lon":7.56522,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"4056","condg":["Healthy volunteers"],"nct":"NCT03912974","study":"Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects","sstatus":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","official":"Matthias E Liechti, MD, MAS (University Hospital, Basel, Switzerland)","src":"https://clinicaltrials.gov/study/NCT03912974","phase":"Phase 1","enroll":27,"start":"2019-07-04","eid":"x:site:nct03912974-university-hospital-basel-clinical-trial-unit-basel"},{"id":"nct05557643-huntsman-mental-health-institute-salt-lake-city","cat":"research","name":"Huntsman Mental Health Institute","city":"Salt Lake City","region":"Utah","country":"United States","cc":"US","lat":40.75113,"lon":-111.89147,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"84108","condg":["Depression"],"nct":"NCT05557643","study":"PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout","sstatus":"COMPLETED","sponsor":"University of Utah","src":"https://clinicaltrials.gov/study/NCT05557643","phase":"Phase 1","enroll":24,"start":"2023-01-02","eid":"x:site:nct05557643-huntsman-mental-health-institute-salt-lake-city"},{"id":"nct05832255-kgk-science-inc-london","cat":"research","name":"KGK Science Inc.","city":"London","region":"Ontario","country":"Canada","cc":"CA","lat":42.97591,"lon":-81.23883,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"N6B 3L1","condg":["Neurology & cognition"],"nct":"NCT05832255","study":"An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome","sstatus":"SUSPENDED","sponsor":"Nova Mentis Life Science Corp","official":"David Crowley, MD (KGK Science Inc.); Marvin Hausman, MD (Nova Mentis Life Science Corp)","src":"https://clinicaltrials.gov/study/NCT05832255","phase":"Phase 2","enroll":10,"start":"2023-03-28","eid":"x:site:nct05832255-kgk-science-inc-london"},{"id":"nct03715127-psychiatrische-universitatsklinik-zurich-zurich","cat":"research","name":"Psychiatrische Universitätsklinik Zürich","city":"Zurich","country":"Switzerland","cc":"CH","lat":47.36672,"lon":8.54609,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"8032","condg":["Depression"],"nct":"NCT03715127","study":"Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept","sstatus":"COMPLETED","sponsor":"University of Zurich","src":"https://clinicaltrials.gov/study/NCT03715127","phase":"Phase 2","enroll":55,"start":"2019-03-11","eid":"x:site:nct03715127-psychiatrische-universitatsklinik-zurich-zurich"},{"id":"nct06815653-university-college-london-london","cat":"research","name":"University College London","city":"London","country":"United Kingdom","cc":"GB","lat":51.50782,"lon":-0.13332,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Healthy volunteers"],"status":"RECRUITING","nct":"NCT06815653","study":"Digital Intervention for Psychedelic Preparation (DIPP): Comparing Meditation and Music-Based Programs","sstatus":"RECRUITING","sponsor":"University College, London","src":"https://clinicaltrials.gov/study/NCT06815653","contact":{"n":"Jeremy I Skipper","p":"+44 (0)20 7679 2000","e":"dipp-project@ucl.ac.uk"},"phase":"Phase 1","enroll":40,"start":"2025-03-01","eid":"x:site:nct06815653-university-college-london-london"},{"id":"nct06818994-queen-s-university-kingston","cat":"research","name":"Queen's University","city":"Kingston","region":"Ontario","country":"Canada","cc":"CA","lat":44.23912,"lon":-76.49213,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"K7L 3N6","condg":["Other"],"status":"RECRUITING","nct":"NCT06818994","study":"Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer","sstatus":"RECRUITING","sponsor":"Gustavo Vazquez","src":"https://clinicaltrials.gov/study/NCT06818994","contact":{"n":"Vazquez Gustavo, MD, PhD","p":"613-544-4900","e":"vazquezg@providencecare.ca"},"phase":"Phase 1","enroll":15,"start":"2026-04-01","eid":"x:site:nct06818994-queen-s-university-kingston"},{"id":"nct05160220-instituto-de-fisica-de-buenos-aires-ifiba-buenos-aires","cat":"research","name":"Instituto de Fisica de Buenos Aires (IFIBA)","city":"Buenos Aires","country":"Argentina","cc":"AR","lat":-34.60971,"lon":-58.37285,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"1428","condg":["Neurology & cognition"],"nct":"NCT05160220","study":"Naturalistic Study of Microdosing With Psilocybin","sstatus":"COMPLETED","sponsor":"National Council of Scientific and Technical Research, Argentina","official":"Enzo Tagliazucchi, PhD (National Council of Scientific and Technical Research, Argentina)","src":"https://clinicaltrials.gov/study/NCT05160220","phase":"N/A","enroll":34,"start":"2021-01-20","eid":"x:site:nct05160220-instituto-de-fisica-de-buenos-aires-ifiba-buenos-aires"},{"id":"nct06407635-johns-hopkins-center-for-psychedelic-and-consciousness-research-balt","cat":"research","name":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29184,"lon":-76.6129,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["PTSD & trauma"],"nct":"NCT06407635","study":"A Study of Psilocybin for PTSD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","official":"Sandeep Nayak, MD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT06407635","phase":"Phase 1","enroll":20,"start":"2024-06-07","eid":"x:site:nct06407635-johns-hopkins-center-for-psychedelic-and-consciousness-research-balt"},{"id":"nct05035927-university-of-florida-gainesville","cat":"research","name":"University of Florida","city":"Gainesville","region":"Florida","country":"United States","cc":"US","lat":29.65262,"lon":-82.32205,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"32608","condg":["Eating disorders"],"nct":"NCT05035927","study":"Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder","sstatus":"COMPLETED","sponsor":"TRYP Therapeutics","official":"Jennifer Miller, MD (University of Florida)","src":"https://clinicaltrials.gov/study/NCT05035927","phase":"Phase 2","enroll":5,"start":"2022-03-16","eid":"x:site:nct05035927-university-of-florida-gainesville"},{"id":"nct06898606-federal-university-of-latin-american-integration-foz-do-iguacu","cat":"research","name":"Federal University of Latin American Integration","city":"Foz do Iguaçu","region":"Paraná","country":"Brazil","cc":"BR","lat":-25.54378,"lon":-54.57964,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"85870-650","condg":["Depression"],"status":"RECRUITING","nct":"NCT06898606","study":"Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression","sstatus":"RECRUITING","sponsor":"Federal University of Latin American Integration","official":"Francisney P Nascimento, 1 (Federal University of Latin American Integration)","src":"https://clinicaltrials.gov/study/NCT06898606","contact":{"n":"Francisney P Nascimento, 1","p":"+55 45 99933-3479","e":"ensaios.clinicos.lcp@unila.edu.br"},"phase":"Phase 1/Phase 2","enroll":24,"start":"2024-09-05","eid":"x:site:nct06898606-federal-university-of-latin-american-integration-foz-do-iguacu"},{"id":"nct06160232-brugmann-university-hospital-brussels","cat":"research","name":"Brugmann University Hospital","city":"Brussels","country":"Belgium","cc":"BE","lat":50.84965,"lon":4.34083,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT06160232","study":"Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder","sstatus":"UNKNOWN","sponsor":"Brugmann University Hospital","official":"Charles Kornreich, M.D. Ph.D. (Brugmann University Hospital, Free University of Brussels)","src":"https://clinicaltrials.gov/study/NCT06160232","contact":{"n":"Laetitia Vanderijst, M.Sc.","p":"02 477 22 33","e":"laetitia.vanderijst@ulb.be"},"phase":"Phase 2","enroll":62,"start":"2024-02-15","eid":"x:site:nct06160232-brugmann-university-hospital-brussels"},{"id":"nct07565493-center-for-psychedelics-and-consciousness-research-baltimore","cat":"research","name":"Center for Psychedelics and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29739,"lon":-76.60424,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224-5010","condg":["Healthy volunteers"],"status":"RECRUITING","nct":"NCT07565493","study":"Psilocybin Administration With 5-HT1a Blockade","sstatus":"RECRUITING","sponsor":"Johns Hopkins University","official":"Sandeep M Nayak, MD (Center for Psychedelics and Consciousness Research)","src":"https://clinicaltrials.gov/study/NCT07565493","contact":{"n":"Zarmeen Zahid, PhD","p":"667-208-8099","e":"psilblock@jh.edu"},"phase":"EARLY_Phase 1","enroll":18,"start":"2026-08-12","eid":"x:site:nct07565493-center-for-psychedelics-and-consciousness-research-baltimore"},{"id":"nct05651126-king-s-college-london-london","cat":"research","name":"King's College London","city":"London","country":"United Kingdom","cc":"GB","lat":51.51319,"lon":-0.12315,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"SE5 8AF","condg":["Other"],"nct":"NCT05651126","study":"Psilocybin in Adults With and Without Autism Spectrum Disorder","sstatus":"COMPLETED","sponsor":"King's College London","src":"https://clinicaltrials.gov/study/NCT05651126","phase":"N/A","enroll":67,"start":"2022-12-12","eid":"x:site:nct05651126-king-s-college-london-london"},{"id":"nct04754061-the-ottawa-hospital-ottawa","cat":"research","name":"The Ottawa Hospital","city":"Ottawa","region":"Ontario","country":"Canada","cc":"CA","lat":45.40595,"lon":-75.70438,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"K1H 8L6","condg":["Depression","Anxiety"],"nct":"NCT04754061","study":"PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Ottawa Hospital Research Institute","official":"James Downar, MDCM, MSc (Ottawa Hospital Research Institute)","src":"https://clinicaltrials.gov/study/NCT04754061","phase":"Phase 1/Phase 2","enroll":20,"start":"2024-01-08","eid":"x:site:nct04754061-the-ottawa-hospital-ottawa"},{"id":"nct04754061-bruyere-continuing-care-ottawa","cat":"research","name":"Bruyere Continuing Care","city":"Ottawa","region":"Ontario","country":"Canada","cc":"CA","lat":45.40821,"lon":-75.696,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"K1R 6K9","condg":["Depression","Anxiety"],"nct":"NCT04754061","study":"PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Ottawa Hospital Research Institute","official":"James Downar, MDCM, MSc (Ottawa Hospital Research Institute)","src":"https://clinicaltrials.gov/study/NCT04754061","phase":"Phase 1/Phase 2","enroll":20,"start":"2024-01-08","eid":"x:site:nct04754061-bruyere-continuing-care-ottawa"},{"id":"nct05220046-university-of-nebraska-medical-center-omaha","cat":"research","name":"University of Nebraska Medical Center","city":"Omaha","region":"Nebraska","country":"United States","cc":"US","lat":41.26817,"lon":-95.94885,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"68198","condg":["Cancer-related distress"],"nct":"NCT05220046","study":"Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers","sstatus":"COMPLETED","sponsor":"University of Nebraska","official":"Lou Lukas, MD (University of Nebraska)","src":"https://clinicaltrials.gov/study/NCT05220046","phase":"Phase 1","enroll":18,"start":"2023-04-10","eid":"x:site:nct05220046-university-of-nebraska-medical-center-omaha"},{"id":"nct07610135-johns-hopkins-center-for-psychedelic-and-consciousness-research-balt","cat":"research","name":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28459,"lon":-76.61553,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Healthy volunteers"],"status":"RECRUITING","nct":"NCT07610135","study":"Psilocybin Efficacy With or Without Pimavanserin Pretreatment","sstatus":"RECRUITING","sponsor":"Johns Hopkins University","official":"David B. Yaden, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT07610135","contact":{"n":"Arozo Azimi","p":"410-550-0007","e":"aazimi2@jh.edu"},"phase":"Phase 1/Phase 2","enroll":20,"start":"2026-10-30","eid":"x:site:nct07610135-johns-hopkins-center-for-psychedelic-and-consciousness-research-balt"},{"id":"nct04410913-pacific-treatment-research-in-psychedelics-santa-monica","cat":"research","name":"Pacific Treatment & Research in Psychedelics","city":"Santa Monica","region":"California","country":"United States","cc":"US","lat":34.01389,"lon":-118.4983,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"90404","condg":["Addiction & substance use"],"nct":"NCT04410913","study":"Pilot Trial of Visual Healing® in Psilocybin-assisted Therapy for Alcohol Use Disorder","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Keith Heinzerling","src":"https://clinicaltrials.gov/study/NCT04410913","phase":"Phase 2","enroll":20,"start":"2021-02-18","eid":"x:site:nct04410913-pacific-treatment-research-in-psychedelics-santa-monica"},{"id":"nct07582120-washington-university-school-of-medicine-st-louis","cat":"research","name":"Washington University School of Medicine","city":"St Louis","region":"Missouri","country":"United States","cc":"US","lat":38.63146,"lon":-90.18965,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"63110","condg":["Depression"],"nct":"NCT07582120","study":"Psilocybin-Assisted Therapy as a Treatment for Depression","sstatus":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","src":"https://clinicaltrials.gov/study/NCT07582120","contact":{"n":"Dawnita Reathaford","p":"314-362-5939","e":"dawnita@wustl.edu"},"phase":"Phase 2","enroll":50,"start":"2026-06","eid":"x:site:nct07582120-washington-university-school-of-medicine-st-louis"},{"id":"nct06235411-chu-nimes","cat":"research","name":"CHU","city":"Nîmes","region":"Nîmes","country":"France","cc":"FR","lat":43.83077,"lon":4.35652,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30029","condg":["Depression","Addiction & substance use"],"nct":"NCT06235411","study":"Psilocybin in Alcohol Use Disorder With Comorbid Depression","sstatus":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","official":"Amandine Luquiens (CHU de Nimes)","src":"https://clinicaltrials.gov/study/NCT06235411","phase":"N/A","enroll":30,"start":"2024-02-05","eid":"x:site:nct06235411-chu-nimes"},{"id":"nct06899165-the-parsons-research-center-for-psychedelic-healing-new-york","cat":"research","name":"The Parsons Research Center for Psychedelic Healing","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71018,"lon":-74.01053,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10025","condg":["Depression","Anxiety"],"status":"RECRUITING","nct":"NCT06899165","study":"Psilocybin-Assisted Therapy for Intergenerational Trauma","sstatus":"RECRUITING","sponsor":"Rachel Yehuda","official":"Rachel Yehuda, PhD (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT06899165","contact":{"n":"Lauren Lepow, MD, PhD","p":"646-438-5044","e":"lauren.lepow@mountsinai.org"},"phase":"Phase 2","enroll":100,"start":"2026-08-28","eid":"x:site:nct06899165-the-parsons-research-center-for-psychedelic-healing-new-york"},{"id":"nct06650800-chu-de-nimes-hopital-universitaire-caremeau-nimes","cat":"research","name":"CHU de Nîmes, Hôpital Universitaire Carémeau","city":"Nîmes","country":"France","cc":"FR","lat":43.84451,"lon":4.35482,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30029","condg":["Depression"],"nct":"NCT06650800","study":"Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression","sstatus":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","official":"Ismaël Conejero (CHU Nimes)","src":"https://clinicaltrials.gov/study/NCT06650800","phase":"N/A","enroll":10,"start":"2024-11-19","eid":"x:site:nct06650800-chu-de-nimes-hopital-universitaire-caremeau-nimes"},{"id":"nct03775200-kadima-neuropsychiatry-institute-la-jolla","cat":"research","name":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","cc":"US","lat":32.84892,"lon":-117.28488,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92037","condg":["Depression"],"nct":"NCT03775200","study":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT03775200","phase":"Phase 2","enroll":233,"start":"2019-03-01","eid":"x:site:nct03775200-kadima-neuropsychiatry-institute-la-jolla"},{"id":"nct03775200-altman-clinical-and-translational-research-institute-university-of-c","cat":"research","name":"Altman Clinical and Translational Research Institute, University of California","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.72093,"lon":-117.15921,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92093","condg":["Depression"],"nct":"NCT03775200","study":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT03775200","phase":"Phase 2","enroll":233,"start":"2019-03-01","eid":"x:site:nct03775200-altman-clinical-and-translational-research-institute-university-of-c"},{"id":"nct03775200-stanford-department-of-psychiatry-stanford","cat":"research","name":"Stanford Department of Psychiatry","city":"Stanford","region":"California","country":"United States","cc":"US","lat":37.43291,"lon":-122.165,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94305","condg":["Depression"],"nct":"NCT03775200","study":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT03775200","phase":"Phase 2","enroll":233,"start":"2019-03-01","eid":"x:site:nct03775200-stanford-department-of-psychiatry-stanford"},{"id":"nct03775200-mood-and-anxiety-disorders-program-emory-university-school-of-medici","cat":"research","name":"Mood and Anxiety Disorders Program Emory University School of Medicine","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.73973,"lon":-84.38934,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30329","condg":["Depression"],"nct":"NCT03775200","study":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT03775200","phase":"Phase 2","enroll":233,"start":"2019-03-01","eid":"x:site:nct03775200-mood-and-anxiety-disorders-program-emory-university-school-of-medici"},{"id":"nct03775200-ray-worthy-psychiatry-llc-new-orleans","cat":"research","name":"Ray Worthy Psychiatry LLC","city":"New Orleans","region":"Louisiana","country":"United States","cc":"US","lat":29.95743,"lon":-90.06872,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"70123","condg":["Depression"],"nct":"NCT03775200","study":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT03775200","phase":"Phase 2","enroll":233,"start":"2019-03-01","eid":"x:site:nct03775200-ray-worthy-psychiatry-llc-new-orleans"},{"id":"nct03775200-sheppard-pratt-health-system-baltimore","cat":"research","name":"Sheppard Pratt Health System","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.294,"lon":-76.61186,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21204","condg":["Depression"],"nct":"NCT03775200","study":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT03775200","phase":"Phase 2","enroll":233,"start":"2019-03-01","eid":"x:site:nct03775200-sheppard-pratt-health-system-baltimore"},{"id":"nct03775200-new-york-state-psychiatric-institute-new-york","cat":"research","name":"New York State Psychiatric Institute","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.721,"lon":-73.99585,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10032","condg":["Depression"],"nct":"NCT03775200","study":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT03775200","phase":"Phase 2","enroll":233,"start":"2019-03-01","eid":"x:site:nct03775200-new-york-state-psychiatric-institute-new-york"},{"id":"nct03775200-ut-center-of-excellence-on-mood-disorders-university-of-texas-health","cat":"research","name":"UT Center of Excellence on Mood Disorders, University of Texas Health Science Center","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.77001,"lon":-95.35598,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"77054","condg":["Depression"],"nct":"NCT03775200","study":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT03775200","phase":"Phase 2","enroll":233,"start":"2019-03-01","eid":"x:site:nct03775200-ut-center-of-excellence-on-mood-disorders-university-of-texas-health"},{"id":"nct03775200-canadian-rapid-treatment-centre-of-excellence-mississauga","cat":"research","name":"Canadian Rapid Treatment Centre of Excellence","city":"Mississauga","region":"Ontario","country":"Canada","cc":"CA","lat":43.58168,"lon":-79.65712,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT03775200","study":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT03775200","phase":"Phase 2","enroll":233,"start":"2019-03-01","eid":"x:site:nct03775200-canadian-rapid-treatment-centre-of-excellence-mississauga"},{"id":"nct03775200-centre-for-addiction-and-mental-health-toronto","cat":"research","name":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70403,"lon":-79.39605,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT03775200","study":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT03775200","phase":"Phase 2","enroll":233,"start":"2019-03-01","eid":"x:site:nct03775200-centre-for-addiction-and-mental-health-toronto"},{"id":"nct03775200-national-institute-of-mental-health-czech-republic-klecany","cat":"research","name":"National Institute of Mental Health Czech Republic","city":"Klecany","country":"Czechia","cc":"CZ","lat":50.17519,"lon":14.41115,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT03775200","study":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT03775200","phase":"Phase 2","enroll":233,"start":"2019-03-01","eid":"x:site:nct03775200-national-institute-of-mental-health-czech-republic-klecany"},{"id":"nct03775200-enhed-for-psykiatrisk-forskning-psykiatrien-i-aalborg-aalborg","cat":"research","name":"Enhed for Psykiatrisk Forskning, Psykiatrien i Aalborg","city":"Aalborg","country":"Denmark","cc":"DK","lat":57.05642,"lon":9.91376,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT03775200","study":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT03775200","phase":"Phase 2","enroll":233,"start":"2019-03-01","eid":"x:site:nct03775200-enhed-for-psykiatrisk-forskning-psykiatrien-i-aalborg-aalborg"},{"id":"nct03775200-charite-universitatsmedizin-berlin-department-of-psychiatry-and-psyc","cat":"research","name":"Charité - Universitätsmedizin Berlin, Department of Psychiatry and Psychotherapy, Campus Benjamin Franklin","city":"Berlin","country":"Germany","cc":"DE","lat":52.51604,"lon":13.40964,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"12203","condg":["Depression"],"nct":"NCT03775200","study":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT03775200","phase":"Phase 2","enroll":233,"start":"2019-03-01","eid":"x:site:nct03775200-charite-universitatsmedizin-berlin-department-of-psychiatry-and-psyc"},{"id":"nct03775200-tallaght-university-hospital-dublin","cat":"research","name":"Tallaght University Hospital","city":"Dublin","country":"Ireland","cc":"IE","lat":53.34497,"lon":-6.25628,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT03775200","study":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT03775200","phase":"Phase 2","enroll":233,"start":"2019-03-01","eid":"x:site:nct03775200-tallaght-university-hospital-dublin"},{"id":"nct03775200-groningen-university-medical-centre-groningen","cat":"research","name":"Groningen University Medical Centre","city":"Groningen","country":"Netherlands","cc":"NL","lat":53.22355,"lon":6.57594,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT03775200","study":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT03775200","phase":"Phase 2","enroll":233,"start":"2019-03-01","eid":"x:site:nct03775200-groningen-university-medical-centre-groningen"},{"id":"nct03775200-leiden-university-medical-centre-leiden","cat":"research","name":"Leiden University Medical Centre","city":"Leiden","country":"Netherlands","cc":"NL","lat":52.15047,"lon":4.48586,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT03775200","study":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT03775200","phase":"Phase 2","enroll":233,"start":"2019-03-01","eid":"x:site:nct03775200-leiden-university-medical-centre-leiden"},{"id":"nct03775200-utrecht-university-medical-centre-utrecht","cat":"research","name":"Utrecht University Medical Centre","city":"Utrecht","country":"Netherlands","cc":"NL","lat":52.0969,"lon":5.11615,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT03775200","study":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT03775200","phase":"Phase 2","enroll":233,"start":"2019-03-01","eid":"x:site:nct03775200-utrecht-university-medical-centre-utrecht"},{"id":"nct03775200-unidade-de-neuropsiquiatria-centro-clinico-champalimaud-lisbon","cat":"research","name":"Unidade de Neuropsiquiatria, Centro Clinico Champalimaud","city":"Lisbon","country":"Portugal","cc":"PT","lat":38.73304,"lon":-9.14439,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT03775200","study":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT03775200","phase":"Phase 2","enroll":233,"start":"2019-03-01","eid":"x:site:nct03775200-unidade-de-neuropsiquiatria-centro-clinico-champalimaud-lisbon"},{"id":"nct03775200-hospital-de-dia-numancia-barcelona","cat":"research","name":"Hospital de Dia Numancia","city":"Barcelona","country":"Spain","cc":"ES","lat":41.38921,"lon":2.15546,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT03775200","study":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT03775200","phase":"Phase 2","enroll":233,"start":"2019-03-01","eid":"x:site:nct03775200-hospital-de-dia-numancia-barcelona"},{"id":"nct03775200-institute-hospital-del-mar-of-medical-research-imim-barcelona","cat":"research","name":"Institute Hospital del Mar of Medical Research (IMIM)","city":"Barcelona","country":"Spain","cc":"ES","lat":41.39985,"lon":2.1484,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT03775200","study":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT03775200","phase":"Phase 2","enroll":233,"start":"2019-03-01","eid":"x:site:nct03775200-institute-hospital-del-mar-of-medical-research-imim-barcelona"},{"id":"nct03775200-clinical-research-and-imaging-centre-bristol","cat":"research","name":"Clinical Research and Imaging Centre","city":"Bristol","region":"Avon","country":"United Kingdom","cc":"GB","lat":51.46318,"lon":-2.59114,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT03775200","study":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT03775200","phase":"Phase 2","enroll":233,"start":"2019-03-01","eid":"x:site:nct03775200-clinical-research-and-imaging-centre-bristol"},{"id":"nct03775200-wolfson-research-centre-campus-for-ageing-and-vitality-newcastle-upo","cat":"research","name":"Wolfson Research Centre, Campus for Ageing and Vitality","city":"Newcastle upon Tyne","region":"Tyne and Wear","country":"United Kingdom","cc":"GB","lat":54.98387,"lon":-1.62248,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"NE4 5PL","condg":["Depression"],"nct":"NCT03775200","study":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT03775200","phase":"Phase 2","enroll":233,"start":"2019-03-01","eid":"x:site:nct03775200-wolfson-research-centre-campus-for-ageing-and-vitality-newcastle-upo"},{"id":"nct03775200-st-pancras-clinical-research-london","cat":"research","name":"St. Pancras Clinical Research","city":"London","country":"United Kingdom","cc":"GB","lat":51.50095,"lon":-0.11412,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"EC2Y 8EA","condg":["Depression"],"nct":"NCT03775200","study":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT03775200","phase":"Phase 2","enroll":233,"start":"2019-03-01","eid":"x:site:nct03775200-st-pancras-clinical-research-london"},{"id":"nct03775200-kings-college-london-institute-of-psychiatry-psychology-and-neurolog","cat":"research","name":"Kings College London, Institute of Psychiatry, Psychology and Neurology","city":"London","country":"United Kingdom","cc":"GB","lat":51.50895,"lon":-0.11826,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT03775200","study":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT03775200","phase":"Phase 2","enroll":233,"start":"2019-03-01","eid":"x:site:nct03775200-kings-college-london-institute-of-psychiatry-psychology-and-neurolog"},{"id":"nct03775200-greater-manchester-mental-health-foundation-trust-manchester","cat":"research","name":"Greater Manchester Mental Health Foundation Trust","city":"Manchester","country":"United Kingdom","cc":"GB","lat":53.48175,"lon":-2.24821,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT03775200","study":"The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT03775200","phase":"Phase 2","enroll":233,"start":"2019-03-01","eid":"x:site:nct03775200-greater-manchester-mental-health-foundation-trust-manchester"},{"id":"nct06416085-princess-margaret-cancer-centre-toronto","cat":"research","name":"Princess Margaret Cancer Centre","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.71805,"lon":-79.40584,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"M5G 2M9","condg":["Cancer-related distress"],"nct":"NCT06416085","study":"Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","official":"Sarah Hales, MD (University Health Network, Toronto)","src":"https://clinicaltrials.gov/study/NCT06416085","phase":"Phase 2","enroll":15,"start":"2024-06-06","eid":"x:site:nct06416085-princess-margaret-cancer-centre-toronto"},{"id":"nct07227909-md-anderson-cancer-center-houston","cat":"research","name":"MD Anderson Cancer Center","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.75702,"lon":-95.37508,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"77030","condg":["Other"],"nct":"NCT07227909","study":"NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy","sstatus":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","official":"Moran Amit, MD (M.D. Anderson Cancer Center)","src":"https://clinicaltrials.gov/study/NCT07227909","contact":{"n":"Moran Amit, MD","p":"713-794-5304","e":"mamit@mdanderson.org"},"phase":"Phase 2","enroll":83,"start":"2026-11-04","eid":"x:site:nct07227909-md-anderson-cancer-center-houston"},{"id":"nct03554174-va-connecticut-healthcare-system-west-haven-campus-west-haven","cat":"research","name":"VA Connecticut Healthcare System, West Haven Campus","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.26129,"lon":-72.94324,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"06516","condg":["Depression"],"nct":"NCT03554174","study":"Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","official":"Deepak D'Souza, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT03554174","phase":"Phase 1","enroll":18,"start":"2018-02-27","eid":"x:site:nct03554174-va-connecticut-healthcare-system-west-haven-campus-west-haven"},{"id":"nct06706232-the-university-of-texas-health-science-center-at-houston-houston","cat":"research","name":"The University of Texas Health Science Center at Houston","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.76107,"lon":-95.36755,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"77006","condg":["Depression","Bipolar"],"status":"RECRUITING","nct":"NCT06706232","study":"Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality","sstatus":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","official":"Thomas Meyer, PhD (The University of Texas Health Science Center, Houston)","src":"https://clinicaltrials.gov/study/NCT06706232","contact":{"n":"Thomas Meyer, PhD","p":"713-486-2643","e":"thomas.d.meyer@uth.tmc.edu"},"phase":"Phase 2","enroll":10,"start":"2025-07-07","eid":"x:site:nct06706232-the-university-of-texas-health-science-center-at-houston-houston"},{"id":"nct05265546-university-of-california-berkeley-berkeley","cat":"research","name":"University of California, Berkeley","city":"Berkeley","region":"California","country":"United States","cc":"US","lat":37.85997,"lon":-122.27214,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94720","condg":["Other"],"status":"RECRUITING","nct":"NCT05265546","study":"Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain","sstatus":"RECRUITING","sponsor":"University of California, Berkeley","src":"https://clinicaltrials.gov/study/NCT05265546","contact":{"n":"BCSP Research Staff","p":"(415) 874-1308","e":"BCSPresearchsubjects@berkeley.edu"},"phase":"Phase 1","enroll":80,"start":"2024-03-08","eid":"x:site:nct05265546-university-of-california-berkeley-berkeley"},{"id":"nct04433845-sheppard-pratt-baltimore","cat":"research","name":"Sheppard Pratt","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28167,"lon":-76.62024,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21204","condg":["Depression"],"nct":"NCT04433845","study":"The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.","sstatus":"UNKNOWN","sponsor":"Sheppard Pratt Health System","official":"Scott Aaronson, MD (Sheppard Pratt Health System)","src":"https://clinicaltrials.gov/study/NCT04433845","phase":"Phase 2","enroll":15,"start":"2021-03-01","eid":"x:site:nct04433845-sheppard-pratt-baltimore"},{"id":"nct04424225-university-of-minnesota-minneapolis","cat":"research","name":"University of Minnesota","city":"Minneapolis","region":"Minnesota","country":"United States","cc":"US","lat":44.9915,"lon":-93.27113,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"55455","condg":["Other"],"nct":"NCT04424225","study":"Visual Surround Suppression and Perceptual Expectation Under Psilocybin","sstatus":"TERMINATED","sponsor":"University of Minnesota","official":"Jessica Nielson, PhD (University of Minnesota); Link Swanson, PhD(c) (University of Minnesota)","src":"https://clinicaltrials.gov/study/NCT04424225","phase":"Phase 1","enroll":10,"start":"2021-08-30","eid":"x:site:nct04424225-university-of-minnesota-minneapolis"},{"id":"nct04950608-care-dimensions-danvers","cat":"research","name":"Care Dimensions","city":"Danvers","region":"Massachusetts","country":"United States","cc":"US","lat":42.587,"lon":-70.92134,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"01923","condg":["End-of-life & palliative","Cancer-related distress"],"nct":"NCT04950608","study":"Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care","sstatus":"COMPLETED","sponsor":"Yvan Beaussant, MD, MSci","official":"Yvan Beaussant, MD (Dana-Farber Cancer Institute)","src":"https://clinicaltrials.gov/study/NCT04950608","phase":"Phase 2","enroll":15,"start":"2022-03-09","eid":"x:site:nct04950608-care-dimensions-danvers"},{"id":"nct06518720-centre-for-addiction-and-mental-health-toronto","cat":"research","name":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.71787,"lon":-79.4097,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"M6J1H4","condg":["Depression","Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06518720","study":"Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)","sstatus":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","official":"Ishrat Husain, MBBS, MD (Centre for Addiction and Mental Health)","src":"https://clinicaltrials.gov/study/NCT06518720","contact":{"n":"Emily Gilbert, MSc","p":"4165358501","e":"emily.gilbert@camh.ca"},"phase":"Phase 2","enroll":16,"start":"2025-04-01","eid":"x:site:nct06518720-centre-for-addiction-and-mental-health-toronto"},{"id":"nct04280055-neurobiology-research-unit-rigshospitalet-copenhagen","cat":"research","name":"Neurobiology Research Unit, Rigshospitalet","city":"Copenhagen","country":"Denmark","cc":"DK","lat":55.6726,"lon":12.56925,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"2100","condg":["Chronic pain & headache"],"nct":"NCT04280055","study":"Prophylactic Effects of Psilocybin on Chronic Cluster Headache","sstatus":"TERMINATED","sponsor":"Gitte Moos Knudsen","official":"Gitte Moos Knudsen, MD, DMSc (Neurobiology Research Unit, Rigshospitalet)","src":"https://clinicaltrials.gov/study/NCT04280055","phase":"Phase 1/Phase 2","enroll":10,"start":"2020-01-21","eid":"x:site:nct04280055-neurobiology-research-unit-rigshospitalet-copenhagen"},{"id":"nct04522804-huntsman-cancer-institute-salt-lake-city","cat":"research","name":"Huntsman Cancer Institute","city":"Salt Lake City","region":"Utah","country":"United States","cc":"US","lat":40.75744,"lon":-111.89364,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"84112","condg":["Cancer-related distress"],"nct":"NCT04522804","study":"Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer","sstatus":"COMPLETED","sponsor":"University of Utah","official":"Anna Beck, MD (Huntsman Cancer Institute)","src":"https://clinicaltrials.gov/study/NCT04522804","phase":"EARLY_Phase 1","enroll":12,"start":"2021-10-04","eid":"x:site:nct04522804-huntsman-cancer-institute-salt-lake-city"},{"id":"nct07210112-ghu-paris-psychiatrie-and-neurosciences-paris","cat":"research","name":"GHU Paris Psychiatrie and Neurosciences","city":"Paris","country":"France","cc":"FR","lat":48.86522,"lon":2.3384,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"75014","condg":["Depression"],"status":"RECRUITING","nct":"NCT07210112","study":"Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)","sstatus":"RECRUITING","sponsor":"Centre Hospitalier St Anne","official":"Lucie BERKOVITCH, MD (GHU Paris Psychiatrie and Neurosciences - Neuromodulation Institute)","src":"https://clinicaltrials.gov/study/NCT07210112","contact":{"n":"Lucie BERKOVITCH, MD","p":"+33 145657481","e":"l.berkovitch@ghu-paris.fr"},"phase":"Phase 2","enroll":112,"start":"2026-06-30","eid":"x:site:nct07210112-ghu-paris-psychiatrie-and-neurosciences-paris"},{"id":"nct05227742-university-of-alabama-at-birmingham-birmingham","cat":"research","name":"University of Alabama at Birmingham","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.53238,"lon":-86.80113,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"35209","condg":["Other"],"nct":"NCT05227742","study":"Exploratory Study of Low Dose Psilocybin","sstatus":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","src":"https://clinicaltrials.gov/study/NCT05227742","phase":"EARLY_Phase 1","start":"2023-08-15","eid":"x:site:nct05227742-university-of-alabama-at-birmingham-birmingham"},{"id":"nct06644170-fred-hutch-university-of-washington-cancer-consortium-seattle","cat":"research","name":"Fred Hutch/University of Washington Cancer Consortium","city":"Seattle","region":"Washington","country":"United States","cc":"US","lat":47.6007,"lon":-122.33268,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"98109","condg":["Cancer-related distress"],"nct":"NCT06644170","study":"A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer","sstatus":"COMPLETED","sponsor":"University of Washington","official":"Anthony L. Back, MD (Fred Hutch/University of Washington Cancer Consortium)","src":"https://clinicaltrials.gov/study/NCT06644170","phase":"Phase 1","enroll":15,"start":"2024-11-19","eid":"x:site:nct06644170-fred-hutch-university-of-washington-cancer-consortium-seattle"},{"id":"nct05592379-university-of-wisconsin-hospital-and-clinics-madison","cat":"research","name":"University of Wisconsin Hospital and Clinics","city":"Madison","region":"Wisconsin","country":"United States","cc":"US","lat":43.06952,"lon":-89.39619,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"53715","condg":["Healthy volunteers"],"nct":"NCT05592379","study":"Consciousness, Psilocybin, and Well-Being","sstatus":"COMPLETED","sponsor":"University of Wisconsin, Madison","official":"Charles Raison, MD (University of Wisconsin, Madison)","src":"https://clinicaltrials.gov/study/NCT05592379","phase":"Phase 1","enroll":6,"start":"2023-11-07","eid":"x:site:nct05592379-university-of-wisconsin-hospital-and-clinics-madison"},{"id":"nct04842045-uwhealth-600-highland-avenue-madison","cat":"research","name":"UWHealth, 600 Highland Avenue","city":"Madison","region":"Wisconsin","country":"United States","cc":"US","lat":43.07893,"lon":-89.40165,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"53792","condg":["Other"],"nct":"NCT04842045","study":"Pilot RECAP Study in Healthy Volunteers","sstatus":"COMPLETED","sponsor":"University of Wisconsin, Madison","official":"Christopher R Nicholas, MD,PHD (University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United State, 53715)","src":"https://clinicaltrials.gov/study/NCT04842045","phase":"Phase 1","enroll":8,"start":"2021-05-21","eid":"x:site:nct04842045-uwhealth-600-highland-avenue-madison"},{"id":"nct07079930-hadassah-medical-organization-jerusalem-israel-jerusalem","cat":"research","name":"Hadassah Medical Organization, Jerusalem, Israel","city":"Jerusalem","country":"Israel","cc":"IL","lat":31.7689,"lon":35.22786,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Healthy volunteers"],"status":"RECRUITING","nct":"NCT07079930","study":"Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers","sstatus":"RECRUITING","sponsor":"Hadassah Medical Organization","src":"https://clinicaltrials.gov/study/NCT07079930","contact":{"n":"Hadas Lemberg, PhD","p":"00 972 2 6777572","e":"lhadas@hadassah.org.il"},"phase":"Phase 1","enroll":10,"start":"2025-12-11","eid":"x:site:nct07079930-hadassah-medical-organization-jerusalem-israel-jerusalem"},{"id":"nct06102434-university-of-california-los-angeles-los-angeles","cat":"research","name":"University of California, Los Angeles","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.04117,"lon":-118.2506,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"90095","condg":["Addiction & substance use"],"nct":"NCT06102434","study":"Safety Profile of Psilocybin for Cocaine Use Disorder","sstatus":"SUSPENDED","sponsor":"University of California, Los Angeles","src":"https://clinicaltrials.gov/study/NCT06102434","phase":"EARLY_Phase 1","enroll":10,"start":"2029-02-01","eid":"x:site:nct06102434-university-of-california-los-angeles-los-angeles"},{"id":"nct06230757-university-of-colorado-anschutz-medical-campus-aurora","cat":"research","name":"University of Colorado Anschutz Medical Campus","city":"Aurora","region":"Colorado","country":"United States","cc":"US","lat":39.74096,"lon":-104.82312,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"80045","condg":["Depression"],"nct":"NCT06230757","study":"Psilocybin for Treatment-Resistant Depression","sstatus":"COMPLETED","sponsor":"University of Colorado, Denver","official":"Andrew M Novick, MD, PhD (University of Colorado, Denver)","src":"https://clinicaltrials.gov/study/NCT06230757","phase":"Phase 2","enroll":20,"start":"2024-07-08","eid":"x:site:nct06230757-university-of-colorado-anschutz-medical-campus-aurora"},{"id":"nct03356483-connecticut-mental-health-center-new-haven","cat":"research","name":"Connecticut Mental Health Center","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31177,"lon":-72.9235,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"06519","condg":["OCD"],"nct":"NCT03356483","study":"Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.","sstatus":"COMPLETED","sponsor":"Yale University","official":"Benjamin Kelmendi, MD (Yale University); Christopher Pittenger, MD, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT03356483","phase":"Phase 1","enroll":31,"start":"2018-11-13","eid":"x:site:nct03356483-connecticut-mental-health-center-new-haven"},{"id":"nct07189988-innertrek-patient-service-center-portland","cat":"research","name":"Innertrek Patient Service Center","city":"Portland","region":"Oregon","country":"United States","cc":"US","lat":45.53216,"lon":-122.6803,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"97232","condg":["Addiction & substance use"],"nct":"NCT07189988","study":"Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Healing Advocacy Fund","official":"Noah Craft, MD (People Science, Inc.)","src":"https://clinicaltrials.gov/study/NCT07189988","enroll":20,"start":"2025-03-05","eid":"x:site:nct07189988-innertrek-patient-service-center-portland"},{"id":"nct07607938-nyu-langone-health-new-york","cat":"research","name":"NYU Langone Health","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71676,"lon":-74.00395,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10016","condg":["Other"],"status":"RECRUITING","nct":"NCT07607938","study":"Psilocybin as a Novel Therapy for Residual Anhedonia","sstatus":"RECRUITING","sponsor":"NYU Langone Health","official":"Joshua Siegel, MD, PhD (NYU Langone Health)","src":"https://clinicaltrials.gov/study/NCT07607938","contact":{"n":"Julia Diamond","p":"646-754-4744","e":"Julia.Diamond@nyulangone.org"},"phase":"Phase 1","enroll":90,"start":"2026-09","eid":"x:site:nct07607938-nyu-langone-health-new-york"},{"id":"nct02037126-uab-outpatient-clinical-research-unit-birmingham","cat":"research","name":"UAB Outpatient Clinical Research Unit","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.51421,"lon":-86.79633,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"35294","condg":["Addiction & substance use"],"nct":"NCT02037126","study":"Psilocybin-facilitated Treatment for Cocaine Use","sstatus":"COMPLETED","sponsor":"University of Alabama at Birmingham","official":"Peter S. Hendricks, Ph.D. (UAB Department of Psychiatry)","src":"https://clinicaltrials.gov/study/NCT02037126","phase":"Phase 2","enroll":40,"start":"2015-05","eid":"x:site:nct02037126-uab-outpatient-clinical-research-unit-birmingham"},{"id":"nct01988311-behavioral-pharmacology-research-unit-johns-hopkins-bayview-medical-","cat":"research","name":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29052,"lon":-76.60819,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Other"],"nct":"NCT01988311","study":"Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators","sstatus":"COMPLETED","sponsor":"Johns Hopkins University","official":"Roland R Griffiths, Ph.D. (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT01988311","phase":"Phase 1","enroll":10,"start":"2013-05","eid":"x:site:nct01988311-behavioral-pharmacology-research-unit-johns-hopkins-bayview-medical-"},{"id":"nct06464367-va-connecticut-healthcare-system-west-haven","cat":"research","name":"VA Connecticut Healthcare System","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.26919,"lon":-72.95453,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"06516","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06464367","study":"Mechanistic Studies of Psilocybin in Headache Disorders","sstatus":"RECRUITING","sponsor":"Yale University","src":"https://clinicaltrials.gov/study/NCT06464367","contact":{"n":"Erik Zorrilla, PhD","p":"203-932-5711","e":"erik.zorrilla@yale.edu"},"phase":"EARLY_Phase 1","enroll":50,"start":"2025-05-19","eid":"x:site:nct06464367-va-connecticut-healthcare-system-west-haven"},{"id":"nct07251491-james-j-peters-department-of-veterans-affairs-medical-center-the-bro","cat":"research","name":"James J. Peters Department of Veterans Affairs Medical Center","city":"The Bronx","region":"New York","country":"United States","cc":"US","lat":40.85281,"lon":-73.85714,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10468","condg":["Depression"],"status":"RECRUITING","nct":"NCT07251491","study":"Psilocybin to Treat Depression in Spinal Cord Injury","sstatus":"RECRUITING","sponsor":"James J. Peters Veterans Affairs Medical Center","official":"Jill M Wecht, EdD (James J Peters VA Medical Center)","src":"https://clinicaltrials.gov/study/NCT07251491","contact":{"n":"Thomas W Sutor, PhD","p":"718-584-9000","e":"thomas.sutor@mountsinai.org"},"phase":"Phase 1/Phase 2","enroll":30,"start":"2026-08-06","eid":"x:site:nct07251491-james-j-peters-department-of-veterans-affairs-medical-center-the-bro"},{"id":"nct05163496-university-of-washington-seattle","cat":"research","name":"University of Washington","city":"Seattle","region":"Washington","country":"United States","cc":"US","lat":47.60532,"lon":-122.33588,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"98195","condg":["Depression","PTSD & trauma"],"nct":"NCT05163496","study":"Frontline Clinician Psilocybin Study","sstatus":"COMPLETED","sponsor":"University of Washington","official":"Anthony Back, MD (University of Washington)","src":"https://clinicaltrials.gov/study/NCT05163496","phase":"Phase 3","enroll":30,"start":"2022-03-03","eid":"x:site:nct05163496-university-of-washington-seattle"},{"id":"nct06308653-university-of-alabama-clinical-research-unit-birmingham","cat":"research","name":"University of Alabama Clinical Research Unit","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.51628,"lon":-86.79905,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"35209","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-university-of-alabama-clinical-research-unit-birmingham"},{"id":"nct06308653-preferred-research-partners-nwa-llc-fayetteville","cat":"research","name":"Preferred Research Partners-NWA, LLC","city":"Fayetteville","region":"Arkansas","country":"United States","cc":"US","lat":35.04885,"lon":-78.88697,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"72703","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-preferred-research-partners-nwa-llc-fayetteville"},{"id":"nct06308653-preferred-research-partners-inc-little-rock","cat":"research","name":"Preferred Research Partners, Inc.","city":"Little Rock","region":"Arkansas","country":"United States","cc":"US","lat":34.75274,"lon":-92.29171,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"72211","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-preferred-research-partners-inc-little-rock"},{"id":"nct06308653-kadima-neuropsychiatry-institute-la-jolla","cat":"research","name":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","cc":"US","lat":32.85776,"lon":-117.27886,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92037","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-kadima-neuropsychiatry-institute-la-jolla"},{"id":"nct06308653-west-la-va-medical-center-mental-health-department-los-angeles","cat":"research","name":"West LA VA Medical Center - Mental Health Department","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.05717,"lon":-118.25455,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"90073","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-west-la-va-medical-center-mental-health-department-los-angeles"},{"id":"nct06308653-pacific-neuroscience-institute-pni-at-saint-john-s-physician-partner","cat":"research","name":"Pacific Neuroscience Institute (PNI) at Saint John's Physician Partners","city":"Santa Monica","region":"California","country":"United States","cc":"US","lat":34.02471,"lon":-118.49218,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"90404","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-pacific-neuroscience-institute-pni-at-saint-john-s-physician-partner"},{"id":"nct06308653-psychedelic-science-institute-santa-monica","cat":"research","name":"Psychedelic Science Institute","city":"Santa Monica","region":"California","country":"United States","cc":"US","lat":34.01935,"lon":-118.48983,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"90404","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-psychedelic-science-institute-santa-monica"},{"id":"nct06308653-mountain-view-clinical-research-denver","cat":"research","name":"Mountain View Clinical Research","city":"Denver","region":"Colorado","country":"United States","cc":"US","lat":39.7456,"lon":-104.9855,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"80209","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-mountain-view-clinical-research-denver"},{"id":"nct06308653-connecticut-mental-health-center-yale-university-new-haven","cat":"research","name":"Connecticut Mental Health Center, Yale University","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31855,"lon":-72.92557,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"06519","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-connecticut-mental-health-center-yale-university-new-haven"},{"id":"nct06308653-clinical-neuroscience-solutions-inc-jacksonville","cat":"research","name":"Clinical Neuroscience Solutions Inc.","city":"Jacksonville","region":"Florida","country":"United States","cc":"US","lat":30.32507,"lon":-81.66586,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"32256","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-clinical-neuroscience-solutions-inc-jacksonville"},{"id":"nct06308653-innovative-clinical-research-inc-lauderhill","cat":"research","name":"Innovative Clinical Research, Inc.","city":"Lauderhill","region":"Florida","country":"United States","cc":"US","lat":26.14521,"lon":-80.2026,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"33319","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-innovative-clinical-research-inc-lauderhill"},{"id":"nct06308653-clinical-neuroscience-solutions-inc-orlando","cat":"research","name":"Clinical Neuroscience Solutions, Inc.","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.52653,"lon":-81.38399,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"32801","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-clinical-neuroscience-solutions-inc-orlando"},{"id":"nct06308653-emory-university-atlanta","cat":"research","name":"Emory University","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.74707,"lon":-84.38134,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30329","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-emory-university-atlanta"},{"id":"nct06308653-cenexel-iresearch-llc-decatur","cat":"research","name":"CenExel iResearch, LLC","city":"Decatur","region":"Georgia","country":"United States","cc":"US","lat":39.83198,"lon":-88.95212,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30030","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-cenexel-iresearch-llc-decatur"},{"id":"nct06308653-great-lakes-clinical-trials-chicago","cat":"research","name":"Great Lakes Clinical Trials","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.85892,"lon":-87.64897,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"60640","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-great-lakes-clinical-trials-chicago"},{"id":"nct06308653-johns-hopkins-school-of-medicine-center-for-psychedelic-and-consciou","cat":"research","name":"Johns Hopkins School of Medicine, Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29843,"lon":-76.60226,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-johns-hopkins-school-of-medicine-center-for-psychedelic-and-consciou"},{"id":"nct06308653-sunstone-medical-pc-rockville","cat":"research","name":"Sunstone Medical PC","city":"Rockville","region":"Maryland","country":"United States","cc":"US","lat":39.07878,"lon":-77.14707,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"20850","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-sunstone-medical-pc-rockville"},{"id":"nct06308653-washington-university-school-of-medicine-st-louis","cat":"research","name":"Washington University School of Medicine","city":"St Louis","region":"Missouri","country":"United States","cc":"US","lat":38.63061,"lon":-90.20688,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"63110","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-washington-university-school-of-medicine-st-louis"},{"id":"nct06308653-va-nebraska-western-iowa-health-care-system-omaha","cat":"research","name":"VA Nebraska Western Iowa Health Care System","city":"Omaha","region":"Nebraska","country":"United States","cc":"US","lat":41.25922,"lon":-95.94048,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"68105","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-va-nebraska-western-iowa-health-care-system-omaha"},{"id":"nct06308653-global-medical-institutes-llc-princeton-medical-institute-princeton","cat":"research","name":"Global Medical Institutes, LLC; Princeton Medical Institute","city":"Princeton","region":"New Jersey","country":"United States","cc":"US","lat":25.54573,"lon":-80.41002,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"08540","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-global-medical-institutes-llc-princeton-medical-institute-princeton"},{"id":"nct06308653-university-of-new-mexico-unm-interdisciplinary-substance-use-and-bra","cat":"research","name":"University of New Mexico (UNM) Interdisciplinary Substance Use and Brain Injury (ISUBI) Center","city":"Albuquerque","region":"New Mexico","country":"United States","cc":"US","lat":35.08614,"lon":-106.64018,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"87106","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-university-of-new-mexico-unm-interdisciplinary-substance-use-and-bra"},{"id":"nct06308653-nyu-clinical-translational-science-institute-new-york","cat":"research","name":"NYU Clinical & Translational Science Institute","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71921,"lon":-74.00112,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10016","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-nyu-clinical-translational-science-institute-new-york"},{"id":"nct06308653-bronx-veterans-research-foundation-at-the-james-j-peters-vamc-the-br","cat":"research","name":"Bronx Veterans Research Foundation at the James J. Peters VAMC","city":"The Bronx","region":"New York","country":"United States","cc":"US","lat":40.84199,"lon":-73.87352,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10468","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-bronx-veterans-research-foundation-at-the-james-j-peters-vamc-the-br"},{"id":"nct06308653-aim-trials-llc-plano","cat":"research","name":"AIM Trials, LLC","city":"Plano","region":"Texas","country":"United States","cc":"US","lat":33.02704,"lon":-96.71023,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"75093","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-aim-trials-llc-plano"},{"id":"nct06308653-clinical-trials-of-texas-llc-san-antonio","cat":"research","name":"Clinical Trials of Texas, LLC","city":"San Antonio","region":"Texas","country":"United States","cc":"US","lat":29.43386,"lon":-98.48784,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"78229","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-clinical-trials-of-texas-llc-san-antonio"},{"id":"nct06308653-cedar-clinical-research-draper","cat":"research","name":"Cedar Clinical Research","city":"Draper","region":"Utah","country":"United States","cc":"US","lat":40.51747,"lon":-111.86311,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"84020","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-cedar-clinical-research-draper"},{"id":"nct06308653-cedar-clinical-research-inc-murray","cat":"research","name":"Cedar Clinical Research, Inc.","city":"Murray","region":"Utah","country":"United States","cc":"US","lat":40.65828,"lon":-111.89528,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"84107","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-cedar-clinical-research-inc-murray"},{"id":"nct06308653-seattle-neuropsychiatric-treatment-center-bellevue","cat":"research","name":"Seattle Neuropsychiatric Treatment Center","city":"Bellevue","region":"Washington","country":"United States","cc":"US","lat":47.61626,"lon":-122.20327,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"98004","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-seattle-neuropsychiatric-treatment-center-bellevue"},{"id":"nct06308653-va-portland-health-care-system-vancouver","cat":"research","name":"VA Portland Health Care System","city":"Vancouver","region":"Washington","country":"United States","cc":"US","lat":45.62767,"lon":-122.67227,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"98661","condg":["Depression"],"nct":"NCT06308653","study":"Psilocybin for Major Depressive Disorder (MDD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT06308653","phase":"Phase 3","enroll":238,"start":"2024-03-13","eid":"x:site:nct06308653-va-portland-health-care-system-vancouver"},{"id":"nct07638553-centre-hospitalier-de-la-cote-basque-bayonne","cat":"research","name":"Centre Hospitalier de la Côte Basque","city":"Bayonne","country":"France","cc":"FR","lat":43.48615,"lon":-1.48349,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression","Addiction & substance use"],"status":"NOT_YET_RECRUITING","nct":"NCT07638553","study":"Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms","sstatus":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","official":"Amandine Luquiens (Centre Hospitalier Universitaire de Nīmes)","src":"https://clinicaltrials.gov/study/NCT07638553","contact":{"n":"Sophie-Athéna CHARPON","p":"05 59 44 42 19","e":"sachapron@ch-cotebasque.fr"},"phase":"Phase 3","enroll":172,"start":"2026-06-30","eid":"x:site:nct07638553-centre-hospitalier-de-la-cote-basque-bayonne"},{"id":"nct07638553-chu-besancon-besancon","cat":"research","name":"CHU Besançon","city":"Besançon","country":"France","cc":"FR","lat":47.25033,"lon":6.0085,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression","Addiction & substance use"],"status":"NOT_YET_RECRUITING","nct":"NCT07638553","study":"Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms","sstatus":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","official":"Amandine Luquiens (Centre Hospitalier Universitaire de Nīmes)","src":"https://clinicaltrials.gov/study/NCT07638553","contact":{"n":"Julie GIUSTNIANI","p":"03.81.21.90.08","e":"jgiustiniani@chu-besancon.fr"},"phase":"Phase 3","enroll":172,"start":"2026-06-30","eid":"x:site:nct07638553-chu-besancon-besancon"},{"id":"nct07638553-chu-de-bordeaux-bordeaux","cat":"research","name":"CHU de Bordeaux","city":"Bordeaux","country":"France","cc":"FR","lat":44.83931,"lon":-0.57439,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression","Addiction & substance use"],"status":"NOT_YET_RECRUITING","nct":"NCT07638553","study":"Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms","sstatus":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","official":"Amandine Luquiens (Centre Hospitalier Universitaire de Nīmes)","src":"https://clinicaltrials.gov/study/NCT07638553","contact":{"n":"Mélina FATSEAS","p":"05 47 75 75 75","e":"melina.fatseas@u-bordeaux.fr"},"phase":"Phase 3","enroll":172,"start":"2026-06-30","eid":"x:site:nct07638553-chu-de-bordeaux-bordeaux"},{"id":"nct07638553-chu-brest-brest","cat":"research","name":"CHU Brest","city":"Brest","country":"France","cc":"FR","lat":48.39777,"lon":-4.48586,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression","Addiction & substance use"],"status":"NOT_YET_RECRUITING","nct":"NCT07638553","study":"Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms","sstatus":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","official":"Amandine Luquiens (Centre Hospitalier Universitaire de Nīmes)","src":"https://clinicaltrials.gov/study/NCT07638553","contact":{"n":"Morgane GUILLOU","p":"02 98 34 23 48","e":"morgane.guillou@chu-brest.fr"},"phase":"Phase 3","enroll":172,"start":"2026-06-30","eid":"x:site:nct07638553-chu-brest-brest"},{"id":"nct07638553-ch-le-vinatier-bron","cat":"research","name":"CH Le Vinatier","city":"Bron","country":"France","cc":"FR","lat":45.74237,"lon":4.91204,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression","Addiction & substance use"],"status":"NOT_YET_RECRUITING","nct":"NCT07638553","study":"Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms","sstatus":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","official":"Amandine Luquiens (Centre Hospitalier Universitaire de Nīmes)","src":"https://clinicaltrials.gov/study/NCT07638553","contact":{"n":"Benjamin ROLLAND","p":"04 37 91 50 75","e":"benjamin.rolland@univ-lyon1.fr"},"phase":"Phase 3","enroll":172,"start":"2026-06-30","eid":"x:site:nct07638553-ch-le-vinatier-bron"},{"id":"nct07638553-chu-de-nantes-nantes","cat":"research","name":"CHU de Nantes","city":"Nantes","country":"France","cc":"FR","lat":47.2124,"lon":-1.55303,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression","Addiction & substance use"],"status":"NOT_YET_RECRUITING","nct":"NCT07638553","study":"Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms","sstatus":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","official":"Amandine Luquiens (Centre Hospitalier Universitaire de Nīmes)","src":"https://clinicaltrials.gov/study/NCT07638553","contact":{"n":"Marie GRALL-BRONNEC","p":"02.40.20.66.40","e":"marie.bronnec@chu-nantes.fr"},"phase":"Phase 3","enroll":172,"start":"2026-06-30","eid":"x:site:nct07638553-chu-de-nantes-nantes"},{"id":"nct07638553-chu-de-nimes-nimes","cat":"research","name":"CHU de Nîmes","city":"Nîmes","country":"France","cc":"FR","lat":43.84658,"lon":4.35275,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30029","condg":["Depression","Addiction & substance use"],"status":"RECRUITING","nct":"NCT07638553","study":"Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms","sstatus":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","official":"Amandine Luquiens (Centre Hospitalier Universitaire de Nīmes)","src":"https://clinicaltrials.gov/study/NCT07638553","contact":{"n":"Anissa Megzari","p":"04.66.68.42.36","e":"drc@chu-nimes.fr"},"phase":"Phase 3","enroll":172,"start":"2026-06-30","eid":"x:site:nct07638553-chu-de-nimes-nimes"},{"id":"nct07638553-chu-saint-etienne-saint-priest","cat":"research","name":"CHU Saint-Etienne","city":"Saint-Priest","country":"France","cc":"FR","lat":45.6894,"lon":4.9342,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression","Addiction & substance use"],"status":"NOT_YET_RECRUITING","nct":"NCT07638553","study":"Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms","sstatus":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","official":"Amandine Luquiens (Centre Hospitalier Universitaire de Nīmes)","src":"https://clinicaltrials.gov/study/NCT07638553","contact":{"n":"Aurélia GAY","p":"04 77 12 02 31","e":"aurelia.gay@chu-st-etienne.fr"},"phase":"Phase 3","enroll":172,"start":"2026-06-30","eid":"x:site:nct07638553-chu-saint-etienne-saint-priest"},{"id":"nct05452772-university-of-alabama-at-birmingham-birmingham","cat":"research","name":"University of Alabama at Birmingham","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.51346,"lon":-86.8079,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"35294","condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT05452772","study":"5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder","sstatus":"RECRUITING","sponsor":"Johns Hopkins University","official":"Matthew Johnson, Ph.D (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT05452772","contact":{"n":"Seher Premani, M.P.H.","p":"205-975-7721","e":"spremani@uab.edu"},"phase":"Phase 2","enroll":66,"start":"2023-11-01","eid":"x:site:nct05452772-university-of-alabama-at-birmingham-birmingham"},{"id":"nct05452772-johns-hopkins-university-school-of-medicine-baltimore","cat":"research","name":"Johns Hopkins University School of Medicine","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.2892,"lon":-76.62155,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Addiction & substance use"],"status":"ACTIVE_NOT_RECRUITING","nct":"NCT05452772","study":"5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder","sstatus":"RECRUITING","sponsor":"Johns Hopkins University","official":"Matthew Johnson, Ph.D (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT05452772","contact":{"n":"Matthew Johnson, Ph.D","p":"410-550-0056","e":"mwj@jhu.edu"},"phase":"Phase 2","enroll":66,"start":"2023-11-01","eid":"x:site:nct05452772-johns-hopkins-university-school-of-medicine-baltimore"},{"id":"nct05452772-new-york-university-new-york","cat":"research","name":"New York University","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70923,"lon":-74.00206,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10016","condg":["Addiction & substance use"],"status":"ACTIVE_NOT_RECRUITING","nct":"NCT05452772","study":"5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder","sstatus":"RECRUITING","sponsor":"Johns Hopkins University","official":"Matthew Johnson, Ph.D (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT05452772","contact":{"n":"Matthew Johnson, Ph.D","p":"410-550-0056","e":"mwj@jhu.edu"},"phase":"Phase 2","enroll":66,"start":"2023-11-01","eid":"x:site:nct05452772-new-york-university-new-york"},{"id":"nct06798636-imperial-college-london-london","cat":"research","name":"Imperial College London","city":"London","country":"United Kingdom","cc":"GB","lat":51.51018,"lon":-0.124,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Other"],"status":"RECRUITING","nct":"NCT06798636","study":"PsiloIMAGINE: A Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm","sstatus":"RECRUITING","sponsor":"Imperial College London","official":"Martina Di Simplicio, Dr (Imperial College London); David Nutt, Prof (Imperial College London)","src":"https://clinicaltrials.gov/study/NCT06798636","contact":{"n":"Joanna Vamvakopoulou","p":"+44 (0) 7942292199","e":"imagine@imperial.ac.uk"},"phase":"EARLY_Phase 1","enroll":30,"start":"2025-10-01","eid":"x:site:nct06798636-imperial-college-london-london"},{"id":"nct06560658-national-university-of-natural-medicine-portland","cat":"research","name":"National University of Natural Medicine","city":"Portland","region":"Oregon","country":"United States","cc":"US","lat":45.52867,"lon":-122.68388,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"97201","condg":["Other"],"nct":"NCT06560658","study":"Optimizing Microdosing and Meditation","sstatus":"WITHDRAWN","sponsor":"National University of Natural Medicine","official":"Matthew Hicks, ND, MS (National University of Natural Medicine)","src":"https://clinicaltrials.gov/study/NCT06560658","phase":"N/A","start":"2024-10-01","eid":"x:site:nct06560658-national-university-of-natural-medicine-portland"},{"id":"nct07063862-william-osler-health-system-brampton","cat":"research","name":"William Osler Health System","city":"Brampton","region":"Ontario","country":"Canada","cc":"CA","lat":43.68299,"lon":-79.76675,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Other"],"status":"NOT_YET_RECRUITING","nct":"NCT07063862","study":"Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT)","sstatus":"RECRUITING","sponsor":"Bruyère Health Research Institute.","src":"https://clinicaltrials.gov/study/NCT07063862","contact":{"n":"Martin Chasen, MD","p":"905-494-2120","e":"martin.chasen@williamoslerhs.ca"},"phase":"Phase 3","enroll":120,"start":"2026-01-28","eid":"x:site:nct07063862-william-osler-health-system-brampton"},{"id":"nct07063862-providence-care-hospital-kingston","cat":"research","name":"Providence Care Hospital","city":"Kingston","region":"Ontario","country":"Canada","cc":"CA","lat":44.21785,"lon":-76.48037,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Other"],"status":"RECRUITING","nct":"NCT07063862","study":"Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT)","sstatus":"RECRUITING","sponsor":"Bruyère Health Research Institute.","src":"https://clinicaltrials.gov/study/NCT07063862","contact":{"n":"Danielle Kain, MD","p":"613-548-2485","e":"danielle.kain@kingstonhsc.ca"},"phase":"Phase 3","enroll":120,"start":"2026-01-28","eid":"x:site:nct07063862-providence-care-hospital-kingston"},{"id":"nct07063862-st-joseph-s-healthcare-london","cat":"research","name":"St. Joseph's Healthcare","city":"London","region":"Ontario","country":"Canada","cc":"CA","lat":42.97741,"lon":-81.23149,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Other"],"status":"NOT_YET_RECRUITING","nct":"NCT07063862","study":"Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT)","sstatus":"RECRUITING","sponsor":"Bruyère Health Research Institute.","src":"https://clinicaltrials.gov/study/NCT07063862","contact":{"n":"Anne Boyle, MD","p":"905-521-2100","e":"aboyle@mcmaster.ca"},"phase":"Phase 3","enroll":120,"start":"2026-01-28","eid":"x:site:nct07063862-st-joseph-s-healthcare-london"},{"id":"nct07063862-south-lake-regional-health-centre-newmarket","cat":"research","name":"South Lake Regional Health Centre","city":"Newmarket","region":"Ontario","country":"Canada","cc":"CA","lat":44.04856,"lon":-79.46786,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Other"],"status":"RECRUITING","nct":"NCT07063862","study":"Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT)","sstatus":"RECRUITING","sponsor":"Bruyère Health Research Institute.","src":"https://clinicaltrials.gov/study/NCT07063862","contact":{"n":"Arnell Baguio, MD","p":"905-895-4521","e":"jdownar@toh.ca"},"phase":"Phase 3","enroll":120,"start":"2026-01-28","eid":"x:site:nct07063862-south-lake-regional-health-centre-newmarket"},{"id":"nct07063862-bruyere-health-ottawa","cat":"research","name":"Bruyere Health","city":"Ottawa","region":"Ontario","country":"Canada","cc":"CA","lat":45.41611,"lon":-75.69864,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Other"],"status":"RECRUITING","nct":"NCT07063862","study":"Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT)","sstatus":"RECRUITING","sponsor":"Bruyère Health Research Institute.","src":"https://clinicaltrials.gov/study/NCT07063862","contact":{"n":"Julie Lapenskie, MSc","p":"613-562-6262","e":"jlapenskie@bruyere.org"},"phase":"Phase 3","enroll":120,"start":"2026-01-28","eid":"x:site:nct07063862-bruyere-health-ottawa"},{"id":"nct07063862-the-ottawa-hospital-ottawa","cat":"research","name":"The Ottawa Hospital","city":"Ottawa","region":"Ontario","country":"Canada","cc":"CA","lat":45.40491,"lon":-75.70344,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Other"],"status":"NOT_YET_RECRUITING","nct":"NCT07063862","study":"Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT)","sstatus":"RECRUITING","sponsor":"Bruyère Health Research Institute.","src":"https://clinicaltrials.gov/study/NCT07063862","contact":{"n":"Julie Lapenskie, MSc","p":"613-562-6262","e":"jlapenskie@bruyere.org"},"phase":"Phase 3","enroll":120,"start":"2026-01-28","eid":"x:site:nct07063862-the-ottawa-hospital-ottawa"},{"id":"nct07063862-mcgill-university-health-centre-montreal","cat":"research","name":"McGill University Health Centre","city":"Montreal","region":"Quebec","country":"Canada","cc":"CA","lat":45.49778,"lon":-73.59181,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Other"],"status":"NOT_YET_RECRUITING","nct":"NCT07063862","study":"Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT)","sstatus":"RECRUITING","sponsor":"Bruyère Health Research Institute.","src":"https://clinicaltrials.gov/study/NCT07063862","contact":{"n":"Justin Sanders, MD","p":"514-398-7375","e":"justin.sanders@mcgill.ca"},"phase":"Phase 3","enroll":120,"start":"2026-01-28","eid":"x:site:nct07063862-mcgill-university-health-centre-montreal"},{"id":"nct06656702-johns-hopkins-center-for-psychedelic-and-consciousness-research-balt","cat":"research","name":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28723,"lon":-76.61647,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Other"],"status":"RECRUITING","nct":"NCT06656702","study":"Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis","sstatus":"RECRUITING","sponsor":"Johns Hopkins University","official":"Ambereen K Mehta, MD, MPH, FAAHPM (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT06656702","contact":{"n":"Ian Geithner, MPS","p":"410-550-0037","e":"igeithn1@jhmi.edu"},"phase":"EARLY_Phase 1","enroll":24,"start":"2025-04-09","eid":"x:site:nct06656702-johns-hopkins-center-for-psychedelic-and-consciousness-research-balt"},{"id":"nct04052568-behavioral-pharmacology-research-unit-baltimore","cat":"research","name":"Behavioral Pharmacology Research Unit","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28864,"lon":-76.62184,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Eating disorders"],"nct":"NCT04052568","study":"Effects of Psilocybin in Anorexia Nervosa","sstatus":"COMPLETED","sponsor":"Johns Hopkins University","official":"Roland Griffiths, Ph.D. (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT04052568","phase":"Phase 1","enroll":22,"start":"2019-08-26","eid":"x:site:nct04052568-behavioral-pharmacology-research-unit-baltimore"},{"id":"nct04161066-university-of-wisconsin-madison","cat":"research","name":"University of Wisconsin","city":"Madison","region":"Wisconsin","country":"United States","cc":"US","lat":43.06576,"lon":-89.3977,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"53705","condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT04161066","study":"Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine","sstatus":"RECRUITING","sponsor":"University of Wisconsin, Madison","official":"Randall Brown, MD PhD (University of Wisconsin, Madison)","src":"https://clinicaltrials.gov/study/NCT04161066","contact":{"n":"Randall Brown, MD PhD","p":"608-444-2397","e":"protea.research@mailplus.wisc.edu"},"phase":"Phase 1","enroll":10,"start":"2021-01-13","eid":"x:site:nct04161066-university-of-wisconsin-madison"},{"id":"nct03429075-imperial-college-hammersmith-campus-london","cat":"research","name":"Imperial College Hammersmith campus","city":"London","country":"United Kingdom","cc":"GB","lat":51.51658,"lon":-0.11798,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"W12 0NN","condg":["Depression"],"nct":"NCT03429075","study":"Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms","sstatus":"COMPLETED","sponsor":"Imperial College London","official":"David J Nutt, Medicine (Imperial College London)","src":"https://clinicaltrials.gov/study/NCT03429075","phase":"Phase 2","enroll":59,"start":"2019-01-07","eid":"x:site:nct03429075-imperial-college-hammersmith-campus-london"},{"id":"nct07499583-goodman-hall-dept-of-psychiatry-indiana-university-indianapolis","cat":"research","name":"Goodman Hall, Dept of Psychiatry, Indiana University","city":"Indianapolis","region":"Indiana","country":"United States","cc":"US","lat":39.76673,"lon":-86.14802,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"46202-3082","condg":["Depression","Addiction & substance use"],"nct":"NCT07499583","study":"Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder","sstatus":"NOT_YET_RECRUITING","sponsor":"Indiana University","official":"Susan K Conroy, PhD (Indiana University)","src":"https://clinicaltrials.gov/study/NCT07499583","contact":{"n":"Susan K Conroy, MD","p":"317-948-5450","e":"sconroy@iu.edu"},"phase":"Phase 1/Phase 2","enroll":50,"start":"2026-08-01","eid":"x:site:nct07499583-goodman-hall-dept-of-psychiatry-indiana-university-indianapolis"},{"id":"nct07499583-the-stark-neuroscience-building-goodman-hall-indianapolis","cat":"research","name":"The Stark Neuroscience Building (Goodman Hall)","city":"Indianapolis","region":"Indiana","country":"United States","cc":"US","lat":39.76532,"lon":-86.15159,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"46202","condg":["Depression","Addiction & substance use"],"nct":"NCT07499583","study":"Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder","sstatus":"NOT_YET_RECRUITING","sponsor":"Indiana University","official":"Susan K Conroy, PhD (Indiana University)","src":"https://clinicaltrials.gov/study/NCT07499583","contact":{"n":"Susan K Conroy, MD","p":"317-948-5450","e":"sconroy@iu.edu"},"phase":"Phase 1/Phase 2","enroll":50,"start":"2026-08-01","eid":"x:site:nct07499583-the-stark-neuroscience-building-goodman-hall-indianapolis"},{"id":"nct06372197-national-university-of-natural-medicine-portland","cat":"research","name":"National University of Natural Medicine","city":"Portland","region":"Oregon","country":"United States","cc":"US","lat":45.51474,"lon":-122.6659,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"97201","condg":["Depression"],"nct":"NCT06372197","study":"Low-Income Group Psilocybin Assisted Therapy for Depression","sstatus":"COMPLETED","sponsor":"Matthew Hicks","official":"Matthew R Hicks, ND, MS (National University of Natural Medicine)","src":"https://clinicaltrials.gov/study/NCT06372197","phase":"N/A","enroll":20,"start":"2024-08-01","eid":"x:site:nct06372197-national-university-of-natural-medicine-portland"},{"id":"nct04353921-innovative-clinical-research-inc-formerly-segal-trials-lauderhill","cat":"research","name":"Innovative Clinical Research, Inc. (formerly Segal Trials)","city":"Lauderhill","region":"Florida","country":"United States","cc":"US","lat":26.13655,"lon":-80.22538,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"33319","condg":["Depression"],"nct":"NCT04353921","study":"PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder","sstatus":"TERMINATED","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT04353921","enroll":26,"start":"2020-06-30","eid":"x:site:nct04353921-innovative-clinical-research-inc-formerly-segal-trials-lauderhill"},{"id":"nct07719088-vail-health-behavioral-health-edwards","cat":"research","name":"Vail Health Behavioral Health","city":"Edwards","region":"Colorado","country":"United States","cc":"US","lat":39.6536,"lon":-106.59604,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"81632","condg":["Other"],"nct":"NCT07719088","study":"Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life","sstatus":"NOT_YET_RECRUITING","sponsor":"Charles Raison","src":"https://clinicaltrials.gov/study/NCT07719088","contact":{"n":"BHIC Study Team","p":"970-855-7374","e":"bhic@vailhealth.org"},"phase":"Phase 1","enroll":50,"start":"2026-12","eid":"x:site:nct07719088-vail-health-behavioral-health-edwards"},{"id":"nct07053917-johns-hopkins-baltimore","cat":"research","name":"Johns Hopkins","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28949,"lon":-76.62033,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21287","condg":["Neurology & cognition"],"status":"RECRUITING","nct":"NCT07053917","study":"Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability","sstatus":"RECRUITING","sponsor":"Johns Hopkins University","official":"Victor Urrutia, M.D. (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT07053917","contact":{"n":"Steven R Zeiler, M.D., Ph.D.","p":"303-520-7404","e":"sz@jhmi.edu"},"phase":"Phase 1","enroll":20,"start":"2026-02-09","eid":"x:site:nct07053917-johns-hopkins-baltimore"},{"id":"nct05711940-lighthouse-psychiatry-scottsdale-gilbert","cat":"research","name":"Lighthouse Psychiatry Scottsdale","city":"Gilbert","region":"Arizona","country":"United States","cc":"US","lat":33.36379,"lon":-111.79679,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"85234","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-lighthouse-psychiatry-scottsdale-gilbert"},{"id":"nct05711940-clinical-innovations-inc-bellflower","cat":"research","name":"Clinical Innovations, Inc.","city":"Bellflower","region":"California","country":"United States","cc":"US","lat":33.8853,"lon":-118.11677,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"90706","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-clinical-innovations-inc-bellflower"},{"id":"nct05711940-m3-wake-research-encino","cat":"research","name":"M3 Wake Research","city":"Encino","region":"California","country":"United States","cc":"US","lat":34.15799,"lon":-118.48985,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"91316","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-m3-wake-research-encino"},{"id":"nct05711940-the-regents-of-the-university-of-california-san-diego-la-jolla","cat":"research","name":"The Regents of the University of California - San Diego","city":"La Jolla","region":"California","country":"United States","cc":"US","lat":32.84158,"lon":-117.26305,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92037-1337","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-the-regents-of-the-university-of-california-san-diego-la-jolla"},{"id":"nct05711940-kadima-neuropsychiatry-institute-la-jolla","cat":"research","name":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","cc":"US","lat":32.83734,"lon":-117.27114,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92037","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-kadima-neuropsychiatry-institute-la-jolla"},{"id":"nct05711940-calneuro-research-group-inc-los-angeles","cat":"research","name":"CalNeuro Research Group, Inc","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.05407,"lon":-118.23657,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"90025","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-calneuro-research-group-inc-los-angeles"},{"id":"nct05711940-catalina-research-institute-llc-montclair","cat":"research","name":"Catalina Research Institute, LLC","city":"Montclair","region":"California","country":"United States","cc":"US","lat":40.83398,"lon":-74.19938,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"91763","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-catalina-research-institute-llc-montclair"},{"id":"nct05711940-piedmont-hospital-neuroscience-centre-oakland","cat":"research","name":"Piedmont Hospital Neuroscience Centre","city":"Oakland","region":"California","country":"United States","cc":"US","lat":37.80696,"lon":-122.26407,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94610","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-piedmont-hospital-neuroscience-centre-oakland"},{"id":"nct05711940-atp-clinical-research-inc-orange","cat":"research","name":"ATP Clinical Research, Inc.","city":"Orange","region":"California","country":"United States","cc":"US","lat":33.79348,"lon":-117.85702,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92868","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-atp-clinical-research-inc-orange"},{"id":"nct05711940-citrials-riverside","cat":"research","name":"CITrials","city":"Riverside","region":"California","country":"United States","cc":"US","lat":33.95951,"lon":-117.39367,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92506","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-citrials-riverside"},{"id":"nct05711940-lumos-clinical-research-center-san-jose","cat":"research","name":"Lumos Clinical Research Center","city":"San Jose","region":"California","country":"United States","cc":"US","lat":37.33144,"lon":-121.9063,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"95124","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-lumos-clinical-research-center-san-jose"},{"id":"nct05711940-syrentis-clinical-research-santa-ana","cat":"research","name":"Syrentis Clinical Research","city":"Santa Ana","region":"California","country":"United States","cc":"US","lat":33.74477,"lon":-117.8771,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92705","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-syrentis-clinical-research-santa-ana"},{"id":"nct05711940-stanford-university-stanford","cat":"research","name":"Stanford University","city":"Stanford","region":"California","country":"United States","cc":"US","lat":37.42444,"lon":-122.16857,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94305","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-stanford-university-stanford"},{"id":"nct05711940-asclepes-research-centers-thousand-oaks","cat":"research","name":"ASCLEPES Research Centers","city":"Thousand Oaks","region":"California","country":"United States","cc":"US","lat":34.16835,"lon":-118.8494,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"93012","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-asclepes-research-centers-thousand-oaks"},{"id":"nct05711940-pacific-clinical-research-management-group-llc-upland","cat":"research","name":"Pacific Clinical Research Management Group, LLC","city":"Upland","region":"California","country":"United States","cc":"US","lat":34.09596,"lon":-117.65286,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"91786","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-pacific-clinical-research-management-group-llc-upland"},{"id":"nct05711940-innovative-clinical-research-inc-lauderhill","cat":"research","name":"Innovative Clinical Research, Inc.","city":"Lauderhill","region":"Florida","country":"United States","cc":"US","lat":26.14502,"lon":-80.21023,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"33319","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-innovative-clinical-research-inc-lauderhill"},{"id":"nct05711940-central-miami-medical-institute-llc-miami","cat":"research","name":"Central Miami Medical Institute, LLC","city":"Miami","region":"Florida","country":"United States","cc":"US","lat":25.78627,"lon":-80.20284,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"33125","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-central-miami-medical-institute-llc-miami"},{"id":"nct05711940-behavioral-clinical-research-inc-miami-lakes","cat":"research","name":"Behavioral Clinical Research, Inc.","city":"Miami Lakes","region":"Florida","country":"United States","cc":"US","lat":25.91309,"lon":-80.31247,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"33016","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-behavioral-clinical-research-inc-miami-lakes"},{"id":"nct05711940-health-synergy-clinical-research-okeechobee","cat":"research","name":"Health Synergy Clinical Research","city":"Okeechobee","region":"Florida","country":"United States","cc":"US","lat":27.23748,"lon":-80.81957,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"34972","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-health-synergy-clinical-research-okeechobee"},{"id":"nct05711940-clinical-neurosciecne-solutions-inc-dba-cns-healthcare-orlando","cat":"research","name":"Clinical Neurosciecne Solutions, Inc. dba CNS Healthcare","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.52643,"lon":-81.3807,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"32801","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-clinical-neurosciecne-solutions-inc-dba-cns-healthcare-orlando"},{"id":"nct05711940-apg-research-llc-advanced-psychiatric-group-orlando","cat":"research","name":"APG Research, LLC- Advanced Psychiatric Group","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.53462,"lon":-81.36988,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"32803","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-apg-research-llc-advanced-psychiatric-group-orlando"},{"id":"nct05711940-university-south-florida-tampa","cat":"research","name":"University South Florida","city":"Tampa","region":"Florida","country":"United States","cc":"US","lat":27.95237,"lon":-82.45264,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"33613-4788","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-university-south-florida-tampa"},{"id":"nct05711940-stedman-clinical-trials-tampa","cat":"research","name":"Stedman Clinical Trials","city":"Tampa","region":"Florida","country":"United States","cc":"US","lat":27.93759,"lon":-82.46017,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"33613","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-stedman-clinical-trials-tampa"},{"id":"nct05711940-health-synergy-clinical-research-llc-west-palm-beach","cat":"research","name":"Health Synergy Clinical Research, LLC","city":"West Palm Beach","region":"Florida","country":"United States","cc":"US","lat":26.71294,"lon":-80.06226,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"33407","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-health-synergy-clinical-research-llc-west-palm-beach"},{"id":"nct05711940-atlanta-center-for-medical-research-atlanta","cat":"research","name":"Atlanta Center for Medical Research","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.74669,"lon":-84.39659,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30331","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-atlanta-center-for-medical-research-atlanta"},{"id":"nct05711940-iresearch-atlanta-decatur","cat":"research","name":"iResearch Atlanta","city":"Decatur","region":"Georgia","country":"United States","cc":"US","lat":39.8477,"lon":-88.954,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30030","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-iresearch-atlanta-decatur"},{"id":"nct05711940-rush-university-medical-center-chicago","cat":"research","name":"Rush University Medical Center","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.85271,"lon":-87.64737,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"60612-3227","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-rush-university-medical-center-chicago"},{"id":"nct05711940-uptown-research-institute-llc-chicago","cat":"research","name":"Uptown Research Institute, LLC","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.85657,"lon":-87.65527,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"60640","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-uptown-research-institute-llc-chicago"},{"id":"nct05711940-psychiatric-medicine-associates-skokie","cat":"research","name":"Psychiatric Medicine Associates","city":"Skokie","region":"Illinois","country":"United States","cc":"US","lat":42.04404,"lon":-87.73955,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"60076","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-psychiatric-medicine-associates-skokie"},{"id":"nct05711940-harvard-medical-school-mclean-hospital-belmont","cat":"research","name":"Harvard Medical School - McLean Hospital","city":"Belmont","region":"Massachusetts","country":"United States","cc":"US","lat":37.51725,"lon":-122.26926,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"02478-1064","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-harvard-medical-school-mclean-hospital-belmont"},{"id":"nct05711940-adams-clinical-boston-copley-clinical-boston","cat":"research","name":"Adams Clinical - Boston (Copley Clinical)","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.35311,"lon":-71.06989,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"02116","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-adams-clinical-boston-copley-clinical-boston"},{"id":"nct05711940-university-of-massachusetts-medical-school-north-worcester","cat":"research","name":"University of Massachusetts Medical School","city":"North Worcester","region":"Massachusetts","country":"United States","cc":"US","lat":42.27007,"lon":-71.80431,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"01655","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-university-of-massachusetts-medical-school-north-worcester"},{"id":"nct05711940-adams-clinical-boston-watertown","cat":"research","name":"Adams Clinical - Boston","city":"Watertown","region":"Massachusetts","country":"United States","cc":"US","lat":42.37126,"lon":-71.19389,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"02472","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-adams-clinical-boston-watertown"},{"id":"nct05711940-michigan-clinical-research-institute-pc-ann-arbor","cat":"research","name":"Michigan Clinical Research Institute PC","city":"Ann Arbor","region":"Michigan","country":"United States","cc":"US","lat":42.28448,"lon":-83.74159,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"48105","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-michigan-clinical-research-institute-pc-ann-arbor"},{"id":"nct05711940-university-of-michigan-comprehensive-depression-center-ann-arbor","cat":"research","name":"University Of Michigan Comprehensive Depression Center","city":"Ann Arbor","region":"Michigan","country":"United States","cc":"US","lat":42.26989,"lon":-83.75232,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"48109-2700","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-university-of-michigan-comprehensive-depression-center-ann-arbor"},{"id":"nct05711940-institute-for-integrative-therapies-eden-prairie","cat":"research","name":"Institute for Integrative Therapies","city":"Eden Prairie","region":"Minnesota","country":"United States","cc":"US","lat":44.85643,"lon":-93.46717,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"55347","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-institute-for-integrative-therapies-eden-prairie"},{"id":"nct05711940-st-charles-psychiatric-associates-midwest-research-group-saint-charl","cat":"research","name":"St. Charles Psychiatric Associates - Midwest Research Group","city":"Saint Charles","region":"Missouri","country":"United States","cc":"US","lat":38.78719,"lon":-90.48664,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"63304","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-st-charles-psychiatric-associates-midwest-research-group-saint-charl"},{"id":"nct05711940-alivation-research-llc-lincoln","cat":"research","name":"Alivation Research, LLC.","city":"Lincoln","region":"Nebraska","country":"United States","cc":"US","lat":40.80456,"lon":-96.6783,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"68526","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-alivation-research-llc-lincoln"},{"id":"nct05711940-hassman-research-institute-berlin","cat":"research","name":"Hassman Research Institute","city":"Berlin","region":"New Jersey","country":"United States","cc":"US","lat":44.47945,"lon":-71.19181,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"08009","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-hassman-research-institute-berlin"},{"id":"nct05711940-princeton-medical-institute-princeton","cat":"research","name":"Princeton Medical Institute","city":"Princeton","region":"New Jersey","country":"United States","cc":"US","lat":25.5318,"lon":-80.41068,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"08540","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-princeton-medical-institute-princeton"},{"id":"nct05711940-bio-behavioral-health-toms-river","cat":"research","name":"Bio Behavioral Health","city":"Toms River","region":"New Jersey","country":"United States","cc":"US","lat":39.96413,"lon":-74.2087,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"08755","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-bio-behavioral-health-toms-river"},{"id":"nct05711940-dent-neurosciences-research-center-inc-amherst","cat":"research","name":"Dent Neurosciences Research Center, Inc.","city":"Amherst","region":"New York","country":"United States","cc":"US","lat":42.99001,"lon":-78.79256,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"14226-1727","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-dent-neurosciences-research-center-inc-amherst"},{"id":"nct05711940-fieve-clinical-research-inc-new-york","cat":"research","name":"Fieve Clinical Research, Inc","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71319,"lon":-74.00762,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10017","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-fieve-clinical-research-inc-new-york"},{"id":"nct05711940-spectrum-neuroscience-and-treatment-institute-new-york","cat":"research","name":"Spectrum Neuroscience and Treatment Institute","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70726,"lon":-74.00555,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10021-4157","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-spectrum-neuroscience-and-treatment-institute-new-york"},{"id":"nct05711940-adams-clinical-new-york-new-york","cat":"research","name":"Adams Clinical - New York","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71338,"lon":-74.00442,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10029","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-adams-clinical-new-york-new-york"},{"id":"nct05711940-new-york-state-psychiatric-institute-new-york","cat":"research","name":"New York State Psychiatric Institute","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71686,"lon":-74.01326,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10032","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-new-york-state-psychiatric-institute-new-york"},{"id":"nct05711940-richmond-behavioral-associates-staten-island","cat":"research","name":"Richmond Behavioral Associates","city":"Staten Island","region":"New York","country":"United States","cc":"US","lat":40.5668,"lon":-74.12908,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10312","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-richmond-behavioral-associates-staten-island"},{"id":"nct05711940-adams-clinical-new-york-the-bronx","cat":"research","name":"Adams Clinical - New York","city":"The Bronx","region":"New York","country":"United States","cc":"US","lat":40.8467,"lon":-73.85441,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10461","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-adams-clinical-new-york-the-bronx"},{"id":"nct05711940-university-of-cincinnati-department-of-psychiatry-behavirol-neurosci","cat":"research","name":"University of Cincinnati, Department of Psychiatry & Behavirol Neuroscience","city":"Cincinnati","region":"Ohio","country":"United States","cc":"US","lat":39.12603,"lon":-84.52281,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"45219","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-university-of-cincinnati-department-of-psychiatry-behavirol-neurosci"},{"id":"nct05711940-cleveland-clinic-lutheran-hospital-cleveland","cat":"research","name":"Cleveland Clinic - Lutheran Hospital","city":"Cleveland","region":"Ohio","country":"United States","cc":"US","lat":41.4891,"lon":-81.69423,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"44113-3108","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-cleveland-clinic-lutheran-hospital-cleveland"},{"id":"nct05711940-the-ohio-state-university-columbus","cat":"research","name":"The Ohio State University","city":"Columbus","region":"Ohio","country":"United States","cc":"US","lat":39.96367,"lon":-82.99187,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"43210","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-the-ohio-state-university-columbus"},{"id":"nct05711940-suburban-research-associates-media","cat":"research","name":"Suburban Research Associates","city":"Media","region":"Pennsylvania","country":"United States","cc":"US","lat":39.91391,"lon":-75.38727,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"19063","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-suburban-research-associates-media"},{"id":"nct05711940-the-university-of-texas-at-austin-dell-medical-school-austin","cat":"research","name":"The University of Texas at Austin - Dell Medical School","city":"Austin","region":"Texas","country":"United States","cc":"US","lat":30.25967,"lon":-97.7432,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"78712","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-the-university-of-texas-at-austin-dell-medical-school-austin"},{"id":"nct05711940-houston-clinical-trials-llc-bellaire","cat":"research","name":"Houston Clinical Trials, LLC","city":"Bellaire","region":"Texas","country":"United States","cc":"US","lat":29.70904,"lon":-95.46245,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"77401","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-houston-clinical-trials-llc-bellaire"},{"id":"nct05711940-relaro-medical-trials-dallas","cat":"research","name":"Relaro Medical Trials","city":"Dallas","region":"Texas","country":"United States","cc":"US","lat":32.77915,"lon":-96.81425,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"75243","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-relaro-medical-trials-dallas"},{"id":"nct05711940-center-for-depression-research-and-clinical-care-dallas","cat":"research","name":"Center for Depression Research and Clinical Care","city":"Dallas","region":"Texas","country":"United States","cc":"US","lat":32.77981,"lon":-96.8134,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"75247-9119","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-center-for-depression-research-and-clinical-care-dallas"},{"id":"nct05711940-north-texas-clinical-trials-fort-worth","cat":"research","name":"North Texas Clinical Trials","city":"Fort Worth","region":"Texas","country":"United States","cc":"US","lat":32.72932,"lon":-97.32419,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"76104","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-north-texas-clinical-trials-fort-worth"},{"id":"nct05711940-brain-health-consultants-and-tms-center-houston","cat":"research","name":"Brain Health Consultants and TMS Center","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.75759,"lon":-95.37489,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"77046-2401","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-brain-health-consultants-and-tms-center-houston"},{"id":"nct05711940-hca-healthcare-research-institute-medical-city-green-oaks-hospital-p","cat":"research","name":"HCA Healthcare Research Institute - Medical City Green Oaks Hospital","city":"Plano","region":"Texas","country":"United States","cc":"US","lat":33.03184,"lon":-96.69254,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"75251","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-hca-healthcare-research-institute-medical-city-green-oaks-hospital-p"},{"id":"nct05711940-cedar-clinical-research-draper","cat":"research","name":"Cedar Clinical Research","city":"Draper","region":"Utah","country":"United States","cc":"US","lat":40.51455,"lon":-111.86104,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"84020","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-cedar-clinical-research-draper"},{"id":"nct05711940-the-university-of-utah-huntsman-mental-health-institute-salt-lake-ci","cat":"research","name":"The University of Utah - Huntsman Mental Health Institute","city":"Salt Lake City","region":"Utah","country":"United States","cc":"US","lat":40.75198,"lon":-111.89006,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"84108","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-the-university-of-utah-huntsman-mental-health-institute-salt-lake-ci"},{"id":"nct05711940-seattle-neuropsychiatric-treatment-center-seattle","cat":"research","name":"Seattle Neuropsychiatric Treatment Center","city":"Seattle","region":"Washington","country":"United States","cc":"US","lat":47.60014,"lon":-122.33287,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"98104","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-seattle-neuropsychiatric-treatment-center-seattle"},{"id":"nct05711940-diex-recherche-sherbrooke-inc-quebec","cat":"research","name":"Diex Recherche Sherbrooke Inc.","city":"Québec","region":"B.C.","country":"Canada","cc":"CA","lat":46.81694,"lon":-71.21158,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"J1L 0H8","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-diex-recherche-sherbrooke-inc-quebec"},{"id":"nct05711940-medical-arts-health-research-centre-kamloops-kamloops","cat":"research","name":"Medical Arts Health Research Centre, Kamloops","city":"Kamloops","region":"British Columbia","country":"Canada","cc":"CA","lat":50.6685,"lon":-120.32904,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-medical-arts-health-research-centre-kamloops-kamloops"},{"id":"nct05711940-okanagan-clinical-trials-kelowna","cat":"research","name":"Okanagan Clinical Trials","city":"Kelowna","region":"British Columbia","country":"Canada","cc":"CA","lat":49.8802,"lon":-119.49297,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"V1Y 1Z9","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-okanagan-clinical-trials-kelowna"},{"id":"nct05711940-medical-arts-research-group-penticton-penticton","cat":"research","name":"Medical Arts Research Group - Penticton","city":"Penticton","region":"British Columbia","country":"Canada","cc":"CA","lat":49.47747,"lon":-119.57713,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"V2A 5L5","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-medical-arts-research-group-penticton-penticton"},{"id":"nct05711940-chatham-kent-clnical-trials-centre-chatham","cat":"research","name":"Chatham-Kent Clnical Trials Centre","city":"Chatham","region":"Ontario","country":"Canada","cc":"CA","lat":42.40626,"lon":-82.19496,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-chatham-kent-clnical-trials-centre-chatham"},{"id":"nct05711940-st-michael-s-hospital-toronto","cat":"research","name":"St. Michael's Hospital","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.69669,"lon":-79.38758,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"M5B 1W8","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-st-michael-s-hospital-toronto"},{"id":"nct05711940-centre-for-addiction-and-mental-health-camh-toronto","cat":"research","name":"Centre for Addiction and Mental Health (CAMH)","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.71024,"lon":-79.40076,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-centre-for-addiction-and-mental-health-camh-toronto"},{"id":"nct05711940-centre-for-neurology-studies-vancouver","cat":"research","name":"Centre for Neurology Studies","city":"Vancouver","country":"Canada","cc":"CA","lat":49.25667,"lon":-123.11365,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-centre-for-neurology-studies-vancouver"},{"id":"nct05711940-medical-arts-research-group-vancouver","cat":"research","name":"Medical Arts Research Group","city":"Vancouver","country":"Canada","cc":"CA","lat":49.25206,"lon":-123.11995,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-medical-arts-research-group-vancouver"},{"id":"nct05711940-national-institute-of-mental-health-klecany","cat":"research","name":"National Institute of Mental Health","city":"Klecany","country":"Czechia","cc":"CZ","lat":50.17255,"lon":14.4215,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"25067","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-national-institute-of-mental-health-klecany"},{"id":"nct05711940-neuroterapie-kh-sro-kutna-hora","cat":"research","name":"Neuroterapie KH Sro","city":"Kutná Hora","country":"Czechia","cc":"CZ","lat":49.94552,"lon":15.27781,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"28401","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-neuroterapie-kh-sro-kutna-hora"},{"id":"nct05711940-psychiatric-ambulance-ostrava","cat":"research","name":"Psychiatric Ambulance","city":"Ostrava","country":"Czechia","cc":"CZ","lat":49.83846,"lon":18.29291,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"70868","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-psychiatric-ambulance-ostrava"},{"id":"nct05711940-a-shine-s-r-o-pilsen","cat":"research","name":"A-Shine s.r.o.","city":"Pilsen","country":"Czechia","cc":"CZ","lat":49.7558,"lon":13.38592,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30100","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-a-shine-s-r-o-pilsen"},{"id":"nct05711940-psychedelicka-klinika-s-r-o-prague","cat":"research","name":"Psychedelicka klinika, s.r.o.","city":"Prague","country":"Czechia","cc":"CZ","lat":50.0895,"lon":14.4273,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"16300","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-psychedelicka-klinika-s-r-o-prague"},{"id":"nct05711940-institut-neuropsychiatricke-pece-prague","cat":"research","name":"Institut Neuropsychiatricke Pece","city":"Prague","country":"Czechia","cc":"CZ","lat":50.08338,"lon":14.41789,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"18600","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-institut-neuropsychiatricke-pece-prague"},{"id":"nct05711940-aalborg-universitetshospital-psykiatrien-region-nordjylland-aalborg","cat":"research","name":"Aalborg Universitetshospital-Psykiatrien Region Nordjylland","city":"Aalborg","country":"Denmark","cc":"DK","lat":57.04494,"lon":9.91969,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"9000","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-aalborg-universitetshospital-psykiatrien-region-nordjylland-aalborg"},{"id":"nct05711940-ghu-centre-hospitalier-sainte-anne-centre-de-recherche-clinique-pari","cat":"research","name":"Ghu-Centre Hospitalier Sainte Anne, Centre de Recherche Clinique","city":"Paris","region":"Paris","country":"France","cc":"FR","lat":48.84753,"lon":2.34904,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"75014","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-ghu-centre-hospitalier-sainte-anne-centre-de-recherche-clinique-pari"},{"id":"nct05711940-centre-hospitalier-universitaire-de-nimes-chu-hopital-universitaire-","cat":"research","name":"Centre Hospitalier Universitaire de Nimes (CHU) - Hopital Universitaire Caremeau","city":"Nîmes","country":"France","cc":"FR","lat":43.8335,"lon":4.368,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30000","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-centre-hospitalier-universitaire-de-nimes-chu-hopital-universitaire-"},{"id":"nct05711940-universite-paris-vi-pierre-et-marie-curie-hopital-de-la-salpetriere-","cat":"research","name":"Universite Paris VI Pierre et Marie Curie - Hopital de La Salpetriere - Centre Emotion - USR 3246 (CNRS UMR 7593)","city":"Paris","country":"France","cc":"FR","lat":48.84405,"lon":2.35289,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"75013","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-universite-paris-vi-pierre-et-marie-curie-hopital-de-la-salpetriere-"},{"id":"nct05711940-centre-hospitalier-sainte-anne-clinique-des-maladies-mentales-et-de-","cat":"research","name":"Centre Hospitalier Sainte Anne - Clinique des Maladies Mentales et de l'Encephale (CMME)","city":"Paris","country":"France","cc":"FR","lat":48.86146,"lon":2.35948,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"75014","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-centre-hospitalier-sainte-anne-clinique-des-maladies-mentales-et-de-"},{"id":"nct05711940-charite-universitaetsmedizin-berlin-berlin","cat":"research","name":"Charite-Universitaetsmedizin Berlin","city":"Berlin","country":"Germany","cc":"DE","lat":52.52159,"lon":13.407,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"12203","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-charite-universitaetsmedizin-berlin-berlin"},{"id":"nct05711940-johann-wolfgang-goethe-universitaet-frankfurt-am-main-klinik-fuer-ps","cat":"research","name":"Johann Wolfgang Goethe-Universitaet Frankfurt am Main - Klinik fuer Psychiatrie, Psychosomatik und Psychotherapie","city":"Frankfurt","country":"Germany","cc":"DE","lat":50.10945,"lon":8.68732,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"60528","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-johann-wolfgang-goethe-universitaet-frankfurt-am-main-klinik-fuer-ps"},{"id":"nct05711940-zip-campus-luebeck-lubeck","cat":"research","name":"ZiP Campus Luebeck","city":"Lübeck","country":"Germany","cc":"DE","lat":53.87914,"lon":10.67953,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"23562","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-zip-campus-luebeck-lubeck"},{"id":"nct05711940-tallaght-university-hospital-dublin","cat":"research","name":"Tallaght University Hospital","city":"Dublin","country":"Ireland","cc":"IE","lat":53.33678,"lon":-6.23727,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"D24 NR0A","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-tallaght-university-hospital-dublin"},{"id":"nct05711940-la-nua-day-hospital-mental-health-centre-galway","cat":"research","name":"La Nua Day Hospital Mental Health Centre","city":"Galway","country":"Ireland","cc":"IE","lat":53.274,"lon":-9.06041,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"H91 VE03","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-la-nua-day-hospital-mental-health-centre-galway"},{"id":"nct05711940-university-medical-center-groningen-groningen","cat":"research","name":"University Medical Center Groningen","city":"Groningen","country":"Netherlands","cc":"NL","lat":53.22402,"lon":6.57669,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"9713 GZ","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-university-medical-center-groningen-groningen"},{"id":"nct05711940-leids-universitair-medisch-centrum-lumc-leiden-university-medical-ce","cat":"research","name":"Leids Universitair Medisch Centrum (LUMC) (Leiden University Medical Center) - Leiden Institute for Brain and Cognition (LIBC)","city":"Leiden","country":"Netherlands","cc":"NL","lat":52.166,"lon":4.48379,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"2300","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-leids-universitair-medisch-centrum-lumc-leiden-university-medical-ce"},{"id":"nct05711940-universitair-medisch-centrum-utrecht-umc-utrecht-utrecht","cat":"research","name":"Universitair Medisch Centrum Utrecht (UMC Utrecht)","city":"Utrecht","country":"Netherlands","cc":"NL","lat":52.09238,"lon":5.11276,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"3584 CG","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-universitair-medisch-centrum-utrecht-umc-utrecht-utrecht"},{"id":"nct05711940-promente-osrodek-badan-klinicznych-bydgoszcz","cat":"research","name":"Promente - Ośrodek Badań Klinicznych","city":"Bydgoszcz","country":"Poland","cc":"PL","lat":53.11272,"lon":17.99609,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"85-133","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-promente-osrodek-badan-klinicznych-bydgoszcz"},{"id":"nct05711940-uniwersyteckle-centrum-kliniczne-klinika-psychiatrii-doroslych-gdans","cat":"research","name":"Uniwersyteckle Centrum Kliniczne, Klinika Psychiatrii Doroslych","city":"Gdansk","country":"Poland","cc":"PL","lat":54.35843,"lon":18.65886,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"80-214","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-uniwersyteckle-centrum-kliniczne-klinika-psychiatrii-doroslych-gdans"},{"id":"nct05711940-centrum-badan-klinicznych-pi-house-sp-z-o-o-gdansk","cat":"research","name":"Centrum Badan Klinicznych PI-House Sp. z o.o.","city":"Gdansk","country":"Poland","cc":"PL","lat":54.34441,"lon":18.64738,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"80-546","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-centrum-badan-klinicznych-pi-house-sp-z-o-o-gdansk"},{"id":"nct05711940-hospital-clinic-de-barcelona-barcelona","cat":"research","name":"Hospital Clinic de Barcelona","city":"Barcelona","country":"Spain","cc":"ES","lat":41.40041,"lon":2.15386,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"08036","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-hospital-clinic-de-barcelona-barcelona"},{"id":"nct05711940-parc-sanitari-sant-joan-de-deu-sant-joan-de-deu-serveis-de-salut-men","cat":"research","name":"Parc Sanitari Sant Joan de Deu (Sant Joan de Deu Serveis de Salut Mental)","city":"Barcelona","country":"Spain","cc":"ES","lat":41.37914,"lon":2.17043,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"08830","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-parc-sanitari-sant-joan-de-deu-sant-joan-de-deu-serveis-de-salut-men"},{"id":"nct05711940-hospital-universitario-fundacion-jimenez-diaz-madrid","cat":"research","name":"Hospital Universitario Fundacion Jimenez Diaz","city":"Madrid","country":"Spain","cc":"ES","lat":40.42549,"lon":-3.70477,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"28040","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-hospital-universitario-fundacion-jimenez-diaz-madrid"},{"id":"nct05711940-fidmag-hermanas-hospitalarias-sant-boi-de-llobregat","cat":"research","name":"FIDMAG Hermanas Hospitalarias","city":"Sant Boi de Llobregat","country":"Spain","cc":"ES","lat":41.33515,"lon":2.03588,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"08830","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-fidmag-hermanas-hospitalarias-sant-boi-de-llobregat"},{"id":"nct05711940-hospital-universitario-rio-hortega-de-valladolid-valladolid","cat":"research","name":"Hospital Universitario Río Hortega de Valladolid","city":"Valladolid","country":"Spain","cc":"ES","lat":41.6516,"lon":-4.72452,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"47012","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-hospital-universitario-rio-hortega-de-valladolid-valladolid"},{"id":"nct05711940-hospital-provincial-de-zamora-servicio-de-psiquiatria-zamora","cat":"research","name":"Hospital Provincial de Zamora - Servicio de Psiquiatria","city":"Zamora","country":"Spain","cc":"ES","lat":41.50402,"lon":-5.7512,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"49021","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-hospital-provincial-de-zamora-servicio-de-psiquiatria-zamora"},{"id":"nct05711940-vuxenpsykiatrimottagningen-landskrona","cat":"research","name":"Vuxenpsykiatrimottagningen","city":"Landskrona","country":"Sweden","cc":"SE","lat":55.86304,"lon":12.82908,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"26153","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-vuxenpsykiatrimottagningen-landskrona"},{"id":"nct05711940-lunds-universitet-medicinska-fakulteten-lund-university-faculty-of-m","cat":"research","name":"Lunds Universitet - Medicinska Fakulteten (Lund University Faculty of Medicine)","city":"Lund","country":"Sweden","cc":"SE","lat":55.71285,"lon":13.18686,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"22185","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-lunds-universitet-medicinska-fakulteten-lund-university-faculty-of-m"},{"id":"nct05711940-clinsmart-sweden-ab-solna","cat":"research","name":"ClinSmart Sweden AB","city":"Solna","country":"Sweden","cc":"SE","lat":59.36206,"lon":17.99752,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"17164","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-clinsmart-sweden-ab-solna"},{"id":"nct05711940-halsoklustret-stockholm","cat":"research","name":"Hälsoklustret","city":"Stockholm","country":"Sweden","cc":"SE","lat":59.31851,"lon":18.05972,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"11239","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-halsoklustret-stockholm"},{"id":"nct05711940-cornwall-partnership-nhs-foundation-trust-bodmin","cat":"research","name":"Cornwall Partnership NHS Foundation Trust","city":"Bodmin","region":"Cornwall","country":"United Kingdom","cc":"GB","lat":50.47062,"lon":-4.72604,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"PL31 2QT","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-cornwall-partnership-nhs-foundation-trust-bodmin"},{"id":"nct05711940-abraham-cowley-unit-surrey-and-borders-partnership-nhs-foundation-tr","cat":"research","name":"Abraham Cowley Unit - Surrey and Borders Partnership NHS Foundation Trust","city":"Chertsey","country":"United Kingdom","cc":"GB","lat":51.39024,"lon":-0.50561,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"KT16 9AU","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-abraham-cowley-unit-surrey-and-borders-partnership-nhs-foundation-tr"},{"id":"nct05711940-st-pancras-clinical-research-chester","cat":"research","name":"St. Pancras Clinical Research","city":"Chester","country":"United Kingdom","cc":"GB","lat":53.18518,"lon":-2.8846,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"CH2 1HX","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-st-pancras-clinical-research-chester"},{"id":"nct05711940-grounded-research-hub-rotherham-doncaster-south-humber-nhs-foundatio","cat":"research","name":"Grounded Research Hub - Rotherham Doncaster & South Humber NHS Foundation Trust","city":"Doncaster","country":"United Kingdom","cc":"GB","lat":53.51377,"lon":-1.14071,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"DN4 8QN","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-grounded-research-hub-rotherham-doncaster-south-humber-nhs-foundatio"},{"id":"nct05711940-clinical-research-facility-royal-devon-and-exeter-hospital-exeter","cat":"research","name":"Clinical Research Facility, Royal Devon and Exeter Hospital","city":"Exeter","country":"United Kingdom","cc":"GB","lat":50.72026,"lon":-3.52059,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"EX2 5DW","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-clinical-research-facility-royal-devon-and-exeter-hospital-exeter"},{"id":"nct05711940-fulbourn-hospital-cambridgeshire-and-peterborough-nhs-foundation-tru","cat":"research","name":"Fulbourn Hospital - Cambridgeshire And Peterborough NHS Foundation Trust","city":"Fulbourn","country":"United Kingdom","cc":"GB","lat":52.18062,"lon":0.22964,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"CB21 5EF","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-fulbourn-hospital-cambridgeshire-and-peterborough-nhs-foundation-tru"},{"id":"nct05711940-st-pancras-clinical-research-london","cat":"research","name":"St. Pancras Clinical Research","city":"London","country":"United Kingdom","cc":"GB","lat":51.50641,"lon":-0.13228,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"EC2Y 8EA","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-st-pancras-clinical-research-london"},{"id":"nct05711940-king-s-college-london-institute-of-psychiatry-psychology-london","cat":"research","name":"King's College London - Institute of Psychiatry, Psychology","city":"London","country":"United Kingdom","cc":"GB","lat":51.51432,"lon":-0.11929,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"SE5 8AF","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-king-s-college-london-institute-of-psychiatry-psychology-london"},{"id":"nct05711940-clerkenwell-health-london","cat":"research","name":"Clerkenwell Health","city":"London","country":"United Kingdom","cc":"GB","lat":51.49728,"lon":-0.13473,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"W1G 8DR","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-clerkenwell-health-london"},{"id":"nct05711940-cumbria-northumberland-tyne-and-wear-nhs-foundation-trust-wolfson-re","cat":"research","name":"Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust - Wolfson Research Centre","city":"Newcastle","country":"United Kingdom","cc":"GB","lat":54.22016,"lon":-5.8825,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"NE4 5PL","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-cumbria-northumberland-tyne-and-wear-nhs-foundation-trust-wolfson-re"},{"id":"nct05711940-university-of-nottingham-nottinghamshire-healthcare-trust-institute-","cat":"research","name":"University Of Nottingham/Nottinghamshire Healthcare Trust, Institute Of Mental Health","city":"Nottingham","country":"United Kingdom","cc":"GB","lat":52.96419,"lon":-1.15362,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"NG7 2TU","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-university-of-nottingham-nottinghamshire-healthcare-trust-institute-"},{"id":"nct05711940-the-warneford-hospital-nihr-clinical-research-facility-oxford","cat":"research","name":"The Warneford Hospital- NIHR Clinical Research Facility","city":"Oxford","country":"United Kingdom","cc":"GB","lat":51.74907,"lon":-1.2609,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"OX3 7JX","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-the-warneford-hospital-nihr-clinical-research-facility-oxford"},{"id":"nct05711940-sheffield-health-and-social-care-nhs-foundation-trust-sheffield","cat":"research","name":"Sheffield Health and Social Care NHS Foundation Trust","city":"Sheffield","country":"United Kingdom","cc":"GB","lat":53.37182,"lon":-1.45974,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"S10 3TH","condg":["Depression"],"nct":"NCT05711940","study":"Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05711940","phase":"Phase 3","enroll":572,"start":"2023-02-14","eid":"x:site:nct05711940-sheffield-health-and-social-care-nhs-foundation-trust-sheffield"},{"id":"nct07703722-institute-of-health-science-khyber-medical-university-islamabad","cat":"research","name":"Institute of Health Science, Khyber Medical University","city":"Islamabad","region":"Capital","country":"Pakistan","cc":"PK","lat":33.72623,"lon":73.04174,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"25000","condg":["Depression","PTSD & trauma"],"status":"ACTIVE_NOT_RECRUITING","nct":"NCT07703722","study":"Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Khyber Medical University Peshawar","official":"Dr Omer Malik, PhD (Khyber Medical University Peshawar, Pakistan); Dr Inayat Shah, PhD* (Khyber Medical University)","src":"https://clinicaltrials.gov/study/NCT07703722","contact":{"n":"Bushra Riaz, PhD*","p":"+92 3338000744","e":"bushrariaz098@gmail.com"},"phase":"Phase 3","enroll":60,"start":"2026-04-01","eid":"x:site:nct07703722-institute-of-health-science-khyber-medical-university-islamabad"},{"id":"nct07703722-hayatabad-medical-complex-peshawar-peshawar","cat":"research","name":"Hayatabad Medical Complex Peshawar","city":"Peshawar","region":"KPK","country":"Pakistan","cc":"PK","lat":34.00673,"lon":71.57035,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"25000","condg":["Depression","PTSD & trauma"],"status":"RECRUITING","nct":"NCT07703722","study":"Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Khyber Medical University Peshawar","official":"Dr Omer Malik, PhD (Khyber Medical University Peshawar, Pakistan); Dr Inayat Shah, PhD* (Khyber Medical University)","src":"https://clinicaltrials.gov/study/NCT07703722","contact":{"n":"Dr Owais Qaiser, PhD*","p":"+92 313 9625788","e":"drowaisqaisar.ibms@kmu.edu.pk"},"phase":"Phase 3","enroll":60,"start":"2026-04-01","eid":"x:site:nct07703722-hayatabad-medical-complex-peshawar-peshawar"},{"id":"nct07703722-khyber-medical-university-peshawar","cat":"research","name":"Khyber Medical University","city":"Peshawar","region":"KPK","country":"Pakistan","cc":"PK","lat":34.01953,"lon":71.57534,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression","PTSD & trauma"],"status":"ACTIVE_NOT_RECRUITING","nct":"NCT07703722","study":"Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Khyber Medical University Peshawar","official":"Dr Omer Malik, PhD (Khyber Medical University Peshawar, Pakistan); Dr Inayat Shah, PhD* (Khyber Medical University)","src":"https://clinicaltrials.gov/study/NCT07703722","contact":{"n":"Bushra Riaz, PhD*","p":"+92 3338000744","e":"bushrariaz098@gmail.com"},"phase":"Phase 3","enroll":60,"start":"2026-04-01","eid":"x:site:nct07703722-khyber-medical-university-peshawar"},{"id":"nct07820033-university-health-network-toronto","cat":"research","name":"University Health Network","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70328,"lon":-79.39718,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Cancer-related distress"],"nct":"NCT07820033","study":"Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial","sstatus":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","src":"https://clinicaltrials.gov/study/NCT07820033","contact":{"n":"Sarah Hales, MD","p":"416-340-4800","e":"UHNPPRG@uhn.ca"},"phase":"Phase 2","enroll":46,"start":"2026-09-14","eid":"x:site:nct07820033-university-health-network-toronto"},{"id":"nct06355414-johns-hopkins-university-school-of-medicine-baltimore","cat":"research","name":"Johns Hopkins University School of Medicine","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28807,"lon":-76.61534,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Depression","Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06355414","study":"Psilocybin in Chronic Low Back Pain and Depression","sstatus":"RECRUITING","sponsor":"Johns Hopkins University","official":"David B Yaden, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT06355414","contact":{"n":"David Yaden, PhD","p":"410-550-5250","e":"dyaden1@jhmi.edu"},"phase":"Phase 1","enroll":40,"start":"2024-04-22","eid":"x:site:nct06355414-johns-hopkins-university-school-of-medicine-baltimore"},{"id":"nct06206265-massachusetts-general-hospital-boston","cat":"research","name":"Massachusetts General Hospital","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36525,"lon":-71.0521,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"02114","condg":["Other"],"nct":"NCT06206265","study":"Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"TRYP Therapeutics","official":"Franklin King, MD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT06206265","phase":"Phase 2","enroll":14,"start":"2024-01-17","eid":"x:site:nct06206265-massachusetts-general-hospital-boston"},{"id":"nct06731621-centre-for-addiction-and-mental-health-toronto","cat":"research","name":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.71768,"lon":-79.40179,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT06731621","study":"Psilocybin for Treatment-Resistant Depression in Autism","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Centre for Addiction and Mental Health","official":"Hsiang-Yuan Lin, MD (Centre for Addiction and Mental Health)","src":"https://clinicaltrials.gov/study/NCT06731621","phase":"Phase 1","enroll":20,"start":"2024-11-01","eid":"x:site:nct06731621-centre-for-addiction-and-mental-health-toronto"},{"id":"nct06367738-university-of-california-berkeley-berkeley","cat":"research","name":"University of California, Berkeley","city":"Berkeley","region":"California","country":"United States","cc":"US","lat":37.86326,"lon":-122.26611,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94720","condg":["Other"],"status":"RECRUITING","nct":"NCT06367738","study":"Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults","sstatus":"RECRUITING","sponsor":"University of California, Berkeley","src":"https://clinicaltrials.gov/study/NCT06367738","contact":{"n":"BCSP Research Staff","p":"669-244-2436","e":"bcspresearchsubjects@berkeley.edu"},"phase":"Phase 1","enroll":40,"start":"2025-11","eid":"x:site:nct06367738-university-of-california-berkeley-berkeley"},{"id":"nct06615908-university-of-calgary-calgary","cat":"research","name":"University of Calgary","city":"Calgary","region":"Alberta","country":"Canada","cc":"CA","lat":51.04432,"lon":-114.08524,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"T2N 2T9","condg":["Other"],"status":"RECRUITING","nct":"NCT06615908","study":"Treatment of Persisting Symptoms After Concussion With Psilocybin Assisted Therapy","sstatus":"RECRUITING","sponsor":"University of Calgary","official":"Chantel T Debert, MD MSc FRCPC (University of Calgary)","src":"https://clinicaltrials.gov/study/NCT06615908","contact":{"n":"Chantel T Debert, MD MSc FRCPC CSCN","p":"(403) 944-4500","e":"cdebert@ucalgary.ca"},"phase":"Phase 1","enroll":40,"start":"2025-05-27","eid":"x:site:nct06615908-university-of-calgary-calgary"},{"id":"nct07479550-stanford-university-stanford","cat":"research","name":"Stanford University","city":"Stanford","region":"California","country":"United States","cc":"US","lat":37.4299,"lon":-122.15521,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94304","condg":["Depression"],"nct":"NCT07479550","study":"Study of Psilocybin Under Anesthesia Controlled by EEG","sstatus":"NOT_YET_RECRUITING","sponsor":"Stanford University","official":"Dr. Boris Heifets, MD, PhD (Stanford University)","src":"https://clinicaltrials.gov/study/NCT07479550","contact":{"n":"Dr. Pilleriin Sikka, PhD","p":"6506808801","e":"sikka@stanford.edu"},"phase":"Phase 2","enroll":10,"start":"2026-07","eid":"x:site:nct07479550-stanford-university-stanford"},{"id":"nct06731335-st-michael-s-hospital-unity-health-toronto-toronto","cat":"research","name":"St. Michael's Hospital. Unity Health Toronto","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.69641,"lon":-79.39878,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"M5B 1W8","condg":["Chronic pain & headache"],"status":"NOT_YET_RECRUITING","nct":"NCT06731335","study":"Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN","sstatus":"RECRUITING","sponsor":"Unity Health Toronto","src":"https://clinicaltrials.gov/study/NCT06731335","contact":{"n":"Karim Ladha, MD MSc FRCPC","p":"416-864-5825","e":"karim.ladha@mail.utoronto.ca"},"phase":"Phase 2","enroll":30,"start":"2025-03-05","eid":"x:site:nct06731335-st-michael-s-hospital-unity-health-toronto-toronto"},{"id":"nct06731335-st-michael-s-hospital-unity-health-toronto-toronto-2","cat":"research","name":"St. Michael's Hospital. Unity Health Toronto","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.69791,"lon":-79.3873,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"M5B 1W8","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06731335","study":"Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN","sstatus":"RECRUITING","sponsor":"Unity Health Toronto","src":"https://clinicaltrials.gov/study/NCT06731335","contact":{"n":"Janneth A Pazmino-Canizares, MSc","p":"4168646060","e":"Janneth.Pazmino-Canizares@unityhealth.to"},"phase":"Phase 2","enroll":30,"start":"2025-03-05","eid":"x:site:nct06731335-st-michael-s-hospital-unity-health-toronto-toronto-2"},{"id":"nct06247839-athinoula-a-martinos-center-for-biomedical-imaging-charlestown","cat":"research","name":"Athinoula A. Martinos Center for Biomedical Imaging","city":"Charlestown","region":"Massachusetts","country":"United States","cc":"US","lat":42.38018,"lon":-71.07155,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"02129","condg":["Depression"],"status":"RECRUITING","nct":"NCT06247839","study":"The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Sharmin Ghaznavi","official":"Sharmin Ghaznavi, M.D., Ph.D. (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT06247839","contact":{"n":"Artana Arora","p":"6177262290","e":"cnpcogneuro@mgh.harvard.edu"},"phase":"Phase 3","enroll":20,"start":"2024-09-10","eid":"x:site:nct06247839-athinoula-a-martinos-center-for-biomedical-imaging-charlestown"},{"id":"nct04959253-clinical-research-facility-king-s-college-hospital-london","cat":"research","name":"Clinical Research Facility, King's College Hospital","city":"London","region":"London","country":"United Kingdom","cc":"GB","lat":51.52025,"lon":-0.11666,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"SE5 9RS","condg":["Depression"],"nct":"NCT04959253","study":"Psilocybin in Depression Resistant to Standard Treatments","sstatus":"COMPLETED","sponsor":"King's College London","official":"James Rucker, MD PhD (King's College London)","src":"https://clinicaltrials.gov/study/NCT04959253","phase":"Phase 2","enroll":60,"start":"2021-06-21","eid":"x:site:nct04959253-clinical-research-facility-king-s-college-hospital-london"},{"id":"nct05601648-washington-university-school-of-medicine-st-louis","cat":"research","name":"Washington University School of Medicine","city":"St Louis","region":"Missouri","country":"United States","cc":"US","lat":38.63202,"lon":-90.19229,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"63110","condg":["Depression"],"nct":"NCT05601648","study":"PET Synaptogenesis After Psilocybin In DEpression Recovery","sstatus":"WITHDRAWN","sponsor":"Washington University School of Medicine","src":"https://clinicaltrials.gov/study/NCT05601648","phase":"Phase 2","start":"2023-07-01","eid":"x:site:nct05601648-washington-university-school-of-medicine-st-louis"},{"id":"nct06853912-university-of-washington-center-for-novel-therapeutics-in-addiction-","cat":"research","name":"University of Washington Center for Novel Therapeutics in Addiction Psychiatry","city":"Seattle","region":"Washington","country":"United States","cc":"US","lat":47.59506,"lon":-122.32722,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"98195","condg":["PTSD & trauma","Addiction & substance use"],"nct":"NCT06853912","study":"PsiloStudy: Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Nathan Brashares Sackett","official":"Nathan B Sackett, MD (University of Washington)","src":"https://clinicaltrials.gov/study/NCT06853912","phase":"Phase 2","enroll":40,"start":"2025-06-01","eid":"x:site:nct06853912-university-of-washington-center-for-novel-therapeutics-in-addiction-"},{"id":"nct06692192-uw-school-of-medicine-and-public-health-madison","cat":"research","name":"UW School of Medicine and Public Health","city":"Madison","region":"Wisconsin","country":"United States","cc":"US","lat":43.07169,"lon":-89.40231,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"53792","condg":["Other"],"status":"RECRUITING","nct":"NCT06692192","study":"The RECAP2 Study: Midazolam and Psilocybin","sstatus":"RECRUITING","sponsor":"University of Wisconsin, Madison","official":"Charles Raison, MD (University of Wisconsin, Madison)","src":"https://clinicaltrials.gov/study/NCT06692192","contact":{"n":"RECAP Study Contact","p":"608-263-4852","e":"recap2@psychiatry.wisc.edu"},"phase":"Phase 1","enroll":60,"start":"2025-08-07","eid":"x:site:nct06692192-uw-school-of-medicine-and-public-health-madison"},{"id":"nct07693153-connecticut-mental-health-center-new-haven","cat":"research","name":"Connecticut Mental Health Center","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.29766,"lon":-72.93131,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"06519","condg":["Other"],"nct":"NCT07693153","study":"The Effects of Psilocybin on Social Connectedness","sstatus":"NOT_YET_RECRUITING","sponsor":"Yale University","official":"Anahita Bassir Nia, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT07693153","contact":{"n":"Anahita Bassir Nia, MD","p":"203-932-5711","e":"anahita.bassirnia@yale.edu"},"phase":"Phase 1","enroll":51,"start":"2026-08-31","eid":"x:site:nct07693153-connecticut-mental-health-center-new-haven"},{"id":"nct01534494-university-of-new-mexico-health-sciences-center-albuquerque","cat":"research","name":"University of New Mexico Health Sciences Center","city":"Albuquerque","region":"New Mexico","country":"United States","cc":"US","lat":35.08783,"lon":-106.63923,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"87131","condg":["Addiction & substance use"],"nct":"NCT01534494","study":"Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence","sstatus":"COMPLETED","sponsor":"University of New Mexico","official":"Michael P Bogenschutz, M.D. (University of New Mexico)","src":"https://clinicaltrials.gov/study/NCT01534494","phase":"Phase 2","enroll":10,"start":"2012-01","eid":"x:site:nct01534494-university-of-new-mexico-health-sciences-center-albuquerque"},{"id":"nct03866174-university-of-california-san-francisco-san-francisco","cat":"research","name":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.76566,"lon":-122.41006,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94121","condg":["Depression"],"nct":"NCT03866174","study":"A Study of Psilocybin for Major Depressive Disorder (MDD)","sstatus":"COMPLETED","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT03866174","phase":"Phase 2","enroll":347,"start":"2020-01-23","eid":"x:site:nct03866174-university-of-california-san-francisco-san-francisco"},{"id":"nct03866174-pacific-neuroscience-institute-santa-monica","cat":"research","name":"Pacific Neuroscience Institute","city":"Santa Monica","region":"California","country":"United States","cc":"US","lat":34.01944,"lon":-118.49293,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"91404","condg":["Depression"],"nct":"NCT03866174","study":"A Study of Psilocybin for Major Depressive Disorder (MDD)","sstatus":"COMPLETED","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT03866174","phase":"Phase 2","enroll":347,"start":"2020-01-23","eid":"x:site:nct03866174-pacific-neuroscience-institute-santa-monica"},{"id":"nct03866174-yale-university-new-haven","cat":"research","name":"Yale University","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.29935,"lon":-72.93254,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"06520","condg":["Depression"],"nct":"NCT03866174","study":"A Study of Psilocybin for Major Depressive Disorder (MDD)","sstatus":"COMPLETED","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT03866174","phase":"Phase 2","enroll":347,"start":"2020-01-23","eid":"x:site:nct03866174-yale-university-new-haven"},{"id":"nct03866174-segal-trials-lauderhill","cat":"research","name":"Segal Trials","city":"Lauderhill","region":"Florida","country":"United States","cc":"US","lat":26.13589,"lon":-80.21183,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"33319","condg":["Depression"],"nct":"NCT03866174","study":"A Study of Psilocybin for Major Depressive Disorder (MDD)","sstatus":"COMPLETED","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT03866174","phase":"Phase 2","enroll":347,"start":"2020-01-23","eid":"x:site:nct03866174-segal-trials-lauderhill"},{"id":"nct03866174-emory-university-atlanta","cat":"research","name":"Emory University","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.75771,"lon":-84.39687,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30322","condg":["Depression"],"nct":"NCT03866174","study":"A Study of Psilocybin for Major Depressive Disorder (MDD)","sstatus":"COMPLETED","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT03866174","phase":"Phase 2","enroll":347,"start":"2020-01-23","eid":"x:site:nct03866174-emory-university-atlanta"},{"id":"nct03866174-great-lakes-clinical-trials-chicago","cat":"research","name":"Great Lakes Clinical Trials","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.85657,"lon":-87.65217,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"60640","condg":["Depression"],"nct":"NCT03866174","study":"A Study of Psilocybin for Major Depressive Disorder (MDD)","sstatus":"COMPLETED","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT03866174","phase":"Phase 2","enroll":347,"start":"2020-01-23","eid":"x:site:nct03866174-great-lakes-clinical-trials-chicago"},{"id":"nct03866174-johns-hopkins-university-baltimore","cat":"research","name":"Johns Hopkins University","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29542,"lon":-76.62363,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21229","condg":["Depression"],"nct":"NCT03866174","study":"A Study of Psilocybin for Major Depressive Disorder (MDD)","sstatus":"COMPLETED","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT03866174","phase":"Phase 2","enroll":347,"start":"2020-01-23","eid":"x:site:nct03866174-johns-hopkins-university-baltimore"},{"id":"nct03866174-hassman-research-institute-berlin","cat":"research","name":"Hassman Research Institute","city":"Berlin","region":"New Jersey","country":"United States","cc":"US","lat":44.46298,"lon":-71.19473,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"08009","condg":["Depression"],"nct":"NCT03866174","study":"A Study of Psilocybin for Major Depressive Disorder (MDD)","sstatus":"COMPLETED","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT03866174","phase":"Phase 2","enroll":347,"start":"2020-01-23","eid":"x:site:nct03866174-hassman-research-institute-berlin"},{"id":"nct03866174-new-york-university-school-of-medicine-new-york","cat":"research","name":"New York University School of Medicine","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71921,"lon":-73.99745,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10016","condg":["Depression"],"nct":"NCT03866174","study":"A Study of Psilocybin for Major Depressive Disorder (MDD)","sstatus":"COMPLETED","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT03866174","phase":"Phase 2","enroll":347,"start":"2020-01-23","eid":"x:site:nct03866174-new-york-university-school-of-medicine-new-york"},{"id":"nct03866174-cedar-clinical-research-draper","cat":"research","name":"Cedar Clinical Research","city":"Draper","region":"Utah","country":"United States","cc":"US","lat":40.52745,"lon":-111.85784,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"84020","condg":["Depression"],"nct":"NCT03866174","study":"A Study of Psilocybin for Major Depressive Disorder (MDD)","sstatus":"COMPLETED","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT03866174","phase":"Phase 2","enroll":347,"start":"2020-01-23","eid":"x:site:nct03866174-cedar-clinical-research-draper"},{"id":"nct03866174-university-of-wisconsin-madison-madison","cat":"research","name":"University of Wisconsin - Madison","city":"Madison","region":"Wisconsin","country":"United States","cc":"US","lat":43.0731,"lon":-89.39704,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"53706","condg":["Depression"],"nct":"NCT03866174","study":"A Study of Psilocybin for Major Depressive Disorder (MDD)","sstatus":"COMPLETED","sponsor":"Usona Institute","official":"Charles Raison, MD (Usona Institute)","src":"https://clinicaltrials.gov/study/NCT03866174","phase":"Phase 2","enroll":347,"start":"2020-01-23","eid":"x:site:nct03866174-university-of-wisconsin-madison-madison"},{"id":"nct02421263-nyu-langone-medical-center-tisch-hospital-new-york","cat":"research","name":"NYU Langone Medical Center/Tisch Hospital","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71883,"lon":-74.00715,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10016","condg":["Other"],"nct":"NCT02421263","study":"The Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Religious Professionals","sstatus":"COMPLETED","sponsor":"NYU Langone Health","official":"Anthony Bossis, PhD (New York University); Stephen Ross, MD (New York University)","src":"https://clinicaltrials.gov/study/NCT02421263","phase":"Phase 1","enroll":12,"start":"2015-04","eid":"x:site:nct02421263-nyu-langone-medical-center-tisch-hospital-new-york"},{"id":"nct07216404-ohio-state-university-comprehensive-cancer-center-columbus","cat":"research","name":"Ohio State University Comprehensive Cancer Center","city":"Columbus","region":"Ohio","country":"United States","cc":"US","lat":39.96142,"lon":-83.01023,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"43210","condg":["Depression"],"status":"RECRUITING","nct":"NCT07216404","study":"Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer","sstatus":"RECRUITING","sponsor":"Alan Davis","official":"Alan K Davis, PhD (Ohio State University Comprehensive Cancer Center)","src":"https://clinicaltrials.gov/study/NCT07216404","contact":{"n":"Michelle Pham, M.S.","p":"18002935066","e":"pham.303@osu.edu"},"phase":"Phase 2","enroll":10,"start":"2026-01-01","eid":"x:site:nct07216404-ohio-state-university-comprehensive-cancer-center-columbus"},{"id":"nct05220410-sheppard-pratt-health-system-baltimore","cat":"research","name":"Sheppard Pratt Health System","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28807,"lon":-76.61412,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21204","condg":["Depression"],"nct":"NCT05220410","study":"The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation","sstatus":"COMPLETED","sponsor":"Sheppard Pratt Health System","official":"Scott Aaronson, MD (Sheppard Pratt Health System)","src":"https://clinicaltrials.gov/study/NCT05220410","phase":"Phase 2","enroll":20,"start":"2022-03-28","eid":"x:site:nct05220410-sheppard-pratt-health-system-baltimore"},{"id":"nct04593563-maryland-oncology-hematology-pa-rockville","cat":"research","name":"Maryland Oncology Hematology PA","city":"Rockville","region":"Maryland","country":"United States","cc":"US","lat":39.09468,"lon":-77.16118,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"20850","condg":["Depression"],"nct":"NCT04593563","study":"The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder","sstatus":"UNKNOWN","sponsor":"Maryland Oncology Hematology, PA","src":"https://clinicaltrials.gov/study/NCT04593563","phase":"Phase 2","enroll":30,"start":"2020-09-01","eid":"x:site:nct04593563-maryland-oncology-hematology-pa-rockville"},{"id":"nct06399263-university-of-california-san-francisco-san-francisco","cat":"research","name":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.77093,"lon":-122.4222,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94107","condg":["Eating disorders"],"status":"NOT_YET_RECRUITING","nct":"NCT06399263","study":"Study of Psilocybin for Anorexia in Young Adults","sstatus":"RECRUITING","sponsor":"Marissa Raymond-Flesch, MD, MPH","official":"Marissa Raymond-Flesch, MD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT06399263","contact":{"n":"Lisa Fredenburg, MS","p":"415-993-2486","e":"psilocybin.an.study@ucsf.edu"},"phase":"Phase 2","enroll":40,"start":"2024-11-18","eid":"x:site:nct06399263-university-of-california-san-francisco-san-francisco"},{"id":"nct06399263-university-of-california-san-francisco-san-francisco-2","cat":"research","name":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.76989,"lon":-122.42097,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94143","condg":["Eating disorders"],"status":"RECRUITING","nct":"NCT06399263","study":"Study of Psilocybin for Anorexia in Young Adults","sstatus":"RECRUITING","sponsor":"Marissa Raymond-Flesch, MD, MPH","official":"Marissa Raymond-Flesch, MD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT06399263","contact":{"n":"Lisa Fredenburg, MS","p":"415-993-2486","e":"psilocybin.an.study@ucsf.edu"},"phase":"Phase 2","enroll":40,"start":"2024-11-18","eid":"x:site:nct06399263-university-of-california-san-francisco-san-francisco-2"},{"id":"nct06626139-ucsf-mission-bay-san-francisco","cat":"research","name":"UCSF Mission Bay","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.76321,"lon":-122.42314,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94158","condg":["Healthy volunteers"],"status":"RECRUITING","nct":"NCT06626139","study":"Investigating the Interaction of Psilocybin and Context of Its Administration in Healthy Volunteers","sstatus":"RECRUITING","sponsor":"Robin Carhart-Harris, PhD, MA","official":"Robin Carhart-Harris, PhD (University of California, San Francisco); Jennifer Mitchell, PhD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT06626139","contact":{"n":"Kate Allison, BSc","p":"4158495452","e":"setandsetting@ucsf.edu"},"phase":"Phase 2","enroll":120,"start":"2024-10-20","eid":"x:site:nct06626139-ucsf-mission-bay-san-francisco"},{"id":"nct05370911-enact-research-collaborative-40-temple-st-4th-floor-new-haven","cat":"research","name":"Enact Research Collaborative (40 Temple St, 4th Floor)","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31657,"lon":-72.93583,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"06510","condg":["OCD"],"nct":"NCT05370911","study":"Effects of Repeated Psilocybin Dosing in OCD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","official":"Benjamin Kelmendi, MD (Yale University); Terence Ching, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT05370911","phase":"Phase 1","enroll":28,"start":"2023-07-20","eid":"x:site:nct05370911-enact-research-collaborative-40-temple-st-4th-floor-new-haven"},{"id":"nct05370911-yale-program-for-psychedelic-research-new-haven","cat":"research","name":"Yale Program for Psychedelic Research","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31366,"lon":-72.93677,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"06510","condg":["OCD"],"nct":"NCT05370911","study":"Effects of Repeated Psilocybin Dosing in OCD","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","official":"Benjamin Kelmendi, MD (Yale University); Terence Ching, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT05370911","phase":"Phase 1","enroll":28,"start":"2023-07-20","eid":"x:site:nct05370911-yale-program-for-psychedelic-research-new-haven"},{"id":"nct06969170-kingston-general-health-research-institute-kingston","cat":"research","name":"Kingston General Health Research Institute","city":"Kingston","region":"Ontario","country":"Canada","cc":"CA","lat":44.22011,"lon":-76.48046,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"K7L 2V7","condg":["Anxiety"],"status":"RECRUITING","nct":"NCT06969170","study":"Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder","sstatus":"RECRUITING","sponsor":"Claudio N Soares","src":"https://clinicaltrials.gov/study/NCT06969170","contact":{"n":"Claudio Soares, MD, PhD, FRCPC, MBA","p":"1-613-548-3232","e":"claudio.soares@kingstonhsc.ca"},"phase":"Phase 2","enroll":50,"start":"2025-05-16","eid":"x:site:nct06969170-kingston-general-health-research-institute-kingston"},{"id":"nct06888128-baylor-college-of-medicine-houston","cat":"research","name":"Baylor College of Medicine","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.75476,"lon":-95.37433,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"77030","condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT06888128","study":"State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma","sstatus":"RECRUITING","sponsor":"Baylor College of Medicine","src":"https://clinicaltrials.gov/study/NCT06888128","contact":{"n":"Marika Del Motte, M.Sc.","p":"713-798-3212","e":"marika.delmotte@bcm.edu"},"phase":"Phase 2","enroll":15,"start":"2025-01-30","eid":"x:site:nct06888128-baylor-college-of-medicine-houston"},{"id":"nct05312151-sunstone-therapies-rockville","cat":"research","name":"Sunstone Therapies","city":"Rockville","region":"Maryland","country":"United States","cc":"US","lat":39.08631,"lon":-77.15554,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"20850","condg":["PTSD & trauma"],"nct":"NCT05312151","study":"The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05312151","phase":"Phase 2","enroll":22,"start":"2022-06-10","eid":"x:site:nct05312151-sunstone-therapies-rockville"},{"id":"nct05312151-icahn-school-of-medicine-at-mount-sinai-new-york","cat":"research","name":"Icahn School of Medicine at Mount Sinai","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71695,"lon":-74.00526,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10029","condg":["PTSD & trauma"],"nct":"NCT05312151","study":"The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05312151","phase":"Phase 2","enroll":22,"start":"2022-06-10","eid":"x:site:nct05312151-icahn-school-of-medicine-at-mount-sinai-new-york"},{"id":"nct05312151-kings-college-london-institute-of-psychiatry-psychology-and-neurolog","cat":"research","name":"Kings College London, Institute of Psychiatry, Psychology and Neurology","city":"London","country":"United Kingdom","cc":"GB","lat":51.50265,"lon":-0.11478,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["PTSD & trauma"],"nct":"NCT05312151","study":"The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05312151","phase":"Phase 2","enroll":22,"start":"2022-06-10","eid":"x:site:nct05312151-kings-college-london-institute-of-psychiatry-psychology-and-neurolog"},{"id":"nct06430541-outpatient-ctrc-aurora","cat":"research","name":"Outpatient CTRC","city":"Aurora","region":"Colorado","country":"United States","cc":"US","lat":39.72816,"lon":-104.84204,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"80045","condg":["Cancer-related distress"],"status":"RECRUITING","nct":"NCT06430541","study":"Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence","sstatus":"RECRUITING","sponsor":"University of Colorado, Denver","official":"Stacy Fischer, MD (University of Colorado, Denver)","src":"https://clinicaltrials.gov/study/NCT06430541","contact":{"n":"Stacy Fischer, MD","p":"303-724-5729","e":"mary.mancuso@cuanschutz.edu"},"phase":"Phase 1","enroll":20,"start":"2024-11-21","eid":"x:site:nct06430541-outpatient-ctrc-aurora"},{"id":"nct06430541-university-of-colorado-cancer-center-aurora","cat":"research","name":"University of Colorado Cancer Center","city":"Aurora","region":"Colorado","country":"United States","cc":"US","lat":39.72835,"lon":-104.84006,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"80045","condg":["Cancer-related distress"],"status":"RECRUITING","nct":"NCT06430541","study":"Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence","sstatus":"RECRUITING","sponsor":"University of Colorado, Denver","official":"Stacy Fischer, MD (University of Colorado, Denver)","src":"https://clinicaltrials.gov/study/NCT06430541","contact":{"n":"Stacy Fischer, MD","p":"303-724-2406","e":"stacy.fischer@cuanschutz.edu"},"phase":"Phase 1","enroll":20,"start":"2024-11-21","eid":"x:site:nct06430541-university-of-colorado-cancer-center-aurora"},{"id":"nct05259943-psych-research-toronto","cat":"research","name":"Psych Research","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.71081,"lon":-79.40217,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT05259943","study":"Microdosing Psychedelics to Improve Mood","sstatus":"COMPLETED","sponsor":"Rotem Petranker","src":"https://clinicaltrials.gov/study/NCT05259943","phase":"Phase 2","enroll":39,"start":"2023-07-15","eid":"x:site:nct05259943-psych-research-toronto"},{"id":"nct05478278-altasciences-clinical-kansas-inc-overland-park","cat":"research","name":"Altasciences Clinical Kansas, Inc","city":"Overland Park","region":"Kansas","country":"United States","cc":"US","lat":38.97136,"lon":-94.67667,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"66212","condg":["Other"],"nct":"NCT05478278","study":"An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics","sstatus":"COMPLETED","sponsor":"Usona Institute","src":"https://clinicaltrials.gov/study/NCT05478278","phase":"Phase 1","enroll":60,"start":"2022-06-22","eid":"x:site:nct05478278-altasciences-clinical-kansas-inc-overland-park"},{"id":"nct05227612-ucla-semel-institute-los-angeles","cat":"research","name":"UCLA Semel Institute","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.04305,"lon":-118.2329,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"90095","condg":["Depression"],"nct":"NCT05227612","study":"Psilocybin-assisted CBT for Depression","sstatus":"COMPLETED","sponsor":"University of California, Los Angeles","src":"https://clinicaltrials.gov/study/NCT05227612","phase":"Phase 1","enroll":16,"start":"2023-06-27","eid":"x:site:nct05227612-ucla-semel-institute-los-angeles"},{"id":"nct05594667-centre-for-neurology-studies-x-upstream-abbotsford-british-columbia","cat":"research","name":"Centre for Neurology Studies x Upstream","city":"Abbotsford British Columbia","region":"British Columbia","country":"Canada","cc":"CA","lat":49.0488,"lon":-122.26325,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"V2T 2X5","condg":["Depression"],"nct":"NCT05594667","study":"Effect of SSRIs on Response to Psilocybin Therapy","sstatus":"WITHDRAWN","sponsor":"Cybin Therapeutics Inc.","official":"Reginald Peters, MD (Upstream)","src":"https://clinicaltrials.gov/study/NCT05594667","phase":"Phase 2","start":"2023-01-01","eid":"x:site:nct05594667-centre-for-neurology-studies-x-upstream-abbotsford-british-columbia"},{"id":"nct04661514-altman-clinical-and-translational-research-institute-la-jolla","cat":"research","name":"Altman Clinical and Translational Research Institute","city":"La Jolla","region":"California","country":"United States","cc":"US","lat":32.84242,"lon":-117.28422,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92037","condg":["Eating disorders"],"nct":"NCT04661514","study":"Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy","sstatus":"COMPLETED","sponsor":"University of California, San Diego","src":"https://clinicaltrials.gov/study/NCT04661514","phase":"Phase 2","enroll":16,"start":"2021-05-01","eid":"x:site:nct04661514-altman-clinical-and-translational-research-institute-la-jolla"},{"id":"nct07211438-toronto-western-hospital-university-health-network-toronto","cat":"research","name":"Toronto Western Hospital (University Health Network)","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.7013,"lon":-79.38918,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"M5T 2S8","condg":["Depression"],"status":"RECRUITING","nct":"NCT07211438","study":"Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression","sstatus":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","official":"Ishrat Husain, MBBS, MD (Centre for Addiction and Mental Health)","src":"https://clinicaltrials.gov/study/NCT07211438","contact":{"n":"Noah Chisamore","p":"416-603-5106","e":"Noah.Chisamore@uhn.ca"},"phase":"Phase 2","enroll":40,"start":"2026-07-03","eid":"x:site:nct07211438-toronto-western-hospital-university-health-network-toronto"},{"id":"nct07211438-centre-for-addiction-and-mental-health-toronto","cat":"research","name":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.69754,"lon":-79.40283,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"M6J1H4","condg":["Depression"],"status":"RECRUITING","nct":"NCT07211438","study":"Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression","sstatus":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","official":"Ishrat Husain, MBBS, MD (Centre for Addiction and Mental Health)","src":"https://clinicaltrials.gov/study/NCT07211438","contact":{"n":"Emily Gilbert, MSc","p":"416-535-8501","e":"emily.gilbert@camh.ca"},"phase":"Phase 2","enroll":40,"start":"2026-07-03","eid":"x:site:nct07211438-centre-for-addiction-and-mental-health-toronto"},{"id":"nct07183748-mental-health-center-beer-sheva-beersheba","cat":"research","name":"Mental Health Center Beer Sheva","city":"Beersheba","country":"Israel","cc":"IL","lat":31.25148,"lon":34.79549,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"status":"RECRUITING","nct":"NCT07183748","study":"Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression","sstatus":"RECRUITING","sponsor":"Beersheva Mental Health Center","src":"https://clinicaltrials.gov/study/NCT07183748","contact":{"n":"Dr. Arbel","p":"+972506576691","e":"oded.arbel@pbsh.health.gov.il"},"phase":"Phase 2","enroll":20,"start":"2025-12-01","eid":"x:site:nct07183748-mental-health-center-beer-sheva-beersheba"},{"id":"nct05467761-university-of-wisconsin-madison","cat":"research","name":"University of Wisconsin","city":"Madison","region":"Wisconsin","country":"United States","cc":"US","lat":43.06161,"lon":-89.39158,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"53705","condg":["Healthy volunteers"],"nct":"NCT05467761","study":"Bioavailability Study of Psilocybin in Normal Adults","sstatus":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","official":"Christopher Nicholas, PhD (University of Wisconsin, Madison); Paul Hutson, PharmD (University of Wisconsin, Madison)","src":"https://clinicaltrials.gov/study/NCT05467761","phase":"Phase 1","start":"2023-06","eid":"x:site:nct05467761-university-of-wisconsin-madison"},{"id":"nct07792538-arq-national-psychotrauma-centre-arq-centrum-45-oegstgeest","cat":"research","name":"ARQ National Psychotrauma Centre / ARQ Centrum'45","city":"Oegstgeest","country":"Netherlands","cc":"NL","lat":52.17064,"lon":4.46045,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"2342 EG","condg":["PTSD & trauma"],"nct":"NCT07792538","study":"Psilocybin-Assisted Psychotherapy for Veterans With PTSD","sstatus":"NOT_YET_RECRUITING","sponsor":"ARQ National Psychotrauma Centre","official":"Eric Vermetten, MD, PhD (Leiden University Medical Center)","src":"https://clinicaltrials.gov/study/NCT07792538","contact":{"n":"Annika Wirsching, MSc","p":"088 330 5699","e":"a.wirsching@arq.org"},"phase":"Phase 2","enroll":12,"start":"2026-12","eid":"x:site:nct07792538-arq-national-psychotrauma-centre-arq-centrum-45-oegstgeest"},{"id":"nct05624268-university-of-arizona-college-of-medicine-tuscon-tuscon","cat":"research","name":"University of Arizona College of Medicine - Tuscon","city":"Tuscon","region":"Arizona","country":"United States","cc":"US","lat":33.4202,"lon":-112.0842,"gp":"region","unnamed":0,"drugs":["psilocybin"],"zip":"85724","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-university-of-arizona-college-of-medicine-tuscon-tuscon"},{"id":"nct05624268-proscience-research-group-culver-city","cat":"research","name":"ProScience Research Group","city":"Culver City","region":"California","country":"United States","cc":"US","lat":34.02521,"lon":-118.40141,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"90230","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-proscience-research-group-culver-city"},{"id":"nct05624268-collaborative-neuroscience-network-llc-garden-grove","cat":"research","name":"Collaborative Neuroscience Network, LLC","city":"Garden Grove","region":"California","country":"United States","cc":"US","lat":33.77923,"lon":-117.94027,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92845","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-collaborative-neuroscience-network-llc-garden-grove"},{"id":"nct05624268-kadima-neuropsychiatry-institute-la-jolla","cat":"research","name":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","cc":"US","lat":32.85485,"lon":-117.26465,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92037","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-kadima-neuropsychiatry-institute-la-jolla"},{"id":"nct05624268-university-california-san-diego-la-jolla","cat":"research","name":"University California San Diego","city":"La Jolla","region":"California","country":"United States","cc":"US","lat":32.84948,"lon":-117.27716,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92037","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-university-california-san-diego-la-jolla"},{"id":"nct05624268-california-center-for-psychedelic-therapy-los-angeles","cat":"research","name":"California Center for Psychedelic Therapy","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.06263,"lon":-118.24034,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"90004","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-california-center-for-psychedelic-therapy-los-angeles"},{"id":"nct05624268-calneuro-research-group-inc-los-angeles","cat":"research","name":"CalNeuro Research Group, Inc","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.05011,"lon":-118.24354,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"90025","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-calneuro-research-group-inc-los-angeles"},{"id":"nct05624268-clarity-clinical-research-llc-los-angeles","cat":"research","name":"Clarity Clinical Research, LLC","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.04183,"lon":-118.2362,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"90064","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-clarity-clinical-research-llc-los-angeles"},{"id":"nct05624268-atp-clinical-research-inc-orange","cat":"research","name":"ATP Clinical Research, Inc.","city":"Orange","region":"California","country":"United States","cc":"US","lat":33.78981,"lon":-117.85287,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92868","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-atp-clinical-research-inc-orange"},{"id":"nct05624268-artemis-institute-for-clinical-research-san-diego","cat":"research","name":"Artemis Institute for Clinical Research","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.70484,"lon":-117.1531,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92103","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-artemis-institute-for-clinical-research-san-diego"},{"id":"nct05624268-lumos-clinical-research-center-san-jose","cat":"research","name":"Lumos Clinical Research Center","city":"San Jose","region":"California","country":"United States","cc":"US","lat":37.33784,"lon":-121.89378,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"95124","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-lumos-clinical-research-center-san-jose"},{"id":"nct05624268-stanford-university-stanford","cat":"research","name":"Stanford University","city":"Stanford","region":"California","country":"United States","cc":"US","lat":37.43253,"lon":-122.16086,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94305","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-stanford-university-stanford"},{"id":"nct05624268-asclepes-research-centers-thousand-oaks","cat":"research","name":"ASCLEPES Research Centers","city":"Thousand Oaks","region":"California","country":"United States","cc":"US","lat":34.16835,"lon":-118.8302,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"93012","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-asclepes-research-centers-thousand-oaks"},{"id":"nct05624268-comprehensive-psychiatric-care-norwich","cat":"research","name":"Comprehensive Psychiatric Care","city":"Norwich","region":"Connecticut","country":"United States","cc":"US","lat":41.52337,"lon":-72.07332,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"06360","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-comprehensive-psychiatric-care-norwich"},{"id":"nct05624268-clinical-neurosciecne-solutions-inc-dba-cns-healthcare-orlando","cat":"research","name":"Clinical Neurosciecne Solutions, Inc. dba CNS Healthcare","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.5317,"lon":-81.38559,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"32801","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-clinical-neurosciecne-solutions-inc-dba-cns-healthcare-orlando"},{"id":"nct05624268-apg-research-llc-orlando","cat":"research","name":"APG Research, LLC","city":"Orlando","region":"Florida","country":"United States","cc":"US","lat":28.52926,"lon":-81.38399,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"32803","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-apg-research-llc-orlando"},{"id":"nct05624268-dmi-health-care-group-inc-tampa","cat":"research","name":"DMI Health Care Group, Inc","city":"Tampa","region":"Florida","country":"United States","cc":"US","lat":27.9374,"lon":-82.46478,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"33782","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-dmi-health-care-group-inc-tampa"},{"id":"nct05624268-meridien-research-accel-research-tampa","cat":"research","name":"Meridien Research/Accel Research","city":"Tampa","region":"Florida","country":"United States","cc":"US","lat":27.94183,"lon":-82.45528,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"33803","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-meridien-research-accel-research-tampa"},{"id":"nct05624268-psych-atlanta-atlanta","cat":"research","name":"Psych Atlanta","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.75733,"lon":-84.3964,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30060","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-psych-atlanta-atlanta"},{"id":"nct05624268-emory-university-atlanta","cat":"research","name":"Emory University","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.74914,"lon":-84.38257,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30329-2209","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-emory-university-atlanta"},{"id":"nct05624268-uptown-research-institute-llc-chicago","cat":"research","name":"Uptown Research Institute, LLC","city":"Chicago","region":"Illinois","country":"United States","cc":"US","lat":41.85864,"lon":-87.6516,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"60640","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-uptown-research-institute-llc-chicago"},{"id":"nct05624268-sheppard-pratt-health-system-baltimore","cat":"research","name":"Sheppard Pratt Health System","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.27866,"lon":-76.61835,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21044","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-sheppard-pratt-health-system-baltimore"},{"id":"nct05624268-cbh-health-llc-gaithersburg","cat":"research","name":"CBH Health, LLC","city":"Gaithersburg","region":"Maryland","country":"United States","cc":"US","lat":39.14951,"lon":-77.20801,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"20877","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-cbh-health-llc-gaithersburg"},{"id":"nct05624268-pharmasite-research-inc-pikesville","cat":"research","name":"Pharmasite Research, Inc","city":"Pikesville","region":"Maryland","country":"United States","cc":"US","lat":39.36895,"lon":-76.72798,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21208","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-pharmasite-research-inc-pikesville"},{"id":"nct05624268-university-of-massachusetts-medical-school-north-worcester","cat":"research","name":"University of Massachusetts Medical School","city":"North Worcester","region":"Massachusetts","country":"United States","cc":"US","lat":42.27092,"lon":-71.79311,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"01655","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-university-of-massachusetts-medical-school-north-worcester"},{"id":"nct05624268-university-of-minnesota-minneapolis","cat":"research","name":"University of Minnesota","city":"Minneapolis","region":"Minnesota","country":"United States","cc":"US","lat":44.98585,"lon":-93.26473,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"55416","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-university-of-minnesota-minneapolis"},{"id":"nct05624268-university-of-missouri-columbia","cat":"research","name":"University of Missouri","city":"Columbia","region":"Missouri","country":"United States","cc":"US","lat":33.99662,"lon":-81.04643,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"65212","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-university-of-missouri-columbia"},{"id":"nct05624268-midwest-research-group-saint-charles","cat":"research","name":"Midwest Research Group","city":"Saint Charles","region":"Missouri","country":"United States","cc":"US","lat":38.79086,"lon":-90.48787,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"63304","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-midwest-research-group-saint-charles"},{"id":"nct05624268-washington-university-school-of-medicine-st-louis","cat":"research","name":"Washington University School of Medicine","city":"St Louis","region":"Missouri","country":"United States","cc":"US","lat":38.62863,"lon":-90.19097,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"63110","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-washington-university-school-of-medicine-st-louis"},{"id":"nct05624268-alivation-research-llc-lincoln","cat":"research","name":"Alivation Research, LLC.","city":"Lincoln","region":"Nebraska","country":"United States","cc":"US","lat":40.80306,"lon":-96.65675,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"68526","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-alivation-research-llc-lincoln"},{"id":"nct05624268-bio-behavioral-health-toms-river","cat":"research","name":"Bio Behavioral Health","city":"Toms River","region":"New Jersey","country":"United States","cc":"US","lat":39.94408,"lon":-74.19524,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"08755","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-bio-behavioral-health-toms-river"},{"id":"nct05624268-new-york-state-psychiatric-institute-new-york","cat":"research","name":"New York State Psychiatric Institute","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72326,"lon":-73.99576,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10032","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-new-york-state-psychiatric-institute-new-york"},{"id":"nct05624268-the-medical-research-network-llc-new-york","cat":"research","name":"The Medical Research Network, LLC","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71385,"lon":-73.99463,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10128","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-the-medical-research-network-llc-new-york"},{"id":"nct05624268-insight-clinical-trials-llc-beachwood","cat":"research","name":"Insight Clinical Trials, LLC","city":"Beachwood","region":"Ohio","country":"United States","cc":"US","lat":41.45645,"lon":-81.50426,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"44122","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-insight-clinical-trials-llc-beachwood"},{"id":"nct05624268-neuro-behaviroral-clinical-research-inc-north-canton","cat":"research","name":"Neuro-Behaviroral Clinical Research, Inc.","city":"North Canton","region":"Ohio","country":"United States","cc":"US","lat":40.88648,"lon":-81.40098,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"44720","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-neuro-behaviroral-clinical-research-inc-north-canton"},{"id":"nct05624268-rivus-wellness-research-institute-oklahoma-city","cat":"research","name":"Rivus Wellness & Research Institute","city":"Oklahoma City","region":"Oklahoma","country":"United States","cc":"US","lat":35.46516,"lon":-97.50443,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"73112","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-rivus-wellness-research-institute-oklahoma-city"},{"id":"nct05624268-global-medical-institutes-llc-scranton-medical-institute-moosic","cat":"research","name":"Global Medical Institutes, LLC, Scranton Medical Institute","city":"Moosic","region":"Pennsylvania","country":"United States","cc":"US","lat":41.35619,"lon":-75.74159,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"18507","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-global-medical-institutes-llc-scranton-medical-institute-moosic"},{"id":"nct05624268-ut-health-science-center-at-houston-uthsc-h-houston","cat":"research","name":"UT Health Science Center at Houston (UTHSC-H)","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.7686,"lon":-95.35616,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"77030","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-ut-health-science-center-at-houston-uthsc-h-houston"},{"id":"nct05624268-cedar-clinical-research-draper","cat":"research","name":"Cedar Clinical Research","city":"Draper","region":"Utah","country":"United States","cc":"US","lat":40.53112,"lon":-111.86575,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"84020","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-cedar-clinical-research-draper"},{"id":"nct05624268-core-clinical-research-everett","cat":"research","name":"Core Clinical Research","city":"Everett","region":"Washington","country":"United States","cc":"US","lat":47.9811,"lon":-122.20486,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"98201","condg":["Depression"],"nct":"NCT05624268","study":"Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05624268","phase":"Phase 3","enroll":258,"start":"2023-01-24","eid":"x:site:nct05624268-core-clinical-research-everett"},{"id":"nct07050368-hammersmith-medicines-research-hmr-london","cat":"research","name":"Hammersmith Medicines Research (HMR)","city":"London","country":"United Kingdom","cc":"GB","lat":51.52034,"lon":-0.11685,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"NW10 7EW","condg":["Healthy volunteers"],"nct":"NCT07050368","study":"A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers","sstatus":"COMPLETED","sponsor":"MycoMedica Life Sciences PBC","src":"https://clinicaltrials.gov/study/NCT07050368","phase":"Phase 1","enroll":20,"start":"2025-07-28","eid":"x:site:nct07050368-hammersmith-medicines-research-hmr-london"},{"id":"nct06512220-centre-for-addiction-and-mental-health-toronto","cat":"research","name":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70619,"lon":-79.3952,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"M6J1H4","condg":["Depression"],"status":"RECRUITING","nct":"NCT06512220","study":"Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)","sstatus":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","official":"Ishrat Husain, MBBS, MD (Centre for Addiction and Mental Health)","src":"https://clinicaltrials.gov/study/NCT06512220","contact":{"n":"Emily Gilbert, MSc","p":"416-535-8501","e":"emily.gilbert@camh.ca"},"phase":"Phase 2","enroll":12,"start":"2025-04-21","eid":"x:site:nct06512220-centre-for-addiction-and-mental-health-toronto"},{"id":"nct06378229-ghent-university-hospital-ghent","cat":"research","name":"Ghent University Hospital","city":"Ghent","region":"Oost-Vlaanderen","country":"Belgium","cc":"BE","lat":51.03809,"lon":3.72566,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"9000","condg":["Depression"],"status":"RECRUITING","nct":"NCT06378229","study":"Psilocybin for Hospitalized Patients with Treatment-resistant Depression","sstatus":"RECRUITING","sponsor":"University Hospital, Ghent","official":"Gilbert Lemmens, Prof. dr. (University Hospital, Ghent)","src":"https://clinicaltrials.gov/study/NCT06378229","contact":{"n":"Cisse Geleyn, dr.","p":"+3293328742","e":"cisse.geleyn@uzgent.be"},"phase":"Phase 2","enroll":100,"start":"2024-05-21","eid":"x:site:nct06378229-ghent-university-hospital-ghent"},{"id":"nct05546658-johns-hopkins-university-school-of-medicine-baltimore","cat":"research","name":"Johns Hopkins University School of Medicine","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29278,"lon":-76.60744,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["OCD"],"nct":"NCT05546658","study":"Effects of Psilocybin in Obsessive Compulsive Disorder","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","official":"David B Yaden, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT05546658","phase":"EARLY_Phase 1","enroll":35,"start":"2022-11-28","eid":"x:site:nct05546658-johns-hopkins-university-school-of-medicine-baltimore"},{"id":"nct06072898-sunnybrook-health-sciences-centre-toronto","cat":"research","name":"Sunnybrook Health Sciences Centre","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70412,"lon":-79.40236,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"M4N3M5","condg":["Depression"],"status":"RECRUITING","nct":"NCT06072898","study":"A Randomized Neuroimaging Trial of Psilocybin in Depression","sstatus":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","official":"Sean M Nestor, PhD MD FRCPC (Sunnybrook Health Sciences Centre); Bradley J MacIntosh, PhD (Sunnybrook Research Institute)","src":"https://clinicaltrials.gov/study/NCT06072898","contact":{"n":"EMBRACE Team","p":"416-480-4085","e":"embrace@sunnybrook.ca"},"phase":"Phase 2","enroll":50,"start":"2025-05-28","eid":"x:site:nct06072898-sunnybrook-health-sciences-centre-toronto"},{"id":"nct06801041-the-university-of-texas-m-d-anderson-cancer-center-houston","cat":"research","name":"The University of Texas M. D. Anderson Cancer Center","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.75297,"lon":-95.35202,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"77030","condg":["Depression","Anxiety","Cancer-related distress"],"status":"RECRUITING","nct":"NCT06801041","study":"TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors","sstatus":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","official":"Moran Amit, MD, PHD (M.D. Anderson Cancer Center)","src":"https://clinicaltrials.gov/study/NCT06801041","contact":{"n":"Moran Amit, MD, PHD","p":"713-794-5304","e":"mamit@mdanderson.org"},"phase":"Phase 2","enroll":20,"start":"2025-05-23","eid":"x:site:nct06801041-the-university-of-texas-m-d-anderson-cancer-center-houston"},{"id":"nct05506982-emory-university-winship-cancer-institute-atlanta","cat":"research","name":"Emory University/Winship Cancer Institute","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.74669,"lon":-84.39725,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30322","condg":["Cancer-related distress"],"nct":"NCT05506982","study":"Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain","sstatus":"COMPLETED","sponsor":"Emory University","official":"Ali J. Zarrabi, MD (Emory University Hospital/Winship Cancer Institute)","src":"https://clinicaltrials.gov/study/NCT05506982","phase":"Phase 1","enroll":11,"start":"2022-11-01","eid":"x:site:nct05506982-emory-university-winship-cancer-institute-atlanta"},{"id":"nct05506982-brain-health-center-at-executive-park-atlanta","cat":"research","name":"Brain Health Center at Executive Park","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.75008,"lon":-84.39104,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30329","condg":["Cancer-related distress"],"nct":"NCT05506982","study":"Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain","sstatus":"COMPLETED","sponsor":"Emory University","official":"Ali J. Zarrabi, MD (Emory University Hospital/Winship Cancer Institute)","src":"https://clinicaltrials.gov/study/NCT05506982","phase":"Phase 1","enroll":11,"start":"2022-11-01","eid":"x:site:nct05506982-brain-health-center-at-executive-park-atlanta"},{"id":"nct02243813-behavioral-biology-research-center-johns-hopkins-bayview-baltimore","cat":"research","name":"Behavioral Biology Research Center, Johns Hopkins Bayview","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.30116,"lon":-76.6064,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Healthy volunteers"],"nct":"NCT02243813","study":"Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion","sstatus":"COMPLETED","sponsor":"Johns Hopkins University","official":"Roland R Griffiths, Ph.D. (JHUSOM)","src":"https://clinicaltrials.gov/study/NCT02243813","phase":"Phase 1","enroll":24,"start":"2015-03","eid":"x:site:nct02243813-behavioral-biology-research-center-johns-hopkins-bayview-baltimore"},{"id":"nct07818564-brown-university-school-of-public-health-providence","cat":"research","name":"Brown University School of Public Health","city":"Providence","region":"Rhode Island","country":"United States","cc":"US","lat":41.81538,"lon":-71.41683,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"02903","condg":["Other"],"nct":"NCT07818564","study":"Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation","sstatus":"NOT_YET_RECRUITING","sponsor":"Brown University","src":"https://clinicaltrials.gov/study/NCT07818564","contact":{"n":"Eric A. Miller, M.D.","e":"eric_miller@brown.edu"},"phase":"Phase 1","enroll":24,"start":"2026-11","eid":"x:site:nct07818564-brown-university-school-of-public-health-providence"},{"id":"nct06368492-maastricht-university-maastricht","cat":"research","name":"Maastricht University","city":"Maastricht","region":"Limburg","country":"Netherlands","cc":"NL","lat":50.83991,"lon":5.6799,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"6226AK","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06368492","study":"The Impact of Psilocybin on Pain in Fibromyalgia Patients","sstatus":"RECRUITING","sponsor":"Maastricht University","official":"Johannes G. Ramaekers, PhD (Maastricht University)","src":"https://clinicaltrials.gov/study/NCT06368492","contact":{"n":"Mauro Cavarra, MSc","p":"+313494438261","e":"m.cavarra@maastrichtuniversity.nl"},"phase":"N/A","enroll":35,"start":"2024-05-03","eid":"x:site:nct06368492-maastricht-university-maastricht"},{"id":"nct06368492-leiden-university-medical-center-leiden","cat":"research","name":"Leiden University Medical Center","city":"Leiden","region":"South Holland","country":"Netherlands","cc":"NL","lat":52.14887,"lon":4.49367,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"2333","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT06368492","study":"The Impact of Psilocybin on Pain in Fibromyalgia Patients","sstatus":"RECRUITING","sponsor":"Maastricht University","official":"Johannes G. Ramaekers, PhD (Maastricht University)","src":"https://clinicaltrials.gov/study/NCT06368492","contact":{"n":"Monique van Velzen, PhD","p":"‭+310683029784‬","e":"M.van_Velzen@lumc.nl"},"phase":"N/A","enroll":35,"start":"2024-05-03","eid":"x:site:nct06368492-leiden-university-medical-center-leiden"},{"id":"nct06326606-cmax-clinical-research-pty-ltd-adelaide","cat":"research","name":"CMAX Clinical Research Pty Ltd","city":"Adelaide","region":"South Australia","country":"Australia","cc":"AU","lat":-34.93944,"lon":138.60734,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"5000","condg":["Healthy volunteers"],"nct":"NCT06326606","study":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants","sstatus":"COMPLETED","sponsor":"MycoMedica Life Sciences PBC","official":"Sepehr Shakib (Principal Investigator at CMAX Clinical Research Pty Ltd)","src":"https://clinicaltrials.gov/study/NCT06326606","phase":"Phase 1","enroll":24,"start":"2024-03-27","eid":"x:site:nct06326606-cmax-clinical-research-pty-ltd-adelaide"},{"id":"nct07079852-the-university-of-texas-at-austin-dell-medical-school-austin","cat":"research","name":"The University of Texas at Austin Dell Medical School","city":"Austin","region":"Texas","country":"United States","cc":"US","lat":30.27068,"lon":-97.74038,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"78712","condg":["Healthy volunteers"],"nct":"NCT07079852","study":"The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function","sstatus":"NOT_YET_RECRUITING","sponsor":"Manoj Doss","src":"https://clinicaltrials.gov/study/NCT07079852","contact":{"n":"Manoj Doss, PhD","p":"512-495-5856","e":"manoj.doss@austin.utexas.edu"},"phase":"Phase 1/Phase 2","enroll":48,"start":"2026-09","eid":"x:site:nct07079852-the-university-of-texas-at-austin-dell-medical-school-austin"},{"id":"nct04630964-northern-stockholm-spychiatry-clinic-stockholm","cat":"research","name":"Northern Stockholm Spychiatry Clinic","city":"Stockholm","country":"Sweden","cc":"SE","lat":59.31794,"lon":18.07911,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT04630964","study":"The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density","sstatus":"COMPLETED","sponsor":"Section for Affective Disorders; Northern Stockholm Psychiatry","src":"https://clinicaltrials.gov/study/NCT04630964","phase":"Phase 2","enroll":35,"start":"2021-01-01","eid":"x:site:nct04630964-northern-stockholm-spychiatry-clinic-stockholm"},{"id":"nct04882839-beer-sheva-mental-health-center-beersheba","cat":"research","name":"Beer Sheva Mental Health Center","city":"Beersheba","country":"Israel","cc":"IL","lat":31.26212,"lon":34.79379,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"8461144","condg":["OCD"],"status":"RECRUITING","nct":"NCT04882839","study":"Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe OCD","sstatus":"RECRUITING","sponsor":"Beersheva Mental Health Center","official":"Oded Arbel, MD (Beersheva Mental Health Center)","src":"https://clinicaltrials.gov/study/NCT04882839","contact":{"n":"Oded Arbel, MD","p":"+972506576691","e":"oded.arbel@gmail.com"},"phase":"Phase 2","enroll":15,"start":"2024-11-25","eid":"x:site:nct04882839-beer-sheva-mental-health-center-beersheba"},{"id":"nct05481736-altman-clinical-and-translational-research-institute-san-diego","cat":"research","name":"Altman Clinical and Translational Research Institute","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.7119,"lon":-117.16514,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92037","condg":["Eating disorders"],"nct":"NCT05481736","study":"Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05481736","phase":"Phase 2","enroll":32,"start":"2022-10-12","eid":"x:site:nct05481736-altman-clinical-and-translational-research-institute-san-diego"},{"id":"nct05481736-sheppard-pratt-health-system-baltimore","cat":"research","name":"Sheppard Pratt Health System","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29127,"lon":-76.6065,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21044","condg":["Eating disorders"],"nct":"NCT05481736","study":"Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05481736","phase":"Phase 2","enroll":32,"start":"2022-10-12","eid":"x:site:nct05481736-sheppard-pratt-health-system-baltimore"},{"id":"nct05481736-dell-medical-school-austin","cat":"research","name":"Dell Medical School","city":"Austin","region":"Texas","country":"United States","cc":"US","lat":30.27604,"lon":-97.74894,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"78712","condg":["Eating disorders"],"nct":"NCT05481736","study":"Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05481736","phase":"Phase 2","enroll":32,"start":"2022-10-12","eid":"x:site:nct05481736-dell-medical-school-austin"},{"id":"nct05481736-tallaght-university-hospital-dublin","cat":"research","name":"Tallaght University Hospital","city":"Dublin","country":"Ireland","cc":"IE","lat":53.34148,"lon":-6.256,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Eating disorders"],"nct":"NCT05481736","study":"Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05481736","phase":"Phase 2","enroll":32,"start":"2022-10-12","eid":"x:site:nct05481736-tallaght-university-hospital-dublin"},{"id":"nct05481736-kings-college-london-institute-of-psychiatry-psychology-and-neurolog","cat":"research","name":"Kings College London, Institute of Psychiatry, Psychology and Neurology","city":"London","country":"United Kingdom","cc":"GB","lat":51.51328,"lon":-0.13718,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Eating disorders"],"nct":"NCT05481736","study":"Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05481736","phase":"Phase 2","enroll":32,"start":"2022-10-12","eid":"x:site:nct05481736-kings-college-london-institute-of-psychiatry-psychology-and-neurolog"},{"id":"nct03853577-psychiatrische-universitatsklinik-zurich-zurich","cat":"research","name":"Psychiatrische Universitätsklinik Zürich","city":"Zurich","country":"Switzerland","cc":"CH","lat":47.35674,"lon":8.54892,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"8032","condg":["Healthy volunteers"],"nct":"NCT03853577","study":"Characterization of Altered Waking States of Consciousness in Healthy Humans","sstatus":"COMPLETED","sponsor":"University of Zurich","official":"Franz X. Vollenweider, Prof, MD (Psychiatric Hospital, University of Zurich)","src":"https://clinicaltrials.gov/study/NCT03853577","phase":"N/A","enroll":25,"start":"2020-07-08","eid":"x:site:nct03853577-psychiatrische-universitatsklinik-zurich-zurich"},{"id":"nct07506395-interdisciplinary-substance-use-and-brain-injury-isubi-albuquerque","cat":"research","name":"Interdisciplinary Substance Use and Brain Injury (ISUBI)","city":"Albuquerque","region":"New Mexico","country":"United States","cc":"US","lat":35.07889,"lon":-106.64479,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"87131","condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT07506395","study":"Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder","sstatus":"RECRUITING","sponsor":"University of New Mexico","src":"https://clinicaltrials.gov/study/NCT07506395","contact":{"n":"Victoria Culkin, MA","p":"505-272-1754","e":"vculkin@salud.unm.edu"},"phase":"Phase 1","enroll":36,"start":"2026-05-01","eid":"x:site:nct07506395-interdisciplinary-substance-use-and-brain-injury-isubi-albuquerque"},{"id":"nct06902974-sunstone-medical-pc-rockville","cat":"research","name":"Sunstone Medical, PC","city":"Rockville","region":"Maryland","country":"United States","cc":"US","lat":39.07962,"lon":-77.15572,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"20850","condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT06902974","study":"Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD","sstatus":"RECRUITING","sponsor":"Sunstone Medical","official":"Manish Agrawal, MD, MSC (Sunstone Medical, PC)","src":"https://clinicaltrials.gov/study/NCT06902974","contact":{"n":"Clinical Evaluation Team","p":"301-750-3401","e":"clinical.specialists@sunstonetherapies.com"},"phase":"Phase 2","enroll":70,"start":"2026-05-23","eid":"x:site:nct06902974-sunstone-medical-pc-rockville"},{"id":"nct06506019-toronto-western-hospital-university-health-network-toronto","cat":"research","name":"Toronto Western Hospital - University Health Network","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70968,"lon":-79.4097,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"M5T 2S8","condg":["Depression","Bipolar"],"nct":"NCT06506019","study":"Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","official":"Joshua Rosenblat, MD, MSc (University Health Network, Toronto)","src":"https://clinicaltrials.gov/study/NCT06506019","phase":"Phase 1","enroll":30,"start":"2024-10-09","eid":"x:site:nct06506019-toronto-western-hospital-university-health-network-toronto"},{"id":"nct04656301-new-york-state-psychiatric-institute-1051-riverside-drive-new-york","cat":"research","name":"New York State Psychiatric Institute, 1051 Riverside Drive","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70641,"lon":-74.01392,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10032","condg":["Other"],"nct":"NCT04656301","study":"Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder","sstatus":"COMPLETED","sponsor":"New York State Psychiatric Institute","official":"Franklin Schneier, MD (Research Foundation for Mental Hygiene/NY State Psychiatric Institute)","src":"https://clinicaltrials.gov/study/NCT04656301","phase":"Phase 2","enroll":12,"start":"2021-02-26","eid":"x:site:nct04656301-new-york-state-psychiatric-institute-1051-riverside-drive-new-york"},{"id":"nct07386730-university-of-california-san-francisco-sandler-neuroscience-building","cat":"research","name":"University of California San Francisco, Sandler Neuroscience Building","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.76886,"lon":-122.41533,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94158","condg":["Healthy volunteers"],"status":"RECRUITING","nct":"NCT07386730","study":"A Study of Psychedelics in Healthy Older Adults With Low Well-being","sstatus":"RECRUITING","sponsor":"Jennifer Mitchell","official":"Lorenzo Pasquini, PhD (University of California, San Francisco); Jennifer Mitchell, PhD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT07386730","contact":{"n":"Gabriella Mace","p":"415-707-5399","e":"agingandpsychedelics@ucsf.edu"},"phase":"Phase 1","enroll":80,"start":"2026-06-01","eid":"x:site:nct07386730-university-of-california-san-francisco-sandler-neuroscience-building"},{"id":"nct05698511-university-of-california-san-francisco-san-francisco","cat":"research","name":"University of California, San Francisco","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.77055,"lon":-122.42803,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94158","condg":["Healthy volunteers"],"nct":"NCT05698511","study":"Neural and Physiological Correlates of Psychedelic Sub-states","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Robin Carhart-Harris, PhD, MA","official":"Robin Carhart-Harris, PhD (University of California, San Francisco)","src":"https://clinicaltrials.gov/study/NCT05698511","phase":"Phase 1","enroll":12,"start":"2023-07-31","eid":"x:site:nct05698511-university-of-california-san-francisco-san-francisco"},{"id":"nct04519957-kadima-neuropsychiatry-institute-la-jolla","cat":"research","name":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","cc":"US","lat":32.84995,"lon":-117.28404,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92037","condg":["Depression"],"nct":"NCT04519957","study":"Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT04519957","enroll":66,"start":"2020-07-20","eid":"x:site:nct04519957-kadima-neuropsychiatry-institute-la-jolla"},{"id":"nct04519957-altman-clinical-and-translational-research-institute-university-of-c","cat":"research","name":"Altman Clinical and Translational Research Institute, University of California","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.72649,"lon":-117.15696,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92093","condg":["Depression"],"nct":"NCT04519957","study":"Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT04519957","enroll":66,"start":"2020-07-20","eid":"x:site:nct04519957-altman-clinical-and-translational-research-institute-university-of-c"},{"id":"nct04519957-mood-and-anxiety-disorders-program-emory-university-school-of-medici","cat":"research","name":"Mood and Anxiety Disorders Program Emory University School of Medicine","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.74716,"lon":-84.39932,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30329","condg":["Depression"],"nct":"NCT04519957","study":"Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT04519957","enroll":66,"start":"2020-07-20","eid":"x:site:nct04519957-mood-and-anxiety-disorders-program-emory-university-school-of-medici"},{"id":"nct04519957-ut-center-of-excellence-on-mood-disorders-university-of-texas-health","cat":"research","name":"UT Center of Excellence on Mood Disorders, University of Texas Health Science Center","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.76493,"lon":-95.36586,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"77054","condg":["Depression"],"nct":"NCT04519957","study":"Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT04519957","enroll":66,"start":"2020-07-20","eid":"x:site:nct04519957-ut-center-of-excellence-on-mood-disorders-university-of-texas-health"},{"id":"nct04519957-national-institute-of-mental-health-czech-republic-klecany","cat":"research","name":"National Institute of Mental Health Czech Republic","city":"Klecany","country":"Czechia","cc":"CZ","lat":50.17368,"lon":14.4231,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT04519957","study":"Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT04519957","enroll":66,"start":"2020-07-20","eid":"x:site:nct04519957-national-institute-of-mental-health-czech-republic-klecany"},{"id":"nct04519957-sheaf-house-tallaght-hospital-dublin","cat":"research","name":"Sheaf House, Tallaght Hospital","city":"Dublin","country":"Ireland","cc":"IE","lat":53.32727,"lon":-6.24329,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT04519957","study":"Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT04519957","enroll":66,"start":"2020-07-20","eid":"x:site:nct04519957-sheaf-house-tallaght-hospital-dublin"},{"id":"nct04519957-groningen-university-medical-centre-groningen","cat":"research","name":"Groningen University Medical Centre","city":"Groningen","country":"Netherlands","cc":"NL","lat":53.22505,"lon":6.57801,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT04519957","study":"Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT04519957","enroll":66,"start":"2020-07-20","eid":"x:site:nct04519957-groningen-university-medical-centre-groningen"},{"id":"nct04519957-kings-college-london-institute-of-psychiatry-psychology-and-neurolog","cat":"research","name":"Kings College London, Institute of Psychiatry, Psychology and Neurology","city":"London","country":"United Kingdom","cc":"GB","lat":51.50792,"lon":-0.12758,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT04519957","study":"Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT04519957","enroll":66,"start":"2020-07-20","eid":"x:site:nct04519957-kings-college-london-institute-of-psychiatry-psychology-and-neurolog"},{"id":"nct04739865-kadima-neuropsychiatry-institute-la-jolla","cat":"research","name":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","cc":"US","lat":32.85579,"lon":-117.26832,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92037","condg":["Depression"],"nct":"NCT04739865","study":"The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","official":"Guy Goodwin (University of Oxford)","src":"https://clinicaltrials.gov/study/NCT04739865","phase":"Phase 2","enroll":19,"start":"2020-08-10","eid":"x:site:nct04739865-kadima-neuropsychiatry-institute-la-jolla"},{"id":"nct04739865-sheaf-house-tallaght-hospital-dublin","cat":"research","name":"Sheaf House, Tallaght Hospital","city":"Dublin","country":"Ireland","cc":"IE","lat":53.32887,"lon":-6.24621,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT04739865","study":"The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression","sstatus":"COMPLETED","sponsor":"COMPASS Pathways","official":"Guy Goodwin (University of Oxford)","src":"https://clinicaltrials.gov/study/NCT04739865","phase":"Phase 2","enroll":19,"start":"2020-08-10","eid":"x:site:nct04739865-sheaf-house-tallaght-hospital-dublin"},{"id":"nct07360301-university-of-wisconsin-madison","cat":"research","name":"University of Wisconsin","city":"Madison","region":"Wisconsin","country":"United States","cc":"US","lat":43.06472,"lon":-89.38951,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"53792","condg":["Other"],"nct":"NCT07360301","study":"Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study","sstatus":"NOT_YET_RECRUITING","sponsor":"University of Wisconsin, Madison","official":"Charles Raison, MD (University of Wisconsin, Madison)","src":"https://clinicaltrials.gov/study/NCT07360301","contact":{"n":"CoPEWell Study Contact","p":"608-263-4852","e":"copewell@psychiatry.wisc.edu"},"phase":"Phase 1","enroll":120,"start":"2026-10","eid":"x:site:nct07360301-university-of-wisconsin-madison"},{"id":"nct06835699-johns-hopkins-school-of-medicine-baltimore","cat":"research","name":"Johns Hopkins School of Medicine","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28534,"lon":-76.6064,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21214","condg":["Healthy volunteers"],"nct":"NCT06835699","study":"Psilocybin Brain Stimulation and Imaging Pilot Study","sstatus":"COMPLETED","sponsor":"Johns Hopkins University","official":"Ceyda Sayali, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT06835699","phase":"Phase 1","enroll":10,"start":"2025-04-18","eid":"x:site:nct06835699-johns-hopkins-school-of-medicine-baltimore"},{"id":"nct06660381-johns-hopkins-center-for-psychedelic-and-consciousness-research-balt","cat":"research","name":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29909,"lon":-76.60979,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT06660381","study":"Psilocybin-assisted Treatment for Cannabis Use Disorder","sstatus":"RECRUITING","sponsor":"Johns Hopkins University","official":"Albert Garcia-Romeu, Ph.D. (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT06660381","contact":{"n":"Ian Geithner, MPS","p":"786-239-7990","e":"agromeu77@gmail.com"},"phase":"Phase 1","enroll":12,"start":"2024-11-08","eid":"x:site:nct06660381-johns-hopkins-center-for-psychedelic-and-consciousness-research-balt"},{"id":"nct06768944-university-of-calgary-calgary","cat":"research","name":"University of Calgary","city":"Calgary","region":"Alberta","country":"Canada","cc":"CA","lat":51.03905,"lon":-114.07931,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"T2N 4N1","condg":["Other"],"status":"RECRUITING","nct":"NCT06768944","study":"Subjective Experience Following Psilocybin","sstatus":"RECRUITING","sponsor":"University of Calgary","official":"Leah Mayo, PhD (University of Calgary)","src":"https://clinicaltrials.gov/study/NCT06768944","contact":{"n":"Ana Deutsch, MSc","p":"587-893-0257","e":"septrial@ucalgary.ca"},"phase":"Phase 2","enroll":128,"start":"2026-05-15","eid":"x:site:nct06768944-university-of-calgary-calgary"},{"id":"nct05710237-centre-for-addiction-and-mental-health-toronto","cat":"research","name":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.71156,"lon":-79.39982,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"M6J1H4","condg":["Depression"],"nct":"NCT05710237","study":"Does Psilocybin Require Psychedelic Effects to Treat Depression?","sstatus":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","official":"M. Ishrat Husain, MBBS, MD (Centre for Addiction and Mental Health)","src":"https://clinicaltrials.gov/study/NCT05710237","phase":"Phase 2","enroll":41,"start":"2023-07-01","eid":"x:site:nct05710237-centre-for-addiction-and-mental-health-toronto"},{"id":"nct05733546-kadima-neuropsychiatry-institute-la-jolla","cat":"research","name":"Kadima Neuropsychiatry Institute","city":"La Jolla","region":"California","country":"United States","cc":"US","lat":32.85899,"lon":-117.27265,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92037","condg":["Depression"],"nct":"NCT05733546","study":"A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive…","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05733546","phase":"Phase 2","enroll":102,"start":"2023-01-30","eid":"x:site:nct05733546-kadima-neuropsychiatry-institute-la-jolla"},{"id":"nct05733546-clinical-neuroscience-solutions-inc-jacksonville","cat":"research","name":"Clinical Neuroscience Solutions Inc","city":"Jacksonville","region":"Florida","country":"United States","cc":"US","lat":30.3263,"lon":-81.66614,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"32256","condg":["Depression"],"nct":"NCT05733546","study":"A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive…","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05733546","phase":"Phase 2","enroll":102,"start":"2023-01-30","eid":"x:site:nct05733546-clinical-neuroscience-solutions-inc-jacksonville"},{"id":"nct05733546-sunstone-therapies-rockville","cat":"research","name":"Sunstone Therapies","city":"Rockville","region":"Maryland","country":"United States","cc":"US","lat":39.08405,"lon":-77.15347,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"20850","condg":["Depression"],"nct":"NCT05733546","study":"A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive…","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05733546","phase":"Phase 2","enroll":102,"start":"2023-01-30","eid":"x:site:nct05733546-sunstone-therapies-rockville"},{"id":"nct05733546-elixia-ma-llc-springfield","cat":"research","name":"Elixia MA, LLC","city":"Springfield","region":"Massachusetts","country":"United States","cc":"US","lat":37.22564,"lon":-93.30798,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"01103","condg":["Depression"],"nct":"NCT05733546","study":"A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive…","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05733546","phase":"Phase 2","enroll":102,"start":"2023-01-30","eid":"x:site:nct05733546-elixia-ma-llc-springfield"},{"id":"nct05733546-aims-trial-plano","cat":"research","name":"Aims Trial","city":"Plano","region":"Texas","country":"United States","cc":"US","lat":33.01857,"lon":-96.706,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"75093","condg":["Depression"],"nct":"NCT05733546","study":"A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive…","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"COMPASS Pathways","src":"https://clinicaltrials.gov/study/NCT05733546","phase":"Phase 2","enroll":102,"start":"2023-01-30","eid":"x:site:nct05733546-aims-trial-plano"},{"id":"nct06760533-nyu-langone-health-new-york","cat":"research","name":"NYU Langone Health","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71432,"lon":-74.00649,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10016","condg":["Other"],"nct":"NCT06760533","study":"Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)","sstatus":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","official":"Maysaa El Zoghbi (NYU Langone Health)","src":"https://clinicaltrials.gov/study/NCT06760533","contact":{"n":"Maysaa El Zoghbi","p":"216-835-7626","e":"Maysaa.ElZoghbi@nyulangone.org"},"phase":"EARLY_Phase 1","enroll":10,"start":"2026-08","eid":"x:site:nct06760533-nyu-langone-health-new-york"},{"id":"nct05876481-combat-stress-leatherhead","cat":"research","name":"Combat Stress","city":"Leatherhead","region":"Surrey","country":"United Kingdom","cc":"GB","lat":51.30137,"lon":-0.33771,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"KT22 0BX","condg":["PTSD & trauma"],"nct":"NCT05876481","study":"Evaluation of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military Veterans","sstatus":"UNKNOWN","sponsor":"Combat Stress","official":"Prof. Dominic Murphy (Combat Stress)","src":"https://clinicaltrials.gov/study/NCT05876481","contact":{"n":"Prof. Dominic Murphy","p":"01372 587 017","e":"dominic.murphy@combatstress.org.uk"},"phase":"Phase 2","enroll":8,"start":"2023-06","eid":"x:site:nct05876481-combat-stress-leatherhead"},{"id":"nct00979693-mount-sinai-comprehensive-cancer-center-miami-beach","cat":"research","name":"Mount Sinai Comprehensive Cancer Center","city":"Miami Beach","region":"Florida","country":"United States","cc":"US","lat":25.78938,"lon":-80.13697,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"33140","condg":["Anxiety"],"nct":"NCT00979693","study":"Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma","sstatus":"WITHDRAWN","sponsor":"Multidisciplinary Association for Psychedelic Studies","official":"Sameet Kumar, Ph.D (Psycho-oncologist, Mount Sinai Comprehensive Cancer Center)","src":"https://clinicaltrials.gov/study/NCT00979693","phase":"Phase 2","start":"2012-01","eid":"x:site:nct00979693-mount-sinai-comprehensive-cancer-center-miami-beach"},{"id":"nct07336238-fred-hutch-university-of-washington-cancer-consortium-seattle","cat":"research","name":"Fred Hutch/University of Washington Cancer Consortium","city":"Seattle","region":"Washington","country":"United States","cc":"US","lat":47.60635,"lon":-122.32769,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"98109","condg":["Depression","Anxiety","Cancer-related distress"],"nct":"NCT07336238","study":"Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","official":"Anthony Back, MD (Fred Hutch/University of Washington Cancer Consortium)","src":"https://clinicaltrials.gov/study/NCT07336238","phase":"Phase 2","enroll":18,"start":"2026-05-19","eid":"x:site:nct07336238-fred-hutch-university-of-washington-cancer-consortium-seattle"},{"id":"nct05646303-sabi-mind-calgary","cat":"research","name":"Sabi Mind","city":"Calgary","region":"Alberta","country":"Canada","cc":"CA","lat":51.0398,"lon":-114.07818,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"T3C 0J7","condg":["Addiction & substance use"],"nct":"NCT05646303","study":"Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)","sstatus":"UNKNOWN","sponsor":"Clairvoyant Therapeutics","official":"Hannu Alho, MD (Addiktum Oy)","src":"https://clinicaltrials.gov/study/NCT05646303","phase":"Phase 2","enroll":128,"start":"2022-05-02","eid":"x:site:nct05646303-sabi-mind-calgary"},{"id":"nct05646303-okanagan-clinical-trials-kelowna","cat":"research","name":"Okanagan Clinical Trials","city":"Kelowna","region":"British Columbia","country":"Canada","cc":"CA","lat":49.88312,"lon":-119.48027,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Addiction & substance use"],"nct":"NCT05646303","study":"Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)","sstatus":"UNKNOWN","sponsor":"Clairvoyant Therapeutics","official":"Hannu Alho, MD (Addiktum Oy)","src":"https://clinicaltrials.gov/study/NCT05646303","phase":"Phase 2","enroll":128,"start":"2022-05-02","eid":"x:site:nct05646303-okanagan-clinical-trials-kelowna"},{"id":"nct05646303-centre-for-neurology-studies-surrey","cat":"research","name":"Centre for Neurology Studies","city":"Surrey","region":"British Columbia","country":"Canada","cc":"CA","lat":49.10913,"lon":-122.83361,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Addiction & substance use"],"nct":"NCT05646303","study":"Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)","sstatus":"UNKNOWN","sponsor":"Clairvoyant Therapeutics","official":"Hannu Alho, MD (Addiktum Oy)","src":"https://clinicaltrials.gov/study/NCT05646303","phase":"Phase 2","enroll":128,"start":"2022-05-02","eid":"x:site:nct05646303-centre-for-neurology-studies-surrey"},{"id":"nct05646303-university-of-british-columbia-department-of-psychiatry-brain-lab-va","cat":"research","name":"University of British Columbia, Department of Psychiatry, BRAIN Lab","city":"Vancouver","region":"British Columbia","country":"Canada","cc":"CA","lat":49.25055,"lon":-123.11233,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"V6T 1Z3","condg":["Addiction & substance use"],"nct":"NCT05646303","study":"Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)","sstatus":"UNKNOWN","sponsor":"Clairvoyant Therapeutics","official":"Hannu Alho, MD (Addiktum Oy)","src":"https://clinicaltrials.gov/study/NCT05646303","phase":"Phase 2","enroll":128,"start":"2022-05-02","eid":"x:site:nct05646303-university-of-british-columbia-department-of-psychiatry-brain-lab-va"},{"id":"nct05646303-centricity-research-halifax","cat":"research","name":"Centricity Research","city":"Halifax","region":"Nova Scotia","country":"Canada","cc":"CA","lat":44.6498,"lon":-63.58304,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"B3S 1N2","condg":["Addiction & substance use"],"nct":"NCT05646303","study":"Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)","sstatus":"UNKNOWN","sponsor":"Clairvoyant Therapeutics","official":"Hannu Alho, MD (Addiktum Oy)","src":"https://clinicaltrials.gov/study/NCT05646303","phase":"Phase 2","enroll":128,"start":"2022-05-02","eid":"x:site:nct05646303-centricity-research-halifax"},{"id":"nct05646303-macanxiety-research-centre-hamilton","cat":"research","name":"MacAnxiety Research Centre","city":"Hamilton","region":"Ontario","country":"Canada","cc":"CA","lat":43.25213,"lon":-79.85909,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"L8S 1B7","condg":["Addiction & substance use"],"nct":"NCT05646303","study":"Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)","sstatus":"UNKNOWN","sponsor":"Clairvoyant Therapeutics","official":"Hannu Alho, MD (Addiktum Oy)","src":"https://clinicaltrials.gov/study/NCT05646303","phase":"Phase 2","enroll":128,"start":"2022-05-02","eid":"x:site:nct05646303-macanxiety-research-centre-hamilton"},{"id":"nct05646303-department-of-psychiatry-queen-s-university-kingston","cat":"research","name":"Department of Psychiatry, Queen's University","city":"Kingston","region":"Ontario","country":"Canada","cc":"CA","lat":44.23291,"lon":-76.48244,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Addiction & substance use"],"nct":"NCT05646303","study":"Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)","sstatus":"UNKNOWN","sponsor":"Clairvoyant Therapeutics","official":"Hannu Alho, MD (Addiktum Oy)","src":"https://clinicaltrials.gov/study/NCT05646303","phase":"Phase 2","enroll":128,"start":"2022-05-02","eid":"x:site:nct05646303-department-of-psychiatry-queen-s-university-kingston"},{"id":"nct05646303-centre-for-addiction-and-mental-health-toronto","cat":"research","name":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.7109,"lon":-79.40462,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"M6J 1H4","condg":["Addiction & substance use"],"nct":"NCT05646303","study":"Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)","sstatus":"UNKNOWN","sponsor":"Clairvoyant Therapeutics","official":"Hannu Alho, MD (Addiktum Oy)","src":"https://clinicaltrials.gov/study/NCT05646303","phase":"Phase 2","enroll":128,"start":"2022-05-02","eid":"x:site:nct05646303-centre-for-addiction-and-mental-health-toronto"},{"id":"nct05646303-research-center-oxidi-oy-addiktum-oy-helsinki","cat":"research","name":"Research Center Oxidi Oy / Addiktum Oy","city":"Helsinki","country":"Finland","cc":"FI","lat":60.16561,"lon":24.92505,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Addiction & substance use"],"nct":"NCT05646303","study":"Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)","sstatus":"UNKNOWN","sponsor":"Clairvoyant Therapeutics","official":"Hannu Alho, MD (Addiktum Oy)","src":"https://clinicaltrials.gov/study/NCT05646303","phase":"Phase 2","enroll":128,"start":"2022-05-02","eid":"x:site:nct05646303-research-center-oxidi-oy-addiktum-oy-helsinki"},{"id":"nct05646303-a-klinikka-kouvola","cat":"research","name":"A-Klinikka","city":"Kouvola","country":"Finland","cc":"FI","lat":60.86898,"lon":26.69242,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"45100","condg":["Addiction & substance use"],"nct":"NCT05646303","study":"Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)","sstatus":"UNKNOWN","sponsor":"Clairvoyant Therapeutics","official":"Hannu Alho, MD (Addiktum Oy)","src":"https://clinicaltrials.gov/study/NCT05646303","phase":"Phase 2","enroll":128,"start":"2022-05-02","eid":"x:site:nct05646303-a-klinikka-kouvola"},{"id":"nct05646303-mentacare-oy-oulu","cat":"research","name":"Mentacare Oy","city":"Oulu","country":"Finland","cc":"FI","lat":65.01824,"lon":25.47978,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Addiction & substance use"],"nct":"NCT05646303","study":"Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)","sstatus":"UNKNOWN","sponsor":"Clairvoyant Therapeutics","official":"Hannu Alho, MD (Addiktum Oy)","src":"https://clinicaltrials.gov/study/NCT05646303","phase":"Phase 2","enroll":128,"start":"2022-05-02","eid":"x:site:nct05646303-mentacare-oy-oulu"},{"id":"nct05646303-addiktum-oy-turku","cat":"research","name":"Addiktum Oy","city":"Turku","country":"Finland","cc":"FI","lat":60.45849,"lon":22.2726,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Addiction & substance use"],"nct":"NCT05646303","study":"Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)","sstatus":"UNKNOWN","sponsor":"Clairvoyant Therapeutics","official":"Hannu Alho, MD (Addiktum Oy)","src":"https://clinicaltrials.gov/study/NCT05646303","phase":"Phase 2","enroll":128,"start":"2022-05-02","eid":"x:site:nct05646303-addiktum-oy-turku"},{"id":"nct05068791-uab-beacon-tower-birmingham","cat":"research","name":"UAB Beacon Tower","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.51977,"lon":-86.79981,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"35209","condg":["Chronic pain & headache"],"status":"RECRUITING","nct":"NCT05068791","study":"Psilocybin-facilitated Treatment for Chronic Pain","sstatus":"RECRUITING","sponsor":"University of Alabama at Birmingham","src":"https://clinicaltrials.gov/study/NCT05068791","contact":{"n":"Peter Hendricks, PhD","p":"205-202-1387","e":"pshendricks@uabmc.edu"},"phase":"EARLY_Phase 1","enroll":30,"start":"2023-11-01","eid":"x:site:nct05068791-uab-beacon-tower-birmingham"},{"id":"nct06899594-lsu-health-shreveport-shreveport","cat":"research","name":"LSU Health Shreveport","city":"Shreveport","region":"Louisiana","country":"United States","cc":"US","lat":32.51757,"lon":-93.7618,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"71103","condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT06899594","study":"Psilocybin for Methamphetamine Addiction","sstatus":"RECRUITING","sponsor":"Kevin Murnane","official":"Kevin S Murnane, PhD (Louisiana State University Health Science Center Shreveport)","src":"https://clinicaltrials.gov/study/NCT06899594","contact":{"n":"Kevin S Murnane, PhD","p":"(318) 675-7830","e":"kevin.murnane@lsuhs.edu"},"phase":"EARLY_Phase 1","enroll":20,"start":"2025-04-04","eid":"x:site:nct06899594-lsu-health-shreveport-shreveport"},{"id":"nct07164755-king-s-college-london-institute-of-psychiatry-psychology-and-neurosc","cat":"research","name":"King's College London Institute of Psychiatry, Psychology and Neuroscience","city":"London","country":"United Kingdom","cc":"GB","lat":51.50989,"lon":-0.11609,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"SE5 8AF","condg":["Depression"],"nct":"NCT07164755","study":"Measurement of Serum Inflammatory Markers in Patients Treatment-resistant Depression Given Psilocybin","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"King's College London","src":"https://clinicaltrials.gov/study/NCT07164755","enroll":46,"start":"2021-06-21","eid":"x:site:nct07164755-king-s-college-london-institute-of-psychiatry-psychology-and-neurosc"},{"id":"nct03806985-va-connecticut-healthcare-system-west-haven","cat":"research","name":"VA Connecticut Healthcare System","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.27889,"lon":-72.94154,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"06516","condg":["PTSD & trauma","Chronic pain & headache"],"nct":"NCT03806985","study":"Effects of Psilocybin in Concussion Headache","sstatus":"TERMINATED","sponsor":"Yale University","src":"https://clinicaltrials.gov/study/NCT03806985","phase":"Phase 1","enroll":12,"start":"2019-03-28","eid":"x:site:nct03806985-va-connecticut-healthcare-system-west-haven"},{"id":"nct06067737-johns-hopkins-center-for-psychedelic-and-consciousness-research-balt","cat":"research","name":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29184,"lon":-76.60734,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT06067737","study":"Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder","sstatus":"RECRUITING","sponsor":"Johns Hopkins University","official":"Sandeep Nayak, MD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT06067737","contact":{"n":"Sandeep Nayak, MD","p":"410-550-2253","e":"smn@jhmi.edu"},"phase":"Phase 2","enroll":90,"start":"2024-02-08","eid":"x:site:nct06067737-johns-hopkins-center-for-psychedelic-and-consciousness-research-balt"},{"id":"nct07296328-nyu-langone-health-new-york","cat":"research","name":"NYU Langone Health","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70556,"lon":-74.01797,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10016","condg":["Other"],"nct":"NCT07296328","study":"Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter","sstatus":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","official":"Michael Bogenschutz, MD (NYU Langone Health)","src":"https://clinicaltrials.gov/study/NCT07296328","contact":{"n":"Eric Jackson, PhD","p":"212-992-9470","e":"Ej34@nyu.edu"},"phase":"Phase 2","enroll":25,"start":"2026-01-15","eid":"x:site:nct07296328-nyu-langone-health-new-york"},{"id":"nct02971605-behavioral-pharmacology-research-unit-johns-hopkins-bayview-medical-","cat":"research","name":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28986,"lon":-76.61788,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Healthy volunteers"],"nct":"NCT02971605","study":"Persisting Effects of Psilocybin","sstatus":"COMPLETED","sponsor":"Johns Hopkins University","official":"Frederick S Barrett, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT02971605","phase":"Phase 1/Phase 2","enroll":13,"start":"2017-07-01","eid":"x:site:nct02971605-behavioral-pharmacology-research-unit-johns-hopkins-bayview-medical-"},{"id":"nct07774702-university-of-alabama-at-birmingham-birmingham","cat":"research","name":"University of Alabama at Birmingham","city":"Birmingham","region":"Alabama","country":"United States","cc":"US","lat":33.50988,"lon":-86.79284,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"35294","condg":["Addiction & substance use"],"nct":"NCT07774702","study":"Psilocybin for Methamphetamine Use Disorder","sstatus":"NOT_YET_RECRUITING","sponsor":"Peter Hendricks","official":"Peter S Hendricks, PhD (University of Alabama at Birmingham)","src":"https://clinicaltrials.gov/study/NCT07774702","contact":{"n":"Seher Premani, MPH","p":"205-975-7721","e":"spremani@uab.edu"},"phase":"Phase 2","enroll":42,"start":"2027-02-01","eid":"x:site:nct07774702-university-of-alabama-at-birmingham-birmingham"},{"id":"nct04670081-charite-berlin-campus-mitte-department-of-psychiatry-and-psychothera","cat":"research","name":"Charité Berlin, Campus Mitte, Department of Psychiatry and Psychotherapy","city":"Berlin","country":"Germany","cc":"DE","lat":52.51566,"lon":13.39938,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10117","condg":["Depression"],"nct":"NCT04670081","study":"Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression","sstatus":"COMPLETED","sponsor":"Central Institute of Mental Health, Mannheim","official":"Gerhard Gründer, Prof. Dr. (Central Institute of Mental Health, Mannheim)","src":"https://clinicaltrials.gov/study/NCT04670081","phase":"Phase 2","enroll":144,"start":"2021-06-10","eid":"x:site:nct04670081-charite-berlin-campus-mitte-department-of-psychiatry-and-psychothera"},{"id":"nct04670081-central-institute-of-mental-health-cimh-mannheim","cat":"research","name":"Central Institute of Mental Health (CIMH)","city":"Mannheim","country":"Germany","cc":"DE","lat":49.48463,"lon":8.4604,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"68159","condg":["Depression"],"nct":"NCT04670081","study":"Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression","sstatus":"COMPLETED","sponsor":"Central Institute of Mental Health, Mannheim","official":"Gerhard Gründer, Prof. Dr. (Central Institute of Mental Health, Mannheim)","src":"https://clinicaltrials.gov/study/NCT04670081","phase":"Phase 2","enroll":144,"start":"2021-06-10","eid":"x:site:nct04670081-central-institute-of-mental-health-cimh-mannheim"},{"id":"nct05398484-university-of-colorado-anschutz-medical-campus-cu-amc-aurora","cat":"research","name":"University of Colorado Anschutz Medical campus (CU AMC)","city":"Aurora","region":"Colorado","country":"United States","cc":"US","lat":39.72609,"lon":-104.83093,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"80045","condg":["Cancer-related distress"],"status":"RECRUITING","nct":"NCT05398484","study":"Psilocybin Therapy in Advanced Cancer","sstatus":"RECRUITING","sponsor":"NYU Langone Health","official":"Stephen Ross, MD (NYU Langone Medical Center)","src":"https://clinicaltrials.gov/study/NCT05398484","contact":{"n":"Stacy Fischer, MD","p":"303-724-2406","e":"Stacy.Fischer@cuanschutz.edu"},"phase":"Phase 2/Phase 3","enroll":200,"start":"2023-05-24","eid":"x:site:nct05398484-university-of-colorado-anschutz-medical-campus-cu-amc-aurora"},{"id":"nct05398484-nyu-langone-health-new-york","cat":"research","name":"NYU Langone Health","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.70528,"lon":-73.99755,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10016","condg":["Cancer-related distress"],"status":"RECRUITING","nct":"NCT05398484","study":"Psilocybin Therapy in Advanced Cancer","sstatus":"RECRUITING","sponsor":"NYU Langone Health","official":"Stephen Ross, MD (NYU Langone Medical Center)","src":"https://clinicaltrials.gov/study/NCT05398484","contact":{"n":"Sydney Weiner, MA","p":"212-263-6283","e":"sydney.weiner@nyulangone.org"},"phase":"Phase 2/Phase 3","enroll":200,"start":"2023-05-24","eid":"x:site:nct05398484-nyu-langone-health-new-york"},{"id":"nct05723276-south-london-and-maudsley-nhs-foundation-trust-london","cat":"research","name":"South London and Maudsley NHS Foundation Trust","city":"London","country":"United Kingdom","cc":"GB","lat":51.52053,"lon":-0.11892,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Other"],"nct":"NCT05723276","study":"Psilocybin in Functional Neurological Disorder","sstatus":"COMPLETED","sponsor":"King's College London","src":"https://clinicaltrials.gov/study/NCT05723276","phase":"N/A","enroll":20,"start":"2024-02-14","eid":"x:site:nct05723276-south-london-and-maudsley-nhs-foundation-trust-london"},{"id":"nct06782724-national-institute-of-mental-health-prague","cat":"research","name":"National Institute of Mental Health","city":"Prague","country":"Czechia","cc":"CZ","lat":50.08188,"lon":14.41892,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression","Neurology & cognition"],"status":"RECRUITING","nct":"NCT06782724","study":"Psilocybin Therapy for Psychological Distress in Palliative Patients","sstatus":"RECRUITING","sponsor":"University Medical Center Groningen","src":"https://clinicaltrials.gov/study/NCT06782724","contact":{"n":"Tomas Palenicek","p":"050 361 2008","e":"tomas.palenicek@nudz.cz"},"phase":"Phase 2","enroll":108,"start":"2025-07-01","eid":"x:site:nct06782724-national-institute-of-mental-health-prague"},{"id":"nct06782724-bispebjerg-hospital-copenhagen","cat":"research","name":"Bispebjerg Hospital","city":"Copenhagen","country":"Denmark","cc":"DK","lat":55.67486,"lon":12.55814,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression","Neurology & cognition"],"status":"RECRUITING","nct":"NCT06782724","study":"Psilocybin Therapy for Psychological Distress in Palliative Patients","sstatus":"RECRUITING","sponsor":"University Medical Center Groningen","src":"https://clinicaltrials.gov/study/NCT06782724","contact":{"n":"Kirsten Svenstrup","p":"050 361 2008","e":"kirsten.svenstrup@regionh.dk"},"phase":"Phase 2","enroll":108,"start":"2025-07-01","eid":"x:site:nct06782724-bispebjerg-hospital-copenhagen"},{"id":"nct06782724-university-medical-center-groningen-groningen","cat":"research","name":"University Medical Center Groningen","city":"Groningen","region":"Provincie Groningen","country":"Netherlands","cc":"NL","lat":53.20717,"lon":6.57331,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression","Neurology & cognition"],"status":"RECRUITING","nct":"NCT06782724","study":"Psilocybin Therapy for Psychological Distress in Palliative Patients","sstatus":"RECRUITING","sponsor":"University Medical Center Groningen","src":"https://clinicaltrials.gov/study/NCT06782724","contact":{"n":"Robert Schoevers","p":"050 361 2008","e":"r.a.schoevers@umcg.nl"},"phase":"Phase 2","enroll":108,"start":"2025-07-01","eid":"x:site:nct06782724-university-medical-center-groningen-groningen"},{"id":"nct06782724-champalimaud-foundation-lisbon","cat":"research","name":"Champalimaud Foundation","city":"Lisbon","country":"Portugal","cc":"PT","lat":38.7226,"lon":-9.15032,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression","Neurology & cognition"],"status":"RECRUITING","nct":"NCT06782724","study":"Psilocybin Therapy for Psychological Distress in Palliative Patients","sstatus":"RECRUITING","sponsor":"University Medical Center Groningen","src":"https://clinicaltrials.gov/study/NCT06782724","contact":{"n":"Albino Oliveira-Maia","p":"050 361 2008","e":"albino.maia@neuro.fchampalimaud.org"},"phase":"Phase 2","enroll":108,"start":"2025-07-01","eid":"x:site:nct06782724-champalimaud-foundation-lisbon"},{"id":"nct07449351-olin-neuropsychiatry-research-center-hartford","cat":"research","name":"Olin Neuropsychiatry Research Center","city":"Hartford","region":"Connecticut","country":"United States","cc":"US","lat":41.76479,"lon":-72.67356,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"06106","condg":["Other"],"nct":"NCT07449351","study":"Psilocybin Microdosing on Cognition, Mood and Quality of Life","sstatus":"NOT_YET_RECRUITING","sponsor":"Yale University","official":"Godfrey Pearlson, MD (Yale University)","src":"https://clinicaltrials.gov/study/NCT07449351","contact":{"n":"Diana King","p":"860-545-7563","e":"diana.king@hhchealth.org"},"phase":"EARLY_Phase 1","enroll":20,"start":"2026-10-01","eid":"x:site:nct07449351-olin-neuropsychiatry-research-center-hartford"},{"id":"nct07296094-brigham-and-women-s-hospital-boston","cat":"research","name":"Brigham and Women's Hospital","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36619,"lon":-71.04777,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"02115","condg":["Addiction & substance use"],"nct":"NCT07296094","study":"Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder","sstatus":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","official":"Joji Suzuki, MD (Brigham and Women's Hospital)","src":"https://clinicaltrials.gov/study/NCT07296094","contact":{"n":"Emily A Clinical Research Project Manager, BA, MS, DNP, RN, PMHNP-BC, PMP","p":"6175250676","e":"enolan4@bwh.harvard.edu"},"phase":"Phase 2","enroll":36,"start":"2026-11-15","eid":"x:site:nct07296094-brigham-and-women-s-hospital-boston"},{"id":"nct05416229-psychiatric-center-copenhagen-frederiksberg-hospital-frederiksberg","cat":"research","name":"Psychiatric Center Copenhagen, Frederiksberg Hospital","city":"Frederiksberg","country":"Denmark","cc":"DK","lat":55.68762,"lon":12.52479,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"2000","condg":["Addiction & substance use"],"nct":"NCT05416229","study":"Psilocybin-assisted Therapy for Treatment of Alcohol Use Disorder","sstatus":"COMPLETED","sponsor":"Anders Fink-Jensen, MD, DMSci","official":"Anders Fink-Jensen, Professor (Psychiatric Center Copenhagen, Frederiksberg Hospital)","src":"https://clinicaltrials.gov/study/NCT05416229","phase":"Phase 2","enroll":60,"start":"2023-09-01","eid":"x:site:nct05416229-psychiatric-center-copenhagen-frederiksberg-hospital-frederiksberg"},{"id":"nct04505189-imperial-college-hammersmith-campus-london","cat":"research","name":"Imperial College Hammersmith campus","city":"London","country":"United Kingdom","cc":"GB","lat":51.50679,"lon":-0.12946,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"W12 0NN","condg":["Eating disorders"],"nct":"NCT04505189","study":"Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study","sstatus":"COMPLETED","sponsor":"Imperial College London","src":"https://clinicaltrials.gov/study/NCT04505189","phase":"Phase 1/Phase 2","enroll":21,"start":"2021-05-28","eid":"x:site:nct04505189-imperial-college-hammersmith-campus-london"},{"id":"nct05042466-ross-allison-npi-1437519899-administrator-of-study-bozeman","cat":"research","name":"Ross Allison NPI #1437519899 Administrator Of Study","city":"Bozeman","region":"Montana","country":"United States","cc":"US","lat":45.66916,"lon":-111.04717,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"59718","condg":["PTSD & trauma"],"nct":"NCT05042466","study":"Northwest Therapies Trauma Psilocybin Study Compassionate Use Study","sstatus":"UNKNOWN","sponsor":"NWTraumatherapies","official":"Ross M Allison, Provider (NW Therapies Trauma Unit)","src":"https://clinicaltrials.gov/study/NCT05042466","contact":{"n":"Ross M Allison, Plant Medicine On Boarding","p":"206-234-3087","e":"geriatric.bozemanhealth@gmail.com"},"phase":"Phase 1","enroll":30,"start":"2023-09-03","eid":"x:site:nct05042466-ross-allison-npi-1437519899-administrator-of-study-bozeman"},{"id":"nct07516405-university-of-california-san-francisco-ucsf-department-of-neurology-","cat":"research","name":"University of California San Francisco (UCSF) Department of Neurology","city":"San Francisco","region":"California","country":"United States","cc":"US","lat":37.76397,"lon":-122.4302,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"94158","condg":["Healthy volunteers"],"status":"RECRUITING","nct":"NCT07516405","study":"Safety and Tolerability Trial of Psilocybin in Healthy Older Adults","sstatus":"RECRUITING","sponsor":"University of Colorado, Denver","src":"https://clinicaltrials.gov/study/NCT07516405","contact":{"n":"Jennifer Mitchell, PhD","p":"510-985-3522","e":"psy.elder@ucsf.edu"},"phase":"Phase 1","enroll":40,"start":"2026-04-01","eid":"x:site:nct07516405-university-of-california-san-francisco-ucsf-department-of-neurology-"},{"id":"nct07516405-university-of-colorado-anschutz-medical-campus-aurora","cat":"research","name":"University of Colorado Anschutz Medical Campus","city":"Aurora","region":"Colorado","country":"United States","cc":"US","lat":39.72581,"lon":-104.84128,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"80045","condg":["Healthy volunteers"],"status":"RECRUITING","nct":"NCT07516405","study":"Safety and Tolerability Trial of Psilocybin in Healthy Older Adults","sstatus":"RECRUITING","sponsor":"University of Colorado, Denver","src":"https://clinicaltrials.gov/study/NCT07516405","contact":{"n":"Mary Mancuso, MS","p":"303-724-5729","e":"inspire@cuanschutz.edu"},"phase":"Phase 1","enroll":40,"start":"2026-04-01","eid":"x:site:nct07516405-university-of-colorado-anschutz-medical-campus-aurora"},{"id":"nct07516405-emory-university-brain-health-center-atlanta","cat":"research","name":"Emory University Brain Health Center","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.74604,"lon":-84.39546,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30329","condg":["Healthy volunteers"],"status":"RECRUITING","nct":"NCT07516405","study":"Safety and Tolerability Trial of Psilocybin in Healthy Older Adults","sstatus":"RECRUITING","sponsor":"University of Colorado, Denver","src":"https://clinicaltrials.gov/study/NCT07516405","contact":{"n":"Tanja Mletzko, MA","p":"404-778-6663","e":"study@emory.edu"},"phase":"Phase 1","enroll":40,"start":"2026-04-01","eid":"x:site:nct07516405-emory-university-brain-health-center-atlanta"},{"id":"nct07516405-dana-farber-cancer-institute-boston","cat":"research","name":"Dana-Farber Cancer Institute","city":"Boston","region":"Massachusetts","country":"United States","cc":"US","lat":42.36921,"lon":-71.06528,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"02215","condg":["Healthy volunteers"],"status":"RECRUITING","nct":"NCT07516405","study":"Safety and Tolerability Trial of Psilocybin in Healthy Older Adults","sstatus":"RECRUITING","sponsor":"University of Colorado, Denver","src":"https://clinicaltrials.gov/study/NCT07516405","contact":{"n":"Gabriel Najarian","p":"3037245729","e":"patresearch@dfci.harvard.edu"},"phase":"Phase 1","enroll":40,"start":"2026-04-01","eid":"x:site:nct07516405-dana-farber-cancer-institute-boston"},{"id":"nct07516405-university-of-nebraska-medical-center-omaha","cat":"research","name":"University of Nebraska Medical Center","city":"Omaha","region":"Nebraska","country":"United States","cc":"US","lat":41.26694,"lon":-95.92918,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"68105","condg":["Healthy volunteers"],"status":"RECRUITING","nct":"NCT07516405","study":"Safety and Tolerability Trial of Psilocybin in Healthy Older Adults","sstatus":"RECRUITING","sponsor":"University of Colorado, Denver","src":"https://clinicaltrials.gov/study/NCT07516405","contact":{"n":"Jennifer Wettschreck, MS","p":"402-559-3342","e":"jemurray@unmc.edu"},"phase":"Phase 1","enroll":40,"start":"2026-04-01","eid":"x:site:nct07516405-university-of-nebraska-medical-center-omaha"},{"id":"nct07516405-new-york-university-langone-health-center-for-psychedelic-medicine-n","cat":"research","name":"New York University Langone Health, Center for Psychedelic Medicine","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71705,"lon":-73.99425,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10016","condg":["Healthy volunteers"],"status":"RECRUITING","nct":"NCT07516405","study":"Safety and Tolerability Trial of Psilocybin in Healthy Older Adults","sstatus":"RECRUITING","sponsor":"University of Colorado, Denver","src":"https://clinicaltrials.gov/study/NCT07516405","contact":{"n":"Denise Balili, MS","p":"646-501-2623","e":"denise.balili@nyulangone.org"},"phase":"Phase 1","enroll":40,"start":"2026-04-01","eid":"x:site:nct07516405-new-york-university-langone-health-center-for-psychedelic-medicine-n"},{"id":"nct07391332-nantes-university-hospital-nantes","cat":"research","name":"Nantes University Hospital","city":"Nantes","country":"France","cc":"FR","lat":47.2141,"lon":-1.54663,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Addiction & substance use"],"nct":"NCT07391332","study":"Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a Pilot Study","sstatus":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","src":"https://clinicaltrials.gov/study/NCT07391332","contact":{"n":"Benoit SCHRECK","p":"+33.2.40.84.76.20","e":"benoit.schreck@chu-nantes.fr"},"phase":"Phase 2","enroll":30,"start":"2026-04-01","eid":"x:site:nct07391332-nantes-university-hospital-nantes"},{"id":"nct06319378-region-vastra-gotaland-gothenburg","cat":"research","name":"region Västra Götaland","city":"Gothenburg","region":"Göteborg","country":"Sweden","cc":"SE","lat":57.69855,"lon":11.97474,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"status":"RECRUITING","nct":"NCT06319378","study":"Cancer Related Major Depression Treated With a Single Dose of Psilocybin","sstatus":"RECRUITING","sponsor":"Section for Affective Disorders; Northern Stockholm Psychiatry","official":"Johan Lundberg, MD PhD (Norra Stockholms Psykiatri and Karolinska Institutet)","src":"https://clinicaltrials.gov/study/NCT06319378","contact":{"n":"Helena Werin Sjögren, MD","p":"0812340000","e":"helena.werin.sjogren@vgregion.se"},"phase":"Phase 2","enroll":100,"start":"2024-04-19","eid":"x:site:nct06319378-region-vastra-gotaland-gothenburg"},{"id":"nct06319378-norra-stockholms-psykiatri-stockholm","cat":"research","name":"Norra Stockholms Psykiatri","city":"Stockholm","region":"Stockholm County","country":"Sweden","cc":"SE","lat":59.33234,"lon":18.07045,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"status":"RECRUITING","nct":"NCT06319378","study":"Cancer Related Major Depression Treated With a Single Dose of Psilocybin","sstatus":"RECRUITING","sponsor":"Section for Affective Disorders; Northern Stockholm Psychiatry","official":"Johan Lundberg, MD PhD (Norra Stockholms Psykiatri and Karolinska Institutet)","src":"https://clinicaltrials.gov/study/NCT06319378","contact":{"n":"Evana Lopez, MD","p":"0812340000","e":"evana.lopez@ki.se"},"phase":"Phase 2","enroll":100,"start":"2024-04-19","eid":"x:site:nct06319378-norra-stockholms-psykiatri-stockholm"},{"id":"nct06319378-psykiatriska-kliniken-akademiska-sjukhuset-uppsala","cat":"research","name":"Psykiatriska Kliniken, Akademiska Sjukhuset","city":"Uppsala","region":"Uppsala County","country":"Sweden","cc":"SE","lat":59.86131,"lon":17.62689,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"status":"RECRUITING","nct":"NCT06319378","study":"Cancer Related Major Depression Treated With a Single Dose of Psilocybin","sstatus":"RECRUITING","sponsor":"Section for Affective Disorders; Northern Stockholm Psychiatry","official":"Johan Lundberg, MD PhD (Norra Stockholms Psykiatri and Karolinska Institutet)","src":"https://clinicaltrials.gov/study/NCT06319378","contact":{"n":"Evana Lopez","p":"0812340000","e":"evana.lopez@ki.se"},"phase":"Phase 2","enroll":100,"start":"2024-04-19","eid":"x:site:nct06319378-psykiatriska-kliniken-akademiska-sjukhuset-uppsala"},{"id":"nct06319378-orebro-sjukhus-orebro","cat":"research","name":"Örebro sjukhus","city":"Örebro","region":"Örebro County","country":"Sweden","cc":"SE","lat":59.28245,"lon":15.20514,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"status":"RECRUITING","nct":"NCT06319378","study":"Cancer Related Major Depression Treated With a Single Dose of Psilocybin","sstatus":"RECRUITING","sponsor":"Section for Affective Disorders; Northern Stockholm Psychiatry","official":"Johan Lundberg, MD PhD (Norra Stockholms Psykiatri and Karolinska Institutet)","src":"https://clinicaltrials.gov/study/NCT06319378","contact":{"n":"Axel Nordenskjöld, MD PhD","p":"0812340000","e":"johan.lundberg@ki.se"},"phase":"Phase 2","enroll":100,"start":"2024-04-19","eid":"x:site:nct06319378-orebro-sjukhus-orebro"},{"id":"nct07118332-department-of-veterans-affairs-west-haven","cat":"research","name":"Department of Veterans Affairs","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.28077,"lon":-72.95519,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"06516","condg":["Addiction & substance use","Chronic pain & headache"],"status":"NOT_YET_RECRUITING","nct":"NCT07118332","study":"Psilocybin as a Treatment for Chronic Pain in Smokers","sstatus":"RECRUITING","sponsor":"Yale University","src":"https://clinicaltrials.gov/study/NCT07118332","contact":{"n":"Mehmet Sofuoglu, M.D., Ph.D.","p":"203-932-5711","e":"Mehmet.Sofuoglu@va.gov"},"phase":"EARLY_Phase 1","enroll":10,"start":"2026-07-06","eid":"x:site:nct07118332-department-of-veterans-affairs-west-haven"},{"id":"nct07118332-department-of-veterans-affairs-west-haven-2","cat":"research","name":"Department of Veterans Affairs","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.28058,"lon":-72.94691,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"06516","condg":["Addiction & substance use","Chronic pain & headache"],"status":"RECRUITING","nct":"NCT07118332","study":"Psilocybin as a Treatment for Chronic Pain in Smokers","sstatus":"RECRUITING","sponsor":"Yale University","src":"https://clinicaltrials.gov/study/NCT07118332","contact":{"n":"Mehmet Sofuoglu,, M.D., Ph.D.","p":"203-932-5711 ext 12299","e":"Mehmet.sofuoglu@va.gov"},"phase":"EARLY_Phase 1","enroll":10,"start":"2026-07-06","eid":"x:site:nct07118332-department-of-veterans-affairs-west-haven-2"},{"id":"nct06041152-centre-for-addiction-and-mental-health-toronto","cat":"research","name":"Centre for Addiction and Mental Health","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.71062,"lon":-79.39483,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"M5T 1R8","condg":["Neurology & cognition"],"nct":"NCT06041152","study":"Does Psilocybin Change Synaptic Density in Amnestic Mild Cognitive Impairment","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Centre for Addiction and Mental Health","official":"Philip Gerretsen, MD, PhD (Centre for Addiction and Mental Health)","src":"https://clinicaltrials.gov/study/NCT06041152","phase":"Phase 2","enroll":10,"start":"2023-11-27","eid":"x:site:nct06041152-centre-for-addiction-and-mental-health-toronto"},{"id":"nct07373535-jewish-general-hospital-montreal","cat":"research","name":"Jewish General Hospital","city":"Montreal","region":"Quebec","country":"Canada","cc":"CA","lat":45.50945,"lon":-73.59463,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"H3T 1E2","condg":["Depression"],"nct":"NCT07373535","study":"Understanding Music and Mindfulness Preferences in Psilocybin-Assisted Psychotherapy","sstatus":"NOT_YET_RECRUITING","sponsor":"Kyle Greenway","official":"Kyle T Greenway, MD (Jewish General Hospital)","src":"https://clinicaltrials.gov/study/NCT07373535","contact":{"n":"Julien Thibault Lévesque","p":"(514) 340-8222","e":"julien.thibaultlevesque.comtl@ssss.gouv.qc.ca"},"phase":"Phase 2","enroll":16,"start":"2026-05","eid":"x:site:nct07373535-jewish-general-hospital-montreal"},{"id":"nct07373535-jewish-general-hospital-montreal-2","cat":"research","name":"Jewish General Hospital","city":"Montreal","region":"Quebec","country":"Canada","cc":"CA","lat":45.51199,"lon":-73.58005,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression"],"nct":"NCT07373535","study":"Understanding Music and Mindfulness Preferences in Psilocybin-Assisted Psychotherapy","sstatus":"NOT_YET_RECRUITING","sponsor":"Kyle Greenway","official":"Kyle T Greenway, MD (Jewish General Hospital)","src":"https://clinicaltrials.gov/study/NCT07373535","phase":"Phase 2","enroll":16,"start":"2026-05","eid":"x:site:nct07373535-jewish-general-hospital-montreal-2"},{"id":"nct06724289-university-of-virginia-charlottesville","cat":"research","name":"University of Virginia","city":"Charlottesville","region":"Virginia","country":"United States","cc":"US","lat":38.03924,"lon":-78.48059,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"22903","condg":["Other"],"status":"RECRUITING","nct":"NCT06724289","study":"Psilocybin for Prolonged Grief Disorder","sstatus":"RECRUITING","sponsor":"University of Virginia","official":"Jennifer K Penberthy, PhD (University of Virginia)","src":"https://clinicaltrials.gov/study/NCT06724289","contact":{"n":"Fatma Wise, PhD","p":"(434) 243-0568","e":"uvagrieftrial@uvahealth.org"},"phase":"EARLY_Phase 1","enroll":12,"start":"2026-03-24","eid":"x:site:nct06724289-university-of-virginia-charlottesville"},{"id":"nct07332143-emory-university-hospital-atlanta","cat":"research","name":"Emory University Hospital","city":"Atlanta","region":"Georgia","country":"United States","cc":"US","lat":33.75648,"lon":-84.39254,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"30322","condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT07332143","study":"Psilocybin-Assisted Therapy","sstatus":"RECRUITING","sponsor":"Emory University","official":"Anna Wise, PhD (Emory University)","src":"https://clinicaltrials.gov/study/NCT07332143","contact":{"n":"Anna Wise, PhD","p":"404-712-1035","e":"patstudy@emory.edu"},"phase":"Phase 2","enroll":150,"start":"2026-06-08","eid":"x:site:nct07332143-emory-university-hospital-atlanta"},{"id":"nct06442423-connecticut-mental-health-center-yale-school-of-medicine-new-haven","cat":"research","name":"Connecticut Mental Health Center - Yale School of Medicine","city":"New Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.31403,"lon":-72.93094,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"06519","condg":["Depression","Anxiety","PTSD & trauma","Addiction & substance use"],"status":"RECRUITING","nct":"NCT06442423","study":"Open-Label Psilocybin Study in Transdiagnostic Population","sstatus":"RECRUITING","sponsor":"Yale University","official":"Benjamin Kelmendi, MD (Yale University); Gabrielle Agin-Liebes, PhD (Yale University)","src":"https://clinicaltrials.gov/study/NCT06442423","contact":{"n":"Gabby Agin-Liebes, PhD","p":"(203) 444-1795","e":"enact@yale.edu"},"phase":"Phase 1","enroll":50,"start":"2024-10-17","eid":"x:site:nct06442423-connecticut-mental-health-center-yale-school-of-medicine-new-haven"},{"id":"nct05947383-sunstone-medical-pc-rockville","cat":"research","name":"Sunstone Medical, PC","city":"Rockville","region":"Maryland","country":"United States","cc":"US","lat":39.09336,"lon":-77.1529,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"20850","condg":["Depression","Cancer-related distress"],"nct":"NCT05947383","study":"Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Sunstone Medical","src":"https://clinicaltrials.gov/study/NCT05947383","phase":"Phase 2","enroll":56,"start":"2023-10-23","eid":"x:site:nct05947383-sunstone-medical-pc-rockville"},{"id":"nct06592833-icahn-school-of-medicine-at-mount-sinai-center-for-psychedelic-thera","cat":"research","name":"Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.72326,"lon":-74.0047,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10025","condg":["Depression"],"status":"RECRUITING","nct":"NCT06592833","study":"Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder","sstatus":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","official":"James Murrough (Icahn School of Medicine at Mount Sinai); Rachel Fremont (Icahn School of Medicine at Mount Sinai)","src":"https://clinicaltrials.gov/study/NCT06592833","contact":{"n":"Depression and Anxiety Center","p":"212-241-6539","e":"dac@mssm.edu"},"phase":"Phase 2","enroll":60,"start":"2025-02-25","eid":"x:site:nct06592833-icahn-school-of-medicine-at-mount-sinai-center-for-psychedelic-thera"},{"id":"nct07566104-ucla-semel-institute-los-angeles","cat":"research","name":"UCLA Semel Institute","city":"Los Angeles","region":"California","country":"United States","cc":"US","lat":34.04936,"lon":-118.23337,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"90095","condg":["Depression","Neurology & cognition"],"nct":"NCT07566104","study":"Group PACBT for Depression","sstatus":"NOT_YET_RECRUITING","sponsor":"University of California, Los Angeles","src":"https://clinicaltrials.gov/study/NCT07566104","contact":{"n":"Shelby Grody","p":"3108254354","e":"UCLAPAT@mednet.ucla.edu"},"phase":"Phase 2","enroll":30,"start":"2027-01","eid":"x:site:nct07566104-ucla-semel-institute-los-angeles"},{"id":"nct06643637-cmax-clinical-research-adelaide","cat":"research","name":"CMAX Clinical Research","city":"Adelaide","region":"South Australia","country":"Australia","cc":"AU","lat":-34.93106,"lon":138.59463,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"5000","condg":["Healthy volunteers"],"nct":"NCT06643637","study":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy Participants","sstatus":"COMPLETED","sponsor":"MycoMedica Life Sciences PBC","src":"https://clinicaltrials.gov/study/NCT06643637","phase":"Phase 1","enroll":16,"start":"2024-11-08","eid":"x:site:nct06643637-cmax-clinical-research-adelaide"},{"id":"nct03341689-va-connecticut-healthcare-system-west-haven-campus-west-haven","cat":"research","name":"VA Connecticut Healthcare System, West Haven Campus","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.26289,"lon":-72.94427,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"06516","condg":["Chronic pain & headache"],"nct":"NCT03341689","study":"Psilocybin for the Treatment of Migraine Headache","sstatus":"COMPLETED","sponsor":"Yale University","src":"https://clinicaltrials.gov/study/NCT03341689","phase":"Phase 1","enroll":14,"start":"2017-11-01","eid":"x:site:nct03341689-va-connecticut-healthcare-system-west-haven-campus-west-haven"},{"id":"nct04905121-king-s-college-london-london","cat":"research","name":"King's College London","city":"London","country":"United Kingdom","cc":"GB","lat":51.50029,"lon":-0.12692,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Chronic pain & headache"],"nct":"NCT04905121","study":"Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)","sstatus":"TERMINATED","sponsor":"Beckley Psytech Limited","src":"https://clinicaltrials.gov/study/NCT04905121","phase":"Phase 1","enroll":4,"start":"2021-08-11","eid":"x:site:nct04905121-king-s-college-london-london"},{"id":"nct03300947-university-of-arizona-tucson","cat":"research","name":"University of Arizona","city":"Tucson","region":"Arizona","country":"United States","cc":"US","lat":32.22847,"lon":-110.93726,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"85724","condg":["OCD"],"nct":"NCT03300947","study":"Psilocybin for Treatment of Obsessive Compulsive Disorder","sstatus":"COMPLETED","sponsor":"University of Arizona","official":"Francisco A. Moreno, MD (Professor of Psychiatry and Associate Vice President, Diversity and Inclusion)","src":"https://clinicaltrials.gov/study/NCT03300947","phase":"Phase 1","enroll":15,"start":"2019-01-02","eid":"x:site:nct03300947-university-of-arizona-tucson"},{"id":"nct07406828-upmc-presbyterian-pittsburgh","cat":"research","name":"UPMC Presbyterian","city":"Pittsburgh","region":"Pennsylvania","country":"United States","cc":"US","lat":40.42871,"lon":-79.99989,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"15213","condg":["Chronic pain & headache"],"nct":"NCT07406828","study":"Psilocybin After Trauma Surgery for Pain","sstatus":"NOT_YET_RECRUITING","sponsor":"Trent Emerick","official":"Trent D. Emerick (University of Pittsburgh / UPMC)","src":"https://clinicaltrials.gov/study/NCT07406828","contact":{"n":"Trent Emerick, MD","p":"412-692-2234","e":"emericktd@upmc.edu"},"phase":"Phase 1","enroll":70,"start":"2027-12-31","eid":"x:site:nct07406828-upmc-presbyterian-pittsburgh"},{"id":"nct07791901-arthur-child-comprehensive-cancer-centre-calgary","cat":"research","name":"Arthur Child Comprehensive Cancer Centre","city":"Calgary","region":"Alberta","country":"Canada","cc":"CA","lat":51.05882,"lon":-114.08383,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"T2N 4N1","condg":["Cancer-related distress"],"nct":"NCT07791901","study":"MB-PAT for Demoralization in Advanced Cancer ('PAT-MIND') Trial","sstatus":"NOT_YET_RECRUITING","sponsor":"University of Calgary","official":"Linda E. Carlson, Ph.D., R.Psych, FCAHS, FABMR (University of Calgary); Ron Shore, MPA, PhD (Queen's University)","src":"https://clinicaltrials.gov/study/NCT07791901","contact":{"n":"Christopher P. Albertyn, PhD","p":"587-231-3984","e":"christopher.albertyn@ucalgary.ca"},"phase":"Phase 2","enroll":60,"start":"2026-10-30","eid":"x:site:nct07791901-arthur-child-comprehensive-cancer-centre-calgary"},{"id":"nct07791901-providence-care-hospital-kingston","cat":"research","name":"Providence Care Hospital","city":"Kingston","region":"Ontario","country":"Canada","cc":"CA","lat":44.23912,"lon":-76.47613,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"K7L 4X3","condg":["Cancer-related distress"],"nct":"NCT07791901","study":"MB-PAT for Demoralization in Advanced Cancer ('PAT-MIND') Trial","sstatus":"NOT_YET_RECRUITING","sponsor":"University of Calgary","official":"Linda E. Carlson, Ph.D., R.Psych, FCAHS, FABMR (University of Calgary); Ron Shore, MPA, PhD (Queen's University)","src":"https://clinicaltrials.gov/study/NCT07791901","contact":{"n":"Claudio N Soares, MD, PhD, FRCPC, MBA","p":"587-231-3984","e":"claudio.soares@kingstonhsc.ca"},"phase":"Phase 2","enroll":60,"start":"2026-10-30","eid":"x:site:nct07791901-providence-care-hospital-kingston"},{"id":"nct04123314-johns-hopkins-center-for-psychedelic-and-consciousness-research-balt","cat":"research","name":"Johns Hopkins Center for Psychedelic and Consciousness Research","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29852,"lon":-76.61798,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Depression","Neurology & cognition"],"status":"RECRUITING","nct":"NCT04123314","study":"Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease","sstatus":"RECRUITING","sponsor":"Johns Hopkins University","official":"Albert Garcia-Romeu, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT04123314","contact":{"n":"Ian Geithner, MPS","p":"410-550-5466","e":"igeithn1@jhmi.edu"},"phase":"EARLY_Phase 1","enroll":20,"start":"2021-03-24","eid":"x:site:nct04123314-johns-hopkins-center-for-psychedelic-and-consciousness-research-balt"},{"id":"nct06200155-md-anderson-cancer-center-houston","cat":"research","name":"MD Anderson Cancer Center","city":"Houston","region":"Texas","country":"United States","cc":"US","lat":29.76069,"lon":-95.36576,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"77030","condg":["Depression","Anxiety","Cancer-related distress"],"status":"RECRUITING","nct":"NCT06200155","study":"Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy","sstatus":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","official":"Moran Amit, MD (M.D. Anderson Cancer Center)","src":"https://clinicaltrials.gov/study/NCT06200155","contact":{"n":"Moran Amit, MD","p":"713-794-5304","e":"mamit@mdanderson.org"},"phase":"Phase 2","enroll":48,"start":"2024-04-16","eid":"x:site:nct06200155-md-anderson-cancer-center-houston"},{"id":"nct06992999-university-of-arizona-tucson-tucson","cat":"research","name":"University of Arizona-Tucson","city":"Tucson","region":"Arizona","country":"United States","cc":"US","lat":32.22988,"lon":-110.93406,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"85724","condg":["OCD"],"nct":"NCT06992999","study":"Psilocybin for Treatment of OCD-2","sstatus":"NOT_YET_RECRUITING","sponsor":"Francisco A Moreno","official":"Francisco Moreno, MD (University of Arizona, College of Medicine, Tucson)","src":"https://clinicaltrials.gov/study/NCT06992999","contact":{"n":"Esmeralda Terrazas","p":"520-626-8000","e":"esmeralda97h@arizona.edu"},"phase":"Phase 1/Phase 2","enroll":20,"start":"2026-09-08","eid":"x:site:nct06992999-university-of-arizona-tucson-tucson"},{"id":"nct06386003-st-michael-s-hospital-unity-health-toronto-toronto","cat":"research","name":"St. Michael's Hospital, Unity Health Toronto","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70149,"lon":-79.4032,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"M5S 1A1","condg":["PTSD & trauma"],"status":"RECRUITING","nct":"NCT06386003","study":"Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD","sstatus":"RECRUITING","sponsor":"Unity Health Toronto","src":"https://clinicaltrials.gov/study/NCT06386003","contact":{"n":"Venkat Bhat","p":"4163604000","e":"Venkat.Bhat@unityhealth.to"},"phase":"Phase 2","enroll":15,"start":"2026-06","eid":"x:site:nct06386003-st-michael-s-hospital-unity-health-toronto-toronto"},{"id":"nct05243329-halucenex-life-sciences-inc-windsor","cat":"research","name":"Halucenex Life Sciences Inc.","city":"Windsor","region":"Nova Scotia","country":"Canada","cc":"CA","lat":42.29843,"lon":-83.00605,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"B0N2T0","condg":["PTSD & trauma"],"nct":"NCT05243329","study":"Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder","sstatus":"UNKNOWN","sponsor":"Halucenex Life Sciences Inc.","official":"Lisa Batten, PhD (Halucenex Life Sciences); Paige Stevens, MD (Contracted)","src":"https://clinicaltrials.gov/study/NCT05243329","phase":"Phase 2","enroll":20,"start":"2022-10-03","eid":"x:site:nct05243329-halucenex-life-sciences-inc-windsor"},{"id":"nct07180108-center-for-psychedelics-and-consciousness-research-in-the-behavioral","cat":"research","name":"Center for Psychedelics and Consciousness Research in the Behavioral Biology Research Center","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28214,"lon":-76.61967,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Other"],"status":"RECRUITING","nct":"NCT07180108","study":"PRoMiSS: Psilocybin and the Role of Music in Set and Setting","sstatus":"RECRUITING","sponsor":"Johns Hopkins University","official":"Frederick S Barrett, PhD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT07180108","contact":{"n":"Albert Garcia-Romeu, PhD","p":"786-239-7990","e":"AGarci33@jhmi.edu"},"phase":"Phase 1","enroll":100,"start":"2025-08-12","eid":"x:site:nct07180108-center-for-psychedelics-and-consciousness-research-in-the-behavioral"},{"id":"nct06225232-macanxiety-research-centre-hamilton","cat":"research","name":"MacAnxiety Research Centre","city":"Hamilton","region":"Ontario","country":"Canada","cc":"CA","lat":43.24573,"lon":-79.84921,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"L8S 1B8","condg":["Addiction & substance use"],"nct":"NCT06225232","study":"Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"McMaster University","src":"https://clinicaltrials.gov/study/NCT06225232","phase":"Phase 2","enroll":16,"start":"2025-03-21","eid":"x:site:nct06225232-macanxiety-research-centre-hamilton"},{"id":"nct05995769-university-of-calgary-calgary","cat":"research","name":"University of Calgary","city":"Calgary","region":"Alberta","country":"Canada","cc":"CA","lat":51.03952,"lon":-114.0924,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"T2N 4Z6","condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT05995769","study":"Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder","sstatus":"RECRUITING","sponsor":"University of Calgary","official":"Leah Mayo, PhD (University of Calgary)","src":"https://clinicaltrials.gov/study/NCT05995769","contact":{"n":"Kaitlin O'Grady","p":"587-893-0257","e":"pactlab@ucalgary.ca"},"phase":"Phase 2","enroll":128,"start":"2024-03-20","eid":"x:site:nct05995769-university-of-calgary-calgary"},{"id":"nct05866471-university-of-wisconsin-madison-madison","cat":"research","name":"University of Wisconsin - Madison","city":"Madison","region":"Wisconsin","country":"United States","cc":"US","lat":43.06914,"lon":-89.41323,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"53715","condg":["Healthy volunteers"],"status":"RECRUITING","nct":"NCT05866471","study":"The ENHANCE Study: taVNS and Psilocybin","sstatus":"RECRUITING","sponsor":"University of Wisconsin, Madison","official":"Charles Raison, MD (University of Wisconsin, Madison)","src":"https://clinicaltrials.gov/study/NCT05866471","contact":{"n":"Program Manager","p":"608-265-4987","e":"enhance@psychiatry.wisc.edu"},"phase":"Phase 1","enroll":108,"start":"2025-01-27","eid":"x:site:nct05866471-university-of-wisconsin-madison-madison"},{"id":"nct05847686-fred-hutch-university-of-washington-cancer-consortium-seattle","cat":"research","name":"Fred Hutch/University of Washington Cancer Consortium","city":"Seattle","region":"Washington","country":"United States","cc":"US","lat":47.61021,"lon":-122.33814,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"98109","condg":["Cancer-related distress"],"nct":"NCT05847686","study":"Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer","sstatus":"COMPLETED","sponsor":"University of Washington","official":"Anthony Back (Fred Hutch/University of Washington Cancer Consortium)","src":"https://clinicaltrials.gov/study/NCT05847686","phase":"Phase 1/Phase 2","enroll":55,"start":"2023-06-27","eid":"x:site:nct05847686-fred-hutch-university-of-washington-cancer-consortium-seattle"},{"id":"nct04982796-portland-va-health-care-system-vancouver","cat":"research","name":"Portland VA Health Care System","city":"Vancouver","region":"Washington","country":"United States","cc":"US","lat":45.648,"lon":-122.65034,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"98661","condg":["Other"],"nct":"NCT04982796","study":"Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder","sstatus":"ACTIVE_NOT_RECRUITING","sponsor":"Portland VA Research Foundation, Inc","official":"Chris Stauffer, MD (Oregon Health and Science University)","src":"https://clinicaltrials.gov/study/NCT04982796","phase":"Phase 1/Phase 2","enroll":30,"start":"2022-07-07","eid":"x:site:nct04982796-portland-va-health-care-system-vancouver"},{"id":"nct06450210-5510-nathan-shock-drive-baltimore","cat":"research","name":"5510 Nathan Shock Drive","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.30144,"lon":-76.60706,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Other"],"nct":"NCT06450210","study":"Safety for Home Administration of Microdose Psilocybin Use","sstatus":"COMPLETED","sponsor":"Johns Hopkins University","official":"Sandeep M. Nayak, MD (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT06450210","phase":"Phase 1","enroll":17,"start":"2024-12-06","eid":"x:site:nct06450210-5510-nathan-shock-drive-baltimore"},{"id":"nct06796062-duke-city-recovery-toolbox-albuquerque","cat":"research","name":"Duke City Recovery Toolbox","city":"Albuquerque","region":"New Mexico","country":"United States","cc":"US","lat":35.07795,"lon":-106.64027,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"87102","condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT06796062","study":"Psilocybin for Opioid Use Disorder (OUD)","sstatus":"RECRUITING","sponsor":"NYU Langone Health","official":"Michael Bogenschutz, MD (NYU Langone Health)","src":"https://clinicaltrials.gov/study/NCT06796062","contact":{"n":"Michael Bogenschutz, MD","p":"646-501-4026","e":"Michael.bogenschutz@nyulangone.org"},"phase":"Phase 2","enroll":480,"start":"2025-12-17","eid":"x:site:nct06796062-duke-city-recovery-toolbox-albuquerque"},{"id":"nct06796062-university-of-new-mexico-albuquerque","cat":"research","name":"University of New Mexico","city":"Albuquerque","region":"New Mexico","country":"United States","cc":"US","lat":35.08388,"lon":-106.63914,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"87106","condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT06796062","study":"Psilocybin for Opioid Use Disorder (OUD)","sstatus":"RECRUITING","sponsor":"NYU Langone Health","official":"Michael Bogenschutz, MD (NYU Langone Health)","src":"https://clinicaltrials.gov/study/NCT06796062","contact":{"n":"Michael Bogenschutz, MD","p":"646-501-4026","e":"Michael.bogenschutz@nyulangone.org"},"phase":"Phase 2","enroll":480,"start":"2025-12-17","eid":"x:site:nct06796062-university-of-new-mexico-albuquerque"},{"id":"nct06796062-startcare-brooklyn","cat":"research","name":"StartCare","city":"Brooklyn","region":"New York","country":"United States","cc":"US","lat":40.65448,"lon":-73.9453,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"11206","condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT06796062","study":"Psilocybin for Opioid Use Disorder (OUD)","sstatus":"RECRUITING","sponsor":"NYU Langone Health","official":"Michael Bogenschutz, MD (NYU Langone Health)","src":"https://clinicaltrials.gov/study/NCT06796062","contact":{"n":"Michael Bogenschutz, MD","p":"646-501-4026","e":"Michael.bogenschutz@nyulangone.org"},"phase":"Phase 2","enroll":480,"start":"2025-12-17","eid":"x:site:nct06796062-startcare-brooklyn"},{"id":"nct06796062-nyu-langone-health-new-york","cat":"research","name":"NYU Langone Health","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71347,"lon":-74.0047,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10016","condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT06796062","study":"Psilocybin for Opioid Use Disorder (OUD)","sstatus":"RECRUITING","sponsor":"NYU Langone Health","official":"Michael Bogenschutz, MD (NYU Langone Health)","src":"https://clinicaltrials.gov/study/NCT06796062","contact":{"n":"Michael Bogenschutz, MD","p":"646-501-4026","e":"Michael.bogenschutz@nyulangone.org"},"phase":"Phase 2","enroll":480,"start":"2025-12-17","eid":"x:site:nct06796062-nyu-langone-health-new-york"},{"id":"nct06796062-vip-community-services-inc-the-bronx","cat":"research","name":"VIP Community Services, Inc","city":"The Bronx","region":"New York","country":"United States","cc":"US","lat":40.83945,"lon":-73.86166,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10457","condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT06796062","study":"Psilocybin for Opioid Use Disorder (OUD)","sstatus":"RECRUITING","sponsor":"NYU Langone Health","official":"Michael Bogenschutz, MD (NYU Langone Health)","src":"https://clinicaltrials.gov/study/NCT06796062","contact":{"n":"Michael Bogenschutz, MD","p":"646-501-4026","e":"Michael.bogenschutz@nyulangone.org"},"phase":"Phase 2","enroll":480,"start":"2025-12-17","eid":"x:site:nct06796062-vip-community-services-inc-the-bronx"},{"id":"nct06005662-johns-hopkins-university-baltimore","cat":"research","name":"Johns Hopkins University","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29777,"lon":-76.62278,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Addiction & substance use"],"nct":"NCT06005662","study":"Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder","sstatus":"WITHDRAWN","sponsor":"Johns Hopkins University","official":"Sandeep Nayak, MD (Johns Hopkins School of Medicine)","src":"https://clinicaltrials.gov/study/NCT06005662","phase":"Phase 2","start":"2027-04","eid":"x:site:nct06005662-johns-hopkins-university-baltimore"},{"id":"nct05581797-university-of-otago-christchurch","cat":"research","name":"University of Otago","city":"Christchurch","country":"New Zealand","cc":"NZ","lat":-43.53526,"lon":172.62434,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"8001","condg":["Depression"],"nct":"NCT05581797","study":"Psilocybin-assisted Interpersonal Therapy for Depression","sstatus":"COMPLETED","sponsor":"University of Otago","official":"Cameron Lacey, PhD (University of Otago)","src":"https://clinicaltrials.gov/study/NCT05581797","phase":"N/A","enroll":5,"start":"2023-03-15","eid":"x:site:nct05581797-university-of-otago-christchurch"},{"id":"nct07737990-toronto-western-hospital-toronto","cat":"research","name":"Toronto Western Hospital","city":"Toronto","region":"Ontario","country":"Canada","cc":"CA","lat":43.70215,"lon":-79.40848,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"M5T 2S8","condg":["Depression"],"nct":"NCT07737990","study":"Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression","sstatus":"ENROLLING_BY_INVITATION","sponsor":"Joshua Rosenblat","src":"https://clinicaltrials.gov/study/NCT07737990","phase":"N/A","enroll":65,"start":"2026-07-01","eid":"x:site:nct07737990-toronto-western-hospital-toronto"},{"id":"nct05585229-university-of-british-columbia-okanagan-campus-kelowna","cat":"research","name":"University of British Columbia - Okanagan Campus","city":"Kelowna","region":"British Columbia","country":"Canada","cc":"CA","lat":49.87333,"lon":-119.48177,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"V1V 1V7","condg":["Addiction & substance use","Chronic pain & headache"],"status":"RECRUITING","nct":"NCT05585229","study":"Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication","sstatus":"RECRUITING","sponsor":"University of British Columbia","official":"W. Francois Louw, MD (University of British Columbia)","src":"https://clinicaltrials.gov/study/NCT05585229","contact":{"n":"W. Francois Louw, MD","p":"250-860-9754","e":"doclouw@mail.ubc.ca"},"phase":"Phase 2","enroll":10,"start":"2025-10-27","eid":"x:site:nct05585229-university-of-british-columbia-okanagan-campus-kelowna"},{"id":"nct04989972-fms-department-of-psychiatry-kingston","cat":"research","name":"FMS Department of Psychiatry","city":"Kingston","country":"Jamaica","cc":"JM","lat":17.98709,"lon":-76.79513,"gp":"city","unnamed":0,"drugs":["psilocybin"],"condg":["Depression","Anxiety"],"nct":"NCT04989972","study":"Assessing the Efficacy of Micro-dosed Psilocybin on Reducing Anxiety & Depression Levels in Adults","sstatus":"WITHDRAWN","sponsor":"Wake Network, Inc.","official":"Roger Gibson (Faculty of Medical Sciences UWI Mona); Sharon White (Wake Network, Inc.)","src":"https://clinicaltrials.gov/study/NCT04989972","phase":"Phase 2","start":"2022-09-15","eid":"x:site:nct04989972-fms-department-of-psychiatry-kingston"},{"id":"nct06810310-university-of-pennsylvania-philadelphia","cat":"research","name":"University of Pennsylvania","city":"Philadelphia","region":"Pennsylvania","country":"United States","cc":"US","lat":39.95591,"lon":-75.15746,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"19104","condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT06810310","study":"Psilocybin on Brain Mechanisms of Motivation in OUD","sstatus":"RECRUITING","sponsor":"University of Pennsylvania","src":"https://clinicaltrials.gov/study/NCT06810310","contact":{"n":"Megan Ivey, MS","p":"215-746-7712","e":"megan.ivey@pennmedicine.upenn.edu"},"phase":"Phase 2","enroll":24,"start":"2025-12-22","eid":"x:site:nct06810310-university-of-pennsylvania-philadelphia"},{"id":"nct04218539-va-connecticut-healthcare-system-west-haven","cat":"research","name":"VA Connecticut Healthcare System","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.26072,"lon":-72.9391,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"06516","condg":["Chronic pain & headache"],"nct":"NCT04218539","study":"Repeat Dosing of Psilocybin in Migraine Headache","sstatus":"COMPLETED","sponsor":"Yale University","src":"https://clinicaltrials.gov/study/NCT04218539","phase":"Phase 1","enroll":18,"start":"2021-08-10","eid":"x:site:nct04218539-va-connecticut-healthcare-system-west-haven"},{"id":"nct06132178-health-discovery-building-hdb-1601-trinity-st-bldg-b-z0600-austin","cat":"research","name":"Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600","city":"Austin","region":"Texas","country":"United States","cc":"US","lat":30.26456,"lon":-97.74668,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"78712","condg":["Depression"],"status":"RECRUITING","nct":"NCT06132178","study":"Psilocybin rTMS for Treatment Resistant Depression","sstatus":"RECRUITING","sponsor":"University of Texas at Austin","official":"Gregory A Fonzo, Ph.D. (The University of Texas at Austin)","src":"https://clinicaltrials.gov/study/NCT06132178","contact":{"n":"Lauren Enten, B.S.A.","p":"512-495-5856","e":"fonzolab@austin.utexas.edu"},"phase":"Phase 2","enroll":100,"start":"2025-01-10","eid":"x:site:nct06132178-health-discovery-building-hdb-1601-trinity-st-bldg-b-z0600-austin"},{"id":"nct06885996-university-of-calgary-calgary","cat":"research","name":"University of Calgary","city":"Calgary","region":"Alberta","country":"Canada","cc":"CA","lat":51.05072,"lon":-114.08581,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"T2N 2T9","condg":["PTSD & trauma"],"nct":"NCT06885996","study":"Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence","sstatus":"NOT_YET_RECRUITING","sponsor":"University of Calgary","official":"Sandy Shultz, PhD (The Institute on Aging & Lifelong Health, Faculty of Health, University of Victoria); Leah Mayo, PhD (Parker Psychedelics Research Chair and Assistant Professor, Department of Psychiatry, University of Calgary, Cumming School of Medicine)","src":"https://clinicaltrials.gov/study/NCT06885996","contact":{"n":"Chantel T Debert","p":"(403) 944-4500","e":"cdebert@ucalgary.ca"},"phase":"Phase 2","enroll":76,"start":"2026-10-01","eid":"x:site:nct06885996-university-of-calgary-calgary"},{"id":"nct06885996-the-university-of-british-columbia-okanagan-campus-kelowna","cat":"research","name":"The University of British Columbia - Okanagan Campus","city":"Kelowna","region":"British Columbia","country":"Canada","cc":"CA","lat":49.88839,"lon":-119.48046,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"V1V 1V7","condg":["PTSD & trauma"],"nct":"NCT06885996","study":"Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence","sstatus":"NOT_YET_RECRUITING","sponsor":"University of Calgary","official":"Sandy Shultz, PhD (The Institute on Aging & Lifelong Health, Faculty of Health, University of Victoria); Leah Mayo, PhD (Parker Psychedelics Research Chair and Assistant Professor, Department of Psychiatry, University of Calgary, Cumming School of Medicine)","src":"https://clinicaltrials.gov/study/NCT06885996","contact":{"n":"Zachary Walsh","p":"403) 944-4500","e":"zachary.walsh@ubc.ca"},"phase":"Phase 2","enroll":76,"start":"2026-10-01","eid":"x:site:nct06885996-the-university-of-british-columbia-okanagan-campus-kelowna"},{"id":"nct06349083-nyu-langone-health-new-york","cat":"research","name":"NYU Langone Health","city":"New York","region":"New York","country":"United States","cc":"US","lat":40.71968,"lon":-73.99858,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"10016","condg":["Addiction & substance use"],"status":"RECRUITING","nct":"NCT06349083","study":"Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD","sstatus":"RECRUITING","sponsor":"NYU Langone Health","official":"Michael Bogenschutz, MD (NYU Langone Health)","src":"https://clinicaltrials.gov/study/NCT06349083","contact":{"n":"Michael Bogenschutz, MD","p":"646-501-4026","e":"Michael.bogenschutz@nyulangone.org"},"phase":"Phase 2","enroll":200,"start":"2026-09-01","eid":"x:site:nct06349083-nyu-langone-health-new-york"},{"id":"nct00802282-behavioral-pharmacology-research-unit-johns-hopkins-bayview-medical-","cat":"research","name":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28403,"lon":-76.61619,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"21224","condg":["Healthy volunteers"],"nct":"NCT00802282","study":"Psilocybin and Spiritual Practice","sstatus":"COMPLETED","sponsor":"Johns Hopkins University","official":"Roland R Griffiths, Ph.D. (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT00802282","phase":"Phase 1","enroll":75,"start":"2009-08","eid":"x:site:nct00802282-behavioral-pharmacology-research-unit-johns-hopkins-bayview-medical-"},{"id":"nct05128162-chronic-pain-and-fatigue-research-center-ann-arbor","cat":"research","name":"Chronic Pain and Fatigue Research Center","city":"Ann Arbor","region":"Michigan","country":"United States","cc":"US","lat":42.26688,"lon":-83.74789,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"48106","condg":["Chronic pain & headache"],"nct":"NCT05128162","study":"Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia","sstatus":"COMPLETED","sponsor":"Kevin Boehnke","official":"Kevin F Boehnke, PhD (University of Michigan)","src":"https://clinicaltrials.gov/study/NCT05128162","phase":"Phase 2","enroll":17,"start":"2023-09-27","eid":"x:site:nct05128162-chronic-pain-and-fatigue-research-center-ann-arbor"},{"id":"nct05381974-athinoula-a-martinos-center-for-biomedical-imaging-charlestown","cat":"research","name":"Athinoula A. Martinos Center for Biomedical Imaging","city":"Charlestown","region":"Massachusetts","country":"United States","cc":"US","lat":42.37265,"lon":-71.05565,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"02129","condg":["Depression"],"nct":"NCT05381974","study":"The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD","sstatus":"WITHDRAWN","sponsor":"Massachusetts General Hospital","official":"Sharmin Ghaznavi, MD, PhD (Massachusetts General Hospital)","src":"https://clinicaltrials.gov/study/NCT05381974","phase":"Phase 2","start":"2022-09-15","eid":"x:site:nct05381974-athinoula-a-martinos-center-for-biomedical-imaging-charlestown"},{"id":"nct05322954-university-of-wisconsin-madison","cat":"research","name":"University of Wisconsin","city":"Madison","region":"Wisconsin","country":"United States","cc":"US","lat":43.07978,"lon":-89.39187,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"53705","condg":["Addiction & substance use"],"nct":"NCT05322954","study":"Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder","sstatus":"TERMINATED","sponsor":"University of Wisconsin, Madison","official":"Christopher Nicholas, PhD (University of Wisconsin, Madison)","src":"https://clinicaltrials.gov/study/NCT05322954","phase":"Phase 1","enroll":5,"start":"2023-03-03","eid":"x:site:nct05322954-university-of-wisconsin-madison"},{"id":"nct04141501-psychiatrische-universitatsklinik-zurich-zurich","cat":"research","name":"Psychiatrische Universitätsklinik Zürich","city":"Zurich","country":"Switzerland","cc":"CH","lat":47.37378,"lon":8.55325,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"8032","condg":["Addiction & substance use"],"nct":"NCT04141501","study":"Clinical and Mechanistic Effects of Psilocybin in Alcohol Addicted Patients","sstatus":"COMPLETED","sponsor":"University of Zurich","official":"Katrin Preller, Dr. (Psychiatric University Clinic)","src":"https://clinicaltrials.gov/study/NCT04141501","phase":"Phase 2","enroll":37,"start":"2020-06-08","eid":"x:site:nct04141501-psychiatrische-universitatsklinik-zurich-zurich"},{"id":"nct05224336-university-of-california-san-diego-san-diego","cat":"research","name":"University of California, San Diego","city":"San Diego","region":"California","country":"United States","cc":"US","lat":32.70635,"lon":-117.17474,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"92093","condg":["Chronic pain & headache"],"nct":"NCT05224336","study":"Psilocybin-assisted Therapy for Phantom Limb Pain","sstatus":"COMPLETED","sponsor":"University of California, San Diego","src":"https://clinicaltrials.gov/study/NCT05224336","phase":"Phase 1","enroll":10,"start":"2022-10-03","eid":"x:site:nct05224336-university-of-california-san-diego-san-diego"},{"id":"nct07169747-psykiatrikliniken-baravagen-1-lund","cat":"research","name":"Psykiatrikliniken, Baravägen 1","city":"Lund","country":"Sweden","cc":"SE","lat":55.70608,"lon":13.18667,"gp":"city","unnamed":0,"drugs":["psilocybin"],"zip":"22240","condg":["Eating disorders"],"status":"RECRUITING","nct":"NCT07169747","study":"Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young Adults With Anorexia Nervosa","sstatus":"RECRUITING","sponsor":"Region Skane","official":"Pouya Movahed Rad, Associate Professor (Department of Clinical Sciences, Lund University, Sweden)","src":"https://clinicaltrials.gov/study/NCT07169747","contact":{"n":"David Sjöström, MD, PhD-student","p":"+46739075390","e":"david.sjostrom@med.lu.se"},"phase":"Phase 2","enroll":40,"start":"2026-07-20","eid":"x:site:nct07169747-psykiatrikliniken-baravagen-1-lund"},{"id":"nct00996411-behavioral-pharmacology-research-unit-johnson-hopkins-univ-school-of","cat":"research","name":"Behavioral Pharmacology Research Unit, Johnson Hopkins Univ. School of Med.","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.28742,"lon":-76.60311,"gp":"city","unnamed":0,"drugs":["salvinorin A"],"zip":"21224","condg":["Healthy volunteers"],"nct":"NCT00996411","study":"Human Psychopharmacology of Salvinorin A","sstatus":"COMPLETED","sponsor":"Johns Hopkins University","official":"Roland Griffiths, Ph.D. (Johns Hopkins University); Matthew W Johnson, Ph.D. (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT00996411","phase":"Phase 1","enroll":14,"start":"2008-11","eid":"x:site:nct00996411-behavioral-pharmacology-research-unit-johnson-hopkins-univ-school-of"},{"id":"nct00996411-behavioral-pharmacology-research-unit-baltimore","cat":"research","name":"Behavioral Pharmacology Research Unit","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29654,"lon":-76.61468,"gp":"city","unnamed":0,"drugs":["salvinorin A"],"zip":"21224","condg":["Healthy volunteers"],"nct":"NCT00996411","study":"Human Psychopharmacology of Salvinorin A","sstatus":"COMPLETED","sponsor":"Johns Hopkins University","official":"Roland Griffiths, Ph.D. (Johns Hopkins University); Matthew W Johnson, Ph.D. (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT00996411","phase":"Phase 1","enroll":14,"start":"2008-11","eid":"x:site:nct00996411-behavioral-pharmacology-research-unit-baltimore"},{"id":"nct03418714-behavioral-pharmacology-research-unit-johns-hopkins-bayview-medical-","cat":"research","name":"Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center","city":"Baltimore","region":"Maryland","country":"United States","cc":"US","lat":39.29071,"lon":-76.62334,"gp":"city","unnamed":0,"drugs":["salvinorin A"],"zip":"21224","condg":["Other"],"nct":"NCT03418714","study":"Effects of Salvinorin A on Brain Function","sstatus":"COMPLETED","sponsor":"Johns Hopkins University","official":"Frederick S Barrett, Ph.D. (Johns Hopkins University)","src":"https://clinicaltrials.gov/study/NCT03418714","phase":"Phase 1/Phase 2","enroll":13,"start":"2017-12-14","eid":"x:site:nct03418714-behavioral-pharmacology-research-unit-johns-hopkins-bayview-medical-"},{"id":"nct00700596-va-connecticut-healthcare-system-west-haven","cat":"research","name":"VA Connecticut Healthcare System","city":"West Haven","region":"Connecticut","country":"United States","cc":"US","lat":41.26891,"lon":-72.93872,"gp":"city","unnamed":0,"drugs":["salvinorin A"],"zip":"06516","condg":["Healthy volunteers"],"nct":"NCT00700596","study":"Effects of Salvinorin A in Healthy Controls","sstatus":"COMPLETED","sponsor":"Yale University","official":"Mohini Ranganathan, M.D. (Yale University School of Medicine, Dept of Psychiatry)","src":"https://clinicaltrials.gov/study/NCT00700596","phase":"EARLY_Phase 1","enroll":105,"start":"2009-02-12","eid":"x:site:nct00700596-va-connecticut-healthcare-system-west-haven"}]}